https://biobriefs.com/us-drug-tariff-crackdown-targets BioBriefs en 2026-04-03T21:32:14Z US drug tariff crackdown targets branded medicines—carveouts hinge on domestic manufacturing deals https://biobriefs.com/fda-decision-timeline-looms-for BioBriefs en 2026-04-03T21:32:14Z FDA decision timeline looms for COVID-19–era MCED adoption after endpoint miss in NHS trial https://biobriefs.com/reimbursement-and-dispute-pressure-heats BioBriefs en 2026-04-03T21:32:14Z Reimbursement and dispute pressure heats up around 340B and CMS DSH safety-net payments https://biobriefs.com/crispr-patent-battle-reaches-a BioBriefs en 2026-04-03T21:32:14Z CRISPR patent battle reaches a final stop as Supreme Court denies Agilent appeal https://biobriefs.com/next-gen-obesity-race-fda BioBriefs en 2026-04-03T21:32:14Z Next-gen obesity race: FDA clears Eli Lilly’s oral GLP-1 Foundayo as Novo pushes oral Wegovy narrative https://biobriefs.com/major-biotech-m-a-shakes BioBriefs en 2026-04-03T21:32:14Z Major biotech M&A shakes sentiment as Biogen prepares to buy Apellis for $5.6B https://biobriefs.com/ambrosia-raises-100m-series-b BioBriefs en 2026-04-03T21:32:14Z Ambrosia raises $100M Series B to push oral obesity small-molecule pipeline into Phase 1 https://biobriefs.com/fda-clearance-for-campus-developed BioBriefs en 2026-04-03T21:32:14Z FDA clearance for campus-developed CAR T marks a milestone for next-gen academic cell therapy https://biobriefs.com/proactive-supportive-care-in-egfr BioBriefs en 2026-04-03T21:32:14Z Proactive supportive care in EGFR-mutant lung cancer cuts dermatologic toxicity by half https://biobriefs.com/trinetx-and-regeneron-expand-data BioBriefs en 2026-04-03T21:32:14Z TriNetX and Regeneron expand data link-up to scale genomic and proteomic discovery https://biobriefs.com/us-pharmaceutical-tariffs-and-pricing BioBriefs en 2026-04-03T16:32:10Z US pharmaceutical tariffs and pricing carveouts https://biobriefs.com/fda-approves-eli-lillys-oral BioBriefs en 2026-04-03T16:32:10Z FDA approves Eli Lilly’s oral GLP-1 Foundayo and sparks a competitive response https://biobriefs.com/biogen-buys-apellis-for-5 BioBriefs en 2026-04-03T16:32:10Z Biogen buys Apellis for $5.6B to expand nephrology footprint https://biobriefs.com/grail-mced-test-implementation-stalls BioBriefs en 2026-04-03T16:32:10Z Grail MCED test implementation stalls after endpoint miss https://biobriefs.com/trinetx-and-regeneron-connect-genomic BioBriefs en 2026-04-03T16:32:10Z TriNetX and Regeneron connect genomic and proteomic real-world data https://biobriefs.com/syneron-closes-a-150m-series BioBriefs en 2026-04-03T16:32:10Z Syneron closes a $150M Series B to expand macrocyclic peptide platform https://biobriefs.com/landmark-ev-construction-for-oral BioBriefs en 2026-04-03T16:32:10Z Landmark EV construction for oral peptides—Syneron plus manufacturing attention https://biobriefs.com/car-t-breakthrough-at-university BioBriefs en 2026-04-03T16:32:10Z CAR T breakthrough at University of Colorado earns first US FDA approval for campus-developed therapy https://biobriefs.com/drug-pipeline-setback-alto-halts BioBriefs en 2026-04-03T16:32:10Z Drug pipeline setback—Alto halts schizophrenia program after Phase 2 miss https://biobriefs.com/us-ip-finality-for-crispr BioBriefs en 2026-04-03T16:32:10Z US IP finality for CRISPR gRNA modifications as Supreme Court denies Agilent review https://biobriefs.com/regulatory-trade-shocks-to-drug BioBriefs en 2026-04-03T14:32:06Z Regulatory & trade shocks to drug pricing and access https://biobriefs.com/obesity-drugs-enter-the-oral BioBriefs en 2026-04-03T14:32:06Z Obesity drugs enter the oral GLP-1 race https://biobriefs.com/biopharma-m-a-accelerates-with BioBriefs en 2026-04-03T14:32:06Z Biopharma M&A accelerates with major acquisition moves https://biobriefs.com/clinical-pipeline-readouts-and-trial BioBriefs en 2026-04-03T14:32:06Z Clinical pipeline readouts and trial outcomes https://biobriefs.com/precision-oncology-trial-signal-sclc BioBriefs en 2026-04-03T14:32:06Z Precision oncology trial signal: SCLC biomarker analytics https://biobriefs.com/cell-therapy-and-regenerative-innovation BioBriefs en 2026-04-03T14:32:06Z Cell therapy and regenerative innovation at the FDA threshold https://biobriefs.com/launch-platform-and-data-partnerships BioBriefs en 2026-04-03T14:32:06Z Launch platform and data partnerships in drug discovery https://biobriefs.com/gene-therapy-momentum-early-approvals BioBriefs en 2026-04-03T14:32:06Z Gene therapy momentum: early approvals and emerging targets https://biobriefs.com/biotech-funding-and-platform-expansion BioBriefs en 2026-04-03T14:32:06Z Biotech funding and platform expansion https://biobriefs.com/regulatory-science-and-new-approach BioBriefs en 2026-04-03T14:32:06Z Regulatory science and new approach methodologies in toxicity testing https://biobriefs.com/glp-1-oral-obesity-approvals BioBriefs en 2026-04-03T10:32:32Z GLP-1 oral obesity approvals ignite a new competitive era https://biobriefs.com/trumps-100-drug-tariffs-carveouts BioBriefs en 2026-04-03T10:32:32Z Trump’s 100% drug tariffs—carveouts and pricing deals reshape leverage https://biobriefs.com/ema-endorses-first-virtual-controls BioBriefs en 2026-04-03T10:32:32Z EMA endorses first virtual controls approach for toxicity testing (NAM milestone) https://biobriefs.com/orca-bios-cell-therapy-approval BioBriefs en 2026-04-03T10:32:32Z Orca Bio’s cell therapy approval timeline shifts after manufacturing data update https://biobriefs.com/car-t-for-the-first BioBriefs en 2026-04-03T10:32:32Z CAR T for the first time built on-campus gains FDA IND clearance https://biobriefs.com/sclc-trial-biomarker-analysis-spotlights BioBriefs en 2026-04-03T10:32:32Z SCLC trial biomarker analysis spotlights AZD2811 response monitoring https://biobriefs.com/cancer-immunotherapy-science-st-jude BioBriefs en 2026-04-03T10:32:32Z Cancer immunotherapy science: St. Jude study points to dendritic cell ‘gatekeeper’ suppression mechanism https://biobriefs.com/biotech-m-a-momentum-biogen BioBriefs en 2026-04-03T10:32:32Z Biotech M&A momentum: Biogen to buy Apellis for $5.6B https://biobriefs.com/drug-delivery-and-formulation-innovation BioBriefs en 2026-04-03T10:32:32Z Drug delivery and formulation innovation: Pfizer’s new fluid program? (AAV manufacturing process stability) https://biobriefs.com/regenerative-medicine-platform-ucl-hydrogel BioBriefs en 2026-04-03T10:32:32Z Regenerative medicine platform: UCL hydrogel axon model reshapes MS remyelination testing https://biobriefs.com/oncology-early-stage-biomarker-strategy BioBriefs en 2026-04-03T09:31:54Z Oncology early-stage biomarker strategy for AZD2811 in SCLC https://biobriefs.com/regulatory-pathway-shifts-for-organoid BioBriefs en 2026-04-03T09:31:54Z Regulatory pathway shifts for organoid-supported drug development https://biobriefs.com/fda-dates-and-setbacks-for BioBriefs en 2026-04-03T09:31:54Z FDA dates and setbacks for oncolytic virus and Treg cell therapies https://biobriefs.com/us-trade-policy-raises-the BioBriefs en 2026-04-03T09:31:54Z US trade policy raises the cost and complexity of brand-name drug imports https://biobriefs.com/fda-approval-expands-oral-glp BioBriefs en 2026-04-03T09:31:54Z FDA approval expands oral GLP-1 competition for obesity https://biobriefs.com/ambrosia-lands-series-b-funding BioBriefs en 2026-04-03T09:31:54Z Ambrosia lands Series B funding for oral obesity small-molecule pipeline https://biobriefs.com/car-t-program-moves-forward BioBriefs en 2026-04-03T09:31:54Z CAR T program moves forward with first campus-developed FDA approval https://biobriefs.com/biopharma-dealmaking-accelerates-biogen-buys BioBriefs en 2026-04-03T09:31:54Z Biopharma dealmaking accelerates: Biogen buys Apellis for $5.6B https://biobriefs.com/europes-ema-signals-a-first BioBriefs en 2026-04-03T09:31:54Z Europe’s EMA signals a first step toward NAM acceptance in toxicity testing https://biobriefs.com/biotech-manufacturing-and-platform-signals BioBriefs en 2026-04-03T09:31:54Z Biotech manufacturing and platform signals: Hydrogel axon model improves remyelination screening https://biobriefs.com/fda-signals-faster-path-for BioBriefs en 2026-04-03T04:31:56Z FDA signals faster path for human-first studies; EMA backs first virtual toxicity approach https://biobriefs.com/lilly-and-novo-ignite-oral BioBriefs en 2026-04-03T04:31:56Z Lilly and Novo ignite oral obesity competition after FDA approvals and pricing battles https://biobriefs.com/biogen-pays-5-6b-for BioBriefs en 2026-04-03T04:31:56Z Biogen pays $5.6B for Apellis to expand immunology and kidney franchise https://biobriefs.com/car-t-regulatory-milestone-at BioBriefs en 2026-04-03T04:31:56Z CAR T regulatory milestone at University of Colorado for campus-developed therapy https://biobriefs.com/gilead-cancels-long-acting-hiv BioBriefs en 2026-04-03T04:31:56Z Gilead cancels long-acting HIV pill program amid ongoing FDA clinical hold https://biobriefs.com/regulatory-and-legal-pressure-reshapes BioBriefs en 2026-04-03T04:31:56Z Regulatory and legal pressure reshapes CRISPR IP landscape https://biobriefs.com/immunovants-fcrn-inhibitor-fails-phase BioBriefs en 2026-04-03T04:31:56Z Immunovant’s FcRn inhibitor fails Phase 3 in thyroid eye disease https://biobriefs.com/ambrosia-secures-100m-series-b BioBriefs en 2026-04-03T04:31:56Z Ambrosia secures $100M Series B to advance oral obesity GLP-1 candidate https://biobriefs.com/home-grown-clinical-model-hydrogel BioBriefs en 2026-04-03T04:31:56Z Home-grown clinical model: hydrogel-based axon platform improves MS remyelination testing https://biobriefs.com/therapy-development-disrupted-by-trial BioBriefs en 2026-04-03T04:31:56Z Therapy development disrupted by trial logistics: Pfizer and BioNTech pause COVID study over enrollment https://biobriefs.com/fda-approves-lillys-oral-glp BioBriefs en 2026-04-02T21:32:06Z FDA approves Lilly’s oral GLP-1 for obesity, intensifying market rivalry https://biobriefs.com/ambrosia-raises-100m-series-b BioBriefs en 2026-04-02T21:32:06Z Ambrosia raises $100M Series B to advance oral obesity pipeline https://biobriefs.com/biotech-dealmaking-accelerates-biogen-buys BioBriefs en 2026-04-02T21:32:06Z Biotech dealmaking accelerates: Biogen buys Apellis for $5.6B https://biobriefs.com/fda-and-policy-shift-to BioBriefs en 2026-04-02T21:32:06Z FDA and policy shift to reduce animal testing in oncology development https://biobriefs.com/cancer-immunotherapy-dendritic-cell-mechanism BioBriefs en 2026-04-02T21:32:06Z Cancer immunotherapy: dendritic-cell mechanism reshapes ‘checkpoint gatekeeper’ strategy https://biobriefs.com/new-preclinical-dual-hif-inhibition BioBriefs en 2026-04-02T21:32:06Z New preclinical dual HIF inhibition erases multiple tumor types with immunotherapy in mice https://biobriefs.com/car-t-gets-first-ever BioBriefs en 2026-04-02T21:32:06Z CAR T gets first-ever FDA approval for campus-developed therapy via IND clearance https://biobriefs.com/genomics-tooling-geneus-obtains-ce BioBriefs en 2026-04-02T21:32:06Z Genomics tooling: Geneus obtains CE IVDR mark for nanopore sequencer https://biobriefs.com/virology-and-safety-pfizer-and BioBriefs en 2026-04-02T21:32:06Z Virology and safety: Pfizer and BioNTech pause updated COVID trial over enrollment https://biobriefs.com/deal-and-regulatory-planning-ema BioBriefs en 2026-04-02T21:32:06Z Deal and regulatory planning: EMA endorses first NAM to replace live animal controls in toxicity tests https://biobriefs.com/obesity-glp-1-rivalry-heats BioBriefs en 2026-04-02T16:32:03Z Obesity GLP-1 rivalry heats up after FDA approves Lilly’s oral Foundayo https://biobriefs.com/biogens-5-6b-apellis-deal BioBriefs en 2026-04-02T16:32:03Z Biogen’s $5.6B Apellis deal accelerates immunology and nephrology push https://biobriefs.com/court-blocks-agilents-crispr-patent BioBriefs en 2026-04-02T16:32:03Z Court blocks Agilent’s CRISPR patent bid, ending appeals in Synthego fight https://biobriefs.com/federal-procurement-and-regulatory-scrutiny BioBriefs en 2026-04-02T16:32:03Z Federal procurement and regulatory scrutiny intersect with obesity pharma pricing and access https://biobriefs.com/series-b-capital-pours-into BioBriefs en 2026-04-02T16:32:03Z Series B capital pours into Ambrosia as oral small-molecule GLP-1 moves toward Phase I https://biobriefs.com/immunovants-fcrn-blocker-batoclimab-fails BioBriefs en 2026-04-02T16:32:03Z Immunovant’s FcRn blocker batoclimab fails again in Phase 3 TED trials https://biobriefs.com/fda-tariff-rumors-raise-new BioBriefs en 2026-04-02T16:32:03Z FDA tariff rumors raise new compliance and cost risks for drugmakers https://biobriefs.com/lilly-acquires-centessa-for-up BioBriefs en 2026-04-02T16:32:03Z Lilly acquires Centessa for up to $7.8B, expanding sleep/wake neuroscience ambitions https://biobriefs.com/fosun-gains-nmpa-approval-to BioBriefs en 2026-04-02T16:32:03Z Fosun gains NMPA approval to start trial of FXB-0871 in China https://biobriefs.com/new-gene-therapy-and-trial BioBriefs en 2026-04-02T16:32:03Z New gene therapy and trial-readiness milestones in early-stage pipeline https://biobriefs.com/obesity-drug-approvals-and-competitive BioBriefs en 2026-04-02T14:32:04Z Obesity drug approvals and competitive oral GLP-1 race https://biobriefs.com/big-pharma-dealmaking-biogens-apellis BioBriefs en 2026-04-02T14:32:04Z Big pharma dealmaking: Biogen’s Apellis acquisition https://biobriefs.com/big-pharma-dealmaking-lillys-centessa BioBriefs en 2026-04-02T14:32:04Z Big pharma dealmaking: Lilly’s Centessa acquisition and neuro pipeline expansion https://biobriefs.com/clinical-trial-failures-in-immune BioBriefs en 2026-04-02T14:32:04Z Clinical trial failures in immune/eye disease: Immunovant’s FcRn program https://biobriefs.com/fda-and-regulatory-scrutiny-tavneos BioBriefs en 2026-04-02T14:32:04Z FDA and regulatory scrutiny: Tavneos liver injury warnings https://biobriefs.com/regulatory-decision-in-crispr-patent BioBriefs en 2026-04-02T14:32:04Z Regulatory decision in CRISPR patent battle: Agilent vs Synthego https://biobriefs.com/cell-therapy-and-gene-editing BioBriefs en 2026-04-02T14:32:04Z Cell therapy and gene editing access: FDA shifting to digital health tech guidance https://biobriefs.com/funding-and-company-momentum-new BioBriefs en 2026-04-02T14:32:04Z Funding and company momentum: new seed financing for epigenetic protein interface drugs https://biobriefs.com/precision-oncology-diagnostics-multi-cancer BioBriefs en 2026-04-02T14:32:04Z Precision oncology diagnostics: multi-cancer early detection results solidify Caris Detect outlook https://biobriefs.com/next-gen-delivery-and-trial BioBriefs en 2026-04-02T14:32:04Z Next-gen delivery and trial execution: NGS tumor profiling partnership https://biobriefs.com/obesity-drugs-fda-clears-lillys BioBriefs en 2026-04-02T10:31:39Z Obesity drugs: FDA clears Lilly’s oral GLP-1 Foundayo https://biobriefs.com/big-obesity-funding-ambrosia-lands BioBriefs en 2026-04-02T10:31:39Z Big obesity funding: Ambrosia lands $100M to scale oral GLP-1 program https://biobriefs.com/astrazenecas-hypophosphatasia-enzyme-therapy-stumbles BioBriefs en 2026-04-02T10:31:39Z AstraZeneca’s hypophosphatasia enzyme therapy stumbles in pivotal phase https://biobriefs.com/immunology-m-a-biogen-to BioBriefs en 2026-04-02T10:31:39Z Immunology M&A: Biogen to buy Apellis for $5.6B https://biobriefs.com/sleep-medicine-m-a-lilly BioBriefs en 2026-04-02T10:31:39Z Sleep medicine M&A: Lilly agrees to buy Centessa for $6.3B https://biobriefs.com/oncology-active-surveillance-consensus-for BioBriefs en 2026-04-02T10:31:39Z Oncology: Active surveillance consensus for low-grade NMIBC https://biobriefs.com/gene-therapy-wound-care-hydrogel BioBriefs en 2026-04-02T10:31:39Z Gene therapy/wound care: Hydrogel + AAV8-sTβRII reduces skin scarring https://biobriefs.com/diagnostics-caris-shares-surge-after BioBriefs en 2026-04-02T10:31:39Z Diagnostics: Caris shares surge after finalized Achieve I multi-cancer early detection results https://biobriefs.com/dealmaking-for-rare-neurodegeneration-korsana BioBriefs en 2026-04-02T10:31:39Z Dealmaking for rare neurodegeneration: Korsana to go public via reverse merger https://biobriefs.com/regulatory-policy-fda-looks-to BioBriefs en 2026-04-02T10:31:39Z Regulatory & policy: FDA looks to reduce data burden to start new drug trials https://biobriefs.com/obesity-pills-go-oral-lilly BioBriefs en 2026-04-02T09:32:03Z Obesity pills go oral—Lilly secures FDA approval https://biobriefs.com/mega-m-a-reshapes-neuro BioBriefs en 2026-04-02T09:32:03Z Mega M&A reshapes neuro and immunology portfolios https://biobriefs.com/fda-tariffs-draft-signals-new BioBriefs en 2026-04-02T09:32:03Z FDA tariffs draft signals new cost pressure on drug imports https://biobriefs.com/hiv-development-disrupted-gilead-terminates BioBriefs en 2026-04-02T09:32:03Z HIV development disrupted—Gilead terminates long-acting pill trial under FDA hold https://biobriefs.com/caris-achieve-i-finalized-data BioBriefs en 2026-04-02T09:32:03Z Caris ‘Achieve I’ finalized data lifts confidence in multi-cancer early detection https://biobriefs.com/gene-therapy-delivery-tissue-targeting BioBriefs en 2026-04-02T09:32:03Z Gene therapy delivery—tissue-targeting hydrogel reduces skin scarring https://biobriefs.com/regenerative-manufacturing-place-of-care BioBriefs en 2026-04-02T09:32:03Z Regenerative manufacturing—place-of-care gene-modified HSC collaboration advances toward Phase I/II https://biobriefs.com/biotech-lab-automation-digital-formulator BioBriefs en 2026-04-02T09:32:03Z Biotech lab automation—digital formulator links to self-driving tableting https://biobriefs.com/diagnostics-baebies-expands-clia-waived BioBriefs en 2026-04-02T09:32:03Z Diagnostics—Baebies expands CLIA-waived molecular testing on a POC platform https://biobriefs.com/company-setback-io-biotech-files BioBriefs en 2026-04-02T09:32:03Z Company setback—IO Biotech files for bankruptcy after failed cancer vaccine outcome https://biobriefs.com/obesity-drugs-oral-glp-1 BioBriefs en 2026-04-02T04:32:07Z Obesity drugs: oral GLP-1 race heats up https://biobriefs.com/big-pharma-deals-lilly-enters BioBriefs en 2026-04-02T04:32:06Z Big pharma deals: Lilly enters sleep disorder neuroscience https://biobriefs.com/big-pharma-deals-biogen-expands BioBriefs en 2026-04-02T04:32:06Z Big pharma deals: Biogen expands immunology with Apellis https://biobriefs.com/regulatory-policy-tariffs-targeting-imported BioBriefs en 2026-04-02T04:32:06Z Regulatory policy: Tariffs targeting imported drugs prepared https://biobriefs.com/hiv-pipeline-setback-gilead-ends BioBriefs en 2026-04-02T04:32:06Z HIV pipeline setback: Gilead ends Phase 2/3 long-acting pill trial https://biobriefs.com/cell-therapy-manufacturing-at-scale BioBriefs en 2026-04-02T04:32:06Z Cell therapy manufacturing at scale: more robust AAV process economics https://biobriefs.com/diagnostics-and-surveillance-multi-cancer BioBriefs en 2026-04-02T04:32:06Z Diagnostics and surveillance: multi-cancer early detection results finalized https://biobriefs.com/company-collapse-io-biotech-seeks BioBriefs en 2026-04-02T04:32:06Z Company collapse: IO Biotech seeks bankruptcy after cancer vaccine failure https://biobriefs.com/payer-and-trial-policy-fda BioBriefs en 2026-04-02T04:32:06Z Payer and trial policy: FDA explores using digital health technologies in drug trials https://biobriefs.com/ai-and-clinical-care-operations BioBriefs en 2026-04-02T04:32:06Z AI and clinical care operations: ambient scribe impact in the real world https://biobriefs.com/obesity-pills-enter-a-new BioBriefs en 2026-04-01T21:32:18Z Obesity pills enter a new oral GLP-1 era https://biobriefs.com/big-biotech-makes-dual-immunology BioBriefs en 2026-04-01T21:32:18Z Big biotech makes dual immunology plays https://biobriefs.com/lilly-returns-to-sleep-disorders BioBriefs en 2026-04-01T21:32:18Z Lilly returns to sleep disorders with Centessa acquisition https://biobriefs.com/us-fda-targets-faster-trial BioBriefs en 2026-04-01T21:32:18Z US FDA targets faster trial starts via reduced safety-only datasets https://biobriefs.com/gene-editing-access-meets-manufacturing BioBriefs en 2026-04-01T21:32:18Z Gene editing access meets manufacturing reality checks https://biobriefs.com/caris-multi-cancer-early-detection BioBriefs en 2026-04-01T21:32:18Z Caris multi-cancer early detection test clears key data milestone https://biobriefs.com/diagnostics-move-toward-eu-ivdr BioBriefs en 2026-04-01T21:32:18Z Diagnostics move toward EU IVDR compliance for long-read nanopore sequencing https://biobriefs.com/aav-manufacturing-new-approach-targets BioBriefs en 2026-04-01T21:32:18Z AAV manufacturing: new approach targets transfection timing risk https://biobriefs.com/digital-trial-tools-expand-interoperability BioBriefs en 2026-04-01T21:32:18Z Digital trial tools expand interoperability with IRT and eCOA integration https://biobriefs.com/biotech-m-a-continues-with BioBriefs en 2026-04-01T21:32:18Z Biotech M&A continues with Merck antibody search partnership https://biobriefs.com/fda-approval-ushers-in-a BioBriefs en 2026-04-01T16:31:44Z FDA approval ushers in a new oral obesity battleground https://biobriefs.com/deal-frenzy-reshapes-neuroscience-and BioBriefs en 2026-04-01T16:31:44Z Deal frenzy reshapes neuroscience and immunology portfolios https://biobriefs.com/corporate-survival-and-turnaround-risk BioBriefs en 2026-04-01T16:31:44Z Corporate survival and turnaround risk after clinical setbacks https://biobriefs.com/pipeline-financing-keeps-oral-obesity BioBriefs en 2026-04-01T16:31:44Z Pipeline financing keeps oral obesity competition in motion https://biobriefs.com/new-oncology-early-detection-data BioBriefs en 2026-04-01T16:31:44Z New oncology early-detection data lifts investor expectations https://biobriefs.com/cancer-immunotherapy-targets-the-tumor BioBriefs en 2026-04-01T16:31:44Z Cancer immunotherapy targets the tumor microenvironment for broader reach https://biobriefs.com/regulator-timeline-stretches-as-manufacturing BioBriefs en 2026-04-01T16:31:44Z Regulator timeline stretches as manufacturing data pile grows https://biobriefs.com/regulatory-tooling-for-gene-and BioBriefs en 2026-04-01T16:31:44Z Regulatory tooling for gene- and antibody-based discovery scales in Europe https://biobriefs.com/reverse-merger-brings-alzheimers-antibody BioBriefs en 2026-04-01T16:31:44Z Reverse merger brings Alzheimer’s antibody program to public markets https://biobriefs.com/emerging-therapy-access-model-aims BioBriefs en 2026-04-01T16:31:44Z Emerging therapy access model aims to bring gene-modified HSC manufacturing to the point of care https://biobriefs.com/big-pharma-m-a-biogen BioBriefs en 2026-04-01T14:32:34Z Big pharma M&A: Biogen expands immunology with Apellis https://biobriefs.com/big-pharma-m-a-lilly BioBriefs en 2026-04-01T14:32:34Z Big pharma M&A: Lilly bets on orexin biology with Centessa https://biobriefs.com/big-pharma-to-ai-discovery BioBriefs en 2026-04-01T14:32:34Z Big pharma to AI discovery: Lilly extends Insilico Medicine pact https://biobriefs.com/regulation-fda-delay-on-orca BioBriefs en 2026-04-01T14:32:34Z Regulation: FDA delay on Orca Bio cell therapy decision https://biobriefs.com/cell-therapy-at-scale-icon BioBriefs en 2026-04-01T14:32:34Z Cell therapy at scale: ICON and Advarra link for AI-driven site operations https://biobriefs.com/clinical-stage-oncology-oric-advances BioBriefs en 2026-04-01T14:32:34Z Clinical stage oncology: Oric advances PRC2 inhibitor into Phase 3 in prostate cancer https://biobriefs.com/market-and-funding-genomeweb-top BioBriefs en 2026-04-01T14:32:34Z Market and funding: GenomeWeb Top 40 tracks -7% decline https://biobriefs.com/cell-therapy-and-trials-ipf BioBriefs en 2026-04-01T14:32:34Z Cell therapy and trials: IPF trial endpoints lift United’s Tyvaso program https://biobriefs.com/diagnostics-baebies-gets-fda-510 BioBriefs en 2026-04-01T14:32:34Z Diagnostics: Baebies gets FDA 510(k) and CLIA waiver for triplex respiratory test https://biobriefs.com/biotech-insolvency-and-regulatory-outcomes BioBriefs en 2026-04-01T14:32:34Z Biotech insolvency and regulatory outcomes: IO Biotech shuts down after FDA refusal https://biobriefs.com/dealmaking-big-pharma-moves-into BioBriefs en 2026-04-01T10:31:56Z Dealmaking: big pharma moves into new neuroscience and immunology growth engines https://biobriefs.com/fda-scrutiny-of-drugs-after BioBriefs en 2026-04-01T10:31:56Z FDA scrutiny of drugs after adverse events: Tavneos safety signal expands https://biobriefs.com/regulatory-pathway-for-prior-crls BioBriefs en 2026-04-01T10:31:56Z Regulatory pathway for prior CRLs: FDA meetings signal new review strategy for setbacks https://biobriefs.com/oncology-advances-early-stage-data BioBriefs en 2026-04-01T10:31:56Z Oncology advances: early-stage data and preclinical immune mechanisms https://biobriefs.com/target-discovery-and-platform-licensing BioBriefs en 2026-04-01T10:31:56Z Target discovery and platform licensing: Merck expands immunology antibody engine https://biobriefs.com/inflammation-and-immunology-drug-development BioBriefs en 2026-04-01T10:31:56Z Inflammation and immunology drug development: IL-22/IL-13 and atopic dermatitis targets in focus https://biobriefs.com/precision-oncology-biomarkers-and-molecular BioBriefs en 2026-04-01T10:31:56Z Precision oncology: biomarkers and molecular mechanisms to refine cancer treatment decisions https://biobriefs.com/cell-and-gene-therapy-manufacturing BioBriefs en 2026-04-01T10:31:56Z Cell and gene therapy manufacturing: automation moves toward place-of-care HSC workflows https://biobriefs.com/biotech-funding-and-pipeline-scaling BioBriefs en 2026-04-01T10:31:56Z Biotech funding and pipeline scaling: Semarion raises to expand cell assay tech https://biobriefs.com/clinical-stage-company-updates-and BioBriefs en 2026-04-01T10:31:56Z Clinical-stage company updates and financing appetite: obesity pipeline IPO activity https://biobriefs.com/lilly-and-biogens-blockbuster-m BioBriefs en 2026-04-01T09:32:32Z Lilly and Biogen’s blockbuster M&A reshapes sleep and immunology portfolios https://biobriefs.com/fda-regulatory-scrutiny-tightens-around BioBriefs en 2026-04-01T09:32:32Z FDA regulatory scrutiny tightens around therapies with safety signals https://biobriefs.com/astrazenecas-rare-disease-program-stumbles BioBriefs en 2026-04-01T09:32:32Z AstraZeneca’s rare-disease program stumbles in pivotal testing https://biobriefs.com/viridians-thyroid-eye-disease-phase BioBriefs en 2026-04-01T09:32:32Z Viridian’s thyroid eye disease Phase 3 clears the bar on secondary questions but triggers investor debate https://biobriefs.com/merck-accelerates-inflammatory-biology-target BioBriefs en 2026-04-01T09:32:32Z Merck accelerates inflammatory-biology target discovery with Quotient collaboration https://biobriefs.com/antibody-discovery-platform-deal-merck BioBriefs en 2026-04-01T09:32:32Z Antibody discovery platform deal: Merck funds AI-first Infinimmune library expansion https://biobriefs.com/astrazeneca-insilico-style-ai-expansion BioBriefs en 2026-04-01T09:32:32Z AstraZeneca/Insilico style AI expansion: Lilly expands AI drug discovery via multibillion-dollar Insilico deal https://biobriefs.com/rna-therapeutics-industrialization-first-clinical BioBriefs en 2026-04-01T09:32:32Z RNA therapeutics industrialization: first clinical trial for a reusable tRNA platform https://biobriefs.com/place-of-care-cell-and BioBriefs en 2026-04-01T09:32:32Z Place-of-care cell and gene therapy manufacturing alliance targets cost and scalability https://biobriefs.com/fda-and-health-systems-keep BioBriefs en 2026-04-01T09:32:32Z FDA and health systems keep pushing multiplex diagnostics closer to point of care https://biobriefs.com/big-pharma-buyouts-reshape-neuroscience BioBriefs en 2026-04-01T04:31:55Z Big Pharma buyouts reshape neuroscience and immunology https://biobriefs.com/merck-expands-with-somatic-genomics BioBriefs en 2026-04-01T04:31:55Z Merck expands with somatic genomics push in inflammatory bowel disease https://biobriefs.com/fda-safety-signal-lights-up BioBriefs en 2026-04-01T04:31:55Z FDA safety signal lights up Amgen’s Tavneos liver injury risk https://biobriefs.com/clinical-trial-volatility-vandas-tradipitant BioBriefs en 2026-04-01T04:31:55Z Clinical trial volatility: Vanda’s tradipitant hurdles in gastroparesis https://biobriefs.com/astrazenecas-rare-disease-miss-underscores BioBriefs en 2026-04-01T04:31:55Z AstraZeneca’s rare disease miss underscores late-stage risk https://biobriefs.com/us-approval-signals-car-t BioBriefs en 2026-04-01T04:31:55Z US approval signals: CAR-T breakthrough designation for Wugen program https://biobriefs.com/clinical-stage-dermatology-win-for BioBriefs en 2026-04-01T04:31:55Z Clinical-stage dermatology win for Simcere’s rademikibart https://biobriefs.com/diagnostics-push-baebies-gets-510 BioBriefs en 2026-04-01T04:31:55Z Diagnostics push: Baebies gets 510(k) and CLIA waiver for multiplex triplex respiratory testing https://biobriefs.com/genomics-and-data-dealmaking-continues BioBriefs en 2026-04-01T04:31:55Z Genomics-and-data dealmaking continues: ICON partners with Advarra for trial site network integration https://biobriefs.com/investment-and-funding-ambrosia-raises BioBriefs en 2026-04-01T04:31:55Z Investment and funding: Ambrosia raises $100M for oral GLP-1 small molecule https://biobriefs.com/major-m-a-lilly-locks BioBriefs en 2026-03-31T21:32:13Z Major M&A: Lilly locks in OX2R sleep-wake pipeline https://biobriefs.com/major-m-a-biogen-acquires BioBriefs en 2026-03-31T21:32:13Z Major M&A: Biogen acquires Apellis to deepen immunology and complement franchise https://biobriefs.com/major-m-a-otsuka-buys BioBriefs en 2026-03-31T21:32:13Z Major M&A: Otsuka buys Transcend for oral neuroplastogen PTSD program https://biobriefs.com/regulatory-safety-fda-links-deaths BioBriefs en 2026-03-31T21:32:13Z Regulatory safety: FDA links deaths to Amgen’s Tavneos liver injury signal https://biobriefs.com/clinical-trial-readout-braveheart-posts BioBriefs en 2026-03-31T21:32:13Z Clinical trial readout: Braveheart posts Phase 2 win in obstructive hypertrophic cardiomyopathy https://biobriefs.com/phase-3-simceres-rademikibart-hits BioBriefs en 2026-03-31T21:32:13Z Phase 3: Simcere’s rademikibart hits primary endpoint in atopic dermatitis https://biobriefs.com/clinical-development-innovents-ibi-302 BioBriefs en 2026-03-31T21:32:13Z Clinical development: Innovent’s IBI-302 meets Phase 3 endpoints in neovascular AMD https://biobriefs.com/funding-platform-scale-up-semarion BioBriefs en 2026-03-31T21:32:13Z Funding & platform scale-up: Semarion raises $3.8M to scale cell assay tech https://biobriefs.com/fda-clia-diagnostics-baebies-gets BioBriefs en 2026-03-31T21:32:13Z FDA/CLIA diagnostics: Baebies gets clearance for multiplex respiratory test on Finder https://biobriefs.com/ai-driven-dealmaking-merck-expands BioBriefs en 2026-03-31T21:32:13Z AI-driven dealmaking: Merck expands collaboration with Infinimmune for antibody discovery https://biobriefs.com/weight-loss-access-and-pricing BioBriefs en 2026-03-31T16:32:00Z Weight-loss access and pricing models https://biobriefs.com/oral-glp-1-innovation-funding BioBriefs en 2026-03-31T16:32:00Z Oral GLP-1 innovation funding https://biobriefs.com/metabolic-pipeline-arms-race-oral BioBriefs en 2026-03-31T16:32:00Z Metabolic pipeline arms race: oral triple incretin https://biobriefs.com/mid-stage-results-and-pipeline BioBriefs en 2026-03-31T16:32:00Z Mid-stage results and pipeline follow-through in ophthalmology https://biobriefs.com/dealmaking-reshapes-immunology-portfolios BioBriefs en 2026-03-31T16:32:00Z Dealmaking reshapes immunology portfolios https://biobriefs.com/neuroscience-mega-deals-ai-plus BioBriefs en 2026-03-31T16:32:00Z Neuroscience mega-deals: AI plus sleep disorder focus https://biobriefs.com/cardiomyopathy-progress-and-trial-signaling BioBriefs en 2026-03-31T16:32:00Z Cardiomyopathy progress and trial signaling https://biobriefs.com/autoimmune-eye-disease-setback-with BioBriefs en 2026-03-31T16:32:00Z Autoimmune eye disease setback with competing mechanism positioning https://biobriefs.com/regulatory-milestone-in-gene-editing BioBriefs en 2026-03-31T16:32:00Z Regulatory milestone in gene editing manufacturing oversight https://biobriefs.com/clinical-trial-and-regulatory-traction BioBriefs en 2026-03-31T16:32:00Z Clinical trial and regulatory traction in immunology therapeutics https://biobriefs.com/large-pharma-deals-and-platform BioBriefs en 2026-03-31T14:32:04Z Large pharma deals and platform expansion https://biobriefs.com/immunology-blockbuster-asset-m-a BioBriefs en 2026-03-31T14:32:04Z Immunology blockbuster asset M&A https://biobriefs.com/antibody-discovery-collaboration BioBriefs en 2026-03-31T14:32:04Z Antibody discovery collaboration https://biobriefs.com/company-strategy-allergy-and-rare BioBriefs en 2026-03-31T14:32:04Z Company strategy: allergy and rare disease trial shifts via deals https://biobriefs.com/clinical-trial-funding-for-cancer BioBriefs en 2026-03-31T14:32:04Z Clinical trial funding for cancer immunotherapy https://biobriefs.com/clinical-progress-in-immunology-and BioBriefs en 2026-03-31T14:32:04Z Clinical progress in immunology and pulmonary fibrosis https://biobriefs.com/regulatory-clinical-stage-pipeline-fast BioBriefs en 2026-03-31T14:32:04Z Regulatory: clinical-stage pipeline fast-track designation https://biobriefs.com/manufacturing-and-diagnostics-automation-approvals BioBriefs en 2026-03-31T14:32:04Z Manufacturing and diagnostics automation approvals https://biobriefs.com/startup-funding-and-first-clinical BioBriefs en 2026-03-31T14:32:04Z Startup funding and first clinical trial momentum https://biobriefs.com/ai-and-clinical-operations-investment BioBriefs en 2026-03-31T14:32:04Z AI and clinical operations investment via trial-site connectivity https://biobriefs.com/obesity-drug-development-and-ipo BioBriefs en 2026-03-31T10:31:55Z Obesity drug development and IPO momentum https://biobriefs.com/ai-drug-discovery-dealmaking-at BioBriefs en 2026-03-31T10:31:55Z AI drug discovery dealmaking at scale https://biobriefs.com/rare-disease-gene-therapy-reaches BioBriefs en 2026-03-31T10:31:55Z Rare disease gene therapy reaches FDA approval https://biobriefs.com/large-lung-disease-readouts-strengthen BioBriefs en 2026-03-31T10:31:55Z Large-lung disease readouts strengthen late-stage lung pipeline https://biobriefs.com/immuno-oncology-platform-advances-into BioBriefs en 2026-03-31T10:31:55Z Immuno-oncology platform advances into clinical positioning https://biobriefs.com/biotech-m-a-signals-continued BioBriefs en 2026-03-31T10:31:55Z Biotech M&A signals continued deal intensity https://biobriefs.com/clinical-trial-signal-in-rare BioBriefs en 2026-03-31T10:31:55Z Clinical trial signal in rare thyroid eye disease shifts investor view https://biobriefs.com/laboratory-automation-expands-with-fda BioBriefs en 2026-03-31T10:31:55Z Laboratory automation expands with FDA clearance https://biobriefs.com/clinical-diagnostics-automation-and-genomic BioBriefs en 2026-03-31T10:31:55Z Clinical diagnostics automation and genomic medicine infrastructure https://biobriefs.com/clinical-outsourcing-optimization-for-trial BioBriefs en 2026-03-31T10:31:55Z Clinical outsourcing optimization for trial execution https://biobriefs.com/obesity-glp-1-gip-pipeline BioBriefs en 2026-03-31T09:32:13Z Obesity GLP-1/GIP pipeline funding via IPO https://biobriefs.com/ai-drug-discovery-deal-expands BioBriefs en 2026-03-31T09:32:13Z AI drug discovery deal expands Lilly’s pipeline https://biobriefs.com/fda-accelerates-oncology-cell-therapy BioBriefs en 2026-03-31T09:32:13Z FDA accelerates oncology cell therapy pathway with Breakthrough designation https://biobriefs.com/company-acquisition-expands-immune-inflammation BioBriefs en 2026-03-31T09:32:13Z Company acquisition expands immune/inflammation and allergy assets https://biobriefs.com/uk-and-clinical-trial-operations BioBriefs en 2026-03-31T09:32:13Z UK and clinical trial operations: ICON teams with Advarra on integrated site network https://biobriefs.com/biopharma-labor-and-restructuring-pressure BioBriefs en 2026-03-31T09:32:13Z Biopharma labor and restructuring pressure: Takeda layoffs in Cambridge https://biobriefs.com/autoimmune-eye-disease-viridians-elegrobart BioBriefs en 2026-03-31T09:32:13Z Autoimmune eye disease: Viridian’s elegrobart Phase 3 wins but investors demand more https://biobriefs.com/idiopathic-pulmonary-fibrosis-uniteds-tyvaso BioBriefs en 2026-03-31T09:32:13Z Idiopathic pulmonary fibrosis: United’s Tyvaso hits endpoints in second Phase 3 trial https://biobriefs.com/cardiovascular-med-device-boston-scientific BioBriefs en 2026-03-31T09:32:13Z Cardiovascular med device: Boston Scientific Watchman FLX trial supports stroke reduction profile https://biobriefs.com/private-capital-blackstone-closes-record BioBriefs en 2026-03-31T09:32:13Z Private capital: Blackstone closes record $6.3B life sciences fund https://biobriefs.com/gene-therapy-regulatory-milestone BioBriefs en 2026-03-31T04:32:10Z Gene therapy regulatory milestone https://biobriefs.com/clinical-success-in-cardiology-and BioBriefs en 2026-03-31T04:32:10Z Clinical success in cardiology and device-therapy performance https://biobriefs.com/cro-and-clinical-operations-modernization BioBriefs en 2026-03-31T04:32:10Z CRO and clinical operations modernization https://biobriefs.com/ai-deal-expansion-in-drug BioBriefs en 2026-03-31T04:32:10Z AI deal expansion in drug discovery https://biobriefs.com/targeted-immunology-and-checkpoint-like BioBriefs en 2026-03-31T04:32:10Z Targeted immunology and checkpoint-like competition in dermatology https://biobriefs.com/obesity-pipeline-funding-and-ipo BioBriefs en 2026-03-31T04:32:10Z Obesity pipeline funding and IPO momentum https://biobriefs.com/workforce-reshaping-at-big-pharma BioBriefs en 2026-03-31T04:32:10Z Workforce reshaping at big pharma https://biobriefs.com/regulatory-speed-pathway-for-drugs BioBriefs en 2026-03-31T04:32:10Z Regulatory speed pathway for drugs and biologics https://biobriefs.com/genomics-platform-rollout-in-routine BioBriefs en 2026-03-31T04:32:10Z Genomics platform rollout in routine diagnostics https://biobriefs.com/clinical-evidence-for-next-generation BioBriefs en 2026-03-31T04:32:10Z Clinical evidence for next-generation gene editing https://biobriefs.com/regulatory-late-stage-pipeline-decisions BioBriefs en 2026-03-30T21:32:18Z Regulatory & late-stage pipeline decisions https://biobriefs.com/ai-enabled-discovery-and-big BioBriefs en 2026-03-30T21:32:18Z AI-enabled discovery and big pharma dealmaking https://biobriefs.com/trial-readouts-reshape-market-expectations BioBriefs en 2026-03-30T21:32:18Z Trial readouts reshape market expectations in oncology and rare disease https://biobriefs.com/m-a-and-partnership-momentum BioBriefs en 2026-03-30T21:32:18Z M&A and partnership momentum in immunotherapy and specialty pharma https://biobriefs.com/gene-therapy-milestone-rare-immune BioBriefs en 2026-03-30T21:32:18Z Gene therapy milestone: rare immune disorder approval https://biobriefs.com/clinical-operations-and-digital-infrastructure BioBriefs en 2026-03-30T21:32:18Z Clinical operations and digital infrastructure for trial execution https://biobriefs.com/investing-and-capital-formation-private BioBriefs en 2026-03-30T21:32:18Z Investing and capital formation: private fund scale https://biobriefs.com/delivery-assays-and-lab-automation BioBriefs en 2026-03-30T21:32:18Z Delivery, assays, and lab automation tooling https://biobriefs.com/obesity-pipeline-moves-to-public BioBriefs en 2026-03-30T21:32:18Z Obesity pipeline moves to public markets https://biobriefs.com/immunotherapy-research-engineered-immune-cell BioBriefs en 2026-03-30T21:32:18Z Immunotherapy research: engineered immune cell engagers https://biobriefs.com/ai-drug-discovery-partnerships BioBriefs en 2026-03-30T16:31:58Z AI drug discovery partnerships https://biobriefs.com/fda-approvals-and-oncology-pipeline BioBriefs en 2026-03-30T16:31:58Z FDA approvals and oncology pipeline updates https://biobriefs.com/workforce-and-restructuring-signals-from BioBriefs en 2026-03-30T16:31:58Z Workforce and restructuring signals from big pharma https://biobriefs.com/clinical-trial-operations-and-site BioBriefs en 2026-03-30T16:31:58Z Clinical trial operations and site infrastructure https://biobriefs.com/regulatory-and-diagnostics-automation-rollouts BioBriefs en 2026-03-30T16:31:58Z Regulatory and diagnostics automation rollouts https://biobriefs.com/obesity-drug-development-and-ipo BioBriefs en 2026-03-30T16:31:58Z Obesity drug development and IPO pipeline https://biobriefs.com/clinical-readouts-in-rare-and BioBriefs en 2026-03-30T16:31:58Z Clinical readouts in rare and autoimmune disease https://biobriefs.com/oncology-trial-strategy-managing-combinations BioBriefs en 2026-03-30T16:31:58Z Oncology trial strategy: managing combinations in solid tumors https://biobriefs.com/biotech-ipo-and-capital-markets BioBriefs en 2026-03-30T16:31:58Z Biotech IPO and capital markets activity in tools and diagnostics https://biobriefs.com/autoimmune-monetization-via-partnership-financing BioBriefs en 2026-03-30T16:31:58Z Autoimmune monetization via partnership financing https://biobriefs.com/regulatory-clearance-and-new-diagnostics BioBriefs en 2026-03-30T14:32:23Z Regulatory clearance and new diagnostics automation https://biobriefs.com/ai-drug-discovery-expansion-and BioBriefs en 2026-03-30T14:32:23Z AI drug discovery expansion and commercialization licensing https://biobriefs.com/phase-3-eczema-competitive-readout BioBriefs en 2026-03-30T14:32:23Z Phase 3 eczema competitive readout https://biobriefs.com/phase-3-thyroid-eye-disease BioBriefs en 2026-03-30T14:32:23Z Phase 3 thyroid eye disease rival to Tepezza https://biobriefs.com/gene-therapy-commercialization-milestone BioBriefs en 2026-03-30T14:32:23Z Gene therapy commercialization milestone https://biobriefs.com/fda-clinical-trial-readouts-and BioBriefs en 2026-03-30T14:32:23Z FDA/clinical trial readouts and pipeline reshaping in obesity https://biobriefs.com/corporate-science-event-tied-to BioBriefs en 2026-03-30T14:32:23Z Corporate science event tied to obesity/heart failure dosing strategy https://biobriefs.com/biologic-pipeline-progress-in-autoimmune BioBriefs en 2026-03-30T14:32:23Z Biologic pipeline progress in autoimmune lupus https://biobriefs.com/clinical-molecular-diagnostics-automation-workflow BioBriefs en 2026-03-30T14:32:23Z Clinical molecular diagnostics automation workflow partnerships https://biobriefs.com/microbiome-test-access-via-consumer BioBriefs en 2026-03-30T14:32:23Z Microbiome test access via consumer platform partnership https://biobriefs.com/regulatory-milestone BioBriefs en 2026-03-30T10:31:50Z Regulatory milestone https://biobriefs.com/phase-2-efficacy-signal-meets BioBriefs en 2026-03-30T10:31:50Z Phase 2 efficacy signal meets mechanistic endpoint https://biobriefs.com/obesity-drug-early-data-disappoints BioBriefs en 2026-03-30T10:31:50Z Obesity drug early data disappoints investors https://biobriefs.com/autoimmune-pipeline-momentum BioBriefs en 2026-03-30T10:31:50Z Autoimmune pipeline momentum https://biobriefs.com/clinical-trial-dose-strategy-tweak BioBriefs en 2026-03-30T10:31:50Z Clinical trial dose strategy tweak for late-stage heart failure program https://biobriefs.com/ai-for-clinical-operations-oversight BioBriefs en 2026-03-30T10:31:50Z AI for clinical operations oversight https://biobriefs.com/ai-drug-discovery-commercialization-deal BioBriefs en 2026-03-30T10:31:50Z AI drug discovery commercialization deal https://biobriefs.com/startup-backed-gene-therapy-expansion BioBriefs en 2026-03-30T10:31:50Z Startup-backed gene therapy expansion https://biobriefs.com/blood-cancer-research-collaboration BioBriefs en 2026-03-30T10:31:50Z Blood-cancer research collaboration https://biobriefs.com/cell-therapy-grade-protein-delivery BioBriefs en 2026-03-30T10:31:50Z Cell therapy-grade protein delivery concept (preclinical/innovation) https://biobriefs.com/ai-tooling-for-clinical-oversight BioBriefs en 2026-03-30T09:32:00Z AI tooling for clinical oversight https://biobriefs.com/wave-obesity-disappointment-and-stock BioBriefs en 2026-03-30T09:32:00Z Wave obesity disappointment and stock reaction https://biobriefs.com/insilico-and-lilly-commercialization-expansion BioBriefs en 2026-03-30T09:32:00Z Insilico and Lilly commercialization expansion https://biobriefs.com/merck-doses-shift-in-phase BioBriefs en 2026-03-30T09:32:00Z Merck doses shift in Phase 3 for Winrevair https://biobriefs.com/biogen-lupus-trial-momentum BioBriefs en 2026-03-30T09:32:00Z Biogen lupus trial momentum https://biobriefs.com/kresladi-gene-therapy-wins-fda BioBriefs en 2026-03-30T09:32:00Z Kresladi gene therapy wins FDA nod for ultra-rare immune disorder https://biobriefs.com/kailera-targets-ipo-to-fund BioBriefs en 2026-03-30T09:32:00Z Kailera targets IPO to fund obesity pipeline https://biobriefs.com/kailera-ipo-filing-and-obesity BioBriefs en 2026-03-30T09:32:00Z Kailera IPO filing and obesity pipeline funding push https://biobriefs.com/biontech-origin-story-and-early BioBriefs en 2026-03-30T09:32:00Z BioNTech origin story and early strategic partnerships https://biobriefs.com/everlywell-and-jona-expand-gut BioBriefs en 2026-03-30T09:32:00Z Everlywell and Jona expand gut microbiome testing access https://biobriefs.com/regulatory-milestone-for-rare-pediatric BioBriefs en 2026-03-30T04:31:59Z Regulatory milestone for rare pediatric immune disorder gene therapy https://biobriefs.com/big-pharma-adjusts-phase-3 BioBriefs en 2026-03-30T04:31:59Z Big pharma adjusts Phase 3 dosing strategy for heart-failure candidate https://biobriefs.com/phase-2-readout-for-biogens BioBriefs en 2026-03-30T04:31:59Z Phase 2 readout for Biogen’s anti-BDCA2 lupus immunotherapy https://biobriefs.com/obesity-rnai-disappointment-triggers-stock BioBriefs en 2026-03-30T04:31:59Z Obesity RNAi disappointment triggers stock rout for Wave https://biobriefs.com/ipo-plans-for-kaileras-phase BioBriefs en 2026-03-30T04:31:59Z IPO plans for Kailera’s Phase 3 obesity program backed by Hengrui https://biobriefs.com/ai-drug-developer-and-lilly BioBriefs en 2026-03-30T04:31:59Z AI drug developer and Lilly ink commercialization deal https://biobriefs.com/targeting-underserved-users-with-a BioBriefs en 2026-03-30T04:31:59Z Targeting underserved users with a gut microbiome test distribution partnership https://biobriefs.com/new-immuno-oncology-biomarker-for BioBriefs en 2026-03-30T04:31:59Z New immuno-oncology biomarker for gastric cancer response to neoadjuvant immunotherapy https://biobriefs.com/early-lung-cancer-screening-evidence BioBriefs en 2026-03-30T04:31:59Z Early lung cancer screening evidence for never-smokers from China https://biobriefs.com/academic-acceleration-nci-funding-for BioBriefs en 2026-03-30T04:31:59Z Academic acceleration: NCI funding for cancer-research workforce and health equity programs https://biobriefs.com/gene-therapy-approval-in-ultra BioBriefs en 2026-03-29T21:31:57Z Gene therapy approval in ultra-rare immune deficiency https://biobriefs.com/phase-2-lupus-readout-advances BioBriefs en 2026-03-29T21:31:57Z Phase 2 lupus readout advances immunology pipeline https://biobriefs.com/ai-enabled-targeting-of-immunotherapy BioBriefs en 2026-03-29T21:31:57Z AI-enabled targeting of immunotherapy support needs in survivorship care https://biobriefs.com/biomarker-test-to-guide-gastric BioBriefs en 2026-03-29T21:31:57Z Biomarker test to guide gastric cancer immunotherapy selection https://biobriefs.com/merck-win-signals-dose-strategy BioBriefs en 2026-03-29T21:31:57Z Merck win signals dose strategy shift in Phase 3 heart failure program https://biobriefs.com/cancer-drug-delivery-innovation-funded BioBriefs en 2026-03-29T21:31:57Z Cancer drug delivery innovation funded by UKRI https://biobriefs.com/targeted-protein-degradation-platform-expands BioBriefs en 2026-03-29T21:31:57Z Targeted protein degradation platform expands proteasome chimeras https://biobriefs.com/corporate-commercialization-deal-for-ai BioBriefs en 2026-03-29T21:31:57Z Corporate commercialization deal for AI-discovered oral therapeutics https://biobriefs.com/nci-funding-supports-health-equity BioBriefs en 2026-03-29T21:31:57Z NCI funding supports health-equity cancer research training https://biobriefs.com/home-based-cervical-cancer-screening BioBriefs en 2026-03-29T21:31:57Z Home-based cervical cancer screening option for disabled women https://biobriefs.com/phase-2-to-phase-3 BioBriefs en 2026-03-29T16:32:06Z Phase 2-to-Phase 3 dose strategy for Merck’s heart failure drug https://biobriefs.com/biogen-advances-lupus-immunology-with BioBriefs en 2026-03-29T16:32:06Z Biogen advances lupus immunology with Phase 2 win https://biobriefs.com/tanabes-rare-disease-strategy-hits BioBriefs en 2026-03-29T16:32:06Z Tanabe’s rare-disease strategy hits Phase 3 milestone https://biobriefs.com/otsuka-expands-neuropsychiatric-psychedelics-pipeline BioBriefs en 2026-03-29T16:32:06Z Otsuka expands neuropsychiatric psychedelics pipeline via Transcend acquisition https://biobriefs.com/ema-chmp-backs-multiple-drugs BioBriefs en 2026-03-29T16:32:06Z EMA CHMP backs multiple drugs, including label and route changes https://biobriefs.com/on-the-radar-drug-pricing BioBriefs en 2026-03-29T16:32:06Z On-the-radar drug pricing policy engagement with pharma https://biobriefs.com/mced-screening-funding-and-cms BioBriefs en 2026-03-29T16:32:06Z MCED screening funding and CMS coverage ambitions https://biobriefs.com/new-implantable-living-pharmacy-platform BioBriefs en 2026-03-29T16:32:06Z New implantable “living pharmacy” platform demonstrates multi-drug delivery https://biobriefs.com/gut-immune-mechanism-in-multiple BioBriefs en 2026-03-29T16:32:06Z Gut-immune mechanism in multiple sclerosis points to intestinal epithelial targets https://biobriefs.com/uterus-perfusion-device-keeps-donated BioBriefs en 2026-03-29T16:32:06Z Uterus perfusion device keeps donated tissue alive outside the body https://biobriefs.com/regulatory-approvals-gene-therapy BioBriefs en 2026-03-29T14:32:16Z Regulatory approvals—gene therapy https://biobriefs.com/regulatory-updates-europe-mpox-indication BioBriefs en 2026-03-29T14:32:16Z Regulatory updates—Europe mpox indication withdrawal https://biobriefs.com/immunology-pipeline-phase-2-lupus BioBriefs en 2026-03-29T14:32:16Z Immunology pipeline—Phase 2 lupus data https://biobriefs.com/drug-development-phase-3-rare BioBriefs en 2026-03-29T14:32:16Z Drug development—Phase 3 rare disease pain after light exposure https://biobriefs.com/oncology-ret-fusion-trial-readout BioBriefs en 2026-03-29T14:32:16Z Oncology—RET fusion trial readout (Phase I/II) https://biobriefs.com/biopharma-m-a-otsuka-acquires BioBriefs en 2026-03-29T14:32:16Z Biopharma M&A—Otsuka acquires Transcend Therapeutics https://biobriefs.com/immunology-biology-gut-epithelial-mhc BioBriefs en 2026-03-29T14:32:16Z Immunology biology—gut epithelial MHC II links to MS neuroinflammation https://biobriefs.com/drug-delivery-and-advanced-platforms BioBriefs en 2026-03-29T14:32:16Z Drug delivery and advanced platforms—implantable living pharmacy https://biobriefs.com/ai-and-healthcare-operations-clinical BioBriefs en 2026-03-29T14:32:16Z AI and healthcare operations—clinical trust and governance https://biobriefs.com/diagnostics-and-cancer-screening-real BioBriefs en 2026-03-29T14:32:16Z Diagnostics and cancer screening—real-world MCED expansion in Maryland https://biobriefs.com/regulatory-approvals-gene-therapy-for BioBriefs en 2026-03-29T10:32:05Z Regulatory approvals – gene therapy for ultra-rare immune disease https://biobriefs.com/phase-3-readouts-lupus-immunology BioBriefs en 2026-03-29T10:32:05Z Phase 3 readouts – lupus immunology pipeline signal https://biobriefs.com/phase-3-results-copd-antibody BioBriefs en 2026-03-29T10:32:05Z Phase 3 results – COPD antibody reaches late-stage success https://biobriefs.com/m-a-otsuka-acquires-transcend BioBriefs en 2026-03-29T10:32:05Z M&A – Otsuka acquires Transcend Therapeutics for neuropsychiatric pipeline https://biobriefs.com/m-a-novartis-expands-allergy BioBriefs en 2026-03-29T10:32:05Z M&A – Novartis expands allergy platform with Excellergy https://biobriefs.com/diagnostics-expanded-multi-cancer-early BioBriefs en 2026-03-29T10:32:05Z Diagnostics – expanded multi-cancer early detection testing in the U.S. https://biobriefs.com/clinical-pipeline-checkpoint-free-cancer BioBriefs en 2026-03-29T10:32:05Z Clinical pipeline – checkpoint-free cancer drug exposure update (RET fusion NSCLC) https://biobriefs.com/biotech-financing-vc-push-tied BioBriefs en 2026-03-29T10:32:05Z Biotech financing – VC push tied to clinical milestones https://biobriefs.com/regulatory-ip-crispr-cas9-patent BioBriefs en 2026-03-29T10:32:05Z Regulatory/IP – CRISPR/Cas9 patent priority reaffirmed https://biobriefs.com/biology-breakthrough-gut-epithelial-antigen BioBriefs en 2026-03-29T10:32:05Z Biology breakthrough – gut-epithelial antigen presentation links to MS neuroinflammation https://biobriefs.com/us-regulators-approve-first-in BioBriefs en 2026-03-29T09:31:53Z US regulators approve first-in-class weekly insulin https://biobriefs.com/ema-moves-on-oncology-and BioBriefs en 2026-03-29T09:31:53Z EMA moves on oncology and label expansions https://biobriefs.com/us-fda-grants-first-gene BioBriefs en 2026-03-29T09:31:53Z US FDA grants first gene therapy for ultra-rare immune deficiency https://biobriefs.com/biogen-advances-lupus-immunology-with BioBriefs en 2026-03-29T09:31:53Z Biogen advances lupus immunology with Phase 2 results https://biobriefs.com/new-phase-3-milestone-for BioBriefs en 2026-03-29T09:31:53Z New Phase 3 milestone for Bain-backed rare-disease oral therapy https://biobriefs.com/otsuka-buys-transcend-therapeutics-for BioBriefs en 2026-03-29T09:31:53Z Otsuka buys Transcend Therapeutics for PTSD drug development https://biobriefs.com/novartis-expands-allergy-immunology-with BioBriefs en 2026-03-29T09:31:53Z Novartis expands allergy immunology with Excellergy acquisition https://biobriefs.com/clinical-readout-support-for-pralsetinib BioBriefs en 2026-03-29T09:31:53Z Clinical readout support for pralsetinib in RET fusion NSCLC https://biobriefs.com/multi-drug-living-pharmacy-implant BioBriefs en 2026-03-29T09:31:53Z Multi-drug “living pharmacy” implant advances in animals https://biobriefs.com/personalized-cancer-detection-scales-in BioBriefs en 2026-03-29T09:31:53Z Personalized cancer detection scales in Maryland https://biobriefs.com/regulatory-approvals BioBriefs en 2026-03-29T04:32:00Z Regulatory approvals https://biobriefs.com/us-insulin-market-milestone BioBriefs en 2026-03-29T04:32:00Z US insulin market milestone https://biobriefs.com/biogen-lupus-trial-readout BioBriefs en 2026-03-29T04:32:00Z Biogen lupus trial readout https://biobriefs.com/european-regulatory-label-updates BioBriefs en 2026-03-29T04:32:00Z European regulatory label updates https://biobriefs.com/m-a-otsuka-buying-transcend BioBriefs en 2026-03-29T04:32:00Z M&A: Otsuka buying Transcend for PTSD and psychiatric pipeline https://biobriefs.com/m-a-novartis-expands-allergy BioBriefs en 2026-03-29T04:32:00Z M&A: Novartis expands allergy immunology with Excellergy https://biobriefs.com/clinical-oncology-pralaet-pralsetinib-arrow BioBriefs en 2026-03-29T04:32:00Z Clinical oncology: pralaet? pralsetinib ARROW final data https://biobriefs.com/late-stage-immunology-astrazeneca-copd BioBriefs en 2026-03-29T04:32:00Z Late-stage immunology: AstraZeneca COPD antibody surprise https://biobriefs.com/rare-disease-cell-gene-therapy BioBriefs en 2026-03-29T04:32:00Z Rare disease cell/gene therapy pipeline: Wave obesity shock and trial-linked context https://biobriefs.com/diagnostics-and-coverage-push-20 BioBriefs en 2026-03-29T04:32:00Z Diagnostics and coverage push: 20/20 BioLabs OneTest for MCED https://biobriefs.com/regulatory-approvals-in-rare-disease BioBriefs en 2026-03-28T21:32:05Z Regulatory approvals in rare disease gene therapy https://biobriefs.com/eu-regulator-backs-new-cancer BioBriefs en 2026-03-28T21:32:05Z EU regulator backs new cancer and label changes https://biobriefs.com/big-pharma-m-a-reshapes BioBriefs en 2026-03-28T21:32:05Z Big pharma M&A reshapes next-gen immunology https://biobriefs.com/psychiatry-m-a-otsuka-moves BioBriefs en 2026-03-28T21:32:05Z Psychiatry M&A: Otsuka moves into neuroplasticity drug development https://biobriefs.com/clinical-pipeline-setback-turns-into BioBriefs en 2026-03-28T21:32:05Z Clinical pipeline setback turns into market signal for Wave obesity program https://biobriefs.com/late-stage-success-expands-copd BioBriefs en 2026-03-28T21:32:05Z Late-stage success expands COPD biologics competition https://biobriefs.com/diagnostics-reimbursement-push-for-multi BioBriefs en 2026-03-28T21:32:05Z Diagnostics reimbursement push for multi-cancer early detection https://biobriefs.com/cancer-pipeline-risk-and-immunology BioBriefs en 2026-03-28T21:32:05Z Cancer pipeline risk and immunology platform investment via VC funding https://biobriefs.com/precision-immunology-discovery-gut-immune BioBriefs en 2026-03-28T21:32:05Z Precision immunology discovery: gut-immune mechanism in MS https://biobriefs.com/patent-landscape-in-genome-editing BioBriefs en 2026-03-28T21:32:05Z Patent landscape in genome editing: Broad CRISPR/Cas9 priority reaffirmed https://biobriefs.com/regulatory-approvals-gene-therapy-for BioBriefs en 2026-03-28T16:31:59Z Regulatory approvals – gene therapy for ultra-rare immune deficiency https://biobriefs.com/regulatory-ema-moves-to-withdraw BioBriefs en 2026-03-28T16:31:59Z Regulatory – EMA moves to withdraw mpox label https://biobriefs.com/drug-approvals-novo-nordisks-first BioBriefs en 2026-03-28T16:31:59Z Drug approvals – Novo Nordisk’s first once-weekly basal insulin in the US https://biobriefs.com/m-a-otsuka-to-acquire BioBriefs en 2026-03-28T16:31:59Z M&A – Otsuka to acquire Transcend for a PTSD-focused neuroplasticity program https://biobriefs.com/m-a-novartis-pays-up BioBriefs en 2026-03-28T16:31:59Z M&A – Novartis pays up to $2B for allergy biotech Excellergy https://biobriefs.com/clinical-and-pipeline-signal-astrazenecas BioBriefs en 2026-03-28T16:31:59Z Clinical and pipeline signal – AstraZeneca’s tozorakimab posts Phase 3 COPD wins https://biobriefs.com/oncology-wave-life-sciences-sinks BioBriefs en 2026-03-28T16:31:59Z Oncology – Wave Life Sciences sinks on obesity data linked to INHBE targeting https://biobriefs.com/precision-medicine-ucla-atlas-biobank BioBriefs en 2026-03-28T16:31:59Z Precision medicine – UCLA ATLAS biobank ties genetics to ancestry-specific disease risk and semaglutide response https://biobriefs.com/biomedical-innovation-implantable-living-pharmacy BioBriefs en 2026-03-28T16:31:59Z Biomedical innovation – implantable “living pharmacy” devices produce multiple drugs in vivo https://biobriefs.com/diagnostics-maryland-awards-520k-to BioBriefs en 2026-03-28T16:31:59Z Diagnostics – Maryland awards $520K to expand multi-cancer early detection screening with 20/20 BioLabs assay https://biobriefs.com/big-pharma-acquisitions-reshape-near BioBriefs en 2026-03-28T14:32:09Z Big Pharma acquisitions reshape near-term pipeline bets https://biobriefs.com/fda-approvals-rare-disease-gene BioBriefs en 2026-03-28T14:32:09Z FDA approvals—rare disease gene therapy and next-gen diabetes care https://biobriefs.com/ema-chmp-backs-new-oncology BioBriefs en 2026-03-28T14:32:09Z EMA CHMP backs new oncology and label expansions https://biobriefs.com/car-t-and-advanced-cell BioBriefs en 2026-03-28T14:32:09Z CAR-T and advanced cell therapy—risk, safety, and platform direction https://biobriefs.com/oncology-diagnostics-molecular-testing-improves BioBriefs en 2026-03-28T14:32:09Z Oncology diagnostics—molecular testing improves bile duct cancer detection https://biobriefs.com/novel-therapeutics-biology-gut-immune BioBriefs en 2026-03-28T14:32:09Z Novel therapeutics biology—gut-immune mechanisms in multiple sclerosis https://biobriefs.com/implantable-drug-delivery-multi-drug BioBriefs en 2026-03-28T14:32:09Z Implantable drug delivery—multi-drug “living pharmacy” platform advances in rodents https://biobriefs.com/u-s-real-world-screening BioBriefs en 2026-03-28T14:32:09Z U.S. real-world screening expansion—multi-cancer early detection for firefighters in Maryland https://biobriefs.com/robotic-and-ai-assisted-medicine BioBriefs en 2026-03-28T14:32:09Z Robotic and AI-assisted medicine—stroke telesurgery infrastructure https://biobriefs.com/biotech-r-d-finance-pinnacles BioBriefs en 2026-03-28T14:32:09Z Biotech R&D finance—Pinnacle’s funding and Wave’s obesity setback https://biobriefs.com/fda-approvals-and-label-moves BioBriefs en 2026-03-28T10:31:57Z FDA approvals and label moves https://biobriefs.com/eu-regulatory-actions BioBriefs en 2026-03-28T10:31:57Z EU regulatory actions https://biobriefs.com/m-a-and-major-dealmaking BioBriefs en 2026-03-28T10:31:57Z M&A and major dealmaking https://biobriefs.com/oncology-deals-and-pipeline-consolidation BioBriefs en 2026-03-28T10:31:57Z Oncology deals and pipeline consolidation https://biobriefs.com/immunology-and-allergy-m-a BioBriefs en 2026-03-28T10:31:57Z Immunology and allergy M&A https://biobriefs.com/clinical-data-catalysts-in-respiratory BioBriefs en 2026-03-28T10:31:57Z Clinical data catalysts in respiratory disease https://biobriefs.com/rare-disease-and-immune-therapy BioBriefs en 2026-03-28T10:31:57Z Rare disease and immune therapy risk signals from regulators or science https://biobriefs.com/wave-obesity-program-setback-drives BioBriefs en 2026-03-28T10:31:57Z Wave obesity program setback drives market repricing https://biobriefs.com/drug-delivery-and-implantable-living BioBriefs en 2026-03-28T10:31:57Z Drug delivery and implantable “living pharmacy” platforms https://biobriefs.com/biomarkers-and-diagnostics-for-cancer BioBriefs en 2026-03-28T10:31:57Z Biomarkers and diagnostics for cancer detection https://biobriefs.com/alzheimers-drug-candidate BioBriefs en 2026-03-28T09:32:05Z Alzheimer’s drug candidate https://biobriefs.com/regulatory-approvals-rare-disease-gene BioBriefs en 2026-03-28T09:32:05Z Regulatory approvals: rare disease gene therapy https://biobriefs.com/regulatory-approvals-ema-label-decisions BioBriefs en 2026-03-28T09:32:05Z Regulatory approvals: EMA label decisions https://biobriefs.com/dealmaking-otsuka-transcend-psychiatric-acquisition BioBriefs en 2026-03-28T09:32:05Z Dealmaking: Otsuka-Transcend psychiatric acquisition https://biobriefs.com/dealmaking-novartis-allergy-expansion BioBriefs en 2026-03-28T09:32:05Z Dealmaking: Novartis allergy expansion https://biobriefs.com/m-a-merck-pushes-oncology BioBriefs en 2026-03-28T09:32:05Z M&A: Merck pushes oncology with Terns bid https://biobriefs.com/clinical-progress-copd-antibody-phase BioBriefs en 2026-03-28T09:32:05Z Clinical progress: COPD antibody Phase 3 win https://biobriefs.com/clinical-development-ocular-gene-antibody BioBriefs en 2026-03-28T09:32:05Z Clinical development: ocular gene/antibody progress in diabetic retinopathy https://biobriefs.com/clinical-trial-data-gut-immune BioBriefs en 2026-03-28T09:32:05Z Clinical trial data: gut-immune mechanism in multiple sclerosis https://biobriefs.com/funding-pinnacle-raises-for-oral BioBriefs en 2026-03-28T09:32:05Z Funding: Pinnacle raises for oral peptide pipeline https://biobriefs.com/gene-therapy-approval-for-ultra BioBriefs en 2026-03-28T04:32:02Z Gene therapy approval for ultra-rare immune disease https://biobriefs.com/us-oncology-pipeline-readouts-and BioBriefs en 2026-03-28T04:32:02Z US oncology pipeline readouts and next regulatory steps https://biobriefs.com/immunology-drug-deal-with-psychiatry BioBriefs en 2026-03-28T04:32:02Z Immunology drug deal with psychiatry crossover https://biobriefs.com/u-s-regulator-action-new BioBriefs en 2026-03-28T04:32:02Z U.S. regulator action: new once-weekly insulin approval https://biobriefs.com/mced-screening-expansion-backed-by BioBriefs en 2026-03-28T04:32:02Z MCED screening expansion backed by state funding https://biobriefs.com/european-regulator-guidance-for-multiple BioBriefs en 2026-03-28T04:32:02Z European regulator guidance for multiple myeloma label expansion https://biobriefs.com/oncology-acquisition-and-portfolio-reshaping BioBriefs en 2026-03-28T04:32:02Z Oncology acquisition and portfolio reshaping https://biobriefs.com/immunology-deal-in-allergy-with BioBriefs en 2026-03-28T04:32:02Z Immunology deal in allergy with potential Xolair successor https://biobriefs.com/crispr-patent-dispute-resurfaces-after BioBriefs en 2026-03-28T04:32:02Z CRISPR patent dispute resurfaces after USPTO reaffirmation https://biobriefs.com/cns-immunology-mechanism-gut-epithelial BioBriefs en 2026-03-28T04:32:02Z CNS immunology mechanism: gut epithelial MHC II drives MS-like disease in mice https://biobriefs.com/regulatory-approval-gene-therapy-for BioBriefs en 2026-03-27T21:32:00Z Regulatory approval: gene therapy for ultra-rare immune disorder https://biobriefs.com/regulatory-approval-once-weekly-basal BioBriefs en 2026-03-27T21:32:00Z Regulatory approval: once-weekly basal insulin https://biobriefs.com/european-regulator-label-updates-and BioBriefs en 2026-03-27T21:32:00Z European regulator: label updates and new subcutaneous myeloma form https://biobriefs.com/clinical-readouts-astrazeneca-copd-antibody BioBriefs en 2026-03-27T21:32:00Z Clinical readouts: AstraZeneca COPD antibody posts Phase 3 success https://biobriefs.com/acquisition-m-a-otsuka-buys BioBriefs en 2026-03-27T21:32:00Z Acquisition/M&A: Otsuka buys Transcend Therapeutics for PTSD-focused TSND-201 https://biobriefs.com/dealmaking-novartis-buys-allergy-startup BioBriefs en 2026-03-27T21:32:00Z Dealmaking: Novartis buys allergy startup Excellergy for up to $2B https://biobriefs.com/clinical-trial-evidence-mced-screening BioBriefs en 2026-03-27T21:32:00Z Clinical trial evidence: MCED screening expands via Maryland grant https://biobriefs.com/regulatory-industrial-capacity-ucb-selects BioBriefs en 2026-03-27T21:32:00Z Regulatory/industrial capacity: UCB selects Georgia for $2B biologics factory https://biobriefs.com/drug-discovery-platform-implantable-living BioBriefs en 2026-03-27T21:32:00Z Drug discovery platform: implantable “living pharmacy” makes multiple biologics https://biobriefs.com/diagnostics-approval-validation-ce-ivdr BioBriefs en 2026-03-27T21:32:00Z Diagnostics approval/validation: CE-IVDR mark for B-cell clonal expansion test https://biobriefs.com/ptsd-and-psychiatric-innovation-via BioBriefs en 2026-03-27T16:32:16Z PTSD and psychiatric innovation via neuroplasticity https://biobriefs.com/regulatory-approval-for-rare-disease BioBriefs en 2026-03-27T16:32:16Z Regulatory approval for rare-disease gene therapy https://biobriefs.com/immunology-dealmaking-to-refresh-xolair BioBriefs en 2026-03-27T16:32:16Z Immunology dealmaking to refresh Xolair-era allergy pipeline https://biobriefs.com/fda-approval-expands-brain-penetrating BioBriefs en 2026-03-27T16:32:16Z FDA approval expands brain-penetrating protein therapy platform https://biobriefs.com/crispr-patent-fight-heads-back BioBriefs en 2026-03-27T16:32:16Z CRISPR patent fight heads back into focus after USPTO reaffirmation https://biobriefs.com/oncology-device-class-diagnostics-molecular BioBriefs en 2026-03-27T16:32:16Z Oncology device-class diagnostics: molecular test improves bile duct cancer detection https://biobriefs.com/strategic-pipeline-reshaping-at-innate BioBriefs en 2026-03-27T16:32:16Z Strategic pipeline reshaping at Innate Pharma https://biobriefs.com/gene-therapy-company-pushes-from BioBriefs en 2026-03-27T16:32:16Z Gene therapy company pushes from preclinical into gene-editing platform validation https://biobriefs.com/funding-oral-peptide-platform-attracts BioBriefs en 2026-03-27T16:32:16Z Funding: oral peptide platform attracts fresh capital https://biobriefs.com/biotech-m-a-momentum-in BioBriefs en 2026-03-27T16:32:16Z Biotech M&A momentum in oncology: Merck buys Terns for $6.7B https://biobriefs.com/patent-fight-over-crispr-cas9 BioBriefs en 2026-03-27T14:32:00Z Patent fight over CRISPR/Cas9 inventorship https://biobriefs.com/fda-approval-of-first-ever BioBriefs en 2026-03-27T14:32:00Z FDA approval of first-ever longer-acting once-weekly insulin https://biobriefs.com/new-fda-clearance-for-rare BioBriefs en 2026-03-27T14:32:00Z New FDA clearance for rare immune disorder gene therapy https://biobriefs.com/big-pharma-m-a-to BioBriefs en 2026-03-27T14:32:00Z Big pharma M&A to build immunology and allergy pipeline https://biobriefs.com/big-pharma-acquisition-to-diversify BioBriefs en 2026-03-27T14:32:00Z Big pharma acquisition to diversify oncology hematology exposure https://biobriefs.com/fda-accelerated-approval-for-hunter BioBriefs en 2026-03-27T14:32:00Z FDA accelerated approval for Hunter syndrome drug https://biobriefs.com/clinical-efficacy-and-safety-update BioBriefs en 2026-03-27T14:32:00Z Clinical efficacy and safety update for AstraZeneca’s COPD antibody https://biobriefs.com/oncology-diagnostics-fda-review-submission BioBriefs en 2026-03-27T14:32:00Z Oncology diagnostics: FDA review submission for kidney transplant rejection test https://biobriefs.com/direct-to-cell-delivery-innovation BioBriefs en 2026-03-27T14:32:00Z Direct-to-cell delivery innovation and regulatory pathway progress https://biobriefs.com/regulatory-path-for-molecular-oncology BioBriefs en 2026-03-27T14:32:00Z Regulatory path for molecular oncology testing in Europe https://biobriefs.com/merck-terns-m-a-signals BioBriefs en 2026-03-27T10:31:58Z Merck-Terns M&A signals next-gen oncology push https://biobriefs.com/fda-clears-denalis-brain-penetrating BioBriefs en 2026-03-27T10:31:58Z FDA clears Denali’s brain-penetrating Hunter syndrome therapy https://biobriefs.com/denali-and-corcept-add-early BioBriefs en 2026-03-27T10:31:58Z Denali and Corcept add early FDA wins for oncology and rare disease https://biobriefs.com/kodiaks-zenkuda-delivers-phase-3 BioBriefs en 2026-03-27T10:31:58Z Kodiak’s Zenkuda delivers Phase 3 win and ramps accelerated BLA plan https://biobriefs.com/mazes-apol1-inhibitor-posts-phase BioBriefs en 2026-03-27T10:31:58Z Maze’s APOL1 inhibitor posts Phase 2 kidney results amid investor pullback https://biobriefs.com/ucb-commits-2b-for-us BioBriefs en 2026-03-27T10:31:58Z UCB commits $2B for US biologics manufacturing hub in Georgia https://biobriefs.com/novartis-buys-excellergy-for-next BioBriefs en 2026-03-27T10:31:58Z Novartis buys Excellergy for next-gen anti-IgE allergy therapy https://biobriefs.com/fda-moves-on-brain-shuttle BioBriefs en 2026-03-27T10:31:58Z FDA moves on brain-shuttle rare disease and diagnostics, plus EU device clearance https://biobriefs.com/pinnacle-medicines-closes-89m-series BioBriefs en 2026-03-27T10:31:58Z Pinnacle Medicines closes $89M Series B for oral peptide pipeline https://biobriefs.com/neion-bio-emerges-from-stealth BioBriefs en 2026-03-27T10:31:58Z Neion Bio emerges from stealth with egg-based biologics co-development deal https://biobriefs.com/regulatory-approvals-rare-disease BioBriefs en 2026-03-27T09:31:54Z Regulatory approvals – rare disease https://biobriefs.com/gene-therapy-fda-rare-immune BioBriefs en 2026-03-27T09:31:54Z Gene therapy – FDA rare immune approval https://biobriefs.com/oncology-m-a-mercks-6 BioBriefs en 2026-03-27T09:31:54Z Oncology M&A – Merck’s $6.7B Terns bid https://biobriefs.com/ocular-drug-development-kodiaks-phase BioBriefs en 2026-03-27T09:31:54Z Ocular drug development – Kodiak’s Phase 3 progress https://biobriefs.com/obesity-pipeline-waves-disappointing-early BioBriefs en 2026-03-27T09:31:54Z Obesity pipeline – Wave’s disappointing early efficacy https://biobriefs.com/diabetes-drug-competition-triple-incretin BioBriefs en 2026-03-27T09:31:53Z Diabetes drug competition – triple incretin outperformance https://biobriefs.com/womens-health-oncology-fda-ovarian BioBriefs en 2026-03-27T09:31:53Z Women’s health oncology – FDA ovarian cancer approval https://biobriefs.com/drug-platform-deal-novartis-buys BioBriefs en 2026-03-27T09:31:53Z Drug platform deal – Novartis buys allergy biotech https://biobriefs.com/biotech-funding-pinnacles-89m-series BioBriefs en 2026-03-27T09:31:53Z Biotech funding – Pinnacle’s $89M Series B https://biobriefs.com/diagnostics-and-regulation-ce-ivdr BioBriefs en 2026-03-27T09:31:53Z Diagnostics and regulation – CE-IVDR test certification https://biobriefs.com/regulatory-approvals-rare-disease-hunter BioBriefs en 2026-03-27T04:32:10Z Regulatory approvals – rare disease (Hunter syndrome) https://biobriefs.com/regulatory-approvals-ovarian-cancer-corcept BioBriefs en 2026-03-27T04:32:10Z Regulatory approvals – ovarian cancer (Corcept) https://biobriefs.com/m-a-merck-buys-terns BioBriefs en 2026-03-27T04:32:10Z M&A – Merck buys Terns for CML asset https://biobriefs.com/late-stage-clinical-development-diabetic BioBriefs en 2026-03-27T04:32:10Z Late-stage/clinical development – diabetic retinopathy (Kodiak) https://biobriefs.com/clinical-development-oral-peptide-pipeline BioBriefs en 2026-03-27T04:32:10Z Clinical development – oral peptide pipeline financing (Pinnacle) https://biobriefs.com/manufacturing-expansion-ucbs-new-u BioBriefs en 2026-03-27T04:32:10Z Manufacturing expansion – UCB’s new U.S. biologics plant https://biobriefs.com/fda-approval-gene-therapy-lad BioBriefs en 2026-03-27T04:32:10Z FDA approval – gene therapy (LAD-1) https://biobriefs.com/company-funding-intracellular-pan-cancer BioBriefs en 2026-03-27T04:32:10Z Company funding – intracellular pan-cancer delivery (Idel) https://biobriefs.com/diagnostics-regulation-ce-ivdr-for BioBriefs en 2026-03-27T04:32:10Z Diagnostics regulation – CE-IVDR for B-cell clonality testing (Invivoscribe) https://biobriefs.com/clinical-development-setbacks-wave-obesity BioBriefs en 2026-03-27T04:32:10Z Clinical development setbacks – Wave obesity trial disappoints https://biobriefs.com/fda-fast-tracks-rare-disease BioBriefs en 2026-03-26T21:32:16Z FDA fast-tracks rare disease therapies https://biobriefs.com/mercks-6-7b-terns-acquisition BioBriefs en 2026-03-26T21:32:16Z Merck’s $6.7B Terns acquisition reshapes CML strategy https://biobriefs.com/ocular-biotech-kodiaks-glow2-sets BioBriefs en 2026-03-26T21:32:16Z Ocular biotech Kodiak’s Glow2 sets up accelerated BLA https://biobriefs.com/wave-life-sciences-stumbles-after BioBriefs en 2026-03-26T21:32:16Z Wave Life Sciences stumbles after obesity Phase 1 readout https://biobriefs.com/apol1-kidney-disease-bet-faces BioBriefs en 2026-03-26T21:32:16Z APOL1 kidney disease bet faces choppy reaction https://biobriefs.com/novo-united-biotechnology-triple-incretin BioBriefs en 2026-03-26T21:32:16Z Novo–United Biotechnology triple incretin raises competitive heat in China https://biobriefs.com/pinnacle-medicines-raises-89m-for BioBriefs en 2026-03-26T21:32:16Z Pinnacle Medicines raises $89M for oral peptide pipeline https://biobriefs.com/korea-dealmaking-points-to-active BioBriefs en 2026-03-26T21:32:16Z Korea dealmaking points to active BD in platforms and oncology https://biobriefs.com/regulatory-pushback-novartis-hit-with BioBriefs en 2026-03-26T21:32:16Z Regulatory pushback: Novartis hit with data-sharing class action https://biobriefs.com/cerebro-immune-linkage-found-in BioBriefs en 2026-03-26T21:32:16Z Cerebro-immune linkage found in anti-NMDA receptor encephalitis https://biobriefs.com/rare-disease-approvals-and-fda BioBriefs en 2026-03-26T16:32:03Z Rare disease approvals and FDA stance https://biobriefs.com/big-pharma-m-a-to BioBriefs en 2026-03-26T16:32:03Z Big Pharma M&A to replenish oncology pipeline https://biobriefs.com/precision-oncology-regulatory-reach-in BioBriefs en 2026-03-26T16:32:03Z Precision oncology regulatory reach in Japan https://biobriefs.com/precision-medicine-assays-and-eu BioBriefs en 2026-03-26T16:32:03Z Precision medicine assays and EU diagnostics standards https://biobriefs.com/clinical-trial-updates-in-kidney BioBriefs en 2026-03-26T16:32:03Z Clinical trial updates in kidney disease drug development https://biobriefs.com/cdx-and-data-driven-oncology BioBriefs en 2026-03-26T16:32:03Z CDx- and data-driven oncology AI partnerships https://biobriefs.com/oral-peptide-platforms-add-new BioBriefs en 2026-03-26T16:32:03Z Oral peptide platforms add new institutional firepower https://biobriefs.com/regulatory-and-trial-strategy-disruption BioBriefs en 2026-03-26T16:32:03Z Regulatory and trial strategy disruption at Innate Pharma https://biobriefs.com/beam-data-update-for-gene BioBriefs en 2026-03-26T16:32:03Z Beam data update for gene editing in AATD https://biobriefs.com/u-s-manufacturing-scale-up BioBriefs en 2026-03-26T16:32:03Z U.S. manufacturing scale-up for complex biologics https://biobriefs.com/mercks-cml-dealmaking-terns-acquisition BioBriefs en 2026-03-26T14:32:05Z Merck’s CML dealmaking – Terns acquisition https://biobriefs.com/fda-approvals-early-wins-in BioBriefs en 2026-03-26T14:32:05Z FDA approvals – early wins in ovarian cancer and Hunter syndrome https://biobriefs.com/rare-disease-regulator-action-denali BioBriefs en 2026-03-26T14:32:05Z Rare disease regulator action – Denali accelerated approval and prior rejection context https://biobriefs.com/kidney-disease-pipeline-maze-phase BioBriefs en 2026-03-26T14:32:05Z Kidney disease pipeline – Maze Phase 2 AMKD readout https://biobriefs.com/cell-therapy-pipeline-decision-innate BioBriefs en 2026-03-26T14:32:05Z Cell therapy pipeline decision – Innate ends NK cell engager study https://biobriefs.com/gene-editing-advance-beam-base BioBriefs en 2026-03-26T14:32:05Z Gene editing advance – Beam base editing update for AATD https://biobriefs.com/immunotherapy-data-tempus-and-daiichi BioBriefs en 2026-03-26T14:32:05Z Immunotherapy+data – Tempus and Daiichi Sankyo build AI models for ADC patient selection https://biobriefs.com/diagnostics-manufacturing-systems-ce-mark BioBriefs en 2026-03-26T14:32:05Z Diagnostics + manufacturing systems – CE mark for Countable Labs single-molecule PCR https://biobriefs.com/cdmo-site-expansion-rentschlers-milford BioBriefs en 2026-03-26T14:32:05Z CDMO + site expansion – Rentschler’s Milford manufacturing growth https://biobriefs.com/startup-financing-excalipoint-seed-for BioBriefs en 2026-03-26T14:32:05Z Startup financing – Excalipoint seed for solid-tumor T-cell engagers https://biobriefs.com/m-a BioBriefs en 2026-03-26T10:32:02Z M&A https://biobriefs.com/m-a-immunology-bispecifics BioBriefs en 2026-03-26T10:32:02Z M&A & Immunology Bispecifics https://biobriefs.com/regulatory-approvals-oncology BioBriefs en 2026-03-26T10:32:02Z Regulatory Approvals – Oncology https://biobriefs.com/regulatory-approvals-rare-disease BioBriefs en 2026-03-26T10:32:02Z Regulatory Approvals – Rare Disease https://biobriefs.com/clinical-development-nk-cell-engagement BioBriefs en 2026-03-26T10:32:02Z Clinical Development – NK Cell Engagement Shutdown https://biobriefs.com/clinical-development-gene-editing-in BioBriefs en 2026-03-26T10:32:02Z Clinical Development – Gene Editing in Rare Liver/Lung Disease https://biobriefs.com/clinical-development-kidney-disease-proteinuria BioBriefs en 2026-03-26T10:32:02Z Clinical Development – Kidney Disease Proteinuria Reduction https://biobriefs.com/diagnostics-ce-mark-for-single BioBriefs en 2026-03-26T10:32:02Z Diagnostics – CE Mark for Single-Molecule PCR https://biobriefs.com/ai-for-drug-development-clinical BioBriefs en 2026-03-26T10:32:02Z AI for Drug Development – Clinical Trial Automation https://biobriefs.com/biomanufacturing-analytical-methods-targeted-hcp BioBriefs en 2026-03-26T10:32:02Z Biomanufacturing & Analytical Methods – Targeted HCP Proteomics https://biobriefs.com/m-a-merck-terns-deal BioBriefs en 2026-03-26T09:32:05Z M&A: Merck-Terns deal reshapes targeted oncology pipeline https://biobriefs.com/regulatory-fda-greenlights-denalis-avlayah BioBriefs en 2026-03-26T09:32:05Z Regulatory: FDA greenlights Denali’s Avlayah for Hunter syndrome https://biobriefs.com/regulatory-corcept-wins-early-fda BioBriefs en 2026-03-26T09:32:05Z Regulatory: Corcept wins early FDA approval for Lifyorli in ovarian cancer https://biobriefs.com/clinical-update-beam-reports-positive BioBriefs en 2026-03-26T09:32:05Z Clinical update: Beam reports positive base-editing data in AATD https://biobriefs.com/clinical-update-maze-reports-proteinuria BioBriefs en 2026-03-26T09:32:05Z Clinical update: Maze reports proteinuria reduction in Phase 2 AMKD program https://biobriefs.com/deals-gilead-buys-ouro-medicines BioBriefs en 2026-03-26T09:32:05Z Deals: Gilead buys Ouro Medicines, expands autoimmune bispecific platform https://biobriefs.com/diagnostics-quality-countable-labs-secures BioBriefs en 2026-03-26T09:32:05Z Diagnostics/Quality: Countable Labs secures CE mark for single-molecule PCR https://biobriefs.com/proteomics-manufacturing-analytics-scout-triggered BioBriefs en 2026-03-26T09:32:05Z Proteomics & manufacturing analytics: scout-triggered MRM improves HCP control https://biobriefs.com/ai-platform-in-clinical-trials BioBriefs en 2026-03-26T09:32:05Z AI platform in clinical trials: PhaseV launches AI Conductor with $54M backing https://biobriefs.com/funding-proteomedge-secures-seed-round BioBriefs en 2026-03-26T09:32:05Z Funding: ProteomEdge secures seed round for absolute quantitation proteomics https://biobriefs.com/big-pharma-m-a-to BioBriefs en 2026-03-26T04:31:55Z Big Pharma M&A to refill oncology pipeline https://biobriefs.com/fda-approvals-advance-rare-disease BioBriefs en 2026-03-26T04:31:55Z FDA approvals advance rare disease and cancer settings https://biobriefs.com/kidney-disease-trial-readout-sharpens BioBriefs en 2026-03-26T04:31:55Z Kidney disease trial readout sharpens competitive race for APOL1 inhibition https://biobriefs.com/gene-editing-update-renews-push BioBriefs en 2026-03-26T04:31:55Z Gene editing update renews push for accelerated approvals in AATD https://biobriefs.com/clinical-stage-ai-software-launches BioBriefs en 2026-03-26T04:31:55Z Clinical-stage AI software launches to automate trial operations https://biobriefs.com/pathology-real-world-data-partnerships BioBriefs en 2026-03-26T04:31:55Z Pathology + real-world data partnerships expand translational decision support https://biobriefs.com/new-spatial-biology-atlas-to BioBriefs en 2026-03-26T04:31:55Z New spatial biology atlas to power disease digital twins https://biobriefs.com/diagnostics-and-bioprocess-tools-tighten BioBriefs en 2026-03-26T04:31:55Z Diagnostics and bioprocess tools tighten data reliability https://biobriefs.com/fda-signals-tighter-enforcement-on BioBriefs en 2026-03-26T04:31:55Z FDA signals tighter enforcement on overstated claims for cancer drug https://biobriefs.com/company-level-investment-for-liquid BioBriefs en 2026-03-26T04:31:55Z Company-level investment for liquid biopsy banking and downstream molecular testing https://biobriefs.com/regulatory-approvals-in-oncology-and BioBriefs en 2026-03-25T21:32:12Z Regulatory approvals in oncology and rare disease https://biobriefs.com/competitive-kidney-disease-pipeline-and BioBriefs en 2026-03-25T21:32:12Z Competitive kidney disease pipeline and Vertex-style targeting https://biobriefs.com/big-pharma-m-a-reshapes BioBriefs en 2026-03-25T21:32:12Z Big pharma M&A reshapes oncology pipeline priorities https://biobriefs.com/gene-editing-advances-move-from BioBriefs en 2026-03-25T21:32:12Z Gene editing advances move from concept to clinical momentum https://biobriefs.com/rare-disease-manufacturing-access-in BioBriefs en 2026-03-25T21:32:12Z Rare disease manufacturing access in Europe https://biobriefs.com/ai-enabled-clinical-operations-and BioBriefs en 2026-03-25T21:32:12Z AI-enabled clinical operations and compliance tooling https://biobriefs.com/somatic-genomics-partnerships-deepen-in BioBriefs en 2026-03-25T21:32:12Z Somatic genomics partnerships deepen in inflammatory bowel disease https://biobriefs.com/autoimmune-t-cell-engager-m BioBriefs en 2026-03-25T21:32:12Z Autoimmune T-cell engager M&A expands Gilead’s inflammation cell-therapy portfolio https://biobriefs.com/translational-ocular-gene-therapy-advances BioBriefs en 2026-03-25T21:32:12Z Translational ocular gene therapy advances to Phase 3 with investor sensitivity https://biobriefs.com/oncology-imaging-and-ai-pathology BioBriefs en 2026-03-25T21:32:12Z Oncology imaging and AI pathology workflows expand in clinical research https://biobriefs.com/regulatory-approvals-and-evidence-standards BioBriefs en 2026-03-25T16:31:57Z Regulatory approvals and evidence standards in rare disease https://biobriefs.com/rare-disease-rna-therapeutics-early BioBriefs en 2026-03-25T16:31:57Z Rare disease RNA therapeutics—early clinical readouts reshape expectations https://biobriefs.com/big-pharma-m-a-merck BioBriefs en 2026-03-25T16:31:57Z Big Pharma M&A—Merck expands oncology with Terns acquisition https://biobriefs.com/immunology-deals-gilead-buys-ouro BioBriefs en 2026-03-25T16:31:57Z Immunology deals—Gilead buys Ouro for $2B and targets autoimmune reset https://biobriefs.com/clinical-signals-in-oncology-maze BioBriefs en 2026-03-25T16:31:57Z Clinical signals in oncology—Maze reports phase 2 kidney data while stock reacts https://biobriefs.com/autoimmune-and-oncology-funding-seed BioBriefs en 2026-03-25T16:31:57Z Autoimmune and oncology funding—seed expansion for dark proteome discovery https://biobriefs.com/therapeutic-pipeline-advancement-ind-clearances BioBriefs en 2026-03-25T16:31:57Z Therapeutic pipeline advancement—IND clearances and clinic entry in China https://biobriefs.com/phase-3-readouts-in-skin BioBriefs en 2026-03-25T16:31:57Z Phase 3 readouts in skin inflammation—Pfizer tilrekimig advances after eczema trial https://biobriefs.com/diagnostic-and-clinical-data-platform BioBriefs en 2026-03-25T16:31:57Z Diagnostic and clinical data platform partnerships—real-world oncology data integration https://biobriefs.com/regulatory-enforcement-fda-warning-over BioBriefs en 2026-03-25T16:31:57Z Regulatory enforcement—FDA warning over misleading claims for Anktiva https://biobriefs.com/m-a BioBriefs en 2026-03-25T14:32:04Z M&A https://biobriefs.com/m-a BioBriefs en 2026-03-25T14:32:04Z M&A https://biobriefs.com/clinical-data BioBriefs en 2026-03-25T14:32:04Z Clinical data https://biobriefs.com/oncology-pipeline-competition BioBriefs en 2026-03-25T14:32:04Z Oncology / pipeline competition https://biobriefs.com/clinical-development-regulatory-path BioBriefs en 2026-03-25T14:32:04Z Clinical development / regulatory path https://biobriefs.com/diagnostics-approvals BioBriefs en 2026-03-25T14:32:04Z Diagnostics / approvals https://biobriefs.com/platform-funding BioBriefs en 2026-03-25T14:32:04Z Platform / funding https://biobriefs.com/clinical-stage-immunotherapy-platform BioBriefs en 2026-03-25T14:32:04Z Clinical-stage immunotherapy platform https://biobriefs.com/funding-early-company-build-out BioBriefs en 2026-03-25T14:32:04Z Funding / early company build-out https://biobriefs.com/biotech-platform-collaboration BioBriefs en 2026-03-25T14:32:04Z Biotech platform / collaboration https://biobriefs.com/gilead-acquisition-and-galapagos-alliance BioBriefs en 2026-03-25T10:32:01Z Gilead acquisition and Galapagos alliance reshaping autoimmune immunotherapy https://biobriefs.com/ibd-drug-discovery-deal-expands BioBriefs en 2026-03-25T10:32:01Z IBD drug discovery deal expands somatic genomics contracting https://biobriefs.com/karyopharm-phase-3-signal-drives BioBriefs en 2026-03-25T10:32:01Z Karyopharm phase 3 signal drives FDA filing discussions for Xpovio in myelofibrosis https://biobriefs.com/sanofi-pulls-kt501-into-autoimmune BioBriefs en 2026-03-25T10:32:01Z Sanofi pulls KT501 into autoimmune T-cell engager strategy via large collaboration https://biobriefs.com/china-obesity-race-intensifies-with BioBriefs en 2026-03-25T10:32:01Z China obesity race intensifies with BrightGene oral dual agonist early readouts https://biobriefs.com/china-us-clinical-expansion-and BioBriefs en 2026-03-25T10:32:01Z China/US clinical expansion and dealmaking pipeline via RA Capital SPAC move https://biobriefs.com/dark-proteome-discovery-startup-rybodyn BioBriefs en 2026-03-25T10:32:01Z Dark proteome discovery startup RyboDyn raises seed financing for oncology targets https://biobriefs.com/endometriosis-diagnostics-push-moves-toward BioBriefs en 2026-03-25T10:32:01Z Endometriosis diagnostics push moves toward multiomics menstrual-blood tests https://biobriefs.com/fda-warning-targets-immunitybios-anktiva BioBriefs en 2026-03-25T10:32:01Z FDA warning targets ImmunityBio’s Anktiva claims in marketing and podcast https://biobriefs.com/clinical-trial-governance-uk-house BioBriefs en 2026-03-25T10:32:01Z Clinical trial governance: UK House of Lords to examine AI’s role in speeding trials and delivery https://biobriefs.com/big-pharma-dealmaking-in-autoimmune BioBriefs en 2026-03-25T09:31:53Z Big Pharma dealmaking in autoimmune bispecifics https://biobriefs.com/genomics-platform-expansion-for-ibd BioBriefs en 2026-03-25T09:31:53Z Genomics platform expansion for IBD target discovery https://biobriefs.com/sanofi-licenses-tri-specific-t BioBriefs en 2026-03-25T09:31:53Z Sanofi licenses tri-specific T-cell engager KT501 for autoimmune disease https://biobriefs.com/phase-3-outcomes-and-regulatory BioBriefs en 2026-03-25T09:31:53Z Phase 3 outcomes and regulatory path: myelofibrosis in focus https://biobriefs.com/clinical-stage-biotech-m-a BioBriefs en 2026-03-25T09:31:53Z Clinical-stage biotech M&A and consolidation: outsourcing risk and late-stage appetite https://biobriefs.com/new-ai-enabled-oncology-biomarker BioBriefs en 2026-03-25T09:31:53Z New AI-enabled oncology biomarker workflow partnerships https://biobriefs.com/new-startup-funding-dark-proteome BioBriefs en 2026-03-25T09:31:53Z New startup funding: dark proteome target discovery https://biobriefs.com/platform-commercialization-in-diagnostics-ai BioBriefs en 2026-03-25T09:31:53Z Platform commercialization in diagnostics: AI and next-gen testing systems https://biobriefs.com/industry-financing-and-portfolio-risk BioBriefs en 2026-03-25T09:31:53Z Industry financing and portfolio risk: obesity trial pauses pressure pipelines https://biobriefs.com/regulatory-enforcement-fda-warns-immunitybio BioBriefs en 2026-03-25T09:31:53Z Regulatory enforcement: FDA warns ImmunityBio over misleading Anktiva claims https://biobriefs.com/gilead-buys-ouro-medicines-to BioBriefs en 2026-03-25T07:58:21Z Gilead buys Ouro Medicines to accelerate autoimmune T-cell engager strategy https://biobriefs.com/sanofi-expands-autoimmune-immunology-portfolio BioBriefs en 2026-03-25T07:58:21Z Sanofi expands autoimmune immunology portfolio via Kali trispecific KT501 license https://biobriefs.com/merck-and-flagship-startup-quotient BioBriefs en 2026-03-25T07:58:21Z Merck and Flagship startup Quotient deepen somatic genomics footprint in IBD https://biobriefs.com/karyopharm-eyes-fda-filing-after BioBriefs en 2026-03-25T07:58:21Z Karyopharm eyes FDA filing after Phase 3 Sentry myelofibrosis readout https://biobriefs.com/cutting-edge-sensing-and-imaging BioBriefs en 2026-03-25T07:58:21Z Cutting-edge sensing and imaging: lymph node-tropic mRNA lipid nanoparticles https://biobriefs.com/diagnostic-innovation-roche-gets-ce BioBriefs en 2026-03-25T07:58:21Z Diagnostic innovation: Roche gets CE mark for expanded respiratory pathogen panel https://biobriefs.com/ai-for-trial-and-pathology BioBriefs en 2026-03-25T07:58:21Z AI for trial and pathology workflows: Mindpeak and Discovery Life Sciences combine platforms https://biobriefs.com/clinical-evidence-who-upgrades-tuberculosis BioBriefs en 2026-03-25T07:58:21Z Clinical evidence: WHO upgrades tuberculosis testing recommendations toward nPOC NAATs https://biobriefs.com/womens-health-diagnostics-menstrual-blood BioBriefs en 2026-03-25T07:58:21Z Women’s health diagnostics: menstrual-blood multiomics to shorten endometriosis diagnosis https://biobriefs.com/research-integrity-and-governance-risk BioBriefs en 2026-03-25T07:58:21Z Research integrity and governance risk: Portuguese scientists report “grey zone” behaviors https://biobriefs.com/gilead-ouro-autoimmune-t-cell BioBriefs en 2026-03-25T07:54:06Z Gilead-Ouro autoimmune T-cell engager deal https://biobriefs.com/merck-and-quotient-expand-somatic BioBriefs en 2026-03-25T07:54:06Z Merck and Quotient expand somatic genomics for IBD drug discovery https://biobriefs.com/kali-sanofi-trispecific-kt501-autoimmune BioBriefs en 2026-03-25T07:54:06Z Kali–Sanofi trispecific KT501 autoimmune collaboration https://biobriefs.com/karyopharm-sentry-phase-3-selinexor BioBriefs en 2026-03-25T07:54:06Z Karyopharm Sentry Phase 3 selinexor-myelofibrosis update ahead of potential sNDA https://biobriefs.com/clinical-validation-push-for-tuberculosis BioBriefs en 2026-03-25T07:54:06Z Clinical validation push for tuberculosis point-of-care diagnostics https://biobriefs.com/ocugen-moves-gene-therapy-for BioBriefs en 2026-03-25T07:54:06Z Ocugen moves gene therapy for geographic atrophy into Phase 3 https://biobriefs.com/biotech-startup-seed-funding-for BioBriefs en 2026-03-25T07:54:06Z Biotech startup seed funding for cryptic target discovery (dark proteome) https://biobriefs.com/crossbow-therapeutics-series-b-to BioBriefs en 2026-03-25T07:54:06Z Crossbow Therapeutics Series B to advance T-cell engager in myeloid cancers https://biobriefs.com/rivia-raises-series-a-for BioBriefs en 2026-03-25T07:54:06Z Rivia raises Series A for agentic AI to manage clinical trial data quality https://biobriefs.com/sanofi-extends-180m-for-kali BioBriefs en 2026-03-25T07:54:06Z Sanofi extends $180M for Kali trispecific—double signal on KT501 clinical start https://biobriefs.com/gilead-snaps-up-ouro-to BioBriefs en 2026-03-25T04:32:35Z Gilead snaps up Ouro to boost autoimmune bispecifics – dual pact with Galapagos https://biobriefs.com/merck-inks-deal-with-quotient BioBriefs en 2026-03-25T04:32:35Z Merck inks deal with Quotient to mine somatic genomics for IBD targets https://biobriefs.com/sanofi-licenses-kalis-trispecific-kt501 BioBriefs en 2026-03-25T04:32:35Z Sanofi licenses Kali’s trispecific KT501 – $180M up front for autoimmune trispecific https://biobriefs.com/apogees-long-interval-eczema-antibody BioBriefs en 2026-03-25T04:32:35Z Apogee’s long‑interval eczema antibody posts robust maintenance data – investors react https://biobriefs.com/karyopharm-posts-mixed-phase-iii BioBriefs en 2026-03-25T04:32:35Z Karyopharm posts mixed Phase III myelofibrosis readout – FDA meeting next https://biobriefs.com/novartis-shells-out-2b-for BioBriefs en 2026-03-25T04:32:35Z Novartis shells out $2B for Synnovation’s PI3Kα program – SNV4818 acquisition https://biobriefs.com/arolnps-retarget-mrna-vaccines-to BioBriefs en 2026-03-25T04:32:35Z AroLNPs retarget mRNA vaccines to lymph nodes – liver detargeting breakthrough https://biobriefs.com/e3-ligase-atlas-released-to BioBriefs en 2026-03-25T04:32:35Z E3 ligase atlas released to expand targeted‑protein‑degradation discovery https://biobriefs.com/rybodyn-raises-10m-seed-to BioBriefs en 2026-03-25T04:32:35Z RyboDyn raises $10M seed to mine the 'dark proteome' for cancer targets https://biobriefs.com/who-urges-rapid-roll-out BioBriefs en 2026-03-25T04:32:35Z WHO urges rapid roll‑out of near‑point‑of‑care TB tests — new testing guidance https://biobriefs.com/gilead-buys-ouro-medicines-for BioBriefs en 2026-03-24T21:33:00Z Gilead buys Ouro Medicines for $2.17 billion – Adds autoimmune T‑cell engager https://biobriefs.com/merck-taps-quotients-somatic-genomics BioBriefs en 2026-03-24T21:33:00Z Merck taps Quotient’s somatic genomics: $20M now, $2.2B possible https://biobriefs.com/fda-flags-immunitybio-agency-says BioBriefs en 2026-03-24T21:33:00Z FDA flags ImmunityBio — Agency says ads, podcast misled on cancer claims https://biobriefs.com/china-seed-rounds-and-us BioBriefs en 2026-03-24T21:33:00Z China seed rounds and US Series B: New money flows into T‑cell engager startups https://biobriefs.com/novartis-to-pay-2-billion BioBriefs en 2026-03-24T21:33:00Z Novartis to pay $2 billion for Synnovation PI3Kα program – Strategic bolt‑on https://biobriefs.com/apogees-long-acting-il-13 BioBriefs en 2026-03-24T21:33:00Z Apogee’s long‑acting IL‑13 antibody shows durable control — Less‑frequent dosing touted https://biobriefs.com/pfizer-and-valneva-lyme-vaccine BioBriefs en 2026-03-24T21:33:00Z Pfizer and Valneva: Lyme vaccine cuts cases but misses statistical bar — Regulators next https://biobriefs.com/engineered-lnps-detour-the-liver BioBriefs en 2026-03-24T21:33:00Z Engineered LNPs detour the liver and home to lymph nodes — New delivery route for mRNA vaccines https://biobriefs.com/uk-probes-ai-for-trials BioBriefs en 2026-03-24T21:33:00Z UK probes AI for trials as startups scale agentic platforms for clinical data https://biobriefs.com/who-urges-rapid-roll-out BioBriefs en 2026-03-24T21:33:00Z WHO urges rapid roll‑out of near‑point‑of‑care TB tests — New guidance endorsed https://biobriefs.com/gilead-front-loads-1-675b BioBriefs en 2026-03-24T16:33:22Z Gilead front-loads $1.675B for Ouro... reshapes Galapagos role https://biobriefs.com/novartis-buys-synnovations-pi3ka-program BioBriefs en 2026-03-24T16:33:22Z Novartis buys Synnovation’s PI3Kα program — $2B upfront https://biobriefs.com/pfizer-valneva-miss-statistical-bar BioBriefs en 2026-03-24T16:33:22Z Pfizer, Valneva miss statistical bar on Lyme shot — plan to file anyway https://biobriefs.com/apogee-posts-long-acting-eczema BioBriefs en 2026-03-24T16:33:22Z Apogee posts long‑acting eczema wins — dosing every 3–6 months shows durability https://biobriefs.com/sanofi-pays-180m-up-front BioBriefs en 2026-03-24T16:33:22Z Sanofi pays $180M up front for Kali’s trispecific — big autoimmune bet https://biobriefs.com/rybodyn-raises-10m-to-mine BioBriefs en 2026-03-24T16:33:22Z RyboDyn raises $10M to mine the dark proteome for cancer targets https://biobriefs.com/crossbow-closes-77m-series-b BioBriefs en 2026-03-24T16:33:22Z Crossbow closes $77M Series B to advance T‑Bolt T‑cell engagers https://biobriefs.com/fda-clears-ind-for-endo BioBriefs en 2026-03-24T16:33:22Z FDA clears IND for ENDO‑205 — first‑in‑class nonhormonal endometriosis peptide https://biobriefs.com/arolnps-redirect-mrna-vaccines-to BioBriefs en 2026-03-24T16:33:22Z AroLNPs redirect mRNA vaccines to lymph nodes — liver detargeting breakthrough https://biobriefs.com/who-urges-rollout-of-near BioBriefs en 2026-03-24T16:33:22Z WHO urges rollout of near point‑of‑care TB molecular tests — new guidance https://biobriefs.com/gileads-1-68b-bet-ouro BioBriefs en 2026-03-24T14:32:58Z Gilead’s $1.68B bet: Ouro buyout reshapes Galapagos role https://biobriefs.com/novartis-spends-big-on-pi3ka BioBriefs en 2026-03-24T14:32:58Z Novartis spends big on PI3Kα: Pikavation deal expands breast‑cancer pipeline https://biobriefs.com/pfizer-valneva-press-regulators-lyme BioBriefs en 2026-03-24T14:32:58Z Pfizer, Valneva press regulators... Lyme vaccine hits statistical snag https://biobriefs.com/apogees-long-interval-eczema-win BioBriefs en 2026-03-24T14:32:58Z Apogee’s long‑interval eczema win: durability with quarterly to semiannual dosing https://biobriefs.com/sanofi-returns-to-t-cell BioBriefs en 2026-03-24T14:32:58Z Sanofi returns to T‑cell engagers: $1.2B pact for Kali’s trispecific https://biobriefs.com/engineered-lnps-steer-mrna-to BioBriefs en 2026-03-24T14:32:58Z Engineered LNPs steer mRNA to lymph nodes — liver detargeting demonstrated https://biobriefs.com/rapid-diagnostics-surge-roches-ce BioBriefs en 2026-03-24T14:32:58Z Rapid diagnostics surge: Roche’s CE mark and Diasorin’s US bet https://biobriefs.com/washington-hears-biotech-on-china BioBriefs en 2026-03-24T14:32:58Z Washington hears biotech on China: investors and experts press urgency https://biobriefs.com/dna-and-ivd-capacity-builds BioBriefs en 2026-03-24T14:32:58Z DNA and IVD capacity builds: Artis opens synthetic DNA hub; IDT moves into clinical assays https://biobriefs.com/immunotherapy-financings-crossbow-77m-immutrin BioBriefs en 2026-03-24T14:32:58Z Immunotherapy financings: Crossbow $77M, Immutrin $86M to advance candidates https://biobriefs.com/gilead-pays-2-2b-for BioBriefs en 2026-03-24T10:32:59Z Gilead pays $2.2B for Ouro T‑cell engager – Galapagos to absorb assets https://biobriefs.com/novartis-snaps-up-pikavation-for BioBriefs en 2026-03-24T10:32:59Z Novartis snaps up Pikavation for $2B – bets on mutant‑selective PI3Kα https://biobriefs.com/sanofi-inks-1-2b-deal BioBriefs en 2026-03-24T10:32:59Z Sanofi inks $1.2B deal for Kali trispecific – $180M up front https://biobriefs.com/apogee-shows-long-acting-eczema BioBriefs en 2026-03-24T10:32:59Z Apogee shows long‑acting eczema edge – investors bid shares higher https://biobriefs.com/pfizer-valneva-vaccine-cuts-lyme BioBriefs en 2026-03-24T10:32:59Z Pfizer, Valneva vaccine cuts Lyme by ~73%…statistical miss clouds regulatory path https://biobriefs.com/rivia-raises-15m-to-scale BioBriefs en 2026-03-24T10:32:59Z Rivia raises $15M to scale agentic AI for trials – eyes US expansion https://biobriefs.com/crossbow-raises-77m-series-b BioBriefs en 2026-03-24T10:32:59Z Crossbow raises $77M Series B – T‑bolt engagers advance to clinic https://biobriefs.com/immutrin-nets-86m-to-advance BioBriefs en 2026-03-24T10:32:59Z Immutrin nets $86M to advance amyloidosis antibody https://biobriefs.com/aardvark-pauses-ard-201-trials BioBriefs en 2026-03-24T10:32:59Z Aardvark pauses ARD‑201 trials – entire pipeline on hold https://biobriefs.com/metformin-linked-mechanism-may-delay BioBriefs en 2026-03-24T10:32:59Z Metformin‑linked mechanism may delay HIV rebound – Gladstone multiomic study https://biobriefs.com/gilead-pays-2-2b-for BioBriefs en 2026-03-24T09:32:53Z Gilead pays $2.2B for T‑cell engager: Galapagos to absorb operations https://biobriefs.com/novartis-to-buy-pikavation-for BioBriefs en 2026-03-24T09:32:53Z Novartis to buy Pikavation for up to $3B: SNV4818 added to breast‑cancer suite https://biobriefs.com/pfizer-valneva-to-seek-approval BioBriefs en 2026-03-24T09:32:53Z Pfizer, Valneva to seek approval after mixed Lyme readout – 73% efficacy but statistical miss https://biobriefs.com/apogee-touts-long-interval-eczema BioBriefs en 2026-03-24T09:32:53Z Apogee touts long‑interval eczema wins – durable response with three‑ and six‑month dosing https://biobriefs.com/sanofi-pays-180m-up-front BioBriefs en 2026-03-24T09:32:53Z Sanofi pays $180M up front for Kali trispecific – deal could top $1.2B https://biobriefs.com/crossbow-nets-77m-series-b BioBriefs en 2026-03-24T09:32:53Z Crossbow nets $77M Series B – funds T‑Bolt T‑cell engagers for myeloid cancers https://biobriefs.com/rivia-raises-15m-to-scale BioBriefs en 2026-03-24T09:32:53Z Rivia raises $15M to scale agentic AI for clinical trials – targets Boston expansion https://biobriefs.com/aardvark-pauses-obesity-trials-entire BioBriefs en 2026-03-24T09:32:53Z Aardvark pauses obesity trials – entire pipeline on hold after safety review https://biobriefs.com/idt-enters-clinical-ivd-space BioBriefs en 2026-03-24T09:32:53Z IDT enters clinical IVD space – launches two Archer NGS library‑prep assays https://biobriefs.com/oryon-unveils-neuron-replacement-parkinsons BioBriefs en 2026-03-24T09:32:53Z Oryon unveils neuron‑replacement Parkinson’s program; Ron Cohen joins as CEO https://biobriefs.com/novartis-to-buy-pikavation-for BioBriefs en 2026-03-24T04:32:50Z Novartis to buy Pikavation for up to $3bn: adds mutant‑selective PI3Kα candidate https://biobriefs.com/pfizer-valneva-post-mixed-phase BioBriefs en 2026-03-24T04:32:50Z Pfizer, Valneva post mixed Phase III results: >70% efficacy but trial missed primary bar https://biobriefs.com/apogee-data-show-long-acting BioBriefs en 2026-03-24T04:32:50Z Apogee data show long‑acting eczema drug sustains relief: less frequent dosing works https://biobriefs.com/oryon-unveils-autologous-neuron-replacement BioBriefs en 2026-03-24T04:32:50Z Oryon unveils autologous neuron replacement therapy – presents Phase Ib/IIa data https://biobriefs.com/kali-inks-1-2bn-sanofi BioBriefs en 2026-03-24T04:32:50Z Kali inks $1.2bn Sanofi deal – trispecific KT‑501 licensed for autoimmune indications https://biobriefs.com/rivia-raises-15m-agentic-ai BioBriefs en 2026-03-24T04:32:50Z Rivia raises $15m – agentic AI to cut trial data review timelines https://biobriefs.com/study-finds-metformin-activates-genetic BioBriefs en 2026-03-24T04:32:50Z Study finds metformin activates genetic 'locks' – delays HIV rebound after ART https://biobriefs.com/bionano-reports-revenue-dip-but BioBriefs en 2026-03-24T04:32:50Z Bionano reports revenue dip but narrows loss; CMS hikes OGM reimbursement https://biobriefs.com/crossbow-closes-77m-series-b BioBriefs en 2026-03-24T04:32:50Z Crossbow closes $77m Series B to advance T‑bolt T‑cell engagers https://biobriefs.com/idt-enters-ivd-market-with BioBriefs en 2026-03-24T04:32:50Z IDT enters IVD market with Archer FusionPlex‑HT Dx and VariantPlex‑HT Dx assays https://biobriefs.com/novartis-to-buy-pikavation-up BioBriefs en 2026-03-23T21:33:45Z Novartis to buy Pikavation—up to $3B for mutant‑selective PI3Kα https://biobriefs.com/pfizer-valneva-lyme-vaccine-cuts BioBriefs en 2026-03-23T21:33:45Z Pfizer, Valneva: Lyme vaccine cuts ~73% of cases — misses key statistical hurdle https://biobriefs.com/apogees-long-acting-eczema-drug BioBriefs en 2026-03-23T21:33:45Z Apogee’s long‑acting eczema drug: 3‑ and 6‑month dosing sustains response https://biobriefs.com/kali-inks-1-2b-sanofi BioBriefs en 2026-03-23T21:33:45Z Kali inks $1.2B Sanofi pact — trispecific T‑cell engager licensed https://biobriefs.com/crossbow-raises-77m-funds-cbx BioBriefs en 2026-03-23T21:33:45Z Crossbow raises $77M — funds CBX‑250 first‑in‑human push https://biobriefs.com/rivia-raises-15m-agentic-ai BioBriefs en 2026-03-23T21:33:45Z Rivia raises $15M — agentic AI to cut trial review times https://biobriefs.com/chinas-trial-reforms-implied-approval BioBriefs en 2026-03-23T21:33:45Z China’s trial reforms: implied approval accelerates IND starts https://biobriefs.com/insmeds-arikayce-wins-late-stage BioBriefs en 2026-03-23T21:33:45Z Insmed’s Arikayce wins late‑stage trial — eyes front‑line lung use https://biobriefs.com/laigo-extends-seed-to-eur17m BioBriefs en 2026-03-23T21:33:45Z Laigo extends seed to €17M — protein‑degradation tech moves toward clinic https://biobriefs.com/tessera-wins-gates-grant-genetic BioBriefs en 2026-03-23T21:33:45Z Tessera wins Gates grant — genetic strategies for scalable HIV cure https://biobriefs.com/lyme-vaccine-shows-strong-efficacy BioBriefs en 2026-03-23T16:33:09Z Lyme vaccine shows strong efficacy: Pfizer, Valneva vow regulatory push https://biobriefs.com/insmed-eyes-front-line-expansion BioBriefs en 2026-03-23T16:33:09Z Insmed eyes front-line expansion after Arikayce late‑stage win https://biobriefs.com/apogees-long-acting-eczema-drug BioBriefs en 2026-03-23T16:33:09Z Apogee’s long‑acting eczema drug promises less frequent dosing — rivals in sight https://biobriefs.com/novartis-buys-pikavation-for-up BioBriefs en 2026-03-23T16:33:09Z Novartis buys Pikavation for up to $3B — bolsters PI3Kα cancer push https://biobriefs.com/sanofi-inks-1-2b-deal BioBriefs en 2026-03-23T16:33:09Z Sanofi inks $1.2B deal for Kali trispecific — $180M upfront signals renewed T‑cell bet https://biobriefs.com/crossbow-closes-77m-series-b BioBriefs en 2026-03-23T16:33:09Z Crossbow closes $77M Series B to advance T‑cell engager for myeloid malignancies https://biobriefs.com/gates-foundation-funds-tessera-to BioBriefs en 2026-03-23T16:33:09Z Gates Foundation funds Tessera to pursue scalable genetic approaches toward HIV cure https://biobriefs.com/bio-board-member-warns-congress BioBriefs en 2026-03-23T16:33:09Z BIO board member warns Congress: China’s trial speed gives biotech advantage https://biobriefs.com/varseta-m-data-jolt-cytomx BioBriefs en 2026-03-23T16:33:09Z Varseta‑M data jolt CytomX shares: 32% ORR ignites volatile trading https://biobriefs.com/wuxi-apptec-shifts-revenue-mix BioBriefs en 2026-03-23T16:33:09Z WuXi AppTec shifts revenue mix toward US amid military‑link scrutiny https://biobriefs.com/aurinia-boardroom-coup-kevin-tang BioBriefs en 2026-03-23T14:33:02Z Aurinia boardroom coup — Kevin Tang ousts CEO and C-suite https://biobriefs.com/zegfrovy-beats-chemo-dizal-posts BioBriefs en 2026-03-23T14:33:02Z Zegfrovy beats chemo: Dizal posts Phase 3 first-line lung cancer win https://biobriefs.com/lyme-vaccine-shows-73-efficacy BioBriefs en 2026-03-23T14:33:02Z Lyme vaccine shows 73% efficacy... misses statistical threshold https://biobriefs.com/diasorin-commits-eur10m-to-us BioBriefs en 2026-03-23T14:33:02Z Diasorin commits €10M to US launch — pivots China strategy, shutters German plant https://biobriefs.com/congress-hearing-bio-board-member BioBriefs en 2026-03-23T14:33:02Z Congress hearing: BIO board member says China speeds trials, threatens US lead https://biobriefs.com/apogees-long-acting-eczema-drug BioBriefs en 2026-03-23T14:33:02Z Apogee’s long‑acting eczema drug shows durable control with infrequent dosing https://biobriefs.com/insmeds-arikayce-wins-late-stage BioBriefs en 2026-03-23T14:33:02Z Insmed’s Arikayce wins late‑stage trial — eyes earlier use in MAC lung disease https://biobriefs.com/sanofi-returns-to-t-cell BioBriefs en 2026-03-23T14:33:02Z Sanofi returns to T‑cell engagers with $1.2B pact for phase‑1 trispecific https://biobriefs.com/crossbow-raises-77m-series-b BioBriefs en 2026-03-23T14:33:02Z Crossbow raises $77M Series B — funds lead Phase I for CBX‑250 https://biobriefs.com/novartis-agrees-up-to-3b BioBriefs en 2026-03-23T14:33:02Z Novartis agrees up to $3B acquisition — picks up mutant‑selective PI3Kα asset SNV4818 https://biobriefs.com/crossbow-closes-77m-series-b BioBriefs en 2026-03-23T10:32:35Z Crossbow closes $77m Series B to push T‑cell engager into clinic https://biobriefs.com/novartis-inks-up-to-3b BioBriefs en 2026-03-23T10:32:35Z Novartis inks up to $3B deal for mutant‑selective PI3Kα program https://biobriefs.com/cytomx-posts-32-orr-in BioBriefs en 2026-03-23T10:32:35Z CytomX posts 32% ORR in mCRC dose expansion; shares roller‑coaster https://biobriefs.com/reinforced-biotubes-unveiled-as-off BioBriefs en 2026-03-23T10:32:35Z Reinforced biotubes unveiled as off‑the‑shelf regenerative vascular grafts https://biobriefs.com/alectinib-plus-car-t-shows BioBriefs en 2026-03-23T10:32:35Z Alectinib plus CAR T shows synergy in ALK‑driven neuroblastoma models https://biobriefs.com/hkust-deciphers-how-dicer-trims BioBriefs en 2026-03-23T10:32:35Z HKUST deciphers how DICER trims microRNAs with single‑nucleotide precision https://biobriefs.com/ada2-deficiency-linked-to-rampant BioBriefs en 2026-03-23T10:32:35Z ADA2 deficiency linked to rampant cell death and metabolic collapse https://biobriefs.com/acinetobacter-capsule-biology-alters-antibiotic BioBriefs en 2026-03-23T10:32:35Z Acinetobacter capsule biology alters antibiotic resistance and host immunity https://biobriefs.com/new-antimalarial-dimers-discovered-in BioBriefs en 2026-03-23T10:32:35Z New antimalarial dimers discovered in deep‑sea fungus https://biobriefs.com/pocket-dart-scope-and-human BioBriefs en 2026-03-23T10:32:35Z Pocket DART scope and Human Organ Atlas push faster, label‑free molecular imaging https://biobriefs.com/crossbow-raises-77m-to-advance BioBriefs en 2026-03-23T09:32:24Z Crossbow raises $77M to advance T‑cell engager program https://biobriefs.com/novartis-inks-up-to-3b BioBriefs en 2026-03-23T09:32:24Z Novartis inks up to $3B deal for mutant‑selective PI3Kα asset https://biobriefs.com/positive-colorectal-data-sends-cytomx BioBriefs en 2026-03-23T09:32:24Z Positive colorectal data sends CytomX shares on a rollercoaster https://biobriefs.com/alectinib-boosts-car-t-efficacy BioBriefs en 2026-03-23T09:32:24Z Alectinib boosts CAR T efficacy in ALK‑driven neuroblastoma models https://biobriefs.com/uk-trial-finds-no-extra BioBriefs en 2026-03-23T09:32:24Z UK trial finds no extra benefit from surfactant in severe infant bronchiolitis https://biobriefs.com/nearly-one-in-five-pediatric BioBriefs en 2026-03-23T09:32:24Z Nearly one‑in‑five pediatric hospital deaths linked to sepsis — JAMA study https://biobriefs.com/reinforced-biotubes-offer-off-the BioBriefs en 2026-03-23T09:32:24Z Reinforced biotubes offer off‑the‑shelf vascular graft alternative https://biobriefs.com/hkust-reveals-dicers-single-nucleotide BioBriefs en 2026-03-23T09:32:24Z HKUST reveals DICER’s single‑nucleotide precision in microRNA processing https://biobriefs.com/acinetobacter-capsule-structure-drives-resistance BioBriefs en 2026-03-23T09:32:24Z Acinetobacter capsule structure drives resistance and immune evasion https://biobriefs.com/blood-brain-barrier-remains-leaky BioBriefs en 2026-03-23T09:32:24Z Blood–brain barrier remains leaky years after contact sports — long‑term risk signal https://biobriefs.com/novartis-agrees-up-to-3b BioBriefs en 2026-03-23T04:32:48Z Novartis agrees up to $3B for Pikavation – adds mutant‑selective PI3Kα https://biobriefs.com/cytomxs-adc-posts-32-orr BioBriefs en 2026-03-23T04:32:48Z CytomX’s ADC posts 32% ORR in mCRC... Stock whipsaws after data https://biobriefs.com/ai-fuels-n-of-1 BioBriefs en 2026-03-23T04:32:48Z AI fuels N‑of‑1 medicine... Bespoke therapies move from idea to pilots https://biobriefs.com/worlds-brightest-x-rays-map BioBriefs en 2026-03-23T04:32:48Z World’s brightest X‑rays map intact organs: New open‑access organ atlas https://biobriefs.com/cellares-automation-closed-systems-and BioBriefs en 2026-03-23T04:32:48Z Cellares: Automation, closed systems and networks to scale cell therapy https://biobriefs.com/how-dicer-cuts-micrornas-single BioBriefs en 2026-03-23T04:32:48Z How DICER cuts microRNAs: Single‑nucleotide precision revealed https://biobriefs.com/acinetobacter-capsules-reshape-antibiotic-resistance BioBriefs en 2026-03-23T04:32:48Z Acinetobacter capsules reshape antibiotic resistance and immune evasion https://biobriefs.com/new-live-attenuated-vee-vaccines BioBriefs en 2026-03-23T04:32:48Z New live‑attenuated VEE vaccines advance as outbreak countermeasure https://biobriefs.com/utah-pilots-ai-refill-bot BioBriefs en 2026-03-23T04:32:48Z Utah pilots AI refill bot: Researchers flag security and safety gaps https://biobriefs.com/glassworm-hides-malware-in-invisible BioBriefs en 2026-03-23T04:32:48Z GlassWorm hides malware in invisible text... Open‑source supply chain at risk https://biobriefs.com/novartis-pays-up-to-3b BioBriefs en 2026-03-22T21:32:40Z Novartis pays up to $3B for Pikavation – adds PI3Kα mutant‑selective asset https://biobriefs.com/study-sepsis-tied-to-nearly BioBriefs en 2026-03-22T21:32:40Z Study: sepsis tied to nearly 20% of US pediatric hospital deaths https://biobriefs.com/measles-surge-and-acip-upheaval BioBriefs en 2026-03-22T21:32:40Z Measles surge and ACIP upheaval... US vaccine policy in flux https://biobriefs.com/ai-systems-enter-clinical-care BioBriefs en 2026-03-22T21:32:40Z AI systems enter clinical care—trial shows benefit, security researchers raise alarms https://biobriefs.com/scientists-identify-genes-that-let BioBriefs en 2026-03-22T21:32:40Z Scientists identify genes that let some people suppress HIV without ART https://biobriefs.com/startup-pays-donors-for-menstrual BioBriefs en 2026-03-22T21:32:40Z Startup pays donors for menstrual blood to build stem‑cell biobank https://biobriefs.com/environment-and-bacteria-reshape-antimicrobial BioBriefs en 2026-03-22T21:32:40Z Environment and bacteria reshape antimicrobial risk—unexpected exposures surface https://biobriefs.com/single-cell-tools-map-cells BioBriefs en 2026-03-22T21:32:40Z Single‑cell tools map cells to outcomes and reveal cardiac repair signals https://biobriefs.com/molecular-discoveries-alter-therapy-landscape BioBriefs en 2026-03-22T21:32:40Z Molecular discoveries alter therapy landscape—ATGL, DICER reveal new levers https://biobriefs.com/neonatal-care-studies-deliver-actionable BioBriefs en 2026-03-22T21:32:40Z Neonatal care studies deliver actionable signals—neurobehavior links and surfactant null result https://biobriefs.com/novartis-pays-2b-for-mutant BioBriefs en 2026-03-22T16:32:22Z Novartis pays $2B for mutant‑selective PI3Kα pill – broadens breast cancer arsenal https://biobriefs.com/ai-drugmaker-earendil-hauls-in BioBriefs en 2026-03-22T16:32:22Z AI drugmaker Earendil hauls in $787M – scales biologics pipeline https://biobriefs.com/fda-insists-on-sham-surgery BioBriefs en 2026-03-22T16:32:22Z FDA insists on sham surgery control for uniQure’s Huntington’s gene therapy https://biobriefs.com/tumor-whole-genome-sequencing-shows BioBriefs en 2026-03-22T16:32:22Z Tumor whole‑genome sequencing shows broad clinical utility – Nature Medicine https://biobriefs.com/engineered-esophagus-restores-function-in BioBriefs en 2026-03-22T16:32:22Z Engineered esophagus restores function in pig model – step toward pediatric therapy https://biobriefs.com/cytomx-draws-250m-after-varsetatug BioBriefs en 2026-03-22T16:32:22Z CytomX draws $250M after varsetatug ADC data – funds expansion https://biobriefs.com/excalipoint-secures-68-7m-to BioBriefs en 2026-03-22T16:32:22Z Excalipoint secures $68.7M to push masked T‑cell engagers into clinic https://biobriefs.com/ai-clinical-decision-support-improves BioBriefs en 2026-03-22T16:32:22Z AI clinical decision support improves stroke outcomes in randomized trial https://biobriefs.com/utah-pilots-autonomous-rx-refill BioBriefs en 2026-03-22T16:32:22Z Utah pilots autonomous Rx refill bot — researchers flag security flaws https://biobriefs.com/ai-powered-oct-analytics-map BioBriefs en 2026-03-22T16:32:22Z AI‑powered OCT analytics map wound healing dynamics – Duke/Nokia https://biobriefs.com/novartis-pays-2-billion-buys BioBriefs en 2026-03-22T14:32:41Z Novartis pays $2 billion — buys Synnovation’s PI3Kα candidate https://biobriefs.com/ai-biotech-earendil-bags-787m BioBriefs en 2026-03-22T14:32:41Z AI biotech Earendil bags $787M — readies clinic push https://biobriefs.com/fda-insists-on-sham-surgery BioBriefs en 2026-03-22T14:32:41Z FDA insists on sham surgery for uniQure’s Huntington’s gene therapy https://biobriefs.com/roche-halts-emugrobart-program-patients BioBriefs en 2026-03-22T14:32:41Z Roche halts emugrobart program — patients notified https://biobriefs.com/tumor-wgs-shows-broad-real BioBriefs en 2026-03-22T14:32:41Z Tumor WGS shows broad real‑world utility — 888‑patient study https://biobriefs.com/lab-grown-esophagus-restores-swallowing BioBriefs en 2026-03-22T14:32:41Z Lab‑grown esophagus restores swallowing in growing pig model https://biobriefs.com/ai-decision-support-improves-stroke BioBriefs en 2026-03-22T14:32:41Z AI decision support improves stroke care — cluster RCT in BMJ https://biobriefs.com/automation-push-aims-to-make BioBriefs en 2026-03-22T14:32:41Z Automation push aims to make cell therapy a scalable medicine https://biobriefs.com/cytomx-alto-raise-cash-to BioBriefs en 2026-03-22T14:32:41Z CytomX, Alto raise cash to support clinical programs https://biobriefs.com/fda-clears-four-nmes-approvals BioBriefs en 2026-03-22T14:32:41Z FDA clears four NMEs — approvals hit 26 in first two months https://biobriefs.com/novartis-pays-2b-for-synnovations BioBriefs en 2026-03-22T10:32:49Z Novartis pays $2B for Synnovation’s next‑gen PI3Kα https://biobriefs.com/earendil-raises-787m-to-scale BioBriefs en 2026-03-22T10:32:49Z Earendil raises $787M to scale AI‑driven biologics https://biobriefs.com/fda-wants-sham-surgery-control BioBriefs en 2026-03-22T10:32:49Z FDA wants sham‑surgery control for uniQure’s Huntington program https://biobriefs.com/roche-halts-muscle-growth-drug BioBriefs en 2026-03-22T10:32:49Z Roche halts muscle‑growth drug after mixed trial results https://biobriefs.com/abbott-set-to-close-23b BioBriefs en 2026-03-22T10:32:49Z Abbott set to close $23B Exact Sciences takeover https://biobriefs.com/engineered-esophagus-restores-swallowing-in BioBriefs en 2026-03-22T10:32:49Z Engineered esophagus restores swallowing in growing pig model https://biobriefs.com/tumor-whole-genome-sequencing-changes BioBriefs en 2026-03-22T10:32:49Z Tumor whole‑genome sequencing changes care for 41% of patients https://biobriefs.com/fda-expands-imcivree-for-acquired BioBriefs en 2026-03-22T10:32:49Z FDA expands Imcivree for acquired hypothalamic obesity https://biobriefs.com/fda-clears-four-nmes-as BioBriefs en 2026-03-22T10:32:49Z FDA clears four NMEs as approvals pace holds in 2026 https://biobriefs.com/ohio-to-build-30m-life BioBriefs en 2026-03-22T10:32:49Z Ohio to build $30M life‑science training center in New Albany https://biobriefs.com/novartis-buys-next-gen-pi3ka BioBriefs en 2026-03-22T09:33:31Z Novartis buys next‑gen PI3Kα: $2B upfront in Synnovation pact https://biobriefs.com/earendil-hauls-in-787m-ai BioBriefs en 2026-03-22T09:33:31Z Earendil hauls in $787M: AI drugmaker scales biologics pipeline https://biobriefs.com/abbott-closes-exact-sciences-deal BioBriefs en 2026-03-22T09:33:31Z Abbott closes Exact Sciences deal: $23B acquisition to expand diagnostics https://biobriefs.com/fda-demands-sham-arm-for BioBriefs en 2026-03-22T09:33:31Z FDA demands sham arm for Huntington’s gene therapy: uniQure faces new trial hurdle https://biobriefs.com/muscle-drug-setbacks-roche-and BioBriefs en 2026-03-22T09:33:31Z Muscle drug setbacks: Roche and Genentech halt programs after negative efficacy https://biobriefs.com/tumor-whole-genome-sequencing-shows BioBriefs en 2026-03-22T09:33:31Z Tumor whole‑genome sequencing shows clinical value: 888‑patient real‑world study https://biobriefs.com/lab-grown-esophagus-restores-swallowing BioBriefs en 2026-03-22T09:33:31Z Lab‑grown esophagus restores swallowing in pigs — pediatric grafts on horizon https://biobriefs.com/fda-expands-imcivree-use-acquired BioBriefs en 2026-03-22T09:33:31Z FDA expands Imcivree use: acquired hypothalamic obesity cleared https://biobriefs.com/ai-clinical-support-improves-stroke BioBriefs en 2026-03-22T09:33:31Z AI clinical support improves stroke care: cluster trial shows outcome gains https://biobriefs.com/fda-clears-four-nmes-approvals BioBriefs en 2026-03-22T09:33:31Z FDA clears four NMEs: approvals reach 26 in first two months of 2026 https://biobriefs.com/novartis-pays-2-billion-upfront BioBriefs en 2026-03-22T04:33:09Z Novartis pays $2 billion upfront for Synnovation PI3Kα asset — Deal secures next‑gen breast cancer candidate https://biobriefs.com/earendil-labs-raises-787m-to BioBriefs en 2026-03-22T04:33:09Z Earendil Labs raises $787M to scale AI‑driven biologics R&D — Backing from Dimension, Luminous, Sanofi https://biobriefs.com/abbott-closes-exact-sciences-deal BioBriefs en 2026-03-22T04:33:09Z Abbott closes Exact Sciences deal Monday — $23B buy adds cancer‑screening and diagnostics assets https://biobriefs.com/fda-insists-on-sham-surgery BioBriefs en 2026-03-22T04:33:09Z FDA insists on sham‑surgery control for uniQure’s Huntington’s gene therapy — Regulators question external controls https://biobriefs.com/roche-halts-development-of-experimental BioBriefs en 2026-03-22T04:33:09Z Roche halts development of experimental SMA drug emugrobart — Patient letter cites insufficient benefit https://biobriefs.com/tumor-whole-genome-sequencing-shows BioBriefs en 2026-03-22T04:33:09Z Tumor whole‑genome sequencing shows real‑world clinical utility — 888‑patient Nature Medicine study https://biobriefs.com/lab-grown-esophagus-functions-in BioBriefs en 2026-03-22T04:33:09Z Lab‑grown esophagus functions in growing pigs — GOSH/UCL report advances pediatric regeneration https://biobriefs.com/startup-pays-women-for-menstrual BioBriefs en 2026-03-22T04:33:09Z Startup pays women for menstrual stem‑cell donations — Muse Bio targets regenerative and fertility markets https://biobriefs.com/fda-expands-rhythms-imcivree-to BioBriefs en 2026-03-22T04:33:09Z FDA expands Rhythm’s Imcivree to acquired hypothalamic obesity — First drug for the rare condition https://biobriefs.com/ai-clinical-decision-support-improves BioBriefs en 2026-03-22T04:33:09Z AI clinical decision support improves stroke care and outcomes — Cluster‑randomized BMJ trial in China https://biobriefs.com/novartis-pays-2b-for-pi3ka BioBriefs en 2026-03-21T21:33:43Z Novartis pays $2B for PI3Kα inhibitor: Bolsters breast‑cancer arsenal https://biobriefs.com/earendil-raises-787m-ai-biologics BioBriefs en 2026-03-21T21:33:43Z Earendil raises $787M: AI biologics developer scales pipeline https://biobriefs.com/abbott-to-close-23b-exact BioBriefs en 2026-03-21T21:33:43Z Abbott to close $23B Exact Sciences deal – Expands diagnostics footprint https://biobriefs.com/big-pharma-shutters-muscle-growth BioBriefs en 2026-03-21T21:33:43Z Big pharma shutters muscle‑growth bets – Roche, Genentech scale back programs https://biobriefs.com/fda-asks-for-sham-surgery BioBriefs en 2026-03-21T21:33:43Z FDA asks for sham‑surgery control in uniQure Huntington’s trial – Ethics and timing at stake https://biobriefs.com/tumor-whole-genome-sequencing-actionable BioBriefs en 2026-03-21T21:33:43Z Tumor whole‑genome sequencing: actionable biomarkers found in 73% of cases https://biobriefs.com/scaling-cell-therapy-automation-and BioBriefs en 2026-03-21T21:33:43Z Scaling cell therapy: automation and light‑gated CARs aim to expand access https://biobriefs.com/generalist-biological-ai-nature-biotechnology BioBriefs en 2026-03-21T21:33:43Z Generalist biological AI: Nature Biotechnology frames cross‑domain vision https://biobriefs.com/acip-turmoil-claims-of-disbanding BioBriefs en 2026-03-21T21:33:43Z ACIP turmoil: claims of disbanding follow judge’s injunction https://biobriefs.com/lab-grown-esophagus-restores-swallowing BioBriefs en 2026-03-21T21:33:43Z Lab‑grown esophagus restores swallowing in pig models – Leap for pediatric repair https://biobriefs.com/novartis-pays-2b-upfront-for BioBriefs en 2026-03-21T16:33:43Z Novartis pays $2B upfront for Synnovation PI3Kα program https://biobriefs.com/ai-drugmaker-earendil-raises-787m BioBriefs en 2026-03-21T16:33:43Z AI drugmaker Earendil raises $787M to scale biologics pipeline https://biobriefs.com/fda-clears-high-dose-wegovy BioBriefs en 2026-03-21T16:33:43Z FDA clears high‑dose Wegovy under commissioner’s voucher https://biobriefs.com/abbott-closes-23b-exact-sciences BioBriefs en 2026-03-21T16:33:43Z Abbott closes $23B Exact Sciences acquisition — expands diagnostics https://biobriefs.com/tumor-whole-genome-sequencing-informs BioBriefs en 2026-03-21T16:33:43Z Tumor whole‑genome sequencing informs care in 41% of real‑world cases https://biobriefs.com/engineered-autologous-esophagus-integrates-and BioBriefs en 2026-03-21T16:33:43Z Engineered autologous esophagus integrates and restores function in growing pigs https://biobriefs.com/acip-turmoil-judge-freezes-appointments BioBriefs en 2026-03-21T16:33:43Z ACIP turmoil: judge freezes appointments — membership status in flux https://biobriefs.com/fda-asks-uniqure-for-sham BioBriefs en 2026-03-21T16:33:43Z FDA asks uniQure for sham‑surgery controlled trial for Huntington’s gene therapy https://biobriefs.com/scaling-cell-therapy-industry-maps BioBriefs en 2026-03-21T16:33:43Z Scaling cell therapy: industry maps automation, closed systems and manufacturing roadmaps https://biobriefs.com/roche-and-genentech-halt-muscle BioBriefs en 2026-03-21T16:33:43Z Roche and Genentech halt muscle‑building programs — raises questions for obesity efforts https://biobriefs.com/novartis-pays-2b-upfront-buys BioBriefs en 2026-03-21T14:32:46Z Novartis pays $2B upfront — buys Synnovation’s PI3Kα program https://biobriefs.com/earendil-labs-raises-787m-ai BioBriefs en 2026-03-21T14:32:46Z Earendil Labs raises $787M — AI biotech scales toward clinic https://biobriefs.com/retatrutide-hits-phase-iii-goals BioBriefs en 2026-03-21T14:32:46Z Retatrutide hits phase III goals — Lilly posts weight and A1C wins https://biobriefs.com/fda-clears-high-dose-wegovy BioBriefs en 2026-03-21T14:32:46Z FDA clears high‑dose Wegovy fast — approval under commissioner’s voucher https://biobriefs.com/fda-asks-uniqure-for-sham BioBriefs en 2026-03-21T14:32:46Z FDA asks uniQure for sham‑surgery control in Huntington’s trial — ethical debate erupts https://biobriefs.com/roche-halts-experimental-sma-drug BioBriefs en 2026-03-21T14:32:46Z Roche halts experimental SMA drug — development stopped after inconsistent benefit https://biobriefs.com/cell-therapy-at-scale-automation BioBriefs en 2026-03-21T14:32:46Z Cell therapy at scale: automation, closed systems and commercialization hurdles https://biobriefs.com/lab-grown-esophagus-restores-feeding BioBriefs en 2026-03-21T14:32:46Z Lab‑grown esophagus restores feeding in pigs — step toward pediatric grafts https://biobriefs.com/nautilus-voyager-debuts-baylor-first BioBriefs en 2026-03-21T14:32:46Z Nautilus Voyager debuts — Baylor first customer for single‑molecule proteomics https://biobriefs.com/csl-reports-global-stockout-of BioBriefs en 2026-03-21T14:32:46Z CSL reports global stockout of hemophilia B gene therapy — patient access risk https://biobriefs.com/novartis-shells-out-2b-buys BioBriefs en 2026-03-21T10:32:44Z Novartis shells out $2B — buys Synnovation’s next‑gen PI3Kα program https://biobriefs.com/lillys-triple-agonist-retatrutide-hits BioBriefs en 2026-03-21T10:32:44Z Lilly’s triple‑agonist retatrutide hits Phase III goals — diabetes A1C and weight fall https://biobriefs.com/fda-clears-high-dose-wegovy BioBriefs en 2026-03-21T10:32:44Z FDA clears high‑dose Wegovy fast — Novo leverages commissioner’s voucher https://biobriefs.com/earendil-labs-pulls-in-787m BioBriefs en 2026-03-21T10:32:44Z Earendil Labs pulls in $787M — AI‑driven biologics startup scales pipeline https://biobriefs.com/engineered-esophagus-integrates-and-functions BioBriefs en 2026-03-21T10:32:44Z Engineered esophagus integrates and functions in growing pigs — path to paediatric grafts https://biobriefs.com/oncolytic-virus-pelareorep-wins-fda BioBriefs en 2026-03-21T10:32:44Z Oncolytic virus pelareorep wins FDA fast‑track — targets KRAS‑mutant metastatic CRC https://biobriefs.com/roche-shelves-emugrobart-genentech-halts BioBriefs en 2026-03-21T10:32:44Z Roche shelves emugrobart — Genentech halts muscle‑preserving antibody after failure https://biobriefs.com/fda-asks-uniqure-for-sham BioBriefs en 2026-03-21T10:32:44Z FDA asks uniQure for sham‑surgery‑controlled study — Huntington’s gene therapy path clouded https://biobriefs.com/acip-turmoil-deepens-after-injunction BioBriefs en 2026-03-21T10:32:44Z ACIP turmoil deepens after injunction — committee membership and future in flux https://biobriefs.com/abbott-completes-exact-sciences-buy BioBriefs en 2026-03-21T10:32:44Z Abbott completes Exact Sciences buy — diagnostics leader expands cancer‑testing footprint https://biobriefs.com/novartis-pays-2-billion-buys BioBriefs en 2026-03-21T09:33:06Z Novartis pays $2 billion — buys mutant‑selective PI3Kα to shore up breast‑cancer franchise https://biobriefs.com/earendil-hauls-in-787-million BioBriefs en 2026-03-21T09:33:06Z Earendil hauls in $787 million — AI‑powered biologics blitz expands pipeline https://biobriefs.com/retatrutide-lillys-triple-agonist-delivers BioBriefs en 2026-03-21T09:33:06Z Retatrutide: Lilly’s triple‑agonist delivers on glucose and weight — phase III win https://biobriefs.com/fda-clears-high-dose-wegovy BioBriefs en 2026-03-21T09:33:06Z FDA clears high‑dose Wegovy under voucher — Novo pushes to reclaim market share https://biobriefs.com/genentech-roche-halt-muscle-growth BioBriefs en 2026-03-21T09:33:06Z Genentech, Roche halt muscle‑growth program — late‑stage failure prompts pipeline cull https://biobriefs.com/fda-asks-uniqure-for-sham BioBriefs en 2026-03-21T09:33:06Z FDA asks uniQure for sham‑surgery randomized trial for Huntington’s gene therapy — ethical alarm https://biobriefs.com/tumor-whole-genome-sequencing-shows BioBriefs en 2026-03-21T09:33:06Z Tumor whole‑genome sequencing shows real‑world clinical utility — Nature Medicine dataset https://biobriefs.com/nccn-adds-genomic-profiling-recommendation BioBriefs en 2026-03-21T09:33:06Z NCCN adds genomic profiling recommendation for pancreatic cancer — NGS use expands https://biobriefs.com/excalipoint-raises-68-7m-shanghai BioBriefs en 2026-03-21T09:33:06Z Excalipoint raises $68.7M — Shanghai startup advances trispecific T‑cell engagers for solid tumors https://biobriefs.com/abbott-closes-23-billion-exact BioBriefs en 2026-03-21T09:33:06Z Abbott closes $23 billion Exact Sciences acquisition — diagnostics push accelerates https://biobriefs.com/measles-resurgence-u-s-records BioBriefs en 2026-03-21T04:32:55Z Measles resurgence: U.S. records sustained transmission after vaccination declines https://biobriefs.com/acip-upheaval-court-injunction-fuels BioBriefs en 2026-03-21T04:32:55Z ACIP upheaval – court injunction fuels claims of panel reshuffle https://biobriefs.com/fda-demands-sham-controlled-trial BioBriefs en 2026-03-21T04:32:55Z FDA demands sham-controlled trial for life‑prolonging Huntington’s gene therapy https://biobriefs.com/earendil-raises-787m-ai-driven BioBriefs en 2026-03-21T04:32:55Z Earendil raises $787M... AI-driven biologics startup scales toward clinic https://biobriefs.com/retatrutide-hits-phase-iii-endpoints BioBriefs en 2026-03-21T04:32:55Z Retatrutide hits phase III endpoints — triple‑agonist shows A1C and weight gains https://biobriefs.com/wegovy-hd-approved-fda-uses BioBriefs en 2026-03-21T04:32:55Z Wegovy HD approved: FDA uses commissioner voucher to speed review https://biobriefs.com/novartis-pays-2b-for-next BioBriefs en 2026-03-21T04:32:55Z Novartis pays $2B for next‑generation PI3Kα to shore up breast‑cancer franchise https://biobriefs.com/engineered-esophagus-integrates-in-growing BioBriefs en 2026-03-21T04:32:55Z Engineered esophagus integrates in growing pigs—functional graft restores feeding https://biobriefs.com/tumor-whole-genome-sequencing-shows BioBriefs en 2026-03-21T04:32:55Z Tumor whole‑genome sequencing shows routine clinical impact in solid cancers https://biobriefs.com/fda-seeks-public-input-on BioBriefs en 2026-03-21T04:32:55Z FDA seeks public input on commissioner’s voucher pilot ahead of summer meeting https://biobriefs.com/earendil-labs-hauls-in-787m BioBriefs en 2026-03-20T21:33:16Z Earendil Labs hauls in $787M — AI biologics bankroll expands https://biobriefs.com/fda-clears-high-dose-wegovy BioBriefs en 2026-03-20T21:33:16Z FDA clears high‑dose Wegovy under voucher — Novo wins fast review https://biobriefs.com/lillys-triple-agonist-retatrutide-meets BioBriefs en 2026-03-20T21:33:16Z Lilly’s triple‑agonist retatrutide meets Phase III goals — diabetes and weight outcomes https://biobriefs.com/novartis-pays-2b-up-front BioBriefs en 2026-03-20T21:33:16Z Novartis pays $2B up front for Synnovation PI3Kα programs — franchise defense https://biobriefs.com/muscle-building-hopes-fade-roche BioBriefs en 2026-03-20T21:33:16Z Muscle‑building hopes fade — Roche and Genentech halt candidates https://biobriefs.com/fda-presses-for-sham-surgery BioBriefs en 2026-03-20T21:33:16Z FDA presses for sham‑surgery control in uniQure’s Huntington gene trial — regulator unmoved by external controls https://biobriefs.com/tumor-whole-genome-sequencing-shows BioBriefs en 2026-03-20T21:33:16Z Tumor whole‑genome sequencing shows real‑world clinical utility — Nature Medicine series https://biobriefs.com/abbott-to-close-exact-sciences BioBriefs en 2026-03-20T21:33:16Z Abbott to close Exact Sciences buy — $23B deal seals diagnostics push https://biobriefs.com/nautilus-voyager-lands-baylor-access BioBriefs en 2026-03-20T21:33:16Z Nautilus Voyager lands Baylor access — single‑molecule proteomics readied for research use https://biobriefs.com/in-vivo-car-t-edges BioBriefs en 2026-03-20T21:33:16Z In vivo CAR‑T edges closer — researchers reprogram T cells inside living hosts https://biobriefs.com/earendil-labs-raises-787m-ai BioBriefs en 2026-03-20T16:33:53Z Earendil Labs raises $787M — AI platform scales drug pipeline https://biobriefs.com/verily-raises-300m-alphabet-loses BioBriefs en 2026-03-20T16:33:53Z Verily raises $300M: Alphabet loses majority control https://biobriefs.com/abbott-closes-23b-exact-sciences BioBriefs en 2026-03-20T16:33:53Z Abbott closes $23B Exact Sciences buy — Diagnostics becomes core growth play https://biobriefs.com/novartis-pays-2b-upfront-next BioBriefs en 2026-03-20T16:33:53Z Novartis pays $2B upfront — Next‑gen PI3Kα joins breast cancer arsenal https://biobriefs.com/roche-and-genentech-abandon-muscle BioBriefs en 2026-03-20T16:33:53Z Roche and Genentech abandon muscle‑building programs — Trials fail to show benefit https://biobriefs.com/lillys-triple-agonist-retatrutide-clears BioBriefs en 2026-03-20T16:33:53Z Lilly’s triple‑agonist retatrutide clears Phase III A1C and weight endpoints https://biobriefs.com/fda-clears-high-dose-wegovy BioBriefs en 2026-03-20T16:33:53Z FDA clears high‑dose Wegovy fast — Commissioner’s voucher accelerates review https://biobriefs.com/fda-and-nih-push-to BioBriefs en 2026-03-20T16:33:53Z FDA and NIH push to pare animal testing — Draft guidance issued https://biobriefs.com/in-vivo-car-t-edges BioBriefs en 2026-03-20T16:33:53Z In vivo CAR‑T edges closer — Precision engineering generates CAR T inside patients https://biobriefs.com/pelareorep-wins-fda-fast-track BioBriefs en 2026-03-20T16:33:53Z Pelareorep wins FDA fast track — Oncolytic virus targets KRAS‑mutant colorectal cancer https://biobriefs.com/abbott-to-close-23-billion BioBriefs en 2026-03-20T14:33:33Z Abbott to close $23 billion Exact Sciences deal Monday – Enters cancer‑screening market https://biobriefs.com/novartis-pays-2b-upfront-for BioBriefs en 2026-03-20T14:33:33Z Novartis pays $2B upfront for next‑gen PI3Kα – Rivalry around breast‑cancer franchise intensifies https://biobriefs.com/lillys-triple-agonist-retatrutide-wins BioBriefs en 2026-03-20T14:33:33Z Lilly’s triple‑agonist retatrutide wins Phase III endpoints – Major A1C and weight gains reported https://biobriefs.com/fda-widens-rare-obesity-label BioBriefs en 2026-03-20T14:33:33Z FDA widens rare‑obesity label; J&J gets oral IL‑23 pill — regulators clear niche and mainstream drugs https://biobriefs.com/car-t-made-inside-the BioBriefs en 2026-03-20T14:33:33Z CAR‑T made inside the patient: Dual‑vector in vivo integration shows tumor clearance in preclinical models https://biobriefs.com/generalist-biological-ai-and-a BioBriefs en 2026-03-20T14:33:33Z Generalist biological AI... and a trillion‑gene push: Big data meets drug design https://biobriefs.com/astrazeneca-doubles-down-on-china BioBriefs en 2026-03-20T14:33:33Z AstraZeneca doubles down on China: Cell‑therapy R&D and manufacturing hub goes ahead https://biobriefs.com/decentralized-diagnostics-diasorin-distribution-deal BioBriefs en 2026-03-20T14:33:33Z Decentralized diagnostics: Diasorin distribution deal and WHO’s new TB nPOC‑NAAT class https://biobriefs.com/congress-revives-sbir-sttr-seed BioBriefs en 2026-03-20T14:33:33Z Congress revives SBIR/STTR seed funding – Biotech early‑stage lifeline restored https://biobriefs.com/congruence-raises-fresh-capital-as BioBriefs en 2026-03-20T14:33:33Z Congruence raises fresh capital as it starts human trials – Protein‑misfolding correctors advance https://biobriefs.com/programmable-in-vivo-car-t BioBriefs en 2026-03-20T10:33:09Z Programmable in vivo CAR‑T: Dual‑vector system inserts large DNA payload https://biobriefs.com/retatrutide-triple-agonist-slashes-a1c BioBriefs en 2026-03-20T10:33:09Z Retatrutide: triple‑agonist slashes A1C and sheds 36.6 lbs in Phase III https://biobriefs.com/fda-greenlights-high-dose-wegovy BioBriefs en 2026-03-20T10:33:09Z FDA greenlights high‑dose Wegovy — approval fast‑tracked by commissioner’s voucher https://biobriefs.com/j-j-s-icotyde-fda BioBriefs en 2026-03-20T10:33:09Z J&J's Icotyde: FDA clears oral IL‑23 pill for plaque psoriasis https://biobriefs.com/nautilus-voyager-lands-baylor-single BioBriefs en 2026-03-20T10:33:09Z Nautilus Voyager lands Baylor: single‑molecule proteomics enters cancer research https://biobriefs.com/collegium-buys-azstarys-from-corium BioBriefs en 2026-03-20T10:33:09Z Collegium buys AZSTARYS from Corium for $650m — ADHD play https://biobriefs.com/verily-raises-300m-alphabet-cedes BioBriefs en 2026-03-20T10:33:09Z Verily raises $300m; Alphabet cedes majority control https://biobriefs.com/terrapower-to-build-450m-actinium BioBriefs en 2026-03-20T10:33:09Z TerraPower to build $450m actinium‑225 plant — nuclear supply for radiotherapies https://biobriefs.com/gilead-hands-hbv-candidate-back BioBriefs en 2026-03-20T10:33:09Z Gilead hands HBV candidate back to Assembly — ABI‑4334 rights revert https://biobriefs.com/arvinas-protac-penetrates-brain-arv BioBriefs en 2026-03-20T10:33:09Z Arvinas PROTAC penetrates brain: ARV‑102 halves LRRK2 in CSF https://biobriefs.com/lillys-triple-agonist-posts-phase BioBriefs en 2026-03-20T09:33:19Z Lilly’s triple‑agonist posts phase III win — A1C down, dramatic weight loss https://biobriefs.com/fda-clears-high-dose-wegovy BioBriefs en 2026-03-20T09:33:19Z FDA clears high‑dose Wegovy — Novo uses commissioner voucher for rapid review https://biobriefs.com/j-j-lands-oral-il BioBriefs en 2026-03-20T09:33:19Z J&J lands oral IL‑23 approval — Icotyde positioned to take on injectables https://biobriefs.com/car-t-made-inside-the BioBriefs en 2026-03-20T09:33:19Z CAR‑T made inside the body: targeted gene integration clears tumors in mice https://biobriefs.com/protac-clears-cns-hurdle-arvinas BioBriefs en 2026-03-20T09:33:19Z PROTAC clears CNS hurdle — Arvinas shows LRRK2 degradation in cerebrospinal fluid https://biobriefs.com/fda-fast-tracks-oncolytic-pelareorep BioBriefs en 2026-03-20T09:33:19Z FDA fast‑tracks oncolytic pelareorep for KRAS‑mutant CRC — response signals cited https://biobriefs.com/trillion-gene-atlas-unveiled-massive BioBriefs en 2026-03-20T09:33:19Z Trillion Gene Atlas unveiled — massive evolutionary dataset to fuel AI drug design https://biobriefs.com/regulators-shift-away-from-animal BioBriefs en 2026-03-20T09:33:19Z Regulators shift away from animal studies — FDA drafts guidance, NIH marks progress https://biobriefs.com/congress-revives-sbir-sttr-seed BioBriefs en 2026-03-20T09:33:19Z Congress revives SBIR/STTR — seed funding rebooted for five years https://biobriefs.com/astrazeneca-builds-china-cell-therapy BioBriefs en 2026-03-20T09:33:19Z AstraZeneca builds China cell‑therapy hub — end‑to‑end manufacturing and R&D in Shanghai https://biobriefs.com/lillys-triple-agonist-hits-primary BioBriefs en 2026-03-20T04:33:02Z Lilly’s triple agonist hits primary endpoints – diabetes trial posts strong A1C and weight gains https://biobriefs.com/wegovy-hd-cleared-fast-fda BioBriefs en 2026-03-20T04:33:02Z Wegovy HD cleared fast: FDA uses commissioner voucher to accelerate review https://biobriefs.com/j-js-icotyde-wins-approval BioBriefs en 2026-03-20T04:33:02Z J&J’s Icotyde wins approval – oral IL‑23 pill positions to challenge injectables https://biobriefs.com/in-vivo-car-t-advances BioBriefs en 2026-03-20T04:33:02Z In vivo CAR‑T advances: targeted, site‑specific integration and dual‑vector systems show efficacy in animals https://biobriefs.com/arvinas-protac-achieves-central-target BioBriefs en 2026-03-20T04:33:02Z Arvinas PROTAC achieves central target knockdown in Parkinson’s patients https://biobriefs.com/thymus-health-resurfaces-as-determinant BioBriefs en 2026-03-20T04:33:02Z Thymus health resurfaces as determinant of longevity and immunotherapy outcomes https://biobriefs.com/basecamp-launches-trillion-gene-atlas BioBriefs en 2026-03-20T04:33:02Z Basecamp launches Trillion Gene Atlas with AI partners to scale evolutionary data for drug design https://biobriefs.com/oncolytics-pelareorep-granted-fda-fast BioBriefs en 2026-03-20T04:33:02Z Oncolytics’ pelareorep granted FDA fast‑track in KRAS‑mutant metastatic colorectal cancer https://biobriefs.com/nautilus-opens-early-access-to BioBriefs en 2026-03-20T04:33:02Z Nautilus opens early access to Voyager proteomics platform with Baylor collaboration https://biobriefs.com/congress-restores-sbir-sttr-funding BioBriefs en 2026-03-20T04:33:02Z Congress restores SBIR/STTR funding — reauthorization clears crucial early‑stage support https://biobriefs.com/lillys-triple-agonist-slashes-a1c BioBriefs en 2026-03-19T21:33:14Z Lilly’s triple‑agonist slashes A1C and body weight – phase III wins https://biobriefs.com/fda-clears-high-dose-wegovy BioBriefs en 2026-03-19T21:33:14Z FDA clears high‑dose Wegovy under voucher – Novo speeds comeback https://biobriefs.com/j-js-oral-il-23 BioBriefs en 2026-03-19T21:33:14Z J&J’s oral IL‑23 pill Icotyde wins FDA nod – a straight shot at injectables https://biobriefs.com/in-vivo-car-t-advances BioBriefs en 2026-03-19T21:33:14Z In vivo CAR‑T advances: programmable engineering inside the patient https://biobriefs.com/trillion-gene-atlas-launched-ambitious BioBriefs en 2026-03-19T21:33:14Z Trillion Gene Atlas launched: ambitious data bet to power AI drug design https://biobriefs.com/protac-reaches-the-brain-arvinas BioBriefs en 2026-03-19T21:33:14Z PROTAC reaches the brain: Arvinas posts CSF LRRK2 degradation in PD https://biobriefs.com/nautilus-voyager-lands-baylor-trial BioBriefs en 2026-03-19T21:33:14Z Nautilus’ Voyager lands Baylor trial slot for isoform‑level tumor proteomics https://biobriefs.com/cell-free-manufacturing-validated-at BioBriefs en 2026-03-19T21:33:14Z Cell‑free manufacturing validated at pilot scale: eXoZymes passes external run https://biobriefs.com/congress-restores-sbir-sttr-seed BioBriefs en 2026-03-19T21:33:14Z Congress restores SBIR/STTR seed funding – early‑stage biotech lifeline renewed https://biobriefs.com/fda-signals-regulatory-flexibility-fewer BioBriefs en 2026-03-19T21:33:14Z FDA signals regulatory flexibility: fewer animal studies and RMAT for on‑hold programs https://biobriefs.com/retatrutide-hits-endpoints-lilly-posts BioBriefs en 2026-03-19T16:34:20Z Retatrutide hits endpoints — Lilly posts large weight and glucose declines https://biobriefs.com/pfizer-seeks-earlier-talzenna-use BioBriefs en 2026-03-19T16:34:20Z Pfizer seeks earlier Talzenna use after Phase 3 win https://biobriefs.com/fda-clears-icotyde-j-j BioBriefs en 2026-03-19T16:34:20Z FDA clears Icotyde: J&J lands oral IL‑23 pill for psoriasis https://biobriefs.com/in-vivo-car-t-dual BioBriefs en 2026-03-19T16:34:20Z In vivo CAR‑T: Dual‑vector system inserts large payloads and clears tumors https://biobriefs.com/astrazeneca-bets-on-china-builds BioBriefs en 2026-03-19T16:34:19Z AstraZeneca bets on China — builds cell‑therapy R&D and manufacturing hub https://biobriefs.com/fda-fast-tracks-pelareorep-combo BioBriefs en 2026-03-19T16:34:19Z FDA fast‑tracks pelareorep combo for KRAS‑mutant colorectal cancer https://biobriefs.com/trillion-gene-atlas-partners-pledge BioBriefs en 2026-03-19T16:34:19Z Trillion Gene Atlas: partners pledge massive evolutionary dataset for AI drug design https://biobriefs.com/excalipoint-nets-68-7m-seed BioBriefs en 2026-03-19T16:34:19Z Excalipoint nets $68.7M seed — backs T‑cell engagers for solid tumors https://biobriefs.com/engineered-e-coli-sustains-intratumoral BioBriefs en 2026-03-19T16:34:19Z Engineered E. coli sustains intratumoral NO — reshapes tumor microenvironment https://biobriefs.com/fda-pivots-on-preclinical-rules BioBriefs en 2026-03-19T16:34:19Z FDA pivots on preclinical rules — draft guidance and RMAT clarifications issued https://biobriefs.com/lillys-triple-g-delivers-strong BioBriefs en 2026-03-19T14:32:56Z Lilly’s triple‑G delivers strong glycemic, weight wins – mixed reads vs Mounjaro https://biobriefs.com/j-js-oral-il-23 BioBriefs en 2026-03-19T14:32:56Z J&J’s oral IL‑23 pill Icotyde wins FDA — rivals injectable blockbusters https://biobriefs.com/in-vivo-car-t-advances BioBriefs en 2026-03-19T14:32:56Z In vivo CAR‑T advances: two-vector approaches show programmable, site‑specific edits https://biobriefs.com/basecamp-launches-trillion-gene-atlas BioBriefs en 2026-03-19T14:32:56Z Basecamp launches Trillion Gene Atlas — big data for AI drug design https://biobriefs.com/who-debuts-near-poc-tb BioBriefs en 2026-03-19T14:32:56Z WHO debuts near‑POC TB test class — Pluslife’s MiniDock leads push for decentralized diagnostics https://biobriefs.com/cell-therapy-scale-up-astrazeneca BioBriefs en 2026-03-19T14:32:56Z Cell therapy scale-up: AstraZeneca invests in China; Sartorius unveils Eveo manufacturing stack https://biobriefs.com/precision-oncology-diagnostics-myriads-mychoice BioBriefs en 2026-03-19T14:32:56Z Precision oncology diagnostics: Myriad’s MyChoice gains FDA nod as partners co‑develop liquid and tissue tests https://biobriefs.com/sbir-sttr-reauthorization-returns-congress BioBriefs en 2026-03-19T14:32:56Z SBIR/STTR reauthorization returns — Congress restores seed funding for startups https://biobriefs.com/fda-shifts-rmats-for-trials BioBriefs en 2026-03-19T14:32:56Z FDA shifts: RMATs for trials on clinical hold; guidance nudges reduction of animal testing https://biobriefs.com/investors-back-next-gen-t BioBriefs en 2026-03-19T14:32:56Z Investors back next‑gen T‑cell programs: Crossbow, Excalipoint raise major rounds https://biobriefs.com/j-js-icotyde-wins-fda BioBriefs en 2026-03-19T10:33:20Z J&J’s Icotyde wins FDA nod — Oral IL‑23 pill cleared for plaque psoriasis https://biobriefs.com/ucsf-dual-vector-and-azalea BioBriefs en 2026-03-19T10:33:20Z UCSF dual‑vector and Azalea show in vivo CAR‑T advances — programmable editing inside patients https://biobriefs.com/basecamp-launches-trillion-gene-atlas BioBriefs en 2026-03-19T10:33:20Z Basecamp launches Trillion Gene Atlas — partners with Anthropic, Ultima and PacBio https://biobriefs.com/single-molecule-peptide-sequencing-and BioBriefs en 2026-03-19T10:33:20Z Single‑molecule peptide sequencing and new proteomics methods expand protein readout capabilities https://biobriefs.com/lipid-nanoparticles-repurpose-immune-metabolism BioBriefs en 2026-03-19T10:33:20Z Lipid nanoparticles repurpose immune metabolism — new LNP designs revive exhausted T cells and boost vaccines https://biobriefs.com/us-research-funding-shifts-omb BioBriefs en 2026-03-19T10:33:20Z US research funding shifts: OMB lifts NIH spending hold; Congress reauthorizes SBIR/STTR https://biobriefs.com/cell-therapy-scale-up-experts BioBriefs en 2026-03-19T10:33:20Z Cell‑therapy scale‑up: experts call for AI, automation and workforce training; Sartorius launches integrated Eveo platform https://biobriefs.com/bicycle-therapeutics-cuts-workforce-after BioBriefs en 2026-03-19T10:33:20Z Bicycle Therapeutics cuts workforce after regulatory setback — lead ADC deprioritized https://biobriefs.com/fda-issues-third-crl-to BioBriefs en 2026-03-19T10:33:20Z FDA issues third CRL to Aldeyra — reproxalap fails to show consistent efficacy https://biobriefs.com/engineered-e-coli-sustain-intratumoral BioBriefs en 2026-03-19T10:33:20Z Engineered E. coli sustain intratumoral nitric oxide — vascular normalization boosts checkpoint therapy in mice https://biobriefs.com/car-t-made-inside-the BioBriefs en 2026-03-19T09:33:38Z CAR‑T made inside the body: targeted dual‑vector integration reported https://biobriefs.com/j-js-oral-il-23 BioBriefs en 2026-03-19T09:33:38Z J&J’s oral IL‑23 pill wins FDA clearance — first major challenger to injectables https://biobriefs.com/protein-sequencing-leap-single-molecule BioBriefs en 2026-03-19T09:33:38Z Protein sequencing leap: single‑molecule peptide reads and scalable platforms https://biobriefs.com/trillion-gene-atlas-launched-ai BioBriefs en 2026-03-19T09:33:38Z Trillion Gene Atlas launched: AI partners aim to expand evolutionary data 100‑fold https://biobriefs.com/engineered-e-coli-sustains-intratumoral BioBriefs en 2026-03-19T09:33:38Z Engineered E. coli sustains intratumoral NO — tumors sensitized to PD‑L1 blockade https://biobriefs.com/nanoparticles-rethink-immunotherapy-and-vaccines BioBriefs en 2026-03-19T09:33:38Z Nanoparticles rethink immunotherapy and vaccines: LNPs revive exhausted T cells and reprogram DC metabolism https://biobriefs.com/thymus-health-emerges-as-predictor BioBriefs en 2026-03-19T09:33:38Z Thymus health emerges as predictor of immunotherapy and long‑term outcomes https://biobriefs.com/congress-reauthorizes-sbir-sttr-early BioBriefs en 2026-03-19T09:33:38Z Congress reauthorizes SBIR/STTR — early‑stage biotech funding restored https://biobriefs.com/scaling-cell-therapies-integrated-manufacturing BioBriefs en 2026-03-19T09:33:38Z Scaling cell therapies: integrated manufacturing platforms and automation to cut bottlenecks https://biobriefs.com/t-cell-engager-funding-surge BioBriefs en 2026-03-19T09:33:38Z T‑cell engager funding surge: Crossbow, Excalipoint close major rounds https://biobriefs.com/in-body-car-t-ucsf BioBriefs en 2026-03-19T04:33:47Z In‑body CAR‑T: UCSF and Azalea show programmable T cells inside patients https://biobriefs.com/engineered-e-coli-sustained-nitric BioBriefs en 2026-03-19T04:33:46Z Engineered E. coli: sustained nitric oxide reprograms tumors and boosts PD‑L1 therapy https://biobriefs.com/fda-clears-icotyde-j-j BioBriefs en 2026-03-19T04:33:46Z FDA clears Icotyde: J&J lands oral IL‑23 pill for plaque psoriasis https://biobriefs.com/protein-sequencing-leaps-single-molecule BioBriefs en 2026-03-19T04:33:46Z Protein sequencing leaps: single‑molecule peptide decoding and scalable proteomics https://biobriefs.com/implantable-charging-station-revives-engineered BioBriefs en 2026-03-19T04:33:46Z Implantable charging station revives engineered immune cells – a new route to durable cell therapy https://biobriefs.com/trillion-gene-atlas-basecamp-anthropic BioBriefs en 2026-03-19T04:33:46Z Trillion Gene Atlas: Basecamp, Anthropic and partners launch massive evolutionary data project https://biobriefs.com/dna-script-widens-global-reach BioBriefs en 2026-03-19T04:33:46Z DNA Script widens global reach: SYNTAX oligo synthesis lands in Latin America and East Asia https://biobriefs.com/fda-opens-rmat-door-regenerative BioBriefs en 2026-03-19T04:33:46Z FDA opens RMAT door: regenerative medicine designations for therapies on clinical hold https://biobriefs.com/sbir-sttr-reauthorized-congress-restores BioBriefs en 2026-03-19T04:33:46Z SBIR/STTR reauthorized: Congress restores five years of seed funding for biotech startups https://biobriefs.com/white-house-lifts-nih-hold BioBriefs en 2026-03-19T04:33:46Z White House lifts NIH hold: agency cleared to spend 2026 research budget https://biobriefs.com/j-js-psoriasis-pill-clears BioBriefs en 2026-03-18T21:32:49Z J&J’s psoriasis pill clears FDA: Icotyde approved https://biobriefs.com/basecamps-trillion-gene-atlas-a BioBriefs en 2026-03-18T21:32:49Z Basecamp’s Trillion Gene Atlas... a new evolutionary data push https://biobriefs.com/arvinas-protac-shows-cns-penetration BioBriefs en 2026-03-18T21:32:49Z Arvinas PROTAC shows CNS penetration: LRRK2 degraded in CSF https://biobriefs.com/in-vivo-car-t-clears BioBriefs en 2026-03-18T21:32:49Z In vivo CAR‑T clears tumors in mice: Azalea posts Nature paper https://biobriefs.com/dna-script-expands-syntax-reach BioBriefs en 2026-03-18T21:32:49Z DNA Script expands SYNTAX reach: distributors in Latin America and East Asia https://biobriefs.com/crossbow-raises-77m-to-push BioBriefs en 2026-03-18T21:32:49Z Crossbow raises $77M to push T‑cell engagers into clinic https://biobriefs.com/white-house-lifts-nih-spending BioBriefs en 2026-03-18T21:32:49Z White House lifts NIH spending hold: agency cleared to spend 2026 budget https://biobriefs.com/sbir-sttr-funding-reauthorized-congress BioBriefs en 2026-03-18T21:32:49Z SBIR/STTR funding reauthorized: Congress preserves seed grants for biotech https://biobriefs.com/fda-will-consider-rmats-for BioBriefs en 2026-03-18T21:32:49Z FDA will consider RMATs for therapies on clinical hold – policy shift https://biobriefs.com/leica-bio-techne-automate-rnascope BioBriefs en 2026-03-18T21:32:49Z Leica, Bio‑Techne automate RNAscope on BOND‑PRIME: US launch https://biobriefs.com/j-j-wins-fda-nod BioBriefs en 2026-03-18T16:33:23Z J&J wins FDA nod for psoriasis pill – First oral IL‑23 blocker cleared https://biobriefs.com/azaleas-in-vivo-car-t BioBriefs en 2026-03-18T16:33:23Z Azalea’s in vivo CAR‑T clears tumors in mice: Nature paper shows proof https://biobriefs.com/white-house-lifts-nih-spending BioBriefs en 2026-03-18T16:33:23Z White House lifts NIH spending hold — Grants, hiring to resume https://biobriefs.com/basecamp-anthropic-pacbio-launch-trillion BioBriefs en 2026-03-18T16:33:23Z Basecamp, Anthropic, PacBio launch Trillion Gene Atlas: AI‑driven biodiversity push https://biobriefs.com/arvinas-protac-hits-brain-target BioBriefs en 2026-03-18T16:33:23Z Arvinas’ PROTAC hits brain target — ARV‑102 reduces LRRK2 in CSF >50% https://biobriefs.com/crossbow-banks-77m-to-advance BioBriefs en 2026-03-18T16:33:23Z Crossbow banks $77M to advance TCR‑mimetic T‑cell engagers https://biobriefs.com/structure-posts-injectable-like-oral BioBriefs en 2026-03-18T16:33:23Z Structure posts injectable‑like oral GLP‑1 results — 44‑week Phase 2 shows ~16% weight loss https://biobriefs.com/engineered-e-coli-sustains-intratumoral BioBriefs en 2026-03-18T16:33:23Z Engineered E. coli sustains intratumoral NO — Vascular normalization boosts anti‑PD‑L1 responses https://biobriefs.com/fda-clears-myriads-mychoice-cdx BioBriefs en 2026-03-18T16:33:23Z FDA clears Myriad’s MyChoice CDx as companion for GSK’s Zejula https://biobriefs.com/roche-plans-massive-ai-factory BioBriefs en 2026-03-18T16:33:23Z Roche plans massive 'AI factory' — Nvidia deal to accelerate drug and diagnostic R&D https://biobriefs.com/j-js-icotyde-wins-fda BioBriefs en 2026-03-18T14:33:28Z J&J’s Icotyde wins FDA approval — oral psoriasis option cleared https://biobriefs.com/protac-reaches-the-brain-arvinas BioBriefs en 2026-03-18T14:33:28Z PROTAC reaches the brain... Arvinas posts central LRRK2 degradation https://biobriefs.com/oral-glp-1-posts-injectable BioBriefs en 2026-03-18T14:33:28Z Oral GLP‑1 posts injectable‑like results — Structure’s aleniglipron advances https://biobriefs.com/masked-adc-shows-responses-in BioBriefs en 2026-03-18T14:33:28Z Masked ADC shows responses in late‑line CRC — CytomX expands readout https://biobriefs.com/excalipoint-raises-68-7m-chinas BioBriefs en 2026-03-18T14:33:28Z Excalipoint raises $68.7M — China’s T‑cell engager push https://biobriefs.com/roche-builds-an-ai-factory BioBriefs en 2026-03-18T14:33:28Z Roche builds an AI factory: Nvidia pact to scale drug discovery https://biobriefs.com/engineered-e-coli-sustains-tumor BioBriefs en 2026-03-18T14:33:28Z Engineered E. coli sustains tumor NO — sensitizes tumors to PD‑L1 https://biobriefs.com/in-vivo-base-editing-reverses BioBriefs en 2026-03-18T14:33:28Z In vivo base editing reverses disorder — new editors cut bystander edits https://biobriefs.com/protein-sequencing-scales-up-single BioBriefs en 2026-03-18T14:33:28Z Protein sequencing scales up — single‑molecule peptide reads emerge https://biobriefs.com/ai-meets-in-vivo-functional BioBriefs en 2026-03-18T14:33:28Z AI meets in‑vivo functional genomics — PerturbAI’s atlas, Xaira’s X‑Cell https://biobriefs.com/roche-builds-biggest-ai-factory BioBriefs en 2026-03-18T10:33:26Z Roche builds biggest AI factory in pharma — supercomputing push underway https://biobriefs.com/white-house-lifts-nih-spending BioBriefs en 2026-03-18T10:33:26Z White House lifts NIH spending hold — grants and hiring to restart https://biobriefs.com/federal-court-pauses-hhs-vaccine BioBriefs en 2026-03-18T10:33:26Z Federal court pauses HHS vaccine overhaul — ACIP and new schedule blocked https://biobriefs.com/structure-s-oral-glp-1 BioBriefs en 2026-03-18T10:33:26Z Structure's oral GLP‑1 posts injectable‑like results — Phase II data out https://biobriefs.com/masked-adcs-show-activity-cytomx BioBriefs en 2026-03-18T10:33:26Z Masked ADCs show activity — CytomX updates as Astellas ends big collaboration https://biobriefs.com/bicycle-therapeutics-shrinks-after-regulatory BioBriefs en 2026-03-18T10:33:26Z Bicycle Therapeutics shrinks after regulatory setback — lead ADC deprioritized https://biobriefs.com/base-editors-advance-precision-abes BioBriefs en 2026-03-18T10:33:26Z Base editors advance: precision ABEs and in‑vivo rescue reported https://biobriefs.com/engineered-e-coli-drives-intratumoral BioBriefs en 2026-03-18T10:33:26Z Engineered E. coli drives intratumoral nitric oxide — tumors sensitized to PD‑L1 blockade https://biobriefs.com/manufacturing-bottlenecks-integrated-cell-therapy BioBriefs en 2026-03-18T10:33:26Z Manufacturing bottlenecks: integrated cell‑therapy systems and AI for gene‑therapy scale https://biobriefs.com/diagnostics-fda-oks-myriad-mychoice BioBriefs en 2026-03-18T10:33:26Z Diagnostics: FDA OKs Myriad MyChoice CDx and CMS covers NeoGenomics liquid biopsy https://biobriefs.com/white-house-clears-nih-apportionment BioBriefs en 2026-03-18T09:33:41Z White House clears NIH apportionment: grants to resume https://biobriefs.com/roche-bets-on-an-ai BioBriefs en 2026-03-18T09:33:41Z Roche bets on an AI factory: Nvidia collab to power drug R&D https://biobriefs.com/oral-glp-1s-heat-up BioBriefs en 2026-03-18T09:33:41Z Oral GLP-1s heat up: Structure posts 'injectable-like' Phase 2 win https://biobriefs.com/masked-adc-shows-activity-in BioBriefs en 2026-03-18T09:33:41Z Masked ADC shows activity in CRC... Investors take notice https://biobriefs.com/astellas-walks-away-1-6b BioBriefs en 2026-03-18T09:33:41Z Astellas walks away: $1.6B CytomX pact ends https://biobriefs.com/metapipeline-dna-standardizes-sequencing-automated BioBriefs en 2026-03-18T09:33:41Z Metapipeline‑DNA standardizes sequencing: automated genomics at scale https://biobriefs.com/alphafold-expands-to-complexes-millions BioBriefs en 2026-03-18T09:33:41Z AlphaFold expands to complexes: millions of protein interactions added https://biobriefs.com/perturbai-releases-8m-cell-crispr BioBriefs en 2026-03-18T09:33:41Z PerturbAI releases 8M‑cell CRISPR atlas—startup emerges from stealth https://biobriefs.com/fda-clears-myriad-mychoice-as BioBriefs en 2026-03-18T09:33:41Z FDA clears Myriad MyChoice as Zejula companion: ovarian CDx approved https://biobriefs.com/fda-rejects-aldeyra-again-third BioBriefs en 2026-03-18T09:33:41Z FDA rejects Aldeyra again: third CRL for reproxalap https://biobriefs.com/nih-funding-hold-lifted-grants BioBriefs en 2026-03-18T04:33:56Z NIH funding hold lifted: grants and hiring to resume https://biobriefs.com/federal-court-halts-vaccine-schedule BioBriefs en 2026-03-18T04:33:56Z Federal court halts vaccine schedule overhaul, ACIP appointments stayed https://biobriefs.com/oral-glp-1-pill-posts BioBriefs en 2026-03-18T04:33:56Z Oral GLP‑1 pill posts strong Phase 2 weight loss – 16% at 44 weeks https://biobriefs.com/roche-and-nvidia-strike-deal BioBriefs en 2026-03-18T04:33:56Z Roche and Nvidia strike deal: building pharma’s largest AI 'factory' https://biobriefs.com/manufacturing-push-arpa-h-funds BioBriefs en 2026-03-18T04:33:56Z Manufacturing push: ARPA‑H funds digital gene‑therapy platform; AutoCell automation advances https://biobriefs.com/astellas-ends-cytomx-pact-as BioBriefs en 2026-03-18T04:33:56Z Astellas ends CytomX pact as CytomX posts encouraging CRC ADC data https://biobriefs.com/perturbai-publishes-8m-cell-in BioBriefs en 2026-03-18T04:33:56Z PerturbAI publishes 8M‑cell in vivo CRISPR atlas and exits stealth https://biobriefs.com/lipid-innovations-sharpen-tissue-targeting BioBriefs en 2026-03-18T04:33:56Z Lipid innovations sharpen tissue targeting and immune tuning for LNPs https://biobriefs.com/in-vivo-base-editing-reverses BioBriefs en 2026-03-18T04:33:56Z In vivo base editing reverses neurodevelopmental disorder in preclinical model https://biobriefs.com/r1-therapeutics-raises-77-5m BioBriefs en 2026-03-18T04:33:56Z R1 Therapeutics raises $77.5M to advance AP‑306 for hyperphosphatemia in CKD https://biobriefs.com/oral-glp-1-pill-rivals BioBriefs en 2026-03-17T21:33:29Z Oral GLP-1 pill rivals injectables: Structure posts 44‑week, phase‑2 win https://biobriefs.com/federal-judge-freezes-acip-overhaul BioBriefs en 2026-03-17T21:33:29Z Federal judge freezes ACIP overhaul: vaccine schedule, appointments stayed https://biobriefs.com/cytomx-data-and-astellas-exit BioBriefs en 2026-03-17T21:33:29Z CytomX data and Astellas exit: masked ADC story tightens https://biobriefs.com/standardizing-genomic-pipeline-metapipeline-dna BioBriefs en 2026-03-17T21:33:29Z Standardizing genomic pipeline: metapipeline‑DNA goes cloud‑scale https://biobriefs.com/arpa-h-funds-digital-gene BioBriefs en 2026-03-17T21:33:29Z ARPA‑H funds digital gene‑therapy manufacturing: $9.3M award to BioCurie https://biobriefs.com/lnp-chemistry-advances-redesigned-lipids BioBriefs en 2026-03-17T21:33:29Z LNP chemistry advances: redesigned lipids and media tweaks raise delivery bar https://biobriefs.com/perturbai-publishes-8m-cell-in BioBriefs en 2026-03-17T21:33:29Z PerturbAI publishes 8M‑cell in‑vivo CRISPR atlas: public resource for causal genomics https://biobriefs.com/big-pharma-builds-an-ai BioBriefs en 2026-03-17T21:33:29Z Big pharma builds an AI factory: Roche, Nvidia expand compute for drug R&D https://biobriefs.com/in-vivo-base-editing-reverses BioBriefs en 2026-03-17T21:33:29Z In vivo base editing reverses neurodevelopmental disorder – preclinical milestone https://biobriefs.com/new-renal-biotech-r1-raises BioBriefs en 2026-03-17T21:33:29Z New renal biotech R1 raises $77.5M to advance oral hyperphosphatemia drug https://biobriefs.com/judge-halts-overhaul-of-u BioBriefs en 2026-03-17T16:33:04Z Judge halts overhaul of U.S. childhood vaccine policy — ACIP appointments stayed https://biobriefs.com/r1-therapeutics-launches-with-77 BioBriefs en 2026-03-17T16:33:04Z R1 Therapeutics launches with $77.5M to advance AP306 for dialysis-related hyperphosphatemia https://biobriefs.com/structures-oral-glp-1-pill BioBriefs en 2026-03-17T16:33:04Z Structure’s oral GLP‑1 pill posts 44‑week weight loss that rivals injectables https://biobriefs.com/cytomxs-masked-adc-posts-responses BioBriefs en 2026-03-17T16:33:04Z CytomX’s masked ADC posts responses in late‑line colorectal cancer — stock rallies https://biobriefs.com/bicycle-therapeutics-cuts-30-of BioBriefs en 2026-03-17T16:33:04Z Bicycle Therapeutics cuts 30% of workforce after regulatory setback on lead oncology asset https://biobriefs.com/perturbai-releases-largest-in-vivo BioBriefs en 2026-03-17T16:33:04Z PerturbAI releases largest in‑vivo CRISPR brain atlas — dataset of 8M cells https://biobriefs.com/roche-inks-nvidia-partnership-to BioBriefs en 2026-03-17T16:33:04Z Roche inks Nvidia partnership to build a large‑scale pharma 'AI factory' https://biobriefs.com/wemerfish-whole-embryo-3d-spatial BioBriefs en 2026-03-17T16:33:04Z weMERFISH: whole‑embryo, 3D spatial transcriptomics advances developmental mapping https://biobriefs.com/arpa-h-awards-biocurie-up BioBriefs en 2026-03-17T16:33:04Z ARPA‑H awards BioCurie up to $9.3M to build AI‑driven gene therapy manufacturing platform https://biobriefs.com/trenchant-and-invetech-advance-fully BioBriefs en 2026-03-17T16:33:04Z Trenchant and Invetech advance fully automated, point‑of‑care CGT AutoCell manufacturing https://biobriefs.com/perturbai-exits-stealth-publishes-8m BioBriefs en 2026-03-17T14:32:30Z PerturbAI exits stealth—publishes 8M-cell in vivo CRISPR atlas https://biobriefs.com/alphafold-db-expands-millions-of BioBriefs en 2026-03-17T14:32:30Z AlphaFold DB expands—millions of new protein complex predictions added https://biobriefs.com/generative-ai-drives-petascale-designed BioBriefs en 2026-03-17T14:32:30Z Generative AI drives petascale designed DNA synthesis — Nature Biotechnology https://biobriefs.com/roche-strikes-nvidia-pact-aims BioBriefs en 2026-03-17T14:32:30Z Roche strikes Nvidia pact—aims to build pharma’s largest AI compute hub https://biobriefs.com/mayo-clinic-engineers-milk-derived BioBriefs en 2026-03-17T14:32:30Z Mayo Clinic engineers milk‑derived nanoparticles for targeted gene therapy https://biobriefs.com/structures-oral-glp-1-posts BioBriefs en 2026-03-17T14:32:30Z Structure’s oral GLP‑1 posts up to 16% weight loss — Phase 2 readout https://biobriefs.com/biomarin-pauses-voxzogo-dosing-after BioBriefs en 2026-03-17T14:32:30Z BioMarin pauses Voxzogo dosing after hip safety signal https://biobriefs.com/r1-therapeutics-raises-77-5m BioBriefs en 2026-03-17T14:32:30Z R1 Therapeutics raises $77.5M to advance kidney disease candidate https://biobriefs.com/arpa-h-backs-biocurie-9 BioBriefs en 2026-03-17T14:32:30Z ARPA‑H backs BioCurie—$9.3M to digitize gene therapy manufacturing https://biobriefs.com/trenchant-invetech-partner-to-commercialize BioBriefs en 2026-03-17T14:32:30Z Trenchant, Invetech partner to commercialize fully automated CGT manufacturing https://biobriefs.com/structures-oral-glp-1-delivers BioBriefs en 2026-03-17T10:32:54Z Structure’s oral GLP‑1 delivers 16% weight loss – Plans phase 3 https://biobriefs.com/cytomx-posts-promising-adc-data BioBriefs en 2026-03-17T10:32:54Z CytomX posts promising ADC data; partner exits a multi‑year T‑cell pact https://biobriefs.com/alphafold-expands-into-protein-complexes BioBriefs en 2026-03-17T10:32:54Z AlphaFold expands into protein complexes: Massive database release https://biobriefs.com/researchers-build-neurobots-with-self BioBriefs en 2026-03-17T10:32:54Z Researchers build neurobots with self‑organizing nervous systems https://biobriefs.com/arpa-h-backs-ai-platform BioBriefs en 2026-03-17T10:32:54Z ARPA‑H backs AI platform to scale gene‑therapy manufacturing https://biobriefs.com/trenchant-and-invetech-target-fully BioBriefs en 2026-03-17T10:32:54Z Trenchant and Invetech target fully automated point‑of‑care CGT manufacturing https://biobriefs.com/circode-cleared-to-start-u BioBriefs en 2026-03-17T10:32:54Z CirCode cleared to start U.S. trial of circular RNA therapy https://biobriefs.com/roche-inks-nvidia-deal-to BioBriefs en 2026-03-17T10:32:54Z Roche inks Nvidia deal to supercharge AI drug and diagnostic factory https://biobriefs.com/biovie-positions-spinout-for-19 BioBriefs en 2026-03-17T10:32:54Z BioVie positions spinout for $19.7M IPO to fund liver‑disease program https://biobriefs.com/judge-stays-rfk-jr-vaccine BioBriefs en 2026-03-17T10:32:54Z Judge stays RFK Jr. vaccine overhaul – ACIP meetings and schedule frozen https://biobriefs.com/alphafold-database-expands-millions-of BioBriefs en 2026-03-17T09:32:54Z AlphaFold database expands: Millions of protein complexes released https://biobriefs.com/structures-oral-glp-1-shows BioBriefs en 2026-03-17T09:32:54Z Structure’s oral GLP‑1 shows injectable‑like efficacy – 44‑week Phase 2 https://biobriefs.com/masked-adc-posts-responses-in BioBriefs en 2026-03-17T09:32:54Z Masked ADC posts responses in CRC – partnership fallout follows https://biobriefs.com/biomarin-pauses-voxzogo-dosing-after BioBriefs en 2026-03-17T09:32:54Z BioMarin pauses Voxzogo dosing after hip safety signal https://biobriefs.com/arpa-h-awards-9-3m BioBriefs en 2026-03-17T09:32:54Z ARPA‑H awards $9.3M to BioCurie: building AI‑driven gene therapy manufacturing https://biobriefs.com/trenchant-and-invetech-to-commercialize BioBriefs en 2026-03-17T09:32:54Z Trenchant and Invetech to commercialize AutoCell: automated point‑of‑care CGT manufacturing https://biobriefs.com/federal-judge-stays-rfk-jr BioBriefs en 2026-03-17T09:32:54Z Federal judge stays RFK Jr. vaccine actions: ACIP votes and schedule changes paused https://biobriefs.com/mayo-clinic-engineers-milk-derived BioBriefs en 2026-03-17T09:32:54Z Mayo Clinic engineers milk‑derived nanoparticles for targeted cholangiocarcinoma gene therapy https://biobriefs.com/illumina-and-veritas-form-preventive BioBriefs en 2026-03-17T09:32:54Z Illumina and Veritas form preventive genomics consortium: whole‑genome sequencing for routine care https://biobriefs.com/circode-clears-fda-ind-for BioBriefs en 2026-03-17T09:32:54Z CirCode clears FDA IND for circular RNA therapy trial in the US https://biobriefs.com/judge-stays-hhs-vaccine-overhaul BioBriefs en 2026-03-17T04:32:34Z Judge stays HHS vaccine overhaul — ACIP appointments and schedule frozen https://biobriefs.com/structures-oral-glp-1-posts BioBriefs en 2026-03-17T04:32:34Z Structure’s oral GLP‑1 posts 16% weight loss — company eyes Phase 3 https://biobriefs.com/cytomx-masked-adc-shows-responses BioBriefs en 2026-03-17T04:32:34Z CytomX masked ADC shows responses in late‑line colorectal — shares rally https://biobriefs.com/biomarin-halts-voxzogo-dosing-after BioBriefs en 2026-03-17T04:32:34Z BioMarin halts Voxzogo dosing after hip‑related safety signal https://biobriefs.com/arpa-h-backs-ai-led BioBriefs en 2026-03-17T04:32:34Z ARPA‑H backs AI‑led gene‑therapy manufacturing platform — $9.3M award https://biobriefs.com/trenchant-invetech-partner-to-commercialize BioBriefs en 2026-03-17T04:32:34Z Trenchant, Invetech partner to commercialize fully automated CGT platform https://biobriefs.com/illumina-and-veritas-launch-preventive BioBriefs en 2026-03-17T04:32:34Z Illumina and Veritas launch preventive genomics consortium — WGS enters care https://biobriefs.com/circode-clears-fda-to-test BioBriefs en 2026-03-17T04:32:34Z CirCode clears FDA to test circular RNA therapy in U.S. trial https://biobriefs.com/unixell-gains-fda-ind-for BioBriefs en 2026-03-17T04:32:34Z Unixell gains FDA IND for iPSC‑derived allogeneic cell therapy in epilepsy https://biobriefs.com/roche-inks-nvidia-deal-to BioBriefs en 2026-03-17T04:32:34Z Roche inks Nvidia deal to accelerate AI drug and diagnostic factory https://biobriefs.com/structures-oral-glp-1-rivals BioBriefs en 2026-03-16T21:33:01Z Structure’s oral GLP-1 rivals injectables — 16% weight loss in Phase 2 https://biobriefs.com/federal-judge-freezes-kennedy-vaccine BioBriefs en 2026-03-16T21:33:01Z Federal judge freezes Kennedy vaccine overhaul — CDC changes blocked https://biobriefs.com/cytomx-posts-adc-responses-partner BioBriefs en 2026-03-16T21:33:01Z CytomX posts ADC responses; partner pulls out of T-cell engager pact https://biobriefs.com/biomarin-pauses-voxzogo-dosing-after BioBriefs en 2026-03-16T21:33:01Z BioMarin pauses Voxzogo dosing after hip safety signal https://biobriefs.com/arpa-h-funds-biocurie-to BioBriefs en 2026-03-16T21:33:01Z ARPA‑H funds BioCurie to build AI‑driven gene therapy manufacturing platform https://biobriefs.com/trenchant-invetech-race-to-automate BioBriefs en 2026-03-16T21:33:01Z Trenchant, Invetech race to automate point‑of‑care CGT manufacturing https://biobriefs.com/cmic-integrates-agentic-ai-to BioBriefs en 2026-03-16T21:33:01Z CMIC integrates agentic AI to speed regulatory trial documentation https://biobriefs.com/illumina-veritas-launch-preventive-genomics BioBriefs en 2026-03-16T21:33:01Z Illumina, Veritas launch preventive genomics consortium — WGS into care https://biobriefs.com/circode-wins-fda-clearance-to BioBriefs en 2026-03-16T21:33:01Z CirCode wins FDA clearance to test circular RNA therapy in the US https://biobriefs.com/cms-covers-neogenomics-pantracer-lbx BioBriefs en 2026-03-16T21:33:01Z CMS covers NeoGenomics PanTracer LBx — liquid biopsy gets reimbursed https://biobriefs.com/structures-oral-glp-1-pill BioBriefs en 2026-03-16T16:33:23Z Structure’s oral GLP-1 pill posts strong midstage results — dosing tweak steadies tolerability https://biobriefs.com/illumina-and-veritas-launch-preventive BioBriefs en 2026-03-16T16:33:23Z Illumina and Veritas launch preventive genomics consortium — WGS moves upstream https://biobriefs.com/circode-wins-fda-clearance-to BioBriefs en 2026-03-16T16:33:23Z CirCode wins FDA clearance to begin first-in-human circular RNA trial in US https://biobriefs.com/unixells-ipsc-derived-cell-therapy BioBriefs en 2026-03-16T16:33:23Z Unixell’s iPSC-derived cell therapy gets FDA IND for focal epilepsy https://biobriefs.com/akeso-secures-nmpa-go-ahead BioBriefs en 2026-03-16T16:33:23Z Akeso secures NMPA go-ahead for trispecific cancer antibody AK-150 https://biobriefs.com/neogenomics-pantracer-liquid-biopsy-wins BioBriefs en 2026-03-16T16:33:23Z NeoGenomics’ PanTracer liquid biopsy wins CMS coverage — reimbursement expands blood-based CGP https://biobriefs.com/signal-bioscience-pushes-multiplexed-dpcr BioBriefs en 2026-03-16T16:33:23Z Signal Bioscience pushes multiplexed dPCR/qPCR — seed round seeking collaborators https://biobriefs.com/unnatural-products-raises-45m-series BioBriefs en 2026-03-16T16:33:23Z Unnatural Products raises $45M Series B — macrocycles push toward clinic after Novartis pact https://biobriefs.com/cytomx-partnership-frays-as-astellas BioBriefs en 2026-03-16T16:33:23Z CytomX partnership frays as Astellas exits — company posts late-line CRC ADC data https://biobriefs.com/kyron-inks-research-pact-with BioBriefs en 2026-03-16T16:33:23Z Kyron inks research pact with Servier — programmable glycoprotein control moves to collaboration https://biobriefs.com/circode-wins-fda-clearance-us BioBriefs en 2026-03-16T14:33:06Z CirCode wins FDA clearance: US trial to test circular RNA therapy https://biobriefs.com/signal-bioscience-pitches-high-plex BioBriefs en 2026-03-16T14:33:06Z Signal Bioscience pitches high‑plex PCR: seed round and partner hunt https://biobriefs.com/cms-backs-neogenomics-liquid-biopsy BioBriefs en 2026-03-16T14:33:06Z CMS backs NeoGenomics liquid biopsy: PanTracer LBx gets coverage https://biobriefs.com/oral-glp-1-posts-16 BioBriefs en 2026-03-16T14:33:06Z Oral GLP‑1 posts 16% weight loss... Structure aims phase‑3 push https://biobriefs.com/unnatural-products-nets-45m-macrocycles BioBriefs en 2026-03-16T14:33:06Z Unnatural Products nets $45M — macrocycles move toward clinic after Novartis pact https://biobriefs.com/cytomx-posts-adc-data-in BioBriefs en 2026-03-16T14:33:06Z CytomX posts ADC data in late‑line CRC — Varseta‑M shows activity https://biobriefs.com/her2-adc-posts-53-response BioBriefs en 2026-03-16T14:33:06Z HER2 ADC posts ~53% response in urothelial cancer — RC48 data https://biobriefs.com/alliance-launches-phase-iii-for BioBriefs en 2026-03-16T14:33:06Z Alliance launches Phase III for grade‑3 IDH‑mutant astrocytoma https://biobriefs.com/team-revives-neuronal-activity-in BioBriefs en 2026-03-16T14:33:06Z Team revives neuronal activity in vitrified mouse brains — PNAS report https://biobriefs.com/genetic-code-expanded-five-noncanonical BioBriefs en 2026-03-16T14:33:06Z Genetic code expanded: five noncanonical amino acids encoded at once https://biobriefs.com/waste-plastic-to-parkinsons-drug BioBriefs en 2026-03-16T10:32:57Z Waste plastic to Parkinson’s drug: bacteria-made L‑DOPA https://biobriefs.com/genetic-code-expansion-five-noncanonical BioBriefs en 2026-03-16T10:32:57Z Genetic code expansion: five noncanonical amino acids in one protein https://biobriefs.com/her2-adc-posts-50-response BioBriefs en 2026-03-16T10:32:57Z HER2 ADC posts >50% response in advanced urothelial cancer https://biobriefs.com/lantheus-gets-tentative-fda-nod BioBriefs en 2026-03-16T10:32:57Z Lantheus gets tentative FDA nod for Lutathera copy – patent clash looms https://biobriefs.com/vitamin-b2-metabolism-shields-tumors BioBriefs en 2026-03-16T10:32:57Z Vitamin B2 metabolism shields tumors from ferroptosis: CRISPR screen https://biobriefs.com/long-acting-cabotegravir-rilpivirine-alters BioBriefs en 2026-03-16T10:32:57Z Long‑acting cabotegravir–rilpivirine alters monocyte immunity in people with HIV https://biobriefs.com/researchers-restore-activity-in-vitrified BioBriefs en 2026-03-16T10:32:57Z Researchers restore activity in vitrified mouse brains — partial function returns https://biobriefs.com/tyk2-drives-neuroinflammation-in-alzheimers BioBriefs en 2026-03-16T10:32:57Z TYK2 drives neuroinflammation in Alzheimer’s with TDP‑43 pathology https://biobriefs.com/icu-transmission-pathways-of-multidrug BioBriefs en 2026-03-16T10:32:57Z ICU transmission pathways of multidrug‑resistant Acinetobacter documented https://biobriefs.com/global-federated-ai-builds-prognostic BioBriefs en 2026-03-16T10:32:57Z Global federated AI builds prognostic models for anal cancer https://biobriefs.com/fda-tentatively-clears-lutathera-generic BioBriefs en 2026-03-16T09:32:50Z FDA tentatively clears Lutathera generic — patent fight looms https://biobriefs.com/new-her2-adc-posts-high BioBriefs en 2026-03-16T09:32:50Z New HER2 ADC posts high response in bladder cancer — ASCO data https://biobriefs.com/long-acting-hiv-injectables-reshape BioBriefs en 2026-03-16T09:32:50Z Long‑acting HIV injectables reshape monocyte immunity — study https://biobriefs.com/riboflavin-metabolism-shields-tumors-from BioBriefs en 2026-03-16T09:32:50Z Riboflavin metabolism shields tumors from ferroptosis — Nature Cell Biology https://biobriefs.com/vitrified-mouse-brains-regain-activity BioBriefs en 2026-03-16T09:32:50Z Vitrified mouse brains regain activity — PNAS report https://biobriefs.com/genetic-code-expansion-five-noncanonical BioBriefs en 2026-03-16T09:32:50Z Genetic code expansion: five noncanonical amino acids in one protein https://biobriefs.com/spr-moves-upstream-vega-platform BioBriefs en 2026-03-16T09:32:50Z SPR moves upstream: Vega platform speeds early‑stage screening https://biobriefs.com/tyk2-implicated-in-tdp-43 BioBriefs en 2026-03-16T09:32:50Z TYK2 implicated in TDP‑43 Alzheimer’s inflammation — Nature Communications https://biobriefs.com/zoledronic-acid-improves-outcomes-in BioBriefs en 2026-03-16T09:32:50Z Zoledronic acid improves outcomes in Ewing sarcoma — phase III results https://biobriefs.com/prostate-screening-compares-to-breast BioBriefs en 2026-03-16T09:32:50Z Prostate screening compares to breast screening — EAU presentation https://biobriefs.com/her2-adc-posts-50-response BioBriefs en 2026-03-16T04:33:18Z HER2 ADC Posts >50% Response in Bladder Cancer – Phase 2 RC48G001 https://biobriefs.com/fda-gives-tentative-ok-to BioBriefs en 2026-03-16T04:33:18Z FDA Gives Tentative OK to Lutathera Generic — Patent Fight Looms https://biobriefs.com/cadonilimab-combo-improves-first-line BioBriefs en 2026-03-16T04:33:18Z Cadonilimab Combo Improves First-Line Outcomes in Advanced Cervical Cancer — Phase 3 https://biobriefs.com/vitamin-b2-metabolism-shields-tumors BioBriefs en 2026-03-16T04:33:18Z Vitamin B2 Metabolism Shields Tumors from Ferroptosis — New Target Identified https://biobriefs.com/vitrification-revives-neural-activity-in BioBriefs en 2026-03-16T04:33:18Z Vitrification Revives Neural Activity in Mouse Brains — Cryopreservation Advance https://biobriefs.com/spr-comes-upstream-carterras-vega BioBriefs en 2026-03-16T04:33:18Z SPR Comes Upstream: Carterra’s Vega Brings High-Throughput Label-Free Screening https://biobriefs.com/five-noncanonical-amino-acids-inserted BioBriefs en 2026-03-16T04:33:18Z Five Noncanonical Amino Acids Inserted Simultaneously — Genetic Code Expansion https://biobriefs.com/federated-ai-prognostic-models-developed BioBriefs en 2026-03-16T04:33:18Z Federated AI Prognostic Models Developed for Anal Cancer — Multi‑Center Study https://biobriefs.com/tyk2-drives-neuroinflammation-in-alzheimers BioBriefs en 2026-03-16T04:33:18Z TYK2 Drives Neuroinflammation in Alzheimer’s with TDP-43 — New Therapeutic Angle https://biobriefs.com/monocyte-signatures-shift-after-switch BioBriefs en 2026-03-16T04:33:18Z Monocyte Signatures Shift After Switch to Long‑Acting HIV Injectables: Immune Implications https://biobriefs.com/tentative-fda-ok-for-lutathera BioBriefs en 2026-03-15T21:32:50Z Tentative FDA OK for Lutathera Generic — Lantheus Locked in Patent War https://biobriefs.com/her2-adc-posts-50-response BioBriefs en 2026-03-15T21:32:50Z HER2 ADC Posts >50% Response in Bladder Cancer – Phase 2 Data https://biobriefs.com/cadonilimab-combo-improves-outcomes-in BioBriefs en 2026-03-15T21:32:50Z Cadonilimab Combo Improves Outcomes in Advanced Cervical Cancer — Phase 3 https://biobriefs.com/novel-diketopiperazine-alkaloids-discovered-via BioBriefs en 2026-03-15T21:32:50Z Novel Diketopiperazine Alkaloids Discovered via Heterologous Expression https://biobriefs.com/antibody-sirna-conjugate-reaches-muscle BioBriefs en 2026-03-15T21:32:50Z Antibody‑siRNA Conjugate Reaches Muscle — Promising Data in Myotonic Dystrophy https://biobriefs.com/targeting-p3h1-slows-pancreatic-cancer BioBriefs en 2026-03-15T21:32:50Z Targeting P3H1 Slows Pancreatic Cancer Growth and Reprograms Tumor Immunity https://biobriefs.com/tyk2-implicated-in-tdp-43 BioBriefs en 2026-03-15T21:32:50Z TYK2 Implicated in TDP‑43 Neuroinflammation in Alzheimer’s — New Therapeutic Angle https://biobriefs.com/wireless-high-resolution-sensor-promises BioBriefs en 2026-03-15T21:32:50Z Wireless High‑Resolution Sensor Promises Continuous Hemodialysis Access Monitoring https://biobriefs.com/high-throughput-spr-moves-upstream BioBriefs en 2026-03-15T21:32:50Z High‑Throughput SPR Moves Upstream in Drug Discovery — Carterra’s Vega https://biobriefs.com/orphan-drug-sales-to-top BioBriefs en 2026-03-15T21:32:50Z Orphan Drug Sales to Top $400 Billion by 2032 — Evaluate Forecast https://biobriefs.com/car-t-persistence-cytokine-scaffold BioBriefs en 2026-03-15T16:32:39Z CAR-T Persistence... Cytokine scaffold extends durability https://biobriefs.com/antibody-sirna-conjugate-first-clinical BioBriefs en 2026-03-15T16:32:39Z Antibody‑siRNA Conjugate – First clinical signs of muscle delivery https://biobriefs.com/doxorubicin-biosynthesis-unlocked-engineered-bacteria BioBriefs en 2026-03-15T16:32:39Z Doxorubicin biosynthesis unlocked – Engineered bacteria scale production https://biobriefs.com/lutathera-generic-fda-tentatively-clears BioBriefs en 2026-03-15T16:32:39Z Lutathera generic... FDA tentatively clears ANDA amid patent fight https://biobriefs.com/old-drug-new-label-fda BioBriefs en 2026-03-15T16:32:39Z Old drug, new label: FDA okays leucovorin for cerebral folate deficiency https://biobriefs.com/frozen-brains-revived-vitrification-restores BioBriefs en 2026-03-15T16:32:39Z Frozen brains revived – Vitrification restores activity in mouse tissue https://biobriefs.com/spr-goes-high-throughput-vega BioBriefs en 2026-03-15T16:32:39Z SPR goes high‑throughput: Vega brings binding data to early screening https://biobriefs.com/orphan-drugs-to-409b-by BioBriefs en 2026-03-15T16:32:39Z Orphan drugs to $409B by 2032 – Evaluate projects rare market surge https://biobriefs.com/cadonilimab-combo-improves-first-line BioBriefs en 2026-03-15T16:32:39Z Cadonilimab combo improves first‑line outcomes in cervical cancer https://biobriefs.com/insilico-joins-hang-seng-ai BioBriefs en 2026-03-15T16:32:39Z Insilico joins Hang Seng... AI biotech hits index milestone https://biobriefs.com/efti-phase-iii-halts-immutep BioBriefs en 2026-03-15T14:33:22Z Efti Phase III Halts – Immutep Trial Discontinued for Futility https://biobriefs.com/fda-tentatively-clears-lutathera-copy BioBriefs en 2026-03-15T14:33:22Z FDA Tentatively Clears Lutathera Copy: Lantheus vs Novartis Patent Fight https://biobriefs.com/cadonilimab-combo-improves-outcomes-in BioBriefs en 2026-03-15T14:33:22Z Cadonilimab Combo Improves Outcomes in Advanced Cervical Cancer https://biobriefs.com/il-7-il-15-il BioBriefs en 2026-03-15T14:33:22Z IL‑7/IL‑15/IL‑21 Scaffold Recharges CAR‑T Cells: Longer‑Lived Cells in Mice https://biobriefs.com/antibody-sirna-conjugate-reaches-muscle BioBriefs en 2026-03-15T14:33:22Z Antibody‑siRNA Conjugate Reaches Muscle – Early Human Data in Myotonic Dystrophy https://biobriefs.com/engineered-bacteria-boost-doxorubicin-yield BioBriefs en 2026-03-15T14:33:22Z Engineered Bacteria Boost Doxorubicin Yield – Production Barrier Overcome https://biobriefs.com/eurofins-pushes-adc-manufacturing-expression BioBriefs en 2026-03-15T14:33:22Z Eurofins Pushes ADC Manufacturing: Expression Platform and AI Formulation Tools https://biobriefs.com/gsk-backs-uk-digital-twin BioBriefs en 2026-03-15T14:33:22Z GSK Backs UK Digital‑Twin Center to Model Lungs, Liver and Kidneys https://biobriefs.com/china-clears-first-commercial-brain BioBriefs en 2026-03-15T14:33:22Z China Clears First Commercial Brain Implant for Spinal‑Cord Injury https://biobriefs.com/lucence-a-star-and-nccs BioBriefs en 2026-03-15T14:33:22Z Lucence, A*STAR and NCCS Launch S$6M Multiomic Cancer Profiling Project https://biobriefs.com/fda-gives-tentative-nod-to BioBriefs en 2026-03-15T10:32:48Z FDA gives tentative nod to Lantheus’ Lutathera copy — patent fight looms https://biobriefs.com/disitamab-vedotin-posts-50-response BioBriefs en 2026-03-15T10:32:48Z Disitamab vedotin posts >50% response in urothelial cancer...her2 low responds too https://biobriefs.com/immuteps-lag-3-program-halted BioBriefs en 2026-03-15T10:32:48Z Immutep’s LAG‑3 program halted — stock collapses, company scrambles https://biobriefs.com/ultragenyx-gene-therapy-hits-a BioBriefs en 2026-03-15T10:32:48Z Ultragenyx gene therapy hits a primary endpoint in rare ammonia disorder trial https://biobriefs.com/vima-ups-series-a-with BioBriefs en 2026-03-15T10:32:48Z Vima ups Series A with $40m extension to push movement‑disorder candidates https://biobriefs.com/engineered-bacteria-clear-decades-old BioBriefs en 2026-03-15T10:32:48Z Engineered bacteria clear decades‑old bottleneck in doxorubicin manufacturing https://biobriefs.com/cytokine-fusion-scaffold-produces-long BioBriefs en 2026-03-15T10:32:48Z Cytokine‑fusion scaffold produces long‑lived CAR‑T cells in preclinical models https://biobriefs.com/antibody-sirna-conjugate-reaches-muscle BioBriefs en 2026-03-15T10:32:48Z Antibody‑siRNA conjugate reaches muscle—early DM1 trial shows target knockdown https://biobriefs.com/china-approves-first-commercial-brain BioBriefs en 2026-03-15T10:32:48Z China approves first commercial brain implant for spinal‑injury patients https://biobriefs.com/senolytic-strategy-clears-therapy-resistant BioBriefs en 2026-03-15T10:32:48Z Senolytic strategy clears therapy‑resistant cells in pancreatic cancer models https://biobriefs.com/immuteps-phase-iii-flop-stock BioBriefs en 2026-03-15T09:32:48Z Immutep’s phase III flop – Stock tumbles after futility stop https://biobriefs.com/lantheus-wins-tentative-fda-anda BioBriefs en 2026-03-15T09:32:48Z Lantheus wins tentative FDA ANDA – Patent battle with Novartis heats up https://biobriefs.com/her2-adc-shows-activity-in BioBriefs en 2026-03-15T09:32:48Z HER2 ADC shows activity in urothelial cancer – High response rates in phase 2 https://biobriefs.com/engineering-car-t-persistence-cytokine BioBriefs en 2026-03-15T09:32:48Z Engineering CAR‑T persistence: cytokine scaffolds extend durability https://biobriefs.com/antibody-sirna-conjugate-reaches-muscle BioBriefs en 2026-03-15T09:32:48Z Antibody‑siRNA conjugate reaches muscle—first signals in myotonic dystrophy trial https://biobriefs.com/ultragenyx-gene-therapy-clears-a BioBriefs en 2026-03-15T09:32:48Z Ultragenyx gene therapy clears a Phase 3 milestone in urea cycle disorder https://biobriefs.com/vitestro-raises-70m-to-scale BioBriefs en 2026-03-15T09:32:48Z Vitestro raises $70M to scale robotic blood draws – Push toward FDA De Novo https://biobriefs.com/scientists-unlock-doxorubicin-bottleneck-engineered BioBriefs en 2026-03-15T09:32:48Z Scientists unlock doxorubicin bottleneck – Engineered bacteria boost chemo production https://biobriefs.com/stanley-family-adds-280m-to BioBriefs en 2026-03-15T09:32:48Z Stanley Family adds $280M to Broad’s psychiatric genetics push https://biobriefs.com/high-throughput-spr-moves-upstream BioBriefs en 2026-03-15T09:32:48Z High‑throughput SPR moves upstream: Carterra’s Vega aims at primary screening https://biobriefs.com/immuteps-phase-iii-flop-efti BioBriefs en 2026-03-15T04:32:50Z Immutep’s phase‑III flop – efti trial stopped for futility https://biobriefs.com/lantheus-wins-tentative-fda-anda BioBriefs en 2026-03-15T04:32:50Z Lantheus wins tentative FDA ANDA nod amid Lutathera patent war https://biobriefs.com/new-her2-adc-posts-high BioBriefs en 2026-03-15T04:32:50Z New HER2 ADC posts high response in urothelial cancer – RC48 data https://biobriefs.com/ultragenyx-gene-therapy-hits-primary BioBriefs en 2026-03-15T04:32:50Z Ultragenyx gene therapy hits primary endpoint in rare metabolic trial https://biobriefs.com/fda-draft-guidance-loosens-rules BioBriefs en 2026-03-15T04:32:50Z FDA draft guidance loosens rules for biosimilar testing – a market opener https://biobriefs.com/evaluate-predicts-409b-rare-disease BioBriefs en 2026-03-15T04:32:50Z Evaluate predicts $409B rare‑disease market by 2032 – industry growth forecast https://biobriefs.com/ai-biotechs-advance-insilico-joins BioBriefs en 2026-03-15T04:32:50Z AI biotechs advance: Insilico joins Hang Seng; Waiv spins out with $33M https://biobriefs.com/new-car-t-manufacturing-tricks BioBriefs en 2026-03-15T04:32:50Z New CAR‑T manufacturing tricks extend persistence – scaffold and cytokine fusions https://biobriefs.com/vitestro-raises-70m-to-scale BioBriefs en 2026-03-15T04:32:50Z Vitestro raises $70M to scale robotic phlebotomy ahead of US push https://biobriefs.com/antibody-sirna-conjugate-reaches-muscle BioBriefs en 2026-03-15T04:32:50Z Antibody‑siRNA conjugate reaches muscle in humans – del‑desiran shows promise https://biobriefs.com/immutep-trial-halted-for-futility BioBriefs en 2026-03-14T21:32:25Z Immutep trial halted for futility – stock collapses https://biobriefs.com/fda-tentatively-clears-lutathera-generic BioBriefs en 2026-03-14T21:32:25Z FDA tentatively clears Lutathera generic – patent fight ahead https://biobriefs.com/new-her2-adc-posts-robust BioBriefs en 2026-03-14T21:32:25Z New HER2 ADC posts robust responses in urothelial cancer https://biobriefs.com/cadonilimab-combo-improves-outcomes-in BioBriefs en 2026-03-14T21:32:25Z Cadonilimab combo improves outcomes in advanced cervical cancer https://biobriefs.com/ultragenyx-gene-therapy-clears-key BioBriefs en 2026-03-14T21:32:25Z Ultragenyx gene therapy clears key Phase 3 bar for OTC deficiency https://biobriefs.com/multi-cytokine-scaffold-produces-longer BioBriefs en 2026-03-14T21:32:25Z Multi‑cytokine scaffold produces longer‑lived CAR‑T cells https://biobriefs.com/genetic-code-expansion-five-noncanonical BioBriefs en 2026-03-14T21:32:25Z Genetic code expansion: five noncanonical amino acids in one protein https://biobriefs.com/ai-plus-autonomous-lab-cuts BioBriefs en 2026-03-14T21:32:25Z AI plus autonomous lab cuts cycle time for biological discovery https://biobriefs.com/fda-drafts-guidance-to-ease BioBriefs en 2026-03-14T21:32:25Z FDA drafts guidance to ease biosimilar testing — competition could accelerate https://biobriefs.com/orphan-drug-market-set-to BioBriefs en 2026-03-14T21:32:25Z Orphan drug market set to surge past $400B by 2032 https://biobriefs.com/immuteps-phase-iii-shock-efti BioBriefs en 2026-03-14T16:32:49Z Immutep’s phase III shock: efti trial stopped for futility https://biobriefs.com/ultragenyx-gene-therapy-clears-major BioBriefs en 2026-03-14T16:32:49Z Ultragenyx gene therapy clears major Phase 3 endpoint in OTC deficiency https://biobriefs.com/lantheus-wins-tentative-fda-anda BioBriefs en 2026-03-14T16:32:49Z Lantheus wins tentative FDA ANDA for Lutathera rival amid patent war https://biobriefs.com/gsk-wins-expanded-fda-clearance BioBriefs en 2026-03-14T16:32:49Z GSK wins expanded FDA clearance for RSV vaccine Arexvy https://biobriefs.com/china-approves-first-commercial-brain BioBriefs en 2026-03-14T16:32:49Z China approves first commercial brain‑computer implant for spinal injuries https://biobriefs.com/genetic-code-expanded-five-noncanonical BioBriefs en 2026-03-14T16:32:49Z Genetic code expanded: five noncanonical amino acids incorporated in a single mammalian protein https://biobriefs.com/src-appears-on-tumor-surface BioBriefs en 2026-03-14T16:32:49Z Src appears on tumor surface — antibody therapies get a new target https://biobriefs.com/trispecific-macrophage-engager-enhances-solid BioBriefs en 2026-03-14T16:32:49Z Trispecific macrophage engager enhances solid‑tumor killing https://biobriefs.com/amino-acid-supplement-boosts-lnp BioBriefs en 2026-03-14T16:32:49Z Amino acid supplement boosts LNP delivery for mRNA and CRISPR in vivo https://biobriefs.com/bacterial-strain-breakthrough-could-unblock BioBriefs en 2026-03-14T16:32:49Z Bacterial strain breakthrough could unblock doxorubicin production bottleneck https://biobriefs.com/immuteps-lag-3-gamble-fails BioBriefs en 2026-03-14T14:32:57Z Immutep’s LAG‑3 gamble fails: stock plunges after Phase III futility https://biobriefs.com/cadonilimab-combo-extends-benefit-in BioBriefs en 2026-03-14T14:32:57Z Cadonilimab combo extends benefit in advanced cervical cancer – Phase III https://biobriefs.com/ultragenyx-gene-therapy-clears-key BioBriefs en 2026-03-14T14:32:57Z Ultragenyx gene therapy clears key bar: late‑stage endpoint met in OTC study https://biobriefs.com/sana-cell-therapy-shows-persistent BioBriefs en 2026-03-14T14:32:57Z Sana cell therapy shows persistent insulin production: 14‑month follow‑up https://biobriefs.com/senolytic-strategy-stalls-pancreatic-cancers BioBriefs en 2026-03-14T14:32:57Z Senolytic strategy stalls pancreatic cancer’s growth in preclinical models – new avenue https://biobriefs.com/engineered-bacteria-break-decades-old BioBriefs en 2026-03-14T14:32:57Z Engineered bacteria break decades‑old doxorubicin bottleneck: scalable biosynthesis https://biobriefs.com/src-appears-on-tumor-surfaces BioBriefs en 2026-03-14T14:32:57Z Src appears on tumor surfaces: antibody therapies gain a new target https://biobriefs.com/modular-cytokine-scaffold-lengthens-car BioBriefs en 2026-03-14T14:32:57Z Modular cytokine scaffold lengthens CAR‑T persistence – Science Advances https://biobriefs.com/psma-pet-reduces-need-for BioBriefs en 2026-03-14T14:32:57Z PSMA PET reduces need for prostate biopsies: PRIMARY2 shows diagnostic impact https://biobriefs.com/fda-draft-eases-biosimilar-testing BioBriefs en 2026-03-14T14:32:57Z FDA draft eases biosimilar testing: agency proposes lower barriers for approvals https://biobriefs.com/immuteps-lag-3-miss-phase BioBriefs en 2026-03-14T10:32:39Z Immutep’s LAG‑3 miss: Phase III stopped, stock tanks https://biobriefs.com/ultragenyx-hits-co-primary-endpoint BioBriefs en 2026-03-14T10:32:39Z Ultragenyx hits co‑primary endpoint: gene therapy advances in urea‑cycle disease https://biobriefs.com/fda-expands-arexvy-label-gsk BioBriefs en 2026-03-14T10:32:39Z FDA expands Arexvy label: GSK wins broader RSV clearance https://biobriefs.com/china-approves-commercial-bci-neuracles BioBriefs en 2026-03-14T10:32:39Z China approves commercial BCI: Neuracle’s brain implant cleared for spinal‑injury use https://biobriefs.com/cadonilimab-combo-phase-iii-compassion BioBriefs en 2026-03-14T10:32:39Z Cadonilimab combo: Phase III COMPASSION‑16 shows first‑line benefit in advanced cervical cancer https://biobriefs.com/kras-interception-halts-precancerous-pancreatic BioBriefs en 2026-03-14T10:32:39Z KRAS interception halts precancerous pancreatic lesions; senolytics show therapy promise https://biobriefs.com/car-t-durability-reengineered-cytokine BioBriefs en 2026-03-14T10:32:39Z CAR‑T durability reengineered: cytokine scaffolds and manufacturing tweaks boost persistence https://biobriefs.com/amino-acid-cocktail-supercharges-lnp BioBriefs en 2026-03-14T10:32:39Z Amino acid cocktail supercharges LNP delivery: improved in vivo mRNA and CRISPR efficacy https://biobriefs.com/stryker-hit-by-cyberattack-global BioBriefs en 2026-03-14T10:32:39Z Stryker hit by cyberattack: global internal systems disrupted, operations delayed https://biobriefs.com/orphan-drug-boom-meets-fda BioBriefs en 2026-03-14T10:32:39Z Orphan drug boom meets FDA flexibility: $400B sales forecast alongside RDEP trial leeway https://biobriefs.com/immuteps-lag-3-drug-fails BioBriefs en 2026-03-14T09:32:45Z Immutep’s LAG‑3 drug fails Phase III — Stock tumbles https://biobriefs.com/cadonilimab-combo-extends-control-in BioBriefs en 2026-03-14T09:32:45Z Cadonilimab combo extends control in advanced cervical cancer — Phase 3 readout https://biobriefs.com/ultragenyx-gene-therapy-hits-co BioBriefs en 2026-03-14T09:32:45Z Ultragenyx gene therapy hits co‑primary endpoint — Mid‑trial success in urea cycle disorder https://biobriefs.com/fda-draft-allows-non-us BioBriefs en 2026-03-14T09:32:45Z FDA draft allows non‑US comparators — Biosimilar testing bar lowered https://biobriefs.com/triple-cytokine-scaffold-boosts-car BioBriefs en 2026-03-14T09:32:45Z Triple‑cytokine scaffold boosts CAR‑T durability — Preclinical persistence gains https://biobriefs.com/src-flips-to-cell-surface BioBriefs en 2026-03-14T09:32:45Z Src flips to cell surface: antibody payloads shrink tumors in mice https://biobriefs.com/openai-and-ginkgo-ai-designs BioBriefs en 2026-03-14T09:32:45Z OpenAI and Ginkgo: AI designs and runs real biology experiments https://biobriefs.com/lucence-leads-s-6m-multiomic BioBriefs en 2026-03-14T09:32:45Z Lucence leads S$6M multiomic tumor profiling push — UNITED 2.0 https://biobriefs.com/rare-disease-drug-sales-to BioBriefs en 2026-03-14T09:32:45Z Rare disease drug sales to top $400B by 2032 — Evaluate forecast https://biobriefs.com/evotec-to-cut-800-jobs BioBriefs en 2026-03-14T09:32:45Z Evotec to cut 800 jobs, close four sites — Large restructuring under way https://biobriefs.com/immutep-trial-stops-for-futility BioBriefs en 2026-03-14T04:33:01Z Immutep trial stops for futility — shares crater https://biobriefs.com/ultragenyx-gene-therapy-clears-key BioBriefs en 2026-03-14T04:33:01Z Ultragenyx gene therapy clears key phase‑3 endpoint — rare disease win https://biobriefs.com/stryker-systems-down-after-cyberattack BioBriefs en 2026-03-14T04:33:01Z Stryker systems down after cyberattack — restoration under way https://biobriefs.com/fda-broadens-gsk-rsv-shot BioBriefs en 2026-03-14T04:33:01Z FDA broadens GSK RSV shot clearance — wider label granted https://biobriefs.com/china-approves-first-commercial-brain BioBriefs en 2026-03-14T04:33:01Z China approves first commercial brain implant — BCI enters clinic https://biobriefs.com/orphan-drugs-to-exceed-400b BioBriefs en 2026-03-14T04:33:01Z Orphan drugs to exceed $400B by 2032 — Evaluate projects surge https://biobriefs.com/cytokine-scaffold-extends-car-t BioBriefs en 2026-03-14T04:33:01Z Cytokine scaffold extends CAR‑T life — durability advances in preclinical models https://biobriefs.com/ai-in-biotech-insilico-joins BioBriefs en 2026-03-14T04:33:01Z AI in biotech: Insilico joins index — models speed lab discovery https://biobriefs.com/tumor-surface-flag-and-trispecific BioBriefs en 2026-03-14T04:33:01Z Tumor surface 'flag' and trispecific engager open new immunotherapy routes https://biobriefs.com/amino-acids-and-new-assays BioBriefs en 2026-03-14T04:33:01Z Amino acids and new assays boost nanoparticle delivery — delivery bottleneck loosened https://biobriefs.com/immuteps-lag-3-gamble-collapses BioBriefs en 2026-03-13T21:32:55Z Immutep’s LAG‑3 gamble collapses: phase III efti trial stopped https://biobriefs.com/ultragenyx-clears-a-phase-3 BioBriefs en 2026-03-13T21:32:55Z Ultragenyx clears a Phase 3 bar: gene therapy lowers ammonia in urea‑cycle trial https://biobriefs.com/in-vivo-car-t-by BioBriefs en 2026-03-13T21:32:55Z In vivo CAR‑T by injection: nanoparticles generate therapeutic T cells https://biobriefs.com/bacterial-biosynthesis-breakthrough-cracks-doxorubicin BioBriefs en 2026-03-13T21:32:55Z Bacterial biosynthesis breakthrough cracks doxorubicin bottleneck https://biobriefs.com/eurofins-cdmo-alphora-scales-next BioBriefs en 2026-03-13T21:32:55Z Eurofins CDMO Alphora scales next‑gen ADC tools and deploys AI salt screening https://biobriefs.com/gsk-oxford-and-imperial-launch BioBriefs en 2026-03-13T21:32:55Z GSK, Oxford and Imperial launch MiMeC: digital twins for drug development https://biobriefs.com/ai-drives-faster-bench-science BioBriefs en 2026-03-13T21:32:55Z AI drives faster bench science: OpenAI and Ginkgo demonstrate autonomous discovery loop https://biobriefs.com/amino-acid-cocktail-boosts-lnp BioBriefs en 2026-03-13T21:32:55Z Amino‑acid cocktail boosts LNP performance: simple metabolic tweak improves delivery https://biobriefs.com/fda-draft-eases-biosimilar-pathway BioBriefs en 2026-03-13T21:32:55Z FDA draft eases biosimilar pathway: foreign comparators and reduced testing proposed https://biobriefs.com/china-greenlights-first-commercial-brain BioBriefs en 2026-03-13T21:32:55Z China greenlights first commercial brain implant: Neuracle wins BCI approval https://biobriefs.com/china-biotech-milestone-first-commercial BioBriefs en 2026-03-13T16:34:20Z China biotech milestone: first commercial BCI approved; US cell‑therapy trial cleared https://biobriefs.com/gsk-expands-rsv-shot-use BioBriefs en 2026-03-13T16:34:20Z GSK expands RSV shot use: FDA grants broader clearance https://biobriefs.com/immuteps-phase-3-miss-sinks BioBriefs en 2026-03-13T16:34:20Z Immutep’s Phase‑3 miss sinks stock — LAG‑3 candidate stopped for futility https://biobriefs.com/ultragenyx-posts-phase-3-win BioBriefs en 2026-03-13T16:34:20Z Ultragenyx posts Phase‑3 win: gene therapy lowers ammonia in urea‑cycle disorder https://biobriefs.com/enodia-acquires-kezar-sec61-programs BioBriefs en 2026-03-13T16:34:20Z Enodia acquires Kezar Sec61 programs — push into targeted protein degradation https://biobriefs.com/in-vivo-car-t-via BioBriefs en 2026-03-13T16:34:20Z In vivo CAR‑T via nanoparticles: Johns Hopkins demonstrates systemic T‑cell engineering https://biobriefs.com/amino-acid-boost-supercharges-lnp BioBriefs en 2026-03-13T16:34:20Z Amino‑acid boost supercharges LNP delivery — simple metabolic tweak improves mRNA and CRISPR efficacy https://biobriefs.com/vitestro-raises-70m-to-scale BioBriefs en 2026-03-13T16:34:20Z Vitestro raises $70M to scale robotic phlebotomy — clinical pilots and FDA path in focus https://biobriefs.com/vima-expands-movement-disorder-program BioBriefs en 2026-03-13T16:34:20Z Vima expands movement disorder program — Series A reaches $100M as Parkinson’s added https://biobriefs.com/fda-to-unify-adverse-event BioBriefs en 2026-03-13T16:34:20Z FDA to unify adverse‑event trackers: single platform for safety surveillance https://biobriefs.com/ultragenyx-gene-therapy-hits-co BioBriefs en 2026-03-13T14:34:01Z Ultragenyx gene therapy hits co‑primary ammonia endpoint — Phase 3 posts mid‑trial win https://biobriefs.com/immutep-halts-phase-3-efti BioBriefs en 2026-03-13T14:34:01Z Immutep halts Phase 3 efti trial for futility — stock collapses https://biobriefs.com/evotec-to-cut-800-jobs BioBriefs en 2026-03-13T14:34:01Z Evotec to cut 800 jobs, shutter four sites — multi‑year ‘Horizons’ restructure https://biobriefs.com/vima-expands-series-a-to BioBriefs en 2026-03-13T14:34:01Z Vima expands Series A to $100M — adds Parkinson’s to movement‑disorder remit https://biobriefs.com/vitestro-secures-70m-to-scale BioBriefs en 2026-03-13T14:34:01Z Vitestro secures $70M to scale robotic phlebotomy — US De Novo pathway targeted https://biobriefs.com/fda-to-unify-adverse-event BioBriefs en 2026-03-13T14:34:01Z FDA to unify adverse‑event reporting — agency rolls AEMS into single safety platform https://biobriefs.com/biodegradable-mrna-nanoparticles-generate-car BioBriefs en 2026-03-13T14:34:01Z Biodegradable mRNA nanoparticles generate CAR‑T cells in vivo — preclinical B‑cell depletion https://biobriefs.com/immune-evasive-dna-donors-license BioBriefs en 2026-03-13T14:34:01Z Immune‑evasive DNA donors license kilobase insertions — safer path for large gene writing https://biobriefs.com/tumors-present-extracellular-src-flag BioBriefs en 2026-03-13T14:34:01Z Tumors present extracellular Src 'flag' — UCSF identifies broad antibody target https://biobriefs.com/enodia-acquires-kezars-sec61-program BioBriefs en 2026-03-13T14:34:01Z Enodia acquires Kezar’s Sec61 program — $1M upfront, $127M in milestones https://biobriefs.com/vitestro-raises-70m-robot-to BioBriefs en 2026-03-13T10:34:20Z Vitestro raises $70m — robot to scale autonomous blood draws https://biobriefs.com/fda-to-consolidate-adverse-event BioBriefs en 2026-03-13T10:34:20Z FDA to consolidate adverse‑event tracking — AEMS centralizes safety reports https://biobriefs.com/amino-acid-trio-boosts-lnp BioBriefs en 2026-03-13T10:34:20Z Amino‑acid trio boosts LNP payload delivery — simple metabolic tweak raises in vivo efficacy https://biobriefs.com/immune-evasive-dna-donors-enable BioBriefs en 2026-03-13T10:34:20Z Immune‑evasive DNA donors enable safer, gene‑sized insertions https://biobriefs.com/nanoparticles-program-car-t-cells BioBriefs en 2026-03-13T10:34:20Z Nanoparticles program CAR T cells in vivo — Johns Hopkins demonstrates mRNA‑NP route https://biobriefs.com/regenxbios-dmd-program-posts-steady BioBriefs en 2026-03-13T10:34:20Z Regenxbio’s DMD program posts steady safety and function ahead of pivotal readout https://biobriefs.com/optical-genome-mapping-and-structural BioBriefs en 2026-03-13T10:34:20Z Optical genome mapping and structural‑variant atlas reveal variants missed by standard tests https://biobriefs.com/evotec-restructures-800-jobs-and BioBriefs en 2026-03-13T10:34:20Z Evotec restructures — 800 jobs and four site closures in multiyear overhaul https://biobriefs.com/gsk-sells-linerixibat-rights-to BioBriefs en 2026-03-13T10:34:20Z GSK sells linerixibat rights to Alfasigma in up‑to $690m deal as FDA decision nears https://biobriefs.com/pfizer-shutters-ignite-pharmaco-incubator BioBriefs en 2026-03-13T10:34:20Z Pfizer shutters Ignite — pharmaco‑incubator winds down https://biobriefs.com/fda-consolidates-safety-surveillance-agency BioBriefs en 2026-03-13T09:33:21Z FDA consolidates safety surveillance: agency rolls out AEMS https://biobriefs.com/lilly-flags-impurity-risk-compounded BioBriefs en 2026-03-13T09:33:21Z Lilly flags impurity risk: compounded GLP‑1s under fire https://biobriefs.com/evotec-shrinks-800-jobs-cut BioBriefs en 2026-03-13T09:33:21Z Evotec shrinks: 800 jobs cut as restructuring accelerates https://biobriefs.com/amino-acid-boost-lnps-get BioBriefs en 2026-03-13T09:33:21Z Amino acid boost… LNPs get a simple efficiency fix https://biobriefs.com/regenxbios-dmd-program-holds-as BioBriefs en 2026-03-13T09:33:21Z Regenxbio’s DMD program holds as pivotal readout nears https://biobriefs.com/in-vivo-car-t-by BioBriefs en 2026-03-13T09:33:21Z In vivo CAR T by nanoparticles: bench method edges toward clinic https://biobriefs.com/optical-genome-mapping-finds-hidden BioBriefs en 2026-03-13T09:33:21Z Optical genome mapping finds hidden variants in acute leukemia https://biobriefs.com/pediatric-cancer-pan-cancer-structural BioBriefs en 2026-03-13T09:33:21Z Pediatric cancer: pan‑cancer structural‑variant atlas released https://biobriefs.com/immune-evasive-dna-donors-clear BioBriefs en 2026-03-13T09:33:21Z Immune‑evasive DNA donors clear path for large gene insertions https://biobriefs.com/targeted-protein-deals-and-rna BioBriefs en 2026-03-13T09:33:21Z Targeted protein deals and RNA‑to‑heart spinout reshape dealflow https://biobriefs.com/fda-to-unify-adverse-event BioBriefs en 2026-03-13T04:33:28Z FDA to unify adverse-event trackers: agency consolidates safety surveillance https://biobriefs.com/nanoparticle-mrna-sparks-car-t BioBriefs en 2026-03-13T04:33:28Z Nanoparticle mRNA sparks CAR T generation in vivo — Johns Hopkins shows proof in mice https://biobriefs.com/amino-acids-supercharge-lnps-biohub BioBriefs en 2026-03-13T04:33:28Z Amino acids supercharge LNPs — Biohub finds metabolic tweak boosts mRNA and CRISPR delivery https://biobriefs.com/src-kinase-flips-outside-tumor BioBriefs en 2026-03-13T04:33:28Z Src kinase flips outside tumor cells — UCSF identifies new pan‑tumor antibody target https://biobriefs.com/largest-pediatric-cancer-structural-variant BioBriefs en 2026-03-13T04:33:28Z Largest pediatric cancer structural‑variant atlas released — St. Jude and NCI publish pan‑cancer dataset https://biobriefs.com/romiplostim-prevents-severe-chemo-thrombocytopenia BioBriefs en 2026-03-13T04:33:28Z Romiplostim prevents severe chemo thrombocytopenia — global phase 3 shows positive results https://biobriefs.com/psma-pet-ct-cuts-prostate BioBriefs en 2026-03-13T04:33:28Z PSMA PET/CT cuts prostate biopsies: PRIMARY2 shows imaging can reduce invasive sampling https://biobriefs.com/evotec-to-cut-800-jobs BioBriefs en 2026-03-13T04:33:28Z Evotec to cut ~800 jobs — multi‑year restructuring shutters four sites https://biobriefs.com/enodia-acquires-kezars-sec61-assets BioBriefs en 2026-03-13T04:33:28Z Enodia acquires Kezar’s Sec61 assets — deal nets Kezar $1M upfront plus milestones https://biobriefs.com/novartis-spins-cardiology-rna-programs BioBriefs en 2026-03-13T04:33:28Z Novartis spins cardiology RNA programs into Atrium — $270M backing to target genetic heart disease https://biobriefs.com/fda-consolidates-safety-tracking-one BioBriefs en 2026-03-12T21:33:47Z FDA consolidates safety tracking: one dashboard for drugs and vaccines https://biobriefs.com/enodia-buys-kezar-sec61-program BioBriefs en 2026-03-12T21:33:47Z Enodia buys Kezar Sec61 program: $1m now, $127m on milestones https://biobriefs.com/evotec-cuts-800-jobs-big BioBriefs en 2026-03-12T21:33:47Z Evotec cuts 800 jobs – big restructuring to sharpen drug-discovery services https://biobriefs.com/new-in-vivo-lnp-assays BioBriefs en 2026-03-12T21:33:47Z New in vivo LNP assays pinpoint endosomal escape to guide RNA delivery https://biobriefs.com/nanoparticles-make-car-t-in BioBriefs en 2026-03-12T21:33:47Z Nanoparticles make CAR T in patients: mRNA particles program T cells in vivo https://biobriefs.com/regenxbios-dmd-program-holds-safety BioBriefs en 2026-03-12T21:33:47Z Regenxbio’s DMD program holds: safety clean as pivotal readout approaches https://biobriefs.com/immune-evasive-dna-donors-enable BioBriefs en 2026-03-12T21:33:47Z Immune-evasive DNA donors enable kilobase writing—safer path to gene insertion https://biobriefs.com/avidity-carves-out-atrium-with BioBriefs en 2026-03-12T21:33:47Z Avidity carves out Atrium with $270m; Vima ups Series A to $100m https://biobriefs.com/pfizer-shutters-ignite-end-of BioBriefs en 2026-03-12T21:33:47Z Pfizer shutters Ignite – end of an R&D services arm for startups https://biobriefs.com/fda-approves-wellcovorin-for-rare BioBriefs en 2026-03-12T21:33:47Z FDA approves Wellcovorin for rare cerebral folate deficiency, not autism https://biobriefs.com/nanoparticles-program-car-t-cells BioBriefs en 2026-03-12T16:33:54Z Nanoparticles program CAR T cells in vivo: Johns Hopkins demos systemic B-cell depletion https://biobriefs.com/scientists-quantify-lnp-endosomal-escape BioBriefs en 2026-03-12T16:33:54Z Scientists quantify LNP endosomal escape in vivo – a design tool for RNA therapeutics https://biobriefs.com/stealth-dna-donors-enable-kilobase BioBriefs en 2026-03-12T16:33:54Z Stealth DNA donors enable kilobase insertions... labs report safer, recombinase-compatible donors https://biobriefs.com/amino-acid-boost-improves-lnp BioBriefs en 2026-03-12T16:33:54Z Amino acid boost improves LNP delivery... new tools sharpen liver targeting https://biobriefs.com/ultragenyx-gene-therapy-meets-co BioBriefs en 2026-03-12T16:33:54Z Ultragenyx gene therapy meets co‑primary endpoint in phase 3: midtrial win https://biobriefs.com/muscle-therapies-advance-regenxbio-posts BioBriefs en 2026-03-12T16:33:54Z Muscle therapies advance: Regenxbio posts clean DMD safety; BridgeBio muscle drug shows phase‑3 efficacy https://biobriefs.com/rna-to-heart-spinout-lands BioBriefs en 2026-03-12T16:33:54Z RNA‑to‑heart spinout lands $270M; Vima expands to $100M... cardiac and movement disorder bets draw capital https://biobriefs.com/lilly-escalates-compounder-fight-impurity BioBriefs en 2026-03-12T16:33:54Z Lilly escalates compounder fight: impurity flagged in vitamin‑B12‑spiked tirzepatide https://biobriefs.com/fda-consolidates-adverse-event-trackers BioBriefs en 2026-03-12T16:33:54Z FDA consolidates adverse‑event trackers: single system for drug and vaccine safety https://biobriefs.com/hiv-diagnostics-push-bioneer-gains BioBriefs en 2026-03-12T16:33:54Z HIV diagnostics push: Bioneer gains CE‑IVDR for HIV‑1 quant kit; Gates backs Altratech POC viral‑load test https://biobriefs.com/nanoparticles-generate-car-t-cells BioBriefs en 2026-03-12T14:33:22Z Nanoparticles generate CAR T cells in vivo – Johns Hopkins shows mouse proof https://biobriefs.com/stealth-dna-circles-enable-kilobase BioBriefs en 2026-03-12T14:33:22Z Stealth DNA circles enable kilobase gene insertion... a safer route to big edits https://biobriefs.com/new-in-vivo-assays-quantify BioBriefs en 2026-03-12T14:33:22Z New in vivo assays quantify LNP endosomal escape — a delivery bottleneck solved https://biobriefs.com/vertex-files-bla-after-rainier BioBriefs en 2026-03-12T14:33:22Z Vertex files BLA after Rainier win — IgAN proteinuria plunges in Phase III https://biobriefs.com/lilly-bets-3bn-on-china BioBriefs en 2026-03-12T14:33:22Z Lilly bets $3bn on China production – doubles down on Asia supply https://biobriefs.com/lilly-warns-of-impurity-risk BioBriefs en 2026-03-12T14:33:22Z Lilly warns of impurity risk — compounders squeeze GLP-1 pricing https://biobriefs.com/fda-consolidates-adverse-event-trackers BioBriefs en 2026-03-12T14:33:22Z FDA consolidates adverse-event trackers: one database for safety signals https://biobriefs.com/270m-spinout-targets-rna-delivery BioBriefs en 2026-03-12T14:33:22Z $270m spinout targets RNA delivery to the heart — Atrium formed from Avidity assets https://biobriefs.com/optical-genome-mapping-spots-extra BioBriefs en 2026-03-12T14:33:22Z Optical genome mapping spots extra actionable variants in ~20% of acute leukemias https://biobriefs.com/cms-proposes-wider-coverage-for BioBriefs en 2026-03-12T14:33:22Z CMS proposes wider coverage for CRC biomarker tests — age lowered, bar raised https://biobriefs.com/fda-greenlights-leucovorin-for-rare BioBriefs en 2026-03-12T10:34:00Z FDA greenlights leucovorin for rare folate disorder — autism claim not endorsed https://biobriefs.com/fda-consolidates-safety-signals-one BioBriefs en 2026-03-12T10:34:00Z FDA consolidates safety signals: one adverse-event database for all centers https://biobriefs.com/new-in-vivo-assays-map BioBriefs en 2026-03-12T10:34:00Z New in vivo assays map LNP endosomal escape — liver delivery leaps forward https://biobriefs.com/immune-evasive-dna-donors-enable BioBriefs en 2026-03-12T10:34:00Z Immune‑evasive DNA donors enable safe, gene‑sized insertions https://biobriefs.com/regenxbio-posts-clean-dmd-safety BioBriefs en 2026-03-12T10:34:00Z Regenxbio posts clean DMD safety ahead of pivotal readout; FDA revisits another DMD program https://biobriefs.com/gsk-sells-linerixibat-to-alfasigma BioBriefs en 2026-03-12T10:34:00Z GSK sells linerixibat to Alfasigma in $690m deal as FDA decision looms https://biobriefs.com/avidity-spinout-atrium-raises-270m BioBriefs en 2026-03-12T10:34:00Z Avidity spinout Atrium raises $270m to deliver RNA to the heart https://biobriefs.com/vertex-files-bla-after-rainier BioBriefs en 2026-03-12T10:34:00Z Vertex files BLA after Rainier win — povetacicept seeks accelerated approval https://biobriefs.com/evotec-cuts-roughly-800-roles BioBriefs en 2026-03-12T10:34:00Z Evotec cuts roughly 800 roles as restructuring widens https://biobriefs.com/biontech-founders-to-depart-and BioBriefs en 2026-03-12T10:34:00Z BioNTech founders to depart and launch next‑gen mRNA startup https://biobriefs.com/immune-evasive-dna-donors-clear BioBriefs en 2026-03-12T09:33:56Z Immune‑evasive DNA donors clear kilobase insertion barrier https://biobriefs.com/in-vivo-endosomal-assays-pinpoint BioBriefs en 2026-03-12T09:33:56Z In vivo endosomal assays pinpoint LNP escape—liver delivery optimized https://biobriefs.com/nanoparticles-program-car-t-cells BioBriefs en 2026-03-12T09:33:56Z Nanoparticles program CAR T cells in vivo: mice show B‑cell depletion https://biobriefs.com/securitization-and-spinouts-fuel-cell BioBriefs en 2026-03-12T09:33:56Z Securitization and spinouts fuel cell and gene therapy scale‑up https://biobriefs.com/fda-narrows-leucovorin-to-rare BioBriefs en 2026-03-12T09:33:56Z FDA narrows leucovorin to rare cerebral folate deficiency—autism claims checked https://biobriefs.com/lonza-expands-capacity-to-make BioBriefs en 2026-03-12T09:33:56Z Lonza expands capacity to make ZYNTEGLO—gene‑therapy scale‑up https://biobriefs.com/optical-genome-mapping-finds-hidden BioBriefs en 2026-03-12T09:33:56Z Optical genome mapping finds hidden variants in acute leukemia https://biobriefs.com/ucbs-bimzelx-bests-abbvies-skyrizi BioBriefs en 2026-03-12T09:33:56Z UCB’s Bimzelx bests AbbVie’s Skyrizi in psoriatic arthritis head‑to‑head https://biobriefs.com/salspera-files-ipo-to-fund BioBriefs en 2026-03-12T09:33:56Z Salspera files IPO to fund phase 3 of salmonella IL‑2 cancer therapy https://biobriefs.com/nanoliposomes-revive-antibiotics-against-multidrug BioBriefs en 2026-03-12T09:33:56Z Nanoliposomes revive antibiotics against multidrug‑resistant Salmonella https://biobriefs.com/fda-narrows-leucovorin-use-approves BioBriefs en 2026-03-12T04:33:50Z FDA narrows leucovorin use: approves for rare cerebral folate defect, not autism https://biobriefs.com/optical-genome-mapping-finds-hidden BioBriefs en 2026-03-12T04:33:50Z Optical genome mapping finds hidden variants in acute leukemia — nearly 1 in 5 cases https://biobriefs.com/nanoparticles-program-in-vivo-car BioBriefs en 2026-03-12T04:33:50Z Nanoparticles program in vivo CAR T cells: Johns Hopkins reports mouse success https://biobriefs.com/safe-large-dna-insertion-stealth BioBriefs en 2026-03-12T04:33:50Z Safe large‑DNA insertion: stealth DNA circles enable kilobase‑scale genome writing https://biobriefs.com/quantifying-endosomal-escape-new-in BioBriefs en 2026-03-12T04:33:50Z Quantifying endosomal escape: new in vivo assays guide LNP design for liver delivery https://biobriefs.com/vertex-races-to-fda-phase BioBriefs en 2026-03-12T04:33:50Z Vertex races to FDA: phase‑3 win for povetacicept yields near‑50% proteinuria cut https://biobriefs.com/glp-1-drugs-linked-to BioBriefs en 2026-03-12T04:33:50Z GLP‑1 drugs linked to lower substance‑use risk in large veterans cohort https://biobriefs.com/biontech-founders-exit-to-start BioBriefs en 2026-03-12T04:33:50Z BioNTech founders exit to start next‑gen mRNA company as firm refocuses on oncology https://biobriefs.com/china-firms-push-lower-cost BioBriefs en 2026-03-12T04:33:50Z China firms push lower‑cost rivals to Zolgensma: four gene‑therapy contenders emerge https://biobriefs.com/securitization-pitched-to-fund-cell BioBriefs en 2026-03-12T04:33:50Z Securitization pitched to fund cell and gene therapy costs — new financing model proposed https://biobriefs.com/fda-clears-leucovorin-for-rare BioBriefs en 2026-03-11T21:35:49Z FDA clears leucovorin for rare folate defect — autism use rejected https://biobriefs.com/vertex-files-bla-after-phase BioBriefs en 2026-03-11T21:35:49Z Vertex files BLA after Phase III Rainier win — race to FDA https://biobriefs.com/quantifying-endosomal-escape-new-in BioBriefs en 2026-03-11T21:35:49Z Quantifying endosomal escape: new in vivo assays point the way for liver LNPs https://biobriefs.com/biontech-founders-exit-next-gen BioBriefs en 2026-03-11T21:35:49Z BioNTech founders exit — next‑gen mRNA spinout in the works https://biobriefs.com/atrium-therapeutics-launched-with-270m BioBriefs en 2026-03-11T21:35:49Z Atrium Therapeutics launched with $270M — RNA delivery to the heart https://biobriefs.com/evotec-deepens-restructuring-800-roles BioBriefs en 2026-03-11T21:35:49Z Evotec deepens restructuring — 800 roles and multiple site closures https://biobriefs.com/manufacturing-scale-up-lonza-expands BioBriefs en 2026-03-11T21:35:49Z Manufacturing scale‑up: Lonza expands gene‑therapy capacity — CSL builds $1.5B plasma plant https://biobriefs.com/investors-double-down-on-ai BioBriefs en 2026-03-11T21:35:49Z Investors double down on AI biology — Breakout $114M, Living Models $7M https://biobriefs.com/electrical-stimulation-advances-restore-movement BioBriefs en 2026-03-11T21:35:49Z Electrical stimulation advances restore movement and sensation after SCI https://biobriefs.com/fda-consolidates-adverse-event-tracking BioBriefs en 2026-03-11T21:35:49Z FDA consolidates adverse‑event tracking — single monitoring system planned https://biobriefs.com/vertex-races-to-fda-bla BioBriefs en 2026-03-11T16:33:33Z Vertex races to FDA: BLA filing looms after Phase III win https://biobriefs.com/fda-narrows-leucovorin-approval-not BioBriefs en 2026-03-11T16:33:33Z FDA narrows leucovorin approval — not for autism https://biobriefs.com/biontech-founders-exit-next-gen BioBriefs en 2026-03-11T16:33:33Z BioNTech founders exit... next‑gen mRNA startup incoming https://biobriefs.com/in-vivo-assay-quantifies-endosomal BioBriefs en 2026-03-11T16:33:33Z In vivo assay quantifies endosomal escape: guides LNP liver delivery https://biobriefs.com/lilly-pledges-3b-to-china BioBriefs en 2026-03-11T16:33:33Z Lilly pledges $3B to China — builds GLP‑1 manufacturing; $500M for Korea https://biobriefs.com/xenons-kv7-comeback-phase-iii BioBriefs en 2026-03-11T16:33:33Z Xenon’s Kv7 comeback: Phase III X‑TOLE2 smashes seizure endpoint https://biobriefs.com/biomimetic-ferritin-engager-car-t BioBriefs en 2026-03-11T16:33:33Z Biomimetic ferritin engager: CAR‑T potency rises without reengineering https://biobriefs.com/atrium-launches-with-270m-rna BioBriefs en 2026-03-11T16:33:33Z Atrium launches with $270M — RNA delivery to the heart in sights https://biobriefs.com/qiagen-clears-gi-panels-for BioBriefs en 2026-03-11T16:33:33Z Qiagen clears GI panels for QiaStat‑Dx Rise — hour‑long syndromic testing https://biobriefs.com/cms-eyes-colorectal-ncd-change BioBriefs en 2026-03-11T16:33:33Z CMS eyes colorectal NCD change: coverage from 45, tighter test performance https://biobriefs.com/vertex-files-bla-after-phase BioBriefs en 2026-03-11T14:32:56Z Vertex files BLA after Phase III win — IgAN race heats up https://biobriefs.com/biontech-founders-depart-next-gen BioBriefs en 2026-03-11T14:32:56Z BioNTech founders depart: next‑gen mRNA startup on the way https://biobriefs.com/xenons-kv7-opener-delivers-phase BioBriefs en 2026-03-11T14:32:56Z Xenon’s Kv7 opener delivers — Phase III clears primary endpoint https://biobriefs.com/salspera-files-91m-ipo-to BioBriefs en 2026-03-11T14:32:56Z Salspera files $91M IPO to fund phase 3 of salmonella‑based immunotherapy https://biobriefs.com/atrium-therapeutics-spins-out-with BioBriefs en 2026-03-11T14:32:56Z Atrium Therapeutics spins out with $270M to target genetic cardiomyopathies https://biobriefs.com/fda-clears-qiagen-gi-panels BioBriefs en 2026-03-11T14:32:56Z FDA clears Qiagen GI panels for QiaStat‑Dx Rise — labs gain throughput https://biobriefs.com/cms-proposes-crc-coverage-from BioBriefs en 2026-03-11T14:32:56Z CMS proposes CRC coverage from age 45 — tougher test performance rules https://biobriefs.com/quantifying-endosomal-escape-two-nature BioBriefs en 2026-03-11T14:32:56Z Quantifying endosomal escape: two Nature Biotechnology papers guide LNP design https://biobriefs.com/neuland-expands-peptide-capacity-module BioBriefs en 2026-03-11T14:32:56Z Neuland expands peptide capacity — Module One to begin commercial runs this summer https://biobriefs.com/ipsen-withdraws-tazverik-after-safety BioBriefs en 2026-03-11T14:32:56Z Ipsen withdraws Tazverik after safety signals — trials halted https://biobriefs.com/vertex-races-to-fda-bla BioBriefs en 2026-03-11T10:33:17Z Vertex races to FDA: BLA filed after Phase III win https://biobriefs.com/xenons-kv7-drug-shocks-epilepsy BioBriefs en 2026-03-11T10:33:17Z Xenon’s Kv7 drug shocks epilepsy field — Phase III clears primary goal https://biobriefs.com/biontech-founders-depart-next-gen BioBriefs en 2026-03-11T10:33:17Z BioNTech founders depart: next‑gen mRNA spinout in the works https://biobriefs.com/uhs-buys-talkspace-for-835m BioBriefs en 2026-03-11T10:33:17Z UHS buys Talkspace for $835M — virtual care scales into hospital network https://biobriefs.com/ipsen-withdraws-tazverik-amid-safety BioBriefs en 2026-03-11T10:33:17Z Ipsen withdraws Tazverik amid safety signal — company halts trials and sales https://biobriefs.com/sandoz-splits-off-biosimilars-unit BioBriefs en 2026-03-11T10:33:17Z Sandoz splits off biosimilars unit — firm bets on coming patent cliff https://biobriefs.com/neuland-expands-peptide-capacity-commercial BioBriefs en 2026-03-11T10:33:17Z Neuland expands peptide capacity — commercial module to open this summer https://biobriefs.com/biomimetic-face-boosts-car-t BioBriefs en 2026-03-11T10:33:17Z Biomimetic ‘FACE’ boosts CAR‑T potency without re‑engineering cells https://biobriefs.com/ema-moves-to-speed-trial BioBriefs en 2026-03-11T10:33:17Z EMA moves to speed trial approvals in emergencies — draft rules released https://biobriefs.com/cirena-licenses-long-rna-synthesis BioBriefs en 2026-03-11T10:33:17Z Cirena licenses long‑RNA synthesis tech from CU Boulder — enables ultra‑long constructs https://biobriefs.com/xenons-kv7-data-stun-markets BioBriefs en 2026-03-11T09:33:30Z Xenon’s Kv7 data stun markets – Seizure drug headed for FDA filing https://biobriefs.com/vertex-races-to-fda-iga BioBriefs en 2026-03-11T09:33:30Z Vertex races to FDA – IgA nephropathy drug eyes accelerated pathway https://biobriefs.com/biontech-founders-exit-to-launch BioBriefs en 2026-03-11T09:33:30Z BioNTech founders exit to launch next‑gen mRNA startup https://biobriefs.com/sandoz-doubles-down-on-biosimilars BioBriefs en 2026-03-11T09:33:30Z Sandoz doubles down on biosimilars – Dedicated unit to capture patent cliff https://biobriefs.com/ema-drafts-faster-trial-approvals BioBriefs en 2026-03-11T09:33:30Z EMA drafts faster trial approvals for health emergencies https://biobriefs.com/ipsen-pulls-tazverik-after-safety BioBriefs en 2026-03-11T09:33:30Z Ipsen pulls Tazverik after safety alarm – Market access and trials halted https://biobriefs.com/roches-breast-cancer-pill-fails BioBriefs en 2026-03-11T09:33:30Z Roche’s breast cancer pill fails pivotal test – Competitors react https://biobriefs.com/fda-widens-leucovorin-label-white BioBriefs en 2026-03-11T09:33:30Z FDA widens leucovorin label — White House claims collide with regulator https://biobriefs.com/big-pharma-doubles-down-in BioBriefs en 2026-03-11T09:33:30Z Big pharma doubles down in South Korea — $1bn+ in new commitments https://biobriefs.com/novo-and-hims-strike-peace BioBriefs en 2026-03-11T09:33:30Z Novo and Hims strike peace — GLP‑1 distribution deal ends feud https://biobriefs.com/vertex-claims-best-in-class BioBriefs en 2026-03-11T04:33:18Z Vertex claims best-in-class IgAN win — FDA filing imminent https://biobriefs.com/xenons-epilepsy-pill-delivers-knockout BioBriefs en 2026-03-11T04:33:18Z Xenon’s epilepsy pill delivers knockout Phase 3 data — filing ahead https://biobriefs.com/biontech-founders-to-exit-and BioBriefs en 2026-03-11T04:33:18Z BioNTech founders to exit and form next‑gen mRNA startup https://biobriefs.com/sandoz-spins-out-biosimilars-unit BioBriefs en 2026-03-11T04:33:18Z Sandoz spins out biosimilars unit — regulators ease biosimilar testing rules https://biobriefs.com/ipsen-pulls-tazverik-after-safety BioBriefs en 2026-03-11T04:33:18Z Ipsen pulls Tazverik after safety signal — trials and sales halted https://biobriefs.com/roches-oral-serd-flunks-first BioBriefs en 2026-03-11T04:33:18Z Roche’s oral SERD flunks first‑line trial — competitors and partners take hits https://biobriefs.com/peptide-and-cdmo-capacity-grows BioBriefs en 2026-03-11T04:33:18Z Peptide and CDMO capacity grows — Neuland ramps peptides, Lonza reshapes portfolio https://biobriefs.com/big-pharma-m-a-and BioBriefs en 2026-03-11T04:33:18Z Big pharma M&A and capital deals move pipelines — Servier, Teva score major funding https://biobriefs.com/regulators-move-to-speed-emergency BioBriefs en 2026-03-11T04:33:18Z Regulators move to speed emergency studies — U.S. broadens access, FDA widens label use https://biobriefs.com/car-t-innovation-biomimetic-enhancers BioBriefs en 2026-03-11T04:33:18Z CAR T innovation: biomimetic enhancers and in‑vivo strategies race to scale https://biobriefs.com/vertex-races-to-fda-after BioBriefs en 2026-03-10T21:33:23Z Vertex races to FDA after Phase‑3 kidney win https://biobriefs.com/biontech-founders-to-spin-out BioBriefs en 2026-03-10T21:33:23Z BioNTech founders to spin out next‑gen mRNA company https://biobriefs.com/xenons-epilepsy-pill-exceeds-expectations BioBriefs en 2026-03-10T21:33:23Z Xenon’s epilepsy pill exceeds expectations – files to follow https://biobriefs.com/novo-and-hims-end-feud BioBriefs en 2026-03-10T21:33:23Z Novo and Hims end feud — GLP‑1 distribution deal struck https://biobriefs.com/ema-proposes-faster-trial-approvals BioBriefs en 2026-03-10T21:33:23Z EMA proposes faster trial approvals during public‑health emergencies https://biobriefs.com/biocartis-wins-ivdr-nod-for BioBriefs en 2026-03-10T21:33:23Z Biocartis wins IVDR nod for automated MSI colorectal companion test https://biobriefs.com/neuland-moves-into-commercial-peptide BioBriefs en 2026-03-10T21:33:23Z Neuland moves into commercial peptide manufacturing as demand surges https://biobriefs.com/chinas-biotechs-race-to-build BioBriefs en 2026-03-10T21:33:23Z China’s biotechs race to build low‑cost rivals to $2M gene therapy https://biobriefs.com/fda-trims-foreign-comparator-testing BioBriefs en 2026-03-10T21:33:23Z FDA trims foreign comparator testing in draft biosimilar guidance https://biobriefs.com/ipsen-withdraws-tazverik-after-safety BioBriefs en 2026-03-10T21:33:23Z Ipsen withdraws Tazverik after safety monitors flag secondary cancers https://biobriefs.com/vertexs-kidney-drug-clears-phase BioBriefs en 2026-03-10T16:33:48Z Vertex’s kidney drug clears Phase 3 — FDA filing imminent https://biobriefs.com/biontech-founders-exit-to-launch BioBriefs en 2026-03-10T16:33:48Z BioNTech founders exit to launch next‑gen mRNA spinout https://biobriefs.com/xenons-epilepsy-pill-smashes-expectations BioBriefs en 2026-03-10T16:33:48Z Xenon’s epilepsy pill smashes expectations — filing set for Q3 https://biobriefs.com/roches-oral-serd-fails-pivotal BioBriefs en 2026-03-10T16:33:48Z Roche’s oral SERD fails pivotal first‑line study — program setback https://biobriefs.com/ipsen-pulls-tazverik-from-market BioBriefs en 2026-03-10T16:33:48Z Ipsen pulls Tazverik from market after safety signal https://biobriefs.com/sanofi-inks-1-4b-deal BioBriefs en 2026-03-10T16:33:48Z Sanofi inks $1.4B deal to in‑license China’s first‑in‑class JAK/ROCK https://biobriefs.com/fda-clarifies-leucovorin-use-autism BioBriefs en 2026-03-10T16:33:48Z FDA clarifies leucovorin use — autism claims roll back https://biobriefs.com/big-biopharma-backs-south-korea BioBriefs en 2026-03-10T16:33:48Z Big biopharma backs South Korea — multi‑hundred‑million investments https://biobriefs.com/servier-buys-day-one-biopharmaceuticals BioBriefs en 2026-03-10T16:33:48Z Servier buys Day One Biopharmaceuticals for $2.5B — rare‑cancer push https://biobriefs.com/fda-reopens-review-of-dmd BioBriefs en 2026-03-10T16:33:48Z FDA reopens review of DMD cell therapy as preclinical DMD work advances https://biobriefs.com/xenons-epilepsy-pill-smashes-phase BioBriefs en 2026-03-10T14:33:08Z Xenon’s epilepsy pill smashes Phase 3—FDA filing set https://biobriefs.com/vertexs-kidney-drug-clears-phase BioBriefs en 2026-03-10T14:33:08Z Vertex’s kidney drug clears Phase 3—accelerated approval bid begins https://biobriefs.com/servier-to-buy-day-one BioBriefs en 2026-03-10T14:33:08Z Servier to buy Day One for $2.5bn—rare cancer pipeline expands https://biobriefs.com/biontech-founders-to-exit-new BioBriefs en 2026-03-10T14:33:08Z BioNTech founders to exit—new mRNA spinout incoming https://biobriefs.com/bristol-myers-celmod-mezigdomide-clears BioBriefs en 2026-03-10T14:33:08Z Bristol Myers’ CELMoD mezigdomide clears Phase 3—myeloma program advances https://biobriefs.com/ipsen-withdraws-tazverik-after-safety BioBriefs en 2026-03-10T14:33:08Z Ipsen withdraws Tazverik after safety signal—market removal implemented https://biobriefs.com/blackstone-backs-teva-with-up BioBriefs en 2026-03-10T14:33:08Z Blackstone backs Teva with up to $400m—IBD antibody gets fuel https://biobriefs.com/verily-and-samsung-link-smartwatch BioBriefs en 2026-03-10T14:33:08Z Verily and Samsung link smartwatch data to trials—wearables move into endpoints https://biobriefs.com/in-vivo-car-t-approaches BioBriefs en 2026-03-10T14:33:08Z In vivo CAR T approaches escalate—industry bets on off‑the‑shelf engineering https://biobriefs.com/ai-tool-accelerates-synthetic-routes BioBriefs en 2026-03-10T14:33:08Z AI tool accelerates synthetic routes—cheminformatics meets bench chemistry https://biobriefs.com/teva-taps-blackstone-for-400m BioBriefs en 2026-03-10T10:33:09Z Teva Taps Blackstone for $400m Push on Late‑Stage IBD Antibody https://biobriefs.com/vertexs-kidney-drug-halves-key BioBriefs en 2026-03-10T10:33:09Z Vertex’s Kidney Drug Halves Key IgA Nephropathy Marker in Phase 3 https://biobriefs.com/ferritin-bridge-strengthens-car-t BioBriefs en 2026-03-10T10:33:09Z Ferritin bridge strengthens CAR‑T engagement – a non‑genetic fix for relapse https://biobriefs.com/xenons-epilepsy-pill-slashes-seizures BioBriefs en 2026-03-10T10:33:09Z Xenon’s epilepsy pill slashes seizures — phase 3 blowout https://biobriefs.com/roches-oral-serd-fails-first BioBriefs en 2026-03-10T10:33:09Z Roche’s oral SERD fails first‑line test — ripples across the oral SERD field https://biobriefs.com/ipsen-pulls-tazverik-after-trial BioBriefs en 2026-03-10T10:33:09Z Ipsen pulls Tazverik after trial monitors spot secondary blood cancers https://biobriefs.com/verily-and-samsung-link-wearables BioBriefs en 2026-03-10T10:33:09Z Verily and Samsung link wearables to trials — AI also matches doctors to studies https://biobriefs.com/novo-hims-strike-deal-to BioBriefs en 2026-03-10T10:33:09Z Novo, Hims strike deal to curb compounding and widen GLP‑1 access https://biobriefs.com/in-vivo-car-t-and BioBriefs en 2026-03-10T10:33:09Z In‑vivo CAR‑T and predictive biomarkers: two fronts for widening cell therapy access https://biobriefs.com/who-to-recommend-near-patient BioBriefs en 2026-03-10T10:33:09Z WHO to recommend near‑patient molecular TB tests and tongue swabs https://biobriefs.com/vertex-kidney-drug-hits-phase BioBriefs en 2026-03-10T09:32:37Z Vertex kidney drug hits Phase 3 goal – best‑in‑class hopes rise https://biobriefs.com/xenons-epilepsy-pill-crushes-phase BioBriefs en 2026-03-10T09:32:37Z Xenon’s epilepsy pill crushes Phase 3 target: seizure rates halved https://biobriefs.com/bristol-myers-celmod-mezigdomide-clears BioBriefs en 2026-03-10T09:32:37Z Bristol Myers’ CELMoD mezigdomide clears Phase 3 — multiple myeloma PFS improves https://biobriefs.com/ipsen-pulls-tazverik-after-safety BioBriefs en 2026-03-10T09:32:37Z Ipsen pulls Tazverik after safety signals — market withdrawal and trial halts https://biobriefs.com/roches-giredestrant-flunks-persevera-first BioBriefs en 2026-03-10T09:32:37Z Roche’s giredestrant flunks PersevERA — first‑line oral SERD setback https://biobriefs.com/agilent-snaps-up-biocare-for BioBriefs en 2026-03-10T09:32:37Z Agilent snaps up Biocare for $950M to expand pathology reach https://biobriefs.com/fda-updates-biosimilar-q-as BioBriefs en 2026-03-10T09:32:37Z FDA updates biosimilar Q&As: reissues guidance and posts revised draft — clarity on BPCI Act https://biobriefs.com/ferritin-face-platform-boosts-car BioBriefs en 2026-03-10T09:32:37Z Ferritin 'FACE' platform boosts CAR‑T avidity without re‑engineering receptors https://biobriefs.com/verily-and-samsung-team-to BioBriefs en 2026-03-10T09:32:37Z Verily and Samsung team to feed Galaxy smartwatch data into clinical trials https://biobriefs.com/doctr-ai-matches-doctors-to BioBriefs en 2026-03-10T09:32:37Z DocTr AI matches doctors to trials with 58% higher accuracy — trial site selection gets smarter https://biobriefs.com/azetukalner-cuts-focal-seizures-53 BioBriefs en 2026-03-10T04:32:52Z Azetukalner cuts focal seizures 53% – Xenon aims Q3 filing https://biobriefs.com/vertexs-acquired-drug-halves-iga BioBriefs en 2026-03-10T04:32:52Z Vertex’s acquired drug halves IgA marker – late‑stage win https://biobriefs.com/mezigdomide-improves-pfs-bms-de BioBriefs en 2026-03-10T04:32:52Z Mezigdomide improves PFS – BMS de‑risks CELMoD slate https://biobriefs.com/ipsen-pulls-tazverik-after-safety BioBriefs en 2026-03-10T04:32:52Z Ipsen pulls Tazverik after safety monitors flag secondary cancers https://biobriefs.com/ferritin-engager-boosts-car-t BioBriefs en 2026-03-10T04:32:52Z Ferritin engager boosts CAR‑T avidity…less cells, less CRS https://biobriefs.com/in-vivo-car-t-bets BioBriefs en 2026-03-10T04:32:52Z In‑vivo CAR‑T bets accelerate – delivery and safety still central https://biobriefs.com/gene-edited-probiotic-shows-safety BioBriefs en 2026-03-10T04:32:52Z Gene‑edited probiotic shows safety gains in preclinical tests https://biobriefs.com/verily-and-samsung-link-galaxy BioBriefs en 2026-03-10T04:32:52Z Verily and Samsung link Galaxy data to trial platform – wearables go mainstream https://biobriefs.com/sartorius-unveils-cho-host-with BioBriefs en 2026-03-10T04:32:52Z Sartorius unveils CHO host with up to 3× productivity – manufacturing edge https://biobriefs.com/agilent-buys-biocare-for-950m BioBriefs en 2026-03-10T04:32:52Z Agilent buys Biocare for $950M – beefs up pathology reagent portfolio https://biobriefs.com/crispr-edits-mitochondria-fresh-path BioBriefs en 2026-03-09T21:33:09Z CRISPR edits mitochondria: fresh path for heart-failure repair https://biobriefs.com/listeria-repurposed-bacteria-deliver-cancer BioBriefs en 2026-03-09T21:33:09Z Listeria repurposed: bacteria deliver cancer payloads to colorectal tumors https://biobriefs.com/bristol-myers-celmod-wins-mezigdomide BioBriefs en 2026-03-09T21:33:09Z Bristol Myers’ CELMoD wins...mezigdomide shows PFS gain https://biobriefs.com/xenons-azetukalner-halves-focal-seizures BioBriefs en 2026-03-09T21:33:09Z Xenon’s azetukalner halves focal seizures – paves way for FDA filing https://biobriefs.com/ipsen-withdraws-tazverik-safety-monitors BioBriefs en 2026-03-09T21:33:09Z Ipsen withdraws Tazverik: safety monitors flag secondary blood cancers https://biobriefs.com/novo-hims-strike-truce-glp BioBriefs en 2026-03-09T21:33:09Z Novo, Hims strike truce: GLP-1 access restored, compounding curtailed https://biobriefs.com/agilent-buys-biocare-for-950m BioBriefs en 2026-03-09T21:33:09Z Agilent buys Biocare for $950M – expands pathology arsenal https://biobriefs.com/cho-reboot-sartorius-engineered-host BioBriefs en 2026-03-09T21:33:09Z CHO reboot: Sartorius’ engineered host doubles titers https://biobriefs.com/lonza-extends-zynteglo-deal-scales BioBriefs en 2026-03-09T21:33:09Z Lonza extends ZYNTEGLO deal – scales commercial gene therapy supply https://biobriefs.com/who-readies-new-tb-testing BioBriefs en 2026-03-09T21:33:09Z WHO readies new TB testing guidance: near‑patient MDx and tongue swabs https://biobriefs.com/roches-oral-serd-flunks-first BioBriefs en 2026-03-09T16:33:10Z Roche’s oral SERD flunks first‑line trial — mechanism questioned https://biobriefs.com/xenons-phase-3-win-blows BioBriefs en 2026-03-09T16:33:10Z Xenon’s phase 3 win blows past expectations — FDA filing planned https://biobriefs.com/ipsen-pulls-tazverik-after-safety BioBriefs en 2026-03-09T16:33:10Z Ipsen pulls Tazverik after safety signal — confirmatory trial triggers withdrawal https://biobriefs.com/novo-ends-fight-with-hims BioBriefs en 2026-03-09T16:33:10Z Novo ends fight with Hims — branded GLP‑1s land on telehealth https://biobriefs.com/abbvies-350m-amylin-bet-posts BioBriefs en 2026-03-09T16:33:10Z AbbVie’s $350M amylin bet posts near‑10% weight loss at 12 weeks https://biobriefs.com/lonza-to-sell-capsule-and BioBriefs en 2026-03-09T16:33:10Z Lonza to sell capsule and health ingredients unit in $3bn deal — pivots to CDMO https://biobriefs.com/lonza-expands-zynteglo-capacity-genetix BioBriefs en 2026-03-09T16:33:10Z Lonza expands ZYNTEGLO capacity — Genetix scales commercial gene‑therapy supply https://biobriefs.com/fda-turbulence-lifts-gene-therapy BioBriefs en 2026-03-09T16:33:10Z FDA turbulence lifts gene‑therapy stocks — Prasad exit fuels market swings https://biobriefs.com/cenevo-launches-agentic-lab-ai BioBriefs en 2026-03-09T16:33:10Z Cenevo launches agentic lab AI; Primera adopts Labguru for digitization https://biobriefs.com/agilent-to-buy-biocare-medical BioBriefs en 2026-03-09T16:33:10Z Agilent to buy Biocare Medical for $950M — pathology portfolio expands https://biobriefs.com/roches-oral-serd-flunks-first BioBriefs en 2026-03-09T14:33:04Z Roche’s oral SERD flunks first‑line trial — questions on mechanism https://biobriefs.com/fdas-pressure-on-uniqure-spurs BioBriefs en 2026-03-09T14:33:04Z FDA’s pressure on uniQure spurs stock swings — CBER boss to exit https://biobriefs.com/agilent-buys-biocare-for-950m BioBriefs en 2026-03-09T14:33:04Z Agilent buys Biocare for $950M — fluorescence, IHC and FISH added https://biobriefs.com/lonza-narrows-focus-sells-capsules BioBriefs en 2026-03-09T14:33:04Z Lonza narrows focus—sells Capsules & Health Ingredients in $3B deal https://biobriefs.com/fda-issues-crl-to-incyte BioBriefs en 2026-03-09T14:33:04Z FDA issues CRL to Incyte tied to third‑party plant problems https://biobriefs.com/xenon-posts-phase-3-win BioBriefs en 2026-03-09T14:33:04Z Xenon posts Phase‑3 win — azetukalner cuts seizure frequency https://biobriefs.com/big-pharma-obesity-bets-show BioBriefs en 2026-03-09T14:33:04Z Big pharma obesity bets show traction — AbbVie and Regeneron report gains https://biobriefs.com/daraxonrasib-posts-high-responses-moves BioBriefs en 2026-03-09T14:33:04Z Daraxonrasib posts high responses — moves toward Phase‑3 in PDAC https://biobriefs.com/hiv-adapts-to-lenacapavir-new BioBriefs en 2026-03-09T14:33:04Z HIV adapts to lenacapavir — new resistance routes mapped https://biobriefs.com/high-throughput-dnd-assay-spots BioBriefs en 2026-03-09T14:33:04Z High‑throughput DnD assay spots hidden antibiotic resistance https://biobriefs.com/lonza-sells-chi-to-lone BioBriefs en 2026-03-09T10:32:50Z Lonza sells CHI to Lone Star — Company pivots to pure‑play CDMO https://biobriefs.com/fda-shuns-advisory-panels-uniqure BioBriefs en 2026-03-09T10:32:50Z FDA shuns advisory panels: uniQure gene therapy faces fresh agency scrutiny https://biobriefs.com/roches-breast-cancer-pill-fails BioBriefs en 2026-03-09T10:32:50Z Roche’s breast‑cancer pill fails first‑line Phase 3 — Program setback https://biobriefs.com/daraxonrasib-posts-high-responses-moves BioBriefs en 2026-03-09T10:32:50Z Daraxonrasib posts high responses — Moves toward Phase 3 in RAS‑mutant pancreatic cancer https://biobriefs.com/dna-repair-mutations-modulate-pancreatic BioBriefs en 2026-03-09T10:32:50Z DNA‑repair mutations modulate pancreatic cancer response — Treatment stratification insight https://biobriefs.com/new-resistance-pathways-mapped-for BioBriefs en 2026-03-09T10:32:50Z New resistance pathways mapped for lenacapavir — HIV drug under evolutionary pressure https://biobriefs.com/high-throughput-dnd-assay-exposes BioBriefs en 2026-03-09T10:32:50Z High‑throughput DnD assay exposes hidden antibiotic resistance — Diagnostic leap https://biobriefs.com/wireless-retinal-implant-restores-reading BioBriefs en 2026-03-09T10:32:50Z Wireless retinal implant restores reading for geographic atrophy patients https://biobriefs.com/mri-steered-catheter-and-mid BioBriefs en 2026-03-09T10:32:50Z MRI‑steered catheter and mid‑IR fiber probe — New tools for real‑time tissue access and monitoring https://biobriefs.com/ppq-strategies-for-cell-and BioBriefs en 2026-03-09T10:32:50Z PPQ strategies for cell and gene therapies — Preventing quality and compliance setbacks https://biobriefs.com/uniqure-fda-standoff-agency-presses BioBriefs en 2026-03-09T09:33:01Z uniQure-FDA standoff: agency presses for sham-surgery trial https://biobriefs.com/roches-pivotal-miss-breast-cancer BioBriefs en 2026-03-09T09:33:01Z Roche’s pivotal miss — breast‑cancer pill fails first‑line trial https://biobriefs.com/daraxonrasib-posts-47-orr-revolution BioBriefs en 2026-03-09T09:33:01Z Daraxonrasib posts 47% ORR — Revolution targets Phase 3 in RAS PDAC https://biobriefs.com/wireless-eye-implant-blind-patients BioBriefs en 2026-03-09T09:33:01Z Wireless eye implant... blind patients read again https://biobriefs.com/petrelintide-meets-endpoints-but-weight BioBriefs en 2026-03-09T09:33:01Z Petrelintide meets endpoints — but weight loss lags expectations https://biobriefs.com/study-maps-new-hiv-1 BioBriefs en 2026-03-09T09:33:01Z Study maps new HIV‑1 resistance routes to lenacapavir https://biobriefs.com/high-throughput-dnd-assay-reveals BioBriefs en 2026-03-09T09:33:01Z High‑throughput DnD assay reveals hidden antibiotic resistances https://biobriefs.com/itk-targeting-ramps-up-anti BioBriefs en 2026-03-09T09:33:01Z ITK targeting ramps up anti‑CD19 CAR‑T potency https://biobriefs.com/dna-repair-defects-alter-chemotherapy BioBriefs en 2026-03-09T09:33:01Z DNA‑repair defects alter chemotherapy outcomes in metastatic PDAC https://biobriefs.com/video-ai-quantifies-parkinsons-finger BioBriefs en 2026-03-09T09:33:01Z Video AI quantifies Parkinson’s finger‑tapping motor signs https://biobriefs.com/uniqure-and-fda-sham-surgery BioBriefs en 2026-03-09T04:32:31Z uniQure and FDA... Sham-surgery demand fuels stock roller-coaster https://biobriefs.com/daraxonrasib-47-55-orr-pushes BioBriefs en 2026-03-09T04:32:31Z Daraxonrasib... 47–55% ORR pushes RAS drug toward Phase 3 https://biobriefs.com/roche-zealand-obesity-peptide-meets BioBriefs en 2026-03-09T04:32:31Z Roche, Zealand: Obesity peptide meets Phase 2 goals – weight loss under expectations https://biobriefs.com/lenacapavir-resistance-pathways-mapped-hiv BioBriefs en 2026-03-09T04:32:31Z Lenacapavir resistance pathways mapped: HIV finds new escape routes https://biobriefs.com/dilution-and-delay-assay-high BioBriefs en 2026-03-09T04:32:31Z Dilution-and-delay assay... High-throughput detection exposes hidden antibiotic resistance https://biobriefs.com/itk-targeting-rewiring-t-cells BioBriefs en 2026-03-09T04:32:31Z ITK targeting... Rewiring T cells to boost anti‑CD19 CAR‑T potency https://biobriefs.com/dna-repair-mutations-reshape-pdac BioBriefs en 2026-03-09T04:32:31Z DNA repair mutations reshape PDAC chemo response — biomarker implications https://biobriefs.com/ai-mines-mammograms-routine-screens BioBriefs en 2026-03-09T04:32:31Z AI mines mammograms: routine screens flag future heart disease risk https://biobriefs.com/worlds-tiniest-robot-sub-millimeter BioBriefs en 2026-03-09T04:32:31Z World’s tiniest robot... sub‑millimeter machines promise biomedical applications https://biobriefs.com/the-age-of-animal-experiments BioBriefs en 2026-03-09T04:32:31Z The age of animal experiments may be waning: NAMs scale up https://biobriefs.com/vinay-prasad-to-depart-fda BioBriefs en 2026-03-08T21:34:19Z Vinay Prasad to depart FDA again — agency leadership shift in April https://biobriefs.com/daraxonrasib-posts-strong-responses-phase BioBriefs en 2026-03-08T21:34:19Z Daraxonrasib posts strong responses — Phase 3 push in RAS-mutant pancreatic cancer https://biobriefs.com/roche-zealand-peptide-meets-endpoints BioBriefs en 2026-03-08T21:34:19Z Roche–Zealand peptide meets endpoints — obesity readout shows tolerability, modest weight loss https://biobriefs.com/new-high-throughput-dnd-assay BioBriefs en 2026-03-08T21:34:19Z New high-throughput DnD assay finds hidden antibiotic resistances — diagnostic advance https://biobriefs.com/study-maps-new-hiv-1 BioBriefs en 2026-03-08T21:34:19Z Study maps new HIV‑1 lenacapavir resistance paths — implications for long‑acting therapy https://biobriefs.com/targeting-itk-enhances-anti-cd19 BioBriefs en 2026-03-08T21:34:19Z Targeting ITK enhances anti‑CD19 CAR‑T potency — preclinical route to better cell therapies https://biobriefs.com/low-cost-sample-hashing-scales BioBriefs en 2026-03-08T21:34:19Z Low‑cost sample hashing scales single‑cell multiomics — clinical sample workflows advance https://biobriefs.com/penn-unveils-sub-millimeter-robots BioBriefs en 2026-03-08T21:34:19Z Penn unveils sub‑millimeter robots with sensors and onboard compute — medical microrobotics step https://biobriefs.com/phase-iii-acwy-tt-vaccine BioBriefs en 2026-03-08T21:34:19Z Phase III ACWY‑TT vaccine shows safety and efficacy in toddlers — pediatric meningococcal option advances https://biobriefs.com/esc-issues-patient-facing-pregnancy BioBriefs en 2026-03-08T21:34:19Z ESC issues patient‑facing pregnancy CVD guidance — shared decision tools released https://biobriefs.com/servier-boosts-rare-cancer-push BioBriefs en 2026-03-08T16:32:53Z Servier boosts rare-cancer push: $2.5B Day One buyout https://biobriefs.com/vinay-prasad-to-depart-fda BioBriefs en 2026-03-08T16:32:53Z Vinay Prasad to depart FDA again — exit set for end of April https://biobriefs.com/fda-doubles-down-uniqure-must BioBriefs en 2026-03-08T16:32:53Z FDA doubles down: uniQure must run sham‑controlled Huntington’s trial https://biobriefs.com/petrelintide-misses-lofty-bar-roche BioBriefs en 2026-03-08T16:32:53Z Petrelintide misses lofty bar—Roche/Zealand readout disappoints investors https://biobriefs.com/high-throughput-dnd-assay-new BioBriefs en 2026-03-08T16:32:53Z High‑throughput DnD assay: new tool to unmask hidden antibiotic resistance https://biobriefs.com/new-study-maps-lenacapavir-resistance BioBriefs en 2026-03-08T16:32:53Z New study maps lenacapavir resistance — HIV finds recurrent and unique escape routes https://biobriefs.com/car-astrocytes-prevent-and-reduce BioBriefs en 2026-03-08T16:32:53Z CAR‑astrocytes prevent and reduce amyloid plaques in mice — single injection effect https://biobriefs.com/fda-clears-claire-perimeter-wins BioBriefs en 2026-03-08T16:32:53Z FDA clears Claire: Perimeter wins approval for intraoperative AI margin imaging https://biobriefs.com/japan-approves-first-ipsc-derived BioBriefs en 2026-03-08T16:32:53Z Japan approves first iPSC‑derived therapy for Parkinson’s — regulatory milestone https://biobriefs.com/penn-unveils-microscopic-robot-sub BioBriefs en 2026-03-08T16:32:53Z Penn unveils microscopic robot — sub‑millimeter machines pack sensors and solar power https://biobriefs.com/prasad-to-leave-fda-departure BioBriefs en 2026-03-08T14:33:03Z Prasad to leave FDA: departure caps tumultuous term https://biobriefs.com/fda-stands-by-sham-control BioBriefs en 2026-03-08T14:33:03Z FDA stands by sham-control demand: uniQure fight intensifies https://biobriefs.com/servier-buys-day-one-2 BioBriefs en 2026-03-08T14:33:03Z Servier buys Day One: $2.5B deal expands rare oncology portfolio https://biobriefs.com/petrelintide-falls-short-amylin-candidate BioBriefs en 2026-03-08T14:33:03Z Petrelintide falls short: amylin candidate underwhelms vs. Lilly https://biobriefs.com/fda-clears-perimeters-claire-ai BioBriefs en 2026-03-08T14:33:03Z FDA clears Perimeter’s Claire: AI imaging for breast‑conserving surgery https://biobriefs.com/modulating-car-t-itk-inhibition BioBriefs en 2026-03-08T14:33:03Z Modulating CAR‑T: ITK inhibition and ketone boost efficacy in preclinical work https://biobriefs.com/car-astrocytes-clear-amyloid-cellular BioBriefs en 2026-03-08T14:33:03Z CAR‑astrocytes clear amyloid: cellular immunotherapy for Alzheimer’s in mice https://biobriefs.com/dnd-assay-unmasks-hidden-resistance BioBriefs en 2026-03-08T14:33:03Z DnD assay unmasks hidden resistance: new high‑throughput antibiotic test https://biobriefs.com/microrobots-shrink-to-medical-scale BioBriefs en 2026-03-08T14:33:03Z Microrobots shrink to medical scale: Penn builds solar‑powered devices https://biobriefs.com/japan-approves-first-ipsc-therapy BioBriefs en 2026-03-08T14:33:03Z Japan approves first iPSC therapy for Parkinson’s: regenerative milestone https://biobriefs.com/fdas-vaccines-and-biologics-chief BioBriefs en 2026-03-08T10:32:50Z FDA’s vaccines and biologics chief to leave in April — second exit https://biobriefs.com/servier-pays-2-5b-for BioBriefs en 2026-03-08T10:32:50Z Servier pays $2.5B for Day One — gains pediatric glioma drug https://biobriefs.com/fda-doubles-down-on-sham BioBriefs en 2026-03-08T10:32:50Z FDA doubles down on sham‑control demand — uniQure dispute escalates https://biobriefs.com/fda-fast-tracks-tecvayli-darzalex BioBriefs en 2026-03-08T10:32:50Z FDA fast‑tracks Tecvayli–Darzalex combo: national‑priority clearance https://biobriefs.com/perimeters-claire-imaging-device-wins BioBriefs en 2026-03-08T10:32:50Z Perimeter’s Claire imaging device wins FDA premarket approval — intraoperative AI https://biobriefs.com/car-astrocytes-remove-amyloid-in BioBriefs en 2026-03-08T10:32:50Z CAR‑astrocytes remove amyloid in mice — single‑dose proof of concept https://biobriefs.com/kestrels-pan-kras-oral-inhibitor BioBriefs en 2026-03-08T10:32:50Z Kestrel’s pan‑KRAS oral inhibitor cleared for IND — FIH trial to start https://biobriefs.com/study-maps-hiv-1-lenacapavir BioBriefs en 2026-03-08T10:32:50Z Study maps HIV‑1 lenacapavir resistance pathways — surveillance implications https://biobriefs.com/japan-clears-first-ipsc-derived BioBriefs en 2026-03-08T10:32:50Z Japan clears first iPSC‑derived therapy for Parkinson’s — regulatory milestone https://biobriefs.com/scalable-sample-hashing-boosts-single BioBriefs en 2026-03-08T10:32:50Z Scalable sample hashing boosts single‑cell multiomics for clinical samples https://biobriefs.com/fdas-vinay-prasad-to-depart BioBriefs en 2026-03-08T09:33:10Z FDA’s Vinay Prasad to depart in April — Replacement unclear https://biobriefs.com/servier-buys-day-one-for BioBriefs en 2026-03-08T09:33:10Z Servier buys Day One for $2.5B — Gains pediatric glioma franchise https://biobriefs.com/fda-doubles-down-on-sham BioBriefs en 2026-03-08T09:33:10Z FDA doubles down on sham‑control for uniQure’s Huntington therapy — Dispute escalates https://biobriefs.com/petrelintide-underwhelms-investors-zealand-shares BioBriefs en 2026-03-08T09:33:10Z Petrelintide underwhelms investors — Zealand shares tumble after mid‑stage readout https://biobriefs.com/car-astrocytes-clear-amyloid-in BioBriefs en 2026-03-08T09:33:10Z CAR‑astrocytes clear amyloid in mice — Single dose halves plaque burden https://biobriefs.com/perimeters-ai-margin-imaging-claire BioBriefs en 2026-03-08T09:33:10Z Perimeter’s AI margin‑imaging Claire cleared by FDA — Point‑of‑care pathology for breast surgery https://biobriefs.com/kestrel-wins-ind-for-oral BioBriefs en 2026-03-08T09:33:10Z Kestrel wins IND for oral pan‑KRAS inhibitor — First‑in‑human trial slated https://biobriefs.com/fda-uses-expedited-pathway-for BioBriefs en 2026-03-08T09:33:10Z FDA uses expedited pathway for J&J myeloma combo — Tecvayli‑Darzalex wins rapid clearance https://biobriefs.com/dilution-and-delay-assay-reveals BioBriefs en 2026-03-08T09:33:10Z Dilution‑and‑delay assay reveals hidden antibiotic resistance — High‑throughput tool emerges https://biobriefs.com/penn-unveils-sub-millimeter-solar BioBriefs en 2026-03-08T09:33:10Z Penn unveils sub‑millimeter solar‑powered robot — Microrobots aimed at biomedical tasks https://biobriefs.com/fda-shake-up-vinay-prasad BioBriefs en 2026-03-08T04:33:23Z FDA shake-up: Vinay Prasad to exit at end of April https://biobriefs.com/fda-doubles-down-uniqure-must BioBriefs en 2026-03-08T04:33:23Z FDA doubles down — uniQure must run sham‑controlled Huntington trial https://biobriefs.com/servier-bets-2-5b-on BioBriefs en 2026-03-08T04:33:23Z Servier bets $2.5B on pediatric glioma — Day One buy seals rare‑cancer push https://biobriefs.com/petrelintide-underwhelms-roche-zealand-readout BioBriefs en 2026-03-08T04:33:23Z Petrelintide underwhelms — Roche/Zealand readout misses investor marks https://biobriefs.com/fda-fast-tracks-j-j BioBriefs en 2026-03-08T04:33:23Z FDA fast‑tracks J&J myeloma combo — Tecvayli‑Darzalex cleared under priority pilot https://biobriefs.com/perimeters-claire-wins-fda-premarket BioBriefs en 2026-03-08T04:33:23Z Perimeter’s Claire wins FDA premarket approval — real‑time margin imaging cleared https://biobriefs.com/ind-advances-kestrels-pan-kras BioBriefs en 2026-03-08T04:33:23Z IND advances: Kestrel’s pan‑KRAS oral candidate cleared — epigenetic immunoactivator also greenlighted https://biobriefs.com/biopharma-cash-returns-financings-surge BioBriefs en 2026-03-08T04:33:23Z Biopharma cash returns: financings surge — Solid Biosciences raises $240M https://biobriefs.com/new-neuro-approaches-car-astrocytes BioBriefs en 2026-03-08T04:33:23Z New neuro approaches: CAR‑astrocytes clear amyloid in mice; tanycytes tied to tau clearance https://biobriefs.com/targeting-hidden-resistance-new-assays BioBriefs en 2026-03-08T04:33:23Z Targeting hidden resistance: new assays and AI models map antimicrobial escape https://biobriefs.com/fdas-embattled-vaccine-chief-prasad BioBriefs en 2026-03-07T21:33:45Z FDA’s embattled vaccine chief Prasad exits again — April departure https://biobriefs.com/servier-picks-up-day-one BioBriefs en 2026-03-07T21:33:45Z Servier picks up Day One: $2.5B deal for pediatric glioma drug https://biobriefs.com/fda-doubles-down-on-uniqure BioBriefs en 2026-03-07T21:33:45Z FDA doubles down on uniQure — defends sham‑controlled trial demand https://biobriefs.com/petrelintide-underwhelms-investors-roche-zealand BioBriefs en 2026-03-07T21:33:45Z Petrelintide underwhelms investors: Roche/Zealand readout misses expectations https://biobriefs.com/car-astrocyte-therapy-single-injection BioBriefs en 2026-03-07T21:33:45Z CAR‑astrocyte therapy: single injection prevents and clears amyloid in mice https://biobriefs.com/fda-greenlights-tecvayli-darzalex-swift BioBriefs en 2026-03-07T21:33:45Z FDA greenlights Tecvayli‑Darzalex: swift approval under CNPV pilot https://biobriefs.com/kestrel-wins-ind-for-pan BioBriefs en 2026-03-07T21:33:45Z Kestrel wins IND for pan‑KRAS oral inhibitor — FALCON trial set https://biobriefs.com/perimeters-claire-gets-fda-pma BioBriefs en 2026-03-07T21:33:45Z Perimeter’s Claire gets FDA PMA — real‑time margin imaging for breast surgery https://biobriefs.com/lonza-agrees-2-2b-sale BioBriefs en 2026-03-07T21:33:45Z Lonza agrees $2.2B sale of capsule and health‑ingredients business https://biobriefs.com/biopharma-financings-jump-81-in BioBriefs en 2026-03-07T21:33:45Z Biopharma financings jump 81% in early 2026 — $16.78B raised https://biobriefs.com/servier-shells-out-2-5b BioBriefs en 2026-03-07T16:32:24Z Servier shells out $2.5B for Day One – picks up pediatric glioma drug https://biobriefs.com/prasad-exits-fda-in-april BioBriefs en 2026-03-07T16:32:24Z Prasad exits FDA in April — tenure marked by high‑profile clashes https://biobriefs.com/fda-doubles-down-uniqure-told BioBriefs en 2026-03-07T16:32:24Z FDA doubles down: uniQure told to run sham‑controlled Huntington’s trial https://biobriefs.com/roche-zealand-amylin-falls-short BioBriefs en 2026-03-07T16:32:24Z Roche/Zealand amylin falls short — petrelintide’s weight loss underwhelms https://biobriefs.com/fda-greenlights-j-j-tecvayli BioBriefs en 2026-03-07T16:32:24Z FDA greenlights J&J Tecvayli‑Darzalex combo under priority pathway — approval comes fast https://biobriefs.com/japan-clears-first-ipsc-derived BioBriefs en 2026-03-07T16:32:24Z Japan clears first iPSC‑derived therapy for Parkinson’s — regulatory milestone for regenerative medicine https://biobriefs.com/illumina-expands-alliance-dataset-adds BioBriefs en 2026-03-07T16:32:24Z Illumina expands alliance dataset — adds 50,000 genomes with paired proteomics https://biobriefs.com/alnylam-inks-cardio-pact-with BioBriefs en 2026-03-07T16:32:24Z Alnylam inks cardio pact with Tenaya — $10M upfront, $1.13B potential https://biobriefs.com/kestrel-wins-ind-for-oral BioBriefs en 2026-03-07T16:32:24Z Kestrel wins IND for oral pan‑KRAS inhibitor KST‑6051 — first‑in‑human trial imminent https://biobriefs.com/perimeter-wins-fda-clearance-for BioBriefs en 2026-03-07T16:32:24Z Perimeter wins FDA clearance for Claire — AI‑powered margin imaging for breast surgery https://biobriefs.com/servier-buys-day-one-for BioBriefs en 2026-03-07T14:32:49Z Servier buys Day One for $2.5B — Gains pediatric glioma drug and pipeline https://biobriefs.com/fda-vaccine-and-biologics-chief BioBriefs en 2026-03-07T14:32:49Z FDA vaccine and biologics chief Vinay Prasad to leave at month end — Agency transition underway https://biobriefs.com/fda-doubles-down-on-sham BioBriefs en 2026-03-07T14:32:49Z FDA doubles down on sham‑control for uniQure’s Huntington’s gene therapy — Tensions escalate https://biobriefs.com/zealands-amylin-fails-to-match BioBriefs en 2026-03-07T14:32:49Z Zealand’s amylin fails to match Lilly’s benchmark — Market punishes shares https://biobriefs.com/fda-grants-fast-approval-to BioBriefs en 2026-03-07T14:32:49Z FDA grants fast approval to J&J two‑drug myeloma combo — National priority pathway used https://biobriefs.com/kestrel-clears-ind-for-oral BioBriefs en 2026-03-07T14:32:49Z Kestrel clears IND for oral pan‑KRAS inhibitor — First‑in‑human trial planned https://biobriefs.com/illumina-expands-pharma-genomics-with BioBriefs en 2026-03-07T14:32:49Z Illumina expands pharma genomics with proteomics add‑on — 50K genomes to gain paired proteome https://biobriefs.com/lonza-sells-capsule-and-health BioBriefs en 2026-03-07T14:32:49Z Lonza sells capsule and health‑ingredients unit for $2.2B — Portfolio reshaped https://biobriefs.com/pepgen-faces-partial-fda-hold BioBriefs en 2026-03-07T14:32:49Z PepGen faces partial FDA hold on DM1 trial — US sites paused, global program continues https://biobriefs.com/merck-kgaa-trims-oncology-pipeline BioBriefs en 2026-03-07T14:32:49Z Merck KGaA trims oncology pipeline after SpringWorks buyout — Two programs cut https://biobriefs.com/servier-buys-day-one-for BioBriefs en 2026-03-07T10:32:52Z Servier buys Day One for $2.5B — pediatric glioma drug in hand https://biobriefs.com/fdas-vinay-prasad-to-leave BioBriefs en 2026-03-07T10:32:52Z FDA’s Vinay Prasad to leave in April — tenure marked by controversy https://biobriefs.com/fda-doubles-down-on-sham BioBriefs en 2026-03-07T10:32:52Z FDA doubles down on sham control for uniQure Huntington’s trial — agency rebuffs company https://biobriefs.com/fda-speeds-tecvayli-darzalex-approval BioBriefs en 2026-03-07T10:32:52Z FDA speeds Tecvayli‑Darzalex approval via priority pilot — myeloma label widened https://biobriefs.com/zealands-amylin-candidate-falls-short BioBriefs en 2026-03-07T10:32:52Z Zealand’s amylin candidate falls short — ambivalent Phase II readout dents hopes https://biobriefs.com/lilly-targets-employers-to-expand BioBriefs en 2026-03-07T10:32:52Z Lilly targets employers to expand GLP‑1 access — insurers bypassed https://biobriefs.com/japan-approves-first-ipsc-derived BioBriefs en 2026-03-07T10:32:52Z Japan approves first iPSC‑derived therapy for Parkinson’s — regenerative milestone https://biobriefs.com/cell-therapies-for-neurodegeneration-advance BioBriefs en 2026-03-07T10:32:52Z Cell therapies for neurodegeneration advance — CAR astrocytes and boosted brain phagocytes https://biobriefs.com/fda-policy-friction-grows-industry BioBriefs en 2026-03-07T10:32:52Z FDA policy friction grows — industry seeks clarity on single‑trial rule and advisory panels https://biobriefs.com/genomics-meets-proteomics-and-ai BioBriefs en 2026-03-07T10:32:52Z Genomics meets proteomics and AI imaging clears margins — diagnostics scale up https://biobriefs.com/fda-turmoil-vinay-prasad-set BioBriefs en 2026-03-07T09:33:02Z FDA turmoil: Vinay Prasad set to leave CBER in April https://biobriefs.com/servier-buys-day-one-for BioBriefs en 2026-03-07T09:33:02Z Servier buys Day One for $2.5B – gains pediatric glioma drug https://biobriefs.com/fda-doubles-down-agency-demands BioBriefs en 2026-03-07T09:33:02Z FDA doubles down: agency demands sham‑controlled trial for uniQure’s Huntington’s gene therapy https://biobriefs.com/amylin-setback-roche-zealand-obesity BioBriefs en 2026-03-07T09:33:02Z Amylin setback: Roche‑Zealand obesity drug falls short of expectations https://biobriefs.com/fda-speeds-tecvayli-darzalex-approval BioBriefs en 2026-03-07T09:33:02Z FDA speeds Tecvayli‑Darzalex approval: rare fast‑track nod for myeloma combo https://biobriefs.com/kestrel-lands-ind-for-oral BioBriefs en 2026-03-07T09:33:02Z Kestrel lands IND for oral pan‑KRAS candidate – first‑in‑human study planned https://biobriefs.com/tenaya-and-alnylam-strike-1b BioBriefs en 2026-03-07T09:33:02Z Tenaya and Alnylam strike $1B+ deal to mine genetic heart‑disease targets https://biobriefs.com/fda-places-partial-hold-on BioBriefs en 2026-03-07T09:33:02Z FDA places partial hold on PepGen’s DM1 mid‑stage trial over preclinical signal https://biobriefs.com/illumina-expands-alliance-for-genomic BioBriefs en 2026-03-07T09:33:02Z Illumina expands Alliance for Genomic Discovery with proteomics add‑on https://biobriefs.com/perimeters-claire-wins-fda-pma BioBriefs en 2026-03-07T09:33:02Z Perimeter’s Claire wins FDA PMA: AI imaging cleared for breast‑conserving surgery https://biobriefs.com/fdas-vaccines-chief-to-depart BioBriefs en 2026-03-07T04:33:16Z FDA’s vaccines chief to depart in April – Prasad exits https://biobriefs.com/fda-doubles-down-on-sham BioBriefs en 2026-03-07T04:33:16Z FDA doubles down on sham-control for uniQure’s Huntington’s gene therapy https://biobriefs.com/servier-to-buy-day-one BioBriefs en 2026-03-07T04:33:16Z Servier to buy Day One for $2.5B – gains pediatric glioma asset https://biobriefs.com/petrelintide-underwhelms-investors-amylin-rival BioBriefs en 2026-03-07T04:33:16Z Petrelintide underwhelms investors – amylin rival trails Lilly’s GLP-1s https://biobriefs.com/fda-fast-tracks-j-j BioBriefs en 2026-03-07T04:33:16Z FDA fast‑tracks J&J myeloma combo under national priority pilot https://biobriefs.com/alnylam-pays-tenaya-to-mine BioBriefs en 2026-03-07T04:33:16Z Alnylam pays Tenaya to mine up to 15 genetic cardio targets — deal tops $1B https://biobriefs.com/ketone-metabolite-bhb-sharpens-car BioBriefs en 2026-03-07T04:33:16Z Ketone metabolite BHB sharpens CAR‑T potency in preclinical work; human trials launched https://biobriefs.com/fda-places-partial-hold-on BioBriefs en 2026-03-07T04:33:16Z FDA places partial hold on PepGen’s DM1 Phase 2 trial after re‑examining preclinical data https://biobriefs.com/illumina-expands-alliance-for-genomic BioBriefs en 2026-03-07T04:33:16Z Illumina expands Alliance for Genomic Discovery with 50,000 proteomes https://biobriefs.com/perimeter-wins-fda-approval-for BioBriefs en 2026-03-07T04:33:16Z Perimeter wins FDA approval for Claire: AI‑guided margin imaging for breast conservation https://biobriefs.com/servier-expands-rare-cancer-push BioBriefs en 2026-03-06T21:32:56Z Servier expands rare-cancer push: to buy Day One for $2.5B https://biobriefs.com/fda-doubles-down-demands-sham BioBriefs en 2026-03-06T21:32:56Z FDA doubles down: demands sham-controlled trial for uniQure’s Huntington’s gene therapy https://biobriefs.com/fda-accelerates-tecvayli-darzalex-approval BioBriefs en 2026-03-06T21:32:56Z FDA accelerates Tecvayli-Darzalex approval: national priority pathway used https://biobriefs.com/roche-zealand-amylin-misses-lilly BioBriefs en 2026-03-06T21:32:56Z Roche-Zealand amylin misses Lilly bar: phase‑2 efficacy disappoints https://biobriefs.com/fda-halts-pepgen-us-phase BioBriefs en 2026-03-06T21:32:56Z FDA halts PepGen US Phase 2 over preclinical safety questions https://biobriefs.com/alnylam-pays-tenaya-for-heart BioBriefs en 2026-03-06T21:32:56Z Alnylam pays Tenaya for heart‑disease genetics: up to $1.13B pact https://biobriefs.com/billiontoone-doubles-revenue-raises-full BioBriefs en 2026-03-06T21:32:56Z BillionToOne doubles revenue — raises full‑year guidance and inks UHC contract https://biobriefs.com/kestrel-clears-ind-for-oral BioBriefs en 2026-03-06T21:32:56Z Kestrel clears IND for oral pan‑KRAS inhibitor — first‑in‑human trial due https://biobriefs.com/ucla-engineers-car-t-to BioBriefs en 2026-03-06T21:32:56Z UCLA engineers CAR‑T to breach solid‑tumor defenses https://biobriefs.com/gene-therapy-cuts-seizures-in BioBriefs en 2026-03-06T21:32:56Z Gene therapy cuts seizures in Dravet: zorevunersen shows large reductions https://biobriefs.com/fda-and-uniqure-clash-agency BioBriefs en 2026-03-06T16:33:01Z FDA and uniQure clash: agency demands randomized sham control for Huntington’s gene therapy https://biobriefs.com/fda-converts-tecvayli-accelerated-approval BioBriefs en 2026-03-06T16:33:01Z FDA converts Tecvayli accelerated approval and greenlights Tec‑Dara combo under priority voucher https://biobriefs.com/servier-to-buy-day-one BioBriefs en 2026-03-06T16:33:01Z Servier to buy Day One for $2.5B: acquires pediatric brain‑tumor drug Ojemda https://biobriefs.com/tenaya-and-alnylam-sign-1b BioBriefs en 2026-03-06T16:33:01Z Tenaya and Alnylam sign $1B‑plus cardio research pact: $10M upfront, big milestones https://biobriefs.com/moderna-to-pay-up-to BioBriefs en 2026-03-06T16:33:01Z Moderna to pay up to $2.25B to settle lipid nanoparticle patent fight https://biobriefs.com/fda-places-partial-hold-on BioBriefs en 2026-03-06T16:33:01Z FDA places partial hold on PepGen’s DM1 trial after reviewers flag preclinical signals https://biobriefs.com/kestrel-clears-ind-for-oral BioBriefs en 2026-03-06T16:33:01Z Kestrel clears IND for oral pan‑KRAS KST‑6051, moves toward first‑in‑human trial https://biobriefs.com/illumina-expands-pharma-research-alliance BioBriefs en 2026-03-06T16:33:01Z Illumina expands pharma research alliance with 50,000 genomes paired to proteomics https://biobriefs.com/liquid-biopsy-moves-beyond-cancer BioBriefs en 2026-03-06T16:33:01Z Liquid biopsy moves beyond cancer: cfDNA fragmentomics detects liver fibrosis and chronic disease indicators https://biobriefs.com/ucb-licenses-antengenes-atg-201 BioBriefs en 2026-03-06T16:33:01Z UCB licenses Antengene’s ATG‑201 in $1.1B autoimmune deal: bispecific T‑cell engager pact https://biobriefs.com/moderna-to-pay-up-to BioBriefs en 2026-03-06T14:32:55Z Moderna to pay up to $2.25B: patent settlement ends LNP fight https://biobriefs.com/ucb-inks-1-1b-deal BioBriefs en 2026-03-06T14:32:55Z UCB inks $1.1B deal... Antengene’s CD19/CD3 T‑cell engager https://biobriefs.com/zealands-amylin-analog-posts-phase BioBriefs en 2026-03-06T14:32:55Z Zealand’s amylin analog posts Phase 2 gains – Roche backs tolerability https://biobriefs.com/lilly-pushes-employers-new-programs BioBriefs en 2026-03-06T14:32:55Z Lilly pushes employers: new programs aim to broaden GLP‑1 access https://biobriefs.com/liquid-biopsy-beyond-cancer-cfdna BioBriefs en 2026-03-06T14:32:55Z Liquid biopsy beyond cancer: cfDNA fragmentomics flags liver disease https://biobriefs.com/fda-places-partial-hold-on BioBriefs en 2026-03-06T14:32:55Z FDA places partial hold on PepGen’s DM1 trial – shares tumble https://biobriefs.com/evo-2-dna-foundation-model BioBriefs en 2026-03-06T14:32:55Z Evo 2: DNA foundation model scales genome design across life https://biobriefs.com/ucla-builds-next-gen-car BioBriefs en 2026-03-06T14:32:55Z UCLA builds next‑gen CAR‑T to breach solid tumor resistance https://biobriefs.com/zorevunersen-reduces-seizures-dramatically-first BioBriefs en 2026-03-06T14:32:55Z Zorevunersen reduces seizures dramatically: first Dravet gene therapy data https://biobriefs.com/illumina-adds-proteomics-to-pharma BioBriefs en 2026-03-06T14:32:55Z Illumina adds proteomics to pharma research alliance—50k paired datasets https://biobriefs.com/ucb-bets-on-bispecifics-1 BioBriefs en 2026-03-06T10:33:02Z UCB bets on bispecifics: $1.1bn Antengene license https://biobriefs.com/fda-surprises-pepgen-partial-hold BioBriefs en 2026-03-06T10:33:02Z FDA surprises PepGen: partial hold on DM1 Phase II https://biobriefs.com/illumina-expands-genomic-alliance-adds BioBriefs en 2026-03-06T10:33:02Z Illumina expands genomic alliance: adds proteomics to 50,000 genomes https://biobriefs.com/zealands-amylin-posts-phase-2 BioBriefs en 2026-03-06T10:33:02Z Zealand’s amylin posts phase‑2: tolerability touted by Roche partner https://biobriefs.com/oral-glp-1-era-begins BioBriefs en 2026-03-06T10:33:02Z Oral GLP‑1 era begins: pills arrive as employers get new access pathways https://biobriefs.com/ai-liquid-biopsy-spots-liver BioBriefs en 2026-03-06T10:33:02Z AI liquid biopsy spots liver disease: fragmentomics moves beyond cancer https://biobriefs.com/fda-pivots-on-advisory-panels BioBriefs en 2026-03-06T10:33:02Z FDA pivots on advisory panels and single‑trial defaults… industry asks for clarity https://biobriefs.com/atavistik-doubles-down-series-b BioBriefs en 2026-03-06T10:33:02Z Atavistik doubles down: Series B extension funds HHT clinical push https://biobriefs.com/zorevunersen-slashes-seizures-gene-therapy BioBriefs en 2026-03-06T10:33:02Z Zorevunersen slashes seizures: gene therapy shows unprecedented Dravet results https://biobriefs.com/new-immunotherapy-routes-car-t BioBriefs en 2026-03-06T10:33:02Z New immunotherapy routes: CAR‑T for solids and a proteomic target to boost immunogenicity https://biobriefs.com/oral-glp-1s-arrive-pills BioBriefs en 2026-03-06T09:33:18Z Oral GLP-1s Arrive: Pills, approvals and the rebound question https://biobriefs.com/fda-rethinks-process-advisory-panels BioBriefs en 2026-03-06T09:33:18Z FDA rethinks process: Advisory panels and single-trial default under scrutiny https://biobriefs.com/pepgen-hit-with-partial-hold BioBriefs en 2026-03-06T09:33:18Z PepGen hit with partial hold — U.S. sites paused, global program continues https://biobriefs.com/illumina-expands-alliance-adds-50000 BioBriefs en 2026-03-06T09:33:18Z Illumina expands alliance: Adds 50,000 genomes with paired proteomics https://biobriefs.com/tenaya-taps-alnylam-in-1 BioBriefs en 2026-03-06T09:33:18Z Tenaya taps Alnylam in $1.13B target pact — RNAi joins cardiac discovery https://biobriefs.com/evo-2-ai-model-designs BioBriefs en 2026-03-06T09:33:18Z Evo 2: AI model designs genomes across the tree of life https://biobriefs.com/liquid-biopsy-goes-systemic-cfdna BioBriefs en 2026-03-06T09:33:18Z Liquid biopsy goes systemic: cfDNA fragmentomics detects liver disease https://biobriefs.com/atavistik-raises-160m-to-push BioBriefs en 2026-03-06T09:33:18Z Atavistik raises $160M to push allosteric drugs for blood disorders https://biobriefs.com/gene-regulation-therapy-cuts-seizures BioBriefs en 2026-03-06T09:33:18Z Gene regulation therapy cuts seizures in Dravet: unprecedented clinical results https://biobriefs.com/moderna-to-pay-up-to BioBriefs en 2026-03-06T04:32:49Z Moderna to pay up to $2.25B — ends LNP patent saga https://biobriefs.com/fda-places-partial-hold-on BioBriefs en 2026-03-06T04:32:49Z FDA places partial hold on PepGen’s DM1 study: regulators probe preclinical data https://biobriefs.com/illumina-expands-pharma-alliance-adds BioBriefs en 2026-03-06T04:32:49Z Illumina expands pharma alliance: adds 50,000 genomes with paired proteomics https://biobriefs.com/roche-pledges-w710b-to-south BioBriefs en 2026-03-06T04:32:49Z Roche pledges ₩710B to South Korea — builds global clinical‑trial hub https://biobriefs.com/ucb-inks-1-1b-deal BioBriefs en 2026-03-06T04:32:49Z UCB inks $1.1B deal for Antengene’s CD19/CD3 T‑cell engager https://biobriefs.com/tenaya-alnylam-sign-1-13b BioBriefs en 2026-03-06T04:32:49Z Tenaya, Alnylam sign $1.13B cardio discovery pact: $10M up front https://biobriefs.com/atavistik-raises-40m-extension-series BioBriefs en 2026-03-06T04:32:49Z Atavistik raises $40M extension — Series B totals $160M to fund HHT trial https://biobriefs.com/cognito-raises-105m-series-c BioBriefs en 2026-03-06T04:32:49Z Cognito raises $105M Series C to advance Spectris into pivotal study https://biobriefs.com/gene-therapy-cuts-seizures-in BioBriefs en 2026-03-06T04:32:49Z Gene therapy cuts seizures in Dravet: single‑gene approach posts large gains https://biobriefs.com/ai-fragmentomics-flags-liver-fibrosis BioBriefs en 2026-03-06T04:32:49Z AI fragmentomics flags liver fibrosis and cirrhosis from blood https://biobriefs.com/illumina-expands-pharma-research-alliance BioBriefs en 2026-03-05T21:34:01Z Illumina expands pharma research alliance: adds 50,000 genomes with proteomics https://biobriefs.com/zealand-posts-phase-2-win BioBriefs en 2026-03-05T21:34:01Z Zealand posts Phase 2 win: amylin analog yields up to 10.7% mean https://biobriefs.com/lilly-offers-employer-program-study BioBriefs en 2026-03-05T21:34:01Z Lilly offers employer program — study finds GLP‑1 weight regain plateaus below baseline https://biobriefs.com/moderna-to-pay-up-to BioBriefs en 2026-03-05T21:34:01Z Moderna to pay up to $2.25B — settlement narrows LNP patent risk https://biobriefs.com/pepgen-hit-with-fda-partial BioBriefs en 2026-03-05T21:34:01Z PepGen hit with FDA partial hold — U.S. trial enrollment paused https://biobriefs.com/atavistik-boosts-series-b-to BioBriefs en 2026-03-05T21:34:01Z Atavistik boosts Series B to $160M — advances HHT clinical program https://biobriefs.com/dravet-gene-therapy-posts-dramatic BioBriefs en 2026-03-05T21:34:01Z Dravet gene therapy posts dramatic seizure reductions in early trials https://biobriefs.com/cell-free-chromatin-tracing-maps BioBriefs en 2026-03-05T21:34:01Z Cell‑free chromatin tracing maps tissue origins: cf‑EpiTracing goes automated https://biobriefs.com/liquid-biopsy-moves-beyond-cancer BioBriefs en 2026-03-05T21:34:01Z Liquid biopsy moves beyond cancer: cfDNA fragmentomics spots liver disease https://biobriefs.com/ucb-enters-t-cell-engager BioBriefs en 2026-03-05T21:34:01Z UCB enters T‑cell engager field: $1.1B deal for Antengene’s ATG‑201 https://biobriefs.com/liquid-biopsy-moves-beyond-cancer BioBriefs en 2026-03-05T16:33:39Z Liquid biopsy moves beyond cancer: cfDNA epigenomics detects liver disease https://biobriefs.com/moderna-to-pay-up-to BioBriefs en 2026-03-05T16:33:39Z Moderna to pay up to $2.25B: LNP patent settlement ends long‑running suit https://biobriefs.com/fda-targets-compounding-of-glp BioBriefs en 2026-03-05T16:33:39Z FDA targets compounding of GLP‑1s: 30 warning letters hit telehealth firms https://biobriefs.com/prime-to-test-fda-flexibility BioBriefs en 2026-03-05T16:33:39Z Prime to test FDA flexibility: Two‑patient gene‑editing bid for rare disease https://biobriefs.com/gyre-acquires-cullgen-300m-deal BioBriefs en 2026-03-05T16:33:39Z Gyre acquires Cullgen: $300M deal brings targeted protein degrader engine https://biobriefs.com/ucb-bets-on-tces-1 BioBriefs en 2026-03-05T16:33:39Z UCB bets on TCEs: $1.1B licensing deal for Antengene’s ATG‑201 https://biobriefs.com/fda-puts-pepgen-trial-on BioBriefs en 2026-03-05T16:33:39Z FDA puts PepGen trial on partial hold — company and analysts respond https://biobriefs.com/billiontoone-scales-q4-revenue-surges BioBriefs en 2026-03-05T16:33:39Z BillionToOne scales: Q4 revenue surges, UnitedHealthcare in‑network deal https://biobriefs.com/parkin-gene-therapy-rescues-dopamine BioBriefs en 2026-03-05T16:33:39Z Parkin gene therapy rescues dopamine neurons: Preclinical in vivo success https://biobriefs.com/gene-regulation-cuts-seizures-in BioBriefs en 2026-03-05T16:33:39Z Gene regulation cuts seizures in Dravet: zorevunersen posts dramatic trial results https://biobriefs.com/moderna-settlement-ends-lnp-war BioBriefs en 2026-03-05T14:34:11Z Moderna settlement ends LNP war: $950M upfront, up to $2.25B at stake https://biobriefs.com/fda-pivots-to-one-pivotal BioBriefs en 2026-03-05T14:34:11Z FDA pivots to one pivotal trial: CROs and developers demand rulebook https://biobriefs.com/pepgen-trial-paused-fda-partial BioBriefs en 2026-03-05T14:34:11Z PepGen trial paused: FDA partial hold hobbles rare‑disease program https://biobriefs.com/gene-regulation-therapy-slashes-seizures BioBriefs en 2026-03-05T14:34:11Z Gene regulation therapy slashes seizures in Dravet trials — unprecedented readouts https://biobriefs.com/glp-1s-reshape-care-prescriptions BioBriefs en 2026-03-05T14:34:11Z GLP‑1s reshape care — prescriptions spike, surgeries fall; FDA targets compounders https://biobriefs.com/big-bets-on-brain-and BioBriefs en 2026-03-05T14:34:11Z Big bets on brain and blood: Cognito raises $105M; Atavistik banks $160M https://biobriefs.com/ucla-engineers-car-t-to BioBriefs en 2026-03-05T14:34:11Z UCLA engineers CAR‑T to confront solid tumors — next‑gen design reported https://biobriefs.com/ucb-inks-tce-pact-antengenes BioBriefs en 2026-03-05T14:34:11Z UCB inks TCE pact: Antengene’s CD19xCD3 program licensed for up to $1.1B https://biobriefs.com/theravance-shutters-r-d-after BioBriefs en 2026-03-05T14:34:11Z Theravance shutters R&D after Phase III failure — mass cuts follow https://biobriefs.com/liquid-biopsy-goes-beyond-cancer BioBriefs en 2026-03-05T14:34:11Z Liquid biopsy goes beyond cancer: cfDNA fragmentomics flags liver disease https://biobriefs.com/moderna-to-pay-up-to BioBriefs en 2026-03-05T10:33:51Z Moderna to pay up to $2.25B — ends mRNA lipid nanoparticle patent fight https://biobriefs.com/gyre-agrees-to-absorb-cullgen BioBriefs en 2026-03-05T10:33:51Z Gyre agrees to absorb Cullgen... $300M all‑stock transaction expands TPD, DAC pipeline https://biobriefs.com/gene-therapy-zorevunersen-dramatically-lowers BioBriefs en 2026-03-05T10:33:51Z Gene therapy zorevunersen dramatically lowers seizures in Dravet — NEJM data https://biobriefs.com/prime-tests-fda-flexibility-seeks BioBriefs en 2026-03-05T10:33:51Z Prime tests FDA flexibility — seeks approval from two‑patient prime editing study https://biobriefs.com/theravance-halves-workforce-ends-r BioBriefs en 2026-03-05T10:33:51Z Theravance halves workforce, ends R&D after pivotal ampreloxetine failure https://biobriefs.com/fda-escalates-crackdown-on-compounded BioBriefs en 2026-03-05T10:33:51Z FDA escalates crackdown on compounded GLP‑1s — 30 warning letters target telehealth firms https://biobriefs.com/liquid-biopsy-fragmentomics-extends-beyond BioBriefs en 2026-03-05T10:33:51Z Liquid biopsy fragmentomics extends beyond cancer — cfDNA patterns identify liver disease https://biobriefs.com/ucla-engineers-car-t-cells BioBriefs en 2026-03-05T10:33:51Z UCLA engineers CAR‑T cells designed to breach solid‑tumor defenses https://biobriefs.com/evo-2-dna-foundation-model BioBriefs en 2026-03-05T10:33:51Z Evo 2 DNA foundation model: AI designs genomes across life and flags disease variants https://biobriefs.com/arpa-h-backs-lymphedema-programs BioBriefs en 2026-03-05T10:33:51Z ARPA‑H backs lymphedema programs — Rice and Georgia Tech win major grants https://biobriefs.com/gene-therapy-cuts-seizures-in BioBriefs en 2026-03-05T09:33:06Z Gene therapy cuts seizures in Dravet: NEJM reports dramatic drops https://biobriefs.com/moderna-to-pay-up-to BioBriefs en 2026-03-05T09:33:06Z Moderna to pay up to $2.25B: settlement ends long LNP patent fight https://biobriefs.com/fda-escalates-crackdown-on-glp BioBriefs en 2026-03-05T09:33:06Z FDA escalates crackdown on GLP‑1 compounders — studies add new clinical angles https://biobriefs.com/theravance-halts-r-d-after BioBriefs en 2026-03-05T09:33:06Z Theravance halts R&D after Phase 3 miss — workforce and strategy slashed https://biobriefs.com/ucb-pays-up-to-1 BioBriefs en 2026-03-05T09:33:06Z UCB pays up to $1.1B for Antengene TCE — Belgian drugmaker enters bispecific arena https://biobriefs.com/liquid-biopsy-moves-beyond-cancer BioBriefs en 2026-03-05T09:33:06Z Liquid biopsy moves beyond cancer: cfDNA fragmentomics flags liver disease https://biobriefs.com/prime-seeks-fda-blessing-on BioBriefs en 2026-03-05T09:33:06Z Prime seeks FDA blessing on two‑patient prime‑editing trial: a regulator test case https://biobriefs.com/fda-rejects-regenxbios-hunter-submission BioBriefs en 2026-03-05T09:33:06Z FDA rejects Regenxbio’s Hunter submission: controls and surrogate endpoints cited https://biobriefs.com/gsk-doubles-down-on-oligonucleotide BioBriefs en 2026-03-05T09:33:06Z GSK doubles down on oligonucleotide and PH assets: siRNA licence plus $950M buy https://biobriefs.com/next-gen-cell-therapies-target BioBriefs en 2026-03-05T09:33:06Z Next‑gen cell therapies target solid tumors — CAR‑T and oncolytic vectors advance https://biobriefs.com/zorevunersen-cuts-seizures-ucl-gosh BioBriefs en 2026-03-05T04:33:10Z Zorevunersen cuts seizures: UCL–GOSH trials report major gains https://biobriefs.com/evo-2-ai-models-whole BioBriefs en 2026-03-05T04:33:10Z Evo 2: AI models whole genomes — Nature publishes foundation-model claims https://biobriefs.com/glp-1s-linked-to-lower BioBriefs en 2026-03-05T04:33:10Z GLP‑1s linked to lower addiction risk and mapped to addiction biology https://biobriefs.com/fragmentomics-hits-liver-disease-cfdna BioBriefs en 2026-03-05T04:33:10Z Fragmentomics hits liver disease: cfDNA tests flag fibrosis and cirrhosis https://biobriefs.com/ucla-engineers-car-t-to BioBriefs en 2026-03-05T04:33:10Z UCLA engineers CAR‑T to breach solid tumor defenses https://biobriefs.com/moderna-settles-lnp-dispute-up BioBriefs en 2026-03-05T04:33:10Z Moderna settles LNP dispute: up to $2.25 billion resolves long-running patents https://biobriefs.com/ucb-licenses-antengene-tce-1 BioBriefs en 2026-03-05T04:33:10Z UCB licenses Antengene TCE: $1.1B deal enters autoimmune T‑cell engager race https://biobriefs.com/theravance-halves-staff-ends-r BioBriefs en 2026-03-05T04:33:10Z Theravance halves staff, ends R&D after Phase 3 failure https://biobriefs.com/arpa-h-funds-lymphatic-repair BioBriefs en 2026-03-05T04:33:10Z ARPA‑H funds lymphatic repair: Rice and Georgia Tech win multimillion grants https://biobriefs.com/big-pharma-and-academic-ai BioBriefs en 2026-03-05T04:33:10Z Big pharma and academic AI pacts: Merck–Tempus and Vanderbilt–Bertis tie up https://biobriefs.com/moderna-pays-950m-upfront-ends BioBriefs en 2026-03-04T21:34:06Z Moderna pays $950M upfront — ends long LNP patent fight https://biobriefs.com/fda-escalates-crackdown-30-warning BioBriefs en 2026-03-04T21:34:06Z FDA escalates crackdown: 30+ warning letters target compounded GLP‑1s https://biobriefs.com/ucb-bets-1-1b-on BioBriefs en 2026-03-04T21:34:06Z UCB bets $1.1B on Antengene’s CD19xCD3 TCE — enters TCE arena https://biobriefs.com/theravance-slashes-r-d-halts BioBriefs en 2026-03-04T21:34:06Z Theravance slashes R&D — halts pipeline after late‑stage failure https://biobriefs.com/prime-to-test-fda-flexibility BioBriefs en 2026-03-04T21:34:06Z Prime to test FDA flexibility — seeks approval on a two‑patient gene edit https://biobriefs.com/liquid-biopsy-moves-beyond-cancer BioBriefs en 2026-03-04T21:34:06Z Liquid biopsy moves beyond cancer — cfDNA fragmentomics IDs liver disease https://biobriefs.com/agbt-signals-a-high-throughput BioBriefs en 2026-03-04T21:34:06Z AGBT signals a high‑throughput shakeup — sequencing and spatial updates https://biobriefs.com/arpa-h-awards-21-8m BioBriefs en 2026-03-04T21:34:06Z ARPA‑H awards $21.8M — funds Georgia Tech lymphatic disease therapeutic effort https://biobriefs.com/stanford-debuts-iism-label-free BioBriefs en 2026-03-04T21:34:06Z Stanford debuts iISM — label‑free microscope shows live cells at 120‑nm resolution https://biobriefs.com/roche-commits-480m-to-south BioBriefs en 2026-03-04T21:34:06Z Roche commits $480M to South Korea — builds a global clinical‑trial ecosystem https://biobriefs.com/evo-2-dna-model-ai BioBriefs en 2026-03-04T16:33:50Z Evo 2 DNA model: AI designs genomes across the tree of life https://biobriefs.com/prime-medicine-reverses-course-pursues BioBriefs en 2026-03-04T16:33:50Z Prime Medicine reverses course – pursues FDA approval for prime‑editing therapy https://biobriefs.com/moderna-pays-big-upfront-cash BioBriefs en 2026-03-04T16:33:50Z Moderna pays big: upfront cash in global LNP patent settlement https://biobriefs.com/fda-targets-compounders-fresh-warning BioBriefs en 2026-03-04T16:33:50Z FDA targets compounders: fresh warning letters hit GLP‑1 telehealth sellers https://biobriefs.com/theravance-winds-down-r-d BioBriefs en 2026-03-04T16:33:50Z Theravance winds down R&D after phase III failure – major layoffs follow https://biobriefs.com/agbt-reveals-high-throughput-sequencing BioBriefs en 2026-03-04T16:33:50Z AGBT reveals high‑throughput sequencing arms race: Illumina faces new rivals https://biobriefs.com/cellanome-r3200-live-cell-imaging BioBriefs en 2026-03-04T16:33:50Z Cellanome R3200: live‑cell imaging tied to sequencing for longitudinal functional analysis https://biobriefs.com/gsk-licenses-frontiers-sirna-assets BioBriefs en 2026-03-04T16:33:50Z GSK licenses Frontier’s siRNA assets: $40M upfront, near‑$1B upside https://biobriefs.com/ucb-enters-t-cell-engager BioBriefs en 2026-03-04T16:33:50Z UCB enters T‑cell engager race: $80M upfront for Antengene’s CD19xCD3 asset https://biobriefs.com/atrium-therapeutics-spins-out-to BioBriefs en 2026-03-04T16:33:50Z Atrium Therapeutics spins out to focus on RNA therapies for cardiomyopathies https://biobriefs.com/moderna-to-pay-950m-upfront BioBriefs en 2026-03-04T14:33:12Z Moderna to pay $950M upfront — settles long-running Covid vaccine patent fight https://biobriefs.com/theravance-winds-down-r-d BioBriefs en 2026-03-04T14:33:12Z Theravance winds down R&D — halves workforce after Phase III failure https://biobriefs.com/ucb-inks-antengene-tce-pact BioBriefs en 2026-03-04T14:33:12Z UCB inks Antengene TCE pact: Belgian drugmaker steps into bispecific space https://biobriefs.com/gsk-expands-oligonucleotide-and-pah BioBriefs en 2026-03-04T14:33:12Z GSK expands oligonucleotide and PAH bets: two deals push immunology and pulmonary pipeline https://biobriefs.com/fda-tightens-bar-on-gene BioBriefs en 2026-03-04T14:33:12Z FDA tightens bar on gene therapies — Regenxbio, UniQure face fresh regulatory hurdles https://biobriefs.com/fda-clears-ascendis-once-weekly BioBriefs en 2026-03-04T14:33:12Z FDA clears Ascendis’ once‑weekly dwarfism shot: accelerated approval granted https://biobriefs.com/blackstone-backs-teva-with-400m BioBriefs en 2026-03-04T14:33:12Z Blackstone backs Teva with $400M — funds Sanofi‑partnered anti‑TL1A development https://biobriefs.com/candid-to-go-public-via BioBriefs en 2026-03-04T14:33:12Z Candid to go public via RallyBio reverse merger — $505M in new funding https://biobriefs.com/sequencing-arms-race-big-vendors BioBriefs en 2026-03-04T14:33:12Z Sequencing arms race... Big vendors roll new high‑throughput options, price pressure hits Illumina https://biobriefs.com/biotech-funding-roundup-150m-mental BioBriefs en 2026-03-04T14:33:12Z Biotech funding roundup: $150M mental‑health play and top February rounds https://biobriefs.com/moderna-settles-long-running-mrna BioBriefs en 2026-03-04T10:33:12Z Moderna settles long-running mRNA patent fight: $950M now, up to $2.25B possible https://biobriefs.com/theravance-collapses-r-d-after BioBriefs en 2026-03-04T10:33:12Z Theravance collapses R&D after pivotal failure — workforce halved https://biobriefs.com/fda-tightens-rare-disease-bar BioBriefs en 2026-03-04T10:33:12Z FDA tightens rare‑disease bar: Regenxbio, UniQure meet resubmission demands https://biobriefs.com/private-capital-backs-tevas-ibd BioBriefs en 2026-03-04T10:33:12Z Private capital backs Teva’s IBD push: Blackstone to fund anti‑TL1A program https://biobriefs.com/gsk-bulks-up-oligonucleotide-and BioBriefs en 2026-03-04T10:33:12Z GSK bulks up oligonucleotide and PAH pipelines with two big buys https://biobriefs.com/ascendis-wins-fda-nod-for BioBriefs en 2026-03-04T10:33:12Z Ascendis wins FDA nod for once‑weekly dwarfism shot — market shifts https://biobriefs.com/agbt-sparks-high-throughput-sequencing BioBriefs en 2026-03-04T10:33:12Z AGBT sparks high‑throughput sequencing war — Illumina faces new challengers https://biobriefs.com/earendil-and-wuxi-xdc-ink BioBriefs en 2026-03-04T10:33:12Z Earendil and WuXi XDC ink up to $885M ADC partnership https://biobriefs.com/asahi-kasei-buys-aicuris-for BioBriefs en 2026-03-04T10:33:12Z Asahi Kasei buys Aicuris for €780M — antiviral portfolio expands https://biobriefs.com/candid-goes-public-reverse-merger BioBriefs en 2026-03-04T10:33:12Z Candid goes public: reverse merger with Rallybio and $505M raise https://biobriefs.com/fda-presses-for-sham-controlled BioBriefs en 2026-03-04T09:33:35Z FDA presses for sham‑controlled trial — uniQure’s Huntington bid stalls https://biobriefs.com/theravance-winds-down-r-d BioBriefs en 2026-03-04T09:33:35Z Theravance winds down R&D — halves workforce after Phase 3 loss https://biobriefs.com/blackstone-backs-teva-400m-to BioBriefs en 2026-03-04T09:33:35Z Blackstone backs Teva: $400M to accelerate Sanofi‑partnered IBD drug https://biobriefs.com/gsk-doubles-down-on-oligonucleotides BioBriefs en 2026-03-04T09:33:35Z GSK doubles down on oligonucleotides: siRNA license and $950M buy https://biobriefs.com/fda-lifts-hold-on-intellia BioBriefs en 2026-03-04T09:33:35Z FDA lifts hold on Intellia CRISPR trials — safety caveats attached https://biobriefs.com/moderna-settles-patent-dispute-950m BioBriefs en 2026-03-04T09:33:35Z Moderna settles patent dispute: $950M upfront to Arbutus and Roivant https://biobriefs.com/candid-to-list-via-reverse BioBriefs en 2026-03-04T09:33:35Z Candid to list via reverse merger — $505M cash to push T‑cell engager pipeline https://biobriefs.com/agbt-sparks-high-throughput-sequencing BioBriefs en 2026-03-04T09:33:35Z AGBT sparks high‑throughput sequencing race — rivals circle Illumina https://biobriefs.com/prime-medicine-pivots-to-file BioBriefs en 2026-03-04T09:33:35Z Prime Medicine pivots to file — prime editing therapy moves toward FDA https://biobriefs.com/pharma-leans-on-ai-tempus BioBriefs en 2026-03-04T09:33:35Z Pharma leans on AI: Tempus‑Merck biomarker pact and Evinova trial deals https://biobriefs.com/fda-urges-sham-surgery-control BioBriefs en 2026-03-04T04:33:01Z FDA urges sham‑surgery control — uniQure’s Huntington program stalls https://biobriefs.com/fda-faults-controls-and-surrogates BioBriefs en 2026-03-04T04:33:01Z FDA faults controls and surrogates — Regenxbio’s Hunter filing rejected https://biobriefs.com/phase-3-failure-forces-restructuring BioBriefs en 2026-03-04T04:33:01Z Phase‑3 failure forces restructuring — Theravance ends R&D, halves workforce https://biobriefs.com/moderna-pays-up-950m-upfront BioBriefs en 2026-03-04T04:33:01Z Moderna pays up — $950M upfront, deal could swell to $2.25B https://biobriefs.com/gsk-doubles-down-on-oligonucleotide BioBriefs en 2026-03-04T04:33:01Z GSK doubles down on oligonucleotide and PAH bets — two asset deals https://biobriefs.com/fda-grants-accelerated-approval-ascendis BioBriefs en 2026-03-04T04:33:01Z FDA grants accelerated approval — Ascendis’ weekly dwarfism shot cleared https://biobriefs.com/prime-editing-edges-toward-clinic BioBriefs en 2026-03-04T04:33:01Z Prime editing edges toward clinic — company files for rare immune disease approval https://biobriefs.com/roche-posts-third-phase-3 BioBriefs en 2026-03-04T04:33:01Z Roche posts third Phase 3 MS win — liver safety questions follow https://biobriefs.com/aardvark-halts-phase-3-hero BioBriefs en 2026-03-04T04:33:01Z Aardvark halts Phase 3 HERO after cardiac signals — shares tumble https://biobriefs.com/big-pharma-bets-on-ai BioBriefs en 2026-03-04T04:33:01Z Big pharma bets on AI for biomarkers and trial ops — Merck, Tempus and Evinova deals https://biobriefs.com/theravance-collapses-phase-3-flop BioBriefs en 2026-03-03T21:33:15Z Theravance collapses: Phase 3 flop triggers R&D shutdown https://biobriefs.com/fda-rebukes-regenxbio-rejection-cites BioBriefs en 2026-03-03T21:33:15Z FDA rebukes Regenxbio: rejection cites controls and surrogate endpoints https://biobriefs.com/fda-pressures-uniqure-sham-controlled BioBriefs en 2026-03-03T21:33:15Z FDA pressures uniQure: sham‑controlled trial urged for Huntington’s program https://biobriefs.com/intellia-cleared-with-conditions-crispr BioBriefs en 2026-03-03T21:33:15Z Intellia cleared with conditions: CRISPR trials resume under tighter monitoring https://biobriefs.com/ascendis-wins-fda-nod-weekly BioBriefs en 2026-03-03T21:33:15Z Ascendis wins FDA nod: weekly dwarfism shot cleared on accelerated basis https://biobriefs.com/gsk-doubles-down-sirna-license BioBriefs en 2026-03-03T21:33:15Z GSK doubles down: siRNA license and $950M buy amplify pipeline bets https://biobriefs.com/merck-ends-gardasil-runs-at BioBriefs en 2026-03-03T21:33:15Z Merck ends Gardasil runs at Durham plant — vaccine demand slump forces cuts https://biobriefs.com/aardvark-pauses-phase-3-hero BioBriefs en 2026-03-03T21:33:15Z Aardvark pauses Phase 3 HERO trial after cardiac signals in volunteers https://biobriefs.com/agbt-fallout-sequencing-vendors-tee BioBriefs en 2026-03-03T21:33:15Z AGBT fallout: sequencing vendors tee up a high‑throughput showdown https://biobriefs.com/fda-seeks-sham-controlled-study BioBriefs en 2026-03-03T16:32:40Z FDA Seeks Sham-Controlled Study – UniQure's Huntington Program Stalls https://biobriefs.com/fda-lifts-hold-on-intellias BioBriefs en 2026-03-03T16:32:40Z FDA Lifts Hold on Intellia’s CRISPR Trial... Safety Conditions Apply https://biobriefs.com/fda-clears-ascendis-weekly-dwarfism BioBriefs en 2026-03-03T16:32:40Z FDA Clears Ascendis’ Weekly Dwarfism Shot – Market Battle Begins https://biobriefs.com/cardiac-signal-halts-aardvarks-phase BioBriefs en 2026-03-03T16:32:40Z Cardiac Signal Halts Aardvark’s Phase 3 Hunger Trial – Data Review Underway https://biobriefs.com/candid-to-go-public-via BioBriefs en 2026-03-03T16:32:40Z Candid to Go Public via Rallybio Reverse Merger – $505M War Chest https://biobriefs.com/merck-expands-biomarker-hunt-with BioBriefs en 2026-03-03T16:32:40Z Merck Expands Biomarker Hunt With Tempus AI – Precision Oncology Focus https://biobriefs.com/asia-deals-gsk-buys-sirna BioBriefs en 2026-03-03T16:32:40Z Asia Deals: GSK Buys siRNA Programs; Astellas Taps Vir for a T‑Cell Engager https://biobriefs.com/earendil-locks-payload-linker-tech BioBriefs en 2026-03-03T16:32:40Z Earendil Locks Payload-Linker Tech With WuXi XDC in Up‑to‑$885M Pact https://biobriefs.com/hepion-pivots-to-liquid-biopsy BioBriefs en 2026-03-03T16:32:40Z Hepion Pivots to Liquid Biopsy – Licenses ctRNA Assay for Early HCC Detection https://biobriefs.com/theravance-winds-down-r-d BioBriefs en 2026-03-03T16:32:40Z Theravance Winds Down R&D After Phase 3 Failure – Major Jobs Impact https://biobriefs.com/fda-demands-sham-controlled-study BioBriefs en 2026-03-03T14:33:16Z FDA Demands Sham-Controlled Study: uniQure’s AMT-130 Approval Path Blocked https://biobriefs.com/phase-iii-halted-aardvark-pauses BioBriefs en 2026-03-03T14:33:16Z Phase III Halted: Aardvark Pauses PWS HERO Trial After Cardiac Signals https://biobriefs.com/fda-grants-accelerated-approval-ascendis BioBriefs en 2026-03-03T14:33:16Z FDA Grants Accelerated Approval: Ascendis’ Yuviwel Cleared for Achondroplasia https://biobriefs.com/fda-lifts-hold-intellia-restarts BioBriefs en 2026-03-03T14:33:16Z FDA Lifts Hold: Intellia Restarts Phase 3 CRISPR Trial With Safety Limits https://biobriefs.com/oxford-nanopore-restructures-revenue-up BioBriefs en 2026-03-03T14:33:16Z Oxford Nanopore Restructures – Revenue Up 22% Amid Layoffs and Refocus https://biobriefs.com/candid-to-go-public-via BioBriefs en 2026-03-03T14:33:16Z Candid to Go Public via Reverse Merger – $505M Fuels TCE Push https://biobriefs.com/earendil-secures-wuxi-xdc-payload BioBriefs en 2026-03-03T14:33:16Z Earendil Secures WuXi XDC Payload-Linker Deal in Up-to-$885M ADC Partnership https://biobriefs.com/bioatla-cuts-70-of-workforce BioBriefs en 2026-03-03T14:33:16Z BioAtla Cuts 70% of Workforce, Seeks Strategic Options for Antibody Assets https://biobriefs.com/powerful-na-targeting-antibody-shows BioBriefs en 2026-03-03T14:33:16Z Powerful NA‑Targeting Antibody Shows Broad H5N1 Neutralization https://biobriefs.com/engineered-probiotic-reverses-type-2 BioBriefs en 2026-03-03T14:33:16Z Engineered Probiotic Reverses Type 2 Diabetes in Mice: Gut‑Host Axis Reset https://biobriefs.com/fda-says-sham-controlled-trial BioBriefs en 2026-03-03T10:33:29Z FDA says sham‑controlled trial needed – uniQure’s Huntington program stalls https://biobriefs.com/fda-lifts-crispr-hold-intellia BioBriefs en 2026-03-03T10:33:29Z FDA lifts CRISPR hold – Intellia cleared to restart Magnitude trials with caveats https://biobriefs.com/aardvark-halts-phase-iii-hero BioBriefs en 2026-03-03T10:33:29Z Aardvark halts Phase III HERO after cardiac signals – program paused https://biobriefs.com/roche-wins-phase-3-in BioBriefs en 2026-03-03T10:33:29Z Roche wins Phase 3 in MS – liver‑safety signal clouds approval path https://biobriefs.com/fda-grants-accelerated-approval-ascendis BioBriefs en 2026-03-03T10:33:29Z FDA grants accelerated approval: Ascendis’ once‑weekly Yuviwel cleared for achondroplasia https://biobriefs.com/candid-to-go-public-via BioBriefs en 2026-03-03T10:33:29Z Candid to go public via reverse merger – $505M backs T‑cell engager push https://biobriefs.com/earendil-taps-wuxi-xdc-for BioBriefs en 2026-03-03T10:33:29Z Earendil taps WuXi XDC for ADC development – pact worth up to $885M https://biobriefs.com/merck-to-end-gardasil-runs BioBriefs en 2026-03-03T10:33:29Z Merck to end Gardasil runs at Durham plant – >150 jobs to be cut https://biobriefs.com/fda-clears-delivery-date-ai BioBriefs en 2026-03-03T10:33:29Z FDA clears Delivery Date AI: De Novo nod for ultrasound‑based prediction software https://biobriefs.com/universal-newborn-ccmv-screening-boosts BioBriefs en 2026-03-03T10:33:29Z Universal newborn cCMV screening boosts early detection – Minnesota study shows gains https://biobriefs.com/fda-demands-sham-controlled-trial BioBriefs en 2026-03-03T09:34:05Z FDA Demands Sham-Controlled Trial – UniQure’s Huntington Path Stalls https://biobriefs.com/aardvark-halts-phase-iii-hero BioBriefs en 2026-03-03T09:34:05Z Aardvark Halts Phase III HERO Trial – Cardiac Signals Trigger Safety Pause https://biobriefs.com/candid-to-go-public-through BioBriefs en 2026-03-03T09:34:05Z Candid to Go Public Through Reverse Merger With Rallybio – $505M Backing https://biobriefs.com/fda-lifts-clinical-hold-on BioBriefs en 2026-03-03T09:34:05Z FDA Lifts Clinical Hold on Intellia CRISPR Trials – New Safeguards Imposed https://biobriefs.com/roches-btk-pill-clears-another BioBriefs en 2026-03-03T09:34:05Z Roche’s BTK Pill Clears Another Phase 3 — Safety Signal Complicates Approval Path https://biobriefs.com/nanopore-momentum-oxford-posts-revenue BioBriefs en 2026-03-03T09:34:05Z Nanopore Momentum: Oxford Posts Revenue Gain as CHOP, Seattle Children’s Adopt Rapid Sequencing https://biobriefs.com/evinova-signs-ai-pacts-with BioBriefs en 2026-03-03T09:34:05Z Evinova Signs AI Pacts With Big Pharma to Benchmark and Speed Clinical Trials https://biobriefs.com/earendil-licenses-wuxi-payload-linker BioBriefs en 2026-03-03T09:34:05Z Earendil Licenses WuXi Payload‑Linker Tech in Up‑to‑$885M ADC Deal https://biobriefs.com/fda-accelerates-approval-of-ascendis BioBriefs en 2026-03-03T09:34:05Z FDA Accelerates Approval of Ascendis’ Yuviwel – New Challenger in Achondroplasia https://biobriefs.com/plasma-mcfdna-sequencing-predicts-bloodstream BioBriefs en 2026-03-03T09:34:05Z Plasma mcfDNA Sequencing Predicts Bloodstream Infections Days Earlier in Pediatric Leukemia https://biobriefs.com/uniqure-blocked-by-fda-sham BioBriefs en 2026-03-03T04:33:44Z UniQure blocked by FDA: sham‑surgery trial requested https://biobriefs.com/fda-lifts-hold-on-intellia BioBriefs en 2026-03-03T04:33:44Z FDA lifts hold on Intellia CRISPR trial – Magnitude restarts with caveats https://biobriefs.com/ascendis-wins-accelerated-fda-ok BioBriefs en 2026-03-03T04:33:44Z Ascendis wins accelerated FDA OK – weekly achondroplasia shot cleared https://biobriefs.com/aardvark-pauses-phase-iii-hero BioBriefs en 2026-03-03T04:33:44Z Aardvark pauses Phase III HERO trial after cardiac signals – shares tumble https://biobriefs.com/roches-btk-pill-clears-a BioBriefs en 2026-03-03T04:33:44Z Roche’s BTK pill clears a Phase 3 but safety questions mount https://biobriefs.com/candid-to-go-public-via BioBriefs en 2026-03-03T04:33:44Z Candid to go public via reverse merger with Rallybio — $505M raised https://biobriefs.com/evinova-inks-enterprise-ai-deals BioBriefs en 2026-03-03T04:33:44Z Evinova inks enterprise AI deals with AstraZeneca, BMS and Astellas https://biobriefs.com/earendil-licenses-wuxi-xdc-payload BioBriefs en 2026-03-03T04:33:44Z Earendil licenses WuXi XDC payload‑linker tech in up‑to‑$885M ADC deal https://biobriefs.com/oxford-nanopore-trims-portfolio-after BioBriefs en 2026-03-03T04:33:44Z Oxford Nanopore trims portfolio after restructuring as revenue rises 22% https://biobriefs.com/united-therapeutics-preps-fda-filing BioBriefs en 2026-03-03T04:33:44Z United Therapeutics preps FDA filing after Phase 3 ralinepag win in PAH https://biobriefs.com/fda-grants-ascendis-accelerated-approval BioBriefs en 2026-03-02T21:33:22Z FDA grants Ascendis accelerated approval – Yuviwel cleared for achondroplasia https://biobriefs.com/fda-urges-randomized-sham-controlled BioBriefs en 2026-03-02T21:33:22Z FDA urges randomized sham‑controlled trial for uniQure's AMT‑130 – shares tumble https://biobriefs.com/aardvark-pauses-phase-3-hero BioBriefs en 2026-03-02T21:33:22Z Aardvark pauses Phase 3 HERO study after cardiac signals – enrollment halted https://biobriefs.com/fda-lifts-hold-on-intellias BioBriefs en 2026-03-02T21:33:22Z FDA lifts hold on Intellia’s Magnitude Phase 3 – safety guardrails imposed https://biobriefs.com/nanopore-moment-oxford-nanopore-posts BioBriefs en 2026-03-02T21:33:22Z Nanopore moment: Oxford Nanopore posts 22% revenue growth as clinics adopt rapid sequencing https://biobriefs.com/candid-to-go-public-via BioBriefs en 2026-03-02T21:33:22Z Candid to go public via reverse merger with Rallybio – $505M raised https://biobriefs.com/earendil-inks-up-to-885m BioBriefs en 2026-03-02T21:33:22Z Earendil inks up to $885M ADC pact with WuXi XDC – expands ADC and T‑cell engager programs https://biobriefs.com/roches-fenebrutinib-posts-pivotal-phase BioBriefs en 2026-03-02T21:33:22Z Roche’s fenebrutinib posts pivotal Phase 3 wins – safety signals prompt scrutiny https://biobriefs.com/united-therapeutics-posts-phase-3 BioBriefs en 2026-03-02T21:33:22Z United Therapeutics posts Phase 3 win in PAH – ralinepag filing planned https://biobriefs.com/regulators-clear-ai-and-software BioBriefs en 2026-03-02T21:33:22Z Regulators clear AI and software tools — FDA De Novo, EU IVDR Class C signposts https://biobriefs.com/united-therapeutics-to-seek-fda BioBriefs en 2026-03-02T16:33:25Z United Therapeutics to seek FDA: ralinepag halves risk of PAH clinical worsening https://biobriefs.com/fda-lifts-holds-intellia-clears BioBriefs en 2026-03-02T16:33:25Z FDA lifts holds – Intellia clears path to resume Phase 3 CRISPR trials https://biobriefs.com/aardvark-halts-phase-3-after BioBriefs en 2026-03-02T16:33:25Z Aardvark halts Phase 3 after cardiac signals – shares tumble https://biobriefs.com/roche-nails-another-phase-3 BioBriefs en 2026-03-02T16:33:25Z Roche nails another Phase 3 in MS – liver signal and deaths prompt scrutiny https://biobriefs.com/fda-prefers-randomized-trial-uniqures BioBriefs en 2026-03-02T16:33:25Z FDA prefers randomized trial: UniQure’s AMT‑130 pathway stalls, stock plunges https://biobriefs.com/earendil-taps-wuxi-xdc-in BioBriefs en 2026-03-02T16:33:25Z Earendil taps WuXi XDC in up‑to‑$885M ADC pact https://biobriefs.com/oxford-nanopore-grows-revenue-22 BioBriefs en 2026-03-02T16:33:25Z Oxford Nanopore grows revenue 22% — restructures and trims R&D https://biobriefs.com/merck-winds-down-gardasil-output BioBriefs en 2026-03-02T16:33:25Z Merck winds down Gardasil output in Durham — more than 150 jobs cut https://biobriefs.com/bioatla-lays-off-70-and BioBriefs en 2026-03-02T16:33:25Z BioAtla lays off 70% and launches strategic review of antibody portfolio https://biobriefs.com/atrium-launches-with-270m-takes BioBriefs en 2026-03-02T16:33:25Z Atrium launches with $270M... takes RNA cardio assets from Novartis deal https://biobriefs.com/fda-presses-uniqure-randomized-sham BioBriefs en 2026-03-02T14:32:52Z FDA presses uniQure: randomized sham‑control preferred for AMT‑130 https://biobriefs.com/aardvark-halts-phase-3-hero BioBriefs en 2026-03-02T14:32:52Z Aardvark halts phase 3 HERO study after cardiac signals in volunteers https://biobriefs.com/roches-fenebrutinib-clears-phase-3 BioBriefs en 2026-03-02T14:32:52Z Roche’s fenebrutinib clears phase 3 endpoint — mortality signal clouds outlook https://biobriefs.com/belzutifan-plus-keytruda-extends-disease BioBriefs en 2026-03-02T14:32:52Z Belzutifan plus Keytruda extends disease‑free survival in high‑risk kidney cancer https://biobriefs.com/atrium-launches-with-270m-to BioBriefs en 2026-03-02T14:32:52Z Atrium launches with $270M to pursue RNA therapies for rare cardiac disorders https://biobriefs.com/chinese-obesity-biotech-ql-biopharm BioBriefs en 2026-03-02T14:32:52Z Chinese obesity biotech QL Biopharm secures $72M Series C with OrbiMed backing https://biobriefs.com/bavarian-nordic-ceo-paul-chaplin BioBriefs en 2026-03-02T14:32:52Z Bavarian Nordic CEO Paul Chaplin resigns after failed $3B takeover bid https://biobriefs.com/novartis-tests-rhapsido-beyond-hives BioBriefs en 2026-03-02T14:32:52Z Novartis tests Rhapsido beyond hives — phase 2 food‑allergy readout posted https://biobriefs.com/car-macrophages-breach-brain-barriers BioBriefs en 2026-03-02T14:32:52Z CAR macrophages breach brain barriers in preclinical lung‑metastasis models https://biobriefs.com/ai-pathology-under-fire-models BioBriefs en 2026-03-02T14:32:52Z AI pathology under fire: models learn shortcuts instead of biology https://biobriefs.com/close-open-steps-cell-therapy BioBriefs en 2026-03-02T10:32:48Z Close open steps: cell therapy manufacturers race to cut contamination risk https://biobriefs.com/spain-unveils-end-to-end BioBriefs en 2026-03-02T10:32:48Z Spain unveils end-to-end spatial‑omics platform: IRB Barcelona ties cores https://biobriefs.com/fda-offers-bonus-pay-reviewers BioBriefs en 2026-03-02T10:32:48Z FDA offers bonus pay: reviewers to be rewarded for faster drug reviews https://biobriefs.com/atrium-spins-out-with-270m BioBriefs en 2026-03-02T10:32:48Z Atrium spins out with $270M: RNA therapies target rare cardiac disorders https://biobriefs.com/belzutifan-pembrolizumab-cuts-relapse-risk BioBriefs en 2026-03-02T10:32:48Z Belzutifan+pembrolizumab cuts relapse risk: LITESPARK‑022 posts Phase 3 disease‑free survival gains https://biobriefs.com/novartis-tests-rhapsido-in-food BioBriefs en 2026-03-02T10:32:48Z Novartis tests Rhapsido in food allergy — Phase 2 signals https://biobriefs.com/viral-proteins-reveal-bacterial-kill BioBriefs en 2026-03-02T10:32:48Z Viral proteins reveal bacterial 'kill switch' — MurJ locked and defeated https://biobriefs.com/x-ray-activated-platinum-complex BioBriefs en 2026-03-02T10:32:48Z X‑ray activated platinum complex boosts radiotherapy and immunotherapy response https://biobriefs.com/microfluidic-chips-predict-implantation-chemiluminescent BioBriefs en 2026-03-02T10:32:48Z Microfluidic chips predict implantation: chemiluminescent metabolic assay for IVF https://biobriefs.com/wearable-ultrasound-microneedle-patch-delivers BioBriefs en 2026-03-02T10:32:48Z Wearable ultrasound microneedle patch delivers on‑demand gout therapy https://biobriefs.com/atrium-spins-out-with-270m BioBriefs en 2026-03-02T09:32:36Z Atrium spins out with $270M to back RNA cardiac programs https://biobriefs.com/fda-pilots-bonuses-to-speed BioBriefs en 2026-03-02T09:32:36Z FDA pilots bonuses to speed drug reviews — Makary leads change https://biobriefs.com/belzutifan-plus-pembrolizumab-extends-disease BioBriefs en 2026-03-02T09:32:36Z Belzutifan plus pembrolizumab extends disease-free survival in kidney cancer https://biobriefs.com/novartis-rhapsido-shows-phase-2 BioBriefs en 2026-03-02T09:32:36Z Novartis’ Rhapsido shows Phase 2 signal in food allergy https://biobriefs.com/merck-seeks-label-expansion-for BioBriefs en 2026-03-02T09:32:36Z Merck seeks label expansion for Welireg in kidney cancer combinations https://biobriefs.com/researchers-uncover-viral-kill-switch BioBriefs en 2026-03-02T09:32:36Z Researchers uncover viral 'kill switch' targeting critical bacterial protein https://biobriefs.com/x-ray-activated-platinum-complex BioBriefs en 2026-03-02T09:32:36Z X-ray–activated platinum complex enhances radiotherapy immune effects https://biobriefs.com/irb-barcelona-launches-spains-first BioBriefs en 2026-03-02T09:32:36Z IRB Barcelona launches Spain’s first end-to-end spatial omics platform https://biobriefs.com/foundation-models-reshape-spatial-multi BioBriefs en 2026-03-02T09:32:36Z Foundation models reshape spatial multi-omic analysis https://biobriefs.com/microfluidic-chemiluminescent-chip-predicts-embryo BioBriefs en 2026-03-02T09:32:36Z Microfluidic chemiluminescent chip predicts embryo implantation potential https://biobriefs.com/belzutifan-pembrolizumab-combo-extends-disease BioBriefs en 2026-03-02T04:32:35Z Belzutifan–pembrolizumab combo extends disease‑free survival in high‑risk kidney cancer https://biobriefs.com/fda-offers-bonus-pay-for BioBriefs en 2026-03-02T04:32:35Z FDA offers bonus pay for faster drug reviews: pilot program unveiled https://biobriefs.com/atrium-launches-with-270m-rna BioBriefs en 2026-03-02T04:32:35Z Atrium launches with $270M — RNA therapies target rare inherited cardiac disorders https://biobriefs.com/merck-seeks-welireg-label-expansion BioBriefs en 2026-03-02T04:32:35Z Merck seeks Welireg label expansion — filings target Keytruda and Lenvima combos https://biobriefs.com/health-gorilla-fights-epic-suit BioBriefs en 2026-03-02T04:32:35Z Health Gorilla fights Epic suit — frames case as attack on interoperability https://biobriefs.com/x-ray-activated-platinum-complex BioBriefs en 2026-03-02T04:32:35Z X‑ray‑activated platinum complex boosts radiotherapy and immune response https://biobriefs.com/dual-receptor-knockout-amplifies-car BioBriefs en 2026-03-02T04:32:35Z Dual‑receptor knockout amplifies CAR‑T potency against solid tumours https://biobriefs.com/viral-proteins-expose-bacterial-kill BioBriefs en 2026-03-02T04:32:35Z Viral proteins expose bacterial 'kill switch' — MurJ locked to stop cell‑wall assembly https://biobriefs.com/archaeon-reads-stop-codon-as BioBriefs en 2026-03-02T04:32:35Z Archaeon reads stop codon as sense codon — rule‑bending genetic code discovered https://biobriefs.com/novartis-explores-rhapsido-for-food BioBriefs en 2026-03-02T04:32:35Z Novartis explores Rhapsido for food allergy — Phase 2 shows promising signals https://biobriefs.com/belzutifan-pembrolizumab-combo-cuts-recurrence BioBriefs en 2026-03-01T21:32:45Z Belzutifan–pembrolizumab combo cuts recurrence risk in kidney cancer https://biobriefs.com/fda-to-pay-bonuses-for BioBriefs en 2026-03-01T21:32:45Z FDA to pay bonuses for faster drug reviews — pilot sparks debate https://biobriefs.com/fda-approves-ascendis-weekly-achondroplasia BioBriefs en 2026-03-01T21:32:45Z FDA approves Ascendis' weekly achondroplasia drug — EU decision pending https://biobriefs.com/ema-panel-backs-three-orphan BioBriefs en 2026-03-01T21:32:45Z EMA panel backs three orphan drugs — rebuffs two FDA programs https://biobriefs.com/biontech-dualitybio-greenlight-b7-h3 BioBriefs en 2026-03-01T21:32:45Z BioNTech, DualityBio greenlight B7‑H3 ADC into phase 3 — mCRPC race tightens https://biobriefs.com/atrium-spins-out-with-270m BioBriefs en 2026-03-01T21:32:45Z Atrium spins out with $270M — RNA push for rare heart diseases https://biobriefs.com/researchers-find-viral-kill-switch BioBriefs en 2026-03-01T21:32:45Z Researchers find viral 'kill switch' that locks MurJ: new bacterial target https://biobriefs.com/dual-receptor-knockout-enhances-car BioBriefs en 2026-03-01T21:32:45Z Dual receptor knockout enhances CAR‑T activity against solid tumors https://biobriefs.com/goodrx-launches-employer-program-employers BioBriefs en 2026-03-01T21:32:45Z GoodRx launches employer program: employers can subsidize GLP‑1s https://biobriefs.com/novartis-tests-rhapsido-for-food BioBriefs en 2026-03-01T21:32:45Z Novartis tests Rhapsido for food allergy...Phase 2 shows dose responses https://biobriefs.com/moderna-wins-eu-backing-combo BioBriefs en 2026-03-01T16:33:03Z Moderna wins EU backing: combo flu–COVID vaccine cleared by CHMP https://biobriefs.com/biontech-advances-b7-h3-adc BioBriefs en 2026-03-01T16:33:03Z BioNTech advances B7-H3 ADC: phase 3 start in prostate cancer https://biobriefs.com/atrium-spins-out-rna-cardio BioBriefs en 2026-03-01T16:33:03Z Atrium spins out RNA cardio programs — $270M bankroll https://biobriefs.com/generate-raises-400m-ai-driven BioBriefs en 2026-03-01T16:33:03Z Generate raises $400M: AI‑driven protein design firm prices IPO https://biobriefs.com/abbott-floats-20b-notes-to BioBriefs en 2026-03-01T16:33:03Z Abbott floats $20B notes to fund Exact Sciences buy — debt package unveiled https://biobriefs.com/fda-to-pilot-bonuses-for BioBriefs en 2026-03-01T16:33:03Z FDA to pilot bonuses for faster reviews — incentive plan raises questions https://biobriefs.com/u-s-probes-chinese-state BioBriefs en 2026-03-01T16:33:03Z U.S. probes Chinese state support and pricing in biotech — ITC inquiry opened https://biobriefs.com/systimmunes-iza-bren-clears-phase BioBriefs en 2026-03-01T16:33:03Z Systimmune’s iza‑bren clears phase 3 endpoints in China — survival gains reported https://biobriefs.com/ascendis-wins-fda-approval-for BioBriefs en 2026-03-01T16:33:03Z Ascendis wins FDA approval for achondroplasia drug — weekly TransCon CNP cleared https://biobriefs.com/uniqure-stock-tumbles-after-fda BioBriefs en 2026-03-01T16:33:03Z UniQure stock tumbles after FDA remarks — investor nerves over rare‑disease reviews https://biobriefs.com/atrium-launches-with-270m-avidity BioBriefs en 2026-03-01T14:33:06Z Atrium launches with $270M—Avidity spinout targets cardiac RNA https://biobriefs.com/generate-prices-400m-ipo-ai BioBriefs en 2026-03-01T14:33:06Z Generate prices $400M IPO—AI‑designed TSLP program backed for pivotal tests https://biobriefs.com/ema-backs-modernas-flu-covid BioBriefs en 2026-03-01T14:33:06Z EMA backs Moderna’s flu–COVID combo—EU clears path for first‑in‑class shot https://biobriefs.com/fda-pilots-reviewer-bonuses-and BioBriefs en 2026-03-01T14:33:06Z FDA pilots reviewer bonuses and retools trial default—approval norms shift https://biobriefs.com/caris-detect-interim-validation-sensitivity BioBriefs en 2026-03-01T14:33:06Z Caris Detect interim validation—sensitivity climbs with cancer stage https://biobriefs.com/systimmunes-iza-bren-clears-phase BioBriefs en 2026-03-01T14:33:06Z Systimmune’s iza‑bren clears phase III goals in China—survival gains reported https://biobriefs.com/fda-clears-ascendis-once-weekly BioBriefs en 2026-03-01T14:33:06Z FDA clears Ascendis’ once‑weekly achondroplasia drug—new option for rare growth disorder https://biobriefs.com/u-s-opens-probe-of BioBriefs en 2026-03-01T14:33:06Z U.S. opens probe of Chinese biotech support—trade stakes rise https://biobriefs.com/abbott-files-20b-note-offering BioBriefs en 2026-03-01T14:33:06Z Abbott files $20B note offering to fund Exact Sciences takeover https://biobriefs.com/ctdna-blood-test-may-spare BioBriefs en 2026-03-01T14:33:06Z ctDNA blood test may spare bladder surgery—RETAIN‑2 phase 2 shows promise https://biobriefs.com/modernas-mcombriax-wins-chmp-backing BioBriefs en 2026-03-01T10:32:43Z Moderna’s mCombriax wins CHMP backing — EU path cleared https://biobriefs.com/belzutifan-plus-pembrolizumab-improves-disease BioBriefs en 2026-03-01T10:32:43Z Belzutifan plus pembrolizumab improves disease-free survival in high‑risk kidney cancer https://biobriefs.com/fda-to-pilot-bonuses-for BioBriefs en 2026-03-01T10:32:43Z FDA to pilot bonuses for faster drug reviews — internal pay shakeup https://biobriefs.com/generate-biomedicines-prices-400m-ipo BioBriefs en 2026-03-01T10:32:43Z Generate Biomedicines prices $400M IPO to fund pivotal asthma program https://biobriefs.com/caris-detect-interim-validation-shows BioBriefs en 2026-03-01T10:32:43Z Caris Detect interim validation shows promising MCED sensitivity and specificity https://biobriefs.com/atrium-therapeutics-debuts-with-avidity BioBriefs en 2026-03-01T10:32:43Z Atrium Therapeutics debuts with Avidity cardio programs and $270M cash https://biobriefs.com/ascendis-wins-fda-approval-for BioBriefs en 2026-03-01T10:32:43Z Ascendis wins FDA approval for once‑weekly achondroplasia therapy https://biobriefs.com/abbott-lines-up-20b-debt BioBriefs en 2026-03-01T10:32:43Z Abbott lines up $20B debt package to finance Exact Sciences buy https://biobriefs.com/u-s-probe-targets-chinese BioBriefs en 2026-03-01T10:32:43Z U.S. probe targets Chinese state support and pricing in biotech — trade scrutiny rises https://biobriefs.com/systimmunes-iza-bren-meets-phase BioBriefs en 2026-03-01T10:32:43Z Systimmune’s iza‑bren meets phase III endpoints in Chinese triple‑negative breast cancer study https://biobriefs.com/generate-biomedicines-prices-400m-ipo BioBriefs en 2026-03-01T09:33:10Z Generate Biomedicines prices $400M IPO: AI-designed TSLP program funded https://biobriefs.com/ema-recommends-moderna-combo-shot BioBriefs en 2026-03-01T09:33:10Z EMA recommends Moderna combo shot: Europe clears path for flu–COVID vaccine https://biobriefs.com/fda-rolls-out-reviewer-bonus BioBriefs en 2026-03-01T09:33:10Z FDA rolls out reviewer bonus pilot — payments tied to faster approvals https://biobriefs.com/us-opens-trade-probe-into BioBriefs en 2026-03-01T09:33:10Z US opens trade probe into Chinese biotech: ITC examines state support, pricing https://biobriefs.com/abbott-lines-up-20b-debt BioBriefs en 2026-03-01T09:33:10Z Abbott lines up $20B debt package to fund Exact Sciences buyout https://biobriefs.com/merck-seeks-welireg-label-expansion BioBriefs en 2026-03-01T09:33:10Z Merck seeks Welireg label expansion after combo readouts — kidney cancer push https://biobriefs.com/atrium-launches-from-avidity-spinoff BioBriefs en 2026-03-01T09:33:10Z Atrium launches from Avidity spinoff — $270M to pursue RNA cardio programs https://biobriefs.com/disc-medicine-cuts-staff-after BioBriefs en 2026-03-01T09:33:10Z Disc Medicine cuts staff after FDA rejection — company files layoffs https://biobriefs.com/two-car-t-advances-aim BioBriefs en 2026-03-01T09:33:10Z Two CAR T advances aim at solid tumors: receptor edits and ultra‑sensitive HIT cells https://biobriefs.com/ctdna-steers-care-retain-2 BioBriefs en 2026-03-01T09:33:10Z ctDNA steers care: RETAIN‑2 and multicenter studies refine precision treatment https://biobriefs.com/modernas-flu-covid-combo-gets BioBriefs en 2026-03-01T04:33:05Z Moderna’s flu–COVID combo gets CHMP nod — EU clearance nears https://biobriefs.com/generate-prices-400m-ipo-betting BioBriefs en 2026-03-01T04:33:05Z Generate prices $400M IPO — betting on AI‑designed TSLP antibody https://biobriefs.com/atrium-launches-with-270m-takes BioBriefs en 2026-03-01T04:33:05Z Atrium launches with $270M — takes Avidity’s cardiac RNA work https://biobriefs.com/earendil-inks-up-to-885m BioBriefs en 2026-03-01T04:33:05Z Earendil inks up to $885M deal for WuXi XDC linker‑payload tech https://biobriefs.com/biontech-pushes-b7-h3-adc BioBriefs en 2026-03-01T04:33:05Z BioNTech pushes B7‑H3 ADC into phase 3 with a trimmed trial https://biobriefs.com/padcev-keytruda-combo-posts-fresh BioBriefs en 2026-03-01T04:33:05Z Padcev–Keytruda combo posts fresh positive bladder cancer data https://biobriefs.com/systimmunes-iza-bren-meets-phase BioBriefs en 2026-03-01T04:33:05Z Systimmune’s iza‑bren meets phase‑III PFS and OS targets in China https://biobriefs.com/fda-will-pilot-bonus-pay BioBriefs en 2026-03-01T04:33:05Z FDA will pilot bonus pay to speed drug reviews — critics raise flags https://biobriefs.com/fda-shifts-trial-expectations-one BioBriefs en 2026-03-01T04:33:05Z FDA shifts trial expectations — one‑trial default and rare‑disease pathway proposed https://biobriefs.com/abbott-proposes-20b-debt-sale BioBriefs en 2026-03-01T04:33:05Z Abbott proposes $20B debt sale to fund Exact Sciences acquisition https://biobriefs.com/p53-reactivation-shows-clinical-activity BioBriefs en 2026-02-28T21:33:29Z p53 reactivation shows clinical activity – Rezatapopt posts Phase I data https://biobriefs.com/generate-prices-400m-ipo-market BioBriefs en 2026-02-28T21:33:29Z Generate prices $400M IPO – Market backs AI‑designed TSLP program https://biobriefs.com/chmp-backs-modernas-flu-covid BioBriefs en 2026-02-28T21:33:29Z CHMP backs Moderna’s flu–COVID combo: EU path clears https://biobriefs.com/fda-to-pay-bonuses-for BioBriefs en 2026-02-28T21:33:29Z FDA to pay bonuses for faster reviews – Pilot ties time savings to awards https://biobriefs.com/atrium-launches-from-avidity-buyout BioBriefs en 2026-02-28T21:33:29Z Atrium launches from Avidity buyout – Cardiac RNA franchise moves forward https://biobriefs.com/biontech-pushes-b7-h3-adc BioBriefs en 2026-02-28T21:33:29Z BioNTech pushes B7‑H3 ADC into phase 3 – MCRPC program accelerates https://biobriefs.com/iza-bren-hits-phase-iii BioBriefs en 2026-02-28T21:33:29Z Iza‑bren hits Phase III goals in China – Survival improved in TNBC https://biobriefs.com/ctdna-guides-bladder-preservation-retain BioBriefs en 2026-02-28T21:33:29Z ctDNA guides bladder preservation – RETAIN‑2 shows surgical avoidance possible https://biobriefs.com/us-launches-probe-into-chinese BioBriefs en 2026-02-28T21:33:29Z US launches probe into Chinese biotech support – Trade review could shift deals https://biobriefs.com/ultra-sensitive-car-t-cells BioBriefs en 2026-02-28T21:33:29Z Ultra‑sensitive CAR T cells target solid tumors – HIT receptors broaden scope https://biobriefs.com/generates-400m-ipo-ai-drug BioBriefs en 2026-02-28T16:32:14Z Generate’s $400M IPO: AI drug designer backs late‑stage asthma push https://biobriefs.com/ema-recommends-modernas-mcombriax-first BioBriefs en 2026-02-28T16:32:14Z EMA recommends Moderna’s mCombriax — first flu/COVID combo on the table https://biobriefs.com/atrium-rises-from-avidity-deal BioBriefs en 2026-02-28T16:32:14Z Atrium rises from Avidity deal: RNA heart programs keep going https://biobriefs.com/earendil-and-wuxi-xdc-ink BioBriefs en 2026-02-28T16:32:14Z Earendil and WuXi XDC ink up to $885M ADC pact https://biobriefs.com/systimmunes-iza-bren-clears-phase BioBriefs en 2026-02-28T16:32:14Z Systimmune’s iza‑bren clears phase III goals in China — survival endpoints met https://biobriefs.com/mutant-p53-reactivation-rezatapopt-shows BioBriefs en 2026-02-28T16:32:14Z Mutant p53 reactivation: rezatapopt shows clinical activity in NEJM report https://biobriefs.com/next-gen-car-t-ultra BioBriefs en 2026-02-28T16:32:14Z Next‑gen CAR‑T: ultra‑sensitive HIT receptors and receptor knockouts advance solid‑tumor work https://biobriefs.com/ctdna-steers-care-blood-tests BioBriefs en 2026-02-28T16:32:14Z ctDNA steers care: blood tests predict bladder outcomes and guide FGFR therapy https://biobriefs.com/fda-trial-rules-shift-one BioBriefs en 2026-02-28T16:32:14Z FDA trial rules shift: one‑trial default and rare‑disease framework spark debate https://biobriefs.com/u-s-probe-targets-chinese BioBriefs en 2026-02-28T16:32:14Z U.S. probe targets Chinese state support and pricing in biotech https://biobriefs.com/generate-biomedicines-prices-400m-ipo BioBriefs en 2026-02-28T14:33:06Z Generate Biomedicines prices $400M IPO — AI drug design bet https://biobriefs.com/ema-endorses-modernas-flu-covid BioBriefs en 2026-02-28T14:33:06Z EMA endorses Moderna’s flu–COVID combo — EU clearance likely https://biobriefs.com/atrium-launches-with-aviditys-cardiac BioBriefs en 2026-02-28T14:33:06Z Atrium launches with Avidity’s cardiac RNA assets — $270M war chest https://biobriefs.com/emas-chmp-backs-three-orphan BioBriefs en 2026-02-28T14:33:06Z EMA’s CHMP backs three orphan drugs — rejects two FDA‑cleared programs https://biobriefs.com/us-opens-probe-into-chinas BioBriefs en 2026-02-28T14:33:06Z US opens probe into China’s biotech support and pricing — ITC inquiry https://biobriefs.com/car-t-advances-for-solid BioBriefs en 2026-02-28T14:33:06Z CAR‑T advances for solid tumors: receptor edits and ultra‑sensitive HIT cells https://biobriefs.com/rezatapopt-shows-proof-of-concept BioBriefs en 2026-02-28T14:33:06Z Rezatapopt shows proof‑of‑concept in TP53 Y220C tumors — NEJM report https://biobriefs.com/ctdna-steers-bladder-preservation-and BioBriefs en 2026-02-28T14:33:06Z ctDNA steers bladder preservation and FGFR therapy decisions https://biobriefs.com/fda-floats-plausible-mechanism-pathway BioBriefs en 2026-02-28T14:33:06Z FDA floats 'plausible mechanism' pathway; senators press agency on rare approvals https://biobriefs.com/earendil-inks-up-to-885m BioBriefs en 2026-02-28T14:33:06Z Earendil inks up to $885M ADC pact with WuXi XDC — linker license https://biobriefs.com/modernas-combo-shot-clears-eu BioBriefs en 2026-02-28T10:33:06Z Moderna’s combo shot clears EU — EMA backs mCombriax https://biobriefs.com/generate-prices-400m-ipo-funds BioBriefs en 2026-02-28T10:33:06Z Generate prices $400M IPO — Funds go to phase‑3 asthma push https://biobriefs.com/avidity-spinout-atrium-launches-270m BioBriefs en 2026-02-28T10:33:06Z Avidity spinout Atrium launches — $270M to pursue RNA heart drugs https://biobriefs.com/fdas-one-trial-default-raises BioBriefs en 2026-02-28T10:33:06Z FDA’s one‑trial default raises global questions — reviewers, industry push back https://biobriefs.com/u-s-probes-chinese-biotech BioBriefs en 2026-02-28T10:33:06Z U.S. probes Chinese biotech subsidies, pricing — trade scrutiny escalates https://biobriefs.com/caris-detect-posts-strong-interim BioBriefs en 2026-02-28T10:33:06Z Caris Detect posts strong interim results — MCED launch moves closer https://biobriefs.com/reactivating-mutant-p53-pmvs-rezatapopt BioBriefs en 2026-02-28T10:33:06Z Reactivating mutant p53: PMV’s rezatapopt shows proof‑of‑concept in NEJM https://biobriefs.com/iza-bren-hits-endpoints-in BioBriefs en 2026-02-28T10:33:06Z Iza‑bren hits endpoints in China phase III — boost for licensee Bristol Myers https://biobriefs.com/bladder-cancer-padcev-keytruda-wins BioBriefs en 2026-02-28T10:33:06Z Bladder cancer: Padcev–Keytruda wins more data; ctDNA predicts who can skip surgery https://biobriefs.com/two-car-t-upgrades-expand BioBriefs en 2026-02-28T10:33:06Z Two CAR‑T upgrades expand solid tumor reach — dual receptor knockout and ultra‑sensitive HIT cells https://biobriefs.com/generate-prices-400m-ipo-ai BioBriefs en 2026-02-28T09:32:59Z Generate prices $400M IPO – AI-designed TSLP push https://biobriefs.com/ema-recommends-modernas-flu-covid BioBriefs en 2026-02-28T09:32:59Z EMA recommends Moderna’s flu–COVID combo: European path cleared https://biobriefs.com/atrium-launches-with-270m-avidity BioBriefs en 2026-02-28T09:32:59Z Atrium launches with $270M – Avidity cardiac RNA programs continue https://biobriefs.com/earendil-inks-up-to-885m BioBriefs en 2026-02-28T09:32:59Z Earendil inks up to $885M ADC pact with WuXi XDC https://biobriefs.com/chmp-recommends-three-orphan-drugs BioBriefs en 2026-02-28T09:32:59Z CHMP recommends three orphan drugs; rebuffs two FDA‑approved programs https://biobriefs.com/u-s-launches-probe-into BioBriefs en 2026-02-28T09:32:59Z U.S. launches probe into Chinese biotech support – ITC examines pricing https://biobriefs.com/rezatapopt-shows-clinical-activity-in BioBriefs en 2026-02-28T09:32:59Z Rezatapopt shows clinical activity in TP53 Y220C tumors – NEJM report https://biobriefs.com/ultra-sensitive-car-t-advances BioBriefs en 2026-02-28T09:32:59Z Ultra‑sensitive CAR‑T advances: HIT receptors and NR2F6 deletion boost potency https://biobriefs.com/roche-details-axelios-sequencer-150 BioBriefs en 2026-02-28T09:32:59Z Roche details Axelios sequencer: $150 per human genome claim https://biobriefs.com/fda-trial-default-and-political BioBriefs en 2026-02-28T09:32:59Z FDA trial default and political defense collide — one trial standard questioned https://biobriefs.com/generate-biomedicines-ipo-400m-to BioBriefs en 2026-02-28T04:33:03Z Generate Biomedicines IPO: $400M to fund phase‑3 TSLP push https://biobriefs.com/ema-recommends-modernas-flu-covid BioBriefs en 2026-02-28T04:33:03Z EMA recommends Moderna’s flu–COVID combo: mCombriax nears EU clearance https://biobriefs.com/atrium-therapeutics-rises-from-avidity BioBriefs en 2026-02-28T04:33:03Z Atrium Therapeutics rises from Avidity: $270M, cardiac RNA programs https://biobriefs.com/wuxi-xdc-licenses-adc-linker BioBriefs en 2026-02-28T04:33:03Z WuXi XDC licenses ADC linker to Earendil — up to $885M pact https://biobriefs.com/biontech-and-duality-advance-b7 BioBriefs en 2026-02-28T04:33:03Z BioNTech and Duality advance B7‑H3 ADC into phase 3 — lean trial design https://biobriefs.com/caris-detect-interim-data-ctdna BioBriefs en 2026-02-28T04:33:03Z Caris Detect interim data: ctDNA signals support MCED launch https://biobriefs.com/pmvs-rezatapopt-validates-p53-reactivation BioBriefs en 2026-02-28T04:33:03Z PMV’s rezatapopt validates p53 reactivation: NEJM reports responses https://biobriefs.com/systimmunes-iza-bren-hits-primary BioBriefs en 2026-02-28T04:33:03Z Systimmune’s iza‑bren hits primary endpoints in China phase 3 — survival gains https://biobriefs.com/boehringer-wins-accelerated-approval-hernexeos BioBriefs en 2026-02-28T04:33:03Z Boehringer wins accelerated approval: Hernexeos cleared for first‑line lung use https://biobriefs.com/makary-defends-fda-rejections-rare BioBriefs en 2026-02-28T04:33:03Z Makary defends FDA rejections — rare‑disease stocks wobble as UniQure slides https://biobriefs.com/modernas-combo-vaccine-clears-eu BioBriefs en 2026-02-27T21:33:13Z Moderna’s combo vaccine clears EU hurdle: CHMP backs mCombriax https://biobriefs.com/fda-trial-rule-shift-global BioBriefs en 2026-02-27T21:33:13Z FDA trial rule shift… global ripple expected https://biobriefs.com/generate-biomedicines-raises-400m-ai BioBriefs en 2026-02-27T21:33:13Z Generate Biomedicines raises $400M: AI design funds pivotal asthma trials https://biobriefs.com/systimmunes-iza-bren-passes-china BioBriefs en 2026-02-27T21:33:13Z Systimmune’s iza‑bren passes China phase III endpoints — survival gains reported https://biobriefs.com/caris-detect-interim-readout-ctdna BioBriefs en 2026-02-27T21:33:13Z Caris Detect interim readout: ctDNA‑guided MCED shows stage‑dependent sensitivity https://biobriefs.com/atrium-rises-from-avidity-sale BioBriefs en 2026-02-27T21:33:13Z Atrium rises from Avidity sale – $270M spinout to pursue cardiac RNA programs https://biobriefs.com/earendil-inks-up-to-885m BioBriefs en 2026-02-27T21:33:13Z Earendil inks up to $885M pact with WuXi XDC — ADC linker access secured https://biobriefs.com/asahi-kasei-buys-aicuris-for BioBriefs en 2026-02-27T21:33:13Z Asahi Kasei buys Aicuris for $920M — expands antiviral portfolio https://biobriefs.com/regulator-rhetoric-rattles-market-uniqure BioBriefs en 2026-02-27T21:33:13Z Regulator rhetoric rattles market — UniQure slides after FDA comments https://biobriefs.com/fda-proposes-plausible-mechanism-route BioBriefs en 2026-02-27T21:33:13Z FDA proposes ‘plausible mechanism’ route — new framework for ultra‑rare therapies https://biobriefs.com/earendil-wuxi-xdc-pact-885m BioBriefs en 2026-02-27T16:33:23Z Earendil–WuXi XDC pact: $885M play for next‑gen ADC linkers https://biobriefs.com/atrium-launches-as-novartis-closes BioBriefs en 2026-02-27T16:33:23Z Atrium launches as Novartis closes $12B Avidity buyout https://biobriefs.com/generate-prices-400m-ipo-ai BioBriefs en 2026-02-27T16:33:23Z Generate prices $400M IPO: AI drug discovery lists on Nasdaq https://biobriefs.com/caris-detect-interim-mced-assay BioBriefs en 2026-02-27T16:33:23Z Caris Detect interim: MCED assay posts high specificity, stage‑linked sensitivity https://biobriefs.com/rezatapopt-nejm-p53-reactivation-shows BioBriefs en 2026-02-27T16:33:23Z Rezatapopt NEJM: p53 reactivation shows activity in TP53 Y220C tumors https://biobriefs.com/ginkgo-divests-biosecurity-arm-as BioBriefs en 2026-02-27T16:33:23Z Ginkgo divests biosecurity arm as Q4 revenue drops 24% https://biobriefs.com/doj-asks-scotus-to-revive BioBriefs en 2026-02-27T16:33:23Z DOJ asks SCOTUS to revive generic pathway: solicitor general backs Hikma https://biobriefs.com/sequencing-showdown-roches-150-genome BioBriefs en 2026-02-27T16:33:23Z Sequencing showdown: Roche’s $150 genome vs Ultima’s UG200 throughput leap https://biobriefs.com/ultra-sensitive-car-t-hit BioBriefs en 2026-02-27T16:33:23Z Ultra‑sensitive CAR‑T (HIT cells): preclinical eradication of multiple solid tumors https://biobriefs.com/ctdna-momentum-natera-eyes-medicare BioBriefs en 2026-02-27T16:33:23Z ctDNA momentum: Natera eyes Medicare wins as tumor‑informed tests scale https://biobriefs.com/mutant-p53-reactivation-shows-clinical BioBriefs en 2026-02-27T14:33:45Z Mutant p53 reactivation shows clinical responses – NEJM phase I https://biobriefs.com/ultra-sensitive-car-t-and BioBriefs en 2026-02-27T14:33:45Z Ultra‑sensitive CAR‑T and checkpoint edits push into solid tumors https://biobriefs.com/earendil-inks-885m-deal-with BioBriefs en 2026-02-27T14:33:45Z Earendil inks $885M deal with WuXi XDC for next‑gen ADC tech https://biobriefs.com/novo-nordisk-bets-up-to BioBriefs en 2026-02-27T14:33:45Z Novo Nordisk bets up to $2.1B on Vivtex oral biologics push https://biobriefs.com/generate-prices-400m-ipo-ai BioBriefs en 2026-02-27T14:33:45Z Generate prices $400M IPO – AI drug discovery raises fresh capital https://biobriefs.com/natera-targets-expanded-mrd-reimbursement BioBriefs en 2026-02-27T14:33:45Z Natera targets expanded MRD reimbursement — MolDx submissions drive 2026 outlook https://biobriefs.com/lex-diagnostics-commercializes-10-minute BioBriefs en 2026-02-27T14:33:45Z Lex Diagnostics commercializes 10‑minute point‑of‑care qPCR https://biobriefs.com/roche-reveals-axelios-details-150 BioBriefs en 2026-02-27T14:33:45Z Roche reveals Axelios details — $150 human genome claim at AGBT https://biobriefs.com/astellas-and-vir-sign-up BioBriefs en 2026-02-27T14:33:45Z Astellas and Vir sign up‑to‑$1.7B deal for masked PSMA T‑cell engager https://biobriefs.com/fda-drafts-plausible-mechanism-fast BioBriefs en 2026-02-27T14:33:45Z FDA drafts 'plausible mechanism' fast‑track for ultra‑rare personalized drugs https://biobriefs.com/generate-prices-400m-ipo-nasdaq BioBriefs en 2026-02-27T10:33:27Z Generate prices $400M IPO — Nasdaq debut tops biotech listings https://biobriefs.com/novo-nordisk-bets-2-1b BioBriefs en 2026-02-27T10:33:27Z Novo Nordisk bets $2.1B on oral biologics: Vivtex pact https://biobriefs.com/mutant-p53-reactivation-shows-clinical BioBriefs en 2026-02-27T10:33:27Z Mutant p53 reactivation shows clinical activity — NEJM phase I results https://biobriefs.com/fda-uses-national-priority-voucher BioBriefs en 2026-02-27T10:33:27Z FDA uses national‑priority voucher — Boehringer gets first‑line lung label https://biobriefs.com/two-car-t-moves-narrow BioBriefs en 2026-02-27T10:33:27Z Two CAR‑T moves narrow the gap to solid tumors: checkpoint deletion and ultra‑sensitive receptors https://biobriefs.com/gut-microbes-reshape-cancer-therapy BioBriefs en 2026-02-27T10:33:27Z Gut microbes reshape cancer therapy — mechanistic link and new microbiome metric https://biobriefs.com/breezebio-lands-60m-to-convert BioBriefs en 2026-02-27T10:33:27Z BreezeBio lands $60M to convert delivery tech into internal mRNA pipeline https://biobriefs.com/fda-floats-rapid-pathways-for BioBriefs en 2026-02-27T10:33:27Z FDA floats rapid pathways for rare and ultra‑rare therapies https://biobriefs.com/sequencing-price-and-throughput-battle BioBriefs en 2026-02-27T10:33:27Z Sequencing price and throughput battle heats up: Roche’s $150 genome vs Ultima’s UG200 https://biobriefs.com/astellas-vir-tie-up-on BioBriefs en 2026-02-27T10:33:27Z Astellas, Vir tie up on masked TCE — up to $1.7B for prostate program https://biobriefs.com/novo-nordisk-commits-2-1b BioBriefs en 2026-02-27T09:34:00Z Novo Nordisk Commits $2.1B to Oral Biologics – Vivtex Deal https://biobriefs.com/sequencing-price-war-roches-150 BioBriefs en 2026-02-27T09:34:00Z Sequencing Price War: Roche’s $150 Genome and Ultima’s UG200 Launch https://biobriefs.com/mutant-p53-reactivation-shows-clinical BioBriefs en 2026-02-27T09:34:00Z Mutant p53 Reactivation Shows Clinical Activity – Rezatapopt in NEJM https://biobriefs.com/car-t-reboot-nr2f6-deletion BioBriefs en 2026-02-27T09:34:00Z CAR‑T Reboot: NR2F6 Deletion and Ultra‑Sensitive Cells Target Solids https://biobriefs.com/gsk-expands-pulmonary-and-rna BioBriefs en 2026-02-27T09:34:00Z GSK Expands Pulmonary and RNA Plays: 35Pharma Buy and Frontier siRNA Deal https://biobriefs.com/asahi-kasei-buys-aicuris-for BioBriefs en 2026-02-27T09:34:00Z Asahi Kasei Buys Aicuris for $920M to Bulk Up Antiviral R&D https://biobriefs.com/fda-proposes-plausible-mechanism-and BioBriefs en 2026-02-27T09:34:00Z FDA Proposes 'Plausible Mechanism' and Ultra‑Rare Frameworks — Faster Paths https://biobriefs.com/fda-under-fire-senators-and BioBriefs en 2026-02-27T09:34:00Z FDA Under Fire: Senators and Advocates Challenge Rare‑Disease Rejections https://biobriefs.com/breezebio-shifts-to-internal-pipeline BioBriefs en 2026-02-27T09:34:00Z BreezeBio Shifts to Internal Pipeline After $60M Raise https://biobriefs.com/lex-diagnostics-starts-commercialization-of BioBriefs en 2026-02-27T09:34:00Z Lex Diagnostics Starts Commercialization of 10‑Minute POC qPCR https://biobriefs.com/p53-pocket-drug-rezatapopt-yields BioBriefs en 2026-02-27T04:33:32Z p53 pocket drug rezatapopt yields responses in Y220C tumors — NEJM https://biobriefs.com/fda-voucher-speeds-boehringer-label BioBriefs en 2026-02-27T04:33:32Z FDA voucher speeds Boehringer label expansion for HER2 lung cancer https://biobriefs.com/novo-nordisk-inks-up-to BioBriefs en 2026-02-27T04:33:32Z Novo Nordisk inks up-to-$2.1B deal to get Vivtex oral biologics tech https://biobriefs.com/astellas-to-co-develop-virs BioBriefs en 2026-02-27T04:33:32Z Astellas to co‑develop Vir’s masked T‑cell engager for prostate cancer — $1.7B https://biobriefs.com/gsk-pays-950m-for-35pharma BioBriefs en 2026-02-27T04:33:32Z GSK pays $950M for 35Pharma and its PAH candidate HS235 https://biobriefs.com/senate-hearing-and-patient-outcry BioBriefs en 2026-02-27T04:33:32Z Senate hearing and patient outcry spotlight FDA rare‑disease review tensions https://biobriefs.com/ultra-sensitive-car-t-designs BioBriefs en 2026-02-27T04:33:32Z Ultra‑sensitive CAR‑T designs and novel cell therapies push into solid tumors... https://biobriefs.com/tumor-informed-ctdna-predicts-recurrence BioBriefs en 2026-02-27T04:33:32Z Tumor‑informed ctDNA predicts recurrence and survival in anal cancer — Nature Commun. https://biobriefs.com/sequencing-arms-race-roche-reveals BioBriefs en 2026-02-27T04:33:32Z Sequencing arms race: Roche reveals $150 genome for Axelios; Ultima launches UG200 https://biobriefs.com/city-therapeutics-pursues-cityrna-delivery BioBriefs en 2026-02-27T04:33:32Z City Therapeutics pursues cityRNA delivery; BreezeBio raises $60M for mRNA diabetes https://biobriefs.com/novo-inks-potential-2-1b BioBriefs en 2026-02-26T21:32:49Z Novo inks potential $2.1B pact with Vivtex: oral biologics push https://biobriefs.com/gsk-to-buy-35pharma-for BioBriefs en 2026-02-26T21:32:49Z GSK to buy 35Pharma for $950M: HS235 joins pipeline https://biobriefs.com/asahi-kasei-pays-920m-for BioBriefs en 2026-02-26T21:32:49Z Asahi Kasei pays $920M for Aicuris: bolsters antiviral portfolio https://biobriefs.com/ultima-launches-ug200-series-automation BioBriefs en 2026-02-26T21:32:49Z Ultima launches UG200 series – automation deal with Hamilton https://biobriefs.com/roche-pegs-axelios-at-150 BioBriefs en 2026-02-26T21:32:49Z Roche pegs Axelios at $150 a genome: sequencing price war heats https://biobriefs.com/illumina-launches-trupath-genome-set BioBriefs en 2026-02-26T21:32:49Z Illumina launches TruPath genome set – PacBio face‑off https://biobriefs.com/senate-hearing-fda-slammed-over BioBriefs en 2026-02-26T21:32:49Z Senate hearing: FDA slammed over rare disease reviews https://biobriefs.com/lillys-oral-glp-1-outperforms BioBriefs en 2026-02-26T21:32:49Z Lilly’s oral GLP‑1 outperforms Novo in head‑to‑head trials – side‑effect tradeoffs https://biobriefs.com/tumor-informed-ctdna-flags-anal BioBriefs en 2026-02-26T21:32:49Z Tumor‑informed ctDNA flags anal cancer recurrence: Nature Communications https://biobriefs.com/lex-starts-commercialization-of-velo BioBriefs en 2026-02-26T21:32:49Z Lex starts commercialization of Velo: FDA‑cleared 10‑minute POC qPCR https://biobriefs.com/ultima-genomics-launches-ug200-series BioBriefs en 2026-02-26T16:33:32Z Ultima Genomics Launches UG200 Series: Solaris 2.0 Promises Faster, Cheaper Sequencing https://biobriefs.com/spt-labtech-illumina-partner-automated BioBriefs en 2026-02-26T16:33:32Z SPT Labtech, Illumina Partner: Automated MiSeq i100 Prep for Decentralized Genomics https://biobriefs.com/lex-diagnostics-commercializes-velo-fda BioBriefs en 2026-02-26T16:33:32Z Lex Diagnostics Commercializes Velo: FDA‑Cleared 10‑Minute qPCR Hits Market https://biobriefs.com/novo-nordisk-stakes-up-to BioBriefs en 2026-02-26T16:33:32Z Novo Nordisk Stakes up to $2.1B on Vivtex Tech for Oral Biologics https://biobriefs.com/gsk-buys-35pharma-for-950m BioBriefs en 2026-02-26T16:33:32Z GSK Buys 35Pharma for $950M — Adds HS‑235 Pulmonary Hypertension Asset https://biobriefs.com/astellas-and-vir-ink-partnership BioBriefs en 2026-02-26T16:33:32Z Astellas and Vir Ink Partnership on Masked PSMA T‑Cell Engager — Deal Tops $1.7B https://biobriefs.com/fda-unveils-ultra-rare-therapy BioBriefs en 2026-02-26T16:33:32Z FDA Unveils Ultra‑Rare Therapy Framework — Makary Defends Recent Rare‑Drug Rejections https://biobriefs.com/laser-ablation-plus-pembrolizumab-shows BioBriefs en 2026-02-26T16:33:32Z Laser Ablation Plus Pembrolizumab Shows Promise in Recurrent High‑Grade Astrocytoma https://biobriefs.com/beam-advances-beam-304-base BioBriefs en 2026-02-26T16:33:32Z Beam Advances BEAM‑304 Base Editing Program for PKU — IND Planned in 2026 https://biobriefs.com/protagonist-opts-for-400m-cash BioBriefs en 2026-02-26T16:33:32Z Protagonist Opts for $400M Cash Over Profit‑Share with Takeda on Rusfertide https://biobriefs.com/vir-astellas-ink-up-to BioBriefs en 2026-02-26T14:32:56Z Vir, Astellas ink up-to-$1.7B PSMA T‑cell engager pact: Co‑develop and co‑commercialize VIR‑5500 https://biobriefs.com/gsk-pays-950m-for-35pharma BioBriefs en 2026-02-26T14:32:56Z GSK pays $950M for 35Pharma — buys a pulmonary‑hypertension challenger https://biobriefs.com/fda-backtracks-immedicas-loargys-accelerated BioBriefs en 2026-02-26T14:32:56Z FDA backtracks: Immedica’s Loargys accelerated to patients after earlier rejection https://biobriefs.com/fda-outlines-personalized-path-for BioBriefs en 2026-02-26T14:32:56Z FDA outlines personalized path for ultra‑rare therapies: Plausible mechanism draft guidance https://biobriefs.com/novo-picks-vivtex-for-oral BioBriefs en 2026-02-26T14:32:56Z Novo picks Vivtex for oral biologics push — potential $2.1B collaboration https://biobriefs.com/beam-expands-gene-editing-and BioBriefs en 2026-02-26T14:32:56Z Beam expands gene editing and secures strategic license deals — PKU program advances https://biobriefs.com/novo-cuts-glp-1-list BioBriefs en 2026-02-26T14:32:56Z Novo cuts GLP‑1 list prices amid competitive pressure and new data https://biobriefs.com/pacbio-and-dnastack-launch-federated BioBriefs en 2026-02-26T14:32:56Z PacBio and DNAstack launch federated HiFi platform for global rare‑disease genomics https://biobriefs.com/slate-medicines-raises-130m-to BioBriefs en 2026-02-26T14:32:56Z Slate Medicines raises $130M to advance anti‑PACAP migraine antibody https://biobriefs.com/ultima-genomics-taps-hamilton-to BioBriefs en 2026-02-26T14:32:56Z Ultima Genomics taps Hamilton to automate high‑throughput sequencing workflows https://biobriefs.com/novo-nordisk-doubles-down-on BioBriefs en 2026-02-26T10:33:40Z Novo Nordisk doubles down on oral biologics: $2.1B Vivtex pact https://biobriefs.com/astellas-and-vir-team-on BioBriefs en 2026-02-26T10:33:40Z Astellas and Vir team on masked T‑cell engager: up to $1.7B https://biobriefs.com/gsk-pays-950m-for-35pharma BioBriefs en 2026-02-26T10:33:40Z GSK pays $950M for 35Pharma – adds PAH candidate HS‑235 https://biobriefs.com/scale-breakthrough-220000-variants-mapped BioBriefs en 2026-02-26T10:33:40Z Scale breakthrough: 220,000 variants mapped to cell function https://biobriefs.com/fda-reverses-course-approves-immedicas BioBriefs en 2026-02-26T10:33:40Z FDA reverses course: approves Immedica’s Loargys for ARG1‑D https://biobriefs.com/pfizer-secures-beam-liver-editor BioBriefs en 2026-02-26T10:33:40Z Pfizer secures Beam liver editor; Beam advances PKU base‑editing program https://biobriefs.com/arpa-h-backs-anti-aging BioBriefs en 2026-02-26T10:33:40Z ARPA‑H backs anti‑aging research: $144M program and $38M grant https://biobriefs.com/pharma-builds-federated-admet-network BioBriefs en 2026-02-26T10:33:40Z Pharma builds federated ADMET network; AI tools gain capital https://biobriefs.com/polymer-proteomimetics-degrade-undruggable-myc BioBriefs en 2026-02-26T10:33:40Z Polymer proteomimetics degrade ‘undruggable’ MYC and KRAS https://biobriefs.com/fda-halts-macrogenics-enrollment-after BioBriefs en 2026-02-26T10:33:40Z FDA halts MacroGenics enrollment after treatment‑related fatality https://biobriefs.com/astellas-vir-strike-big-masked BioBriefs en 2026-02-26T09:33:20Z Astellas, Vir Strike Big: Masked T‑Cell Engager Deal https://biobriefs.com/fda-reverses-course-immedicas-arg1 BioBriefs en 2026-02-26T09:33:20Z FDA Reverses Course: Immedica’s ARG1‑D Drug Clears Accelerated Approval https://biobriefs.com/gsk-pays-950m-for-35pharma BioBriefs en 2026-02-26T09:33:20Z GSK Pays $950M for 35Pharma — Adds PAH Candidate HS‑235 https://biobriefs.com/novo-vivtex-tie-up-big BioBriefs en 2026-02-26T09:33:20Z Novo, Vivtex Tie Up: Big Bet on Oral Biologics https://biobriefs.com/novo-cuts-prices-posts-competitive BioBriefs en 2026-02-26T09:33:20Z Novo Cuts Prices, Posts Competitive Triple‑G Data — Market Repositions https://biobriefs.com/beam-advances-liver-base-editing BioBriefs en 2026-02-26T09:33:20Z Beam Advances Liver Base Editing for PKU; Pfizer Secures License Rights https://biobriefs.com/safety-signal-macrogenics-trial-halted BioBriefs en 2026-02-26T09:33:20Z Safety Signal: MacroGenics Trial Halted After Patient Death https://biobriefs.com/massive-mpra-study-links-220k BioBriefs en 2026-02-26T09:33:20Z Massive MPRA Study Links 220K Variants to Cellular Function https://biobriefs.com/proteomimetic-polymers-target-undruggable-oncogenes BioBriefs en 2026-02-26T09:33:20Z Proteomimetic Polymers Target 'Undruggable' Oncogenes for Degradation https://biobriefs.com/ultra-fast-poc-qpcr-and BioBriefs en 2026-02-26T09:33:20Z Ultra‑Fast POC qPCR and Automation Partnerships Scale Molecular Testing https://biobriefs.com/vir-astellas-link-on-masked BioBriefs en 2026-02-26T04:33:10Z Vir, Astellas Link on Masked T‑Cell Engager – Up to $1.7B Deal https://biobriefs.com/novo-invests-2-1b-in BioBriefs en 2026-02-26T04:33:10Z Novo Invests $2.1B in Vivtex—Push for Oral Biologics https://biobriefs.com/gsk-buys-35pharma-950m-for BioBriefs en 2026-02-26T04:33:10Z GSK Buys 35Pharma — $950M for HS‑235 in Pulmonary Hypertension https://biobriefs.com/fda-freezes-macrogenics-trial-after BioBriefs en 2026-02-26T04:33:10Z FDA Freezes MacroGenics Trial After Severe Toxicity https://biobriefs.com/beam-launches-liver-targeted-base BioBriefs en 2026-02-26T04:33:10Z Beam Launches Liver‑Targeted Base Editing Program for PKU https://biobriefs.com/northwestern-creates-proteomimetic-polymers-to BioBriefs en 2026-02-26T04:33:10Z Northwestern Creates Proteomimetic Polymers to Degrade MYC and KRAS https://biobriefs.com/sequencing-scale-up-ultima-hamilton BioBriefs en 2026-02-26T04:33:10Z Sequencing Scale‑Up: Ultima, Hamilton and SPT‑Illumina Automation Deals https://biobriefs.com/arpa-h-commits-anti-aging BioBriefs en 2026-02-26T04:33:10Z ARPA‑H Commits Anti‑Aging Funds; Barshop Nets $38M to Lead Research https://biobriefs.com/cifi-long-read-hi-c BioBriefs en 2026-02-26T04:33:10Z CiFi Long‑Read Hi‑C and Global HiFi Data Network Accelerate Genomics https://biobriefs.com/gut-microbiome-shapes-pd-1 BioBriefs en 2026-02-26T04:33:10Z Gut Microbiome Shapes PD‑1 Response — Bial Prize Goes to Microbiome Study https://biobriefs.com/novo-vivtex-pact-2-1b BioBriefs en 2026-02-25T21:32:34Z Novo, Vivtex pact: $2.1B push to make oral biologics real https://biobriefs.com/gsk-shells-out-950m-for BioBriefs en 2026-02-25T21:32:34Z GSK shells out $950m for 35Pharma’s pulmonary hypertension asset https://biobriefs.com/gsk-inks-up-to-1b BioBriefs en 2026-02-25T21:32:34Z GSK inks up to $1B siRNA pact with Frontier Biotechnologies https://biobriefs.com/gilead-merck-race-on-new BioBriefs en 2026-02-25T21:32:34Z Gilead, Merck race on new daily HIV pills — weekly candidate also eyed https://biobriefs.com/pharma-joins-federated-ai-for BioBriefs en 2026-02-25T21:32:34Z Pharma joins federated AI for ADMET: Apheris launches ADMET Network https://biobriefs.com/samsung-biologics-signs-with-cepi BioBriefs en 2026-02-25T21:32:34Z Samsung Biologics signs with CEPI to prep rapid vaccine surge capacity https://biobriefs.com/gilead-doubles-down-on-cell BioBriefs en 2026-02-25T21:32:34Z Gilead doubles down on cell therapy — Arcellx takeover seen as strategic play https://biobriefs.com/pfizer-secures-global-rights-to BioBriefs en 2026-02-25T21:32:34Z Pfizer secures global rights to Beam’s liver base‑editing candidate https://biobriefs.com/cell-free-csf-proteomics-yields BioBriefs en 2026-02-25T21:32:34Z Cell‑free CSF proteomics yields 22‑protein MS marker panel in Cell https://biobriefs.com/proteomimetic-polymers-degrade-myc-and BioBriefs en 2026-02-25T21:32:34Z Proteomimetic polymers degrade MYC and KRAS — new route to 'undruggable' targets https://biobriefs.com/gilead-buys-arcellx-7-8b BioBriefs en 2026-02-25T16:33:57Z Gilead buys Arcellx: $7.8B deal to own anito‑cel https://biobriefs.com/beam-targets-pku-with-base BioBriefs en 2026-02-25T16:33:57Z Beam targets PKU with base editing – Pfizer secures liver rights https://biobriefs.com/novo-slashes-glp-1-prices BioBriefs en 2026-02-25T16:33:57Z Novo slashes GLP‑1 prices: $675 list, touts near‑20% triple‑G data https://biobriefs.com/gsk-shells-out-950m-buys BioBriefs en 2026-02-25T16:33:57Z GSK shells out $950M: buys 35Pharma to add HS235 for pulmonary hypertension https://biobriefs.com/arpa-h-awards-38m-utsas BioBriefs en 2026-02-25T16:33:57Z ARPA‑H awards $38M: UTSA’s Barshop named national aging hub https://biobriefs.com/fda-pivots-single-pivotal-trial BioBriefs en 2026-02-25T16:33:57Z FDA pivots: single pivotal trial plus evidence now acceptable https://biobriefs.com/fda-halts-macrogenics-trial-after BioBriefs en 2026-02-25T16:33:57Z FDA halts MacroGenics trial after patient death – enrollment frozen https://biobriefs.com/breezebio-raises-60m-polymer-nanoparticles BioBriefs en 2026-02-25T16:33:57Z BreezeBio raises $60M: polymer nanoparticles to carry mRNA diabetes program https://biobriefs.com/pacbio-dnastack-launch-federated-hifi BioBriefs en 2026-02-25T16:33:57Z PacBio, DNAstack launch federated HiFi data hub for rare disease https://biobriefs.com/fda-approves-loargys-for-arg1 BioBriefs en 2026-02-25T16:33:57Z FDA approves Loargys for ARG1‑D: accelerated nod for ultrarare disorder https://biobriefs.com/gilead-buys-arcellx-for-7 BioBriefs en 2026-02-25T14:33:30Z Gilead buys Arcellx for $7.8B—takes full control of anito‑cel https://biobriefs.com/novo-nordisk-inks-vivtex-pact BioBriefs en 2026-02-25T14:33:30Z Novo Nordisk inks Vivtex pact—slashes GLP‑1 list prices https://biobriefs.com/fda-ends-two-trial-dogma BioBriefs en 2026-02-25T14:33:30Z FDA ends two‑trial dogma: single well‑controlled trial may suffice https://biobriefs.com/gsk-buys-pulmonary-asset-doubles BioBriefs en 2026-02-25T14:33:30Z GSK buys pulmonary asset, doubles down on oligos—$950M and $1B bets https://biobriefs.com/beam-launches-beam-304-for BioBriefs en 2026-02-25T14:33:30Z Beam launches BEAM‑304 for PKU—base editors aim to correct PAH mutations https://biobriefs.com/breezebio-raises-60m-retools-delivery BioBriefs en 2026-02-25T14:33:30Z BreezeBio raises $60M—retools delivery for mRNA diabetes and T1D tolerance work https://biobriefs.com/caredx-moves-into-cell-therapy BioBriefs en 2026-02-25T14:33:30Z CareDx moves into cell‑therapy surveillance—AlloHeme predicts relapse signals https://biobriefs.com/pacbio-dnastack-federate-hifi-genomes BioBriefs en 2026-02-25T14:33:30Z PacBio, DNAstack federate HiFi genomes—global rare‑disease data sharing https://biobriefs.com/northwestern-reveals-hydrac-polymers-targets BioBriefs en 2026-02-25T14:33:30Z Northwestern reveals HYDRAC polymers—targets MYC and KRAS for degradation https://biobriefs.com/fda-freezes-macrogenics-trial-after BioBriefs en 2026-02-25T14:33:30Z FDA freezes MacroGenics trial after fatal event—enrollment halted https://biobriefs.com/gilead-agrees-7-8b-buyout BioBriefs en 2026-02-25T10:33:09Z Gilead agrees $7.8B buyout of Arcellx – Anito‑cel in focus https://biobriefs.com/novo-halves-glp-1-list BioBriefs en 2026-02-25T10:33:09Z Novo halves GLP‑1 list price for 2027 – Pricing and program shakeup https://biobriefs.com/fda-reverses-two-trial-dogma BioBriefs en 2026-02-25T10:33:09Z FDA reverses two‑trial dogma: single pivotal study now viable https://biobriefs.com/gsk-to-buy-35pharma-for BioBriefs en 2026-02-25T10:33:09Z GSK to buy 35Pharma for $950M – Pulmonary hypertension pick‑up https://biobriefs.com/beam-launches-beam-304-base BioBriefs en 2026-02-25T10:33:09Z Beam launches BEAM‑304 base edit program for PKU – Backed by $500M deal https://biobriefs.com/astellas-vir-ink-1-3b BioBriefs en 2026-02-25T10:33:09Z Astellas, Vir ink $1.3B pact for masked CD3 engager – Oncology push https://biobriefs.com/fda-halts-macrogenics-trial-after BioBriefs en 2026-02-25T10:33:09Z FDA halts MacroGenics trial after death – Safety probe underway https://biobriefs.com/new-polymers-target-undruggable-myc BioBriefs en 2026-02-25T10:33:09Z New polymers target 'undruggable' MYC and KRAS – Proteomimetic degraders https://biobriefs.com/caredx-pivots-to-cell-therapy BioBriefs en 2026-02-25T10:33:09Z CareDx pivots to cell‑therapy surveillance — LCD draft poses headwind https://biobriefs.com/fda-resurrects-loargys-for-arg1 BioBriefs en 2026-02-25T10:33:09Z FDA resurrects Loargys for ARG1‑D – Accelerated approval granted https://biobriefs.com/gilead-buys-arcellx-for-7 BioBriefs en 2026-02-25T09:33:50Z Gilead buys Arcellx for $7.8B – doubles down on CAR‑T https://biobriefs.com/novos-next-gen-stumble-cagrisema BioBriefs en 2026-02-25T09:33:50Z Novo’s next‑gen stumble: CagriSema falls short – price cuts follow https://biobriefs.com/fda-pivots-single-pivotal-trials BioBriefs en 2026-02-25T09:33:50Z FDA pivots: single pivotal trials and bespoke therapies gain runway https://biobriefs.com/beam-launches-pku-base-editing BioBriefs en 2026-02-25T09:33:50Z Beam launches PKU base‑editing program – $500M financing pact in tow https://biobriefs.com/astellas-pays-up-1-3b BioBriefs en 2026-02-25T09:33:50Z Astellas pays up — $1.3B pact with Vir for masked CD3 T‑cell engager https://biobriefs.com/caredx-pivots-to-cell-therapy BioBriefs en 2026-02-25T09:33:50Z CareDx pivots to cell‑therapy surveillance – validation data in hand https://biobriefs.com/gossamers-phase-iii-miss-sends BioBriefs en 2026-02-25T09:33:50Z Gossamer’s Phase III miss sends stock tumbling – program under review https://biobriefs.com/new-polymers-degrade-undruggable-myc BioBriefs en 2026-02-25T09:33:50Z New polymers degrade ‘undruggable’ MYC and KRAS – HYDRACs show preclinical activity https://biobriefs.com/flagships-generate-eyes-blockbuster-ipo BioBriefs en 2026-02-25T09:33:50Z Flagship’s Generate eyes blockbuster IPO — platform play in public markets https://biobriefs.com/pharma-groups-ready-legal-fight BioBriefs en 2026-02-25T09:33:50Z Pharma groups ready legal fight over CMS pricing demos — industry aligns https://biobriefs.com/gilead-snaps-up-arcellx-for BioBriefs en 2026-02-25T04:32:46Z Gilead snaps up Arcellx for $7.8B – Bets on CAR‑T lead https://biobriefs.com/novos-next-gen-miss-and BioBriefs en 2026-02-25T04:32:46Z Novo’s next‑gen miss and price cuts reshape obesity market https://biobriefs.com/fda-unveils-bespoke-therapy-pathway BioBriefs en 2026-02-25T04:32:46Z FDA unveils bespoke therapy pathway: plausible‑mechanism draft https://biobriefs.com/beam-expands-base-editing-to BioBriefs en 2026-02-25T04:32:46Z Beam expands base editing to PKU – BEAM‑304 enters IND path https://biobriefs.com/northwestern-engineers-polymers-to-degrade BioBriefs en 2026-02-25T04:32:46Z Northwestern engineers polymers to degrade MYC and KRAS… https://biobriefs.com/astellas-pays-up-to-1 BioBriefs en 2026-02-25T04:32:46Z Astellas pays up to $1.3B for Vir’s masked CD3 engager https://biobriefs.com/generate-targets-big-ipo-to BioBriefs en 2026-02-25T04:32:46Z Generate targets big IPO to fund antibody trials – $425M on deck https://biobriefs.com/fda-halts-macrogenics-enrollment-after BioBriefs en 2026-02-25T04:32:46Z FDA halts MacroGenics enrollment after fatal toxicity event https://biobriefs.com/gsk-inks-sirna-pact-with BioBriefs en 2026-02-25T04:32:46Z GSK inks siRNA pact with Frontier – $1B potential to expand oligo reach https://biobriefs.com/merck-splits-oncology-into-standalone BioBriefs en 2026-02-25T04:32:46Z Merck splits oncology into standalone unit – Strategy for post‑Keytruda era https://biobriefs.com/gilead-inks-7-8b-buyout BioBriefs en 2026-02-24T21:33:03Z Gilead inks $7.8B buyout: Takes full control of CAR‑T https://biobriefs.com/fda-shifts-to-single-trial BioBriefs en 2026-02-24T21:33:03Z FDA shifts to single‑trial approvals: 'Two‑trial dogma' ends https://biobriefs.com/novo-cuts-list-prices-cagrisema BioBriefs en 2026-02-24T21:33:03Z Novo cuts list prices — CagriSema falls short vs Lilly https://biobriefs.com/astellas-vir-pact-1-3b BioBriefs en 2026-02-24T21:33:03Z Astellas‑Vir pact: $1.3B for masked CD3 prostate engager https://biobriefs.com/beam-launches-pku-base-editing BioBriefs en 2026-02-24T21:33:03Z Beam launches PKU base‑editing push — $500M financing attached https://biobriefs.com/fda-halts-macrogenics-trial-safety BioBriefs en 2026-02-24T21:33:03Z FDA halts MacroGenics trial: Safety probe after patient death https://biobriefs.com/madrigal-buys-sirna-assets-in BioBriefs en 2026-02-24T21:33:03Z Madrigal buys siRNA assets in $4.4B Ribo deal https://biobriefs.com/generate-eyes-up-to-425m BioBriefs en 2026-02-24T21:33:03Z Generate eyes up to $425M IPO: Platform funds antibody Phase‑3 https://biobriefs.com/slate-nets-130m-anti-pacap BioBriefs en 2026-02-24T21:33:03Z Slate nets $130M: Anti‑PACAP migraine program moves to clinic https://biobriefs.com/innovacell-lists-in-tokyo-y BioBriefs en 2026-02-24T21:33:03Z Innovacell lists in Tokyo: ¥14.16B IPO to back cell therapies https://biobriefs.com/gilead-to-buy-arcellx-for BioBriefs en 2026-02-24T16:33:11Z Gilead to buy Arcellx for $7.8B: Stakes on CAR‑T anito‑cel https://biobriefs.com/novos-cagrisema-falls-short-lillys BioBriefs en 2026-02-24T16:33:11Z Novo’s CagriSema falls short – Lilly’s Zepbound wins head‑to‑head https://biobriefs.com/fda-endorses-single-trial-approvals BioBriefs en 2026-02-24T16:33:11Z FDA endorses single‑trial approvals: Agency updates pivotal evidence standard https://biobriefs.com/fda-unveils-plausible-mechanism-draft BioBriefs en 2026-02-24T16:33:11Z FDA unveils plausible‑mechanism draft: Roadmap for individualized therapies https://biobriefs.com/gsk-bets-on-sirna-40m BioBriefs en 2026-02-24T16:33:11Z GSK bets on siRNA: $40M upfront, near‑$1B milestones from Frontier https://biobriefs.com/gilead-deepens-synthetic-lethality-push BioBriefs en 2026-02-24T16:33:11Z Gilead deepens synthetic‑lethality push... $1.53B Genhouse license https://biobriefs.com/madrigal-buys-six-sirna-preclinical BioBriefs en 2026-02-24T16:33:11Z Madrigal buys six siRNA preclinical programs in $4.4B Ribo pact https://biobriefs.com/harbour-spins-out-solstice-outlicenses BioBriefs en 2026-02-24T16:33:11Z Harbour spins out Solstice, outlicenses CTLA‑4 in $1.2B package https://biobriefs.com/biomarin-pulls-roctavian-off-market BioBriefs en 2026-02-24T16:33:11Z BioMarin pulls Roctavian off market after buyer search fails https://biobriefs.com/fda-grants-priority-review-to BioBriefs en 2026-02-24T16:33:11Z FDA grants priority review to Takeda’s oral narcolepsy drug – TAK‑681 https://biobriefs.com/gilead-to-buy-arcellx-7 BioBriefs en 2026-02-24T14:32:23Z Gilead to buy Arcellx: $7.8B takeover for CAR‑T play https://biobriefs.com/novos-obesity-gambit-falters-cagrisema BioBriefs en 2026-02-24T14:32:23Z Novo’s obesity gambit falters: CagriSema loses to Lilly https://biobriefs.com/fda-unveils-bespoke-therapy-rules BioBriefs en 2026-02-24T14:32:23Z FDA unveils bespoke‑therapy rules: plausible‑mechanism pathway detailed https://biobriefs.com/gsk-expands-sirna-footprint-1b BioBriefs en 2026-02-24T14:32:23Z GSK expands siRNA footprint: $1B‑plus deal with Frontier Biotech https://biobriefs.com/generate-biomedicines-plots-big-ipo BioBriefs en 2026-02-24T14:32:23Z Generate Biomedicines plots big IPO: cash to fund antibody trials https://biobriefs.com/guardant-buys-metasight-metabolomics-to BioBriefs en 2026-02-24T14:32:23Z Guardant buys MetaSight: metabolomics to boost Shield cancer test https://biobriefs.com/immedica-wins-fda-accelerated-approval BioBriefs en 2026-02-24T14:32:23Z Immedica wins FDA accelerated approval: ARG1‑D therapy revived https://biobriefs.com/slate-medicines-raises-130m-pacap BioBriefs en 2026-02-24T14:32:23Z Slate Medicines raises $130M: PACAP migraine program moves West https://biobriefs.com/turbine-closes-25m-series-b BioBriefs en 2026-02-24T14:32:23Z Turbine closes $25M Series B: Virtual Lab commercial push https://biobriefs.com/abcuros-klrg1-antibody-flunks-pivotal BioBriefs en 2026-02-24T14:32:23Z Abcuro’s KLRG1 antibody flunks pivotal trial – IBM goals missed https://biobriefs.com/gilead-bets-7-8b-on BioBriefs en 2026-02-24T10:33:02Z Gilead bets $7.8B on CAR‑T — Arcellx takeover https://biobriefs.com/fda-unveils-bespoke-therapy-road BioBriefs en 2026-02-24T10:33:02Z FDA unveils bespoke therapy road map: plausible‑mechanism draft https://biobriefs.com/merck-splits-oncology-reorg-ahead BioBriefs en 2026-02-24T10:33:02Z Merck splits oncology — reorg ahead of Keytruda cliff https://biobriefs.com/novos-cagrisema-falls-short-zepbound BioBriefs en 2026-02-24T10:33:02Z Novo’s CagriSema falls short — Zepbound wins head‑to‑head https://biobriefs.com/sequencing-arms-race-illumina-and BioBriefs en 2026-02-24T10:33:02Z Sequencing arms race... Illumina and Ultima upgrade platforms https://biobriefs.com/switchable-car-t-drug-control BioBriefs en 2026-02-24T10:33:02Z Switchable CAR‑T: drug control may curb toxicity https://biobriefs.com/generate-plans-425m-ipo-bankrolls BioBriefs en 2026-02-24T10:33:02Z Generate plans $425M IPO — bankrolls antibody phase‑3 asthma trials https://biobriefs.com/syndex-raises-15-5m-to BioBriefs en 2026-02-24T10:33:02Z Syndex raises $15.5M to scale methylation‑preserving PCR https://biobriefs.com/korsana-raises-175m-advances-brain BioBriefs en 2026-02-24T10:33:02Z Korsana raises $175M — advances brain‑penetrant Alzheimer’s program https://biobriefs.com/gossamers-pah-drug-fails-phase BioBriefs en 2026-02-24T10:33:02Z Gossamer’s PAH drug fails Phase 3 — shares collapse https://biobriefs.com/gilead-pays-7-8b-arcellx BioBriefs en 2026-02-24T09:33:01Z Gilead pays $7.8B — Arcellx deal brings anito‑cel in‑house https://biobriefs.com/fda-unveils-pathway-for-individualized BioBriefs en 2026-02-24T09:33:01Z FDA unveils pathway for individualized therapies: plausible‑mechanism guidance https://biobriefs.com/novos-cagrisema-falls-short-zepbound BioBriefs en 2026-02-24T09:33:01Z Novo’s CagriSema falls short — Zepbound wins head‑to‑head https://biobriefs.com/merck-splits-businesses-standalone-oncology BioBriefs en 2026-02-24T09:33:01Z Merck splits businesses — standalone oncology arm created ahead of Keytruda cliff https://biobriefs.com/sequencer-showdown-illumina-upgrades-novaseq BioBriefs en 2026-02-24T09:33:01Z Sequencer showdown: Illumina upgrades NovaSeq X — Ultima launches UG200 https://biobriefs.com/drug-switchable-car-t-drop BioBriefs en 2026-02-24T09:33:01Z Drug‑switchable CAR T: DROP‑CAR offers reversible control with venetoclax https://biobriefs.com/explainable-ai-spots-hidden-pancreatic BioBriefs en 2026-02-24T09:33:01Z Explainable AI spots hidden pancreatic traits linked to type‑2 diabetes https://biobriefs.com/syndex-raises-15-5m-mcpcr BioBriefs en 2026-02-24T09:33:01Z Syndex raises $15.5M — mcPCR to preserve methylation during amplification https://biobriefs.com/generate-files-for-ipo-425m BioBriefs en 2026-02-24T09:33:01Z Generate files for IPO — $425M to fund antibody phase‑3 trials https://biobriefs.com/gossamers-seralutinib-fails-phase-iii BioBriefs en 2026-02-24T09:33:01Z Gossamer’s seralutinib fails phase‑III — Prosera miss triggers sharp sell‑off https://biobriefs.com/gilead-to-buy-arcellx-for BioBriefs en 2026-02-24T04:32:45Z Gilead to buy Arcellx for $7.8B – bets company on BCMA CAR‑T anito‑cel https://biobriefs.com/novos-cagrisema-falls-short-in BioBriefs en 2026-02-24T04:32:45Z Novo’s CagriSema falls short in head‑to‑head vs Lilly’s Zepbound https://biobriefs.com/fda-unveils-plausible-mechanism-pathway BioBriefs en 2026-02-24T04:32:45Z FDA unveils plausible‑mechanism pathway: draft guidance for individualized therapies https://biobriefs.com/gossamers-phase-iii-miss-in BioBriefs en 2026-02-24T04:32:45Z Gossamer’s Phase III miss in PAH sends shares tumbling – seralutinib falls short https://biobriefs.com/merck-splits-oncology-into-standalone BioBriefs en 2026-02-24T04:32:45Z Merck splits oncology into standalone unit as Keytruda exclusivity approaches https://biobriefs.com/drug-controlled-car-t-cells BioBriefs en 2026-02-24T04:32:45Z Drug‑controlled CAR T cells: researchers build a venetoclax‑switchable CAR platform https://biobriefs.com/ai-maps-hidden-pancreatic-features BioBriefs en 2026-02-24T04:32:45Z AI maps hidden pancreatic features linked to type 2 diabetes https://biobriefs.com/syndex-bio-raises-15-5m BioBriefs en 2026-02-24T04:32:45Z Syndex Bio raises $15.5M to commercialize methylation‑preserving PCR https://biobriefs.com/mrna-encoded-nanobodies-curb-colorectal BioBriefs en 2026-02-24T04:32:45Z mRNA‑encoded nanobodies curb colorectal tumors in preclinical models https://biobriefs.com/illumina-upgrades-novaseq-x-promises BioBriefs en 2026-02-24T04:32:45Z Illumina upgrades NovaSeq X… promises higher throughput and Q50+ read quality https://biobriefs.com/gilead-to-buy-arcellx-for BioBriefs en 2026-02-23T21:33:06Z Gilead to buy Arcellx for $7.8B — bets on BCMA CAR‑T https://biobriefs.com/fda-drafts-plausible-mechanism-pathway BioBriefs en 2026-02-23T21:33:06Z FDA drafts plausible‑mechanism pathway for individualized therapies https://biobriefs.com/novos-cagrisema-falls-short-vs BioBriefs en 2026-02-23T21:33:06Z Novo’s CagriSema falls short vs Lilly’s Zepbound — Phase 3 head‑to‑head https://biobriefs.com/merck-splits-human-health-unit BioBriefs en 2026-02-23T21:33:06Z Merck splits human‑health unit: oncology becomes standalone https://biobriefs.com/sequencing-race-heats-up-illumina BioBriefs en 2026-02-23T21:33:06Z Sequencing race heats up: Illumina upgrades while Ultima unveils UG200 https://biobriefs.com/flagships-generate-eyes-big-ipo BioBriefs en 2026-02-23T21:33:06Z Flagship’s Generate eyes big IPO to fund antibody phase‑3 trials https://biobriefs.com/gossamers-pah-candidate-misses-phase BioBriefs en 2026-02-23T21:33:06Z Gossamer’s PAH candidate misses Phase 3 — trial failure sends shares tumbling https://biobriefs.com/syndex-raises-15-5m-to BioBriefs en 2026-02-23T21:33:06Z Syndex raises $15.5M to commercialize methyl‑preserving PCR for epigenetics https://biobriefs.com/korsana-pulls-in-175m-to BioBriefs en 2026-02-23T21:33:06Z Korsana pulls in $175M to advance brain‑penetrant Alzheimer antibody https://biobriefs.com/swiss-rockets-to-acquire-complete BioBriefs en 2026-02-23T21:33:06Z Swiss Rockets to acquire Complete Genomics — sheds Chinese ownership https://biobriefs.com/gilead-pays-7-8b-to BioBriefs en 2026-02-23T16:33:19Z Gilead pays $7.8B to buy Arcellx: Secures BCMA CAR‑T https://biobriefs.com/merck-splits-oncology-from-specialty BioBriefs en 2026-02-23T16:33:19Z Merck splits oncology from specialty unit – Keytruda cliff looms https://biobriefs.com/cagrisema-falls-short-lillys-zepbound BioBriefs en 2026-02-23T16:33:19Z CagriSema falls short: Lilly’s Zepbound wins head‑to‑head https://biobriefs.com/gossamers-pah-program-fails-clinical BioBriefs en 2026-02-23T16:33:19Z Gossamer’s PAH program fails — clinical miss and stock rout https://biobriefs.com/illumina-maps-novaseq-x-upgrades BioBriefs en 2026-02-23T16:33:19Z Illumina maps NovaSeq X upgrades — Ultima counters with UG200... https://biobriefs.com/syndex-raises-15-5m-seed BioBriefs en 2026-02-23T16:33:19Z Syndex raises $15.5M seed: mcPCR aims to boost methylation diagnostics https://biobriefs.com/candel-secures-two-pronged-200m BioBriefs en 2026-02-23T16:33:19Z Candel secures two‑pronged $200M financing to back prostate gene therapy https://biobriefs.com/moonlakes-il-17-nanobody-posts BioBriefs en 2026-02-23T16:33:19Z MoonLake’s IL‑17 nanobody posts Phase 2 win; company readies filing https://biobriefs.com/vanda-wins-fda-nod-for BioBriefs en 2026-02-23T16:33:19Z Vanda wins FDA nod for Bysanti — atypical antipsychotic cleared https://biobriefs.com/vc-shifts-to-late-stage BioBriefs en 2026-02-23T16:33:19Z VC shifts to late‑stage bets: PitchBook finds $33.8B in 2025 funding https://biobriefs.com/gilead-to-buy-arcellx-for BioBriefs en 2026-02-23T14:33:04Z Gilead to buy Arcellx for $7.8B — moves to control near‑approval CAR‑T https://biobriefs.com/fda-reopens-moderna-flu-vaccine BioBriefs en 2026-02-23T14:33:04Z FDA reopens Moderna flu‑vaccine review: PDUFA Aug. 5 set https://biobriefs.com/syndex-closes-15-5m-seed BioBriefs en 2026-02-23T14:33:04Z Syndex closes $15.5M seed to preserve methylation in PCR workflows https://biobriefs.com/ultima-genomics-launches-ug200-cheaper BioBriefs en 2026-02-23T14:33:04Z Ultima Genomics launches UG200: cheaper, faster high‑throughput sequencer https://biobriefs.com/complete-genomics-to-shift-from BioBriefs en 2026-02-23T14:33:04Z Complete Genomics to shift from Chinese parent—Swiss Rockets moves in https://biobriefs.com/korsana-raises-175m-to-advance BioBriefs en 2026-02-23T14:33:04Z Korsana raises $175M to advance brain‑penetrant Alzheimer’s antibodies https://biobriefs.com/moonlake-posts-phase-2-win BioBriefs en 2026-02-23T14:33:04Z MoonLake posts Phase 2 win for IL‑17 nanobody sonelokimab in axSpA https://biobriefs.com/lillys-zepbound-edges-novos-cagrisema BioBriefs en 2026-02-23T14:33:04Z Lilly’s Zepbound edges Novo’s CagriSema — head‑to‑head loss dents Novo shares https://biobriefs.com/forbion-sanofi-lead-75m-to BioBriefs en 2026-02-23T14:33:04Z Forbion, Sanofi lead $75M to push Altesa’s vapendavir into Phase IIb https://biobriefs.com/gossamers-pulmonary-arterial-hypertension-drug BioBriefs en 2026-02-23T14:33:04Z Gossamer’s pulmonary arterial hypertension drug misses Phase 3 — company still pursuing approval https://biobriefs.com/zepbound-tops-cagrisema-redefine-4 BioBriefs en 2026-02-23T10:33:02Z Zepbound tops CagriSema: REDEFINE 4 reshuffles obesity race https://biobriefs.com/fda-reopens-moderna-flu-review BioBriefs en 2026-02-23T10:33:02Z FDA reopens Moderna flu review: Type A meeting clears pathway https://biobriefs.com/isomorphic-labs-unveils-isodde-proprietary BioBriefs en 2026-02-23T10:33:02Z Isomorphic Labs unveils IsoDDE: proprietary AI ignites debate https://biobriefs.com/korsana-raises-175m-brain-penetrant BioBriefs en 2026-02-23T10:33:02Z Korsana raises $175M: brain‑penetrant antibody platform draws capital https://biobriefs.com/messy-lnps-deliver-better-single BioBriefs en 2026-02-23T10:33:02Z Messy LNPs deliver better: single‑particle study flips design rules https://biobriefs.com/forbion-and-sanofi-back-altesa BioBriefs en 2026-02-23T10:33:02Z Forbion and Sanofi back Altesa with $75M: vapendavir Phase IIb set to start https://biobriefs.com/moonlake-posts-mid-stage-arthritis BioBriefs en 2026-02-23T10:33:02Z MoonLake posts mid‑stage arthritis win: confidence ahead of FDA filing https://biobriefs.com/illuminare-1-lights-nerves-in BioBriefs en 2026-02-23T10:33:02Z Illuminare‑1 lights nerves in humans: Phase 1 shows rapid, sustained visualization https://biobriefs.com/electrical-readouts-for-organoids-new BioBriefs en 2026-02-23T10:33:02Z Electrical readouts for organoids: new probes aim to cut late‑stage failures https://biobriefs.com/eanm-launches-award-to-accelerate BioBriefs en 2026-02-23T10:33:02Z EANM launches award to accelerate alpha‑RLT research for prostate cancer https://biobriefs.com/korsana-biosciences-raises-175m-brain BioBriefs en 2026-02-23T09:33:47Z Korsana Biosciences Raises $175M – Brain‑penetrant Alzheimer’s Antibody Push https://biobriefs.com/fda-reverses-course-will-review BioBriefs en 2026-02-23T09:33:47Z FDA Reverses Course: Will Review Moderna’s Seasonal mRNA Flu Shot https://biobriefs.com/moonlake-discloses-mid-stage-arthritis BioBriefs en 2026-02-23T09:33:47Z MoonLake Discloses Mid‑Stage Arthritis Win... Confidence Ahead of FDA Filing https://biobriefs.com/fluorescent-nerve-agent-shows-early BioBriefs en 2026-02-23T09:33:47Z Fluorescent Nerve Agent Shows Early Safety – Phase 1 Signals Rapid Visualization https://biobriefs.com/isomorphics-isodde-stuns-scientists-proprietary BioBriefs en 2026-02-23T09:33:47Z Isomorphic’s IsoDDE Stuns Scientists – Proprietary Drug‑Discovery AI Unveiled https://biobriefs.com/disorganized-lnps-release-more-mrna BioBriefs en 2026-02-23T09:33:47Z Disorganized LNPs Release More mRNA – Single‑Particle Study Shows https://biobriefs.com/pdha1-drives-ferroptosis-resistance-in BioBriefs en 2026-02-23T09:33:47Z PDHA1 Drives Ferroptosis Resistance in Prostate Cancer – New Target Emerges https://biobriefs.com/focused-ultrasound-opens-blood-brain BioBriefs en 2026-02-23T09:33:47Z Focused Ultrasound Opens Blood‑Brain Barrier Safely – Tight‑junctions Reorganized https://biobriefs.com/intestinal-il-22-raises-glp BioBriefs en 2026-02-23T09:33:47Z Intestinal IL‑22 Raises GLP‑1 Levels – Improves Glucose Control in Mice https://biobriefs.com/eanm-launches-award-to-accelerate BioBriefs en 2026-02-23T09:33:47Z EANM Launches Award to Accelerate Alpha Radioligand Therapy Research https://biobriefs.com/fda-reopens-modernas-flu-file BioBriefs en 2026-02-23T04:32:45Z FDA reopens Moderna’s flu file: PDUFA date set for Aug. 5 https://biobriefs.com/korsana-secures-175m-to-push BioBriefs en 2026-02-23T04:32:45Z Korsana secures $175M to push brain-penetrant Alzheimer’s antibodies https://biobriefs.com/moonlake-posts-mid-stage-win BioBriefs en 2026-02-23T04:32:45Z MoonLake posts mid‑stage win, says FDA filing confidence growing https://biobriefs.com/first-in-human-nerve-visualization BioBriefs en 2026-02-23T04:32:45Z First‑in‑human nerve‑visualization agent shows rapid, sustained imaging https://biobriefs.com/lipid-nanoparticles-a-little-disorder BioBriefs en 2026-02-23T04:32:45Z Lipid nanoparticles: a little disorder improves delivery – new data https://biobriefs.com/isomorphics-isodde-wows-scientists-ai BioBriefs en 2026-02-23T04:32:45Z Isomorphic’s IsoDDE wows scientists – AI drug engine kept closed https://biobriefs.com/electrical-probes-bring-organoids-closer BioBriefs en 2026-02-23T04:32:45Z Electrical probes bring organoids closer to predictive drug screens https://biobriefs.com/gwas-expansion-links-140-loci BioBriefs en 2026-02-23T04:32:45Z GWAS expansion links 140 loci to age‑related hearing loss https://biobriefs.com/intestinal-il-22-increases-glp BioBriefs en 2026-02-23T04:32:45Z Intestinal IL‑22 increases GLP‑1: a new metabolic lever in mice https://biobriefs.com/pulsed-lasers-may-sharpen-cryo BioBriefs en 2026-02-23T04:32:45Z Pulsed lasers may sharpen cryo‑ET — sub‑picosecond timing for clearer images https://biobriefs.com/moderna-wins-fda-reprieve-agency BioBriefs en 2026-02-22T21:33:20Z Moderna wins FDA reprieve — agency agrees to review mRNA‑1010 https://biobriefs.com/deepmind-spin-off-keeps-next BioBriefs en 2026-02-22T21:33:20Z DeepMind spin‑off keeps next‑gen drug AI under wraps — scientists stunned https://biobriefs.com/korsana-pulls-in-175m-to BioBriefs en 2026-02-22T21:33:20Z Korsana pulls in $175M to advance BBB‑crossing Alzheimer’s drug https://biobriefs.com/moonlake-reports-mid-stage-win BioBriefs en 2026-02-22T21:33:20Z MoonLake reports mid‑stage win — confidence ahead of FDA submission https://biobriefs.com/disordered-lipid-nanoparticles-deliver-better BioBriefs en 2026-02-22T21:33:20Z Disordered lipid nanoparticles deliver better — studies challenge packing dogma https://biobriefs.com/focused-ultrasound-opens-bbb-via BioBriefs en 2026-02-22T21:33:20Z Focused ultrasound opens BBB via tight‑junction reorganization https://biobriefs.com/illuminare-1-lights-nerves-in BioBriefs en 2026-02-22T21:33:20Z Illuminare‑1 lights nerves in humans — Phase 1 shows rapid visualization https://biobriefs.com/fda-clears-vandas-bysanti-new BioBriefs en 2026-02-22T21:33:20Z FDA clears Vanda’s Bysanti — new label for schizophrenia and bipolar I episodes https://biobriefs.com/led-by-giroir-altesa-raises BioBriefs en 2026-02-22T21:33:20Z Led by Giroir: Altesa raises $75M to advance antiviral programs https://biobriefs.com/grape-lm-yields-rna-aptamers BioBriefs en 2026-02-22T21:33:20Z GRAPE‑LM yields RNA aptamers in a single round — faster evolution for therapeutics https://biobriefs.com/grails-galleri-stumbles-nhs-trial BioBriefs en 2026-02-22T16:32:54Z Grail’s Galleri stumbles: NHS trial misses primary endpoint, shares plunge https://biobriefs.com/fda-reverses-course-on-moderna BioBriefs en 2026-02-22T16:32:54Z FDA reverses course on Moderna flu shot – agency sets PDUFA date https://biobriefs.com/korsana-raises-175m-to-push BioBriefs en 2026-02-22T16:32:54Z Korsana raises $175M to push brain‑penetrant Alzheimer’s antibodies https://biobriefs.com/illuminares-fluorescent-nerve-agent-clears BioBriefs en 2026-02-22T16:32:54Z Illuminare’s fluorescent nerve agent clears Phase 1 – surgery visualization advances https://biobriefs.com/moonlake-posts-mid-stage-arthritis BioBriefs en 2026-02-22T16:32:54Z MoonLake posts mid‑stage arthritis win ahead of FDA filing https://biobriefs.com/altesa-raises-75m-series-b BioBriefs en 2026-02-22T16:32:54Z Altesa raises $75M series B led by former official Giroir https://biobriefs.com/japan-backs-two-ipsc-therapies BioBriefs en 2026-02-22T16:32:54Z Japan backs two iPSC therapies under conditional approval pathway https://biobriefs.com/bioversys-reports-clinical-proof-of BioBriefs en 2026-02-22T16:32:54Z Bioversys reports clinical proof‑of‑concept for TB combo in NEJM https://biobriefs.com/messy-lnps-deliver-better-new BioBriefs en 2026-02-22T16:32:54Z Messy LNPs deliver better: new data reshapes mRNA delivery assumptions https://biobriefs.com/bacterial-rnr-control-unraveled-new BioBriefs en 2026-02-22T16:32:54Z Bacterial RNR control unraveled – new target class for antimicrobials https://biobriefs.com/korsana-raises-175m-funds-brain BioBriefs en 2026-02-22T14:32:57Z Korsana raises $175M: Funds brain‑penetrant Alzheimer's antibody push https://biobriefs.com/illuminare-1-lights-nerves-phase BioBriefs en 2026-02-22T14:32:57Z Illuminare-1 lights nerves: Phase 1 shows rapid, sustained surgical visualization https://biobriefs.com/fda-resets-course-on-moderna BioBriefs en 2026-02-22T14:32:57Z FDA resets course on Moderna flu vaccine: Agency will review application https://biobriefs.com/grails-galleri-misses-primary-endpoint BioBriefs en 2026-02-22T14:32:57Z Grail’s Galleri misses primary endpoint – shares crater https://biobriefs.com/guardant-acquires-metasight-shield-screening BioBriefs en 2026-02-22T14:32:57Z Guardant acquires MetaSight: Shield screening business set to scale https://biobriefs.com/ionis-halts-alzheimers-program-for BioBriefs en 2026-02-22T14:32:57Z Ionis halts Alzheimer’s program for people with Down syndrome https://biobriefs.com/japan-endorses-two-ipsc-drugs BioBriefs en 2026-02-22T14:32:57Z Japan endorses two iPSC drugs: Regulatory first for cell‑derived therapies https://biobriefs.com/insilico-and-lilly-map-prompt BioBriefs en 2026-02-22T14:32:57Z Insilico and Lilly map 'prompt‑to‑drug' autonomous R&D https://biobriefs.com/novartis-to-sell-india-unit BioBriefs en 2026-02-22T14:32:57Z Novartis to sell India unit – keeps R&D and commercial operations https://biobriefs.com/bioversys-reports-tb-proof-of BioBriefs en 2026-02-22T14:32:57Z Bioversys reports TB proof‑of‑concept in NEJM: Alpibectir potentiates ethionamide https://biobriefs.com/grails-galleri-misses-nhs-endpoint BioBriefs en 2026-02-22T10:33:10Z Grail’s Galleri misses NHS endpoint – shares plunge https://biobriefs.com/fda-reopens-review-of-modernas BioBriefs en 2026-02-22T10:33:10Z FDA reopens review of Moderna’s mRNA flu shot – political pressure scrutinized https://biobriefs.com/guardant-buys-metasight-lifts-2026 BioBriefs en 2026-02-22T10:33:10Z Guardant buys MetaSight, lifts 2026 screening outlook https://biobriefs.com/japan-backs-two-ipsc-therapies BioBriefs en 2026-02-22T10:33:10Z Japan backs two iPSC therapies under conditional approval pathway https://biobriefs.com/fda-sets-dec-18-decision BioBriefs en 2026-02-22T10:33:10Z FDA sets Dec. 18 decision date for Roche’s oral SERD giredestrant https://biobriefs.com/industry-leadership-churn-daiichi-names BioBriefs en 2026-02-22T10:33:10Z Industry leadership churn: Daiichi names John Tsai; CFO hires surge https://biobriefs.com/ionis-halts-alzheimers-candidate-for BioBriefs en 2026-02-22T10:33:10Z Ionis halts Alzheimer’s candidate for people with Down syndrome https://biobriefs.com/disordered-lipid-nanoparticles-boost-delivery BioBriefs en 2026-02-22T10:33:10Z Disordered lipid nanoparticles boost delivery efficiency – new evidence https://biobriefs.com/structural-control-of-bacterial-dna BioBriefs en 2026-02-22T10:33:10Z Structural control of bacterial DNA synthesis reveals new antimicrobial target https://biobriefs.com/insilico-lilly-blueprint-and-synthetic BioBriefs en 2026-02-22T10:33:10Z Insilico-Lilly blueprint and synthetic data push AI deeper into drug R&D https://biobriefs.com/grails-galleri-misses-uk-goal BioBriefs en 2026-02-22T09:32:52Z Grail’s Galleri misses UK goal – shares collapse https://biobriefs.com/fda-reverses-course-on-modernas BioBriefs en 2026-02-22T09:32:52Z FDA reverses course on Moderna’s mRNA flu shot https://biobriefs.com/guardant-accelerates-screening-push-buys BioBriefs en 2026-02-22T09:32:52Z Guardant accelerates screening push, buys MetaSight https://biobriefs.com/danaher-to-acquire-masimo-diagnostic BioBriefs en 2026-02-22T09:32:52Z Danaher to acquire Masimo; diagnostic contractors tapped by CDC https://biobriefs.com/roche-gets-fda-decision-date BioBriefs en 2026-02-22T09:32:52Z Roche gets FDA decision date on oral SERD giredestrant https://biobriefs.com/ionis-halts-alzheimers-candidate-for BioBriefs en 2026-02-22T09:32:52Z Ionis halts Alzheimer’s candidate for people with Down syndrome https://biobriefs.com/bioversys-shows-early-clinical-proof BioBriefs en 2026-02-22T09:32:52Z Bioversys shows early clinical proof‑of‑concept in tuberculosis https://biobriefs.com/new-structural-insights-open-target BioBriefs en 2026-02-22T09:32:52Z New structural insights open target space in bacterial DNA control https://biobriefs.com/insilico-and-lilly-map-a BioBriefs en 2026-02-22T09:32:52Z Insilico and Lilly map a ‘prompt‑to‑drug’ autonomous R&D future https://biobriefs.com/japan-backs-first-ipsc-derived BioBriefs en 2026-02-22T09:32:52Z Japan backs first iPSC‑derived therapies under conditional approvals https://biobriefs.com/fda-reverses-modernas-mrna-flu BioBriefs en 2026-02-22T04:33:04Z FDA reverses: Moderna’s mRNA flu shot moved back into review https://biobriefs.com/grails-galleri-misses-primary-goal BioBriefs en 2026-02-22T04:33:04Z Grail’s Galleri misses primary goal — market rout follows https://biobriefs.com/guardant-expands-screening-push-buys BioBriefs en 2026-02-22T04:33:04Z Guardant expands screening push — buys MetaSight and lifts Shield outlook https://biobriefs.com/fda-clears-vandas-bysanti-new BioBriefs en 2026-02-22T04:33:04Z FDA clears Vanda’s Bysanti — new antipsychotic approval https://biobriefs.com/japan-backs-two-ipsc-therapies BioBriefs en 2026-02-22T04:33:04Z Japan backs two iPSC therapies under conditional pathway https://biobriefs.com/rnr-regulation-decoded-structural-insights BioBriefs en 2026-02-22T04:33:04Z RNR regulation decoded — structural insights point to new antibacterial targets https://biobriefs.com/disorder-helps-messy-lipid-nanoparticles BioBriefs en 2026-02-22T04:33:04Z Disorder helps: messy lipid nanoparticles improve RNA delivery https://biobriefs.com/ai-arms-race-in-drug BioBriefs en 2026-02-22T04:33:04Z AI arms race in drug discovery — autonomous 'prompt‑to‑drug' vs closed proprietary models https://biobriefs.com/car-nk-tweaks-boost-tumor BioBriefs en 2026-02-22T04:33:04Z CAR‑NK tweaks boost tumor killing in preclinical models https://biobriefs.com/diagnostics-consolidation-and-new-platforms BioBriefs en 2026-02-22T04:33:04Z Diagnostics consolidation and new platforms reshape testing market https://biobriefs.com/grails-galleri-misses-endpoint-shares BioBriefs en 2026-02-21T21:33:06Z Grail’s Galleri misses endpoint — shares plunge https://biobriefs.com/fda-reverses-course-moderna-flu BioBriefs en 2026-02-21T21:33:06Z FDA reverses course: Moderna flu vaccine under review https://biobriefs.com/guardant-expands-screening-play-metasight BioBriefs en 2026-02-21T21:33:06Z Guardant expands screening play — MetaSight buy and Shield ramp https://biobriefs.com/danaher-shells-out-nearly-10b BioBriefs en 2026-02-21T21:33:06Z Danaher shells out nearly $10B for Masimo — diagnostics consolidation https://biobriefs.com/japan-backs-two-ipsc-therapies BioBriefs en 2026-02-21T21:33:06Z Japan backs two iPSC therapies under early‑approval pathway https://biobriefs.com/ionis-halts-alzheimer-candidate-for BioBriefs en 2026-02-21T21:33:06Z Ionis halts Alzheimer candidate for Down syndrome https://biobriefs.com/stanford-mucosal-vaccine-protects-mice BioBriefs en 2026-02-21T21:33:06Z Stanford mucosal vaccine protects mice from diverse respiratory threats https://biobriefs.com/cryo-em-maps-csn5i-3 BioBriefs en 2026-02-21T21:33:06Z Cryo‑EM maps CSN5i‑3 binding — orthosteric molecular‑glue revealed https://biobriefs.com/new-structural-insights-into-bacterial BioBriefs en 2026-02-21T21:33:06Z New structural insights into bacterial DNA synthesis control point to antimicrobial target https://biobriefs.com/grails-galleri-flops-in-nhs BioBriefs en 2026-02-21T16:32:55Z Grail’s Galleri flops in NHS study: shares tumble https://biobriefs.com/fda-formalizes-one-trial-default BioBriefs en 2026-02-21T16:32:55Z FDA formalizes one-trial default: NEJM authors set new standard https://biobriefs.com/modernas-flu-vaccine-review-reverses BioBriefs en 2026-02-21T16:32:55Z Moderna’s flu vaccine review reverses course: FDA will now review https://biobriefs.com/danaher-shells-out-10b-for BioBriefs en 2026-02-21T16:32:55Z Danaher shells out $10B for Masimo — diagnostics consolidation accelerates https://biobriefs.com/guardant-ramps-screening-business-buys BioBriefs en 2026-02-21T16:32:55Z Guardant ramps screening business, buys MetaSight — Shield growth accelerated https://biobriefs.com/altesa-raises-75m-to-reboot BioBriefs en 2026-02-21T16:32:55Z Altesa raises $75M to reboot antiviral vapendavir program https://biobriefs.com/japan-backs-two-ipsc-therapies BioBriefs en 2026-02-21T16:32:55Z Japan backs two iPSC therapies under conditional approval pathway https://biobriefs.com/novartis-to-sell-india-unit BioBriefs en 2026-02-21T16:32:55Z Novartis to sell India unit — keeps R&D and commercial operations separate https://biobriefs.com/disordered-lipid-nanoparticles-boost-cargo BioBriefs en 2026-02-21T16:32:55Z Disordered lipid nanoparticles boost cargo release — delivery rethink https://biobriefs.com/element-unveils-vitari-100-genome BioBriefs en 2026-02-21T16:32:55Z Element unveils Vitari: $100 genome on 36‑hour runs https://biobriefs.com/grail-s-galleri-misses-nhs BioBriefs en 2026-02-21T14:33:04Z Grail's Galleri misses NHS goal — market rout follows https://biobriefs.com/fda-formalizes-single-trial-default BioBriefs en 2026-02-21T14:33:04Z FDA formalizes single‑trial default — NEJM perspective https://biobriefs.com/fda-reverses-moderna-refusal-review BioBriefs en 2026-02-21T14:33:04Z FDA reverses Moderna refusal — review resumes https://biobriefs.com/guardant-buys-metasight-shield-screening BioBriefs en 2026-02-21T14:33:04Z Guardant buys MetaSight; Shield screening set to scale https://biobriefs.com/altesa-raises-75m-to-advance BioBriefs en 2026-02-21T14:33:04Z Altesa raises $75M to advance vapendavir trials https://biobriefs.com/structures-of-bacterial-rnr-control BioBriefs en 2026-02-21T14:33:04Z Structures of bacterial RNR control point to new antibiotic strategies https://biobriefs.com/disorganized-lnps-release-rna-more BioBriefs en 2026-02-21T14:33:04Z Disorganized LNPs release RNA more efficiently — single‑particle study https://biobriefs.com/functional-electrophysiology-probe-aims-to BioBriefs en 2026-02-21T14:33:04Z Functional electrophysiology probe aims to improve organoid screening https://biobriefs.com/element-unveils-vitari-100-30x BioBriefs en 2026-02-21T14:33:04Z Element unveils Vitari — $100 30X genome in 36 hours https://biobriefs.com/stanford-reports-universal-intranasal-vaccine BioBriefs en 2026-02-21T14:33:04Z Stanford reports universal intranasal vaccine protecting mice across respiratory threats https://biobriefs.com/grails-galleri-misses-nhs-goal BioBriefs en 2026-02-21T10:33:01Z Grail’s Galleri misses NHS goal — stock tumbles https://biobriefs.com/fda-formalizes-single-pivotal-trial BioBriefs en 2026-02-21T10:33:01Z FDA formalizes single pivotal-trial default — approval bar shifts https://biobriefs.com/japan-backs-two-ipsc-therapies BioBriefs en 2026-02-21T10:33:01Z Japan backs two iPSC therapies: first-in-world approvals near https://biobriefs.com/danaher-agrees-10b-masimo-takeover BioBriefs en 2026-02-21T10:33:01Z Danaher agrees $10B Masimo takeover — diagnostics consolidation accelerates https://biobriefs.com/guardant-doubles-down-on-screening BioBriefs en 2026-02-21T10:33:01Z Guardant doubles down on screening — acquires MCED startup, raises guidance https://biobriefs.com/altesa-raises-75m-to-advance BioBriefs en 2026-02-21T10:33:01Z Altesa raises $75M to advance antivirals — Giroir leads Series B https://biobriefs.com/novartis-commits-100m-to-macrocycle BioBriefs en 2026-02-21T10:33:01Z Novartis commits $100M to macrocycle startup — peptide frontier expands https://biobriefs.com/fda-reverses-moderna-refusal-agency BioBriefs en 2026-02-21T10:33:01Z FDA reverses Moderna refusal — agency turmoil lands in Washington https://biobriefs.com/ai-to-lab-in-loop BioBriefs en 2026-02-21T10:33:01Z AI to lab-in‑loop: Insilico, Lilly and rapid evolution reshape R&D https://biobriefs.com/high-throughput-sequencing-race-heats BioBriefs en 2026-02-21T10:33:01Z High‑throughput sequencing race heats up — Element’s Vitari and new platforms https://biobriefs.com/grails-galleri-misses-nhs-endpoint BioBriefs en 2026-02-21T09:33:08Z Grail’s Galleri misses NHS endpoint — shares collapse https://biobriefs.com/fda-makes-single-pivotal-trial BioBriefs en 2026-02-21T09:33:08Z FDA makes single pivotal trial the default — NEJM chiefs explain https://biobriefs.com/japan-backs-two-ipsc-therapies BioBriefs en 2026-02-21T09:33:08Z Japan backs two iPSC therapies under early‑approval pathway https://biobriefs.com/altesa-closes-75m-series-b BioBriefs en 2026-02-21T09:33:08Z Altesa closes $75M Series B to push antivirals into COPD trials https://biobriefs.com/korsana-emerges-with-175m-to BioBriefs en 2026-02-21T09:33:08Z Korsana emerges with $175M to pursue Alzheimer’s brain‑shuttle antibody https://biobriefs.com/guardant-ramps-screening-push-shield BioBriefs en 2026-02-21T09:33:08Z Guardant ramps screening push — Shield demand and MetaSight buy https://biobriefs.com/danaher-to-buy-masimo-diagnostics BioBriefs en 2026-02-21T09:33:08Z Danaher to buy Masimo — diagnostics M&A accelerates https://biobriefs.com/novartis-to-sell-india-generics BioBriefs en 2026-02-21T09:33:08Z Novartis to sell India generics arm to PE — keeps R&D presence https://biobriefs.com/roche-gets-fda-decision-date BioBriefs en 2026-02-21T09:33:08Z Roche gets FDA decision date for SERD giredestrant; leadership shuffle https://biobriefs.com/multi-evolve-and-lab-in BioBriefs en 2026-02-21T09:33:08Z MULTI‑evolve and lab‑in‑loop frameworks speed complex protein design https://biobriefs.com/galleri-misses-primary-goal-grail BioBriefs en 2026-02-21T04:33:03Z Galleri misses primary goal—Grail shares plunge after NHS trial https://biobriefs.com/fda-formalizes-one-trial-default BioBriefs en 2026-02-21T04:33:03Z FDA formalizes one‑trial default: approval bar lowered as NEJM piece sets tone https://biobriefs.com/guardant-buys-metasight-screens-set BioBriefs en 2026-02-21T04:33:03Z Guardant buys MetaSight—screens set to scale with Shield guidance https://biobriefs.com/danaher-moves-on-masimo-10b BioBriefs en 2026-02-21T04:33:03Z Danaher moves on Masimo: $10B takeover to bulk up diagnostics and monitoring https://biobriefs.com/japan-backs-first-ipsc-drugs BioBriefs en 2026-02-21T04:33:03Z Japan backs first iPSC drugs—conditional clearances eyed under CEA pathway https://biobriefs.com/novartis-to-sell-india-generics BioBriefs en 2026-02-21T04:33:03Z Novartis to sell India generics unit—PE takeover for $159M https://biobriefs.com/ionis-halts-alzheimers-program-for BioBriefs en 2026-02-21T04:33:03Z Ionis halts Alzheimer’s program for people with Down syndrome https://biobriefs.com/korsana-emerges-with-175m-to BioBriefs en 2026-02-21T04:33:03Z Korsana emerges with $175M to back Alzheimer’s shuttle antibody program https://biobriefs.com/element-launches-vitari-aims-100 BioBriefs en 2026-02-21T04:33:03Z Element launches Vitari—aims $100 30X genome with high‑throughput platform https://biobriefs.com/insilico-and-lilly-outline-prompt BioBriefs en 2026-02-21T04:33:03Z Insilico and Lilly outline 'prompt‑to‑drug' vision—AI‑first R&D framework revealed https://biobriefs.com/grails-galleri-test-flops-shares BioBriefs en 2026-02-20T21:33:02Z Grail’s Galleri test flops -- shares halve after UK trial misses endpoint https://biobriefs.com/fda-formalizes-one-trial-default BioBriefs en 2026-02-20T21:33:02Z FDA formalizes one‑trial default: regulators shift approval bar https://biobriefs.com/japan-backs-first-ipsc-drugs BioBriefs en 2026-02-20T21:33:02Z Japan backs first iPSC drugs: conditional approvals advance regenerative therapies https://biobriefs.com/guardant-doubles-down-on-screening BioBriefs en 2026-02-20T21:33:02Z Guardant doubles down on screening -- buys MetaSight and lifts 2026 guidance https://biobriefs.com/novartis-to-divest-india-branded BioBriefs en 2026-02-20T21:33:02Z Novartis to divest India branded generics arm — keeps R&D and commercial footprint https://biobriefs.com/korsana-raises-175m-to-chase BioBriefs en 2026-02-20T21:33:02Z Korsana raises $175M to chase Alzheimer’s brain‑shuttle antibodies https://biobriefs.com/pepyrus-improves-hla-peptide-detection BioBriefs en 2026-02-20T21:33:02Z Pepyrus improves HLA peptide detection with custom peptide libraries https://biobriefs.com/ai-prompt-to-drug-and BioBriefs en 2026-02-20T21:33:02Z AI ‘prompt‑to‑drug’ and lab‑in‑loop evolution push autonomous discovery https://biobriefs.com/plasma-p-tau217-clocks-estimate BioBriefs en 2026-02-20T21:33:02Z Plasma p‑tau217 ‘clocks’ estimate timing of Alzheimer’s symptom onset https://biobriefs.com/alpibectir-combination-shows-proof-of BioBriefs en 2026-02-20T21:33:02Z Alpibectir combination shows proof‑of‑concept against drug‑resistant TB https://biobriefs.com/insilico-and-lilly-outline-prompt BioBriefs en 2026-02-20T16:34:05Z Insilico and Lilly Outline 'Prompt‑to‑Drug' Vision: Autonomous AI for drug discovery https://biobriefs.com/element-debuts-vitari-100-30x BioBriefs en 2026-02-20T16:34:05Z Element Debuts Vitari: $100 30X Genome, High‑Throughput Sequencing Push https://biobriefs.com/guardant-eyes-screening-ramp-buys BioBriefs en 2026-02-20T16:34:05Z Guardant Eyes Screening Ramp, Buys MetaSight to Expand MCED Portfolio https://biobriefs.com/grail-s-galleri-fails-primary BioBriefs en 2026-02-20T16:34:05Z Grail's Galleri Fails Primary Goal in NHS Trial — Stock Collapses https://biobriefs.com/fda-reverses-refusal-will-review BioBriefs en 2026-02-20T16:34:05Z FDA Reverses Refusal, Will Review Moderna's mRNA Flu Shot https://biobriefs.com/fda-formalizes-one-pivotal-trial BioBriefs en 2026-02-20T16:34:05Z FDA Formalizes One‑Pivotal‑Trial Default: NEJM Perspective Sparks Debate https://biobriefs.com/novartis-plugs-1-8b-into BioBriefs en 2026-02-20T16:34:05Z Novartis Plugs $1.8B Into Macrocyclic Peptides — Unnatural Products Partnership https://biobriefs.com/electronic-cyborg-mesh-drives-islet BioBriefs en 2026-02-20T16:34:05Z Electronic 'Cyborg' Mesh Drives Islet Cell Maturation — Diabetes Implications https://biobriefs.com/m-pact-methylation-classifier-identifies BioBriefs en 2026-02-20T16:34:05Z M‑PACT: Methylation Classifier Identifies Pediatric Brain Tumors from CSF https://biobriefs.com/altesa-raises-75m-to-reposition BioBriefs en 2026-02-20T16:34:05Z Altesa Raises $75M to Reposition Vapendavir for COPD Exacerbations https://biobriefs.com/grails-galleri-test-fails-uk BioBriefs en 2026-02-20T14:33:50Z Grail’s Galleri test fails UK endpoint — shares tumble https://biobriefs.com/fda-reverses-course-moderna-mrna BioBriefs en 2026-02-20T14:33:50Z FDA reverses course — Moderna mRNA flu shot accepted for review https://biobriefs.com/fda-makes-one-pivotal-trial BioBriefs en 2026-02-20T14:33:50Z FDA makes one pivotal trial the default — NEJM perspective https://biobriefs.com/element-launches-vitari-sequencer-30x BioBriefs en 2026-02-20T14:33:50Z Element launches Vitari sequencer: 30× genome for $100 https://biobriefs.com/novartis-bets-on-macrocycles-1 BioBriefs en 2026-02-20T14:33:50Z Novartis bets on macrocycles — $1.8bn Unnatural Products deal https://biobriefs.com/korsana-launches-with-175m-to BioBriefs en 2026-02-20T14:33:50Z Korsana launches with $175m to pursue Alzheimer’s shuttle antibody https://biobriefs.com/danaher-pays-10bn-for-masimo BioBriefs en 2026-02-20T14:33:50Z Danaher pays $10bn for Masimo — diagnostics consolidation accelerates https://biobriefs.com/big-bets-on-biologics-capacity BioBriefs en 2026-02-20T14:33:50Z Big bets on biologics capacity — J&J $1bn plant; Lonza expands ADC capabilities https://biobriefs.com/lilly-licenses-csls-il-6 BioBriefs en 2026-02-20T14:33:50Z Lilly licenses CSL’s IL‑6 antibody — $100m up front https://biobriefs.com/merck-mayo-clinic-partner-on BioBriefs en 2026-02-20T14:33:50Z Merck, Mayo Clinic partner on AI‑driven drug discovery R&D https://biobriefs.com/fda-formalizes-single-trial-default BioBriefs en 2026-02-20T10:32:59Z FDA formalizes single-trial default – industry recalibrates https://biobriefs.com/fda-reverses-itself-moderna-flu BioBriefs en 2026-02-20T10:32:59Z FDA reverses itself — Moderna flu vaccine back under review https://biobriefs.com/korsana-launches-with-175m-new BioBriefs en 2026-02-20T10:32:59Z Korsana launches with $175M — new entrant in Alzheimer’s antibody race https://biobriefs.com/grails-galleri-misses-primary-goal BioBriefs en 2026-02-20T10:32:59Z Grail’s Galleri misses primary goal in UK study — market reaction sharp https://biobriefs.com/novartis-bets-on-macrocyclic-peptides BioBriefs en 2026-02-20T10:32:59Z Novartis bets on macrocyclic peptides — up to $1.8B pact with Unnatural Products https://biobriefs.com/altesa-raises-75m-to-revive BioBriefs en 2026-02-20T10:32:59Z Altesa raises $75M to revive vapendavir for COPD — Sanofi joins syndicate https://biobriefs.com/element-unveils-vitari-sequencer-3 BioBriefs en 2026-02-20T10:32:59Z Element unveils Vitari sequencer — 3 Tb runs, $100 30× genome claim https://biobriefs.com/cyborg-electronic-mesh-drives-islet BioBriefs en 2026-02-20T10:32:59Z ‘Cyborg’ electronic mesh drives islet maturation — new path for diabetes cell therapy https://biobriefs.com/stanford-nasal-vaccine-shows-broad BioBriefs en 2026-02-20T10:32:59Z Stanford nasal vaccine shows broad lung protection in mice https://biobriefs.com/lilly-pays-100m-for-csls BioBriefs en 2026-02-20T10:32:59Z Lilly pays $100M for CSL’s IL‑6 antibody rights — split indications carved out https://biobriefs.com/fda-reverses-course-will-review BioBriefs en 2026-02-20T09:33:04Z FDA reverses course: will review Moderna’s mRNA flu vaccine https://biobriefs.com/korsana-launches-with-175m-to BioBriefs en 2026-02-20T09:33:04Z Korsana launches with $175M to push an amyloid‑clearing Alzheimer’s antibody https://biobriefs.com/novartis-doubles-down-on-macrocycles BioBriefs en 2026-02-20T09:33:04Z Novartis doubles down on macrocycles: big-dollar pact with Unnatural Products https://biobriefs.com/fda-formalizes-one-pivotal-trial BioBriefs en 2026-02-20T09:33:04Z FDA formalizes one pivotal‑trial default — policy shift in NEJM perspective https://biobriefs.com/grails-galleri-falls-short-uk BioBriefs en 2026-02-20T09:33:04Z Grail’s Galleri falls short: UK study misses primary endpoint https://biobriefs.com/element-unveils-vitari-sequencer-30x BioBriefs en 2026-02-20T09:33:04Z Element unveils Vitari sequencer — 30× genome for about $100 https://biobriefs.com/merck-taps-mayo-clinic-data BioBriefs en 2026-02-20T09:33:04Z Merck taps Mayo Clinic data and AI to accelerate target discovery https://biobriefs.com/lilly-pays-100m-for-csls BioBriefs en 2026-02-20T09:33:04Z Lilly pays $100M for CSL’s IL‑6 antibody rights — deal splits indications https://biobriefs.com/altesa-raises-75m-to-reposition BioBriefs en 2026-02-20T09:33:04Z Altesa raises $75M to reposition vapendavir for COPD exacerbations https://biobriefs.com/stanfords-intranasal-vaccine-protects-mice BioBriefs en 2026-02-20T09:33:04Z Stanford’s intranasal vaccine protects mice against viruses, bacteria and allergens https://biobriefs.com/fda-pivots-to-one-pivotal BioBriefs en 2026-02-20T04:33:21Z FDA pivots to one pivotal trial — NEJM authors formalize new default https://biobriefs.com/fda-reverses-course-on-moderna BioBriefs en 2026-02-20T04:33:21Z FDA reverses course on Moderna flu shot — agency accepts revised filing https://biobriefs.com/novartis-inks-up-to-1 BioBriefs en 2026-02-20T04:33:21Z Novartis inks up‑to‑$1.8B macrocycle pact — Unnatural Products deal https://biobriefs.com/korsana-raises-175m-new-alzheimers BioBriefs en 2026-02-20T04:33:21Z Korsana raises $175M — new Alzheimer’s antibody startup emerges https://biobriefs.com/grails-galleri-misses-primary-goal BioBriefs en 2026-02-20T04:33:21Z Grail’s Galleri misses primary goal in UK study — shares plunge https://biobriefs.com/stanford-unveils-nasal-universal-vaccine BioBriefs en 2026-02-20T04:33:21Z Stanford unveils nasal 'universal' vaccine — broad lung protection in mice https://biobriefs.com/m-pact-methylation-classifier-identifies BioBriefs en 2026-02-20T04:33:21Z M‑PACT: methylation classifier identifies pediatric brain tumors from CSF https://biobriefs.com/electronic-mesh-implants-drive-islet BioBriefs en 2026-02-20T04:33:21Z Electronic mesh implants drive islet maturation — 'cyborg' pancreatic organoids https://biobriefs.com/plasma-p-tau217-clocks-forecast BioBriefs en 2026-02-20T04:33:21Z Plasma p‑tau217 ‘clocks’ forecast Alzheimer’s symptom onset within 3–4 years https://biobriefs.com/element-unveils-vitari-sequencer-3tb BioBriefs en 2026-02-20T04:33:20Z Element unveils Vitari sequencer — 3Tb runs, $100 30X genome claim https://biobriefs.com/novartis-bets-1-8b-on BioBriefs en 2026-02-19T21:33:39Z Novartis bets $1.8B on macrocycles: Unnatural Products deal https://biobriefs.com/fda-pivots-single-pivotal-trial BioBriefs en 2026-02-19T21:33:39Z FDA pivots: single pivotal trial becomes new default https://biobriefs.com/fda-reverses-will-review-modernas BioBriefs en 2026-02-19T21:33:39Z FDA reverses: will review Moderna’s mRNA flu shot https://biobriefs.com/altesa-raises-75m-to-revive BioBriefs en 2026-02-19T21:33:39Z Altesa raises $75M to revive rhinovirus antiviral for COPD https://biobriefs.com/liquid-biopsy-for-kids-m BioBriefs en 2026-02-19T21:33:39Z Liquid biopsy for kids: M‑PACT classifies brain tumors from CSF https://biobriefs.com/blood-clock-p-tau217-predicts BioBriefs en 2026-02-19T21:33:39Z Blood clock: p‑tau217 predicts when Alzheimer’s symptoms will start https://biobriefs.com/electronic-meshes-bridge-tissues-and BioBriefs en 2026-02-19T21:33:39Z Electronic meshes bridge tissues and electronics: organoids go 'cyborg' https://biobriefs.com/element-unveils-vitari-high-throughput BioBriefs en 2026-02-19T21:33:39Z Element unveils Vitari: high‑throughput sequencing hits $100 genome goal https://biobriefs.com/biomanufacturing-build-out-lonza-scales BioBriefs en 2026-02-19T21:33:39Z Biomanufacturing build‑out: Lonza scales ADC tooling; J&J invests $1B in cell therapy https://biobriefs.com/organoids-expose-indirect-liver-toxicity BioBriefs en 2026-02-19T21:33:39Z Organoids expose indirect liver toxicity; vascularized liver 'tissueoid' models advance https://biobriefs.com/fda-reconsiders-moderna-flu-mrna BioBriefs en 2026-02-19T16:32:58Z FDA reconsiders Moderna: flu mRNA shot back on review https://biobriefs.com/tempus-sued-over-genetic-data BioBriefs en 2026-02-19T16:32:58Z Tempus sued over genetic-data transfers: class action filed in Illinois https://biobriefs.com/korsana-surfaces-with-175m-alzheimers BioBriefs en 2026-02-19T16:32:58Z Korsana surfaces with $175M — Alzheimer’s antibody push begins https://biobriefs.com/compass-posts-second-phase-iii BioBriefs en 2026-02-19T16:32:58Z Compass posts second Phase III win – psychedelics stocks rally https://biobriefs.com/novartis-signs-big-macrocycle-pact BioBriefs en 2026-02-19T16:32:58Z Novartis signs big macrocycle pact: up to $1.8B with Unnatural Products https://biobriefs.com/merck-inks-r-d-tie BioBriefs en 2026-02-19T16:32:58Z Merck inks R&D tie with Mayo Clinic to pair clinical data and AI https://biobriefs.com/danaher-to-buy-masimo-9 BioBriefs en 2026-02-19T16:32:58Z Danaher to buy Masimo: $9.9B deal to bulk up diagnostics https://biobriefs.com/fda-accepts-bms-protein-degrader BioBriefs en 2026-02-19T16:32:58Z FDA accepts BMS protein degrader for review — regulatory milestone https://biobriefs.com/altesa-raises-75m-as-sanofi BioBriefs en 2026-02-19T16:32:58Z Altesa raises $75M as Sanofi backs rhinovirus antiviral pivot https://biobriefs.com/fda-chief-warns-u-s BioBriefs en 2026-02-19T16:32:58Z FDA chief warns U.S. losing ground to China in early drug development https://biobriefs.com/fda-reverses-course-moderna-flu BioBriefs en 2026-02-19T14:32:56Z FDA reverses course: Moderna flu vaccine accepted for review https://biobriefs.com/psilocybin-wins-again-compass-edges BioBriefs en 2026-02-19T14:32:56Z Psilocybin wins again: Compass edges toward regulatory filing https://biobriefs.com/altesa-raises-75m-sanofi-joins BioBriefs en 2026-02-19T14:32:56Z Altesa raises $75M — Sanofi joins Series B to back respiratory program https://biobriefs.com/korsana-surfaces-with-175m-to BioBriefs en 2026-02-19T14:32:56Z Korsana surfaces with $175M to pursue anti‑amyloid antibody https://biobriefs.com/novartis-bets-big-on-macrocycles BioBriefs en 2026-02-19T14:32:56Z Novartis bets big on macrocycles: UNP pact could top $1.8B https://biobriefs.com/merck-and-mayo-clinic-link BioBriefs en 2026-02-19T14:32:56Z Merck and Mayo Clinic link data and AI for drug discovery https://biobriefs.com/j-j-pauses-enrollment-in BioBriefs en 2026-02-19T14:32:56Z J&J pauses enrollment in mid‑stage Alzheimer’s trial with AC Immune https://biobriefs.com/gene-editing-milestones-in-vivo BioBriefs en 2026-02-19T14:32:56Z Gene‑editing milestones: in vivo base editing reverses behavior — LNPs insert full gene into airway cells https://biobriefs.com/protein-ai-and-manufacturing-1 BioBriefs en 2026-02-19T14:32:56Z Protein AI and manufacturing: 1.4M validated models meet an LLM production fix https://biobriefs.com/regulatory-showdown-fda-warns-us BioBriefs en 2026-02-19T14:32:56Z Regulatory showdown — FDA warns US losing ground while China speeds trial reviews https://biobriefs.com/fda-reverses-course-modernas-mrna BioBriefs en 2026-02-19T10:32:46Z FDA reverses course: Moderna’s mRNA flu vaccine accepted for review https://biobriefs.com/psilocybin-scores-again-compass-nears BioBriefs en 2026-02-19T10:32:46Z Psilocybin scores again — Compass nears FDA filing after second Phase III win https://biobriefs.com/novartis-bets-on-macrocycles-big BioBriefs en 2026-02-19T10:32:46Z Novartis bets on macrocycles: Big-dollar pact to hunt cardiovascular targets https://biobriefs.com/merck-and-mayo-clinic-link BioBriefs en 2026-02-19T10:32:46Z Merck and Mayo Clinic link up: AI and clinical genomics to fuel discovery https://biobriefs.com/alzheimers-entrant-raises-175m-korsana BioBriefs en 2026-02-19T10:32:46Z Alzheimer’s entrant raises $175M: Korsana emerges with anti‑amyloid antibody program https://biobriefs.com/j-j-commits-1b-new BioBriefs en 2026-02-19T10:32:46Z J&J commits $1B: New U.S. cell‑therapy manufacturing site to scale production https://biobriefs.com/psbench-released-1-4m-checked BioBriefs en 2026-02-19T10:32:46Z PSBench released: 1.4M checked protein models to sharpen AI predictions https://biobriefs.com/lilly-buys-rights-100m-upfront BioBriefs en 2026-02-19T10:32:46Z Lilly buys rights: $100M upfront deal for CSL’s IL‑6 antibody to broaden immunology slate https://biobriefs.com/danaher-to-buy-masimo-9 BioBriefs en 2026-02-19T10:32:46Z Danaher to buy Masimo — $9.9B deal reshapes diagnostics landscape https://biobriefs.com/gilead-expands-synthetic-lethality-push BioBriefs en 2026-02-19T10:32:46Z Gilead expands synthetic‑lethality push: $1.5B‑plus deal for Genhouse MAT2A inhibitor https://biobriefs.com/fda-u-turn-modernas-mrna BioBriefs en 2026-02-19T09:33:45Z FDA U-turn — Moderna’s mRNA flu shot accepted for review https://biobriefs.com/psilocybin-scores-compass-posts-second BioBriefs en 2026-02-19T09:33:45Z Psilocybin scores: Compass posts second Phase III win, eyes U.S. filing https://biobriefs.com/novartis-bets-on-macrocycles-1 BioBriefs en 2026-02-19T09:33:45Z Novartis bets on macrocycles: $1.8B Unnatural Products pact https://biobriefs.com/lilly-jumps-on-il-6 BioBriefs en 2026-02-19T09:33:45Z Lilly jumps on IL‑6: $100M deal for CSL antibody rights https://biobriefs.com/korsana-emerges-with-175m-to BioBriefs en 2026-02-19T09:33:45Z Korsana emerges with $175M to develop anti‑amyloid antibody https://biobriefs.com/merck-inks-mayo-clinic-deal BioBriefs en 2026-02-19T09:33:45Z Merck inks Mayo Clinic deal: AI meets clinical‑genomic datasets https://biobriefs.com/stressed-tumors-call-for-help BioBriefs en 2026-02-19T09:33:45Z Stressed tumors call for help — LCN2 drives immune evasion https://biobriefs.com/axpaxli-advantage-oculars-wet-amd BioBriefs en 2026-02-19T09:33:45Z Axpaxli advantage — Ocular’s wet‑AMD drug tops low‑dose Eylea https://biobriefs.com/sensei-revives-via-faeth-merger BioBriefs en 2026-02-19T09:33:45Z Sensei revives via Faeth merger — gains Piktor and $200M https://biobriefs.com/fda-commissioner-warns-u-s BioBriefs en 2026-02-19T09:33:45Z FDA commissioner warns U.S. trails China in early drug development https://biobriefs.com/fda-u-turn-agency-will BioBriefs en 2026-02-19T04:33:11Z FDA U‑turn: Agency will review Moderna’s mRNA flu shot https://biobriefs.com/compass-nears-nda-second-phase BioBriefs en 2026-02-19T04:33:11Z Compass nears NDA – Second Phase III confirms psilocybin efficacy https://biobriefs.com/novartis-bets-on-macrocycles-two BioBriefs en 2026-02-19T04:33:11Z Novartis bets on macrocycles: Two‑pronged pact with Unnatural Products https://biobriefs.com/merck-taps-mayo-clinic-data BioBriefs en 2026-02-19T04:33:11Z Merck taps Mayo Clinic data and AI for drug discovery https://biobriefs.com/lilly-pays-100m-upfront-for BioBriefs en 2026-02-19T04:33:11Z Lilly pays $100M upfront for CSL’s IL‑6 antibody rights https://biobriefs.com/j-j-commits-1b-to BioBriefs en 2026-02-19T04:33:11Z J&J commits $1B to cell therapy manufacturing hub in Pennsylvania https://biobriefs.com/korsana-raises-175m-to-pursue BioBriefs en 2026-02-19T04:33:11Z Korsana raises $175M to pursue anti‑amyloid Alzheimer antibody https://biobriefs.com/stress-protein-lcn2-helps-tumors BioBriefs en 2026-02-19T04:33:11Z Stress protein LCN2 helps tumors evade immunity – NYU preclinical work https://biobriefs.com/psbench-1-4m-validated-protein BioBriefs en 2026-02-19T04:33:11Z PSBench: 1.4M validated protein models to sharpen structure AI https://biobriefs.com/ai-reprograms-yeast-to-cut BioBriefs en 2026-02-19T04:33:11Z AI reprograms yeast to cut protein‑drug costs https://biobriefs.com/fda-reverses-will-review-moderna BioBriefs en 2026-02-18T21:32:59Z FDA reverses, will review Moderna flu shot: PDUFA set for Aug. 5 https://biobriefs.com/compass-scores-second-phase-iii BioBriefs en 2026-02-18T21:32:59Z Compass scores second phase III: Psilocybin heads toward NDA https://biobriefs.com/merck-partners-with-mayo-clinic BioBriefs en 2026-02-18T21:32:59Z Merck partners with Mayo Clinic: AI and clinical genomics to drive discovery https://biobriefs.com/gilead-pays-into-synthetic-lethality BioBriefs en 2026-02-18T21:32:59Z Gilead pays into synthetic‑lethality pipeline: $1.53B deal for Genhouse MAT2A asset https://biobriefs.com/lilly-buys-rights-to-csls BioBriefs en 2026-02-18T21:32:59Z Lilly buys rights to CSL’s IL‑6 antibody: $100M upfront to expand inflammation lineup https://biobriefs.com/korsana-launches-with-175m-to BioBriefs en 2026-02-18T21:32:59Z Korsana launches with $175M to chase Alzheimer’s antibodies https://biobriefs.com/sensei-rescues-faeth-gains-phase BioBriefs en 2026-02-18T21:32:59Z Sensei rescues Faeth, gains phase II oncology asset and $200M placement https://biobriefs.com/j-j-doubles-down-on BioBriefs en 2026-02-18T21:32:59Z J&J doubles down on cell therapy: $1B+ manufacturing site planned in Pennsylvania https://biobriefs.com/oculars-axpaxli-beats-low-dose BioBriefs en 2026-02-18T21:32:59Z Ocular’s Axpaxli beats low‑dose Eylea in Phase III – market questions follow https://biobriefs.com/ai-cuts-protein-drug-development BioBriefs en 2026-02-18T21:32:59Z AI cuts protein drug development costs: MIT model speeds yeast engineering https://biobriefs.com/ai-decodes-yeast-dna-manufacturers BioBriefs en 2026-02-18T16:33:17Z AI decodes yeast DNA: manufacturers chase cheaper protein drugs https://biobriefs.com/fda-backtracks-modernas-mrna-flu BioBriefs en 2026-02-18T16:33:17Z FDA backtracks: Moderna’s mRNA flu shot put back on review track https://biobriefs.com/compass-nears-fda-bid-after BioBriefs en 2026-02-18T16:33:17Z Compass nears FDA bid after second pivotal psilocybin victory https://biobriefs.com/novartis-bets-on-macrocycles-100m BioBriefs en 2026-02-18T16:33:17Z Novartis bets on macrocycles: $100M now, $1.7B on the table https://biobriefs.com/merck-and-mayo-clinic-tie BioBriefs en 2026-02-18T16:33:17Z Merck and Mayo Clinic tie up to fuse clinical data with AI discovery https://biobriefs.com/danaher-to-buy-masimo-for BioBriefs en 2026-02-18T16:33:17Z Danaher to buy Masimo for $9.9B to bulk up diagnostics https://biobriefs.com/korsana-raises-175m-to-chase BioBriefs en 2026-02-18T16:33:17Z Korsana raises $175M to chase Alzheimer’s antibody slot https://biobriefs.com/axpaxli-meets-superiority-endpoint-vs BioBriefs en 2026-02-18T16:33:17Z Axpaxli meets superiority endpoint vs Eylea in Phase 3 — market reaction mixed https://biobriefs.com/ucla-lipid-nanoparticles-insert-full BioBriefs en 2026-02-18T16:33:17Z UCLA lipid nanoparticles insert full‑length CFTR gene in airway cells https://biobriefs.com/sensei-rescues-faeth-reverse-merger BioBriefs en 2026-02-18T16:33:17Z Sensei rescues Faeth: reverse merger supplies new lead cancer asset and $200M https://biobriefs.com/fda-reverses-course-will-review BioBriefs en 2026-02-18T14:32:47Z FDA reverses course: will review Moderna’s flu vaccine https://biobriefs.com/psilocybin-scores-again-compass-nears BioBriefs en 2026-02-18T14:32:47Z Psilocybin scores again: Compass nears NDA after second Phase III win https://biobriefs.com/korsana-launches-with-175m-to BioBriefs en 2026-02-18T14:32:47Z Korsana launches with $175M to test anti‑amyloid Alzheimer's antibody https://biobriefs.com/oculars-axpaxli-tops-low-dose BioBriefs en 2026-02-18T14:32:47Z Ocular’s Axpaxli tops low‑dose Eylea in Phase III – market reaction mixed https://biobriefs.com/fda-rejects-discs-bitopertin-crl BioBriefs en 2026-02-18T14:32:47Z FDA rejects Disc’s bitopertin: CRL raises questions about surrogate endpoint use https://biobriefs.com/nektar-resurfaces-rezpeg-maintenance-data BioBriefs en 2026-02-18T14:32:47Z Nektar resurfaces: rezpeg maintenance data fuels stock surge and $460M offering https://biobriefs.com/nanoparticle-gene-editing-inserts-full BioBriefs en 2026-02-18T14:32:47Z Nanoparticle gene editing inserts full gene into airway cells – CF therapy advance https://biobriefs.com/boehringer-halts-inhaled-cf-gene BioBriefs en 2026-02-18T14:32:47Z Boehringer halts inhaled CF gene program after Phase I/II readout https://biobriefs.com/fda-moves-to-curb-compounded BioBriefs en 2026-02-18T14:32:47Z FDA moves to curb compounded GLP‑1 weight‑loss drugs – Hims & Hers flagged https://biobriefs.com/danaher-to-buy-masimo-for BioBriefs en 2026-02-18T14:32:47Z Danaher to buy Masimo for $9.9B – diagnostics push accelerates https://biobriefs.com/compass-psilocybin-nears-nda-second BioBriefs en 2026-02-18T10:33:08Z Compass psilocybin nears NDA – second Phase III hit https://biobriefs.com/oculars-axpaxli-beats-eylea-in BioBriefs en 2026-02-18T10:33:08Z Ocular’s Axpaxli beats Eylea in Phase III – superiority met https://biobriefs.com/danaher-to-buy-masimo-9 BioBriefs en 2026-02-18T10:33:08Z Danaher to buy Masimo: $9.9 billion diagnostics push https://biobriefs.com/nektar-rezpeg-maintenance-data-fuels BioBriefs en 2026-02-18T10:33:08Z Nektar rezpeg maintenance data fuels comeback — Phase IIb success https://biobriefs.com/fda-rejects-discs-bitopertin-voucher BioBriefs en 2026-02-18T10:33:08Z FDA rejects Disc’s bitopertin — voucher program’s first negative outcome https://biobriefs.com/fda-clears-velo-point-of BioBriefs en 2026-02-18T10:33:08Z FDA clears Velo point‑of‑care PCR system — 6–10 minute respiratory test https://biobriefs.com/medpace-to-run-zellunas-first BioBriefs en 2026-02-18T10:33:08Z Medpace to run Zelluna’s first‑in‑human solid tumor cell therapy trial https://biobriefs.com/niaid-told-to-de-emphasize BioBriefs en 2026-02-18T10:33:08Z NIAID told to de‑emphasize ‘pandemic preparedness’ — agency reshapes priorities https://biobriefs.com/argentag-links-with-pacbio-long BioBriefs en 2026-02-18T10:33:08Z ArgenTag links with PacBio — long‑read single‑cell transcriptomics pact https://biobriefs.com/german-grant-backs-dnazyme-cancer BioBriefs en 2026-02-18T10:33:08Z German grant backs DNAzyme cancer platform — 'DNAmazing' gets €3.2M https://biobriefs.com/compass-psilocybin-scores-again-second BioBriefs en 2026-02-18T09:32:59Z Compass psilocybin scores again: second Phase III paves path to NDA https://biobriefs.com/oculars-axpaxli-tops-low-dose BioBriefs en 2026-02-18T09:32:59Z Ocular’s Axpaxli tops low‑dose Eylea in Phase III — market questions linger https://biobriefs.com/danaher-to-buy-masimo-for BioBriefs en 2026-02-18T09:32:59Z Danaher to buy Masimo for $9.9B: diagnostics push accelerates https://biobriefs.com/nektars-rezpeg-posts-strong-maintenance BioBriefs en 2026-02-18T09:32:59Z Nektar’s rezpeg posts strong maintenance data — shares and financing surge https://biobriefs.com/fda-rejects-discs-bitopertin-accelerated BioBriefs en 2026-02-18T09:32:59Z FDA rejects Disc’s bitopertin… accelerated‑voucher test yields CRL https://biobriefs.com/nih-reshapes-niaid-pandemic-preparedness BioBriefs en 2026-02-18T09:32:59Z NIH reshapes NIAID: 'pandemic preparedness' language removed https://biobriefs.com/gilead-pays-80m-upfront-for BioBriefs en 2026-02-18T09:32:59Z Gilead pays $80M upfront for Genhouse’s GH31 — $1.45B upside https://biobriefs.com/argentag-joins-pacbio-program-long BioBriefs en 2026-02-18T09:32:59Z ArgenTag joins PacBio program: long‑read single‑cell transcriptomics goes portable https://biobriefs.com/ml-predicted-insulin-resistance-linked BioBriefs en 2026-02-18T09:32:59Z ML‑predicted insulin resistance linked to 12 cancers: population‑scale study https://biobriefs.com/st-jude-unveils-m-pact BioBriefs en 2026-02-18T09:32:59Z St. Jude unveils M‑PACT: AI liquid biopsy classifies pediatric brain tumors https://biobriefs.com/compass-psilocybin-second-phase-3 BioBriefs en 2026-02-18T04:32:22Z Compass psilocybin... Second Phase‑3 Hit Paves NDA Push https://biobriefs.com/oculars-axpaxli-tops-low-dose BioBriefs en 2026-02-18T04:32:22Z Ocular’s Axpaxli Tops Low‑Dose Eylea – Market Reaction Tepid https://biobriefs.com/danaher-to-buy-masimo-9 BioBriefs en 2026-02-18T04:32:22Z Danaher to buy Masimo: $9.9 billion deal announced https://biobriefs.com/nektars-rezpeg-mid-stage-win BioBriefs en 2026-02-18T04:32:22Z Nektar’s rezpeg... Mid‑stage win sparks comeback and $460M raise https://biobriefs.com/fda-rejects-discs-bitopertin-voucher BioBriefs en 2026-02-18T04:32:22Z FDA rejects Disc’s bitopertin—voucher program faces first failure https://biobriefs.com/lex-diagnostics-gets-fda-greenlight BioBriefs en 2026-02-18T04:32:22Z Lex Diagnostics gets FDA greenlight for Velo PCR: 510(k) and CLIA waiver https://biobriefs.com/zelluna-hires-medpace-to-run BioBriefs en 2026-02-18T04:32:22Z Zelluna hires Medpace to run Phase I of off‑the‑shelf TCR‑NK therapy https://biobriefs.com/argentag-and-pacbio-partner-to BioBriefs en 2026-02-18T04:32:22Z ArgenTag and PacBio partner to enable long‑read single‑cell isoform sequencing https://biobriefs.com/systematic-molecular-glue-discovery-new BioBriefs en 2026-02-18T04:32:22Z Systematic molecular‑glue discovery... New high‑throughput ligand diversification method https://biobriefs.com/compass-nails-second-phase-3 BioBriefs en 2026-02-17T21:33:04Z Compass nails second Phase 3: psilocybin meets endpoint in treatment‑resistant depression https://biobriefs.com/oculars-axpaxli-shows-superiority-at BioBriefs en 2026-02-17T21:33:04Z Ocular’s Axpaxli shows superiority at week 36 – trial beats low‑dose Eylea https://biobriefs.com/federal-judge-narrows-modernas-defenses BioBriefs en 2026-02-17T21:33:04Z Federal judge narrows Moderna’s defenses in long mRNA patent fight with Arbutus https://biobriefs.com/velo-cleared-in-us-ella BioBriefs en 2026-02-17T21:33:04Z Velo cleared in US; Ella platform wins EU mark — point‑of‑care and benchtop diagnostics advance https://biobriefs.com/fda-rejects-disc-medicines-bitopertin BioBriefs en 2026-02-17T21:33:04Z FDA rejects Disc Medicine’s bitopertin: agency questions surrogate endpoint https://biobriefs.com/niaid-told-to-drop-pandemic BioBriefs en 2026-02-17T21:33:04Z NIAID told to drop 'pandemic preparedness' language — institute refocuses mission https://biobriefs.com/zelluna-hires-medpace-to-run BioBriefs en 2026-02-17T21:33:04Z Zelluna hires Medpace to run Phase I of off‑the‑shelf TCR‑NK solid tumor program https://biobriefs.com/gilead-buys-genhouse-mat2a-asset BioBriefs en 2026-02-17T21:33:04Z Gilead buys Genhouse MAT2A asset: $80M upfront, billion‑dollar milestones for synthetic‑lethal cancer drug https://biobriefs.com/fujifilm-opens-uk-mega-cdmo BioBriefs en 2026-02-17T21:33:04Z Fujifilm opens UK mega‑CDMO: single‑use capacity and innovation hub go live https://biobriefs.com/public-cash-backs-early-biotech BioBriefs en 2026-02-17T21:33:04Z Public cash backs early biotech: Germany funds DNAzyme platform, Sweden’s CubaseBio raises €5.9M https://biobriefs.com/fda-says-no-to-discs BioBriefs en 2026-02-17T16:32:44Z FDA says no to Disc’s bitopertin: voucher program faces its first major test https://biobriefs.com/compass-posts-second-pivotal-win BioBriefs en 2026-02-17T16:32:44Z Compass posts second pivotal win – psilocybin approval push intensifies https://biobriefs.com/axpaxli-edges-out-low-dose BioBriefs en 2026-02-17T16:32:44Z Axpaxli edges out low‑dose Eylea – wet‑AMD durability data draw close scrutiny https://biobriefs.com/fda-clears-lexs-velo-poc BioBriefs en 2026-02-17T16:32:44Z FDA clears Lex’s Velo POC PCR and grants CLIA waiver – multiplex respiratory test cleared https://biobriefs.com/watchmaker-licenses-caribous-crispr-cas9 BioBriefs en 2026-02-17T16:32:44Z Watchmaker licenses Caribou’s CRISPR‑Cas9 to solve NGS bottlenecks https://biobriefs.com/swedens-cubasebio-launches-with-eur5 BioBriefs en 2026-02-17T16:32:44Z Sweden’s CubaseBio launches with €5.9M to map 3D transcriptomes https://biobriefs.com/fujifilm-opens-uk-mega-cdmo BioBriefs en 2026-02-17T16:32:44Z Fujifilm opens UK mega‑CDMO: 19,000 L single‑use capacity comes online https://biobriefs.com/gilead-pays-upfront-for-chinas BioBriefs en 2026-02-17T16:32:44Z Gilead pays upfront for China’s Genhouse MAT2A asset – $1.5B deal on the table https://biobriefs.com/fda-clears-ind-for-cspcs BioBriefs en 2026-02-17T16:32:44Z FDA clears IND for CSPC’s SYH‑2082: new GLP‑1/GIP candidate enters US trials https://biobriefs.com/neogenomics-posts-11-q4-growth BioBriefs en 2026-02-17T16:32:44Z NeoGenomics posts 11% Q4 growth; NGS sales accelerate and salesforce to expand https://biobriefs.com/compass-posts-second-phase-3 BioBriefs en 2026-02-17T14:32:12Z Compass posts second Phase‑3 win — Approval push begins https://biobriefs.com/oculars-axpaxli-edges-eylea-durability BioBriefs en 2026-02-17T14:32:12Z Ocular’s Axpaxli edges Eylea — Durability data sparks debate https://biobriefs.com/fda-rejects-discs-bitopertin-agency BioBriefs en 2026-02-17T14:32:12Z FDA rejects Disc’s bitopertin — Agency wants clinical endpoints https://biobriefs.com/gilead-pays-80m-upfront-for BioBriefs en 2026-02-17T14:32:12Z Gilead pays $80m upfront for China’s synthetic‑lethality asset — $1.45bn upside https://biobriefs.com/fujifilm-opens-uk-mega-cdmo BioBriefs en 2026-02-17T14:32:12Z Fujifilm opens UK mega‑CDMO — 19,000 L capacity online H1 2026 https://biobriefs.com/prima-mente-deploys-ai-epigenome BioBriefs en 2026-02-17T14:32:12Z Prima Mente deploys AI epigenome test for early Alzheimer’s — 89–97% detection reported https://biobriefs.com/boehringer-halts-inhaled-cf-gene BioBriefs en 2026-02-17T14:32:12Z Boehringer halts inhaled CF gene therapy program — Early trials terminated https://biobriefs.com/former-fda-oncology-chief-pazdur BioBriefs en 2026-02-17T14:32:12Z Former FDA oncology chief Pazdur says he was pressured on trial cuts — Agency turmoil https://biobriefs.com/european-vcs-form-elsc-to BioBriefs en 2026-02-17T14:32:12Z European VCs form ELSC to unblock life‑sciences funding — €24bn in assets behind push https://biobriefs.com/cell-type-gene-regulatory-map BioBriefs en 2026-02-17T14:32:12Z Cell‑type gene regulatory map for Alzheimer’s — SIGNET reveals causal hubs https://biobriefs.com/pazdur-i-was-asked-to BioBriefs en 2026-02-17T10:32:26Z Pazdur: I was asked to cosign FDA trial cuts https://biobriefs.com/prasad-under-fire-staff-complaints BioBriefs en 2026-02-17T10:32:26Z Prasad under fire — staff complaints and Moderna rift https://biobriefs.com/fda-rejects-discs-bitopertin-questions BioBriefs en 2026-02-17T10:32:26Z FDA rejects Disc’s bitopertin — questions over biomarker https://biobriefs.com/gilead-pays-up-for-chinas BioBriefs en 2026-02-17T10:32:26Z Gilead pays up for China’s Genhouse — $1.5B deal https://biobriefs.com/fujifilm-opens-uk-mega-cdmo BioBriefs en 2026-02-17T10:32:26Z Fujifilm opens UK mega‑CDMO — single‑use capacity expands https://biobriefs.com/europes-vcs-form-coalition-to BioBriefs en 2026-02-17T10:32:26Z Europe’s VCs form coalition to fix life‑sciences funding gap https://biobriefs.com/ai-targets-biology-yeast-dna BioBriefs en 2026-02-17T10:32:26Z AI targets biology: yeast DNA and antibiotic discovery https://biobriefs.com/new-algorithm-assembles-near-complete BioBriefs en 2026-02-17T10:32:26Z New algorithm assembles near‑complete genomes without ultra‑long reads https://biobriefs.com/first-cell-type-gene-regulatory BioBriefs en 2026-02-17T10:32:26Z First cell‑type gene regulatory map for Alzheimer’s built with SIGNET https://biobriefs.com/china-nmpa-clears-gensci-136 BioBriefs en 2026-02-17T10:32:26Z China NMPA clears Gensci‑136 for IgA nephropathy trials https://biobriefs.com/ai-learns-yeast-dna-language BioBriefs en 2026-02-17T09:32:24Z AI learns yeast DNA language: boosts protein drug output https://biobriefs.com/fda-rejects-discs-bitopertin-agency BioBriefs en 2026-02-17T09:32:24Z FDA rejects Disc’s bitopertin — agency demands clinical endpoints https://biobriefs.com/gilead-buys-china-cancer-asset BioBriefs en 2026-02-17T09:32:24Z Gilead buys China cancer asset: $80M upfront, $1.45B in milestones https://biobriefs.com/fujifilm-opens-uk-mega-cdmo BioBriefs en 2026-02-17T09:32:24Z Fujifilm opens UK mega‑CDMO: single‑use capacity and process hub https://biobriefs.com/fda-turmoil-senior-resignations-and BioBriefs en 2026-02-17T09:32:24Z FDA turmoil: senior resignations and ethics complaints roil agency https://biobriefs.com/new-algorithm-builds-near-complete BioBriefs en 2026-02-17T09:32:24Z New algorithm builds near‑complete genomes without ultra‑long reads https://biobriefs.com/ai-predicted-insulin-resistance-tied BioBriefs en 2026-02-17T09:32:24Z AI‑predicted insulin resistance tied to 12 cancers in UK Biobank https://biobriefs.com/systematic-ligand-diversification-finds-molecular BioBriefs en 2026-02-17T09:32:24Z Systematic ligand diversification finds molecular glue that degrades leukemia driver https://biobriefs.com/new-oncology-probes-kif18a-and BioBriefs en 2026-02-17T09:32:24Z New oncology probes: KIF18A and KARS inhibitors enter IP and synthesis reports https://biobriefs.com/regulatory-green-lights-nmpa-oks BioBriefs en 2026-02-17T09:32:24Z Regulatory green lights: NMPA OKs Gensci‑136 trials; FDA clears CSPC IND https://biobriefs.com/fda-rejects-discs-rare-disease BioBriefs en 2026-02-17T04:32:25Z FDA rejects Disc’s rare-disease drug — biomarker questions https://biobriefs.com/fda-leadership-clash-former-officials BioBriefs en 2026-02-17T04:32:25Z FDA leadership clash — former officials and current chiefs at odds https://biobriefs.com/fujifilm-opens-uk-mega-cdmo BioBriefs en 2026-02-17T04:32:25Z Fujifilm opens UK mega‑CDMO — single‑use capacity expands https://biobriefs.com/algorithm-assembles-human-genomes-without BioBriefs en 2026-02-17T04:32:25Z Algorithm assembles human genomes without ultra‑long reads https://biobriefs.com/cell-type-causal-map-for BioBriefs en 2026-02-17T04:32:25Z Cell‑type causal map for Alzheimer’s — new GRN method https://biobriefs.com/high-throughput-ligand-diversification-yields BioBriefs en 2026-02-17T04:32:25Z High‑throughput ligand diversification yields molecular glue for leukemia https://biobriefs.com/china-clears-dual-april-baff BioBriefs en 2026-02-17T04:32:25Z China clears dual APRIL/BAFF candidate for IgA nephropathy trials https://biobriefs.com/fda-accepts-ind-for-cspcs BioBriefs en 2026-02-17T04:32:25Z FDA accepts IND for CSPC’s GLP‑1/GIP dual agonist for weight management https://biobriefs.com/ai-links-insulin-resistance-to BioBriefs en 2026-02-17T04:32:25Z AI links insulin resistance to risk for 12 cancers in 500K cohort https://biobriefs.com/nyu-langone-forecasts-autonomous-clinical BioBriefs en 2026-02-17T04:32:25Z NYU Langone forecasts autonomous clinical AI within five years https://biobriefs.com/fda-turmoil-two-senior-exits BioBriefs en 2026-02-16T21:32:21Z FDA turmoil: Two senior exits and allegations roil agency https://biobriefs.com/fda-rejects-disc-medicine-drug BioBriefs en 2026-02-16T21:32:21Z FDA rejects Disc Medicine drug: surrogate endpoint fails to convince https://biobriefs.com/genome-assembly-without-ultra-long BioBriefs en 2026-02-16T21:32:21Z Genome assembly without ultra-long reads: algorithm narrows the gap https://biobriefs.com/fda-clears-ind-for-cspcs BioBriefs en 2026-02-16T21:32:21Z FDA clears IND for CSPC’s GLP-1/GIP candidate for weight management https://biobriefs.com/fujifilm-opens-uk-mega-cdmo BioBriefs en 2026-02-16T21:32:21Z Fujifilm opens UK mega-CDMO: 19,000 L single-use capacity comes online https://biobriefs.com/ai-hunts-antibiotics-peptides-mined BioBriefs en 2026-02-16T21:32:21Z AI hunts antibiotics: peptides mined from ancient genomes and venoms https://biobriefs.com/alzheimers-cell-type-gene-map BioBriefs en 2026-02-16T21:32:21Z Alzheimer’s cell-type gene map: SIGNET reveals causal regulatory hubs https://biobriefs.com/high-throughput-molecular-glues-uncover BioBriefs en 2026-02-16T21:32:21Z High-throughput molecular glues uncover leukemia degrader https://biobriefs.com/pan-inflammasome-blocker-surfaces-for BioBriefs en 2026-02-16T21:32:21Z Pan-inflammasome blocker surfaces for hidradenitis suppurativa https://biobriefs.com/engineered-cell-therapies-for-autoimmunity BioBriefs en 2026-02-16T21:32:21Z Engineered cell therapies for autoimmunity: clinical landscape tightens https://biobriefs.com/ex-fda-oncology-chief-says BioBriefs en 2026-02-16T16:32:29Z Ex‑FDA oncology chief says he was pressured to back trial cuts https://biobriefs.com/cber-director-faces-complaints-as BioBriefs en 2026-02-16T16:32:29Z CBER director faces complaints as Moderna flu review stalls https://biobriefs.com/fda-rejects-discs-rare-disease BioBriefs en 2026-02-16T16:32:29Z FDA rejects Disc’s rare‑disease drug…fast‑track status didn’t help https://biobriefs.com/fujifilm-opens-uk-single-use BioBriefs en 2026-02-16T16:32:29Z Fujifilm opens UK single‑use CDMO — £400m campus expansion https://biobriefs.com/china-clears-gensci-136-trials BioBriefs en 2026-02-16T16:32:29Z China clears Gensci‑136 trials — dual APRIL/BAFF antagonist enters clinic https://biobriefs.com/researchers-map-cell-type-gene BioBriefs en 2026-02-16T16:32:29Z Researchers map cell‑type gene regulatory networks for Alzheimer’s https://biobriefs.com/high-throughput-chemistry-unearths-a BioBriefs en 2026-02-16T16:32:29Z High‑throughput chemistry unearths a molecular glue that degrades leukemia driver https://biobriefs.com/nature-biotechnology-review-engineered-cell BioBriefs en 2026-02-16T16:32:29Z Nature Biotechnology review: engineered cell therapies make clinical headway in autoimmunity https://biobriefs.com/fda-accepts-cspcs-ind-for BioBriefs en 2026-02-16T16:32:29Z FDA accepts CSPC’s IND for SYH‑2082 — dual GLP‑1/GIP weight program enters US studies https://biobriefs.com/ai-predicted-insulin-resistance-tied BioBriefs en 2026-02-16T16:32:29Z AI‑predicted insulin resistance tied to 12 cancers in UK Biobank analysis https://biobriefs.com/ai-tool-links-insulin-resistance BioBriefs en 2026-02-16T14:32:31Z AI tool links insulin resistance to 12 cancers: population-scale finding https://biobriefs.com/cell-type-gene-map-for BioBriefs en 2026-02-16T14:32:31Z Cell‑type gene map for Alzheimer’s reveals causal hub genes – new analysis method https://biobriefs.com/high-throughput-chemistry-uncovers-molecular BioBriefs en 2026-02-16T14:32:31Z High‑throughput chemistry uncovers molecular glue that degrades leukemia driver https://biobriefs.com/fujifilm-opens-uk-single-use BioBriefs en 2026-02-16T14:32:30Z Fujifilm opens UK single‑use CDMO campus: 19,000 L capacity, £400m investment https://biobriefs.com/cber-chiefs-conduct-and-moderna BioBriefs en 2026-02-16T14:32:30Z CBER chief’s conduct and Moderna RTF ignite FDA internal revolt https://biobriefs.com/ai-hunts-antibiotics-in-genomes BioBriefs en 2026-02-16T14:32:30Z AI hunts antibiotics in genomes and ancient sequences — Penn group scales search https://biobriefs.com/drinkable-gene-therapy-foam-targets BioBriefs en 2026-02-16T14:32:30Z Drinkable gene‑therapy foam targets esophageal tumors: noninvasive local delivery https://biobriefs.com/extracellular-vesicles-rise-as-nonviral BioBriefs en 2026-02-16T14:32:30Z Extracellular vesicles rise as nonviral delivery platform for genes and proteins https://biobriefs.com/clinical-engineered-cell-therapies-for BioBriefs en 2026-02-16T14:32:30Z Clinical engineered‑cell therapies for autoimmunity: review flags early wins and gaps https://biobriefs.com/new-broad-spectrum-prevention-method BioBriefs en 2026-02-16T14:32:30Z New broad‑spectrum prevention method blocks resistant bacteria and influenza https://biobriefs.com/cber-chief-under-fire-moderna BioBriefs en 2026-02-16T10:32:33Z CBER chief under fire: Moderna flu filing returned after internal pushback https://biobriefs.com/fujifilm-bets-ps400m-uk-site BioBriefs en 2026-02-16T10:32:33Z Fujifilm bets £400m: UK site becomes largest single-use CDMO https://biobriefs.com/engineered-cell-therapies-for-autoimmunity BioBriefs en 2026-02-16T10:32:33Z Engineered cell therapies for autoimmunity — Nature Biotechnology outlines clinical advances https://biobriefs.com/base-barrier-cells-new-brain BioBriefs en 2026-02-16T10:32:33Z Base barrier cells: new brain‑barrier compartmentalization discovered https://biobriefs.com/universal-ai-model-raises-mri BioBriefs en 2026-02-16T10:32:33Z Universal AI model raises MRI accuracy: cross‑site brain imaging generalizes https://biobriefs.com/tumor-microenvironment-targeted-ferroptosis-nanotherapy BioBriefs en 2026-02-16T10:32:33Z Tumor microenvironment targeted — ferroptosis nanotherapy rewires CAFs; metabolism drives immunosuppression https://biobriefs.com/two-delivery-routes-advance-gene BioBriefs en 2026-02-16T10:32:33Z Two delivery routes advance gene therapy: drinkable foam and extracellular vesicles https://biobriefs.com/regeneration-insights-axolotl-thymus-rebuilds BioBriefs en 2026-02-16T10:32:33Z Regeneration insights: axolotl thymus rebuilds and apple snail regenerates eye https://biobriefs.com/ultrasound-and-ai-converge-acoustoelectric BioBriefs en 2026-02-16T10:32:33Z Ultrasound and AI converge: acoustoelectric neural readout and real‑time acoustic trapping https://biobriefs.com/rna-methylation-and-neddylation-emerge BioBriefs en 2026-02-16T10:32:33Z RNA methylation and neddylation emerge as oncology targets: RCC and CRC mechanisms https://biobriefs.com/cber-head-faces-internal-revolt BioBriefs en 2026-02-16T09:32:37Z CBER head faces internal revolt: Moderna flu filing returned https://biobriefs.com/fujifilm-doubles-uk-capacity-ps400m BioBriefs en 2026-02-16T09:32:37Z Fujifilm doubles UK capacity – £400m CDMO opens https://biobriefs.com/ultrasound-in-the-clinic-real BioBriefs en 2026-02-16T09:32:37Z Ultrasound in the clinic: real-time microbubble control and in vivo neural reads https://biobriefs.com/new-broad-spectrum-defenses-hospital BioBriefs en 2026-02-16T09:32:37Z New broad-spectrum defenses: hospital barriers and nicotine‑derived antivirals https://biobriefs.com/extracellular-vesicles-meet-ddpcr-precision BioBriefs en 2026-02-16T09:32:37Z Extracellular vesicles meet ddPCR: precision delivery and measurement for gene therapies https://biobriefs.com/universal-foundation-model-advances-human BioBriefs en 2026-02-16T09:32:37Z Universal foundation model advances human brain MRI analysis https://biobriefs.com/axolotls-regrow-thymus-full-immune BioBriefs en 2026-02-16T09:32:37Z Axolotls regrow thymus: full immune‑organ regeneration observed https://biobriefs.com/oral-foam-delivers-gene-therapy BioBriefs en 2026-02-16T09:32:37Z Oral foam delivers gene therapy to esophageal tumors: a new delivery route https://biobriefs.com/next-gen-ccr5-antibody-revives BioBriefs en 2026-02-16T09:32:37Z Next‑gen CCR5 antibody revives immunomodulation strategies https://biobriefs.com/ferroptosis-nanotherapy-reprograms-colorectal-tumor BioBriefs en 2026-02-16T09:32:37Z Ferroptosis nanotherapy reprograms colorectal tumor stroma https://biobriefs.com/cber-boss-in-spotlight-moderna BioBriefs en 2026-02-16T04:32:07Z CBER boss in spotlight: Moderna flu filing returned https://biobriefs.com/ultrasound-opens-acoustoelectric-window-first BioBriefs en 2026-02-16T04:32:07Z Ultrasound opens acoustoelectric window—first in vivo neural recordings https://biobriefs.com/universal-brain-mri-model-ai BioBriefs en 2026-02-16T04:32:07Z Universal brain MRI model: AI that generalizes across scanners https://biobriefs.com/base-barrier-cells-discovered-new BioBriefs en 2026-02-16T04:32:07Z Base barrier cells discovered—new compartmentalizer of choroid plexus https://biobriefs.com/gaas-hybrid-pixel-detector-enhances BioBriefs en 2026-02-16T04:32:07Z GaAs hybrid-pixel detector enhances 100 keV cryo-EM imaging https://biobriefs.com/ferroptosis-nanotherapy-reprograms-colorectal-cancer BioBriefs en 2026-02-16T04:32:07Z Ferroptosis nanotherapy reprograms colorectal cancer fibroblasts https://biobriefs.com/oral-foam-delivers-gene-therapy BioBriefs en 2026-02-16T04:32:07Z Oral foam delivers gene therapy—targets constrictive esophageal carcinoma https://biobriefs.com/extracellular-vesicles-repurposed-for-precise BioBriefs en 2026-02-16T04:32:07Z Extracellular vesicles repurposed for precise, nonviral delivery https://biobriefs.com/glp-1-triggers-katp-in BioBriefs en 2026-02-16T04:32:07Z GLP‑1 triggers KATP in coronary pericytes—mechanism for cardioprotection https://biobriefs.com/bdnf-derived-dodecapeptide-antagonizes-tlr4 BioBriefs en 2026-02-16T04:32:07Z BDNF‑derived dodecapeptide antagonizes TLR4—potential ALI therapy https://biobriefs.com/exact-sciences-revenue-rises-23 BioBriefs en 2026-02-15T21:32:04Z Exact Sciences Revenue Rises 23%—Shareholders Set to Vote on $23B Abbott Deal https://biobriefs.com/bridgebios-infigratinib-matches-voxzogo-on BioBriefs en 2026-02-15T21:32:04Z BridgeBio’s Infigratinib Matches Voxzogo on Height: Oral FGFR3 Option Emerges https://biobriefs.com/fda-setback-on-disc-questions BioBriefs en 2026-02-15T21:32:04Z FDA Setback on Disc: Questions Grow About Accelerated Approval Vouchers https://biobriefs.com/anterior-raises-40m-ai-to BioBriefs en 2026-02-15T21:32:04Z Anterior Raises $40M: AI to Speed Care Approvals from Weeks to Minutes https://biobriefs.com/droplet-digital-pcr-absolute-quantification BioBriefs en 2026-02-15T21:32:04Z Droplet digital PCR... Absolute quantification without standard curves https://biobriefs.com/gaas-detector-boosts-100-kev BioBriefs en 2026-02-15T21:32:04Z GaAs detector boosts 100 keV cryo‑EM — higher-resolution imaging for biology https://biobriefs.com/drinkable-foam-delivers-gene-therapy BioBriefs en 2026-02-15T21:32:04Z Drinkable foam delivers gene therapy: New oral route targets esophageal cancer https://biobriefs.com/cells-own-packages-repurposed-extracellular BioBriefs en 2026-02-15T21:32:04Z Cells’ own packages repurposed: Extracellular vesicles for safer gene delivery https://biobriefs.com/glp-1-activates-katp-channels BioBriefs en 2026-02-15T21:32:04Z GLP‑1 activates KATP channels—pericyte mechanism shields heart https://biobriefs.com/ferroptosis-nanotherapy-reverses-cafs-remodels BioBriefs en 2026-02-15T21:32:04Z Ferroptosis nanotherapy reverses CAFs: Remodels colorectal tumor stroma https://biobriefs.com/exact-sciences-posts-strong-quarter BioBriefs en 2026-02-15T16:32:24Z Exact Sciences Posts Strong Quarter – Shareholders Set to Vote on $23B Abbott Deal https://biobriefs.com/fda-rejects-discs-rare-disease BioBriefs en 2026-02-15T16:32:24Z FDA Rejects Disc’s Rare-Disease Drug: Voucher Program Faces First Test https://biobriefs.com/bridgebios-oral-infigratinib-matches-voxzogo BioBriefs en 2026-02-15T16:32:24Z BridgeBio’s Oral Infigratinib Matches Voxzogo on Height – Adds Patient‑Friendly Option https://biobriefs.com/vertex-sees-casgevy-uptick-gene BioBriefs en 2026-02-15T16:32:24Z Vertex Sees Casgevy Uptick – Gene‑Edited Therapy Bolsters Results https://biobriefs.com/ptc-withdraws-translarna-fda-bid BioBriefs en 2026-02-15T16:32:24Z PTC Withdraws Translarna FDA Bid – Data Gaps Cited https://biobriefs.com/australia-launches-first-pediatric-mrna BioBriefs en 2026-02-15T16:32:24Z Australia Launches First Pediatric mRNA Brain‑Cancer Trial https://biobriefs.com/anterior-raises-40m-to-automate BioBriefs en 2026-02-15T16:32:24Z Anterior Raises $40M to Automate Care Approvals with AI https://biobriefs.com/agios-advances-mitapivat-tebapivat-in BioBriefs en 2026-02-15T16:32:24Z Agios Advances Mitapivat, Tebapivat in Sickle‑Cell After Thalassemia Win https://biobriefs.com/nihs-all-of-us-tops BioBriefs en 2026-02-15T16:32:24Z NIH’s All of Us Tops 1 Million — Representative Genomic Resource Achieved https://biobriefs.com/niaid-restructures-biodefense-and-pandemic BioBriefs en 2026-02-15T16:32:24Z NIAID Restructures: Biodefense and Pandemic Prep Deprioritized, Emails Show https://biobriefs.com/fda-rejects-disc-medicines-bitopertin BioBriefs en 2026-02-15T14:32:37Z FDA Rejects Disc Medicine’s Bitopertin—Biomarker Link Deemed Uncertain https://biobriefs.com/modernas-flu-review-stalls-regulatory BioBriefs en 2026-02-15T14:32:37Z Moderna’s Flu Review Stalls... Regulatory Pushback Ripples Through Biotech https://biobriefs.com/exact-sciences-q4-revenue-jumps BioBriefs en 2026-02-15T14:32:37Z Exact Sciences Q4 Revenue Jumps 23% — Shareholders to Vote on $23B Abbott Deal https://biobriefs.com/bio-rads-ddpcr-lift-product BioBriefs en 2026-02-15T14:32:37Z Bio‑Rad’s ddPCR Lift—Product Momentum Meets Technology Adoption https://biobriefs.com/ultragenyx-cuts-10-of-workforce BioBriefs en 2026-02-15T14:32:37Z Ultragenyx Cuts 10% of Workforce as FDA Flags Gene‑Therapy Gaps https://biobriefs.com/lyell-launches-first-of-its BioBriefs en 2026-02-15T14:32:37Z Lyell Launches First‑of‑Its‑Kind CAR‑T Trial—Direct Test vs Marketed Products https://biobriefs.com/anterior-raises-40m-ai-platform BioBriefs en 2026-02-15T14:32:37Z Anterior Raises $40M—AI Platform to Slash Care‑Approval Times https://biobriefs.com/australia-launches-world-first-pediatric BioBriefs en 2026-02-15T14:32:37Z Australia Launches World‑First Pediatric mRNA Brain‑Cancer Trial https://biobriefs.com/vertexs-crispr-therapy-rebounds-casgevy BioBriefs en 2026-02-15T14:32:37Z Vertex’s CRISPR Therapy Rebounds—Casgevy Sales Triple in Latest Quarter https://biobriefs.com/vcs-launch-european-life-science BioBriefs en 2026-02-15T14:32:37Z VCs Launch European Life Science Coalition: €24B to Mobilize Investment https://biobriefs.com/fda-rejects-disc-therapy-expedited BioBriefs en 2026-02-15T10:32:20Z FDA rejects Disc therapy — expedited voucher route falters https://biobriefs.com/niaid-reshapes-priorities-biodefense-and BioBriefs en 2026-02-15T10:32:20Z NIAID reshapes priorities: biodefense and pandemic preparedness deprioritized https://biobriefs.com/bridgebios-oral-fgfr3-matches-voxzogo BioBriefs en 2026-02-15T10:32:20Z BridgeBio’s oral FGFR3 matches Voxzogo on height — adds pill option https://biobriefs.com/lyell-launches-head-to-head BioBriefs en 2026-02-15T10:32:20Z Lyell launches head-to-head CAR-T trial: experimental therapy to face rivals https://biobriefs.com/quantx-closes-85m-series-b BioBriefs en 2026-02-15T10:32:20Z Quantx closes $85M Series B to advance oral immunology pipeline https://biobriefs.com/australia-launches-world-first-pediatric BioBriefs en 2026-02-15T10:32:20Z Australia launches world‑first pediatric mRNA brain‑cancer vaccine trial https://biobriefs.com/all-of-us-hits-1m BioBriefs en 2026-02-15T10:32:20Z All of Us hits 1M participants — national diverse cohort complete https://biobriefs.com/10x-braces-for-modest-growth BioBriefs en 2026-02-15T10:32:20Z 10x braces for modest growth — imaging‑free spatial tools advance https://biobriefs.com/fda-declines-to-review-moderna BioBriefs en 2026-02-15T10:32:20Z FDA declines to review Moderna flu shot — regulatory uncertainty ripples https://biobriefs.com/gilead-buys-genhouse-cancer-drug BioBriefs en 2026-02-15T10:32:20Z Gilead buys Genhouse cancer drug: $80M upfront for global rights https://biobriefs.com/fda-rejects-discs-bitopertin-voucher BioBriefs en 2026-02-15T09:32:28Z FDA rejects Disc’s bitopertin: Voucher-backed rare-disease bid fails https://biobriefs.com/ptc-pulls-translarna-two-decade BioBriefs en 2026-02-15T09:32:28Z PTC pulls Translarna: Two-decade Duchenne bid stalls https://biobriefs.com/fda-balks-at-moderna-flu BioBriefs en 2026-02-15T09:32:28Z FDA balks at Moderna flu: Review refused – industry on edge https://biobriefs.com/niaid-shifts-focus-biodefense-and BioBriefs en 2026-02-15T09:32:28Z NIAID shifts focus: 'Biodefense' and pandemic preparedness deprioritized https://biobriefs.com/lyell-launches-head-to-head BioBriefs en 2026-02-15T09:32:28Z Lyell launches head-to-head CAR‑T trial: First-of-its-kind test https://biobriefs.com/australia-launches-first-pediatric-mrna BioBriefs en 2026-02-15T09:32:28Z Australia launches first pediatric mRNA brain-cancer trial https://biobriefs.com/all-of-us-hits-1 BioBriefs en 2026-02-15T09:32:28Z All of Us hits 1 million: NIH dataset reaches diversity goal https://biobriefs.com/dna-origami-vaccine-induces-broadly BioBriefs en 2026-02-15T09:32:28Z DNA origami vaccine induces broadly neutralizing HIV antibodies https://biobriefs.com/engineered-exosomes-carry-antibodies-targeted BioBriefs en 2026-02-15T09:32:28Z Engineered exosomes carry antibodies: targeted IBD delivery in preclinical models https://biobriefs.com/biotech-financing-roundup-quantx-85m BioBriefs en 2026-02-15T09:32:28Z Biotech financing roundup: Quantx $85M; Anterior $40M to scale AI approvals https://biobriefs.com/fda-rejects-discs-porphyria-drug BioBriefs en 2026-02-15T04:32:14Z FDA rejects Disc’s porphyria drug: biomarker link questioned https://biobriefs.com/fda-refusal-rattles-moderna-flu BioBriefs en 2026-02-15T04:32:14Z FDA refusal rattles Moderna — flu program and guidance clouded https://biobriefs.com/ptc-withdraws-translarna-us-bid BioBriefs en 2026-02-15T04:32:14Z PTC withdraws Translarna US bid — data won’t meet FDA threshold https://biobriefs.com/australia-launches-first-pediatric-mrna BioBriefs en 2026-02-15T04:32:14Z Australia launches first pediatric mRNA brain‑cancer trial https://biobriefs.com/lyell-opens-first-of-its BioBriefs en 2026-02-15T04:32:14Z Lyell opens first‑of‑its‑kind CAR‑T head‑to‑head study https://biobriefs.com/gilead-buys-genhouse-oral-cancer BioBriefs en 2026-02-15T04:32:14Z Gilead buys Genhouse oral cancer drug for $80M up front https://biobriefs.com/quantx-raises-85m-to-advance BioBriefs en 2026-02-15T04:32:14Z Quantx raises $85M to advance oral immunology programs https://biobriefs.com/anterior-nets-40m-to-automate BioBriefs en 2026-02-15T04:32:14Z Anterior nets $40M to automate care approvals with AI https://biobriefs.com/all-of-us-reaches-1m BioBriefs en 2026-02-15T04:32:14Z All of Us reaches 1M participants: dataset now representative https://biobriefs.com/niaid-told-to-downplay-pandemic BioBriefs en 2026-02-15T04:32:14Z NIAID told to downplay pandemic preparedness: staff ordered to scrub pages https://biobriefs.com/fda-rejects-discs-porphyria-drug BioBriefs en 2026-02-14T21:32:21Z FDA rejects Disc’s porphyria drug: biomarker link questioned https://biobriefs.com/fda-refuses-to-file-modernas BioBriefs en 2026-02-14T21:32:21Z FDA refuses to file Moderna’s flu shot — company says it was blindsided https://biobriefs.com/lyell-launches-head-to-head BioBriefs en 2026-02-14T21:32:21Z Lyell launches head‑to‑head CAR‑T trial versus marketed therapies https://biobriefs.com/vertexs-crispr-therapy-rebounds-casgevy BioBriefs en 2026-02-14T21:32:21Z Vertex’s CRISPR therapy rebounds — Casgevy sales surge https://biobriefs.com/exact-sciences-posts-23-q4 BioBriefs en 2026-02-14T21:32:21Z Exact Sciences posts 23% Q4 revenue gain — Abbott acquisition heads to vote https://biobriefs.com/bridgebios-oral-infigratinib-matches-voxzogo BioBriefs en 2026-02-14T21:32:21Z BridgeBio’s oral infigratinib matches Voxzogo on height — adds pill option https://biobriefs.com/quantx-raises-85m-to-advance BioBriefs en 2026-02-14T21:32:21Z Quantx raises $85M to advance oral immunology drugs into trials https://biobriefs.com/anterior-grabs-40m-ai-to BioBriefs en 2026-02-14T21:32:21Z Anterior grabs $40M — AI to speed payer approvals to minutes https://biobriefs.com/australia-launches-world-first-pediatric BioBriefs en 2026-02-14T21:32:21Z Australia launches world‑first pediatric individualized mRNA brain‑cancer trial https://biobriefs.com/nektar-evommune-post-positive-phase BioBriefs en 2026-02-14T21:32:21Z Nektar, Evommune post positive Phase II readouts in atopic dermatitis https://biobriefs.com/fda-rejects-discs-porphyria-drug BioBriefs en 2026-02-14T16:32:35Z FDA rejects Disc’s porphyria drug — biomarker link questioned https://biobriefs.com/fda-refuse-to-file-blindsides BioBriefs en 2026-02-14T16:32:35Z FDA refuse-to-file blindsides Moderna — flu program under scrutiny https://biobriefs.com/infigratinib-phase-iii-clears-bar BioBriefs en 2026-02-14T16:32:35Z Infigratinib phase III clears bar — BridgeBio adds oral option for achondroplasia https://biobriefs.com/all-of-us-reaches-1 BioBriefs en 2026-02-14T16:32:35Z All of Us reaches 1 million participants — diversity milestone for precision medicine https://biobriefs.com/lyell-launches-head-to-head BioBriefs en 2026-02-14T16:32:35Z Lyell launches head‑to‑head CAR‑T trial — first direct test against marketed products https://biobriefs.com/ultragenyx-cuts-10-as-fda BioBriefs en 2026-02-14T16:32:35Z Ultragenyx cuts 10% as FDA manufacturing and trial setbacks press cost plan https://biobriefs.com/ptc-withdraws-translarna-us-bid BioBriefs en 2026-02-14T16:32:35Z PTC withdraws Translarna US bid — FDA doubts sufficiency of evidence https://biobriefs.com/quantx-closes-85m-series-b BioBriefs en 2026-02-14T16:32:35Z Quantx closes $85M series B to push oral STAT6 and IL‑17 programs to clinic https://biobriefs.com/australia-launches-world-first-pediatric BioBriefs en 2026-02-14T16:32:35Z Australia launches world‑first pediatric mRNA brain‑cancer vaccine trial https://biobriefs.com/anterior-raises-40m-ai-to BioBriefs en 2026-02-14T16:32:35Z Anterior raises $40M — AI to automate care approvals for health plans https://biobriefs.com/fda-nixes-disc-medicines-porphyria BioBriefs en 2026-02-14T14:32:26Z FDA nixes Disc Medicine’s porphyria drug — expedited voucher route fails https://biobriefs.com/bridgebios-oral-fgfr3-drug-clears BioBriefs en 2026-02-14T14:32:26Z BridgeBio’s oral FGFR3 drug clears Phase III — adds oral option for achondroplasia https://biobriefs.com/fda-refuses-to-file-modernas BioBriefs en 2026-02-14T14:32:26Z FDA refuses to file Moderna’s flu vaccine — company and regulators at odds https://biobriefs.com/vertexs-crispr-drug-rebounds-casgevy BioBriefs en 2026-02-14T14:32:26Z Vertex’s CRISPR drug rebounds — Casgevy sales more than triple https://biobriefs.com/exact-sciences-posts-q4-beat BioBriefs en 2026-02-14T14:32:26Z Exact Sciences posts Q4 beat — shareholders to vote on $23B Abbott deal https://biobriefs.com/all-of-us-hits-1 BioBriefs en 2026-02-14T14:32:26Z All of Us hits 1 million participants — NIH achieves representative cohort https://biobriefs.com/lyell-launches-head-to-head BioBriefs en 2026-02-14T14:32:26Z Lyell launches head‑to‑head CAR‑T trial — first test against marketed therapies https://biobriefs.com/quantx-raises-85m-funds-oral BioBriefs en 2026-02-14T14:32:26Z Quantx raises $85M — funds oral STAT6 and IL‑17 programs https://biobriefs.com/anterior-grabs-40m-ai-to BioBriefs en 2026-02-14T14:32:26Z Anterior grabs $40M — AI to speed care approvals for payers https://biobriefs.com/fda-trims-boxed-warnings-on BioBriefs en 2026-02-14T14:32:26Z FDA trims boxed warnings on menopausal HRTs — risk statements narrowed https://biobriefs.com/fda-rejects-discs-therapy-voucher BioBriefs en 2026-02-14T10:32:25Z FDA rejects Disc’s therapy: voucher fast-track falters https://biobriefs.com/bridgebios-oral-drug-clears-phase BioBriefs en 2026-02-14T10:32:25Z BridgeBio’s oral drug clears Phase 3 — oral rival to Voxzogo https://biobriefs.com/fda-refuses-to-file-modernas BioBriefs en 2026-02-14T10:32:25Z FDA refuses to file Moderna’s flu vaccine — company blindsided https://biobriefs.com/ultragenyx-trims-staff-10-as BioBriefs en 2026-02-14T10:32:25Z Ultragenyx trims staff 10% as FDA stalls gene‑therapy plans https://biobriefs.com/fda-drops-boxed-warnings-for BioBriefs en 2026-02-14T10:32:25Z FDA drops boxed warnings for six HRTs — labels narrowed https://biobriefs.com/lyell-launches-head-to-head BioBriefs en 2026-02-14T10:32:25Z Lyell launches head‑to‑head CAR‑T trial against marketed therapies https://biobriefs.com/caredx-plans-alloheme-launch-after BioBriefs en 2026-02-14T10:32:25Z CareDx plans AlloHeme launch after validation shows 41‑day relapse lead https://biobriefs.com/quantx-secures-85m-to-advance BioBriefs en 2026-02-14T10:32:25Z Quantx secures $85M to advance oral immunology pipeline https://biobriefs.com/pacbio-posts-14-q4-growth BioBriefs en 2026-02-14T10:32:25Z PacBio posts 14% Q4 growth — clinical and European demand climbs https://biobriefs.com/gilead-buys-genhouse-cancer-drug BioBriefs en 2026-02-14T10:32:25Z Gilead buys Genhouse cancer drug — $80M upfront https://biobriefs.com/bridgebios-oral-dwarfism-pill-wins BioBriefs en 2026-02-14T09:32:16Z BridgeBio’s oral dwarfism pill wins Phase 3 — regulatory filing planned https://biobriefs.com/fda-rejects-disc-medicines-bitopertin BioBriefs en 2026-02-14T09:32:16Z FDA rejects Disc Medicine’s bitopertin — voucher fast-track fails https://biobriefs.com/modernas-flu-program-stalled-fda BioBriefs en 2026-02-14T09:32:16Z Moderna’s flu program stalled: FDA refuse-to-file sparks industry alarm https://biobriefs.com/niaid-told-to-deprioritize-pandemic BioBriefs en 2026-02-14T09:32:16Z NIAID told to deprioritize pandemic work: agency pivots under NIH directive https://biobriefs.com/fda-removes-boxed-warnings-for BioBriefs en 2026-02-14T09:32:16Z FDA removes boxed warnings for six menopausal HRTs — label overhaul takes effect https://biobriefs.com/lyell-launches-first-head-to BioBriefs en 2026-02-14T09:32:16Z Lyell launches first head‑to‑head CAR‑T trial — challengers to market incumbents https://biobriefs.com/european-investors-form-life-sciences BioBriefs en 2026-02-14T09:32:16Z European investors form life‑sciences coalition — capital push for biotech https://biobriefs.com/nih-all-of-us-reaches BioBriefs en 2026-02-14T09:32:16Z NIH All of Us reaches 1M participants — dataset hits diversity target https://biobriefs.com/quantx-closes-85m-series-b BioBriefs en 2026-02-14T09:32:16Z Quantx closes $85M Series B — oral immunology drugs move toward clinic https://biobriefs.com/ultragenyx-cuts-10-of-staff BioBriefs en 2026-02-14T09:32:16Z Ultragenyx cuts 10% of staff amid manufacturing and regulatory setbacks https://biobriefs.com/fda-refuse-to-file-modernas BioBriefs en 2026-02-14T04:32:40Z FDA refuse-to-file — Moderna’s mRNA flu program stumbles https://biobriefs.com/rare-disease-approvals-derail-disc BioBriefs en 2026-02-14T04:32:40Z Rare‑disease approvals derail: Disc and PTC hit regulatory roadblocks https://biobriefs.com/bridgebios-win-infigratinib-clears-phase BioBriefs en 2026-02-14T04:32:40Z BridgeBio’s win — infigratinib clears Phase III hurdle in achondroplasia https://biobriefs.com/lyell-launches-head-to-head BioBriefs en 2026-02-14T04:32:40Z Lyell launches head‑to‑head CAR‑T trial — experimental therapy to face marketed rivals https://biobriefs.com/ribo-and-madrigal-team-up BioBriefs en 2026-02-14T04:32:40Z Ribo and Madrigal team up: $60M upfront to push siRNA portfolio in MASH https://biobriefs.com/quantx-raises-85m-to-advance BioBriefs en 2026-02-14T04:32:40Z Quantx raises $85M to advance oral immunology candidates https://biobriefs.com/caredx-readies-alloheme-launch-after BioBriefs en 2026-02-14T04:32:40Z CareDx readies AlloHeme launch after validation shows early relapse lead time https://biobriefs.com/all-of-us-hits-1 BioBriefs en 2026-02-14T04:32:40Z All of Us hits 1 million: NIH milestone expands precision‑medicine resource https://biobriefs.com/world-first-pediatric-mrna-brain BioBriefs en 2026-02-14T04:32:40Z World‑first pediatric mRNA brain‑cancer trial launches in Australia https://biobriefs.com/inhaled-gene-therapy-shows-early BioBriefs en 2026-02-14T04:32:40Z Inhaled gene therapy shows early promise in lung cancer delivery https://biobriefs.com/fda-refuses-to-review-moderna BioBriefs en 2026-02-13T21:32:32Z FDA refuses to review Moderna flu shot — company says letter blindsided team https://biobriefs.com/niaid-told-to-drop-biodefense BioBriefs en 2026-02-13T21:32:32Z NIAID told to drop 'biodefense' and 'pandemic preparedness' — agency shifts funding focus https://biobriefs.com/bridgebios-oral-fgfr3-inhibitor-posts BioBriefs en 2026-02-13T21:32:32Z BridgeBio’s oral FGFR3 inhibitor posts Phase 3 win — files planned this year https://biobriefs.com/ptc-withdraws-us-approval-bid BioBriefs en 2026-02-13T21:32:32Z PTC withdraws US approval bid for Translarna — FDA doubts clinical benefit https://biobriefs.com/ultragenyx-cuts-10-of-workforce BioBriefs en 2026-02-13T21:32:32Z Ultragenyx cuts 10% of workforce as FDA presses on gene therapy review https://biobriefs.com/lyell-starts-first-head-to BioBriefs en 2026-02-13T21:32:32Z Lyell starts first head-to-head CAR‑T trial... testing new cell therapy against market leaders https://biobriefs.com/quantx-raises-85m-to-advance BioBriefs en 2026-02-13T21:32:32Z Quantx raises $85M to advance oral STAT6 and IL‑17 programs https://biobriefs.com/caredxs-alloheme-shows-high-sensitivity BioBriefs en 2026-02-13T21:32:32Z CareDx’s AlloHeme shows high sensitivity, 41‑day lead time — commercial launch planned https://biobriefs.com/european-vcs-form-coalition-new BioBriefs en 2026-02-13T21:32:32Z European VCs form coalition — new push to keep biotech funding and exits in the EU https://biobriefs.com/gilead-buys-global-rights-to BioBriefs en 2026-02-13T21:32:32Z Gilead buys global rights to Genhouse oral cancer drug — $80M upfront https://biobriefs.com/fda-refusal-halts-moderna-flu BioBriefs en 2026-02-13T16:32:35Z FDA refusal halts Moderna flu review — mRNA vaccine program in limbo https://biobriefs.com/bridgebios-oral-drug-boosts-growth BioBriefs en 2026-02-13T16:32:35Z BridgeBio’s oral drug boosts growth in children — Phase 3 win sets up FDA filing https://biobriefs.com/ultragenyx-cuts-10-as-late BioBriefs en 2026-02-13T16:32:35Z Ultragenyx cuts 10% as late‑stage failures force restructuring — gene therapy review stalled https://biobriefs.com/fda-removes-black-box-warnings BioBriefs en 2026-02-13T16:32:35Z FDA removes black‑box warnings from six menopausal therapies — labeling overhaul https://biobriefs.com/pacbio-posts-14-q4-revenue BioBriefs en 2026-02-13T16:32:35Z PacBio posts 14% Q4 revenue rise — clinical customers and Europe drive growth https://biobriefs.com/caredxs-alloheme-posts-strong-validation BioBriefs en 2026-02-13T16:32:35Z CareDx’s AlloHeme posts strong validation — company eyes 2027 commercial launch https://biobriefs.com/quantx-closes-85m-series-b BioBriefs en 2026-02-13T16:32:35Z Quantx closes $85M Series B — oral STAT6 and IL‑17 programs move to clinic https://biobriefs.com/policy-shakeup-at-hhs-and BioBriefs en 2026-02-13T16:32:35Z Policy shakeup at HHS and FDA — RFK Jr. tenure and Prasad scrutiny reshape regulation https://biobriefs.com/madrigal-buys-into-sirna-mash BioBriefs en 2026-02-13T16:32:35Z Madrigal buys into siRNA MASH pipeline — $60M up front, $4.4B potential https://biobriefs.com/ribbon-bio-launches-cell-free BioBriefs en 2026-02-13T16:32:35Z Ribbon Bio launches cell‑free long‑DNA service — targets nucleic acid therapeutics https://biobriefs.com/fda-refuses-moderna-flu-review BioBriefs en 2026-02-13T14:32:52Z FDA refuses Moderna flu review — industry warns of chilling precedent https://biobriefs.com/bridgebio-phase-3-win-infigratinib BioBriefs en 2026-02-13T14:32:52Z BridgeBio phase 3 win — infigratinib readies for FDA filing https://biobriefs.com/maha-movement-outlines-anti-vaccine BioBriefs en 2026-02-13T14:32:52Z MAHA movement outlines anti‑vaccine strategy — policy shifts accelerate https://biobriefs.com/ultragenyx-cuts-10-as-fda BioBriefs en 2026-02-13T14:32:52Z Ultragenyx cuts 10% as FDA stalls gene therapy approval https://biobriefs.com/caredx-eyes-launch-of-alloheme BioBriefs en 2026-02-13T14:32:52Z CareDx eyes launch of AlloHeme transplant surveillance test https://biobriefs.com/ribbon-rolls-out-cell-free BioBriefs en 2026-02-13T14:32:52Z Ribbon rolls out cell‑free long‑DNA service — aims at nucleic‑acid developers https://biobriefs.com/pacbio-posts-better-than-expected BioBriefs en 2026-02-13T14:32:52Z PacBio posts better‑than‑expected Q4 — consumables hit record https://biobriefs.com/thermo-fisher-inks-datavant-deal BioBriefs en 2026-02-13T14:32:52Z Thermo Fisher inks Datavant deal — secure RWD linkage for trials https://biobriefs.com/madrigal-buys-ribo-sirnas-60m BioBriefs en 2026-02-13T14:32:52Z Madrigal buys Ribo siRNAs — $60M now, $4.4B possible https://biobriefs.com/microbiotica-mb-310-induces-remission BioBriefs en 2026-02-13T14:32:52Z Microbiotica MB‑310 induces remission in phase Ib — promising UC signal https://biobriefs.com/fda-refuses-to-file-moderna BioBriefs en 2026-02-13T10:32:24Z FDA refuses-to-file Moderna flu shot: review halted https://biobriefs.com/bridgebios-oral-dwarfism-drug-wins BioBriefs en 2026-02-13T10:32:24Z BridgeBio’s oral dwarfism drug wins Phase III — filing planned https://biobriefs.com/ultragenyx-cuts-10-as-fda BioBriefs en 2026-02-13T10:32:24Z Ultragenyx cuts 10% as FDA requests more manufacturing documents https://biobriefs.com/caredxs-alloheme-shows-high-sensitivity BioBriefs en 2026-02-13T10:32:24Z CareDx’s AlloHeme shows high sensitivity — commercial launch eyed https://biobriefs.com/microbioticas-live-microbiome-pill-posts BioBriefs en 2026-02-13T10:32:24Z Microbiotica’s live microbiome pill posts positive Phase Ib remission data https://biobriefs.com/madrigal-buys-six-ribo-sirna BioBriefs en 2026-02-13T10:32:24Z Madrigal buys six Ribo siRNA programs — deal could top $4.4B https://biobriefs.com/viking-advances-oral-glp-1 BioBriefs en 2026-02-13T10:32:24Z Viking advances oral GLP‑1/GIP into phase III obesity trial https://biobriefs.com/quantx-closes-85m-series-b BioBriefs en 2026-02-13T10:32:24Z Quantx closes $85M Series B to start clinical trials for oral immunology drugs https://biobriefs.com/iliad-raises-115m-to-push BioBriefs en 2026-02-13T10:32:24Z ILiAD raises $115M to push intranasal pertussis vaccine toward Phase III https://biobriefs.com/thermo-fisher-and-datavant-partner BioBriefs en 2026-02-13T10:32:24Z Thermo Fisher and Datavant partner to link clinical RWD at scale https://biobriefs.com/fda-refuses-to-review-moderna BioBriefs en 2026-02-13T09:32:18Z FDA refuses to review Moderna flu vaccine: rare refuse-to-file https://biobriefs.com/bridgebios-oral-drug-wins-phase BioBriefs en 2026-02-13T09:32:18Z BridgeBio’s oral drug wins phase III – infigratinib speeds growth in dwarfism https://biobriefs.com/madrigal-inks-60m-deal-with BioBriefs en 2026-02-13T09:32:18Z Madrigal inks $60M deal with Ribo – adds siRNA MASH portfolio https://biobriefs.com/iliad-raises-115m-to-push BioBriefs en 2026-02-13T09:32:18Z ILiAD raises $115M to push pertussis vaccine into phase III https://biobriefs.com/caredxs-alloheme-shows-high-sensitivity BioBriefs en 2026-02-13T09:32:18Z CareDx’s AlloHeme shows high sensitivity and long lead time in transplant surveillance https://biobriefs.com/seres-cuts-30-of-staff BioBriefs en 2026-02-13T09:32:18Z Seres cuts 30% of staff, pauses lead program in strategic reset https://biobriefs.com/thermo-fisher-datavant-partner-to BioBriefs en 2026-02-13T09:32:18Z Thermo Fisher, Datavant partner to link RWD across 80,000 sites https://biobriefs.com/pacbio-posts-q4-beat-consumables BioBriefs en 2026-02-13T09:32:18Z PacBio posts Q4 beat; consumables record and SPRQ‑Nx planned https://biobriefs.com/microbioticas-oral-live-biotic-induces BioBriefs en 2026-02-13T09:32:18Z Microbiotica’s oral live biotic induces remission in UC phase Ib – 12 of 19 patients https://biobriefs.com/ribbon-launches-cell-free-long BioBriefs en 2026-02-13T09:32:18Z Ribbon launches cell‑free long‑DNA program – early access for therapeutic makers https://biobriefs.com/fda-refuses-to-review-moderna BioBriefs en 2026-02-13T04:32:15Z FDA refuses to review Moderna flu vaccine — rare refusal-to-file https://biobriefs.com/fdas-vaccines-chief-overrules-staff BioBriefs en 2026-02-13T04:32:15Z FDA’s vaccines chief overrules staff — regulators tighten vaccine gatekeeping https://biobriefs.com/bridgebios-infigratinib-clears-phase-3 BioBriefs en 2026-02-13T04:32:15Z BridgeBio’s infigratinib clears Phase 3 — approval path on deck https://biobriefs.com/madrigal-inks-60m-ribo-deal BioBriefs en 2026-02-13T04:32:15Z Madrigal inks $60M Ribo deal — siRNAs added to MASH arsenal https://biobriefs.com/caredx-plans-alloheme-launch-assay BioBriefs en 2026-02-13T04:32:15Z CareDx plans AlloHeme launch — assay spots relapse with 41-day lead https://biobriefs.com/pacbio-posts-revenue-beat-long BioBriefs en 2026-02-13T04:32:15Z PacBio posts revenue beat; long‑read push gains clinical traction https://biobriefs.com/ribbon-opens-early-access-to BioBriefs en 2026-02-13T04:32:15Z Ribbon opens early access to cell‑free long‑DNA — GMP‑friendly supply for CGT https://biobriefs.com/thermo-fisher-links-ppd-to BioBriefs en 2026-02-13T04:32:15Z Thermo Fisher links PPD to Datavant — real‑world data linkage expanded https://biobriefs.com/quantx-raises-85m-to-start BioBriefs en 2026-02-13T04:32:15Z Quantx raises $85M to start trials — oral STAT6 and IL‑17 programs https://biobriefs.com/microbioticas-live-microbiome-shows-phase BioBriefs en 2026-02-13T04:32:15Z Microbiotica’s live microbiome shows phase Ib remission signal in UC https://biobriefs.com/fda-refuses-to-review-moderna BioBriefs en 2026-02-12T21:32:29Z FDA refuses to review Moderna flu shot — agency cites trial design https://biobriefs.com/bridgebio-s-oral-dwarfism-drug BioBriefs en 2026-02-12T21:32:29Z BridgeBio's oral dwarfism drug clears pivotal test — FDA filing planned https://biobriefs.com/madrigal-bets-big-on-sirna BioBriefs en 2026-02-12T21:32:29Z Madrigal bets big on siRNA — $60M upfront, $4.4B potential deal with Ribo https://biobriefs.com/caredxs-alloheme-flags-relapse-weeks BioBriefs en 2026-02-12T21:32:29Z CareDx’s AlloHeme flags relapse weeks early — high sensitivity and specificity https://biobriefs.com/seres-pauses-lead-program-and BioBriefs en 2026-02-12T21:32:29Z Seres pauses lead program and trims workforce — microbiome strategy shifts https://biobriefs.com/ribbon-bio-launches-cell-free BioBriefs en 2026-02-12T21:32:29Z Ribbon Bio launches cell‑free long‑DNA service — clinics and gene therapy makers targeted https://biobriefs.com/oncolytic-virus-injection-reprograms-glioblastoma BioBriefs en 2026-02-12T21:32:29Z Oncolytic virus injection reprograms glioblastoma microenvironment — single‑dose immune effect https://biobriefs.com/microbiotica-posts-positive-phase-ib BioBriefs en 2026-02-12T21:32:29Z Microbiotica posts positive Phase Ib data in ulcerative colitis — oral live therapeutic shows remission https://biobriefs.com/thermo-fisher-datavant-tie-up BioBriefs en 2026-02-12T21:32:29Z Thermo Fisher, Datavant tie up — encrypted tokens to link RWD across trials and registries https://biobriefs.com/dewpoint-nominates-myc-condensate-modulator BioBriefs en 2026-02-12T21:32:29Z Dewpoint nominates MYC condensate modulator — small molecule targets transcriptional condensates https://biobriefs.com/fda-refuses-to-review-moderna BioBriefs en 2026-02-12T16:32:50Z FDA refuses to review Moderna flu shot: agency cites trial design https://biobriefs.com/bridgebios-oral-dwarfism-drug-wins BioBriefs en 2026-02-12T16:32:50Z BridgeBio’s oral dwarfism drug wins Phase 3 — company eyes approval push https://biobriefs.com/madrigal-inks-ribo-sirna-pact BioBriefs en 2026-02-12T16:32:50Z Madrigal inks Ribo siRNA pact — $60M up front, $4.4B in milestones https://biobriefs.com/quidelortho-waits-on-fda-for BioBriefs en 2026-02-12T16:32:50Z QuidelOrtho waits on FDA for Lex Dx clearance — acquisition conditional https://biobriefs.com/thermo-fisher-links-with-datavant BioBriefs en 2026-02-12T16:32:50Z Thermo Fisher links with Datavant: real‑world data joins clinical research https://biobriefs.com/iliad-raises-115m-to-advance BioBriefs en 2026-02-12T16:32:50Z ILiAD raises $115M to advance intranasal pertussis vaccine into Phase III https://biobriefs.com/seres-pauses-lead-program-and BioBriefs en 2026-02-12T16:32:50Z Seres pauses lead program and trims headcount amid strategic shift https://biobriefs.com/ai-drug-discovery-models-face BioBriefs en 2026-02-12T16:32:50Z AI drug‑discovery models face scrutiny — ‘cheating’ claims and model rivalries https://biobriefs.com/condensates-take-center-stage-dewpoint BioBriefs en 2026-02-12T16:32:50Z Condensates take center stage — Dewpoint names MYC modulator; new discovery tools emerge https://biobriefs.com/precision-biosciences-cleared-to-begin BioBriefs en 2026-02-12T16:32:50Z Precision Biosciences cleared to begin PBGENE‑DMD clinical trial https://biobriefs.com/fda-refuses-to-review-moderna BioBriefs en 2026-02-12T14:32:42Z FDA refuses to review Moderna flu shot: agency cites trial design https://biobriefs.com/bridgebios-oral-dwarfism-drug-wins BioBriefs en 2026-02-12T14:32:42Z BridgeBio’s oral dwarfism drug wins Phase 3 – preps FDA push https://biobriefs.com/fda-issues-complete-response-for BioBriefs en 2026-02-12T14:32:42Z FDA issues complete response for Regenxbio gene therapy: data questions linger https://biobriefs.com/madrigal-inks-4-4b-sirna BioBriefs en 2026-02-12T14:32:42Z Madrigal inks $4.4B siRNA pact with Ribo: MASH pipeline expands https://biobriefs.com/atopic-dermatitis-evommune-and-nektar BioBriefs en 2026-02-12T14:32:42Z Atopic dermatitis — Evommune and Nektar post strong Phase II signals, stocks surge https://biobriefs.com/iliad-raises-115m-to-push BioBriefs en 2026-02-12T14:32:42Z ILiAD raises $115M to push live attenuated pertussis vaccine toward Phase III https://biobriefs.com/microbioticas-oral-live-biotherapeutic-shows BioBriefs en 2026-02-12T14:32:42Z Microbiotica’s oral live biotherapeutic shows remission signals in ulcerative colitis https://biobriefs.com/medicare-covers-personalis-mrd-test BioBriefs en 2026-02-12T14:32:42Z Medicare covers Personalis MRD test for lung cancer surveillance https://biobriefs.com/thermo-fisher-partners-with-datavant BioBriefs en 2026-02-12T14:32:42Z Thermo Fisher partners with Datavant to link trials and real‑world patient data https://biobriefs.com/precision-biosciences-cleared-to-start BioBriefs en 2026-02-12T14:32:42Z Precision Biosciences cleared to start PBGENE‑DMD clinical trial https://biobriefs.com/fda-refuses-to-review-moderna BioBriefs en 2026-02-12T10:32:53Z FDA refuses to review Moderna mRNA flu shot — internal split surfaces https://biobriefs.com/atopic-dermatitis-readouts-move-markets BioBriefs en 2026-02-12T10:32:53Z Atopic dermatitis readouts move markets — Evommune and Nektar jump https://biobriefs.com/madrigal-doubles-down-on-mash BioBriefs en 2026-02-12T10:32:53Z Madrigal doubles down on MASH: $4.4B siRNA pact from China https://biobriefs.com/iliad-nets-115m-to-push BioBriefs en 2026-02-12T10:32:53Z ILiAD nets $115M to push intranasal pertussis vaccine toward pivotal studies https://biobriefs.com/lilly-to-acquire-orna-in BioBriefs en 2026-02-12T10:32:53Z Lilly to acquire Orna — in vivo CAR‑T bet tops $2.4bn https://biobriefs.com/fda-issues-crl-to-regenxbio BioBriefs en 2026-02-12T10:32:53Z FDA issues CRL to Regenxbio — another gene‑therapy setback https://biobriefs.com/microbioticas-oral-live-therapeutic-posts BioBriefs en 2026-02-12T10:32:53Z Microbiotica’s oral live therapeutic posts robust Phase Ib remission rates https://biobriefs.com/medicare-expands-coverage-for-personalis BioBriefs en 2026-02-12T10:32:53Z Medicare expands coverage for Personalis MRD assay in lung cancer surveillance https://biobriefs.com/thermo-fisher-and-datavant-link BioBriefs en 2026-02-12T10:32:53Z Thermo Fisher and Datavant link RWD platforms — privacy tokens at scale https://biobriefs.com/capsida-confirms-cerebral-edema-in BioBriefs en 2026-02-12T10:32:53Z Capsida confirms cerebral edema in AAV trial fatality — probe continues https://biobriefs.com/fda-refuses-to-review-modernas BioBriefs en 2026-02-12T09:32:28Z FDA refuses to review Moderna’s mRNA flu vaccine: regulator flags trial design https://biobriefs.com/fda-issues-complete-response-for BioBriefs en 2026-02-12T09:32:28Z FDA issues complete response for Regenxbio gene therapy – approval pathway stalls https://biobriefs.com/capsida-confirms-cerebral-edema-in BioBriefs en 2026-02-12T09:32:28Z Capsida confirms cerebral edema in AAV trial fatality: autopsy stops short of cause https://biobriefs.com/madrigal-buys-six-ribo-sirna BioBriefs en 2026-02-12T09:32:28Z Madrigal buys six Ribo siRNA programs – $60M upfront, $4.4B potential https://biobriefs.com/eczema-readouts-lift-stocks-evommune BioBriefs en 2026-02-12T09:32:28Z Eczema readouts lift stocks: Evommune posts Dupixent-like Phase II; Nektar shows one-year maintenance https://biobriefs.com/iliad-raises-115m-to-push BioBriefs en 2026-02-12T09:32:28Z ILiAD raises $115M to push live-attenuated pertussis vaccine into Phase III https://biobriefs.com/cms-covers-personalis-mrd-assay BioBriefs en 2026-02-12T09:32:28Z CMS covers Personalis MRD assay for lung cancer surveillance: commercial access expands https://biobriefs.com/ai-designed-antibody-company-generate BioBriefs en 2026-02-12T09:32:28Z AI-designed antibody company Generate files IPO as Phase III asthma dosing begins https://biobriefs.com/oncolytic-virus-reshapes-glioblastoma-microenvironment BioBriefs en 2026-02-12T09:32:28Z Oncolytic virus reshapes glioblastoma microenvironment – one-injection immune remodelling https://biobriefs.com/thermo-fisher-teams-with-datavant BioBriefs en 2026-02-12T09:32:28Z Thermo Fisher teams with Datavant to link research datasets with real‑world patient records https://biobriefs.com/fda-refuses-review-of-modernas BioBriefs en 2026-02-12T04:32:44Z FDA refuses review of Moderna’s mRNA flu shot — company pushes back https://biobriefs.com/evommunes-il-18-fusion-posts BioBriefs en 2026-02-12T04:32:44Z Evommune’s IL‑18 fusion posts Dupixent-like phase II gains — stock rockets https://biobriefs.com/madrigal-pays-upfront-to-add BioBriefs en 2026-02-12T04:32:44Z Madrigal pays upfront to add six siRNA MASH programs — $4.4B upside https://biobriefs.com/iliad-raises-115m-series-b BioBriefs en 2026-02-12T04:32:44Z ILiAD raises $115M Series B to fast‑track intranasal pertussis vaccine https://biobriefs.com/fda-issues-crl-to-regenxbio BioBriefs en 2026-02-12T04:32:44Z FDA issues CRL to Regenxbio — gene‑therapy approval delayed https://biobriefs.com/capsida-confirms-cerebral-edema-in BioBriefs en 2026-02-12T04:32:44Z Capsida confirms cerebral edema in halted AAV trial — investigation continues https://biobriefs.com/cms-covers-personalis-next-personal BioBriefs en 2026-02-12T04:32:44Z CMS covers Personalis NeXT Personal MRD test for lung cancer surveillance https://biobriefs.com/thermo-fisher-and-datavant-tie BioBriefs en 2026-02-12T04:32:44Z Thermo Fisher and Datavant tie trial data to real‑world records — privacy tokens enabled https://biobriefs.com/generate-biomedicines-files-ipo-as BioBriefs en 2026-02-12T04:32:44Z Generate Biomedicines files IPO as Phase III dosing begins for AI‑designed antibody https://biobriefs.com/microbioticas-oral-live-biotherapeutic-posts BioBriefs en 2026-02-12T04:32:44Z Microbiotica’s oral live biotherapeutic posts positive Phase Ib UC remission rates https://biobriefs.com/fda-refuses-to-review-modernas BioBriefs en 2026-02-11T21:33:25Z FDA refuses to review Moderna’s mRNA flu shot: regulator flags trial design https://biobriefs.com/ptab-invalidates-exact-sciences-patents BioBriefs en 2026-02-11T21:33:25Z PTAB invalidates Exact Sciences patents: Geneoscopy says it clears path for ColoSense https://biobriefs.com/iliad-raises-115m-to-push BioBriefs en 2026-02-11T21:33:25Z ILiAD raises $115M to push live pertussis vaccine into pivotal testing https://biobriefs.com/eczema-readouts-shake-up-immunology BioBriefs en 2026-02-11T21:33:25Z Eczema readouts shake up immunology field — Evommune and Nektar post strong Phase II data https://biobriefs.com/fda-issues-complete-response-letter BioBriefs en 2026-02-11T21:33:25Z FDA issues complete response letter to Regenxbio gene therapy — regulator flags data gaps https://biobriefs.com/capsida-confirms-cerebral-edema-in BioBriefs en 2026-02-11T21:33:25Z Capsida confirms cerebral edema in fatal trial case — investigations continue https://biobriefs.com/madrigal-expands-mash-arsenal-60m BioBriefs en 2026-02-11T21:33:25Z Madrigal expands MASH arsenal: $60M upfront, up to $4.4B in siRNA deal with Ribo https://biobriefs.com/medicare-covers-personalis-next-personal BioBriefs en 2026-02-11T21:33:25Z Medicare covers Personalis’ NeXT Personal MRD test for lung‑cancer surveillance https://biobriefs.com/thermo-fisher-datavant-partner-to BioBriefs en 2026-02-11T21:33:25Z Thermo Fisher, Datavant partner to link clinical research with large real‑world data sets https://biobriefs.com/lilly-buys-orna-in-multimodal BioBriefs en 2026-02-11T21:33:25Z Lilly buys Orna in multimodal deal — in vivo CAR‑T and circular RNA technologies in focus https://biobriefs.com/fda-refuses-to-review-moderna BioBriefs en 2026-02-11T16:34:02Z FDA refuses to review Moderna mRNA flu vaccine — CBER flags trial design https://biobriefs.com/fda-issues-complete-response-letter BioBriefs en 2026-02-11T16:34:02Z FDA issues complete response letter to Regenxbio — Hunter syndrome approval paused https://biobriefs.com/capsida-confirms-cerebral-edema-in BioBriefs en 2026-02-11T16:34:02Z Capsida confirms cerebral edema in AAV trial fatality — probe continues https://biobriefs.com/iliad-raises-115m-series-b BioBriefs en 2026-02-11T16:34:02Z ILiAD raises $115M Series B to launch pivotal pertussis program https://biobriefs.com/madrigal-snaps-up-six-china BioBriefs en 2026-02-11T16:34:02Z Madrigal snaps up six China‑sourced siRNAs: $60M now, $4.4B possible https://biobriefs.com/atopic-dermatitis-shakeup-evommune-posts BioBriefs en 2026-02-11T16:34:02Z Atopic dermatitis shakeup: Evommune posts Dupixent‑competitive Phase II... Nektar shows year‑long durability https://biobriefs.com/lilly-acquires-orna-for-up BioBriefs en 2026-02-11T16:34:02Z Lilly acquires Orna for up to $2.4B — accelerates in vivo CAR‑T strategy https://biobriefs.com/medicare-covers-personalis-next-personal BioBriefs en 2026-02-11T16:34:02Z Medicare covers Personalis NeXT Personal MRD test for lung cancer surveillance https://biobriefs.com/precision-biosciences-cleared-to-start BioBriefs en 2026-02-11T16:34:02Z Precision Biosciences cleared to start PBGENE‑DMD trial — IND accepted https://biobriefs.com/oncodna-rolls-out-fragmentomics-liquid BioBriefs en 2026-02-11T16:34:02Z OncoDNA rolls out fragmentomics liquid biopsy OncoXplore for therapy guidance https://biobriefs.com/fda-refuses-review-of-moderna BioBriefs en 2026-02-11T14:33:22Z FDA refuses review of Moderna's mRNA flu shot: regulator flags trial design https://biobriefs.com/fda-issues-complete-response-to BioBriefs en 2026-02-11T14:33:22Z FDA issues complete response to Regenxbio’s Hunter syndrome gene therapy — approval paused https://biobriefs.com/lilly-buys-orna-in-vivo BioBriefs en 2026-02-11T14:33:22Z Lilly buys Orna... in vivo CAR‑T bet expands pharma playbook https://biobriefs.com/madrigal-pays-60m-upfront-4 BioBriefs en 2026-02-11T14:33:22Z Madrigal pays $60M upfront — $4.4B deal for siRNA programs to bolster MASH strategy https://biobriefs.com/iliad-raises-115m-to-push BioBriefs en 2026-02-11T14:33:22Z ILiAD raises $115M to push intranasal pertussis vaccine into pivotal testing https://biobriefs.com/evommune-and-nektar-post-mid BioBriefs en 2026-02-11T14:33:22Z Evommune and Nektar post mid‑stage wins — rivals to Dupixent gain steam https://biobriefs.com/cms-grants-medicare-coverage-for BioBriefs en 2026-02-11T14:33:22Z CMS grants Medicare coverage for Personalis MRD test in lung cancer surveillance https://biobriefs.com/generate-biomedicines-files-ipo-to BioBriefs en 2026-02-11T14:33:22Z Generate Biomedicines files IPO to bankroll Phase III for AI‑designed asthma antibody https://biobriefs.com/capsida-confirms-cerebral-edema-in BioBriefs en 2026-02-11T14:33:22Z Capsida confirms cerebral edema in halted AAV trial, cause remains unresolved https://biobriefs.com/post-hoc-live-biotech-vs BioBriefs en 2026-02-11T14:33:22Z Post‑Hoc Live: biotech vs FDA — public tensions escalate https://biobriefs.com/lilly-buys-orna-2-4b BioBriefs en 2026-02-11T10:33:58Z Lilly buys Orna: $2.4B push into in‑vivo CAR‑T https://biobriefs.com/fda-refuses-to-review-moderna BioBriefs en 2026-02-11T10:33:58Z FDA refuses to review Moderna flu shot: agency flags comparator in trial https://biobriefs.com/atopic-dermatitis-shakeup-evommune-and BioBriefs en 2026-02-11T10:33:58Z Atopic dermatitis shakeup: Evommune and Nektar post mid‑stage wins https://biobriefs.com/fda-issues-crl-to-regenxbio BioBriefs en 2026-02-11T10:33:58Z FDA issues CRL to Regenxbio: Hunter syndrome gene therapy setback https://biobriefs.com/capsida-confirms-cerebral-edema-in BioBriefs en 2026-02-11T10:33:58Z Capsida confirms cerebral edema in gene‑therapy trial fatality https://biobriefs.com/gilead-slips-as-yeztugo-falls BioBriefs en 2026-02-11T10:33:58Z Gilead slips as Yeztugo falls short of lofty expectations https://biobriefs.com/medicare-expands-coverage-personalis-mrd BioBriefs en 2026-02-11T10:33:58Z Medicare expands coverage: Personalis MRD test cleared for lung‑cancer surveillance https://biobriefs.com/takeda-taps-iambic-ai-1 BioBriefs en 2026-02-11T10:33:58Z Takeda taps Iambic AI: $1.7B pact to accelerate small‑molecule discovery https://biobriefs.com/generate-biomedicines-files-ipo-as BioBriefs en 2026-02-11T10:33:58Z Generate Biomedicines files IPO as Phase III asthma program advances https://biobriefs.com/nih-director-bhattacharya-outlines-grant BioBriefs en 2026-02-11T10:33:58Z NIH director Bhattacharya outlines grant and funding overhaul https://biobriefs.com/atopic-dermatitis-new-biologics-dent BioBriefs en 2026-02-11T09:33:14Z Atopic dermatitis... New biologics dent Dupixent's lead https://biobriefs.com/lilly-buys-orna-in-vivo BioBriefs en 2026-02-11T09:33:14Z Lilly buys Orna – in vivo CAR‑T race accelerates https://biobriefs.com/fda-issues-crl-to-regenxbio BioBriefs en 2026-02-11T09:33:14Z FDA issues CRL to Regenxbio – gene therapy setback deepens https://biobriefs.com/modernas-flu-shot-spat-with BioBriefs en 2026-02-11T09:33:14Z Moderna’s flu shot spat with FDA: review refused https://biobriefs.com/regulatory-tug-of-war-accelerated BioBriefs en 2026-02-11T09:33:14Z Regulatory tug‑of‑war: accelerated approvals collide with CRLs https://biobriefs.com/takeda-bets-big-on-ai BioBriefs en 2026-02-11T09:33:14Z Takeda bets big on AI: $1.7B pact with Iambic https://biobriefs.com/money-flow-record-january-financings BioBriefs en 2026-02-11T09:33:14Z Money flow: record January financings and AI‑designed drug IPO https://biobriefs.com/ai-agents-and-verifai-regulators BioBriefs en 2026-02-11T09:33:14Z AI agents and VerifAI... regulators and sites adopt automation https://biobriefs.com/spatial-omics-quality-control-tools BioBriefs en 2026-02-11T09:33:14Z Spatial omics: quality control tools and national platforms emerge https://biobriefs.com/oral-ms-drugs-fenebrutinib-posts BioBriefs en 2026-02-11T09:33:14Z Oral MS drugs... fenebrutinib posts wins at phase III and ACTRIMS https://biobriefs.com/fda-refuses-to-file-modernas BioBriefs en 2026-02-11T04:33:14Z FDA refuses to file Moderna’s mRNA flu shot: agency flags trial control https://biobriefs.com/fda-issues-complete-response-letters BioBriefs en 2026-02-11T04:33:14Z FDA issues complete response letters to Regenxbio—gene therapy pathway questioned https://biobriefs.com/eczema-drugs-deliver-evommune-and BioBriefs en 2026-02-11T04:33:14Z Eczema drugs deliver: Evommune and Nektar post winning mid‑stage data https://biobriefs.com/lilly-buys-orna-2-4bn BioBriefs en 2026-02-11T04:33:14Z Lilly buys Orna: $2.4bn push into in‑vivo CAR‑T and circular RNA https://biobriefs.com/takeda-bets-big-on-ai BioBriefs en 2026-02-11T04:33:14Z Takeda bets big on AI: multiyear discovery pact with Iambic valued at $1.7bn https://biobriefs.com/capital-flows-iliads-115m-and BioBriefs en 2026-02-11T04:33:14Z Capital flows: ILiAD’s $115M and Generate Biomedicines’ IPO push https://biobriefs.com/ai-driven-biologics-keep-drawing BioBriefs en 2026-02-11T04:33:14Z AI‑driven biologics keep drawing cash: Galux and QuantX close rounds https://biobriefs.com/top-medical-groups-launch-independent BioBriefs en 2026-02-11T04:33:14Z Top medical groups launch independent vaccine review as NIH signals reforms https://biobriefs.com/capsida-confirms-cerebral-edema-in BioBriefs en 2026-02-11T04:33:14Z Capsida confirms cerebral edema in halted gene‑therapy trial fatality https://biobriefs.com/diagnostics-momentum-personalis-wins-medicare BioBriefs en 2026-02-11T04:33:14Z Diagnostics momentum: Personalis wins Medicare coverage; VolitionRx expands to Japan https://biobriefs.com/lilly-buys-orna-2-4bn BioBriefs en 2026-02-10T21:33:06Z Lilly buys Orna: $2.4bn bet on in vivo CAR‑T https://biobriefs.com/fda-rejects-regenxbio-therapy-rare BioBriefs en 2026-02-10T21:33:06Z FDA rejects Regenxbio therapy — rare‑disease program stalled https://biobriefs.com/nektars-rezpeg-holds-up-at BioBriefs en 2026-02-10T21:33:06Z Nektar’s rezpeg holds up at 1 year — durability claim strengthens https://biobriefs.com/evommunes-evo301-challenges-dupixent-phase BioBriefs en 2026-02-10T21:33:06Z Evommune’s EVO301 challenges Dupixent — phase II moves market https://biobriefs.com/takeda-taps-iambics-ai-1 BioBriefs en 2026-02-10T21:33:06Z Takeda taps Iambic’s AI — $1.7bn discovery pact https://biobriefs.com/startups-raise-fresh-capital-iliad BioBriefs en 2026-02-10T21:33:06Z Startups raise fresh capital: ILiAD $115M; Galux $29M https://biobriefs.com/ai-drug-engines-accelerate-isomorphic BioBriefs en 2026-02-10T21:33:06Z AI drug engines accelerate: Isomorphic claims advance; Insilico expands https://biobriefs.com/ovrlpy-exposes-3d-overlaps-in BioBriefs en 2026-02-10T21:33:06Z Ovrlpy exposes 3D overlaps in spatial transcriptomics https://biobriefs.com/smart-vascular-grafts-magnetoelastic-sensors BioBriefs en 2026-02-10T21:33:06Z Smart vascular grafts: magnetoelastic sensors enable real‑time stenosis monitoring https://biobriefs.com/medicare-covers-personalis-next-personal BioBriefs en 2026-02-10T21:33:06Z Medicare covers Personalis’ NeXT Personal MRD test for lung cancer surveillance https://biobriefs.com/lilly-buys-orna-2-4b BioBriefs en 2026-02-10T16:33:14Z Lilly buys Orna: $2.4B bet on in vivo CAR‑T https://biobriefs.com/fda-rejects-regenxbio-therapy-hunter BioBriefs en 2026-02-10T16:33:14Z FDA rejects Regenxbio therapy: Hunter syndrome bid turned down https://biobriefs.com/novo-nordisk-sues-hims-wegovy BioBriefs en 2026-02-10T16:33:14Z Novo Nordisk sues Hims – Wegovy compounding clash escalates https://biobriefs.com/medicare-covers-personalis-mrd-test BioBriefs en 2026-02-10T16:33:14Z Medicare covers Personalis MRD test: lung cancer surveillance win https://biobriefs.com/circular-genomics-licenses-circrna-alzheimers BioBriefs en 2026-02-10T16:33:14Z Circular Genomics licenses circRNA Alzheimer’s IP from WUSTL, MDC https://biobriefs.com/eczema-drug-race-evommune-and BioBriefs en 2026-02-10T16:33:14Z Eczema drug race... Evommune and Nektar post encouraging long‑term data https://biobriefs.com/takeda-inks-1-7b-ai BioBriefs en 2026-02-10T16:33:14Z Takeda inks $1.7B AI pact – Iambic collaboration formalized https://biobriefs.com/thermo-fisher-prices-3-8b BioBriefs en 2026-02-10T16:33:14Z Thermo Fisher prices $3.8B notes: financing Clario acquisition https://biobriefs.com/waters-completes-bd-biosciences-buy BioBriefs en 2026-02-10T16:33:14Z Waters completes BD biosciences buy – integration starts https://biobriefs.com/capsida-confirms-cerebral-edema-in BioBriefs en 2026-02-10T16:33:14Z Capsida confirms cerebral edema in trial fatality; probe continues https://biobriefs.com/lilly-snaps-up-orna-2 BioBriefs en 2026-02-10T14:33:01Z Lilly snaps up Orna: $2.4bn bet on in vivo CAR‑T https://biobriefs.com/fda-rejects-regenxbio-hunter-syndrome BioBriefs en 2026-02-10T14:33:01Z FDA rejects Regenxbio: Hunter syndrome therapy turned down https://biobriefs.com/capsida-confirms-cerebral-edema-probe BioBriefs en 2026-02-10T14:33:01Z Capsida confirms cerebral edema — probe continues https://biobriefs.com/generate-files-ipo-gb-0895 BioBriefs en 2026-02-10T14:33:01Z Generate files IPO: GB‑0895 advances into Phase III https://biobriefs.com/takeda-inks-multiyear-pact-with BioBriefs en 2026-02-10T14:33:01Z Takeda inks multiyear pact with Iambic — AI for small molecules https://biobriefs.com/ai-drug-design-draws-capital BioBriefs en 2026-02-10T14:33:01Z AI drug design draws capital: Galux and QuantX close big rounds https://biobriefs.com/regulator-and-originator-push-back BioBriefs en 2026-02-10T14:33:01Z Regulator and originator push back on copycat semaglutide https://biobriefs.com/fda-updates-yescarta-label-primary BioBriefs en 2026-02-10T14:33:01Z FDA updates Yescarta label — primary CNS lymphoma allowed https://biobriefs.com/rezpeg-maintains-responses-at-one BioBriefs en 2026-02-10T14:33:01Z Rezpeg maintains responses at one year — Nektar posts durable data https://biobriefs.com/british-journal-of-cancer-retracts BioBriefs en 2026-02-10T14:33:01Z British Journal of Cancer retracts circular‑RNA gastric cancer paper https://biobriefs.com/lilly-buys-orna-2-4b BioBriefs en 2026-02-10T10:33:00Z Lilly buys Orna: $2.4B bet on in‑vivo CAR‑T https://biobriefs.com/fda-rejects-regenxbios-gene-therapy BioBriefs en 2026-02-10T10:33:00Z FDA rejects Regenxbio’s gene therapy: regulator flags trial design https://biobriefs.com/generate-files-ipo-ai-designed BioBriefs en 2026-02-10T10:33:00Z Generate files IPO: AI‑designed antibody advances to Phase III https://biobriefs.com/takeda-inks-multiyear-pact-with BioBriefs en 2026-02-10T10:33:00Z Takeda inks multiyear pact with Iambic – AI for small‑molecule discovery https://biobriefs.com/quantx-raises-85m-series-b BioBriefs en 2026-02-10T10:33:00Z QuantX raises $85M Series B: Big‑pharma VC backs AI immunology push https://biobriefs.com/medable-launches-agentic-ai-pis BioBriefs en 2026-02-10T10:33:00Z Medable launches Agentic AI: PIs get help with clinical outcome review https://biobriefs.com/shingles-shot-linked-to-lower BioBriefs en 2026-02-10T10:33:00Z Shingles shot linked to lower dementia risk: observational analysis https://biobriefs.com/engineered-immune-cells-cut-toxic BioBriefs en 2026-02-10T10:33:00Z Engineered immune cells cut toxic brain proteins: preclinical advance https://biobriefs.com/histone-lactylation-fuels-immune-escape BioBriefs en 2026-02-10T10:33:00Z Histone lactylation fuels immune escape in pancreatic cancer https://biobriefs.com/irb-barcelona-opens-spains-first BioBriefs en 2026-02-10T10:33:00Z IRB Barcelona opens Spain’s first spatial omics platform — national scale hub https://biobriefs.com/lilly-buys-orna-for-2 BioBriefs en 2026-02-10T09:33:09Z Lilly buys Orna for $2.4B — stakes a claim in in vivo CAR‑T https://biobriefs.com/fda-rejects-regenxbio-gene-therapy BioBriefs en 2026-02-10T09:33:09Z FDA rejects Regenxbio gene therapy — Hunter syndrome bid denied https://biobriefs.com/novo-nordisk-sues-hims-fda BioBriefs en 2026-02-10T09:33:09Z Novo Nordisk sues Hims — FDA warns against copycat Wegovy pills https://biobriefs.com/takeda-taps-iambic-another-pharma BioBriefs en 2026-02-10T09:33:09Z Takeda taps Iambic — another pharma AI drug‑discovery tie‑up https://biobriefs.com/ai-agents-move-into-trials BioBriefs en 2026-02-10T09:33:09Z AI agents move into trials — sites get decision‑support tools https://biobriefs.com/fda-revises-yescarta-label-opens BioBriefs en 2026-02-10T09:33:09Z FDA revises Yescarta label — opens CD19 CAR‑T to primary CNS lymphoma https://biobriefs.com/first-in-human-immune-cell BioBriefs en 2026-02-10T09:33:09Z First‑in‑human immune cell therapy shows responses in advanced lymphoma https://biobriefs.com/pre-op-chemotherapy-improves-survival BioBriefs en 2026-02-10T09:33:09Z Pre‑op chemotherapy improves survival in early‑stage pancreatic cancer — Mayo study https://biobriefs.com/shingles-vaccine-associated-with-lower BioBriefs en 2026-02-10T09:33:09Z Shingles vaccine associated with lower dementia risk — observational finding https://biobriefs.com/faster-rna-synthesis-and-cleaner BioBriefs en 2026-02-10T09:33:09Z Faster RNA synthesis and cleaner sequencing — new tools to speed RNA therapeutics https://biobriefs.com/lilly-to-buy-orna-therapeutics BioBriefs en 2026-02-10T04:32:42Z Lilly to buy Orna Therapeutics — in vivo CAR-T push https://biobriefs.com/fda-rejects-regenxbio-gene-therapy BioBriefs en 2026-02-10T04:32:42Z FDA rejects Regenxbio gene therapy: Hunter syndrome bid denied https://biobriefs.com/novo-nordisk-sues-hims-wegovy BioBriefs en 2026-02-10T04:32:42Z Novo Nordisk sues Hims... Wegovy pill dispute heats up https://biobriefs.com/medable-launches-agentic-ai-trial BioBriefs en 2026-02-10T04:32:42Z Medable launches Agentic AI — trial oversight enters the machine age https://biobriefs.com/takeda-signs-multiyear-ai-deal BioBriefs en 2026-02-10T04:32:42Z Takeda signs multiyear AI deal with Iambic — small‑molecule focus https://biobriefs.com/engineered-immune-cells-target-and BioBriefs en 2026-02-10T04:32:42Z Engineered immune cells target and reduce toxic brain proteins https://biobriefs.com/mayo-clinic-study-neoadjuvant-chemo BioBriefs en 2026-02-10T04:32:42Z Mayo Clinic study: neoadjuvant chemo raises survival in early pancreatic cancer https://biobriefs.com/oak-ridge-tool-cracks-microbial BioBriefs en 2026-02-10T04:32:42Z Oak Ridge tool cracks microbial defense codes — speeds bioengineering https://biobriefs.com/irb-barcelona-unveils-spains-first BioBriefs en 2026-02-10T04:32:42Z IRB Barcelona unveils Spain’s first integrated spatial omics platform https://biobriefs.com/histone-lactylation-drives-immune-escape BioBriefs en 2026-02-10T04:32:42Z Histone lactylation drives immune escape in pancreatic cancer https://biobriefs.com/lilly-bets-on-in-vivo BioBriefs en 2026-02-09T21:32:46Z Lilly bets on in vivo CAR‑T: Orna deal worth up to $2.4B https://biobriefs.com/fda-rejects-regenxbios-hunter-syndrome BioBriefs en 2026-02-09T21:32:46Z FDA rejects Regenxbio’s Hunter syndrome gene therapy — regulator flags endpoints https://biobriefs.com/wegovy-legal-fight-escalates-novo BioBriefs en 2026-02-09T21:32:46Z Wegovy legal fight escalates: Novo sues Hims as FDA warns on copycats https://biobriefs.com/fda-clears-yescarta-label-change BioBriefs en 2026-02-09T21:32:46Z FDA clears Yescarta label change: primary CNS lymphoma no longer contraindicated https://biobriefs.com/roches-btk-shock-fenebrutinib-edges BioBriefs en 2026-02-09T21:32:46Z Roche’s BTK shock: fenebrutinib edges Ocrevus in PPMS data https://biobriefs.com/shingles-shot-tied-to-lower BioBriefs en 2026-02-09T21:32:46Z Shingles shot tied to lower dementia risk: large observational study https://biobriefs.com/first-in-human-immune-cell BioBriefs en 2026-02-09T21:32:46Z First‑in‑human immune cell therapy posts encouraging safety, activity in lymphoma https://biobriefs.com/medable-launches-agentic-ai-pi BioBriefs en 2026-02-09T21:32:46Z Medable launches Agentic AI: PI‑focused tool for clinical outcome review https://biobriefs.com/takeda-taps-iambic-for-ai BioBriefs en 2026-02-09T21:32:46Z Takeda taps Iambic for AI drug discovery — multiyear small‑molecule pact https://biobriefs.com/quantx-secures-85m-series-b BioBriefs en 2026-02-09T21:32:46Z QuantX secures $85M Series B: Big Pharma VCs back immunology push https://biobriefs.com/lilly-snaps-up-orna-2 BioBriefs en 2026-02-09T16:33:34Z Lilly snaps up Orna: $2.4B bet on in vivo CAR‑T https://biobriefs.com/medable-unveils-agentic-ai-pi BioBriefs en 2026-02-09T16:33:34Z Medable unveils Agentic AI... PI oversight in focus https://biobriefs.com/fda-vows-crackdown-mass-marketing BioBriefs en 2026-02-09T16:33:34Z FDA vows crackdown: mass-marketing of copycat drugs in the crosshairs https://biobriefs.com/waters-completes-bd-deal-acquired BioBriefs en 2026-02-09T16:33:34Z Waters completes BD deal – acquired diagnostics unit underperformed https://biobriefs.com/takeda-inks-multiyear-ai-pact BioBriefs en 2026-02-09T16:33:34Z Takeda inks multiyear AI pact with Iambic – small‑molecule push https://biobriefs.com/fenebrutinib-edges-ocrevus-phase-3 BioBriefs en 2026-02-09T16:33:34Z Fenebrutinib edges Ocrevus – phase 3 shows 12% cut in progression risk https://biobriefs.com/aerska-raises-39m-brain-shuttle BioBriefs en 2026-02-09T16:33:34Z Aerska raises $39M: brain‑shuttle startup doubles down on neuro targets https://biobriefs.com/lilly-innovent-strike-8-8b BioBriefs en 2026-02-09T16:33:34Z Lilly, Innovent strike $8.8B‑era collaboration – big upfront R&D push https://biobriefs.com/uae-colossal-launch-biovault-dubai BioBriefs en 2026-02-09T16:33:34Z UAE, Colossal launch BioVault – Dubai to host global genetic archive https://biobriefs.com/roivant-s-licensed-jak-tyk2 BioBriefs en 2026-02-09T16:33:34Z Roivant's licensed JAK/TYK2 drug meets POC in cutaneous sarcoidosis https://biobriefs.com/lilly-to-buy-orna-therapeutics BioBriefs en 2026-02-09T14:33:04Z Lilly to buy Orna Therapeutics: $2.4B push into in‑vivo CAR‑T https://biobriefs.com/roches-btk-drug-edges-ocrevus BioBriefs en 2026-02-09T14:33:04Z Roche’s BTK drug edges Ocrevus: fenebrutinib trims disability risk 12% https://biobriefs.com/takeda-inks-multiyear-ai-pact BioBriefs en 2026-02-09T14:33:04Z Takeda inks multiyear AI pact with Iambic – small‑molecule hunt https://biobriefs.com/novo-nordisk-sues-hims-wegovy BioBriefs en 2026-02-09T14:33:04Z Novo Nordisk sues Hims: Wegovy patent fight could cost 'hundreds of millions' https://biobriefs.com/lilly-innovent-sign-8-8b BioBriefs en 2026-02-09T14:33:04Z Lilly, Innovent sign $8.8B oncology‑immunology pact – $350M upfront https://biobriefs.com/aerska-raises-39m-back-to BioBriefs en 2026-02-09T14:33:04Z Aerska raises $39M — back‑to‑back financing to ferry siRNA past the blood‑brain barrier https://biobriefs.com/phage-antibiotic-combo-defeats-resistant BioBriefs en 2026-02-09T14:33:04Z Phage‑antibiotic combo defeats resistant peritonitis in study https://biobriefs.com/cell-and-gene-therapy-supply BioBriefs en 2026-02-09T14:33:04Z Cell and gene therapy supply chains: navigating scale, cold chain and identity https://biobriefs.com/illegal-biolab-raid-in-las BioBriefs en 2026-02-09T14:33:04Z Illegal biolab raid in Las Vegas: Israeli national arrested after 'deathly ill' exposures https://biobriefs.com/openevidence-hits-12b-valuation-clinician BioBriefs en 2026-02-09T14:33:04Z OpenEvidence hits $12B valuation — clinician uptake and ad model draw scrutiny https://biobriefs.com/lilly-plunks-down-350m-expands BioBriefs en 2026-02-09T10:32:55Z Lilly plunks down $350M: Expands Innovent tie on cancer and immune drugs https://biobriefs.com/hims-halts-glp-1-rollouts BioBriefs en 2026-02-09T10:32:55Z Hims halts GLP‑1 rollouts... regulators and rivals push back https://biobriefs.com/roivants-brepocitinib-clears-proof-of BioBriefs en 2026-02-09T10:32:55Z Roivant’s brepocitinib clears proof‑of‑concept: Pivotal testing next https://biobriefs.com/sanofi-unpacks-failed-tolebrutinib-phase BioBriefs en 2026-02-09T10:32:55Z Sanofi unpacks failed tolebrutinib Phase 3 – retreat from PPMS https://biobriefs.com/las-vegas-biolab-raid-fbi BioBriefs en 2026-02-09T10:32:55Z Las Vegas biolab raid: FBI seizes samples after residents fall "deathly ill" https://biobriefs.com/phage-plus-antibiotic-defeats-resistant BioBriefs en 2026-02-09T10:32:55Z Phage plus antibiotic defeats resistant Klebsiella peritonitis – study https://biobriefs.com/metabolism-drives-fungal-invasion-ccmb BioBriefs en 2026-02-09T10:32:55Z Metabolism drives fungal invasion: CCMB identifies therapeutic levers https://biobriefs.com/triple-blockade-ignites-cxcl16-cxcr6 BioBriefs en 2026-02-09T10:32:55Z Triple blockade ignites CXCL16–CXCR6 tumor immunity – STING, TGF‑β, PD‑L1 targeted https://biobriefs.com/inflammasome-protein-asc-rewires-pancreatic BioBriefs en 2026-02-09T10:32:55Z Inflammasome protein ASC rewires pancreatic cancer metabolism – Nature Communications https://biobriefs.com/3d-gut-brain-vascular-model BioBriefs en 2026-02-09T10:32:55Z 3D gut‑brain‑vascular model maps bidirectional disease mechanisms https://biobriefs.com/brepocitinib-proof-of-concept-clears BioBriefs en 2026-02-09T09:33:12Z Brepocitinib proof-of-concept clears cutaneous sarcoidosis – Roivant advances to pivotal https://biobriefs.com/sanofi-data-drop-tolebrutinib-misses BioBriefs en 2026-02-09T09:33:12Z Sanofi data drop: tolebrutinib misses primary in PPMS – program retreats https://biobriefs.com/phage-plus-antibiotic-defeats-mdr BioBriefs en 2026-02-09T09:33:12Z Phage plus antibiotic defeats MDR Klebsiella peritonitis – new combo therapy shown https://biobriefs.com/asc-inflammasome-links-immune-sensing BioBriefs en 2026-02-09T09:33:12Z ASC inflammasome links immune sensing to metabolism in pancreatic cancer https://biobriefs.com/sting-tgf-b-pd-l1 BioBriefs en 2026-02-09T09:33:12Z STING–TGF‑β–PD‑L1 triple targeting magnifies CXCL16–CXCR6 tumor response https://biobriefs.com/lrrk2-r1627p-intensifies-gut-inflammation BioBriefs en 2026-02-09T09:33:12Z LRRK2 R1627P intensifies gut inflammation and α‑synuclein in models https://biobriefs.com/ccmb-finds-fungal-metabolic-switches BioBriefs en 2026-02-09T09:33:12Z CCMB finds fungal metabolic switches that enable invasion and alter antifungal response https://biobriefs.com/las-vegas-raid-israeli-linked BioBriefs en 2026-02-09T09:33:12Z Las Vegas raid: Israeli-linked biolab leaves residents 'deathly ill' — FBI seizes samples https://biobriefs.com/hims-halts-compounded-glp-1 BioBriefs en 2026-02-09T09:33:12Z Hims halts compounded GLP‑1 sales after federal and industry legal pressure https://biobriefs.com/openevidence-hits-12b-valuation-doctors BioBriefs en 2026-02-09T09:33:12Z OpenEvidence hits $12B valuation — doctors driving adoption, pharma ads follow https://biobriefs.com/hims-halts-glp-1-sales BioBriefs en 2026-02-09T04:32:40Z Hims halts GLP‑1 sales — FDA legal threat forces U‑turn https://biobriefs.com/roivants-brepocitinib-clears-proof-of BioBriefs en 2026-02-09T04:32:40Z Roivant’s brepocitinib clears proof‑of‑concept — pivotal test next https://biobriefs.com/las-vegas-raid-seizes-makeshift BioBriefs en 2026-02-09T04:32:40Z Las Vegas raid seizes makeshift biolab — Israeli national arrested, samples sent to FBI https://biobriefs.com/openevidence-valuation-hits-12b-430000 BioBriefs en 2026-02-09T04:32:40Z OpenEvidence valuation hits $12B: 430,000 clinicians using free AI search https://biobriefs.com/phage-plus-antibiotic-halts-resistant BioBriefs en 2026-02-09T04:32:40Z Phage plus antibiotic halts resistant peritonitis — synergy shown in Nature Communications https://biobriefs.com/inflammasome-protein-asc-rewires-pancreatic BioBriefs en 2026-02-09T04:32:40Z Inflammasome protein ASC rewires pancreatic cancer metabolism — Nature Communications https://biobriefs.com/3d-gut-brain-vascular-model BioBriefs en 2026-02-09T04:32:40Z 3D gut‑brain‑vascular model exposes gut‑driven neuropathology https://biobriefs.com/parkinsons-linked-lrrk2r1627p-mutation-ramps BioBriefs en 2026-02-09T04:32:40Z Parkinson’s‑linked LRRK2R1627P mutation ramps gut inflammation — rat study ties to α‑synuclein https://biobriefs.com/nitazene-deaths-likely-underreported-by BioBriefs en 2026-02-09T04:32:40Z Nitazene deaths likely underreported by up to 33% — King’s College finds https://biobriefs.com/charles-river-and-thermo-fisher BioBriefs en 2026-02-09T04:32:40Z Charles River and Thermo Fisher cut staff — site closures trigger layoffs https://biobriefs.com/hims-halts-compounded-glp-1 BioBriefs en 2026-02-08T21:32:39Z Hims halts compounded GLP‑1 program: Regulators close in https://biobriefs.com/roivant-posts-proof-of-concept BioBriefs en 2026-02-08T21:32:39Z Roivant posts proof‑of‑concept win – Brepocitinib eyes pivotal testing https://biobriefs.com/sanofi-unveils-failed-tolebrutinib-data BioBriefs en 2026-02-08T21:32:39Z Sanofi unveils failed tolebrutinib data – PPMS program collapses https://biobriefs.com/phage-plus-antibiotic-clears-resistant BioBriefs en 2026-02-08T21:32:39Z Phage plus antibiotic clears resistant peritonitis in preclinical model https://biobriefs.com/inflammasome-protein-asc-rewires-pancreatic BioBriefs en 2026-02-08T21:32:39Z Inflammasome protein ASC rewires pancreatic cancer metabolism https://biobriefs.com/succinate-receptor-sucnr1-restrains-hematopoiesis BioBriefs en 2026-02-08T21:32:39Z Succinate receptor SUCNR1 restrains hematopoiesis and limits AML https://biobriefs.com/ferritin-scaffold-mers-spike-vaccine BioBriefs en 2026-02-08T21:32:39Z Ferritin‑scaffold MERS spike vaccine shows potent responses https://biobriefs.com/dual-targeting-of-viral-and BioBriefs en 2026-02-08T21:32:39Z Dual targeting of viral and host pathways yields synergistic COVID activity https://biobriefs.com/bispecific-sirnas-silence-two-oncogenic BioBriefs en 2026-02-08T21:32:39Z Bispecific siRNAs silence two oncogenic nodes at once https://biobriefs.com/eikon-agomab-pull-350m-in BioBriefs en 2026-02-08T21:32:39Z Eikon, Agomab pull $350M in IPOs — aftermarket punishes debut stocks https://biobriefs.com/hims-halts-compounded-wegovy-amid BioBriefs en 2026-02-08T16:33:09Z Hims halts compounded Wegovy amid federal pressure https://biobriefs.com/plpro-and-ripk1-inhibitors-synergize BioBriefs en 2026-02-08T16:33:09Z PLpro and RIPK1 inhibitors synergize against SARS‑CoV‑2 in mice https://biobriefs.com/brepocitinib-clears-proof-of-concept BioBriefs en 2026-02-08T16:33:09Z Brepocitinib clears proof‑of‑concept — Roivant advances to pivotal testing https://biobriefs.com/sanofi-dissects-failed-tolebrutinib-ppms BioBriefs en 2026-02-08T16:33:09Z Sanofi dissects failed tolebrutinib PPMS study — company retreats https://biobriefs.com/arpa-h-trims-commercialization-staff BioBriefs en 2026-02-08T16:33:09Z ARPA‑H trims commercialization staff amid restructure https://biobriefs.com/biotech-markets-thaw-ipos-lift BioBriefs en 2026-02-08T16:33:09Z Biotech markets thaw: IPOs lift nearly $1bn as Series A steadies https://biobriefs.com/crispr-strategy-exploits-oncogene-amplification BioBriefs en 2026-02-08T16:33:09Z CRISPR strategy exploits oncogene amplification to target tumors https://biobriefs.com/ai-native-pharma-scales-clinical BioBriefs en 2026-02-08T16:33:09Z AI‑native pharma scales clinical development; Insilico hires oncology lead https://biobriefs.com/rice-secures-arpa-h-print BioBriefs en 2026-02-08T16:33:09Z Rice secures ARPA‑H PRINT funding to bioprint kidney tissue https://biobriefs.com/guideline-issues-therapeutic-drug-monitoring BioBriefs en 2026-02-08T16:33:09Z Guideline issues: therapeutic drug monitoring recommended for IBD biologics https://biobriefs.com/hims-halts-compounded-wegovy-pill BioBriefs en 2026-02-08T14:32:51Z Hims halts compounded Wegovy pill: regulator, industry pressure forces retreat https://biobriefs.com/bayer-unveils-phase-3-win BioBriefs en 2026-02-08T14:32:51Z Bayer unveils Phase 3 win: asundexian cuts secondary stroke risk https://biobriefs.com/adaptive-projects-mrd-boom-clonoseq BioBriefs en 2026-02-08T14:32:51Z Adaptive projects MRD boom: ClonoSeq poised for rapid revenue growth https://biobriefs.com/uniqure-pauses-mid-high-doses BioBriefs en 2026-02-08T14:32:51Z UniQure pauses mid, high doses in Fabry gene trial after liver toxicity https://biobriefs.com/sanofi-unpacks-failed-phase-3 BioBriefs en 2026-02-08T14:32:51Z Sanofi unpacks failed Phase 3: tolebrutinib misses in PPMS https://biobriefs.com/biotech-ipos-return-eikon-agomab BioBriefs en 2026-02-08T14:32:51Z Biotech IPOs return: Eikon, Agomab and more push public market revival https://biobriefs.com/formation-bio-scales-ai-native BioBriefs en 2026-02-08T14:32:51Z Formation Bio scales AI‑native drug development: CTO outlines clinical focus https://biobriefs.com/rice-wins-arpa-h-backing BioBriefs en 2026-02-08T14:32:51Z Rice wins ARPA‑H backing: $24.8M grant to bioprint kidney tissue https://biobriefs.com/crispr-tactic-exploits-oncogene-overload BioBriefs en 2026-02-08T14:32:51Z CRISPR tactic exploits oncogene overload: new tumor targeting approach https://biobriefs.com/phage-plus-antibiotic-clears-resistant BioBriefs en 2026-02-08T14:32:51Z Phage plus antibiotic clears resistant peritonitis in mice: combo shows synergy https://biobriefs.com/hims-halts-compounded-wegovy-sales BioBriefs en 2026-02-08T10:32:40Z Hims halts compounded Wegovy sales: FDA pressure forces retreat https://biobriefs.com/uniqure-pauses-higher-fabry-gene BioBriefs en 2026-02-08T10:32:40Z uniQure pauses higher Fabry gene therapy doses after toxicities https://biobriefs.com/biotech-ipos-rebound-four-drugmakers BioBriefs en 2026-02-08T10:32:40Z Biotech IPOs rebound: Four drugmakers raise nearly $1 billion https://biobriefs.com/priovants-brepocitinib-posts-strong-phase BioBriefs en 2026-02-08T10:32:40Z Priovant’s brepocitinib posts strong Phase 2 results in cutaneous sarcoidosis https://biobriefs.com/bayers-asundexian-cuts-recurrent-stroke BioBriefs en 2026-02-08T10:32:40Z Bayer’s asundexian cuts recurrent stroke without raising bleeding https://biobriefs.com/adaptive-biotechnologies-bets-mrd-will BioBriefs en 2026-02-08T10:32:40Z Adaptive Biotechnologies bets MRD will power 2026 growth https://biobriefs.com/rice-wins-arpa-h-grant BioBriefs en 2026-02-08T10:32:40Z Rice wins ARPA‑H grant to bioprint kidney tissues—$24.8M boost https://biobriefs.com/researchers-decode-phantom-limb-movements BioBriefs en 2026-02-08T10:32:40Z Researchers decode phantom limb movements from intraneural signals https://biobriefs.com/phage-antibiotic-combo-clears-resistant BioBriefs en 2026-02-08T10:32:40Z Phage‑antibiotic combo clears resistant peritonitis in preclinical model https://biobriefs.com/adapt-ms-trains-clinical-proteomic BioBriefs en 2026-02-08T10:32:40Z ADAPT‑MS trains clinical proteomic classifiers directly from discovery data https://biobriefs.com/hims-backs-down-stops-selling BioBriefs en 2026-02-08T09:32:25Z Hims backs down: Stops selling compounded Wegovy after federal pressure https://biobriefs.com/hhs-scraps-340b-rebate-pilot BioBriefs en 2026-02-08T09:32:25Z HHS scraps 340B rebate pilot — providers claim a win https://biobriefs.com/uniqure-pauses-fabry-gene-therapy BioBriefs en 2026-02-08T09:32:25Z uniQure pauses Fabry gene‑therapy doses after liver toxicities https://biobriefs.com/ipo-comeback-eikon-prices-381m BioBriefs en 2026-02-08T09:32:25Z IPO comeback: Eikon prices $381m; four drugmakers raise nearly $1bn https://biobriefs.com/adaptive-bets-on-mrd-company BioBriefs en 2026-02-08T09:32:25Z Adaptive bets on MRD: Company forecasts double‑digit growth for 2026 https://biobriefs.com/intraneural-recordings-decode-phantom-limb BioBriefs en 2026-02-08T09:32:25Z Intraneural recordings decode phantom limb movements — neuroprosthetics advance https://biobriefs.com/3d-gut-brain-vascular-platform BioBriefs en 2026-02-08T09:32:25Z 3D gut‑brain‑vascular platform reveals disease links https://biobriefs.com/phage-plus-antibiotic-clears-resistant BioBriefs en 2026-02-08T09:32:25Z Phage plus antibiotic clears resistant Klebsiella peritonitis in model https://biobriefs.com/pancreatic-cancer-inflammasome-and-epigenetic BioBriefs en 2026-02-08T09:32:25Z Pancreatic cancer: Inflammasome and epigenetic levers identified https://biobriefs.com/bispecific-sirnas-silence-two-cancer BioBriefs en 2026-02-08T09:32:25Z Bispecific siRNAs silence two cancer genes at once https://biobriefs.com/hims-halts-compounded-glp-1 BioBriefs en 2026-02-08T04:32:40Z Hims halts compounded GLP‑1 offering after US scrutiny https://biobriefs.com/bayer-unveils-phase-3-win BioBriefs en 2026-02-08T04:32:40Z Bayer unveils Phase 3 win: asundexian lowers secondary stroke risk https://biobriefs.com/uniqure-pauses-higher-doses-in BioBriefs en 2026-02-08T04:32:40Z uniQure pauses higher doses in Fabry gene therapy after liver toxicities https://biobriefs.com/next-gen-glp-1-and BioBriefs en 2026-02-08T04:32:40Z Next‑gen GLP‑1 and multi‑hormone drugs promise larger weight losses https://biobriefs.com/trumprx-rollout-draws-scrutiny-discounts BioBriefs en 2026-02-08T04:32:40Z TrumpRx rollout draws scrutiny: discounts limited, generics undercut claims https://biobriefs.com/biotech-ipo-surge-eikon-prices BioBriefs en 2026-02-08T04:32:40Z Biotech IPO surge: Eikon prices big debut as market appetite returns https://biobriefs.com/adaptive-projects-mrd-business-growth BioBriefs en 2026-02-08T04:32:40Z Adaptive projects MRD business growth as ClonoSeq adoption climbs https://biobriefs.com/phage-antibiotic-combo-clears-resistant BioBriefs en 2026-02-08T04:32:40Z Phage‑antibiotic combo clears resistant peritonitis in preclinical model https://biobriefs.com/two-studies-map-immune-metabolic BioBriefs en 2026-02-08T04:32:40Z Two studies map immune‑metabolic levers in pancreatic cancer https://biobriefs.com/crispr-tactic-exploits-oncogene-amplification BioBriefs en 2026-02-08T04:32:40Z CRISPR tactic exploits oncogene amplification to target tumors https://biobriefs.com/hims-halts-compounded-glp-1 BioBriefs en 2026-02-07T21:32:17Z Hims halts compounded GLP‑1 sales after legal pressure — Washington probes https://biobriefs.com/uniqure-pauses-fabry-gene-therapy BioBriefs en 2026-02-07T21:32:17Z UniQure pauses Fabry gene‑therapy doses after liver toxicities emerge https://biobriefs.com/eikon-prices-big-ipo-agomab BioBriefs en 2026-02-07T21:32:17Z Eikon prices big IPO — Agomab and SpyGlass bank $350m in Nasdaq wave https://biobriefs.com/bayers-factor-xia-pill-cuts BioBriefs en 2026-02-07T21:32:17Z Bayer’s Factor XIa pill cuts secondary stroke risk 26% — no extra bleeding https://biobriefs.com/two-pronged-pancreatic-assault-inflammasome BioBriefs en 2026-02-07T21:32:17Z Two-pronged pancreatic assault: inflammasome rewires metabolism — epigenetics restores tumor antigenicity https://biobriefs.com/lrrk2-mutation-and-3d-gut BioBriefs en 2026-02-07T21:32:17Z LRRK2 mutation and 3D gut‑brain platform tie gut inflammation to neurodegeneration https://biobriefs.com/phage-plus-antibiotic-clears-drug BioBriefs en 2026-02-07T21:32:17Z Phage plus antibiotic clears drug‑resistant peritonitis in preclinical report https://biobriefs.com/dual-plpro-and-ripk1-inhibitors BioBriefs en 2026-02-07T21:32:17Z Dual PLpro and RIPK1 inhibitors show synergistic antiviral activity in mice https://biobriefs.com/mussel-inspired-adhesive-patch-attacks BioBriefs en 2026-02-07T21:32:17Z Mussel‑inspired adhesive patch attacks glioblastoma cells https://biobriefs.com/sequencing-and-mrd-uptake-accelerate BioBriefs en 2026-02-07T21:32:17Z Sequencing and MRD uptake accelerate: Adaptive raises guidance as Illumina sees clinical consumables growth https://biobriefs.com/uniqure-pauses-higher-fabry-gene BioBriefs en 2026-02-07T16:32:49Z UniQure pauses higher Fabry gene doses — safety signal emerges https://biobriefs.com/hims-launches-wegovy-knockoff-regulators BioBriefs en 2026-02-07T16:32:49Z Hims launches Wegovy knockoff — regulators take aim https://biobriefs.com/white-house-rolls-out-trumprx BioBriefs en 2026-02-07T16:32:49Z White House rolls out TrumpRx — early reach looks limited https://biobriefs.com/biotech-ipo-surge-returns-eikon BioBriefs en 2026-02-07T16:32:49Z Biotech IPO surge returns — Eikon leads big public raises https://biobriefs.com/illumina-leans-into-clinical-sequencing BioBriefs en 2026-02-07T16:32:49Z Illumina leans into clinical sequencing as sales stabilize https://biobriefs.com/adaptive-forecasts-mrd-boom-clonoseq BioBriefs en 2026-02-07T16:32:49Z Adaptive forecasts MRD boom — ClonoSeq adoption accelerating https://biobriefs.com/ai-native-drug-development-scales BioBriefs en 2026-02-07T16:32:49Z AI-native drug development scales — Formation, Insilico expand teams https://biobriefs.com/new-tools-target-antibiotic-resistance BioBriefs en 2026-02-07T16:32:49Z New tools target antibiotic resistance — phage plus genetics https://biobriefs.com/nanoparticle-vaccines-advance-mers-candidate BioBriefs en 2026-02-07T16:32:49Z Nanoparticle vaccines advance — MERS candidate, avian‑flu funding https://biobriefs.com/bayers-asundexian-cuts-secondary-stroke BioBriefs en 2026-02-07T16:32:49Z Bayer’s asundexian cuts secondary stroke risk — trial shows 26% benefit https://biobriefs.com/hims-sells-compounded-wegovy-pill BioBriefs en 2026-02-07T14:32:28Z Hims sells compounded Wegovy pill — regulator and rivals push back https://biobriefs.com/hhs-scraps-340b-rebate-pilot BioBriefs en 2026-02-07T14:32:28Z HHS scraps 340B rebate pilot — providers say relief wins https://biobriefs.com/biotech-ipos-revive-eikon-leads BioBriefs en 2026-02-07T14:32:28Z Biotech IPOs revive: Eikon leads $381m haul as market warms https://biobriefs.com/bayers-asundexian-lowers-recurrent-stroke BioBriefs en 2026-02-07T14:32:28Z Bayer’s asundexian lowers recurrent stroke risk — no extra bleeding https://biobriefs.com/uniqure-pauses-fabry-gene-therapy BioBriefs en 2026-02-07T14:32:28Z uniQure pauses Fabry gene‑therapy doses after liver toxicities emerge https://biobriefs.com/illumina-pivots-to-clinical-sequencing BioBriefs en 2026-02-07T14:32:28Z Illumina pivots to clinical sequencing as FY revenue holds steady https://biobriefs.com/ai-drug-development-scales-formation BioBriefs en 2026-02-07T14:32:28Z AI drug development scales: Formation Bio builds; Latent Labs designs biologics https://biobriefs.com/priovants-brepocitinib-posts-robust-midstage BioBriefs en 2026-02-07T14:32:28Z Priovant’s brepocitinib posts robust midstage gains in rare skin disease https://biobriefs.com/new-tumor-targeting-strategies-crispr BioBriefs en 2026-02-07T14:32:28Z New tumor‑targeting strategies: CRISPR exploits oncogene amplifications; Wistar crafts dual‑action conjugate https://biobriefs.com/adaptive-biotechnologies-lifts-mrd-outlook BioBriefs en 2026-02-07T14:32:28Z Adaptive Biotechnologies lifts MRD outlook — ClonoSeq adoption accelerates https://biobriefs.com/hims-pushes-compounded-wegovy-federal BioBriefs en 2026-02-07T10:33:13Z Hims pushes compounded Wegovy — federal scrutiny mounts https://biobriefs.com/white-house-rolls-out-trumprx BioBriefs en 2026-02-07T10:33:13Z White House rolls out TrumpRx — pharma signs on https://biobriefs.com/biotech-ipo-rebound-eikon-agomab BioBriefs en 2026-02-07T10:33:13Z Biotech IPO rebound: Eikon, Agomab, SpyGlass raise fresh capital https://biobriefs.com/uniqure-pauses-fabry-gene-therapy BioBriefs en 2026-02-07T10:33:13Z UniQure pauses Fabry gene therapy dosing after liver toxicities https://biobriefs.com/bayers-asundexian-cuts-secondary-stroke BioBriefs en 2026-02-07T10:33:13Z Bayer’s asundexian cuts secondary stroke risk — bleeding unchanged https://biobriefs.com/adaptive-biotechnologies-projects-mrd-growth BioBriefs en 2026-02-07T10:33:13Z Adaptive Biotechnologies projects MRD growth as ClonoSeq adoption rises https://biobriefs.com/illumina-leans-into-clinical-sequencing BioBriefs en 2026-02-07T10:33:13Z Illumina leans into clinical sequencing — small M&A adds optionality https://biobriefs.com/priovants-brepocitinib-posts-strong-phase BioBriefs en 2026-02-07T10:33:13Z Priovant’s brepocitinib posts strong Phase 2 results in cutaneous sarcoidosis https://biobriefs.com/generate-files-for-ipo-after BioBriefs en 2026-02-07T10:33:13Z Generate files for IPO after rapid AI-driven progress https://biobriefs.com/ai-native-drugmakers-scale-latent BioBriefs en 2026-02-07T10:33:13Z AI-native drugmakers scale: Latent Labs, Formation Bio press design-to-clinic edge https://biobriefs.com/uniqure-pauses-dosing-after-liver BioBriefs en 2026-02-07T09:33:22Z uniQure pauses dosing after liver toxicities: Fabry gene therapy trial hit https://biobriefs.com/hims-sells-compounded-wegovy-pill BioBriefs en 2026-02-07T09:33:22Z Hims sells compounded Wegovy pill...FDA warns and makers threaten suits https://biobriefs.com/biotech-ipo-wave-returns-eikon BioBriefs en 2026-02-07T09:33:22Z Biotech IPO wave returns: Eikon and Agomab/SpyGlass raise hundreds of millions https://biobriefs.com/priovants-brepocitinib-posts-strong-phase BioBriefs en 2026-02-07T09:33:22Z Priovant’s brepocitinib posts strong Phase 2 results — rare skin disease responds https://biobriefs.com/bayers-asundexian-cuts-recurrent-stroke BioBriefs en 2026-02-07T09:33:22Z Bayer’s asundexian cuts recurrent stroke risk 26% — Phase 3 surprise https://biobriefs.com/adaptive-biotechnologies-projects-mrd-boom BioBriefs en 2026-02-07T09:33:22Z Adaptive Biotechnologies projects MRD boom: ClonoSeq adoption fueling 2026 growth https://biobriefs.com/insilico-advances-ai-designed-nlrp3 BioBriefs en 2026-02-07T09:33:22Z Insilico advances AI‑designed NLRP3 inhibitor...company touts global partnerships https://biobriefs.com/novel-gene-editing-and-neoantigen BioBriefs en 2026-02-07T09:33:22Z Novel gene‑editing and neoantigen T‑cell platforms advance personalized cancer approaches https://biobriefs.com/mussel-inspired-bioadhesive-patch-attacks BioBriefs en 2026-02-07T09:33:22Z Mussel‑inspired bioadhesive patch attacks glioblastoma cells — new local therapy https://biobriefs.com/ai-native-drugmakers-scale-formation BioBriefs en 2026-02-07T09:33:22Z AI‑native drugmakers scale: Formation Bio builds clinical engine — Latent Labs designs biologics https://biobriefs.com/hims-pushes-compounded-wegovy-pill BioBriefs en 2026-02-07T04:32:47Z Hims pushes compounded Wegovy pill; FDA signals crackdown https://biobriefs.com/trumprx-debuts-limited-reach-for BioBriefs en 2026-02-07T04:32:47Z TrumpRx debuts... limited reach for insured patients https://biobriefs.com/ipo-wave-returns-eikon-agomab BioBriefs en 2026-02-07T04:32:47Z IPO wave returns — Eikon, Agomab, SpyGlass raise fresh capital https://biobriefs.com/generate-files-for-ipo-ai BioBriefs en 2026-02-07T04:32:47Z Generate files for IPO; AI biologics startup gains profile https://biobriefs.com/bayers-asundexian-cuts-secondary-stroke BioBriefs en 2026-02-07T04:32:47Z Bayer’s asundexian cuts secondary stroke risk 26% — safety profile intact https://biobriefs.com/uniqure-pauses-fabry-gene-therapy BioBriefs en 2026-02-07T04:32:47Z uniQure pauses Fabry gene‑therapy doses after liver toxicities https://biobriefs.com/adaptive-bets-on-mrd-growth BioBriefs en 2026-02-07T04:32:47Z Adaptive bets on MRD growth as diagnostics take center stage https://biobriefs.com/sucnr1-discovered-as-metabolic-brake BioBriefs en 2026-02-07T04:32:47Z SUCNR1 discovered as metabolic brake on hematopoiesis and AML progression https://biobriefs.com/mussel-inspired-bioadhesive-patch-targets BioBriefs en 2026-02-07T04:32:47Z Mussel‑inspired bioadhesive patch targets glioblastoma cells https://biobriefs.com/insilico-names-preclinical-nlrp3-inhibitor BioBriefs en 2026-02-07T04:32:47Z Insilico names preclinical NLRP3 inhibitor and showcases WHX presence https://biobriefs.com/uniqure-pauses-fabry-high-dose BioBriefs en 2026-02-06T21:33:34Z UniQure pauses Fabry high-dose arms: safety signals halt escalation https://biobriefs.com/trumprx-debuts-white-house-platform BioBriefs en 2026-02-06T21:33:34Z TrumpRx debuts: White House platform launches with narrow discounts https://biobriefs.com/hims-ships-compounded-wegovy-pill BioBriefs en 2026-02-06T21:33:34Z Hims ships compounded Wegovy pill — legal fight ignites https://biobriefs.com/bayers-asundexian-cuts-secondary-stroke BioBriefs en 2026-02-06T21:33:34Z Bayer’s asundexian cuts secondary stroke risk: data spotlight https://biobriefs.com/eikon-prices-381m-ipo-cash BioBriefs en 2026-02-06T21:33:34Z Eikon prices $381M IPO: cash to fuel cancer trials https://biobriefs.com/illumina-leans-into-clinical-sequencing BioBriefs en 2026-02-06T21:33:34Z Illumina leans into clinical sequencing as revenue plateaus https://biobriefs.com/adaptive-projects-mrd-growth-as BioBriefs en 2026-02-06T21:33:34Z Adaptive projects MRD growth as ClonoSeq adoption expands https://biobriefs.com/arpa-h-trims-commercialization-ranks BioBriefs en 2026-02-06T21:33:34Z ARPA‑H trims commercialization ranks: layoffs hit translation staff https://biobriefs.com/generate-biomedicines-files-ipo-ai BioBriefs en 2026-02-06T21:33:34Z Generate:Biomedicines files IPO — AI‑designed antibody programs in view https://biobriefs.com/priovants-brepocitinib-posts-strong-phase BioBriefs en 2026-02-06T21:33:34Z Priovant’s brepocitinib posts strong Phase 2 signal in cutaneous sarcoidosis https://biobriefs.com/bayers-asundexian-cuts-recurrent-stroke BioBriefs en 2026-02-06T16:34:12Z Bayer’s asundexian cuts recurrent stroke risk: Phase 3 shows 26% reduction https://biobriefs.com/uniqure-halts-higher-dose-fabry BioBriefs en 2026-02-06T16:34:12Z UniQure halts higher-dose Fabry gene arm after liver toxicity; Aro posts Pompe data https://biobriefs.com/adaptive-biotechnologies-pins-2026-growth BioBriefs en 2026-02-06T16:34:12Z Adaptive Biotechnologies pins 2026 growth on MRD testing: ClonoSeq adoption driving revenue https://biobriefs.com/illumina-steadies-clinical-consumables-climb BioBriefs en 2026-02-06T16:34:12Z Illumina steadies: clinical consumables climb while overall revenue flat in 2025 https://biobriefs.com/eikons-381m-ipo-revives-biotech BioBriefs en 2026-02-06T16:34:12Z Eikon’s $381M IPO revives biotech listings — proceeds to fund oncology trials https://biobriefs.com/generate-biomedicines-files-for-ipo BioBriefs en 2026-02-06T16:34:12Z Generate:Biomedicines files for IPO — AI‑designed antibodies move toward clinic https://biobriefs.com/veradermics-prices-256m-ipo-oral BioBriefs en 2026-02-06T16:34:12Z Veradermics prices $256M IPO — oral minoxidil trials to fund pivotal work https://biobriefs.com/fda-safety-notice-dpyd-deficiency BioBriefs en 2026-02-06T16:34:12Z FDA safety notice: DPYD deficiency labeling update applies to both Xeloda and 5‑FU https://biobriefs.com/barda-launches-100m-antiviral-prize BioBriefs en 2026-02-06T16:34:12Z BARDA launches $100M antiviral prize to seed broad‑spectrum small‑molecule programs https://biobriefs.com/bio-hails-pediatric-prv-reauthorization BioBriefs en 2026-02-06T16:34:12Z BIO hails pediatric PRV reauthorization and PBM reforms — industry incentive restored https://biobriefs.com/ipo-revival-eikon-leads-biotech BioBriefs en 2026-02-06T14:33:33Z IPO revival: Eikon leads biotech float wave https://biobriefs.com/wegovy-knockoffs-telehealth-seller-draws BioBriefs en 2026-02-06T14:33:33Z Wegovy knockoffs... Telehealth seller draws regulator heat https://biobriefs.com/glp-1-market-split-lilly BioBriefs en 2026-02-06T14:33:33Z GLP-1 market split: Lilly surges as Novo warns of slowdown https://biobriefs.com/stroke-drug-breakthrough-bayers-asundexian BioBriefs en 2026-02-06T14:33:33Z Stroke drug breakthrough: Bayer’s asundexian posts Phase 3 win https://biobriefs.com/brepocitinib-shows-strong-mid-stage BioBriefs en 2026-02-06T14:33:33Z Brepocitinib shows strong mid‑stage efficacy in rare skin diseases https://biobriefs.com/barda-offers-100m-prize-to BioBriefs en 2026-02-06T14:33:33Z BARDA offers $100m prize to accelerate broad‑spectrum antivirals https://biobriefs.com/ai-drug-discovery-milestone-insilico BioBriefs en 2026-02-06T14:33:33Z AI drug discovery milestone: Insilico nominates ISM5059 as preclinical candidate https://biobriefs.com/generate-biomedicines-files-ipo-as BioBriefs en 2026-02-06T14:33:33Z Generate:Biomedicines files IPO as AI-driven drug discovery scales up https://biobriefs.com/personalized-neoantigen-t-cell-therapy BioBriefs en 2026-02-06T14:33:33Z Personalized neoantigen T‑cell therapy advances with NEO‑STIM https://biobriefs.com/crispr-therapy-rollout-stalls-vertex BioBriefs en 2026-02-06T14:33:33Z CRISPR therapy rollout stalls: Vertex struggles to scale Casgevy production https://biobriefs.com/agomab-spyglass-head-to-nasdaq BioBriefs en 2026-02-06T10:33:16Z Agomab, SpyGlass Head to Nasdaq: $350M in Dual IPOs https://biobriefs.com/eikon-upsizes-ipo-381m-haul BioBriefs en 2026-02-06T10:33:16Z Eikon Upsizes IPO: $381M Haul Tops Recent Biotech Listings https://biobriefs.com/veradermics-prices-256m-ipo-oral BioBriefs en 2026-02-06T10:33:16Z Veradermics Prices $256M IPO — Oral Minoxidil Trials Funded https://biobriefs.com/generate-files-for-ipo-ai BioBriefs en 2026-02-06T10:33:16Z Generate Files for IPO: AI-Designed Drugs Hit the Market Push https://biobriefs.com/lilly-surges-novo-warns-glp BioBriefs en 2026-02-06T10:33:16Z Lilly Surges, Novo Warns — GLP-1 Rivalry Reorders Winners https://biobriefs.com/hims-begins-sales-of-compounded BioBriefs en 2026-02-06T10:33:16Z Hims Begins Sales of Compounded Wegovy Pill — Legal Fight Looms https://biobriefs.com/white-house-launches-trumprx-consumer BioBriefs en 2026-02-06T10:33:16Z White House Launches TrumpRx: Consumer Drug‑Price Hub Goes Live https://biobriefs.com/fda-asks-for-tavneos-withdrawal BioBriefs en 2026-02-06T10:33:16Z FDA-Asks for Tavneos Withdrawal; Amgen Pushes Back — Data Under Review https://biobriefs.com/bayers-asundexian-cuts-recurrent-stroke BioBriefs en 2026-02-06T10:33:16Z Bayer’s Asundexian Cuts Recurrent Stroke 26% — Phase 3 Readout Shifts Field https://biobriefs.com/angitia-raises-130m-series-d BioBriefs en 2026-02-06T10:33:16Z Angitia Raises $130M Series D — Musculoskeletal Biologics Advance https://biobriefs.com/eikons-381m-nasdaq-debut-cash BioBriefs en 2026-02-06T09:33:10Z Eikon’s $381M Nasdaq Debut — Cash for Cancer Trials https://biobriefs.com/generate-biomedicines-files-for-ipo BioBriefs en 2026-02-06T09:33:10Z Generate:Biomedicines Files for IPO — AI Antibody Push https://biobriefs.com/hims-vs-novo-knockoff-wegovy BioBriefs en 2026-02-06T09:33:10Z Hims vs. Novo: Knockoff Wegovy Pill Sparks Legal Fight https://biobriefs.com/bayers-asundexian-cuts-recurrent-stroke BioBriefs en 2026-02-06T09:33:10Z Bayer’s Asundexian Cuts Recurrent Stroke Risk — Phase 3 Win https://biobriefs.com/barda-launches-100m-prize-for BioBriefs en 2026-02-06T09:33:10Z BARDA Launches $100M Prize for Broad-Spectrum Antivirals https://biobriefs.com/illumina-shifts-toward-healthcare-after BioBriefs en 2026-02-06T09:33:10Z Illumina Shifts Toward Healthcare After NIH Funding Shock https://biobriefs.com/fda-reopens-tavneos-review-amgen BioBriefs en 2026-02-06T09:33:10Z FDA Reopens Tavneos Review — Amgen Refuses Market Withdrawal https://biobriefs.com/ai-drives-new-biotech-startups BioBriefs en 2026-02-06T09:33:10Z AI Drives New Biotech Startups — Latent Labs and Phylo Raise Stakes https://biobriefs.com/eu-funds-personalized-cancer-medicine BioBriefs en 2026-02-06T09:33:10Z EU Funds Personalized Cancer Medicine Project; UK Builds Cancer AI Datasets https://biobriefs.com/biotech-ipo-wave-continues-agomab BioBriefs en 2026-02-06T09:33:10Z Biotech IPO Wave Continues — Agomab, SpyGlass and Veradermics Raise Cash https://biobriefs.com/ipo-wave-returns-agomab-spyglass BioBriefs en 2026-02-06T04:32:51Z IPO wave returns: Agomab, SpyGlass and Eikon lead a $631m biotech surge https://biobriefs.com/generate-files-for-market-flagships BioBriefs en 2026-02-06T04:32:51Z Generate files for market: Flagship’s AI drug shop moves toward an IPO https://biobriefs.com/hims-launches-wegovy-knockoff-novo BioBriefs en 2026-02-06T04:32:51Z Hims launches Wegovy knockoff: Novo threatens suit, legal case shows cracks https://biobriefs.com/trumprx-rollout-white-house-unveils BioBriefs en 2026-02-06T04:32:51Z TrumpRx rollout: White House unveils consumer drug-price hub https://biobriefs.com/bayer-links-asundexian-to-26 BioBriefs en 2026-02-06T04:32:51Z Bayer links asundexian to 26% stroke cut – competitor race widens https://biobriefs.com/fda-safety-alert-dpyd-update BioBriefs en 2026-02-06T04:32:51Z FDA safety alert: DPYD update covers Xeloda and 5‑FU https://biobriefs.com/barda-launches-100m-prize-to BioBriefs en 2026-02-06T04:32:51Z BARDA launches $100m prize to accelerate broad‑spectrum antivirals https://biobriefs.com/vc-momentum-sante-closes-330m BioBriefs en 2026-02-06T04:32:51Z VC momentum: Santé closes $330m fund; Phylo raises $13.5m seed https://biobriefs.com/rare-pediatric-prv-reauthorized-industry BioBriefs en 2026-02-06T04:32:51Z Rare pediatric PRV reauthorized: industry wins reprieve through 2029 https://biobriefs.com/china-tightens-drug-rules-lifecycle BioBriefs en 2026-02-06T04:32:51Z China tightens drug rules: lifecycle accountability moves to center stage https://biobriefs.com/hims-launches-compounded-wegovy-pill BioBriefs en 2026-02-05T21:33:55Z Hims launches compounded Wegovy pill — Novo threatens court fight https://biobriefs.com/trumprx-goes-live-white-house BioBriefs en 2026-02-05T21:33:55Z TrumpRx goes live: White House debuts direct-to-consumer drug hub https://biobriefs.com/bayer-links-asundexian-to-26 BioBriefs en 2026-02-05T21:33:55Z Bayer links asundexian to 26% stroke reduction — rivals scramble https://biobriefs.com/eikon-upsizes-ipo-to-381m BioBriefs en 2026-02-05T21:33:55Z Eikon upsizes IPO to $381M — biggest biotech float since 2024 https://biobriefs.com/generate-biomedicines-files-s-1 BioBriefs en 2026-02-05T21:33:55Z Generate:Biomedicines files S‑1 — Flagship’s AI antibody play eyes public market https://biobriefs.com/lilly-surges-novo-warns-of BioBriefs en 2026-02-05T21:33:55Z Lilly surges — Novo warns of 2026 sales decline amid GLP‑1 price shifts https://biobriefs.com/menstrual-pad-hpv-test-performs BioBriefs en 2026-02-05T21:33:55Z Menstrual‑pad HPV test performs like clinician swabs — Hologic wins expanded FDA clearance https://biobriefs.com/fda-seeks-tavneos-withdrawal-amgen BioBriefs en 2026-02-05T21:33:55Z FDA seeks Tavneos withdrawal — Amgen rejects request https://biobriefs.com/casgevy-rollout-stalls-centers-cant BioBriefs en 2026-02-05T21:33:55Z Casgevy rollout stalls: centers can’t collect enough cells for CRISPR sickle‑cell therapy https://biobriefs.com/big-data-push-in-cancer BioBriefs en 2026-02-05T21:33:55Z Big-data push in cancer research: BC Platforms inks OmicsBank; PharosAI to build NHS cancer atlas https://biobriefs.com/eikon-upsizes-ipo-381m-raise BioBriefs en 2026-02-05T16:33:14Z Eikon upsizes IPO: $381M raise crowns biotech rebound https://biobriefs.com/generate-biomedicines-files-for-ipo BioBriefs en 2026-02-05T16:33:14Z Generate:Biomedicines files for IPO – AI‑designed drugs on deck https://biobriefs.com/novo-warns-sales-to-shrink BioBriefs en 2026-02-05T16:33:14Z Novo warns sales to shrink in 2026 – Pricing deal cited https://biobriefs.com/pfizers-metsera-shot-meets-phase BioBriefs en 2026-02-05T16:33:14Z Pfizer’s Metsera shot meets Phase 2 marks – Phase 3 dose to double https://biobriefs.com/congress-paves-medicare-path-for BioBriefs en 2026-02-05T16:33:14Z Congress paves Medicare path for MCED tests: FDA approval now key https://biobriefs.com/fda-asks-to-yank-tavneos BioBriefs en 2026-02-05T16:33:14Z FDA asks to yank Tavneos; Amgen pushes back – Data dispute escalates https://biobriefs.com/barda-offers-100m-prize-to BioBriefs en 2026-02-05T16:33:14Z BARDA offers $100M prize to speed broad‑spectrum antivirals https://biobriefs.com/pharosai-taps-10xs-xenium-nhs BioBriefs en 2026-02-05T16:33:14Z PharosAI taps 10x’s Xenium: NHS archives to power multimodal cancer AI https://biobriefs.com/bc-platforms-inks-omicsbank-deal BioBriefs en 2026-02-05T16:33:14Z BC Platforms inks OmicsBank deal: 12M Indian patient records added https://biobriefs.com/wearable-aptamer-patch-reads-drugs BioBriefs en 2026-02-05T16:33:14Z Wearable aptamer patch reads drugs continuously – Pilot human trial https://biobriefs.com/generate-biomedicines-files-for-ipo BioBriefs en 2026-02-05T14:33:20Z Generate:Biomedicines files for IPO — AI-designed antibody push https://biobriefs.com/eikon-upsized-ipo-nets-381m BioBriefs en 2026-02-05T14:33:20Z Eikon upsized IPO nets $381M — biggest biotech listing since 2024 https://biobriefs.com/veradermics-prices-256m-ipo-funds BioBriefs en 2026-02-05T14:33:20Z Veradermics prices $256M IPO — funds pivotal oral hair-loss trials https://biobriefs.com/pfizers-monthly-glp-1-shows BioBriefs en 2026-02-05T14:33:20Z Pfizer’s monthly GLP-1 shows efficacy — Phase 3 program expands https://biobriefs.com/novo-warns-of-2026-sales BioBriefs en 2026-02-05T14:33:20Z Novo warns of 2026 sales drop — considers long-acting GLP-1 options https://biobriefs.com/barda-and-hhs-launch-100m BioBriefs en 2026-02-05T14:33:20Z BARDA and HHS launch $100M antiviral prize — broad-spectrum focus https://biobriefs.com/congress-clears-medicare-path-for BioBriefs en 2026-02-05T14:33:20Z Congress clears Medicare path for FDA‑approved MCED tests — coverage set https://biobriefs.com/ai-in-drug-discovery-and BioBriefs en 2026-02-05T14:33:20Z AI in drug discovery and lab automation — Insilico selects candidate; Phylo raises seed https://biobriefs.com/next-gen-immune-therapies-advance BioBriefs en 2026-02-05T14:33:20Z Next‑gen immune therapies advance — exhaustion reversal and safer IL‑12 variants https://biobriefs.com/cirm-commits-100m-to-platform BioBriefs en 2026-02-05T14:33:20Z CIRM commits $100M to platform gene‑therapy program for rare diseases https://biobriefs.com/eikon-upsizes-ipo-to-381m BioBriefs en 2026-02-05T10:33:41Z Eikon Upsizes IPO to $381M — Biotech Lists with Cancer R&D War Chest https://biobriefs.com/veradermics-prices-256m-ipo-oral BioBriefs en 2026-02-05T10:33:41Z Veradermics Prices $256M IPO — Oral Rogaine Advances to Pivotal Trials https://biobriefs.com/pfizers-metsera-glp-1-posts BioBriefs en 2026-02-05T10:33:41Z Pfizer’s Metsera GLP‑1 Posts Positive Data — Market Reaction Mixed https://biobriefs.com/congress-reauthorizes-pediatric-prv-industry BioBriefs en 2026-02-05T10:33:41Z Congress Reauthorizes Pediatric PRV — Industry Wins; PBM Reforms Included https://biobriefs.com/fda-asks-amgen-to-withdraw BioBriefs en 2026-02-05T10:33:41Z FDA Asks Amgen to Withdraw Tavneos — Amgen Declines, Regulatory Fight Looms https://biobriefs.com/barda-launches-100m-antiviral-prize BioBriefs en 2026-02-05T10:33:41Z BARDA Launches $100M Antiviral Prize — Norovirus Culture Breakthrough Follows https://biobriefs.com/wearable-drug-monitoring-patch-validated BioBriefs en 2026-02-05T10:33:41Z Wearable Drug‑Monitoring Patch Validated in Pilot — Continuous TDM Enters Clinic https://biobriefs.com/ai-meets-regenerative-medicine-foundation BioBriefs en 2026-02-05T10:33:41Z AI Meets Regenerative Medicine — Foundation Models and Phylo’s $13.5M Seed https://biobriefs.com/platform-strategy-for-rare-genetic BioBriefs en 2026-02-05T10:33:41Z Platform Strategy for Rare Genetic Therapies: CIRM $100M RAPID and PrimeGen SPAC Move https://biobriefs.com/genetic-and-cellular-routes-to BioBriefs en 2026-02-05T10:33:41Z Genetic and Cellular Routes to Stronger Immunotherapy — New T‑cell and NKT Findings https://biobriefs.com/eikon-therapeutics-prices-381m-ipo BioBriefs en 2026-02-05T09:33:33Z Eikon Therapeutics Prices $381M IPO: Mapping Proteins to Markets https://biobriefs.com/veradermics-upsizes-ipo-to-256m BioBriefs en 2026-02-05T09:33:33Z Veradermics Upsizes IPO to $256M: Oral Minoxidil Trials Funded https://biobriefs.com/pfizers-monthly-glp-1-data BioBriefs en 2026-02-05T09:33:33Z Pfizer’s Monthly GLP‑1 Data: Modest Weight Loss, Bigger Phase III Plan https://biobriefs.com/phylo-raises-13-5m-seed BioBriefs en 2026-02-05T09:33:33Z Phylo Raises $13.5M Seed: Agentic AI for Lab Workflows https://biobriefs.com/fda-asks-for-tavneos-withdrawal BioBriefs en 2026-02-05T09:33:33Z FDA Asks for Tavneos Withdrawal — Amgen Refuses: Regulation in the Hot Seat https://biobriefs.com/barda-hhs-pledge-100m-prize BioBriefs en 2026-02-05T09:33:33Z BARDA/HHS Pledge $100M Prize for Broad‑Spectrum Antivirals https://biobriefs.com/cirm-commits-100m-to-platform BioBriefs en 2026-02-05T09:33:33Z CIRM Commits $100M to Platform Gene‑Therapy Paths for Rare Diseases https://biobriefs.com/wearable-aptamer-patch-clears-human BioBriefs en 2026-02-05T09:33:33Z Wearable Aptamer Patch Clears Human Pilot: Continuous Drug Monitoring Arrives https://biobriefs.com/hologic-wins-expanded-fda-clearance BioBriefs en 2026-02-05T09:33:33Z Hologic Wins Expanded FDA Clearance for Aptima HPV: Clinician‑Collected Primary Screening https://biobriefs.com/congress-clears-medicare-path-for BioBriefs en 2026-02-05T09:33:33Z Congress Clears Medicare Path for FDA‑Approved MCED Tests — Coverage Comes in 2029 https://biobriefs.com/biotech-ipo-rebound-eikon-prices BioBriefs en 2026-02-05T04:33:55Z Biotech IPO rebound: Eikon prices at top, Veradermics upsizes offering https://biobriefs.com/pfizers-metsera-buy-shows-promise BioBriefs en 2026-02-05T04:33:55Z Pfizer’s Metsera buy shows promise: monthly GLP‑1 posts competitive Phase 2 results https://biobriefs.com/lilly-surge-glp-1-sales BioBriefs en 2026-02-05T04:33:55Z Lilly surge... GLP‑1 sales lift results and outlook https://biobriefs.com/pediatric-prv-reauthorized-lawmakers-restore BioBriefs en 2026-02-05T04:33:55Z Pediatric PRV reauthorized: lawmakers restore a rare‑disease incentive https://biobriefs.com/nih-turmoil-escalates-senate-report BioBriefs en 2026-02-05T04:33:55Z NIH turmoil escalates: Senate report and leadership clashes put research at risk https://biobriefs.com/fda-signals-tailored-oversight-car BioBriefs en 2026-02-05T04:33:55Z FDA signals tailored oversight: CAR‑T for autoimmune disease gets a cautious green light https://biobriefs.com/virology-breakthroughs-single-shot-hiv BioBriefs en 2026-02-05T04:33:55Z Virology breakthroughs: single‑shot HIV neutralization and continuous norovirus culture https://biobriefs.com/scaling-spatial-and-computational-genomics BioBriefs en 2026-02-05T04:33:55Z Scaling spatial and computational genomics: PharosAI teams with 10x; Nature Biotech debuts PlasMAAG https://biobriefs.com/platform-funding-and-market-moves BioBriefs en 2026-02-05T04:33:55Z Platform funding and market moves: CIRM backs scalable gene therapy; PrimeGen pursues SPAC https://biobriefs.com/ai-native-lab-tools-phylo BioBriefs en 2026-02-05T04:33:55Z AI‑native lab tools: Phylo raises $13.5M to commercialize Biomni Lab https://biobriefs.com/barda-launches-100m-antiviral-prize BioBriefs en 2026-02-04T21:33:17Z BARDA launches $100M antiviral prize: first stage open https://biobriefs.com/medicare-to-cover-fda-approved BioBriefs en 2026-02-04T21:33:17Z Medicare to cover FDA‑approved MCEDs: reimbursement path cleared https://biobriefs.com/cirm-commits-100m-to-platform BioBriefs en 2026-02-04T21:33:17Z CIRM commits $100M to platform gene‑therapy approaches for rare diseases https://biobriefs.com/illumina-to-sequence-san-diego BioBriefs en 2026-02-04T21:33:17Z Illumina to sequence San Diego Zoo Frozen Zoo: conservation genomics push https://biobriefs.com/phylo-nets-13-5m-seed BioBriefs en 2026-02-04T21:33:17Z Phylo nets $13.5M seed to build AI‑native lab workspace https://biobriefs.com/veradermics-prices-256m-ipo-to BioBriefs en 2026-02-04T21:33:17Z Veradermics prices $256M IPO to fund pivotal hair‑loss trials https://biobriefs.com/pfizers-monthly-glp-1-posts BioBriefs en 2026-02-04T21:33:17Z Pfizer’s monthly GLP‑1 posts double‑digit weight loss in phase 2b https://biobriefs.com/novo-warns-of-2026-sales BioBriefs en 2026-02-04T21:33:17Z Novo warns of 2026 sales decline—pricing deal and rivals bite https://biobriefs.com/rare-pediatric-prv-reauthorized-industry BioBriefs en 2026-02-04T21:33:17Z Rare pediatric PRV reauthorized — industry hails incentives and PBM reforms https://biobriefs.com/amgen-resists-fda-request-to BioBriefs en 2026-02-04T21:33:17Z Amgen resists FDA request to withdraw Tavneos — dispute centers on trial re‑adjudication https://biobriefs.com/lilly-outpaces-street-glp-1 BioBriefs en 2026-02-04T16:33:16Z Lilly outpaces Street: GLP-1 sales top $36B https://biobriefs.com/pfizers-metsera-win-phase-3 BioBriefs en 2026-02-04T16:33:16Z Pfizer’s Metsera win... Phase 3 program expands https://biobriefs.com/who-frames-obesity-glp-1s BioBriefs en 2026-02-04T16:33:16Z WHO frames obesity: GLP-1s recommended for long-term care https://biobriefs.com/congress-opens-medicare-to-mceds BioBriefs en 2026-02-04T16:33:16Z Congress opens Medicare to MCEDs: FDA approval becomes reimbursement trigger https://biobriefs.com/10x-pharosai-build-nhs-cancer BioBriefs en 2026-02-04T16:33:16Z 10x, PharosAI build NHS cancer atlas: spatial data meets AI https://biobriefs.com/fda-clears-expanded-aptima-hpv BioBriefs en 2026-02-04T16:33:16Z FDA clears expanded Aptima HPV use — clinician‑collected primary screening https://biobriefs.com/cirm-bets-100m-on-platform BioBriefs en 2026-02-04T16:33:16Z CIRM bets $100M on platform gene therapy — RAPID program launches https://biobriefs.com/ultragenyx-publishes-ux-111-data BioBriefs en 2026-02-04T16:33:16Z Ultragenyx publishes UX‑111 data as FDA resubmission advances https://biobriefs.com/accuredit-raises-75m-to-advance BioBriefs en 2026-02-04T16:33:16Z AccurEdit raises $75M to advance CRISPR pipeline from China https://biobriefs.com/congress-restores-nih-funding-fy2026 BioBriefs en 2026-02-04T16:33:16Z Congress restores NIH funding: FY2026 rises to $48.7B https://biobriefs.com/pfizers-monthly-glp-1-hits BioBriefs en 2026-02-04T14:33:03Z Pfizer’s monthly GLP‑1 hits efficacy mark — Phase 3 program expands https://biobriefs.com/who-endorses-long-term-glp BioBriefs en 2026-02-04T14:33:03Z WHO endorses long‑term GLP‑1 use: obesity reframed as chronic disease https://biobriefs.com/novos-combo-shot-outperforms-semaglutide BioBriefs en 2026-02-04T14:33:03Z Novo’s combo shot outperforms semaglutide — diabetes and obesity win https://biobriefs.com/pfizer-posts-4-4b-impairment BioBriefs en 2026-02-04T14:33:03Z Pfizer posts $4.4B impairment — CEO signals pipeline focus https://biobriefs.com/congress-paves-path-for-medicare BioBriefs en 2026-02-04T14:33:03Z Congress paves path for Medicare coverage of FDA‑approved MCEDs https://biobriefs.com/pacbio-exits-short-read-tech BioBriefs en 2026-02-04T14:33:03Z PacBio exits short‑read tech to Illumina — long‑read push intensifies https://biobriefs.com/fda-launches-precheck-pilot-to BioBriefs en 2026-02-04T14:33:03Z FDA launches PreCheck pilot to speed U.S. plant builds https://biobriefs.com/cirm-puts-100m-behind-platform BioBriefs en 2026-02-04T14:33:03Z CIRM puts $100M behind platform gene‑therapy acceleration for rare diseases https://biobriefs.com/nateras-mrd-portfolio-advances-latitude BioBriefs en 2026-02-04T14:33:03Z Natera’s MRD portfolio advances — Latitude prognostic, Signatera seeks PMA https://biobriefs.com/fda-seeks-withdrawal-of-amgens BioBriefs en 2026-02-04T14:33:03Z FDA seeks withdrawal of Amgen’s Tavneos — company resists https://biobriefs.com/pfizers-monthly-glp-1-meets BioBriefs en 2026-02-04T10:33:21Z Pfizer’s monthly GLP‑1 meets efficacy target – $4.4B charge tempers gains https://biobriefs.com/congress-preserves-nih-funding-fy2026 BioBriefs en 2026-02-04T10:33:21Z Congress preserves NIH funding: FY2026 rises to $48.7B https://biobriefs.com/congress-clears-medicare-path-for BioBriefs en 2026-02-04T10:33:21Z Congress clears Medicare path for FDA‑approved MCED tests – reimbursement set for 2029 https://biobriefs.com/pacbio-exits-short-reads-illumina BioBriefs en 2026-02-04T10:33:21Z PacBio exits short reads – Illumina picks up assets as PacBio doubles down on long reads https://biobriefs.com/cirm-commits-100m-to-platform BioBriefs en 2026-02-04T10:33:21Z CIRM commits $100M to platform gene‑therapy model – RAPID funds scalable rare‑disease approaches https://biobriefs.com/ultragenyx-rolls-out-ux-111 BioBriefs en 2026-02-04T10:33:21Z Ultragenyx rolls out UX‑111 data – resubmission targets Sanfilippo type A approval https://biobriefs.com/natera-mrd-assays-validated-in BioBriefs en 2026-02-04T10:33:21Z Natera MRD assays validated in colorectal study — Signatera heads to FDA for bladder CDx https://biobriefs.com/medtronic-to-acquire-cathworks-for BioBriefs en 2026-02-04T10:33:21Z Medtronic to acquire CathWorks for up to $585M – expands coronary physiology offerings https://biobriefs.com/wistar-reports-single-shot-hiv BioBriefs en 2026-02-04T10:33:21Z Wistar reports single‑shot HIV vaccine neutralization in nonhuman primates https://biobriefs.com/accuredit-raises-75m-to-push BioBriefs en 2026-02-04T10:33:21Z AccurEdit raises $75M to push CRISPR therapies toward clinic https://biobriefs.com/pfizers-monthly-glp-1-posts BioBriefs en 2026-02-04T09:33:06Z Pfizer’s monthly GLP‑1 posts meaningful Phase 2b weight loss — $4.4B charge follows https://biobriefs.com/congress-raises-nih-funding-in BioBriefs en 2026-02-04T09:33:06Z Congress raises NIH funding in final spending bill — small uptick, big signal https://biobriefs.com/natera-mrd-and-signatera-move BioBriefs en 2026-02-04T09:33:06Z Natera MRD and Signatera move toward clinical utility and regulatory clearance https://biobriefs.com/illumina-to-sequence-frozen-zoo BioBriefs en 2026-02-04T09:33:06Z Illumina to sequence Frozen Zoo; PacBio exits short‑read tech to refocus long reads https://biobriefs.com/cirm-launches-100m-rapid-program BioBriefs en 2026-02-04T09:33:06Z CIRM launches $100M RAPID program to scale platform gene‑therapy approaches https://biobriefs.com/ultragenyx-presents-new-ux-111 BioBriefs en 2026-02-04T09:33:06Z Ultragenyx presents new UX‑111 data as BLA resubmission targets FDA review https://biobriefs.com/deepmind-rolls-out-alphagenome-tools BioBriefs en 2026-02-04T09:33:06Z DeepMind rolls out AlphaGenome tools to decode noncoding DNA and RNA splicing https://biobriefs.com/fda-signals-cautious-tailored-pathway BioBriefs en 2026-02-04T09:33:06Z FDA signals cautious, tailored pathway for CAR‑T in autoimmune disease — calls for long follow‑up https://biobriefs.com/chinas-accuredit-raises-75m-to BioBriefs en 2026-02-04T09:33:06Z China’s AccurEdit raises $75M to scale CRISPR therapeutics https://biobriefs.com/medtronic-to-acquire-cathworks-for BioBriefs en 2026-02-04T09:33:06Z Medtronic to acquire Cathworks for up to $585M to expand coronary physiology offerings https://biobriefs.com/pfizer-ramps-phase-3-plan BioBriefs en 2026-02-04T04:32:51Z Pfizer ramps phase 3 plan – Monthly GLP‑1 to anchor obesity push https://biobriefs.com/who-endorses-long-term-glp BioBriefs en 2026-02-04T04:32:51Z WHO endorses long-term GLP‑1 care: obesity reclassified as chronic disease https://biobriefs.com/congress-raises-nih-budget-fy2026 BioBriefs en 2026-02-04T04:32:51Z Congress raises NIH budget – FY2026 gets $48.7B, $415M boost https://biobriefs.com/congress-paves-path-for-medicare BioBriefs en 2026-02-04T04:32:51Z Congress paves path for Medicare coverage: FDA‑approved MCEDs eligible under new spending bill https://biobriefs.com/pacbio-sheds-short-read-tech BioBriefs en 2026-02-04T04:32:51Z PacBio sheds short‑read tech: sale funds long‑read push https://biobriefs.com/nateras-mrd-assays-show-prognostic BioBriefs en 2026-02-04T04:32:51Z Natera’s MRD assays show prognostic power – company seeks expanded regulatory use https://biobriefs.com/cirm-launches-100m-rapid-platform BioBriefs en 2026-02-04T04:32:51Z CIRM launches $100M RAPID: platform approach to rare genetic therapies https://biobriefs.com/genentech-pays-200m-upfront-in BioBriefs en 2026-02-04T04:32:51Z Genentech pays $200M upfront in RNAi tie‑up with Sanegene – up to $1.7B total https://biobriefs.com/fda-signals-tailored-car-t BioBriefs en 2026-02-04T04:32:51Z FDA signals tailored CAR‑T oversight for autoimmune use – long‑term surveillance urged https://biobriefs.com/ai-milestones-insilico-and-studies BioBriefs en 2026-02-04T04:32:51Z AI milestones: Insilico and studies show AI trimming drug discovery timelines https://biobriefs.com/pfizers-monthly-glp-1-shows BioBriefs en 2026-02-03T21:33:05Z Pfizer’s monthly GLP-1 shows real-world momentum — mixed market reaction https://biobriefs.com/novos-cagrisema-upends-semaglutide-in BioBriefs en 2026-02-03T21:33:05Z Novo’s CagriSema upends semaglutide in diabetes trial — obesity implications loom https://biobriefs.com/congress-paves-medicare-path-for BioBriefs en 2026-02-03T21:33:05Z Congress paves Medicare path for FDA‑cleared MCED tests: reimbursement starts 2029 https://biobriefs.com/cirm-launches-100m-rapid-program BioBriefs en 2026-02-03T21:33:05Z CIRM launches $100M RAPID program to scale rare‑disease genetic platforms https://biobriefs.com/pacbio-exits-short-read-race BioBriefs en 2026-02-03T21:33:05Z PacBio exits short‑read race — Illumina picks up assets as PacBio doubles down on long reads https://biobriefs.com/illumina-to-sequence-san-diego BioBriefs en 2026-02-03T21:33:05Z Illumina to sequence San Diego Zoo’s Frozen Zoo® — conservation genomics scales up https://biobriefs.com/fda-signals-tailored-long-term BioBriefs en 2026-02-03T21:33:05Z FDA signals tailored, long‑term oversight for CAR‑T in autoimmune diseases https://biobriefs.com/pfizer-takes-4-4b-hit BioBriefs en 2026-02-03T21:33:05Z Pfizer takes $4.4B hit amid pipeline pruning — strategy refocuses R&D spend https://biobriefs.com/protein-language-models-reprogram-crispr BioBriefs en 2026-02-03T21:33:05Z Protein language models reprogram CRISPR PAM specificity — new editing frontier https://biobriefs.com/single-shot-hiv-vaccine-shows BioBriefs en 2026-02-03T21:33:05Z Single‑shot HIV vaccine shows neutralizing responses in primates — Wistar announces breakthrough https://biobriefs.com/genentech-inks-1-7b-rnai BioBriefs en 2026-02-03T16:34:27Z Genentech inks $1.7B RNAi pact with SanegeneBio — $200M upfront https://biobriefs.com/accuredit-snaps-up-75m-china BioBriefs en 2026-02-03T16:34:27Z AccurEdit snaps up $75M — China CRISPR startup scales clinic push https://biobriefs.com/who-backs-long-term-glp BioBriefs en 2026-02-03T16:34:27Z WHO backs long-term GLP-1s for obesity — first global guideline https://biobriefs.com/promega-wins-nmpa-approval-msi BioBriefs en 2026-02-03T16:34:27Z Promega wins NMPA approval — MSI kit cleared as Keytruda companion diagnostic https://biobriefs.com/diasorin-files-15-minute-molecular BioBriefs en 2026-02-03T16:34:27Z Diasorin files 15‑minute molecular strep test to FDA — seeks CLIA waiver https://biobriefs.com/fda-opens-precheck-program-drugmakers BioBriefs en 2026-02-03T16:34:27Z FDA opens PreCheck program — drugmakers invited to speed US factory builds https://biobriefs.com/ultragenyx-unveils-new-sanfilippo-a BioBriefs en 2026-02-03T16:34:27Z Ultragenyx unveils new Sanfilippo A data — aims to sway FDA on resubmission https://biobriefs.com/insilico-hits-milestone-after-ai BioBriefs en 2026-02-03T16:34:27Z Insilico hits milestone after AI‑designed MEN2501 dosed in humans — $5M paid https://biobriefs.com/mgi-to-buy-bgi-spatial BioBriefs en 2026-02-03T16:34:27Z MGI to buy BGI spatial and nanopore units — bets on a 'Seq All' strategy https://biobriefs.com/pacbio-sells-short-read-assets BioBriefs en 2026-02-03T16:34:27Z PacBio sells short‑read assets to Illumina — shifts focus to long‑read platform https://biobriefs.com/ai-designs-drug-insilico-hits BioBriefs en 2026-02-03T14:33:51Z AI designs drug — Insilico hits clinic, VCs back lab-born scientist https://biobriefs.com/ultragenyx-unwraps-data-new-readout BioBriefs en 2026-02-03T14:33:51Z Ultragenyx unwraps data — new readout targets FDA resubmission https://biobriefs.com/pfizers-metsera-bet-pays-off BioBriefs en 2026-02-03T14:33:51Z Pfizer’s Metsera bet pays off — monthly GLP-1 posts competitive weight loss https://biobriefs.com/novos-combo-shot-tops-semaglutide BioBriefs en 2026-02-03T14:33:51Z Novo’s combo shot tops semaglutide: Phase 3 win sharpens obesity drug rivalry https://biobriefs.com/big-pharma-doubles-down-on BioBriefs en 2026-02-03T14:33:51Z Big pharma doubles down on RNAi — Genentech and Roche strike Sanegene pacts https://biobriefs.com/fda-pushes-long-term-car BioBriefs en 2026-02-03T14:33:51Z FDA pushes long-term CAR-T follow-up — in vivo CAR advances complicate safety planning https://biobriefs.com/single-shot-hiv-vaccine-shows BioBriefs en 2026-02-03T14:33:51Z Single-shot HIV vaccine shows neutralization in primates — Wistar reports breakthrough https://biobriefs.com/diagnostics-push-mrd-companion-seeks BioBriefs en 2026-02-03T14:33:51Z Diagnostics push: MRD companion seeks FDA OK while epigenetic liquid biopsy advances https://biobriefs.com/sequencing-sector-consolidates-pacbio-exits BioBriefs en 2026-02-03T14:33:51Z Sequencing sector consolidates — PacBio exits short-read, MGI scoops BGI units https://biobriefs.com/gsk-walks-from-rna-editing BioBriefs en 2026-02-03T14:33:51Z GSK walks from RNA-editing pact — Wave reclaims lead on AATD program https://biobriefs.com/genentech-licenses-sanegene-rnai-200 BioBriefs en 2026-02-03T10:33:03Z Genentech licenses Sanegene RNAi: $200 million upfront https://biobriefs.com/novos-cagrisema-tops-semaglutide-in BioBriefs en 2026-02-03T10:33:03Z Novo’s CagriSema tops semaglutide in Phase 3 diabetes readout https://biobriefs.com/paclitaxel-shifts-tumor-immunity-trem2 BioBriefs en 2026-02-03T10:33:03Z Paclitaxel shifts tumor immunity: TREM2+ macrophages rise https://biobriefs.com/daratumumab-shows-activity-in-phase BioBriefs en 2026-02-03T10:33:03Z Daratumumab shows activity in phase 2 lupus trial https://biobriefs.com/ai-guides-reprogramming-of-crispr BioBriefs en 2026-02-03T10:33:03Z AI guides reprogramming of CRISPR PAM specificity https://biobriefs.com/aav-delivered-suppressor-trna-enables BioBriefs en 2026-02-03T10:33:03Z AAV-delivered suppressor tRNA enables disease‑agnostic in vivo approach https://biobriefs.com/natera-files-pma-for-signatera BioBriefs en 2026-02-03T10:33:03Z Natera files PMA for Signatera MRD assay in bladder cancer https://biobriefs.com/pacbio-sells-short-read-assets BioBriefs en 2026-02-03T10:33:03Z PacBio sells short‑read assets to Illumina for $48.1 million https://biobriefs.com/fda-opens-precheck-pilot-to BioBriefs en 2026-02-03T10:33:03Z FDA opens PreCheck pilot to accelerate U.S. drug manufacturing builds https://biobriefs.com/sanofis-venglustat-posts-split-phase BioBriefs en 2026-02-03T10:33:03Z Sanofi’s venglustat posts split Phase 3 results — Gaucher success, Fabry failure https://biobriefs.com/genentech-licenses-sanegene-rnai-program BioBriefs en 2026-02-03T09:33:02Z Genentech licenses Sanegene RNAi program: $200M upfront, $1.7B upside https://biobriefs.com/novos-cagrisema-edges-semaglutide-phase BioBriefs en 2026-02-03T09:33:02Z Novo’s CagriSema edges semaglutide – Phase 3 diabetes readout https://biobriefs.com/avidity-schedules-spin-off-record BioBriefs en 2026-02-03T09:33:02Z Avidity schedules spin-off record date: RNA therapeutics unit on track https://biobriefs.com/fda-opens-precheck-submissions-push BioBriefs en 2026-02-03T09:33:02Z FDA opens PreCheck submissions: push to speed US drug factory builds https://biobriefs.com/emas-chmp-backs-six-new BioBriefs en 2026-02-03T09:33:02Z EMA’s CHMP backs six new products in January https://biobriefs.com/daratumumab-shows-efficacy-signals-in BioBriefs en 2026-02-03T09:33:02Z Daratumumab shows efficacy signals in Phase 2 lupus trial https://biobriefs.com/ai-multiomics-model-improves-personalized BioBriefs en 2026-02-03T09:33:02Z AI multiomics model improves personalized cardiovascular risk prediction https://biobriefs.com/johns-hopkins-blood-test-detects BioBriefs en 2026-02-03T09:33:02Z Johns Hopkins blood test detects early cancers via epigenetic instability https://biobriefs.com/aav-delivered-uga-suppressor-trna BioBriefs en 2026-02-03T09:33:02Z AAV‑delivered UGA suppressor tRNA enables disease‑agnostic in vivo therapy https://biobriefs.com/protein-language-models-reprogram-crispr BioBriefs en 2026-02-03T09:33:02Z Protein language models reprogram CRISPR PAMs: broader editing access https://biobriefs.com/genentech-licenses-sanegenebio-rnai-program BioBriefs en 2026-02-03T04:33:04Z Genentech licenses SanegeneBio RNAi program: $200M upfront, up to $1.5B https://biobriefs.com/novos-cagrisema-edges-out-semaglutide BioBriefs en 2026-02-03T04:33:04Z Novo’s CagriSema edges out semaglutide in phase 3 diabetes readouts https://biobriefs.com/natera-files-signatera-mrd-cdx BioBriefs en 2026-02-03T04:33:04Z Natera files Signatera MRD CDx to FDA for bladder cancer approval https://biobriefs.com/hopkins-unveils-blood-test-for BioBriefs en 2026-02-03T04:33:04Z Hopkins unveils blood test for early cancers using epigenetic instability https://biobriefs.com/in-vivo-car-t-reduces BioBriefs en 2026-02-03T04:33:04Z In vivo CAR‑T reduces liver fibrosis in preclinical MASH models https://biobriefs.com/fda-urges-long-term-follow BioBriefs en 2026-02-03T04:33:04Z FDA urges long‑term follow‑up for CAR‑T use in autoimmune disease https://biobriefs.com/pacbio-sells-short-read-assets BioBriefs en 2026-02-03T04:33:04Z PacBio sells short‑read assets to Illumina for $48.1M — sharp strategic shift https://biobriefs.com/fda-opens-precheck-pilot-to BioBriefs en 2026-02-03T04:33:04Z FDA opens PreCheck pilot to speed US prescription drug manufacturing builds https://biobriefs.com/university-of-pittsburgh-releases-hemolens BioBriefs en 2026-02-03T04:33:04Z University of Pittsburgh releases HemoLens: open‑source hemodynamics tool https://biobriefs.com/ai-mammography-reduces-interval-cancers BioBriefs en 2026-02-03T04:33:04Z AI mammography reduces interval cancers 12% in 100,000‑woman Lancet trial https://biobriefs.com/novos-cagrisema-beats-semaglutide-phase BioBriefs en 2026-02-02T21:33:49Z Novo’s CagriSema Beats Semaglutide: Phase 3 Diabetes Readout https://biobriefs.com/mgi-acquires-bgi-spatial-and BioBriefs en 2026-02-02T21:33:49Z MGI Acquires BGI Spatial and Nanopore Units: Sequencing Consolidation https://biobriefs.com/johns-hopkins-tests-epigenetic-instability BioBriefs en 2026-02-02T21:33:49Z Johns Hopkins Tests Epigenetic Instability to Spot Early Cancers https://biobriefs.com/mit-unveils-portable-ultrasound-aiming BioBriefs en 2026-02-02T21:33:49Z MIT Unveils Portable Ultrasound: Aiming at Earlier, More Accessible Breast Screening https://biobriefs.com/natera-files-signatera-pma-mrd BioBriefs en 2026-02-02T21:33:49Z Natera Files Signatera PMA: MRD Companion Diagnostic for Bladder Cancer https://biobriefs.com/sanegenes-rnai-chemistry-attracts-big BioBriefs en 2026-02-02T21:33:49Z Sanegene’s RNAi Chemistry Attracts Big Pharma: $200M Upfront Deals https://biobriefs.com/pacbio-narrows-focus-sells-short BioBriefs en 2026-02-02T21:33:49Z PacBio Narrows Focus: Sells Short‑Read Assets to Illumina for $48.1M https://biobriefs.com/twists-revenue-rises-17-as BioBriefs en 2026-02-02T21:33:49Z Twist’s Revenue Rises 17% as AI‑Enabled Discovery Drives New Orders https://biobriefs.com/gsk-returns-rna-editing-rights BioBriefs en 2026-02-02T21:33:49Z GSK Returns RNA Editing Rights to Wave: Wave Reclaims Lead Asset https://biobriefs.com/fda-pauses-regenxbio-trials-after BioBriefs en 2026-02-02T21:33:49Z FDA Pauses Regenxbio Trials After Patient Cancer Case: Clinical Holds Raised https://biobriefs.com/twists-ai-push-pays-off BioBriefs en 2026-02-02T16:35:18Z Twist’s AI push pays off: Q1 revenue climbs 17% https://biobriefs.com/pacbio-pares-assets-short-read BioBriefs en 2026-02-02T16:35:18Z PacBio pares assets: short‑read tech sold to Illumina for cash https://biobriefs.com/roche-genentech-bet-on-sanegene BioBriefs en 2026-02-02T16:35:18Z Roche/Genentech bet on Sanegene RNAi: multibillion‑dollar upside https://biobriefs.com/natera-seeks-fda-pma-for BioBriefs en 2026-02-02T16:35:18Z Natera seeks FDA PMA for Signatera MRD test in bladder cancer https://biobriefs.com/fda-opens-precheck-submissions-drugmakers BioBriefs en 2026-02-02T16:35:18Z FDA opens PreCheck submissions: drugmakers can pitch faster factory builds https://biobriefs.com/daiichi-halts-next-gen-adc BioBriefs en 2026-02-02T16:35:18Z Daiichi halts next‑gen ADC development as Datroway readout slips https://biobriefs.com/fda-places-regenxbio-trials-on BioBriefs en 2026-02-02T16:35:18Z FDA places Regenxbio trials on hold after patient cancer case https://biobriefs.com/skye-recovers-with-cb1-glp BioBriefs en 2026-02-02T16:35:18Z Skye recovers with CB1–GLP‑1 combo: 22.3% weight loss at 52 weeks https://biobriefs.com/sanofis-venglustat-splits-results-gaucher BioBriefs en 2026-02-02T16:35:18Z Sanofi’s venglustat splits results: Gaucher win, Fabry failure https://biobriefs.com/trace-wins-ind-for-nerve BioBriefs en 2026-02-02T16:35:18Z Trace wins IND for nerve imaging agent: first‑in‑human trial cleared https://biobriefs.com/roche-returns-to-rna-200m BioBriefs en 2026-02-02T14:33:08Z Roche returns to RNA: $200M upfront, $1.5B in milestones https://biobriefs.com/sanofis-gcs-inhibitor-passes-gaucher BioBriefs en 2026-02-02T14:33:08Z Sanofi’s GCS inhibitor: passes Gaucher, fails Fabry https://biobriefs.com/fda-places-holds-on-regenxbio BioBriefs en 2026-02-02T14:33:08Z FDA places holds on Regenxbio trials after cancer case https://biobriefs.com/mrna-tactic-neutralizes-haemozoin-block BioBriefs en 2026-02-02T14:33:08Z mRNA tactic neutralizes haemozoin block in malaria models https://biobriefs.com/intranasal-h5n1-vaccine-prevents-infection BioBriefs en 2026-02-02T14:33:08Z Intranasal H5N1 vaccine prevents infection in rodent models https://biobriefs.com/skye-posts-52-week-interim BioBriefs en 2026-02-02T14:33:08Z Skye posts 52‑week interim gain for nimacimab plus semaglutide https://biobriefs.com/bio-tells-congress-to-shore BioBriefs en 2026-02-02T14:33:08Z BIO tells Congress to shore up US biotech lead with tax and manufacturing incentives https://biobriefs.com/gsk-exits-wave-rna-editing BioBriefs en 2026-02-02T14:33:08Z GSK exits Wave RNA‑editing program; Wave says it will advance candidate https://biobriefs.com/ai-rewires-crispr-pam-specificity BioBriefs en 2026-02-02T14:33:08Z AI rewires CRISPR PAM specificity to widen editing targets https://biobriefs.com/fda-issues-crl-to-pharming BioBriefs en 2026-02-02T14:33:08Z FDA issues CRL to Pharming over pediatric expansion of Joenja https://biobriefs.com/fda-halts-regenxbio-trials-cancer BioBriefs en 2026-02-02T10:32:27Z FDA halts Regenxbio trials: cancer case stalls gene-therapy push https://biobriefs.com/us-vaccine-advisory-reconsiders-all BioBriefs en 2026-02-02T10:32:27Z US vaccine advisory reconsiders all recommendations: chair signals review https://biobriefs.com/eu-reworks-drug-rules-orphan BioBriefs en 2026-02-02T10:32:27Z EU reworks drug rules: orphan developers could face earlier competition https://biobriefs.com/nasal-h5n1-vaccine-prevents-infection BioBriefs en 2026-02-02T10:32:27Z Nasal H5N1 vaccine prevents infection in animal tests – WashU https://biobriefs.com/phase-ii-data-and-leadership BioBriefs en 2026-02-02T10:32:27Z Phase II data and leadership exit – Cardiff shares halve in two days https://biobriefs.com/thermo-fisher-shutters-mass-site BioBriefs en 2026-02-02T10:32:27Z Thermo Fisher shutters Mass. site: layoffs exceed 100 https://biobriefs.com/abbvie-bets-on-precision-immunology BioBriefs en 2026-02-02T10:32:27Z AbbVie bets on precision immunology: reverse translation to guide combos https://biobriefs.com/lentiviral-vectors-take-center-stage BioBriefs en 2026-02-02T10:32:27Z Lentiviral vectors take center stage in next‑gen gene therapies https://biobriefs.com/in-vivo-cars-move-closer BioBriefs en 2026-02-02T10:32:27Z In vivo CARs move closer to clinic – new reagents and protocols emerge https://biobriefs.com/brown-uncovers-molecular-switch-to BioBriefs en 2026-02-02T10:32:27Z Brown uncovers molecular switch to sensitize glioblastoma to therapy https://biobriefs.com/fda-halts-regenxbio-trials-cancer BioBriefs en 2026-02-02T09:32:57Z FDA Halts Regenxbio Trials: Cancer Case Prompts Clinical Hold https://biobriefs.com/eu-overhauls-rules-generics-and BioBriefs en 2026-02-02T09:32:57Z EU Overhauls Rules: Generics and Biosimilars Could Come Sooner https://biobriefs.com/thermo-fisher-shutters-mass-site BioBriefs en 2026-02-02T09:32:57Z Thermo Fisher Shutters Mass. Site: 100+ Employees Affected https://biobriefs.com/neoadjuvant-folfirinox-nivolumab-pilot-phase BioBriefs en 2026-02-02T09:32:57Z Neoadjuvant FOLFIRINOX–Nivolumab: Pilot Phase 1 Yields Promising Signals in PDAC https://biobriefs.com/brown-identifies-pathway-to-sensitize BioBriefs en 2026-02-02T09:32:57Z Brown Identifies Pathway to Sensitize Glioblastoma to Therapy https://biobriefs.com/intranasal-h5n1-vaccine-prevents-infection BioBriefs en 2026-02-02T09:32:57Z Intranasal H5N1 Vaccine Prevents Infection in Rodents — WashU Study https://biobriefs.com/university-of-ottawa-launches-omari BioBriefs en 2026-02-02T09:32:57Z University of Ottawa Launches OMARI: Medical AI Hub Established https://biobriefs.com/machine-learning-tool-maps-scope BioBriefs en 2026-02-02T09:32:57Z Machine Learning Tool Maps Scope of Paper-Mill Fraud in Cancer Science https://biobriefs.com/c-suite-shakeup-and-data BioBriefs en 2026-02-02T09:32:57Z C‑Suite Shakeup and Data Release Send Cardiff Stock Down 45% https://biobriefs.com/in-vivo-cars-new-reagent BioBriefs en 2026-02-02T09:32:57Z In vivo CARs: New Reagent Suites Target Translation Bottlenecks https://biobriefs.com/fda-halts-regenxbio-trials-cancer BioBriefs en 2026-02-02T04:32:31Z FDA halts Regenxbio trials: cancer case triggers clinical holds https://biobriefs.com/thermo-fisher-shutters-franklin-lab BioBriefs en 2026-02-02T04:32:31Z Thermo Fisher shutters Franklin lab — more than 100 layoffs https://biobriefs.com/cardiff-leadership-exit-shares-plunge BioBriefs en 2026-02-02T04:32:31Z Cardiff leadership exit: shares plunge after Phase II update https://biobriefs.com/nasal-h5n1-vaccine-prevents-infection BioBriefs en 2026-02-02T04:32:31Z Nasal H5N1 vaccine prevents infection in rodents: WashU reports https://biobriefs.com/iu-chemists-discover-chemical-approach BioBriefs en 2026-02-02T04:32:31Z IU chemists discover chemical approach to combat antibiotic resistance https://biobriefs.com/brown-study-reveals-pathway-to BioBriefs en 2026-02-02T04:32:31Z Brown study reveals pathway to boost glioblastoma therapy response https://biobriefs.com/lentiviral-vectors-retool-gene-therapy BioBriefs en 2026-02-02T04:32:31Z Lentiviral vectors retool gene therapy delivery — new techniques reported https://biobriefs.com/scientists-program-microbes-to-synthesize BioBriefs en 2026-02-02T04:32:31Z Scientists program microbes to synthesize compounds with light https://biobriefs.com/ai-system-diagnoses-sarcopenia-accurately BioBriefs en 2026-02-02T04:32:31Z AI system diagnoses sarcopenia accurately — new decision support tool https://biobriefs.com/machine-learning-exposes-scope-of BioBriefs en 2026-02-02T04:32:31Z Machine learning exposes scope of paper‑mill fraud in cancer research https://biobriefs.com/astrazeneca-doubles-down-on-obesity BioBriefs en 2026-02-01T21:32:07Z AstraZeneca doubles down on obesity — $1.2B up front in CSPC China pact https://biobriefs.com/intranasal-h5n1-vaccine-prevents-infection BioBriefs en 2026-02-01T21:32:07Z Intranasal H5N1 vaccine prevents infection in rodents: WashU study https://biobriefs.com/fda-halts-two-regenxbio-gene BioBriefs en 2026-02-01T21:32:07Z FDA halts two Regenxbio gene‑therapy trials — cancer case raises approval doubts https://biobriefs.com/cardiffs-ceo-exit-rattles-investors BioBriefs en 2026-02-01T21:32:07Z Cardiff’s CEO exit rattles investors — shares plunge despite Phase II news https://biobriefs.com/czi-lays-off-70-staff BioBriefs en 2026-02-01T21:32:07Z CZI lays off 70 staff — overhauls for AI‑powered biology push https://biobriefs.com/thermo-fisher-to-close-massachusetts BioBriefs en 2026-02-01T21:32:07Z Thermo Fisher to close Massachusetts site — 100+ layoffs at Franklin facility https://biobriefs.com/lentiviral-vectors-redefine-gene-delivery BioBriefs en 2026-02-01T21:32:07Z Lentiviral vectors redefine gene delivery — study maps new therapeutic techniques https://biobriefs.com/machine-learning-tool-uncovers-paper BioBriefs en 2026-02-01T21:32:07Z Machine‑learning tool uncovers paper‑mill fraud in cancer literature — reproducibility alarm https://biobriefs.com/md-anderson-picks-iakovos-toumazis BioBriefs en 2026-02-01T21:32:07Z MD Anderson picks Iakovos Toumazis to lead oncology data science — prevention focus https://biobriefs.com/black-market-glp-1-trade BioBriefs en 2026-02-01T21:32:07Z Black‑market GLP‑1 trade booms — peptides shipped from China amid shortages https://biobriefs.com/nasal-h5n1-vaccine-halts-infection BioBriefs en 2026-02-01T16:32:34Z Nasal H5N1 vaccine halts infection in rodents — WashU study https://biobriefs.com/gene-therapy-regulatory-shock-regenxbio BioBriefs en 2026-02-01T16:32:34Z Gene therapy regulatory shock: Regenxbio trials held; Ultragenyx resubmits https://biobriefs.com/astrazeneca-pays-1-2b-up BioBriefs en 2026-02-01T16:32:34Z AstraZeneca pays $1.2B up front for CSPC obesity and diabetes assets https://biobriefs.com/beckman-coulter-and-automata-link BioBriefs en 2026-02-01T16:32:34Z Beckman Coulter and Automata link instruments to AI‑ready automation https://biobriefs.com/sino-biological-accelerates-nipah-research BioBriefs en 2026-02-01T16:32:34Z Sino Biological accelerates Nipah research with expanded reagents https://biobriefs.com/genyro-licenses-caltechs-sidewinder-to BioBriefs en 2026-02-01T16:32:34Z Genyro licenses Caltech’s Sidewinder to write complex DNA at scale https://biobriefs.com/origami-and-ipsen-team-up BioBriefs en 2026-02-01T16:32:34Z Origami and Ipsen team up to advance protein degrader program https://biobriefs.com/single-cell-pan-cancer-atlas BioBriefs en 2026-02-01T16:32:34Z Single‑cell pan‑cancer atlas finds bone‑metastasis clusters and microenvironment cues https://biobriefs.com/the-glp-1-carry-trade BioBriefs en 2026-02-01T16:32:34Z The GLP‑1 carry trade: grey‑market peptides flood demand and pose risk https://biobriefs.com/eu-advisers-block-lillys-mounjaro BioBriefs en 2026-02-01T16:32:34Z EU advisers block Lilly’s Mounjaro for heart failure; back Novo’s semaglutide https://biobriefs.com/fda-halts-regenxbio-gene-trials BioBriefs en 2026-02-01T14:32:59Z FDA halts Regenxbio gene trials: cancer case prompts clinical holds https://biobriefs.com/phase-iii-flop-derails-quince BioBriefs en 2026-02-01T14:32:59Z Phase III flop derails Quince: lead steroid therapy misses endpoints https://biobriefs.com/illumina-closes-somalogic-deal-proteomics BioBriefs en 2026-02-01T14:32:59Z Illumina closes SomaLogic deal: proteomics joins sequencing stack https://biobriefs.com/beckman-automata-tie-up-danaher BioBriefs en 2026-02-01T14:32:59Z Beckman, Automata tie up — Danaher backs automation scale-up https://biobriefs.com/astrazeneca-doubles-down-in-china BioBriefs en 2026-02-01T14:32:59Z AstraZeneca doubles down in China: $1.2B CSPC deal and $15B pledge https://biobriefs.com/lilly-builds-3-5b-obesity BioBriefs en 2026-02-01T14:32:59Z Lilly builds $3.5B obesity plant: retatrutide manufacturing scales up https://biobriefs.com/grail-files-galleri-with-fda BioBriefs en 2026-02-01T14:32:59Z Grail files Galleri with FDA: multi‑cancer blood test seeks premarket approval https://biobriefs.com/ultragenyx-resubmits-aav-therapy-sanfilippo BioBriefs en 2026-02-01T14:32:59Z Ultragenyx resubmits AAV therapy: Sanfilippo program back in front of FDA https://biobriefs.com/gut-microbes-shift-asparagines-role BioBriefs en 2026-02-01T14:32:59Z Gut microbes shift asparagine’s role in tumors: immunity versus growth https://biobriefs.com/fda-recommends-mrd-for-myeloma BioBriefs en 2026-02-01T14:32:59Z FDA recommends MRD for myeloma accelerated approvals: draft raises standards https://biobriefs.com/astrazeneca-doubles-down-on-weight BioBriefs en 2026-02-01T10:33:31Z AstraZeneca doubles down on weight-loss and China bets: $1.2B upfront, $15B horizon https://biobriefs.com/illumina-finalizes-somalogic-buy-proteomics BioBriefs en 2026-02-01T10:33:31Z Illumina finalizes SomaLogic buy: proteomics joins sequencing stack https://biobriefs.com/beckman-coulter-ties-instruments-to BioBriefs en 2026-02-01T10:33:31Z Beckman Coulter ties instruments to Automata’s AI-ready automation https://biobriefs.com/quinces-phase-iii-failure-devastates BioBriefs en 2026-02-01T10:33:31Z Quince’s Phase III failure devastates A-T program and market value https://biobriefs.com/nanomosaic-wins-fda-amt-designation BioBriefs en 2026-02-01T10:33:31Z NanoMosaic wins FDA AMT designation for AAV QC nanoneedle https://biobriefs.com/grail-seeks-fda-premarket-approval BioBriefs en 2026-02-01T10:33:31Z Grail seeks FDA premarket approval for Galleri multi‑cancer test https://biobriefs.com/lilly-brings-manufacturing-scale-3 BioBriefs en 2026-02-01T10:33:31Z Lilly brings manufacturing scale: $3.5B plant for retatrutide and future obesity injectables https://biobriefs.com/corcepts-approval-bid-collides-with BioBriefs en 2026-02-01T10:33:31Z Corcept’s approval bid collides with FDA concerns: agency says warnings were raised early https://biobriefs.com/ultragenyx-resubmits-aav-gene-therapy BioBriefs en 2026-02-01T10:33:31Z Ultragenyx resubmits AAV gene therapy for Sanfilippo type A https://biobriefs.com/fda-recommends-mrd-for-accelerated BioBriefs en 2026-02-01T10:33:31Z FDA recommends MRD for accelerated approvals in multiple myeloma https://biobriefs.com/astrazeneca-makes-18-5bn-bet BioBriefs en 2026-02-01T09:32:22Z AstraZeneca makes $18.5bn bet on CSPC obesity drugs https://biobriefs.com/lilly-unveils-3-5b-factory BioBriefs en 2026-02-01T09:32:22Z Lilly unveils $3.5B factory to scale next‑gen obesity injectables https://biobriefs.com/illumina-closes-somalogic-acquisition-for BioBriefs en 2026-02-01T09:32:22Z Illumina closes SomaLogic acquisition for $350M https://biobriefs.com/beckman-coulter-automata-link-instruments BioBriefs en 2026-02-01T09:32:22Z Beckman Coulter, Automata link instruments to AI‑ready automation https://biobriefs.com/fda-grants-amt-designation-to BioBriefs en 2026-02-01T09:32:22Z FDA grants AMT designation to NanoMosaic’s Nanoneedle for AAV QC https://biobriefs.com/grail-submits-galleri-multi-cancer BioBriefs en 2026-02-01T09:32:22Z Grail submits Galleri multi‑cancer test for FDA premarket approval https://biobriefs.com/chmp-rejects-lillys-mounjaro-for BioBriefs en 2026-02-01T09:32:22Z CHMP rejects Lilly’s Mounjaro for heart‑failure use; backs Novo’s semaglutide in liver disease https://biobriefs.com/quince-halts-edsp-development-after BioBriefs en 2026-02-01T09:32:22Z Quince halts eDSP development after Phase III failure; shares collapse https://biobriefs.com/toolbox-update-bio-techne-seekgene BioBriefs en 2026-02-01T09:32:22Z Toolbox update: Bio‑Techne, SeekGene, RAN and Reprocell launch lab products and services https://biobriefs.com/genyro-licenses-caltech-sidewinder-to BioBriefs en 2026-02-01T09:32:22Z Genyro licenses Caltech Sidewinder to scale DNA writing at industrial scale https://biobriefs.com/astrazeneca-bets-on-obesity-1 BioBriefs en 2026-02-01T04:32:20Z AstraZeneca bets on obesity: $1.2B upfront for CSPC roster https://biobriefs.com/lilly-builds-capacity-3-5b BioBriefs en 2026-02-01T04:32:20Z Lilly builds capacity: $3.5B factory to make retatrutide and next‑gen injectables https://biobriefs.com/illumina-closes-somalogic-deal-proteomics BioBriefs en 2026-02-01T04:32:20Z Illumina closes SomaLogic deal: proteomics meets NGS https://biobriefs.com/fda-grants-amt-to-nanomosaics BioBriefs en 2026-02-01T04:32:20Z FDA grants AMT to NanoMosaic’s nanoneedle — AAV QC technology advances https://biobriefs.com/grail-seeks-fda-ok-for BioBriefs en 2026-02-01T04:32:20Z Grail seeks FDA OK for Galleri: large data set drives PMA push https://biobriefs.com/phase-iii-miss-sinks-quince BioBriefs en 2026-02-01T04:32:20Z Phase III miss sinks Quince... eDSP program shelved https://biobriefs.com/beckman-automata-pair-up-danaher BioBriefs en 2026-02-01T04:32:20Z Beckman, Automata pair up: Danaher backs lab automation push https://biobriefs.com/trumprx-launch-delayed-senators-probe BioBriefs en 2026-02-01T04:32:20Z TrumpRx launch delayed — senators probe anti‑kickback and oversight https://biobriefs.com/fda-says-it-warned-corcept BioBriefs en 2026-02-01T04:32:20Z FDA says it warned Corcept early — rejected Cushing’s filing in focus https://biobriefs.com/origami-inks-global-degrader-pact BioBriefs en 2026-02-01T04:32:20Z Origami inks global degrader pact with Ipsen: protein‑degrader program https://biobriefs.com/astrazeneca-bets-18-5b-on BioBriefs en 2026-01-31T21:33:36Z AstraZeneca bets $18.5B on CSPC obesity push https://biobriefs.com/lilly-unveils-3-5b-plant BioBriefs en 2026-01-31T21:33:36Z Lilly unveils $3.5B plant to make retatrutide and devices https://biobriefs.com/illumina-closes-somalogic-deal-to BioBriefs en 2026-01-31T21:33:36Z Illumina closes SomaLogic deal to deepen proteomics https://biobriefs.com/beckman-coulter-plugs-into-automatas BioBriefs en 2026-01-31T21:33:36Z Beckman Coulter plugs into Automata’s AI‑ready lab platform https://biobriefs.com/nanomosaic-wins-fda-amt-designation BioBriefs en 2026-01-31T21:33:36Z NanoMosaic wins FDA AMT designation for AAV quality control https://biobriefs.com/grail-files-galleri-for-fda BioBriefs en 2026-01-31T21:33:36Z Grail files Galleri for FDA premarket approval https://biobriefs.com/quince-halts-edsp-program-after BioBriefs en 2026-01-31T21:33:36Z Quince halts eDSP program after Neat Phase III miss https://biobriefs.com/moderna-reshuffles-cmo-exits-as BioBriefs en 2026-01-31T21:33:36Z Moderna reshuffles: CMO exits as rare‑disease asset licensed https://biobriefs.com/regulatory-clash-fda-says-it BioBriefs en 2026-01-31T21:33:36Z Regulatory clash: FDA says it flagged Corcept issues before submission https://biobriefs.com/dna-immunotherapy-posts-major-survival BioBriefs en 2026-01-31T21:33:36Z DNA immunotherapy posts major survival gains in ovarian cancer trials https://biobriefs.com/astrazeneca-bets-big-on-cspc BioBriefs en 2026-01-31T16:32:36Z AstraZeneca bets big on CSPC: $18.5bn obesity push https://biobriefs.com/lilly-factories-3-5bn-plant BioBriefs en 2026-01-31T16:32:36Z Lilly factories: $3.5bn plant to feed obesity supply https://biobriefs.com/nanomosaic-gets-fda-amt-nod BioBriefs en 2026-01-31T16:32:36Z NanoMosaic gets FDA AMT nod: Gene therapy QC speeds up https://biobriefs.com/illumina-closes-somalogic-buy-proteomics BioBriefs en 2026-01-31T16:32:36Z Illumina closes SomaLogic buy: Proteomics meets sequencing https://biobriefs.com/quinces-phase-iii-flop-steroid BioBriefs en 2026-01-31T16:32:36Z Quince’s Phase III flop: Steroid therapy shelved, shares collapse https://biobriefs.com/ema-probes-amgens-tavneos-data BioBriefs en 2026-01-31T16:32:36Z EMA probes Amgen’s Tavneos: data-integrity review opened https://biobriefs.com/grail-files-galleri-for-fda BioBriefs en 2026-01-31T16:32:36Z Grail files Galleri for FDA PMA: large clinical dataset submitted https://biobriefs.com/beckman-pairs-with-automata-danaher BioBriefs en 2026-01-31T16:32:36Z Beckman pairs with Automata — Danaher backs automation scale https://biobriefs.com/ultragenyx-resubmits-ux111-gene-therapy BioBriefs en 2026-01-31T16:32:36Z Ultragenyx resubmits UX111: gene therapy for Sanfilippo A refiled https://biobriefs.com/repertoire-signs-lilly-pact-85m BioBriefs en 2026-01-31T16:32:36Z Repertoire signs Lilly pact: $85m upfront, $1.84bn in milestones https://biobriefs.com/astrazeneca-bets-18-5bn-on BioBriefs en 2026-01-31T14:33:16Z AstraZeneca bets $18.5bn on CSPC obesity lineup https://biobriefs.com/beckman-coulter-partners-automata-scale BioBriefs en 2026-01-31T14:33:16Z Beckman Coulter partners Automata: scale AI‑ready lab automation https://biobriefs.com/nanomosaic-earns-fda-amt-designation BioBriefs en 2026-01-31T14:33:16Z NanoMosaic earns FDA AMT designation – speeds AAV QC https://biobriefs.com/illumina-completes-somalogic-acquisition-to BioBriefs en 2026-01-31T14:33:16Z Illumina completes SomaLogic acquisition to expand proteomics https://biobriefs.com/repertoire-lands-lillys-1-9bn BioBriefs en 2026-01-31T14:33:16Z Repertoire lands Lilly’s $1.9bn autoimmune pact https://biobriefs.com/phase-iii-fizzle-quince-collapses BioBriefs en 2026-01-31T14:33:16Z Phase III fizzle... Quince collapses https://biobriefs.com/fda-drafts-myeloma-guidance-mrd BioBriefs en 2026-01-31T14:33:16Z FDA drafts myeloma guidance: MRD favored for accelerated approvals https://biobriefs.com/grail-submits-galleri-multi-cancer BioBriefs en 2026-01-31T14:33:16Z Grail submits Galleri multi‑cancer test to FDA for PMA https://biobriefs.com/deepmind-launches-alphagenome-predicts-regulatory BioBriefs en 2026-01-31T14:33:16Z DeepMind launches AlphaGenome: predicts regulatory variant effects https://biobriefs.com/corcept-says-fda-warned-it BioBriefs en 2026-01-31T14:33:16Z Corcept says FDA warned it — regulatory dispute surfaces https://biobriefs.com/astrazeneca-bets-on-china-15bn BioBriefs en 2026-01-31T10:33:03Z AstraZeneca bets on China: $15bn push and $1.2bn CSPC obesity pact https://biobriefs.com/illumina-closes-somalogic-buy-proteomics BioBriefs en 2026-01-31T10:33:03Z Illumina closes SomaLogic buy: proteomics scales inside NGS ecosystem https://biobriefs.com/nanomosaic-wins-fda-amt-nod BioBriefs en 2026-01-31T10:33:03Z NanoMosaic wins FDA AMT nod: gene therapy QC tech prioritized https://biobriefs.com/tenpoints-presbyopia-win-fda-clears BioBriefs en 2026-01-31T10:33:03Z Tenpoint’s presbyopia win: FDA clears dual‑agent drop and backstops launch with $235M https://biobriefs.com/phase-iii-miss-implodes-quince BioBriefs en 2026-01-31T10:33:03Z Phase‑III miss implodes Quince: steroid therapy for A‑T abandoned https://biobriefs.com/lilly-taps-repertoire-1-92bn BioBriefs en 2026-01-31T10:33:03Z Lilly taps Repertoire: $1.92bn alliance to decode and treat autoimmunity https://biobriefs.com/grail-files-galleri-for-fda BioBriefs en 2026-01-31T10:33:03Z Grail files Galleri for FDA PMA: large prospective datasets underpin bid https://biobriefs.com/deepminds-alphagenome-long-context-model BioBriefs en 2026-01-31T10:33:03Z DeepMind’s AlphaGenome: long‑context model decodes regulatory variants https://biobriefs.com/beckman-automata-tie-up-danaher BioBriefs en 2026-01-31T10:33:03Z Beckman–Automata tie-up: Danaher strategic backing, $45M Series C to scale lab automation https://biobriefs.com/thermo-fisher-raises-2026-outlook BioBriefs en 2026-01-31T10:33:03Z Thermo Fisher raises 2026 outlook: mid‑single digit growth expected after strong quarter https://biobriefs.com/astrazenecas-china-bet-1-2b BioBriefs en 2026-01-31T09:32:28Z AstraZeneca’s China bet: $1.2B CSPC obesity pact and $15B China push https://biobriefs.com/illumina-snaps-up-somalogic-proteomics BioBriefs en 2026-01-31T09:32:28Z Illumina snaps up SomaLogic: proteomics meets sequencing https://biobriefs.com/fda-backs-nanomosaic-amt-designation BioBriefs en 2026-01-31T09:32:28Z FDA backs NanoMosaic: AMT designation for gene therapy QC https://biobriefs.com/lab-automation-scales-beckman-pairs BioBriefs en 2026-01-31T09:32:28Z Lab automation scales: Beckman pairs with Automata; Automata nets $45M https://biobriefs.com/quinces-phase-3-failure-stalls BioBriefs en 2026-01-31T09:32:28Z Quince’s Phase‑3 failure stalls eDSP program — company written down https://biobriefs.com/repertoire-inks-big-autoimmune-pact BioBriefs en 2026-01-31T09:32:28Z Repertoire inks big autoimmune pact: Lilly deal validates Decode platform https://biobriefs.com/tenpoint-wins-fda-nod-for BioBriefs en 2026-01-31T09:32:28Z Tenpoint wins FDA nod for dual‑agent presbyopia drop and secures $235M https://biobriefs.com/lilly-builds-capacity-for-obesity BioBriefs en 2026-01-31T09:32:28Z Lilly builds capacity for obesity era: $3.5B Lehigh Valley factory https://biobriefs.com/deepminds-alphagenome-maps-non-coding BioBriefs en 2026-01-31T09:32:28Z DeepMind’s AlphaGenome maps non‑coding DNA: regulatory variant predictions https://biobriefs.com/ultragenyx-resubmits-sanfilippo-aav-therapy BioBriefs en 2026-01-31T09:32:28Z Ultragenyx resubmits Sanfilippo AAV therapy: FDA re‑filing after rejection https://biobriefs.com/astrazeneca-vows-15b-china-push BioBriefs en 2026-01-31T04:32:43Z AstraZeneca vows $15B China push—R&D and manufacturing expansion https://biobriefs.com/lilly-builds-3-5b-factory BioBriefs en 2026-01-31T04:32:43Z Lilly builds $3.5B factory—retatrutide and next-gen obesity drugs slated https://biobriefs.com/tenpoint-wins-fda-nod-dual BioBriefs en 2026-01-31T04:32:43Z Tenpoint wins FDA nod—dual-agent presbyopia drop cleared and $235M secured https://biobriefs.com/illumina-closes-somalogic-buy-proteomics BioBriefs en 2026-01-31T04:32:43Z Illumina closes SomaLogic buy—proteomics and CLIA lab fold into NGS leader https://biobriefs.com/nanomosaic-wins-fda-amt-nanoneedle BioBriefs en 2026-01-31T04:32:43Z NanoMosaic wins FDA AMT—nanoneedle QC platform fast-tracked for gene therapy https://biobriefs.com/beckman-coulter-and-automata-pair BioBriefs en 2026-01-31T04:32:43Z Beckman Coulter and Automata pair up—Danaher joins Automata’s Series C https://biobriefs.com/deepmind-publishes-alphagenome-ai-models BioBriefs en 2026-01-31T04:32:43Z DeepMind publishes AlphaGenome—AI models the regulatory 'dark genome' https://biobriefs.com/repertoire-inks-1-92b-autoimmune BioBriefs en 2026-01-31T04:32:43Z Repertoire inks $1.92B autoimmune pact with Lilly—tolerizing vaccines push forward https://biobriefs.com/grail-files-galleri-for-fda BioBriefs en 2026-01-31T04:32:43Z Grail files Galleri for FDA premarket approval—large multi-study evidence package https://biobriefs.com/phase-iii-failure-collapses-quince BioBriefs en 2026-01-31T04:32:43Z Phase III failure collapses Quince—monthly steroid therapy for A‑T halted https://biobriefs.com/astrazeneca-bankrolls-cspc-up-to BioBriefs en 2026-01-30T21:33:42Z AstraZeneca bankrolls CSPC: up to $18.5B for next‑gen obesity drugs https://biobriefs.com/fda-clears-duo-drop-tenpoint BioBriefs en 2026-01-30T21:33:42Z FDA clears duo‑drop: Tenpoint wins approval and $235M to commercialize Yuvezzi https://biobriefs.com/fda-grants-amt-nanomosaics-nanoneedle BioBriefs en 2026-01-30T21:33:42Z FDA grants AMT: NanoMosaic’s nanoneedle QC platform wins regulatory fast‑track https://biobriefs.com/beckman-coulter-integrates-with-automata BioBriefs en 2026-01-30T21:33:42Z Beckman Coulter integrates with Automata — Danaher backs automation scale‑up https://biobriefs.com/eli-lilly-bets-on-repertoire BioBriefs en 2026-01-30T21:33:42Z Eli Lilly bets on Repertoire: $1.9B autoimmune collaboration validates Decode platform https://biobriefs.com/phase-iii-fizzle-topples-quince BioBriefs en 2026-01-30T21:33:42Z Phase‑III fizzle topples Quince: steroid therapy fails in ataxia trial https://biobriefs.com/ema-probes-amgens-tavneos-amgen BioBriefs en 2026-01-30T21:33:42Z EMA probes Amgen’s Tavneos — Amgen pares down immunology program https://biobriefs.com/lecanemab-aria-linked-to-cd8 BioBriefs en 2026-01-30T21:33:42Z Lecanemab ARIA linked to CD8 expansion — immune mechanism surfaces https://biobriefs.com/grail-files-galleri-for-fda BioBriefs en 2026-01-30T21:33:42Z Grail files Galleri for FDA PMA — multi‑cancer blood test moves toward market https://biobriefs.com/deepmind-publishes-alphagenome-ai-decodes BioBriefs en 2026-01-30T21:33:42Z DeepMind publishes AlphaGenome — AI decodes noncoding variant effects https://biobriefs.com/astrazeneca-bets-18-5bn-china BioBriefs en 2026-01-30T16:33:19Z AstraZeneca bets $18.5bn: China tie brings next‑gen weight‑loss shots https://biobriefs.com/fda-designates-nanomosaics-nanoneedle-gene BioBriefs en 2026-01-30T16:33:19Z FDA designates NanoMosaic’s nanoneedle — gene therapy QC cleared for priority engagement https://biobriefs.com/trumprx-launch-postponed-compliance-and BioBriefs en 2026-01-30T16:33:19Z TrumpRx launch postponed... compliance and anti‑kickback questions stall rollout https://biobriefs.com/amgen-jilts-kyowa-kirin-high BioBriefs en 2026-01-30T16:33:19Z Amgen jilts Kyowa Kirin — high‑stakes immunology asset returns after program exit https://biobriefs.com/quinces-phase-3-miss-steroid BioBriefs en 2026-01-30T16:33:19Z Quince’s Phase 3 miss: steroid program fails, company halts development https://biobriefs.com/illumina-closes-somalogic-deal-350m BioBriefs en 2026-01-30T16:33:19Z Illumina closes SomaLogic deal: $350m buy expands proteomics and CLIA lab reach https://biobriefs.com/lilly-ramps-capacity-3-5b BioBriefs en 2026-01-30T16:33:19Z Lilly ramps capacity: $3.5B Lehigh Valley plant to make retatrutide and injectables https://biobriefs.com/fda-draft-mrd-recommended-for BioBriefs en 2026-01-30T16:33:19Z FDA draft: MRD recommended for accelerated multiple myeloma approvals https://biobriefs.com/grail-files-galleri-for-fda BioBriefs en 2026-01-30T16:33:19Z Grail files Galleri for FDA premarket approval — large study evidence included https://biobriefs.com/tenpoint-wins-fda-approval-presbyopia BioBriefs en 2026-01-30T16:33:19Z Tenpoint wins FDA approval — presbyopia duo‑drop cleared with $235M financing https://biobriefs.com/astrazeneca-bets-18-5bn-on BioBriefs en 2026-01-30T14:33:16Z AstraZeneca bets $18.5bn on CSPC weight‑loss drugs: $1.2bn upfront https://biobriefs.com/astrazeneca-in-china-venture-bets BioBriefs en 2026-01-30T14:33:16Z AstraZeneca in China... venture bets and dealmaking to fuel $15bn plan https://biobriefs.com/fda-grants-nanomosaic-amt-designation BioBriefs en 2026-01-30T14:33:16Z FDA grants NanoMosaic AMT designation – gene‑therapy QC gets regulatory nod https://biobriefs.com/repertoire-adds-lilly-to-partnership BioBriefs en 2026-01-30T14:33:16Z Repertoire adds Lilly to partnership roster – autoimmune pact tops $2.6bn https://biobriefs.com/tenpoint-wins-fda-clearance-for BioBriefs en 2026-01-30T14:33:16Z Tenpoint wins FDA clearance for combo presbyopia drop – financing follows https://biobriefs.com/fda-suspends-regenxbio-gene-therapy BioBriefs en 2026-01-30T14:33:16Z FDA suspends Regenxbio gene‑therapy trials after tumor finding – regulator steps in https://biobriefs.com/cms-names-drugs-for-round BioBriefs en 2026-01-30T14:33:16Z CMS names drugs for Round‑Three negotiation: Part B biologics included https://biobriefs.com/eikon-pushes-public-markets-dual BioBriefs en 2026-01-30T14:33:16Z Eikon pushes public markets: dual IPO filings point to large raise for oncology push https://biobriefs.com/moderna-spins-out-late-stage BioBriefs en 2026-01-30T14:33:16Z Moderna spins out late‑stage rare disease asset to Recordati: $50m upfront https://biobriefs.com/amgen-walks-away-from-kyowa BioBriefs en 2026-01-30T14:33:16Z Amgen walks away from Kyowa $400m autoimmune pact – program halted https://biobriefs.com/fda-halts-regenxbio-gene-trials BioBriefs en 2026-01-30T10:32:58Z FDA halts Regenxbio gene trials: tumor triggers safety pause https://biobriefs.com/fda-grants-amt-to-nanomosaic BioBriefs en 2026-01-30T10:32:58Z FDA grants AMT to NanoMosaic: gene therapy QC gets priority access https://biobriefs.com/astrazeneca-doubles-down-on-china BioBriefs en 2026-01-30T10:32:58Z AstraZeneca doubles down on China: $15B plan and regional deals https://biobriefs.com/repertoire-expands-big-pharma-footprint BioBriefs en 2026-01-30T10:32:58Z Repertoire expands Big‑Pharma footprint: Lilly deal tops prior partnerships https://biobriefs.com/tenpoint-wins-fda-approval-dual BioBriefs en 2026-01-30T10:32:58Z Tenpoint wins FDA approval: dual‑agent presbyopia drop gets funding https://biobriefs.com/lilly-bets-on-recombinase-editing BioBriefs en 2026-01-30T10:32:58Z Lilly bets on recombinase editing: Seamless tie could top $1.1B https://biobriefs.com/revita-procedure-cuts-weight-regain BioBriefs en 2026-01-30T10:32:58Z Revita procedure cuts weight‑regain after GLP‑1s: 70% reduction https://biobriefs.com/moderna-outlicenses-rare-disease-asset BioBriefs en 2026-01-30T10:32:58Z Moderna outlicenses rare‑disease asset: $50M upfront to Recordati https://biobriefs.com/eikon-sets-ipo-terms-eyes BioBriefs en 2026-01-30T10:32:58Z Eikon sets IPO terms: eyes $317M to advance oncology platform https://biobriefs.com/manufacturing-surge-cellares-raises-257m BioBriefs en 2026-01-30T10:32:58Z Manufacturing surge: Cellares raises $257M; automaton funding follows https://biobriefs.com/fda-halts-regenxbio-aav-trials BioBriefs en 2026-01-30T09:33:19Z FDA halts Regenxbio AAV trials after patient tumor discovery https://biobriefs.com/lilly-bets-1-12b-on BioBriefs en 2026-01-30T09:33:19Z Lilly bets $1.12B on recombinase editing — Seamless deal https://biobriefs.com/repertoire-adds-lilly-in-near BioBriefs en 2026-01-30T09:33:19Z Repertoire adds Lilly in near‑$2B autoimmune decode deal https://biobriefs.com/fda-clears-tenpoints-dual-agent BioBriefs en 2026-01-30T09:33:19Z FDA clears Tenpoint’s dual‑agent presbyopia drop; financing follows https://biobriefs.com/fda-grants-amt-to-nanomosaic BioBriefs en 2026-01-30T09:33:19Z FDA grants AMT to NanoMosaic — gene‑therapy QC gets regulatory lift https://biobriefs.com/deepminds-alphagenome-decodes-noncoding-dna BioBriefs en 2026-01-30T09:33:19Z DeepMind’s AlphaGenome decodes noncoding DNA: variant effects in seconds https://biobriefs.com/moderna-merck-mrna-antibody-combo BioBriefs en 2026-01-30T09:33:19Z Moderna + Merck mRNA‑antibody combo halves melanoma recurrence in interim readout https://biobriefs.com/revita-endoscopic-procedure-cuts-post BioBriefs en 2026-01-30T09:33:19Z Revita endoscopic procedure cuts post‑GLP‑1 weight regain ~70% https://biobriefs.com/roche-trims-pipeline-after-futility BioBriefs en 2026-01-30T09:33:19Z Roche trims pipeline after futility finds; flags China diagnostic headwinds https://biobriefs.com/dna-protein-crosslinks-activate-cgas BioBriefs en 2026-01-30T09:33:19Z DNA‑protein crosslinks activate cGAS‑STING and drive progeroid disease https://biobriefs.com/fda-halts-regenxbio-gene-therapy BioBriefs en 2026-01-30T04:33:08Z FDA halts Regenxbio gene therapy trials — safety scare weeks before approval https://biobriefs.com/fda-designates-nanomosaics-tessie-platform BioBriefs en 2026-01-30T04:33:08Z FDA designates NanoMosaic’s Tessie platform as advanced manufacturing tech https://biobriefs.com/lilly-inks-up-to-1 BioBriefs en 2026-01-30T04:33:08Z Lilly inks up‑to‑$1.12B Seamless deal — recombinase editing enters big‑pharma orbit https://biobriefs.com/repertoire-lands-lilly-collaboration-1 BioBriefs en 2026-01-30T04:33:08Z Repertoire lands Lilly collaboration — $1.9B autoimmune programs add Big Pharma backing https://biobriefs.com/fda-clears-tenpoints-dual-agent BioBriefs en 2026-01-30T04:33:08Z FDA clears Tenpoint’s dual‑agent presbyopia drop — startup secures $235M push https://biobriefs.com/deepmind-releases-alphagenome-ai-predicts BioBriefs en 2026-01-30T04:33:08Z DeepMind releases AlphaGenome — AI predicts noncoding DNA function at scale https://biobriefs.com/fractyls-revita-shows-large-cut BioBriefs en 2026-01-30T04:33:08Z Fractyl’s Revita shows large cut in post‑GLP‑1 weight regain — six‑month trial readout https://biobriefs.com/cellares-raises-257m-to-scale BioBriefs en 2026-01-30T04:33:08Z Cellares raises $257M to scale cell‑therapy manufacturing ahead of IPO https://biobriefs.com/eikon-targets-273-274m-ipo BioBriefs en 2026-01-30T04:33:08Z Eikon targets $273–274M IPO to fund oncology imaging and discovery platform https://biobriefs.com/thermo-fisher-projects-4-6 BioBriefs en 2026-01-30T04:33:08Z Thermo Fisher projects 4–6% revenue growth in 2026 — life‑sciences demand steadies https://biobriefs.com/fda-halts-regenxbio-studies-tumor BioBriefs en 2026-01-29T21:33:22Z FDA halts Regenxbio studies — tumor found in trial participant https://biobriefs.com/fda-designates-nanomosaic-as-amt BioBriefs en 2026-01-29T21:33:22Z FDA designates NanoMosaic as AMT: gene therapy QC platform gains fast-track access https://biobriefs.com/cms-names-15-drugs-for BioBriefs en 2026-01-29T21:33:22Z CMS names 15 drugs for round three negotiations — Part B biologics included https://biobriefs.com/repertoire-and-lilly-expand-autoimmune BioBriefs en 2026-01-29T21:33:22Z Repertoire and Lilly expand autoimmune push — multibillion platform validation https://biobriefs.com/lilly-backs-recombinase-editing-seamless BioBriefs en 2026-01-29T21:33:22Z Lilly backs recombinase editing — Seamless deal targets genetic hearing loss https://biobriefs.com/tenpoint-wins-fda-approval-for BioBriefs en 2026-01-29T21:33:22Z Tenpoint wins FDA approval for dual‑agent presbyopia drop — $235M financing closes https://biobriefs.com/en-cartas-point-of-care BioBriefs en 2026-01-29T21:33:22Z En Carta’s point‑of‑care Lyme test gets FDA breakthrough designation https://biobriefs.com/deepminds-alphagenome-debuts-community-presses BioBriefs en 2026-01-29T21:33:22Z DeepMind’s AlphaGenome debuts — community presses for validation https://biobriefs.com/cellares-raises-257m-to-scale BioBriefs en 2026-01-29T21:33:22Z Cellares raises $257M to scale cell therapy manufacturing ahead of IPO https://biobriefs.com/summits-pd-1xvegf-bispecific-accepted BioBriefs en 2026-01-29T21:33:22Z Summit’s PD‑1xVEGF bispecific accepted — FDA sets November decision date https://biobriefs.com/fda-pauses-regenxbio-gene-trials BioBriefs en 2026-01-29T16:34:30Z FDA pauses Regenxbio gene trials: tumor found in child https://biobriefs.com/lilly-inks-up-to-1 BioBriefs en 2026-01-29T16:34:30Z Lilly inks up-to-$1.12B recombinase pact with Seamless https://biobriefs.com/repertoire-adds-lilly-to-partner BioBriefs en 2026-01-29T16:34:30Z Repertoire adds Lilly to partner roster — blockbuster autoimmune pact https://biobriefs.com/moderna-and-merck-report-49 BioBriefs en 2026-01-29T16:34:30Z Moderna and Merck report 49% drop in melanoma recurrence with mRNA combo https://biobriefs.com/summit-secures-fda-date-for BioBriefs en 2026-01-29T16:34:30Z Summit secures FDA date for PD‑1/VEGF bispecific https://biobriefs.com/tenpoint-wins-fda-approval-for BioBriefs en 2026-01-29T16:34:30Z Tenpoint wins FDA approval for presbyopia drop — raises $235M to launch https://biobriefs.com/thermo-fisher-raises-guide-after BioBriefs en 2026-01-29T16:34:30Z Thermo Fisher raises guide after strong Q4 — sees mid‑single‑digit growth for 2026 https://biobriefs.com/oxford-nanopore-reverses-phase-out BioBriefs en 2026-01-29T16:34:30Z Oxford Nanopore reverses phase‑out plan — P2 Solo supported through 2030 https://biobriefs.com/cms-opens-round-3-of BioBriefs en 2026-01-29T16:34:30Z CMS opens Round 3 of IRA drug negotiations — 15 medicines named, Part B included https://biobriefs.com/cellares-raises-257m-as-it BioBriefs en 2026-01-29T16:34:30Z Cellares raises $257M as it scales automated cell‑therapy manufacturing https://biobriefs.com/fda-halts-regenxbio-gene-trials BioBriefs en 2026-01-29T14:33:51Z FDA halts Regenxbio gene trials: brain tumor sparks holds https://biobriefs.com/fda-lifts-partial-hold-on BioBriefs en 2026-01-29T14:33:51Z FDA lifts partial hold on Intellia CRISPR trial – one study resumes https://biobriefs.com/lilly-inks-1-12b-recombinase BioBriefs en 2026-01-29T14:33:51Z Lilly inks $1.12B recombinase pact with Seamless – hearing loss push https://biobriefs.com/cms-names-15-drugs-for BioBriefs en 2026-01-29T14:33:51Z CMS names 15 drugs for round‑three price talks: Part B drugs included https://biobriefs.com/roches-glp-1-gip-ct BioBriefs en 2026-01-29T14:33:51Z Roche’s GLP‑1/GIP CT‑388 posts competitive Phase‑2 weight loss https://biobriefs.com/tenpoint-eye-drop-cleared-presbyopia BioBriefs en 2026-01-29T14:33:51Z Tenpoint eye drop cleared: presbyopia approval paired with $235M raise https://biobriefs.com/moderna-merck-mrna-antibody-combo BioBriefs en 2026-01-29T14:33:51Z Moderna/Merck mRNA‑antibody combo halves melanoma recurrence in interim read https://biobriefs.com/cellares-grabs-257m-to-scale BioBriefs en 2026-01-29T14:33:51Z Cellares grabs $257M to scale cell‑therapy manufacturing and prep IPO https://biobriefs.com/abbvie-pledges-100b-in-u BioBriefs en 2026-01-29T14:33:51Z AbbVie pledges $100B in U.S. investment under administration deal https://biobriefs.com/roche-drops-100m-fibrosis-asset BioBriefs en 2026-01-29T14:33:51Z Roche drops $100M fibrosis asset after futility read—pipeline pared https://biobriefs.com/fda-halts-regenxbio-trials-brain BioBriefs en 2026-01-29T10:32:47Z FDA halts Regenxbio trials — brain tumor found in pediatric patient https://biobriefs.com/abbvie-pledges-100bn-to-us BioBriefs en 2026-01-29T10:32:47Z AbbVie pledges $100bn to US R&D — deal with Trump administration https://biobriefs.com/lilly-inks-up-to-1 BioBriefs en 2026-01-29T10:32:47Z Lilly inks up-to‑$1.12B recombinant gene-editing pact with Seamless for hearing loss https://biobriefs.com/roches-ct-388-posts-competitive BioBriefs en 2026-01-29T10:32:47Z Roche’s CT‑388 posts competitive Phase 2 weight‑loss — heads to Phase 3 https://biobriefs.com/cms-opens-round-three-of BioBriefs en 2026-01-29T10:32:47Z CMS opens round three of Medicare drug price talks — 15 drugs named https://biobriefs.com/fda-lifts-hold-on-one BioBriefs en 2026-01-29T10:32:47Z FDA lifts hold on one Intellia CRISPR trial — cardiac study still paused https://biobriefs.com/deepmind-releases-alphagenome-ai-maps BioBriefs en 2026-01-29T10:32:47Z DeepMind releases AlphaGenome — AI maps noncoding DNA function https://biobriefs.com/moderna-merck-interim-data-mrna BioBriefs en 2026-01-29T10:32:47Z Moderna + Merck interim data: mRNA neo‑antigen plus pembrolizumab halves melanoma recurrence https://biobriefs.com/oxford-nanopore-reverses-course-p2 BioBriefs en 2026-01-29T10:32:47Z Oxford Nanopore reverses course — P2 Solo support extended to 2030 https://biobriefs.com/fda-greenlights-life-biosciences-reprogramming BioBriefs en 2026-01-29T10:32:47Z FDA greenlights Life Biosciences’ reprogramming trial — first human test of age‑reversal approach https://biobriefs.com/fda-halts-regenxbio-trials-brain BioBriefs en 2026-01-29T09:32:59Z FDA halts Regenxbio trials: brain tumor prompts clinical holds https://biobriefs.com/lilly-inks-up-to-1 BioBriefs en 2026-01-29T09:32:59Z Lilly inks up-to-$1.12B recombinase pact – Seamless deal validates platform https://biobriefs.com/cms-names-round-3-drugs BioBriefs en 2026-01-29T09:32:59Z CMS names Round 3 drugs: 15 medicines enter Medicare price talks https://biobriefs.com/roches-glp-1-gip-posts BioBriefs en 2026-01-29T09:32:59Z Roche’s GLP-1/GIP posts competitive Phase 2 weight loss…Phase 3 next https://biobriefs.com/intellia-resumes-one-crispr-phase BioBriefs en 2026-01-29T09:32:59Z Intellia resumes one CRISPR Phase 3 — another remains paused https://biobriefs.com/deepminds-alphagenome-ai-decodes-noncoding BioBriefs en 2026-01-29T09:32:59Z DeepMind’s AlphaGenome: AI decodes noncoding DNA at scale https://biobriefs.com/moderna-keytruda-combo-cuts-melanoma BioBriefs en 2026-01-29T09:32:59Z Moderna+Keytruda combo cuts melanoma recurrence in Phase 2 interim readout https://biobriefs.com/ex-google-ceos-hologen-raises BioBriefs en 2026-01-29T09:32:59Z Ex‑Google CEO’s Hologen raises ambitions; Insilico launches specialized ‘gym’ for drug LLMs https://biobriefs.com/mrna-manufacturing-advances-acid-denaturation BioBriefs en 2026-01-29T09:32:59Z mRNA manufacturing advances: acid denaturation of dsRNA and real‑time cell‑health sensors https://biobriefs.com/cell-therapy-capacity-race-cellares BioBriefs en 2026-01-29T09:32:59Z Cell therapy capacity race: Cellares raises $257M as bioprocess demand surges https://biobriefs.com/fda-halts-regenxbio-trials-after BioBriefs en 2026-01-29T04:32:53Z FDA halts Regenxbio trials after tumor found – agency suspends studies https://biobriefs.com/fda-lifts-hold-on-intellia BioBriefs en 2026-01-29T04:32:53Z FDA lifts hold on Intellia CRISPR trial – one study resumes https://biobriefs.com/lilly-inks-up-to-1 BioBriefs en 2026-01-29T04:32:53Z Lilly inks up‑to‑$1.12B recombinase pact with Seamless – hearing loss push https://biobriefs.com/cms-names-15-drugs-for BioBriefs en 2026-01-29T04:32:53Z CMS names 15 drugs for third‑round IRA negotiations — Medicare pricing moves https://biobriefs.com/moderna-merck-personalized-mrna-combo BioBriefs en 2026-01-29T04:32:53Z Moderna/Merck personalized mRNA combo shows benefit — mRNA manufacturing advances https://biobriefs.com/single-molecule-proteomics-maps-alpha BioBriefs en 2026-01-29T04:32:53Z Single‑molecule proteomics maps alpha‑synuclein — Nautilus, Weill Cornell team up https://biobriefs.com/deepminds-alphagenome-draws-scrutiny-users BioBriefs en 2026-01-29T04:32:53Z DeepMind’s AlphaGenome draws scrutiny — users ask for benchmark comparisons https://biobriefs.com/insilico-launches-science-mmai-gym BioBriefs en 2026-01-29T04:32:53Z Insilico launches Science MMAI Gym; inks $120M cardiometabolic pact https://biobriefs.com/sequencing-vendors-shift-support-and BioBriefs en 2026-01-29T04:32:53Z Sequencing vendors shift support and distribution — Oxford extends P2 Solo life https://biobriefs.com/cell-therapy-manufacturing-and-automation BioBriefs en 2026-01-29T04:32:53Z Cell‑therapy manufacturing and automation scale up — Cellares raises $257M https://biobriefs.com/cms-picks-15-drugs-for BioBriefs en 2026-01-28T21:32:34Z CMS picks 15 drugs for round three: Biologics and Part B join negotiations https://biobriefs.com/fda-suspends-regenxbio-trials-after BioBriefs en 2026-01-28T21:32:34Z FDA suspends Regenxbio trials after brain tumor discovery – Approval clock paused https://biobriefs.com/fda-lifts-hold-on-one BioBriefs en 2026-01-28T21:32:34Z FDA lifts hold on one Intellia Phase 3 – CRISPR program advances cautiously https://biobriefs.com/lilly-inks-1-12b-recombinase BioBriefs en 2026-01-28T21:32:34Z Lilly inks $1.12B recombinase pact – gene editing targets hearing loss https://biobriefs.com/deepminds-alphagenome-draws-scrutiny-users BioBriefs en 2026-01-28T21:32:34Z DeepMind’s AlphaGenome draws scrutiny: users push validation and benchmarks https://biobriefs.com/stealth-ai-biotech-hologen-seeks BioBriefs en 2026-01-28T21:32:34Z Stealth AI biotech Hologen seeks $150M to build ‘large medicine models’ https://biobriefs.com/abbvie-agrees-100b-u-s BioBriefs en 2026-01-28T21:32:34Z AbbVie agrees $100B U.S. investment deal with administration to expand access https://biobriefs.com/personalized-mrna-plus-pembrolizumab-halves BioBriefs en 2026-01-28T21:32:34Z Personalized mRNA plus pembrolizumab halves melanoma relapse risk at five years https://biobriefs.com/hhs-issues-guidance-to-shield BioBriefs en 2026-01-28T21:32:34Z HHS issues guidance to shield manufacturers for TrumpRx direct‑to‑consumer sales https://biobriefs.com/cellares-raises-257m-as-cell BioBriefs en 2026-01-28T21:32:34Z Cellares raises $257M as cell‑therapy manufacturing scales toward IPO https://biobriefs.com/fda-halts-regenxbio-trials-amid BioBriefs en 2026-01-28T16:32:35Z FDA halts Regenxbio trials amid pediatric brain‑tumor finding https://biobriefs.com/lilly-bets-up-to-1 BioBriefs en 2026-01-28T16:32:35Z Lilly bets up to $1.12B on recombinase gene editing for hearing https://biobriefs.com/fda-partially-lifts-hold-on BioBriefs en 2026-01-28T16:32:35Z FDA partially lifts hold on Intellia’s CRISPR program — one study still suspended https://biobriefs.com/roche-advances-dual-agonist-obesity BioBriefs en 2026-01-28T16:32:35Z Roche advances dual‑agonist obesity shot after robust mid‑stage readout https://biobriefs.com/en-carta-wins-fda-breakthrough BioBriefs en 2026-01-28T16:32:35Z En Carta wins FDA breakthrough device tag for microneedle Lyme test https://biobriefs.com/sensorion-raises-eur60m-as-sanofi BioBriefs en 2026-01-28T16:32:35Z Sensorion raises €60M as Sanofi takes strategic stake to back hearing programs https://biobriefs.com/cellares-secures-257m-to-scale BioBriefs en 2026-01-28T16:32:35Z Cellares secures $257M to scale global cell‑therapy manufacturing and eye IPO https://biobriefs.com/eclipsebio-acquires-terrain-bio-to BioBriefs en 2026-01-28T16:32:35Z Eclipsebio acquires Terrain Bio to fuse ML RNA design with sequencing analytics https://biobriefs.com/danaher-posts-stronger-than-expected BioBriefs en 2026-01-28T16:32:35Z Danaher posts stronger‑than‑expected Q4 as bioprocessing sales drive growth https://biobriefs.com/biopharma-sentiment-index-climbs-optimism BioBriefs en 2026-01-28T16:32:35Z Biopharma Sentiment Index climbs — optimism returns but uncertainty remains https://biobriefs.com/fda-lifts-hold-on-one BioBriefs en 2026-01-28T14:32:37Z FDA lifts hold on one Intellia trial: Magnitude-2 cleared, cardiomyopathy study remains paused https://biobriefs.com/fda-halts-regenxbio-gene-therapy BioBriefs en 2026-01-28T14:32:37Z FDA halts Regenxbio gene therapy trials after child develops brain tumor https://biobriefs.com/lilly-inks-up-to-1 BioBriefs en 2026-01-28T14:32:37Z Lilly inks up-to-$1.12B Seamless pact: recombinase editing for hearing loss https://biobriefs.com/cellares-raises-257m-cell-therapy BioBriefs en 2026-01-28T14:32:37Z Cellares raises $257M: cell therapy contract manufacturer scales toward IPO https://biobriefs.com/roches-mid-stage-obesity-shot BioBriefs en 2026-01-28T14:32:37Z Roche’s mid‑stage obesity shot posts double‑digit loss... Phase 3 next https://biobriefs.com/parse-and-graph-join-to BioBriefs en 2026-01-28T14:32:37Z Parse and Graph join to build massive immune perturbation atlas https://biobriefs.com/eclipsebio-buys-terrain-bio-rna BioBriefs en 2026-01-28T14:32:37Z Eclipsebio buys Terrain Bio: RNA design meets sequencing analytics https://biobriefs.com/ixcells-and-rosebud-pair-up BioBriefs en 2026-01-28T14:32:37Z iXCells and Rosebud pair up on organoids... rare disease models scaled https://biobriefs.com/ai-designed-anti-crisprs-de BioBriefs en 2026-01-28T14:32:37Z AI‑designed anti‑CRISPRs: de novo proteins switch off Cas13 fast https://biobriefs.com/in-vivo-car-t-reduces BioBriefs en 2026-01-28T14:32:37Z In vivo CAR‑T reduces liver fibrosis: stellate cell targeting shows reversal https://biobriefs.com/fda-lifts-hold-on-intellia BioBriefs en 2026-01-28T10:33:53Z FDA lifts hold on Intellia CRISPR trial – one Phase 3 resumes after liver event https://biobriefs.com/fda-clears-life-biosciences-reprogramming BioBriefs en 2026-01-28T10:33:53Z FDA clears Life Biosciences reprogramming study – first human test of age‑rewind approach https://biobriefs.com/roches-glp-1-gip-ct BioBriefs en 2026-01-28T10:33:53Z Roche’s GLP‑1/GIP CT‑388 posts weight‑loss signal — company pushes to Phase 3 https://biobriefs.com/eclipsebio-buys-terrain-bio-ai BioBriefs en 2026-01-28T10:33:53Z Eclipsebio buys Terrain Bio – AI design meets sequencing analytics for RNA drugs https://biobriefs.com/parse-and-graph-partner-to BioBriefs en 2026-01-28T10:33:53Z Parse and Graph partner to build immune perturbation atlas – scale and context for AI drug discovery https://biobriefs.com/insilico-inks-120m-pact-with BioBriefs en 2026-01-28T10:33:53Z Insilico inks $120M pact with Qilu — AI‑powered cardiometabolic discovery deal https://biobriefs.com/altido-bio-raises-seed-to BioBriefs en 2026-01-28T10:33:53Z Altido Bio raises seed to commercialize MGH CAR‑T for glioblastoma – early tumor shrinkage seen https://biobriefs.com/trexbio-extends-series-b-with BioBriefs en 2026-01-28T10:33:53Z TRexBio extends Series B with $50M — funds Treg‑activating programs into the clinic https://biobriefs.com/10x-genomics-pushes-into-clinical BioBriefs en 2026-01-28T10:33:53Z 10x Genomics pushes into clinical diagnostics – CLIA lab, hospital partnerships in motion https://biobriefs.com/oxford-nanopore-reverses-p2-solo BioBriefs en 2026-01-28T10:33:53Z Oxford Nanopore reverses P2 Solo sunset – support extended to 2030 after backlash https://biobriefs.com/cms-adds-15-drugs-for BioBriefs en 2026-01-28T09:32:40Z CMS Adds 15 Drugs for IRA Price Talks — $27B at Stake https://biobriefs.com/fda-greenlights-reprogramming-trial-life BioBriefs en 2026-01-28T09:32:40Z FDA Greenlights Reprogramming Trial: Life Biosciences to Test ER‑100 https://biobriefs.com/roche-pushes-ct-388-to BioBriefs en 2026-01-28T09:32:40Z Roche Pushes CT‑388 to Phase 3 — 22.5% Placebo‑Adjusted Weight Loss https://biobriefs.com/fda-lifts-hold-on-one BioBriefs en 2026-01-28T09:32:40Z FDA Lifts Hold on One Intellia CRISPR Trial — Cardiac Study Remains Paused https://biobriefs.com/oxford-nanopore-reverses-course-p2 BioBriefs en 2026-01-28T09:32:40Z Oxford Nanopore Reverses Course — P2 Solo Supported Through 2030 https://biobriefs.com/nrichdx-and-hamilton-automate-liquid BioBriefs en 2026-01-28T09:32:40Z nRichDx and Hamilton Automate Liquid‑Biopsy Workflow — Wash & Elute Now Integrated https://biobriefs.com/eclipsebio-acquires-terrain-bio-assembles BioBriefs en 2026-01-28T09:32:40Z Eclipsebio Acquires Terrain Bio — Assembles RNA Design‑to‑Manufacturing Stack https://biobriefs.com/trexbio-nets-50m-extension-to BioBriefs en 2026-01-28T09:32:40Z TRexBio Nets $50M Extension to Advance Treg Programs — TRB‑061 in Phase 1 https://biobriefs.com/genmab-halts-enrollment-in-early BioBriefs en 2026-01-28T09:32:40Z Genmab Halts Enrollment in Early‑Stage Trial of ProfoundBio Asset https://biobriefs.com/alphamabs-her2-bispecific-cuts-progression BioBriefs en 2026-01-28T09:32:40Z Alphamab’s HER2 Bispecific Cuts Progression Risk 75% in Phase 3 https://biobriefs.com/cms-names-15-drugs-for BioBriefs en 2026-01-28T04:32:57Z CMS names 15 drugs for IRA price talks — new prices due 2028 https://biobriefs.com/fda-lifts-hold-on-one BioBriefs en 2026-01-28T04:32:57Z FDA lifts hold on one Intellia CRISPR trial — Magnitude‑2 cleared to resume https://biobriefs.com/roche-posts-competitive-phase-2 BioBriefs en 2026-01-28T04:32:57Z Roche posts competitive Phase 2 weight loss — CT‑388 headed to Phase 3 https://biobriefs.com/trexbio-raises-50m-extension-funds BioBriefs en 2026-01-28T04:32:57Z TRexBio raises $50M extension — funds Treg‑targeted eczema program https://biobriefs.com/corxel-raises-287m-series-d BioBriefs en 2026-01-28T04:32:57Z Corxel raises $287M Series D — advancing oral GLP‑1 CX‑11 globally https://biobriefs.com/eclipsebio-acquires-terrain-bio-stitches BioBriefs en 2026-01-28T04:32:57Z Eclipsebio acquires Terrain Bio — stitches AI RNA design into sequencing analytics https://biobriefs.com/parse-biosciences-and-graph-therapeutics BioBriefs en 2026-01-28T04:32:57Z Parse Biosciences and Graph Therapeutics partner — build massive immune perturbation atlas https://biobriefs.com/10x-genomics-moves-into-clinic BioBriefs en 2026-01-28T04:32:57Z 10x Genomics moves into clinic — clinical collaborations and a CLIA lab on deck https://biobriefs.com/oxford-nanopore-reverses-p2-solo BioBriefs en 2026-01-28T04:32:57Z Oxford Nanopore reverses P2 Solo phase‑out — support extended to end of 2030 https://biobriefs.com/belay-diagnostics-posts-csf-genomic BioBriefs en 2026-01-28T04:32:57Z Belay Diagnostics posts CSF genomic profiling validation — plans insurer billing https://biobriefs.com/fda-clears-one-intellia-crispr BioBriefs en 2026-01-27T21:32:50Z FDA clears one Intellia CRISPR Phase 3 trial: study resumes after safety review https://biobriefs.com/alphamabs-her2-bispecific-halves-progression BioBriefs en 2026-01-27T21:32:50Z Alphamab’s HER2 bispecific halves progression risk – phase III shows 75% cut https://biobriefs.com/roches-ct-388-posts-22 BioBriefs en 2026-01-27T21:32:50Z Roche’s CT‑388 posts 22.5% placebo‑adjusted weight loss: Phase 3 planned https://biobriefs.com/trexbio-raises-50m-to-bankroll BioBriefs en 2026-01-27T21:32:50Z TRexBio raises $50M to bankroll Treg‑activating eczema program https://biobriefs.com/in-vivo-car-t-reverses BioBriefs en 2026-01-27T21:32:50Z In vivo CAR‑T reverses liver fibrosis in MASH models — targeted FAP depletion https://biobriefs.com/nrichdx-and-hamilton-automate-liquid BioBriefs en 2026-01-27T21:32:50Z nRichDx and Hamilton automate liquid biopsy extraction: integrated workflow unveiled https://biobriefs.com/field-effect-aware-urine-assay BioBriefs en 2026-01-27T21:32:50Z Field‑effect aware urine assay improves MRD tracking after bladder cancer surgery https://biobriefs.com/fda-greenlights-life-biosciences-first BioBriefs en 2026-01-27T21:32:50Z FDA greenlights Life Biosciences’ first human test of cellular reprogramming therapy https://biobriefs.com/eclipsebio-buys-terrain-bio-rna BioBriefs en 2026-01-27T21:32:50Z Eclipsebio buys Terrain Bio — RNA design meets sequencing analytics in one platform https://biobriefs.com/parse-biosciences-and-graph-therapeutics BioBriefs en 2026-01-27T21:32:50Z Parse Biosciences and Graph Therapeutics to build massive immune perturbation atlas https://biobriefs.com/fda-lifts-partial-hold-on BioBriefs en 2026-01-27T16:32:43Z FDA lifts partial hold on Intellia CRISPR trials — one study cleared https://biobriefs.com/insilico-and-qilu-ink-120m BioBriefs en 2026-01-27T16:32:43Z Insilico and Qilu ink $120M pact — AI fuels cardiometabolic push https://biobriefs.com/boehringer-inks-billion-euro-ibd BioBriefs en 2026-01-27T16:32:43Z Boehringer inks billion-euro IBD bet with Simcere — bispecific licensed https://biobriefs.com/roche-advances-obesity-program-dual BioBriefs en 2026-01-27T16:32:43Z Roche advances obesity program — dual agonists head to Phase 3 https://biobriefs.com/glp-1-patent-surge-novo BioBriefs en 2026-01-27T16:32:43Z GLP‑1 patent surge — Novo Nordisk and Chinese groups file new agonists https://biobriefs.com/sarepta-touts-three-year-durability BioBriefs en 2026-01-27T16:32:43Z Sarepta touts three‑year durability for Elevidys — efficacy narrative returns https://biobriefs.com/ai-designs-anti-crisprs-new BioBriefs en 2026-01-27T16:32:43Z AI designs anti‑CRISPRs — new off‑switches for Cas editors in weeks https://biobriefs.com/eclipsebio-buys-terrain-bio-rna BioBriefs en 2026-01-27T16:32:43Z Eclipsebio buys Terrain Bio — RNA design meets sequencing analytics https://biobriefs.com/10x-genomics-pivots-toward-clinical BioBriefs en 2026-01-27T16:32:43Z 10x Genomics pivots toward clinical diagnostics — CLIA lab, hospital collaborations https://biobriefs.com/worldwide-clinical-trials-buys-catalyst BioBriefs en 2026-01-27T16:32:43Z Worldwide Clinical Trials buys Catalyst — CRO consolidation in oncology https://biobriefs.com/boehringer-pens-eur1-05b-deal BioBriefs en 2026-01-27T14:33:40Z Boehringer pens €1.05B deal for Simcere's IBD bispecific https://biobriefs.com/roches-glp-1-gip-posts BioBriefs en 2026-01-27T14:33:40Z Roche’s GLP‑1/GIP posts 22.5% weight loss — heads to phase 3 https://biobriefs.com/corxel-closes-287m-to-advance BioBriefs en 2026-01-27T14:33:40Z Corxel closes $287M to advance oral GLP‑1 CX11 https://biobriefs.com/trexbio-nets-50m-to-push BioBriefs en 2026-01-27T14:33:40Z TRexBio nets $50M to push Treg programs into clinic https://biobriefs.com/eclipsebio-buys-terrain-bio-expands BioBriefs en 2026-01-27T14:33:40Z Eclipsebio buys Terrain Bio — expands RNA design‑to‑manufacturing stack https://biobriefs.com/ai-designed-anti-crisprs-rapid BioBriefs en 2026-01-27T14:33:40Z AI‑designed anti‑CRISPRs... rapid Cas13 inhibitors emerge https://biobriefs.com/fortitude-launches-glue-dac-to BioBriefs en 2026-01-27T14:33:40Z Fortitude launches GLUE‑DAC to tackle ADC resistance — $13M seed https://biobriefs.com/fda-greenlights-life-biosciences-gene BioBriefs en 2026-01-27T14:33:40Z FDA greenlights Life Biosciences gene‑therapy study to test cellular 'rewinding' https://biobriefs.com/industry-splits-over-fda-plan BioBriefs en 2026-01-27T14:33:40Z Industry splits over FDA plan to cut comparative efficacy studies for biosimilars https://biobriefs.com/parse-biosciences-graph-therapeutics-to BioBriefs en 2026-01-27T14:33:40Z Parse Biosciences, Graph Therapeutics to build massive immune perturbation atlas https://biobriefs.com/ai-designed-anti-crisprs-rapid BioBriefs en 2026-01-27T10:33:02Z AI‑designed anti‑CRISPRs: Rapid off‑switches for Cas13 https://biobriefs.com/photon-counting-ct-lower-dose BioBriefs en 2026-01-27T10:33:02Z Photon‑counting CT: Lower dose, same cardiac contrast‑to‑noise https://biobriefs.com/10x-genomics-pivots-to-clinic BioBriefs en 2026-01-27T10:33:02Z 10x Genomics pivots to clinic: partnerships and CLIA plan https://biobriefs.com/eclipsebio-buys-terrain-bio-push BioBriefs en 2026-01-27T10:33:02Z Eclipsebio buys Terrain Bio: Push to an end‑to‑end RNA platform https://biobriefs.com/worldwide-clinical-trials-acquires-catalyst BioBriefs en 2026-01-27T10:33:02Z Worldwide Clinical Trials acquires Catalyst: CRO consolidates oncology muscle https://biobriefs.com/large-immune-atlas-parse-and BioBriefs en 2026-01-27T10:33:02Z Large immune atlas: Parse and Graph to profile hundreds of millions of cells https://biobriefs.com/corxel-bags-287m-to-advance BioBriefs en 2026-01-27T10:33:02Z Corxel bags $287M to advance oral GLP‑1 CX11 https://biobriefs.com/chinas-gene-and-cell-therapy BioBriefs en 2026-01-27T10:33:02Z China’s gene and cell therapy push: New rules and durable early‑stage edge https://biobriefs.com/fortitude-biomedicines-launches-glue-dac BioBriefs en 2026-01-27T10:33:02Z Fortitude Biomedicines launches: GLUE‑DAC ADCs target resistance https://biobriefs.com/sareptas-elevidys-three-year-durability BioBriefs en 2026-01-27T10:33:02Z Sarepta’s Elevidys: Three‑year durability amid safety scrutiny https://biobriefs.com/ai-designed-anti-crisprs-rapid BioBriefs en 2026-01-27T09:32:57Z AI-designed anti-CRISPRs: rapid off-switch proteins for Cas13 https://biobriefs.com/sareptas-elevidys-three-year-data BioBriefs en 2026-01-27T09:32:57Z Sarepta’s Elevidys: three-year data revives efficacy conversation https://biobriefs.com/worldwide-clinical-trials-buys-catalyst BioBriefs en 2026-01-27T09:32:57Z Worldwide Clinical Trials buys Catalyst to bulk up early‑phase oncology https://biobriefs.com/eclipsebio-acquires-terrain-bio-to BioBriefs en 2026-01-27T09:32:57Z Eclipsebio acquires Terrain Bio to build end‑to‑end RNA platform https://biobriefs.com/10x-genomics-pivots-to-clinical BioBriefs en 2026-01-27T09:32:57Z 10x Genomics pivots to clinical: CLIA lab and analysis partnerships https://biobriefs.com/epidarex-capital-raises-145m-to BioBriefs en 2026-01-27T09:32:57Z Epidarex Capital raises $145M to back next‑gen UK‑US life science startups https://biobriefs.com/cultivated-meat-startup-innocent-meat BioBriefs en 2026-01-27T09:32:57Z Cultivated‑meat startup Innocent Meat raises €6M to build demo production https://biobriefs.com/fda-approvals-27-in-december BioBriefs en 2026-01-27T09:32:57Z FDA approvals: 27 in December brings 2025 total to 226 https://biobriefs.com/industry-sues-ira-drug-pricing BioBriefs en 2026-01-27T09:32:57Z Industry sues IRA drug pricing: petitions reach Supreme Court https://biobriefs.com/parse-and-graph-partner-to BioBriefs en 2026-01-27T09:32:57Z Parse and Graph partner to build massive functional immune perturbation atlas https://biobriefs.com/fda-draft-nudges-biosimilars-away BioBriefs en 2026-01-27T04:33:18Z FDA draft nudges biosimilars away from efficacy trials – industry splits https://biobriefs.com/ai-designs-anti-crisprs-rapid BioBriefs en 2026-01-27T04:33:18Z AI designs anti‑CRISPRs: rapid Cas13 inhibitors emerge in eight weeks https://biobriefs.com/10x-genomics-pivots-to-clinic BioBriefs en 2026-01-27T04:33:18Z 10x Genomics pivots to clinic – CLIA lab build and hospital deals announced https://biobriefs.com/eclipsebio-buys-terrain-bio-stacks BioBriefs en 2026-01-27T04:33:18Z Eclipsebio buys Terrain Bio – stacks AI RNA design with sequencing analytics https://biobriefs.com/worldwide-clinical-trials-buys-catalyst BioBriefs en 2026-01-27T04:33:18Z Worldwide Clinical Trials buys Catalyst – early‑phase oncology push via FSP https://biobriefs.com/sarepta-three-year-elevidys-data BioBriefs en 2026-01-27T04:33:18Z Sarepta: three‑year Elevidys data claim growing efficacy despite prior safety and sales headwinds https://biobriefs.com/parse-and-graph-aim-to BioBriefs en 2026-01-27T04:33:18Z Parse and Graph aim to profile hundreds of millions of immune cells – an atlas for AI drug discovery https://biobriefs.com/corxel-closes-287m-to-advance BioBriefs en 2026-01-27T04:33:18Z Corxel closes $287M to advance oral GLP‑1 CX11 into pivotal testing https://biobriefs.com/genmab-halts-enrollment-in-early BioBriefs en 2026-01-27T04:33:18Z Genmab halts enrollment in early trial of ProfoundBio asset after acquisition https://biobriefs.com/catalent-to-close-gosselies-cell BioBriefs en 2026-01-27T04:33:18Z Catalent to close Gosselies cell therapy site – manufacturing realignment continues https://biobriefs.com/worldwide-clinical-trials-buys-catalyst BioBriefs en 2026-01-26T21:33:15Z Worldwide Clinical Trials buys Catalyst – Early‑phase oncology push https://biobriefs.com/eclipsebio-acquires-terrain-bio-rna BioBriefs en 2026-01-26T21:33:15Z Eclipsebio acquires Terrain Bio: RNA design meets sequencing analytics https://biobriefs.com/parse-and-graph-therapeutics-pair BioBriefs en 2026-01-26T21:33:15Z Parse and Graph Therapeutics pair up... build massive immune perturbation atlas https://biobriefs.com/fortitude-launches-glue-dac-platform BioBriefs en 2026-01-26T21:33:15Z Fortitude launches GLUE‑DAC platform – ADCs with degrader payloads https://biobriefs.com/corxel-closes-287m-funds-oral BioBriefs en 2026-01-26T21:33:15Z Corxel closes $287M — Funds oral GLP‑1 CX11 development https://biobriefs.com/sarepta-reframes-elevidys-three-year BioBriefs en 2026-01-26T21:33:15Z Sarepta reframes Elevidys: three‑year durability claims amid safety debate https://biobriefs.com/drug-pricing-on-trial-and BioBriefs en 2026-01-26T21:33:15Z Drug pricing on trial and in policy: IRA petitions and insurer targeting https://biobriefs.com/diasorin-inks-thermo-fisher-pact BioBriefs en 2026-01-26T21:33:15Z Diasorin inks Thermo Fisher pact: 15‑minute molecular PCR for US hospitals https://biobriefs.com/catalent-to-close-belgium-cell BioBriefs en 2026-01-26T21:33:15Z Catalent to close Belgium cell‑therapy site — raw‑material risks spotlighted https://biobriefs.com/genmab-halts-enrollment-in-profoundbio BioBriefs en 2026-01-26T21:33:15Z Genmab halts enrollment in ProfoundBio‑sourced cancer trial https://biobriefs.com/sarepta-reports-three-year-durability BioBriefs en 2026-01-26T16:32:50Z Sarepta reports three-year durability after gene therapy despite patient deaths https://biobriefs.com/diasorin-inks-thermo-fisher-pact BioBriefs en 2026-01-26T16:32:50Z Diasorin inks Thermo Fisher pact to push rapid POC qPCR into US hospitals https://biobriefs.com/genmab-halts-enrollment-in-early BioBriefs en 2026-01-26T16:32:50Z Genmab halts enrollment in early cancer trial from ProfoundBio buyout https://biobriefs.com/insilico-secures-fda-ind-for BioBriefs en 2026-01-26T16:32:50Z Insilico secures FDA IND for Parkinson’s candidate ISM‑8969 https://biobriefs.com/fortitude-launches-with-seed-cash BioBriefs en 2026-01-26T16:32:50Z Fortitude launches with seed cash to graft molecular glues onto ADCs https://biobriefs.com/corxel-lands-287m-to-push BioBriefs en 2026-01-26T16:32:50Z Corxel lands $287M to push oral GLP‑1 CX11 toward late‑stage trials https://biobriefs.com/qiagen-explores-strategic-options-takeover BioBriefs en 2026-01-26T16:32:50Z Qiagen explores strategic options — takeover chatter lifts shares https://biobriefs.com/nk-cell-infusions-show-safety BioBriefs en 2026-01-26T16:32:50Z NK cell infusions show safety signal in liver‑transplant cancer cohort https://biobriefs.com/cro-consolidation-continues-worldwide-clinical BioBriefs en 2026-01-26T16:32:50Z CRO consolidation continues — Worldwide Clinical Trials to buy Catalyst https://biobriefs.com/biotech-investor-cormorant-secures-150m BioBriefs en 2026-01-26T16:32:50Z Biotech investor Cormorant secures $150M to pursue another SPAC https://biobriefs.com/oral-glp-1-cash-infusion BioBriefs en 2026-01-26T14:32:32Z Oral GLP‑1 cash infusion – Regulators raid illegal imports https://biobriefs.com/genmab-pauses-enrollment-profoundbio-asset BioBriefs en 2026-01-26T14:32:32Z Genmab pauses enrollment – ProfoundBio asset review https://biobriefs.com/express-scripts-settlement-talks-ftc BioBriefs en 2026-01-26T14:32:32Z Express Scripts settlement talks – FTC insulin probe intensifies https://biobriefs.com/qiagen-in-play-strategic-review BioBriefs en 2026-01-26T14:32:32Z Qiagen in play – Strategic review draws takeover chatter https://biobriefs.com/cro-consolidation-continues-worldwide-to BioBriefs en 2026-01-26T14:32:32Z CRO consolidation continues – Worldwide to buy Catalyst https://biobriefs.com/car-t-redesigns-tumor-aware BioBriefs en 2026-01-26T14:32:32Z CAR‑T redesigns: tumor‑aware cells on the rise https://biobriefs.com/nanozyme-therapy-emerges-granzyme-b BioBriefs en 2026-01-26T14:32:32Z Nanozyme therapy emerges: Granzyme B mimic in preclinical spotlight https://biobriefs.com/spark-trial-new-combo-posts BioBriefs en 2026-01-26T14:32:32Z SPARK trial... New combo posts activity in recurrent TNBC https://biobriefs.com/nk-cell-infusions-show-promise BioBriefs en 2026-01-26T14:32:32Z NK cell infusions show promise in post‑transplant liver cancer https://biobriefs.com/teletherapy-funding-answersnow-raises-40m BioBriefs en 2026-01-26T14:32:32Z Teletherapy funding: AnswersNow raises $40m to scale autism care https://biobriefs.com/spark-trial-sitravatinib-tislelizumab-shows BioBriefs en 2026-01-26T10:33:13Z SPARK trial: Sitravatinib–tislelizumab shows activity in recurrent TNBC https://biobriefs.com/nk-cell-infusion-trial-early BioBriefs en 2026-01-26T10:33:13Z NK cell infusion trial: early signals of control in recurrent HCC post-transplant https://biobriefs.com/car-t-redesign-targeting-tumor BioBriefs en 2026-01-26T10:33:13Z CAR‑T redesign: targeting tumor features to sharpen efficacy https://biobriefs.com/granzyme-b-mimic-nanozyme-targeted BioBriefs en 2026-01-26T10:33:13Z Granzyme B mimic nanozyme... targeted nanovesicles kill cancer cells https://biobriefs.com/twas-identifies-new-causal-genes BioBriefs en 2026-01-26T10:33:13Z TWAS identifies new causal genes for diabetic nephropathy https://biobriefs.com/qiagen-weighs-sale-options-suitors BioBriefs en 2026-01-26T10:33:13Z Qiagen weighs sale options — suitors circle diagnostics firm https://biobriefs.com/plausible-mechanism-pathway-fda-plan BioBriefs en 2026-01-26T10:33:13Z Plausible mechanism pathway: FDA plan for personalized gene editing meets skepticism https://biobriefs.com/answersnow-raises-40m-to-scale BioBriefs en 2026-01-26T10:33:13Z AnswersNow raises $40M to scale autism therapy access https://biobriefs.com/study-maps-venetoclax-toxicity-efficacy BioBriefs en 2026-01-26T10:33:13Z Study maps venetoclax toxicity–efficacy tradeoffs to predict patient risk https://biobriefs.com/kc1036-shows-promise-against-ewing BioBriefs en 2026-01-26T10:33:13Z KC1036 shows promise against Ewing sarcoma in preclinical work https://biobriefs.com/granzyme-b-mimic-nanozyme-nanovesicle BioBriefs en 2026-01-26T09:32:43Z Granzyme B-mimic nanozyme: nanovesicle targets cancer cells https://biobriefs.com/engineered-car-ts-exploit-tumor BioBriefs en 2026-01-26T09:32:43Z Engineered CAR-Ts exploit tumor traits to improve potency https://biobriefs.com/spark-trial-sitravatinib-tislelizumab-shows BioBriefs en 2026-01-26T09:32:43Z SPARK trial: Sitravatinib–tislelizumab shows responses in TNBC https://biobriefs.com/nk-cell-infusion-early-safety BioBriefs en 2026-01-26T09:32:43Z NK cell infusion: early safety signal in post‑transplant liver cancer https://biobriefs.com/gpnmb-macrophages-drive-vascular-fibrosis BioBriefs en 2026-01-26T09:32:43Z GPNMB+ macrophages drive vascular fibrosis in glioblastoma https://biobriefs.com/usp7-identified-as-immunotherapy-target BioBriefs en 2026-01-26T09:32:43Z USP7 identified as immunotherapy target in colorectal cancer https://biobriefs.com/twas-implicates-novel-causal-genes BioBriefs en 2026-01-26T09:32:43Z TWAS implicates novel causal genes in diabetic nephropathy https://biobriefs.com/niraparib-maintenance-patient-reported-outcomes BioBriefs en 2026-01-26T09:32:43Z Niraparib maintenance: patient-reported outcomes show long-term benefit https://biobriefs.com/answersnow-raises-40m-scales-autism BioBriefs en 2026-01-26T09:32:43Z AnswersNow raises $40M—scales autism therapy platform https://biobriefs.com/qiagen-evaluates-strategic-options-buyers BioBriefs en 2026-01-26T09:32:43Z Qiagen evaluates strategic options—buyers circle, stock rebounds https://biobriefs.com/moderna-curbs-vaccine-trial-investments BioBriefs en 2026-01-26T04:32:44Z Moderna curbs vaccine-trial investments: CEO flags US backlash https://biobriefs.com/qiagen-evaluates-sale-options-shares BioBriefs en 2026-01-26T04:32:44Z Qiagen evaluates sale options — shares rebound on takeover chatter https://biobriefs.com/worldwide-clinical-to-buy-catalyst BioBriefs en 2026-01-26T04:32:44Z Worldwide Clinical to buy Catalyst: private-equity CRO consolidation continues https://biobriefs.com/answersnow-raises-40m-telehealth-expands BioBriefs en 2026-01-26T04:32:44Z AnswersNow raises $40M — telehealth expands autism therapy access https://biobriefs.com/researchers-redesign-car-t-next BioBriefs en 2026-01-26T04:32:44Z Researchers redesign CAR-T: next-gen cells target tumor traits https://biobriefs.com/nk-cell-infusion-shows-early BioBriefs en 2026-01-26T04:32:44Z NK-cell infusion shows early signals in liver cancer trial — phase I data https://biobriefs.com/spark-trial-reports-responses-sitravatinib BioBriefs en 2026-01-26T04:32:44Z SPARK trial reports responses: sitravatinib plus tislelizumab in TNBC https://biobriefs.com/new-causal-genes-for-diabetic BioBriefs en 2026-01-26T04:32:44Z New causal genes for diabetic nephropathy identified — TWAS and genomics https://biobriefs.com/pgs-hub-benchmarks-polygenic-scores BioBriefs en 2026-01-26T04:32:44Z PGS-hub benchmarks polygenic scores across ancestries — new standard https://biobriefs.com/antibiotic-resistance-is-rising-four BioBriefs en 2026-01-26T04:32:44Z Antibiotic resistance is rising — four trends that could change the course https://biobriefs.com/erasca-upsizes-offering-258-8m BioBriefs en 2026-01-25T21:32:36Z Erasca upsizes offering — $258.8M raised https://biobriefs.com/qiagen-in-play-assessing-strategic BioBriefs en 2026-01-25T21:32:36Z Qiagen in play: assessing strategic options https://biobriefs.com/answersnow-raises-40m-to-scale BioBriefs en 2026-01-25T21:32:36Z AnswersNow raises $40M to scale autism therapy https://biobriefs.com/zarminali-secures-110m-series-a BioBriefs en 2026-01-25T21:32:36Z Zarminali secures $110M Series A to rework pediatric care https://biobriefs.com/spark-trial-sitravatinib-plus-tislelizumab BioBriefs en 2026-01-25T21:32:36Z SPARK trial: Sitravatinib plus tislelizumab shows activity in TNBC https://biobriefs.com/nk-cell-infusion-shows-safety BioBriefs en 2026-01-25T21:32:36Z NK cell infusion shows safety signals in post‑transplant liver cancer https://biobriefs.com/gut-microbes-shape-cancer-immunity BioBriefs en 2026-01-25T21:32:36Z Gut microbes shape cancer immunity — metabolites and population genomes https://biobriefs.com/ai-models-sharpen-proteomics-and BioBriefs en 2026-01-25T21:32:36Z AI models sharpen proteomics and chromatin prediction https://biobriefs.com/stroma-and-epigenetics-drive-lung BioBriefs en 2026-01-25T21:32:36Z Stroma and epigenetics drive lung cancer spread https://biobriefs.com/moderna-scales-back-vaccine-investments BioBriefs en 2026-01-25T21:32:36Z Moderna scales back vaccine investments amid US backlash https://biobriefs.com/biotech-cash-sprint-erasca-raises BioBriefs en 2026-01-25T16:32:37Z Biotech cash sprint: Erasca raises $258.8M – Corxel banks $287M https://biobriefs.com/appeals-court-remands-guardant-twinstrand BioBriefs en 2026-01-25T16:32:37Z Appeals court remands Guardant-TwinStrand feud: patent validity sent back to PTAB https://biobriefs.com/encodia-shutters-protein-sequencing-start BioBriefs en 2026-01-25T16:32:37Z Encodia shutters: protein sequencing start‑up ceases operations https://biobriefs.com/novartis-expands-rnai-push-ceo BioBriefs en 2026-01-25T16:32:37Z Novartis expands RNAi push — CEO outlines de‑risking strategy https://biobriefs.com/sanofi-moves-forward-with-amlitelimab BioBriefs en 2026-01-25T16:32:37Z Sanofi moves forward with amlitelimab filings... despite mixed Phase III reads https://biobriefs.com/macrophage-targeting-car-t-reprograms BioBriefs en 2026-01-25T16:32:37Z Macrophage‑targeting CAR T reprograms tumor microenvironment — survival improves in models https://biobriefs.com/nk-cell-infusions-show-promise BioBriefs en 2026-01-25T16:32:37Z NK cell infusions show promise in liver cancer post‑transplant trial https://biobriefs.com/spark-trial-sitravatinib-plus-tislelizumab BioBriefs en 2026-01-25T16:32:37Z SPARK trial: sitravatinib plus tislelizumab shows activity in recurrent/metastatic TNBC https://biobriefs.com/eu-launches-fast-eu-pilot BioBriefs en 2026-01-25T16:32:37Z EU launches FAST‑EU pilot to accelerate multinational clinical trials https://biobriefs.com/new-products-roll-tempus-ai BioBriefs en 2026-01-25T16:32:37Z New products roll: Tempus AI, Navinci Diagnostics, Parse Biosciences and Zepto Life launch clinical tools https://biobriefs.com/erasca-closes-upsized-offering-258 BioBriefs en 2026-01-25T14:32:43Z Erasca closes upsized offering — $258.8M raised https://biobriefs.com/corxel-banks-287m-to-push BioBriefs en 2026-01-25T14:32:43Z Corxel banks $287M to push oral GLP‑1 https://biobriefs.com/sanofi-presses-forward-filings-eyed BioBriefs en 2026-01-25T14:32:43Z Sanofi presses forward: filings eyed for amlitelimab after mixed Phase 3 https://biobriefs.com/wegovy-pill-takes-off-prescriptions BioBriefs en 2026-01-25T14:32:43Z Wegovy pill takes off: prescriptions surge in second week https://biobriefs.com/federal-circuit-remands-guardant-patent BioBriefs en 2026-01-25T14:32:43Z Federal Circuit remands Guardant patent case to appeals board https://biobriefs.com/protein-sequencing-start-up-encodia BioBriefs en 2026-01-25T14:32:43Z Protein‑sequencing start‑up Encodia shutters — assets headed to auction https://biobriefs.com/venter-backed-diploid-genomics-launches BioBriefs en 2026-01-25T14:32:43Z Venter‑backed Diploid Genomics launches with seed funding https://biobriefs.com/eu-rolls-out-fast-eu BioBriefs en 2026-01-25T14:32:43Z EU rolls out FAST‑EU pilot: 70‑day target to start multinational trials https://biobriefs.com/fda-drafts-guidance-for-cuffless BioBriefs en 2026-01-25T14:32:43Z FDA drafts guidance for cuffless blood‑pressure monitors — oversight tightens https://biobriefs.com/f2g-plans-olorofim-fda-resubmission BioBriefs en 2026-01-25T14:32:43Z F2G plans olorofim FDA resubmission after collecting Phase 3 data https://biobriefs.com/erasca-raises-258-8m-in BioBriefs en 2026-01-25T10:32:53Z Erasca raises $258.8m in upsized offering https://biobriefs.com/protein-sequencing-startup-encodia-folds BioBriefs en 2026-01-25T10:32:53Z Protein sequencing startup Encodia folds... auctions lab equipment https://biobriefs.com/appeals-court-remands-guardant-patent BioBriefs en 2026-01-25T10:32:53Z Appeals court remands Guardant patent case to PTAB – damages in flux https://biobriefs.com/novos-wegovy-pill-surges-prescriptions BioBriefs en 2026-01-25T10:32:53Z Novo’s Wegovy pill surges: prescriptions jump 500% in week two https://biobriefs.com/corxel-banks-287m-to-advance BioBriefs en 2026-01-25T10:32:53Z Corxel banks $287m to advance oral GLP‑1 CX‑11 https://biobriefs.com/sanofi-to-file-for-amlitelimab BioBriefs en 2026-01-25T10:32:53Z Sanofi to file for amlitelimab despite mixed Phase 3 reads https://biobriefs.com/venter-cofounds-diploid-genomics-ai BioBriefs en 2026-01-25T10:32:53Z Venter cofounds Diploid Genomics: AI‑driven genomics analytics spinout https://biobriefs.com/macrophage-targeting-car-t-reshapes BioBriefs en 2026-01-25T10:32:53Z Macrophage‑targeting CAR T reshapes tumors: preclinical survival gains https://biobriefs.com/mendra-nets-82m-to-build BioBriefs en 2026-01-25T10:32:53Z Mendra nets $82m to build rare‑disease portfolio using AI https://biobriefs.com/diagnostics-and-pathology-tools-roll BioBriefs en 2026-01-25T10:32:53Z Diagnostics and pathology tools roll out: Tempus Predict, Navinci, Zepto; FDA clears 4‑in‑1 home test https://biobriefs.com/erasca-upsizes-offering-258-8m BioBriefs en 2026-01-25T09:32:32Z Erasca upsizes offering: $258.8M raised to fund RAS/MAPK programs https://biobriefs.com/corxel-lands-287m-series-d BioBriefs en 2026-01-25T09:32:32Z Corxel lands $287M series D to push oral GLP‑1 CX‑11 into phase III preparation https://biobriefs.com/wegovy-pill-demand-surges-prescriptions BioBriefs en 2026-01-25T09:32:32Z Wegovy pill demand surges: prescriptions spike and market reaction follows https://biobriefs.com/encodia-collapse-protein-sequencing-startup BioBriefs en 2026-01-25T09:32:32Z Encodia collapse: protein‑sequencing startup shutters, assets up for auction https://biobriefs.com/guardant-patent-fight-remanded-appeals BioBriefs en 2026-01-25T09:32:32Z Guardant patent fight remanded: appeals court sends case back to PTAB https://biobriefs.com/diploid-genomics-launches-venter-led BioBriefs en 2026-01-25T09:32:32Z Diploid Genomics launches: Venter‑led spinout promises AI genomics analytics https://biobriefs.com/macrophage-targeted-car-t-trojan BioBriefs en 2026-01-25T09:32:32Z Macrophage‑targeted CAR T: Trojan horse approach reprograms solid tumor microenvironment https://biobriefs.com/spark-trial-posts-activity-sitravatinib BioBriefs en 2026-01-25T09:32:32Z SPARK trial posts activity: sitravatinib plus tislelizumab shows signals in TNBC https://biobriefs.com/moderna-pulls-back-from-late BioBriefs en 2026-01-25T09:32:32Z Moderna pulls back from late‑stage vaccine trials amid political pushback https://biobriefs.com/nvidia-lilly-build-1b-ai BioBriefs en 2026-01-25T04:32:55Z NVIDIA, Lilly Build $1B AI Lab—Drug Discovery Reboot https://biobriefs.com/wegovy-pill-ramps-up-prescriptions BioBriefs en 2026-01-25T04:32:55Z Wegovy Pill Ramps Up... Prescriptions Spike 500% Week Two https://biobriefs.com/erasca-upsized-offering-258-8m BioBriefs en 2026-01-25T04:32:55Z Erasca Upsized Offering—$258.8M Raised https://biobriefs.com/sanofi-to-file-for-eczema BioBriefs en 2026-01-25T04:32:55Z Sanofi to File for Eczema Drug Despite Mixed Phase III Data https://biobriefs.com/trojan-horse-car-t-macrophage BioBriefs en 2026-01-25T04:32:55Z Trojan‑Horse CAR T: Macrophage Targeting Reshapes Tumors https://biobriefs.com/protein-sequencing-startup-encodia-shuts BioBriefs en 2026-01-25T04:32:55Z Protein Sequencing Startup Encodia Shuts Down—Lab Assets Up for Sale https://biobriefs.com/appeals-court-remands-guardant-patent BioBriefs en 2026-01-25T04:32:55Z Appeals Court Remands Guardant Patent Ruling to PTAB https://biobriefs.com/fda-targets-cuffless-blood-pressure BioBriefs en 2026-01-25T04:32:55Z FDA Targets Cuffless Blood‑Pressure Monitors in New Draft Guidance https://biobriefs.com/moderna-scales-back-late-stage BioBriefs en 2026-01-25T04:32:55Z Moderna Scales Back Late‑Stage Vaccine Trials—Political Backlash Cited https://biobriefs.com/venter-cofounder-launches-diploid-genomics BioBriefs en 2026-01-25T04:32:55Z Venter Cofounder Launches Diploid Genomics—AI Meets Clinical Sequencing https://biobriefs.com/erasca-upsized-offering-nets-258 BioBriefs en 2026-01-24T21:32:40Z Erasca upsized offering: nets $258.8M https://biobriefs.com/corxel-draws-287m-to-advance BioBriefs en 2026-01-24T21:32:40Z Corxel draws $287M to advance oral GLP‑1 https://biobriefs.com/mendra-raises-82m-series-a BioBriefs en 2026-01-24T21:32:40Z Mendra raises $82M Series A – AI‑driven rare disease play https://biobriefs.com/nvidia-eli-lilly-build-1b BioBriefs en 2026-01-24T21:32:40Z NVIDIA, Eli Lilly build $1B AI lab: drug discovery gets heavy bet https://biobriefs.com/sanofi-to-file-for-amlitelimab BioBriefs en 2026-01-24T21:32:40Z Sanofi to file for amlitelimab despite mixed phase 3 https://biobriefs.com/proteomics-startup-encodia-ceases-operations BioBriefs en 2026-01-24T21:32:40Z Proteomics startup Encodia ceases operations and auctions assets https://biobriefs.com/cellular-origins-fresenius-kabi-integrate BioBriefs en 2026-01-24T21:32:40Z Cellular Origins, Fresenius Kabi integrate robotic CGT systems – milestone cleared https://biobriefs.com/macrophage-targeting-car-t-reshapes BioBriefs en 2026-01-24T21:32:40Z Macrophage‑targeting CAR T reshapes solid tumor strategy in mice https://biobriefs.com/genomics-pioneer-venter-launches-diploid BioBriefs en 2026-01-24T21:32:40Z Genomics pioneer Venter launches Diploid Genomics with seed backing https://biobriefs.com/eu-launches-fast-eu-pilot BioBriefs en 2026-01-24T21:32:40Z EU launches FAST‑EU pilot: 70‑day ambition to speed multinational trials https://biobriefs.com/nvidia-and-eli-lilly-launch BioBriefs en 2026-01-24T16:32:37Z NVIDIA and Eli Lilly Launch $1B AI Lab — Drug discovery on fast track https://biobriefs.com/bristol-myers-backs-janux-tumor BioBriefs en 2026-01-24T16:32:37Z Bristol Myers Backs Janux — Tumor‑activated T‑cell engager pact valued up to $850M https://biobriefs.com/corxel-raises-287m-advancing-oral BioBriefs en 2026-01-24T16:32:37Z Corxel Raises $287M: advancing oral GLP‑1 into global trials https://biobriefs.com/j-craig-venter-spins-out BioBriefs en 2026-01-24T16:32:37Z J. Craig Venter Spins Out Diploid Genomics — AI‑driven clinical sequencing analytics https://biobriefs.com/sanofi-to-file-for-amlitelimab BioBriefs en 2026-01-24T16:32:37Z Sanofi to file for amlitelimab despite mixed Phase III reads https://biobriefs.com/moderna-pares-late-stage-vaccine BioBriefs en 2026-01-24T16:32:37Z Moderna pares late‑stage vaccine bets — political backlash reshapes infectious‑disease R&D https://biobriefs.com/erasca-closes-upsized-offering-258 BioBriefs en 2026-01-24T16:32:37Z Erasca closes upsized offering — $258.8M to sharpen RAS oncology push https://biobriefs.com/sequencing-sector-shaken-guardant-remand BioBriefs en 2026-01-24T16:32:37Z Sequencing sector shaken: Guardant remand, Encodia shuts down https://biobriefs.com/eu-and-uk-move-to BioBriefs en 2026-01-24T16:32:37Z EU and UK move to speed trials: FAST‑EU pilot, new UK clinical rules https://biobriefs.com/macrophage-targeting-car-t-reprograms BioBriefs en 2026-01-24T16:32:37Z Macrophage‑targeting CAR T reprograms tumor microenvironment — survival gains in mice https://biobriefs.com/erasca-closes-upsized-stock-sale BioBriefs en 2026-01-24T14:32:51Z Erasca closes upsized stock sale: $258.8M raised https://biobriefs.com/corxel-draws-287m-advances-oral BioBriefs en 2026-01-24T14:32:51Z Corxel draws $287M — Advances oral GLP‑1 CX‑11 https://biobriefs.com/guardant360-cdx-wins-fda-nod BioBriefs en 2026-01-24T14:32:51Z Guardant360 CDx wins FDA nod: Liquid biopsy cleared as companion test https://biobriefs.com/nvidia-eli-lilly-commit-1b BioBriefs en 2026-01-24T14:32:51Z NVIDIA, Eli Lilly commit $1B to Bay Area AI lab for drug discovery https://biobriefs.com/bristol-myers-bets-on-janux BioBriefs en 2026-01-24T14:32:51Z Bristol Myers bets on Janux: $50M upfront for masked T‑cell engagers https://biobriefs.com/corcept-reports-survival-win-relacorilant BioBriefs en 2026-01-24T14:32:51Z Corcept reports survival win: Relacorilant cuts death risk in ovarian cancer https://biobriefs.com/moderna-curbs-late-stage-vaccine BioBriefs en 2026-01-24T14:32:51Z Moderna curbs late‑stage vaccine bets amid US backlash https://biobriefs.com/j-craig-venter-launches-diploid BioBriefs en 2026-01-24T14:32:51Z J. Craig Venter launches Diploid Genomics: AI‑driven sequencing analytics https://biobriefs.com/nih-ends-fetal-tissue-research BioBriefs en 2026-01-24T14:32:51Z NIH ends fetal tissue research: funding halted amid political decision https://biobriefs.com/nanopore-cytogenetics-enters-clinic-4bases BioBriefs en 2026-01-24T14:32:51Z Nanopore cytogenetics enters clinic: 4bases and Florence run KaryoSolver pilots https://biobriefs.com/erasca-closes-upsized-offering-258 BioBriefs en 2026-01-24T10:32:39Z Erasca closes upsized offering — $258.8M raised https://biobriefs.com/corxel-nets-287m-to-advance BioBriefs en 2026-01-24T10:32:39Z Corxel nets $287M to advance oral GLP‑1 — global trials next https://biobriefs.com/nvidia-and-eli-lilly-1b BioBriefs en 2026-01-24T10:32:39Z NVIDIA and Eli Lilly: $1B AI lab to power drug discovery https://biobriefs.com/guardant-liquid-biopsy-cleared-as BioBriefs en 2026-01-24T10:32:39Z Guardant liquid biopsy cleared as CDx for Pfizer BRAF combo https://biobriefs.com/bms-bets-on-janux-masked BioBriefs en 2026-01-24T10:32:39Z BMS bets on Janux — masked T‑cell engagers deal https://biobriefs.com/corcepts-relacorilant-shows-survival-gain BioBriefs en 2026-01-24T10:32:39Z Corcept’s relacorilant shows survival gain — commercial questions follow https://biobriefs.com/macrophage-targeting-car-t-resets BioBriefs en 2026-01-24T10:32:39Z Macrophage‑targeting CAR‑T resets tumor microenvironment in mice https://biobriefs.com/singapore-scientists-identify-egfr-bodyguard BioBriefs en 2026-01-24T10:32:39Z Singapore scientists identify EGFR 'bodyguard' — targetable P2Y2‑integrin axis https://biobriefs.com/protein-sequencing-startup-encodia-shutters BioBriefs en 2026-01-24T10:32:39Z Protein‑sequencing startup Encodia shutters — assets up for auction https://biobriefs.com/moderna-curbs-late-stage-vaccine BioBriefs en 2026-01-24T10:32:39Z Moderna curbs late‑stage vaccine investments: CEO cites US backlash https://biobriefs.com/nvidia-eli-lilly-launch-1 BioBriefs en 2026-01-24T09:33:50Z NVIDIA, Eli Lilly Launch $1 Billion AI Lab: Drug discovery push https://biobriefs.com/j-craig-venter-launches-diploid BioBriefs en 2026-01-24T09:33:50Z J. Craig Venter launches Diploid Genomics: AI genomics play https://biobriefs.com/corxel-banks-287m-oral-glp BioBriefs en 2026-01-24T09:33:50Z Corxel banks $287M: Oral GLP‑1 program scales toward global trials https://biobriefs.com/mendra-raises-82m-biomarin-vets BioBriefs en 2026-01-24T09:33:50Z Mendra raises $82M: BioMarin vets form rare‑disease roll‑up https://biobriefs.com/janux-bms-strike-tumor-activated BioBriefs en 2026-01-24T09:33:50Z Janux, BMS strike tumor‑activated deal — $50M up front https://biobriefs.com/appeals-court-remands-guardant-case BioBriefs en 2026-01-24T09:33:50Z Appeals court remands Guardant case — Guardant360 CDx wins FDA approval https://biobriefs.com/corcept-posts-survival-win-relacorilant BioBriefs en 2026-01-24T09:33:50Z Corcept posts survival win — relacorilant reads as FDA‑fileable https://biobriefs.com/macrophage-targeted-car-t-reshapes BioBriefs en 2026-01-24T09:33:50Z Macrophage‑targeted CAR T reshapes tumor microenvironment — preclinical survival gains https://biobriefs.com/tumor-plasticity-and-myc-immune BioBriefs en 2026-01-24T09:33:50Z Tumor plasticity and MYC immune‑silencing revealed — new targetable biology https://biobriefs.com/nih-stops-fetal-tissue-research BioBriefs en 2026-01-24T09:33:50Z NIH stops fetal‑tissue research funding — Congress moves to shield the agency https://biobriefs.com/nvidia-lilly-1-billion-ai BioBriefs en 2026-01-24T04:32:44Z NVIDIA‑Lilly $1 billion AI lab: Discovery pushed to scale https://biobriefs.com/guardant-wins-fda-cdx-nod BioBriefs en 2026-01-24T04:32:44Z Guardant wins FDA CDx nod — patent fight remanded to PTAB https://biobriefs.com/corxel-raises-287m-to-advance BioBriefs en 2026-01-24T04:32:44Z Corxel raises $287M to advance oral GLP‑1: Global phase plans funded https://biobriefs.com/sanofi-to-file-amlitelimab-mixed BioBriefs en 2026-01-24T04:32:44Z Sanofi to file amlitelimab — mixed Phase 3 muddies pathway https://biobriefs.com/bms-bets-on-janux-850m BioBriefs en 2026-01-24T04:32:44Z BMS bets on Janux: $850M deal to develop tumor‑activated T‑cell engagers https://biobriefs.com/macrophage-targeting-car-t-resets BioBriefs en 2026-01-24T04:32:44Z Macrophage‑targeting CAR T resets tumor microenvironment — preclinical survival gains https://biobriefs.com/singapore-scientists-reveal-bodyguard-for BioBriefs en 2026-01-24T04:32:44Z Singapore scientists reveal 'bodyguard' for mutant EGFR: P2Y2‑integrin axis https://biobriefs.com/corcepts-relacorilant-shows-survival-gain BioBriefs en 2026-01-24T04:32:44Z Corcept’s relacorilant shows survival gain — phase 3 ovarian win lifts outlook https://biobriefs.com/encodia-shutters-lab-operations-proteocode BioBriefs en 2026-01-24T04:32:44Z Encodia shutters lab operations: ProteoCode protein‑sequencing startup folds https://biobriefs.com/venter-led-diploid-genomics-launches BioBriefs en 2026-01-24T04:32:44Z Venter‑led Diploid Genomics launches: AI genomics analytics spinout debuts https://biobriefs.com/nvidia-lilly-invest-1b-in BioBriefs en 2026-01-23T21:32:43Z NVIDIA, Lilly invest $1B in AI drug lab https://biobriefs.com/fda-clears-guardant360-as-companion BioBriefs en 2026-01-23T21:32:43Z FDA clears Guardant360 as companion test for Pfizer colorectal combo https://biobriefs.com/bristol-myers-inks-pact-with BioBriefs en 2026-01-23T21:32:43Z Bristol Myers inks pact with Janux – up to $850M https://biobriefs.com/corcepts-relacorilant-posts-survival-gain BioBriefs en 2026-01-23T21:32:43Z Corcept’s relacorilant posts survival gain in ovarian cancer https://biobriefs.com/corxel-secures-287m-to-advance BioBriefs en 2026-01-23T21:32:43Z Corxel secures $287M to advance oral GLP‑1 program https://biobriefs.com/j-craig-venter-co-founds BioBriefs en 2026-01-23T21:32:43Z J. Craig Venter co‑founds Diploid Genomics to marry AI and sequencing https://biobriefs.com/mount-sinais-macrophage-targeted-car BioBriefs en 2026-01-23T21:32:43Z Mount Sinai’s macrophage‑targeted CAR T reprograms solid tumors in mice https://biobriefs.com/fda-advances-mrd-guidance-new BioBriefs en 2026-01-23T21:32:43Z FDA advances MRD guidance — new path to speed multiple myeloma trials https://biobriefs.com/nanopore-cytogenetics-hits-clinical-pilots BioBriefs en 2026-01-23T21:32:43Z Nanopore cytogenetics hits clinical pilots in Italy https://biobriefs.com/nvidia-lilly-1b-ai-lab BioBriefs en 2026-01-23T16:32:53Z NVIDIA–Lilly $1B AI lab: drug discovery scales up https://biobriefs.com/bristol-myers-bets-on-janux BioBriefs en 2026-01-23T16:32:53Z Bristol Myers bets on Janux – $50M upfront, $850M possible https://biobriefs.com/corxel-raises-287m-oral-glp BioBriefs en 2026-01-23T16:32:53Z Corxel raises $287M: oral GLP‑1 clinical push https://biobriefs.com/biomarin-vets-form-mendra-82m BioBriefs en 2026-01-23T16:32:53Z BioMarin vets form Mendra: $82M to buy rare‑disease assets https://biobriefs.com/corcepts-relacorilant-phase-3-survival BioBriefs en 2026-01-23T16:32:53Z Corcept’s relacorilant: phase 3 survival win lifts approval odds https://biobriefs.com/fda-opens-mrd-path-draft BioBriefs en 2026-01-23T16:32:53Z FDA opens MRD path: draft guidance for multiple myeloma https://biobriefs.com/guardant360-cdx-cleared-liquid-biopsy BioBriefs en 2026-01-23T16:32:53Z Guardant360 CDx cleared: liquid biopsy wins new companion role https://biobriefs.com/venter-launches-diploid-genomics-ai BioBriefs en 2026-01-23T16:32:53Z Venter launches Diploid Genomics: AI meets clinical‑grade sequencing https://biobriefs.com/robotics-milestone-integrated-automation-for BioBriefs en 2026-01-23T16:32:53Z Robotics milestone: integrated automation for cell and gene therapy https://biobriefs.com/nih-ends-fetal-tissue-research BioBriefs en 2026-01-23T16:32:53Z NIH ends fetal tissue research: policy shift draws criticism https://biobriefs.com/nvidia-lilly-pact-1b-ai BioBriefs en 2026-01-23T14:32:52Z Nvidia-Lilly pact: $1B AI lab to power drug discovery https://biobriefs.com/corxel-raises-287m-funds-oral BioBriefs en 2026-01-23T14:32:52Z Corxel raises $287M — funds oral GLP‑1 global development https://biobriefs.com/mendra-raises-82m-ai-guided BioBriefs en 2026-01-23T14:32:52Z Mendra raises $82M — AI-guided rare disease roll-up https://biobriefs.com/bristol-myers-bets-50m-on BioBriefs en 2026-01-23T14:32:52Z Bristol Myers bets $50M on Janux’s masked T‑cell engagers https://biobriefs.com/guardant360-cdx-wins-fda-nod BioBriefs en 2026-01-23T14:32:52Z Guardant360 CDx wins FDA nod for Pfizer BRAF colorectal combo https://biobriefs.com/corcepts-relacorilant-extends-survival-ovarian BioBriefs en 2026-01-23T14:32:52Z Corcept’s relacorilant extends survival — ovarian cancer win https://biobriefs.com/fda-drafts-mrd-guidance-faster BioBriefs en 2026-01-23T14:32:52Z FDA drafts MRD guidance: Faster paths for multiple‑myeloma drugs https://biobriefs.com/cellular-origins-fresenius-complete-cgt BioBriefs en 2026-01-23T14:32:52Z Cellular Origins, Fresenius complete CGT automation milestone https://biobriefs.com/nanopore-cytogenetics-4bases-launches-hospital BioBriefs en 2026-01-23T14:32:52Z Nanopore cytogenetics: 4bases launches hospital pilots in Italy https://biobriefs.com/neok-bio-wins-fda-ind BioBriefs en 2026-01-23T14:32:52Z Neok Bio wins FDA IND for bispecific ADC NEOK‑001 https://biobriefs.com/nvidia-and-lilly-launch-1b BioBriefs en 2026-01-23T10:33:38Z Nvidia and Lilly Launch $1B AI Lab — Accelerate Drug Discovery https://biobriefs.com/corxel-raises-287m-funds-global BioBriefs en 2026-01-23T10:33:38Z Corxel Raises $287M — Funds Global Oral GLP‑1 Trials https://biobriefs.com/bms-signs-850m-janux-pact BioBriefs en 2026-01-23T10:33:38Z BMS Signs $850M Janux Pact — Tumor‑Activated T‑Cell Engager Push https://biobriefs.com/relacorilant-shows-35-mortality-drop BioBriefs en 2026-01-23T10:33:38Z Relacorilant Shows 35% Mortality Drop — Corcept Readies FDA Bid https://biobriefs.com/fda-issues-draft-mrd-guidance BioBriefs en 2026-01-23T10:33:38Z FDA Issues Draft MRD Guidance — Myeloma Endpoints Evolve https://biobriefs.com/regulators-clear-new-diagnostics-paths BioBriefs en 2026-01-23T10:33:38Z Regulators Clear New Diagnostics Paths — Liquid Biopsy and MCED Move https://biobriefs.com/fda-clears-inds-for-two BioBriefs en 2026-01-23T10:33:38Z FDA Clears INDs for Two Tumor‑Targeted Programs — Clinic Start Imminent https://biobriefs.com/nanorobots-and-oligodendrocyte-biology-advance BioBriefs en 2026-01-23T10:33:38Z Nanorobots and Oligodendrocyte Biology Advance Neural Repair Strategies https://biobriefs.com/simpler-alzheimer-tests-move-forward BioBriefs en 2026-01-23T10:33:38Z Simpler Alzheimer Tests Move Forward — Plasma and Finger‑Prick Trials https://biobriefs.com/mycs-rna-role-and-plasticity BioBriefs en 2026-01-23T10:33:38Z MYC’s RNA Role and Plasticity States Expose New Cancer Vulnerabilities https://biobriefs.com/nvidia-and-lilly-launch-1 BioBriefs en 2026-01-23T09:33:52Z Nvidia and Lilly Launch $1 Billion AI Drug Lab https://biobriefs.com/pharma-bets-on-ai-platforms BioBriefs en 2026-01-23T09:33:52Z Pharma Bets on AI Platforms: Deals Flood In https://biobriefs.com/corxel-raises-287m-pushes-oral BioBriefs en 2026-01-23T09:33:52Z Corxel Raises $287M — Pushes Oral GLP‑1 Global https://biobriefs.com/bristol-myers-backs-janux-50m BioBriefs en 2026-01-23T09:33:52Z Bristol Myers Backs Janux — $50M Upfront, $850M Deal Possible https://biobriefs.com/relacorilant-cuts-death-risk-corcept BioBriefs en 2026-01-23T09:33:52Z Relacorilant Cuts Death Risk: Corcept Eyes $2.1B Market https://biobriefs.com/fda-drafts-mrd-guidance-faster BioBriefs en 2026-01-23T09:33:52Z FDA Drafts MRD Guidance: Faster Paths for Myeloma Drugs https://biobriefs.com/guardant360-gets-fda-cdx-approval BioBriefs en 2026-01-23T09:33:52Z Guardant360 Gets FDA CDx Approval for BRAF Colorectal Combo https://biobriefs.com/myc-multimers-silence-innate-alarms BioBriefs en 2026-01-23T09:33:52Z MYC Multimers Silence Innate Alarms — Tumors Evade Immunity https://biobriefs.com/4bases-and-florence-launch-nanopore BioBriefs en 2026-01-23T09:33:52Z 4bases and Florence Launch Nanopore Cytogenetics Pilots https://biobriefs.com/j-craig-venter-launches-diploid BioBriefs en 2026-01-23T09:33:52Z J. Craig Venter Launches Diploid Genomics: AI‑Driven Human Genomics https://biobriefs.com/big-pharma-banks-on-ai BioBriefs en 2026-01-23T04:32:52Z Big pharma banks on AI platforms – multiyear deals roll out https://biobriefs.com/fda-moves-to-speed-multiple BioBriefs en 2026-01-23T04:32:52Z FDA moves to speed multiple myeloma approvals: MRD guidance issued https://biobriefs.com/corcept-posts-survival-win-relacorilant BioBriefs en 2026-01-23T04:32:52Z Corcept posts survival win – relacorilant heads toward regulatory test https://biobriefs.com/bms-banks-on-tumor-activated BioBriefs en 2026-01-23T04:32:52Z BMS banks on tumor‑activated T‑cell engagers – Janux tie-up expands https://biobriefs.com/corxel-secures-financing-to-advance BioBriefs en 2026-01-23T04:32:52Z Corxel secures financing to advance oral GLP‑1 program https://biobriefs.com/venter-launches-diploid-genomics-ai BioBriefs en 2026-01-23T04:32:52Z Venter launches Diploid Genomics: AI‑driven human genomics startup https://biobriefs.com/congress-clears-a-route-for BioBriefs en 2026-01-23T04:32:52Z Congress clears a route for Medicare coverage of MCED tests https://biobriefs.com/nih-ends-fetal-tissue-research BioBriefs en 2026-01-23T04:32:52Z NIH ends fetal tissue research support — policy move draws fire https://biobriefs.com/nanopore-cytogenetics-hits-clinical-pilots BioBriefs en 2026-01-23T04:32:52Z Nanopore cytogenetics hits clinical pilots — 4bases rolls out KaryoSolver https://biobriefs.com/nanorobots-guide-macrophages-to-boost BioBriefs en 2026-01-23T04:32:52Z Nanorobots guide macrophages to boost neural repair https://biobriefs.com/guardant360-cleared-liquid-biopsy-cdx BioBriefs en 2026-01-22T21:33:15Z Guardant360 cleared: Liquid biopsy CDx for Pfizer regimen https://biobriefs.com/fda-draft-guidance-mrd-could BioBriefs en 2026-01-22T21:33:15Z FDA draft guidance: MRD could speed multiple myeloma approvals https://biobriefs.com/relacorilant-cuts-death-risk-35 BioBriefs en 2026-01-22T21:33:15Z Relacorilant cuts death risk 35%: Corcept eyes FDA decision https://biobriefs.com/bms-bets-on-masked-t BioBriefs en 2026-01-22T21:33:15Z BMS bets on masked T‑cell engagers: Janux pact https://biobriefs.com/pharma-bets-big-on-ai BioBriefs en 2026-01-22T21:33:15Z Pharma bets big on AI platforms... platform deals roll out https://biobriefs.com/corxel-raises-287m-funds-oral BioBriefs en 2026-01-22T21:33:15Z Corxel raises $287M — funds oral GLP‑1 trials https://biobriefs.com/nanopore-cytogenetics-enters-clinic-4bases BioBriefs en 2026-01-22T21:33:15Z Nanopore cytogenetics enters clinic: 4bases launches pilots https://biobriefs.com/two-ind-clears-avacta-and BioBriefs en 2026-01-22T21:33:15Z Two IND clears: Avacta and Neok Bio push solid‑tumor programs https://biobriefs.com/next-gen-cancer-vaccines-pull BioBriefs en 2026-01-22T21:33:15Z Next‑gen cancer vaccines pull funding — clinics follow https://biobriefs.com/congress-paves-path-for-mced BioBriefs en 2026-01-22T21:33:15Z Congress paves path for MCED coverage: appropriations include provision https://biobriefs.com/fda-drafts-mrd-guidance-new BioBriefs en 2026-01-22T16:33:24Z FDA drafts MRD guidance: New route for myeloma approvals https://biobriefs.com/guardant-lands-fda-nod-liquid BioBriefs en 2026-01-22T16:33:24Z Guardant lands FDA nod: Liquid biopsy cleared as CDx for Pfizer combo https://biobriefs.com/corcept-posts-phase-3-survival BioBriefs en 2026-01-22T16:33:24Z Corcept posts phase 3 survival win – momentum after setback https://biobriefs.com/gsk-buys-rapt-for-2 BioBriefs en 2026-01-22T16:33:24Z GSK buys Rapt for $2.2B: Big bet on food allergy https://biobriefs.com/bristol-myers-bets-up-to BioBriefs en 2026-01-22T16:33:24Z Bristol Myers bets up to $850M on Janux T‑cell engager https://biobriefs.com/corxel-pulls-287m-to-fund BioBriefs en 2026-01-22T16:33:24Z Corxel pulls $287M to fund oral GLP‑1 obesity studies https://biobriefs.com/ex-biomarin-execs-launch-mendra BioBriefs en 2026-01-22T16:33:24Z Ex‑BioMarin execs launch Mendra with $82M to buy rare assets https://biobriefs.com/two-ind-clears-hit-solid BioBriefs en 2026-01-22T16:33:24Z Two IND clears hit solid‑tumor pipeline — Neok and Avacta https://biobriefs.com/congress-carves-medicare-path-for BioBriefs en 2026-01-22T16:33:24Z Congress carves Medicare path for MCED tests in spending bill https://biobriefs.com/gsk-buys-rapt-for-2 BioBriefs en 2026-01-22T14:33:03Z GSK buys Rapt for $2.2B — adds long‑acting IgE drug https://biobriefs.com/fda-readies-mrd-pathway-draft BioBriefs en 2026-01-22T14:33:03Z FDA readies MRD pathway: draft guidance released https://biobriefs.com/bms-pens-850m-pact-with BioBriefs en 2026-01-22T14:33:03Z BMS pens $850M pact with Janux — $50M up front https://biobriefs.com/erasca-upsizes-equity-raise-225m BioBriefs en 2026-01-22T14:33:03Z Erasca upsizes equity raise — $225M priced, $150M filed https://biobriefs.com/think-bioscience-nets-55m-to BioBriefs en 2026-01-22T14:33:03Z Think Bioscience nets $55M to target ‘undruggable’ proteins https://biobriefs.com/biomarin-veterans-launch-new-rare BioBriefs en 2026-01-22T14:33:03Z BioMarin veterans launch new rare‑disease biotech with $82M https://biobriefs.com/cms-backs-illumina-test-and BioBriefs en 2026-01-22T14:33:03Z CMS backs Illumina test — and Guardant partners with Merck https://biobriefs.com/valneva-withdraws-chikungunya-vaccine-from BioBriefs en 2026-01-22T14:33:03Z Valneva withdraws chikungunya vaccine from US amid safety probe https://biobriefs.com/next-gen-biomanufacturing-self-sufficient BioBriefs en 2026-01-22T14:33:03Z Next‑gen biomanufacturing: self‑sufficient CHO cells and 3D‑printed bioreactors https://biobriefs.com/china-opens-faster-trial-routes BioBriefs en 2026-01-22T14:33:03Z China opens faster trial routes — global CROs circle the market https://biobriefs.com/gsk-buys-rapt-2-2b BioBriefs en 2026-01-22T10:32:22Z GSK buys Rapt: $2.2B deal adds long‑acting anti‑IgE https://biobriefs.com/fda-issues-mrd-draft-guidance BioBriefs en 2026-01-22T10:32:22Z FDA issues MRD draft guidance: Accelerated approval path clarified https://biobriefs.com/erasca-prices-upsized-offering-225m BioBriefs en 2026-01-22T10:32:22Z Erasca prices upsized offering: $225M cash infusion for RAS/MAPK programs https://biobriefs.com/corvus-pill-phase-i-surge BioBriefs en 2026-01-22T10:32:22Z Corvus pill…phase I surge: Oral ITK inhibitor posts strong eczema readout https://biobriefs.com/illumina-wins-cms-reimbursement-trusight BioBriefs en 2026-01-22T10:32:22Z Illumina wins CMS reimbursement: TruSight Oncology gets $2,989 rate https://biobriefs.com/valneva-withdraws-u-s-chikungunya BioBriefs en 2026-01-22T10:32:22Z Valneva withdraws U.S. chikungunya dossier: Safety concerns prompt exit https://biobriefs.com/congress-moves-mced-coverage-medicare BioBriefs en 2026-01-22T10:32:22Z Congress moves MCED coverage: Medicare pathway included in spending bill https://biobriefs.com/insilico-splits-nlrp3-rights-66m BioBriefs en 2026-01-22T10:32:22Z Insilico splits NLRP3 rights: $66M deal and China license accelerate ISM‑8969 https://biobriefs.com/beam-biomarkers-for-approval-fda BioBriefs en 2026-01-22T10:32:22Z Beam…biomarkers for approval: FDA agrees biomarker‑based path in AATD https://biobriefs.com/engineered-cho-cells-cut-feeds BioBriefs en 2026-01-22T10:32:22Z Engineered CHO cells cut feeds and wastes: Self‑sufficient amino‑acid producers https://biobriefs.com/gsk-buys-rapt-for-2 BioBriefs en 2026-01-22T09:33:10Z GSK buys Rapt for $2.2B — Adds long‑acting anti‑IgE https://biobriefs.com/fda-opens-path-mrd-negativity BioBriefs en 2026-01-22T09:33:10Z FDA opens path: MRD negativity could back myeloma accelerated approvals https://biobriefs.com/erasca-prices-upsized-offering-225m BioBriefs en 2026-01-22T09:33:10Z Erasca prices upsized offering — $225M gross proceeds https://biobriefs.com/corvus-pill-soars-itk-inhibitor BioBriefs en 2026-01-22T09:33:10Z Corvus pill soars — ITK inhibitor posts strong Phase I eczema results https://biobriefs.com/illumina-wins-cms-reimbursement-trusight BioBriefs en 2026-01-22T09:33:10Z Illumina wins CMS reimbursement — TruSight Oncology Comprehensive covered https://biobriefs.com/valneva-pulls-chikungunya-from-u BioBriefs en 2026-01-22T09:33:10Z Valneva pulls chikungunya from U.S. after FDA safety probe https://biobriefs.com/beam-wins-biomarker-path-fda BioBriefs en 2026-01-22T09:33:10Z Beam wins biomarker path: FDA allows MRD‑style route for BEAM‑302 https://biobriefs.com/merck-guardant-pair-up-companion BioBriefs en 2026-01-22T09:33:10Z Merck, Guardant pair up — Companion diagnostics tied to global trials https://biobriefs.com/appropriations-bill-would-ease-medicare BioBriefs en 2026-01-22T09:33:10Z Appropriations bill would ease Medicare coverage for FDA‑approved MCED tests https://biobriefs.com/insilico-splits-nlrp3-rights-china BioBriefs en 2026-01-22T09:33:10Z Insilico splits NLRP3 rights — China deals and licensing cash https://biobriefs.com/gsk-to-buy-rapt-for BioBriefs en 2026-01-22T04:33:04Z GSK to buy Rapt for $2.2B — adds long‑acting anti‑IgE https://biobriefs.com/corvus-atopic-dermatitis-pill-shares BioBriefs en 2026-01-22T04:33:04Z Corvus’ atopic dermatitis pill... shares surge on phase I readout https://biobriefs.com/merck-moderna-cancer-vaccine-sustains BioBriefs en 2026-01-22T04:33:04Z Merck‑Moderna cancer vaccine sustains 49% risk cut at five years https://biobriefs.com/erasca-upsized-offering-at-10 BioBriefs en 2026-01-22T04:33:04Z Erasca upsized offering at $10 — raises $225M for RAS/MAPK programs https://biobriefs.com/cms-backs-illumina-s-trusight BioBriefs en 2026-01-22T04:33:04Z CMS backs Illumina's TruSight test — $2,989.55 reimbursement set https://biobriefs.com/congress-drafts-medicare-pathway-for BioBriefs en 2026-01-22T04:33:04Z Congress drafts Medicare pathway for MCED tests — coverage starts 2029 https://biobriefs.com/biomakers-raises-8m-ai-oncology BioBriefs en 2026-01-22T04:33:04Z Biomakers raises $8M — AI oncology platform to scale into Latin America https://biobriefs.com/cho-cells-engineered-to-make BioBriefs en 2026-01-22T04:33:04Z CHO cells engineered to make amino acids — lower waste, simplify feeds https://biobriefs.com/quantum-enabled-proteins-engineered-sensors BioBriefs en 2026-01-22T04:33:04Z Quantum‑enabled proteins... engineered sensors reach living cells https://biobriefs.com/astellas-licenses-myoaav-capsid-for BioBriefs en 2026-01-22T04:33:04Z Astellas licenses MyoAAV capsid for XLMTM — low‑dose gene therapy enters clinic https://biobriefs.com/gsk-pays-2-2b-for BioBriefs en 2026-01-21T21:32:52Z GSK pays $2.2B for Rapt: long‑acting food‑allergy bet https://biobriefs.com/pfizer-exits-viiv-stake-shionogi BioBriefs en 2026-01-21T21:32:52Z Pfizer exits ViiV stake: Shionogi expands HIV holdings https://biobriefs.com/valneva-pulls-chikungunya-from-u BioBriefs en 2026-01-21T21:32:52Z Valneva pulls chikungunya from U.S.: safety probe prompts withdrawal https://biobriefs.com/medicare-pivots-on-diagnostics-cms BioBriefs en 2026-01-21T21:32:52Z Medicare pivots on diagnostics: CMS pays Illumina test; MCED path emerges https://biobriefs.com/merck-moderna-vaccine-holds-at BioBriefs en 2026-01-21T21:32:52Z Merck‑Moderna vaccine holds at five years: durable melanoma benefit https://biobriefs.com/fda-agrees-biomarker-path-for BioBriefs en 2026-01-21T21:32:52Z FDA agrees biomarker path for base editing: Beam wins accelerated route https://biobriefs.com/corvus-pill-shocks-markets-itk BioBriefs en 2026-01-21T21:32:52Z Corvus pill shocks markets: ITK inhibitor posts strong Phase I eczema data https://biobriefs.com/tanabe-pill-clears-phase-iii BioBriefs en 2026-01-21T21:32:52Z Tanabe pill clears Phase III: oral option for rare photodermatoses https://biobriefs.com/small-biotechs-advance-boundless-immunomic BioBriefs en 2026-01-21T21:32:52Z Small biotechs advance: Boundless, Immunomic secure IND clearances https://biobriefs.com/china-remakes-clinical-trials-faster BioBriefs en 2026-01-21T21:32:52Z China remakes clinical trials: faster INDs open CRO, sponsor opportunities https://biobriefs.com/gsk-buys-rapt-2-2b BioBriefs en 2026-01-21T16:33:16Z GSK buys Rapt — $2.2B for long‑acting anti‑IgE https://biobriefs.com/merck-moderna-personalized-melanoma-vaccine BioBriefs en 2026-01-21T16:33:16Z Merck, Moderna: personalized melanoma vaccine holds at five years https://biobriefs.com/cms-clears-payment-for-illumina BioBriefs en 2026-01-21T16:33:16Z CMS clears payment for Illumina test: $2,989 per genomic profile https://biobriefs.com/congress-writes-medicare-path-for BioBriefs en 2026-01-21T16:33:16Z Congress writes Medicare path for MCED tests into spending bill https://biobriefs.com/beam-may-use-biomarkers-for BioBriefs en 2026-01-21T16:33:16Z Beam may use biomarkers for accelerated approval — FDA nod opens path https://biobriefs.com/boundless-wins-ind-for-oral BioBriefs en 2026-01-21T16:33:16Z Boundless wins IND for oral kinesin degrader — KOMODO‑1 to start H1 https://biobriefs.com/insilico-splits-nlrp3-rights-66m BioBriefs en 2026-01-21T16:33:16Z Insilico splits NLRP3 rights — $66M deal sparks China tie‑ups https://biobriefs.com/qiagen-draws-buyout-interest-shares BioBriefs en 2026-01-21T16:33:16Z Qiagen draws buyout interest — shares jump on sale chatter https://biobriefs.com/guardant-and-merck-partner-on BioBriefs en 2026-01-21T16:33:16Z Guardant and Merck partner on companion diagnostics — liquid biopsy tie‑up https://biobriefs.com/novo-exits-cell-therapy-bets BioBriefs en 2026-01-21T16:33:16Z Novo exits cell therapy bets — Aspect acquires diabetes assets https://biobriefs.com/gsk-snaps-up-rapt-for BioBriefs en 2026-01-21T14:32:00Z GSK snaps up Rapt for food-allergy antibody — $2.2B deal https://biobriefs.com/merck-moderna-vaccine-benefit-endures BioBriefs en 2026-01-21T14:32:00Z Merck‑Moderna vaccine benefit endures — 5‑year melanoma data https://biobriefs.com/fda-flexibility-helps-beam-push BioBriefs en 2026-01-21T14:32:00Z FDA flexibility helps Beam push base editor toward accelerated path https://biobriefs.com/illumina-wins-cms-reimbursement-broadens BioBriefs en 2026-01-21T14:32:00Z Illumina wins CMS reimbursement — broadens access to CGP https://biobriefs.com/congress-advances-medicare-pathway-for BioBriefs en 2026-01-21T14:32:00Z Congress advances Medicare pathway for multi‑cancer early detection https://biobriefs.com/insilico-splits-rights-on-brain BioBriefs en 2026-01-21T14:32:00Z Insilico splits rights on brain‑penetrant NLRP3 inhibitor — $66M accord https://biobriefs.com/guardant-and-merck-partner-on BioBriefs en 2026-01-21T14:32:00Z Guardant and Merck partner on liquid and tissue companion diagnostics https://biobriefs.com/exciva-raises-eur51m-to-fund BioBriefs en 2026-01-21T14:32:00Z Exciva raises €51M to fund Alzheimer’s agitation pivotal program https://biobriefs.com/astellas-relaunches-xlmtm-gene-therapy BioBriefs en 2026-01-21T14:32:00Z Astellas relaunches XLMTM gene therapy with MyoAAV capsid program https://biobriefs.com/valneva-withdraws-chikungunya-vaccine-from BioBriefs en 2026-01-21T14:32:00Z Valneva withdraws chikungunya vaccine from U.S. after FDA concerns https://biobriefs.com/gsk-buys-rapt-for-2 BioBriefs en 2026-01-21T10:32:33Z GSK buys Rapt for $2.2B – adds long‑acting anti‑IgE https://biobriefs.com/boston-scientific-buys-penumbra-in BioBriefs en 2026-01-21T10:32:33Z Boston Scientific buys Penumbra in $14.5B deal – expands thrombectomy portfolio https://biobriefs.com/cms-reimburses-illumina-oncology-test BioBriefs en 2026-01-21T10:32:33Z CMS reimburses Illumina oncology test – $2,989 rate opens precision‑oncology access https://biobriefs.com/merck-moderna-vaccine-sustains-49 BioBriefs en 2026-01-21T10:32:33Z Merck‑Moderna vaccine sustains 49% melanoma risk cut at 5 years https://biobriefs.com/astellas-relaunches-xlmtm-gene-therapy BioBriefs en 2026-01-21T10:32:33Z Astellas relaunches XLMTM gene therapy effort with MyoAAV capsid https://biobriefs.com/valneva-withdraws-u-s-chikungunya BioBriefs en 2026-01-21T10:32:33Z Valneva withdraws U.S. chikungunya shot amid FDA safety probe https://biobriefs.com/parse-and-graph-build-immune BioBriefs en 2026-01-21T10:32:33Z Parse and Graph build immune perturbation atlas – single‑cell scale https://biobriefs.com/cepheid-wins-fda-510-k BioBriefs en 2026-01-21T10:32:33Z Cepheid wins FDA 510(k) for Xpert GI panel – rapid syndromic stool testing https://biobriefs.com/guardant-and-merck-partner-to BioBriefs en 2026-01-21T10:32:33Z Guardant and Merck partner to co‑develop companion diagnostics for trials https://biobriefs.com/weill-cornell-wins-5-2m BioBriefs en 2026-01-21T10:32:33Z Weill Cornell wins $5.2M ARPA‑H grant to fast‑track lymphatic diagnostics https://biobriefs.com/gsk-buys-rapt-for-2 BioBriefs en 2026-01-21T09:32:46Z GSK buys Rapt for $2.2B — long‑acting anti‑IgE joins pipeline https://biobriefs.com/boston-scientific-to-buy-penumbra BioBriefs en 2026-01-21T09:32:46Z Boston Scientific to buy Penumbra for $14.5B — moves into thrombectomy https://biobriefs.com/astrazeneca-pays-up-to-630m BioBriefs en 2026-01-21T09:32:46Z AstraZeneca pays up to $630M for China rights to GPC3 CAR‑T – global control secured https://biobriefs.com/valneva-pulls-chikungunya-shot-from BioBriefs en 2026-01-21T09:32:46Z Valneva pulls chikungunya shot from U.S. — FDA safety probe prompts withdrawal https://biobriefs.com/cms-backs-illumina-cgp-reimbursement BioBriefs en 2026-01-21T09:32:46Z CMS backs Illumina CGP — reimbursement set at $2,989.55 per test https://biobriefs.com/cepheid-cleared-for-multiplex-xpert BioBriefs en 2026-01-21T09:32:46Z Cepheid cleared for multiplex Xpert GI panel — rapid syndromic GI testing arrives https://biobriefs.com/guardant-merck-partner-on-companion BioBriefs en 2026-01-21T09:32:46Z Guardant, Merck partner on companion diagnostics — liquid biopsies to support trials https://biobriefs.com/qiagen-shares-jump-on-sale BioBriefs en 2026-01-21T09:32:46Z Qiagen shares jump on sale speculation — advisers engaged, suitors eyed https://biobriefs.com/fda-clears-d3-bio-ind BioBriefs en 2026-01-21T09:32:46Z FDA clears D3 Bio IND for KRAS G12D inhibitor — first‑in‑human trial to start https://biobriefs.com/merck-moderna-cancer-vaccine-sustains BioBriefs en 2026-01-21T09:32:46Z Merck‑Moderna cancer vaccine sustains 49% melanoma risk cut at 5 years — durable adjuvant effect https://biobriefs.com/gsk-buys-rapt-for-2 BioBriefs en 2026-01-21T04:32:49Z GSK buys Rapt for $2.2B — bets on long‑acting anti‑IgE https://biobriefs.com/astrazeneca-pays-up-to-630m BioBriefs en 2026-01-21T04:32:49Z AstraZeneca pays up to $630M for China CAR‑T rights https://biobriefs.com/qiagen-mulls-sale-shares-jump BioBriefs en 2026-01-21T04:32:49Z Qiagen mulls sale: shares jump on buyout chatter https://biobriefs.com/valneva-withdraws-u-s-chikungunya BioBriefs en 2026-01-21T04:32:49Z Valneva withdraws U.S. chikungunya filing amid safety probe https://biobriefs.com/cms-backs-illumina-test-reimbursement BioBriefs en 2026-01-21T04:32:49Z CMS backs Illumina test — reimbursement opens precision oncology door https://biobriefs.com/capricor-updates-bla-amid-fda BioBriefs en 2026-01-21T04:32:49Z Capricor updates BLA amid FDA review of HOPE‑3 topline data https://biobriefs.com/merck-moderna-cancer-vaccine-sustains BioBriefs en 2026-01-21T04:32:49Z Merck, Moderna cancer vaccine sustains 49% melanoma risk cut at 5 years https://biobriefs.com/astellas-restarts-xlmtm-push-with BioBriefs en 2026-01-21T04:32:49Z Astellas restarts XLMTM push with MyoAAV capsid gene therapy https://biobriefs.com/guardant-and-merck-partner-on BioBriefs en 2026-01-21T04:32:49Z Guardant and Merck partner on companion diagnostics for trials https://biobriefs.com/cepheid-wins-fda-clearance-for BioBriefs en 2026-01-21T04:32:49Z Cepheid wins FDA clearance for Xpert GI panel — enters syndromic PCR market https://biobriefs.com/gsk-agrees-to-buy-rapt BioBriefs en 2026-01-20T21:33:22Z GSK agrees to buy Rapt for $2.2B – adds long‑acting anti‑IgE https://biobriefs.com/astrazeneca-pays-up-to-630m BioBriefs en 2026-01-20T21:33:22Z AstraZeneca pays up to $630M for China rights to Abelzeta CAR‑T https://biobriefs.com/cms-sets-2989-55-rate BioBriefs en 2026-01-20T21:33:22Z CMS sets $2,989.55 rate — Illumina wins reimbursement for TruSight https://biobriefs.com/valneva-pulls-chikungunya-shot-from BioBriefs en 2026-01-20T21:33:22Z Valneva pulls chikungunya shot from U.S. after FDA safety probe https://biobriefs.com/merck-moderna-vaccine-49-reduction BioBriefs en 2026-01-20T21:33:22Z Merck–Moderna vaccine: 49% reduction in melanoma recurrence at 5 years https://biobriefs.com/astellas-restarts-xlmtm-effort-with BioBriefs en 2026-01-20T21:33:22Z Astellas restarts XLMTM effort with MyoAAV capsid—first‑in‑human VALOR trial https://biobriefs.com/parse-and-graph-therapeutics-partner BioBriefs en 2026-01-20T21:33:22Z Parse and Graph Therapeutics partner to build immune‑cell perturbation atlas https://biobriefs.com/engineered-living-glue-detects-gi BioBriefs en 2026-01-20T21:33:22Z Engineered living 'glue' detects GI bleeding and delivers therapy in IBD models https://biobriefs.com/fda-clears-ind-for-d3 BioBriefs en 2026-01-20T21:33:22Z FDA clears IND for D3 Bio’s KRAS G12D inhibitor D3S‑003 https://biobriefs.com/guardant-and-merck-team-on BioBriefs en 2026-01-20T21:33:22Z Guardant and Merck team on liquid‑tissue companion diagnostics for trials https://biobriefs.com/gsk-agrees-2-2b-deal BioBriefs en 2026-01-20T16:33:06Z GSK agrees $2.2B deal: picks up Rapt’s long‑acting anti‑IgE https://biobriefs.com/boston-scientific-to-buy-penumbra BioBriefs en 2026-01-20T16:33:06Z Boston Scientific to buy Penumbra: $14.5B move into thrombectomy https://biobriefs.com/capricor-updates-bla-after-fda BioBriefs en 2026-01-20T16:33:06Z Capricor updates BLA after FDA review of HOPE‑3 topline results https://biobriefs.com/cms-oks-reimbursement-for-illuminas BioBriefs en 2026-01-20T16:33:06Z CMS OKs reimbursement for Illumina’s TruSight: $2,989.55 per test https://biobriefs.com/engineered-bacteria-secrete-adhesive-therapeutics BioBriefs en 2026-01-20T16:33:06Z Engineered bacteria secrete adhesive therapeutics: Living glue treats IBD in mice https://biobriefs.com/engineered-uga-suppressor-trna-broadens BioBriefs en 2026-01-20T16:33:06Z Engineered UGA suppressor tRNA: Broadens AAV therapeutic reach https://biobriefs.com/scientists-build-bacteriophages-with-ai BioBriefs en 2026-01-20T16:33:06Z Scientists build bacteriophages with AI... Raises biosecurity questions https://biobriefs.com/fda-clears-ind-d3-bios BioBriefs en 2026-01-20T16:33:06Z FDA clears IND: D3 Bio’s KRAS G12D inhibitor moves to clinic https://biobriefs.com/parse-graph-team-up-atlas BioBriefs en 2026-01-20T16:33:06Z Parse, Graph team up – Atlas to profile hundreds of millions of immune cells https://biobriefs.com/guardant-merck-ink-multi-year BioBriefs en 2026-01-20T16:33:06Z Guardant, Merck ink multi‑year deal – Liquid and tissue tests to support trials https://biobriefs.com/gsk-buys-rapt-for-2 BioBriefs en 2026-01-20T14:33:16Z GSK buys Rapt for $2.2B—ozureprubart eyed for 12-week dosing https://biobriefs.com/boston-scientific-to-acquire-penumbra BioBriefs en 2026-01-20T14:33:16Z Boston Scientific to acquire Penumbra for $14.5B—cardio and neurovascular scale-up https://biobriefs.com/merck-moderna-vaccine-sustains-49 BioBriefs en 2026-01-20T14:33:16Z Merck–Moderna vaccine sustains 49% melanoma risk cut at five years https://biobriefs.com/astrazeneca-pays-up-to-630m BioBriefs en 2026-01-20T14:33:16Z AstraZeneca pays up to $630M for China rights to AbelZeta CAR‑T https://biobriefs.com/d3-bio-wins-ind-clearance BioBriefs en 2026-01-20T14:33:16Z D3 Bio wins IND clearance for KRAS G12D inhibitor—first‑in‑human trial cleared https://biobriefs.com/engineered-living-glue-bacteria-sense BioBriefs en 2026-01-20T14:33:16Z Engineered living glue: bacteria sense bleeding and secrete therapeutics in IBD models https://biobriefs.com/engineered-suppressor-trna-broadens-aav BioBriefs en 2026-01-20T14:33:16Z Engineered suppressor tRNA broadens AAV delivery—disease‑agnostic translation tool https://biobriefs.com/exciva-raises-eur51m-59m-series BioBriefs en 2026-01-20T14:33:16Z Exciva raises €51M ($59M) Series B to push Alzheimer’s agitation candidate into Phase 2 https://biobriefs.com/ai-designs-bacteriophages-from-scratch BioBriefs en 2026-01-20T14:33:16Z AI designs bacteriophages from scratch—scientists flag biosecurity implications https://biobriefs.com/monod-bio-unveils-ai-designed BioBriefs en 2026-01-20T14:33:16Z Monod Bio unveils AI‑designed ‘NovoBodies’—compact, customizable antibody mimics https://biobriefs.com/gsk-buys-rapt-for-food BioBriefs en 2026-01-20T10:33:00Z GSK buys Rapt for food-allergy IgE antibody: $2.2B deal https://biobriefs.com/boston-scientific-to-buy-penumbra BioBriefs en 2026-01-20T10:33:00Z Boston Scientific to buy Penumbra: $14.5B cardiovascular push https://biobriefs.com/astrazeneca-pays-up-for-c BioBriefs en 2026-01-20T10:33:00Z AstraZeneca pays up for C-CAR031 China rights — $630M pact https://biobriefs.com/engineered-living-glues-target-gut BioBriefs en 2026-01-20T10:33:00Z Engineered living glues target gut bleeding: autonomous IBD therapy https://biobriefs.com/uga-suppressor-trna-for-aav BioBriefs en 2026-01-20T10:33:00Z UGA suppressor tRNA for AAV delivery unveiled — broad tropism move https://biobriefs.com/d3-bio-wins-ind-clearance BioBriefs en 2026-01-20T10:33:00Z D3 Bio wins IND clearance for KRAS G12D inhibitor — first‑in‑human next https://biobriefs.com/car-t-manufacturing-boost-dextran BioBriefs en 2026-01-20T10:33:00Z CAR‑T manufacturing boost: dextran nanoparticles and real‑time monitoring https://biobriefs.com/ai-builds-bacteriophages-from-scratch BioBriefs en 2026-01-20T10:33:00Z AI builds bacteriophages from scratch — breakthrough with biosecurity alarm https://biobriefs.com/exciva-raises-eur51m-59m-series BioBriefs en 2026-01-20T10:33:00Z Exciva raises €51M ($59M) Series B to push Alzheimer’s agitation drug https://biobriefs.com/fda-turmoil-clouds-2025-approvals BioBriefs en 2026-01-20T10:33:00Z FDA turmoil clouds 2025 approvals — agency in transition https://biobriefs.com/boston-scientific-buys-penumbra-14 BioBriefs en 2026-01-20T09:32:50Z Boston Scientific buys Penumbra: $14.5bn cardiovascular push https://biobriefs.com/astrazeneca-secures-china-rights-to BioBriefs en 2026-01-20T09:32:50Z AstraZeneca secures China rights to CAR-T C‑CAR031: $630M deal https://biobriefs.com/exciva-closes-eur51m-series-b BioBriefs en 2026-01-20T09:32:50Z Exciva closes €51m Series B — advance Alzheimer’s agitation candidate https://biobriefs.com/fda-clears-d3-bio-ind BioBriefs en 2026-01-20T09:32:50Z FDA clears D3 Bio IND: KRAS G12D inhibitor D3S‑003 goes to clinic https://biobriefs.com/engineered-living-glues-bacteria-stick BioBriefs en 2026-01-20T09:32:50Z Engineered living glues: bacteria stick therapeutics to bleeding gut… https://biobriefs.com/therapeutic-suppressor-trna-widens-aav BioBriefs en 2026-01-20T09:32:50Z Therapeutic suppressor tRNA widens AAV delivery: Nature Biotech https://biobriefs.com/first-circrna-protein-replacement-therapy BioBriefs en 2026-01-20T09:32:50Z First circRNA protein‑replacement therapy targets liver fibrosis https://biobriefs.com/ai-builds-bacteriophages-from-scratch BioBriefs en 2026-01-20T09:32:50Z AI builds bacteriophages from scratch: new era — and new risks https://biobriefs.com/dextran-nanoparticles-ramp-car-t BioBriefs en 2026-01-20T09:32:50Z Dextran nanoparticles ramp CAR‑T manufacture: scalable platform reported https://biobriefs.com/fda-turmoil-overshadows-2025-approvals BioBriefs en 2026-01-20T09:32:50Z FDA turmoil overshadows 2025 approvals: agency in transition https://biobriefs.com/boston-scientific-to-buy-penumbra BioBriefs en 2026-01-20T04:32:33Z Boston Scientific to buy Penumbra for $14.5 billion — broadens cardiovascular reach https://biobriefs.com/astrazeneca-pays-up-to-630m BioBriefs en 2026-01-20T04:32:33Z AstraZeneca pays up to $630M to own CAR‑T rights in China — full global control secured https://biobriefs.com/d3-bio-wins-fda-ind BioBriefs en 2026-01-20T04:32:33Z D3 Bio wins FDA IND for KRAS G12D inhibitor — first‑in‑human trial cleared https://biobriefs.com/engineered-bacteria-act-as-adhesive BioBriefs en 2026-01-20T04:32:33Z Engineered bacteria act as adhesive, on‑demand drug factories for IBD — Nature report https://biobriefs.com/engineered-uga-suppressor-trna-broadens BioBriefs en 2026-01-20T04:32:33Z Engineered UGA suppressor tRNA broadens AAV delivery options — Nature Biotechnology https://biobriefs.com/first-circrna-encoded-protein-therapy BioBriefs en 2026-01-20T04:32:33Z First circRNA‑encoded protein therapy enters liver‑fibrosis conversation — Shanghai teams https://biobriefs.com/ai-designed-bacteriophages-built-from BioBriefs en 2026-01-20T04:32:33Z AI‑designed bacteriophages built from scratch — capability raises biosecurity questions https://biobriefs.com/nanosystem-delivers-continuous-timp-1 BioBriefs en 2026-01-20T04:32:33Z Nanosystem delivers continuous TIMP‑1 therapy for idiopathic pulmonary fibrosis — Nature Communications https://biobriefs.com/real-time-metabolic-monitoring-enters BioBriefs en 2026-01-20T04:32:33Z Real‑time metabolic monitoring enters cell & gene therapy manufacturing workflows https://biobriefs.com/nature-biotechnology-fda-leadership-turmoil BioBriefs en 2026-01-20T04:32:33Z Nature Biotechnology: FDA leadership turmoil shadows 2025 approvals — agency shifts noted https://biobriefs.com/boston-scientific-expands-vascular-reach BioBriefs en 2026-01-19T21:33:26Z Boston Scientific expands vascular reach: buys Penumbra for $14.5bn https://biobriefs.com/astrazeneca-snaps-up-china-rights BioBriefs en 2026-01-19T21:33:26Z AstraZeneca snaps up China rights to armored CAR‑T – $630M pact https://biobriefs.com/fda-clears-ind-for-d3 BioBriefs en 2026-01-19T21:33:26Z FDA clears IND for D3 Bio’s KRAS G12D inhibitor: human trials start https://biobriefs.com/engineered-bacteria-act-as-therapeutic BioBriefs en 2026-01-19T21:33:26Z Engineered bacteria act as therapeutic glue... heal IBD in mice https://biobriefs.com/uga-suppressor-trna-widens-aav BioBriefs en 2026-01-19T21:33:26Z UGA‑suppressor tRNA widens AAV delivery potential – platform advance https://biobriefs.com/ai-designs-phages-and-golden BioBriefs en 2026-01-19T21:33:26Z AI designs phages and Golden Gate accelerates synthetic phage engineering https://biobriefs.com/fda-turmoil-shadows-2025-approvals BioBriefs en 2026-01-19T21:33:26Z FDA turmoil shadows 2025 approvals – agency faces staffing and policy shifts https://biobriefs.com/tiprelestat-shows-benefit-in-hospitalized BioBriefs en 2026-01-19T21:33:26Z Tiprelestat shows benefit in hospitalized COVID‑19 – COMCOVID randomized trial https://biobriefs.com/first-circrna-based-protein-replacement BioBriefs en 2026-01-19T21:33:26Z First circRNA‑based protein replacement reverses liver fibrosis in preclinical tests https://biobriefs.com/agomab-spyglass-file-ipo-plans BioBriefs en 2026-01-19T21:33:26Z Agomab, SpyGlass file IPO plans as biotech window reopens https://biobriefs.com/engineered-bacteria-glue-seals-gut BioBriefs en 2026-01-19T16:33:24Z Engineered bacteria glue seals gut bleeds — durable mucosal repair in mice https://biobriefs.com/fda-clears-ind-for-d3 BioBriefs en 2026-01-19T16:33:24Z FDA clears IND for D3 Bio KRAS G12D inhibitor — first‑in‑human trial next https://biobriefs.com/astrazeneca-buys-remaining-china-rights BioBriefs en 2026-01-19T16:33:24Z AstraZeneca buys remaining China rights to armored CAR‑T — deal worth up to $630M https://biobriefs.com/ai-builds-bacteriophages-from-scratch BioBriefs en 2026-01-19T16:33:24Z AI builds bacteriophages from scratch — researchers flag opportunities and risks https://biobriefs.com/fda-turmoil-overshadows-2025-approvals BioBriefs en 2026-01-19T16:33:24Z FDA turmoil overshadows 2025 approvals — pipeline produced more follow‑ons than first‑in‑class https://biobriefs.com/engineered-uga-suppressor-trna-expands BioBriefs en 2026-01-19T16:33:24Z Engineered UGA‑suppressor tRNA expands AAV delivery window — disease‑agnostic approach https://biobriefs.com/circrna-protein-replacement-first-preclinical BioBriefs en 2026-01-19T16:33:24Z CircRNA protein replacement: first preclinical candidate reverses liver fibrosis https://biobriefs.com/unedited-cd7-car-t-exploits BioBriefs en 2026-01-19T16:33:24Z Unedited CD7 CAR‑T exploits fratricide to target T‑cell leukemia https://biobriefs.com/novel-nopv2-shows-higher-genetic BioBriefs en 2026-01-19T16:33:24Z Novel nOPV2 shows higher genetic stability amid neurovirulent poliovirus strains https://biobriefs.com/ai-in-biology-generative-agents BioBriefs en 2026-01-19T16:33:24Z AI in biology: generative agents and probes speed discovery — from targets to live‑cell imaging https://biobriefs.com/living-bacterial-glue-targets-bleeding BioBriefs en 2026-01-19T14:32:32Z Living bacterial glue targets bleeding... a new IBD therapy https://biobriefs.com/fda-under-strain-approvals-leadership BioBriefs en 2026-01-19T14:32:32Z FDA under strain: approvals, leadership and legal questions https://biobriefs.com/ai-built-phages-raise-biosecurity BioBriefs en 2026-01-19T14:32:32Z AI-built phages raise biosecurity alarms https://biobriefs.com/trna-trick-disease-agnostic-aav BioBriefs en 2026-01-19T14:32:32Z tRNA trick: disease-agnostic AAV delivery https://biobriefs.com/sarepta-sales-miss-rekindles-gene BioBriefs en 2026-01-19T14:32:32Z Sarepta sales miss rekindles gene‑therapy safety debate https://biobriefs.com/unedited-cd7-car-t-shows BioBriefs en 2026-01-19T14:32:32Z Unedited CD7 CAR‑T shows promise in T‑cell leukemia https://biobriefs.com/two-step-genome-editing-creates BioBriefs en 2026-01-19T14:32:32Z Two‑step genome editing creates full‑length humanized mice https://biobriefs.com/real-time-monitoring-for-cell BioBriefs en 2026-01-19T14:32:32Z Real‑time monitoring for cell & gene manufacturing and in vivo pH imaging https://biobriefs.com/targeting-cgas-sting-a-double BioBriefs en 2026-01-19T14:32:32Z Targeting cGAS–STING: a double‑edged oncology target https://biobriefs.com/ai-agents-and-probes-accelerate BioBriefs en 2026-01-19T14:32:32Z AI agents and probes accelerate cancer research workflows https://biobriefs.com/sarepta-misses-elevidys-targets-stock BioBriefs en 2026-01-19T10:33:10Z Sarepta misses Elevidys targets — stock tumbles https://biobriefs.com/nih-fy2026-showdown-preserve-48 BioBriefs en 2026-01-19T10:33:10Z NIH FY2026 showdown: preserve $48.7B https://biobriefs.com/legal-doubts-swirl-over-fdas BioBriefs en 2026-01-19T10:33:10Z Legal doubts swirl over FDA’s new expedited program https://biobriefs.com/unedited-cd7-car-t-shows BioBriefs en 2026-01-19T10:33:10Z Unedited CD7 CAR‑T shows promise in T‑cell leukemia https://biobriefs.com/tgfb-driven-shape-shift-lets BioBriefs en 2026-01-19T10:33:10Z TGFβ-driven shape shift lets dormant cancer hide — MSK https://biobriefs.com/whole-transcriptome-diagnostics-scaled-to BioBriefs en 2026-01-19T10:33:10Z Whole-transcriptome diagnostics scaled to 1,233 FFPE tumors https://biobriefs.com/real-time-metabolic-monitoring-tightens BioBriefs en 2026-01-19T10:33:10Z Real-time metabolic monitoring tightens CGT manufacturing control https://biobriefs.com/ai-redesigns-antibodies-into-live BioBriefs en 2026-01-19T10:33:10Z AI redesigns antibodies into live-cell reporters — Colorado State https://biobriefs.com/enterococcus-redox-metabolism-blocks-wound BioBriefs en 2026-01-19T10:33:10Z Enterococcus redox metabolism blocks wound healing — target found https://biobriefs.com/targeting-innate-immunity-cgas-sting BioBriefs en 2026-01-19T10:33:10Z Targeting innate immunity: cGAS–STING mapped — MERTK inhibitor disrupts efferocytosis https://biobriefs.com/sareptas-elevidys-shortfall-ceo-defends BioBriefs en 2026-01-19T09:32:42Z Sarepta’s Elevidys shortfall — CEO defends sales as stock slips https://biobriefs.com/fda-backs-hemostemix-basket-approach BioBriefs en 2026-01-19T09:32:42Z FDA backs Hemostemix basket approach — regulator signals support https://biobriefs.com/fda-expedited-approvals-under-fire BioBriefs en 2026-01-19T09:32:42Z FDA expedited approvals under fire: who will sign off? https://biobriefs.com/nih-fy2026-at-stake-advocates BioBriefs en 2026-01-19T09:32:42Z NIH FY2026 at stake: advocates urge House to preserve $48.7B https://biobriefs.com/real-time-metabolic-monitoring-deeper BioBriefs en 2026-01-19T09:32:42Z Real-time metabolic monitoring: deeper control for cell and gene therapy https://biobriefs.com/ai-agents-move-into-oncology BioBriefs en 2026-01-19T09:32:42Z AI agents move into oncology labs — from classification to decision-making https://biobriefs.com/dormant-metastases-go-soft-msk BioBriefs en 2026-01-19T09:32:42Z Dormant metastases go soft — MSK shows shape‑shift shields cells from immunity https://biobriefs.com/e-faecalis-redox-metabolism-impairs BioBriefs en 2026-01-19T09:32:42Z E. faecalis redox metabolism impairs healing — study points to new therapies https://biobriefs.com/unedited-cd7-car-ts-beat BioBriefs en 2026-01-19T09:32:42Z Unedited CD7 CAR‑Ts beat T‑cell leukemia in preclinical tests — fratricide exploited https://biobriefs.com/whole-transcriptome-diagnostics-validated-1233 BioBriefs en 2026-01-19T09:32:42Z Whole-transcriptome diagnostics validated: 1,233 FFPE tumor cohort reported https://biobriefs.com/sarepta-sales-miss-opens-fresh BioBriefs en 2026-01-19T04:32:29Z Sarepta sales miss opens fresh gene‑therapy safety questions – stock tumbles https://biobriefs.com/tgfb-drives-shape-switch-in BioBriefs en 2026-01-19T04:32:29Z TGFβ drives shape switch in dormant lung metastases… immune evasion mechanism revealed https://biobriefs.com/enterococcus-faecalis-redox-metabolism-implicated BioBriefs en 2026-01-19T04:32:29Z Enterococcus faecalis redox metabolism implicated in chronic wound failure – new therapeutic target https://biobriefs.com/fratricide-driven-unedited-cd7-car BioBriefs en 2026-01-19T04:32:29Z Fratricide‑driven, unedited CD7 CAR‑T shows efficacy in T‑cell leukemia models https://biobriefs.com/two-step-genome-editing-creates BioBriefs en 2026-01-19T04:32:29Z Two‑step genome editing creates full‑length humanized mouse models – new tool for in vivo human gene studies https://biobriefs.com/real-time-metabolic-monitoring-enters BioBriefs en 2026-01-19T04:32:29Z Real‑time metabolic monitoring enters cell and gene therapy manufacturing workflows https://biobriefs.com/fda-signals-support-for-hemostemix BioBriefs en 2026-01-19T04:32:29Z FDA signals support for Hemostemix basket protocol approach https://biobriefs.com/legal-questions-surface-over-fdas BioBriefs en 2026-01-19T04:32:29Z Legal questions surface over FDA’s new expedited drug pathway – sign‑off and oversight in focus https://biobriefs.com/advocates-push-congress-to-preserve BioBriefs en 2026-01-19T04:32:29Z Advocates push Congress to preserve NIH FY2026 funding at $48.7B – urgent call to action https://biobriefs.com/ai-trained-antibody-probes-let BioBriefs en 2026-01-19T04:32:29Z AI‑trained antibody probes let scientists see protein activity inside living cells https://biobriefs.com/fda-backs-hemostemix-regulator-signals BioBriefs en 2026-01-18T21:33:07Z FDA backs Hemostemix: regulator signals support for basket protocol https://biobriefs.com/sareptas-elevidys-sales-fall-short BioBriefs en 2026-01-18T21:33:07Z Sarepta’s Elevidys sales fall short – shares slide amid gene therapy safety cloud https://biobriefs.com/tgfb-induced-shape-shift-dormant BioBriefs en 2026-01-18T21:33:07Z TGFβ-induced shape shift: dormant lung cancer cells evade immune attack https://biobriefs.com/enterococcus-faecalis-weaponizes-redox-metabolism BioBriefs en 2026-01-18T21:33:07Z Enterococcus faecalis weaponizes redox metabolism: EET activation stalls wound healing https://biobriefs.com/fratricide-driven-cd7-car-t BioBriefs en 2026-01-18T21:33:07Z Fratricide-driven CD7 CAR‑T: unedited cells demonstrate efficacy in T‑cell leukemia https://biobriefs.com/real-time-metabolic-monitoring-firms BioBriefs en 2026-01-18T21:33:07Z Real-time metabolic monitoring: firms deploy sensors to stabilize cell and gene therapy manufacture https://biobriefs.com/two-step-genome-editing-enables BioBriefs en 2026-01-18T21:33:07Z Two-step genome editing enables full-length humanized mouse models https://biobriefs.com/ai-tuned-antibodies-act-as BioBriefs en 2026-01-18T21:33:07Z AI-tuned antibodies act as intracellular lights: researchers accelerate in-cell probes https://biobriefs.com/tetraspanin-immunocapture-high-depth-proteomics BioBriefs en 2026-01-18T21:33:07Z Tetraspanin immunocapture: high‑depth proteomics of CSF extracellular vesicles https://biobriefs.com/spyglass-agomab-file-for-ipos BioBriefs en 2026-01-18T21:33:07Z SpyGlass, Agomab file for IPOs; Novo Nordisk Foundation pledges $850M to scale startups https://biobriefs.com/nih-fy2026-urgent-push-to BioBriefs en 2026-01-18T21:33:07Z NIH FY2026: urgent push to preserve Senate-approved $48.7B and grant terms https://biobriefs.com/epkinly-fails-overall-survival-end BioBriefs en 2026-01-18T16:33:11Z Epkinly fails overall survival end point: AbbVie and Genmab report https://biobriefs.com/sareptas-elevidys-sales-miss-ceo BioBriefs en 2026-01-18T16:33:11Z Sarepta’s Elevidys sales miss – CEO defends program amid safety questions https://biobriefs.com/immunitybio-car-nk-drives-complete BioBriefs en 2026-01-18T16:33:11Z ImmunityBio CAR‑NK drives complete responses in Waldenström’s – no lymphodepletion https://biobriefs.com/novo-nordisk-foundation-pledges-up BioBriefs en 2026-01-18T16:33:11Z Novo Nordisk Foundation pledges up to $850M to scale European startups https://biobriefs.com/spyglass-agomab-file-ipos-after BioBriefs en 2026-01-18T16:33:11Z SpyGlass, Agomab file IPOs after JPM momentum https://biobriefs.com/extracellular-tac-degraders-go-bispecific BioBriefs en 2026-01-18T16:33:11Z Extracellular TAC degraders go bispecific – new lysosomal and membrane E3 strategies https://biobriefs.com/fda-clears-topical-pan-jak BioBriefs en 2026-01-18T16:33:11Z FDA clears topical pan‑JAK Anzupgo for chronic hand eczema https://biobriefs.com/enterococcus-faecalis-uses-extracellular-electron BioBriefs en 2026-01-18T16:33:11Z Enterococcus faecalis uses extracellular electron transport to stall wound repair https://biobriefs.com/dormant-metastases-soften-to-evade BioBriefs en 2026-01-18T16:33:11Z Dormant metastases soften to evade immune mechanosurveillance – MSK uncovers TGFβ‑linked EMT shift https://biobriefs.com/fratricide-driven-unedited-cd7-car BioBriefs en 2026-01-18T16:33:11Z Fratricide‑driven unedited CD7 CAR‑T shows activity in T‑cell leukemia https://biobriefs.com/immunitybio-car-nk-delivers-durable BioBriefs en 2026-01-18T14:32:50Z ImmunityBio CAR‑NK Delivers Durable Complete Responses – Waldenström’s Trial https://biobriefs.com/epkinly-fails-to-extend-survival BioBriefs en 2026-01-18T14:32:50Z Epkinly Fails to Extend Survival – AbbVie, Genmab https://biobriefs.com/uc-san-diego-wins-arpa BioBriefs en 2026-01-18T14:32:50Z UC San Diego Wins ARPA‑H Grant: $25.8M to 3D‑Print Patient Livers https://biobriefs.com/fda-clears-topical-jak-inhibitor BioBriefs en 2026-01-18T14:32:50Z FDA Clears Topical JAK Inhibitor for Hand Eczema – Anzupgo Approval https://biobriefs.com/foli-bio-tests-stool-rna BioBriefs en 2026-01-18T14:32:50Z Foli Bio Tests Stool RNA to Monitor IBD, Predict Drug Response https://biobriefs.com/destina-genomica-wins-eur2-2m BioBriefs en 2026-01-18T14:32:50Z Destina Genomica Wins €2.2M to Advance Drug‑Induced Liver Injury Assay https://biobriefs.com/legal-scrutiny-grows-over-fdas BioBriefs en 2026-01-18T14:32:50Z Legal Scrutiny Grows Over FDA’s New Expedited Drug Program: Who Signs Off? https://biobriefs.com/novo-nordisk-foundation-pledges-up BioBriefs en 2026-01-18T14:32:50Z Novo Nordisk Foundation Pledges Up to $850M to Scale European Biotech https://biobriefs.com/conference-week-drives-fresh-capital BioBriefs en 2026-01-18T14:32:50Z Conference Week Drives Fresh Capital Into Biotech — Finance Report https://biobriefs.com/ai-designed-antibodies-act-as BioBriefs en 2026-01-18T14:32:50Z AI‑Designed Antibodies Act as Live‑Cell Probes — Colorado State Team https://biobriefs.com/immunitybios-off-the-shelf-car BioBriefs en 2026-01-18T10:32:35Z ImmunityBio’s off‑the‑shelf CAR‑NK posts durable complete responses – Waldenström’s data https://biobriefs.com/arpa-h-backs-uc-san BioBriefs en 2026-01-18T10:32:35Z ARPA‑H backs UC San Diego’s bid to 3D‑print patient livers – $25.8M award https://biobriefs.com/abbvie-genmabs-epkinly-fails-to BioBriefs en 2026-01-18T10:32:35Z AbbVie, Genmab’s Epkinly fails to extend overall survival in DLBCL – Phase 3 miss https://biobriefs.com/vedanta-cuts-headcount-pivots-resources BioBriefs en 2026-01-18T10:32:35Z Vedanta cuts headcount, pivots resources to VE303 phase 3 – layoffs to focus on C. difficile program https://biobriefs.com/ntu-geneva-identify-e-faecalis BioBriefs en 2026-01-18T10:32:35Z NTU, Geneva identify E. faecalis redox mechanism that blocks wound healing – new therapeutic target https://biobriefs.com/foli-bio-developing-stool-rna BioBriefs en 2026-01-18T10:32:35Z Foli Bio developing stool RNA‑seq panels to predict IBD response — noninvasive monitoring aim https://biobriefs.com/gt-biopharma-files-ind-for BioBriefs en 2026-01-18T10:32:35Z GT Biopharma files IND for GTB‑5550 TriKE – NK engager targets B7‑H3 in solid tumors https://biobriefs.com/bispecific-antibody-oligo-conjugate-offers BioBriefs en 2026-01-18T10:32:35Z Bispecific antibody‑oligo conjugate offers neuron‑specific delivery…proof in vivo https://biobriefs.com/fda-signals-and-process-shifts BioBriefs en 2026-01-18T10:32:35Z FDA signals and process shifts: Phase‑1 rule tweaks and delayed voucher reviews https://biobriefs.com/big-money-heads-to-biotech BioBriefs en 2026-01-18T10:32:35Z Big money heads to biotech: Novo Nordisk Foundation $850M pledge and JPM funding surge https://biobriefs.com/epkinly-misses-overall-survival-in BioBriefs en 2026-01-18T09:32:33Z Epkinly misses overall survival in DLBCL — AbbVie, Genmab disclose https://biobriefs.com/uc-san-diego-wins-25 BioBriefs en 2026-01-18T09:32:33Z UC San Diego wins $25.8M ARPA‑H award to 3D‑print patient livers https://biobriefs.com/off-the-shelf-car-nk BioBriefs en 2026-01-18T09:32:33Z Off‑the‑shelf CAR‑NK yields durable CRs in Waldenström’s — ImmunityBio https://biobriefs.com/enterococcus-faecalis-uses-redox-metabolism BioBriefs en 2026-01-18T09:32:33Z Enterococcus faecalis uses redox metabolism to stall wound healing — NTU‑led study https://biobriefs.com/two-step-genome-editing-creates BioBriefs en 2026-01-18T09:32:33Z Two‑step genome editing creates full‑length humanized mice — new model https://biobriefs.com/cells-rewired-as-rna-recorders BioBriefs en 2026-01-18T09:32:33Z Cells rewired as RNA recorders: new intracellular recording devices https://biobriefs.com/retrons-drive-synthetic-dna-systems BioBriefs en 2026-01-18T09:32:33Z Retrons drive synthetic DNA systems for protein targeting in cells https://biobriefs.com/foli-bio-builds-stool-rna BioBriefs en 2026-01-18T09:32:33Z Foli Bio builds stool RNA panels to predict IBD drug response — Columbia spinout https://biobriefs.com/vedanta-cuts-staff-refocuses-cash BioBriefs en 2026-01-18T09:32:33Z Vedanta cuts staff, refocuses cash on VE303 phase‑3 push https://biobriefs.com/novo-nordisk-foundation-pledges-up BioBriefs en 2026-01-18T09:32:33Z Novo Nordisk Foundation pledges up to $850M to scale European biotech incubator https://biobriefs.com/immunitybio-car-nk-durable-complete BioBriefs en 2026-01-18T04:32:46Z ImmunityBio CAR‑NK: durable complete responses in Waldenström’s lymphoma https://biobriefs.com/epkinly-misses-overall-survival-abbvie BioBriefs en 2026-01-18T04:32:46Z Epkinly misses overall survival: AbbVie, Genmab disclose Phase 3 failure in DLBCL https://biobriefs.com/uc-san-diego-wins-arpa BioBriefs en 2026-01-18T04:32:46Z UC San Diego wins ARPA‑H grant: $25.8M drive to 3D‑print patient livers https://biobriefs.com/vedanta-trims-workforce-narrows-focus BioBriefs en 2026-01-18T04:32:46Z Vedanta trims workforce, narrows focus to VE303: phase‑3 push for C. difficile https://biobriefs.com/labcorp-expands-mrd-portfolio-plasma BioBriefs en 2026-01-18T04:32:46Z Labcorp expands MRD portfolio: Plasma Detect ID and Genome go nationwide https://biobriefs.com/delfi-eyes-fda-firstlook-lung BioBriefs en 2026-01-18T04:32:46Z Delfi eyes FDA: FirstLook Lung pivotal readouts and reimbursement push in 2026 https://biobriefs.com/novo-nordisk-foundation-commits-up BioBriefs en 2026-01-18T04:32:46Z Novo Nordisk Foundation commits up to $850M: BioInnovation Institute to scale across Europe https://biobriefs.com/dna-fragments-dodge-screening-researchers BioBriefs en 2026-01-18T04:32:46Z DNA fragments dodge screening: researchers show synthesis checks can be bypassed https://biobriefs.com/gt-biopharma-files-ind-for BioBriefs en 2026-01-18T04:32:46Z GT Biopharma files IND for TriKE — Medicenna advances MDNA‑113 toward IND https://biobriefs.com/u-k-launches-synthetic-human BioBriefs en 2026-01-18T04:32:46Z U.K. launches Synthetic Human Genome moonshot: £10M SynHG to build genome‑writing tools https://biobriefs.com/off-the-shelf-car-nk BioBriefs en 2026-01-17T21:32:31Z Off-the-shelf CAR‑NK: Durable complete responses in Waldenström’s https://biobriefs.com/arpa-h-funds-uc-san BioBriefs en 2026-01-17T21:32:31Z ARPA‑H funds UC San Diego to 3D‑print patient livers https://biobriefs.com/epkinly-misses-endpoint-no-overall BioBriefs en 2026-01-17T21:32:31Z Epkinly misses endpoint: No overall survival benefit in DLBCL study https://biobriefs.com/vedanta-refocuses-on-ve303-deep BioBriefs en 2026-01-17T21:32:31Z Vedanta refocuses on VE303 — deep cuts to preserve Phase 3 runway https://biobriefs.com/labcorp-expands-mrd-and-ngs BioBriefs en 2026-01-17T21:32:31Z Labcorp expands MRD and NGS offerings; Watchmaker, Saga add tools https://biobriefs.com/novo-nordisk-foundation-pledges-up BioBriefs en 2026-01-17T21:32:31Z Novo Nordisk Foundation pledges up to $850M to scale European biotech https://biobriefs.com/spyglass-agomab-file-ipos-after BioBriefs en 2026-01-17T21:32:31Z SpyGlass, Agomab file IPOs after JPM — investor momentum continues https://biobriefs.com/eu-grant-backs-destinas-liverace BioBriefs en 2026-01-17T21:32:31Z EU grant backs Destina’s LiverAce assay for drug‑induced liver injury https://biobriefs.com/jpm-week-funding-surge-cash BioBriefs en 2026-01-17T21:32:31Z JPM week funding surge: cash inflows and headline stock moves https://biobriefs.com/gene-drive-moves-into-field BioBriefs en 2026-01-17T21:32:31Z Gene‑drive moves into field‑relevant testing in Africa https://biobriefs.com/immunitybio-car-nk-posts-durable BioBriefs en 2026-01-17T16:33:29Z ImmunityBio CAR‑NK posts durable complete responses – outpatient regimen https://biobriefs.com/tecvayli-shows-survival-benefit-johnson BioBriefs en 2026-01-17T16:33:29Z Tecvayli shows survival benefit — Johnson & Johnson presses advantage https://biobriefs.com/epkinly-fails-to-extend-overall BioBriefs en 2026-01-17T16:33:29Z Epkinly fails to extend overall survival in late‑stage lymphoma https://biobriefs.com/uc-san-diego-wins-arpa BioBriefs en 2026-01-17T16:33:29Z UC San Diego wins ARPA‑H grant to 3D‑print patient livers — $25.8M award https://biobriefs.com/vedanta-cuts-workforce-to-focus BioBriefs en 2026-01-17T16:33:29Z Vedanta cuts workforce to focus on VE303 Phase 3 push https://biobriefs.com/conference-week-fuels-capital-flows BioBriefs en 2026-01-17T16:33:29Z Conference week fuels capital flows — financings and Q4 pickup https://biobriefs.com/gene-drive-mosquitoes-validated-against BioBriefs en 2026-01-17T16:33:29Z Gene‑drive mosquitoes validated against diverse parasites in Tanzania tests https://biobriefs.com/u-s-leans-into-mfn BioBriefs en 2026-01-17T16:33:29Z U.S. leans into MFN drug pricing; White House seeks codification https://biobriefs.com/boston-scientific-expands-pelvic-health BioBriefs en 2026-01-17T16:33:29Z Boston Scientific expands pelvic health with Valencia buy; deal values hit records https://biobriefs.com/new-molecular-insights-in-parkinsons BioBriefs en 2026-01-17T16:33:29Z New molecular insights in Parkinson’s: cuproptosis genes and microglial FcγR https://biobriefs.com/immunitybio-car-nk-posts-durable BioBriefs en 2026-01-17T14:32:56Z ImmunityBio CAR‑NK posts durable complete responses in Waldenström’s https://biobriefs.com/boston-scientific-to-buy-penumbra BioBriefs en 2026-01-17T14:32:56Z Boston Scientific to buy Penumbra for $14.5B – vascular push https://biobriefs.com/arpa-h-backs-uc-san BioBriefs en 2026-01-17T14:32:56Z ARPA‑H backs UC San Diego to 3D‑print patient‑specific human livers https://biobriefs.com/tecvayli-cuts-death-or-progression BioBriefs en 2026-01-17T14:32:56Z Tecvayli cuts death or progression risk sharply in early multiple myeloma https://biobriefs.com/glp-1-class-splits-outcomes BioBriefs en 2026-01-17T14:32:56Z GLP‑1 class splits outcomes — Alzheimer’s trial fails; tirzepatide resolves MASH https://biobriefs.com/mrd-market-crystallizes-veracyte-launches BioBriefs en 2026-01-17T14:32:56Z MRD market crystallizes: Veracyte launches TrueMRD; BloodPAC issues validation protocols https://biobriefs.com/novo-nordisk-foundation-pledges-up BioBriefs en 2026-01-17T14:32:56Z Novo Nordisk Foundation pledges up to $850M to scale European biotech https://biobriefs.com/conference-cash-flow-jpm-lifts BioBriefs en 2026-01-17T14:32:56Z Conference cash flow: JPM lifts biotech financings and deal activity https://biobriefs.com/vedanta-cuts-staff-to-prioritize BioBriefs en 2026-01-17T14:32:56Z Vedanta cuts staff to prioritize phase‑3 VE303 for C. difficile https://biobriefs.com/hhs-greenlights-controversial-newborn-hepatitis BioBriefs en 2026-01-17T14:32:56Z HHS greenlights controversial newborn hepatitis B trial in Africa — ethics debate continues https://biobriefs.com/immunitybios-off-the-shelf-car BioBriefs en 2026-01-17T10:32:54Z ImmunityBio’s off‑the‑shelf CAR‑NK: durable complete responses in Waldenström’s https://biobriefs.com/tecvayli-tops-standard-regimens-j BioBriefs en 2026-01-17T10:32:54Z Tecvayli tops standard regimens – J&J cites survival gains in earlier multiple myeloma https://biobriefs.com/uc-san-diego-wins-arpa BioBriefs en 2026-01-17T10:32:54Z UC San Diego wins ARPA‑H grant: $25.8M to 3D‑print patient‑specific livers https://biobriefs.com/mrd-moves-bloodpac-issues-validation BioBriefs en 2026-01-17T10:32:54Z MRD moves: BloodPAC issues validation protocols as Veracyte primes TrueMRD launch https://biobriefs.com/novo-nordisk-foundation-pledges-up BioBriefs en 2026-01-17T10:32:54Z Novo Nordisk Foundation pledges up to $850M to seed European life‑science startups https://biobriefs.com/white-house-pushes-great-healthcare BioBriefs en 2026-01-17T10:32:54Z White House pushes ‘Great Healthcare Plan’ — drug‑pricing fight shifts to Congress https://biobriefs.com/vedanta-trims-workforce-to-concentrate BioBriefs en 2026-01-17T10:32:54Z Vedanta trims workforce to concentrate resources on VE303 phase‑3 for C. difficile https://biobriefs.com/fda-grants-rmat-to-iregenes BioBriefs en 2026-01-17T10:32:54Z FDA grants RMAT to iRegene’s NouvNeu001 — regulatory double‑play for iPSC Parkinson’s therapy https://biobriefs.com/cellares-inks-long-term-lease BioBriefs en 2026-01-17T10:32:54Z Cellares inks long‑term lease in Leiden to expand automated cell‑therapy manufacturing network https://biobriefs.com/agenus-seals-141m-collaboration-with BioBriefs en 2026-01-17T10:32:54Z Agenus seals $141M collaboration with Zydus to accelerate BOT+BAL immunotherapy and US manufacturing https://biobriefs.com/immunitybio-car-nk-posts-durable BioBriefs en 2026-01-17T09:33:16Z ImmunityBio CAR‑NK posts durable complete responses https://biobriefs.com/arpa-h-backs-3d-printed BioBriefs en 2026-01-17T09:33:16Z ARPA‑H backs 3D‑printed livers: UC San Diego lands major grant https://biobriefs.com/boston-scientific-goes-all-in BioBriefs en 2026-01-17T09:33:16Z Boston Scientific goes all‑in: $14.5B bid for Penumbra https://biobriefs.com/tecvayli-shows-survival-gains-in BioBriefs en 2026-01-17T09:33:16Z Tecvayli shows survival gains in earlier multiple myeloma – J&J https://biobriefs.com/mrd-testing-bloodpac-issues-standards BioBriefs en 2026-01-17T09:33:16Z MRD testing: BloodPAC issues standards as labs roll out assays https://biobriefs.com/novo-nordisk-foundation-commits-big BioBriefs en 2026-01-17T09:33:16Z Novo Nordisk Foundation commits big to scale Danish biotech innovation https://biobriefs.com/big-tech-and-lab-automation BioBriefs en 2026-01-17T09:33:16Z Big tech and lab automation collide: NVIDIA deals with Thermo Fisher and Lilly https://biobriefs.com/cellares-expands-idmo-footprint-with BioBriefs en 2026-01-17T09:33:16Z Cellares expands IDMO footprint with Leiden Smart Factory lease https://biobriefs.com/gene-drive-mosquitoes-validated-against BioBriefs en 2026-01-17T09:33:16Z Gene‑drive mosquitoes validated against diverse malaria strains in Tanzania https://biobriefs.com/fda-grants-rmat-to-iregenes BioBriefs en 2026-01-17T09:33:16Z FDA grants RMAT to iRegene’s iPSC‑derived Parkinson’s therapy https://biobriefs.com/off-the-shelf-car-nk BioBriefs en 2026-01-17T04:32:55Z Off‑the‑shelf CAR‑NK: Durable complete responses in Waldenström https://biobriefs.com/arpa-h-backs-ucsd-25 BioBriefs en 2026-01-17T04:32:55Z ARPA‑H backs UCSD: $25.8M push to 3D‑print patient‑specific livers https://biobriefs.com/novo-nordisk-foundation-pours-dkk5 BioBriefs en 2026-01-17T04:32:55Z Novo Nordisk Foundation Pours DKK5.5B ($850M) into BioInnovation Institute https://biobriefs.com/tecvayli-survival-win-j-j BioBriefs en 2026-01-17T04:32:55Z Tecvayli survival win: J&J reports major Phase 3 benefit in multiple myeloma https://biobriefs.com/boston-scientific-to-buy-penumbra BioBriefs en 2026-01-17T04:32:55Z Boston Scientific to buy Penumbra for $14.5B – Big play in thrombectomy https://biobriefs.com/fda-grants-rmat-to-iregenes BioBriefs en 2026-01-17T04:32:55Z FDA grants RMAT to iRegene’s iPSC therapy – Regulatory double‑play for Parkinson’s https://biobriefs.com/bloodpac-issues-mrd-validation-protocols BioBriefs en 2026-01-17T04:32:55Z BloodPAC issues MRD validation protocols – Toward analytic standards for ctDNA https://biobriefs.com/myriad-maps-mrd-rollout-sequenced BioBriefs en 2026-01-17T04:32:55Z Myriad maps MRD rollout: Sequenced launches and reimbursement playbook https://biobriefs.com/cellares-inks-leiden-smart-factory BioBriefs en 2026-01-17T04:32:55Z Cellares inks Leiden smart‑factory lease – Regional IDMO capacity for cell therapies https://biobriefs.com/vedanta-trims-workforce-to-fund BioBriefs en 2026-01-17T04:32:55Z Vedanta trims workforce to fund VE303 Phase 3 push – Cash‑constrained refocus https://biobriefs.com/epkinly-misses-overall-survival-abbvie BioBriefs en 2026-01-16T21:33:17Z Epkinly misses overall survival: AbbVie, Genmab report Phase 3 setback https://biobriefs.com/off-the-shelf-car-nk BioBriefs en 2026-01-16T21:33:17Z Off‑the‑shelf CAR‑NK posts complete responses up to 15 months — ImmunityBio https://biobriefs.com/tecvayli-tops-standard-regimens-j BioBriefs en 2026-01-16T21:33:17Z Tecvayli tops standard regimens — J&J reports survival and progression wins https://biobriefs.com/arpa-h-backs-patient-specific BioBriefs en 2026-01-16T21:33:17Z ARPA‑H backs patient‑specific 3D livers: UC San Diego wins $25.8M https://biobriefs.com/fda-grants-rmat-to-iregenes BioBriefs en 2026-01-16T21:33:17Z FDA grants RMAT to iRegene’s iPSC therapy: NouvNeu001 earns accelerated pathway https://biobriefs.com/boston-scientific-to-buy-penumbra BioBriefs en 2026-01-16T21:33:17Z Boston Scientific to buy Penumbra for $14.5B — bet on thrombectomy and embolization https://biobriefs.com/vedanta-cuts-headcount-to-focus BioBriefs en 2026-01-16T21:33:17Z Vedanta cuts headcount to focus resources on VE303 phase 3 program https://biobriefs.com/bloodpac-issues-mrd-validation-protocols BioBriefs en 2026-01-16T21:33:17Z BloodPAC issues MRD validation protocols — consortium sets analytic standards https://biobriefs.com/labcorp-saga-expand-mrd-and BioBriefs en 2026-01-16T21:33:17Z Labcorp, Saga expand MRD and genomic assays — Watchmaker launches RPA enzymes https://biobriefs.com/veracyte-to-commercialize-truemrd-for BioBriefs en 2026-01-16T21:33:17Z Veracyte to commercialize TrueMRD for bladder cancer — sequencing‑based MRD push https://biobriefs.com/arpa-h-backs-uc-san BioBriefs en 2026-01-16T16:33:18Z ARPA‑H backs UC San Diego to 3D‑print patient livers: $25.8M award https://biobriefs.com/wegovy-pill-jumps-off-the BioBriefs en 2026-01-16T16:33:18Z Wegovy pill jumps off the line... Lilly races for oral approval https://biobriefs.com/boston-scientific-bets-14-5b BioBriefs en 2026-01-16T16:33:18Z Boston Scientific bets $14.5B on thrombectomy with Penumbra deal https://biobriefs.com/j-js-tecvayli-posts-phase BioBriefs en 2026-01-16T16:33:18Z J&J’s Tecvayli posts Phase‑3 wins – pushes earlier use case https://biobriefs.com/gene-drive-mosquitos-tested-against BioBriefs en 2026-01-16T16:33:18Z Gene‑drive mosquitos tested against real‑world malaria diversity in Tanzania https://biobriefs.com/crispr-cas3-advances-as-a BioBriefs en 2026-01-16T16:33:18Z CRISPR–Cas3 advances as a therapeutic genome‑editing tool https://biobriefs.com/panman-shrinks-pangenomes-storage-bottleneck BioBriefs en 2026-01-16T16:33:18Z PanMAN shrinks pangenomes... storage bottleneck eased https://biobriefs.com/ai-powered-classic-maps-genetic BioBriefs en 2026-01-16T16:33:18Z AI‑powered CLASSIC maps genetic design space... millions of circuits https://biobriefs.com/immunitybio-touts-durable-responses-in BioBriefs en 2026-01-16T16:33:18Z ImmunityBio touts durable responses in off‑the‑shelf CAR‑NK trials https://biobriefs.com/bloodpac-issues-mrd-validation-protocols BioBriefs en 2026-01-16T16:33:18Z BloodPAC issues MRD validation protocols – Veracyte targets TrueMRD launch https://biobriefs.com/boston-scientific-swings-for-the BioBriefs en 2026-01-16T14:33:41Z Boston Scientific swings for the fences — $14.5B Penumbra buy https://biobriefs.com/tecvayli-extends-survival-j-js BioBriefs en 2026-01-16T14:33:40Z Tecvayli extends survival — J&J’s Phase 3 shows earlier use benefit https://biobriefs.com/lilly-targets-quick-review-oral BioBriefs en 2026-01-16T14:33:40Z Lilly targets quick review — oral GLP-1 on track as FDA eases labels https://biobriefs.com/liquid-biopsy-standards-and-readouts BioBriefs en 2026-01-16T14:33:40Z Liquid biopsy standards and readouts — Delfi previews pivotal lung data https://biobriefs.com/cell-therapy-scale-up-cellares BioBriefs en 2026-01-16T14:33:40Z Cell-therapy scale-up — Cellares takes Leiden lease as Agenus secures U.S. capacity https://biobriefs.com/lab-ai-and-automation-instruments BioBriefs en 2026-01-16T14:33:40Z Lab AI and automation: instruments meet validated workflows https://biobriefs.com/jpm-stress-test-investor-optimism BioBriefs en 2026-01-16T14:33:40Z JPM stress test — investor optimism meets uneven financing recovery https://biobriefs.com/chemical-reprogramming-human-t-cells BioBriefs en 2026-01-16T14:33:40Z Chemical reprogramming: human T cells turned to pluripotency https://biobriefs.com/spatial-biology-accelerates-ariadne-ai BioBriefs en 2026-01-16T14:33:40Z Spatial biology accelerates — Ariadne.ai builds TumorTwin as multiomics reveals immune maps https://biobriefs.com/ai-designs-working-gene-circuits BioBriefs en 2026-01-16T14:33:40Z AI designs working gene circuits — CLASSIC maps genetic design space https://biobriefs.com/tecvayli-survival-win-j-j BioBriefs en 2026-01-16T10:33:27Z Tecvayli survival win – J&J pushes antibody earlier in myeloma https://biobriefs.com/boston-scientific-to-buy-penumbra BioBriefs en 2026-01-16T10:33:27Z Boston Scientific to buy Penumbra for $14.5B – Medtech consolidation returns https://biobriefs.com/thermo-fisher-taps-nvidia-ai BioBriefs en 2026-01-16T10:33:27Z Thermo Fisher taps NVIDIA: AI to power smarter labs and instruments https://biobriefs.com/novo-nordisk-foundation-backs-bii BioBriefs en 2026-01-16T10:33:27Z Novo Nordisk Foundation backs BII with up to $857M – scaling Europe’s spinouts https://biobriefs.com/cellares-secures-leiden-site-expands BioBriefs en 2026-01-16T10:33:27Z Cellares secures Leiden site — expands automated cell therapy manufacturing in Europe https://biobriefs.com/ariadne-ai-to-build-tumortwin BioBriefs en 2026-01-16T10:33:27Z Ariadne.ai to build TumorTwin – spatial multiomics goes virtual https://biobriefs.com/panman-compresses-pangenomes-big-genomics BioBriefs en 2026-01-16T10:33:27Z PanMAN compresses pangenomes—big genomics storage meets efficiency https://biobriefs.com/classic-ai-accelerates-genetic-circuit BioBriefs en 2026-01-16T10:33:27Z CLASSIC: AI accelerates genetic circuit design in human cells https://biobriefs.com/dsherlock-digital-crispr-diagnostics-quantify BioBriefs en 2026-01-16T10:33:27Z dSHERLOCK: digital CRISPR diagnostics quantify Candida auris and resistance https://biobriefs.com/eikon-eyes-ipo-as-clinical BioBriefs en 2026-01-16T10:33:27Z Eikon eyes IPO as clinical-stage pipeline powers public push https://biobriefs.com/tecvayli-survival-gains-in-earlier BioBriefs en 2026-01-16T09:32:56Z Tecvayli survival gains in earlier myeloma – J&J releases Phase 3 readouts https://biobriefs.com/boston-scientific-moves-to-buy BioBriefs en 2026-01-16T09:32:56Z Boston Scientific moves to buy Penumbra for $14.5B – deal to expand thrombectomy portfolio https://biobriefs.com/novo-nordisk-foundation-pledges-up BioBriefs en 2026-01-16T09:32:56Z Novo Nordisk Foundation pledges up to €736M to scale BioInnovation Institute – decade-long funding https://biobriefs.com/lilly-and-nvidia-form-1b BioBriefs en 2026-01-16T09:32:56Z Lilly and NVIDIA form $1B AI drug-discovery lab: in silico first, wet lab feedback loop https://biobriefs.com/thermo-fisher-and-nvidia-partner BioBriefs en 2026-01-16T09:32:56Z Thermo Fisher and NVIDIA partner to embed AI across instruments and lab workflows https://biobriefs.com/natera-veracyte-push-mrd-commercialization BioBriefs en 2026-01-16T09:32:56Z Natera, Veracyte push MRD commercialization – labs add sequencing upgrades and launch plans https://biobriefs.com/bloodpac-issues-mrd-analytical-validation BioBriefs en 2026-01-16T09:32:56Z BloodPAC issues MRD analytical-validation protocols – industry standardization move https://biobriefs.com/panman-compresses-pangenomes-new-data BioBriefs en 2026-01-16T09:32:56Z PanMAN compresses pangenomes – new data structure cuts storage and speeds analyses https://biobriefs.com/cellares-signs-lease-for-leiden BioBriefs en 2026-01-16T09:32:56Z Cellares signs lease for Leiden Smart Factory – European cell‑therapy IDMO hub https://biobriefs.com/ai-designs-genetic-circuits-at BioBriefs en 2026-01-16T09:32:56Z AI designs genetic circuits at human‑cell scale – CLASSIC maps ultra‑high‑throughput design space https://biobriefs.com/tecvayli-j-j-shows-major BioBriefs en 2026-01-16T04:33:51Z Tecvayli: J&J shows major survival gain in Phase 3 https://biobriefs.com/boston-scientific-to-buy-penumbra BioBriefs en 2026-01-16T04:33:51Z Boston Scientific to buy Penumbra for $14.5B – Deal expands thrombectomy reach https://biobriefs.com/agenus-closes-141m-deal-with BioBriefs en 2026-01-16T04:33:51Z Agenus-Closes $141M deal with Zydus — U.S. biologics capacity secured https://biobriefs.com/cellares-inks-lease-in-leiden BioBriefs en 2026-01-16T04:33:51Z Cellares inks lease in Leiden – European smart factory for cell therapies https://biobriefs.com/nvidia-lilly-and-thermo-fisher BioBriefs en 2026-01-16T04:33:51Z NVIDIA, Lilly and Thermo Fisher... AI deals scale up lab automation https://biobriefs.com/truemrd-and-standards-veracyte-bloodpac BioBriefs en 2026-01-16T04:33:51Z TrueMRD and standards: Veracyte, BloodPAC push MRD toward clinic https://biobriefs.com/panman-new-compression-method-slashes BioBriefs en 2026-01-16T04:33:51Z PanMAN: New compression method slashes pangenome storage needs https://biobriefs.com/mint-nanoparticles-disease-responsive-mrna BioBriefs en 2026-01-16T04:33:51Z MINT nanoparticles: disease‑responsive mRNA targets damaged cartilage https://biobriefs.com/ocugen-posts-positive-mid-phase BioBriefs en 2026-01-16T04:33:51Z Ocugen posts positive mid‑phase gene‑therapy reads—GA program advances https://biobriefs.com/oxford-biomedica-confirms-takeover-talks BioBriefs en 2026-01-16T04:33:51Z Oxford Biomedica confirms takeover talks with EQT — CMO sector under M&A lens https://biobriefs.com/mrd-validation-framework-lands-bloodpac BioBriefs en 2026-01-15T21:32:57Z MRD validation framework lands: BloodPAC issues protocols, Veracyte plans TrueMRD launch https://biobriefs.com/tecvayli-survival-data-j-j BioBriefs en 2026-01-15T21:32:57Z Tecvayli survival data... J&J claims earlier multiple‑myeloma benefit https://biobriefs.com/big-tech-and-lab-giants BioBriefs en 2026-01-15T21:32:57Z Big tech and lab giants double down on AI: billion‑dollar labs and instrument deals https://biobriefs.com/boston-scientific-to-buy-penumbra BioBriefs en 2026-01-15T21:32:57Z Boston Scientific to buy Penumbra: $14.5B deal expands thrombectomy footprint https://biobriefs.com/oxford-biomedica-confirms-eqt-interest BioBriefs en 2026-01-15T21:32:57Z Oxford Biomedica confirms EQT interest: takeover talks acknowledged https://biobriefs.com/cellares-leases-leiden-hub-automated BioBriefs en 2026-01-15T21:32:57Z Cellares leases Leiden hub: automated cell‑therapy IDMO expands into Europe https://biobriefs.com/novo-nordisk-foundation-backs-bii BioBriefs en 2026-01-15T21:32:57Z Novo Nordisk Foundation backs BII: DKK 5.5B to scale Danish biotech incubator https://biobriefs.com/caldera-launches-with-112m-china BioBriefs en 2026-01-15T21:32:57Z Caldera launches with $112M... China‑sourced bispecific enters Phase 1 https://biobriefs.com/scribe-readies-first-crispr-therapy BioBriefs en 2026-01-15T21:32:57Z Scribe readies first CRISPR therapy: clinic start targeted for summer https://biobriefs.com/illumina-unveils-billion-cell-atlas BioBriefs en 2026-01-15T21:32:57Z Illumina unveils Billion Cell Atlas... massive dataset to train drug‑discovery AI https://biobriefs.com/boston-scientific-to-buy-penumbra BioBriefs en 2026-01-15T16:32:47Z Boston Scientific to buy Penumbra — $14.5B deal and device nod https://biobriefs.com/nvidia-deepens-lab-bets-1b BioBriefs en 2026-01-15T16:32:47Z NVIDIA deepens lab bets: $1B with Lilly, Thermo Fisher tie-up https://biobriefs.com/bloodpac-issues-mrd-validation-protocols BioBriefs en 2026-01-15T16:32:47Z BloodPAC issues MRD validation protocols — companies ready to commercialize https://biobriefs.com/cellares-signs-lease-for-european BioBriefs en 2026-01-15T16:32:47Z Cellares signs lease for European Smart Factory at Leiden Bio Science Park https://biobriefs.com/j-js-tecvayli-posts-positive BioBriefs en 2026-01-15T16:32:47Z J&J’s Tecvayli posts positive Phase 3 readout in earlier myeloma https://biobriefs.com/natera-doubles-down-on-signatera BioBriefs en 2026-01-15T16:32:47Z Natera doubles down on Signatera: ASPs, tech upgrades and reimbursement bets https://biobriefs.com/oral-glp-1-race-tightens BioBriefs en 2026-01-15T16:32:47Z Oral GLP‑1 race tightens: Lilly’s orforglipron review and label updates https://biobriefs.com/illumina-launches-billion-cell-atlas BioBriefs en 2026-01-15T16:32:47Z Illumina launches Billion Cell Atlas — pharma partners to power AI drug discovery https://biobriefs.com/liquid-biopsy-financing-surges-cyclomics BioBriefs en 2026-01-15T16:32:47Z Liquid biopsy financing surges: Cyclomics raises €2.6M, Precede nets $84M https://biobriefs.com/crispr-clinic-timeline-scribe-readies BioBriefs en 2026-01-15T16:32:47Z CRISPR clinic timeline: Scribe readies first in‑human study; Cas3 shows therapeutic promise https://biobriefs.com/fda-removes-suicide-warning-from BioBriefs en 2026-01-15T14:33:26Z FDA removes suicide warning from GLP-1 labels – regulators update risk assessment https://biobriefs.com/illumina-launches-billion-cell-atlas BioBriefs en 2026-01-15T14:33:26Z Illumina launches Billion Cell Atlas... AI drug discovery gets a training set https://biobriefs.com/cellares-signs-lease-in-leiden BioBriefs en 2026-01-15T14:33:26Z Cellares signs lease in Leiden – European smart factory set for 2026 https://biobriefs.com/natera-doubles-down-on-signatera BioBriefs en 2026-01-15T14:33:26Z Natera doubles down on Signatera: MRD upgrades and commercial cadence set for 2026 https://biobriefs.com/panman-compresses-pangenomes-a-storage BioBriefs en 2026-01-15T14:33:26Z PanMAN compresses pangenomes – a storage fix for large-scale genomics https://biobriefs.com/digital-crispr-diagnostics-rapid-c BioBriefs en 2026-01-15T14:33:26Z Digital CRISPR diagnostics: Rapid C. auris detection and resistance profiling https://biobriefs.com/j-j-posts-positive-phase BioBriefs en 2026-01-15T14:33:26Z J&J posts positive Phase 3 for Tecvayli – survival gains in earlier myeloma https://biobriefs.com/myriad-maps-mrd-expansion-at BioBriefs en 2026-01-15T14:33:26Z Myriad maps MRD expansion at JPM – five cancer assays, early access plans https://biobriefs.com/thermo-fisher-and-nvidia-partner BioBriefs en 2026-01-15T14:33:26Z Thermo Fisher and NVIDIA partner to embed AI across lab instruments and workflows https://biobriefs.com/gut-microbiota-steer-tumor-immunity BioBriefs en 2026-01-15T14:33:26Z Gut microbiota steer tumor immunity – microbiome links to immunoresistance emerge https://biobriefs.com/illuminas-billion-cell-atlas-ai BioBriefs en 2026-01-15T10:32:39Z Illumina’s Billion Cell Atlas: AI drug discovery gets a cell‑scale training set https://biobriefs.com/novo-nordisk-foundation-to-bankroll BioBriefs en 2026-01-15T10:32:39Z Novo Nordisk Foundation to bankroll European biotech incubator: €5.5bn through 2035 https://biobriefs.com/fda-clears-glp-1-labels BioBriefs en 2026-01-15T10:32:39Z FDA clears GLP‑1 labels of suicide link: warnings removed after review https://biobriefs.com/abbvie-signs-mfn-deal-with BioBriefs en 2026-01-15T10:32:39Z AbbVie signs MFN deal with White House: pledges manufacturing and price concessions https://biobriefs.com/nvidia-and-lilly-launch-1b BioBriefs en 2026-01-15T10:32:39Z NVIDIA and Lilly launch $1B AI co‑innovation lab: compute meets drug discovery https://biobriefs.com/dsherlock-crispr-based-digital-assay BioBriefs en 2026-01-15T10:32:39Z dSHERLOCK: CRISPR‑based digital assay quantifies Candida auris and resistance https://biobriefs.com/myriad-maps-mrd-rollout-five BioBriefs en 2026-01-15T10:32:39Z Myriad maps MRD rollout: five tissue‑informed tests and AI prostate assay planned https://biobriefs.com/precede-biosciences-raises-84m-to BioBriefs en 2026-01-15T10:32:39Z Precede Biosciences raises $84M to scale liquid biopsy platform for pharma https://biobriefs.com/asimov-licenses-lv-edge-single BioBriefs en 2026-01-15T10:32:39Z Asimov licenses LV Edge: single‑plasmid lentiviral packaging for CDMOs https://biobriefs.com/charles-river-acquires-pathoquest-and BioBriefs en 2026-01-15T10:32:39Z Charles River acquires PathoQuest and primate supplier: bolstering QC and supply https://biobriefs.com/novo-nordisk-foundation-bankrolls-european BioBriefs en 2026-01-15T09:32:39Z Novo Nordisk Foundation bankrolls European biotech incubator: 5.5bn DKK through 2035 https://biobriefs.com/illumina-launches-billion-cell-atlas BioBriefs en 2026-01-15T09:32:39Z Illumina launches Billion Cell Atlas — pharma partners sign on for AI training https://biobriefs.com/fda-removes-suicide-warning-from BioBriefs en 2026-01-15T09:32:39Z FDA removes suicide warning from GLP‑1 obesity drugs — labeling updated https://biobriefs.com/fda-clears-zycubo-first-therapy BioBriefs en 2026-01-15T09:32:39Z FDA clears Zycubo — first therapy for Menkes disease wins approval https://biobriefs.com/mrd-market-heats-up-myriad BioBriefs en 2026-01-15T09:32:39Z MRD market heats up: Myriad lays out multi‑cancer roadmap — Natera upgrades Signatera https://biobriefs.com/precede-biosciences-raises-83-5m BioBriefs en 2026-01-15T09:32:39Z Precede Biosciences raises $83.5M to scale liquid biopsy for drug development https://biobriefs.com/proxima-ex-vantai-nets-80m BioBriefs en 2026-01-15T09:32:39Z Proxima (ex‑VantAI) nets $80M seed — AI for proximity‑modulating medicines https://biobriefs.com/caldera-launches-with-china-sourced BioBriefs en 2026-01-15T09:32:39Z Caldera launches with China‑sourced IBD bispecific and Series A funding https://biobriefs.com/crispr-clinic-countdown-scribe-readies BioBriefs en 2026-01-15T09:32:39Z CRISPR clinic countdown: Scribe readies first human trial — Cas3 shows therapeutic promise https://biobriefs.com/abbvie-strikes-mfn-pricing-deal BioBriefs en 2026-01-15T09:32:39Z AbbVie strikes MFN pricing deal with White House — pledges industrial investments https://biobriefs.com/illumina-launches-billion-cell-atlas BioBriefs en 2026-01-15T04:33:43Z Illumina launches billion‑cell atlas: AI gets a genome‑scale training set https://biobriefs.com/fda-asks-industry-to-drop BioBriefs en 2026-01-15T04:33:43Z FDA asks industry to drop suicide warnings from GLP‑1 labels — regulators revise post‑market risk language https://biobriefs.com/fda-clears-zycubo-first-approved BioBriefs en 2026-01-15T04:33:43Z FDA clears Zycubo: first approved treatment for Menkes disease https://biobriefs.com/abbvie-inks-pd-1-vegf BioBriefs en 2026-01-15T04:33:43Z AbbVie inks PD‑1/VEGF deal and signs MFN pact: global strategy widens https://biobriefs.com/nvidia-and-lilly-pledge-1b BioBriefs en 2026-01-15T04:33:43Z NVIDIA and Lilly pledge $1B AI lab: co‑innovation to speed drug discovery https://biobriefs.com/proxima-raises-80m-roivant-spinout BioBriefs en 2026-01-15T04:33:43Z Proxima raises $80M — Roivant spinout rebrands and targets proximity‑modulating drugs https://biobriefs.com/precede-raises-84m-to-scale BioBriefs en 2026-01-15T04:33:43Z Precede raises $84M to scale liquid‑biopsy partnerships with pharma https://biobriefs.com/soley-nets-200m-series-c BioBriefs en 2026-01-15T04:33:43Z Soley nets $200M Series C — advancing stress‑modulation therapeutics toward INDs https://biobriefs.com/caldera-launches-with-112m-china BioBriefs en 2026-01-15T04:33:43Z Caldera launches with $112M: China‑origin bispecific enters clinic for IBD https://biobriefs.com/verana-buys-cota-for-52m BioBriefs en 2026-01-15T04:33:43Z Verana buys COTA for $52M — real‑world data capabilities expand into oncology https://biobriefs.com/illuminas-billion-cell-atlas-ai BioBriefs en 2026-01-14T21:33:03Z Illumina’s billion-cell atlas: AI drug discovery gets a data engine https://biobriefs.com/abbvie-licenses-pd-1-vegf BioBriefs en 2026-01-14T21:33:03Z AbbVie licenses PD‑1/VEGF bispecific from RemeGen: $650M upfront, $5B in milestones https://biobriefs.com/fda-clears-zycubo-first-ever BioBriefs en 2026-01-14T21:33:03Z FDA clears Zycubo: first‑ever therapy for Menkes disease https://biobriefs.com/proxima-raises-80m-seed-ai BioBriefs en 2026-01-14T21:33:03Z Proxima raises $80M seed: AI‑driven proximity medicines backed https://biobriefs.com/precede-raises-84m-pairs-liquid BioBriefs en 2026-01-14T21:33:03Z Precede raises $84M — pairs liquid biopsy with next‑gen precision drugs https://biobriefs.com/caldera-launches-with-112-5m BioBriefs en 2026-01-14T21:33:03Z Caldera launches with $112.5M: China‑sourced IBD bispecific enters clinic https://biobriefs.com/natera-leans-on-signatera-growth BioBriefs en 2026-01-14T21:33:03Z Natera leans on Signatera growth — phased‑variant MRD upgrade due mid‑2026 https://biobriefs.com/fda-asks-lilly-novo-to BioBriefs en 2026-01-14T21:33:03Z FDA asks Lilly, Novo to remove suicide warnings from GLP‑1 labels https://biobriefs.com/jazz-sells-priority-review-voucher BioBriefs en 2026-01-14T21:33:03Z Jazz sells priority review voucher for $200M — top price in a decade https://biobriefs.com/soley-lands-200m-series-c BioBriefs en 2026-01-14T21:33:03Z Soley lands $200M Series C: pushes stress‑reduction drugs toward clinic https://biobriefs.com/illumina-launches-billion-cell-atlas BioBriefs en 2026-01-14T16:34:28Z Illumina launches billion‑cell atlas — AI drug discovery scale‑up https://biobriefs.com/nvidia-inks-multi-partner-ai BioBriefs en 2026-01-14T16:34:28Z Nvidia inks multi‑partner AI pacts — pharma and lab giants join https://biobriefs.com/abbvie-buys-ex-china-rights BioBriefs en 2026-01-14T16:34:28Z AbbVie buys ex‑China rights to PD‑1/VEGF bispecific — $650m up front https://biobriefs.com/proxima-formerly-vantai-raises-80m BioBriefs en 2026-01-14T16:34:28Z Proxima (formerly VantAI) raises $80M — AI for proximity medicines https://biobriefs.com/caldera-launches-with-112-5m BioBriefs en 2026-01-14T16:34:28Z Caldera launches with $112.5M — China‑sourced bispecific enters clinic https://biobriefs.com/precede-banks-83-5m-liquid BioBriefs en 2026-01-14T16:34:28Z Precede banks $83.5M — liquid biopsy platform scales for drug development https://biobriefs.com/fda-clears-zycubo-first-treatment BioBriefs en 2026-01-14T16:34:28Z FDA clears Zycubo — first treatment for Menkes disease https://biobriefs.com/fda-extends-travere-review-label BioBriefs en 2026-01-14T16:34:28Z FDA extends Travere review — label expansion for sparsentan delayed https://biobriefs.com/rage-bio-starts-clinic-work BioBriefs en 2026-01-14T16:34:28Z Rage Bio starts clinic work — inhaled splice‑switching oligo for COPD https://biobriefs.com/fda-signals-cgt-flexibility-packaging BioBriefs en 2026-01-14T16:34:28Z FDA signals CGT flexibility — packaging, manufacturing moves follow https://biobriefs.com/illuminas-billion-cell-atlas-largest BioBriefs en 2026-01-14T14:33:36Z Illumina’s Billion Cell Atlas: Largest perturbation dataset to turbocharge AI drug discovery https://biobriefs.com/nvidia-and-pharma-co-invest BioBriefs en 2026-01-14T14:33:36Z NVIDIA and pharma co‑invest: $1B AI lab with Lilly and direct partnerships to embed AI across discovery https://biobriefs.com/fda-clears-first-menkes-therapy BioBriefs en 2026-01-14T14:33:36Z FDA clears first Menkes therapy: Zycubo approved for rare copper‑absorption disease https://biobriefs.com/eikon-therapeutics-eyes-nasdaq-ipo BioBriefs en 2026-01-14T14:33:36Z Eikon Therapeutics eyes Nasdaq IPO — oncology pipeline and PARP programs in focus https://biobriefs.com/abbvie-clinches-mfn-pricing-deal BioBriefs en 2026-01-14T14:33:36Z AbbVie clinches MFN pricing deal and ties it to major US manufacturing commitments https://biobriefs.com/tahoe-arc-institute-and-biohub BioBriefs en 2026-01-14T14:33:36Z Tahoe, Arc Institute and Biohub commit to a massive virtual‑cell perturbation dataset https://biobriefs.com/mrd-and-liquid-biopsy-players BioBriefs en 2026-01-14T14:33:36Z MRD and liquid‑biopsy players scale: Precede raises cash as Natera expands Signatera https://biobriefs.com/automation-and-regulatory-flexibility-aim BioBriefs en 2026-01-14T14:33:36Z Automation and regulatory flexibility aim to ease CGT scale‑up bottlenecks https://biobriefs.com/proxima-raises-80m-seed-to BioBriefs en 2026-01-14T14:33:36Z Proxima raises $80M seed to apply AI to proximity‑modulating drug design https://biobriefs.com/panman-compressive-pangenomics-new-data BioBriefs en 2026-01-14T14:33:36Z PanMAN compressive pangenomics: new data structure to scale genome‑wide analyses https://biobriefs.com/illumina-unveils-billion-cell-atlas BioBriefs en 2026-01-14T10:32:55Z Illumina unveils Billion Cell Atlas: AI models get drug-discovery map https://biobriefs.com/nvidia-and-lilly-commit-1b BioBriefs en 2026-01-14T10:32:55Z Nvidia and Lilly commit $1B: AI co‑innovation lab—partnerships multiply https://biobriefs.com/abbvie-pays-650m-upfront-for BioBriefs en 2026-01-14T10:32:55Z AbbVie pays $650M upfront for PD‑1/VEGF bispecific: up to $5.6B https://biobriefs.com/novartis-licenses-amyloid-and-peptide BioBriefs en 2026-01-14T10:32:55Z Novartis licenses amyloid and peptide assets: $165M upfront for SciNeuro program https://biobriefs.com/fda-clears-zycubo-as-first BioBriefs en 2026-01-14T10:32:55Z FDA clears Zycubo as first Menkes treatment: PRV, commercialization rights detailed https://biobriefs.com/trenchant-claims-autocell-prototype-slashes BioBriefs en 2026-01-14T10:32:55Z Trenchant claims AutoCell prototype slashes CGT timelines and cost https://biobriefs.com/immusoft-advances-redosable-cgt-isp BioBriefs en 2026-01-14T10:32:55Z Immusoft advances redosable CGT: ISP platform enables repeat dosing in MPS I https://biobriefs.com/precede-raises-83-5m-to BioBriefs en 2026-01-14T10:32:55Z Precede raises $83.5M to scale liquid biopsy for pharma development https://biobriefs.com/proxima-raises-80m-seed-to BioBriefs en 2026-01-14T10:32:55Z Proxima raises $80M seed to pursue AI‑driven proximity medicines https://biobriefs.com/allele-joins-uc-san-diego BioBriefs en 2026-01-14T10:32:55Z Allele joins UC San Diego on ARPA‑H 3D bioprinted liver project https://biobriefs.com/illumina-billion-cell-atlas-pharma BioBriefs en 2026-01-14T09:33:43Z Illumina Billion Cell Atlas... Pharma trio signs up https://biobriefs.com/nvidia-lilly-invest-1b-co BioBriefs en 2026-01-14T09:33:43Z Nvidia, Lilly invest $1B: Co‑innovation AI lab opens https://biobriefs.com/abbvie-buys-pd-1-vegf BioBriefs en 2026-01-14T09:33:43Z AbbVie buys PD‑1/VEGF rights — $650M up front https://biobriefs.com/fda-clears-zycubo-first-therapy BioBriefs en 2026-01-14T09:33:43Z FDA clears Zycubo — first therapy for Menkes disease https://biobriefs.com/virtual-scientists-and-autonomous-labs BioBriefs en 2026-01-14T09:33:43Z Virtual scientists and autonomous labs: automation accelerates discovery https://biobriefs.com/redosing-cgts-and-fda-flexibility BioBriefs en 2026-01-14T09:33:43Z Redosing CGTs and FDA flexibility — potential reset for cell therapy https://biobriefs.com/cdmo-moves-reshape-manufacturing-and BioBriefs en 2026-01-14T09:33:43Z CDMO moves reshape manufacturing and viral vector supply chains https://biobriefs.com/sequencing-firms-scale-installed-base BioBriefs en 2026-01-14T09:33:43Z Sequencing firms scale: installed base growth and new benchtop launches https://biobriefs.com/liquid-biopsy-and-mrd-diagnostics BioBriefs en 2026-01-14T09:33:43Z Liquid biopsy and MRD: diagnostics funding meets rising test volumes https://biobriefs.com/intracellular-fabrication-and-mmap-new BioBriefs en 2026-01-14T09:33:43Z Intracellular fabrication and µMAP: new tools to probe living cells https://biobriefs.com/illuminas-billion-cell-atlas-virtual BioBriefs en 2026-01-14T04:33:07Z Illumina’s Billion Cell Atlas... Virtual cell arms race begins https://biobriefs.com/nvidia-lilly-pact-1b-ai BioBriefs en 2026-01-14T04:33:07Z Nvidia‑Lilly pact – $1B AI co‑innovation lab to reshape drug discovery https://biobriefs.com/abbvie-bets-big-on-pd BioBriefs en 2026-01-14T04:33:07Z AbbVie bets big on PD‑1/VEGF bispecific – $650M up front https://biobriefs.com/menkes-gets-its-first-drug BioBriefs en 2026-01-14T04:33:07Z Menkes gets its first drug; FDA delays Travere label review https://biobriefs.com/big-private-rounds-soley-200m BioBriefs en 2026-01-14T04:33:07Z Big private rounds: Soley $200M; Proxima $80M to fuel discovery platforms https://biobriefs.com/automation-and-manufacturing-autocell-claims BioBriefs en 2026-01-14T04:33:07Z Automation and manufacturing: AutoCell claims 2.5‑day CGT run; LV packaging cut plasmids https://biobriefs.com/sequencing-vendors-scale-ultima-installs BioBriefs en 2026-01-14T04:33:07Z Sequencing vendors scale: Ultima installs rise; Element teases $100 genome benchtop https://biobriefs.com/redosing-and-regulatory-ease-reshape BioBriefs en 2026-01-14T04:33:07Z Redosing and regulatory ease reshape CGT strategy https://biobriefs.com/wgs-moves-toward-clinical-utility BioBriefs en 2026-01-14T04:33:07Z WGS moves toward clinical utility: HRD detection and ASO collaborations https://biobriefs.com/jpm-deal-surge-and-biotechs BioBriefs en 2026-01-14T04:33:07Z JPM deal surge and biotech’s renewed M&A momentum https://biobriefs.com/abbvie-licenses-pd-1-vegf BioBriefs en 2026-01-13T21:33:33Z AbbVie licenses PD‑1/VEGF bispecific from RemeGen: $650M upfront https://biobriefs.com/illumina-unveils-billion-cell-atlas BioBriefs en 2026-01-13T21:33:33Z Illumina unveils billion‑cell atlas: AI dataset to speed drug target work https://biobriefs.com/lilly-and-nvidia-commit-up BioBriefs en 2026-01-13T21:33:33Z Lilly and Nvidia commit up to $1B: five‑year AI drug‑discovery lab https://biobriefs.com/precede-raises-83-5m-scales BioBriefs en 2026-01-13T21:33:33Z Precede raises $83.5M, scales liquid biopsy platform for pharma https://biobriefs.com/proximity-drug-startup-proxima-closes BioBriefs en 2026-01-13T21:33:33Z Proximity‑drug startup Proxima closes $80M seed; rebrands from VantAI https://biobriefs.com/fda-approves-zycubo-first-therapy BioBriefs en 2026-01-13T21:33:33Z FDA approves Zycubo — first therapy for Menkes disease https://biobriefs.com/fda-again-rebuffs-ataras-cell BioBriefs en 2026-01-13T21:33:33Z FDA again rebuffs Atara’s cell therapy... company calls agency reversal a 'complete reversal' https://biobriefs.com/wgs-classifier-finds-hrd-missed BioBriefs en 2026-01-13T21:33:33Z WGS classifier finds HRD missed by standard tests: pan‑cancer study https://biobriefs.com/bioprocess-bets-charles-river-buys BioBriefs en 2026-01-13T21:33:33Z Bioprocess bets: Charles River buys PathoQuest and K.F.; Asimov licenses LV Edge to AGC https://biobriefs.com/tahoe-arc-institute-and-biohub BioBriefs en 2026-01-13T21:33:33Z Tahoe, Arc Institute and Biohub fund massive virtual‑cell dataset: 120M+ perturbations https://biobriefs.com/abbvie-buys-pd-1-vegf BioBriefs en 2026-01-13T16:33:27Z AbbVie buys PD‑1/VEGF bispecific: $650m upfront https://biobriefs.com/nvidia-and-lilly-put-1bn BioBriefs en 2026-01-13T16:33:27Z Nvidia and Lilly put $1bn on the table: AI lab for drug discovery https://biobriefs.com/illumina-unveils-billion-cell-atlas BioBriefs en 2026-01-13T16:33:27Z Illumina unveils billion‑cell atlas... pharma signs on https://biobriefs.com/tahoe-arc-and-biohub-build BioBriefs en 2026-01-13T16:33:27Z Tahoe, Arc and Biohub build public virtual‑cell perturbation atlas https://biobriefs.com/soley-raises-200m-series-c BioBriefs en 2026-01-13T16:33:27Z Soley raises $200m Series C – advances stress‑sensing drug pipeline https://biobriefs.com/tessera-restructures-after-regeneron-tie BioBriefs en 2026-01-13T16:33:27Z Tessera restructures after Regeneron tie‑up; advances AATD gene‑editing trial https://biobriefs.com/10x-genomics-pushes-clinical-playbook BioBriefs en 2026-01-13T16:33:27Z 10x Genomics pushes clinical playbook – CLIA lab, partnerships and testing growth https://biobriefs.com/basecamps-eden-ai-designs-insertable BioBriefs en 2026-01-13T16:33:27Z Basecamp’s EDEN AI designs insertable gene sequences: programmable insertion https://biobriefs.com/novartis-pays-165m-for-scineuro BioBriefs en 2026-01-13T16:33:27Z Novartis pays $165m for SciNeuro brain‑shuttle; big‑ticket milestones possible https://biobriefs.com/asimov-licenses-lv-edge-to BioBriefs en 2026-01-13T16:33:27Z Asimov licenses LV Edge to AGC Biologics – simplifies lentiviral manufacturing https://biobriefs.com/abbvie-pays-650m-upfront-for BioBriefs en 2026-01-13T14:33:31Z AbbVie pays $650M upfront for PD-1/VEGF asset — Global rights ex‑China https://biobriefs.com/lilly-and-nvidia-commit-1b BioBriefs en 2026-01-13T14:33:31Z Lilly and Nvidia commit $1B to AI drug‑discovery lab — five‑year pact https://biobriefs.com/illumina-unveils-billion-cell-atlas BioBriefs en 2026-01-13T14:33:31Z Illumina unveils Billion Cell Atlas; Tahoe joins large single‑cell push https://biobriefs.com/ai-designs-programmable-gene-insertion BioBriefs en 2026-01-13T14:33:31Z AI designs programmable gene insertion — Basecamp’s EDEN demonstrates breadth https://biobriefs.com/fda-eases-manufacturing-oversight-for BioBriefs en 2026-01-13T14:33:31Z FDA eases manufacturing oversight for cell and gene therapies — CBER guidance https://biobriefs.com/large-raises-and-funds-parabilis BioBriefs en 2026-01-13T14:33:31Z Large raises and funds: Parabilis nets $305M; Arkin closes $100M early‑stage fund https://biobriefs.com/restructuring-wave-tessera-cuts-35 BioBriefs en 2026-01-13T14:33:31Z Restructuring wave: Tessera cuts 35% as it pivots; Lyra halts development, shutters ops https://biobriefs.com/scale-and-automation-in-cgt BioBriefs en 2026-01-13T14:33:31Z Scale and automation in CGT manufacturing — Asimov licenses LV Edge; Trenchant shows AutoCell data https://biobriefs.com/oncology-diagnostics-surge-natera-and BioBriefs en 2026-01-13T14:33:31Z Oncology diagnostics surge: Natera and Guardant report double‑digit growth in testing https://biobriefs.com/targeted-therapies-advance-flowers-shows BioBriefs en 2026-01-13T14:33:31Z Targeted therapies advance: FLOWERS shows osimertinib combinations; MOUNTAINEER confirms tucatinib benefit https://biobriefs.com/abbvie-jumps-into-pd-1xvegf BioBriefs en 2026-01-13T10:32:54Z AbbVie jumps into PD‑1xVEGF sweepstakes: $650M upfront, multibillion milestones loom https://biobriefs.com/nvidia-and-lilly-double-down BioBriefs en 2026-01-13T10:32:54Z Nvidia and Lilly double down on AI: $1B lab to accelerate drug discovery https://biobriefs.com/basecamps-eden-model-programmable-gene BioBriefs en 2026-01-13T10:32:54Z Basecamp’s EDEN model... programmable gene insertion demonstrated at scale https://biobriefs.com/big-single-cell-dataset-pact BioBriefs en 2026-01-13T10:32:54Z Big single‑cell dataset pact: Tahoe, Arc and Biohub pledge multimillion commitments https://biobriefs.com/engineered-skin-as-a-living BioBriefs en 2026-01-13T10:32:54Z Engineered skin as a living monitor: implanted graft signals inflammation https://biobriefs.com/fda-eases-cgt-controls-cber BioBriefs en 2026-01-13T10:32:54Z FDA eases CGT controls: CBER details greater flexibility for manufacturing and CMC https://biobriefs.com/autocell-promises-dramatic-cgt-scale BioBriefs en 2026-01-13T10:32:54Z AutoCell promises dramatic CGT scale‑up: Trenchant shows prototype data https://biobriefs.com/lyra-halts-lyr-210-program BioBriefs en 2026-01-13T10:32:54Z Lyra halts LYR‑210 program and lays off staff: Board opts for strategic alternatives https://biobriefs.com/crispr-removes-notch2nlc-repeats-new BioBriefs en 2026-01-13T10:32:54Z CRISPR removes NOTCH2NLC repeats: New gene‑editing approach for NIID https://biobriefs.com/sequencing-firms-push-clinical-reach BioBriefs en 2026-01-13T10:32:54Z Sequencing firms push clinical reach: Oxford Nanopore gains IVDR CE/UKCA, PacBio inks ASO collaboration https://biobriefs.com/nvidia-and-lilly-invest-1 BioBriefs en 2026-01-13T09:33:31Z Nvidia and Lilly invest $1 billion: AI drug lab to accelerate discovery https://biobriefs.com/basecamps-eden-ai-models-design BioBriefs en 2026-01-13T09:33:31Z Basecamp’s EDEN: AI models design programmable gene insertion https://biobriefs.com/abbvie-pays-650m-joins-pd BioBriefs en 2026-01-13T09:33:31Z AbbVie pays $650M — joins PD‑1×VEGF bispecific race with RemeGen deal https://biobriefs.com/grail-files-for-fda-premarket BioBriefs en 2026-01-13T09:33:31Z Grail files for FDA premarket approval: Galleri commercial scale rises https://biobriefs.com/10x-genomics-to-open-clia BioBriefs en 2026-01-13T09:33:31Z 10x Genomics to open CLIA lab: clinical collaborations target oncology and autoimmunity https://biobriefs.com/tahoe-arc-institute-and-biohub BioBriefs en 2026-01-13T09:33:31Z Tahoe, Arc Institute and Biohub fund massive virtual‑cell dataset: 120M+ single‑cell perturbations https://biobriefs.com/panman-compressed-pangenomics-scales-whole BioBriefs en 2026-01-13T09:33:31Z PanMAN: compressed pangenomics scales whole‑genome analysis https://biobriefs.com/trenchants-autocell-prototype-claims-2 BioBriefs en 2026-01-13T09:33:31Z Trenchant’s AutoCell prototype claims 2.5‑day CGT run and 7× yield vs today’s standards https://biobriefs.com/tessera-cleared-to-start-tsra BioBriefs en 2026-01-13T09:33:31Z Tessera cleared to start TSRA‑196 trial: in vivo gene editing for AAT deficiency moves to clinic https://biobriefs.com/mirador-raises-250m-positions-to BioBriefs en 2026-01-13T09:33:31Z Mirador raises $250M: positions to expand immunology pipeline and eye an IPO https://biobriefs.com/abbvie-pens-5-6b-pact BioBriefs en 2026-01-13T04:32:42Z AbbVie pens $5.6B pact with RemeGen – joins PD‑1xVEGF race https://biobriefs.com/nvidia-lilly-1b-co-lab BioBriefs en 2026-01-13T04:32:42Z Nvidia–Lilly $1B co‑lab: AI to speed drug discovery https://biobriefs.com/basecamps-eden-ai-programmable-gene BioBriefs en 2026-01-13T04:32:42Z Basecamp’s EDEN AI: programmable gene insertion at scale https://biobriefs.com/tahoe-arc-and-biohub-commit BioBriefs en 2026-01-13T04:32:42Z Tahoe, Arc and Biohub commit multimillion dataset: 120M+ single‑cell perturbations https://biobriefs.com/oxford-nanopore-gets-ce-ukca BioBriefs en 2026-01-13T04:32:42Z Oxford Nanopore gets CE/UKCA mark for GridIon Dx – clinical push ramps https://biobriefs.com/trenchant-claims-autocell-prototype-slashes BioBriefs en 2026-01-13T04:32:42Z Trenchant claims AutoCell prototype slashes CGT timelines: 2.5‑day vein‑to‑vein https://biobriefs.com/10x-genomics-pivots-to-clinic BioBriefs en 2026-01-13T04:32:42Z 10x Genomics pivots to clinic: collaborations and CLIA lab planned https://biobriefs.com/pacbio-teams-with-n-lorem BioBriefs en 2026-01-13T04:32:42Z PacBio teams with n‑Lorem and EspeRare on individualized ASOs; revenue rises https://biobriefs.com/fda-exercises-flexibility-in-cgt BioBriefs en 2026-01-13T04:32:42Z FDA exercises flexibility in CGT chemistry, manufacturing and controls https://biobriefs.com/crispr-excises-notch2nlc-expansions-new BioBriefs en 2026-01-13T04:32:42Z CRISPR excises NOTCH2NLC expansions: new approach targets NIID https://biobriefs.com/lilly-and-nvidia-1b-lab BioBriefs en 2026-01-12T21:33:35Z Lilly and Nvidia: $1B lab to accelerate AI drug discovery https://biobriefs.com/basecamps-eden-models-ai-designs BioBriefs en 2026-01-12T21:33:35Z Basecamp’s EDEN models: AI designs programmable gene insertions https://biobriefs.com/who-flags-equity-gaps-in BioBriefs en 2026-01-12T21:33:35Z WHO flags equity gaps in genomic clinical research: geographic and demographic imbalances https://biobriefs.com/fda-eases-cmc-rules-for BioBriefs en 2026-01-12T21:33:35Z FDA eases CMC rules for cell and gene therapies – more regulatory flexibility https://biobriefs.com/tahoe-arc-and-biohub-join BioBriefs en 2026-01-12T21:33:35Z Tahoe, Arc and Biohub join to build massive perturbation-rich virtual‑cell dataset https://biobriefs.com/diagnostics-surge-tempus-and-guardant BioBriefs en 2026-01-12T21:33:35Z Diagnostics surge: Tempus and Guardant post big preliminary revenue gains https://biobriefs.com/10x-genomics-pushes-diagnostics-clinical BioBriefs en 2026-01-12T21:33:35Z 10x Genomics pushes diagnostics: clinical collaborations and CLIA lab plans https://biobriefs.com/targeted-delivery-and-ind-green BioBriefs en 2026-01-12T21:33:35Z Targeted delivery and IND green light: Tessera cleared for in vivo gene‑editing trial https://biobriefs.com/big-ticket-oncology-licensing-abbvie BioBriefs en 2026-01-12T21:33:35Z Big‑ticket oncology licensing: AbbVie and Novartis make strategic bets https://biobriefs.com/data-and-diagnostics-integration-concertai BioBriefs en 2026-01-12T21:33:35Z Data and diagnostics integration: ConcertAI adds Foundation Medicine; MeMed wins biobank grant https://biobriefs.com/abbvie-bets-big-on-pd BioBriefs en 2026-01-12T16:32:45Z AbbVie bets big on PD‑1xVEGF: $650M upfront with RemeGen https://biobriefs.com/novartis-buys-a-brain-shuttle BioBriefs en 2026-01-12T16:32:45Z Novartis buys a brain‑shuttle ticket: $165M deal with SciNeuro https://biobriefs.com/eli-lilly-nvidia-ink-ai BioBriefs en 2026-01-12T16:32:45Z Eli Lilly, Nvidia ink AI lab pact: five years, up to $1B https://biobriefs.com/oxford-nanopore-clears-ce-ukca BioBriefs en 2026-01-12T16:32:45Z Oxford Nanopore clears CE/UKCA for GridIon Dx — clinical push begins https://biobriefs.com/tessera-clears-ind-in-vivo BioBriefs en 2026-01-12T16:32:45Z Tessera clears IND — in vivo gene editing enters clinic for AATD https://biobriefs.com/parabilis-raises-305m-to-push BioBriefs en 2026-01-12T16:32:45Z Parabilis raises $305M to push desmoid tumor program into Phase III https://biobriefs.com/mirador-raises-250m-building-an BioBriefs en 2026-01-12T16:32:45Z Mirador raises $250M — building an immunology powerhouse https://biobriefs.com/mrd-and-oncology-testing-surge BioBriefs en 2026-01-12T16:32:45Z MRD and oncology testing surge: Natera and Adaptive post sharp revenue gains https://biobriefs.com/testing-boom-fuels-tempus-and BioBriefs en 2026-01-12T16:32:45Z Testing boom fuels Tempus and Guardant revenue leaps https://biobriefs.com/eikon-files-for-ipo-protein BioBriefs en 2026-01-12T16:32:45Z Eikon files for IPO — protein‑movement platform goes public push https://biobriefs.com/in-vivo-genome-editing-delivery BioBriefs en 2026-01-12T14:33:48Z In vivo genome editing: delivery breakthroughs accelerate clinical translation https://biobriefs.com/novartis-licenses-scineuro-amyloid-program BioBriefs en 2026-01-12T14:33:48Z Novartis licenses SciNeuro amyloid program: $165 million upfront https://biobriefs.com/fda-rejects-ataras-ebv-cell BioBriefs en 2026-01-12T14:33:48Z FDA rejects Atara’s EBV cell therapy — regulator stalls approval again https://biobriefs.com/parabilis-raises-305m-funds-phase BioBriefs en 2026-01-12T14:33:48Z Parabilis raises $305M: funds Phase III push for desmoid tumor candidate https://biobriefs.com/kinaset-bags-103m-series-b BioBriefs en 2026-01-12T14:33:48Z Kinaset bags $103M Series B to advance inhaled asthma program https://biobriefs.com/mirador-nets-250m-builds-immunology BioBriefs en 2026-01-12T14:33:48Z Mirador nets $250M — builds immunology platform and eyes IPO https://biobriefs.com/eikon-eyes-ipo-1b-plus BioBriefs en 2026-01-12T14:33:48Z Eikon eyes IPO: $1B-plus private backing and multiple clinical assets https://biobriefs.com/teva-secures-up-to-500m BioBriefs en 2026-01-12T14:33:48Z Teva secures up to $500M from Royalty Pharma for vitiligo program https://biobriefs.com/tempus-posts-strong-q4-preliminary BioBriefs en 2026-01-12T14:33:48Z Tempus posts strong Q4: preliminary revenue jumps 83% on testing growth https://biobriefs.com/guardant-health-q4-revenue-climbs BioBriefs en 2026-01-12T14:33:48Z Guardant Health Q4 revenue climbs 39% as screening and oncology volumes rise https://biobriefs.com/parabilis-closes-305m-series-f BioBriefs en 2026-01-12T10:32:33Z Parabilis closes $305M Series F: Rare-tumor drug moves toward Phase III https://biobriefs.com/eikon-eyes-ipo-billion-dollar BioBriefs en 2026-01-12T10:32:33Z Eikon eyes IPO: Billion-dollar private backing, interim melanoma readout expected https://biobriefs.com/mirador-raises-250m-company-positions BioBriefs en 2026-01-12T10:32:33Z Mirador raises $250M: Company positions itself as immunology contender, eyes IPO https://biobriefs.com/tempus-posts-massive-q4-diagnostics BioBriefs en 2026-01-12T10:32:33Z Tempus posts massive Q4: Diagnostics fuels 83% revenue jump https://biobriefs.com/guardant-health-surges-screening-and BioBriefs en 2026-01-12T10:32:33Z Guardant Health surges: Screening and oncology tests lift Q4 revenue 39% https://biobriefs.com/veracyte-posts-double-digit-growth BioBriefs en 2026-01-12T10:32:33Z Veracyte posts double‑digit growth — guides to further 2026 revenue gains https://biobriefs.com/10x-genomics-consumables-buoy-results BioBriefs en 2026-01-12T10:32:33Z 10x Genomics: consumables buoy results as instrument sales decline https://biobriefs.com/castle-biosciences-tops-guidance-test BioBriefs en 2026-01-12T10:32:33Z Castle Biosciences tops guidance: Test‑report growth lifts full‑year revenue https://biobriefs.com/xella-health-closes-3-7m BioBriefs en 2026-01-12T10:32:33Z Xella Health closes $3.7M pre‑seed — multiomic women's platform readies for launch https://biobriefs.com/sbir-sttr-funding-lapses-federal BioBriefs en 2026-01-12T10:32:33Z SBIR/STTR funding lapses: Federal non‑dilutive pipeline goes dark https://biobriefs.com/eikon-eyes-ipo-merck-vets BioBriefs en 2026-01-12T09:33:54Z Eikon eyes IPO — Merck vets lead $1B drug push https://biobriefs.com/mirador-raises-250m-plots-immunology BioBriefs en 2026-01-12T09:33:54Z Mirador raises $250M — plots immunology scale-up https://biobriefs.com/drugclip-ai-screens-millions-of BioBriefs en 2026-01-12T09:33:54Z DrugCLIP: AI screens millions of compounds in hours https://biobriefs.com/anthropic-follows-openai-into-healthcare BioBriefs en 2026-01-12T09:33:54Z Anthropic follows OpenAI into healthcare — rivals diverge on platform strategy https://biobriefs.com/sbir-sttr-lifeline-goes-dark BioBriefs en 2026-01-12T09:33:54Z SBIR/STTR lifeline goes dark: NIH halts small‑business grants https://biobriefs.com/fda-asks-for-more-data BioBriefs en 2026-01-12T09:33:54Z FDA asks for more data — Stoke's zorevunersen fast‑path request stalled https://biobriefs.com/lucerastat-edges-forward-in-phase BioBriefs en 2026-01-12T09:33:54Z Lucerastat edges forward in Phase 3 — oral Fabry therapy shows promise https://biobriefs.com/novel-imidazotetrazines-overcome-temozolomide-resistance BioBriefs en 2026-01-12T09:33:54Z Novel imidazotetrazines overcome temozolomide resistance in glioblastoma models https://biobriefs.com/testing-surge-tempus-and-guardant BioBriefs en 2026-01-12T09:33:54Z Testing surge... Tempus and Guardant report hefty Q4 revenue gains https://biobriefs.com/lab-tools-and-diagnostics-10x BioBriefs en 2026-01-12T09:33:54Z Lab tools and diagnostics: 10x consumables climb; Veracyte guides double‑digit growth https://biobriefs.com/eikon-files-for-ipo-merck BioBriefs en 2026-01-12T04:32:42Z Eikon files for IPO: Merck vets plot public debut https://biobriefs.com/mirador-raises-250m-aims-to BioBriefs en 2026-01-12T04:32:42Z Mirador raises $250M — aims to become immunology powerhouse https://biobriefs.com/tempus-revenue-surges-diagnostics-drive BioBriefs en 2026-01-12T04:32:42Z Tempus revenue surges: Diagnostics drive an 83% Q4 jump https://biobriefs.com/guardant-q4-jump-screening-and BioBriefs en 2026-01-12T04:32:42Z Guardant Q4 jump: Screening and oncology tests push revenue higher https://biobriefs.com/10x-genomics-consumables-offset-instrument BioBriefs en 2026-01-12T04:32:42Z 10x Genomics: consumables offset instrument weakness — Q4 beat https://biobriefs.com/veracyte-posts-beat-and-2026 BioBriefs en 2026-01-12T04:32:42Z Veracyte posts beat and 2026 guidance: testing fuels growth https://biobriefs.com/castle-biosciences-lifts-full-year BioBriefs en 2026-01-12T04:32:42Z Castle Biosciences lifts full-year revenue as test reports climb https://biobriefs.com/lucerastat-shows-promise-in-phase BioBriefs en 2026-01-12T04:32:42Z Lucerastat shows promise in Phase 3... Fabry disease data emerge https://biobriefs.com/fda-asks-stoke-for-more BioBriefs en 2026-01-12T04:32:42Z FDA asks Stoke for more data — expedited filing for Dravet drug paused https://biobriefs.com/drugclip-unveiled-ai-slashes-virtual BioBriefs en 2026-01-12T04:32:42Z DrugCLIP unveiled: AI slashes virtual screening time by orders of magnitude https://biobriefs.com/10x-genomics-consumables-prop-up BioBriefs en 2026-01-11T21:33:24Z 10x Genomics... Consumables prop up Q4 as instruments slump https://biobriefs.com/stoke-therapeutics-fda-asks-for BioBriefs en 2026-01-11T21:33:24Z Stoke Therapeutics — FDA asks for more on expedited filing for Dravet drug https://biobriefs.com/mirador-raises-250m-building-an BioBriefs en 2026-01-11T21:33:24Z Mirador raises $250M — building an immunology franchise https://biobriefs.com/ipo-queue-tests-biotech-market BioBriefs en 2026-01-11T21:33:24Z IPO queue tests biotech market — Eikon files and Aktis warms investors https://biobriefs.com/veradermics-files-for-ipo-to BioBriefs en 2026-01-11T21:33:24Z Veradermics files for IPO to fund oral Rogaine program https://biobriefs.com/phanes-posts-positive-phase-2 BioBriefs en 2026-01-11T21:33:24Z Phanes posts positive Phase 2 data — bispecific shows promise in frontline PDAC https://biobriefs.com/krystal-posts-early-proof-of BioBriefs en 2026-01-11T21:33:24Z Krystal posts early proof-of-concept for cystic fibrosis gene therapy https://biobriefs.com/illumina-hires-eric-green-as BioBriefs en 2026-01-11T21:33:24Z Illumina hires Eric Green as CMO — clinical genomics push begins https://biobriefs.com/fda-greenlights-seven-nmes-in BioBriefs en 2026-01-11T21:33:24Z FDA greenlights seven NMEs in December — 2025 approvals slip to 46 https://biobriefs.com/biotech-cash-sprint-4-9b BioBriefs en 2026-01-11T21:33:24Z Biotech cash sprint: $4.9B raised ahead of JP Morgan https://biobriefs.com/mirador-raises-250m-plans-ipo BioBriefs en 2026-01-11T16:32:10Z Mirador raises $250M — Plans IPO push https://biobriefs.com/boltz-launches-pbc-to-democratize BioBriefs en 2026-01-11T16:32:10Z Boltz launches PBC to democratize AI drug design https://biobriefs.com/orca-secures-250m-to-launch BioBriefs en 2026-01-11T16:32:10Z Orca secures $250M to launch T-cell therapy commercially https://biobriefs.com/eikon-files-for-ipo-tests BioBriefs en 2026-01-11T16:32:10Z Eikon files for IPO — Tests biotech rally https://biobriefs.com/aktis-prices-ipo-stock-pops BioBriefs en 2026-01-11T16:32:10Z Aktis prices IPO — Stock pops on debut https://biobriefs.com/biotech-fundraising-surge-ahead-of BioBriefs en 2026-01-11T16:32:10Z Biotech fundraising surge ahead of JPM — Billions flow https://biobriefs.com/bio-launches-investment-council-to BioBriefs en 2026-01-11T16:32:10Z BIO launches Investment Council to boost VC access https://biobriefs.com/illumina-names-eric-green-as BioBriefs en 2026-01-11T16:32:10Z Illumina names Eric Green as chief medical officer https://biobriefs.com/krystal-reports-early-proof-of BioBriefs en 2026-01-11T16:32:10Z Krystal reports early proof-of-concept for CF gene therapy https://biobriefs.com/phanes-posts-positive-phase-2 BioBriefs en 2026-01-11T16:32:10Z Phanes posts positive Phase 2 PDAC data at ASCO GI https://biobriefs.com/biotech-cash-flood-4-9b BioBriefs en 2026-01-11T14:33:10Z Biotech cash flood: $4.9B pours into private and public companies ahead of JPM https://biobriefs.com/aktis-pop-radiopharma-ipo-raises BioBriefs en 2026-01-11T14:33:10Z Aktis pop: Radiopharma IPO raises $318M and fuels hopes for biotech listings https://biobriefs.com/big-rounds-fuel-therapy-launches BioBriefs en 2026-01-11T14:33:10Z Big rounds fuel therapy launches: Mirador and Orca secure $250M each https://biobriefs.com/krystal-pushes-mutation-agnostic-cf BioBriefs en 2026-01-11T14:33:10Z Krystal pushes mutation‑agnostic CF gene therapy: early PoC claims and fast path plan https://biobriefs.com/illumina-taps-former-nhgri-chief BioBriefs en 2026-01-11T14:33:10Z Illumina taps former NHGRI chief: Eric Green named chief medical officer https://biobriefs.com/open-tools-and-ai-platforms BioBriefs en 2026-01-11T14:33:10Z Open tools and AI platforms: Boltz launches with $28M; FRAIL advances molecular design https://biobriefs.com/plasmids-to-cho-cdmo-alliances BioBriefs en 2026-01-11T14:33:10Z Plasmids to CHO: CDMO alliances and cell‑line platforms expand biologics supply https://biobriefs.com/spevatamig-shows-activity-in-1l BioBriefs en 2026-01-11T14:33:10Z Spevatamig shows activity in 1L PDAC: Phanes posts positive phase 2 data https://biobriefs.com/enzymatic-oligo-synthesis-gains-ground BioBriefs en 2026-01-11T14:33:10Z Enzymatic oligo synthesis gains ground: ATP‑free NTP production could cut costs https://biobriefs.com/drug-pricing-moves-j-j BioBriefs en 2026-01-11T14:33:10Z Drug pricing moves: J&J signs MFN terms; Genentech cuts PBM exposure to save millions https://biobriefs.com/biotech-ipos-return-aktis-raises BioBriefs en 2026-01-11T10:33:07Z Biotech IPOs Return: Aktis Raises $318M; Eikon Files to Test Market https://biobriefs.com/merck-eyes-revolution-talks-surface BioBriefs en 2026-01-11T10:33:07Z Merck Eyes Revolution: Talks Surface on $28–32B Takeover https://biobriefs.com/krystal-posts-early-cf-gene BioBriefs en 2026-01-11T10:33:07Z Krystal Posts Early CF Gene Therapy Proof: Pivotal Push Underway https://biobriefs.com/ai-drug-discovery-draws-capital BioBriefs en 2026-01-11T10:33:07Z AI Drug Discovery Draws Capital: Boltz Launches; a16z Expands Bio Fund https://biobriefs.com/plasmid-supply-and-cho-capacity BioBriefs en 2026-01-11T10:33:07Z Plasmid Supply and CHO Capacity: Bionova-Syenex Alliance; Aragen’s CHOMax https://biobriefs.com/new-glioblastoma-strategies-imidazotetrazines-and BioBriefs en 2026-01-11T10:33:07Z New Glioblastoma Strategies: Imidazotetrazines and HDAC1 Mechanisms https://biobriefs.com/scaling-cell-therapy-orca-raises BioBriefs en 2026-01-11T10:33:07Z Scaling Cell Therapy: Orca Raises $250M; Cellares Partners with City of Hope https://biobriefs.com/illumina-hires-eric-green-company BioBriefs en 2026-01-11T10:33:07Z Illumina Hires Eric Green: Company Pushes Into Clinical Genomics https://biobriefs.com/bespoke-gene-editing-bets-on BioBriefs en 2026-01-11T10:33:07Z Bespoke Gene Editing Bets on New FDA Pathways: Aurora and Startups https://biobriefs.com/funding-engines-engage-bio-launches BioBriefs en 2026-01-11T10:33:07Z Funding Engines Engage: BIO Launches Investment Council; Private Biotechs Raise $2B https://biobriefs.com/aktis-ipo-318m-raise-fuels BioBriefs en 2026-01-11T09:32:57Z Aktis IPO: $318M Raise Fuels Radiopharma Push https://biobriefs.com/eikon-files-for-ipo-biotech BioBriefs en 2026-01-11T09:32:57Z Eikon Files for IPO... Biotech Market’s Bellwether? https://biobriefs.com/krystals-cf-gene-therapy-early BioBriefs en 2026-01-11T09:32:57Z Krystal’s CF Gene Therapy: Early Proof of Concept https://biobriefs.com/phanes-spevatamig-shows-positive-phase BioBriefs en 2026-01-11T09:32:57Z Phanes: Spevatamig Shows Positive Phase 2 Signals in PDAC https://biobriefs.com/orcas-250m-raise-poised-to BioBriefs en 2026-01-11T09:32:57Z Orca’s $250M Raise... Poised to Launch T‑Cell Therapy https://biobriefs.com/automation-and-cdmo-scale-cellares BioBriefs en 2026-01-11T09:32:57Z Automation and CDMO Scale: Cellares, City of Hope and Aragen Move Fast https://biobriefs.com/plasmid-supply-alliance-bionova-and BioBriefs en 2026-01-11T09:32:57Z Plasmid Supply Alliance: Bionova and Syenex Link Up https://biobriefs.com/open-ai-platforms-for-drug BioBriefs en 2026-01-11T09:32:57Z Open AI Platforms for Drug Discovery: Boltz Launches PBC https://biobriefs.com/m-a-chatter-merck-eyes BioBriefs en 2026-01-11T09:32:57Z M&A Chatter: Merck Eyes Revolution... Bidders Circle https://biobriefs.com/amgen-buys-dark-blue-targeted BioBriefs en 2026-01-11T09:32:57Z Amgen Buys Dark Blue – Targeted Degrader Program Joins Big Pharma https://biobriefs.com/aktis-debut-318m-ipo-lifts BioBriefs en 2026-01-11T04:32:41Z Aktis debut: $318M IPO lifts radiopharma hopes https://biobriefs.com/eikon-tests-public-waters-ipo BioBriefs en 2026-01-11T04:32:41Z Eikon tests public waters: IPO filing gauges market appetite https://biobriefs.com/krystal-pursues-mutation-agnostic-cf BioBriefs en 2026-01-11T04:32:41Z Krystal pursues mutation‑agnostic CF gene therapy: early clinical signals https://biobriefs.com/lucerastat-phase-3-oral-candidate BioBriefs en 2026-01-11T04:32:41Z Lucerastat phase 3: oral candidate posts promising Fabry results https://biobriefs.com/spevatamig-data-at-asco-gi BioBriefs en 2026-01-11T04:32:41Z Spevatamig data at ASCO GI: bispecific shows frontline PDAC activity https://biobriefs.com/boltz-launches-28m-seed-to BioBriefs en 2026-01-11T04:32:41Z Boltz launches: $28M seed to democratize AI drug design https://biobriefs.com/aurora-bets-on-bespoke-crispr BioBriefs en 2026-01-11T04:32:41Z Aurora bets on bespoke CRISPR: startups target FDA’s new pathways https://biobriefs.com/revolution-takeover-chatter-merck-and BioBriefs en 2026-01-11T04:32:41Z Revolution takeover chatter: Merck and bidders circle RAS‑targeting biotech https://biobriefs.com/airnexis-raises-200m-licenses-china BioBriefs en 2026-01-11T04:32:41Z AirNexis raises $200M, licenses China COPD asset for global push https://biobriefs.com/bio-forms-investment-council-to BioBriefs en 2026-01-11T04:32:41Z BIO forms Investment Council to bridge VCs and small biotechs https://biobriefs.com/aktis-prices-318m-ipo-radiopharma BioBriefs en 2026-01-10T21:32:52Z Aktis prices $318M IPO – Radiopharma debut https://biobriefs.com/airnexis-secures-200m-to-advance BioBriefs en 2026-01-10T21:32:52Z AirNexis secures $200M – to advance China COPD asset https://biobriefs.com/boltz-launches-as-pbc-28m BioBriefs en 2026-01-10T21:32:52Z Boltz launches as PBC: $28M to democratize AI drug discovery https://biobriefs.com/illumina-taps-eric-green-former BioBriefs en 2026-01-10T21:32:52Z Illumina taps Eric Green – former NHGRI director named CMO https://biobriefs.com/bio-launches-investment-council-investors BioBriefs en 2026-01-10T21:32:52Z BIO launches Investment Council – investors to link with small biotechs https://biobriefs.com/merck-eyes-revolution-potential-28 BioBriefs en 2026-01-10T21:32:52Z Merck eyes Revolution: potential $28–32B takeover talks https://biobriefs.com/eikon-files-for-ipo-testing BioBriefs en 2026-01-10T21:32:52Z Eikon files for IPO – testing biotech rally https://biobriefs.com/alveus-launches-with-160m-advances BioBriefs en 2026-01-10T21:32:52Z Alveus launches with $160M – advances MariTide‑like obesity program https://biobriefs.com/aragen-rolls-out-chomax-integrated BioBriefs en 2026-01-10T21:32:52Z Aragen rolls out CHOMax: integrated CHO cell‑line and early manufacturing https://biobriefs.com/cellares-inks-city-of-hope BioBriefs en 2026-01-10T21:32:52Z Cellares inks City of Hope deal – automate solid‑tumor CAR T manufacture https://biobriefs.com/aktis-prices-ipo-at-18 BioBriefs en 2026-01-10T16:33:17Z Aktis prices IPO at $18 — raises $318M for radiopharma push https://biobriefs.com/illumina-taps-former-nhgri-director BioBriefs en 2026-01-10T16:33:17Z Illumina taps former NHGRI director: Eric Green named CMO https://biobriefs.com/merck-in-talks-to-buy BioBriefs en 2026-01-10T16:33:17Z Merck in talks to buy Revolution — potential $28–32bn interest reported https://biobriefs.com/lilly-to-buy-ventyx-for BioBriefs en 2026-01-10T16:33:17Z Lilly to buy Ventyx for $1.2B — adds NLRP3 inflammation program https://biobriefs.com/baby-kj-team-launches-aurora BioBriefs en 2026-01-10T16:33:17Z Baby KJ team launches Aurora: startup to scale bespoke CRISPR therapies https://biobriefs.com/alveus-raises-160m-to-fast BioBriefs en 2026-01-10T16:33:17Z Alveus raises $160M to fast‑track MariTide‑like obesity candidate https://biobriefs.com/private-biotechs-pull-in-2b BioBriefs en 2026-01-10T16:33:17Z Private biotechs pull in $2B in huge fundraising week https://biobriefs.com/cellares-and-city-of-hope BioBriefs en 2026-01-10T16:33:17Z Cellares and City of Hope partner to automate CAR‑T for glioblastoma https://biobriefs.com/krystal-reports-early-proof-of BioBriefs en 2026-01-10T16:33:17Z Krystal reports early proof‑of‑concept for mutation‑agnostic CF gene therapy https://biobriefs.com/bio-launches-investment-council-to BioBriefs en 2026-01-10T16:33:17Z BIO launches Investment Council to connect VCs and small biotech innovators https://biobriefs.com/aktis-ipo-pops-radiopharma-startup BioBriefs en 2026-01-10T14:32:21Z Aktis IPO Pops: Radiopharma Startup Raises $318M https://biobriefs.com/lilly-buys-ventyx-for-1 BioBriefs en 2026-01-10T14:32:21Z Lilly buys Ventyx for $1.2B – NLRP3 play expands https://biobriefs.com/parabilis-raises-305m-backing-undruggable BioBriefs en 2026-01-10T14:32:21Z Parabilis Raises $305M – Backing 'Undruggable' Oncology Targets https://biobriefs.com/boltz-launches-open-science-ai BioBriefs en 2026-01-10T14:32:21Z Boltz Launches: Open‑Science AI for Drug Design with $28M Seed https://biobriefs.com/krystals-early-cf-gene-therapy BioBriefs en 2026-01-10T14:32:21Z Krystal’s early CF gene therapy shows promise: eyes pivotal move https://biobriefs.com/orca-secures-250m-to-back BioBriefs en 2026-01-10T14:32:21Z Orca secures $250M to back T‑cell therapy launch https://biobriefs.com/airnexis-gets-200m-licenses-china BioBriefs en 2026-01-10T14:32:21Z AirNexis gets $200M, licenses China COPD asset AN01 https://biobriefs.com/eikon-files-for-us-ipo BioBriefs en 2026-01-10T14:32:21Z Eikon files for US IPO — testing biotech market appetite https://biobriefs.com/illumina-names-eric-green-cmo BioBriefs en 2026-01-10T14:32:21Z Illumina names Eric Green CMO: Genomics steers clinical edge https://biobriefs.com/bio-launches-investment-council-vcs BioBriefs en 2026-01-10T14:32:21Z BIO launches Investment Council: VCs meet small biotechs https://biobriefs.com/aktis-ipo-pops-radiopharma-raises BioBriefs en 2026-01-10T10:32:44Z Aktis IPO Pops – Radiopharma Raises $318M https://biobriefs.com/lilly-buys-ventyx-for-1 BioBriefs en 2026-01-10T10:32:44Z Lilly buys Ventyx for $1.2B – NLRP3 bet https://biobriefs.com/parabilis-closes-305m-undruggable-proteins BioBriefs en 2026-01-10T10:32:44Z Parabilis closes $305M — 'Undruggable' proteins in sight https://biobriefs.com/boltz-launches-pbc-with-28m BioBriefs en 2026-01-10T10:32:44Z Boltz launches PBC with $28M — Open AI for drug discovery https://biobriefs.com/baby-kj-team-spins-out BioBriefs en 2026-01-10T10:32:44Z Baby KJ team spins out Aurora — Betting on bespoke CRISPR path https://biobriefs.com/illumina-taps-eric-green-as BioBriefs en 2026-01-10T10:32:44Z Illumina taps Eric Green as CMO — Clinical genomics pivot https://biobriefs.com/epibiologics-bags-107m-protein-degrading BioBriefs en 2026-01-10T10:32:44Z EpiBiologics bags $107M — Protein‑degrading antibodies head to clinic https://biobriefs.com/airnexis-takes-flight-with-200m BioBriefs en 2026-01-10T10:32:44Z AirNexis takes flight with $200M, buys China COPD asset https://biobriefs.com/alveus-launches-with-160m-targeting BioBriefs en 2026-01-10T10:32:44Z Alveus launches with $160M — Targeting MariTide's landscape https://biobriefs.com/krystal-reports-early-cf-gene BioBriefs en 2026-01-10T10:32:44Z Krystal reports early CF gene‑therapy signal — Eyes pivotal https://biobriefs.com/aktis-ipo-318m-raises-radiopharma BioBriefs en 2026-01-10T09:32:44Z Aktis IPO: $318M raises radiopharma hopes https://biobriefs.com/lilly-buys-ventyx-1-2b BioBriefs en 2026-01-10T09:32:44Z Lilly buys Ventyx: $1.2B bet on NLRP3 inhibitors https://biobriefs.com/parabilis-raises-305m-targets-undruggable BioBriefs en 2026-01-10T09:32:44Z Parabilis raises $305M – Targets 'undruggable' proteins https://biobriefs.com/epibiologics-closes-107m-to-take BioBriefs en 2026-01-10T09:32:44Z EpiBiologics closes $107M to take EPI‑326 into clinic https://biobriefs.com/aurora-launches-bet-on-bespoke BioBriefs en 2026-01-10T09:32:44Z Aurora launches... Bet on bespoke CRISPR pathway https://biobriefs.com/illumina-names-eric-green-as BioBriefs en 2026-01-10T09:32:44Z Illumina names Eric Green as CMO – Genomics pivots to clinic https://biobriefs.com/boltz-launches-with-28m-open BioBriefs en 2026-01-10T09:32:44Z Boltz launches with $28M... Open AI models for drug discovery https://biobriefs.com/pfizer-taps-gordian-for-in BioBriefs en 2026-01-10T09:32:44Z Pfizer taps Gordian for in vivo obesity target hunt https://biobriefs.com/krystal-reports-early-proof-of BioBriefs en 2026-01-10T09:32:44Z Krystal reports early proof‑of‑concept for mutation‑agnostic CF therapy https://biobriefs.com/bio-launches-investment-council-vc BioBriefs en 2026-01-10T09:32:44Z BIO launches Investment Council – VC‑biotech bridge to speed capital https://biobriefs.com/aktis-ipo-raises-318m-radiopharma BioBriefs en 2026-01-10T04:32:57Z Aktis IPO Raises $318M – Radiopharma Rally https://biobriefs.com/lilly-pays-1-2b-for BioBriefs en 2026-01-10T04:32:57Z Lilly Pays $1.2B for Ventyx – NLRP3 Bet https://biobriefs.com/merck-eyes-revolution-medicines-28 BioBriefs en 2026-01-10T04:32:57Z Merck Eyes Revolution Medicines: $28–32B Talks https://biobriefs.com/illumina-taps-eric-green-clinical BioBriefs en 2026-01-10T04:32:57Z Illumina Taps Eric Green: Clinical Push Ahead https://biobriefs.com/boltz-launches-as-pbc-with BioBriefs en 2026-01-10T04:32:57Z Boltz Launches as PBC with $28M — Open AI for Drug Discovery https://biobriefs.com/baby-kj-team-spins-aurora BioBriefs en 2026-01-10T04:32:57Z Baby KJ Team Spins Aurora Therapeutics — $16M Seed https://biobriefs.com/epibiologics-raises-107m-to-advance BioBriefs en 2026-01-10T04:32:57Z EpiBiologics Raises $107M to Advance Protein‑Degrading Antibodies https://biobriefs.com/cellares-and-city-of-hope BioBriefs en 2026-01-10T04:32:57Z Cellares and City of Hope Partner to Automate Solid‑Tumor CAR‑T Manufacturing https://biobriefs.com/gsk-licenses-noetik-foundation-models BioBriefs en 2026-01-10T04:32:57Z GSK Licenses Noetik Foundation Models: $50M Upfront https://biobriefs.com/guardants-shield-wins-tricare-coverage BioBriefs en 2026-01-10T04:32:57Z Guardant’s Shield Wins Tricare Coverage — Military Access Expanded https://biobriefs.com/aktis-prices-upsized-ipo-raises BioBriefs en 2026-01-09T21:33:15Z Aktis prices upsized IPO — Raises $318M https://biobriefs.com/lilly-buys-ventyx-1-2b BioBriefs en 2026-01-09T21:33:15Z Lilly buys Ventyx — $1.2B bet on oral NLRP3 inhibitors https://biobriefs.com/openai-brings-chatgpt-into-care BioBriefs en 2026-01-09T21:33:15Z OpenAI brings ChatGPT into care — Hospitals get ChatGPT Health https://biobriefs.com/aurora-launches-betting-on-fdas BioBriefs en 2026-01-09T21:33:15Z Aurora launches—betting on FDA’s bespoke CRISPR pathway https://biobriefs.com/boltz-spawns-open-ai-drug BioBriefs en 2026-01-09T21:33:15Z Boltz spawns open AI drug platform — $28M seed backs open models https://biobriefs.com/parabilis-raises-305m-eyeing-ipo BioBriefs en 2026-01-09T21:33:15Z Parabilis raises $305M — Eyeing IPO to fund peptide program https://biobriefs.com/orca-pulls-250m-to-launch BioBriefs en 2026-01-09T21:33:15Z Orca pulls $250M to launch allogeneic T‑cell therapy https://biobriefs.com/cellares-and-city-of-hope BioBriefs en 2026-01-09T21:33:15Z Cellares and City of Hope to automate CAR‑T for glioblastoma https://biobriefs.com/aragen-launches-chomax-dna-to BioBriefs en 2026-01-09T21:33:15Z Aragen launches CHOMax — DNA‑to‑IND CHO platform https://biobriefs.com/syantra-launches-2000-patient-study BioBriefs en 2026-01-09T21:33:15Z Syantra launches 2,000‑patient study for early breast cancer blood test https://biobriefs.com/lilly-snaps-up-ventyx-for BioBriefs en 2026-01-09T16:32:44Z Lilly snaps up Ventyx for $1.2bn – NLRP3 drugs added https://biobriefs.com/amgen-buys-dark-blue-ramps BioBriefs en 2026-01-09T16:32:44Z Amgen buys Dark Blue – ramps targeted‑protein degradation push https://biobriefs.com/aktis-goes-public-318m-raised BioBriefs en 2026-01-09T16:32:44Z Aktis goes public: $318m raised for radiopharma rollout https://biobriefs.com/parabilis-raises-305m-aims-at BioBriefs en 2026-01-09T16:32:44Z Parabilis raises $305m: aims at ‘undruggable’ cancer targets https://biobriefs.com/airnexis-secures-200m-licenses-china BioBriefs en 2026-01-09T16:32:44Z AirNexis secures $200m, licenses China COPD asset for US program https://biobriefs.com/cellares-and-city-of-hope BioBriefs en 2026-01-09T16:32:44Z Cellares and City of Hope to automate CAR‑T manufacturing for glioblastoma https://biobriefs.com/aurora-launches-to-scale-bespoke BioBriefs en 2026-01-09T16:32:44Z Aurora launches to scale bespoke CRISPR therapies under new FDA pathway https://biobriefs.com/gsk-licenses-noetiks-cancer-foundation BioBriefs en 2026-01-09T16:32:44Z GSK licenses Noetik’s cancer foundation models in $50m pact https://biobriefs.com/epibiologics-raises-107m-to-ready BioBriefs en 2026-01-09T16:32:44Z EpiBiologics raises $107m to ready protein‑degrading antibody for clinic https://biobriefs.com/medipost-raises-140m-to-bring BioBriefs en 2026-01-09T16:32:44Z Medipost raises $140m to bring Korean stem‑cell therapy to US and Japan https://biobriefs.com/lilly-pays-1-2b-for BioBriefs en 2026-01-09T14:33:00Z Lilly pays $1.2B for Ventyx — buys NLRP3 inflammation program https://biobriefs.com/merck-in-talks-to-buy BioBriefs en 2026-01-09T14:33:00Z Merck in talks to buy Revolution Medicines – $28–32bn reported https://biobriefs.com/aktis-upsized-ipo-raises-318m BioBriefs en 2026-01-09T14:33:00Z Aktis upsized IPO raises $318M — radiopharma player hits Nasdaq https://biobriefs.com/parabilis-lands-305m-series-f BioBriefs en 2026-01-09T14:33:00Z Parabilis lands $305M Series F — pushes peptide platform toward clinic https://biobriefs.com/epibiologics-raises-107m-protein-degrader BioBriefs en 2026-01-09T14:33:00Z EpiBiologics raises $107M — protein‑degrader antibody nears human testing https://biobriefs.com/immuneerings-mek-pill-posts-strong BioBriefs en 2026-01-09T14:33:00Z Immuneering’s MEK pill posts strong survival update — 64% at 12 months https://biobriefs.com/cellares-city-of-hope-to BioBriefs en 2026-01-09T14:33:00Z Cellares, City of Hope to automate CAR‑T manufacturing for glioblastoma https://biobriefs.com/openai-launches-chatgpt-for-healthcare BioBriefs en 2026-01-09T14:33:00Z OpenAI launches ChatGPT for Healthcare — enterprise push into hospitals https://biobriefs.com/analysis-fda-staff-cuts-mostly BioBriefs en 2026-01-09T14:33:00Z Analysis: FDA staff cuts mostly didn’t slow new‑drug reviews https://biobriefs.com/guardants-shield-nabs-tricare-coverage BioBriefs en 2026-01-09T14:33:00Z Guardant’s Shield nabs Tricare coverage — expands military access https://biobriefs.com/lilly-shells-out-1-2b BioBriefs en 2026-01-09T10:33:29Z Lilly shells out $1.2B for Ventyx – oral NLRP3 bet https://biobriefs.com/aktis-prices-ipo-at-18 BioBriefs en 2026-01-09T10:33:29Z Aktis prices IPO at $18 – $318M to advance radiopharma pipeline https://biobriefs.com/mediar-closes-76m-series-b BioBriefs en 2026-01-09T10:33:29Z Mediar closes $76M Series B: anti‑fibrotics advance to clinic https://biobriefs.com/parabilis-nets-305m-series-f BioBriefs en 2026-01-09T10:33:29Z Parabilis nets $305M Series F – corkscrew peptides eye late‑stage push https://biobriefs.com/epibiologics-raises-107m-to-push BioBriefs en 2026-01-09T10:33:29Z EpiBiologics raises $107M to push protein‑degrading antibody into clinic https://biobriefs.com/immuneerings-mek-candidate-posts-strong BioBriefs en 2026-01-09T10:33:29Z Immuneering’s MEK candidate posts strong updated survival in first‑line pancreatic study https://biobriefs.com/openai-moves-into-health-systems BioBriefs en 2026-01-09T10:33:29Z OpenAI moves into health systems: ChatGPT for Healthcare and consumer health tool https://biobriefs.com/gsk-ionis-say-antisense-therapy BioBriefs en 2026-01-09T10:33:29Z GSK, Ionis say antisense therapy meets functional‑cure goal in hepatitis B trials https://biobriefs.com/alveus-launches-with-160m-maritide BioBriefs en 2026-01-09T10:33:29Z Alveus launches with $160M — MariTide‑style candidate enters obesity race https://biobriefs.com/storm-therapeutics-partners-with-alidabio BioBriefs en 2026-01-09T10:33:29Z Storm Therapeutics partners with AlidaBio to map m6A dynamics in cancer trials https://biobriefs.com/radiopharma-ipo-opens-nasdaq-aktis BioBriefs en 2026-01-09T09:34:53Z Radiopharma IPO Opens Nasdaq: Aktis raises $318M https://biobriefs.com/lilly-pays-1-2b-for BioBriefs en 2026-01-09T09:34:53Z Lilly Pays $1.2B for Ventyx – Push into NLRP3 inflammation drugs https://biobriefs.com/parabilis-pulls-305m-series-f BioBriefs en 2026-01-09T09:34:53Z Parabilis Pulls $305M Series F – Tackling 'undruggable' cancer targets https://biobriefs.com/immuneerings-mek-pill-posts-strong BioBriefs en 2026-01-09T09:34:53Z Immuneering’s MEK Pill Posts Strong Survival – Pancreatic update https://biobriefs.com/gsk-and-ionis-claim-phase BioBriefs en 2026-01-09T09:34:53Z GSK and Ionis Claim Phase III Wins — Hepatitis B 'functional cure' https://biobriefs.com/storm-and-alida-link-up BioBriefs en 2026-01-09T09:34:53Z Storm and Alida Link Up to Track m6A Biomarkers in METTL3 Trials https://biobriefs.com/epibiologics-raises-107m-protein-degrader BioBriefs en 2026-01-09T09:34:53Z EpiBiologics Raises $107M — Protein‑degrader Antibodies Move to Clinic https://biobriefs.com/openai-moves-into-hospitals-chatgpt BioBriefs en 2026-01-09T09:34:53Z OpenAI Moves Into Hospitals: ChatGPT for Healthcare Launches https://biobriefs.com/illumina-recruits-ex-nhgri-director BioBriefs en 2026-01-09T09:34:53Z Illumina Recruits Ex‑NHGRI Director as CMO https://biobriefs.com/alveus-launches-with-160m-to BioBriefs en 2026-01-09T09:34:53Z Alveus Launches With $160M to Take On MariTide's Market https://biobriefs.com/lilly-buys-ventyx-for-1 BioBriefs en 2026-01-09T04:33:32Z Lilly buys Ventyx for $1.2B — NLRP3 drugs in focus https://biobriefs.com/aktis-prices-318m-ipo-radiopharma BioBriefs en 2026-01-09T04:33:32Z Aktis prices $318M IPO — radiopharma returns to market https://biobriefs.com/parabilis-closes-305m-series-f BioBriefs en 2026-01-09T04:33:32Z Parabilis closes $305M Series F — 'undruggable' proteins targeted https://biobriefs.com/epibiologics-nets-107m-to-advance BioBriefs en 2026-01-09T04:33:32Z EpiBiologics nets $107M to advance protein-degrading antibody drugs https://biobriefs.com/gsk-ionis-report-phase-3 BioBriefs en 2026-01-09T04:33:32Z GSK, Ionis report Phase 3 wins for bepirovirsen — approval push begins https://biobriefs.com/immuneerings-mek-pill-posts-strong BioBriefs en 2026-01-09T04:33:32Z Immuneering’s MEK pill posts strong survival readout in pancreatic cancer https://biobriefs.com/openai-rolls-chatgpt-into-hospitals BioBriefs en 2026-01-09T04:33:32Z OpenAI rolls ChatGPT into hospitals — asks for health data https://biobriefs.com/alveus-raises-160m-to-chase BioBriefs en 2026-01-09T04:33:32Z Alveus raises $160M to chase MariTide-like obesity program https://biobriefs.com/cbs-stem-cell-route-to BioBriefs en 2026-01-09T04:33:32Z CBS: Stem cell route to helper T cells could enable off‑the‑shelf cell therapies https://biobriefs.com/storm-therapeutics-partners-with-alidabio BioBriefs en 2026-01-09T04:33:32Z Storm Therapeutics partners with AlidaBio to track m6A changes in METTL3 trials https://biobriefs.com/lilly-snaps-up-ventyx-1 BioBriefs en 2026-01-08T21:33:20Z Lilly snaps up Ventyx – $1.2B buy expands oral inflammation arsenal https://biobriefs.com/parabilis-raises-305m-vc-vote BioBriefs en 2026-01-08T21:33:20Z Parabilis raises $305M – VC vote for 'undruggable' protein strategy https://biobriefs.com/epibiologics-nets-107m-protein-degraders BioBriefs en 2026-01-08T21:33:20Z EpiBiologics nets $107M – protein degraders draw Big Pharma backers https://biobriefs.com/vizgen-raises-48m-spatial-biology BioBriefs en 2026-01-08T21:33:20Z Vizgen raises $48M – spatial biology tools race heats up https://biobriefs.com/guardants-shield-wins-tricare-coverage BioBriefs en 2026-01-08T21:33:20Z Guardant’s Shield wins Tricare coverage – screening goes military-wide https://biobriefs.com/storm-therapeutics-partners-with-alida BioBriefs en 2026-01-08T21:33:20Z Storm Therapeutics partners with Alida – m6A biomarkers hit the clinic https://biobriefs.com/gsk-ionis-report-phase-3 BioBriefs en 2026-01-08T21:33:20Z GSK, Ionis report Phase 3 wins — bepirovirsen poised for regulatory push https://biobriefs.com/gordian-and-pfizer-team-up BioBriefs en 2026-01-08T21:33:20Z Gordian and Pfizer team up – in vivo screens seek obesity targets https://biobriefs.com/immuneerings-pancreatic-pill-posts-survival BioBriefs en 2026-01-08T21:33:20Z Immuneering’s pancreatic pill posts survival edge – pivotal plans loom https://biobriefs.com/fda-cuts-didnt-derail-review BioBriefs en 2026-01-08T21:33:20Z FDA cuts didn’t derail review clocks – staff kept drug timetables intact https://biobriefs.com/lilly-buys-ventyx-for-1 BioBriefs en 2026-01-08T16:33:00Z Lilly buys Ventyx for $1.2B – bolsters oral NLRP3 pipeline https://biobriefs.com/parabilis-raises-305m-pushes-corkscrew BioBriefs en 2026-01-08T16:33:00Z Parabilis raises $305M — pushes corkscrew peptides toward late‑stage testing https://biobriefs.com/epibiologics-nets-107m-prepares-epi BioBriefs en 2026-01-08T16:33:00Z EpiBiologics nets $107M — prepares EPI‑326 for first‑in‑human studies https://biobriefs.com/alumis-tyk2-pill-tops-phase BioBriefs en 2026-01-08T16:33:00Z Alumis’ TYK2 pill tops Phase III — envudeucitinib stakes psoriasis claim https://biobriefs.com/immuneerings-pancreatic-pill-posts-64 BioBriefs en 2026-01-08T16:33:00Z Immuneering’s pancreatic pill posts 64% one‑year survival — pivotal next https://biobriefs.com/gsk-and-ionis-claim-phase BioBriefs en 2026-01-08T16:33:00Z GSK and Ionis claim Phase III wins for bepirovirsen — filings planned https://biobriefs.com/gsk-licenses-noetiks-cancer-foundation BioBriefs en 2026-01-08T16:33:00Z GSK licenses Noetik’s cancer foundation models — $50M upfront https://biobriefs.com/guardants-shield-wins-tricare-coverage BioBriefs en 2026-01-08T16:33:00Z Guardant’s Shield wins Tricare coverage — military members gain copay‑free CRC blood test https://biobriefs.com/diagonal-raises-125m-clustering-antibodies BioBriefs en 2026-01-08T16:33:00Z Diagonal raises $125M — clustering antibodies head to first‑in‑human https://biobriefs.com/vizgen-raises-48m-scales-merfish BioBriefs en 2026-01-08T16:33:00Z Vizgen raises $48M — scales MERFISH spatial biology and commercial push https://biobriefs.com/lilly-buys-ventyx-for-1 BioBriefs en 2026-01-08T14:34:00Z Lilly buys Ventyx for $1.2B – Acquires NLRP3 oral drugs https://biobriefs.com/parabilis-raises-305m-push-to BioBriefs en 2026-01-08T14:34:00Z Parabilis raises $305M: Push to advance corkscrew peptides into late-stage cancer testing https://biobriefs.com/epibiologics-nets-107m-funds-first BioBriefs en 2026-01-08T14:34:00Z EpiBiologics nets $107M – Funds first-in-human protein-degrading antibody https://biobriefs.com/alumis-tyk2-pill-clears-phase BioBriefs en 2026-01-08T14:34:00Z Alumis’ TYK2 pill clears Phase III – Psoriasis efficacy intensifies competition https://biobriefs.com/gsk-ionis-claim-phase-3 BioBriefs en 2026-01-08T14:34:00Z GSK, Ionis claim Phase 3 win: Bepirovirsen meets functional cure endpoints https://biobriefs.com/spatial-biology-vizgen-raises-48m BioBriefs en 2026-01-08T14:34:00Z Spatial biology... Vizgen raises $48M; Singleron expands ANZ distribution https://biobriefs.com/pfizer-taps-gordians-in-vivo BioBriefs en 2026-01-08T14:34:00Z Pfizer taps Gordian’s in vivo mosaic screens: Target discovery inside visceral fat https://biobriefs.com/sanofi-inks-up-to-2 BioBriefs en 2026-01-08T14:34:00Z Sanofi inks up-to-$2.56B Earendil pact – AI to discover bispecifics https://biobriefs.com/tessera-to-lay-off-90 BioBriefs en 2026-01-08T14:34:00Z Tessera to lay off 90 as it begins first clinical study https://biobriefs.com/gsk-taps-helix-database-clinico BioBriefs en 2026-01-08T14:34:00Z GSK taps Helix database: Clinico‑genomic access for precision-medicine R&D https://biobriefs.com/lilly-snaps-up-ventyx-1 BioBriefs en 2026-01-08T10:33:07Z Lilly snaps up Ventyx – $1.2B bet on oral NLRP3 https://biobriefs.com/gsk-ionis-claim-hep-b BioBriefs en 2026-01-08T10:33:07Z GSK, Ionis claim hep B win: Phase 3 hits functional-cure goals https://biobriefs.com/alumis-tyk2-pill-shines-phase BioBriefs en 2026-01-08T10:33:07Z Alumis’ TYK2 pill shines – Phase 3 clears psoriasis hurdles https://biobriefs.com/amgen-swoops-on-european-oncology BioBriefs en 2026-01-08T10:33:07Z Amgen swoops on European oncology: two deals worth $1.46B https://biobriefs.com/sanofi-inks-ai-bispecific-pact BioBriefs en 2026-01-08T10:33:07Z Sanofi inks AI bispecific pact: Earendil deal tops $2.5B https://biobriefs.com/arrowhead-rnai-shows-early-adipose BioBriefs en 2026-01-08T10:33:07Z Arrowhead RNAi shows early adipose POC – obesity programs advance https://biobriefs.com/cdc-pares-pediatric-schedule-industry BioBriefs en 2026-01-08T10:33:07Z CDC pares pediatric schedule: industry alarms sound https://biobriefs.com/cortical-gene-therapy-mimics-opioid BioBriefs en 2026-01-08T10:33:07Z Cortical gene therapy mimics opioid pain relief – no addiction in mice https://biobriefs.com/engineered-omvs-amplify-car-t BioBriefs en 2026-01-08T10:33:07Z Engineered OMVs amplify CAR‑T efficacy in solid tumors https://biobriefs.com/boron-neutron-capture-therapy-preserves BioBriefs en 2026-01-08T10:33:07Z Boron neutron capture therapy preserves immunity, primes tumor response https://biobriefs.com/lilly-seals-1-2b-buyout BioBriefs en 2026-01-08T09:33:48Z Lilly seals $1.2B buyout—adds oral NLRP3 drugs https://biobriefs.com/alumis-tyk2-win-psoriasis-stakes BioBriefs en 2026-01-08T09:33:48Z Alumis’ TYK2 win—psoriasis stakes rewritten https://biobriefs.com/gsk-ionis-claim-phase-3 BioBriefs en 2026-01-08T09:33:48Z GSK, Ionis claim Phase 3 win—bepirovirsen reaches functional cure https://biobriefs.com/amgen-expands-oncology-by-buying BioBriefs en 2026-01-08T09:33:48Z Amgen expands oncology by buying Dark Blue—AML degrader added https://biobriefs.com/sanofi-bets-2-56b-on BioBriefs en 2026-01-08T09:33:48Z Sanofi bets $2.56B on Earendil’s AI bispecific discovery https://biobriefs.com/obesity-dealmaking-surges-lilly-nimbus BioBriefs en 2026-01-08T09:33:48Z Obesity dealmaking surges—Lilly, Nimbus $1.3B; RNAi shows fat loss https://biobriefs.com/hhs-pares-pediatric-schedule-industry BioBriefs en 2026-01-08T09:33:48Z HHS pares pediatric schedule—industry raises alarms https://biobriefs.com/openai-rolls-chatgpt-health-seeks BioBriefs en 2026-01-08T09:33:48Z OpenAI rolls ChatGPT Health—seeks richer health data https://biobriefs.com/rakuten-raises-100m-pushes-photoimmunotherapy BioBriefs en 2026-01-08T09:33:48Z Rakuten raises $100M—pushes photoimmunotherapy toward FDA filing https://biobriefs.com/ngs-and-multiomic-tools-advance BioBriefs en 2026-01-08T09:33:48Z NGS and multiomic tools advance—MD Anderson, Sophia; Illumina software https://biobriefs.com/lilly-pays-1-2b-for BioBriefs en 2026-01-08T04:33:11Z Lilly pays $1.2B for Ventyx: adds oral NLRP3 program https://biobriefs.com/gsk-ionis-bepirovirsen-hits-functional BioBriefs en 2026-01-08T04:33:11Z GSK, Ionis: bepirovirsen hits functional cure endpoints – filings planned https://biobriefs.com/amgen-spends-up-to-1 BioBriefs en 2026-01-08T04:33:11Z Amgen spends up to $1.46B – buys Dark Blue, licenses Disco target https://biobriefs.com/alumis-tyk2-pill-clears-phase BioBriefs en 2026-01-08T04:33:11Z Alumis’ TYK2 pill clears Phase 3 – stock surges https://biobriefs.com/arrowhead-rnai-shows-fat-loss BioBriefs en 2026-01-08T04:33:11Z Arrowhead RNAi shows fat loss with tirzepatide combo – adipose proof of concept https://biobriefs.com/sanofi-inks-up-to-2 BioBriefs en 2026-01-08T04:33:11Z Sanofi inks up‑to‑$2.56B Earendil deal: AI‑designed bispecifics https://biobriefs.com/bnct-preserves-immune-cells-engineered BioBriefs en 2026-01-08T04:33:11Z BNCT preserves immune cells; engineered OMVs amplify CAR‑T in solid tumors https://biobriefs.com/cns-and-ocular-gene-therapy BioBriefs en 2026-01-08T04:33:11Z CNS and ocular gene‑therapy moves: non‑addictive pain therapy and intravitreal delivery pact https://biobriefs.com/ai-drug-discovery-insilico-servier BioBriefs en 2026-01-08T04:33:11Z AI drug discovery: Insilico‑Servier oncology pact and 1910’s PEGASUS model https://biobriefs.com/cdc-trims-childhood-vaccine-schedule BioBriefs en 2026-01-08T04:33:11Z CDC trims childhood vaccine schedule: industry warns of risks https://biobriefs.com/gsk-ionis-claim-phase-3 BioBriefs en 2026-01-07T21:32:38Z GSK, Ionis claim Phase 3 success – filings planned https://biobriefs.com/gsk-taps-helixs-genosphere-clinico BioBriefs en 2026-01-07T21:32:38Z GSK taps Helix’s GenoSphere: clinico‑genomic data deal https://biobriefs.com/alumis-tyk2-pill-clears-phase BioBriefs en 2026-01-07T21:32:38Z Alumis’ TYK2 pill clears Phase 3: approval push begins https://biobriefs.com/amgen-buys-dark-blue-840m BioBriefs en 2026-01-07T21:32:38Z Amgen buys Dark Blue – $840M deal for targeted degrader https://biobriefs.com/sanofi-inks-2-56b-ai BioBriefs en 2026-01-07T21:32:38Z Sanofi inks $2.56B AI bispecific deal with Earendil https://biobriefs.com/lilly-returns-to-nimbus-55m BioBriefs en 2026-01-07T21:32:38Z Lilly returns to Nimbus: $55M upfront for oral obesity program https://biobriefs.com/arrowhead-shows-early-fat-loss BioBriefs en 2026-01-07T21:32:38Z Arrowhead shows early fat‑loss signal in RNAi obesity tests https://biobriefs.com/variant-bio-boehringer-ink-120m BioBriefs en 2026-01-07T21:32:38Z Variant Bio, Boehringer ink $120M kidney disease pact https://biobriefs.com/pfizer-taps-cartography-to-hunt BioBriefs en 2026-01-07T21:32:38Z Pfizer taps Cartography to hunt tumor‑selective antigens – deal upsides https://biobriefs.com/cdc-trims-childhood-vaccine-recommendations BioBriefs en 2026-01-07T21:32:38Z CDC trims childhood vaccine recommendations: schedule reduced https://biobriefs.com/gsk-ionis-phase-3-win BioBriefs en 2026-01-07T16:33:36Z GSK, Ionis phase 3 win: bepirovirsen meets endpoints in chronic hepatitis B https://biobriefs.com/cdc-cuts-pediatric-vaccine-schedule BioBriefs en 2026-01-07T16:33:36Z CDC cuts pediatric vaccine schedule... BIO and industry warn of health risks https://biobriefs.com/sanofi-taps-earendil-ai-2 BioBriefs en 2026-01-07T16:33:36Z Sanofi taps Earendil AI: $2.56bn bispecific antibody pact https://biobriefs.com/amgen-buys-dark-blue-up BioBriefs en 2026-01-07T16:33:36Z Amgen buys Dark Blue: up to $840M for AML protein degrader https://biobriefs.com/alumis-envudeucitinib-clears-phase-3 BioBriefs en 2026-01-07T16:33:36Z Alumis envudeucitinib clears Phase 3 — TYK2 contender for psoriasis https://biobriefs.com/arrowhead-rnai-delivers-early-adipose BioBriefs en 2026-01-07T16:33:36Z Arrowhead RNAi delivers early adipose proof‑of‑concept in obesity https://biobriefs.com/lilly-returns-to-nimbus-1 BioBriefs en 2026-01-07T16:33:36Z Lilly returns to Nimbus: $1.3bn pact for an oral obesity candidate https://biobriefs.com/insilico-servier-sign-888m-ai BioBriefs en 2026-01-07T16:33:36Z Insilico, Servier sign $888M AI oncology collaboration https://biobriefs.com/signatera-to-guide-exelixis-phase BioBriefs en 2026-01-07T16:33:36Z Signatera to guide Exelixis Phase 3 — MRD‑directed adjuvant trial for colorectal cancer https://biobriefs.com/moderna-files-for-mrna-flu BioBriefs en 2026-01-07T16:33:36Z Moderna files for mRNA flu vaccine approval — mRNA‑1010 targets older adults https://biobriefs.com/cdc-reduces-routine-childhood-vaccines BioBriefs en 2026-01-07T14:34:12Z CDC reduces routine childhood vaccines: White House directive reshapes U.S. schedule https://biobriefs.com/sanofi-doubles-down-on-ai BioBriefs en 2026-01-07T14:34:12Z Sanofi doubles down on AI bispecifics: $2.56bn Earendil alliance https://biobriefs.com/amgen-acquires-dark-blue-up BioBriefs en 2026-01-07T14:34:12Z Amgen acquires Dark Blue: up to $840M for AML protein degrader https://biobriefs.com/alumis-tyk2-pill-clears-phase BioBriefs en 2026-01-07T14:34:12Z Alumis’ TYK2 pill clears Phase 3 — pivotal psoriasis data propel filing plans https://biobriefs.com/gsks-hepatitis-b-aso-succeeds BioBriefs en 2026-01-07T14:34:12Z GSK’s hepatitis B ASO succeeds in Phase 3 — approval pathway opens https://biobriefs.com/big-bets-on-obesity-r BioBriefs en 2026-01-07T14:34:12Z Big bets on obesity R&D: Lilly returns to Nimbus; RNAi shows early fat loss https://biobriefs.com/ai-deals-accelerate-discovery-insilico BioBriefs en 2026-01-07T14:34:12Z AI deals accelerate discovery: Insilico, Variant Bio land major pharma pacts https://biobriefs.com/autoimmune-pipeline-activity-hutchmed-phase BioBriefs en 2026-01-07T14:34:12Z Autoimmune pipeline activity: Hutchmed Phase 3 win; J&J expands lupus program https://biobriefs.com/cell-therapy-crossroads-car-t BioBriefs en 2026-01-07T14:34:12Z Cell therapy crossroads: CAR‑T setbacks and CAR‑NK progress https://biobriefs.com/appeals-court-blocks-nih-overhead BioBriefs en 2026-01-07T14:34:12Z Appeals court blocks NIH overhead cap: funding stability for institutions https://biobriefs.com/amgen-buys-dark-blue-840m BioBriefs en 2026-01-07T10:33:09Z Amgen buys Dark Blue – $840M push into protein degradation https://biobriefs.com/alumis-tyk2-pill-aces-phase BioBriefs en 2026-01-07T10:33:09Z Alumis’ TYK2 pill aces Phase 3 – approval bid begins https://biobriefs.com/cdc-cuts-pediatric-vaccine-recommendations BioBriefs en 2026-01-07T10:33:09Z CDC cuts pediatric vaccine recommendations – industry alarm https://biobriefs.com/lilly-returns-to-nimbus-1 BioBriefs en 2026-01-07T10:33:09Z Lilly returns to Nimbus – $1.3B oral obesity pact https://biobriefs.com/arrowheads-rnai-obesity-assets-show BioBriefs en 2026-01-07T10:33:09Z Arrowhead’s RNAi obesity assets show early fat-loss proof – move to Phase 2 https://biobriefs.com/ai-discovery-deals-multiply-insilico BioBriefs en 2026-01-07T10:33:09Z AI discovery deals multiply – Insilico, Earendil, Servier and Sanofi ink big pacts https://biobriefs.com/moderna-files-mrna-flu-vaccine BioBriefs en 2026-01-07T10:33:09Z Moderna files mRNA flu vaccine with regulators – global submissions under way https://biobriefs.com/zenas-obexelimab-clears-phase-3 BioBriefs en 2026-01-07T10:33:09Z Zenas’ obexelimab clears Phase 3 yet investors punish stock – competitive caveats https://biobriefs.com/stereotaxis-wins-fda-nod-for BioBriefs en 2026-01-07T10:33:09Z Stereotaxis wins FDA nod for magnetic ablation catheter https://biobriefs.com/pfizer-bets-on-tumor-selective BioBriefs en 2026-01-07T10:33:09Z Pfizer bets on tumor-selective antigens — Cartography collaboration could top $865M https://biobriefs.com/cdc-trims-pediatric-vaccine-recommendations BioBriefs en 2026-01-07T09:33:08Z CDC trims pediatric vaccine recommendations — industry warns https://biobriefs.com/lilly-returns-to-nimbus-up BioBriefs en 2026-01-07T09:33:08Z Lilly returns to Nimbus — up-to-$1.3B oral obesity pact https://biobriefs.com/arrowhead-rnai-early-obesity-fat BioBriefs en 2026-01-07T09:33:08Z Arrowhead RNAi: early obesity fat-loss signal — adipose delivery POC https://biobriefs.com/amgen-to-buy-dark-blue BioBriefs en 2026-01-07T09:33:08Z Amgen to buy Dark Blue — up to $840M for protein degrader AML asset https://biobriefs.com/sanofi-to-buy-dynavax-for BioBriefs en 2026-01-07T09:33:08Z Sanofi to buy Dynavax for $2.2B — beefing up adult vaccines https://biobriefs.com/insilico-inks-888m-servier-oncology BioBriefs en 2026-01-07T09:33:08Z Insilico inks $888M Servier oncology pact — AI discovery validated https://biobriefs.com/alumis-tyk2-pill-clears-phase BioBriefs en 2026-01-07T09:33:08Z Alumis’ TYK2 pill clears Phase 3 — shares surge https://biobriefs.com/bright-minds-posts-seizure-reduction BioBriefs en 2026-01-07T09:33:08Z Bright Minds posts seizure reduction in Phase 2 — Phase 3 planned https://biobriefs.com/moderna-files-for-mrna-flu BioBriefs en 2026-01-07T09:33:08Z Moderna files for mRNA flu vaccine approval — mRNA-1010 in 50+ https://biobriefs.com/appeals-court-upholds-injunction-nih BioBriefs en 2026-01-07T09:33:08Z Appeals court upholds injunction — NIH barred from capping indirect costs https://biobriefs.com/lilly-returns-to-nimbus-1 BioBriefs en 2026-01-07T04:33:43Z Lilly returns to Nimbus – $1.3B oral obesity bet https://biobriefs.com/arrowhead-rnai-combo-shows-fat BioBriefs en 2026-01-07T04:33:43Z Arrowhead RNAi combo shows fat loss signals – Phase 2 next https://biobriefs.com/alumis-tyk2-pill-clears-phase BioBriefs en 2026-01-07T04:33:43Z Alumis’ TYK2 pill clears Phase 3 – stock rockets https://biobriefs.com/amgen-to-buy-dark-blue BioBriefs en 2026-01-07T04:33:43Z Amgen to buy Dark Blue – $840M deal for AML degrader https://biobriefs.com/sanofi-doubles-down-on-earendil BioBriefs en 2026-01-07T04:33:43Z Sanofi doubles down on Earendil – up to $2.56B bispecific push https://biobriefs.com/cdc-trims-routine-pediatric-vaccine BioBriefs en 2026-01-07T04:33:43Z CDC trims routine pediatric vaccine schedule: U.S. moves to 11 diseases https://biobriefs.com/appeals-court-preserves-grant-overheads BioBriefs en 2026-01-07T04:33:43Z Appeals court preserves grant overheads – NIH cap blocked https://biobriefs.com/bright-minds-posts-seizure-reduction BioBriefs en 2026-01-07T04:33:43Z Bright Minds posts seizure reduction in Phase 2 – Phase 3 ahead https://biobriefs.com/ai-discovery-surge-insilicos-888m BioBriefs en 2026-01-07T04:33:43Z AI discovery surge: Insilico’s $888M oncology pact and 1910’s PEGASUS model https://biobriefs.com/new-enabling-tools-illumina-s BioBriefs en 2026-01-07T04:33:43Z New enabling tools: Illumina's multiomics cloud and St. Jude’s CHANGE‑seq‑BE https://biobriefs.com/cdc-slashes-routine-childhood-shots BioBriefs en 2026-01-06T21:33:16Z CDC slashes routine childhood shots: U.S. schedule trimmed to 11 https://biobriefs.com/amgen-snaps-up-dark-blue BioBriefs en 2026-01-06T21:33:16Z Amgen snaps up Dark Blue: $840M deal to add protein degrader for leukemia https://biobriefs.com/lilly-returns-to-nimbus-1 BioBriefs en 2026-01-06T21:33:16Z Lilly returns to Nimbus: $1.3B pact for oral obesity program https://biobriefs.com/alumis-tyk2-pill-clears-pivotal BioBriefs en 2026-01-06T21:33:16Z Alumis’ TYK2 pill clears pivotal tests — prepares FDA filing https://biobriefs.com/arrowhead-rnai-plus-tirzepatide-shows BioBriefs en 2026-01-06T21:33:16Z Arrowhead RNAi plus tirzepatide shows early fat-loss gains — Phase 1 results https://biobriefs.com/moderna-files-for-mrna-flu BioBriefs en 2026-01-06T21:33:16Z Moderna files for mRNA flu shot: regulators in US, EU, Canada, Australia targeted https://biobriefs.com/pfizer-taps-cartography-to-map BioBriefs en 2026-01-06T21:33:16Z Pfizer taps Cartography to map tumor‑selective antigens — deal could top $865M https://biobriefs.com/deep-intelligent-pharma-raises-50m BioBriefs en 2026-01-06T21:33:16Z Deep Intelligent Pharma raises $50M to scale AI clinical‑trial automation https://biobriefs.com/st-jude-unveils-change-seq BioBriefs en 2026-01-06T21:33:16Z St. Jude unveils CHANGE‑seq‑BE: sensitive genome‑wide base‑editor profiling https://biobriefs.com/crispr-cas3-produces-long-deletions BioBriefs en 2026-01-06T21:33:16Z CRISPR–Cas3 produces long deletions, knocks down TTR in mice — distinct from Cas9 https://biobriefs.com/amgen-snaps-up-dark-blue BioBriefs en 2026-01-06T16:33:15Z Amgen snaps up Dark Blue Therapeutics — $840M deal to bolster AML degrader https://biobriefs.com/variant-bio-teams-with-boehringer BioBriefs en 2026-01-06T16:33:15Z Variant Bio teams with Boehringer — up to $120M for kidney‑target discovery https://biobriefs.com/insilico-inks-888m-oncology-pact BioBriefs en 2026-01-06T16:33:15Z Insilico inks $888M oncology pact with Servier after IPO https://biobriefs.com/pfizer-bets-on-tumor-selective BioBriefs en 2026-01-06T16:33:15Z Pfizer bets on tumor‑selective antigens — up to $865M pact with Cartography https://biobriefs.com/arrowhead-rnai-obesity-candidates-show BioBriefs en 2026-01-06T16:33:15Z Arrowhead RNAi obesity candidates show early fat‑loss — moving to Phase 2 https://biobriefs.com/zenas-meets-phase-iii-goal BioBriefs en 2026-01-06T16:33:15Z Zenas meets Phase III goal in IgG4‑RD — investors punish cross‑trial comparison https://biobriefs.com/novo-launches-wegovy-pill-25 BioBriefs en 2026-01-06T16:33:15Z Novo launches Wegovy pill — $25 insured, $149 cash list https://biobriefs.com/appeals-court-blocks-nih-15 BioBriefs en 2026-01-06T16:33:15Z Appeals court blocks NIH 15% indirect‑cost cap — injunction remains https://biobriefs.com/st-jude-maps-base-editor BioBriefs en 2026-01-06T16:33:15Z St. Jude maps base‑editor off‑targets; Cas3 delivers large TTR deletions in vivo https://biobriefs.com/illumina-launches-connected-multiomics-cloud BioBriefs en 2026-01-06T16:33:15Z Illumina launches Connected Multiomics — cloud AI for scaled multiomic analysis https://biobriefs.com/insilico-ipo-servier-inks-888m BioBriefs en 2026-01-06T14:33:16Z Insilico IPO... Servier inks $888M cancer pact https://biobriefs.com/pfizer-bets-on-tumor-selective BioBriefs en 2026-01-06T14:33:16Z Pfizer bets on tumor‑selective antigens – $865M Cartography deal https://biobriefs.com/sanofi-doubles-down-on-ai BioBriefs en 2026-01-06T14:33:16Z Sanofi doubles down on AI biologics – another big Earendil pact https://biobriefs.com/deep-intelligent-pharma-raises-50m BioBriefs en 2026-01-06T14:33:16Z Deep Intelligent Pharma raises $50M: trials go autonomous https://biobriefs.com/arrowhead-advances-rnai-obesity-programs BioBriefs en 2026-01-06T14:33:16Z Arrowhead advances RNAi obesity programs – Phase 2 now https://biobriefs.com/novo-launches-wegovy-pill-insurance BioBriefs en 2026-01-06T14:33:16Z Novo launches Wegovy pill – insurance pricing aims access https://biobriefs.com/zenas-meets-phase-3-endpoint BioBriefs en 2026-01-06T14:33:16Z Zenas meets Phase 3 endpoint — market punishes cross‑trial gap https://biobriefs.com/ikarovec-and-vectorbuilder-eye-an BioBriefs en 2026-01-06T14:33:16Z Ikarovec and VectorBuilder eye an office‑based gene therapy route https://biobriefs.com/cdc-cuts-routine-childhood-vaccine BioBriefs en 2026-01-06T14:33:16Z CDC cuts routine childhood vaccine recommendations to 11 https://biobriefs.com/new-tools-map-base-editor BioBriefs en 2026-01-06T14:33:16Z New tools map base‑editor off‑targets and Cas3 yields large TTR deletions https://biobriefs.com/insilicos-hong-kong-ipo-raises BioBriefs en 2026-01-06T10:33:25Z Insilico’s Hong Kong IPO... Raises ~$292M, then signs Servier oncology pact https://biobriefs.com/singapores-deep-intelligent-pharma-raises BioBriefs en 2026-01-06T10:33:25Z Singapore’s Deep Intelligent Pharma raises $50M — aims to automate clinical trials https://biobriefs.com/sanofi-doubles-down-on-ai BioBriefs en 2026-01-06T10:33:25Z Sanofi doubles down on AI biologics—new deals worth up to $2.56B and $160M near term https://biobriefs.com/zenas-phase-iii-win-and BioBriefs en 2026-01-06T10:33:25Z Zenas’ Phase III win — and a market shock: trial success meets steep share drop https://biobriefs.com/wegovy-pill-rollout-novo-nordisk BioBriefs en 2026-01-06T10:33:25Z Wegovy pill rollout: Novo Nordisk ships oral semaglutide and sets tiered pricing https://biobriefs.com/moderna-files-for-mrna-flu BioBriefs en 2026-01-06T10:33:25Z Moderna files for mRNA flu shot approval across major markets https://biobriefs.com/crispr-cas3-deletes-mutant-ttr BioBriefs en 2026-01-06T10:33:25Z CRISPR–Cas3 deletes mutant TTR in vivo — large deletions lower serum TTR ~80% https://biobriefs.com/st-judes-change-seq-be BioBriefs en 2026-01-06T10:33:25Z St. Jude’s CHANGE‑seq‑BE exposes base‑editor off‑targets — supports clinical safety cases https://biobriefs.com/inhalable-bispecific-exosomes-activate-t BioBriefs en 2026-01-06T10:33:25Z Inhalable bispecific exosomes activate T cells — preclinical reversal of ICI resistance https://biobriefs.com/crispr-knockout-screens-map-neuronal BioBriefs en 2026-01-06T10:33:25Z CRISPR knockout screens map neuronal differentiation — PEDS1 linked to new disorder https://biobriefs.com/sanofi-buys-dynavax-for-2 BioBriefs en 2026-01-06T09:32:28Z Sanofi buys Dynavax for $2.2bn – bolsters adult immunization https://biobriefs.com/moderna-seeks-mrna-flu-approvals BioBriefs en 2026-01-06T09:32:28Z Moderna seeks mRNA flu approvals: files dossiers across major markets https://biobriefs.com/wegovy-pill-hits-u-s BioBriefs en 2026-01-06T09:32:28Z Wegovy pill hits U.S. pharmacies: pricing and access move to center stage https://biobriefs.com/zenas-phase-3-win-sparks BioBriefs en 2026-01-06T09:32:28Z Zenas' phase‑3 win sparks selloff – markets punish cross‑trial comparisons https://biobriefs.com/singapores-deep-intelligent-pharma-raises BioBriefs en 2026-01-06T09:32:28Z Singapore’s Deep Intelligent Pharma raises $50M – aims to automate clinical trials https://biobriefs.com/insilico-inks-888m-pact-with BioBriefs en 2026-01-06T09:32:28Z Insilico inks $888M pact with Servier – AI fuels oncology drug discovery https://biobriefs.com/sanofi-doubles-down-on-earendil BioBriefs en 2026-01-06T09:32:28Z Sanofi doubles down on Earendil: second AI biologics pact could top $2.5bn https://biobriefs.com/crispr-cas3-deletes-ttr-in BioBriefs en 2026-01-06T09:32:28Z CRISPR–Cas3 deletes TTR in vivo – long‑range edits cut serum TTR dramatically https://biobriefs.com/st-jude-unveils-change-seq BioBriefs en 2026-01-06T09:32:28Z St. Jude unveils CHANGE‑seq‑BE: a rapid safety assay for base editors https://biobriefs.com/inhalable-bispecific-exosomes-reprogram-t BioBriefs en 2026-01-06T09:32:28Z Inhalable bispecific exosomes reprogram T cells – activity in ICI‑resistant melanoma https://biobriefs.com/deep-intelligent-pharma-raises-50m BioBriefs en 2026-01-06T04:33:13Z Deep Intelligent Pharma Raises $50M — AI to automate clinical trials https://biobriefs.com/insilico-and-servier-ink-888m BioBriefs en 2026-01-06T04:33:13Z Insilico and Servier Ink $888M Oncology Pact — AI discovery scales https://biobriefs.com/sanofi-doubles-down-on-ai BioBriefs en 2026-01-06T04:33:13Z Sanofi doubles down on AI biologics — repeat pacts with Earendil https://biobriefs.com/wegovy-pill-launches-in-u BioBriefs en 2026-01-06T04:33:13Z Wegovy pill launches in U.S. — pricing and access front and center https://biobriefs.com/sanofi-to-buy-dynavax-for BioBriefs en 2026-01-06T04:33:13Z Sanofi to buy Dynavax for $2.2B — adds HEPLISAV‑B and shingles candidate https://biobriefs.com/zenas-phase-iii-win-in BioBriefs en 2026-01-06T04:33:13Z Zenas’ phase III win in IgG4‑RD sinks stock — investors eye cross‑trial read https://biobriefs.com/moderna-seeks-approvals-for-mrna BioBriefs en 2026-01-06T04:33:13Z Moderna seeks approvals for mRNA flu vaccine — regulatory push for respiratory franchise https://biobriefs.com/crispr-cas3-enables-long-deletions BioBriefs en 2026-01-06T04:33:13Z CRISPR–Cas3 enables long deletions to silence TTR in vivo — new gene‑editing route https://biobriefs.com/change-seq-be-profiles-base BioBriefs en 2026-01-06T04:33:13Z CHANGE‑seq‑BE profiles base‑editor off‑targets — safety tool adopted for emergency FDA case https://biobriefs.com/inhalable-bispecific-exosomes-activate-t BioBriefs en 2026-01-06T04:33:13Z Inhalable bispecific exosomes activate T cells — preclinical reversal of PD‑1 resistance https://biobriefs.com/deep-intelligent-pharma-raises-50m BioBriefs en 2026-01-05T21:32:51Z Deep Intelligent Pharma Raises $50M – AI to automate clinical trials https://biobriefs.com/moderna-seeks-approval-for-mrna BioBriefs en 2026-01-05T21:32:51Z Moderna seeks approval for mRNA flu shot: mRNA-1010 filed globally https://biobriefs.com/sanofi-to-buy-dynavax-for BioBriefs en 2026-01-05T21:32:51Z Sanofi to buy Dynavax for $2.2B: Adds Hep B vaccine and shingles candidate https://biobriefs.com/sanofi-doubles-down-on-earendil BioBriefs en 2026-01-05T21:32:51Z Sanofi doubles down on Earendil – $160M pact for AI‑designed bispecifics https://biobriefs.com/zenas-obexelimab-clears-phase-3 BioBriefs en 2026-01-05T21:32:51Z Zenas’ obexelimab clears Phase 3 endpoint – market punishes outcome https://biobriefs.com/crispr-cas3-enables-large-deletions BioBriefs en 2026-01-05T21:32:51Z CRISPR–Cas3 enables large deletions and 80% serum TTR knockdown in mouse model https://biobriefs.com/inhalable-bispecific-exosomes-activate-t BioBriefs en 2026-01-05T21:32:51Z Inhalable bispecific exosomes activate T cells – new approach for ICI‑resistant tumors https://biobriefs.com/salus-biomeds-rapid-clinical-sequencer BioBriefs en 2026-01-05T21:32:51Z Salus Biomed’s rapid clinical sequencer cleared by China NMPA https://biobriefs.com/orasure-submits-30-minute-ct BioBriefs en 2026-01-05T21:32:51Z OraSure submits 30‑minute CT/NG rapid test to FDA: at‑home collection also filed https://biobriefs.com/comanche-raises-40m-to-fund BioBriefs en 2026-01-05T21:32:51Z Comanche raises $40M to fund preeclampsia siRNA into first human trials https://biobriefs.com/zenas-phase-3-hits-primary BioBriefs en 2026-01-05T16:32:49Z Zenas' Phase 3 hits primary endpoint – stock halves after rival comparison https://biobriefs.com/sanofi-doubles-down-on-earendil BioBriefs en 2026-01-05T16:32:49Z Sanofi doubles down on Earendil – $160M near‑term pact could reach $2.56B https://biobriefs.com/salus-wins-nmpa-nod-rapid BioBriefs en 2026-01-05T16:32:49Z Salus wins NMPA nod – rapid clinical sequencer cleared for China use https://biobriefs.com/orasure-seeks-fda-510-k BioBriefs en 2026-01-05T16:32:49Z OraSure seeks FDA 510(k) for 30‑minute CT/NG self‑test and urine kit https://biobriefs.com/cas3-genome-editing-slashes-ttr BioBriefs en 2026-01-05T16:32:49Z Cas3 genome editing slashes TTR in vivo – long deletions, lower off‑targets https://biobriefs.com/aktis-targets-nasdaq-raise-up BioBriefs en 2026-01-05T16:32:49Z Aktis targets Nasdaq raise up to $209M – funds miniprotein radiopharma trials https://biobriefs.com/abbvie-pays-100m-upfront-to BioBriefs en 2026-01-05T16:32:49Z AbbVie pays $100M upfront to option Zejing’s DLL3 trispecific https://biobriefs.com/servier-taps-insilicos-ai-platform BioBriefs en 2026-01-05T16:32:49Z Servier taps Insilico’s AI platform — multiyear oncology pact worth up to near‑term millions https://biobriefs.com/comanche-secures-40m-to-advance BioBriefs en 2026-01-05T16:32:49Z Comanche secures $40M to advance first‑in‑class preeclampsia siRNA into clinic https://biobriefs.com/psithera-spins-out-of-roivant BioBriefs en 2026-01-05T16:32:49Z Psithera spins out of Roivant with $47.5M — targets immune and inflammatory diseases https://biobriefs.com/cas3-deletes-mutant-ttr-in BioBriefs en 2026-01-05T14:33:24Z Cas3 deletes mutant TTR in vivo — new off-target assay tightens safety https://biobriefs.com/inhalable-exosomes-deliver-bispecific-t BioBriefs en 2026-01-05T14:33:24Z Inhalable exosomes deliver bispecific T‑cell activator — fights ICI‑resistant melanoma https://biobriefs.com/concord-unifies-single-cell-landscapes BioBriefs en 2026-01-05T14:33:24Z CONCORD unifies single‑cell landscapes across studies https://biobriefs.com/splisosm-pins-down-isoforms-in BioBriefs en 2026-01-05T14:33:24Z SPLISOSM pins down isoforms in space — new spatial transcriptomics tool https://biobriefs.com/ai-and-experiments-resolve-rna BioBriefs en 2026-01-05T14:33:24Z AI and experiments resolve RNA structure — integrated toolkit published https://biobriefs.com/abbvie-pays-100m-upfront-for BioBriefs en 2026-01-05T14:33:24Z AbbVie pays $100M upfront for Zejing DLL3 candidate — deal could top $1.07B https://biobriefs.com/comanche-raises-40m-to-push BioBriefs en 2026-01-05T14:33:24Z Comanche raises $40M to push preeclampsia siRNA into human trials https://biobriefs.com/big-pharma-doubles-down-on BioBriefs en 2026-01-05T14:33:24Z Big pharma doubles down on AI discovery: Sanofi and Servier deals land https://biobriefs.com/wegovy-pill-lands-in-us BioBriefs en 2026-01-05T14:33:24Z Wegovy pill lands in US — pricing, employer coverage headaches loom https://biobriefs.com/setrusumab-fails-phase-iii-fracture BioBriefs en 2026-01-05T14:33:24Z Setrusumab fails Phase III fracture endpoints — Ultragenyx and Mereo plan cuts https://biobriefs.com/novo-nordisk-launches-wegovy-pill BioBriefs en 2026-01-05T10:33:00Z Novo Nordisk launches Wegovy pill: $25 insured, $149 cash https://biobriefs.com/setrusumab-misses-primary-endpoints-ultragenyx BioBriefs en 2026-01-05T10:33:00Z Setrusumab misses primary endpoints: Ultragenyx, Mereo to cut costs https://biobriefs.com/st-jude-publishes-assay-to BioBriefs en 2026-01-05T10:33:00Z St. Jude publishes assay to detect base-editor off-targets – improves safety screening https://biobriefs.com/optimized-aav9-improves-safety-efficacy BioBriefs en 2026-01-05T10:33:00Z Optimized AAV9 improves safety, efficacy in SMARD1 models https://biobriefs.com/11-amino-acid-peptide-thwarts BioBriefs en 2026-01-05T10:33:00Z 11‑amino‑acid peptide thwarts CRC immune evasion: Cell Research https://biobriefs.com/romosozumab-outperforms-pth-analogs-fracture BioBriefs en 2026-01-05T10:33:00Z Romosozumab outperforms PTH analogs — fracture reduction evidence mounts https://biobriefs.com/live-tumor-fragment-platform-predicts BioBriefs en 2026-01-05T10:33:00Z Live tumor fragment platform predicts immunotherapy response — translational tool https://biobriefs.com/liquid-biopsy-collaboration-maps-mash BioBriefs en 2026-01-05T10:33:00Z Liquid biopsy collaboration maps MASH biology — Hepta leads effort https://biobriefs.com/serum-biomarkers-track-mis-c BioBriefs en 2026-01-05T10:33:00Z Serum biomarkers track MIS‑C severity and recovery: Pediatric Research https://biobriefs.com/high-cd14-urothelial-cells-drive BioBriefs en 2026-01-05T10:33:00Z High‑CD14 urothelial cells drive neutrophil‑rich microenvironment after radiation https://biobriefs.com/setrusumab-misses-fracture-endpoints-ultragenyx BioBriefs en 2026-01-05T09:33:22Z Setrusumab misses fracture endpoints – Ultragenyx, Mereo to cut costs https://biobriefs.com/st-jude-unveils-method-to BioBriefs en 2026-01-05T09:33:22Z St. Jude unveils method to detect base-editor off-targets – safety tool released https://biobriefs.com/aav9-optimization-advances-for-smard1 BioBriefs en 2026-01-05T09:33:22Z AAV9 optimization advances for SMARD1 – efficiency and safety signals reported https://biobriefs.com/tiny-peptide-reverses-colorectal-immune BioBriefs en 2026-01-05T09:33:22Z Tiny peptide reverses colorectal immune evasion – lipid signature fuels progression https://biobriefs.com/ex-vivo-tumor-fragments-and BioBriefs en 2026-01-05T09:33:22Z Ex vivo tumor fragments and single-cell maps... new tools to test immunotherapies https://biobriefs.com/high-cd14-urothelial-cells-recruit BioBriefs en 2026-01-05T09:33:22Z High‑CD14 urothelial cells recruit neutrophils after radiation – pro‑metastatic niche https://biobriefs.com/psilocybin-assisted-therapy-shows-early BioBriefs en 2026-01-05T09:33:22Z Psilocybin-assisted therapy shows early signal in binge‑eating pilot – small study https://biobriefs.com/serum-biomarkers-map-mis-c BioBriefs en 2026-01-05T09:33:22Z Serum biomarkers map MIS‑C severity and recovery – pediatric immune signatures https://biobriefs.com/lowload-qpcr-spots-low-load BioBriefs en 2026-01-05T09:33:22Z LowLoad‑qPCR spots low‑load bacteremia – diagnostic sensitivity improved https://biobriefs.com/cdh17-tight-junction-tumor-cells BioBriefs en 2026-01-05T09:33:22Z CDH17+, tight‑junction tumor cells identified as liver‑metastasis instigators https://biobriefs.com/ultragenyx-mereo-setrusumab-misses-phase BioBriefs en 2026-01-05T04:32:10Z Ultragenyx, Mereo: setrusumab misses Phase III – expense cuts planned https://biobriefs.com/st-jude-new-method-spots BioBriefs en 2026-01-05T04:32:10Z St. Jude: new method spots off-targets from base editors https://biobriefs.com/beaver-trial-binimetinib-encorafenib-show BioBriefs en 2026-01-05T04:32:10Z BEAVER trial: binimetinib–encorafenib show responses in non‑V600E BRAF tumors https://biobriefs.com/autologous-cd133-cells-early-trial BioBriefs en 2026-01-05T04:32:10Z Autologous CD133+ cells: early trial suggests repair for Asherman https://biobriefs.com/smlm-imaging-extracellular-vesicle-dna BioBriefs en 2026-01-05T04:32:10Z SMLM imaging: extracellular vesicle DNA tracked inside recipient cells https://biobriefs.com/acute-exercise-reshapes-immune-cell BioBriefs en 2026-01-05T04:32:10Z Acute exercise reshapes immune cell proteome – Nature Communications study https://biobriefs.com/cdh17-tight-junction-cells-new BioBriefs en 2026-01-05T04:32:10Z CDH17+ tight-junction cells: new drivers of colorectal liver metastases https://biobriefs.com/mis-c-biomarkers-serum-panel BioBriefs en 2026-01-05T04:32:10Z MIS‑C biomarkers... serum panel tracks severity and recovery https://biobriefs.com/romosozumab-edges-pth-analogs-in BioBriefs en 2026-01-05T04:32:10Z Romosozumab edges PTH analogs in fracture prevention – study https://biobriefs.com/ai-in-digital-pathology-accuracy BioBriefs en 2026-01-05T04:32:10Z AI in digital pathology: accuracy gains collide with deployment hurdles https://biobriefs.com/st-jude-unveils-assay-finds BioBriefs en 2026-01-04T21:32:24Z St. Jude unveils assay: finds off-target edits missed by others https://biobriefs.com/beaver-trial-binimetinib-encorafenib-show BioBriefs en 2026-01-04T21:32:24Z BEAVER trial: binimetinib–encorafenib show activity in non‑V600E BRAF tumors https://biobriefs.com/insilico-surges-after-hong-kong BioBriefs en 2026-01-04T21:32:24Z Insilico surges after Hong Kong listing: finance report https://biobriefs.com/harmeier-returns-to-lead-roche BioBriefs en 2026-01-04T21:32:24Z Harmeier returns to lead Roche venture fund — BioCentury report https://biobriefs.com/mapping-mash-liquid-biopsy-partnership BioBriefs en 2026-01-04T21:32:24Z Mapping MASH: liquid biopsy partnership launched https://biobriefs.com/engineered-co-signaling-receptors-reduce BioBriefs en 2026-01-04T21:32:24Z Engineered co‑signaling receptors: reduce T‑cell off‑target reactivity https://biobriefs.com/phase-1-2-autologous-cd133 BioBriefs en 2026-01-04T21:32:24Z Phase 1/2: autologous CD133+ stem cells tested for Asherman https://biobriefs.com/live-tumor-fragment-platform-predicts BioBriefs en 2026-01-04T21:32:24Z Live tumor‑fragment platform: predicts immunotherapy ex vivo https://biobriefs.com/fluorescent-d-amino-acids-track BioBriefs en 2026-01-04T21:32:24Z Fluorescent D‑amino acids track Lactobacillus in vivo: live probiotic imaging https://biobriefs.com/serum-biomarkers-map-mis-c BioBriefs en 2026-01-04T21:32:24Z Serum biomarkers map MIS‑C severity — pediatric study https://biobriefs.com/abbvie-pays-1-1b-for BioBriefs en 2026-01-04T16:32:44Z AbbVie pays $1.1B for Zelgen T‑cell engager – gains ex‑China rights https://biobriefs.com/insilico-jumps-after-hong-kong BioBriefs en 2026-01-04T16:32:44Z Insilico jumps after Hong Kong listing: finance report https://biobriefs.com/harmeier-returns-to-lead-roche BioBriefs en 2026-01-04T16:32:44Z Harmeier returns to lead Roche venture fund: management shake‑up https://biobriefs.com/third-crl-sinks-outlooks-ons BioBriefs en 2026-01-04T16:32:44Z Third CRL sinks Outlook’s ONS‑5010 – shares tumble https://biobriefs.com/dea-extends-telemedicine-prescribing-flexibilities BioBriefs en 2026-01-04T16:32:44Z DEA extends telemedicine prescribing flexibilities through 2026 – advocates urge permanence https://biobriefs.com/psithera-exits-roivant-with-47 BioBriefs en 2026-01-04T16:32:44Z Psithera exits Roivant with $47.5M Series A – targets immune, inflammatory programs https://biobriefs.com/transcenta-licenses-continuous-biomanufacturing-tech BioBriefs en 2026-01-04T16:32:44Z Transcenta licenses continuous biomanufacturing tech to EirGenix – royalties and milestones expected https://biobriefs.com/st-jude-unveils-method-to BioBriefs en 2026-01-04T16:32:44Z St. Jude unveils method to detect base‑editor off‑targets: boosts safety screening https://biobriefs.com/palbociclib-reverses-venetoclax-resistance-in BioBriefs en 2026-01-04T16:32:44Z Palbociclib reverses venetoclax resistance in AML – OHSU combination shows durable activity https://biobriefs.com/rare-variant-weakens-msi2-lowers BioBriefs en 2026-01-04T16:32:44Z Rare variant weakens MSI2 – lowers clonal hematopoiesis and leukemia risk https://biobriefs.com/abbvie-buys-ex-china-rights BioBriefs en 2026-01-04T14:32:37Z AbbVie buys ex‑China rights to Zelgen's DLL3 engager: $1.1B deal https://biobriefs.com/transcenta-licenses-hicb-to-eirgenix BioBriefs en 2026-01-04T14:32:37Z Transcenta licenses HiCB to EirGenix – push for continuous biomanufacturing https://biobriefs.com/st-jude-unveils-method-to BioBriefs en 2026-01-04T14:32:37Z St. Jude unveils method to detect base‑editor off‑targets: higher sensitivity https://biobriefs.com/venetoclax-resistance-tackled-by-breast BioBriefs en 2026-01-04T14:32:37Z Venetoclax resistance tackled by breast‑cancer drug palbociclib – OHSU study https://biobriefs.com/inherited-variant-slows-clonal-hematopoiesis BioBriefs en 2026-01-04T14:32:37Z Inherited variant slows clonal hematopoiesis: Science reports leukemia protection https://biobriefs.com/fda-issues-third-crl-for BioBriefs en 2026-01-04T14:32:37Z FDA issues third CRL for Outlook's ONS‑5010 – stock dives https://biobriefs.com/psithera-spins-out-of-roivant BioBriefs en 2026-01-04T14:32:37Z Psithera spins out of Roivant with $47.5M – new immunology small‑molecule shop https://biobriefs.com/engineered-co-signaling-receptors-sharpen BioBriefs en 2026-01-04T14:32:37Z Engineered co‑signaling receptors sharpen T‑cell precision: study https://biobriefs.com/autologous-ipsc-lung-on-a BioBriefs en 2026-01-04T14:32:37Z Autologous iPSC lung‑on‑a‑chip models early TB events: personalized platform https://biobriefs.com/engineered-il-10-targets-ldl BioBriefs en 2026-01-04T14:32:37Z Engineered IL‑10 targets LDL to cut vascular inflammation – study https://biobriefs.com/abbvie-buys-ex-china-rights BioBriefs en 2026-01-04T10:32:11Z AbbVie buys ex‑China rights to Zelgen’s DLL3 T‑cell engager – $1.1B pact https://biobriefs.com/transcenta-licenses-hicb-platform-to BioBriefs en 2026-01-04T10:32:11Z Transcenta licenses HiCB platform to EirGenix: CDMO collaboration for continuous biologics https://biobriefs.com/insilico-posts-big-gains-after BioBriefs en 2026-01-04T10:32:11Z Insilico posts big gains after Hong Kong listing – finance report https://biobriefs.com/psithera-exits-roivant-raises-47 BioBriefs en 2026-01-04T10:32:11Z Psithera exits Roivant, raises $47.5M to pursue immune and inflammatory small molecules https://biobriefs.com/third-fda-crl-derails-outlooks BioBriefs en 2026-01-04T10:32:11Z Third FDA CRL derails Outlook’s ONS‑5010 – shares plunge https://biobriefs.com/aml-resistance-tackled-palbociclib-plus BioBriefs en 2026-01-04T10:32:11Z AML resistance tackled... palbociclib plus venetoclax shows durable activity https://biobriefs.com/aim-platform-single-strand-deaminase BioBriefs en 2026-01-04T10:32:11Z AIM platform: single‑strand deaminase enables precise, tunable RNA edits https://biobriefs.com/st-jude-method-better-detection BioBriefs en 2026-01-04T10:32:11Z St. Jude method: better detection of base‑editor off‑targets https://biobriefs.com/inherited-variant-curbs-clonal-hematopoiesis BioBriefs en 2026-01-04T10:32:11Z Inherited variant curbs clonal hematopoiesis, reduces leukemia risk – Science https://biobriefs.com/engineered-t-cells-gain-precision BioBriefs en 2026-01-04T10:32:11Z Engineered T cells gain precision – ex‑vivo platforms test immunotherapy https://biobriefs.com/abbvie-pays-1-1b-gains BioBriefs en 2026-01-04T09:32:24Z AbbVie pays $1.1B — Gains ex‑China rights to Zelgen T‑cell engager https://biobriefs.com/third-fda-crl-outlook-therapeutics BioBriefs en 2026-01-04T09:32:24Z Third FDA CRL... Outlook Therapeutics’ ONS‑5010 rejected again https://biobriefs.com/transcenta-licenses-hicb-platform-to BioBriefs en 2026-01-04T09:32:24Z Transcenta licenses HiCB platform to EirGenix: upfronts and milestones https://biobriefs.com/insilico-posts-big-gain-after BioBriefs en 2026-01-04T09:32:24Z Insilico posts big gain after Hong Kong listing – Finance report https://biobriefs.com/psithera-spins-out-of-roivant BioBriefs en 2026-01-04T09:32:24Z Psithera spins out of Roivant: $47.5M Series A and new CEO https://biobriefs.com/neuro-biotech-nido-shuts-down BioBriefs en 2026-01-04T09:32:24Z Neuro biotech Nido shuts down – Phase 2 readout disappoints https://biobriefs.com/st-jude-unveils-method-to BioBriefs en 2026-01-04T09:32:24Z St. Jude unveils method to detect base‑editor off‑targets: improves precision assessments https://biobriefs.com/single-strand-deaminase-powers-aim BioBriefs en 2026-01-04T09:32:24Z Single‑strand deaminase powers AIM RNA editor: precise, controllable edits https://biobriefs.com/venetoclax-palbociclib-ohsu-finds-combo BioBriefs en 2026-01-04T09:32:24Z Venetoclax + palbociclib — OHSU finds combo overcomes AML resistance https://biobriefs.com/inherited-variant-curbs-clonal-hematopoiesis BioBriefs en 2026-01-04T09:32:24Z Inherited variant curbs clonal hematopoiesis: lowers blood cancer risk https://biobriefs.com/abbvie-buys-ex-china-rights BioBriefs en 2026-01-04T04:32:09Z AbbVie buys ex-China rights to DLL3 trispecific: $1.1B pact https://biobriefs.com/insilico-rallies-after-hong-kong BioBriefs en 2026-01-04T04:32:09Z Insilico rallies after Hong Kong IPO: finance boost https://biobriefs.com/harmeier-returns-to-lead-roche BioBriefs en 2026-01-04T04:32:09Z Harmeier returns to lead Roche Venture Fund: leadership reset https://biobriefs.com/third-fda-crl-sinks-outlooks BioBriefs en 2026-01-04T04:32:09Z Third FDA CRL sinks Outlook’s ONS‑5010... stock collapses https://biobriefs.com/psithera-spins-out-of-roivant BioBriefs en 2026-01-04T04:32:09Z Psithera spins out of Roivant with $47.5M — immune focus https://biobriefs.com/transcenta-licenses-continuous-biomanufacturing-tech BioBriefs en 2026-01-04T04:32:09Z Transcenta licenses continuous‑biomanufacturing tech to EirGenix: CDMO pact https://biobriefs.com/nido-biosciences-shutters-after-phase BioBriefs en 2026-01-04T04:32:09Z Nido Biosciences shutters after phase‑2 miss — neuro biotech fallout https://biobriefs.com/ultragenyx-to-cut-costs-after BioBriefs en 2026-01-04T04:32:09Z Ultragenyx to cut costs after phase‑3 failures — major restructuring planned https://biobriefs.com/nih-leadership-churn-deepens-ninds BioBriefs en 2026-01-04T04:32:09Z NIH leadership churn deepens — NINDS director exits https://biobriefs.com/st-jude-publishes-a-new BioBriefs en 2026-01-04T04:32:09Z St. Jude publishes a new method to detect base‑editor off‑targets: safety tool https://biobriefs.com/off-targets-exposed-genome-wide BioBriefs en 2026-01-03T21:33:03Z Off-targets exposed: genome-wide base-editor maps https://biobriefs.com/adenine-editors-refined-fewer-bystander BioBriefs en 2026-01-03T21:33:03Z Adenine editors refined — fewer bystander edits https://biobriefs.com/rna-rewriting-goes-multi-base BioBriefs en 2026-01-03T21:33:03Z RNA rewriting goes multi-base: single-strand deaminase platforms https://biobriefs.com/antifungal-micelles-deliver-combinatorial-therapy BioBriefs en 2026-01-03T21:33:03Z Antifungal micelles deliver: combinatorial therapy shows efficacy https://biobriefs.com/inherited-resilience-rare-variant-lowers BioBriefs en 2026-01-03T21:33:03Z Inherited resilience: rare variant lowers leukemia risk https://biobriefs.com/cdmo-pact-transcenta-licenses-continuous BioBriefs en 2026-01-03T21:33:03Z CDMO pact: Transcenta licenses continuous biomanufacturing tech https://biobriefs.com/holiday-dealmaking-big-licensing-moves BioBriefs en 2026-01-03T21:33:03Z Holiday dealmaking: big licensing moves for oncology pipelines https://biobriefs.com/aml-resistance-tackled-palbociclib-plus BioBriefs en 2026-01-03T21:33:03Z AML resistance tackled: palbociclib plus venetoclax shows promise https://biobriefs.com/t-cell-engineering-reduces-off BioBriefs en 2026-01-03T21:33:03Z T‑cell engineering reduces off-target cross-reactivity https://biobriefs.com/nih-leadership-gap-widens-as BioBriefs en 2026-01-03T21:33:03Z NIH leadership gap widens as NINDS director exits https://biobriefs.com/rna-editing-retooled-single-strand BioBriefs en 2026-01-03T16:33:28Z RNA editing retooled: single‑strand deaminases enable multi‑base rewrites https://biobriefs.com/base-editing-precision-genome-wide BioBriefs en 2026-01-03T16:33:28Z Base editing precision: genome‑wide off‑target maps and evolved adenine editors https://biobriefs.com/antifungal-micelles-deliver-combination-therapy BioBriefs en 2026-01-03T16:33:28Z Antifungal micelles deliver combination therapy – Nature Biotechnology proof https://biobriefs.com/markets-heat-insilico-jumps-after BioBriefs en 2026-01-03T16:33:28Z Markets heat: Insilico jumps after Hong Kong listing — Psithera nets $47.5M https://biobriefs.com/abbvie-buys-ex-china-rights BioBriefs en 2026-01-03T16:33:28Z AbbVie buys ex‑China rights to DLL3 trispecific – $1.1B package https://biobriefs.com/pharma-trims-failing-programs-j BioBriefs en 2026-01-03T16:33:28Z Pharma trims failing programs: J&J stops eczema candidate; Genmab exits bispecific https://biobriefs.com/third-crl-sinks-outlooks-bevacizumab BioBriefs en 2026-01-03T16:33:28Z Third CRL sinks Outlook’s bevacizumab outlook — stock tumbles https://biobriefs.com/nido-biosciences-closes-after-mid BioBriefs en 2026-01-03T16:33:28Z Nido Biosciences closes after mid‑stage failure in rare neurology trial https://biobriefs.com/inherited-variant-slows-clonal-hematopoiesis BioBriefs en 2026-01-03T16:33:28Z Inherited variant slows clonal hematopoiesis and lowers leukemia risk — Science https://biobriefs.com/venetoclax-resistance-tackled-palbociclib-combination BioBriefs en 2026-01-03T16:33:28Z Venetoclax resistance tackled: palbociclib combination shows activity in AML models https://biobriefs.com/base-editors-change-seq-be BioBriefs en 2026-01-03T14:32:56Z Base editors... CHANGE-seq-BE maps off-targets https://biobriefs.com/single-strand-deaminases-rna-editing BioBriefs en 2026-01-03T14:32:56Z Single-strand deaminases... RNA editing scales https://biobriefs.com/antifungal-micelles-combination-delivery-reduces BioBriefs en 2026-01-03T14:32:56Z Antifungal micelles... combination delivery reduces toxicity https://biobriefs.com/smrtnet-predictive-rna-small-molecule BioBriefs en 2026-01-03T14:32:56Z SMRTnet... predictive RNA–small-molecule platform https://biobriefs.com/holiday-licensing-abbvie-gilead-pick BioBriefs en 2026-01-03T14:32:56Z Holiday licensing... AbbVie, Gilead pick up clinical-stage oncology assets https://biobriefs.com/transcenta-licenses-continuous-biomanufacturing-to BioBriefs en 2026-01-03T14:32:56Z Transcenta licenses continuous biomanufacturing to EirGenix https://biobriefs.com/third-fda-crl-outlooks-bevacizumab BioBriefs en 2026-01-03T14:32:56Z Third FDA CRL... Outlook’s bevacizumab program collapses https://biobriefs.com/ultragenyx-halts-brittle-bone-program BioBriefs en 2026-01-03T14:32:56Z Ultragenyx halts brittle-bone program — prepares major cost cuts https://biobriefs.com/nido-biosciences-folds-after-midstage BioBriefs en 2026-01-03T14:32:56Z Nido Biosciences folds after midstage failure https://biobriefs.com/nih-leadership-churn-ninds-director BioBriefs en 2026-01-03T14:32:56Z NIH leadership churn... NINDS director exits https://biobriefs.com/holiday-licensing-spree-abbvie-gilead BioBriefs en 2026-01-03T10:33:07Z Holiday licensing spree: AbbVie, Gilead pick up clinical cancer assets https://biobriefs.com/transcenta-licenses-continuous-biomanufacturing-to BioBriefs en 2026-01-03T10:33:07Z Transcenta licenses continuous biomanufacturing to EirGenix — CDMO pact https://biobriefs.com/third-fda-crl-tanks-outlooks BioBriefs en 2026-01-03T10:33:07Z Third FDA CRL tanks Outlook’s bevacizumab copy: Stock collapses https://biobriefs.com/ultragenyx-to-cut-costs-after BioBriefs en 2026-01-03T10:33:07Z Ultragenyx to cut costs after phase 3 brittle‑bone failures https://biobriefs.com/neuro-biotech-nido-shuts-after BioBriefs en 2026-01-03T10:33:07Z Neuro biotech Nido shuts after midstage flop — five‑year run ends https://biobriefs.com/single-strand-deaminases-push-rna BioBriefs en 2026-01-03T10:33:07Z Single‑strand deaminases push RNA editing toward multiplex control https://biobriefs.com/base-editors-sharpen-precision-new BioBriefs en 2026-01-03T10:33:07Z Base editors sharpen precision — new profiling and engineered ABEs https://biobriefs.com/combinatorial-antifungal-micelles-show-potent BioBriefs en 2026-01-03T10:33:07Z Combinatorial antifungal micelles show potent, low‑toxicity therapy https://biobriefs.com/venetoclax-resistance-tackled-palbociclib-combo BioBriefs en 2026-01-03T10:33:07Z Venetoclax resistance tackled: palbociclib combo restores AML sensitivity https://biobriefs.com/inherited-variant-reduces-clonal-hematopoiesis BioBriefs en 2026-01-03T10:33:07Z Inherited variant reduces clonal hematopoiesis and leukemia risk https://biobriefs.com/adenine-base-editors-tightened-precision BioBriefs en 2026-01-03T09:33:29Z Adenine base editors tightened: precision gains cut bystander edits https://biobriefs.com/single-strand-deaminase-platform-rewrites BioBriefs en 2026-01-03T09:33:29Z Single‑strand deaminase platform rewrites RNA at scale https://biobriefs.com/self-assembling-peptide-micelles-enable BioBriefs en 2026-01-03T09:33:29Z Self‑assembling peptide micelles enable combinatorial antifungal therapy https://biobriefs.com/ai-model-predicts-small-molecule BioBriefs en 2026-01-03T09:33:29Z AI model predicts small‑molecule–RNA binding without 3D structures https://biobriefs.com/inherited-variant-slows-clonal-hematopoiesis BioBriefs en 2026-01-03T09:33:29Z Inherited variant slows clonal hematopoiesis — lowers leukemia risk https://biobriefs.com/venetoclax-resistance-met-by-palbociclib BioBriefs en 2026-01-03T09:33:29Z Venetoclax resistance met by palbociclib combo in AML models https://biobriefs.com/abbvie-pays-1-1b-for BioBriefs en 2026-01-03T09:33:29Z AbbVie pays $1.1B for ex‑China rights to Zelgen’s DLL3 trispecific https://biobriefs.com/transcenta-licenses-continuous-biomanufacturing-to BioBriefs en 2026-01-03T09:33:29Z Transcenta licenses continuous biomanufacturing to EirGenix https://biobriefs.com/ultragenyx-to-slash-costs-after BioBriefs en 2026-01-03T09:33:29Z Ultragenyx to slash costs after late‑stage brittle‑bone failures https://biobriefs.com/nih-leadership-churn-deepens-neuro BioBriefs en 2026-01-03T09:33:29Z NIH leadership churn deepens — neuro director exits amid instability https://biobriefs.com/antifungal-micelles-enable-combinatorial-therapy BioBriefs en 2026-01-03T04:32:43Z Antifungal micelles enable combinatorial therapy: potent, lower toxicity https://biobriefs.com/single-strand-deaminase-assists-multiplex BioBriefs en 2026-01-03T04:32:43Z Single‑strand deaminase assists multiplex RNA edits: new editing platform https://biobriefs.com/change-seq-be-maps-base BioBriefs en 2026-01-03T04:32:43Z CHANGE‑seq‑BE maps base‑editor off‑targets: unbiased genome‑wide profiling https://biobriefs.com/directed-evolution-tightens-adenine-base BioBriefs en 2026-01-03T04:32:43Z Directed evolution tightens adenine base editors – fewer bystanders https://biobriefs.com/palbociclib-restores-venetoclax-sensitivity-in BioBriefs en 2026-01-03T04:32:43Z Palbociclib restores venetoclax sensitivity in AML: preclinical combo breakthrough https://biobriefs.com/rare-regulatory-variant-slows-clonal BioBriefs en 2026-01-03T04:32:43Z Rare regulatory variant slows clonal hematopoiesis: lowers leukemia risk https://biobriefs.com/transcenta-licenses-hicb-continuous-biomanufacturing BioBriefs en 2026-01-03T04:32:43Z Transcenta licenses HiCB continuous‑biomanufacturing tech to EirGenix https://biobriefs.com/holiday-deal-rush-abbvie-buys BioBriefs en 2026-01-03T04:32:43Z Holiday deal rush: AbbVie buys ex‑China DLL3 T‑cell engager; Gilead picks up Polθ asset https://biobriefs.com/outlook-plunges-after-third-fda BioBriefs en 2026-01-03T04:32:43Z Outlook plunges after third FDA CRL for bevacizumab biosimilar filing https://biobriefs.com/ultragenyx-to-cut-costs-after BioBriefs en 2026-01-03T04:32:43Z Ultragenyx to cut costs after phase‑3 failures in brittle‑bone trials https://biobriefs.com/directed-evolution-sharpens-adenine-base BioBriefs en 2026-01-02T21:32:34Z Directed evolution sharpens adenine base editors – extended guides reduce bystanders https://biobriefs.com/single-strand-deaminases-rewrite-rna BioBriefs en 2026-01-02T21:32:34Z Single‑strand deaminases rewrite RNA – multi‑base edits in one transcript https://biobriefs.com/self-assembling-micelles-co-deliver BioBriefs en 2026-01-02T21:32:34Z Self‑assembling micelles co‑deliver antifungals – combination works in vivo https://biobriefs.com/smrtnet-ai-predicts-small-molecule BioBriefs en 2026-01-02T21:32:34Z SMRTnet AI predicts small‑molecule–RNA interactions without 3D structures https://biobriefs.com/gwas-finds-rs17834140-t-variant BioBriefs en 2026-01-02T21:32:34Z GWAS finds rs17834140‑T variant that restrains clonal hematopoiesis and leukemia https://biobriefs.com/venetoclax-plus-palbociclib-overcomes-resistance BioBriefs en 2026-01-02T21:32:34Z Venetoclax plus palbociclib overcomes resistance in AML – OHSU data https://biobriefs.com/holiday-licensing-rush-big-pharma BioBriefs en 2026-01-02T21:32:34Z Holiday licensing rush: big pharma buys clinical‑stage oncology assets https://biobriefs.com/transcenta-licenses-hicb-platform-to BioBriefs en 2026-01-02T21:32:34Z Transcenta licenses HiCB platform to EirGenix for continuous biologics manufacturing https://biobriefs.com/ultragenyx-prepares-major-cuts-after BioBriefs en 2026-01-02T21:32:34Z Ultragenyx prepares major cuts after two failed phase‑3 brittle bone trials https://biobriefs.com/fda-holiday-rejections-hit-developers BioBriefs en 2026-01-02T21:32:34Z FDA holiday rejections hit developers: Outlook’s third CRL and surprises for Sanofi, Corcept https://biobriefs.com/adenine-base-editors-refined-directed BioBriefs en 2026-01-02T16:33:47Z Adenine base editors refined—directed evolution cuts bystander noise https://biobriefs.com/rna-editors-go-modular-single BioBriefs en 2026-01-02T16:33:47Z RNA editors go modular: single-strand deaminases rewrite transcripts https://biobriefs.com/host-defense-peptide-micelles-co BioBriefs en 2026-01-02T16:33:47Z Host-defense peptide micelles... co-deliver drugs for potent antifungal combo https://biobriefs.com/smrtnet-predicts-small-molecule-rna BioBriefs en 2026-01-02T16:33:47Z SMRTnet predicts small-molecule–RNA interactions without 3D structures https://biobriefs.com/viral-vectors-retooled-to-edit BioBriefs en 2026-01-02T16:33:47Z Viral vectors retooled to edit macrophage RNA in vivo for sepsis https://biobriefs.com/holiday-deals-replenish-pipelines-abbvie BioBriefs en 2026-01-02T16:33:47Z Holiday deals replenish pipelines: AbbVie, Gilead make strategic buys; Blossomhill extends Series B https://biobriefs.com/big-pharmas-write-off-candidates BioBriefs en 2026-01-02T16:33:47Z Big pharmas write off candidates—J&J, Genmab and Ultragenyx prune pipelines https://biobriefs.com/neurology-pipeline-setbacks-force-closures BioBriefs en 2026-01-02T16:33:47Z Neurology pipeline setbacks force closures and reprioritizations https://biobriefs.com/fda-hands-post-holiday-setbacks BioBriefs en 2026-01-02T16:33:47Z FDA hands post‑holiday setbacks to Sanofi and Corcept https://biobriefs.com/regulatory-wins-for-small-markets BioBriefs en 2026-01-02T16:33:47Z Regulatory wins for small markets: Vanda cleared, Axsome gets priority review https://biobriefs.com/rna-editing-leaps-single-strand BioBriefs en 2026-01-02T14:32:33Z RNA editing leaps: Single‑strand deaminase rewrites transcripts https://biobriefs.com/base-editor-safety-change-seq BioBriefs en 2026-01-02T14:32:33Z Base‑editor safety…CHANGE‑seq‑BE maps off‑targets https://biobriefs.com/adenine-editors-tightened-directed-evolution BioBriefs en 2026-01-02T14:32:33Z Adenine editors tightened: Directed evolution improves precision https://biobriefs.com/antifungal-micelles-host-defense-mimic BioBriefs en 2026-01-02T14:32:33Z Antifungal micelles: Host‑defense mimic codelivers drugs https://biobriefs.com/smrtnet-predicts-drug-rna-binds BioBriefs en 2026-01-02T14:32:33Z SMRTnet predicts drug‑RNA binds without 3D structures https://biobriefs.com/engineered-viruses-edit-macrophage-rna BioBriefs en 2026-01-02T14:32:33Z Engineered viruses edit macrophage RNA to fight sepsis https://biobriefs.com/ultragenyx-slashes-spend-after-brittle BioBriefs en 2026-01-02T14:32:33Z Ultragenyx slashes spend after brittle‑bone phase‑3 flops https://biobriefs.com/big-pharm-pulls-projects-j BioBriefs en 2026-01-02T14:32:33Z Big pharm pulls projects: J&J, Genmab drop candidates over hurdles https://biobriefs.com/vanda-gets-fda-nod-first BioBriefs en 2026-01-02T14:32:33Z Vanda gets FDA nod – First new motion‑sickness drug in 40 years https://biobriefs.com/fda-issues-complete-response-to BioBriefs en 2026-01-02T14:32:33Z FDA issues complete response to Corcept’s relacorilant https://biobriefs.com/fda-greenlights-motion-sickness-pill BioBriefs en 2026-01-02T10:32:35Z FDA greenlights motion‑sickness pill: Vanda’s market win https://biobriefs.com/fda-grants-priority-review-axsomes BioBriefs en 2026-01-02T10:32:35Z FDA grants priority review: Axsome’s AXS‑05 for Alzheimer’s agitation https://biobriefs.com/fda-issues-crl-to-corcept BioBriefs en 2026-01-02T10:32:35Z FDA issues CRL to Corcept – relacorilant setback shifts focus to oncology https://biobriefs.com/viral-rna-editing-in-situ BioBriefs en 2026-01-02T10:32:35Z Viral RNA editing in situ: new approach to treat sepsis https://biobriefs.com/gene-therapy-restores-syngap1-seizure BioBriefs en 2026-01-02T10:32:35Z Gene therapy restores SynGAP1: seizure and behavior rescue reported https://biobriefs.com/aav9-silence-and-replace-prevents BioBriefs en 2026-01-02T10:32:35Z AAV9 silence‑and‑replace prevents hereditary spastic paraplegia symptoms https://biobriefs.com/anti-ror1-scfv-shows-preclinical BioBriefs en 2026-01-02T10:32:35Z Anti‑ROR1 scFv shows preclinical activity in triple‑negative breast cancer https://biobriefs.com/bioatla-secures-40m-spv-to BioBriefs en 2026-01-02T10:32:35Z BioAtla secures $40M SPV to advance Oz‑V into Phase 3 https://biobriefs.com/ncats-launches-oligotox-challenge-500k BioBriefs en 2026-01-02T10:32:35Z NCATS launches OligoTox challenge: $500k to spur oligonucleotide safety data https://biobriefs.com/fda-clears-medtronics-hugo-and BioBriefs en 2026-01-02T10:32:35Z FDA clears Medtronic’s Hugo and CMR’s Versius Plus: rivals enter U.S. RAS market https://biobriefs.com/fda-clears-first-new-motion BioBriefs en 2026-01-02T09:32:22Z FDA clears first new motion‑sickness drug in 40 years: Vanda wins approval https://biobriefs.com/fda-fast-tracks-axsomes-axs BioBriefs en 2026-01-02T09:32:22Z FDA fast‑tracks Axsome’s AXS‑05 for Alzheimer’s agitation — PDUFA set https://biobriefs.com/fda-issues-crl-to-corcept BioBriefs en 2026-01-02T09:32:22Z FDA issues CRL to Corcept — relacorilant pivot to ovarian cancer underway https://biobriefs.com/bioengineered-viruses-edit-macrophage-rna BioBriefs en 2026-01-02T09:32:22Z Bioengineered viruses edit macrophage RNA in vivo: new sepsis strategy https://biobriefs.com/bioatla-and-gatc-close-40m BioBriefs en 2026-01-02T09:32:22Z BioAtla and GATC close $40M SPV to push Ozuriftamab vedotin into registrational trial https://biobriefs.com/abbvie-inks-china-deal-for BioBriefs en 2026-01-02T09:32:22Z AbbVie inks China deal for DLL3‑targeted T‑cell engager — Zelgen partner https://biobriefs.com/henlius-wins-nmpa-acceptance-for BioBriefs en 2026-01-02T09:32:22Z Henlius wins NMPA acceptance for three solid‑tumor INDs https://biobriefs.com/fda-clears-new-rivals-in BioBriefs en 2026-01-02T09:32:22Z FDA clears new rivals in soft‑tissue robotics: Medtronic and CMR get nods https://biobriefs.com/gene-therapy-advances-syngap1-restoration BioBriefs en 2026-01-02T09:32:22Z Gene‑therapy advances: SynGAP1 restoration and SPAST‑AAV9 prevent HSP in models https://biobriefs.com/new-tumor-immune-evasion-mechanisms BioBriefs en 2026-01-02T09:32:22Z New tumor immune‑evasion mechanisms challenge PD‑L1 therapies https://biobriefs.com/vanda-wins-fda-nod-first BioBriefs en 2026-01-02T04:32:20Z Vanda wins FDA nod: first motion-sickness drug in 40 years https://biobriefs.com/axsome-gets-priority-review-agitation BioBriefs en 2026-01-02T04:32:20Z Axsome gets priority review: agitation in Alzheimer’s heads to April PDUFA https://biobriefs.com/fda-issues-complete-response-for BioBriefs en 2026-01-02T04:32:20Z FDA issues complete response for relacorilant — Corcept pivots to ovarian cancer https://biobriefs.com/fda-clears-two-robotic-platforms BioBriefs en 2026-01-02T04:32:20Z FDA clears two robotic platforms: more options for hospitals https://biobriefs.com/shenzhen-edge-files-hkex-ipo BioBriefs en 2026-01-02T04:32:20Z Shenzhen Edge files HKEX IPO: $154 million to scale surgical-robotics push https://biobriefs.com/bioatla-and-gatc-fund-registrational BioBriefs en 2026-01-02T04:32:20Z BioAtla and GATC fund registrational push for Ozuriftamab vedotin https://biobriefs.com/nmpa-accepts-three-helius-solid BioBriefs en 2026-01-02T04:32:20Z NMPA accepts three Helius solid‑tumor INDs: China trial window opens https://biobriefs.com/engineered-viral-rna-editors-treat BioBriefs en 2026-01-02T04:32:20Z Engineered viral RNA editors treat sepsis in vivo: macrophages targeted https://biobriefs.com/aav9-silence-and-replace-prevents BioBriefs en 2026-01-02T04:32:20Z AAV9 silence‑and‑replace prevents hereditary spastic paraplegia in models https://biobriefs.com/syngap1-gene-therapy-restores-function BioBriefs en 2026-01-02T04:32:20Z SynGAP1 gene therapy restores function and rescues epilepsy phenotypes https://biobriefs.com/fda-greenlights-nereus-vanda-lands BioBriefs en 2026-01-01T21:32:50Z FDA greenlights Nereus: Vanda lands first motion‑sickness drug in 40 years https://biobriefs.com/fda-gives-priority-review-to BioBriefs en 2026-01-01T21:32:50Z FDA gives priority review to AXS‑05 – Axsome targets Alzheimer’s agitation https://biobriefs.com/fda-issues-crl-to-corcept BioBriefs en 2026-01-01T21:32:50Z FDA issues CRL to Corcept – relacorilant setback in Cushing, pivot to ovarian cancer https://biobriefs.com/abbvie-inks-dll3-t-cell BioBriefs en 2026-01-01T21:32:50Z AbbVie inks DLL3 T‑cell engager deal in China – Zelgen supplies clinical‑stage asset https://biobriefs.com/bioatla-gatc-raise-40m-spv BioBriefs en 2026-01-01T21:32:50Z BioAtla, GATC raise $40M SPV – Oz‑V moves toward registrational OPSCC trial https://biobriefs.com/nmpa-accepts-inds-for-three BioBriefs en 2026-01-01T21:32:50Z NMPA accepts INDs for three Henlius solid‑tumor candidates: China trials to start https://biobriefs.com/engineered-virus-edits-macrophage-rna BioBriefs en 2026-01-01T21:32:50Z Engineered virus edits macrophage RNA in vivo: new sepsis strategy https://biobriefs.com/nih-launches-oligotox-challenge-500k BioBriefs en 2026-01-01T21:32:50Z NIH launches OligoTox challenge: $500K prizes to map oligonucleotide toxicity https://biobriefs.com/shenzhen-edge-prices-hkex-ipo BioBriefs en 2026-01-01T21:32:50Z Shenzhen Edge prices HKEX IPO for $154M – surgical‑robotics maker eyes global footprint https://biobriefs.com/fda-clears-medtronic-cmr-robotic BioBriefs en 2026-01-01T21:32:50Z FDA clears Medtronic, CMR robotic systems – hospitals gain new surgical options https://biobriefs.com/fda-clears-nereus-first-new BioBriefs en 2026-01-01T16:33:01Z FDA clears Nereus: first new motion‑sickness drug in four decades https://biobriefs.com/fda-issues-crl-for-relacorilant BioBriefs en 2026-01-01T16:33:01Z FDA issues CRL for relacorilant – Corcept pivots to ovarian cancer https://biobriefs.com/fda-grants-priority-review-for BioBriefs en 2026-01-01T16:33:01Z FDA grants priority review for AXS‑05 – Alzheimer’s agitation on an expedited clock https://biobriefs.com/engineered-viral-platform-edits-macrophage BioBriefs en 2026-01-01T16:33:01Z Engineered viral platform edits macrophage RNA in vivo – sepsis therapeutic advance https://biobriefs.com/dietary-methionine-restriction-reverses-kidney BioBriefs en 2026-01-01T16:33:01Z Dietary methionine restriction reverses kidney fibrosis – epigenetic mechanism shown https://biobriefs.com/aav9-silence-and-replace-gene BioBriefs en 2026-01-01T16:33:01Z AAV9 'silence‑and‑replace' gene therapy prevents HSP in models https://biobriefs.com/henlius-wins-nmpa-acceptance-for BioBriefs en 2026-01-01T16:33:01Z Henlius wins NMPA acceptance for three solid‑tumor INDs https://biobriefs.com/nih-agrees-to-re-evaluate BioBriefs en 2026-01-01T16:33:01Z NIH agrees to re‑evaluate stalled grants after court challenge https://biobriefs.com/bioatla-and-gatc-form-40m BioBriefs en 2026-01-01T16:33:01Z BioAtla and GATC form $40M SPV to advance ozuriftamab vedotin into registrational trial https://biobriefs.com/sanofi-acquires-dynavax-assets-adds BioBriefs en 2026-01-01T16:33:01Z Sanofi acquires Dynavax assets: adds HBV vaccine and shingles candidate https://biobriefs.com/fda-greenlights-vandas-nereus-first BioBriefs en 2026-01-01T14:32:35Z FDA greenlights Vanda’s Nereus: first motion‑sickness drug in more than 40 years https://biobriefs.com/fda-gives-axsome-priority-review BioBriefs en 2026-01-01T14:32:35Z FDA gives Axsome priority review: AXS‑05 for Alzheimer’s agitation gets April 30 PDUFA https://biobriefs.com/fda-delivers-crl-to-corcept BioBriefs en 2026-01-01T14:32:35Z FDA delivers CRL to Corcept — relacorilant blocked for Cushing’s hypertension https://biobriefs.com/nih-to-re-evaluate-paused BioBriefs en 2026-01-01T14:32:35Z NIH to re‑evaluate paused grants: agency agrees to court‑ordered scientific review https://biobriefs.com/fda-final-bimo-guidance-agency BioBriefs en 2026-01-01T14:32:35Z FDA final BiMo guidance: agency declines to clarify on‑site access restrictions https://biobriefs.com/insilico-caps-year-with-hong BioBriefs en 2026-01-01T14:32:35Z Insilico caps year with Hong Kong IPO: AI drug developer lists in HK https://biobriefs.com/fda-grants-de-novo-to BioBriefs en 2026-01-01T14:32:35Z FDA grants De Novo to HAI Solutions — QIKCAP cleared for UVC microbial reduction https://biobriefs.com/fda-clears-medtronics-hugo-and BioBriefs en 2026-01-01T14:32:35Z FDA clears Medtronic’s Hugo and CMR’s Versius Plus — new robotic systems enter US market https://biobriefs.com/chinas-nmpa-accepts-hutchmeds-fanregratinib BioBriefs en 2026-01-01T14:32:35Z China’s NMPA accepts Hutchmed’s fanregratinib NDA: priority review for FGFR therapy https://biobriefs.com/bioatla-and-gatc-form-40m BioBriefs en 2026-01-01T14:32:35Z BioAtla and GATC form $40M SPV to push Ozuriftamab into registrational Phase 3 https://biobriefs.com/fda-clears-motion-sickness-pill BioBriefs en 2026-01-01T10:33:44Z FDA clears motion-sickness pill: Vanda wins first approval in 40 years https://biobriefs.com/fda-fast-tracks-axsomes-axs BioBriefs en 2026-01-01T10:33:44Z FDA fast-tracks Axsome’s AXS-05: Priority review set for Alzheimer’s agitation https://biobriefs.com/fda-issues-crl-for-relacorilant BioBriefs en 2026-01-01T10:33:44Z FDA issues CRL for relacorilant... Corcept pivots to oncology https://biobriefs.com/asia-ipo-wave-insilico-lists BioBriefs en 2026-01-01T10:33:44Z Asia IPO wave: Insilico lists in Hong Kong; Shenzhen Edge prices $154M offering https://biobriefs.com/fda-clears-two-surgical-robots BioBriefs en 2026-01-01T10:33:44Z FDA clears two surgical robots — competition heats up for Intuitive https://biobriefs.com/viral-rna-editors-in-macrophages BioBriefs en 2026-01-01T10:33:44Z Viral RNA editors in macrophages: A new in vivo sepsis strategy https://biobriefs.com/bioatla-gatc-create-40m-spv BioBriefs en 2026-01-01T10:33:44Z BioAtla, GATC create $40M SPV: Oz‑V pushed into registrational Phase 3 https://biobriefs.com/nih-agrees-to-review-paused BioBriefs en 2026-01-01T10:33:44Z NIH agrees to review paused grants: court settlement reopens applications https://biobriefs.com/judge-halts-340b-rebate-pilot BioBriefs en 2026-01-01T10:33:44Z Judge halts 340B rebate pilot — implementation paused by court order https://biobriefs.com/2025-marks-a-breakthrough-for BioBriefs en 2026-01-01T10:33:44Z 2025 marks a breakthrough for in vivo gene therapies — clinical momentum and new AAV9 data https://biobriefs.com/vanda-wins-fda-sign-off BioBriefs en 2026-01-01T09:35:08Z Vanda wins FDA sign-off: first new motion-sickness pill in 40 years https://biobriefs.com/fda-grants-priority-review-to BioBriefs en 2026-01-01T09:35:08Z FDA grants priority review to Axsome’s AXS-05 for Alzheimer’s agitation https://biobriefs.com/fda-issues-crl-to-corcept BioBriefs en 2026-01-01T09:35:08Z FDA issues CRL to Corcept — company pivots to oncology push https://biobriefs.com/engineered-viruses-edit-macrophage-rna BioBriefs en 2026-01-01T09:35:08Z Engineered viruses edit macrophage RNA in vivo: new sepsis strategy https://biobriefs.com/gene-therapy-momentum-2025-breakthroughs BioBriefs en 2026-01-01T09:35:08Z Gene therapy momentum: 2025 breakthroughs and a SPAST-AAV9 win https://biobriefs.com/adc-program-pushed-into-registrational BioBriefs en 2026-01-01T09:35:08Z ADC program pushed into registrational trial via $40M SPV – field still expanding https://biobriefs.com/biotech-ipos-land-in-hong BioBriefs en 2026-01-01T09:35:08Z Biotech IPOs land in Hong Kong: Insilico soars, Shenzhen Edge raises $154M https://biobriefs.com/policy-shock-nih-agrees-to BioBriefs en 2026-01-01T09:35:08Z Policy shock: NIH agrees to re-evaluate stalled grants; judge blocks 340B pilot https://biobriefs.com/china-oncology-and-t-cell BioBriefs en 2026-01-01T09:35:08Z China oncology and T-cell engager deals accelerate regional strategy https://biobriefs.com/fda-clears-surgical-robots-and BioBriefs en 2026-01-01T09:35:08Z FDA clears surgical robots and grants De Novo for UVC IV‑connector device https://biobriefs.com/fda-clears-motion-sickness-drug BioBriefs en 2026-01-01T04:32:46Z FDA clears motion-sickness drug — Vanda to launch Nereus https://biobriefs.com/fda-issues-complete-response-letter BioBriefs en 2026-01-01T04:32:46Z FDA issues complete response letter — Corcept pivots to ovarian-cancer bid https://biobriefs.com/fda-grants-priority-review-axsomes BioBriefs en 2026-01-01T04:32:46Z FDA grants priority review: Axsome’s Auvelity for Alzheimer’s agitation gets April PDUFA https://biobriefs.com/fda-approves-first-ta-tma BioBriefs en 2026-01-01T04:32:46Z FDA approves first TA-TMA therapy — Omeros’ Yartemlea cleared https://biobriefs.com/engineered-viruses-edit-rna-in BioBriefs en 2026-01-01T04:32:46Z Engineered viruses edit RNA in vivo — part of a breakthrough year for gene therapies https://biobriefs.com/bioatla-and-gatc-form-40m BioBriefs en 2026-01-01T04:32:46Z BioAtla and GATC form $40M SPV — Ozuriftamab moves toward registrational trial https://biobriefs.com/shenzhen-edge-prices-154m-ipo BioBriefs en 2026-01-01T04:32:46Z Shenzhen Edge prices $154M IPO; new surgical robots clear U.S. — competition heats up https://biobriefs.com/insilico-caps-year-with-hong BioBriefs en 2026-01-01T04:32:46Z Insilico caps year with Hong Kong IPO — AI drug hunter goes public https://biobriefs.com/fda-grants-de-novo-for BioBriefs en 2026-01-01T04:32:46Z FDA grants De Novo for UVC QIKCAP — first clearance for microbial reduction on needleless IV connectors https://biobriefs.com/regulatory-turbulence-nih-to-review BioBriefs en 2026-01-01T04:32:46Z Regulatory turbulence: NIH to review stalled grants as 2025 ends https://biobriefs.com/axsome-priority-review-fda-sets BioBriefs en 2025-12-31T21:33:05Z Axsome priority review: FDA sets April 30 PDUFA for AXS-05 https://biobriefs.com/corcept-crl-regulator-rejects-relacorilant BioBriefs en 2025-12-31T21:33:05Z Corcept CRL — regulator rejects relacorilant, company pivots to ovarian cancer https://biobriefs.com/vandas-nereus-greenlight-first-new BioBriefs en 2025-12-31T21:33:05Z Vanda’s Nereus greenlight: first new motion‑sickness drug in four decades https://biobriefs.com/omeros-greenlight-fda-approves-yartemlea BioBriefs en 2025-12-31T21:33:05Z Omeros greenlight: FDA approves Yartemlea for transplant‑related TA‑TMA https://biobriefs.com/nih-reopens-stalled-grants-judge BioBriefs en 2025-12-31T21:33:05Z NIH reopens stalled grants; judge blocks 340B rebate pilot https://biobriefs.com/biotechs-groove-returns-xbi-rally BioBriefs en 2025-12-31T21:33:05Z Biotech’s groove returns: XBI rally and analysts call 2025 an inflection year https://biobriefs.com/china-regulator-keeps-momentum-hutchmed BioBriefs en 2025-12-31T21:33:05Z China regulator keeps momentum: Hutchmed NDA accepted, Innovent ipilimumab approved https://biobriefs.com/adcs-accelerate-field-breakout-and BioBriefs en 2025-12-31T21:33:05Z ADCs accelerate: field breakout and a $40M SPV to push Oz‑V to registrational trial https://biobriefs.com/gene-therapy-momentum-in-vivo BioBriefs en 2025-12-31T21:33:05Z Gene therapy momentum: in vivo gains and SYNGAP1 restoration https://biobriefs.com/ipo-wave-ai-drug-discovery BioBriefs en 2025-12-31T21:33:05Z IPO wave: AI drug discovery and surgical robotics go public in Hong Kong https://biobriefs.com/abbvie-signs-t-cell-engager BioBriefs en 2025-12-31T16:33:00Z AbbVie signs T-cell engager deal in China — Zelgen's DLL3 program expands https://biobriefs.com/vanda-gets-fda-approval-for BioBriefs en 2025-12-31T16:33:00Z Vanda gets FDA approval for motion‑sickness pill: Nereus cleared https://biobriefs.com/fda-rejects-corcepts-cortisol-modulator BioBriefs en 2025-12-31T16:33:00Z FDA rejects Corcept’s cortisol modulator — relacorilant denied for Cushing’s https://biobriefs.com/fda-approves-omeros-narsoplimab-first BioBriefs en 2025-12-31T16:33:00Z FDA approves Omeros’ narsoplimab — first therapy for TA‑TMA cleared https://biobriefs.com/china-approves-innovent-ipilimumab-hutchmeds BioBriefs en 2025-12-31T16:33:00Z China approves Innovent ipilimumab — Hutchmed’s FGFR NDA accepted for priority review https://biobriefs.com/bioatla-gatc-form-40m-spv BioBriefs en 2025-12-31T16:33:00Z BioAtla, GATC form $40M SPV to advance ozuriftamab — Phase 3 planned in OPSCC https://biobriefs.com/insilico-caps-year-with-hong BioBriefs en 2025-12-31T16:33:00Z Insilico caps year with Hong Kong IPO — AI drug discovery firm raises fresh capital https://biobriefs.com/startups-stumble-nido-winds-down BioBriefs en 2025-12-31T16:33:00Z Startups stumble — Nido winds down; setrusumab Phase III failures rattle Mereo, Ultragenyx https://biobriefs.com/nih-to-re-review-stalled BioBriefs en 2025-12-31T16:33:00Z NIH to re‑review stalled grant applications — court settlement reopens scientific review https://biobriefs.com/judge-halts-340b-rebate-pilot BioBriefs en 2025-12-31T16:33:00Z Judge halts 340B rebate pilot — implementation blocked ahead of Jan. 1 rollout https://biobriefs.com/judge-halts-340b-rebate-pilot BioBriefs en 2025-12-31T14:32:53Z Judge halts 340B rebate pilot — Court freezes rollout ahead of Jan. 1 https://biobriefs.com/fda-clears-omeros-yartemlea-first BioBriefs en 2025-12-31T14:32:53Z FDA clears Omeros’ Yartemlea — First approved therapy for TA‑TMA https://biobriefs.com/china-speeds-oncology-reviews-innovent BioBriefs en 2025-12-31T14:32:53Z China speeds oncology reviews — Innovent approved, Hutchmed NDA accepted https://biobriefs.com/late-stage-setrusumab-failures-hammer BioBriefs en 2025-12-31T14:32:53Z Late‑stage setrusumab failures hammer Ultragenyx, Mereo — Stocks collapse https://biobriefs.com/sanofi-snaps-up-dynavax-programs BioBriefs en 2025-12-31T14:32:53Z Sanofi snaps up Dynavax programs — HBV vaccine and shingles candidate added https://biobriefs.com/insilico-lists-in-hong-kong BioBriefs en 2025-12-31T14:32:53Z Insilico lists in Hong Kong — AI drug discovery IPO tops year‑end https://biobriefs.com/nih-to-review-paused-grant BioBriefs en 2025-12-31T14:32:53Z NIH to review paused grant applications — Agreement reopens scientific review https://biobriefs.com/u-s-regulatory-landscape-frays BioBriefs en 2025-12-31T14:32:53Z U.S. regulatory landscape frays — Chaotic uncertainty and new FDA contracting plan https://biobriefs.com/funding-pullback-private-investment-in BioBriefs en 2025-12-31T14:32:53Z Funding pullback: private investment in tools and diagnostics drops 20% in H2 2025 https://biobriefs.com/drug-programs-cut-verastem-and BioBriefs en 2025-12-31T14:32:53Z Drug programs cut — Verastem and Genmab end trials amid pivots https://biobriefs.com/federal-judge-halts-340b-rebate BioBriefs en 2025-12-31T10:32:50Z Federal judge halts 340B rebate pilot — court pauses rollout https://biobriefs.com/fda-greenlights-omeros-narsoplimab-first BioBriefs en 2025-12-31T10:32:50Z FDA greenlights Omeros’ narsoplimab: first TA‑TMA treatment https://biobriefs.com/novartis-bets-big-on-india BioBriefs en 2025-12-31T10:32:50Z Novartis bets big on India: builds largest R&D hub outside Basel https://biobriefs.com/insilico-caps-year-with-hong BioBriefs en 2025-12-31T10:32:50Z Insilico caps year with Hong Kong IPO — AI drug discovery listed https://biobriefs.com/biotechs-groove-is-back-xbi BioBriefs en 2025-12-31T10:32:50Z Biotech’s groove is back — XBI jumps on M&A and lower rates https://biobriefs.com/late-stage-failure-sinks-brittle BioBriefs en 2025-12-31T10:32:50Z Late‑stage failure sinks brittle‑bone programs — stocks crater https://biobriefs.com/china-accepts-hutchmed-nda-asia BioBriefs en 2025-12-31T10:32:50Z China accepts Hutchmed NDA — Asia reshapes global biotech playbook https://biobriefs.com/obesity-deals-dominate-2025-pricing BioBriefs en 2025-12-31T10:32:50Z Obesity deals dominate 2025 — pricing and pill wars heat up https://biobriefs.com/2025-marks-breakthrough-year-for BioBriefs en 2025-12-31T10:32:50Z 2025 marks breakthrough year for in‑vivo gene therapies — momentum builds https://biobriefs.com/adcs-breakout-2025-new-architectures BioBriefs en 2025-12-31T10:32:50Z ADCs’ breakout 2025 — new architectures broaden promise https://biobriefs.com/fda-clears-yartemlea-first-approved BioBriefs en 2025-12-31T09:32:25Z FDA clears Yartemlea: first approved therapy for TA‑TMA https://biobriefs.com/judge-halts-340b-rebate-pilot BioBriefs en 2025-12-31T09:32:25Z Judge halts 340B rebate pilot: rebate model frozen ahead of Jan. 1 https://biobriefs.com/china-approves-innovents-ipilimumab-neoadjuvant BioBriefs en 2025-12-31T09:32:25Z China approves Innovent’s ipilimumab–neoadjuvant option for MSI‑high colon cancer https://biobriefs.com/china-accepts-hutchmed-fgfr-nda BioBriefs en 2025-12-31T09:32:25Z China accepts Hutchmed FGFR NDA: priority review for fanregratinib https://biobriefs.com/sanofi-snaps-up-dynavax-assets BioBriefs en 2025-12-31T09:32:25Z Sanofi snaps up Dynavax assets — HBV vaccine and shingles candidate join pipeline https://biobriefs.com/insilico-caps-year-with-hong BioBriefs en 2025-12-31T09:32:25Z Insilico caps year with Hong Kong IPO — AI drug developer raises proceeds https://biobriefs.com/late-stage-bone-drug-failure BioBriefs en 2025-12-31T09:32:25Z Late‑stage bone drug failure sinks shares — Ultragenyx, Mereo battered https://biobriefs.com/genmab-ends-acasunlimab-program-bispecific BioBriefs en 2025-12-31T09:32:25Z Genmab ends acasunlimab program — bispecific shelved after partner exit https://biobriefs.com/nih-agrees-to-review-paused BioBriefs en 2025-12-31T09:32:25Z NIH agrees to review paused grants — stalled applications to undergo scientific evaluation https://biobriefs.com/nido-bio-to-wind-down BioBriefs en 2025-12-31T09:32:25Z Nido Bio to wind down after weak Phase 2 — startup to close in early 2026 https://biobriefs.com/nih-to-reopen-paused-grants BioBriefs en 2025-12-31T04:32:18Z NIH to Reopen Paused Grants — Court Orders Scientific Review https://biobriefs.com/judge-blocks-340b-rebate-pilot BioBriefs en 2025-12-31T04:32:18Z Judge Blocks 340B Rebate Pilot — Implementation Paused https://biobriefs.com/fda-clears-omeros-yartemlea-first BioBriefs en 2025-12-31T04:32:18Z FDA Clears Omeros’ Yartemlea — First Approved TA‑TMA Treatment https://biobriefs.com/china-accepts-hutchmed-nda-priority BioBriefs en 2025-12-31T04:32:18Z China Accepts Hutchmed NDA — Priority Review for FGFR Inhibitor https://biobriefs.com/novartis-bets-big-on-india BioBriefs en 2025-12-31T04:32:18Z Novartis Bets Big on India: R&D Hub Scales to 9,000 Staff https://biobriefs.com/insilico-caps-year-with-hong BioBriefs en 2025-12-31T04:32:18Z Insilico Caps Year with Hong Kong IPO — AI Drug Developer Lists https://biobriefs.com/biotech-rally-xbi-surges-on BioBriefs en 2025-12-31T04:32:18Z Biotech Rally... XBI Surges on M&A, Lower Rates https://biobriefs.com/late-stage-setrusumab-collapses-mereo BioBriefs en 2025-12-31T04:32:18Z Late‑Stage Setrusumab Collapses — Mereo and Ultragenyx Stocks Crash https://biobriefs.com/genmab-cuts-acasunlimab-program-phase BioBriefs en 2025-12-31T04:32:18Z Genmab Cuts Acasunlimab Program — Phase 3 Terminated https://biobriefs.com/2025-marks-breakthrough-year-for BioBriefs en 2025-12-31T04:32:18Z 2025 Marks Breakthrough Year for In‑Vivo Gene Therapies https://biobriefs.com/fda-greenlights-narsoplimab-first-approved BioBriefs en 2025-12-30T21:33:22Z FDA greenlights narsoplimab: first approved therapy for TA‑TMA https://biobriefs.com/phase-iii-failures-wipe-out BioBriefs en 2025-12-30T21:33:22Z Phase III failures wipe out value: brittle‑bone program collapses https://biobriefs.com/china-approves-innovents-ipilimumab-neoadjuvant BioBriefs en 2025-12-30T21:33:22Z China approves Innovent’s ipilimumab: neoadjuvant label for colon cancer https://biobriefs.com/hutchmeds-fgfr-drug-lands-priority BioBriefs en 2025-12-30T21:33:22Z Hutchmed’s FGFR drug lands priority review: NMPA accepts fanregratinib NDA https://biobriefs.com/insilico-goes-public-in-hong BioBriefs en 2025-12-30T21:33:22Z Insilico goes public in Hong Kong — AI drug discovery rides an IPO wave https://biobriefs.com/funding-cools-for-tools-and BioBriefs en 2025-12-30T21:33:22Z Funding cools for tools and diagnostics: private investment slips in H2 2025 https://biobriefs.com/ask-pharm-expands-china-rights BioBriefs en 2025-12-30T21:33:22Z ASK Pharm expands China rights: Adlai Nortye licenses pan‑RAS AN‑9025 https://biobriefs.com/judge-blocks-340b-rebate-pilot BioBriefs en 2025-12-30T21:33:22Z Judge blocks 340B rebate pilot: implementation paused ahead of Jan. 1 https://biobriefs.com/harbour-biomed-lannacheng-tie-up BioBriefs en 2025-12-30T21:33:22Z Harbour Biomed, Lannacheng tie up on radionuclide‑drug conjugates https://biobriefs.com/pipeline-attrition-and-program-cuts BioBriefs en 2025-12-30T21:33:22Z Pipeline attrition and program cuts: Nido wind‑down, Genmab ends bispecific program https://biobriefs.com/biotechs-comeback-xbi-rallies-on BioBriefs en 2025-12-30T16:32:21Z Biotech’s comeback: XBI rallies on M&A, rate relief https://biobriefs.com/insilico-lands-hong-kong-ipo BioBriefs en 2025-12-30T16:32:21Z Insilico lands Hong Kong IPO — pivots from AI discovery to SIK inhibitors https://biobriefs.com/obesity-deals-dominate-2025-glp BioBriefs en 2025-12-30T16:32:21Z Obesity deals dominate 2025 — GLP‑1 frenzy reshapes M&A https://biobriefs.com/diagnostics-slump-private-investment-slides BioBriefs en 2025-12-30T16:32:21Z Diagnostics slump: private investment slides while POC wins clearance https://biobriefs.com/fda-greenlights-yartemlea-first-approved BioBriefs en 2025-12-30T16:32:21Z FDA greenlights Yartemlea — first approved treatment for TA‑TMA https://biobriefs.com/china-acts-fast-on-oncology BioBriefs en 2025-12-30T16:32:21Z China acts fast on oncology: domestic CTLA‑4 cleared, FGFR NDA accepted https://biobriefs.com/clinical-blowup-setrusumab-phase-iii BioBriefs en 2025-12-30T16:32:21Z Clinical blowup: setrusumab Phase III failures wipe out value for Ultragenyx, Mereo https://biobriefs.com/2025-an-inflection-for-in BioBriefs en 2025-12-30T16:32:21Z 2025 an inflection for in vivo gene therapies — delivery advances surface https://biobriefs.com/cancer-pipeline-reshuffle-verastem-pivots BioBriefs en 2025-12-30T16:32:21Z Cancer pipeline reshuffle: Verastem pivots, Genmab halts bispecific asset https://biobriefs.com/adcs-break-out-in-2025 BioBriefs en 2025-12-30T16:32:21Z ADCs break out in 2025 — novel platforms and TRBV12 targets emerge https://biobriefs.com/late-stage-flop-sinks-brittle BioBriefs en 2025-12-30T14:33:10Z Late-stage flop sinks brittle-bone drugmakers — Ultragenyx, Mereo hit https://biobriefs.com/genmab-ends-development-of-bispecific BioBriefs en 2025-12-30T14:33:10Z Genmab ends development of bispecific acasunlimab — program discontinued https://biobriefs.com/china-approves-innovents-ipilimumab-combo BioBriefs en 2025-12-30T14:33:10Z China approves Innovent’s ipilimumab combo: neoadjuvant option for MSI‑high colon cancer https://biobriefs.com/diasorin-clears-path-into-molecular BioBriefs en 2025-12-30T14:33:10Z Diasorin clears path into molecular point‑of‑care — 15‑minute four‑plex wins FDA clearance https://biobriefs.com/boston-biotech-nido-biosciences-to BioBriefs en 2025-12-30T14:33:10Z Boston biotech Nido Biosciences to wind down after weak Phase II https://biobriefs.com/pan-ras-licensing-deal-sends BioBriefs en 2025-12-30T14:33:10Z Pan‑RAS licensing deal sends AN‑9025 rights into China — Adlai Nortye, ASK Pharm transact https://biobriefs.com/harbour-biomed-and-lannacheng-tie BioBriefs en 2025-12-30T14:33:10Z Harbour Biomed and Lannacheng tie up on radionuclide‑drug conjugates https://biobriefs.com/judge-blocks-340b-rebate-pilot BioBriefs en 2025-12-30T14:33:10Z Judge blocks 340B rebate pilot ahead of rollout — program paused https://biobriefs.com/novo-nordisk-prices-wegovy-pill BioBriefs en 2025-12-30T14:33:10Z Novo Nordisk prices Wegovy pill $299 — direct‑to‑consumer push undercuts Lilly https://biobriefs.com/2025-marks-in-vivo-gene BioBriefs en 2025-12-30T14:33:10Z 2025 marks in‑vivo gene therapy breakthroughs — industry still hunting final editing tool https://biobriefs.com/phase-iii-bone-drug-fails BioBriefs en 2025-12-30T10:32:54Z Phase III bone drug fails – Ultragenyx and Mereo shares tumble https://biobriefs.com/fda-clears-diasorin-molecular-point BioBriefs en 2025-12-30T10:32:54Z FDA clears Diasorin molecular point‑of‑care assay – 15‑minute four‑plex https://biobriefs.com/china-approves-innovents-ipilimumab-sintilimab BioBriefs en 2025-12-30T10:32:54Z China approves Innovent’s ipilimumab–sintilimab neoadjuvant combo https://biobriefs.com/boston-area-startup-nido-bio BioBriefs en 2025-12-30T10:32:54Z Boston‑area startup Nido Bio to wind down after Phase 2 miss https://biobriefs.com/genmab-ends-acasunlimab-program-after BioBriefs en 2025-12-30T10:32:54Z Genmab ends acasunlimab program after BioNTech exit https://biobriefs.com/judge-blocks-340b-rebate-pilot BioBriefs en 2025-12-30T10:32:54Z Judge blocks 340B rebate pilot just before Jan. 1 rollout https://biobriefs.com/twice-yearly-depemokimab-appears-safe BioBriefs en 2025-12-30T10:32:54Z Twice‑yearly depemokimab appears safe in asthma and nasal‑polyp studies https://biobriefs.com/first-in-class-gas41-yeats BioBriefs en 2025-12-30T10:32:54Z First‑in‑class GAS41 YEATS inhibitor surfaces for NSCLC https://biobriefs.com/harbour-biomed-and-lannacheng-partner BioBriefs en 2025-12-30T10:32:54Z Harbour Biomed and Lannacheng partner on radionuclide‑drug conjugates https://biobriefs.com/adlai-nortye-licenses-pan-ras BioBriefs en 2025-12-30T10:32:54Z Adlai Nortye licenses pan‑RAS inhibitor AN‑9025 to Ask Pharm https://biobriefs.com/phase-iii-flop-setrusumab-fails BioBriefs en 2025-12-30T09:33:10Z Phase III flop — setrusumab fails, Mereo and Ultragenyx hit hard https://biobriefs.com/nmpa-clears-innovents-ipilimumab-neoadjuvant BioBriefs en 2025-12-30T09:33:10Z NMPA clears Innovent’s ipilimumab: neoadjuvant label for MSI‑H colon cancer https://biobriefs.com/fda-clears-diasorin-molecular-poc BioBriefs en 2025-12-30T09:33:10Z FDA clears Diasorin molecular POC test — 15‑minute, CLIA‑waived four‑plex https://biobriefs.com/genmab-halts-acasunlimab-program-ends BioBriefs en 2025-12-30T09:33:10Z Genmab halts acasunlimab — program ends after BioNTech walk‑away https://biobriefs.com/nido-bio-to-wind-down BioBriefs en 2025-12-30T09:33:10Z Nido Bio to wind down after Phase II miss — Boston startup to shutter https://biobriefs.com/wegovy-pill-undercuts-lilly-novo BioBriefs en 2025-12-30T09:33:10Z Wegovy pill undercuts Lilly — Novo Nordisk lists direct price at $299 https://biobriefs.com/adlai-nortye-licenses-an-9025 BioBriefs en 2025-12-30T09:33:10Z Adlai Nortye licenses AN‑9025 pan‑RAS to Ask Pharm — China deal https://biobriefs.com/harbour-biomed-lannacheng-form-radionuclide BioBriefs en 2025-12-30T09:33:10Z Harbour Biomed, Lannacheng form radionuclide‑drug conjugate collaboration https://biobriefs.com/first-in-class-gas41-yeats4 BioBriefs en 2025-12-30T09:33:10Z First‑in‑class GAS41 (YEATS4) inhibitor surfaces for NSCLC https://biobriefs.com/gene-editing-tools-multiply-in BioBriefs en 2025-12-30T09:33:10Z Gene‑editing tools multiply — in vivo therapies show 2025 momentum https://biobriefs.com/brittle-bone-drug-flops-ultragenyx BioBriefs en 2025-12-30T04:32:35Z Brittle-bone drug flops: Ultragenyx and Mereo hit by Phase III failures https://biobriefs.com/j-j-abandons-bispecific-for BioBriefs en 2025-12-30T04:32:35Z J&J abandons bispecific for atopic dermatitis after phase IIb miss https://biobriefs.com/genmab-cancels-acasunlimab-program-after BioBriefs en 2025-12-30T04:32:35Z Genmab cancels acasunlimab program after partner exit and Phase 3 review https://biobriefs.com/china-clears-innovents-ipilimumab-combo BioBriefs en 2025-12-30T04:32:35Z China clears Innovent’s ipilimumab combo for resectable MSI‑high colon cancer https://biobriefs.com/diasorin-wins-fda-510-k BioBriefs en 2025-12-30T04:32:35Z Diasorin wins FDA 510(k) and CLIA waiver for four‑plex molecular POC assay https://biobriefs.com/judge-halts-340b-rebate-pilot BioBriefs en 2025-12-30T04:32:35Z Judge halts 340B rebate pilot — legal win for drugmakers ahead of Jan. 1 rollout https://biobriefs.com/nido-biosciences-to-wind-down BioBriefs en 2025-12-30T04:32:35Z Nido Biosciences to wind down after underwhelming Phase 2 data https://biobriefs.com/depemokimab-shows-twice-yearly-dosing BioBriefs en 2025-12-30T04:32:35Z Depemokimab shows twice‑yearly dosing safety in asthma and nasal polyps https://biobriefs.com/adlai-nortye-licenses-pan-ras BioBriefs en 2025-12-30T04:32:35Z Adlai Nortye licenses pan‑RAS AN‑9025 to Ask Pharm — China rights deal follows https://biobriefs.com/phage-ecology-reshaped-massive-lytic BioBriefs en 2025-12-30T04:32:35Z Phage ecology reshaped: massive lytic phage trove and persistent virulent phages discovered https://biobriefs.com/court-blocks-340b-rebate-pilot BioBriefs en 2025-12-29T21:33:28Z Court blocks 340B rebate pilot: rollout paused before Jan. 1 https://biobriefs.com/setrusumab-phase-iii-flop-ultragenyx BioBriefs en 2025-12-29T21:33:28Z Setrusumab phase III flop: Ultragenyx, Mereo shares collapse https://biobriefs.com/genmab-scraps-acasunlimab-phase-3 BioBriefs en 2025-12-29T21:33:28Z Genmab scraps acasunlimab: Phase 3 program terminated https://biobriefs.com/china-clears-innovents-ipilimumab-neoadjuvant BioBriefs en 2025-12-29T21:33:28Z China clears Innovent’s ipilimumab: neoadjuvant combo approved https://biobriefs.com/fda-clears-diasorin-molecular-poc BioBriefs en 2025-12-29T21:33:28Z FDA clears Diasorin molecular POC: 15‑minute four‑plex wins CLIA waiver https://biobriefs.com/adlai-nortye-licenses-pan-ras BioBriefs en 2025-12-29T21:33:28Z Adlai Nortye licenses pan‑RAS AN‑9025 to ASK Pharm: China rights secured https://biobriefs.com/harbour-biomed-lannacheng-tie-up BioBriefs en 2025-12-29T21:33:28Z Harbour Biomed, Lannacheng tie up on radionuclide‑drug conjugates https://biobriefs.com/in-vivo-gene-therapy-momentum BioBriefs en 2025-12-29T21:33:28Z In vivo gene therapy momentum... editing tools still racing to catch up https://biobriefs.com/thousands-of-lytic-phages-uncovered BioBriefs en 2025-12-29T21:33:28Z Thousands of lytic phages uncovered: virulent phages show persistence https://biobriefs.com/new-preclinical-oncology-agents-gas41 BioBriefs en 2025-12-29T21:33:28Z New preclinical oncology agents: GAS41 YEATS inhibitor and selective BTK blockers https://biobriefs.com/late-stage-bone-drug-fails BioBriefs en 2025-12-29T16:33:03Z Late-stage bone drug fails: Ultragenyx, Mereo see stocks tumble https://biobriefs.com/genmab-pulls-plug-on-lung BioBriefs en 2025-12-29T16:33:03Z Genmab pulls plug on lung bispecific... BioNTech had already walked https://biobriefs.com/fda-clears-diasorin-molecular-poc BioBriefs en 2025-12-29T16:33:03Z FDA clears Diasorin molecular POC: Four‑plex test wins 510(k) and CLIA waiver https://biobriefs.com/harbour-biomed-inks-radionuclide-conjugate BioBriefs en 2025-12-29T16:33:03Z Harbour Biomed inks radionuclide conjugate pact with Lannacheng https://biobriefs.com/adlai-nortye-licenses-pan-ras BioBriefs en 2025-12-29T16:33:03Z Adlai Nortye licenses pan‑RAS oral AN‑9025 to Ask Pharm https://biobriefs.com/first-in-class-gas41-yeats BioBriefs en 2025-12-29T16:33:03Z First‑in‑class GAS41 YEATS inhibitor unveiled for NSCLC https://biobriefs.com/new-btk-inhibitors-curb-gbm BioBriefs en 2025-12-29T16:33:03Z New BTK inhibitors curb GBM invasion – selectivity solves ibrutinib's limits https://biobriefs.com/plasma-protein-profile-flags-cancer BioBriefs en 2025-12-29T16:33:03Z Plasma protein profile flags cancer in symptomatic patients https://biobriefs.com/potent-cross-neutralizing-antibodies-neutralize BioBriefs en 2025-12-29T16:33:03Z Potent cross‑neutralizing antibodies neutralize Marburg and Ravn viruses https://biobriefs.com/pcmt1-linked-to-new-degron BioBriefs en 2025-12-29T16:33:03Z PCMT1 linked to new degron pathway on cereblon substrates https://biobriefs.com/diasorin-wins-fda-ok-15 BioBriefs en 2025-12-29T14:32:47Z Diasorin wins FDA OK: 15‑minute molecular POC cleared https://biobriefs.com/plasma-protein-panel-spots-cancer BioBriefs en 2025-12-29T14:32:47Z Plasma protein panel spots cancer in symptomatic patients https://biobriefs.com/meta-analysis-car-t-and BioBriefs en 2025-12-29T14:32:47Z Meta‑analysis: CAR‑T and bispecifics split outcomes in indolent B‑cell NHL https://biobriefs.com/researchers-find-cross-neutralizing-antibodies BioBriefs en 2025-12-29T14:32:47Z Researchers find cross‑neutralizing antibodies vs Marburg and Ravn https://biobriefs.com/senhwa-pushes-cx-5461-into BioBriefs en 2025-12-29T14:32:47Z Senhwa pushes CX‑5461 into combo play with ADC and PD‑1 tie‑up https://biobriefs.com/genetic-screening-in-oncology-adoption BioBriefs en 2025-12-29T14:32:47Z Genetic screening in oncology... adoption lags despite safety gains https://biobriefs.com/antibiotic-pollution-accelerates-resistance-in BioBriefs en 2025-12-29T14:32:47Z Antibiotic pollution accelerates resistance in Indian sewage: Nature Commun. https://biobriefs.com/ai-in-biotech-roadmap-to BioBriefs en 2025-12-29T14:32:47Z AI in biotech... roadmap to drug discovery and personalized care by 2033 https://biobriefs.com/mitochondrial-gene-therapy-progress-reported BioBriefs en 2025-12-29T14:32:47Z Mitochondrial gene therapy: progress reported, obstacles remain https://biobriefs.com/vaccine-targets-immune-evasion-in BioBriefs en 2025-12-29T14:32:47Z Vaccine targets immune evasion in EBV‑linked nasopharyngeal carcinoma https://biobriefs.com/antibiotic-runoff-fuels-resistance-indian BioBriefs en 2025-12-29T10:33:28Z Antibiotic runoff fuels resistance: Indian sewage study https://biobriefs.com/fda-clears-diasorin-molecular-poc BioBriefs en 2025-12-29T10:33:28Z FDA clears Diasorin molecular POC: four‑plex gives 15‑minute results https://biobriefs.com/plasma-protein-panel-detects-cancer BioBriefs en 2025-12-29T10:33:28Z Plasma protein panel detects cancer: minimally invasive screening advances https://biobriefs.com/new-cross-neutralizing-antibodies-discovered BioBriefs en 2025-12-29T10:33:28Z New cross‑neutralizing antibodies discovered against Marburg and Ravn https://biobriefs.com/meta-analysis-pits-car-t BioBriefs en 2025-12-29T10:33:28Z Meta‑analysis pits CAR‑T against bispecifics: efficacy and risk compared https://biobriefs.com/mitochondrial-gene-therapy-progress-outlined BioBriefs en 2025-12-29T10:33:28Z Mitochondrial gene therapy: progress outlined — delivery remains a hurdle https://biobriefs.com/conformal-silicon-hall-sensors-a BioBriefs en 2025-12-29T10:33:28Z Conformal silicon Hall sensors... a new route for early 3‑D tumor monitoring https://biobriefs.com/ai-flags-paroxysmal-af-from BioBriefs en 2025-12-29T10:33:28Z AI flags paroxysmal AF from sinus ECGs — screening gets smarter https://biobriefs.com/nicu-exposures-linked-to-altered BioBriefs en 2025-12-29T10:33:28Z NICU exposures linked to altered newborn brain development https://biobriefs.com/rna-guided-stat3-rewires-cd4 BioBriefs en 2025-12-29T10:33:28Z RNA‑guided STAT3 rewires CD4+ T cells in NSCLC: immunotherapy implications https://biobriefs.com/diasorins-liaison-nes-cleared-510 BioBriefs en 2025-12-29T09:32:35Z Diasorin’s Liaison Nes Cleared: 510(k) and CLIA waiver for four‑plex https://biobriefs.com/broad-marburg-antibodies-discovered-neutralize BioBriefs en 2025-12-29T09:32:35Z Broad Marburg antibodies discovered – neutralize Ravn too https://biobriefs.com/car-t-vs-bispecific-head BioBriefs en 2025-12-29T09:32:35Z CAR‑T vs bispecific... head‑to‑head meta‑analysis in indolent B‑cell NHL https://biobriefs.com/plasma-protein-profiling-predicts-cancer BioBriefs en 2025-12-29T09:32:35Z Plasma protein profiling predicts cancer in symptomatic patients https://biobriefs.com/antibiotic-pollution-drives-amr-in BioBriefs en 2025-12-29T09:32:35Z Antibiotic pollution drives AMR in Indian sewage: study https://biobriefs.com/mitochondrial-gene-therapy-progress-and BioBriefs en 2025-12-29T09:32:35Z Mitochondrial gene therapy: progress and hurdles flagged https://biobriefs.com/rna-guided-stat3-reshapes-t BioBriefs en 2025-12-29T09:32:35Z RNA‑guided STAT3 reshapes T cell fate in NSCLC https://biobriefs.com/nicu-environmental-exposures-linked-to BioBriefs en 2025-12-29T09:32:35Z NICU environmental exposures linked to altered newborn brain development https://biobriefs.com/progenitor-endothelial-niche-interaction-accelerates BioBriefs en 2025-12-29T09:32:35Z Progenitor‑endothelial niche interaction accelerates graft healing https://biobriefs.com/senhwa-pursues-cx-5461-plus BioBriefs en 2025-12-29T09:32:35Z Senhwa pursues CX‑5461 plus ADC combo – clinical collaboration announced https://biobriefs.com/fda-clears-diasorin-four-plex BioBriefs en 2025-12-29T04:32:48Z FDA clears Diasorin four‑plex assay: LIAISON Nes becomes CLIA‑waived https://biobriefs.com/potent-cross-neutralizing-antibodies-discovered BioBriefs en 2025-12-29T04:32:48Z Potent cross‑neutralizing antibodies discovered: Marburg and Ravn targeted https://biobriefs.com/car-t-vs-bispecifics-meta BioBriefs en 2025-12-29T04:32:48Z CAR‑T vs bispecifics... meta‑analysis contrasts treatments in relapsed B‑cell NHL https://biobriefs.com/rna-guided-stat3-reprograms-t BioBriefs en 2025-12-29T04:32:48Z RNA‑guided STAT3 reprograms T‑cell fate in lung cancer https://biobriefs.com/histar-maps-tissue-architecture-hierarchical BioBriefs en 2025-12-29T04:32:48Z HiSTaR maps tissue architecture: hierarchical spatial transcriptomics https://biobriefs.com/conformal-silicon-hall-sensors-early BioBriefs en 2025-12-29T04:32:48Z Conformal silicon Hall sensors... early 3‑D tumor monitoring https://biobriefs.com/ai-spots-hidden-arrhythmia-paroxysmal BioBriefs en 2025-12-29T04:32:48Z AI spots hidden arrhythmia: paroxysmal AF detected from sinus‑rhythm ECGs https://biobriefs.com/ovarian-cancer-mechanisms-dj-1 BioBriefs en 2025-12-29T04:32:48Z Ovarian cancer mechanisms: DJ‑1 autophagy link and lncRNA m6A regulation https://biobriefs.com/multi-omics-spatial-map-identifies BioBriefs en 2025-12-29T04:32:48Z Multi‑omics spatial map identifies lung repair niches in pediatric ARDS https://biobriefs.com/maternal-methylation-signatures-flag-gestational BioBriefs en 2025-12-29T04:32:48Z Maternal methylation signatures flag gestational diabetes across pregnancy https://biobriefs.com/fda-clears-diasorin-four-plex BioBriefs en 2025-12-28T21:33:24Z FDA clears Diasorin four‑plex assay — molecular PCR goes point‑of‑care https://biobriefs.com/white-house-proposes-40-nih BioBriefs en 2025-12-28T21:33:24Z White House proposes 40% NIH cut: researchers brace for disruptions https://biobriefs.com/new-antibodies-neutralize-marburg-and BioBriefs en 2025-12-28T21:33:24Z New antibodies neutralize Marburg...and Ravn https://biobriefs.com/car-t-vs-bispecific-antibodies BioBriefs en 2025-12-28T21:33:24Z CAR‑T vs bispecific antibodies: meta‑analysis compares efficacy in relapsed B‑cell NHL https://biobriefs.com/ai-flags-paroxysmal-af-from BioBriefs en 2025-12-28T21:33:24Z AI flags paroxysmal AF from sinus‑rhythm ECGs — new detection software https://biobriefs.com/conformal-silicon-hall-sensors-catch BioBriefs en 2025-12-28T21:33:24Z Conformal silicon Hall sensors...catch 3D tumors early https://biobriefs.com/rna-guided-stat3-reprograms-cd4 BioBriefs en 2025-12-28T21:33:24Z RNA‑guided STAT3 reprograms CD4+ T cells in NSCLC — immunotherapy angle https://biobriefs.com/cgms-cut-costs-20-but BioBriefs en 2025-12-28T21:33:24Z CGMs cut costs ~20% but 80% of eligible patients still don’t use them https://biobriefs.com/multi-omics-maps-lung-repair BioBriefs en 2025-12-28T21:33:24Z Multi‑omics maps lung repair niches in pediatric ARDS — distinct spatial compartments found https://biobriefs.com/lncrna-cytor-drives-metastasis-and BioBriefs en 2025-12-28T21:33:24Z LncRNA CYTOR drives metastasis and drug resistance in triple‑negative breast cancer https://biobriefs.com/fda-approves-yartemlea-first-therapy BioBriefs en 2025-12-28T16:32:35Z FDA approves Yartemlea — first therapy for fatal stem‑cell transplant complication https://biobriefs.com/cms-launches-medicare-model-expands BioBriefs en 2025-12-28T16:32:35Z CMS launches Medicare model: expands GLP‑1 coverage for weight‑loss drugs https://biobriefs.com/potent-antibodies-neutralize-marburg-cross BioBriefs en 2025-12-28T16:32:35Z Potent antibodies neutralize Marburg... cross‑protection against Ravn virus https://biobriefs.com/car-t-vs-bispecifics-meta BioBriefs en 2025-12-28T16:32:35Z CAR‑T vs bispecifics — meta‑analysis maps outcomes in relapsed B‑cell lymphoma https://biobriefs.com/smart-aavs-tumor-responsive-vectors BioBriefs en 2025-12-28T16:32:35Z Smart AAVs: tumor‑responsive vectors boost targeting precision https://biobriefs.com/ultrathin-silicon-hall-sensors-detect BioBriefs en 2025-12-28T16:32:35Z Ultrathin silicon Hall sensors detect 3‑D tumors — early‑stage tissue monitoring https://biobriefs.com/rna-guided-stat3-controls-cd4 BioBriefs en 2025-12-28T16:32:35Z RNA‑guided STAT3 controls CD4+ T‑cell fate in NSCLC: new immunotherapy lever https://biobriefs.com/nih-under-threat-funding-disruptions BioBriefs en 2025-12-28T16:32:35Z NIH under threat — funding disruptions and proposed 40% cut worry researchers https://biobriefs.com/ai-detects-paroxysmal-atrial-fibrillation BioBriefs en 2025-12-28T16:32:35Z AI detects paroxysmal atrial fibrillation from sinus ECGs: diagnostic advance https://biobriefs.com/cisplatin-plus-silibinin-in-plga BioBriefs en 2025-12-28T16:32:35Z Cisplatin plus silibinin in PLGA: encapsulation boosts cervical cancer delivery https://biobriefs.com/cms-launches-voluntary-glp-1 BioBriefs en 2025-12-28T14:33:07Z CMS launches voluntary GLP‑1 payment model: Medicare widens obesity drug access https://biobriefs.com/fda-approves-yartemlea-first-approved BioBriefs en 2025-12-28T14:33:07Z FDA approves Yartemlea: first approved therapy for a post‑transplant complement complication https://biobriefs.com/j-j-axes-eczema-drug BioBriefs en 2025-12-28T14:33:07Z J&J axes eczema drug from $1.25B buy—program dropped after efficacy miss https://biobriefs.com/biohavens-potassium-channel-drug-fails BioBriefs en 2025-12-28T14:33:07Z Biohaven’s potassium‑channel drug fails Phase 2—another mid‑stage setback https://biobriefs.com/smart-tumor-targeted-aavs-enable BioBriefs en 2025-12-28T14:33:07Z Smart tumor‑targeted AAVs enable dynamic delivery—vectors respond to tumor microenvironment https://biobriefs.com/broad-marburg-antibodies-discovered-cross BioBriefs en 2025-12-28T14:33:07Z Broad Marburg antibodies discovered—cross‑neutralize Ravn virus too https://biobriefs.com/spatialbench-a-benchmark-to-test BioBriefs en 2025-12-28T14:33:07Z SpatialBench... a benchmark to test agents on real spatial biology workflows https://biobriefs.com/ai-detects-paroxysmal-af-from BioBriefs en 2025-12-28T14:33:07Z AI detects paroxysmal AF from sinus ECGs—new screening algorithm https://biobriefs.com/conformal-ultrathin-silicon-hall-sensors BioBriefs en 2025-12-28T14:33:07Z Conformal ultrathin silicon Hall sensors enable early 3D tumor monitoring https://biobriefs.com/targeted-protein-degradation-mapping-health BioBriefs en 2025-12-28T14:33:07Z Targeted protein degradation: mapping health and ecological effects https://biobriefs.com/cms-rolls-out-voluntary-model BioBriefs en 2025-12-28T10:32:35Z CMS rolls out voluntary model: Medicare to expand GLP-1 coverage https://biobriefs.com/fda-greenlights-yartemlea-first-therapy BioBriefs en 2025-12-28T10:32:35Z FDA greenlights Yartemlea — first therapy for deadly stem-cell transplant complication https://biobriefs.com/j-j-cuts-bait-ditches BioBriefs en 2025-12-28T10:32:35Z J&J cuts bait — ditches $1.25 billion eczema asset https://biobriefs.com/biohavens-potassium-channel-drug-fails BioBriefs en 2025-12-28T10:32:35Z Biohaven’s potassium channel drug fails Phase 2 — second mid‑stage setback https://biobriefs.com/new-antibodies-neutralize-marburg-and BioBriefs en 2025-12-28T10:32:35Z New antibodies... neutralize Marburg and Ravn — broad filovirus candidate emerges https://biobriefs.com/smart-aavs-respond-to-tumors BioBriefs en 2025-12-28T10:32:35Z Smart AAVs respond to tumors: design framework boosts targeting https://biobriefs.com/new-study-maps-car-t BioBriefs en 2025-12-28T10:32:35Z New study maps CAR‑T neurotoxicity — safety pathways identified https://biobriefs.com/spatialbench-benchmark-exposes-agents-demo BioBriefs en 2025-12-28T10:32:35Z SpatialBench: benchmark exposes agents’ demo‑to‑deployment gap https://biobriefs.com/nanovaccines-for-hcc-engineered-particles BioBriefs en 2025-12-28T10:32:35Z Nanovaccines for HCC: engineered particles prime liver tumor immunity https://biobriefs.com/targeted-protein-degradation-raises-cross BioBriefs en 2025-12-28T10:32:35Z Targeted protein degradation... raises cross‑species health and ecological questions https://biobriefs.com/fda-approves-yartemlea-first-approved BioBriefs en 2025-12-28T09:32:51Z FDA approves Yartemlea: first approved therapy for a fatal stem‑cell transplant complication https://biobriefs.com/cms-unveils-voluntary-payment-model BioBriefs en 2025-12-28T09:32:51Z CMS unveils voluntary payment model – expands Medicare coverage for GLP‑1 weight‑loss drugs https://biobriefs.com/j-j-drops-eczema-candidate BioBriefs en 2025-12-28T09:32:51Z J&J drops eczema candidate – $1.25bn acquisition yield slashed https://biobriefs.com/biohavens-ion-channel-drug-fails BioBriefs en 2025-12-28T09:32:51Z Biohaven’s ion‑channel drug fails Phase‑2 – depression program stumbles https://biobriefs.com/study-maps-car-t-neurotoxicity BioBriefs en 2025-12-28T09:32:51Z Study maps CAR‑T neurotoxicity mechanisms – route to safer cell therapies https://biobriefs.com/engineered-aavs-vectors-that-sense BioBriefs en 2025-12-28T09:32:51Z Engineered AAVs: vectors that sense the tumor microenvironment and adapt https://biobriefs.com/nanovaccines-for-hcc-engineered-particles BioBriefs en 2025-12-28T09:32:51Z Nanovaccines for HCC: engineered particles enter immunotherapy pipeline https://biobriefs.com/spatialbench-exposes-demo-to-deployment BioBriefs en 2025-12-28T09:32:51Z SpatialBench exposes demo‑to‑deployment gap for AI agents in biology https://biobriefs.com/sybvals-launches-to-validate-biological BioBriefs en 2025-12-28T09:32:51Z SyBValS launches to validate biological pathway maps and curb errors https://biobriefs.com/targeted-protein-degradation-review-flags BioBriefs en 2025-12-28T09:32:51Z Targeted protein degradation – review flags health and ecological considerations https://biobriefs.com/cms-rolls-out-voluntary-medicare BioBriefs en 2025-12-28T04:32:41Z CMS rolls out voluntary Medicare model: GLP‑1 coverage expanded https://biobriefs.com/fda-approves-yartemlea-first-therapy BioBriefs en 2025-12-28T04:32:41Z FDA approves Yartemlea: First therapy for stem‑cell transplant complication https://biobriefs.com/j-j-axes-eczema-drug BioBriefs en 2025-12-28T04:32:41Z J&J axes eczema drug — $1.25B acquisition deal unwinds https://biobriefs.com/car-t-neurotoxicity-studied-new BioBriefs en 2025-12-28T04:32:41Z CAR‑T neurotoxicity studied: new mechanisms identified https://biobriefs.com/car-t-vs-bispecifics-head BioBriefs en 2025-12-28T04:32:41Z CAR‑T vs bispecifics... head‑to‑head in relapsed B‑cell NHL https://biobriefs.com/antibodies-neutralize-marburg-cross-reactivity BioBriefs en 2025-12-28T04:32:41Z Antibodies neutralize Marburg — cross‑reactivity with Ravn identified https://biobriefs.com/nanovaccines-engineered-approach-to-hepatocellular BioBriefs en 2025-12-28T04:32:41Z Nanovaccines: engineered approach to hepatocellular carcinoma immunotherapy https://biobriefs.com/smart-aavs-respond-to-tumor BioBriefs en 2025-12-28T04:32:41Z Smart AAVs respond to tumor microenvironment – precision delivery https://biobriefs.com/spatialbench-agents-face-real-world BioBriefs en 2025-12-28T04:32:41Z SpatialBench... agents face real‑world spatial biology test https://biobriefs.com/ai-prognostics-in-gastric-cancer BioBriefs en 2025-12-28T04:32:41Z AI prognostics in gastric cancer — models refine risk, therapy selection https://biobriefs.com/cms-unveils-voluntary-payment-model BioBriefs en 2025-12-27T21:32:12Z CMS unveils voluntary payment model to expand Medicare GLP‑1 access https://biobriefs.com/fda-approves-yartemlea-first-therapy BioBriefs en 2025-12-27T21:32:12Z FDA approves Yartemlea: first therapy for fatal stem‑cell transplant complication https://biobriefs.com/j-j-drops-eczema-asset BioBriefs en 2025-12-27T21:32:12Z J&J drops eczema asset — $1.25 billion acquisition yields failure https://biobriefs.com/car-t-vs-bispecifics-meta BioBriefs en 2025-12-27T21:32:12Z CAR‑T vs bispecifics... meta‑analysis compares outcomes in relapsed B‑cell NHL https://biobriefs.com/potent-antibodies-target-marburg-and BioBriefs en 2025-12-27T21:32:12Z Potent antibodies target Marburg and Ravn: cross‑neutralizers discovered https://biobriefs.com/tumor-responsive-aavs-enable-precise BioBriefs en 2025-12-27T21:32:12Z Tumor‑responsive AAVs enable precise therapy: smart vectors breach TME https://biobriefs.com/spatialbench-benchmark-for-agents-on BioBriefs en 2025-12-27T21:32:12Z SpatialBench... benchmark for agents on real spatial biology tasks https://biobriefs.com/nanovaccines-target-hcc-new-routes BioBriefs en 2025-12-27T21:32:12Z Nanovaccines target HCC: new routes for liver cancer immunotherapy https://biobriefs.com/car-t-neurotoxicity-fresh-findings BioBriefs en 2025-12-27T21:32:12Z CAR‑T neurotoxicity... fresh findings on mechanisms and management https://biobriefs.com/targeted-protein-degradation-therapeutic-promise BioBriefs en 2025-12-27T21:32:12Z Targeted protein degradation: therapeutic promise and cross‑species impacts https://biobriefs.com/cms-unveils-medicare-glp-1 BioBriefs en 2025-12-27T16:33:32Z CMS unveils Medicare GLP-1 payment model: voluntary pilot to expand access https://biobriefs.com/fda-approves-yartemlea-first-drug BioBriefs en 2025-12-27T16:33:32Z FDA approves Yartemlea: first drug for deadly stem‑cell transplant complication https://biobriefs.com/spatialbench-a-real-world-benchmark BioBriefs en 2025-12-27T16:33:32Z SpatialBench... a real‑world benchmark to stress‑test biology AI agents https://biobriefs.com/tumor-responsive-aavs-engineered-vectors BioBriefs en 2025-12-27T16:33:32Z Tumor‑responsive AAVs: engineered vectors that sense the microenvironment https://biobriefs.com/nanovaccines-target-hcc-nanotechnology-based BioBriefs en 2025-12-27T16:33:32Z Nanovaccines target HCC: nanotechnology-based immunotherapy advances https://biobriefs.com/dual-igf-1r-and-autophagy BioBriefs en 2025-12-27T16:33:32Z Dual IGF‑1R and autophagy blockade halts metastasis: a combinatorial strategy https://biobriefs.com/targeted-protein-degradation-mapping-cross BioBriefs en 2025-12-27T16:33:32Z Targeted protein degradation... mapping cross‑species and health consequences https://biobriefs.com/car-t-neurotoxicity-new-clinical BioBriefs en 2025-12-27T16:33:32Z CAR‑T neurotoxicity: new clinical insights and mitigation strategies https://biobriefs.com/mid-stage-drug-flops-j BioBriefs en 2025-12-27T16:33:32Z Mid‑stage drug flops... J&J, Biohaven cut losses after clinical failures https://biobriefs.com/exosomal-lncrnas-drive-tumor-signaling BioBriefs en 2025-12-27T16:33:32Z Exosomal lncRNAs drive tumor signaling in head, neck and thyroid cancers https://biobriefs.com/cms-unveils-medicare-model-for BioBriefs en 2025-12-27T14:32:40Z CMS unveils Medicare model for GLP‑1s: voluntary pilot to expand access https://biobriefs.com/fda-greenlights-yartemlea-first-approved BioBriefs en 2025-12-27T14:32:40Z FDA greenlights Yartemlea — first approved therapy for fatal post‑transplant complication https://biobriefs.com/big-pharma-pipeline-wobble-j BioBriefs en 2025-12-27T14:32:40Z Big pharma pipeline wobble: J&J scraps eczema asset; Biohaven drug fails mid‑stage https://biobriefs.com/study-maps-car-t-neurotoxicity BioBriefs en 2025-12-27T14:32:40Z Study maps CAR‑T neurotoxicity mechanisms — new safety insights https://biobriefs.com/engineered-aavs-sense-tumors-a BioBriefs en 2025-12-27T14:32:40Z Engineered AAVs sense tumors — a new vector design for precision delivery https://biobriefs.com/nanovaccines-retool-hcc-immunotherapy-preclinical BioBriefs en 2025-12-27T14:32:40Z Nanovaccines retool HCC immunotherapy: preclinical advances https://biobriefs.com/targeted-protein-degradation-expands-study BioBriefs en 2025-12-27T14:32:40Z Targeted protein degradation expands — study flags cross‑species and health impacts https://biobriefs.com/muse-cells-reduce-neurodegeneration-in BioBriefs en 2025-12-27T14:32:40Z Muse cells reduce neurodegeneration in Parkinson’s models https://biobriefs.com/spatialbench-benchmark-exposes-agents-gaps BioBriefs en 2025-12-27T14:32:40Z SpatialBench: benchmark exposes agents’ gaps on real spatial biology tasks https://biobriefs.com/microbiota-signature-links-breast-colorectal BioBriefs en 2025-12-27T14:32:40Z Microbiota signature links breast, colorectal and lung cancers https://biobriefs.com/cms-rolls-out-medicare-glp BioBriefs en 2025-12-27T10:32:55Z CMS rolls out Medicare GLP‑1 model: voluntary expansion of coverage https://biobriefs.com/fda-greenlights-yartemlea-first-therapy BioBriefs en 2025-12-27T10:32:55Z FDA greenlights Yartemlea – first therapy for fatal stem‑cell transplant complication https://biobriefs.com/j-j-shelves-eczema-asset BioBriefs en 2025-12-27T10:32:55Z J&J shelves eczema asset from $1.25B deal: efficacy fails company bar https://biobriefs.com/biohavens-potassium-channel-candidate-fails BioBriefs en 2025-12-27T10:32:55Z Biohaven’s potassium‑channel candidate fails Phase 2 – second mid‑stage setback https://biobriefs.com/tumor-sensing-aavs-design-framework BioBriefs en 2025-12-27T10:32:55Z Tumor‑sensing AAVs: design framework aims to sharpen gene delivery https://biobriefs.com/nanovaccines-for-hcc-engineered-nanoparticles BioBriefs en 2025-12-27T10:32:55Z Nanovaccines for HCC: engineered nanoparticles enter immunotherapy playbook https://biobriefs.com/spatialbench-benchmark-forces-biology-agents BioBriefs en 2025-12-27T10:32:55Z SpatialBench: benchmark forces biology agents out of demo mode https://biobriefs.com/car-t-neurotoxicity-new-findings BioBriefs en 2025-12-27T10:32:55Z CAR‑T neurotoxicity: new findings refine safety profile and monitoring https://biobriefs.com/plga-encapsulation-of-cisplatin-silibinin BioBriefs en 2025-12-27T10:32:55Z PLGA‑encapsulation of cisplatin+silibinin enhances cervical cancer response https://biobriefs.com/targeted-protein-degradation-therapeutic-promise BioBriefs en 2025-12-27T10:32:55Z Targeted protein degradation: therapeutic promise with ecological caveats https://biobriefs.com/cms-launches-medicare-glp-1 BioBriefs en 2025-12-27T09:33:12Z CMS launches Medicare GLP‑1 model: voluntary pilot to widen access https://biobriefs.com/fda-greenlights-therapy-for-fatal BioBriefs en 2025-12-27T09:33:12Z FDA greenlights therapy for fatal transplant complication: first approved option https://biobriefs.com/j-j-axes-eczema-drug BioBriefs en 2025-12-27T09:33:12Z J&J axes eczema drug — $1.25B acquisition bet fails after Phase 2 miss https://biobriefs.com/engineered-aavs-sense-tumors-new BioBriefs en 2025-12-27T09:33:12Z Engineered AAVs sense tumors: new vectors aim for precision delivery https://biobriefs.com/nanovaccines-enter-hcc-immunotherapy-pipeline BioBriefs en 2025-12-27T09:33:12Z Nanovaccines enter HCC immunotherapy pipeline: targeted antigen delivery advances https://biobriefs.com/spatialbench-benchmark-testing-agents-on BioBriefs en 2025-12-27T09:33:12Z SpatialBench benchmark: testing agents on real spatial biology workflows https://biobriefs.com/car-t-neurotoxicity-insights-sharpen BioBriefs en 2025-12-27T09:33:12Z CAR‑T neurotoxicity insights sharpen: new data on mechanisms and management https://biobriefs.com/new-strategies-to-overcome-lung BioBriefs en 2025-12-27T09:33:12Z New strategies to overcome lung cancer drug resistance: emerging combos and targets https://biobriefs.com/dual-agent-plga-delivery-cisplatin BioBriefs en 2025-12-27T09:33:12Z Dual‑agent PLGA delivery: cisplatin plus silibinin enhances cervical cancer efficacy https://biobriefs.com/targeted-protein-degradation-mapped-impacts BioBriefs en 2025-12-27T09:33:12Z Targeted protein degradation: mapped impacts on health, ecology and drug design https://biobriefs.com/cms-rolls-out-voluntary-medicare BioBriefs en 2025-12-27T04:32:45Z CMS rolls out voluntary Medicare payment model for GLP‑1s https://biobriefs.com/fda-greenlights-yartemlea-first-therapy BioBriefs en 2025-12-27T04:32:45Z FDA greenlights Yartemlea — first therapy for post‑transplant complement injury https://biobriefs.com/j-j-shutters-eczema-program BioBriefs en 2025-12-27T04:32:45Z J&J shutters eczema program from $1.25B acquisition — efficacy shortfall https://biobriefs.com/biohavens-ion-channel-drug-flops BioBriefs en 2025-12-27T04:32:45Z Biohaven’s ion‑channel drug flops in Phase 2 — depression setback https://biobriefs.com/tumor-sensing-aavs-vectors-engineered BioBriefs en 2025-12-27T04:32:45Z Tumor‑sensing AAVs: Vectors engineered to switch on in tumors https://biobriefs.com/nanovaccines-for-hcc-preclinical-platform BioBriefs en 2025-12-27T04:32:45Z Nanovaccines for HCC: Preclinical platform primes anti‑tumor immunity https://biobriefs.com/spatialbench-new-benchmark-forces-agents BioBriefs en 2025-12-27T04:32:45Z SpatialBench: New benchmark forces agents into real spatial‑biology workflows https://biobriefs.com/exosomal-blueprint-study-maps-how BioBriefs en 2025-12-27T04:32:45Z Exosomal blueprint: Study maps how tumors prime lungs for metastasis https://biobriefs.com/targeted-protein-degradation-researchers-map BioBriefs en 2025-12-27T04:32:45Z Targeted protein degradation: Researchers map therapy effects across species and health https://biobriefs.com/lung-cancer-resistance-new-combination BioBriefs en 2025-12-27T04:32:45Z Lung cancer resistance: New combination therapies resensitize tumors https://biobriefs.com/cms-model-for-glp-1s BioBriefs en 2025-12-26T21:33:03Z CMS model for GLP‑1s: Medicare tests wider coverage https://biobriefs.com/fda-approves-yartemlea-first-therapy BioBriefs en 2025-12-26T21:33:03Z FDA approves Yartemlea: first therapy for fatal post‑transplant complication https://biobriefs.com/j-j-drops-eczema-asset BioBriefs en 2025-12-26T21:33:03Z J&J drops eczema asset — $1.25B deal unwinds https://biobriefs.com/biohavens-mid-stage-setback-ion BioBriefs en 2025-12-26T21:33:03Z Biohaven’s Mid‑Stage Setback — ion channel drug fails Phase 2 https://biobriefs.com/engineered-vesicles-enhance-oral-antibiotics BioBriefs en 2025-12-26T21:33:03Z Engineered vesicles enhance oral antibiotics — improved absorption and gut safety https://biobriefs.com/tumor-responsive-aavs-a-new BioBriefs en 2025-12-26T21:33:03Z Tumor‑responsive AAVs: a new layer of precision delivery https://biobriefs.com/exosomal-blueprint-maps-lung-tropic BioBriefs en 2025-12-26T21:33:03Z Exosomal blueprint maps lung‑tropic metastasis https://biobriefs.com/spatialbench-a-benchmark-for-real BioBriefs en 2025-12-26T21:33:03Z SpatialBench... a benchmark for real‑world spatial biology agents https://biobriefs.com/nanovaccines-for-hcc-new-immunotherapy BioBriefs en 2025-12-26T21:33:03Z Nanovaccines for HCC: new immunotherapy platform advances https://biobriefs.com/targeted-protein-degradation-broader-health BioBriefs en 2025-12-26T21:33:03Z Targeted protein degradation: broader health and ecological impacts https://biobriefs.com/sanofi-to-buy-dynavax-for BioBriefs en 2025-12-26T16:33:22Z Sanofi to buy Dynavax for $2.2B — Heplisav‑B and shingles candidate added https://biobriefs.com/fda-clears-omeros-yartemlea-first BioBriefs en 2025-12-26T16:33:22Z FDA clears Omeros’ Yartemlea: first therapy for TA‑TMA https://biobriefs.com/medicare-to-test-glp-1 BioBriefs en 2025-12-26T16:33:22Z Medicare to test GLP‑1 coverage — voluntary model could expand access https://biobriefs.com/j-j-scraps-eczema-candidate BioBriefs en 2025-12-26T16:33:22Z J&J scraps eczema candidate from $1.25B buy — efficacy shortfall https://biobriefs.com/biohavens-potassium-channel-program-fails BioBriefs en 2025-12-26T16:33:22Z Biohaven’s potassium‑channel program fails Phase 2 in major depressive disorder https://biobriefs.com/engineered-vesicles-boost-oral-antibiotic BioBriefs en 2025-12-26T16:33:22Z Engineered vesicles boost oral antibiotic uptake — reduce gut dysbiosis https://biobriefs.com/gene-therapy-commercial-pullback-costs BioBriefs en 2025-12-26T16:33:22Z Gene‑therapy commercial pullback — costs, uptake and regulatory friction bite https://biobriefs.com/spatialbench-benchmark-agents-tested-on BioBriefs en 2025-12-26T16:33:22Z SpatialBench benchmark: agents tested on 146 realistic spatial biology tasks https://biobriefs.com/biopharma-fundraising-snapshot-year-to BioBriefs en 2025-12-26T16:33:22Z Biopharma fundraising snapshot — year‑to‑date totals through Dec. 24, 2025 https://biobriefs.com/hanx-bio-ipo-tumbles-46 BioBriefs en 2025-12-26T16:33:22Z Hanx Bio IPO tumbles 46% on HK debut despite $75M raise https://biobriefs.com/sanofi-pays-2-2b-for BioBriefs en 2025-12-26T14:33:30Z Sanofi pays $2.2B for Dynavax – bolsters vaccine pipeline https://biobriefs.com/fda-approves-yartemlea-first-treatment BioBriefs en 2025-12-26T14:33:30Z FDA approves Yartemlea: first treatment for TA‑TMA https://biobriefs.com/medicare-to-test-glp-1 BioBriefs en 2025-12-26T14:33:30Z Medicare to test GLP‑1 coverage – payer access inflection https://biobriefs.com/hhs-proposes-rollback-of-health BioBriefs en 2025-12-26T14:33:30Z HHS proposes rollback of health‑tech rules – AI transparency pared back https://biobriefs.com/court-overturns-fda-ldt-rule BioBriefs en 2025-12-26T14:33:30Z Court overturns FDA LDT rule – labs win major regulatory reprieve https://biobriefs.com/engineered-vesicles-boost-oral-antibiotics BioBriefs en 2025-12-26T14:33:30Z Engineered vesicles boost oral antibiotics... protect gut microbiome https://biobriefs.com/gene-therapy-market-cools-costs BioBriefs en 2025-12-26T14:33:30Z Gene therapy market cools – costs and regulation bite https://biobriefs.com/germline-dna-repair-defects-tied BioBriefs en 2025-12-26T14:33:30Z Germline DNA‑repair defects tied to early GI cancers – screening signal https://biobriefs.com/fda-clears-crescoms-mediai-ba BioBriefs en 2025-12-26T14:33:30Z FDA clears Crescom’s MediAI‑BA: AI pediatric bone‑age tool https://biobriefs.com/biopharma-fundraising-year-end-totals BioBriefs en 2025-12-26T14:33:30Z Biopharma fundraising: year‑end totals and multi‑year flows https://biobriefs.com/sanofi-pays-2-2b-for BioBriefs en 2025-12-26T10:31:45Z Sanofi pays $2.2B for Dynavax — MS CRL clouds pipeline https://biobriefs.com/cms-to-pilot-glp-1 BioBriefs en 2025-12-26T10:31:45Z CMS to pilot GLP‑1 coverage: Medicare edges into obesity drugs https://biobriefs.com/fda-clears-yartemlea-first-therapy BioBriefs en 2025-12-26T10:31:45Z FDA clears Yartemlea — first therapy for stem‑cell transplant TA‑TMA https://biobriefs.com/court-tosses-fda-ldt-rule BioBriefs en 2025-12-26T10:31:44Z Court tosses FDA LDT rule — 2025 regulatory climax https://biobriefs.com/hhs-proposes-rule-overhaul-trims BioBriefs en 2025-12-26T10:31:44Z HHS proposes rule overhaul: trims AI, transparency requirements https://biobriefs.com/vyriad-closes-25m-tranche-funds BioBriefs en 2025-12-26T10:31:44Z Vyriad closes $25M tranche — funds in vivo CAR‑T (VV‑169) clinic push https://biobriefs.com/enveda-clears-ind-for-env BioBriefs en 2025-12-26T10:31:44Z Enveda clears IND for ENV‑6946 — oral small molecule enters IBD clinic https://biobriefs.com/intraperitoneal-mrna-lnps-program-car BioBriefs en 2025-12-26T10:31:44Z Intraperitoneal mRNA LNPs program CAR macrophages — tumor activity rises https://biobriefs.com/engineered-vesicles-boost-oral-antibiotic BioBriefs en 2025-12-26T10:31:44Z Engineered vesicles boost oral antibiotic absorption — gut dysbiosis curbed https://biobriefs.com/fda-approves-aqvesme-mitapivat-for BioBriefs en 2025-12-26T10:31:44Z FDA approves Aqvesme (mitapivat) for thalassemia — Agios clears a major milestone https://biobriefs.com/sanofi-doubles-down-on-vaccines BioBriefs en 2025-12-26T09:32:58Z Sanofi doubles down on vaccines: $2.2B Dynavax buy https://biobriefs.com/fda-clears-omeros-yartemlea-first BioBriefs en 2025-12-26T09:32:58Z FDA clears Omeros’ Yartemlea: first TA‑TMA therapy https://biobriefs.com/agios-wins-approval-mitapivat-branded BioBriefs en 2025-12-26T09:32:58Z Agios wins approval – mitapivat branded Aqvesme for thalassemia https://biobriefs.com/medicare-pilots-glp-1-coverage BioBriefs en 2025-12-26T09:32:58Z Medicare pilots GLP‑1 coverage: obesity drugs move closer to seniors https://biobriefs.com/vyriad-closes-financing-vv-169 BioBriefs en 2025-12-26T09:32:58Z Vyriad closes financing – VV‑169 moves to first‑in‑human https://biobriefs.com/envedas-env-6946-enters-clinic BioBriefs en 2025-12-26T09:32:58Z Enveda’s ENV‑6946 enters clinic: first‑in‑class oral IBD program https://biobriefs.com/engineered-vesicles-improve-oral-antibiotics BioBriefs en 2025-12-26T09:32:58Z Engineered vesicles improve oral antibiotics and preserve gut microbiome https://biobriefs.com/intraperitoneal-mrna-programs-car-macrophages BioBriefs en 2025-12-26T09:32:58Z Intraperitoneal mRNA programs CAR macrophages – a new tumor‑targeting route https://biobriefs.com/court-overturns-fda-ldt-rule BioBriefs en 2025-12-26T09:32:58Z Court overturns FDA LDT rule: regulatory fallout grows https://biobriefs.com/fda-clears-crescoms-mediai-ba BioBriefs en 2025-12-26T09:32:58Z FDA clears Crescom’s MediAI‑BA: pediatric bone‑age AI gets 510(k) https://biobriefs.com/sanofi-snaps-up-dynavax-for BioBriefs en 2025-12-26T04:33:17Z Sanofi snaps up Dynavax for $2.2B — MS drug hits CRL https://biobriefs.com/medicare-to-test-glp-1 BioBriefs en 2025-12-26T04:33:17Z Medicare to test GLP‑1 coverage — obesity access threshold crossed https://biobriefs.com/fda-greenlights-first-ta-tma BioBriefs en 2025-12-26T04:33:17Z FDA greenlights first TA‑TMA drug: Omeros’ Yartemlea cleared https://biobriefs.com/court-voids-fda-ldt-rule BioBriefs en 2025-12-26T04:33:17Z Court voids FDA LDT rule — regulatory landscape upended https://biobriefs.com/engineered-vesicles-revive-oral-antibiotics BioBriefs en 2025-12-26T04:33:17Z Engineered vesicles revive oral antibiotics — gut spared https://biobriefs.com/intraperitoneal-mrna-programs-car-macrophages BioBriefs en 2025-12-26T04:33:17Z Intraperitoneal mRNA programs CAR macrophages — new in‑body cell therapy https://biobriefs.com/vyriad-closes-25m-tranche-in BioBriefs en 2025-12-26T04:33:17Z Vyriad closes $25M tranche — in vivo CAR‑T candidate moves to humans https://biobriefs.com/enveda-starts-phase-i-of BioBriefs en 2025-12-26T04:33:17Z Enveda starts Phase I of ENV‑6946 — first‑in‑class oral IBD candidate https://biobriefs.com/adc-targets-mapped-across-breast BioBriefs en 2025-12-26T04:33:17Z ADC targets mapped across breast cancer metastases — Nature study https://biobriefs.com/fda-clears-crescoms-ai-bone BioBriefs en 2025-12-26T04:33:17Z FDA clears Crescom’s AI bone‑age tool — pediatric device OK'd https://biobriefs.com/sanofi-pays-2-2b-for BioBriefs en 2025-12-25T21:32:54Z Sanofi pays $2.2B for Dynavax: HepB vaccine added to lineup https://biobriefs.com/medicare-to-test-glp-1 BioBriefs en 2025-12-25T21:32:54Z Medicare to test GLP‑1 coverage: obesity‑drug access threshold crossed https://biobriefs.com/fda-approves-omeros-yartemlea-first BioBriefs en 2025-12-25T21:32:54Z FDA approves Omeros’ Yartemlea: first TA‑TMA therapy https://biobriefs.com/court-strikes-down-fdas-ldt BioBriefs en 2025-12-25T21:32:54Z Court strikes down FDA’s LDT rule — regulatory year‑end shock https://biobriefs.com/hhs-proposes-rollback-cuts-health BioBriefs en 2025-12-25T21:32:54Z HHS proposes rollback: cuts health‑tech certification and AI transparency https://biobriefs.com/crescom-wins-fda-clearance-for BioBriefs en 2025-12-25T21:32:54Z Crescom wins FDA clearance for MediAI‑BA: pediatric bone‑age AI cleared https://biobriefs.com/vyriad-closes-25m-tranche-85m BioBriefs en 2025-12-25T21:32:54Z Vyriad closes $25M tranche — $85M series B backs VV‑169 trial https://biobriefs.com/engineered-vesicles-boost-oral-antibiotics BioBriefs en 2025-12-25T21:32:54Z Engineered vesicles boost oral antibiotics: improve absorption, spare gut flora https://biobriefs.com/intraperitoneal-mrna-car-macrophages-in BioBriefs en 2025-12-25T21:32:54Z Intraperitoneal mRNA CAR macrophages — in‑body programming enhances tumor killing https://biobriefs.com/enveda-gets-ind-for-env BioBriefs en 2025-12-25T21:32:54Z Enveda gets IND for ENV‑6946: first‑in‑human IBD trial starts https://biobriefs.com/sanofi-buys-dynavax-for-2 BioBriefs en 2025-12-25T16:32:28Z Sanofi buys Dynavax for $2.2B — vaccine portfolio boost https://biobriefs.com/fda-clears-wegovy-pill-first BioBriefs en 2025-12-25T16:32:28Z FDA clears Wegovy pill — first oral GLP‑1 for weight loss https://biobriefs.com/cms-to-pilot-glp-1 BioBriefs en 2025-12-25T16:32:28Z CMS to pilot GLP‑1 coverage — Medicare edges into obesity drugs https://biobriefs.com/fda-greenlights-omeros-yartemlea-first BioBriefs en 2025-12-25T16:32:28Z FDA greenlights Omeros’ Yartemlea — first TA‑TMA therapy https://biobriefs.com/agios-wins-approval-for-mitapivat BioBriefs en 2025-12-25T16:32:28Z Agios wins approval for mitapivat — launches Aqvesme in thalassemia https://biobriefs.com/engineered-vesicles-boost-oral-antibiotics BioBriefs en 2025-12-25T16:32:28Z Engineered vesicles boost oral antibiotics — absorption and microbiome gains https://biobriefs.com/intraperitoneal-mrna-programs-car-macrophages BioBriefs en 2025-12-25T16:32:28Z Intraperitoneal mRNA programs CAR macrophages — in vivo immune engineering https://biobriefs.com/envedas-env-6946-enters-clinic BioBriefs en 2025-12-25T16:32:28Z Enveda’s ENV‑6946 enters clinic — oral small molecule for IBD https://biobriefs.com/fda-clears-crescoms-mediai-ba BioBriefs en 2025-12-25T16:32:28Z FDA clears Crescom’s MediAI‑BA — pediatric bone‑age AI gets 510(k) https://biobriefs.com/singlera-inks-eu-deal-with BioBriefs en 2025-12-25T16:32:28Z Singlera inks EU deal with Pure Medical — expands cfDNA cancer reach https://biobriefs.com/sanofi-pays-2-2b-for BioBriefs en 2025-12-25T14:32:52Z Sanofi pays $2.2B for Dynavax — boosts hepatitis B and shingles lineup https://biobriefs.com/fda-clears-wegovy-pill-first BioBriefs en 2025-12-25T14:32:52Z FDA clears Wegovy pill: first oral GLP‑1 weight‑loss therapy https://biobriefs.com/fda-approves-omeros-yartemlea-first BioBriefs en 2025-12-25T14:32:52Z FDA approves Omeros’ Yartemlea — first drug for stem‑cell–associated TA‑TMA https://biobriefs.com/cms-to-test-medicare-coverage BioBriefs en 2025-12-25T14:32:52Z CMS to test Medicare coverage for GLP‑1 weight drugs — threshold crossed https://biobriefs.com/agios-wins-fda-approval-for BioBriefs en 2025-12-25T14:32:52Z Agios wins FDA approval for Aqvesme — mitapivat cleared in thalassemia https://biobriefs.com/vyriad-raises-25m-final-tranche BioBriefs en 2025-12-25T14:32:52Z Vyriad raises $25M final tranche — funds VV‑169 first‑in‑human push https://biobriefs.com/envedas-env-6946-clears-ind BioBriefs en 2025-12-25T14:32:52Z Enveda’s ENV‑6946 clears IND: oral IBD candidate enters phase I https://biobriefs.com/intraperitoneal-mrna-lnps-program-car BioBriefs en 2025-12-25T14:32:52Z Intraperitoneal mRNA LNPs program CAR macrophages — enhance peritoneal cancer therapy https://biobriefs.com/fda-clears-crescoms-mediai-ba BioBriefs en 2025-12-25T14:32:52Z FDA clears Crescom’s MediAI‑BA — AI pediatric bone‑age analysis cleared https://biobriefs.com/singlera-inks-eu-distribution-and BioBriefs en 2025-12-25T14:32:52Z Singlera inks EU distribution and research pact with Pure Medical — methylation cfDNA assays to Europe https://biobriefs.com/court-decision-upends-fda-lab BioBriefs en 2025-12-25T14:32:52Z Court decision upends FDA lab‑developed test rule — regulatory shakeup of 2025 https://biobriefs.com/sanofi-buys-dynavax-for-2 BioBriefs en 2025-12-25T10:33:45Z Sanofi buys Dynavax for $2.2B — MS drug CRL also lands https://biobriefs.com/fda-approves-first-therapy-for BioBriefs en 2025-12-25T10:33:45Z FDA approves first therapy for TA‑TMA — Omeros’ Yartemlea cleared https://biobriefs.com/wegovy-pill-cleared-oral-glp BioBriefs en 2025-12-25T10:33:45Z Wegovy pill cleared — oral GLP‑1 launches weight‑loss pill era https://biobriefs.com/cms-to-test-coverage-for BioBriefs en 2025-12-25T10:33:45Z CMS to test coverage for GLP‑1s — Medicare, Medicaid pilot set https://biobriefs.com/courts-rebuke-fda-ldt-rule BioBriefs en 2025-12-25T10:33:45Z Courts rebuke FDA LDT rule — regulatory fight tops 2025 https://biobriefs.com/shionogi-pays-2-5b-for BioBriefs en 2025-12-25T10:33:45Z Shionogi pays $2.5B for ALS drug rights — Tanabe deal closes https://biobriefs.com/patient-death-in-pfizer-hemophilia BioBriefs en 2025-12-25T10:33:45Z Patient death in Pfizer hemophilia trial prompts scrutiny https://biobriefs.com/early-stage-clinic-moves-enveda BioBriefs en 2025-12-25T10:33:45Z Early‑stage clinic moves: Enveda IND greenlight and Vyriad financing https://biobriefs.com/singlera-inks-eu-distribution-deal BioBriefs en 2025-12-25T10:33:45Z Singlera inks EU distribution deal — cfDNA cancer assays head west https://biobriefs.com/agios-mitapivat-approved-as-aqvesme BioBriefs en 2025-12-25T10:33:45Z Agios’ mitapivat approved as Aqvesme — thalassemia label wins FDA https://biobriefs.com/sanofi-buys-dynavax-for-2 BioBriefs en 2025-12-25T09:33:16Z Sanofi buys Dynavax for $2.2B — vaccine boost, pipeline reality check https://biobriefs.com/wegovy-pill-clears-fda-medicare BioBriefs en 2025-12-25T09:33:16Z Wegovy pill clears FDA; Medicare edges toward GLP‑1 coverage https://biobriefs.com/fda-approves-omeros-yartemlea-first BioBriefs en 2025-12-25T09:33:16Z FDA approves Omeros’ Yartemlea — first TA‑TMA therapy https://biobriefs.com/court-upends-fda-ldt-rule BioBriefs en 2025-12-25T09:33:16Z Court upends FDA LDT rule; HHS proposes rollbacks for health‑tech rules https://biobriefs.com/pfizer-discloses-death-in-hympavzi BioBriefs en 2025-12-25T09:33:16Z Pfizer discloses death in Hympavzi hemophilia trial — community questions safety https://biobriefs.com/vyriad-closes-25m-tranche-to BioBriefs en 2025-12-25T09:33:16Z Vyriad closes $25M tranche to advance in vivo CAR‑T into clinic https://biobriefs.com/envedas-env-6946-gets-ind BioBriefs en 2025-12-25T09:33:16Z Enveda’s ENV‑6946 gets IND clearance — oral small molecule enters IBD clinic https://biobriefs.com/singlera-inks-eu-research-and BioBriefs en 2025-12-25T09:33:16Z Singlera inks EU research and distribution pact with Pure Medical for cfDNA assays https://biobriefs.com/crescom-wins-fda-510-k BioBriefs en 2025-12-25T09:33:16Z Crescom wins FDA 510(k) for MediAI‑BA — pediatric bone‑age AI cleared https://biobriefs.com/intraperitoneal-mrna-lnps-program-car BioBriefs en 2025-12-25T09:33:16Z Intraperitoneal mRNA LNPs program CAR macrophages in vivo — preclinical tumor gains https://biobriefs.com/sanofi-bulks-up-vaccines-2 BioBriefs en 2025-12-25T04:33:17Z Sanofi bulks up vaccines: $2.2B Dynavax buy https://biobriefs.com/fda-clears-yartemlea-first-ta BioBriefs en 2025-12-25T04:33:17Z FDA clears Yartemlea: first TA‑TMA therapy https://biobriefs.com/wegovy-goes-oral-fda-clears BioBriefs en 2025-12-25T04:33:17Z Wegovy goes oral: FDA clears Novo’s semaglutide pill https://biobriefs.com/medicare-to-test-glp-1 BioBriefs en 2025-12-25T04:33:17Z Medicare to test GLP‑1 coverage — payer barrier shifts https://biobriefs.com/agios-wins-nod-for-mitapivat BioBriefs en 2025-12-25T04:33:17Z Agios wins nod for mitapivat — approval in thalassemia https://biobriefs.com/court-knocks-out-fda-ldt BioBriefs en 2025-12-25T04:33:17Z Court knocks out FDA LDT rule — regulatory terrain altered https://biobriefs.com/vyriad-raises-tranche-to-push BioBriefs en 2025-12-25T04:33:17Z Vyriad raises tranche to push in‑vivo CAR‑T VV‑169 to clinic https://biobriefs.com/envedas-env-6946-enters-clinic BioBriefs en 2025-12-25T04:33:17Z Enveda’s ENV‑6946 enters clinic — oral IBD candidate https://biobriefs.com/orums-orm-1153-shows-aml BioBriefs en 2025-12-25T04:33:17Z Orum’s ORM‑1153 shows AML edge vs venetoclax in tests https://biobriefs.com/patient-death-disclosed-in-pfizers BioBriefs en 2025-12-25T04:33:17Z Patient death disclosed in Pfizer’s Hympavzi hemophilia trial https://biobriefs.com/sanofi-shells-out-2-2b BioBriefs en 2025-12-24T21:33:03Z Sanofi shells out $2.2B for Dynavax: vaccine push accelerates https://biobriefs.com/fda-clears-wegovy-pill-oral BioBriefs en 2025-12-24T21:33:03Z FDA clears Wegovy pill: oral GLP‑1 enters obesity market https://biobriefs.com/fda-greenlights-omeros-yartemlea-first BioBriefs en 2025-12-24T21:33:03Z FDA greenlights Omeros’ Yartemlea: first TA‑TMA therapy approved https://biobriefs.com/cms-to-pilot-glp-1 BioBriefs en 2025-12-24T21:33:03Z CMS to pilot GLP‑1 coverage: Medicare edges into obesity drugs https://biobriefs.com/asia-deal-wave-harbour-nets BioBriefs en 2025-12-24T21:33:03Z Asia deal wave: Harbour nets BMS tie‑up; Jacobio inks $1.9B AstraZeneca pact https://biobriefs.com/death-in-hympavzi-trial-triggers BioBriefs en 2025-12-24T21:33:03Z Death in Hympavzi trial triggers safety probe — hemophilia program under scrutiny https://biobriefs.com/vyriad-closes-25m-tranche-in BioBriefs en 2025-12-24T21:33:03Z Vyriad closes $25M tranche — in‑vivo CAR‑T candidate moves to clinic https://biobriefs.com/early-clinical-starts-envedas-oral BioBriefs en 2025-12-24T21:33:03Z Early clinical starts: Enveda’s oral IBD drug and Simcere’s cancer candidate enter trials https://biobriefs.com/device-approvals-fda-clears-crescom BioBriefs en 2025-12-24T21:33:03Z Device approvals: FDA clears Crescom AI bone‑age tool; Edwards wins Sapien M3 nod https://biobriefs.com/regulatory-shakeup-court-rejects-fda BioBriefs en 2025-12-24T21:33:03Z Regulatory shakeup: court rejects FDA LDT rule — EU readies breakthrough devices pilot https://biobriefs.com/wegovy-pill-cleared-novo-nordisk BioBriefs en 2025-12-24T16:33:06Z Wegovy pill cleared: Novo Nordisk brings oral GLP‑1 to market https://biobriefs.com/sanofi-buys-dynavax-for-2 BioBriefs en 2025-12-24T16:33:06Z Sanofi buys Dynavax for $2.2 billion — bolsters vaccine lineup https://biobriefs.com/boehringer-inks-white-house-deal BioBriefs en 2025-12-24T16:33:06Z Boehringer inks White House deal — $10 billion US investment and direct‑purchase pact https://biobriefs.com/jacobio-signs-1-9b-pact BioBriefs en 2025-12-24T16:33:06Z Jacobio signs $1.9B pact with AstraZeneca — pan‑KRAS asset outlicensed https://biobriefs.com/harbour-biomed-adds-bristol-myers BioBriefs en 2025-12-24T16:33:06Z Harbour Biomed adds Bristol Myers Squibb collaboration — $90M up front, $1B+ milestones https://biobriefs.com/vyriad-closes-25m-tranche-series BioBriefs en 2025-12-24T16:33:06Z Vyriad closes $25M tranche — series B reaches $85M to fund in‑vivo CAR‑T candidate https://biobriefs.com/singlera-genomics-inks-eu-distribution BioBriefs en 2025-12-24T16:33:06Z Singlera Genomics inks EU distribution, research pact for cfDNA cancer assays https://biobriefs.com/envedas-env-6946-clears-ind BioBriefs en 2025-12-24T16:33:06Z Enveda’s ENV‑6946 clears IND — first‑in‑class oral for IBD enters phase I https://biobriefs.com/merck-daiichi-lung-trial-paused BioBriefs en 2025-12-24T16:33:06Z Merck‑Daiichi lung trial paused: deaths prompt partial hold in phase III https://biobriefs.com/pfizer-discloses-death-in-hympavzi BioBriefs en 2025-12-24T16:33:06Z Pfizer discloses death in Hympavzi hemophilia trial — cerebellar infarct and cerebral hemorrhage https://biobriefs.com/wegovy-pill-cleared-novo-nordisk BioBriefs en 2025-12-24T14:33:26Z Wegovy pill cleared: Novo Nordisk lands first oral GLP‑1 https://biobriefs.com/sanofi-shells-out-2-2b BioBriefs en 2025-12-24T14:33:26Z Sanofi shells out $2.2B: buys Dynavax for hepatitis‑B vaccines https://biobriefs.com/shionogi-pays-2-5b-nabs BioBriefs en 2025-12-24T14:33:26Z Shionogi pays $2.5B: nabs FDA‑approved ALS drug from Tanabe https://biobriefs.com/jacobio-outlicenses-pan-kras-1 BioBriefs en 2025-12-24T14:33:26Z Jacobio outlicenses pan‑KRAS: $1.9B deal with AstraZeneca https://biobriefs.com/harbour-biomed-inks-bms-multispecifics BioBriefs en 2025-12-24T14:33:26Z Harbour Biomed inks BMS multispecifics pact: $90M upfront https://biobriefs.com/phase-iii-recruitment-paused-deaths BioBriefs en 2025-12-24T14:33:26Z Phase‑III recruitment paused: deaths hit Merck‑Daiichi lung ADC study https://biobriefs.com/pfizer-reports-trial-death-hympavzi BioBriefs en 2025-12-24T14:33:26Z Pfizer reports trial death: Hympavzi hemophilia study under scrutiny https://biobriefs.com/guardant360-cdx-cleared-in-japan BioBriefs en 2025-12-24T14:33:26Z Guardant360 CDx cleared in Japan: ESR1 companion for Lilly’s Inluriyo https://biobriefs.com/singlera-signs-eu-distribution-cfdna BioBriefs en 2025-12-24T14:33:26Z Singlera signs EU distribution: cfDNA methylation assays head to Europe https://biobriefs.com/cell-based-and-vesicle-therapies BioBriefs en 2025-12-24T14:33:26Z Cell‑based and vesicle therapies revive ovarian function after chemo https://biobriefs.com/novos-wegovy-pill-cleared-by BioBriefs en 2025-12-24T10:33:08Z Novo’s Wegovy pill cleared by FDA — oral GLP‑1 reaches US market https://biobriefs.com/pfizer-probes-fatal-event-in BioBriefs en 2025-12-24T10:33:08Z Pfizer probes fatal event in Hympavzi hemophilia trial — patient death disclosed https://biobriefs.com/boehringer-inks-us-pact-with BioBriefs en 2025-12-24T10:33:08Z Boehringer inks US pact with White House — $10B investment, TrumpRx participation https://biobriefs.com/singlera-genomics-expands-into-europe BioBriefs en 2025-12-24T10:33:08Z Singlera Genomics expands into Europe with Pure Medical distribution deal https://biobriefs.com/jacobio-outlicenses-pan-kras-program BioBriefs en 2025-12-24T10:33:08Z Jacobio outlicenses pan‑KRAS program to AstraZeneca — $1.9B potential deal https://biobriefs.com/shionogi-pays-2-5b-for BioBriefs en 2025-12-24T10:33:08Z Shionogi pays $2.5B for Tanabe’s edaravone rights — ALS portfolio acquired https://biobriefs.com/harbour-biomed-inks-big-ticket BioBriefs en 2025-12-24T10:33:08Z Harbour Biomed inks big‑ticket BMS collaboration — multispecific antibody program https://biobriefs.com/aktis-files-for-hong-kong BioBriefs en 2025-12-24T10:33:08Z Aktis files for Hong Kong IPO — aims to fund Lilly‑partnered radiopharma pipeline https://biobriefs.com/signatera-mrd-readout-validates-ctdna BioBriefs en 2025-12-24T10:33:08Z Signatera MRD readout validates ctDNA as a treatment selector — IMvigor011 impact https://biobriefs.com/cms-proposes-mandatory-medicare-drug BioBriefs en 2025-12-24T10:33:08Z CMS proposes mandatory Medicare drug demos — pilots would tie U.S. prices to peer nations https://biobriefs.com/wegovy-pill-approved-first-oral BioBriefs en 2025-12-24T09:33:19Z Wegovy pill approved — First oral GLP‑1 cleared for obesity https://biobriefs.com/singlera-inks-eu-pact-pure BioBriefs en 2025-12-24T09:33:19Z Singlera inks EU pact: Pure Medical to distribute cfDNA cancer assays https://biobriefs.com/astrazeneca-bets-on-pan-kras BioBriefs en 2025-12-24T09:33:19Z AstraZeneca bets on pan‑KRAS — $1.9B Jacobio pact https://biobriefs.com/pfizer-probe-after-trial-death BioBriefs en 2025-12-24T09:33:19Z Pfizer probe after trial death — Hympavzi extension under scrutiny https://biobriefs.com/patient-deaths-halt-lung-adc BioBriefs en 2025-12-24T09:33:19Z Patient deaths halt lung ADC Phase III recruitment https://biobriefs.com/harbour-biomed-inks-bms-multispecifics BioBriefs en 2025-12-24T09:33:19Z Harbour Biomed inks BMS multispecifics deal — $90M now, $1B+ later https://biobriefs.com/boehringer-joins-trumprx-10b-us BioBriefs en 2025-12-24T09:33:19Z Boehringer joins TrumpRx — $10B US investment and pricing pact https://biobriefs.com/aktis-files-for-ipo-radiopharma BioBriefs en 2025-12-24T09:33:19Z Aktis files for IPO — radiopharma firm seeks capital for Lilly partnership https://biobriefs.com/mrd-testing-reaches-inflection-signatera BioBriefs en 2025-12-24T09:33:19Z MRD testing reaches inflection — Signatera trial yields randomized evidence https://biobriefs.com/cms-proposes-medicare-pilots-testing BioBriefs en 2025-12-24T09:33:19Z CMS proposes Medicare pilots — testing most‑favored‑nation pricing for beneficiaries https://biobriefs.com/wegovy-pill-cleared-first-oral BioBriefs en 2025-12-24T04:32:41Z Wegovy pill cleared: first oral GLP-1 for obesity https://biobriefs.com/cms-proposes-medicare-demos-trump BioBriefs en 2025-12-24T04:32:41Z CMS proposes Medicare demos: Trump administration pushes MFN-style pricing https://biobriefs.com/boehringer-dealmaking-10b-us-investment BioBriefs en 2025-12-24T04:32:41Z Boehringer dealmaking: $10B US investment and CKD pill pact https://biobriefs.com/astrazeneca-scales-kras-push-big BioBriefs en 2025-12-24T04:32:41Z AstraZeneca scales KRAS push: big ex‑China deal with Jacobio https://biobriefs.com/aktis-eyes-public-markets-radiopharma BioBriefs en 2025-12-24T04:32:41Z Aktis eyes public markets: radiopharma IPO to fund alpha programs https://biobriefs.com/patient-death-clouds-pfizers-hympavzi BioBriefs en 2025-12-24T04:32:41Z Patient death clouds Pfizer’s Hympavzi hemophilia program https://biobriefs.com/phase-iii-halt-merck-daiichi BioBriefs en 2025-12-24T04:32:41Z Phase III halt: Merck‑Daiichi pause lung cancer ADC trial after deaths https://biobriefs.com/shionogi-pays-2-5b-for BioBriefs en 2025-12-24T04:32:41Z Shionogi pays $2.5B for edaravone rights: rare‑disease buy expands portfolio https://biobriefs.com/mrd-testing-matures-pivotal-trial BioBriefs en 2025-12-24T04:32:41Z MRD testing matures: pivotal trial readouts and commercial consolidation https://biobriefs.com/fda-clears-wegovy-pill-first BioBriefs en 2025-12-23T21:33:08Z FDA clears Wegovy pill — first oral GLP‑1 for obesity https://biobriefs.com/astrazeneca-fronts-100m-for-jacobio BioBriefs en 2025-12-23T21:33:08Z AstraZeneca fronts $100M for Jacobio pan‑KRAS — $1.9B deal https://biobriefs.com/boehringer-joins-trumprx-gov-10b BioBriefs en 2025-12-23T21:33:08Z Boehringer joins TrumpRx.gov — $10B U.S. investment pledged https://biobriefs.com/shionogi-agrees-2-5b-deal BioBriefs en 2025-12-23T21:33:08Z Shionogi agrees $2.5B deal: acquires edaravone ALS franchise https://biobriefs.com/feds-charge-six-41m-biopharma BioBriefs en 2025-12-23T21:33:08Z Feds charge six... $41M biopharma insider‑trading ring https://biobriefs.com/samsung-biologics-buys-gsks-rockville BioBriefs en 2025-12-23T21:33:08Z Samsung Biologics buys GSK’s Rockville plant — $280M deal https://biobriefs.com/guardant360-cdx-approved-in-japan BioBriefs en 2025-12-23T21:33:08Z Guardant360 CDx approved in Japan: companion for Lilly’s Inluriyo https://biobriefs.com/harbour-biomed-adds-bms-multispecific BioBriefs en 2025-12-23T21:33:08Z Harbour Biomed adds BMS multispecific pact — $90M upfront, $1B+ milestones https://biobriefs.com/aktis-files-to-go-public BioBriefs en 2025-12-23T21:33:08Z Aktis files to go public — funds radiopharma trials after Big Pharma backing https://biobriefs.com/signatera-trial-backs-mrd-guided BioBriefs en 2025-12-23T21:33:08Z Signatera trial backs MRD‑guided immunotherapy — readout shifts diagnostic landscape https://biobriefs.com/wegovy-pill-wins-fda-novo BioBriefs en 2025-12-23T16:33:24Z Wegovy pill wins FDA: Novo Nordisk eyes wider rollout https://biobriefs.com/boehringer-inks-448m-pact-rectify BioBriefs en 2025-12-23T16:33:24Z Boehringer inks $448M pact: Rectify to develop oral CKD medicines https://biobriefs.com/astrazeneca-fronts-100m-for-jacobio BioBriefs en 2025-12-23T16:33:24Z AstraZeneca fronts $100M for Jacobio pan‑KRAS – $1.9B upside https://biobriefs.com/windward-buys-qyuns-bispecific-700m BioBriefs en 2025-12-23T16:33:24Z Windward buys Qyuns bispecific... $700M potential https://biobriefs.com/gilead-opts-into-assembly-hsv BioBriefs en 2025-12-23T16:33:24Z Gilead opts into Assembly HSV programs: $35M for two antivirals https://biobriefs.com/aktis-files-for-ipo-radiopharma BioBriefs en 2025-12-23T16:33:24Z Aktis files for IPO: radiopharma group to fund miniprotein trials https://biobriefs.com/mrd-testing-market-heats-up BioBriefs en 2025-12-23T16:33:24Z MRD testing market heats up: IMvigor011 validates Signatera as treatment selector https://biobriefs.com/pfizer-discloses-death-in-hympavzi BioBriefs en 2025-12-23T16:33:24Z Pfizer discloses death in Hympavzi hemophilia trial: neurological event reported https://biobriefs.com/samsung-biologics-to-buy-gsks BioBriefs en 2025-12-23T16:33:24Z Samsung Biologics to buy GSK’s U.S. plant: $280M deal secures U.S. capacity https://biobriefs.com/china-mdx-dealmaking-geneplus-files BioBriefs en 2025-12-23T16:33:24Z China MDx dealmaking: GenePlus files for Hong Kong IPO; Guardant wins Japanese CDx for Lilly drug https://biobriefs.com/wegovy-pill-clears-fda-novo BioBriefs en 2025-12-23T14:33:39Z Wegovy pill clears FDA: Novo Nordisk poised for broad launch https://biobriefs.com/myqorzo-cleared-cytokinetics-enters-direct BioBriefs en 2025-12-23T14:33:39Z Myqorzo cleared: Cytokinetics enters direct fight with BMS’ Camzyos https://biobriefs.com/samsung-biologics-buys-gsk-u BioBriefs en 2025-12-23T14:33:39Z Samsung Biologics buys GSK U.S. plant: $280m expansion into Rockville https://biobriefs.com/pfizer-reports-death-in-hympavzi BioBriefs en 2025-12-23T14:33:39Z Pfizer reports death in Hympavzi trial: safety review under way https://biobriefs.com/ingrezza-flunks-dcp-test-neurocrine BioBriefs en 2025-12-23T14:33:39Z Ingrezza flunks DCP test: Neurocrine flags Phase 3 miss https://biobriefs.com/astrazeneca-buys-ex-china-rights BioBriefs en 2025-12-23T14:33:39Z AstraZeneca buys ex‑China rights to Jacobio pan‑KRAS—$1.9B deal https://biobriefs.com/aktis-files-for-ipo-radiopharma BioBriefs en 2025-12-23T14:33:39Z Aktis files for IPO: radiopharma backers push miniprotein programs https://biobriefs.com/boehringer-joins-trumprx-10b-u BioBriefs en 2025-12-23T14:33:39Z Boehringer joins TrumpRx: $10B U.S. investment and tariff protections https://biobriefs.com/white-house-and-cms-push BioBriefs en 2025-12-23T14:33:39Z White House and CMS push pricing pilots: MFN deals and Medicare demos roll out https://biobriefs.com/mrd-testing-matures-imvigor011-readout BioBriefs en 2025-12-23T14:33:39Z MRD testing matures: IMvigor011 readout validates Signatera as a treatment selector https://biobriefs.com/fda-clears-wegovy-pill-novo BioBriefs en 2025-12-23T10:33:23Z FDA clears Wegovy pill: Novo Nordisk eyes broad launch https://biobriefs.com/samsung-biologics-to-buy-u BioBriefs en 2025-12-23T10:33:23Z Samsung Biologics to buy U.S. GSK plant: $280M deal secures 60,000 L capacity https://biobriefs.com/fda-approves-myqorzo-cytokinetics-takes BioBriefs en 2025-12-23T10:33:23Z FDA approves Myqorzo – Cytokinetics takes on Bristol Myers’ Camzyos https://biobriefs.com/astrazeneca-inks-pan-kras-pact BioBriefs en 2025-12-23T10:33:23Z AstraZeneca inks pan‑KRAS pact: up to $1.9B for Jacobio’s clinical asset https://biobriefs.com/aktis-files-for-ipo-radiopharma BioBriefs en 2025-12-23T10:33:23Z Aktis files for IPO: radiopharma startup to fund Lilly‑partnered trials https://biobriefs.com/boehringer-signs-drug-cost-pact BioBriefs en 2025-12-23T10:33:23Z Boehringer signs drug‑cost pact: $10B US investment and TrumpRx participation https://biobriefs.com/cms-proposes-two-medicare-drug BioBriefs en 2025-12-23T10:33:23Z CMS proposes two Medicare drug‑pricing demos: most‑favored‑nation model moves forward https://biobriefs.com/mrd-testing-gains-validation-trial BioBriefs en 2025-12-23T10:33:23Z MRD testing gains validation: trial readouts and consolidation accelerate market https://biobriefs.com/robotic-synthesis-finds-metal-based BioBriefs en 2025-12-23T10:33:23Z Robotic synthesis finds metal‑based antibiotic: iridium candidate emerges https://biobriefs.com/guardant360-cdx-approved-in-japan BioBriefs en 2025-12-23T10:33:23Z Guardant360 CDx approved in Japan: companion test cleared for Lilly breast cancer drug https://biobriefs.com/fda-clears-novo-nordisk-oral BioBriefs en 2025-12-23T09:33:08Z FDA Clears Novo Nordisk Oral Wegovy: First GLP‑1 Pill for Obesity https://biobriefs.com/samsung-biologics-buys-gsks-us BioBriefs en 2025-12-23T09:33:08Z Samsung Biologics Buys GSK’s US Facility for $280 Million https://biobriefs.com/boehringer-ingelheim-joins-white-house BioBriefs en 2025-12-23T09:33:08Z Boehringer Ingelheim Joins White House Drug Push; $10B US Investment https://biobriefs.com/astrazeneca-jacobio-strike-multi-hundred BioBriefs en 2025-12-23T09:33:08Z AstraZeneca, Jacobio Strike Multi‑Hundred‑Million KRAS Deal https://biobriefs.com/aktis-oncology-files-for-ipo BioBriefs en 2025-12-23T09:33:08Z Aktis Oncology Files for IPO to Fund Radiopharmaceutical Pipeline https://biobriefs.com/windward-buys-qyuns-bispecific-700m BioBriefs en 2025-12-23T09:33:08Z Windward Buys Qyuns Bispecific; $700M Deal for Immunology Asset https://biobriefs.com/ipsen-expands-adc-push-with BioBriefs en 2025-12-23T09:33:08Z Ipsen Expands ADC Push with Simcere LRRC15 Asset—$1B Deal https://biobriefs.com/fda-clears-cytokinetics-myqorzo-in BioBriefs en 2025-12-23T09:33:08Z FDA Clears Cytokinetics’ Myqorzo in oHCM — Market Rivalry With BMS https://biobriefs.com/diagnostics-regulatory-moves-guardant360-cdx BioBriefs en 2025-12-23T09:33:08Z Diagnostics regulatory moves: Guardant360 CDx Japan OK and Applied BioCode FDA submission https://biobriefs.com/mrd-testing-gains-ground-trial BioBriefs en 2025-12-23T09:33:08Z MRD Testing Gains Ground: Trial Readouts, M&A and Reimbursement Momentum in 2025 https://biobriefs.com/fda-approves-oral-wegovy-first BioBriefs en 2025-12-23T04:32:57Z FDA approves oral Wegovy — first GLP‑1 pill clears U.S. regulator https://biobriefs.com/samsung-biologics-buys-gsk-u BioBriefs en 2025-12-23T04:32:57Z Samsung Biologics buys GSK U.S. plant — $280M deal, 500 staff retained https://biobriefs.com/astrazeneca-takes-pan-kras-asset BioBriefs en 2025-12-23T04:32:57Z AstraZeneca takes pan‑KRAS asset: $100M upfront, up to $1.9B in milestones https://biobriefs.com/aktis-files-for-ipo-funding BioBriefs en 2025-12-23T04:32:57Z Aktis files for IPO — funding radiopharma trials backed by big pharma https://biobriefs.com/fda-clears-myqorzo-cytokinetics-enters BioBriefs en 2025-12-23T04:32:57Z FDA clears Myqorzo — Cytokinetics enters oHCM market vs. BMS https://biobriefs.com/boehringer-inks-10b-u-s BioBriefs en 2025-12-23T04:32:57Z Boehringer inks $10B U.S. investment — joins TrumpRx to cut medicine prices https://biobriefs.com/white-house-seals-most-favored BioBriefs en 2025-12-23T04:32:57Z White House seals most‑favored‑nation drug deals — three companies remain holdouts https://biobriefs.com/lipid-free-self-amplifying-platform BioBriefs en 2025-12-23T04:32:57Z Lipid‑free self‑amplifying platform boosts vaccines — bypasses LNPs https://biobriefs.com/mrd-testing-wins-randomized-trial BioBriefs en 2025-12-23T04:32:57Z MRD testing wins randomized trial backing — Signatera readout fuels consolidation https://biobriefs.com/guardant360-cdx-approved-in-japan BioBriefs en 2025-12-23T04:32:57Z Guardant360 CDx approved in Japan — companion for Lilly’s Inluriyo on ESR1 mutations https://biobriefs.com/fda-clears-cytokinetics-pill-myqorzo BioBriefs en 2025-12-22T21:32:46Z FDA clears Cytokinetics pill Myqorzo — oHCM gains new oral option https://biobriefs.com/astrazeneca-lands-jacobio-s-pan BioBriefs en 2025-12-22T21:32:46Z AstraZeneca lands Jacobio's pan‑KRAS in $1.9B pact https://biobriefs.com/ipsen-buys-simcere-adc-rights BioBriefs en 2025-12-22T21:32:46Z Ipsen buys Simcere ADC rights — LRRC15 program expands outside China https://biobriefs.com/cms-proposes-two-medicare-drug BioBriefs en 2025-12-22T21:32:46Z CMS proposes two Medicare drug‑pricing demos — mandatory models on the table https://biobriefs.com/boehringer-signs-us-pact-with BioBriefs en 2025-12-22T21:32:46Z Boehringer signs US pact with White House — $10B investment, TrumpRx participation https://biobriefs.com/aktis-files-for-ipo-to BioBriefs en 2025-12-22T21:32:46Z Aktis files for IPO to fund radiopharma pipeline — big‑pharma backers watch https://biobriefs.com/gilead-licenses-two-hsv-candidates BioBriefs en 2025-12-22T21:32:46Z Gilead licenses two HSV candidates from Assembly — $35M upfront grab https://biobriefs.com/guardant360-cdx-wins-japanese-approval BioBriefs en 2025-12-22T21:32:46Z Guardant360 CDx wins Japanese approval as companion diagnostic for Lilly drug https://biobriefs.com/mrd-testing-achieves-pivotal-readouts BioBriefs en 2025-12-22T21:32:46Z MRD testing achieves pivotal readouts and consolidation — Signatera proves clinical value https://biobriefs.com/cro-m-a-cools-2025 BioBriefs en 2025-12-22T21:32:46Z CRO M&A cools — 2025 deals skew smaller, strategic https://biobriefs.com/windward-secures-qyuns-bispecific-in BioBriefs en 2025-12-22T16:32:49Z Windward secures Qyuns bispecific in $700M ex‑China push https://biobriefs.com/ipsen-pays-up-to-1 BioBriefs en 2025-12-22T16:32:49Z Ipsen pays up to $1.06B for Simcere LRRC15 ADC https://biobriefs.com/aktis-files-for-nasdaq-ipo BioBriefs en 2025-12-22T16:32:49Z Aktis files for Nasdaq IPO — radiopharma trials to get cash https://biobriefs.com/boehringer-inks-448m-pact-with BioBriefs en 2025-12-22T16:32:49Z Boehringer inks $448M pact with Rectify to pursue oral CKD drugs https://biobriefs.com/astrazeneca-backs-jacobio-pan-kras BioBriefs en 2025-12-22T16:32:49Z AstraZeneca backs Jacobio pan‑KRAS with $100M upfront https://biobriefs.com/gilead-picks-two-assembly-hsv BioBriefs en 2025-12-22T16:32:49Z Gilead picks two Assembly HSV candidates for $35M upfront https://biobriefs.com/shionogi-agrees-2-5b-buy BioBriefs en 2025-12-22T16:32:49Z Shionogi agrees $2.5B buy to acquire approved ALS therapy https://biobriefs.com/mrd-testing-validated-by-imvigor011 BioBriefs en 2025-12-22T16:32:49Z MRD testing validated by IMvigor011... Signatera readout spurs CDx push https://biobriefs.com/guardant360-cdx-clears-japan-to BioBriefs en 2025-12-22T16:32:49Z Guardant360 CDx clears Japan to select patients for Lilly’s Inluriyo https://biobriefs.com/early-stage-clinics-enveda-starts BioBriefs en 2025-12-22T16:32:49Z Early‑stage clinics: Enveda starts obesity IND; Dexoligo advances anemia siRNA https://biobriefs.com/axonal-translation-switch-eif5a-hypusination BioBriefs en 2025-12-22T14:33:11Z Axonal translation switch: eIF5A hypusination eases FUS‑ALS https://biobriefs.com/ipsen-doubles-down-on-adcs BioBriefs en 2025-12-22T14:33:11Z Ipsen doubles down on ADCs: $1.06B LRRC15 deal with Simcere https://biobriefs.com/aktis-heads-for-market-ipo BioBriefs en 2025-12-22T14:33:11Z Aktis heads for market: IPO to bankroll Lilly‑partnered radiopharma trials https://biobriefs.com/astrazeneca-bets-and-stumbles-100m BioBriefs en 2025-12-22T14:33:11Z AstraZeneca bets and stumbles: $100M pan‑KRAS buy amid phase‑3 lung failure https://biobriefs.com/boehringer-inks-448m-pact-with BioBriefs en 2025-12-22T14:33:11Z Boehringer inks $448M pact with Rectify to develop oral CKD drugs https://biobriefs.com/windward-buys-qyuns-bispecific-up BioBriefs en 2025-12-22T14:33:11Z Windward buys Qyuns bispecific: up to $700M for dual TSLP–IL‑13 program https://biobriefs.com/fda-clears-cytokinetics-myqorzo-first BioBriefs en 2025-12-22T14:33:11Z FDA clears Cytokinetics’ Myqorzo – first approval and a direct rival to Camzyos https://biobriefs.com/antisense-rescue-therapy-reverses-developmental BioBriefs en 2025-12-22T14:33:11Z Antisense rescue: therapy reverses developmental defects in SMA organoids https://biobriefs.com/autophagy-steers-cd8-fate-mitochondrial BioBriefs en 2025-12-22T14:33:11Z Autophagy steers CD8+ fate: mitochondrial inheritance controls T‑cell memory https://biobriefs.com/artificial-metabolism-and-reform-converting BioBriefs en 2025-12-22T14:33:11Z Artificial metabolism and ReForm: converting CO2 into biological building blocks https://biobriefs.com/astrazenecas-synthetic-lethal-program-falters BioBriefs en 2025-12-22T10:32:39Z AstraZeneca’s synthetic‑lethal program falters; bets $100M on pan‑KRAS https://biobriefs.com/fda-clears-cytokinetics-heart-drug BioBriefs en 2025-12-22T10:32:39Z FDA clears Cytokinetics’ heart drug — challenger to Bristol Myers https://biobriefs.com/samsung-biologics-buys-gsk-u BioBriefs en 2025-12-22T10:32:39Z Samsung Biologics buys GSK U.S. plant for $280 million https://biobriefs.com/u-s-funding-freeze-and BioBriefs en 2025-12-22T10:32:39Z U.S. funding freeze and vaccine schedule overhaul — researchers raise alarms https://biobriefs.com/biohacking-trial-unlimited-bio-to BioBriefs en 2025-12-22T10:32:39Z Biohacking trial: Unlimited Bio to inject healthy volunteers with gene therapies https://biobriefs.com/antisense-oligonucleotide-rescues-sma-organoids BioBriefs en 2025-12-22T10:32:39Z Antisense oligonucleotide rescues SMA organoids — developmental defects reversed https://biobriefs.com/engineered-metabolism-converts-co2-into BioBriefs en 2025-12-22T10:32:39Z Engineered metabolism converts CO₂ into biological building blocks https://biobriefs.com/researchers-engineer-microbes-to-break BioBriefs en 2025-12-22T10:32:39Z Researchers engineer microbes to break down microplastics https://biobriefs.com/fruquintinib-plus-sintilimab-shows-activity BioBriefs en 2025-12-22T10:32:39Z Fruquintinib plus sintilimab shows activity in advanced endometrial cancer https://biobriefs.com/graph-attention-network-improves-drug BioBriefs en 2025-12-22T10:32:39Z Graph‑attention network improves drug‑synergy prediction https://biobriefs.com/fda-on-edge-leadership-churn BioBriefs en 2025-12-22T09:32:46Z FDA on edge: leadership churn threatens agency stability https://biobriefs.com/u-s-vaccine-schedule-overhaul BioBriefs en 2025-12-22T09:32:46Z U.S. vaccine schedule overhaul: federal plan to drop several childhood shots https://biobriefs.com/cytokinetics-wins-fda-nod-myqorzo BioBriefs en 2025-12-22T09:32:46Z Cytokinetics wins FDA nod — Myqorzo enters hypertrophic cardiomyopathy market https://biobriefs.com/samsung-biologics-expands-u-s BioBriefs en 2025-12-22T09:32:46Z Samsung Biologics expands U.S. CDMO capacity with GSK plant buy https://biobriefs.com/federal-research-freezes-cost-1 BioBriefs en 2025-12-22T09:32:46Z Federal research freezes cost $1.5B — NIH grants halted in 2025 https://biobriefs.com/fruquintinib-plus-sintilimab-shows-activity BioBriefs en 2025-12-22T09:32:46Z Fruquintinib plus sintilimab shows activity in advanced endometrial cancer https://biobriefs.com/antisense-oligonucleotide-rescues-sma-developmental BioBriefs en 2025-12-22T09:32:46Z Antisense oligonucleotide rescues SMA developmental defects in organoids https://biobriefs.com/antivirals-cut-post-covid-cardiovascular BioBriefs en 2025-12-22T09:32:46Z Antivirals cut post-COVID cardiovascular risk — target trial emulation finds benefit https://biobriefs.com/kglgansynergy-graph-attention-model-predicts BioBriefs en 2025-12-22T09:32:46Z KGLGANSynergy: graph attention model predicts drug synergy https://biobriefs.com/biotech-ipos-may-return-in BioBriefs en 2025-12-22T09:32:46Z Biotech IPOs may return in 2026 — VC predicts as sector stocks recover https://biobriefs.com/cytokinetics-wins-fda-nod-myqorzo BioBriefs en 2025-12-22T04:32:33Z Cytokinetics wins FDA nod – Myqorzo to compete with Bristol Myers https://biobriefs.com/antivirals-cut-post-covid-cardiac BioBriefs en 2025-12-22T04:32:33Z Antivirals cut post‑COVID cardiac risk – target trial emulation shows benefit https://biobriefs.com/antisense-oligo-reverses-sma-defects BioBriefs en 2025-12-22T04:32:33Z Antisense oligo reverses SMA defects in organoids — translational step https://biobriefs.com/fruquintinib-plus-sintilimab-shows-activity BioBriefs en 2025-12-22T04:32:33Z Fruquintinib plus sintilimab shows activity in pMMR endometrial cancer https://biobriefs.com/multivalency-and-fcgriib-engagement-amplify BioBriefs en 2025-12-22T04:32:33Z Multivalency and FcγRIIB engagement amplify anti‑CD27 immunotherapy https://biobriefs.com/graph-attention-ai-predicts-drug BioBriefs en 2025-12-22T04:32:33Z Graph‑attention AI predicts drug synergy: KGLGANSynergy unveiled https://biobriefs.com/new-lrrk2-variant-p1446l-drives BioBriefs en 2025-12-22T04:32:33Z New LRRK2 variant P1446L drives neurodegeneration via microglial inflammation https://biobriefs.com/minflux-maps-cardiac-ryanodine-receptor BioBriefs en 2025-12-22T04:32:33Z MINFLUX maps cardiac ryanodine receptor in 3D in living cells https://biobriefs.com/autophagy-sorts-mitochondria-to-define BioBriefs en 2025-12-22T04:32:33Z Autophagy sorts mitochondria to define CD8+ T cell fate and division https://biobriefs.com/antibiotic-exposure-associated-with-altered BioBriefs en 2025-12-22T04:32:33Z Antibiotic exposure associated with altered breast cancer survival in population study https://biobriefs.com/cytokinetics-lands-first-fda-approval BioBriefs en 2025-12-21T21:32:40Z Cytokinetics lands first FDA approval – Myqorzo cleared for obstructive HCM https://biobriefs.com/biomarin-to-buy-amicus-for BioBriefs en 2025-12-21T21:32:40Z BioMarin to buy Amicus for $4.8B – Fabry and Pompe assets added https://biobriefs.com/insmed-stock-tumbles-after-brinsupri BioBriefs en 2025-12-21T21:32:40Z Insmed stock tumbles after Brinsupri clinical setback https://biobriefs.com/nonprofit-brings-abandoned-rare-disease BioBriefs en 2025-12-21T21:32:40Z Nonprofit brings abandoned rare-disease gene therapy to market – scalability questioned https://biobriefs.com/u-s-research-funding-frozen BioBriefs en 2025-12-21T21:32:40Z U.S. research funding frozen – NIH grant reviews and operations curtailed https://biobriefs.com/u-s-vaccine-schedule-overhaul BioBriefs en 2025-12-21T21:32:40Z U.S. vaccine schedule overhaul proposed — experts warn of risks https://biobriefs.com/jax-completes-nyscf-acquisition-unified BioBriefs en 2025-12-21T21:32:40Z JAX completes NYSCF acquisition: unified nonprofit aims to accelerate translational genetics https://biobriefs.com/antisense-oligonucleotides-reverse-sma-defects BioBriefs en 2025-12-21T21:32:40Z Antisense oligonucleotides reverse SMA defects in organoid models – Nature Commun. https://biobriefs.com/fruquintinib-plus-sintilimab-shows-activity BioBriefs en 2025-12-21T21:32:40Z Fruquintinib plus sintilimab shows activity in pMMR advanced endometrial cancer https://biobriefs.com/oral-antivirals-tied-to-lower BioBriefs en 2025-12-21T21:32:40Z Oral antivirals tied to lower post‑COVID cardiovascular risk – target trial emulation https://biobriefs.com/fda-clears-cytokinetics-heart-drug BioBriefs en 2025-12-21T16:33:02Z FDA clears Cytokinetics heart drug: first U.S. approval https://biobriefs.com/biomarin-buys-amicus-for-4 BioBriefs en 2025-12-21T16:33:02Z BioMarin buys Amicus for $4.8B – rare‑disease footprint expands https://biobriefs.com/partial-hold-on-merck-daiichi BioBriefs en 2025-12-21T16:33:02Z Partial hold on Merck/Daiichi ADC trial after patient deaths https://biobriefs.com/white-house-unveils-nine-most BioBriefs en 2025-12-21T16:33:02Z White House unveils nine most‑favored‑nation drug deals — broad pharma list https://biobriefs.com/galux-and-boehringer-join-on BioBriefs en 2025-12-21T16:33:02Z Galux and Boehringer join on AI protein design — targeted therapeutics push https://biobriefs.com/genomics-partnerships-scale-single-cell BioBriefs en 2025-12-21T16:33:02Z Genomics partnerships scale single‑cell and methylation assays https://biobriefs.com/epigenovo-commercializes-single-cell-chromatin BioBriefs en 2025-12-21T16:33:02Z Epigenovo commercializes single‑cell chromatin assay for FFPE samples https://biobriefs.com/abcellera-bruker-settle-patent-fight BioBriefs en 2025-12-21T16:33:02Z AbCellera, Bruker settle patent fight: $36M plus royalties https://biobriefs.com/jax-completes-nyscf-takeover-unified BioBriefs en 2025-12-21T16:33:02Z JAX completes NYSCF takeover: unified stem‑cell and genetics engine launches https://biobriefs.com/brinsupri-clinical-setback-slashes-insmed BioBriefs en 2025-12-21T16:33:02Z Brinsupri clinical setback slashes Insmed market cap – readout problem https://biobriefs.com/biomarin-to-buy-amicus-for BioBriefs en 2025-12-21T14:32:47Z BioMarin to buy Amicus for $4.8B — rare disease push https://biobriefs.com/cytokinetics-wins-fda-approval-for BioBriefs en 2025-12-21T14:32:47Z Cytokinetics wins FDA approval for heart drug Myqorzo https://biobriefs.com/phase-iii-halt-after-fatal BioBriefs en 2025-12-21T14:32:47Z Phase III halt after fatal ILD events in ADC trial https://biobriefs.com/epigenovo-commercializes-single-cell-ffpe BioBriefs en 2025-12-21T14:32:47Z Epigenovo commercializes single-cell FFPE chromatin assay https://biobriefs.com/galux-and-boehringer-ink-ai BioBriefs en 2025-12-21T14:32:47Z Galux and Boehringer ink AI protein-design research pact https://biobriefs.com/parse-biosciences-and-codebreaker-map BioBriefs en 2025-12-21T14:32:47Z Parse Biosciences and Codebreaker map variant effects in single cells https://biobriefs.com/wasatch-and-agilent-roll-out BioBriefs en 2025-12-21T14:32:47Z Wasatch and Agilent roll out targeted nanopore methylation service https://biobriefs.com/antisense-oligo-rescues-developmental-defects BioBriefs en 2025-12-21T14:32:47Z Antisense oligo rescues developmental defects in SMA organoids https://biobriefs.com/minflux-microscopy-maps-cardiac-ryanodine BioBriefs en 2025-12-21T14:32:47Z MINFLUX microscopy maps cardiac ryanodine receptor in 3D https://biobriefs.com/gut-microbiome-signatures-predict-malaria BioBriefs en 2025-12-21T14:32:47Z Gut microbiome signatures predict malaria severity in monkeys and humans https://biobriefs.com/biomarin-buys-amicus-for-4 BioBriefs en 2025-12-21T10:32:42Z BioMarin buys Amicus for $4.8 billion — rare-disease portfolio expands https://biobriefs.com/cytokinetics-wins-fda-approval-for BioBriefs en 2025-12-21T10:32:42Z Cytokinetics wins FDA approval for obstructive hypertrophic cardiomyopathy drug https://biobriefs.com/patient-deaths-halt-merck-daiichi BioBriefs en 2025-12-21T10:32:42Z Patient deaths halt Merck–Daiichi ADC phase III — safety review launched https://biobriefs.com/white-house-finalizes-nine-drugmakers BioBriefs en 2025-12-21T10:32:42Z White House finalizes nine drugmakers' pricing deals — most‑favored‑nation push https://biobriefs.com/trump-administration-suspends-nih-operations BioBriefs en 2025-12-21T10:32:42Z Trump administration suspends NIH operations — $1.5B in grants canceled https://biobriefs.com/epigenovo-commercializes-scffpe-atac-single BioBriefs en 2025-12-21T10:32:42Z Epigenovo commercializes scFFPE‑ATAC — single‑cell chromatin for archived tissue https://biobriefs.com/parse-biosciences-and-codebreaker-pair BioBriefs en 2025-12-21T10:32:42Z Parse Biosciences and Codebreaker pair up to map variant effects in single cells https://biobriefs.com/cartography-biosciences-clears-ind-for BioBriefs en 2025-12-21T10:32:42Z Cartography Biosciences clears IND for CBI‑1214 — T‑cell engager enters clinic https://biobriefs.com/singlera-and-breakthrough-launch-preclinical BioBriefs en 2025-12-21T10:32:42Z Singlera and Breakthrough launch preclinical study with Pitt — pancreatic early‑detection test https://biobriefs.com/galux-inks-ai-protein-design BioBriefs en 2025-12-21T10:32:42Z Galux inks AI protein‑design pact with Boehringer Ingelheim — purposeful molecules next https://biobriefs.com/biomarin-buys-amicus-4-8b BioBriefs en 2025-12-21T09:32:59Z BioMarin buys Amicus: $4.8B adds Pompe and Fabry franchises https://biobriefs.com/cytokinetics-wins-fda-nod-myqorzo BioBriefs en 2025-12-21T09:32:59Z Cytokinetics wins FDA nod: Myqorzo clears obstructive hypertrophic cardiomyopathy https://biobriefs.com/adc-safety-and-target-momentum BioBriefs en 2025-12-21T09:32:59Z ADC safety and target momentum: Daiichi holds trial; B7‑H3 gains interest https://biobriefs.com/trump-administration-restrictions-freeze-nih BioBriefs en 2025-12-21T09:32:59Z Trump administration restrictions freeze NIH operations: $1.5B in grants affected https://biobriefs.com/epigenovo-commercializes-scffpe-atac-single BioBriefs en 2025-12-21T09:32:59Z Epigenovo commercializes scFFPE‑ATAC: single‑cell chromatin for clinical samples https://biobriefs.com/parse-and-codebreaker-link-variant BioBriefs en 2025-12-21T09:32:59Z Parse and Codebreaker link variant libraries to single‑cell readouts — experimental genomics scale https://biobriefs.com/singlera-breakthrough-join-u-pitt BioBriefs en 2025-12-21T09:32:59Z Singlera, Breakthrough join U Pitt to test early pancreatic‑cancer methylation assay https://biobriefs.com/galux-and-boehringer-agree-ai BioBriefs en 2025-12-21T09:32:58Z Galux and Boehringer agree AI protein‑design research pact https://biobriefs.com/jax-merges-with-nyscf-unified BioBriefs en 2025-12-21T09:32:58Z JAX merges with NYSCF: unified nonprofit to scale genetics and stem‑cell translation https://biobriefs.com/nonprofit-rescues-abandoned-gene-therapy BioBriefs en 2025-12-21T09:32:58Z Nonprofit rescues abandoned gene therapy — tests whether model can scale https://biobriefs.com/biomarin-to-buy-amicus-4 BioBriefs en 2025-12-21T04:33:27Z BioMarin to buy Amicus: $4.8B deal adds Fabry and Pompe drugs https://biobriefs.com/phase-iii-paused-adc-trial BioBriefs en 2025-12-21T04:33:27Z Phase III paused: ADC trial halted after deaths https://biobriefs.com/fda-clears-cytokinetics-heart-drug BioBriefs en 2025-12-21T04:33:27Z FDA clears Cytokinetics’ heart drug – company secures first U.S. approval https://biobriefs.com/single-cell-translation-ramps-ffpe BioBriefs en 2025-12-21T04:33:27Z Single‑cell translation ramps: FFPE chromatin kit and variant–cell mapping pact https://biobriefs.com/galux-boehringer-test-ai-protein BioBriefs en 2025-12-21T04:33:27Z Galux, Boehringer test AI protein design – partnership for purpose‑built molecules https://biobriefs.com/white-house-seals-nine-drug BioBriefs en 2025-12-21T04:33:27Z White House seals nine drug‑pricing pacts: largest batch yet https://biobriefs.com/methylation-blood-test-moves-to BioBriefs en 2025-12-21T04:33:27Z Methylation blood test moves to Pitt: preclinical study for pancreatic cancer https://biobriefs.com/jax-completes-nyscf-acquisition-unified BioBriefs en 2025-12-21T04:33:27Z JAX completes NYSCF acquisition – unified nonprofit launches in New York https://biobriefs.com/bc-platforms-adds-genevault-data BioBriefs en 2025-12-21T04:33:27Z BC Platforms adds GeneVault data – 48M patient multimodal cohort https://biobriefs.com/harbour-inks-90m-antibody-pact BioBriefs en 2025-12-21T04:33:27Z Harbour inks $90M antibody pact with BMS – multi‑specifics and China strategy https://biobriefs.com/biomarin-pays-4-8b-for BioBriefs en 2025-12-20T21:32:02Z BioMarin pays $4.8B for Amicus — rare‑disease portfolio expands https://biobriefs.com/patient-deaths-prompt-partial-hold BioBriefs en 2025-12-20T21:32:02Z Patient deaths prompt partial hold: Merck, Daiichi ADC trial paused https://biobriefs.com/fda-greenlights-myqorzo-cytokinetics-lands BioBriefs en 2025-12-20T21:32:02Z FDA greenlights Myqorzo: Cytokinetics lands first US approval https://biobriefs.com/epigenovo-targets-clinics-single-cell BioBriefs en 2025-12-20T21:32:02Z Epigenovo targets clinics: single‑cell chromatin assay for FFPE tissue https://biobriefs.com/parse-and-codebreaker-pair-single BioBriefs en 2025-12-20T21:32:02Z Parse and Codebreaker pair single‑cell scale with variant libraries https://biobriefs.com/galux-and-boehringer-ink-ai BioBriefs en 2025-12-20T21:32:02Z Galux and Boehringer ink AI design pact: purposeful proteins next https://biobriefs.com/bruker-settles-with-abcellera-36m BioBriefs en 2025-12-20T21:32:02Z Bruker settles with AbCellera — $36M plus royalties to end IP fight https://biobriefs.com/jax-and-nyscf-unify-nonprofit BioBriefs en 2025-12-20T21:32:02Z JAX and NYSCF unify — nonprofit engine for genomics and stem cells https://biobriefs.com/nonprofit-rescues-abandoned-gene-therapy BioBriefs en 2025-12-20T21:32:02Z Nonprofit rescues abandoned gene therapy — can the model scale? https://biobriefs.com/fda-issues-two-form-483s BioBriefs en 2025-12-20T21:32:02Z FDA issues two Form 483s to Catalent’s Maryland gene‑therapy sites https://biobriefs.com/biomarin-buys-amicus-for-4 BioBriefs en 2025-12-20T16:32:55Z BioMarin buys Amicus for $4.8B — rare-disease portfolio enlarged https://biobriefs.com/fda-clears-cytokinetics-heart-drug BioBriefs en 2025-12-20T16:32:55Z FDA clears Cytokinetics’ heart drug — company gets first U.S. approval https://biobriefs.com/partial-hold-on-merck-daiichi BioBriefs en 2025-12-20T16:32:55Z Partial hold on Merck‑Daiichi ADC trial after fatal events https://biobriefs.com/cepi-backs-moderna-h5-mrna BioBriefs en 2025-12-20T16:32:55Z CEPI backs Moderna H5 mRNA program — Phase 3 push funded https://biobriefs.com/single-cell-assays-and-variant BioBriefs en 2025-12-20T16:32:55Z Single‑cell assays and variant mapping: tools for translation https://biobriefs.com/galux-and-boehringer-ink-ai BioBriefs en 2025-12-20T16:32:55Z Galux and Boehringer ink AI protein‑design pact https://biobriefs.com/ai-life-science-funding-heats BioBriefs en 2025-12-20T16:32:55Z AI life‑science funding heats up: Insilico IPO, Edison seed round https://biobriefs.com/white-house-finalizes-nine-mfn BioBriefs en 2025-12-20T16:32:55Z White House finalizes nine MFN drug deals — pricing and policy move https://biobriefs.com/jax-completes-nyscf-unification-new BioBriefs en 2025-12-20T16:32:55Z JAX completes NYSCF unification — new nonprofit research engine https://biobriefs.com/gene-therapy-access-vs-manufacturing BioBriefs en 2025-12-20T16:32:55Z Gene‑therapy access vs. manufacturing scrutiny: nonprofit rescue, Catalent 483s https://biobriefs.com/biomarin-to-buy-amicus-4 BioBriefs en 2025-12-20T14:33:14Z BioMarin to buy Amicus: $4.8B bet on Fabry and Pompe franchises https://biobriefs.com/fda-halts-merck-daiichi-adc BioBriefs en 2025-12-20T14:33:14Z FDA halts Merck–Daiichi ADC trial: deaths trigger partial hold https://biobriefs.com/cytokinetics-wins-fda-green-light BioBriefs en 2025-12-20T14:33:14Z Cytokinetics wins FDA green light: first U.S. drug approved https://biobriefs.com/takedas-tyk2-drug-clears-phase BioBriefs en 2025-12-20T14:33:14Z Takeda’s TYK2 drug clears Phase 3—regulatory filings planned https://biobriefs.com/lillys-oral-glp-1-hits BioBriefs en 2025-12-20T14:33:14Z Lilly’s oral GLP-1 hits maintenance goal — review accelerated https://biobriefs.com/cepi-backs-modernas-h5-mrna BioBriefs en 2025-12-20T14:33:14Z CEPI backs Moderna’s H5 mRNA shot: funds Phase 3 push https://biobriefs.com/parse-and-codebreaker-join-to BioBriefs en 2025-12-20T14:33:14Z Parse and Codebreaker join to map variant effects with single‑cell readouts https://biobriefs.com/epigenovo-pushes-scffpe-atac-single BioBriefs en 2025-12-20T14:33:14Z Epigenovo pushes scFFPE‑ATAC: single‑cell chromatin assay for FFPE tissue https://biobriefs.com/galux-inks-ai-pact-with BioBriefs en 2025-12-20T14:33:14Z Galux inks AI pact with Boehringer – aim to design purpose‑specific proteins https://biobriefs.com/brinsupri-failure-slashes-insmed-market BioBriefs en 2025-12-20T14:33:14Z Brinsupri failure slashes Insmed market cap – program reset https://biobriefs.com/biomarin-buys-amicus-for-4 BioBriefs en 2025-12-20T10:32:25Z BioMarin buys Amicus for $4.8B: gains Fabry and Pompe drugs https://biobriefs.com/fda-clears-cytokinetics-heart-drug BioBriefs en 2025-12-20T10:32:25Z FDA clears Cytokinetics’ heart drug — company wins first U.S. approval https://biobriefs.com/adc-program-fda-pauses-daiichi BioBriefs en 2025-12-20T10:32:25Z ADC program...FDA pauses Daiichi‑Merck Phase 3 after deaths https://biobriefs.com/takedas-tyk2-pill-succeeds-in BioBriefs en 2025-12-20T10:32:25Z Takeda’s TYK2 pill succeeds in Phase 3 — filings planned for 2026 https://biobriefs.com/lillys-oral-glp-1-maintains BioBriefs en 2025-12-20T10:32:25Z Lilly’s oral GLP‑1 maintains weight loss — Phase 3 meets endpoints https://biobriefs.com/moderna-gets-cepi-backing-54m BioBriefs en 2025-12-20T10:32:25Z Moderna gets CEPI backing: $54M to advance H5 pandemic vaccine https://biobriefs.com/jax-and-nyscf-unite-nonprofit BioBriefs en 2025-12-20T10:32:25Z JAX and NYSCF unite: nonprofit research engine launched in NYC https://biobriefs.com/epigenovo-commercializes-scffpe-atac-startup BioBriefs en 2025-12-20T10:32:25Z Epigenovo commercializes scFFPE‑ATAC: startup seeks funding after paper https://biobriefs.com/parse-and-codebreaker-map-variant BioBriefs en 2025-12-20T10:32:25Z Parse and Codebreaker map variant effects at single‑cell scale https://biobriefs.com/galux-and-boehringer-ink-ai BioBriefs en 2025-12-20T10:32:25Z Galux and Boehringer ink AI protein‑design pact — purposeful molecules https://biobriefs.com/patient-deaths-trigger-partial-hold BioBriefs en 2025-12-20T09:32:41Z Patient deaths trigger partial hold: Daiichi, Merck pause global Phase III ADC https://biobriefs.com/biomarin-buys-amicus-for-4 BioBriefs en 2025-12-20T09:32:41Z BioMarin buys Amicus for $4.8B: rare disease portfolio expands https://biobriefs.com/cytokinetics-wins-fda-nod-myqorzo BioBriefs en 2025-12-20T09:32:41Z Cytokinetics wins FDA nod: Myqorzo approved for obstructive HCM https://biobriefs.com/takedas-tyk2-drug-clears-phase BioBriefs en 2025-12-20T09:32:41Z Takeda’s TYK2 drug clears Phase 3: zasocitinib posts dual trial wins https://biobriefs.com/lillys-oral-glp-1-maintains BioBriefs en 2025-12-20T09:32:41Z Lilly’s oral GLP‑1 maintains weight: orforglipron meets Phase 3 goals https://biobriefs.com/moderna-secures-cepi-funding-h5 BioBriefs en 2025-12-20T09:32:41Z Moderna secures CEPI funding: H5 pandemic flu vaccine advances to Phase 3 https://biobriefs.com/vcontact3-and-ml-scale-virus BioBriefs en 2025-12-20T09:32:41Z vConTACT3 and ML scale virus taxonomy: machine learning remaps viral classification https://biobriefs.com/epigenovo-commercializes-single-cell-ffpe BioBriefs en 2025-12-20T09:32:41Z Epigenovo commercializes single‑cell FFPE ATAC: scFFPE‑ATAC heads to market https://biobriefs.com/parse-teams-with-codebreaker-single BioBriefs en 2025-12-20T09:32:41Z Parse teams with Codebreaker: single‑cell variant effect mapping https://biobriefs.com/insmeds-momentum-stalls-brinsupri-fails BioBriefs en 2025-12-20T09:32:41Z Insmed’s momentum stalls: Brinsupri fails nasal inflammation study, market hit https://biobriefs.com/fda-approves-cytokinetics-heart-drug BioBriefs en 2025-12-20T04:32:47Z FDA approves Cytokinetics heart drug — company’s first U.S. launch https://biobriefs.com/biomarin-to-buy-amicus-for BioBriefs en 2025-12-20T04:32:47Z BioMarin to buy Amicus for $4.8B — rare‑disease portfolio expands https://biobriefs.com/fda-places-partial-hold-on BioBriefs en 2025-12-20T04:32:47Z FDA places partial hold on Merck–Daiichi ADC trial: safety probe under way https://biobriefs.com/moderna-lands-cepi-backing-54 BioBriefs en 2025-12-20T04:32:47Z Moderna lands CEPI backing: $54.3M to push H5 mRNA vaccine into Phase 3 https://biobriefs.com/takedas-tyk2-drug-clears-co BioBriefs en 2025-12-20T04:32:47Z Takeda’s TYK2 drug clears co‑primary endpoints in two Phase 3 psoriasis trials https://biobriefs.com/lillys-oral-orforglipron-preserves-weight BioBriefs en 2025-12-20T04:32:47Z Lilly’s oral orforglipron preserves weight loss — maintenance data and expedited review https://biobriefs.com/epigenovo-commercializes-scffpe-atac-single BioBriefs en 2025-12-20T04:32:47Z Epigenovo commercializes scFFPE‑ATAC: single‑cell chromatin profiling for archival tissue https://biobriefs.com/parse-biosciences-and-codebreaker-labs BioBriefs en 2025-12-20T04:32:47Z Parse Biosciences and Codebreaker Labs partner to map variant effects at single‑cell scale https://biobriefs.com/orum-raises-100m-to-advance BioBriefs en 2025-12-20T04:32:47Z Orum raises $100M to advance degrader‑ADC platform — AML candidate prioritized https://biobriefs.com/ccrm-and-ionq-partner-on BioBriefs en 2025-12-20T04:32:46Z CCRM and IonQ partner on quantum computing to accelerate advanced therapies https://biobriefs.com/adc-trial-hit-by-fatal BioBriefs en 2025-12-19T21:33:58Z ADC trial hit by fatal events: FDA places partial hold https://biobriefs.com/biomarin-shells-out-4-8b BioBriefs en 2025-12-19T21:33:58Z BioMarin shells out $4.8B: buys Amicus to bulk up rare‑disease portfolio https://biobriefs.com/tyk2-pill-clears-phase-3 BioBriefs en 2025-12-19T21:33:58Z TYK2 pill clears Phase 3: Takeda eyes 2026 filings https://biobriefs.com/lillys-oral-glp-1-maintains BioBriefs en 2025-12-19T21:33:58Z Lilly’s oral GLP‑1 maintains weight: maintenance trial posts positive readout https://biobriefs.com/cepi-plugs-gap-54-3m BioBriefs en 2025-12-19T21:33:58Z CEPI plugs gap: $54.3M backs Moderna’s H5 pandemic vaccine into Phase 3 https://biobriefs.com/ai-drugtech-fundraising-accelerates-ipos BioBriefs en 2025-12-19T21:33:58Z AI drugtech fundraising accelerates: IPOs and big seed rounds pile up https://biobriefs.com/single-cell-genomics-pushes-clinical BioBriefs en 2025-12-19T21:33:58Z Single‑cell genomics pushes clinical samples and variant mapping forward https://biobriefs.com/white-house-finalizes-nine-drug BioBriefs en 2025-12-19T21:33:58Z White House finalizes nine drug‑pricing pacts: largest batch yet https://biobriefs.com/stat-report-fda-voucher-program BioBriefs en 2025-12-19T21:33:58Z STAT report: FDA voucher program politicized — workforce strains add pressure https://biobriefs.com/liver-delivered-mrna-rewires-aged BioBriefs en 2025-12-19T21:33:58Z Liver‑delivered mRNA rewires aged immunity: boosts vaccines and cancer responses https://biobriefs.com/biomarin-buys-amicus-4-8b BioBriefs en 2025-12-19T16:32:36Z BioMarin buys Amicus: $4.8B deal folds in marketed rare-disease drugs https://biobriefs.com/takedas-tyk2-bet-pays-off BioBriefs en 2025-12-19T16:32:36Z Takeda’s TYK2 bet pays off – zasocitinib wins two Phase 3 trials https://biobriefs.com/lillys-oral-obesity-pill-maintenance BioBriefs en 2025-12-19T16:32:36Z Lilly’s oral obesity pill ... maintenance trial meets goals https://biobriefs.com/moderna-secures-cepi-backing-54m BioBriefs en 2025-12-19T16:32:36Z Moderna secures CEPI backing: $54M to push H5 mRNA vaccine into Phase 3 https://biobriefs.com/fda-places-partial-hold-daiichi BioBriefs en 2025-12-19T16:32:36Z FDA places partial hold: Daiichi‑Merck ADC program paused after excess deaths https://biobriefs.com/harbour-inks-bms-antibody-pact BioBriefs en 2025-12-19T16:32:36Z Harbour inks BMS antibody pact: $90M up front, $1B+ milestones possible https://biobriefs.com/personalis-mrd-assay-predicts-ici BioBriefs en 2025-12-19T16:32:36Z Personalis MRD assay predicts ICI response across solid tumors https://biobriefs.com/machine-learning-remaps-virus-taxonomy BioBriefs en 2025-12-19T16:32:36Z Machine learning remaps virus taxonomy: vConTACT3 enables scalable classification https://biobriefs.com/liver-targeted-mrna-rejuvenates-aged BioBriefs en 2025-12-19T16:32:36Z Liver‑targeted mRNA rejuvenates aged T cells – boosts vaccines and immunotherapy https://biobriefs.com/orum-raises-100m-to-develop BioBriefs en 2025-12-19T16:32:36Z Orum raises $100M to develop degrader‑antibody cancer drugs https://biobriefs.com/takedas-tyk2-pick-clears-two BioBriefs en 2025-12-19T14:33:06Z Takeda’s TYK2 pick clears two phase 3s — approval push under way https://biobriefs.com/lillys-oral-glp-1-holds BioBriefs en 2025-12-19T14:33:06Z Lilly’s oral GLP‑1 holds weight after injectables — fast FDA review likely https://biobriefs.com/cepi-injects-54-3m-to BioBriefs en 2025-12-19T14:33:06Z CEPI injects $54.3M to keep Moderna’s H5 vaccine in phase 3 https://biobriefs.com/fda-places-partial-hold-on BioBriefs en 2025-12-19T14:33:06Z FDA places partial hold on Daiichi–Merck ADC after unexpected deaths https://biobriefs.com/peanut-patch-succeeds-in-pivotal BioBriefs en 2025-12-19T14:33:06Z Peanut patch succeeds in pivotal trial — DBV to seek FDA approval https://biobriefs.com/gsks-twice-yearly-biologic-exdensur BioBriefs en 2025-12-19T14:33:06Z GSK’s twice‑yearly biologic Exdensur wins FDA clearance https://biobriefs.com/harbour-biomed-seals-90m-deal BioBriefs en 2025-12-19T14:33:06Z Harbour BioMed seals $90M deal with Bristol Myers Squibb — $1B upside https://biobriefs.com/vcontact3-machine-learning-remaps-virus BioBriefs en 2025-12-19T14:33:06Z vConTACT3: machine learning remaps virus taxonomy at scale https://biobriefs.com/liver-targeted-mrna-rebuilds-aged BioBriefs en 2025-12-19T14:33:06Z Liver‑targeted mRNA rebuilds aged immunity in mice — translational steps next https://biobriefs.com/insilico-targets-hong-kong-ipo BioBriefs en 2025-12-19T14:33:06Z Insilico targets Hong Kong IPO to raise capital for AI drug pipeline — near $300M https://biobriefs.com/fda-halts-daiichi-merck-adc BioBriefs en 2025-12-19T10:34:00Z FDA halts Daiichi‑Merck ADC trial: enrollment paused after excess deaths https://biobriefs.com/takedas-tyk2-pill-clears-phase BioBriefs en 2025-12-19T10:34:00Z Takeda’s TYK2 pill clears Phase 3... firm prepares 2026 FDA filing https://biobriefs.com/lillys-oral-glp-1-succeeds BioBriefs en 2025-12-19T10:34:00Z Lilly’s oral GLP‑1 succeeds in maintenance setting – FDA review accelerated https://biobriefs.com/cepi-plugs-tens-of-millions BioBriefs en 2025-12-19T10:34:00Z CEPI plugs tens of millions into Moderna’s H5 mRNA shot... Phase 3 next https://biobriefs.com/liver-directed-mrna-reboots-aged BioBriefs en 2025-12-19T10:34:00Z Liver‑directed mRNA reboots aged immunity: mouse data boost vaccines and ICI https://biobriefs.com/engineered-dendritic-cells-capture-tumor BioBriefs en 2025-12-19T10:34:00Z Engineered dendritic cells capture tumor EVs: two bioengineering routes show potency https://biobriefs.com/early-parkinson-signal-two-small BioBriefs en 2025-12-19T10:34:00Z Early Parkinson signal: two small molecules activate GCase—CNS and peripheral data https://biobriefs.com/addition-therapeutics-raises-major-rounds BioBriefs en 2025-12-19T10:34:00Z Addition Therapeutics raises major rounds for RNA 'jumping gene' insertion platform https://biobriefs.com/liquid-biopsy-advances-volitionrxs-capture BioBriefs en 2025-12-19T10:34:00Z Liquid biopsy advances: VolitionRx’s Capture‑Seq and Personalis ctDNA predict responses https://biobriefs.com/regulatory-shakeup-fda-voucher-program BioBriefs en 2025-12-19T10:34:00Z Regulatory shakeup: FDA voucher program and White House pricing pacts raise concerns https://biobriefs.com/daiichi-merck-lung-adc-program BioBriefs en 2025-12-19T09:32:58Z Daiichi‑Merck lung ADC program: FDA imposes partial hold after excess deaths https://biobriefs.com/modernas-h5-pandemic-shot-cepi BioBriefs en 2025-12-19T09:32:58Z Moderna’s H5 pandemic shot: CEPI plugs $54.3M to push candidate into Phase 3 https://biobriefs.com/takedas-tyk2-drug-clears-phase BioBriefs en 2025-12-19T09:32:58Z Takeda’s TYK2 drug clears Phase 3: Company sets 2026 filing plans https://biobriefs.com/lillys-oral-glp-1-orforglipron BioBriefs en 2025-12-19T09:32:58Z Lilly’s oral GLP‑1 orforglipron: maintenance trial meets endpoints https://biobriefs.com/liver-targeted-mrna-restores-aged BioBriefs en 2025-12-19T09:32:58Z Liver‑targeted mRNA restores aged immunity in mice — potential translational path https://biobriefs.com/personalis-mrd-ctdna-test-predicts BioBriefs en 2025-12-19T09:32:58Z Personalis MRD ctDNA test predicts immunotherapy response across tumor types https://biobriefs.com/dbvs-viaskin-peanut-patch-wins BioBriefs en 2025-12-19T09:32:58Z DBV’s Viaskin peanut patch wins pivotal Phase 3 — BLA planned https://biobriefs.com/addition-therapeutics-emerges-with-jumping BioBriefs en 2025-12-19T09:32:58Z Addition Therapeutics emerges with 'jumping gene' LNP platform and $106.5M raise https://biobriefs.com/ai-tools-for-life-sciences BioBriefs en 2025-12-19T09:32:58Z AI tools for life sciences attract capital — Edison and Manifold score fresh funding https://biobriefs.com/regulation-tightens-fda-eases-rwe BioBriefs en 2025-12-19T09:32:58Z Regulation tightens: FDA eases RWE rules while DOJ‑HHS widen False Claims scrutiny https://biobriefs.com/fda-pauses-daiichi-merck-adc BioBriefs en 2025-12-19T04:32:59Z FDA pauses Daiichi‑Merck ADC program — safety probe after patient deaths https://biobriefs.com/takedas-4b-tyk2-bet-clears BioBriefs en 2025-12-19T04:32:59Z Takeda’s $4B TYK2 bet clears Phase 3 — filings expected in 2026 https://biobriefs.com/cepi-backs-modernas-h5-pandemic BioBriefs en 2025-12-19T04:32:59Z CEPI backs Moderna’s H5 pandemic shot — $54M to push Phase 3 https://biobriefs.com/lillys-oral-glp-1-orforglipron BioBriefs en 2025-12-19T04:32:59Z Lilly’s oral GLP‑1 orforglipron sustains weight loss — fast FDA review likely https://biobriefs.com/mit-mrna-liver-therapy-rejuvenates BioBriefs en 2025-12-19T04:32:59Z MIT mRNA liver therapy rejuvenates aged immunity — translational promise https://biobriefs.com/engineered-dendritic-cells-capture-tumor BioBriefs en 2025-12-19T04:32:59Z Engineered dendritic cells capture tumor EVs — EPFL reports robust antitumor activity https://biobriefs.com/volitionrx-adapts-chip-seq-for BioBriefs en 2025-12-19T04:32:59Z VolitionRx adapts ChIP‑seq for liquid biopsy — Capture‑Seq seeks partners https://biobriefs.com/insmeds-expansion-bid-falters-brensocatib BioBriefs en 2025-12-19T04:32:59Z Insmed’s expansion bid falters — brensocatib fails Phase 2b, company pivots https://biobriefs.com/dbvs-viaskin-peanut-patch-clears BioBriefs en 2025-12-19T04:32:59Z DBV’s Viaskin peanut patch clears Phase 3 — BLA planned next year https://biobriefs.com/addition-therapeutics-raises-106-5m BioBriefs en 2025-12-19T04:32:59Z Addition Therapeutics raises $106.5M — all‑RNA LNP ‘jumping gene’ platform advances https://biobriefs.com/patient-deaths-prompt-partial-hold BioBriefs en 2025-12-18T21:32:43Z Patient deaths prompt partial hold: Daiichi–Merck ADC program halted https://biobriefs.com/cepi-plugs-funding-gap-modernas BioBriefs en 2025-12-18T21:32:43Z CEPI plugs funding gap: Moderna’s H5 mRNA vaccine moves to Phase 3 https://biobriefs.com/lillys-oral-glp-1-orforglipron BioBriefs en 2025-12-18T21:32:43Z Lilly’s oral GLP‑1: Orforglipron shows maintenance benefit – fast FDA review in play https://biobriefs.com/takedas-4b-tyk2-bet-pays BioBriefs en 2025-12-18T21:32:43Z Takeda’s $4B TYK2 bet pays off – zasocitinib posts Phase 3 wins https://biobriefs.com/gsk-wins-fda-nod-twice BioBriefs en 2025-12-18T21:32:43Z GSK wins FDA nod: twice‑yearly IL‑5 biologic cleared for severe asthma https://biobriefs.com/liver-targeted-mrna-revives-aged BioBriefs en 2025-12-18T21:32:43Z Liver‑targeted mRNA revives aged immunity: transient reprogramming boosts T cells https://biobriefs.com/addition-therapeutics-emerges-with-printing BioBriefs en 2025-12-18T21:32:43Z Addition Therapeutics emerges with printing‑scale gene insertion and funding https://biobriefs.com/chai-discovery-lands-130m-series BioBriefs en 2025-12-18T21:32:43Z Chai Discovery lands $130M Series B to scale AI antibody design https://biobriefs.com/degrader-adc-financing-orum-nets BioBriefs en 2025-12-18T21:32:43Z Degrader‑ADC financing: Orum nets $100M for degrader‑antibody conjugates https://biobriefs.com/capture-seq-volitionrx-adapts-chip BioBriefs en 2025-12-18T21:32:43Z Capture‑Seq: VolitionRx adapts ChIP‑Seq for ultrasensitive liquid biopsy signals https://biobriefs.com/takedas-tyk2-drug-zasocitinib-wins BioBriefs en 2025-12-18T16:33:27Z Takeda’s TYK2 drug zasocitinib wins two Phase 3 trials – 2026 U.S. filing planned https://biobriefs.com/fda-clears-gsks-twice-yearly BioBriefs en 2025-12-18T16:33:27Z FDA clears GSK’s twice‑yearly asthma biologic Exdensur – two injections a year https://biobriefs.com/dbvs-viaskin-peanut-patch-succeeds BioBriefs en 2025-12-18T16:33:27Z DBV’s Viaskin peanut patch succeeds in Phase 3 Vitesse... BLA planned H1 https://biobriefs.com/moderna-taps-cepi-to-bankroll BioBriefs en 2025-12-18T16:33:27Z Moderna taps CEPI to bankroll H5 pandemic vaccine Phase 3 – CEPI plugs $54M gap https://biobriefs.com/addition-therapeutics-emerges-with-print BioBriefs en 2025-12-18T16:33:27Z Addition Therapeutics emerges with PRINT LNP gene‑insertion platform and $106.5M https://biobriefs.com/chai-discovery-lands-130m-series BioBriefs en 2025-12-18T16:33:27Z Chai Discovery lands $130M Series B – AI designed antibodies at scale https://biobriefs.com/orum-therapeutics-banks-100m-to BioBriefs en 2025-12-18T16:33:27Z Orum Therapeutics banks $100M to push degrader‑antibody conjugates toward clinic https://biobriefs.com/personalis-next-personal-ctdna-assay BioBriefs en 2025-12-18T16:33:27Z Personalis’ NeXT Personal ctDNA assay predicts immunotherapy response across solid tumors https://biobriefs.com/regulators-pivot-fda-signals-looser BioBriefs en 2025-12-18T16:33:27Z Regulators pivot: FDA signals looser RWE rules – Senate readies Biosecure Act curbs on Chinese suppliers https://biobriefs.com/zwitterionic-ionizable-lipid-lnps-reduce BioBriefs en 2025-12-18T16:33:27Z Zwitterionic ionizable lipid LNPs reduce reactogenicity and ramp mRNA antigen expression https://biobriefs.com/fda-clears-gsks-twice-yearly BioBriefs en 2025-12-18T14:34:38Z FDA clears GSK’s twice-yearly asthma drug – dosing edge https://biobriefs.com/viaskin-peanut-patch-phase-iii BioBriefs en 2025-12-18T14:34:38Z Viaskin peanut patch: Phase III success sends DBV back to FDA https://biobriefs.com/atavistik-raises-120m-backing-blood BioBriefs en 2025-12-18T14:34:38Z Atavistik raises $120M – backing blood‑disease small molecules https://biobriefs.com/orum-banks-100m-degrader-payloads BioBriefs en 2025-12-18T14:34:38Z Orum banks $100M — degrader payloads meet antibody targeting https://biobriefs.com/chai-discovery-raises-130m-ai BioBriefs en 2025-12-18T14:34:38Z Chai Discovery raises $130M: AI antibody design moves to scale https://biobriefs.com/addition-emerges-with-novel-rna BioBriefs en 2025-12-18T14:34:38Z Addition emerges with novel RNA 'jumping gene' tech — big funding https://biobriefs.com/liver-mrna-reprogramming-restores-aged BioBriefs en 2025-12-18T14:34:38Z Liver mRNA reprogramming restores aged T cells — transient fix https://biobriefs.com/personalis-ctdna-mrd-test-predicts BioBriefs en 2025-12-18T14:34:38Z Personalis’ ctDNA MRD test predicts immunotherapy response across tumors https://biobriefs.com/fda-eases-rwe-rules-devices BioBriefs en 2025-12-18T14:34:38Z FDA eases RWE rules: devices first, drugs to follow https://biobriefs.com/moderna-taps-cepi-to-prop BioBriefs en 2025-12-18T14:34:38Z Moderna taps CEPI to prop up H5 pandemic‑flu Phase 3 https://biobriefs.com/fda-clears-gsk-twice-yearly BioBriefs en 2025-12-18T10:33:19Z FDA clears GSK twice‑yearly asthma shot — Exdensur approved https://biobriefs.com/peanut-patch-wins-pivotal-test BioBriefs en 2025-12-18T10:33:19Z Peanut patch wins pivotal test: DBV plans U.S. filing after Phase III https://biobriefs.com/addition-emerges-from-stealth-106m BioBriefs en 2025-12-18T10:33:19Z Addition emerges from stealth — $106M for RNA ‘jumping‑gene’ therapies https://biobriefs.com/orum-pockets-100m-antibody-degrader BioBriefs en 2025-12-18T10:33:19Z Orum pockets $100M — antibody‑degrader conjugates target AML https://biobriefs.com/chai-discovery-raises-130m-to BioBriefs en 2025-12-18T10:33:19Z Chai Discovery raises $130M to scale AI antibody design https://biobriefs.com/harbour-biomed-inks-bms-pact BioBriefs en 2025-12-18T10:33:18Z Harbour Biomed inks BMS pact — up to $1.1B for multispecific antibody programs https://biobriefs.com/ctdna-dynamics-predict-immunotherapy-response BioBriefs en 2025-12-18T10:33:18Z ctDNA dynamics predict immunotherapy response; lymph fluid shows MRD promise https://biobriefs.com/fda-signals-looser-standards-for BioBriefs en 2025-12-18T10:33:18Z FDA signals looser standards for real‑world evidence in reviews https://biobriefs.com/cdc-pivots-on-hepatitis-b BioBriefs en 2025-12-18T10:33:18Z CDC pivots on hepatitis B birth dose — universal guidance replaced with individualized approach https://biobriefs.com/link-cell-raises-60m-j BioBriefs en 2025-12-18T10:33:18Z Link Cell raises $60M — J&J backs CAR‑T spinout focused on solid tumors https://biobriefs.com/fda-clears-gsks-twice-yearly BioBriefs en 2025-12-18T09:33:44Z FDA clears GSK’s twice‑yearly asthma drug — dosing shift for biologics https://biobriefs.com/peanut-patch-rebounds-dbvs-viaskin BioBriefs en 2025-12-18T09:33:44Z Peanut patch rebounds — DBV’s Viaskin posts pivotal Phase 3 win https://biobriefs.com/addition-emerges-with-print-all BioBriefs en 2025-12-18T09:33:44Z Addition emerges with PRINT: all‑RNA LNP gene insertion platform https://biobriefs.com/orum-banks-w146bn-100m-to BioBriefs en 2025-12-18T09:33:44Z Orum banks ₩146bn (~$100M) to advance degrader‑antibody conjugates https://biobriefs.com/fda-signals-looser-rules-for BioBriefs en 2025-12-18T09:33:44Z FDA signals looser rules for real‑world evidence — device and drug paths open https://biobriefs.com/cdc-ends-universal-hepatitis-b BioBriefs en 2025-12-18T09:33:44Z CDC ends universal hepatitis B birth‑dose guidance — adopts individualized schedule https://biobriefs.com/personalis-ctdna-mrd-assay-predicts BioBriefs en 2025-12-18T09:33:44Z Personalis ctDNA MRD assay predicts immunotherapy response across solid tumors https://biobriefs.com/harbour-biomed-inks-big-antibody BioBriefs en 2025-12-18T09:33:44Z Harbour Biomed inks big antibody pact with Bristol Myers — $90M up front, $1B+ upside https://biobriefs.com/ptau217-blood-test-goes-large BioBriefs en 2025-12-18T09:33:44Z pTau217 blood test goes large — ALZpath study and Siemens licensing deal https://biobriefs.com/chai-discovery-raises-130m-to BioBriefs en 2025-12-18T09:33:44Z Chai Discovery raises $130M to scale AI‑first antibody design https://biobriefs.com/fda-clears-gsks-twice-yearly BioBriefs en 2025-12-18T04:33:23Z FDA clears GSK’s twice‑yearly asthma drug – dosing cut to two injections a year https://biobriefs.com/ctdna-drop-predicts-checkpoint-benefit BioBriefs en 2025-12-18T04:33:23Z ctDNA drop predicts checkpoint benefit – Personalis assay validated https://biobriefs.com/peanut-patch-passes-pivotal-trial BioBriefs en 2025-12-18T04:33:23Z Peanut patch passes pivotal trial – DBV to file BLA after Phase III win https://biobriefs.com/fda-eases-real-world-evidence BioBriefs en 2025-12-18T04:33:23Z FDA eases real‑world evidence rules – devices first, drugs next https://biobriefs.com/addition-therapeutics-emerges-with-106m BioBriefs en 2025-12-18T04:33:23Z Addition Therapeutics emerges with $106M and an all‑RNA gene‑insertion platform https://biobriefs.com/chai-discovery-nets-130m-series BioBriefs en 2025-12-18T04:33:23Z Chai Discovery nets $130M Series B – AI designs therapeutic antibodies https://biobriefs.com/harbour-biomed-inks-big-antibody BioBriefs en 2025-12-18T04:33:23Z Harbour Biomed inks big antibody deals – BMS pact tops $1B in milestones https://biobriefs.com/fda-warning-letter-lands-on BioBriefs en 2025-12-18T04:33:23Z FDA warning letter lands on Novo Nordisk over acquired Catalent plant – manufacturing in focus https://biobriefs.com/norgine-secures-europe-rights-to BioBriefs en 2025-12-18T04:33:23Z Norgine secures Europe rights to Vir’s hepatitis D combo – regional license signed https://biobriefs.com/valinor-raises-13m-seed-to BioBriefs en 2025-12-18T04:33:23Z Valinor raises $13M seed to use multi‑omics and ML to improve trial design https://biobriefs.com/gsk-wins-fda-nod-twice BioBriefs en 2025-12-17T21:33:10Z GSK wins FDA nod – twice‑yearly asthma biologic https://biobriefs.com/dbv-rebounds-viaskin-patch-clears BioBriefs en 2025-12-17T21:33:10Z DBV rebounds: Viaskin patch clears Phase III in kids https://biobriefs.com/personalis-mrd-assay-flags-immunotherapy BioBriefs en 2025-12-17T21:33:10Z Personalis MRD assay flags immunotherapy responders – study https://biobriefs.com/addition-emerges-with-print-tech BioBriefs en 2025-12-17T21:33:10Z Addition emerges with PRINT tech — deep pockets follow https://biobriefs.com/bms-bets-on-harbours-antibody BioBriefs en 2025-12-17T21:33:10Z BMS bets on Harbour’s antibody engine – big upfront, big upside https://biobriefs.com/yarrow-rtw-grabs-china-antibody BioBriefs en 2025-12-17T21:33:10Z Yarrow/RTW grabs China antibody for autoimmune thyroid disease https://biobriefs.com/ai-drug-design-and-trial BioBriefs en 2025-12-17T21:33:10Z AI drug design and trial AI gets fresh capital — Chai and Valinor fundraises https://biobriefs.com/fda-and-industry-feel-the BioBriefs en 2025-12-17T21:33:10Z FDA and industry feel the squeeze — warning letters and looser RWE rules https://biobriefs.com/xoma-to-buy-generation-bio BioBriefs en 2025-12-17T21:33:10Z XOMA to buy Generation Bio — royalty player expands nucleic‑acid portfolio https://biobriefs.com/two-ind-clears-recludix-stat6 BioBriefs en 2025-12-17T21:33:10Z Two IND clears: Recludix STAT6 inhibitor and Nchroma’s HBV candidate https://biobriefs.com/padcev-keytruda-extends-survival-in BioBriefs en 2025-12-17T16:32:48Z Padcev–Keytruda extends survival in Phase 3: Pfizer, Astellas, Merck to seek approvals https://biobriefs.com/rtws-yarrow-goes-public-via BioBriefs en 2025-12-17T16:32:48Z RTW’s Yarrow goes public via reverse merger – RTW injects cash as it bets on a China antibody https://biobriefs.com/yarrow-picks-china-antibody-in BioBriefs en 2025-12-17T16:32:48Z Yarrow picks China antibody in $1.37B pact: GS‑098 ex‑China rights land with $70M up front https://biobriefs.com/addition-emerges-with-100m-uc BioBriefs en 2025-12-17T16:32:48Z Addition emerges with $100M — UC‑backed startup unveils PRINT delivery claims https://biobriefs.com/chai-discovery-raises-130m-ai BioBriefs en 2025-12-17T16:32:48Z Chai Discovery raises $130M: AI antibody designer scales de novo platform https://biobriefs.com/sanofi-signs-1-04b-pact BioBriefs en 2025-12-17T16:32:48Z Sanofi signs $1.04B pact for ADEL’s tau antibody: $80M up front https://biobriefs.com/fda-eases-the-rules-on BioBriefs en 2025-12-17T16:32:48Z FDA eases the rules on device RWE — and signals broader real‑world data use https://biobriefs.com/fda-clears-enhertu-for-first BioBriefs en 2025-12-17T16:32:48Z FDA clears Enhertu for first‑line HER2 disease — diagnostics follow with Roche approvals https://biobriefs.com/gsk-seeks-fda-label-change BioBriefs en 2025-12-17T16:32:48Z GSK seeks FDA label change for leucovorin to treat developmental disability tied to autism https://biobriefs.com/fda-warning-letter-lands-on BioBriefs en 2025-12-17T16:32:48Z FDA warning letter lands on Novo Nordisk over Catalent‑acquired plant https://biobriefs.com/nchroma-wins-hong-kong-clearance BioBriefs en 2025-12-17T16:32:48Z Nchroma wins Hong Kong clearance for HBV candidate CRMA‑1001 — First‑in‑human trial set https://biobriefs.com/yarrow-picks-gensci-tshr-asset BioBriefs en 2025-12-17T14:33:24Z Yarrow picks GenSci TSHR asset: $1.37B ex‑China deal https://biobriefs.com/sanofi-licenses-adels-tau-antibody BioBriefs en 2025-12-17T14:33:24Z Sanofi licenses ADEL’s tau antibody — $80M now, $1.04B possible https://biobriefs.com/bristol-myers-taps-harbour-biomed BioBriefs en 2025-12-17T14:33:24Z Bristol Myers taps Harbour BioMed: antibody discovery pact up to $1.1B https://biobriefs.com/ai-drug-r-d-draws BioBriefs en 2025-12-17T14:33:24Z AI drug R&D draws cash: Chai $130M Series B; Valinor $13M seed https://biobriefs.com/addition-therapeutics-emerges-with-gene BioBriefs en 2025-12-17T14:33:24Z Addition Therapeutics emerges with gene‑insertion tech and $100M+ https://biobriefs.com/fda-eases-rwe-bar-for BioBriefs en 2025-12-17T14:33:24Z FDA eases RWE bar for devices: lower need for patient‑level records https://biobriefs.com/biosecure-act-edges-toward-law BioBriefs en 2025-12-17T14:33:24Z Biosecure Act edges toward law: supply‑chain and data curbs loom https://biobriefs.com/fda-greenlights-gsks-depemokimab-long BioBriefs en 2025-12-17T14:33:24Z FDA greenlights GSK’s depemokimab: long‑acting add‑on for asthma https://biobriefs.com/immunomes-oral-gamma-secretase-succeeds BioBriefs en 2025-12-17T14:33:24Z Immunome’s oral gamma‑secretase succeeds: Phase III win, NDA planned https://biobriefs.com/xoma-royalty-to-acquire-generation BioBriefs en 2025-12-17T14:33:24Z XOMA Royalty to acquire Generation Bio: adds ctLNP and Moderna royalties https://biobriefs.com/chai-raises-130m-series-b BioBriefs en 2025-12-17T10:32:37Z Chai raises $130M Series B — AI antibody designer hits $1.3B valuation https://biobriefs.com/immunomes-oral-drug-slashes-progression BioBriefs en 2025-12-17T10:32:37Z Immunome’s oral drug slashes progression risk — Phase 3 win in desmoid tumors https://biobriefs.com/kyverna-to-seek-fda-clearance BioBriefs en 2025-12-17T10:32:37Z Kyverna to seek FDA clearance — autoimmune CAR‑T posts pivotal gains in stiff person syndrome https://biobriefs.com/gsk-wins-fda-nod-for BioBriefs en 2025-12-17T10:32:37Z GSK wins FDA nod for long‑acting asthma drug — depemokimab cleared https://biobriefs.com/yarrow-inks-1-37b-gensci BioBriefs en 2025-12-17T10:32:37Z Yarrow inks $1.37B GenSci deal — buys ex‑China rights to TSHR antibody https://biobriefs.com/adaptive-licenses-tcr-tech-to BioBriefs en 2025-12-17T10:32:37Z Adaptive licenses TCR tech to Pfizer — multi‑year pact could top $890M https://biobriefs.com/tumor-selective-mrna-engineered-smrts BioBriefs en 2025-12-17T10:32:37Z Tumor‑selective mRNA: engineered SMRTS toggles cell‑selective gene expression https://biobriefs.com/xoma-to-acquire-generation-bio BioBriefs en 2025-12-17T10:32:37Z XOMA to acquire Generation Bio — royalty aggregator buys ctLNP delivery platform https://biobriefs.com/cdc-ends-universal-newborn-hepatitis BioBriefs en 2025-12-17T10:32:37Z CDC ends universal newborn hepatitis B guidance — major immunization policy shift https://biobriefs.com/sanofis-ms-bet-falters-tolebrutinib BioBriefs en 2025-12-17T10:32:37Z Sanofi’s MS bet falters — tolebrutinib Phase 3 misses primary endpoint https://biobriefs.com/immunomes-phase-3-win-slashes BioBriefs en 2025-12-17T09:33:10Z Immunome’s phase‑3 win slashes desmoid progression — NDA next https://biobriefs.com/sanofi-snaps-up-adels-tau BioBriefs en 2025-12-17T09:33:10Z Sanofi snaps up ADEL’s tau antibody: $1.04B licensing pact https://biobriefs.com/chai-discovery-raises-130m-ai BioBriefs en 2025-12-17T09:33:10Z Chai Discovery raises $130M — AI antibody design goes mainstream https://biobriefs.com/radiopharms-rad-101-pet-tracer BioBriefs en 2025-12-17T09:33:10Z Radiopharm’s RAD‑101 PET tracer hits imaging endpoints in brain mets trial https://biobriefs.com/droplet-validates-postoperative-lymph-fluid BioBriefs en 2025-12-17T09:33:10Z Droplet validates postoperative lymph fluid for MRD detection in head and neck cancer https://biobriefs.com/kyvernas-autoimmune-car-t-posts BioBriefs en 2025-12-17T09:33:10Z Kyverna’s autoimmune CAR‑T posts registrational success — FDA filing planned https://biobriefs.com/abpro-and-celltrion-file-ind BioBriefs en 2025-12-17T09:33:10Z Abpro and Celltrion file IND for HER2×CD3 T‑cell engager — first‑in‑human ahead https://biobriefs.com/fda-clears-enhertu-combo-for BioBriefs en 2025-12-17T09:33:10Z FDA clears Enhertu combo for first‑line HER2+ metastatic breast cancer https://biobriefs.com/ultrasound-activated-polypeptide-primes-innate BioBriefs en 2025-12-17T09:33:10Z Ultrasound‑activated polypeptide primes innate immunity — sono‑adjuvant shows promise https://biobriefs.com/valinor-raises-13m-seed-to BioBriefs en 2025-12-17T09:33:10Z Valinor raises $13M seed to power multiomics ML for smarter trials https://biobriefs.com/immunomes-oral-therapy-slashes-desmoid BioBriefs en 2025-12-17T04:33:49Z Immunome’s oral therapy slashes desmoid progression 84% – NDA planned https://biobriefs.com/sanofis-btk-hopes-dented-phase BioBriefs en 2025-12-17T04:33:49Z Sanofi’s BTK hopes dented — Phase III miss and review delay https://biobriefs.com/kyvernas-car-t-delivers-registrational BioBriefs en 2025-12-17T04:33:49Z Kyverna’s CAR‑T delivers registrational win in stiff person syndrome – FDA path cleared https://biobriefs.com/fda-greenlights-enhertu-combo-for BioBriefs en 2025-12-17T04:33:49Z FDA greenlights Enhertu combo for first‑line HER2 breast cancer https://biobriefs.com/chai-discovery-raises-130m-ai BioBriefs en 2025-12-17T04:33:49Z Chai Discovery raises $130M — AI antibody design scales https://biobriefs.com/xoma-to-acquire-generation-bio BioBriefs en 2025-12-17T04:33:49Z XOMA to acquire Generation Bio — ctLNP delivery and Moderna ties in play https://biobriefs.com/postsurgical-lymph-fluid-outperforms-plasma BioBriefs en 2025-12-17T04:33:49Z Postsurgical lymph fluid outperforms plasma for MRD in head‑and‑neck cancer — Droplet validates https://biobriefs.com/ctdna-edges-toward-clinic-bladder BioBriefs en 2025-12-17T04:33:49Z ctDNA edges toward clinic — bladder and breast studies show promise, call for more trials https://biobriefs.com/adaptive-licenses-tcr-discovery-to BioBriefs en 2025-12-17T04:33:49Z Adaptive licenses TCR discovery to Pfizer — deal could top $890M https://biobriefs.com/year-end-biobucks-sanofi-yarrow BioBriefs en 2025-12-17T04:33:49Z Year‑end biobucks: Sanofi, Yarrow sign billion‑dollar licensing pacts https://biobriefs.com/immunome-phase-3-win-desmoid BioBriefs en 2025-12-16T21:33:06Z Immunome Phase 3 Win: Desmoid drug cuts progression 84% https://biobriefs.com/sanofi-licenses-adels-tau-antibody BioBriefs en 2025-12-16T21:33:06Z Sanofi licenses ADEL’s tau antibody: $80M now, $1.04B upside https://biobriefs.com/genentech-caris-1-1b-cancer BioBriefs en 2025-12-16T21:33:06Z Genentech–Caris: $1.1B cancer collaboration to mine targets https://biobriefs.com/xoma-moves-to-buy-generation BioBriefs en 2025-12-16T21:33:06Z XOMA moves to buy Generation Bio: tender offer, CVR attached https://biobriefs.com/kyverna-close-to-first-fda BioBriefs en 2025-12-16T21:33:06Z Kyverna close to first FDA CAR‑T approval for an autoimmune disease https://biobriefs.com/sanofis-btk-setback-tolebrutinib-misses BioBriefs en 2025-12-16T21:33:06Z Sanofi’s BTK setback: tolebrutinib misses trials and review stalls https://biobriefs.com/chai-discovery-raises-130m-ai BioBriefs en 2025-12-16T21:33:06Z Chai Discovery raises $130M: AI antibody design scales to clinic https://biobriefs.com/dbvs-peanut-patch-clears-phase BioBriefs en 2025-12-16T21:33:06Z DBV’s peanut patch clears Phase 3: another FDA resubmission ahead https://biobriefs.com/nektars-rezpegaldesleukin-narrow-miss-company BioBriefs en 2025-12-16T21:33:06Z Nektar’s rezpegaldesleukin: narrow miss, company blames enrollment errors https://biobriefs.com/pfizer-licenses-adaptives-tcr-tech BioBriefs en 2025-12-16T21:33:06Z Pfizer licenses Adaptive’s TCR tech: up to $890M in upside https://biobriefs.com/enhertu-first-line-approval-fda BioBriefs en 2025-12-16T16:33:27Z Enhertu first-line approval: FDA clears combo for HER2 metastatic patients https://biobriefs.com/genentech-caris-deal-1-1b BioBriefs en 2025-12-16T16:33:27Z Genentech-Caris deal: $1.1B collaboration to mine solid‑tumor targets https://biobriefs.com/xoma-moves-on-generation-bio BioBriefs en 2025-12-16T16:33:27Z XOMA moves on Generation Bio: royalty aggregator targets delivery platform https://biobriefs.com/kyvernas-car-t-clears-registrational BioBriefs en 2025-12-16T16:33:27Z Kyverna’s CAR‑T clears registrational test: path to FDA submission https://biobriefs.com/immunomes-phase-iii-win-oral BioBriefs en 2025-12-16T16:33:27Z Immunome’s Phase III win: oral drug cuts desmoid progression by 84% https://biobriefs.com/sobi-buys-arthrosi-950m-upfront BioBriefs en 2025-12-16T16:33:27Z Sobi buys Arthrosi: $950M upfront to broaden gout portfolio https://biobriefs.com/chai-discovery-raises-130m-ai BioBriefs en 2025-12-16T16:33:27Z Chai Discovery raises $130M: AI‑native drug design scales up https://biobriefs.com/pfizer-doubles-down-on-weight BioBriefs en 2025-12-16T16:33:27Z Pfizer doubles down on weight‑loss market: 15 obesity studies planned https://biobriefs.com/mrna-precision-moves-tumor-selective BioBriefs en 2025-12-16T16:33:27Z mRNA precision moves: tumor‑selective SMRTS and organ‑targeted BiTEs advance https://biobriefs.com/fda-urges-rwd-use-and BioBriefs en 2025-12-16T16:33:27Z FDA urges RWD use and early‑phase reform: regulator seeks modern inputs https://biobriefs.com/ambros-therapeutics-launches-with-125m BioBriefs en 2025-12-16T14:33:07Z Ambros Therapeutics launches with $125M — pain drug heads to U.S. https://biobriefs.com/xoma-royalty-to-acquire-generation BioBriefs en 2025-12-16T14:33:07Z XOMA Royalty to acquire Generation Bio — tender offer includes CVR upside https://biobriefs.com/sanofi-doubles-down-on-alzheimers BioBriefs en 2025-12-16T14:33:07Z Sanofi doubles down on Alzheimer’s and tau: $80M upfront ADEL license https://biobriefs.com/sobi-to-buy-arthrosi-for BioBriefs en 2025-12-16T14:33:07Z Sobi to buy Arthrosi for $950M upfront — pozdeutinurad heads toward Phase 3 readouts https://biobriefs.com/immunomes-oral-desmoid-drug-cuts BioBriefs en 2025-12-16T14:33:07Z Immunome’s oral desmoid drug cuts progression risk 84% — Phase 3 win sets up NDA https://biobriefs.com/kyvernas-autoimmune-car-t-clears BioBriefs en 2025-12-16T14:33:07Z Kyverna’s autoimmune CAR‑T clears registrational hurdle — FDA filing planned https://biobriefs.com/fda-clears-enhertu-for-first BioBriefs en 2025-12-16T14:33:07Z FDA clears Enhertu for first‑line HER2+ disease — Roche tests expanded to match https://biobriefs.com/chai-discovery-raises-130m-series BioBriefs en 2025-12-16T14:33:07Z Chai Discovery raises $130M Series B — AI models design antibody leads https://biobriefs.com/childs-death-after-brain-penetrant BioBriefs en 2025-12-16T14:33:07Z Child’s death after brain‑penetrant viral gene therapy rattles field https://biobriefs.com/fda-signals-regulatory-shifts-more BioBriefs en 2025-12-16T14:33:07Z FDA signals regulatory shifts — more real‑world data, faster reviews after positive readouts https://biobriefs.com/phase-iii-shock-immunomes-oral BioBriefs en 2025-12-16T10:33:12Z Phase III shock: Immunome’s oral desmoid drug slashes progression https://biobriefs.com/autoimmune-first-kyvernas-car-t BioBriefs en 2025-12-16T10:33:12Z Autoimmune first: Kyverna’s CAR‑T shows registrational benefits — filing next https://biobriefs.com/sanofis-btk-setback-tolebrutinib-fails BioBriefs en 2025-12-16T10:33:12Z Sanofi’s BTK setback: tolebrutinib fails trial — U.S. decision delayed https://biobriefs.com/sobi-buys-arthrosi-950m-upfront BioBriefs en 2025-12-16T10:33:12Z Sobi buys Arthrosi — $950M upfront to bolster gout franchise https://biobriefs.com/fda-widens-enhertu-use-diagnostics BioBriefs en 2025-12-16T10:33:12Z FDA widens Enhertu use — diagnostics cleared to match the label https://biobriefs.com/royalty-buyer-moves-in-xoma BioBriefs en 2025-12-16T10:33:12Z Royalty buyer moves in: XOMA Royalty to acquire Generation Bio https://biobriefs.com/chai-discovery-ups-the-ante BioBriefs en 2025-12-16T10:33:12Z Chai Discovery ups the ante: $130M Series B to scale AI drug design https://biobriefs.com/tumor-selective-mrna-engineered-smrts BioBriefs en 2025-12-16T10:33:12Z Tumor‑selective mRNA: engineered SMRTS switches on therapy only in cancer cells https://biobriefs.com/federal-boost-for-fungal-vaccine BioBriefs en 2025-12-16T10:33:12Z Federal boost for fungal vaccine: $40M NIH award funds VXV‑01 Phase I work https://biobriefs.com/adaptives-immune-data-deal-set BioBriefs en 2025-12-16T10:33:12Z Adaptive’s immune data deal set — Pfizer licenses TCR tech and data access https://biobriefs.com/immunomes-phase-3-win-desmoid BioBriefs en 2025-12-16T09:32:16Z Immunome’s phase‑3 win: desmoid tumor drug cuts progression risk 84% https://biobriefs.com/kyvernas-car-t-for-autoimmune BioBriefs en 2025-12-16T09:32:16Z Kyverna’s CAR‑T for autoimmune disease nears FDA filing after pivotal readout https://biobriefs.com/sobi-buys-arthrosi-for-950m BioBriefs en 2025-12-16T09:32:16Z Sobi buys Arthrosi for $950M up front to bulk up gout pipeline https://biobriefs.com/xoma-royalty-to-acquire-generation BioBriefs en 2025-12-16T09:32:16Z XOMA Royalty to acquire Generation Bio — adds ctLNP royalties and Moderna upside https://biobriefs.com/chai-discovery-raises-130m-series BioBriefs en 2025-12-16T09:32:16Z Chai Discovery raises $130M Series B to scale AI drug design — valuation $1.3B https://biobriefs.com/fda-clears-enhertu-first-line BioBriefs en 2025-12-16T09:32:16Z FDA clears Enhertu first‑line combo and broadens Roche HER2 assays for patient ID https://biobriefs.com/sanofis-tolebrutinib-program-hits-setbacks BioBriefs en 2025-12-16T09:32:16Z Sanofi’s tolebrutinib program hits setbacks: phase‑3 miss and U.S. review delay https://biobriefs.com/nih-gives-40m-to-vitalex BioBriefs en 2025-12-16T09:32:16Z NIH gives $40M to Vitalex/Lundquist to advance dual‑antigen fungal vaccine into Phase I https://biobriefs.com/adaptive-signs-multi-deal-with BioBriefs en 2025-12-16T09:32:16Z Adaptive signs multi‑deal with Pfizer to license TCR discovery tech and antigen maps https://biobriefs.com/brain-penetrant-gene-therapy-safety BioBriefs en 2025-12-16T09:32:16Z Brain‑penetrant gene therapy safety questioned after child’s fatal outcome — field reassesses risk https://biobriefs.com/immunomes-oral-desmoid-drug-slashes BioBriefs en 2025-12-16T04:31:54Z Immunome’s oral desmoid drug slashes progression risk – Phase III wins set up FDA filing https://biobriefs.com/sanofis-btk-program-stumbles-phase BioBriefs en 2025-12-16T04:31:54Z Sanofi’s BTK program stumbles: Phase III miss and U.S. review delay https://biobriefs.com/sobi-shells-out-950m-to BioBriefs en 2025-12-16T04:31:54Z Sobi shells out $950M to buy Arthrosi – pozdeutinurad bolsters gout pipeline https://biobriefs.com/kyvernas-car-t-posts-pivotal BioBriefs en 2025-12-16T04:31:54Z Kyverna’s CAR‑T posts pivotal gains in stiff person syndrome – FDA filing eyed https://biobriefs.com/fda-clears-enhertu-first-line BioBriefs en 2025-12-16T04:31:54Z FDA clears Enhertu first‑line combo; Roche assays broaden patient ID https://biobriefs.com/xoma-royalty-moves-to-buy BioBriefs en 2025-12-16T04:31:54Z XOMA Royalty moves to buy Generation Bio – ctLNP platform and Moderna ties included https://biobriefs.com/chai-discovery-raises-130m-series BioBriefs en 2025-12-16T04:31:54Z Chai Discovery raises $130M Series B at $1.3B valuation – AI antibody design scales up https://biobriefs.com/smrts-engineered-mrna-switches-on BioBriefs en 2025-12-16T04:31:54Z SMRTS engineered mRNA switches on in tumors only – precision mRNA shows preclinical selectivity https://biobriefs.com/nih-awards-40m-to-vitalex BioBriefs en 2025-12-16T04:31:54Z NIH awards $40M to Vitalex/Lundquist for VXV‑01 fungal vaccine—Phase I prep under way https://biobriefs.com/adaptive-licenses-tcr-tech-and BioBriefs en 2025-12-16T04:31:54Z Adaptive licenses TCR tech and data to Pfizer – big‑ticket pact to accelerate immunology R&D https://biobriefs.com/enhertu-cleared-for-first-line BioBriefs en 2025-12-15T21:32:21Z Enhertu cleared for first-line use — Roche HER2 tests broaden access https://biobriefs.com/immunomes-oral-desmoid-therapy-slashes BioBriefs en 2025-12-15T21:32:21Z Immunome’s oral desmoid therapy slashes progression risk — Phase III win https://biobriefs.com/kyvernas-car-t-for-a BioBriefs en 2025-12-15T21:32:21Z Kyverna’s CAR‑T for a rare autoimmune disease heads to FDA — registrational success https://biobriefs.com/sobi-pays-950m-upfront-for BioBriefs en 2025-12-15T21:32:21Z Sobi pays $950M upfront for Arthrosi — bolsters gout pipeline https://biobriefs.com/chai-discovery-raises-130m-ai BioBriefs en 2025-12-15T21:32:21Z Chai Discovery raises $130M — AI antibody design scales up https://biobriefs.com/gilead-posts-second-phase-iii BioBriefs en 2025-12-15T21:32:21Z Gilead posts second Phase III win for new HIV regimen — non‑inferior to Biktarvy https://biobriefs.com/sanofis-btk-hopes-stumble-phase BioBriefs en 2025-12-15T21:32:21Z Sanofi’s BTK hopes stumble: Phase III miss and U.S. review delay https://biobriefs.com/mass-general-brigham-spins-out BioBriefs en 2025-12-15T21:32:21Z Mass General Brigham spins out generative AI startup to speed trial screening https://biobriefs.com/adaptive-inks-deals-with-pfizer BioBriefs en 2025-12-15T21:32:21Z Adaptive inks deals with Pfizer — TCR licensing and data access for autoimmune R&D https://biobriefs.com/fda-signals-wider-use-of BioBriefs en 2025-12-15T21:32:21Z FDA signals wider use of real‑world data — calls for early‑phase reform https://biobriefs.com/kyvernas-car-t-wins-pivotal BioBriefs en 2025-12-15T16:33:50Z Kyverna’s CAR-T wins pivotal readout — FDA filing planned https://biobriefs.com/chai-discovery-raises-130m-valuation BioBriefs en 2025-12-15T16:33:50Z Chai Discovery raises $130M — valuation tops $1.3B https://biobriefs.com/sobi-buys-arthrosi-for-950m BioBriefs en 2025-12-15T16:33:50Z Sobi buys Arthrosi for $950M upfront — deal could reach $1.45B https://biobriefs.com/sanofis-ms-gamble-falters-phase BioBriefs en 2025-12-15T16:33:50Z Sanofi’s MS gamble falters: Phase 3 miss and regulatory delay https://biobriefs.com/adaptive-licenses-tcr-tech-to BioBriefs en 2025-12-15T16:33:50Z Adaptive licenses TCR tech to Pfizer — pact could top $890M https://biobriefs.com/child-death-in-brain-virus BioBriefs en 2025-12-15T16:33:50Z Child death in brain-virus trial rattles gene therapy field https://biobriefs.com/immunomes-rare-tumor-drug-posts BioBriefs en 2025-12-15T16:33:50Z Immunome’s rare-tumor drug posts Phase 3 victory — FDA bid ahead https://biobriefs.com/areteia-winds-down-after-late BioBriefs en 2025-12-15T16:33:50Z Areteia winds down after late‑stage asthma terminations https://biobriefs.com/milestone-wins-fda-approval-nasal BioBriefs en 2025-12-15T16:33:50Z Milestone wins FDA approval: nasal spray for PSVT cleared https://biobriefs.com/palvella-posts-positive-phase-2 BioBriefs en 2025-12-15T16:33:50Z Palvella posts positive Phase 2 for rapamycin gel in pediatric skin disease https://biobriefs.com/sobi-buys-arthrosi-950m-upfront BioBriefs en 2025-12-15T14:33:26Z Sobi buys Arthrosi: $950m upfront to lock in Phase‑3 gout asset https://biobriefs.com/argenx-halts-vyvgart-hytrulo-trials BioBriefs en 2025-12-15T14:33:26Z Argenx halts Vyvgart Hytrulo trials: interim review finds low chance of success https://biobriefs.com/sanofis-btk-candidate-fails-phase BioBriefs en 2025-12-15T14:33:26Z Sanofi’s BTK candidate fails Phase 3 – regulatory timeline slips https://biobriefs.com/chai-discovery-raises-130m-series BioBriefs en 2025-12-15T14:33:26Z Chai Discovery raises $130m Series B... valuation at $1.3bn https://biobriefs.com/child-death-after-brain-directed BioBriefs en 2025-12-15T14:33:26Z Child death after brain‑directed gene therapy: Capsida trial under scrutiny https://biobriefs.com/structures-oral-glp-1-soars BioBriefs en 2025-12-15T14:33:26Z Structure’s oral GLP‑1 soars — Phase II weight loss fuels 100% stock rally https://biobriefs.com/laguna-bio-bets-engineered-listeria BioBriefs en 2025-12-15T14:33:26Z Laguna Bio bets engineered Listeria on pediatric leukemia: living drug nears clinic https://biobriefs.com/fertility-gene-prdm9-helps-glioblastoma BioBriefs en 2025-12-15T14:33:26Z Fertility gene PRDM9 helps glioblastoma resist chemo — blocking it clears persisters https://biobriefs.com/open-source-platform-speeds-drug BioBriefs en 2025-12-15T14:33:26Z Open‑source platform speeds drug‑combination discovery: cell‑level screening unveiled https://biobriefs.com/keep-neutrophils-in-night-mode BioBriefs en 2025-12-15T14:33:26Z Keep neutrophils in night mode: ATI2341 reduces post‑MI inflammation in models https://biobriefs.com/child-dies-after-experimental-brain BioBriefs en 2025-12-15T10:32:55Z Child dies after experimental brain gene therapy — field confronts safety alarm https://biobriefs.com/sobi-to-buy-arthrosi-for BioBriefs en 2025-12-15T10:32:55Z Sobi to buy Arthrosi for $950M upfront — gout pipeline deal locks in late‑stage asset https://biobriefs.com/structures-oral-glp-1-posts BioBriefs en 2025-12-15T10:32:55Z Structure’s oral GLP‑1 posts double‑digit weight loss — shares surge after Phase II readout https://biobriefs.com/fda-clears-milestones-nasal-arrhythmia BioBriefs en 2025-12-15T10:32:55Z FDA clears Milestone’s nasal arrhythmia spray — Cardamyst approved after two rejections https://biobriefs.com/laguna-bio-advances-engineered-listeria BioBriefs en 2025-12-15T10:32:55Z Laguna Bio advances engineered Listeria living drug — pediatric leukemia trial planned https://biobriefs.com/ai-and-physics-model-find BioBriefs en 2025-12-15T10:32:55Z AI and physics model find Parkinson’s candidate — Gain Therapeutics announces mechanism‑based lead https://biobriefs.com/human-monoclonal-antibodies-neutralize-clade BioBriefs en 2025-12-15T10:32:55Z Human monoclonal antibodies neutralize clade 2.3.4.4b H5N1 — Nature Communications report https://biobriefs.com/targeting-alkbh5-halts-colorectal-cancer BioBriefs en 2025-12-15T10:32:55Z Targeting ALKBH5 halts colorectal cancer stemness and resistance — Nature Communications discovery https://biobriefs.com/lrba-inhibition-degrades-ctla-4 BioBriefs en 2025-12-15T10:32:55Z LRBA inhibition degrades CTLA‑4 — new route to boost cancer immunity https://biobriefs.com/china-issues-organoid-guidelines-regulatory BioBriefs en 2025-12-15T10:32:55Z China issues organoid guidelines — regulatory and ethical framework released https://biobriefs.com/sobi-to-buy-arthrosi-950m BioBriefs en 2025-12-15T09:32:26Z Sobi to buy Arthrosi: $950M upfront for Phase‑3 gout play https://biobriefs.com/structures-oral-glp-1-shocks BioBriefs en 2025-12-15T09:32:26Z Structure’s oral GLP‑1 shocks investors – stock doubles after Phase II https://biobriefs.com/fda-clears-cardamyst-nasal-arrhythmia BioBriefs en 2025-12-15T09:32:26Z FDA clears Cardamyst: nasal arrhythmia spray approved after prior rejections https://biobriefs.com/laguna-bio-bets-engineered-listeria BioBriefs en 2025-12-15T09:32:26Z Laguna Bio bets engineered Listeria on pediatric leukemia: living drug approach https://biobriefs.com/new-human-antibodies-neutralize-clade BioBriefs en 2025-12-15T09:32:26Z New human antibodies neutralize clade 2.3.4.4b H5N1: potential pandemic countermeasure https://biobriefs.com/sars-cov-2-nucleocapsid-xec BioBriefs en 2025-12-15T09:32:26Z SARS‑CoV‑2 nucleocapsid XEC mutation linked to more severe disease https://biobriefs.com/ai-plus-physics-modeling-surfaces BioBriefs en 2025-12-15T09:32:26Z AI plus physics modeling surfaces a Parkinson’s drug candidate at Gain Therapeutics https://biobriefs.com/glp-1-agonist-shows-benefit BioBriefs en 2025-12-15T09:32:26Z GLP‑1 agonist shows benefit in large‑vessel occlusion stroke trial https://biobriefs.com/targeting-alkbh5-halts-colorectal-cancer BioBriefs en 2025-12-15T09:32:26Z Targeting ALKBH5 halts colorectal cancer stemness and chemoresistance https://biobriefs.com/fucoidan-enhances-car-t-activity BioBriefs en 2025-12-15T09:32:26Z Fucoidan enhances CAR‑T activity in lymphoma models: a natural adjuvant https://biobriefs.com/structures-oral-glp-1-shocks BioBriefs en 2025-12-15T04:32:45Z Structure’s oral GLP-1 shocks investors: shares double after Phase II win https://biobriefs.com/fda-clears-nasal-arrhythmia-spray BioBriefs en 2025-12-15T04:32:45Z FDA clears nasal arrhythmia spray: Milestone’s Cardamyst approved https://biobriefs.com/laguna-bios-engineered-listeria-moves BioBriefs en 2025-12-15T04:32:45Z Laguna Bio’s engineered Listeria... moves into leukemia testing https://biobriefs.com/targeting-alkbh5-halts-colorectal-cancer BioBriefs en 2025-12-15T04:32:45Z Targeting ALKBH5 halts colorectal cancer stemness – study https://biobriefs.com/human-monoclonals-neutralize-h5n1-clade BioBriefs en 2025-12-15T04:32:45Z Human monoclonals neutralize H5N1 clade 2.3.4.4b: Nature Communications report https://biobriefs.com/rsad2-ythdf1-axis-drives-ibd BioBriefs en 2025-12-15T04:32:45Z RSAD2‑YTHDF1 axis drives IBD via mitochondrial transfer https://biobriefs.com/hiv-uses-sialoglycans-to-evade BioBriefs en 2025-12-15T04:32:45Z HIV uses sialoglycans to evade myeloid attack – new mechanism https://biobriefs.com/trehalose-6-phosphate-modulates-candida BioBriefs en 2025-12-15T04:32:45Z Trehalose‑6‑phosphate modulates Candida auris echinocandin resistance https://biobriefs.com/bio-adaptive-hydrogel-reconstructs-trachea BioBriefs en 2025-12-15T04:32:45Z Bio‑adaptive hydrogel reconstructs trachea – Nature Communications advance https://biobriefs.com/ai-and-physics-based-modeling BioBriefs en 2025-12-15T04:32:45Z AI and physics‑based modeling identify new Parkinson’s candidate — Gain Therapeutics https://biobriefs.com/structure-shares-double-oral-glp BioBriefs en 2025-12-14T21:32:25Z Structure shares double: oral GLP‑1 Phase II sparks investor frenzy https://biobriefs.com/laguna-bio-deploys-engineered-listeria BioBriefs en 2025-12-14T21:32:25Z Laguna Bio deploys engineered Listeria: living drug enters pediatric leukemia pipeline https://biobriefs.com/deep-learning-predicts-kidney-transplant BioBriefs en 2025-12-14T21:32:25Z Deep learning predicts kidney transplant outcomes from procurement biopsies https://biobriefs.com/ai-framework-links-drug-biology BioBriefs en 2025-12-14T21:32:25Z AI framework links drug biology to breast cancer response https://biobriefs.com/alkbh5-inhibition-strips-colorectal-tumors BioBriefs en 2025-12-14T21:32:25Z ALKBH5 inhibition strips colorectal tumors of stemness and chemoresistance https://biobriefs.com/targeting-lrba-triggers-ctla-4 BioBriefs en 2025-12-14T21:32:25Z Targeting LRBA triggers CTLA‑4 degradation – a new immune‑checkpoint lever https://biobriefs.com/blocking-chaperone-mediated-autophagy-targets BioBriefs en 2025-12-14T21:32:25Z Blocking chaperone‑mediated autophagy targets glioblastoma stem cells, revives immunity https://biobriefs.com/human-monoclonals-neutralize-clade-2 BioBriefs en 2025-12-14T21:32:25Z Human monoclonals neutralize clade 2.3.4.4b H5N1 – pandemic countermeasure advance https://biobriefs.com/hiv-cloaks-infected-cd4-t BioBriefs en 2025-12-14T21:32:25Z HIV cloaks infected CD4+ T cells with sialoglycans to evade myeloid clearance https://biobriefs.com/c-di-gmp-adjuvant-sharpens BioBriefs en 2025-12-14T21:32:25Z c‑di‑GMP adjuvant sharpens TLR4‑based tuberculosis vaccine responses https://biobriefs.com/gene-edited-cell-transplant-restores BioBriefs en 2025-12-14T16:33:12Z Gene-edited cell transplant restores insulin production in patient https://biobriefs.com/laguna-bios-living-listeria-therapy BioBriefs en 2025-12-14T16:33:12Z Laguna Bio’s living Listeria therapy readies pediatric leukemia trial https://biobriefs.com/lrba-inhibition-degrades-ctla-4 BioBriefs en 2025-12-14T16:33:12Z LRBA inhibition degrades CTLA‑4: a new lever for cancer immunity https://biobriefs.com/alkbh5-blockade-curbs-colorectal-cancer BioBriefs en 2025-12-14T16:33:12Z ALKBH5 blockade curbs colorectal cancer stemness and resistance https://biobriefs.com/fucoidan-enhances-car-t-potency BioBriefs en 2025-12-14T16:33:12Z Fucoidan enhances CAR‑T potency in lymphoma models https://biobriefs.com/plasma-proteomics-predicts-crohns-disease BioBriefs en 2025-12-14T16:33:12Z Plasma proteomics predicts Crohn’s disease up to 16 years early https://biobriefs.com/c-di-gmp-adjuvant-boosts BioBriefs en 2025-12-14T16:33:12Z c-di-GMP adjuvant boosts TLR4 vaccine efficacy against TB https://biobriefs.com/fda-clears-two-new-antibiotics BioBriefs en 2025-12-14T16:33:12Z FDA clears two new antibiotics for gonorrhea — Nuzolvence, Blujepa https://biobriefs.com/emas-chmp-backs-new-drugs BioBriefs en 2025-12-14T16:33:12Z EMA’s CHMP backs new drugs from Hansoh and Cytokinetics https://biobriefs.com/human-monoclonals-neutralize-clade-2 BioBriefs en 2025-12-14T16:33:12Z Human monoclonals neutralize clade 2.3.4.4b H5N1 https://biobriefs.com/gene-edited-cell-transplant-restores BioBriefs en 2025-12-14T14:33:10Z Gene-edited cell transplant restores insulin... patient off immunosuppressants https://biobriefs.com/fda-plans-boxed-warning-for BioBriefs en 2025-12-14T14:33:10Z FDA plans boxed warning for Covid vaccines: sources https://biobriefs.com/arcus-halts-domvanalimab-gastric-trial BioBriefs en 2025-12-14T14:33:10Z Arcus halts domvanalimab gastric trial — futility stop https://biobriefs.com/chmp-recommends-anktiva-ema-panel BioBriefs en 2025-12-14T14:33:10Z CHMP recommends Anktiva; EMA panel backs several new medicines https://biobriefs.com/nucleocapsid-mutation-raises-sars-cov BioBriefs en 2025-12-14T14:33:10Z Nucleocapsid mutation raises SARS‑CoV‑2 severity: Nature Communications https://biobriefs.com/human-monoclonal-antibodies-neutralize-h5n1 BioBriefs en 2025-12-14T14:33:10Z Human monoclonal antibodies neutralize H5N1 clade 2.3.4.4b https://biobriefs.com/targeting-alkbh5-collapses-colorectal-cancer BioBriefs en 2025-12-14T14:33:10Z Targeting ALKBH5 collapses colorectal cancer stemness — Nature Communications https://biobriefs.com/ai-unlocks-drug-insights-for BioBriefs en 2025-12-14T14:33:10Z AI unlocks drug insights for breast cancer... Nature Communications study https://biobriefs.com/c-di-gmp-adjuvant-boosts BioBriefs en 2025-12-14T14:33:10Z c‑di‑GMP adjuvant boosts TLR4 vaccine efficacy against tuberculosis https://biobriefs.com/concordia-expands-biomanufacturing-5m-cfi BioBriefs en 2025-12-14T14:33:10Z Concordia expands biomanufacturing — $5M CFI upgrade for green biofoundry https://biobriefs.com/gene-edited-cell-transplant-restores BioBriefs en 2025-12-14T10:32:18Z Gene-edited cell transplant restores insulin production — type 1 patient off immunosuppression https://biobriefs.com/arcus-stops-domvanalimab-program-after BioBriefs en 2025-12-14T10:32:18Z Arcus stops domvanalimab program after Phase III futility — pivots to casdatifan https://biobriefs.com/fda-clears-two-new-oral BioBriefs en 2025-12-14T10:32:18Z FDA clears two new oral antibiotics for gonorrhea — additional treatment options available https://biobriefs.com/fda-approves-new-formulation-of BioBriefs en 2025-12-14T10:32:18Z FDA approves new formulation of trofinetide for Rett syndrome — DAYBUE STIX gains clearance https://biobriefs.com/plasma-proteomics-predict-crohns-disease BioBriefs en 2025-12-14T10:32:18Z Plasma proteomics predict Crohn’s disease up to 16 years before diagnosis https://biobriefs.com/oncodetect-mrd-shows-prognostic-signal BioBriefs en 2025-12-14T10:32:18Z Oncodetect MRD shows prognostic signal in triple‑negative breast cancer — Exact Sciences presents first data https://biobriefs.com/inotiv-partners-with-vugene-to BioBriefs en 2025-12-14T10:32:18Z Inotiv partners with Vugene to deploy AI multi‑omics for drug discovery https://biobriefs.com/mechanism-for-vaccine-associated-myocarditis BioBriefs en 2025-12-14T10:32:18Z Mechanism for vaccine‑associated myocarditis outlined — CXCL10 and IFN‑γ implicated https://biobriefs.com/c-di-gmp-adjuvant-enhances BioBriefs en 2025-12-14T10:32:18Z c‑di‑GMP adjuvant enhances TLR4 vaccine efficacy against tuberculosis https://biobriefs.com/emas-chmp-backs-multiple-new BioBriefs en 2025-12-14T10:32:18Z EMA’s CHMP backs multiple new medicines including Hansoh and Cytokinetics submissions https://biobriefs.com/gene-edited-islet-transplant-restores BioBriefs en 2025-12-14T09:32:53Z Gene-edited islet transplant restores insulin production: first patient shows function https://biobriefs.com/fda-weighs-boxed-warning-for BioBriefs en 2025-12-14T09:32:53Z FDA weighs boxed warning for Covid vaccines: experts raise alarms https://biobriefs.com/arcus-halts-domvanalimab-gastric-phase BioBriefs en 2025-12-14T09:32:53Z Arcus halts domvanalimab gastric phase III after futility call — pivots to casdatifan https://biobriefs.com/emas-chmp-moves-forward-multiple BioBriefs en 2025-12-14T09:32:53Z EMA’s CHMP moves forward: multiple committee recommendations reshape EU approvals https://biobriefs.com/fda-clears-two-new-gonorrhea BioBriefs en 2025-12-14T09:32:53Z FDA clears two new gonorrhea antibiotics — more options for resistant disease https://biobriefs.com/ai-and-ctdna-converge-in BioBriefs en 2025-12-14T09:32:53Z AI and ctDNA converge in breast cancer: models refine drug insights; MRD predicts recurrence https://biobriefs.com/surfaceome-startup-raises-eur36m-cros BioBriefs en 2025-12-14T09:32:53Z Surfaceome startup raises €36M — CROs and AI firms strike discovery deals https://biobriefs.com/fda-approves-daybue-stix-for BioBriefs en 2025-12-14T09:32:53Z FDA approves DAYBUE STIX for Rett syndrome — new powder trofinetide formulation https://biobriefs.com/human-monoclonal-antibodies-neutralize-clade BioBriefs en 2025-12-14T09:32:53Z Human monoclonal antibodies neutralize clade 2.3.4.4b H5N1 — preclinical advance https://biobriefs.com/chmp-recommends-rejecting-anavex-alzheimer BioBriefs en 2025-12-14T09:32:53Z CHMP recommends rejecting Anavex Alzheimer pill: impurities and weak efficacy cited https://biobriefs.com/gene-edited-cell-transplant-restores BioBriefs en 2025-12-14T04:32:20Z Gene-edited cell transplant restores insulin—no immunosuppression https://biobriefs.com/arcus-halts-domvanalimab-phase-3 BioBriefs en 2025-12-14T04:32:20Z Arcus halts domvanalimab Phase 3 after futility; pivots R&D https://biobriefs.com/chmp-advances-multiple-medicines-european BioBriefs en 2025-12-14T04:32:20Z CHMP advances multiple medicines—European approvals move forward https://biobriefs.com/fda-weighing-boxed-warning-for BioBriefs en 2025-12-14T04:32:20Z FDA weighing boxed warning for Covid vaccines—experts push back https://biobriefs.com/human-monoclonal-antibodies-neutralize-clade BioBriefs en 2025-12-14T04:32:20Z Human monoclonal antibodies neutralize clade 2.3.4.4b H5N1 https://biobriefs.com/hiv-uses-sialoglycans-to-shield BioBriefs en 2025-12-14T04:32:20Z HIV uses sialoglycans to shield infected CD4+ T cells from myeloid attack https://biobriefs.com/ai-and-physics-based-modeling BioBriefs en 2025-12-14T04:32:20Z AI and physics-based modeling spots Parkinson’s candidate—Gain shows lead https://biobriefs.com/plasma-proteomics-predicts-crohns-disease BioBriefs en 2025-12-14T04:32:20Z Plasma proteomics predicts Crohn’s disease up to 16 years early https://biobriefs.com/oncodetect-ctdna-flags-recurrence-risk BioBriefs en 2025-12-14T04:32:20Z Oncodetect ctDNA flags recurrence risk in triple‑negative breast cancer https://biobriefs.com/inotiv-inks-ai-multiomics-pact BioBriefs en 2025-12-14T04:32:20Z Inotiv inks AI multiomics pact with Vugene for discovery https://biobriefs.com/gene-edited-cell-transplant-restores BioBriefs en 2025-12-13T21:32:05Z Gene-edited cell transplant restores insulin production — first patient report https://biobriefs.com/sialoglycans-let-hiv-infected-t BioBriefs en 2025-12-13T21:32:05Z Sialoglycans let HIV-infected T cells dodge myeloid clearance https://biobriefs.com/fda-weighing-boxed-warnings-on BioBriefs en 2025-12-13T21:32:05Z FDA weighing boxed warnings on Covid vaccines — agency debate intensifies https://biobriefs.com/arcus-halts-tigit-program-after BioBriefs en 2025-12-13T21:32:05Z Arcus halts TIGIT program after Phase III futility — R&D pivot underway https://biobriefs.com/emas-chmp-backs-multiple-drug BioBriefs en 2025-12-13T21:32:05Z EMA’s CHMP backs multiple drug recommendations in December meeting https://biobriefs.com/fda-clears-medtronic-onyx-for BioBriefs en 2025-12-13T21:32:05Z FDA clears Medtronic Onyx for subdural hematoma embolization https://biobriefs.com/oncodetect-mrd-test-stratifies-recurrence BioBriefs en 2025-12-13T21:32:05Z Oncodetect MRD test stratifies recurrence risk in triple‑negative breast cancer https://biobriefs.com/natera-and-medsir-launch-mirador BioBriefs en 2025-12-13T21:32:05Z Natera and MEDSIR launch MiRaDoR trial using Signatera to tailor adjuvant therapy https://biobriefs.com/disco-closes-eur36m-seed-to BioBriefs en 2025-12-13T21:32:05Z Disco closes €36M seed to advance surfaceome target discovery https://biobriefs.com/house-passes-invest-act-to BioBriefs en 2025-12-13T21:32:05Z House passes INVEST Act to widen capital access for small biotech https://biobriefs.com/lillys-triple-agonist-sets-new BioBriefs en 2025-12-13T16:33:23Z Lilly’s triple-agonist sets new weight-loss bar – phase 3 data https://biobriefs.com/gene-edited-cell-transplant-restores BioBriefs en 2025-12-13T16:33:23Z Gene‑edited cell transplant restores insulin production – first human case https://biobriefs.com/arcus-and-gileads-tigit-program BioBriefs en 2025-12-13T16:33:23Z Arcus and Gilead’s TIGIT program collapses – late‑stage trials halted https://biobriefs.com/fda-weighing-boxed-warning-for BioBriefs en 2025-12-13T16:33:23Z FDA weighing boxed warning for Covid vaccines — experts push back https://biobriefs.com/ac-immune-posts-biomarker-gains BioBriefs en 2025-12-13T16:33:23Z AC Immune posts biomarker gains in Parkinson’s vaccine – regulator talks next https://biobriefs.com/fda-clears-two-oral-drugs BioBriefs en 2025-12-13T16:33:23Z FDA clears two oral drugs for gonorrhea – new antibiotic options expand https://biobriefs.com/eu-clinches-sweeping-pharma-reform BioBriefs en 2025-12-13T16:33:23Z EU clinches sweeping pharma reform deal – legislative overhaul agreed https://biobriefs.com/disco-closes-eur36m-seed-to BioBriefs en 2025-12-13T16:33:23Z Disco closes €36M seed to advance surfaceome discovery platform https://biobriefs.com/inotiv-taps-vugene-ai-for BioBriefs en 2025-12-13T16:33:23Z Inotiv taps Vugene AI for multiomics-assisted drug discovery https://biobriefs.com/fda-proposes-down-classifying-some BioBriefs en 2025-12-13T16:33:23Z FDA proposes down‑classifying some companion diagnostics – 510(k) route opened https://biobriefs.com/gene-edited-cell-transplant-restores BioBriefs en 2025-12-13T14:33:07Z Gene-edited cell transplant restores insulin—no immunosuppression https://biobriefs.com/lillys-triple-agonist-raises-the BioBriefs en 2025-12-13T14:33:07Z Lilly’s triple agonist raises the bar — blockbuster weight loss readouts https://biobriefs.com/ac-immunes-parkinson-vaccine-posts BioBriefs en 2025-12-13T14:33:07Z AC Immune’s Parkinson vaccine posts biomarker gains…regulatory talks next https://biobriefs.com/fda-weighs-boxed-warning-for BioBriefs en 2025-12-13T14:33:07Z FDA weighs boxed warning for Covid shots — experts sound alarm https://biobriefs.com/emas-december-session-backs-multiple BioBriefs en 2025-12-13T14:33:07Z EMA’s December session backs multiple new drugs — CHMP recommendations roll out https://biobriefs.com/china-raises-big-biotech-rounds BioBriefs en 2025-12-13T14:33:07Z China raises big biotech rounds — venture into surfaceome and diagnostics heats up https://biobriefs.com/diagnostics-consolidation-natera-buys-foresight BioBriefs en 2025-12-13T14:33:07Z Diagnostics consolidation — Natera buys Foresight; Guardant links to trial‑matching AI https://biobriefs.com/fda-clears-medtronic-embolic-device BioBriefs en 2025-12-13T14:33:07Z FDA clears Medtronic embolic device — and OKs first at‑home brain‑stimulation headset https://biobriefs.com/umoja-delays-first-in-vivo BioBriefs en 2025-12-13T14:33:07Z Umoja delays first in‑vivo CAR‑T readout — trial timeline slips https://biobriefs.com/arcus-halts-tigit-push-after BioBriefs en 2025-12-13T14:33:07Z Arcus halts TIGIT push after Phase 3 failure — R&D refocus begins https://biobriefs.com/fda-intends-black-box-warning BioBriefs en 2025-12-13T10:33:30Z FDA intends black-box warning for Covid-19 vaccines — two sources https://biobriefs.com/lillys-triple-agonist-posts-record BioBriefs en 2025-12-13T10:33:30Z Lilly’s triple agonist posts record weight loss — discontinuations raise flags https://biobriefs.com/ac-immune-vaccine-advances-biomarkers BioBriefs en 2025-12-13T10:33:30Z AC Immune vaccine advances biomarkers in Parkinson’s — regulator talks planned https://biobriefs.com/arcus-stops-tigit-program-after BioBriefs en 2025-12-13T10:33:30Z Arcus stops TIGIT program after Phase 3 futility — partner trials scrapped https://biobriefs.com/gene-edited-cell-transplant-restores BioBriefs en 2025-12-13T10:33:30Z Gene‑edited cell transplant restores insulin production in Type 1 patient — off immunosuppression https://biobriefs.com/fda-clears-new-oral-options BioBriefs en 2025-12-13T10:33:30Z FDA clears new oral options for gonorrhea — treatment landscape widens https://biobriefs.com/natera-buys-foresight-expands-mrd BioBriefs en 2025-12-13T10:33:30Z Natera buys Foresight, expands MRD and hematology push https://biobriefs.com/illumina-backs-myome-trial-wgs BioBriefs en 2025-12-13T10:33:30Z Illumina backs MyOme trial — WGS plus AI to test population‑scale risk prediction https://biobriefs.com/parse-tahoe-to-sequence-300m BioBriefs en 2025-12-13T10:33:30Z Parse, Tahoe to sequence 300M cells — building an AI‑trained perturbation atlas https://biobriefs.com/house-passes-bio-backed-invest BioBriefs en 2025-12-13T10:33:30Z House passes BIO‑backed INVEST Act — capital access bill for small biotech clears floor https://biobriefs.com/gene-edited-cell-transplant-restores BioBriefs en 2025-12-13T09:33:56Z Gene-edited cell transplant restores insulin production in type 1 patient https://biobriefs.com/lillys-triple-agonist-posts-record BioBriefs en 2025-12-13T09:33:56Z Lilly’s triple-agonist posts record weight loss — safety caveats emerge https://biobriefs.com/arcus-gileads-anti-tigit-program BioBriefs en 2025-12-13T09:33:56Z Arcus, Gilead’s anti‑TIGIT program fails — company shutters trials and pivots https://biobriefs.com/fda-weighing-black-box-warning BioBriefs en 2025-12-13T09:33:56Z FDA weighing black‑box warning for Covid shots — experts push back https://biobriefs.com/natera-doubles-down-on-ctdna BioBriefs en 2025-12-13T09:33:56Z Natera doubles down on ctDNA — acquisition and trial collaborations aim to boost sensitivity https://biobriefs.com/illumina-backs-myome-investment-and BioBriefs en 2025-12-13T09:33:56Z Illumina backs MyOme — investment and collaboration to test genome‑scale PRS utility https://biobriefs.com/ac-immune-posts-biomarker-gains BioBriefs en 2025-12-13T09:33:56Z AC Immune posts biomarker gains in Parkinson’s vaccine program https://biobriefs.com/emas-chmp-signals-nods-and BioBriefs en 2025-12-13T09:33:56Z EMA’s CHMP signals nods and rejections — multiple drug recommendations in December meeting https://biobriefs.com/house-passes-invest-act-lawmakers BioBriefs en 2025-12-13T09:33:56Z House passes INVEST Act — lawmakers expand capital access for small biotech https://biobriefs.com/parse-and-tahoe-to-build BioBriefs en 2025-12-13T09:33:56Z Parse and Tahoe to build 300M‑cell perturbation atlas to train biology AI https://biobriefs.com/gene-edited-cell-transplant-restores BioBriefs en 2025-12-13T04:33:11Z Gene-edited cell transplant restores insulin — first patient makes insulin without immunosuppression https://biobriefs.com/arcus-shutters-tigit-program-after BioBriefs en 2025-12-13T04:33:11Z Arcus shutters TIGIT program after Phase III futility — company refocuses R&D https://biobriefs.com/fda-eyes-boxed-warning-on BioBriefs en 2025-12-13T04:33:11Z FDA eyes boxed warning on COVID vaccines — experts warn of unprecedented move https://biobriefs.com/ac-immune-posts-biomarker-wins BioBriefs en 2025-12-13T04:33:11Z AC Immune posts biomarker wins in Parkinson’s vaccine — regulator talks planned https://biobriefs.com/lillys-triple-agonist-smashes-weight BioBriefs en 2025-12-13T04:33:11Z Lilly’s triple agonist smashes weight‑loss records — tolerability concerns temper excitement https://biobriefs.com/natera-expands-signatera-trials-buys BioBriefs en 2025-12-13T04:33:11Z Natera expands Signatera trials — buys Foresight to boost MRD sensitivity https://biobriefs.com/fda-proposal-would-loosen-rules BioBriefs en 2025-12-13T04:33:11Z FDA proposal would loosen rules for companion diagnostics — Class II reclassification eyed https://biobriefs.com/two-new-oral-antibiotics-win BioBriefs en 2025-12-13T04:33:11Z Two new oral antibiotics win FDA approval for gonorrhea — expands limited treatment options https://biobriefs.com/house-passes-invest-act-bipartisan BioBriefs en 2025-12-13T04:33:11Z House passes INVEST Act — bipartisan bill to ease capital for small biotechs https://biobriefs.com/disco-closes-eur36m-seed-to BioBriefs en 2025-12-13T04:33:11Z Disco closes €36M seed to back surfaceome platform — €42M final close fuels target discovery https://biobriefs.com/lilly-triple-agonist-28-7 BioBriefs en 2025-12-12T21:33:30Z Lilly triple-agonist: 28.7% weight loss, tolerability concerns https://biobriefs.com/tigit-programs-unravel-arcus-halts BioBriefs en 2025-12-12T21:33:30Z TIGIT programs unravel: Arcus halts late‑stage trials https://biobriefs.com/ac-immune-vaccine-biomarker-wins BioBriefs en 2025-12-12T21:33:30Z AC Immune vaccine: biomarker wins open regulator conversations https://biobriefs.com/ctdna-stakes-rise-exact-sciences BioBriefs en 2025-12-12T21:33:30Z ctDNA stakes rise: Exact Sciences and Natera push MRD strategies https://biobriefs.com/investors-pour-cash-china-mega BioBriefs en 2025-12-12T21:33:30Z Investors pour cash: China mega‑rounds and European seed fuel discovery startups https://biobriefs.com/big-pharma-tie-ups-novartis BioBriefs en 2025-12-12T21:33:30Z Big‑pharma tie‑ups: Novartis, Relation and Zealand’s $2.5bn metabolic pact https://biobriefs.com/fda-vaccine-frictions-internal-review BioBriefs en 2025-12-12T21:33:30Z FDA vaccine frictions: internal review lands amid public pushback https://biobriefs.com/crispr-momentum-in-vivo-successes BioBriefs en 2025-12-12T21:33:30Z CRISPR momentum: in vivo successes and a field‑wide reckoning https://biobriefs.com/scaling-biology-300m-cell-atlas BioBriefs en 2025-12-12T21:33:30Z Scaling biology: 300M‑cell atlas and AI multi‑omics deals accelerate discovery https://biobriefs.com/rezolute-collapses-after-pivotal-miss BioBriefs en 2025-12-12T21:33:30Z Rezolute collapses after pivotal miss — stock implodes https://biobriefs.com/arcus-gilead-halt-tigit-program BioBriefs en 2025-12-12T16:32:44Z Arcus–Gilead halt TIGIT program: Phase 3 failure forces R&D reset https://biobriefs.com/lillys-triple-agonist-smashes-weight BioBriefs en 2025-12-12T16:32:44Z Lilly’s triple agonist smashes weight‑loss records…but tolerability clouds outlook https://biobriefs.com/ac-immune-shows-biomarker-wins BioBriefs en 2025-12-12T16:32:44Z AC Immune shows biomarker wins in Parkinson’s vaccine: regulators next https://biobriefs.com/rezolutes-pivotal-miss-ersodetug-fails BioBriefs en 2025-12-12T16:32:44Z Rezolute’s pivotal miss: ersodetug fails Phase 3, shares implode https://biobriefs.com/mrd-and-ctdna-move-toward BioBriefs en 2025-12-12T16:32:44Z MRD and ctDNA move toward clinic: Exact Sciences, Natera push trials and coverage https://biobriefs.com/regulatory-shifts-fda-diagnostics-reclassification BioBriefs en 2025-12-12T16:32:44Z Regulatory shifts: FDA diagnostics reclassification and House moves to free biotech capital https://biobriefs.com/big-rounds-seed-deals-china BioBriefs en 2025-12-12T16:32:44Z Big rounds, seed deals: China megafunds and European surfaceome startup raise capital https://biobriefs.com/diagnostics-and-cro-m-a BioBriefs en 2025-12-12T16:32:44Z Diagnostics and CRO M&A: Natera expands with Foresight; Paradigm buys Flatiron research arm https://biobriefs.com/car-t-pipeline-turbulence-umoja BioBriefs en 2025-12-12T16:32:44Z CAR‑T pipeline turbulence: Umoja delays in vivo readout; USC posts safer next‑gen CAR‑T preclinical data https://biobriefs.com/gene-editing-and-policy-metagenomic BioBriefs en 2025-12-12T16:32:44Z Gene editing and policy: metagenomic editing in vivo and calls for a rare‑disease approval pathway https://biobriefs.com/lillys-triple-agonist-sets-new BioBriefs en 2025-12-12T14:33:11Z Lilly’s triple agonist sets new efficacy bar — 28.7% weight loss https://biobriefs.com/rezolutes-pivotal-miss-forces-program BioBriefs en 2025-12-12T14:33:11Z Rezolute’s pivotal miss forces program rethink: Phase III fails endpoints https://biobriefs.com/ac-immunes-parkinsons-vaccine-posts BioBriefs en 2025-12-12T14:33:11Z AC Immune’s Parkinson’s vaccine posts biomarker wins — regulator talks planned https://biobriefs.com/umoja-delays-first-in-vivo BioBriefs en 2025-12-12T14:33:11Z Umoja delays first in vivo CAR‑T readout — timelines slip https://biobriefs.com/illumina-backs-myome-trial-to BioBriefs en 2025-12-12T14:33:11Z Illumina backs MyOme — trial to test WGS plus AI for population prevention https://biobriefs.com/natera-buys-foresight-to-beef BioBriefs en 2025-12-12T14:33:11Z Natera buys Foresight to beef up MRD sensitivity — Signatera gains phased‑variant tech https://biobriefs.com/metagenomic-editing-inserts-big-dna BioBriefs en 2025-12-12T14:33:11Z Metagenomic editing inserts big DNA payloads into gut bacteria in vivo https://biobriefs.com/arpa-h-backs-ai-toxicity BioBriefs en 2025-12-12T14:33:11Z ARPA‑H backs AI toxicity models — $21M award to industrial‑academic consortium https://biobriefs.com/paradigm-buys-flatiron-research-unit BioBriefs en 2025-12-12T14:33:11Z Paradigm buys Flatiron research unit — expands trial access with $78M Series B https://biobriefs.com/fda-proposes-lowering-companion-diagnostic BioBriefs en 2025-12-12T14:33:11Z FDA proposes lowering companion‑diagnostic bar — Class II pathway eyed https://biobriefs.com/lillys-triple-agonist-shatters-expectations BioBriefs en 2025-12-12T10:33:08Z Lilly’s triple agonist shatters expectations — efficacy and tolerability collide https://biobriefs.com/ac-immunes-parkinsons-vaccine-biomarker BioBriefs en 2025-12-12T10:33:08Z AC Immune’s Parkinson’s vaccine: biomarker wins, clinical benefit still opaque https://biobriefs.com/regulatory-chaos-fda-staff-alarm BioBriefs en 2025-12-12T10:33:08Z Regulatory chaos: FDA staff alarm and industry confidence wobble https://biobriefs.com/chinas-biotech-cash-surge-multiple BioBriefs en 2025-12-12T10:33:08Z China’s biotech cash surge: multiple $100M rounds reshape dealmaking https://biobriefs.com/fda-greenlights-nonprofit-gene-therapy BioBriefs en 2025-12-12T10:33:08Z FDA greenlights nonprofit gene therapy — Waskyra marks precedent https://biobriefs.com/car-t-landscape-in-vivo BioBriefs en 2025-12-12T10:33:08Z CAR‑T landscape: in vivo delays meet next‑gen constructs in mice https://biobriefs.com/ai-scales-biology-pathology-models BioBriefs en 2025-12-12T10:33:08Z AI scales biology: pathology models and 300M‑cell atlas move forward https://biobriefs.com/illumina-backs-myome-wgs-ai BioBriefs en 2025-12-12T10:33:08Z Illumina backs MyOme — WGS, AI and a prospective trial to prove PRS value https://biobriefs.com/rezolutes-phase-iii-failure-wipes BioBriefs en 2025-12-12T10:33:08Z Rezolute’s phase III failure wipes value — program under review https://biobriefs.com/new-anti-infectives-advance-ganlum BioBriefs en 2025-12-12T10:33:08Z New anti‑infectives advance: GanLum, cholera OmpV inhibitor emerge https://biobriefs.com/lillys-triple-agonist-shatters-weight BioBriefs en 2025-12-12T09:32:54Z Lilly’s triple agonist shatters weight-loss records — but tolerability worries surface https://biobriefs.com/ac-immunes-parkisons-vaccine-posts BioBriefs en 2025-12-12T09:32:54Z AC Immune’s Parkison’s vaccine posts biomarker gains — regulator talks next https://biobriefs.com/rezolutes-phase-3-failure-wipes BioBriefs en 2025-12-12T09:32:54Z Rezolute’s phase‑3 failure wipes out value — stock collapses https://biobriefs.com/industry-alarm-fda-leadership-churn BioBriefs en 2025-12-12T09:32:54Z Industry alarm: FDA leadership churn and policy moves rattle biopharma https://biobriefs.com/illumina-backs-myomes-wgs-ai BioBriefs en 2025-12-12T09:32:54Z Illumina backs MyOme’s WGS+AI trial — $200B health‑system savings pitched https://biobriefs.com/apple-tree-partners-files-bankruptcy BioBriefs en 2025-12-12T09:32:54Z Apple Tree Partners files bankruptcy — portfolio startups kept afloat https://biobriefs.com/fda-greenlights-first-nonprofit-gene BioBriefs en 2025-12-12T09:32:54Z FDA greenlights first nonprofit gene therapy — Waskyra clears path https://biobriefs.com/novartiss-new-malaria-combo-aces BioBriefs en 2025-12-12T09:32:54Z Novartis’s new malaria combo aces Phase 3 — GanLum posts superior cure rates https://biobriefs.com/china-venture-cash-and-big BioBriefs en 2025-12-12T09:32:54Z China venture cash and big rounds signal regional firepower — D3, Sanegene lead https://biobriefs.com/in-vivo-car-t-readout BioBriefs en 2025-12-12T09:32:54Z In‑vivo CAR‑T readout delayed as next‑gen CARs show safer, persistent responses in mice https://biobriefs.com/lillys-retatrutide-posts-record-weight BioBriefs en 2025-12-12T04:33:02Z Lilly’s retatrutide posts record weight loss — tolerability questions surface https://biobriefs.com/ac-immune-reports-biomarker-gains BioBriefs en 2025-12-12T04:33:02Z AC Immune reports biomarker gains in Parkinson’s vaccine — regulators next https://biobriefs.com/rezolutes-pivotal-miss-collapses-stock BioBriefs en 2025-12-12T04:33:02Z Rezolute’s pivotal miss collapses stock — program at inflection https://biobriefs.com/natera-buys-foresight-to-bolster BioBriefs en 2025-12-12T04:33:02Z Natera buys Foresight to bolster Signatera and enter hematology https://biobriefs.com/metagenomic-editing-inserts-large-dna BioBriefs en 2025-12-12T04:33:02Z Metagenomic editing inserts large DNA into gut microbes in vivo https://biobriefs.com/novartis-ganlum-wins-phase-iii BioBriefs en 2025-12-12T04:33:02Z Novartis’ GanLum wins Phase III — high cure rates against falciparum malaria https://biobriefs.com/fda-clears-first-at-home BioBriefs en 2025-12-12T04:33:02Z FDA clears first at‑home tDCS headset for depression — prescription rollout ahead https://biobriefs.com/fda-clears-waskyra-nonprofit-wins BioBriefs en 2025-12-12T04:33:02Z FDA clears Waskyra — nonprofit wins first gene therapy approval https://biobriefs.com/arpa-h-backs-ai-toxicity BioBriefs en 2025-12-12T04:33:02Z ARPA‑H backs AI toxicity project — Inductive Bio leads human‑centric safety models https://biobriefs.com/scaling-single-cell-atlases-and BioBriefs en 2025-12-12T04:33:02Z Scaling single‑cell atlases and sequencing firms double down on multiomics https://biobriefs.com/lillys-triple-agonist-sets-new BioBriefs en 2025-12-11T21:33:09Z Lilly’s triple agonist sets new bar — 28.7% mean weight loss https://biobriefs.com/next-gen-malaria-drug-passes BioBriefs en 2025-12-11T21:33:09Z Next‑gen malaria drug passes Phase 3: Novartis’ GanLum cures 97.4% https://biobriefs.com/teva-recalls-500000-prazosin-bottles BioBriefs en 2025-12-11T21:33:09Z Teva recalls >500,000 prazosin bottles after nitrosamine impurity found https://biobriefs.com/ac-immune-posts-promising-parkinsons BioBriefs en 2025-12-11T21:33:09Z AC Immune posts promising Parkinson’s biomarker signals — regulator engagement planned https://biobriefs.com/rezolute-stock-collapses-after-phase BioBriefs en 2025-12-11T21:33:09Z Rezolute stock collapses after Phase 3 flop — ersodetug misses primary endpoints https://biobriefs.com/apple-tree-partners-files-chapter BioBriefs en 2025-12-11T21:33:09Z Apple Tree Partners files Chapter 11 amid funding fight to keep portfolio afloat https://biobriefs.com/parse-and-tahoe-to-build BioBriefs en 2025-12-11T21:33:09Z Parse and Tahoe to build 300M‑cell perturbation atlas to train biology AI https://biobriefs.com/inductive-bio-lands-arpa-h BioBriefs en 2025-12-11T21:33:09Z Inductive Bio lands ARPA‑H award to build next‑gen AI toxicity models with Amgen https://biobriefs.com/moderna-taps-nanexas-pharmashell-to BioBriefs en 2025-12-11T21:33:09Z Moderna taps Nanexa’s PharmaShell to pursue long‑acting injectables — deal could hit $500M https://biobriefs.com/fda-clears-waskyra-first-gene BioBriefs en 2025-12-11T21:33:09Z FDA clears Waskyra — first gene therapy approved from a nonprofit sponsor https://biobriefs.com/lillys-triple-agonist-blowout-efficacy BioBriefs en 2025-12-11T16:33:32Z Lilly’s triple agonist: blowout efficacy, tolerability questions https://biobriefs.com/rezolutes-phase-3-flop-hypoglycemia BioBriefs en 2025-12-11T16:33:32Z Rezolute’s Phase 3 flop: hypoglycemia drug fails, stock collapses https://biobriefs.com/parse-and-tahoe-commit-to BioBriefs en 2025-12-11T16:33:32Z Parse and Tahoe commit to 300M-cell atlas to train biology AI https://biobriefs.com/natera-buys-foresight-to-boost BioBriefs en 2025-12-11T16:33:32Z Natera buys Foresight to boost MRD sensitivity and enter hematology https://biobriefs.com/moderna-taps-nanexas-pharmashell-to BioBriefs en 2025-12-11T16:33:32Z Moderna taps Nanexa’s PharmaShell to pursue long‑acting injectables https://biobriefs.com/novartis-and-relation-agree-1 BioBriefs en 2025-12-11T16:33:32Z Novartis and Relation agree $1.7B AI‑driven drug discovery pact https://biobriefs.com/fda-approves-waskyra-first-gene BioBriefs en 2025-12-11T16:33:32Z FDA approves Waskyra: first gene therapy cleared from a nonprofit sponsor https://biobriefs.com/arpa-h-funds-ai-toxicity BioBriefs en 2025-12-11T16:33:32Z ARPA‑H funds AI toxicity models: Inductive Bio to lead DATAMAP https://biobriefs.com/paradigm-acquires-flatiron-cru-raises BioBriefs en 2025-12-11T16:33:32Z Paradigm acquires Flatiron CRU, raises $78M to expand trial reach https://biobriefs.com/fda-signals-stricter-bar-for BioBriefs en 2025-12-11T16:33:32Z FDA signals stricter bar for CAR‑T approvals: RCTs preferred https://biobriefs.com/novartis-taps-relation-1-7bn BioBriefs en 2025-12-11T14:33:11Z Novartis taps Relation: $1.7bn AI tie-up for atopic targets https://biobriefs.com/moderna-picks-nanexa-pharmashell-option BioBriefs en 2025-12-11T14:33:11Z Moderna picks Nanexa: PharmaShell option could reshape injectable release https://biobriefs.com/fda-okays-nonprofit-gene-therapy BioBriefs en 2025-12-11T14:33:11Z FDA okays nonprofit gene therapy: Waskyra clears historic regulatory hurdle https://biobriefs.com/fda-shifts-car-t-standard BioBriefs en 2025-12-11T14:33:11Z FDA shifts CAR‑T standard: randomized trials now expected https://biobriefs.com/lillys-retatrutide-dramatic-weight-loss BioBriefs en 2025-12-11T14:33:11Z Lilly’s retatrutide... dramatic weight loss, tolerability questions emerge https://biobriefs.com/prolynx-raises-70m-hires-amgen BioBriefs en 2025-12-11T14:33:11Z Prolynx raises $70M: hires Amgen obesity vet to push long‑acting injectables https://biobriefs.com/biotech-follow-ons-smash-record BioBriefs en 2025-12-11T14:33:11Z Biotech follow‑ons smash record: $3.2B floods market in single wave https://biobriefs.com/arpa-h-backs-ai-toxicity BioBriefs en 2025-12-11T14:33:11Z ARPA‑H backs AI toxicity models: industry consortium to build non‑animal predictors https://biobriefs.com/in-vivo-car-t-data BioBriefs en 2025-12-11T14:33:11Z In‑vivo CAR‑T data fuel momentum: single‑dose approaches show promise https://biobriefs.com/lilly-bets-6b-on-us BioBriefs en 2025-12-11T14:33:11Z Lilly bets $6B on US API onshoring: Huntsville to host peptide and small‑molecule plant https://biobriefs.com/novartis-backs-relation-55m-upfront BioBriefs en 2025-12-11T10:33:50Z Novartis backs Relation: $55M upfront, up to $1.7B deal https://biobriefs.com/fda-clears-waskyra-first-nonprofit BioBriefs en 2025-12-11T10:33:50Z FDA clears Waskyra: first nonprofit gene therapy https://biobriefs.com/fda-raises-bar-for-car BioBriefs en 2025-12-11T10:33:50Z FDA raises bar for CAR‑T approvals: randomized trials expected https://biobriefs.com/inductive-bio-wins-arpa-h BioBriefs en 2025-12-11T10:33:50Z Inductive Bio wins ARPA‑H award to build human‑first toxicity AI https://biobriefs.com/alphafold3-points-to-opg153-new BioBriefs en 2025-12-11T10:33:50Z AlphaFold3 points to OPG153: new mpox vaccine antigen https://biobriefs.com/in-vivo-car-t-reads BioBriefs en 2025-12-11T10:33:50Z In‑vivo CAR‑T reads out: Kelonia posts early multiple myeloma signals https://biobriefs.com/roches-brainshuttle-antibody-clears-amyloid BioBriefs en 2025-12-11T10:33:50Z Roche’s Brainshuttle antibody clears amyloid in early trial https://biobriefs.com/biotech-follow-on-frenzy-eight BioBriefs en 2025-12-11T10:33:50Z Biotech follow‑on frenzy: eight firms raise $3.2B overnight https://biobriefs.com/pow-bio-and-buhler-launch BioBriefs en 2025-12-11T10:33:50Z Pow.Bio and Bühler launch integrated continuous fermentation platform https://biobriefs.com/lipid-nanoparticles-enable-base-editing BioBriefs en 2025-12-11T10:33:50Z Lipid nanoparticles enable base editing for retinitis pigmentosa https://biobriefs.com/novartis-bets-on-ai-1 BioBriefs en 2025-12-11T09:32:38Z Novartis bets on AI: $1.7bn pact with Relation https://biobriefs.com/fda-clears-waskyra-first-nonprofit BioBriefs en 2025-12-11T09:32:38Z FDA clears Waskyra: first nonprofit wins gene‑therapy approval https://biobriefs.com/fda-raises-bar-for-car BioBriefs en 2025-12-11T09:32:38Z FDA raises bar for CAR‑T approvals: randomized trials preferred https://biobriefs.com/arpa-h-funds-ai-driven BioBriefs en 2025-12-11T09:32:38Z ARPA‑H funds AI‑driven toxicity models: Inductive Bio leads $21M effort https://biobriefs.com/scouter-llm-forecasts-transcriptional-responses BioBriefs en 2025-12-11T09:32:38Z Scouter: LLM forecasts transcriptional responses to genetic perturbations https://biobriefs.com/alphafold-3-points-to-opg153 BioBriefs en 2025-12-11T09:32:38Z AlphaFold 3 points to OPG153: new mpox vaccine/antibody target https://biobriefs.com/biotech-market-rally-eight-companies BioBriefs en 2025-12-11T09:32:38Z Biotech market rally: eight companies raise $3.2bn in one session https://biobriefs.com/d3-bio-secures-108m-to BioBriefs en 2025-12-11T09:32:38Z D3 Bio secures $108M to advance KRAS G12C into phase III https://biobriefs.com/lilly-picks-huntsville-for-6bn BioBriefs en 2025-12-11T09:32:38Z Lilly picks Huntsville for $6bn API hub to secure GLP‑1 supply https://biobriefs.com/congressional-action-targets-hhs-leadership BioBriefs en 2025-12-11T09:32:38Z Congressional action targets HHS leadership amid vaccine policy disputes https://biobriefs.com/fda-oks-first-nonprofit-gene BioBriefs en 2025-12-11T04:34:15Z FDA OKs First Nonprofit Gene Therapy: Waskyra Clears Rare Immune Disorder https://biobriefs.com/novartis-pays-55m-upfront-relation BioBriefs en 2025-12-11T04:34:15Z Novartis Pays $55M Upfront — Relation to Drive AI‑Led Atopic Targets https://biobriefs.com/fda-raises-bar-for-car BioBriefs en 2025-12-11T04:34:15Z FDA Raises Bar for CAR‑T Approvals: Randomized Trials Favored https://biobriefs.com/major-ash-reads-shift-myeloma BioBriefs en 2025-12-11T04:34:15Z Major ASH Reads Shift Myeloma Playbook — Bispecifics and In‑Vivo CAR‑T Impress https://biobriefs.com/arpa-h-funds-human-first BioBriefs en 2025-12-11T04:34:15Z ARPA‑H Funds Human‑First Toxicity Models: $21M to $32M Awards https://biobriefs.com/investors-flood-biotech-record-follow BioBriefs en 2025-12-11T04:34:15Z Investors Flood Biotech: Record Follow‑On Deals and Holiday‑Era Offerings https://biobriefs.com/ai-designed-molecules-advance-insilico BioBriefs en 2025-12-11T04:34:15Z AI‑Designed Molecules Advance: Insilico PROTAC and PsiThera’s Oral TNF Play https://biobriefs.com/roches-brainshuttle-antibody-clears-amyloid BioBriefs en 2025-12-11T04:34:15Z Roche’s Brainshuttle Antibody Clears Amyloid: 91% Below Threshold in Early Trial https://biobriefs.com/ai-finds-monkeypox-weak-spot BioBriefs en 2025-12-11T04:34:15Z AI Finds Monkeypox Weak Spot — While Surveillance Flags New Recombinant Strain https://biobriefs.com/lipid-nanoparticles-and-base-editing BioBriefs en 2025-12-11T04:34:15Z Lipid Nanoparticles and Base Editing Show In Vivo Promise for Blinding and Metabolic Disease https://biobriefs.com/fda-tightens-car-t-bar BioBriefs en 2025-12-10T21:33:04Z FDA Tightens CAR‑T Bar: Randomized Trials Now the Default https://biobriefs.com/novartis-plows-1-7b-into BioBriefs en 2025-12-10T21:33:04Z Novartis Plows $1.7B into Relation: AI Targets atopic diseases https://biobriefs.com/arpa-h-funds-two-consortia BioBriefs en 2025-12-10T21:33:04Z ARPA‑H Funds Two Consortia to Replace Animal Toxicology with Human Models https://biobriefs.com/priority-voucher-spurs-fast-approval BioBriefs en 2025-12-10T21:33:04Z Priority Voucher Spurs Fast Approval of US‑Made Amoxicillin https://biobriefs.com/d3-bio-nets-108m-to BioBriefs en 2025-12-10T21:33:04Z D3 Bio Nets $108M to Push KRAS G12C Candidate Into Phase III https://biobriefs.com/roches-brainshuttle-antibody-clears-amyloid BioBriefs en 2025-12-10T21:33:04Z Roche’s Brainshuttle Antibody Clears Amyloid in Early Alzheimer’s Readout https://biobriefs.com/novartis-ianalumab-extends-disease-control BioBriefs en 2025-12-10T21:33:04Z Novartis’ Ianalumab Extends Disease Control in ITP https://biobriefs.com/integrated-continuous-fermentation-platform-readied BioBriefs en 2025-12-10T21:33:04Z Integrated Continuous Fermentation Platform Readied for Industry https://biobriefs.com/ai-designed-protac-targets-pkmyt1 BioBriefs en 2025-12-10T21:33:04Z AI‑Designed PROTAC Targets PKMYT1 in Preclinical Cancer Study https://biobriefs.com/kelonia-in-vivo-car-t BioBriefs en 2025-12-10T21:33:04Z Kelonia In‑Vivo CAR‑T Data Bolster Single‑Dose Strategy https://biobriefs.com/fda-raises-bar-for-car BioBriefs en 2025-12-10T16:33:04Z FDA raises bar for CAR‑T approvals: randomized trials required https://biobriefs.com/tecvayli-plus-darzalex-ash-data BioBriefs en 2025-12-10T16:33:04Z Tecvayli plus Darzalex... ASH data shows massive PFS gain in myeloma https://biobriefs.com/ianalumab-plus-promacta-phase-3 BioBriefs en 2025-12-10T16:33:04Z Ianalumab plus Promacta – Phase 3 shows durable control in ITP https://biobriefs.com/mirum-buys-bluejay-820m-deal BioBriefs en 2025-12-10T16:33:04Z Mirum buys Bluejay – $820M deal adds HDV antibody brelovitug https://biobriefs.com/lilly-picks-huntsville-6b-api BioBriefs en 2025-12-10T16:33:04Z Lilly picks Huntsville: $6B API megasite for GLP‑1 and peptides https://biobriefs.com/pfizer-expands-oral-glp-1 BioBriefs en 2025-12-10T16:33:04Z Pfizer expands oral GLP‑1 roster: $150M upfront China license https://biobriefs.com/novartis-taps-relation-1-7b BioBriefs en 2025-12-10T16:33:04Z Novartis taps Relation: $1.7B pact to mine AI‑driven dermatology targets https://biobriefs.com/ai-designed-protacs-and-ai BioBriefs en 2025-12-10T16:33:04Z AI‑designed PROTACs and AI drug startups: generative chemistry moves to clinic https://biobriefs.com/dna-origami-diagnostics-amplifold-raises BioBriefs en 2025-12-10T16:33:04Z DNA‑origami diagnostics: Amplifold raises €5M to commercialize LFA boost https://biobriefs.com/radboud-goes-live-with-pacbio BioBriefs en 2025-12-10T16:33:04Z Radboud goes live with PacBio long‑read WGS as frontline diagnostic test https://biobriefs.com/roche-oral-serd-30-cut BioBriefs en 2025-12-10T14:34:01Z Roche oral SERD: 30% cut in post‑surgery recurrence https://biobriefs.com/fda-pivots-on-car-t BioBriefs en 2025-12-10T14:34:01Z FDA pivots on CAR‑T: randomized trials now expected https://biobriefs.com/lilly-picks-huntsville-6b-api BioBriefs en 2025-12-10T14:34:01Z Lilly picks Huntsville – $6B API plant for GLP‑1 pill https://biobriefs.com/pfizer-doubles-down-on-oral BioBriefs en 2025-12-10T14:34:01Z Pfizer doubles down on oral GLP‑1s – China deals add heft https://biobriefs.com/mirum-buys-bluejay-adds-late BioBriefs en 2025-12-10T14:34:01Z Mirum buys Bluejay... adds late‑stage HDV antibody https://biobriefs.com/kelonias-in-body-car-t BioBriefs en 2025-12-10T14:34:01Z Kelonia’s in‑body CAR‑T: deep remissions in early MM readout https://biobriefs.com/continuous-fermentation-goes-commercial-pow BioBriefs en 2025-12-10T14:34:01Z Continuous fermentation goes commercial – Pow.Bio joins Bühler https://biobriefs.com/radboud-goes-long-pacbio-long BioBriefs en 2025-12-10T14:34:01Z Radboud goes long: PacBio long‑read WGS frontline diagnostic https://biobriefs.com/ginkgo-deep-origin-win-31 BioBriefs en 2025-12-10T14:34:01Z Ginkgo, Deep Origin win $31.7M ARPA‑H contract for non‑animal safety https://biobriefs.com/dyne-reports-pivotal-duchenne-win BioBriefs en 2025-12-10T14:34:01Z Dyne reports pivotal Duchenne win — FDA submission ahead https://biobriefs.com/fda-demands-randomized-trials-for BioBriefs en 2025-12-10T10:33:37Z FDA demands randomized trials for CAR‑T approvals https://biobriefs.com/tec-dara-combo-posts-landmark BioBriefs en 2025-12-10T10:33:37Z Tec‑dara combo posts landmark PFS at ASH — bispecifics vs CAR‑T https://biobriefs.com/mirum-snaps-up-bluejay-to BioBriefs en 2025-12-10T10:33:37Z Mirum snaps up Bluejay to add late‑stage HDV antibody https://biobriefs.com/lilly-pins-huntsville-for-6b BioBriefs en 2025-12-10T10:33:37Z Lilly pins Huntsville for $6B API plant — onshore GLP‑1 supply https://biobriefs.com/ai-designed-degrader-and-sciscigpt BioBriefs en 2025-12-10T10:33:37Z AI‑designed degrader and SciSciGPT push human–AI science integration https://biobriefs.com/wireless-bci-milestone-65536-electrodes BioBriefs en 2025-12-10T10:33:37Z Wireless BCI milestone: 65,536 electrodes on a single implant https://biobriefs.com/pfizer-doubles-down-on-oral BioBriefs en 2025-12-10T10:33:37Z Pfizer doubles down on oral GLP‑1s with China licensing deals https://biobriefs.com/radboud-umc-launches-pacbio-long BioBriefs en 2025-12-10T10:33:37Z Radboud UMC launches PacBio long‑read WGS as frontline diagnostic https://biobriefs.com/gnps-library-and-online-tool BioBriefs en 2025-12-10T10:33:37Z GNPS library and online tool let labs detect hidden drug exposures https://biobriefs.com/dynes-duchenne-candidate-meets-pivotal BioBriefs en 2025-12-10T10:33:37Z Dyne’s Duchenne candidate meets pivotal endpoint; filing planned https://biobriefs.com/fda-tightens-car-t-approval BioBriefs en 2025-12-10T09:33:14Z FDA tightens CAR‑T approval rules – RCTs now the default https://biobriefs.com/majestec-3-shock-tec-dara BioBriefs en 2025-12-10T09:33:14Z Majestec‑3 shock: Tec‑Dara combo posts blockbuster PFS at ASH https://biobriefs.com/lilly-picks-huntsville-for-6b BioBriefs en 2025-12-10T09:33:14Z Lilly picks Huntsville for $6B API plant — domestic API buildout accelerates https://biobriefs.com/mirum-buys-bluejay-adds-late BioBriefs en 2025-12-10T09:33:14Z Mirum buys Bluejay—adds late‑stage HDV antibody to liver portfolio https://biobriefs.com/pfizer-doubles-down-on-oral BioBriefs en 2025-12-10T09:33:14Z Pfizer doubles down on oral GLP‑1s: multiple China deals expand obesity arsenal https://biobriefs.com/structures-oral-glp-1-posts BioBriefs en 2025-12-10T09:33:14Z Structure’s oral GLP‑1 posts robust weight‑loss in mid‑stage trials https://biobriefs.com/ai-designed-degrader-insilico-unveils BioBriefs en 2025-12-10T09:33:14Z AI‑designed degrader: Insilico unveils PKMYT1 PROTAC with preclinical activity https://biobriefs.com/arpa-h-backs-non-animal BioBriefs en 2025-12-10T09:33:14Z ARPA‑H backs non‑animal drug‑safety models — $31.7M to Ginkgo‑led consortium https://biobriefs.com/fda-floats-higher-fees-for BioBriefs en 2025-12-10T09:33:14Z FDA floats higher fees for programs that run Phase I trials overseas https://biobriefs.com/radboud-umc-rolls-out-long BioBriefs en 2025-12-10T09:33:14Z Radboud UMC rolls out long‑read WGS as a frontline diagnostic — PacBio enters clinic https://biobriefs.com/lilly-picks-huntsville-6b-api BioBriefs en 2025-12-10T04:33:16Z Lilly picks Huntsville: $6B API plant for GLP‑1 pill https://biobriefs.com/delix-clears-phase-ii-design BioBriefs en 2025-12-10T04:33:16Z Delix clears Phase II design – at‑home dosing greenlit https://biobriefs.com/dyne-pivots-to-approval-duchenne BioBriefs en 2025-12-10T04:33:16Z Dyne pivots to approval — Duchenne pivotal win https://biobriefs.com/majestec-3-stuns-tec-dara BioBriefs en 2025-12-10T04:33:16Z Majestec‑3 stuns: Tec‑dara combo shows deep multiple‑myeloma control https://biobriefs.com/mirum-buys-bluejay-620m-bet BioBriefs en 2025-12-10T04:33:16Z Mirum buys Bluejay: $620M bet on hepatitis D antibody https://biobriefs.com/insilicos-ai-made-protac-targets BioBriefs en 2025-12-10T04:33:16Z Insilico’s AI‑made PROTAC targets PKMYT1: preclinical lead disclosed https://biobriefs.com/radboud-goes-live-with-long BioBriefs en 2025-12-10T04:33:16Z Radboud goes live with long‑read WGS: PacBio tech deployed clinically https://biobriefs.com/new-drug-exposure-tools-untargeted BioBriefs en 2025-12-10T04:33:16Z New drug‑exposure tools: untargeted metabolomics meets clinical practice https://biobriefs.com/fda-props-up-us-trials BioBriefs en 2025-12-10T04:33:16Z FDA props up US trials: fee hikes proposed and higher CAR‑T bar https://biobriefs.com/pfizer-doubles-down-on-oral BioBriefs en 2025-12-10T04:33:16Z Pfizer doubles down on oral GLP‑1s: $2B licensing spree https://biobriefs.com/fda-reopens-safety-review-approved BioBriefs en 2025-12-09T21:33:41Z FDA reopens safety review: Approved RSV antibodies scrutinized https://biobriefs.com/delixs-dlx-001-shows-translational BioBriefs en 2025-12-09T21:33:41Z Delix’s DLX‑001 shows translational effect — FDA clears Phase II with at‑home dosing https://biobriefs.com/radboud-umc-goes-frontline-long BioBriefs en 2025-12-09T21:33:41Z Radboud UMC goes frontline: Long‑read WGS replaces multi‑test diagnostic workflow https://biobriefs.com/eli-lilly-bets-6b-on BioBriefs en 2025-12-09T21:33:41Z Eli Lilly bets $6B on Alabama plant — Orforglipron scale‑up underway https://biobriefs.com/pfizer-doubles-down-on-oral BioBriefs en 2025-12-09T21:33:41Z Pfizer doubles down on oral GLP‑1s: Two China deals add pipeline heft https://biobriefs.com/mirum-buys-bluejay-for-620m BioBriefs en 2025-12-09T21:33:41Z Mirum buys Bluejay for $620M — Picks up Phase‑3 hepatitis D antibody https://biobriefs.com/teclistamab-daratumumab-majestec-3-posts BioBriefs en 2025-12-09T21:33:41Z Teclistamab+daratumumab... Majestec‑3 posts 83% three‑year PFS https://biobriefs.com/fda-raises-bar-for-car BioBriefs en 2025-12-09T21:33:41Z FDA raises bar for CAR‑T: New push for randomized superiority trials https://biobriefs.com/dynes-exon-51-program-hits BioBriefs en 2025-12-09T21:33:41Z Dyne’s exon‑51 program hits pivotal goals — Company plans expedited FDA submission https://biobriefs.com/insilicos-ai-designed-protac-targets BioBriefs en 2025-12-09T21:33:41Z Insilico’s AI‑designed PROTAC targets PKMYT1 — Preclinical activity reported https://biobriefs.com/novartis-inks-1-7b-ai BioBriefs en 2025-12-09T16:33:42Z Novartis inks $1.7B AI deal: Relation to hunt atopic targets https://biobriefs.com/mirum-buys-bluejay-for-620m BioBriefs en 2025-12-09T16:33:42Z Mirum buys Bluejay for $620M — wins hepatitis D antibody https://biobriefs.com/fda-raises-bar-car-t BioBriefs en 2025-12-09T16:33:42Z FDA raises bar: CAR‑T developers told to prove superiority https://biobriefs.com/teclistamab-daratumumab-majestec-3-posts BioBriefs en 2025-12-09T16:33:42Z Teclistamab+daratumumab: Majestec‑3 posts dramatic PFS gain https://biobriefs.com/terns-tern-701-shakes-up BioBriefs en 2025-12-09T16:33:42Z Terns’ TERN‑701 shakes up CML: 64% MMR at 24 weeks https://biobriefs.com/kymera-degrader-signals-biologic-like BioBriefs en 2025-12-09T16:33:42Z Kymera degrader signals biologic‑like activity; pill posts Dupixent‑style drop https://biobriefs.com/dyne-targets-fda-duchenne-exon BioBriefs en 2025-12-09T16:33:42Z Dyne targets FDA: Duchenne exon‑51 drug hits pivotal endpoint https://biobriefs.com/oral-glp-1-race-heats BioBriefs en 2025-12-09T16:33:42Z Oral GLP‑1 race heats: Structure posts double‑digit weight loss https://biobriefs.com/ai-designs-protac-insilico-reports BioBriefs en 2025-12-09T16:33:42Z AI designs PROTAC: Insilico reports PKMYT1 degrader; NeurIPS flags biology models https://biobriefs.com/arpa-h-funds-non-animal BioBriefs en 2025-12-09T16:33:42Z ARPA‑H funds non‑animal safety models: $31.7M PREDICTS award https://biobriefs.com/mirum-snaps-up-bluejay-620m BioBriefs en 2025-12-09T14:32:53Z Mirum snaps up Bluejay — $620M for hepatitis D antibody https://biobriefs.com/pfizer-doubles-down-on-oral BioBriefs en 2025-12-09T14:32:53Z Pfizer doubles down on oral GLP‑1: $150M upfront deal https://biobriefs.com/structure-fights-back-oral-glp BioBriefs en 2025-12-09T14:32:53Z Structure fights back — oral GLP‑1 posts strong Phase IIb data https://biobriefs.com/fda-tells-car-t-developers BioBriefs en 2025-12-09T14:32:53Z FDA tells CAR‑T developers: prove superiority over existing therapies https://biobriefs.com/dyne-wins-pivotal-duchenne-study BioBriefs en 2025-12-09T14:32:53Z Dyne wins pivotal Duchenne study — prepping FDA filing https://biobriefs.com/biontech-ctla-4-drug-halves BioBriefs en 2025-12-09T14:32:53Z BioNTech CTLA‑4 drug halves mortality in lung cancer — tolerability caveat https://biobriefs.com/kymeras-twin-wins-degrader-biomarker BioBriefs en 2025-12-09T14:32:53Z Kymera’s twin wins: degrader biomarker activity and Dupixent‑competitive pill https://biobriefs.com/ianalumab-delivers-durable-platelet-control BioBriefs en 2025-12-09T14:32:53Z Ianalumab delivers durable platelet control in ITP — Phase III evidence https://biobriefs.com/gsk-walks-away-from-ideaya BioBriefs en 2025-12-09T14:32:53Z GSK walks away from Ideaya collaboration — hands back two programs https://biobriefs.com/novartis-inks-1-7b-pact BioBriefs en 2025-12-09T14:32:53Z Novartis inks $1.7B pact with AI biotech Relation for immuno‑derm targets https://biobriefs.com/dynes-duchenne-win-pivotal-study BioBriefs en 2025-12-09T10:33:30Z Dyne’s Duchenne win: pivotal study hits endpoint, FDA filing planned https://biobriefs.com/mirum-buys-bluejay-for-620m BioBriefs en 2025-12-09T10:33:30Z Mirum buys Bluejay for $620M — gains Phase 3 HDV antibody https://biobriefs.com/kymera-degrader-readout-biologics-like BioBriefs en 2025-12-09T10:33:30Z Kymera degrader readout: biologics-like biomarker activity sparks rally https://biobriefs.com/structure-back-in-oral-glp BioBriefs en 2025-12-09T10:33:30Z Structure back in oral GLP‑1 race — mid-stage data show double-digit weight loss https://biobriefs.com/kras-g12d-race-more-than BioBriefs en 2025-12-09T10:33:30Z KRAS G12D race: more than 20 programs launched as companies target common mutation https://biobriefs.com/biontech-ctla-4-phase-3 BioBriefs en 2025-12-09T10:33:30Z BioNTech CTLA‑4: Phase 3 survival benefit — tolerability challenge emerges https://biobriefs.com/anito-cel-strengthens-best-in BioBriefs en 2025-12-09T10:33:30Z Anito‑cel strengthens best‑in‑class hopes — Gilead preps launch https://biobriefs.com/fda-raises-bar-for-car BioBriefs en 2025-12-09T10:33:30Z FDA raises bar for CAR‑T: new guidance demands superiority evidence https://biobriefs.com/ash-mrd-surrogate-in-aml BioBriefs en 2025-12-09T10:33:30Z ASH: MRD surrogate in AML — pooled data advocates faster approvals https://biobriefs.com/terns-rises-as-novartis-rival BioBriefs en 2025-12-09T10:33:30Z Terns rises as Novartis rival: leukemia drug posts strong molecular responses https://biobriefs.com/mirum-snaps-up-bluejay-620m BioBriefs en 2025-12-09T09:33:21Z Mirum snaps up Bluejay: $620M buy brings phase‑3 hepatitis D antibody https://biobriefs.com/dyne-readies-fda-push-duchenne BioBriefs en 2025-12-09T09:33:21Z Dyne readies FDA push: Duchenne exon‑51 drug posts landmark dystrophin gains https://biobriefs.com/kymeras-signals-pill-reduces-eczema BioBriefs en 2025-12-09T09:33:21Z Kymera’s signals: pill reduces eczema while degrader shows biologic‑like biomarker activity https://biobriefs.com/structure-surges-oral-glp-1 BioBriefs en 2025-12-09T09:33:21Z Structure surges: oral GLP‑1 pill posts up to 15% weight loss — tolerability debate looms https://biobriefs.com/waves-rna-approach-trims-visceral BioBriefs en 2025-12-09T09:33:21Z Wave’s RNA approach trims visceral fat and preserves muscle — early signals lift stock https://biobriefs.com/biontechs-ctla-4-antibody-improves BioBriefs en 2025-12-09T09:33:21Z BioNTech’s CTLA‑4 antibody improves survival — efficacy offsets tolerability concerns https://biobriefs.com/fda-sets-higher-bar-for BioBriefs en 2025-12-09T09:33:21Z FDA sets higher bar for CAR‑T: superiority now expected — pivotal readouts test the claim https://biobriefs.com/kras-g12d-more-than-20 BioBriefs en 2025-12-09T09:33:21Z KRAS G12D: more than 20 programs launch — companies race to drug common mutation https://biobriefs.com/medtronics-hugo-ras-cleared-by BioBriefs en 2025-12-09T09:33:21Z Medtronic’s Hugo RAS cleared by FDA — a new rival to da Vinci in soft‑tissue surgery https://biobriefs.com/ash-nudge-for-aml-mrd BioBriefs en 2025-12-09T09:33:21Z ASH nudge for AML: MRD surrogate endorsed — targeted therapies outpace chemo https://biobriefs.com/dynes-duchenne-win-fda-filing BioBriefs en 2025-12-09T04:33:05Z Dyne’s Duchenne win — FDA filing in sights https://biobriefs.com/mirum-buys-bluejays-hepatitis-d BioBriefs en 2025-12-09T04:33:05Z Mirum buys Bluejay’s hepatitis D asset — $620M deal https://biobriefs.com/terns-cml-candidate-pressures-novartis BioBriefs en 2025-12-09T04:33:05Z Terns’ CML candidate pressures Novartis — ASH update https://biobriefs.com/oral-glp-1-race-heats BioBriefs en 2025-12-09T04:33:05Z Oral GLP‑1 race heats up — efficacy vs tolerability https://biobriefs.com/fda-raises-the-bar-for BioBriefs en 2025-12-09T04:33:05Z FDA raises the bar for CAR‑T approvals https://biobriefs.com/gileads-anito-cel-posts-deep BioBriefs en 2025-12-09T04:33:05Z Gilead’s anito‑cel posts deep myeloma responses at ASH https://biobriefs.com/mrd-surrogate-could-speed-aml BioBriefs en 2025-12-09T04:33:05Z MRD surrogate could speed AML approvals — Harmony data https://biobriefs.com/fortrea-links-with-sctbio-to BioBriefs en 2025-12-09T04:33:05Z Fortrea links with SCTbio to offer integrated CGT study and manufacturing https://biobriefs.com/wireless-skull-implant-creates-artificial BioBriefs en 2025-12-09T04:33:05Z Wireless skull implant creates artificial perception in mice https://biobriefs.com/biontechs-ctla-4-antibody-extends BioBriefs en 2025-12-09T04:33:05Z BioNTech’s CTLA‑4 antibody extends survival — tolerability caveat https://biobriefs.com/dyne-duchenne-win-readies-accelerated BioBriefs en 2025-12-08T21:33:06Z Dyne Duchenne win — readies accelerated FDA bid https://biobriefs.com/mirum-shells-out-620m-snaps BioBriefs en 2025-12-08T21:33:06Z Mirum shells out $620M: snaps up Bluejay's HDV antibody https://biobriefs.com/fda-heightens-car-t-bar BioBriefs en 2025-12-08T21:33:06Z FDA heightens CAR‑T bar: new therapies must prove superiority https://biobriefs.com/biontech-ctla-4-shows-survival BioBriefs en 2025-12-08T21:33:06Z BioNTech CTLA‑4 shows survival gain — tolerability concerns linger https://biobriefs.com/structure-posts-competitive-weight-loss BioBriefs en 2025-12-08T21:33:06Z Structure posts competitive weight loss — nausea rates raise flags https://biobriefs.com/aml-mrd-surrogate-gains-traction BioBriefs en 2025-12-08T21:33:06Z AML MRD surrogate gains traction — could speed approvals by years https://biobriefs.com/kallyope-advances-elismetrep-to-phase BioBriefs en 2025-12-08T21:33:06Z Kallyope advances elismetrep to Phase 3 after Phase 2b win https://biobriefs.com/gilead-s-anito-cel-posts BioBriefs en 2025-12-08T21:33:06Z Gilead's anito‑cel posts deep responses — Kite prepares commercial push https://biobriefs.com/cogent-s-mastocytosis-drug-meets BioBriefs en 2025-12-08T21:33:06Z Cogent's mastocytosis drug meets Phase 3 endpoint — 2026 filing in view https://biobriefs.com/cdmo-and-diagnostics-deals-fortrea BioBriefs en 2025-12-08T21:33:06Z CDMO and diagnostics deals: Fortrea pairs with SCTbio — Pillar, AstraZeneca expand into China https://biobriefs.com/biontechs-ctla-4-wins-survival BioBriefs en 2025-12-08T16:33:01Z BioNTech’s CTLA‑4 wins survival — tolerability in question https://biobriefs.com/mirum-buys-bluejay-for-620m BioBriefs en 2025-12-08T16:33:01Z Mirum buys Bluejay for $620M — hepatitis D antibody joins rare‑disease portfolio https://biobriefs.com/dyne-prepares-fda-push-after BioBriefs en 2025-12-08T16:33:01Z Dyne prepares FDA push after strong dystrophin gains in DMD https://biobriefs.com/structures-oral-glp-1-posts BioBriefs en 2025-12-08T16:33:01Z Structure’s oral GLP‑1 posts rival weight loss — nausea clouds outlook https://biobriefs.com/pillar-astrazeneca-expand-liquid-biopsy BioBriefs en 2025-12-08T16:33:01Z Pillar, AstraZeneca expand liquid‑biopsy rollout to China https://biobriefs.com/mrd-advances-as-potential-surrogate BioBriefs en 2025-12-08T16:33:01Z MRD advances as potential surrogate — lymphoma and AML data strengthen case https://biobriefs.com/anito-cel-deep-responses-at BioBriefs en 2025-12-08T16:33:01Z Anito‑cel deep responses at ASH — Gilead, Kite position CAR‑T for broader launch https://biobriefs.com/menin-inhibitors-show-high-early BioBriefs en 2025-12-08T16:33:01Z Menin inhibitors show high early responses in AML — push to earlier lines https://biobriefs.com/engineered-bacteria-implantable-sensor-enables BioBriefs en 2025-12-08T16:33:01Z Engineered‑bacteria implantable sensor enables wireless molecular tracking https://biobriefs.com/cogents-bezuclastinib-clears-phase-3 BioBriefs en 2025-12-08T16:33:01Z Cogent’s bezuclastinib clears Phase 3 goal in advanced mastocytosis — regulatory filing planned https://biobriefs.com/structure-pill-cuts-weight-up BioBriefs en 2025-12-08T14:32:29Z Structure pill cuts weight up to 14%—nausea, vomiting rates mount https://biobriefs.com/ascletis-posts-7-7-weight BioBriefs en 2025-12-08T14:32:29Z Ascletis posts 7.7% weight loss in US oral GLP‑1 trial https://biobriefs.com/kymera-pill-rivals-dupixent-in BioBriefs en 2025-12-08T14:32:29Z Kymera pill rivals Dupixent in Phase 1b—early efficacy seen https://biobriefs.com/biontech-ctla-4-antibody-improves BioBriefs en 2025-12-08T14:32:29Z BioNTech CTLA‑4 antibody improves survival—tolerability clouds picture https://biobriefs.com/mirum-to-buy-bluejay-for BioBriefs en 2025-12-08T14:32:29Z Mirum to buy Bluejay for $620M—adds late‑stage hepatitis D antibody https://biobriefs.com/dyne-aims-to-file-after BioBriefs en 2025-12-08T14:32:29Z Dyne aims to file after late‑stage Duchenne exon‑skipper meets endpoints https://biobriefs.com/mrd-nears-surrogate-status-in BioBriefs en 2025-12-08T14:32:29Z MRD nears surrogate status in AML—ASH data supports accelerated paths https://biobriefs.com/gilead-arcellx-show-deep-responses BioBriefs en 2025-12-08T14:32:29Z Gilead, Arcellx show deep responses with anito‑cel in pivotal myeloma study https://biobriefs.com/kallyopes-migraine-drug-clears-phase BioBriefs en 2025-12-08T14:32:29Z Kallyope’s migraine drug clears Phase 2b—company moves to Phase 3 https://biobriefs.com/genetically-engineered-pig-liver-sustains BioBriefs en 2025-12-08T14:32:29Z Genetically engineered pig liver sustains human life—xeno trial underscores complexity https://biobriefs.com/xenotransplant-milestone-genetically-engineered-pig BioBriefs en 2025-12-08T10:33:43Z Xenotransplant milestone: Genetically engineered pig liver sustains human https://biobriefs.com/gene-therapies-push-into-children BioBriefs en 2025-12-08T10:33:43Z Gene therapies push into children — CRISPR and commercial players aim pediatric expansion https://biobriefs.com/gilead-arcellx-car-t-posts BioBriefs en 2025-12-08T10:33:43Z Gilead, Arcellx CAR‑T posts deep, durable responses in multiple myeloma https://biobriefs.com/mrd-as-a-fast-path BioBriefs en 2025-12-08T10:33:43Z MRD as a fast path: New pooled data support surrogate endpoint in AML https://biobriefs.com/ctdna-outperforms-scans-natera-data BioBriefs en 2025-12-08T10:33:43Z ctDNA outperforms scans: Natera data show MRD prognostic across lymphoma subtypes https://biobriefs.com/clascoterone-surprises-market-cosmo-stock BioBriefs en 2025-12-08T10:33:43Z Clascoterone surprises market — Cosmo stock jumps after baldness Phase III wins https://biobriefs.com/axoltis-raises-18m-to-advance BioBriefs en 2025-12-08T10:33:43Z Axoltis raises $18m to advance BBB‑repair drug for ALS https://biobriefs.com/investor-win-apple-tree-partners BioBriefs en 2025-12-08T10:33:43Z Investor win: Apple Tree Partners prevails in court, secures biotech funding https://biobriefs.com/incytes-calreticulin-targeted-approach-shows BioBriefs en 2025-12-08T10:33:43Z Incyte’s calreticulin‑targeted approach shows promise in advanced myelofibrosis https://biobriefs.com/star-therapeutics-readies-pivotal-programs BioBriefs en 2025-12-08T10:33:43Z Star Therapeutics readies pivotal programs — Antibody and monthly VWD shot show early promise https://biobriefs.com/pig-liver-graft-sustains-human BioBriefs en 2025-12-08T09:32:38Z Pig liver graft sustains human for days: xenotransplant demonstrates feasibility https://biobriefs.com/vertexs-crispr-therapy-hits-pediatric BioBriefs en 2025-12-08T09:32:38Z Vertex’s CRISPR therapy hits pediatric milestone – Casgevy shows early efficacy https://biobriefs.com/gileads-anito-cel-posts-deep BioBriefs en 2025-12-08T09:32:38Z Gilead’s anito‑cel posts deep responses: next‑gen CAR‑T reads as best‑in‑class https://biobriefs.com/mrd-negative-status-predicts-survival BioBriefs en 2025-12-08T09:32:38Z MRD‑negative status predicts survival in AML: pooled data support surrogate use https://biobriefs.com/higher-dose-sickle-cell-pill BioBriefs en 2025-12-08T09:32:38Z Higher‑dose sickle cell pill raises fetal hemoglobin: Fulcrum reports ASH data https://biobriefs.com/exa-cel-shows-pediatric-benefit BioBriefs en 2025-12-08T09:32:38Z Exa‑cel shows pediatric benefit: data hint at one‑time functional cure for children https://biobriefs.com/stars-vga039-cuts-bleeding-rates BioBriefs en 2025-12-08T09:32:38Z Star’s VGA039 cuts bleeding rates – phase 1/2 drives pivotal dosing and IPO talk https://biobriefs.com/incytes-novel-myelofibrosis-drug-shows BioBriefs en 2025-12-08T09:32:38Z Incyte’s novel myelofibrosis drug shows spleen and symptom benefit – new mechanism targeted https://biobriefs.com/topical-clascoterone-posts-large-phase BioBriefs en 2025-12-08T09:32:38Z Topical clascoterone posts large Phase III gains – Cosmo stock rallies https://biobriefs.com/natera-ctdna-mrd-outperforms-pet BioBriefs en 2025-12-08T09:32:38Z Natera ctDNA MRD outperforms PET: end‑of‑treatment positivity prognostic across lymphomas https://biobriefs.com/pig-to-human-liver-genetically BioBriefs en 2025-12-08T04:33:21Z Pig-to-human liver: genetically modified graft sustains organ function in proof-of-concept surgery https://biobriefs.com/gilead-arcellx-car-t-pivotal BioBriefs en 2025-12-08T04:33:21Z Gilead, Arcellx CAR-T: pivotal anito-cel shows deep, durable responses — launch ramps up https://biobriefs.com/vertex-crispr-in-kids-casgevy BioBriefs en 2025-12-08T04:33:21Z Vertex CRISPR in kids: Casgevy/exa-cel data push pediatric label and access talks https://biobriefs.com/ctdna-and-mrd-liquid-biopsy BioBriefs en 2025-12-08T04:33:21Z ctDNA and MRD: liquid biopsy and pooled data push MRD closer to regulatory surrogate status https://biobriefs.com/cosmos-clascoterone-phase-iii-toplines BioBriefs en 2025-12-08T04:33:21Z Cosmo’s clascoterone: Phase III toplines trigger stock surge after large hair-count gains https://biobriefs.com/higher-dose-sickle-cell-pill BioBriefs en 2025-12-08T04:33:21Z Higher-dose sickle-cell pill: Fulcrum’s pociredir raises fetal hemoglobin in early study https://biobriefs.com/incyte-targets-calreticulin-experimental-myelofibrosis BioBriefs en 2025-12-08T04:33:21Z Incyte targets calreticulin: experimental myelofibrosis drug shows spleen and symptom benefits https://biobriefs.com/rusfertide-data-protagonist-and-takeda BioBriefs en 2025-12-08T04:33:21Z Rusfertide data: Protagonist and Takeda report Phase 3 durability in polycythemia vera https://biobriefs.com/star-therapeutics-monthly-antibody-cuts BioBriefs en 2025-12-08T04:33:21Z Star Therapeutics: monthly antibody cuts bleeding rates — pivotal dosing underway, IPO considered https://biobriefs.com/hengrui-beone-top-china-innovation BioBriefs en 2025-12-08T04:33:21Z Hengrui, BeOne top China innovation index — new ranking maps R&D leaders https://biobriefs.com/pig-liver-transplant-genetically-engineered BioBriefs en 2025-12-07T21:32:05Z Pig liver transplant: Genetically engineered graft supports human but complications follow https://biobriefs.com/gilead-arcellx-car-t-posts BioBriefs en 2025-12-07T21:32:05Z Gilead, Arcellx CAR‑T posts 96% response rate – pivotal data https://biobriefs.com/vertex-crispr-casgevy-meets-early BioBriefs en 2025-12-07T21:32:05Z Vertex CRISPR: Casgevy meets early targets in pediatric blood disorders https://biobriefs.com/casgevy-for-kids-pediatric-data BioBriefs en 2025-12-07T21:32:05Z Casgevy for kids? Pediatric data point to label expansion – ASH preview https://biobriefs.com/higher-dose-pill-boosts-fetal BioBriefs en 2025-12-07T21:32:05Z Higher-dose pill boosts fetal hemoglobin — Fulcrum posts encouraging sickle cell signal https://biobriefs.com/incyte-drug-shows-spleen-responses BioBriefs en 2025-12-07T21:32:05Z Incyte drug shows spleen responses in myelofibrosis – early data https://biobriefs.com/mrd-inches-toward-surrogate-endpoint BioBriefs en 2025-12-07T21:32:05Z MRD inches toward surrogate endpoint status in AML – pooled ASH dataset https://biobriefs.com/astrazeneca-dual-target-car-t BioBriefs en 2025-12-07T21:32:05Z AstraZeneca dual‑target CAR‑T replicates China results in Western patients https://biobriefs.com/semaglutide-fails-to-reduce-cns BioBriefs en 2025-12-07T21:32:05Z Semaglutide fails to reduce CNS inflammation — trial readout https://biobriefs.com/oric-pill-effective-in-some BioBriefs en 2025-12-07T21:32:05Z ORIC pill: Effective in some NSCLC settings, abandoned for HER2 mutations https://biobriefs.com/hengrui-beone-top-china-s BioBriefs en 2025-12-07T21:32:05Z Hengrui, BeOne top China's pharma innovation index – IDEA/SAI report https://biobriefs.com/gilead-arcellx-next-gen-myeloma BioBriefs en 2025-12-07T16:32:51Z Gilead/Arcellx: next‑gen myeloma CAR‑T posts high remission rates https://biobriefs.com/mrd-biomarker-edges-closer-to BioBriefs en 2025-12-07T16:32:51Z MRD: biomarker edges closer to surrogate endpoint for AML https://biobriefs.com/exa-cel-in-kids-gene BioBriefs en 2025-12-07T16:32:51Z exa‑cel in kids: gene therapy data suggest earlier treatment window https://biobriefs.com/breyanzi-expands-label-first-car BioBriefs en 2025-12-07T16:32:51Z Breyanzi expands label: first CAR‑T cleared for marginal‑zone lymphoma https://biobriefs.com/freenome-spac-liquid-biopsy-firm BioBriefs en 2025-12-07T16:32:51Z Freenome SPAC: liquid‑biopsy firm to access public markets with $330M deal https://biobriefs.com/acip-flips-birth-dose-hepatitis BioBriefs en 2025-12-07T16:32:51Z ACIP flips birth‑dose hepatitis B guidance — panel debate intensifies https://biobriefs.com/regenerons-odronextamab-approval-path-hit BioBriefs en 2025-12-07T16:32:51Z Regeneron’s odronextamab: approval path hit by fresh regulatory, manufacturing snags https://biobriefs.com/ginkgo-wins-47m-doe-contract BioBriefs en 2025-12-07T16:32:51Z Ginkgo wins $47M DOE contract to automate high‑throughput phenotyping https://biobriefs.com/syntax-bio-crispr-cellgorithm-cuts BioBriefs en 2025-12-07T16:32:51Z Syntax Bio: CRISPR ‘Cellgorithm’ cuts stem‑cell timelines from months to weeks https://biobriefs.com/financings-and-m-a-funding BioBriefs en 2025-12-07T16:32:51Z Financings and M&A: funding normalizes while $1B‑plus takeouts climb https://biobriefs.com/acip-scraps-universal-hepatitis-b BioBriefs en 2025-12-07T14:33:07Z ACIP scraps universal hepatitis B birth dose: parents urged to consult clinicians https://biobriefs.com/mrd-edges-toward-regulator-acceptance BioBriefs en 2025-12-07T14:33:07Z MRD edges toward regulator acceptance — Natera snaps up Foresight https://biobriefs.com/vertexs-exa-cel-hits-pediatric BioBriefs en 2025-12-07T14:33:07Z Vertex’s exa‑cel hits pediatric marks — gene therapies push younger https://biobriefs.com/praxis-trial-halted-early-for BioBriefs en 2025-12-07T14:33:07Z Praxis trial halted early for efficacy — stock rallies https://biobriefs.com/astrazenecas-dual-target-car-t BioBriefs en 2025-12-07T14:33:07Z AstraZeneca’s dual‑target CAR‑T replicates China data in West https://biobriefs.com/bristol-myers-breyanzi-cleared-for BioBriefs en 2025-12-07T14:33:07Z Bristol Myers’ Breyanzi cleared for marginal zone lymphoma — first CAR‑T in MZL https://biobriefs.com/regenerons-odronextamab-hits-new-snag BioBriefs en 2025-12-07T14:33:07Z Regeneron’s odronextamab hits new snag — approval roller coaster continues https://biobriefs.com/freenome-to-go-public-via BioBriefs en 2025-12-07T14:33:07Z Freenome to go public via $330M SPAC: prepares for 2026 launch https://biobriefs.com/ginkgo-wins-47m-doe-contract BioBriefs en 2025-12-07T14:33:07Z Ginkgo wins $47M DOE contract — to automate phenotyping at PNNL https://biobriefs.com/hemophilia-gene-therapy-market-stalls BioBriefs en 2025-12-07T14:33:07Z Hemophilia gene therapy market stalls: payers, pricing bite back https://biobriefs.com/cdc-panel-scraps-universal-hepatitis BioBriefs en 2025-12-07T10:33:08Z CDC panel scraps universal hepatitis B birth dose: parents must consult https://biobriefs.com/fda-shakes-up-cder-hoeg BioBriefs en 2025-12-07T10:33:08Z FDA shakes up CDER: Høeg named acting director amid vaccine debate https://biobriefs.com/freenome-to-go-public-via BioBriefs en 2025-12-07T10:33:08Z Freenome to go public via $330M SPAC: readies for 2026 test launch https://biobriefs.com/casgevy-pediatric-data-previewed-at BioBriefs en 2025-12-07T10:33:08Z Casgevy pediatric data previewed at ASH: gene therapy push into younger kids https://biobriefs.com/praxis-stops-pivotal-seizure-trial BioBriefs en 2025-12-07T10:33:08Z Praxis stops pivotal seizure trial early — data spur stock rally https://biobriefs.com/natera-buys-foresight-to-widen BioBriefs en 2025-12-07T10:33:08Z Natera buys Foresight to widen MRD toolkit — MRD gains regulatory traction https://biobriefs.com/ginkgo-wins-47m-doe-contract BioBriefs en 2025-12-07T10:33:08Z Ginkgo wins $47M DOE contract to automate phenotyping at PNNL https://biobriefs.com/bristol-myers-expands-breyanzi-to BioBriefs en 2025-12-07T10:33:08Z Bristol Myers expands Breyanzi to marginal zone lymphoma — first CAR‑T for MZL https://biobriefs.com/biopharma-funding-normalizes-1b-takeouts BioBriefs en 2025-12-07T10:33:08Z Biopharma funding normalizes — $1B+ takeouts are rising https://biobriefs.com/nanites-and-degraders-two-seed BioBriefs en 2025-12-07T10:33:08Z Nanites and degraders: two seed rounds back diagnostics and targeted degradation https://biobriefs.com/acip-scraps-universal-birth-dose BioBriefs en 2025-12-07T09:33:16Z ACIP scraps universal birth-dose — CDC set to revise hepatitis B guidance https://biobriefs.com/freenome-to-go-public-via BioBriefs en 2025-12-07T09:33:16Z Freenome to go public via $330M SPAC — cancer‑screening launch set for 2026 https://biobriefs.com/natera-buys-foresight-phased-variant BioBriefs en 2025-12-07T09:33:16Z Natera buys Foresight — phased‑variant MRD tech added to Signatera https://biobriefs.com/mrd-shows-promise-as-surrogate BioBriefs en 2025-12-07T09:33:16Z MRD shows promise as surrogate endpoint in AML — pooled ASH dataset reported https://biobriefs.com/vertexs-exa-cel-shows-pediatric BioBriefs en 2025-12-07T09:33:16Z Vertex’s exa‑cel shows pediatric promise — push to expand sickle cell label https://biobriefs.com/praxis-halts-pivotal-dee-trial BioBriefs en 2025-12-07T09:33:16Z Praxis halts pivotal DEE trial early — relutrigine shows strong efficacy https://biobriefs.com/bristol-myers-wins-broader-breyanzi BioBriefs en 2025-12-07T09:33:16Z Bristol Myers wins broader Breyanzi use — first CAR‑T for marginal zone lymphoma https://biobriefs.com/ginkgo-wins-47m-doe-contract BioBriefs en 2025-12-07T09:33:16Z Ginkgo wins $47M DOE contract — building automated phenotyping for PNNL https://biobriefs.com/german-court-blocks-mercks-subcutaneous BioBriefs en 2025-12-07T09:33:16Z German court blocks Merck’s subcutaneous Keytruda — Halozyme gains legal edge https://biobriefs.com/encoded-links-dravet-program-to BioBriefs en 2025-12-07T09:33:16Z Encoded links Dravet program to pivotal trial — ETX101 posts 78% seizure drop https://biobriefs.com/acip-scraps-universal-hepatitis-b BioBriefs en 2025-12-07T04:32:59Z ACIP scraps universal hepatitis B birth dose: parents to consult with clinicians https://biobriefs.com/freenome-to-public-markets-via BioBriefs en 2025-12-07T04:32:59Z Freenome to public markets via $330M SPAC... PIPE backs commercialization plans https://biobriefs.com/natera-buys-foresight-for-275m BioBriefs en 2025-12-07T04:32:59Z Natera buys Foresight for $275M — folds phased‑variant MRD into Signatera https://biobriefs.com/mrd-shows-promise-as-surrogate BioBriefs en 2025-12-07T04:32:59Z MRD shows promise as surrogate endpoint in AML trials — ASH dataset suggests predictiveness https://biobriefs.com/vertexs-crispr-therapy-hits-early BioBriefs en 2025-12-07T04:32:59Z Vertex’s CRISPR therapy hits early milestone in children — label expansion in play https://biobriefs.com/bristol-myers-wins-expanded-breyanzi BioBriefs en 2025-12-07T04:32:59Z Bristol Myers wins expanded Breyanzi label: marginal zone lymphoma added https://biobriefs.com/praxis-halts-pivotal-epilepsy-study BioBriefs en 2025-12-07T04:32:59Z Praxis halts pivotal epilepsy study early for efficacy — stock jumps https://biobriefs.com/encoded-links-etx101-to-78 BioBriefs en 2025-12-07T04:32:59Z Encoded links ETX101 to 78% seizure reduction — pivotal Dravet trial planned https://biobriefs.com/ginkgo-wins-47m-doe-contract BioBriefs en 2025-12-07T04:32:59Z Ginkgo wins $47M DOE contract to automate phenotyping at PNNL https://biobriefs.com/paradigm-buys-flatirons-clinical-research BioBriefs en 2025-12-07T04:32:59Z Paradigm buys Flatiron’s clinical research arm: trials embedded into OncoEMR https://biobriefs.com/acip-scraps-universal-hep-b BioBriefs en 2025-12-06T21:32:38Z ACIP scraps universal Hep B birth dose — newborn schedule shifted https://biobriefs.com/fda-churn-intensifies-pazdur-exits BioBriefs en 2025-12-06T21:32:38Z FDA churn intensifies — Pazdur exits, Høeg named acting CDER chief https://biobriefs.com/freenome-heads-for-public-markets BioBriefs en 2025-12-06T21:32:38Z Freenome heads for public markets — $330M SPAC deal clears path to 2026 launch https://biobriefs.com/vertexs-casgevy-shows-promise-in BioBriefs en 2025-12-06T21:32:38Z Vertex’s Casgevy shows promise in kids — pediatric label expansion in view https://biobriefs.com/praxis-halts-trial-early-relutrigine BioBriefs en 2025-12-06T21:32:38Z Praxis halts trial early — relutrigine posts strong efficacy in rare epilepsy https://biobriefs.com/bristol-myers-expands-breyanzi-use BioBriefs en 2025-12-06T21:32:38Z Bristol Myers expands Breyanzi use — first CAR-T approved for marginal zone lymphoma https://biobriefs.com/ginkgo-wins-47m-doe-contract BioBriefs en 2025-12-06T21:32:38Z Ginkgo wins $47M DOE contract — automating phenotyping at PNNL https://biobriefs.com/natera-buys-foresight-275m-upfront BioBriefs en 2025-12-06T21:32:38Z Natera buys Foresight — $275M upfront to bolster MRD and lymphoma reach https://biobriefs.com/early-stage-cell-and-gene BioBriefs en 2025-12-06T21:32:38Z Early-stage cell and gene funding softens — biopharma financing normalizes https://biobriefs.com/in-vivo-hspc-editing-and BioBriefs en 2025-12-06T21:32:38Z In vivo HSPC editing and Dravet gene therapy — gene-editing milestone to pivotal path https://biobriefs.com/pazdur-resigns-as-cder-director BioBriefs en 2025-12-06T16:32:38Z Pazdur resigns as CDER director — another leadership shake-up https://biobriefs.com/12-ex-fda-chiefs-slam BioBriefs en 2025-12-06T16:32:38Z 12 ex-FDA chiefs slam Prasad: vaccine-rule overhaul draws fire https://biobriefs.com/acip-drops-universal-birth-dose BioBriefs en 2025-12-06T16:32:38Z ACIP drops universal birth-dose: hepatitis B guidance flipped https://biobriefs.com/freenome-to-go-public-via BioBriefs en 2025-12-06T16:32:38Z Freenome to go public via $330M SPAC — IPO route for liquid biopsy https://biobriefs.com/vertexs-casgevy-meets-pediatric-goals BioBriefs en 2025-12-06T16:32:38Z Vertex’s Casgevy meets pediatric goals — push to expand label https://biobriefs.com/praxis-halts-pivotal-epilepsy-trial BioBriefs en 2025-12-06T16:32:38Z Praxis halts pivotal epilepsy trial early — efficacy triggers run-up https://biobriefs.com/natera-buys-foresight-to-boost BioBriefs en 2025-12-06T16:32:38Z Natera buys Foresight to boost MRD sensitivity — phased-variant push https://biobriefs.com/crescent-and-kelun-tee-up BioBriefs en 2025-12-06T16:32:38Z Crescent and Kelun tee up PD‑1/VEGF bispecific program — twin-data plan https://biobriefs.com/ginkgo-wins-47m-doe-phenotyping BioBriefs en 2025-12-06T16:32:38Z Ginkgo wins $47M DOE phenotyping contract; Avance opens potency center https://biobriefs.com/seed-crash-in-cell-gene BioBriefs en 2025-12-06T16:32:38Z Seed crash in cell & gene; financing normalizes across biopharma https://biobriefs.com/casgevy-shows-early-pediatric-benefit BioBriefs en 2025-12-06T14:33:26Z Casgevy shows early pediatric benefit: pediatric expansion moves into view https://biobriefs.com/acip-scraps-universal-birth-dose BioBriefs en 2025-12-06T14:33:26Z ACIP scraps universal birth-dose guidance – hepatitis B policy shaken https://biobriefs.com/freenome-to-go-public-330m BioBriefs en 2025-12-06T14:33:26Z Freenome to go public: $330M SPAC backs liquid‑biopsy commercialization https://biobriefs.com/fda-leadership-churn-deepens-hoeg BioBriefs en 2025-12-06T14:33:26Z FDA leadership churn deepens: Høeg named CDER head amid policy shifts https://biobriefs.com/praxis-halts-pivotal-trial-early BioBriefs en 2025-12-06T14:33:26Z Praxis halts pivotal trial early – relutrigine posts efficacy signal https://biobriefs.com/natera-expands-mrd-toolkit-with BioBriefs en 2025-12-06T14:33:26Z Natera expands MRD toolkit with Foresight buy: $275M upfront deal https://biobriefs.com/biomanufacturing-and-automation-spend-rises BioBriefs en 2025-12-06T14:33:26Z Biomanufacturing and automation spend rises: Ginkgo wins DOE contract; BioNexus scales https://biobriefs.com/crescent-inks-kelun-alliance-pd BioBriefs en 2025-12-06T14:33:26Z Crescent inks Kelun alliance – PD‑1/VEGF bispecific race heats up https://biobriefs.com/gene-therapy-commercial-strain-hemophilia BioBriefs en 2025-12-06T14:33:26Z Gene‑therapy commercial strain: hemophilia pullbacks and regulatory setbacks https://biobriefs.com/neutrophil-atlas-and-ehr-enhanced BioBriefs en 2025-12-06T14:33:26Z Neutrophil atlas and EHR‑enhanced PRS sharpen genomics tools https://biobriefs.com/freenome-jumps-to-public-markets BioBriefs en 2025-12-06T10:33:09Z Freenome jumps to public markets: $330M SPAC deal set https://biobriefs.com/acip-scraps-universal-hep-b BioBriefs en 2025-12-06T10:33:09Z ACIP scraps universal hep B birth dose — guidance shifts https://biobriefs.com/praxis-halts-pivotal-trial-early BioBriefs en 2025-12-06T10:33:09Z Praxis halts pivotal trial early — seizure drug posts striking efficacy https://biobriefs.com/bristol-myers-expands-breyanzi-label BioBriefs en 2025-12-06T10:33:09Z Bristol Myers expands Breyanzi label — first CAR‑T for marginal zone lymphoma https://biobriefs.com/fda-churn-hoeg-named-cder BioBriefs en 2025-12-06T10:33:09Z FDA churn: Høeg named CDER head as leadership reshuffle deepens https://biobriefs.com/uniqure-face-plant-fda-signals BioBriefs en 2025-12-06T10:33:09Z UniQure face‑plant: FDA signals tougher path for Huntington’s gene therapy https://biobriefs.com/ginkgo-wins-47m-pnnl-automation BioBriefs en 2025-12-06T10:33:09Z Ginkgo wins $47M PNNL automation contract — phenotyping at scale https://biobriefs.com/terray-hits-bms-milestone-ai BioBriefs en 2025-12-06T10:33:09Z Terray hits BMS milestone — AI‑driven discovery shows traction https://biobriefs.com/triana-raises-120m-to-advance BioBriefs en 2025-12-06T10:33:09Z Triana raises $120M to advance molecular glue program https://biobriefs.com/semaglutide-fails-to-reduce-cns BioBriefs en 2025-12-06T10:33:09Z Semaglutide fails to reduce CNS inflammation — Alzheimer’s readouts confirm https://biobriefs.com/acip-scraps-universal-hepatitis-b BioBriefs en 2025-12-06T09:33:34Z ACIP scraps universal hepatitis B birth dose: parents to consult clinicians https://biobriefs.com/makary-ally-hoeg-named-cder BioBriefs en 2025-12-06T09:33:34Z Makary ally Høeg named CDER chief – agency churn expected https://biobriefs.com/praxis-stops-pivotal-seizure-study BioBriefs en 2025-12-06T09:33:34Z Praxis stops pivotal seizure study early – efficacy triggers readout https://biobriefs.com/freenome-moves-to-public-markets BioBriefs en 2025-12-06T09:33:34Z Freenome moves to public markets via $330M SPAC – commercialization planned 2026 https://biobriefs.com/triana-closes-120m-series-b BioBriefs en 2025-12-06T09:33:34Z Triana closes $120M Series B to push molecular glue degrader into clinic https://biobriefs.com/natera-acquires-foresight-to-expand BioBriefs en 2025-12-06T09:33:34Z Natera acquires Foresight to expand MRD sensitivity and lymphoma reach https://biobriefs.com/ginkgo-wins-47m-doe-contract BioBriefs en 2025-12-06T09:33:34Z Ginkgo wins $47M DOE contract to automate high-throughput phenotyping at PNNL https://biobriefs.com/terray-hits-bms-milestone-ai BioBriefs en 2025-12-06T09:33:34Z Terray hits BMS milestone – AI-backed discovery validates EMMI platform https://biobriefs.com/gene-therapy-programs-face-regulatory BioBriefs en 2025-12-06T09:33:34Z Gene‑therapy programs face regulatory headwinds – UniQure, Denali update timelines https://biobriefs.com/biopharma-funding-normalizes-1b-takeouts BioBriefs en 2025-12-06T09:33:34Z Biopharma funding normalizes; $1B+ takeouts accelerate in targeted therapy areas https://biobriefs.com/acip-drops-universal-hepatitis-b BioBriefs en 2025-12-06T04:33:10Z ACIP drops universal hepatitis B birth dose: panel rewrites newborn guidance https://biobriefs.com/fda-upheaval-hoeg-named-cder BioBriefs en 2025-12-06T04:33:10Z FDA upheaval: Høeg named CDER chief as mRNA coalition warns of agency turmoil https://biobriefs.com/freenome-to-go-public-via BioBriefs en 2025-12-06T04:33:10Z Freenome to go public via $330M SPAC — liquid biopsy developer eyes 2026 launch https://biobriefs.com/natera-expands-mrd-footprint-foresight BioBriefs en 2025-12-06T04:33:10Z Natera expands MRD footprint: Foresight buy aims to boost lymphoma ctDNA testing https://biobriefs.com/crescent-inks-two-way-kelun BioBriefs en 2025-12-06T04:33:10Z Crescent inks two‑way Kelun pact — PD‑1/VEGF bispecific program set for parallel US‑China readouts https://biobriefs.com/praxis-halts-pivotal-seizure-trial BioBriefs en 2025-12-06T04:33:10Z Praxis halts pivotal seizure trial early for efficacy — relutrigine draws investor focus https://biobriefs.com/bristol-myers-extends-breyanzi-label BioBriefs en 2025-12-06T04:33:10Z Bristol Myers extends Breyanzi label: CAR‑T cleared for marginal zone lymphoma https://biobriefs.com/syntax-bio-publishes-crispr-cellgorithm BioBriefs en 2025-12-06T04:33:10Z Syntax Bio publishes CRISPR Cellgorithm: programmable control trims stem‑cell timelines https://biobriefs.com/anti-sfrp2-antibody-suppresses-tnbc BioBriefs en 2025-12-06T04:33:10Z Anti‑SFRP2 antibody suppresses TNBC growth and metastasis in mice — preclinical proof‑of‑concept https://biobriefs.com/triana-closes-120m-series-b BioBriefs en 2025-12-06T04:33:10Z Triana closes $120M Series B to push molecular glue degraders toward clinic https://biobriefs.com/freenome-to-go-public-330m BioBriefs en 2025-12-05T21:32:41Z Freenome to go public: $330M SPAC backs blood-based cancer test push https://biobriefs.com/cdc-panel-scraps-universal-birth BioBriefs en 2025-12-05T21:32:41Z CDC panel scraps universal birth dose: ACIP shifts hepatitis B guidance https://biobriefs.com/fda-upheaval-escalates-hoeg-named BioBriefs en 2025-12-05T21:32:41Z FDA upheaval escalates: Høeg named to run CDER as ex‑chiefs criticize vaccine policy https://biobriefs.com/natera-buys-foresight-275m-acquisition BioBriefs en 2025-12-05T21:32:41Z Natera buys Foresight: $275M acquisition to boost MRD sensitivity https://biobriefs.com/denali-taps-royalty-financing-as BioBriefs en 2025-12-05T21:32:41Z Denali taps royalty financing as FDA action and holds cloud approval timeline https://biobriefs.com/triana-nets-120m-molecular-glue BioBriefs en 2025-12-05T21:32:41Z Triana nets $120M: molecular‑glue degrader program advances to clinic https://biobriefs.com/praxis-halts-pivotal-seizure-trial BioBriefs en 2025-12-05T21:32:41Z Praxis halts pivotal seizure trial early: relutrigine posts strong efficacy https://biobriefs.com/encoded-ties-etx101-to-78 BioBriefs en 2025-12-05T21:32:41Z Encoded ties ETX101 to 78% seizure drop — pivotal trial on track https://biobriefs.com/terray-hits-bms-milestone-ai BioBriefs en 2025-12-05T21:32:41Z Terray hits BMS milestone: AI‑chip platform delivers discovery breakthrough https://biobriefs.com/ginkgo-wins-47m-doe-linked BioBriefs en 2025-12-05T21:32:41Z Ginkgo wins $47M DOE‑linked contract to automate phenotyping at PNNL https://biobriefs.com/acip-in-disarray-hepatitis-b BioBriefs en 2025-12-05T16:33:20Z ACIP in disarray: hepatitis B birth-dose vote delayed then reversed https://biobriefs.com/ex-fda-chiefs-lambaste-vaccine BioBriefs en 2025-12-05T16:33:20Z Ex-FDA chiefs lambaste vaccine policy—agency taps Høeg to run CDER https://biobriefs.com/capricors-dmd-win-ignites-rally BioBriefs en 2025-12-05T16:33:20Z Capricor’s DMD win ignites rally—company prices $150M follow-on https://biobriefs.com/fda-pauses-denali-trial-company BioBriefs en 2025-12-05T16:33:20Z FDA pauses Denali trial... company secures $275M royalty financing https://biobriefs.com/uniqures-huntington-filing-clouded-fda BioBriefs en 2025-12-05T16:33:20Z UniQure’s Huntington filing clouded—FDA feedback forces reassessment https://biobriefs.com/natera-buys-foresight-for-275m BioBriefs en 2025-12-05T16:33:20Z Natera buys Foresight for $275M to bolster MRD detection https://biobriefs.com/triana-closes-120m-series-b BioBriefs en 2025-12-05T16:33:20Z Triana closes $120M Series B to advance molecular-glue degraders https://biobriefs.com/pfizer-ventures-backs-otrs-100m BioBriefs en 2025-12-05T16:33:20Z Pfizer Ventures backs OTR’s $100M series A—China biotech broadens R&D hub https://biobriefs.com/illumina-pivots-to-data-bioinsight BioBriefs en 2025-12-05T16:33:20Z Illumina pivots to data: BioInsight to sell sequencing datasets and analytics https://biobriefs.com/invenirex-raises-seed-cash-for BioBriefs en 2025-12-05T16:33:20Z Invenirex raises seed cash for enzyme‑free 'nanite' nucleic-acid detection https://biobriefs.com/cder-turnover-spikes-pazdur-retires BioBriefs en 2025-12-05T14:33:24Z CDER turnover spikes — Pazdur retires, Høeg steps in https://biobriefs.com/prasad-defends-probe-former-fda BioBriefs en 2025-12-05T14:33:24Z Prasad defends probe: former FDA chiefs issue blistering rebuke https://biobriefs.com/acip-in-disarray-hepatitis-b BioBriefs en 2025-12-05T14:33:24Z ACIP in disarray: hepatitis B birth-dose vote delayed again https://biobriefs.com/duchenne-milestone-capricors-cell-therapy BioBriefs en 2025-12-05T14:33:24Z Duchenne milestone: Capricor’s cell therapy clears Phase III endpoints, stock rockets https://biobriefs.com/semaglutides-alzheimer-hopes-dashed-ctad BioBriefs en 2025-12-05T14:33:24Z Semaglutide’s Alzheimer hopes dashed — CTAD data show no cognitive benefit https://biobriefs.com/triana-pulls-in-120m-molecular BioBriefs en 2025-12-05T14:33:24Z Triana pulls in $120M — molecular glue developer eyes clinic https://biobriefs.com/german-court-blocks-keytruda-sc BioBriefs en 2025-12-05T14:33:24Z German court blocks Keytruda SC — Halozyme wins injunction https://biobriefs.com/in-vivo-editing-of-human BioBriefs en 2025-12-05T14:33:24Z In vivo editing of human HSPCs: envelope‑engineered VLPs enable direct therapy https://biobriefs.com/neumap-atlas-charts-neutrophil-diversity BioBriefs en 2025-12-05T14:33:24Z NeuMap atlas charts neutrophil diversity — a million‑cell single‑cell roadmap https://biobriefs.com/terray-hits-bms-milestone-ai BioBriefs en 2025-12-05T14:33:24Z Terray hits BMS milestone — AI platform finds drugs in unseen chemical space https://biobriefs.com/deramiocel-phase-3-win-capricor BioBriefs en 2025-12-05T10:33:29Z Deramiocel Phase 3 win... Capricor shares surge https://biobriefs.com/fda-names-hoeg-to-cder BioBriefs en 2025-12-05T10:33:29Z FDA names Høeg to CDER: leadership churn continues https://biobriefs.com/vaccine-rules-under-fire-ex BioBriefs en 2025-12-05T10:33:29Z Vaccine rules under fire: ex‑FDA chiefs denounce Prasad https://biobriefs.com/ctad-reveal-semaglutide-fails-to BioBriefs en 2025-12-05T10:33:29Z CTAD reveal: semaglutide fails to slow Alzheimer’s decline https://biobriefs.com/pharvaris-pill-meets-phase-3 BioBriefs en 2025-12-05T10:33:29Z Pharvaris pill meets Phase 3 goals — FDA filing planned https://biobriefs.com/triana-raises-120m-molecular-glues BioBriefs en 2025-12-05T10:33:29Z Triana raises $120M — molecular glues head to clinic https://biobriefs.com/terray-clears-bms-milestone-ai BioBriefs en 2025-12-05T10:33:29Z Terray clears BMS milestone — AI discovery scales binding data https://biobriefs.com/illumina-pivots-to-data-products BioBriefs en 2025-12-05T10:33:29Z Illumina pivots to data products: pharma and AI focus https://biobriefs.com/fda-floats-fee-incentives-higher BioBriefs en 2025-12-05T10:33:29Z FDA floats fee incentives — higher charges for offshore Phase 1s https://biobriefs.com/venture-winter-early-stage-funding BioBriefs en 2025-12-05T10:33:29Z Venture winter: early‑stage funding collapses for US cell & gene https://biobriefs.com/capricors-dmd-cell-therapy-hits BioBriefs en 2025-12-05T09:33:30Z Capricor’s DMD cell therapy hits phase III marks — shares explode https://biobriefs.com/fda-names-tracey-beth-hoeg BioBriefs en 2025-12-05T09:33:30Z FDA names Tracey Beth Høeg to run CDER — rapid leadership shakeup https://biobriefs.com/former-fda-chiefs-and-prasad BioBriefs en 2025-12-05T09:33:30Z Former FDA chiefs and Prasad clash over vaccine rules — NEJM rebuke, defense follows https://biobriefs.com/triana-raises-120m-to-push BioBriefs en 2025-12-05T09:33:30Z Triana raises $120M to push molecular glue degrader toward clinic https://biobriefs.com/genomics-data-and-ai-drive BioBriefs en 2025-12-05T09:33:30Z Genomics data and AI drive new pharma offerings — Illumina, Terray move up https://biobriefs.com/fda-signals-regulatory-shifts-one BioBriefs en 2025-12-05T09:33:30Z FDA signals regulatory shifts: one‑trial default and user‑fee incentives https://biobriefs.com/neumap-atlas-charts-neutrophil-diversity BioBriefs en 2025-12-05T09:33:30Z NeuMap atlas charts neutrophil diversity — million‑cell resource released https://biobriefs.com/spatial-touchstone-issues-standards-for BioBriefs en 2025-12-05T09:33:30Z Spatial Touchstone issues standards for spatial transcriptomics — benchmark dataset https://biobriefs.com/crescent-biopharma-inks-kelun-adc BioBriefs en 2025-12-05T09:33:30Z Crescent Biopharma inks Kelun ADC pact and raises $185M — combo strategy https://biobriefs.com/manufacturing-and-assay-capacity-expands BioBriefs en 2025-12-05T09:33:30Z Manufacturing and assay capacity expands — Avance opens potency center; BioNexus funds build https://biobriefs.com/capricor-s-duchenne-win-fda BioBriefs en 2025-12-05T04:32:55Z Capricor's Duchenne win... FDA standoff shifts to resubmission https://biobriefs.com/12-former-fda-chiefs-strike BioBriefs en 2025-12-05T04:32:55Z 12 former FDA chiefs strike back: vaccine-rule overhaul under fire https://biobriefs.com/pharvaris-oral-hae-pill-clears BioBriefs en 2025-12-05T04:32:55Z Pharvaris' oral HAE pill clears Phase 3 — filing on deck https://biobriefs.com/pfizer-backed-triana-nets-120m BioBriefs en 2025-12-05T04:32:55Z Pfizer‑backed Triana nets $120M — molecular glue moves to clinic https://biobriefs.com/ai-drug-design-terray-hits BioBriefs en 2025-12-05T04:32:55Z AI drug design... Terray hits BMS milestone; Baker lab opens RFdiffusion3 https://biobriefs.com/journal-retracts-monsanto-backed-glyphosate BioBriefs en 2025-12-05T04:32:55Z Journal retracts Monsanto‑backed glyphosate safety paper — legal storm follows https://biobriefs.com/uniqure-told-more-work-needed BioBriefs en 2025-12-05T04:32:55Z UniQure told more work needed on Huntington gene therapy — stock slides https://biobriefs.com/carb-x-doubles-down-on BioBriefs en 2025-12-05T04:32:55Z CARB‑X doubles down on rapid diagnostics — pediatric and STI prizes awarded https://biobriefs.com/neumap-atlas-charts-neutrophil-diversity BioBriefs en 2025-12-05T04:32:55Z NeuMap atlas charts neutrophil diversity — Nature maps 1M+ cells https://biobriefs.com/illumina-pivots-bioinsight-to-sell BioBriefs en 2025-12-05T04:32:55Z Illumina pivots: BioInsight to sell data packages and AI‑ready genomic sets https://biobriefs.com/former-fda-commissioners-sound-alarm BioBriefs en 2025-12-04T21:33:36Z Former FDA commissioners sound alarm: Prasad's vaccine plan 'endangers public health' https://biobriefs.com/acip-in-disarray-vote-on BioBriefs en 2025-12-04T21:33:36Z ACIP in disarray — Vote on newborn hepatitis B shot postponed https://biobriefs.com/capricor-s-cell-therapy-clears BioBriefs en 2025-12-04T21:33:36Z Capricor's cell therapy clears Phase 3 — Shares skyrocket https://biobriefs.com/pharvaris-pill-wins-phase-3 BioBriefs en 2025-12-04T21:33:36Z Pharvaris pill wins Phase 3 — Rapid relief for hereditary angioedema https://biobriefs.com/uniqure-s-amt-130-path BioBriefs en 2025-12-04T21:33:36Z UniQure's AMT‑130 path muddied — shares slide after FDA rebuff https://biobriefs.com/regeneron-tessera-pact-150m-to BioBriefs en 2025-12-04T21:33:36Z Regeneron-Tessera pact: $150m to write genes for AATD https://biobriefs.com/triana-nets-120m-molecular-glue BioBriefs en 2025-12-04T21:33:36Z Triana nets $120m — molecular glue degrader heads to clinic https://biobriefs.com/scineuro-raises-53m-to-revive BioBriefs en 2025-12-04T21:33:36Z SciNeuro raises $53m — to revive a former GSK neuro compound https://biobriefs.com/illumina-pivots-sells-sequencing-data BioBriefs en 2025-12-04T21:33:36Z Illumina pivots: sells sequencing data to pharma — BioInsight launched https://biobriefs.com/spatial-touchstone-sets-benchmarks-standards BioBriefs en 2025-12-04T21:33:36Z Spatial Touchstone sets benchmarks — standards for spatial transcriptomics https://biobriefs.com/capricor-turns-fda-rejection-into BioBriefs en 2025-12-04T16:34:11Z Capricor turns FDA rejection into Phase III win — deramiocel clears endpoints https://biobriefs.com/pharvaris-clocks-phase-iii-win BioBriefs en 2025-12-04T16:34:11Z Pharvaris clocks Phase III win — oral HAE pill poised to file https://biobriefs.com/fda-drug-office-in-flux BioBriefs en 2025-12-04T16:34:11Z FDA drug office in flux: Pazdur exits — Høeg named acting director https://biobriefs.com/fda-drafts-changes-to-antibody BioBriefs en 2025-12-04T16:34:11Z FDA drafts changes to antibody safety testing — fewer monkey studies recommended https://biobriefs.com/ai-drug-discovery-accelerates-rfdiffusion3 BioBriefs en 2025-12-04T16:34:11Z AI drug discovery accelerates: RFdiffusion3 open-sourced — Terray hits BMS milestone https://biobriefs.com/triana-raises-120m-molecular-glue BioBriefs en 2025-12-04T16:34:11Z Triana raises $120M — molecular glue degrader heads to clinic https://biobriefs.com/two-ind-clears-advance-cns BioBriefs en 2025-12-04T16:34:11Z Two IND clears advance CNS and rare-disease programs — Latus and Vectory move to clinic https://biobriefs.com/big-pharma-dealmaking-regeneron-backs BioBriefs en 2025-12-04T16:34:11Z Big pharma dealmaking: Regeneron backs Tessera gene writing ($150M) — AstraZeneca buys Neurimmune asset https://biobriefs.com/diagnostics-scale-up-and-approvals BioBriefs en 2025-12-04T16:34:11Z Diagnostics scale-up and approvals: GeninCode teams with Thermo Fisher — Devyser wins Canada clearance https://biobriefs.com/carb-x-backs-rapid-infectious BioBriefs en 2025-12-04T16:34:11Z CARB‑X backs rapid infectious‑disease diagnostics — funds for ProtonDx and Scout Health https://biobriefs.com/deramiocel-triumphs-capricor-posts-positive BioBriefs en 2025-12-04T14:33:05Z Deramiocel triumphs—Capricor posts positive Phase 3 topline https://biobriefs.com/pharvaris-clocks-phase-3-win BioBriefs en 2025-12-04T14:33:05Z Pharvaris clocks Phase 3 win: oral HAE pill eyes 2026 filing https://biobriefs.com/protego-raises-130m-preps-pivotal BioBriefs en 2025-12-04T14:33:05Z Protego raises $130M—preps pivotal trial for AL amyloidosis stabilizer https://biobriefs.com/regeneron-tessera-deal-150m-upfront BioBriefs en 2025-12-04T14:33:05Z Regeneron-Tessera deal: $150M upfront for AATD gene‑writing program https://biobriefs.com/triana-raises-120m-pushes-molecular BioBriefs en 2025-12-04T14:33:05Z Triana raises $120M—pushes molecular‑glue degrader toward clinic https://biobriefs.com/fda-clears-latus-bio-ind BioBriefs en 2025-12-04T14:33:05Z FDA clears Latus Bio IND for CLN2—designations accelerate program https://biobriefs.com/vectory-wins-ind-clearance-vectorized BioBriefs en 2025-12-04T14:33:05Z Vectory wins IND clearance—vectorized anti‑TDP‑43 enters ALS trials https://biobriefs.com/rfdiffusion3-open-source-de-novo BioBriefs en 2025-12-04T14:33:05Z RFdiffusion3 open source... de novo DNA binders and advanced enzymes https://biobriefs.com/fda-shake-up-pazdur-signals BioBriefs en 2025-12-04T14:33:05Z FDA shake‑up: Pazdur signals exit—Tracy Hoeg named acting CDER chief https://biobriefs.com/crescent-inks-two-way-kelun BioBriefs en 2025-12-04T14:33:05Z Crescent inks two‑way Kelun pact—raises $185M for PD‑1xVEGF and ADC programs https://biobriefs.com/fda-leadership-turmoil-hoeg-installed BioBriefs en 2025-12-04T10:33:22Z FDA leadership turmoil: Høeg installed as Pazdur signals exit https://biobriefs.com/fda-retools-approvals-and-fees BioBriefs en 2025-12-04T10:33:22Z FDA retools approvals and fees: one pivotal trial and user-fee incentives https://biobriefs.com/capricors-deramiocel-shocks-market-phase BioBriefs en 2025-12-04T10:33:22Z Capricor’s deramiocel shocks market: Phase III success revives approval bid https://biobriefs.com/pharvaris-clinches-phase-iii-oral BioBriefs en 2025-12-04T10:33:22Z Pharvaris clinches Phase III: oral HAE pill positions to file in 2026 https://biobriefs.com/protego-raises-130m-to-fund BioBriefs en 2025-12-04T10:33:22Z Protego raises $130M to fund pivotal AL amyloidosis program https://biobriefs.com/triana-raises-120m-to-push BioBriefs en 2025-12-04T10:33:22Z Triana raises $120M to push molecular glue degrader toward clinic https://biobriefs.com/regeneron-and-tessera-agree-150m BioBriefs en 2025-12-04T10:33:22Z Regeneron and Tessera agree $150M pact to pursue gene‑writing therapy https://biobriefs.com/data-and-design-illumina-pivots BioBriefs en 2025-12-04T10:33:22Z Data and design: Illumina pivots to data sales as protein design goes open https://biobriefs.com/fda-reduces-primate-testing-draft BioBriefs en 2025-12-04T10:33:22Z FDA reduces primate testing: draft guidance aims to curb monkey use in mAb programs https://biobriefs.com/pegcetacoplan-shows-major-clinical-effect BioBriefs en 2025-12-04T10:33:22Z Pegcetacoplan shows major clinical effect in C3 glomerulopathy — NEJM report https://biobriefs.com/capricors-phase-iii-win-deramiocel BioBriefs en 2025-12-04T09:32:40Z Capricor’s Phase III win — deramiocel meets muscle and heart endpoints https://biobriefs.com/pharvaris-clocks-phase-iii-win BioBriefs en 2025-12-04T09:32:40Z Pharvaris clocks Phase III win: oral HAE pill hits primary and secondary goals https://biobriefs.com/fda-upheaval-top-drug-regulator BioBriefs en 2025-12-04T09:32:40Z FDA upheaval: top drug regulator to retire as acting appointments shift https://biobriefs.com/regeneron-inks-150m-deal-with BioBriefs en 2025-12-04T09:32:40Z Regeneron inks $150M deal with Tessera — gene writing push for AATD https://biobriefs.com/illumina-pivots-to-data-services BioBriefs en 2025-12-04T09:32:40Z Illumina pivots to data services — BioInsight targets pharma and AI models https://biobriefs.com/fda-proposes-cutting-primate-tests BioBriefs en 2025-12-04T09:32:40Z FDA proposes cutting primate tests for antibodies — new draft guidance surfaces https://biobriefs.com/cedars-sinai-researchers-unveil-ty1 BioBriefs en 2025-12-04T09:32:40Z Cedars‑Sinai researchers unveil TY1 — an RNA exomer that boosts DNA repair in heart injury https://biobriefs.com/pegcetacoplan-shows-strong-benefit-in BioBriefs en 2025-12-04T09:32:40Z Pegcetacoplan shows strong benefit in C3 glomerulopathy — first targeted complement therapy https://biobriefs.com/triana-raises-120m-to-push BioBriefs en 2025-12-04T09:32:40Z Triana raises $120M to push molecular glue degrader toward clinic https://biobriefs.com/rfdiffusion3-open-sourced-all-atom BioBriefs en 2025-12-04T09:32:40Z RFdiffusion3 open‑sourced — all‑atom protein design expands to DNA binders and enzymes https://biobriefs.com/capricors-duchenne-win-approval-fight BioBriefs en 2025-12-04T04:33:02Z Capricor’s Duchenne Win — Approval Fight Reopened https://biobriefs.com/pharvaris-pill-wins-phase-3 BioBriefs en 2025-12-04T04:33:02Z Pharvaris Pill Wins Phase 3 — FDA Filing Targeted 2026 https://biobriefs.com/regeneron-tessera-deal-150m-for BioBriefs en 2025-12-04T04:33:02Z Regeneron–Tessera Deal: $150m for AATD Gene Writing https://biobriefs.com/illuminas-data-pivot-selling-sequencing BioBriefs en 2025-12-04T04:33:02Z Illumina’s Data Pivot: Selling Sequencing Outputs to Pharma https://biobriefs.com/fda-turmoil-pazdur-exit-and BioBriefs en 2025-12-04T04:33:02Z FDA Turmoil: Pazdur Exit and New CDER Leadership https://biobriefs.com/rfdiffusion3-goes-open-source-all BioBriefs en 2025-12-04T04:33:02Z RFdiffusion3 Goes Open Source — All‑Atom Protein Design https://biobriefs.com/protego-raises-130m-to-advance BioBriefs en 2025-12-04T04:33:02Z Protego Raises $130M to Advance AL Amyloidosis Drug https://biobriefs.com/exmoor-ucl-tie-up-to BioBriefs en 2025-12-04T04:33:02Z eXmoor–UCL Tie‑Up to Speed Cell and Gene Therapy Translation https://biobriefs.com/fda-moves-to-cut-primate BioBriefs en 2025-12-04T04:33:02Z FDA Moves to Cut Primate Testing for Some Antibody Programs https://biobriefs.com/cedars-sinais-ty1-exomer-restores BioBriefs en 2025-12-04T04:33:02Z Cedars‑Sinai’s TY1 ‘Exomer’ Restores DNA Repair After Heart Injury https://biobriefs.com/capricors-duchenne-win-phase-3 BioBriefs en 2025-12-03T21:33:30Z Capricor’s Duchenne win: Phase 3 clears primary and cardiac endpoints https://biobriefs.com/triana-raises-big-120m-to BioBriefs en 2025-12-03T21:33:30Z Triana raises big: $120M to push molecular glue degrader to clinic https://biobriefs.com/protego-nets-130m-to-start BioBriefs en 2025-12-03T21:33:30Z Protego nets $130M to start pivotal AL amyloidosis trial https://biobriefs.com/regeneron-pays-tessera-150m-to BioBriefs en 2025-12-03T21:33:30Z Regeneron pays Tessera $150M to co-develop gene-writing therapy for AATD https://biobriefs.com/rfdiffusion3-open-sourced-baker-lab BioBriefs en 2025-12-03T21:33:30Z RFdiffusion3 open-sourced: Baker lab releases all-atom design model https://biobriefs.com/fda-moves-to-curb-primate BioBriefs en 2025-12-03T21:33:30Z FDA moves to curb primate testing for some antibody programs — draft guidance https://biobriefs.com/pharvaris-oral-hae-drug-wins BioBriefs en 2025-12-03T21:33:30Z Pharvaris’ oral HAE drug wins Phase 3 — rapid onset could challenge incumbent https://biobriefs.com/vandrias-mitophagy-drug-shows-target BioBriefs en 2025-12-03T21:33:30Z Vandria’s mitophagy drug shows target engagement — company eyes Series B to fund Phase 2 https://biobriefs.com/latus-bio-clears-ind-for BioBriefs en 2025-12-03T21:33:30Z Latus Bio clears IND for LTS‑101 in CLN2 — gets multiple orphan designations https://biobriefs.com/vectory-gains-ind-clearance-for BioBriefs en 2025-12-03T21:33:30Z Vectory gains IND clearance for vectorized antibody targeting TDP‑43 in ALS https://biobriefs.com/regeneron-backs-tesseras-gene-writing BioBriefs en 2025-12-03T16:33:00Z Regeneron backs Tessera’s gene-writing push: $150M upfront https://biobriefs.com/rfdiffusion3-open-sourced-atomic-protein BioBriefs en 2025-12-03T16:33:00Z RFdiffusion3 open-sourced: atomic protein design goes public https://biobriefs.com/fda-proposes-cutback-on-primate BioBriefs en 2025-12-03T16:33:00Z FDA proposes cutback on primate testing — draft guidance issued https://biobriefs.com/richard-pazdur-set-to-retire BioBriefs en 2025-12-03T16:33:00Z Richard Pazdur set to retire — more churn at FDA’s drug shop https://biobriefs.com/pfizer-backed-triana-raises-120m BioBriefs en 2025-12-03T16:33:00Z Pfizer-backed Triana raises $120M to take molecular glue into clinic https://biobriefs.com/protego-closes-130m-to-fund BioBriefs en 2025-12-03T16:33:00Z Protego closes $130M to fund pivotal AL amyloidosis trial https://biobriefs.com/capricor-wins-phase-3-deramiocel BioBriefs en 2025-12-03T16:33:00Z Capricor wins Phase 3: deramiocel improves heart and muscle function https://biobriefs.com/pharvaris-scores-phase-3-win BioBriefs en 2025-12-03T16:33:00Z Pharvaris scores Phase 3 win: rapid on-demand relief in HAE https://biobriefs.com/roche-wins-clearance-for-15 BioBriefs en 2025-12-03T16:33:00Z Roche wins clearance for 15-minute point-of-care Bordetella PCR test https://biobriefs.com/ind-clearances-open-clinics-for BioBriefs en 2025-12-03T16:33:00Z IND clearances open clinics for two CNS and rare-disease programs https://biobriefs.com/regeneron-backs-tessera-150m-pact BioBriefs en 2025-12-03T14:32:51Z Regeneron backs Tessera: $150m pact to write AATD genes https://biobriefs.com/protego-closes-130m-pivotal-push BioBriefs en 2025-12-03T14:32:51Z Protego closes $130m: Pivotal push for oral AL amyloidosis stabilizer https://biobriefs.com/pharvaris-scores-phase-3-win BioBriefs en 2025-12-03T14:32:51Z Pharvaris scores Phase 3 win – deucrictibant eases HAE attacks faster https://biobriefs.com/capricors-cell-therapy-phase-3 BioBriefs en 2025-12-03T14:32:51Z Capricor’s cell therapy: Phase 3 shows muscle and heart gains in Duchenne https://biobriefs.com/belite-cuts-lesion-growth-in BioBriefs en 2025-12-03T14:32:51Z Belite cuts lesion growth in Stargardt – Phase 3 hit https://biobriefs.com/janux-down-market-overreacts-to BioBriefs en 2025-12-03T14:32:51Z Janux down... market overreacts to prostate T‑cell engager data https://biobriefs.com/fda-pares-monkey-tests-draft BioBriefs en 2025-12-03T14:32:51Z FDA pares monkey tests: draft guidance cuts nonclinical monkey use for some mAbs https://biobriefs.com/prasad-memo-rattles-markets-vaccine BioBriefs en 2025-12-03T14:32:51Z Prasad memo rattles markets: vaccine policy debate dents developers’ stocks https://biobriefs.com/top-fda-drug-regulator-pazdur BioBriefs en 2025-12-03T14:32:51Z Top FDA drug regulator Pazdur to retire — sudden exit adds agency uncertainty https://biobriefs.com/profluent-raises-106m-to-scale BioBriefs en 2025-12-03T14:32:51Z Profluent raises $106m to scale AI‑driven protein design https://biobriefs.com/cder-chief-pazdur-set-to BioBriefs en 2025-12-03T10:32:35Z CDER chief Pazdur set to depart — agency leadership shaken https://biobriefs.com/fda-drafts-guidance-to-curb BioBriefs en 2025-12-03T10:32:35Z FDA drafts guidance to curb primate testing for some antibodies https://biobriefs.com/regeneron-plunks-down-150m-on BioBriefs en 2025-12-03T10:32:35Z Regeneron plunks down $150M on Tessera gene writing — one-and-done bets https://biobriefs.com/belites-oral-stargardt-drug-meets BioBriefs en 2025-12-03T10:32:35Z Belite’s oral Stargardt drug meets Phase 3 goal — path to first approval https://biobriefs.com/protego-secures-130m-to-push BioBriefs en 2025-12-03T10:32:35Z Protego secures $130M to push first-in-class AL amyloidosis program https://biobriefs.com/janux-shares-tumble-after-prostate BioBriefs en 2025-12-03T10:32:35Z Janux shares tumble after prostate T‑cell engager data update https://biobriefs.com/sma-gene-therapy-cleared-as BioBriefs en 2025-12-03T10:32:35Z SMA gene therapy cleared as DMD drug faces new limits — regulatory seesaw https://biobriefs.com/u-k-u-s-trade BioBriefs en 2025-12-03T10:32:35Z U.K.-U.S. trade deal lifts NICE threshold — U.K. to pay more for medicines https://biobriefs.com/generate-biomedicines-advances-tslp-antibody BioBriefs en 2025-12-03T10:32:35Z Generate:Biomedicines advances TSLP antibody into Phase 3 — AI‑driven program scales https://biobriefs.com/recursion-names-najat-khan-ceo BioBriefs en 2025-12-03T10:32:35Z Recursion names Najat Khan CEO — AI drug firm shifts toward clinic https://biobriefs.com/regeneron-backs-tessera-150m-bet BioBriefs en 2025-12-03T09:33:30Z Regeneron backs Tessera: $150M bet on gene writing https://biobriefs.com/pazdur-plans-exit-prasad-memo BioBriefs en 2025-12-03T09:33:30Z Pazdur plans exit — Prasad memo fuels agency turmoil https://biobriefs.com/u-k-will-pay-more BioBriefs en 2025-12-03T09:33:30Z U.K. will pay more for meds to avoid U.S. tariffs — deal struck https://biobriefs.com/tinlarebant-slows-stargardt-lesions-belite BioBriefs en 2025-12-03T09:33:30Z Tinlarebant slows Stargardt lesions — Belite posts Phase III success https://biobriefs.com/protego-nets-130m-advances-al BioBriefs en 2025-12-03T09:33:30Z Protego nets $130M — advances AL amyloidosis program https://biobriefs.com/janux-shares-tumble-50-after BioBriefs en 2025-12-03T09:33:30Z Janux shares tumble 50% after new prostate cancer data cut https://biobriefs.com/fda-draft-eliminate-some-monkey BioBriefs en 2025-12-03T09:33:30Z FDA draft: eliminate some monkey studies for monoclonal antibodies https://biobriefs.com/generate-moves-ai-engineered-tslp BioBriefs en 2025-12-03T09:33:30Z Generate moves AI‑engineered TSLP antibody into Phase III trials https://biobriefs.com/novartis-intrathecal-sma-therapy-cleared BioBriefs en 2025-12-03T09:33:30Z Novartis’ intrathecal SMA therapy cleared — Sarepta faces DMD setback https://biobriefs.com/who-guidance-combine-glp-1 BioBriefs en 2025-12-03T09:33:30Z WHO guidance: combine GLP‑1 drugs with intensive behavioral therapy https://biobriefs.com/top-fda-drug-regulator-pazdur BioBriefs en 2025-12-03T04:32:54Z Top FDA drug regulator Pazdur files to retire — agency leadership in flux https://biobriefs.com/fda-drafts-plan-to-cut BioBriefs en 2025-12-03T04:32:54Z FDA drafts plan to cut primate testing for antibody drugs — new safety pathways https://biobriefs.com/regeneron-bets-150m-on-tesseras BioBriefs en 2025-12-03T04:32:54Z Regeneron bets $150M on Tessera’s gene‑writing program — rare disease push https://biobriefs.com/belites-oral-tinlarebant-hits-phase BioBriefs en 2025-12-03T04:32:54Z Belite’s oral tinlarebant hits Phase III endpoint — FDA filing in view https://biobriefs.com/protego-secures-130m-to-push BioBriefs en 2025-12-03T04:32:54Z Protego secures $130M to push first‑in‑class AL amyloidosis drug toward pivotal https://biobriefs.com/cdmo-tie-ups-accelerate-lbp BioBriefs en 2025-12-03T04:32:54Z CDMO tie‑ups accelerate LBP and biologics scale‑up — Rentschler, Coriolis and Recipharm moves https://biobriefs.com/car-based-immunotherapies-advance-car BioBriefs en 2025-12-03T04:32:54Z CAR‑based immunotherapies advance — CAR‑NK enters clinic while CAR‑T pushes into CNS https://biobriefs.com/ai-and-protein-design-attract BioBriefs en 2025-12-03T04:32:54Z AI and protein design attract capital — Profluent funding and Lilly’s TuneLab reveal strategy https://biobriefs.com/vaccine-policy-shake-up-looms BioBriefs en 2025-12-03T04:32:54Z Vaccine policy shake‑up looms — FDA memo and scientists clash ahead of ACIP vote https://biobriefs.com/imvax-reports-survival-signal-in BioBriefs en 2025-12-03T04:32:54Z Imvax reports survival signal in glioblastoma Phase 2b — FDA meeting planned https://biobriefs.com/fda-drug-czar-exits-pazdur BioBriefs en 2025-12-02T21:33:11Z FDA drug czar exits: Pazdur files for retirement https://biobriefs.com/fda-narrows-primate-testing-for BioBriefs en 2025-12-02T21:33:11Z FDA narrows primate testing for antibodies: new draft guidance https://biobriefs.com/regeneron-bets-150m-on-tessera BioBriefs en 2025-12-02T21:33:11Z Regeneron bets $150M on Tessera gene writing—rare disease target https://biobriefs.com/belites-tinlarebant-wins-phase-iii BioBriefs en 2025-12-02T21:33:11Z Belite’s tinlarebant wins Phase III—first Stargardt success https://biobriefs.com/protego-raises-130m-to-push BioBriefs en 2025-12-02T21:33:11Z Protego raises $130M to push AL amyloidosis drug to pivotal https://biobriefs.com/vaccine-rule-fight-scientists-push BioBriefs en 2025-12-02T21:33:11Z Vaccine rule fight: scientists push to keep newborn hep B shot timing https://biobriefs.com/hiv-remission-case-ccr5d32-transplant BioBriefs en 2025-12-02T21:33:11Z HIV remission case: CCR5Δ32 transplant shows durable control https://biobriefs.com/liquid-biopsy-advances-ctdna-across BioBriefs en 2025-12-02T21:33:11Z Liquid biopsy advances: ctDNA across fluids and ultra‑sensitive sensors https://biobriefs.com/stem-cell-control-and-organoids BioBriefs en 2025-12-02T21:33:11Z Stem cell control and organoids: electrical steering and scaled lung models https://biobriefs.com/big-pharma-opens-ai-lab BioBriefs en 2025-12-02T21:33:11Z Big pharma opens AI lab doors—collaboration replaces secrecy https://biobriefs.com/regeneron-backs-tessera-150m-gene BioBriefs en 2025-12-02T16:33:07Z Regeneron backs Tessera: $150M gene-writing pact for AATD https://biobriefs.com/belites-tinlarebant-meets-phase-iii BioBriefs en 2025-12-02T16:33:07Z Belite’s tinlarebant meets Phase III — Stargardt filing in view https://biobriefs.com/protego-closes-130m-pushes-al BioBriefs en 2025-12-02T16:33:07Z Protego closes $130M — pushes AL amyloidosis drug to pivotal run https://biobriefs.com/generate-biomedicines-heads-to-phase BioBriefs en 2025-12-02T16:33:07Z Generate:Biomedicines heads to Phase 3 — TSLP antibody advances https://biobriefs.com/recursion-names-najat-khan-ceo BioBriefs en 2025-12-02T16:33:07Z Recursion names Najat Khan CEO — pivot to clinical proof points https://biobriefs.com/pfizer-halts-uc-candidate-tiziana BioBriefs en 2025-12-02T16:33:07Z Pfizer halts UC candidate — Tiziana to spin out IL‑6 asset https://biobriefs.com/leaked-cber-memo-roils-vaccine BioBriefs en 2025-12-02T16:33:07Z Leaked CBER memo roils vaccine market — policy overhaul proposed https://biobriefs.com/fda-clears-intrathecal-sma-gene BioBriefs en 2025-12-02T16:33:07Z FDA clears intrathecal SMA gene therapy — DMD program hit by new limits https://biobriefs.com/singapores-precise-teams-with-pharma BioBriefs en 2025-12-02T16:33:07Z Singapore’s PRECISE teams with pharma to mine 100K genomes https://biobriefs.com/icon-commits-300m-to-ai BioBriefs en 2025-12-02T16:33:07Z ICON commits $300M to AI and digital innovation over three years https://biobriefs.com/regeneron-bets-150m-on-tesseras BioBriefs en 2025-12-02T14:32:46Z Regeneron bets $150M on Tessera’s gene writer: TSRA‑196 pact https://biobriefs.com/belites-tinlarebant-clears-phase-iii BioBriefs en 2025-12-02T14:32:46Z Belite’s tinlarebant clears Phase III — FDA filing next https://biobriefs.com/protego-nets-130m-pivots-prot BioBriefs en 2025-12-02T14:32:46Z Protego nets $130M — pivots PROT‑001 toward pivotal study https://biobriefs.com/cber-memo-roils-markets-fda BioBriefs en 2025-12-02T14:32:46Z CBER memo roils markets: FDA vaccine rules under overhaul https://biobriefs.com/cytokinetics-first-approval-nears-prepares BioBriefs en 2025-12-02T14:32:46Z Cytokinetics’ first approval nears — prepares David vs. Goliath fight https://biobriefs.com/imvax-presses-fda-after-mixed BioBriefs en 2025-12-02T14:32:46Z Imvax presses FDA after mixed glioblastoma Phase 2b readout https://biobriefs.com/uk-raises-drug-prices-to BioBriefs en 2025-12-02T14:32:46Z UK raises drug prices to avert US pharma tariffs https://biobriefs.com/profluent-pulls-in-106m-scales BioBriefs en 2025-12-02T14:32:46Z Profluent pulls in $106M — scales AI protein design platform https://biobriefs.com/recursions-leadership-pivot-heavy-ai BioBriefs en 2025-12-02T14:32:46Z Recursion’s leadership pivot — heavy AI users reshape biotech https://biobriefs.com/eib-angelini-commit-eur150m-to BioBriefs en 2025-12-02T14:32:46Z EIB, Angelini commit €150M to seed Europe’s health startups https://biobriefs.com/regeneron-bankrolls-tessera-150m-gene BioBriefs en 2025-12-02T10:33:07Z Regeneron bankrolls Tessera: $150M gene‑writing pact https://biobriefs.com/protego-nets-130m-readies-al BioBriefs en 2025-12-02T10:33:07Z Protego nets $130M: readies AL amyloidosis pivotal study https://biobriefs.com/belite-s-pill-slows-stargardt BioBriefs en 2025-12-02T10:33:07Z Belite's pill slows Stargardt lesions – FDA filing eyed https://biobriefs.com/profluent-raises-106m-ai-protein BioBriefs en 2025-12-02T10:33:07Z Profluent raises $106M: AI protein design scales to therapeutics https://biobriefs.com/researchers-scale-lung-organoids-stirred BioBriefs en 2025-12-02T10:33:07Z Researchers scale lung organoids: stirred bioreactor enables bulk manufacture https://biobriefs.com/singapore-s-precise-taps-big BioBriefs en 2025-12-02T10:33:07Z Singapore's PRECISE taps big pharma: Asian genomics partnership formed https://biobriefs.com/fda-memo-sparks-sell-off BioBriefs en 2025-12-02T10:33:07Z FDA memo sparks sell‑off – vaccine developers brace for tougher rules https://biobriefs.com/stem-cell-transplant-cases-nudge BioBriefs en 2025-12-02T10:33:07Z Stem‑cell transplant cases nudge HIV remission narrative: durable control reported https://biobriefs.com/ind-clearance-and-phase-3 BioBriefs en 2025-12-02T10:33:07Z IND clearance and Phase‑3 launches: ideaya, Generate push oncology and immunology https://biobriefs.com/cdmo-and-cro-deals-accelerate BioBriefs en 2025-12-02T10:33:07Z CDMO and CRO deals accelerate commercial readiness in biologics and trials https://biobriefs.com/tessera-regeneron-ink-150m-gene BioBriefs en 2025-12-02T09:32:33Z Tessera, Regeneron ink $150M gene-writing pact – TSRA-196 development https://biobriefs.com/protego-closes-130m-series-b BioBriefs en 2025-12-02T09:32:33Z Protego closes $130M Series B – advances oral AL amyloidosis program to pivotal https://biobriefs.com/belites-tinlarebant-clears-phase-3 BioBriefs en 2025-12-02T09:32:33Z Belite’s tinlarebant clears Phase 3 – Stargardt approval path opens https://biobriefs.com/prasad-memo-roils-vaccine-sector BioBriefs en 2025-12-02T09:32:33Z Prasad memo roils vaccine sector – market and policy fallout https://biobriefs.com/us-uk-pharma-accord-no BioBriefs en 2025-12-02T09:32:33Z US-UK pharma accord: no tariffs in exchange for higher UK drug spending https://biobriefs.com/recipharm-advanced-bio-begins-ppq BioBriefs en 2025-12-02T09:32:33Z Recipharm Advanced Bio begins PPQ for Infant Bacterial Therapeutics’ LBP https://biobriefs.com/singapores-precise-partners-with-pharma BioBriefs en 2025-12-02T09:32:33Z Singapore’s PRECISE partners with pharma majors to mine Asian genomic data https://biobriefs.com/generate-biomedicines-advances-to-phase BioBriefs en 2025-12-02T09:32:33Z Generate:Biomedicines advances to Phase 3 – TSLP antibody enters pivotal testing https://biobriefs.com/q32-sells-complement-asset-to BioBriefs en 2025-12-02T09:32:33Z Q32 sells complement asset to Akebia — $12M upfront for rare kidney program https://biobriefs.com/craft-car-t-and-car BioBriefs en 2025-12-02T09:32:33Z CRAFT CAR T and CAR T for CNS tumors: engineering safer, broader cell therapies https://biobriefs.com/regeneron-bets-150m-on-tessera BioBriefs en 2025-12-02T04:32:52Z Regeneron bets $150M on Tessera: gene writing for AATD https://biobriefs.com/belite-posts-phase-3-win BioBriefs en 2025-12-02T04:32:52Z Belite posts Phase 3 win — Stargardt drug meets primary endpoint https://biobriefs.com/protego-raises-130m-pushes-al BioBriefs en 2025-12-02T04:32:52Z Protego raises $130M — pushes AL amyloidosis program to pivotal https://biobriefs.com/us-vaccine-path-under-rebuild BioBriefs en 2025-12-02T04:32:52Z US vaccine path under rebuild — Prasad memo sparks policy firestorm https://biobriefs.com/lundbeck-exits-avadel-chase-alkermes BioBriefs en 2025-12-02T04:32:52Z Lundbeck exits Avadel chase — Alkermes cleared to acquire https://biobriefs.com/q32-sells-complement-asset-to BioBriefs en 2025-12-02T04:32:52Z Q32 sells complement asset to Akebia: cash runway extended https://biobriefs.com/uk-us-pharma-price-pact BioBriefs en 2025-12-02T04:32:52Z UK‑US pharma price pact: U.K. loosens rules to avoid U.S. tariffs https://biobriefs.com/janux-data-shuffle-janx007-shows BioBriefs en 2025-12-02T04:32:52Z Janux data shuffle: JANX007 shows mixed early‑stage prostate results https://biobriefs.com/recursion-leadership-change-najat-khan BioBriefs en 2025-12-02T04:32:52Z Recursion leadership change: Najat Khan to take CEO baton https://biobriefs.com/scaled-lung-organoids-stirred-bioreactor BioBriefs en 2025-12-02T04:32:52Z Scaled lung organoids: stirred bioreactor enables bulk production https://biobriefs.com/regeneron-makes-150m-bet-on BioBriefs en 2025-12-01T21:32:24Z Regeneron makes $150M bet on gene writing: Tessera tie-up https://biobriefs.com/protego-raises-130m-to-push BioBriefs en 2025-12-01T21:32:24Z Protego raises $130M to push amyloidosis drug into pivotal test https://biobriefs.com/belites-pill-meets-phase-3 BioBriefs en 2025-12-01T21:32:24Z Belite’s pill meets Phase 3 endpoint: FDA filing next? https://biobriefs.com/fda-clears-intrathecal-sma-gene BioBriefs en 2025-12-01T21:32:24Z FDA clears intrathecal SMA gene therapy... while DMD hits fresh hurdles https://biobriefs.com/uk-ups-drug-spending-to BioBriefs en 2025-12-01T21:32:24Z UK ups drug spending to dodge U.S. tariffs: pricing deal struck https://biobriefs.com/china-approves-innovents-picankibart-first BioBriefs en 2025-12-01T21:32:24Z China approves Innovent’s picankibart: first domestic IL‑23p19 https://biobriefs.com/generate-biomedicines-moves-tslp-antibody BioBriefs en 2025-12-01T21:32:24Z Generate:Biomedicines moves TSLP antibody into Phase 3 https://biobriefs.com/fda-clears-ideaya-ind-for BioBriefs en 2025-12-01T21:32:24Z FDA clears Ideaya IND for IDE‑034: bispecific ADC enters clinic https://biobriefs.com/singapores-precise-taps-pharma-majors BioBriefs en 2025-12-01T21:32:24Z Singapore’s PRECISE taps pharma majors: Asian genomics alliance https://biobriefs.com/janux-reports-30-response-rate BioBriefs en 2025-12-01T21:32:24Z Janux reports 30% response rate in early JANX007 prostate data https://biobriefs.com/protego-raises-130m-gears-up BioBriefs en 2025-12-01T16:33:03Z Protego raises $130M — gears up for pivotal AL amyloidosis trial https://biobriefs.com/regeneron-commits-150m-tessera-deal BioBriefs en 2025-12-01T16:33:03Z Regeneron commits $150M... Tessera deal targets gene writing for AATD https://biobriefs.com/belites-phase-3-win-tinlarebant BioBriefs en 2025-12-01T16:33:03Z Belite’s Phase 3 win — tinlarebant clears primary endpoint in Stargardt https://biobriefs.com/generate-biomedicines-launches-phase-3 BioBriefs en 2025-12-01T16:33:03Z Generate:Biomedicines launches Phase 3 — TSLP antibody moves to registrational studies https://biobriefs.com/circular-genomics-closes-15m-series BioBriefs en 2025-12-01T16:33:03Z Circular Genomics closes $15M Series A — circRNA blood biomarker for Alzheimer’s https://biobriefs.com/morphocell-extends-series-a-with BioBriefs en 2025-12-01T16:33:03Z Morphocell extends Series A with $50M — scales tissue‑engineered liver programs https://biobriefs.com/analysts-initiate-coverage-on-billiontoone BioBriefs en 2025-12-01T16:33:03Z Analysts initiate coverage on BillionToOne — banks set bullish price targets https://biobriefs.com/ideaya-wins-ind-clearance-ide BioBriefs en 2025-12-01T16:33:03Z Ideaya wins IND clearance — IDE‑034 poised for first‑in‑human solid tumor study https://biobriefs.com/rnai-therapeutic-shows-functional-cure BioBriefs en 2025-12-01T16:33:03Z RNAi therapeutic shows functional‑cure promise for chronic hepatitis B https://biobriefs.com/regeneron-bets-150m-on-tesseras BioBriefs en 2025-12-01T14:31:52Z Regeneron bets $150M on Tessera’s gene writing: partnership signed https://biobriefs.com/protego-raises-130m-to-advance BioBriefs en 2025-12-01T14:31:52Z Protego raises $130M to advance oral amyloidosis candidate – pivotal trial planned https://biobriefs.com/generate-biomedicines-launches-two-phase BioBriefs en 2025-12-01T14:31:52Z Generate:Biomedicines launches two Phase 3 trials for TSLP antibody – AI-designed drug advances https://biobriefs.com/belite-wins-phase-3-for BioBriefs en 2025-12-01T14:31:52Z Belite wins Phase 3 for Stargardt drug – U.S. filing now in sight https://biobriefs.com/rnai-therapy-shows-functional-cure BioBriefs en 2025-12-01T14:31:52Z RNAi therapy shows functional‑cure potential for chronic hepatitis B in Nature Communications https://biobriefs.com/menin-inhibitors-advance-as-targeted BioBriefs en 2025-12-01T14:31:52Z Menin inhibitors advance as targeted therapy for KMT2A‑rearranged leukemia https://biobriefs.com/endpoints-signal-launches-bpsi-q4 BioBriefs en 2025-12-01T14:31:52Z Endpoints Signal launches; BPSI Q4 2025 reads 78 – biopharma mood stays dour https://biobriefs.com/fda-biosimilar-plan-collides-with BioBriefs en 2025-12-01T14:31:52Z FDA biosimilar plan collides with patent office policy – regulatory friction grows https://biobriefs.com/quantifying-a-synuclein-seeds-in BioBriefs en 2025-12-01T14:31:52Z Quantifying α‑synuclein seeds in CSF—new assay could change Parkinson’s trials https://biobriefs.com/tcr-therapy-and-vascular-research BioBriefs en 2025-12-01T14:31:52Z TCR therapy and vascular research map barriers in ovarian cancer treatment https://biobriefs.com/rnai-candidate-cuts-hbv-markers BioBriefs en 2025-12-01T10:32:23Z RNAi candidate cuts HBV markers — path to functional cure https://biobriefs.com/menin-inhibitors-breakthrough-targeted-option BioBriefs en 2025-12-01T10:32:23Z Menin inhibitors: breakthrough targeted option for KMT2A leukemia https://biobriefs.com/endpoint-dilution-saa-quantifies-a BioBriefs en 2025-12-01T10:32:23Z Endpoint dilution SAA quantifies α-syn seeds — diagnostic advance https://biobriefs.com/engineered-ace2-decoy-neutralizes-multi BioBriefs en 2025-12-01T10:32:23Z Engineered ACE2 decoy neutralizes multi-variant SARS-CoV-2 https://biobriefs.com/fda-biosimilar-push-runs-into BioBriefs en 2025-12-01T10:32:23Z FDA biosimilar push runs into patent-office resistance https://biobriefs.com/mtorc1-in-ilc2s-neuro-immune BioBriefs en 2025-12-01T10:32:23Z mTORC1 in ILC2s: neuro-immune axis drives allergic lung inflammation https://biobriefs.com/aml-survival-pathways-thrap3-and BioBriefs en 2025-12-01T10:32:23Z AML survival pathways: THRAP3 and RPPH1 drive therapy resistance https://biobriefs.com/tcr-therapy-in-ovarian-cancer BioBriefs en 2025-12-01T10:32:23Z TCR therapy in ovarian cancer: delivery and specificity challenges persist https://biobriefs.com/fucosidase-dependency-new-target-for BioBriefs en 2025-12-01T10:32:23Z Fucosidase dependency: new target for rotavirus and norovirus replication https://biobriefs.com/sepsis-outcomes-tied-to-igg BioBriefs en 2025-12-01T10:32:23Z Sepsis outcomes tied to IgG levels and ferroptosis mechanisms https://biobriefs.com/rnai-for-hbv-nature-communications BioBriefs en 2025-12-01T09:32:25Z RNAi for HBV: Nature Communications flags a possible functional cure https://biobriefs.com/menin-inhibitors-targeted-therapy-advances BioBriefs en 2025-12-01T09:32:25Z Menin inhibitors: targeted therapy advances for KMT2A‑rearranged leukemia https://biobriefs.com/ace2-decoy-receptor-neutralizes-sars BioBriefs en 2025-12-01T09:32:25Z ACE2 decoy receptor neutralizes SARS‑CoV‑2 variants — blocking mutants too https://biobriefs.com/jumbo-phage-targets-mbl-pseudomonas BioBriefs en 2025-12-01T09:32:25Z Jumbo phage targets MBL Pseudomonas — therapeutic candidate for resistant infections https://biobriefs.com/a-synuclein-seed-quantification-new BioBriefs en 2025-12-01T09:32:25Z α‑Synuclein seed quantification: new CSF assay sharpens Parkinson’s diagnostics https://biobriefs.com/renal-igfbp7-a-driver-of BioBriefs en 2025-12-01T09:32:25Z Renal IGFBP7: a driver of diabetic kidney disease identified https://biobriefs.com/sepsis-biology-splits-ferroptosis-role BioBriefs en 2025-12-01T09:32:25Z Sepsis biology splits: ferroptosis role and IgG as a prognostic biomarker https://biobriefs.com/ultrasound-triggered-panoptosis-piezoelectric-nanocatalysts BioBriefs en 2025-12-01T09:32:25Z Ultrasound‑triggered PANoptosis: piezoelectric nanocatalysts provoke tumor collapse https://biobriefs.com/aml-molecular-drivers-thrap3-and BioBriefs en 2025-12-01T09:32:25Z AML molecular drivers: THRAP3 and RPPH1 link to ferroptosis resistance and inflammation https://biobriefs.com/neprilysin-gene-transfer-lowers-ab BioBriefs en 2025-12-01T09:32:25Z Neprilysin gene transfer lowers Aβ and rescues behavior in Alzheimer models https://biobriefs.com/menin-inhibitors-targeted-strike-on BioBriefs en 2025-12-01T04:32:18Z Menin inhibitors: targeted strike on KMT2A leukemia https://biobriefs.com/fda-biosimilar-push-stalls-at BioBriefs en 2025-12-01T04:32:18Z FDA biosimilar push stalls at patent office — regulatory tug‑of‑war https://biobriefs.com/jumbo-phage-attacks-mbl-pseudomonas BioBriefs en 2025-12-01T04:32:18Z Jumbo phage attacks MBL Pseudomonas — a new MDR weapon https://biobriefs.com/ace2-decoy-receptor-neutralizes-sars BioBriefs en 2025-12-01T04:32:18Z ACE2 decoy receptor neutralizes SARS‑CoV‑2 variants https://biobriefs.com/crispr-assay-detects-bk-and BioBriefs en 2025-12-01T04:32:18Z CRISPR assay detects BK and JC viruses after kidney transplant https://biobriefs.com/mtorc1-in-ilc2s-a-neuro BioBriefs en 2025-12-01T04:32:18Z mTORC1 in ILC2s: a neuro‑immune switch for allergic lung disease https://biobriefs.com/sepsis-ferroptosis-mechanism-and-igg BioBriefs en 2025-12-01T04:32:18Z Sepsis: ferroptosis mechanism and IgG as prognostic biomarker https://biobriefs.com/t-cell-receptor-therapy-stalls BioBriefs en 2025-12-01T04:32:18Z T‑cell receptor therapy stalls in ovarian cancer — hurdles persist https://biobriefs.com/wearables-flag-preflare-physiology-in BioBriefs en 2025-12-01T04:32:18Z Wearables flag preflare physiology in rheumatoid arthritis https://biobriefs.com/fucosidase-is-required-for-rotavirus BioBriefs en 2025-12-01T04:32:18Z Fucosidase is required for rotavirus and norovirus replication https://biobriefs.com/fda-plan-to-speed-biosimilars BioBriefs en 2025-11-30T21:32:19Z FDA plan to speed biosimilars: patent office tightening could stall rollout https://biobriefs.com/ace2-decoy-receptor-neutralizes-mutant BioBriefs en 2025-11-30T21:32:19Z ACE2 decoy receptor... neutralizes mutant SARS‑CoV‑2 variants https://biobriefs.com/single-2-ml-mirikizumab-injection BioBriefs en 2025-11-30T21:32:19Z Single 2‑ml mirikizumab injection matches two 1‑ml doses — administration simplified https://biobriefs.com/sibiriline-halts-two-cell-death BioBriefs en 2025-11-30T21:32:19Z Sibiriline halts two cell‑death programs — a dual inhibitor emerges https://biobriefs.com/mtorc1-in-ilc2s-links-nerves BioBriefs en 2025-11-30T21:32:19Z mTORC1 in ILC2s links nerves to allergic lung inflammation https://biobriefs.com/plasma-lps-levels-forecast-mortality BioBriefs en 2025-11-30T21:32:19Z Plasma LPS levels forecast mortality in acutely ill children https://biobriefs.com/crispr-assay-flags-bk-and BioBriefs en 2025-11-30T21:32:19Z CRISPR assay flags BK and JC viruses after kidney transplant https://biobriefs.com/genetic-evidence-ties-gut-microbiota BioBriefs en 2025-11-30T21:32:19Z Genetic evidence ties gut microbiota to human bone mass https://biobriefs.com/ferroptosis-implicated-in-sepsis-and BioBriefs en 2025-11-30T21:32:19Z Ferroptosis implicated in sepsis and gastric cancer — targets multiply https://biobriefs.com/tumor-immunity-rewired-complement-genes BioBriefs en 2025-11-30T21:32:19Z Tumor immunity rewired: complement genes and TBK1/IKKε inhibition https://biobriefs.com/fdas-biosimilar-push-hits-patent BioBriefs en 2025-11-30T16:32:39Z FDA’s biosimilar push hits patent office https://biobriefs.com/ace2-decoy-receptor-blocks-mutant BioBriefs en 2025-11-30T16:32:39Z ACE2 decoy receptor... Blocks mutant SARS-CoV-2 https://biobriefs.com/crispr-assay-detects-bk-and BioBriefs en 2025-11-30T16:32:39Z CRISPR assay detects BK and JC viruses in transplant patients https://biobriefs.com/ferroptosis-drives-sepsis-igg-levels BioBriefs en 2025-11-30T16:32:39Z Ferroptosis drives sepsis — IgG levels predict outcomes https://biobriefs.com/sibiriline-first-dual-inhibitor-of BioBriefs en 2025-11-30T16:32:39Z Sibiriline: first dual inhibitor of necroptosis and ferroptosis https://biobriefs.com/cathepsin-l-dual-hit-targets BioBriefs en 2025-11-30T16:32:39Z Cathepsin L dual hit... Targets tumor growth and muscle wasting https://biobriefs.com/mirikizumab-single-2-ml-injection BioBriefs en 2025-11-30T16:32:39Z Mirikizumab: single 2-ml injection bioequivalent to two 1-ml shots https://biobriefs.com/mtorc1-in-ilc2s-links-neurons BioBriefs en 2025-11-30T16:32:39Z mTORC1 in ILC2s... Links neurons to allergic lung inflammation https://biobriefs.com/complement-genes-alter-pancreatic-cancer BioBriefs en 2025-11-30T16:32:39Z Complement genes: alter pancreatic cancer susceptibility and outcomes https://biobriefs.com/ultrasound-triggered-panoptosis-piezoelectric-nanocatalysts BioBriefs en 2025-11-30T16:32:39Z Ultrasound-triggered PANoptosis: piezoelectric nanocatalysts induce tumor death https://biobriefs.com/fda-biosimilar-plan-patent-office BioBriefs en 2025-11-30T14:32:35Z FDA biosimilar plan: patent office rules threaten rollout https://biobriefs.com/crispr-test-detects-bk-and BioBriefs en 2025-11-30T14:32:35Z CRISPR test detects BK and JC viruses after kidney transplant https://biobriefs.com/sibiriline-single-compound-blocks-necroptosis BioBriefs en 2025-11-30T14:32:35Z Sibiriline: single compound blocks necroptosis and ferroptosis https://biobriefs.com/anti-pd-1-plus-chemotherapy BioBriefs en 2025-11-30T14:32:35Z Anti‑PD‑1 plus chemotherapy rewires early hormone‑positive breast tumors https://biobriefs.com/complement-system-genes-linked-to BioBriefs en 2025-11-30T14:32:35Z Complement‑system genes linked to pancreatic cancer risk and outcomes https://biobriefs.com/beyond-brca-genomic-evolution-mapped BioBriefs en 2025-11-30T14:32:35Z Beyond BRCA: genomic evolution mapped in high‑grade serous ovarian cancer https://biobriefs.com/human-genetics-tie-gut-microbiota BioBriefs en 2025-11-30T14:32:35Z Human genetics tie gut microbiota to bone mass https://biobriefs.com/genome-graphs-reveal-structural-variation BioBriefs en 2025-11-30T14:32:35Z Genome graphs reveal structural variation driving TB evolution https://biobriefs.com/ultrasound-plus-piezoelectric-nanocatalysts-induces BioBriefs en 2025-11-30T14:32:35Z Ultrasound plus piezoelectric nanocatalysts induces tumor PANoptosis https://biobriefs.com/plasma-lps-levels-forecast-mortality BioBriefs en 2025-11-30T14:32:35Z Plasma LPS levels forecast mortality among acutely ill children https://biobriefs.com/mrna-retools-allogeneic-stem-cells BioBriefs en 2025-11-30T10:32:10Z mRNA retools allogeneic stem cells: DC‑25 emerges https://biobriefs.com/hcw11-018-t-cell-engager BioBriefs en 2025-11-30T10:32:10Z HCW11‑018 T‑cell engager shows pancreatic activity https://biobriefs.com/tead-inhibitor-vt-3989-targets BioBriefs en 2025-11-30T10:32:10Z TEAD inhibitor VT‑3989 targets NF2‑deficient tumors https://biobriefs.com/gd2-adc-m-3554-posts BioBriefs en 2025-11-30T10:32:10Z GD2 ADC M‑3554 posts potent antitumor effects https://biobriefs.com/boehringer-discloses-cgas-inhibitors-for BioBriefs en 2025-11-30T10:32:10Z Boehringer discloses cGAS inhibitors for inflammatory and fibrotic disease https://biobriefs.com/lilly-reports-rxfp1-agonists-for BioBriefs en 2025-11-30T10:32:10Z Lilly reports RXFP1 agonists for cardiorenal and kidney disease https://biobriefs.com/kymera-patents-stat6-inhibitors-for BioBriefs en 2025-11-30T10:32:10Z Kymera patents STAT6 inhibitors for broad disease portfolio https://biobriefs.com/single-2-ml-mirikizumab-injection BioBriefs en 2025-11-30T10:32:10Z Single 2‑ml mirikizumab injection proves bioequivalent to two 1‑ml doses https://biobriefs.com/sibiriline-a-dual-inhibitor-of BioBriefs en 2025-11-30T10:32:10Z Sibiriline: a dual inhibitor of necroptosis and ferroptosis https://biobriefs.com/complement-gene-variants-shape-pancreatic BioBriefs en 2025-11-30T10:32:10Z Complement gene variants shape pancreatic cancer susceptibility and outcomes https://biobriefs.com/eli-lilly-unveils-rxfp1-agonists BioBriefs en 2025-11-30T09:32:40Z Eli Lilly unveils RXFP1 agonists — broad therapeutic targets https://biobriefs.com/boehringer-ingelheim-files-cgas-inhibitors BioBriefs en 2025-11-30T09:32:40Z Boehringer Ingelheim files cGAS inhibitors — autoimmune and fibrotic stakes https://biobriefs.com/kymera-patents-stat6-inhibitors-inflammation BioBriefs en 2025-11-30T09:32:40Z Kymera patents STAT6 inhibitors — inflammation to oncology opportunity https://biobriefs.com/telix-faces-shareholder-class-action BioBriefs en 2025-11-30T09:32:40Z Telix faces shareholder class action notice — litigation risk for radiopharma https://biobriefs.com/kedrion-wins-eu-orphan-tag BioBriefs en 2025-11-30T09:32:40Z Kedrion wins EU orphan tag for aceruloplasminemia — rare‑disease push https://biobriefs.com/vivace-tead-inhibitor-shows-preclinical BioBriefs en 2025-11-30T09:32:40Z Vivace TEAD inhibitor shows preclinical hits in NF2 models — meningioma angle https://biobriefs.com/m-3554-adc-shows-anti BioBriefs en 2025-11-30T09:32:40Z M‑3554 ADC shows anti‑tumor activity — GD2 target in sarcoma and neuroblastoma https://biobriefs.com/mrna-engineering-bolsters-allogeneic-msc BioBriefs en 2025-11-30T09:32:40Z mRNA engineering bolsters allogeneic MSC therapy — DC‑25 emerges https://biobriefs.com/map-x-maps-malaria-protein BioBriefs en 2025-11-30T09:32:40Z MAP‑X maps malaria protein networks — dynamic interactome across lifecycle https://biobriefs.com/apalutamide-vs-enzalutamide-survival-debate BioBriefs en 2025-11-30T09:32:40Z Apalutamide vs enzalutamide: survival debate — comparative letters and analyses https://biobriefs.com/fda-proposes-plausible-mechanism-pathway BioBriefs en 2025-11-30T04:33:35Z FDA proposes plausible-mechanism pathway: expedited route for bespoke rare therapies https://biobriefs.com/off-the-shelf-mrna-vaccines BioBriefs en 2025-11-30T04:33:35Z Off-the-shelf mRNA vaccines: new immunotherapy approach for liver cancer https://biobriefs.com/bird-flu-tolerates-fever-pb1 BioBriefs en 2025-11-30T04:33:35Z Bird flu tolerates fever: PB1 gene enables high-temperature replication https://biobriefs.com/mrna-engineering-boosts-allogeneic-stem BioBriefs en 2025-11-30T04:33:35Z mRNA engineering boosts allogeneic stem cells: DC‑25 shows immunotherapy promise https://biobriefs.com/drugmakers-expand-small-molecule-arsenals BioBriefs en 2025-11-30T04:33:35Z Drugmakers expand small-molecule arsenals – Kymera’s STAT6 and Schrödinger’s mutant EGFR https://biobriefs.com/boehringer-discovers-cgas-inhibitors-new BioBriefs en 2025-11-30T04:33:35Z Boehringer discovers cGAS inhibitors: new candidates for interferon-driven diseases https://biobriefs.com/targeting-cell-death-pathways-cathepsin BioBriefs en 2025-11-30T04:33:35Z Targeting cell-death pathways: Cathepsin L and sibiriline offer dual benefits for cancer and degeneration https://biobriefs.com/kedrion-wins-eu-orphan-designation BioBriefs en 2025-11-30T04:33:35Z Kedrion wins EU orphan designation for aceruloplasminemia: plasma-derived therapy advances https://biobriefs.com/single-2-ml-mirikizumab-injection BioBriefs en 2025-11-30T04:33:35Z Single 2‑ml mirikizumab injection bioequivalent to two 1‑ml doses: administration simplified https://biobriefs.com/biotech-funding-lifelines-investors-press BioBriefs en 2025-11-30T04:33:35Z Biotech funding lifelines: investors press maturity, seek alternative financing https://biobriefs.com/fdas-plausible-mechanism-pathway-proposal BioBriefs en 2025-11-29T21:32:27Z FDA’s plausible‑mechanism pathway: proposal to speed bespoke rare‑disease approvals https://biobriefs.com/mrna-boosts-off-the-shelf BioBriefs en 2025-11-29T21:32:27Z mRNA boosts off‑the‑shelf MSC therapy: DC‑25 emerges https://biobriefs.com/off-the-shelf-mrna-cancer BioBriefs en 2025-11-29T21:32:27Z Off‑the‑shelf mRNA cancer vaccines: new candidates target liver tumors https://biobriefs.com/vt-3989-halts-nf2-deficient BioBriefs en 2025-11-29T21:32:27Z VT‑3989 halts NF2‑deficient tumor growth: Vivace posts preclinical efficacy https://biobriefs.com/m-3554-adc-shows-activity BioBriefs en 2025-11-29T21:32:27Z M‑3554 ADC shows activity in soft‑tissue sarcoma models – developer reports https://biobriefs.com/kymera-patents-stat6-inhibitors-new BioBriefs en 2025-11-29T21:32:27Z Kymera patents STAT6 inhibitors: new small‑molecule program disclosed https://biobriefs.com/boehringer-unveils-cgas-inhibitors-candidates BioBriefs en 2025-11-29T21:32:27Z Boehringer unveils cGAS inhibitors: candidates for fibrotic and autoimmune disease https://biobriefs.com/eli-lilly-files-rxfp1-agonists BioBriefs en 2025-11-29T21:32:27Z Eli Lilly files RXFP1 agonists: relaxin‑receptor program surfaces https://biobriefs.com/telix-shareholders-urged-to-contact BioBriefs en 2025-11-29T21:32:27Z Telix shareholders urged to contact Robbins LLP: TLX class action notice https://biobriefs.com/biotech-funding-lifelines-investors-counsel BioBriefs en 2025-11-29T21:32:27Z Biotech funding lifelines: investors counsel strategies to cross ‘valley of death’ https://biobriefs.com/kedrion-wins-ema-orphan-tag BioBriefs en 2025-11-29T16:33:21Z Kedrion wins EMA orphan tag — aceruloplasminemia plasma therapy https://biobriefs.com/vt-3989-shows-preclinical-potency BioBriefs en 2025-11-29T16:33:21Z VT-3989 shows preclinical potency — Vivace targets NF2-deficient tumors https://biobriefs.com/m-3554-adc-shows-strong BioBriefs en 2025-11-29T16:33:21Z M-3554 ADC shows strong activity: soft-tissue sarcoma models https://biobriefs.com/fimecs-astellas-expand-pact-two BioBriefs en 2025-11-29T16:33:21Z Fimecs, Astellas expand pact — two new targets added https://biobriefs.com/boehringer-reveals-cgas-inhibitors-pipeline BioBriefs en 2025-11-29T16:33:21Z Boehringer reveals cGAS inhibitors — pipeline for interferonopathies https://biobriefs.com/kymera-patents-stat6-inhibitors-wide BioBriefs en 2025-11-29T16:33:21Z Kymera patents STAT6 inhibitors: wide therapeutic claims https://biobriefs.com/mrna-engineering-upgrades-allogeneic-mscs BioBriefs en 2025-11-29T16:33:21Z mRNA engineering upgrades allogeneic MSCs — DC-25 emerges https://biobriefs.com/crispr-test-spots-bk-jc BioBriefs en 2025-11-29T16:33:21Z CRISPR test spots BK/JC after kidney transplant — rapid viral surveillance https://biobriefs.com/senescent-cell-vaccine-reduces-solid BioBriefs en 2025-11-29T16:33:21Z Senescent cell vaccine reduces solid tumors: study shows immune clearance https://biobriefs.com/vcs-urge-maturity-first-strategy BioBriefs en 2025-11-29T16:33:21Z VCs urge maturity-first strategy — how biotechs cross the 'valley of death' https://biobriefs.com/fdas-plausible-mechanism-pathway-experts BioBriefs en 2025-11-29T14:32:58Z FDA’s ‘plausible mechanism’ pathway: experts split https://biobriefs.com/valley-of-death-investors-push BioBriefs en 2025-11-29T14:32:58Z Valley of death: investors push biotechs to prove maturity https://biobriefs.com/mrna-retools-mscs-dc-25 BioBriefs en 2025-11-29T14:32:58Z mRNA retools MSCs: DC-25 aims for scalable cell therapy https://biobriefs.com/off-the-shelf-mrna-vaccines BioBriefs en 2025-11-29T14:32:58Z Off-the-shelf mRNA vaccines: new approach targets liver cancer https://biobriefs.com/kedrion-scores-eu-orphan-tag BioBriefs en 2025-11-29T14:32:58Z Kedrion scores EU orphan tag for aceruloplasminemia therapy https://biobriefs.com/preclinical-oncology-surge-tead-inhibitor BioBriefs en 2025-11-29T14:32:58Z Preclinical oncology surge: TEAD inhibitor and GD2 ADC show potency https://biobriefs.com/pancreatic-t-cell-engager-shows BioBriefs en 2025-11-29T14:32:58Z Pancreatic T‑cell engager shows traction – gene‑editing delivery follows https://biobriefs.com/wgs-from-ffpe-clinical-grade BioBriefs en 2025-11-29T14:32:58Z WGS from FFPE: clinical‑grade genomes from archived tissue https://biobriefs.com/car-macrophages-cut-liver-fibrosis BioBriefs en 2025-11-29T14:32:58Z CAR‑macrophages cut liver fibrosis… NEK7 links mitochondrial control https://biobriefs.com/boehringer-reveals-cgas-inhibitors-kymera BioBriefs en 2025-11-29T14:32:58Z Boehringer reveals cGAS inhibitors; Kymera patents STAT6 tools https://biobriefs.com/fdas-plausible-mechanism-pathway-streamlined BioBriefs en 2025-11-29T10:32:29Z FDA’s plausible mechanism pathway: Streamlined route for bespoke rare-disease treatments https://biobriefs.com/nmpa-clears-jmt-206-cspc BioBriefs en 2025-11-29T10:32:29Z NMPA clears JMT-206: CSPC moves obesity candidate to clinic https://biobriefs.com/sk-biopharma-licenses-wt-7695 BioBriefs en 2025-11-29T10:32:29Z SK Biopharma licenses WT‑7695: Acquires global rights to preclinical radiopharmaceutical https://biobriefs.com/crisprbits-nets-3m-to-scale BioBriefs en 2025-11-29T10:32:29Z CrisprBits nets $3M... to scale CRISPR diagnostics and R&D https://biobriefs.com/wgs-from-ffpe-new-method BioBriefs en 2025-11-29T10:32:29Z WGS from FFPE—New method unlocks tumor genomes for precision oncology https://biobriefs.com/mrna-engineered-mscs-dc-25 BioBriefs en 2025-11-29T10:32:29Z mRNA‑engineered MSCs: DC‑25 advances allogeneic cell immunotherapy https://biobriefs.com/car-macrophages-reverse-liver-fibrosis BioBriefs en 2025-11-29T10:32:29Z CAR‑macrophages reverse liver fibrosis in mice—Preclinical proof https://biobriefs.com/microbial-b-glucuronidases-drive-colorectal BioBriefs en 2025-11-29T10:32:29Z Microbial β‑glucuronidases drive colorectal cancer... New Nature Communications study https://biobriefs.com/off-the-shelf-mrna-vaccines BioBriefs en 2025-11-29T10:32:29Z Off‑the‑shelf mRNA vaccines target liver cancer: Preclinical immunotherapy advance https://biobriefs.com/target-nsd2-reverses-drug-resistance BioBriefs en 2025-11-29T10:32:29Z Target NSD2—Reverses drug resistance in neuroendocrine prostate cancer https://biobriefs.com/aspen-raises-115m-scales-autologous BioBriefs en 2025-11-29T09:32:39Z Aspen raises $115m – scales autologous iPSC Parkinson’s program https://biobriefs.com/mrna-engineering-transforms-off-the BioBriefs en 2025-11-29T09:32:39Z mRNA engineering transforms off‑the‑shelf MSCs... DC‑25 emerges https://biobriefs.com/car-macrophage-therapy-reverses-liver BioBriefs en 2025-11-29T09:32:39Z CAR‑macrophage therapy reverses liver fibrosis in mice https://biobriefs.com/next-gen-prmt5-inhibitor-drives BioBriefs en 2025-11-29T09:32:39Z Next‑gen PRMT5 inhibitor drives antitumor activity – TNG‑456 https://biobriefs.com/tead-inhibitor-vt-3989-curbs BioBriefs en 2025-11-29T09:32:39Z TEAD inhibitor VT‑3989 curbs NF2‑deficient tumor growth https://biobriefs.com/boehringer-finds-cgas-inhibitors-new BioBriefs en 2025-11-29T09:32:39Z Boehringer finds cGAS inhibitors – new tools against interferonopathies https://biobriefs.com/kymera-patents-stat6-inhibitors-expanding BioBriefs en 2025-11-29T09:32:39Z Kymera patents STAT6 inhibitors – expanding inflammation and oncology reach https://biobriefs.com/protein-degradation-race-blueprints-cdk4 BioBriefs en 2025-11-29T09:32:39Z Protein‑degradation race: Blueprint’s CDK4 PROTAC and Gluetacs’ molecular glues https://biobriefs.com/eli-lilly-discloses-rxfp1-agonists BioBriefs en 2025-11-29T09:32:39Z Eli Lilly discloses RXFP1 agonists – cardio‑renal pipeline expansion https://biobriefs.com/crisprbits-bags-3m-expands-crispr BioBriefs en 2025-11-29T09:32:39Z CrisprBits bags $3m – expands CRISPR diagnostics and R&D https://biobriefs.com/aspen-neuroscience-raises-115m-series BioBriefs en 2025-11-29T04:32:04Z Aspen Neuroscience Raises $115M Series C to Scale Parkinson’s iPSC Therapy https://biobriefs.com/crisprbits-secures-3m-pre-series BioBriefs en 2025-11-29T04:32:04Z CrisprBits Secures $3M Pre‑Series A to Expand CRISPR Diagnostics https://biobriefs.com/cspc-cleared-to-start-clinical BioBriefs en 2025-11-29T04:32:04Z CSPC Cleared to Start Clinical Trials of JMT‑206 for Obesity in China https://biobriefs.com/sk-biopharma-licenses-wt-7695 BioBriefs en 2025-11-29T04:32:04Z SK Biopharma Licenses WT‑7695 Radiopharmaceutical From WARF https://biobriefs.com/kedrion-wins-ema-orphan-designation BioBriefs en 2025-11-29T04:32:04Z Kedrion Wins EMA Orphan Designation for Aceruloplasminemia Therapy https://biobriefs.com/talquetamab-outperforms-physician-choice-in BioBriefs en 2025-11-29T04:32:04Z Talquetamab Outperforms Physician Choice in Relapsed/Refractory Myeloma Study https://biobriefs.com/vt-3989-tead-inhibitor-shows BioBriefs en 2025-11-29T04:32:04Z VT‑3989 TEAD Inhibitor Shows Preclinical Activity in NF2‑Deficient Tumors https://biobriefs.com/tng-456-a-next-gen BioBriefs en 2025-11-29T04:32:04Z TNG‑456, a Next‑Gen PRMT5 Inhibitor, Shows Brain‑Active Antitumor Efficacy https://biobriefs.com/mrna-engineered-allogeneic-cells-and BioBriefs en 2025-11-29T04:32:04Z mRNA‑Engineered Allogeneic Cells and Off‑the‑Shelf mRNA Vaccines Advance Immuno‑oncology https://biobriefs.com/new-small-molecule-and-immune BioBriefs en 2025-11-29T04:32:04Z New Small‑Molecule and Immune Targets Disclosed — STAT6 and cGAS Inhibitors https://biobriefs.com/aspen-raises-115m-scales-personalized BioBriefs en 2025-11-28T21:32:44Z Aspen raises $115m: scales personalized Parkinson’s cell therapy https://biobriefs.com/fdas-plausible-mechanism-pathway-rare BioBriefs en 2025-11-28T21:32:44Z FDA’s plausible mechanism pathway...rare-disease approvals debated https://biobriefs.com/u-k-budget-boosts-venture BioBriefs en 2025-11-28T21:32:44Z U.K. budget boosts venture funding – lab costs rise for biotechs https://biobriefs.com/crisprbits-bags-3m-investors-push BioBriefs en 2025-11-28T21:32:44Z CrisprBits bags $3m...investors push maturity to cross valley of death https://biobriefs.com/allogeneic-cell-therapies-advance-inkt BioBriefs en 2025-11-28T21:32:44Z Allogeneic cell therapies advance: iNKT cells and mRNA‑enhanced MSCs https://biobriefs.com/china-clears-jmt-206-glp BioBriefs en 2025-11-28T21:32:44Z China clears JMT-206...GLP-1 drugs still pose unanswered safety and efficacy questions https://biobriefs.com/senescent-cell-immunization-two-reports BioBriefs en 2025-11-28T21:32:44Z Senescent cell immunization: two reports propose tumor-targeting vaccine strategy https://biobriefs.com/mechanisms-meet-therapeutics-nek7-biology BioBriefs en 2025-11-28T21:32:44Z Mechanisms meet therapeutics: NEK7 biology and CAR-macrophages attack liver fibrosis https://biobriefs.com/next-gen-oncology-inhibitors-prmt5 BioBriefs en 2025-11-28T21:32:44Z Next‑gen oncology inhibitors: PRMT5 and TEAD programs show preclinical traction https://biobriefs.com/wgs-from-ffpe-method-unlocks BioBriefs en 2025-11-28T21:32:44Z WGS from FFPE: method unlocks archival tumor genomes https://biobriefs.com/aspen-raises-115m-series-c BioBriefs en 2025-11-28T16:33:07Z Aspen raises $115m Series C: scales iPSC Parkinson’s program https://biobriefs.com/vigencells-lymphoma-cell-therapy-meets BioBriefs en 2025-11-28T16:33:07Z Vigencell’s lymphoma cell therapy meets phase II endpoint – regulatory move planned https://biobriefs.com/cspc-cleared-to-start-jmt BioBriefs en 2025-11-28T16:33:07Z CSPC cleared to start JMT‑206 obesity trials in China – NMPA gives green light https://biobriefs.com/novo-files-high-dose-wegovy BioBriefs en 2025-11-28T16:33:07Z Novo files high‑dose Wegovy with FDA – voucher to expedite review https://biobriefs.com/drug-pricing-shakeup-cms-cuts BioBriefs en 2025-11-28T16:33:07Z Drug pricing shakeup: CMS cuts and MFN guidance reshape GLP‑1 economics https://biobriefs.com/sk-biopharma-in-licenses-wt BioBriefs en 2025-11-28T16:33:07Z SK Biopharma in‑licenses WT‑7695: radiopharmaceutical rights inked https://biobriefs.com/wgs-from-ffpe-robust-method BioBriefs en 2025-11-28T16:33:07Z WGS from FFPE: robust method unlocks archival tumor genomes https://biobriefs.com/allogeneic-ipsc-inkt-cells-tested BioBriefs en 2025-11-28T16:33:07Z Allogeneic iPSC‑iNKT cells tested in head and neck cancer – early clinical signals https://biobriefs.com/crisprbits-lands-3m-pre-series BioBriefs en 2025-11-28T16:33:07Z CrisprBits lands $3m pre‑Series A – expands CRISPR diagnostics and R&D https://biobriefs.com/fdas-plausible-mechanism-pathway-experts BioBriefs en 2025-11-28T16:33:07Z FDA’s ‘plausible mechanism pathway’: experts split on bespoke rare‑disease route https://biobriefs.com/aspen-raises-115m-scales-autologous BioBriefs en 2025-11-28T14:32:47Z Aspen raises $115m – scales autologous Parkinson’s iPSC program https://biobriefs.com/cspc-cleared-to-test-jmt BioBriefs en 2025-11-28T14:32:47Z CSPC cleared to test JMT‑206 in China: obesity clinic entry granted https://biobriefs.com/novo-files-high-dose-wegovy BioBriefs en 2025-11-28T14:32:47Z Novo files high‑dose Wegovy – voucher expedites FDA review https://biobriefs.com/cms-posts-second-drug-price BioBriefs en 2025-11-28T14:32:47Z CMS posts second drug‑price list… biopharma braces for deeper cuts https://biobriefs.com/cell-therapy-momentum-ipsc-inkt BioBriefs en 2025-11-28T14:32:47Z Cell therapy momentum... iPSC‑iNKT and VT‑EBV‑N hit clinical milestones https://biobriefs.com/sk-biopharma-inks-warf-license BioBriefs en 2025-11-28T14:32:47Z SK Biopharma inks WARF license for WT‑7695 radiopharmaceutical https://biobriefs.com/drug-degradation-race-blueprint-patents BioBriefs en 2025-11-28T14:32:47Z Drug‑degradation race: Blueprint patents CDK4 PROTACs; Gluetacs shows molecular glues https://biobriefs.com/early-stage-biotech-funding-crisprbits BioBriefs en 2025-11-28T14:32:47Z Early‑stage biotech funding: CrisprBits raises $3m; Myrio touts novel binder tech https://biobriefs.com/fda-policy-shifts-plausible-mechanism BioBriefs en 2025-11-28T14:32:47Z FDA policy shifts: 'Plausible mechanism' for bespoke drugs and companion diagnostics reclassification https://biobriefs.com/next-gen-prmt5-inhibitor-shows BioBriefs en 2025-11-28T14:32:47Z Next‑gen PRMT5 inhibitor shows preclinical brain tumor activity; PRMT5 linked to cardiac risk https://biobriefs.com/otsuka-wins-accelerated-fda-nod BioBriefs en 2025-11-28T10:32:50Z Otsuka wins accelerated FDA nod for IgA nephropathy: Voyxact clears 9-month endpoint https://biobriefs.com/cms-sets-deep-medicare-cuts BioBriefs en 2025-11-28T10:32:50Z CMS sets deep Medicare cuts: 15 drugs to see 2027 price caps https://biobriefs.com/aspen-raises-115m-to-scale BioBriefs en 2025-11-28T10:32:50Z Aspen raises $115M to scale autologous iPSC Parkinson’s program https://biobriefs.com/novo-files-high-dose-wegovy BioBriefs en 2025-11-28T10:32:50Z Novo files high‑dose Wegovy with FDA using voucher: fast track to higher semaglutide dose https://biobriefs.com/fda-proposes-reclassifying-companion-diagnostics BioBriefs en 2025-11-28T10:32:50Z FDA proposes reclassifying companion diagnostics to Class II: 510(k) pathway eyed https://biobriefs.com/allogeneic-ipsc-inkt-cell-therapy BioBriefs en 2025-11-28T10:32:50Z Allogeneic iPSC‑iNKT cell therapy posts Phase 1 data in recurrent head and neck cancer https://biobriefs.com/tangram-seeks-uk-clearance-to BioBriefs en 2025-11-28T10:32:50Z Tangram seeks UK clearance to test TGM‑312 in MASH — phase I/II CTA filed https://biobriefs.com/epigenetic-editing-proposed-to-remove BioBriefs en 2025-11-28T10:32:50Z Epigenetic editing proposed to remove prion protein — Sonia Vallabh shows data https://biobriefs.com/vigencells-antigen-specific-t-cell BioBriefs en 2025-11-28T10:32:50Z Vigencell’s antigen‑specific T‑cell therapy hits phase II endpoint in NKT lymphoma https://biobriefs.com/astrazeneca-unveils-semi-automated-dual BioBriefs en 2025-11-28T10:32:50Z AstraZeneca unveils semi‑automated dual LC‑MS screen to rescue oligo candidates https://biobriefs.com/aspen-raises-115m-scales-ipsc BioBriefs en 2025-11-28T09:32:52Z Aspen raises $115m: scales iPSC Parkinson’s program https://biobriefs.com/otsukas-voyxact-cleared-first-april BioBriefs en 2025-11-28T09:32:52Z Otsuka’s Voyxact cleared: first APRIL blocker for IgAN https://biobriefs.com/cms-sets-2027-prices-major BioBriefs en 2025-11-28T09:32:52Z CMS sets 2027 prices – major drugs face steep negotiated cuts https://biobriefs.com/novo-submits-high-dose-wegovy BioBriefs en 2025-11-28T09:32:52Z Novo submits high‑dose Wegovy: uses voucher to speed FDA review https://biobriefs.com/fda-proposes-reclassifying-companion-diagnostics BioBriefs en 2025-11-28T09:32:52Z FDA proposes reclassifying companion diagnostics: 510(k) pathway eyed https://biobriefs.com/allogeneic-ipsc-inkt-cells-enter BioBriefs en 2025-11-28T09:32:52Z Allogeneic iPSC‑iNKT cells enter clinic: phase 1 head‑and‑neck study reported https://biobriefs.com/tng-456-shows-brain-tumor BioBriefs en 2025-11-28T09:32:52Z TNG‑456 shows brain‑tumor activity: next‑gen PRMT5 inhibitor emerges https://biobriefs.com/astrazenecas-semi-automated-lc-ms BioBriefs en 2025-11-28T09:32:52Z AstraZeneca’s semi‑automated LC‑MS: gives oligo candidates a second chance https://biobriefs.com/crisprbits-nets-3m-funds-crispr BioBriefs en 2025-11-28T09:32:52Z CrisprBits nets $3m: funds CRISPR diagnostics, R&D expansion https://biobriefs.com/tangram-seeks-mhra-clearance-tgm BioBriefs en 2025-11-28T09:32:52Z Tangram seeks MHRA clearance: TGM‑312 head‑to‑head for MASH https://biobriefs.com/aspen-raises-115m-scales-ipsc BioBriefs en 2025-11-28T04:32:37Z Aspen raises $115m—scales iPSC Parkinson’s program https://biobriefs.com/fda-approves-voyxact-first-april BioBriefs en 2025-11-28T04:32:37Z FDA approves Voyxact: first APRIL blocker for IgA nephropathy https://biobriefs.com/cms-sets-2027-medicare-prices BioBriefs en 2025-11-28T04:32:37Z CMS sets 2027 Medicare prices—semaglutide among steep cuts https://biobriefs.com/fda-proposes-reclassifying-companion-diagnostics BioBriefs en 2025-11-28T04:32:37Z FDA proposes reclassifying companion diagnostics: 510(k) route suggested https://biobriefs.com/tangram-seeks-mhra-clearance-for BioBriefs en 2025-11-28T04:32:37Z Tangram seeks MHRA clearance for TGM‑312 in MASH trials https://biobriefs.com/china-clears-cspcs-jmt-206 BioBriefs en 2025-11-28T04:32:37Z China clears CSPC’s JMT‑206 to enter obesity trials https://biobriefs.com/sk-biopharma-licenses-preclinical-radiopharmaceutical BioBriefs en 2025-11-28T04:32:37Z SK Biopharma licenses preclinical radiopharmaceutical WT‑7695 from WARF https://biobriefs.com/vigencells-antigen-specific-t-cells BioBriefs en 2025-11-28T04:32:37Z Vigencell’s antigen‑specific T cells hit phase II endpoint—Korea filing planned https://biobriefs.com/allogeneic-ipsc-derived-inkt-cells BioBriefs en 2025-11-28T04:32:37Z Allogeneic iPSC‑derived iNKT cells enter clinic for recurrent head and neck cancer https://biobriefs.com/robust-wgs-from-ffpe-tissue BioBriefs en 2025-11-28T04:32:37Z Robust WGS from FFPE tissue unlocks clinical‑grade oncology sequencing https://biobriefs.com/aspen-raises-115m-scales-ipsc BioBriefs en 2025-11-27T21:33:11Z Aspen raises $115M – scales iPSC Parkinson’s program https://biobriefs.com/fda-clears-otsukas-voyxact-first BioBriefs en 2025-11-27T21:33:11Z FDA clears Otsuka’s Voyxact: first APRIL inhibitor for IgAN https://biobriefs.com/medicare-price-cuts-land-cms BioBriefs en 2025-11-27T21:33:11Z Medicare price cuts land: CMS sets 2027 negotiated rates – semaglutide included https://biobriefs.com/fda-delays-ascendis-decision-three BioBriefs en 2025-11-27T21:33:11Z FDA delays Ascendis decision – three‑month review on TransCon CNP https://biobriefs.com/allogeneic-ipsc-derived-inkt-cells BioBriefs en 2025-11-27T21:33:11Z Allogeneic iPSC‑derived iNKT cells tested in recurrent head‑and‑neck cancer https://biobriefs.com/vigencells-vt-ebv-n-meets BioBriefs en 2025-11-27T21:33:11Z Vigencell’s VT‑EBV‑N meets phase II endpoint – firm eyes conditional approval in South Korea https://biobriefs.com/in-vivo-gene-editing-pushes BioBriefs en 2025-11-27T21:33:11Z In vivo gene editing pushes forward – delivery and timing remain the bottlenecks https://biobriefs.com/mrna-peptibodies-eradicate-mdr-pneumonia BioBriefs en 2025-11-27T21:33:11Z mRNA peptibodies eradicate MDR pneumonia in mice – new delivery approach https://biobriefs.com/fda-proposes-reclassifying-companion-diagnostics BioBriefs en 2025-11-27T21:33:11Z FDA proposes reclassifying companion diagnostics to Class II – 510(k) route eyed https://biobriefs.com/cspc-clears-jmt-206-to BioBriefs en 2025-11-27T21:33:11Z CSPC clears JMT‑206 to enter clinic in China for obesity trials https://biobriefs.com/fda-greenlights-otsukas-voyxact-first BioBriefs en 2025-11-27T16:32:48Z FDA greenlights Otsuka’s Voyxact — first APRIL blocker for IgAN https://biobriefs.com/cms-sets-medicare-prices-for BioBriefs en 2025-11-27T16:32:48Z CMS sets Medicare prices for Wegovy, Ozempic and 13 drugs — 2027 cuts unveiled https://biobriefs.com/novo-files-high-dose-wegovy BioBriefs en 2025-11-27T16:32:48Z Novo files high‑dose Wegovy — voucher speeds FDA review https://biobriefs.com/aspen-raises-115m-to-scale BioBriefs en 2025-11-27T16:32:48Z Aspen raises $115M to scale personalized Parkinson’s iPSC therapy https://biobriefs.com/allogeneic-ipsc-derived-inkt-cells BioBriefs en 2025-11-27T16:32:48Z Allogeneic iPSC‑derived iNKT cells show safety signals in head‑and‑neck phase 1 https://biobriefs.com/tangram-files-cta-for-tgm BioBriefs en 2025-11-27T16:32:48Z Tangram files CTA for TGM‑312 in MASH — phase I/II planned https://biobriefs.com/vigencells-antigen-specific-t-cell BioBriefs en 2025-11-27T16:32:48Z Vigencell’s antigen‑specific T‑cell therapy hits phase II endpoint in NKTCL https://biobriefs.com/mrna-peptibodies-eradicate-multidrug-resistant BioBriefs en 2025-11-27T16:32:48Z mRNA peptibodies eradicate multidrug‑resistant pneumonia in mice — lung delivery breakthrough https://biobriefs.com/usp-issues-viral-vector-standards BioBriefs en 2025-11-27T16:32:48Z USP issues viral‑vector standards to steady gene‑therapy manufacturing https://biobriefs.com/bracco-limula-and-univ-of BioBriefs en 2025-11-27T16:32:48Z Bracco, Limula and Univ. of Fribourg team up to automate cell‑therapy manufacturing https://biobriefs.com/fda-clears-voyxact-otsukas-anti BioBriefs en 2025-11-27T14:32:51Z FDA clears Voyxact: Otsuka’s anti‑APRIL antibody for IgA nephropathy https://biobriefs.com/cms-unveils-ira-prices-wegovy BioBriefs en 2025-11-27T14:32:51Z CMS unveils IRA prices — Wegovy and Ozempic among high‑profile cuts https://biobriefs.com/novartis-expands-gene-therapy-access BioBriefs en 2025-11-27T14:32:51Z Novartis expands gene‑therapy access: Itvisma approved for older SMA patients https://biobriefs.com/aspen-raises-115m-to-scale BioBriefs en 2025-11-27T14:32:51Z Aspen raises $115M to scale autologous iPSC cell therapy for Parkinson’s https://biobriefs.com/tangram-seeks-mhra-clearance-to BioBriefs en 2025-11-27T14:32:51Z Tangram seeks MHRA clearance to test TGM‑312 for metabolic‑associated steatohepatitis https://biobriefs.com/pioneering-allogeneic-ipsc-derived-inkt BioBriefs en 2025-11-27T14:32:51Z Pioneering allogeneic iPSC‑derived iNKT cells enter clinic for head and neck cancer https://biobriefs.com/fda-proposes-reclassifying-companion-diagnostics BioBriefs en 2025-11-27T14:32:51Z FDA proposes reclassifying companion diagnostics to speed market entry https://biobriefs.com/boltzgen-debuts-mit-unveils-generative BioBriefs en 2025-11-27T14:32:51Z BoltzGen debuts... MIT unveils generative AI model aimed at molecule design https://biobriefs.com/mrna-encoded-peptibody-therapeutics-eradicate BioBriefs en 2025-11-27T14:32:51Z mRNA‑encoded peptibody therapeutics eradicate multidrug‑resistant pneumonia in mice https://biobriefs.com/cell-type-inference-in-cf BioBriefs en 2025-11-27T14:32:51Z Cell‑type inference in cf‑nucleic acid liquid biopsies expands noninvasive diagnostics https://biobriefs.com/otsuka-wins-fda-ok-for BioBriefs en 2025-11-27T10:32:45Z Otsuka wins FDA OK for Voyxact — first APRIL blocker for IgA nephropathy https://biobriefs.com/novartis-expands-sma-gene-therapy BioBriefs en 2025-11-27T10:32:45Z Novartis expands SMA gene therapy: Itvisma cleared for patients 2 and older https://biobriefs.com/cms-names-2027-medicare-prices BioBriefs en 2025-11-27T10:32:45Z CMS names 2027 Medicare prices: Wegovy, Ozempic and 13 others hit by negotiated cuts https://biobriefs.com/astrazeneca-doubles-down-on-u BioBriefs en 2025-11-27T10:32:45Z AstraZeneca doubles down on U.S. biologics: $2 billion Maryland expansion https://biobriefs.com/aspen-raises-115m-scales-autologous BioBriefs en 2025-11-27T10:32:45Z Aspen raises $115m — scales autologous iPSC Parkinson’s program https://biobriefs.com/tangram-files-uk-trial-application BioBriefs en 2025-11-27T10:32:45Z Tangram files UK trial application for TGM‑312 in MASH https://biobriefs.com/toolgen-geneditbio-cross-license-to BioBriefs en 2025-11-27T10:32:45Z Toolgen, Geneditbio cross‑license to advance in‑vivo genome editing https://biobriefs.com/gilead-acquires-sprints-trex1-preclinical BioBriefs en 2025-11-27T10:32:45Z Gilead acquires Sprint’s TREX1 preclinical program — >$400m oncology buy https://biobriefs.com/fda-proposes-reclassifying-companion-diagnostics BioBriefs en 2025-11-27T10:32:45Z FDA proposes reclassifying companion diagnostics to Class II — 510(k) review pathway eyed https://biobriefs.com/phrontline-raises-60m-pre-a BioBriefs en 2025-11-27T10:32:45Z Phrontline raises $60m pre‑A+ to back bispecific ADC pipeline https://biobriefs.com/otsukas-voyxact-cleared-by-fda BioBriefs en 2025-11-27T09:33:21Z Otsuka’s Voyxact cleared by FDA: first APRIL blocker for IgAN https://biobriefs.com/cms-sets-2027-medicare-prices BioBriefs en 2025-11-27T09:33:21Z CMS sets 2027 Medicare prices: Wegovy, Ozempic among cuts https://biobriefs.com/novo-files-high-dose-wegovy BioBriefs en 2025-11-27T09:33:21Z Novo files high‑dose Wegovy voucher: regulator review accelerated https://biobriefs.com/ipsc-derived-inkt-cells-show BioBriefs en 2025-11-27T09:33:21Z iPSC‑derived iNKT cells show promise in recurrent head‑and‑neck trial https://biobriefs.com/usp-issues-viral-vector-guidance BioBriefs en 2025-11-27T09:33:21Z USP issues viral‑vector guidance: standards to steady gene‑therapy scale‑up https://biobriefs.com/mrna-peptibodies-clear-drug-resistant BioBriefs en 2025-11-27T09:33:21Z mRNA peptibodies clear drug‑resistant pneumonia in mice: new delivery model https://biobriefs.com/boltzgen-model-debuts-generative-ai BioBriefs en 2025-11-27T09:33:21Z BoltzGen model debuts: generative AI for molecule design https://biobriefs.com/big-pharma-dealmaking-j-j BioBriefs en 2025-11-27T09:33:21Z Big pharma dealmaking: J&J buys Halda; Abbott’s Exact Sciences bet scrutinized https://biobriefs.com/fda-delays-ascendis-dwarfism-drug BioBriefs en 2025-11-27T09:33:21Z FDA delays Ascendis’ dwarfism drug decision: three‑month review window https://biobriefs.com/fda-proposes-reclassifying-companion-diagnostics BioBriefs en 2025-11-27T09:33:21Z FDA proposes reclassifying companion diagnostics: 510(k) pathway eyed https://biobriefs.com/novartis-expands-sma-access-itvisma BioBriefs en 2025-11-27T09:33:21Z Novartis expands SMA access: Itvisma approved for patients 2 and older https://biobriefs.com/otsuka-wins-fda-approval-for BioBriefs en 2025-11-27T04:32:59Z Otsuka wins FDA approval for first APRIL inhibitor in IgA nephropathy https://biobriefs.com/medicare-finalizes-deep-cuts-cms BioBriefs en 2025-11-27T04:32:59Z Medicare finalizes deep cuts: CMS posts second-round negotiated drug prices https://biobriefs.com/novartis-expands-sma-gene-therapy BioBriefs en 2025-11-27T04:32:59Z Novartis expands SMA gene therapy use — Itvisma cleared for older patients https://biobriefs.com/novos-amycretin-posts-strong-weight BioBriefs en 2025-11-27T04:32:59Z Novo’s amycretin posts strong weight, glycemic data — program moves to pivotal https://biobriefs.com/in-vivo-editing-inches-forward BioBriefs en 2025-11-27T04:32:59Z In vivo editing inches forward: locus‑specific repair restores adrenal function in model https://biobriefs.com/cell-therapy-clinical-momentum-ipsc BioBriefs en 2025-11-27T04:32:59Z Cell therapy clinical momentum — iPSC‑derived iNKT trial reports human data; Vigencell hits Phase II goal https://biobriefs.com/adc-and-bispecific-race-accelerates BioBriefs en 2025-11-27T04:32:59Z ADC and bispecific race accelerates — sac‑TMT plus Keytruda shows first‑line PFS gain; funding follows https://biobriefs.com/standards-and-automation-usp-issues BioBriefs en 2025-11-27T04:32:59Z Standards and automation: USP issues viral‑vector guidance; Bracco and Limula partner on cell‑therapy scale‑up https://biobriefs.com/ai-powers-discovery-and-diagnostics BioBriefs en 2025-11-27T04:32:59Z AI powers discovery and diagnostics: MIT’s BoltzGen debuts generative molecule model; popEVE maps proteome risk https://biobriefs.com/big-manufacturing-bets-astrazeneca-pledges BioBriefs en 2025-11-27T04:32:59Z Big manufacturing bets: AstraZeneca pledges $2B in Maryland; Thermo Fisher prices €2.1B notes https://biobriefs.com/fda-clears-first-april-blocker BioBriefs en 2025-11-26T21:32:10Z FDA clears first APRIL blocker for IgAN — Otsuka wins accelerated approval https://biobriefs.com/novartis-expands-sma-gene-therapy BioBriefs en 2025-11-26T21:32:10Z Novartis expands SMA gene therapy to older patients — Itvisma wins FDA nod https://biobriefs.com/medicare-finalizes-second-round-ira BioBriefs en 2025-11-26T21:32:10Z Medicare finalizes second-round IRA prices — Wegovy, Ozempic among heavy cuts https://biobriefs.com/fda-proposes-reclassifying-companion-diagnostics BioBriefs en 2025-11-26T21:32:10Z FDA proposes reclassifying companion diagnostics — 510(k) route eyed for oncology tests https://biobriefs.com/astrazeneca-to-invest-2b-in BioBriefs en 2025-11-26T21:32:10Z AstraZeneca to invest $2B in U.S. biologics — Maryland manufacturing expansion announced https://biobriefs.com/abbott-to-buy-exact-sciences BioBriefs en 2025-11-26T21:32:10Z Abbott to buy Exact Sciences for $23B — big bet on diagnostics and oncology testing https://biobriefs.com/toolgen-and-geneditbio-cross-license BioBriefs en 2025-11-26T21:32:09Z Toolgen and Geneditbio cross-license to advance in vivo editing therapeutics https://biobriefs.com/crisprbits-raises-3m-to-scale BioBriefs en 2025-11-26T21:32:09Z CrisprBits raises $3M to scale CRISPR diagnostics and editing platforms https://biobriefs.com/myrio-cracks-binder-challenge-higher BioBriefs en 2025-11-26T21:32:09Z Myrio cracks binder challenge — higher affinity and specificity achieved https://biobriefs.com/phrontline-raises-60m-to-fund BioBriefs en 2025-11-26T21:32:09Z Phrontline raises $60M to fund bispecific ADC pipeline — Series pre-A+ round closed https://biobriefs.com/otsukas-anti-april-antibody-clears BioBriefs en 2025-11-26T16:32:43Z Otsuka’s anti-APRIL antibody clears FDA: first-in-class IgAN approval https://biobriefs.com/novartis-wins-fda-nod-for BioBriefs en 2025-11-26T16:32:43Z Novartis wins FDA nod for Itvisma – gene therapy now cleared for older SMA patients https://biobriefs.com/bayers-asundexian-nails-phase-iii BioBriefs en 2025-11-26T16:32:43Z Bayer’s asundexian nails Phase III goal: stroke prevention win for FXIa inhibitors https://biobriefs.com/novos-alzheimer-gambit-fails-oral BioBriefs en 2025-11-26T16:32:43Z Novo’s Alzheimer gambit fails: oral semaglutide misses against cognitive decline https://biobriefs.com/abbott-bets-23b-on-diagnostics BioBriefs en 2025-11-26T16:32:43Z Abbott bets $23B on diagnostics: Exact Sciences deal remakes lab testing landscape https://biobriefs.com/standards-and-partnerships-to-unclog BioBriefs en 2025-11-26T16:32:43Z Standards and partnerships to unclog cell & gene bottlenecks: USP guidance and Bracco–Limula tie-up https://biobriefs.com/fda-moves-to-reclassify-companion BioBriefs en 2025-11-26T16:32:43Z FDA moves to reclassify companion diagnostics: 510(k) pathway proposed https://biobriefs.com/washington-doubles-down-on-ai BioBriefs en 2025-11-26T16:32:43Z Washington doubles down on AI and science funding: commission pushes reform, White House unveils 'Genesis Mission' https://biobriefs.com/capital-tide-cormorant-eyes-400m BioBriefs en 2025-11-26T16:32:43Z Capital tide: Cormorant eyes $400M fund while Phrontline closes $60M for bispecific ADCs https://biobriefs.com/gene-editing-and-in-vivo BioBriefs en 2025-11-26T16:32:43Z Gene editing and in vivo therapies: clinical ambitions meet cross‑license pacts https://biobriefs.com/novo-nordisks-alzheimers-gamble-fails BioBriefs en 2025-11-26T14:32:31Z Novo Nordisk’s Alzheimer’s gamble fails — phase III semaglutide misses endpoints https://biobriefs.com/bayers-oral-fxia-inhibitor-hits BioBriefs en 2025-11-26T14:32:31Z Bayer’s oral FXIa inhibitor hits phase III stroke goal — therapy shows efficacy without added bleeding https://biobriefs.com/novartis-wins-fda-nod-for BioBriefs en 2025-11-26T14:32:31Z Novartis wins FDA nod for Itvisma — gene therapy extended to older SMA patients https://biobriefs.com/abbott-to-buy-exact-sciences BioBriefs en 2025-11-26T14:32:31Z Abbott to buy Exact Sciences — $23 billion deal reshapes diagnostics landscape https://biobriefs.com/otsukas-anti-april-antibody-cleared BioBriefs en 2025-11-26T14:32:31Z Otsuka’s anti‑APRIL antibody cleared by FDA for IgA nephropathy https://biobriefs.com/astrazeneca-commits-2-billion-to BioBriefs en 2025-11-26T14:32:31Z AstraZeneca commits $2 billion to Maryland biologics expansion — onshoring rare‑disease manufacturing https://biobriefs.com/fda-delays-ascendis-achondroplasia-review BioBriefs en 2025-11-26T14:32:31Z FDA delays Ascendis’ achondroplasia review by three months over PMR protocol https://biobriefs.com/keluns-trop2-adc-plus-keytruda BioBriefs en 2025-11-26T14:32:31Z Kelun’s TROP2 ADC plus Keytruda shows first‑line lung benefit in phase III China trial https://biobriefs.com/nervgens-nvg-291-shows-durable BioBriefs en 2025-11-26T14:32:31Z NervGen’s NVG‑291 shows durable gains in chronic spinal cord injury — expanded CONNECT data https://biobriefs.com/usp-issues-new-viral-vector BioBriefs en 2025-11-26T14:32:31Z USP issues new viral‑vector standards to aid gene and cell therapy manufacturing https://biobriefs.com/otsuka-wins-fda-nod-for BioBriefs en 2025-11-26T10:33:29Z Otsuka wins FDA nod for anti-APRIL antibody—first-in-class for IgAN https://biobriefs.com/novartis-expands-sma-gene-therapy BioBriefs en 2025-11-26T10:33:29Z Novartis expands SMA gene therapy to older patients: Itvisma approved https://biobriefs.com/novos-glp-1-alzheimer-gamble BioBriefs en 2025-11-26T10:33:29Z Novo’s GLP‑1 Alzheimer gamble fails—semaglutide misses Phase III endpoints https://biobriefs.com/bayers-asundexian-meets-phase-iii BioBriefs en 2025-11-26T10:33:29Z Bayer’s asundexian meets Phase III stroke goal—FXIa class revived https://biobriefs.com/abbott-to-buy-exact-sciences BioBriefs en 2025-11-26T10:33:29Z Abbott to buy Exact Sciences for $23B—moves big into oncology diagnostics https://biobriefs.com/nervgens-nvg-291-shows-durable BioBriefs en 2025-11-26T10:33:29Z NervGen’s NVG‑291 shows durable, multidimensional gains in chronic spinal cord injury https://biobriefs.com/astrazeneca-to-invest-2b-in BioBriefs en 2025-11-26T10:33:29Z AstraZeneca to invest $2B in U.S. biologics manufacturing—rare disease capacity onshore https://biobriefs.com/gilead-buys-sprints-trex1-oncology BioBriefs en 2025-11-26T10:33:29Z Gilead buys Sprint’s TREX1 oncology program—upfront plus $400M in milestones https://biobriefs.com/indian-crispr-startup-crisprbits-raises BioBriefs en 2025-11-26T10:33:29Z Indian CRISPR startup CrisprBits raises $3M to scale diagnostics and gene‑editing platforms https://biobriefs.com/standards-and-automation-push-to BioBriefs en 2025-11-26T10:33:29Z Standards and automation push to unclog cell and gene therapy manufacturing https://biobriefs.com/otsuka-fda-greenlight-anti-april BioBriefs en 2025-11-26T09:32:47Z Otsuka FDA greenlight: anti‑APRIL therapy for IgA nephropathy https://biobriefs.com/novartis-expands-gene-therapy-reach BioBriefs en 2025-11-26T09:32:47Z Novartis expands gene therapy reach: Itvisma approved for older SMA patients https://biobriefs.com/bayers-asundexian-hits-phase-iii BioBriefs en 2025-11-26T09:32:47Z Bayer’s asundexian hits Phase III: FXIa inhibitor reduces recurrent ischemic stroke https://biobriefs.com/novo-nordisks-alzheimers-gamble-fails BioBriefs en 2025-11-26T09:32:47Z Novo Nordisk’s Alzheimer’s gamble fails: semaglutide misses Phase III endpoints https://biobriefs.com/abbott-buys-exact-sciences-23 BioBriefs en 2025-11-26T09:32:47Z Abbott buys Exact Sciences: $23 billion bet to double diagnostics footprint https://biobriefs.com/fda-probe-opened-after-reports BioBriefs en 2025-11-26T09:32:47Z FDA probe opened after reports tie Takeda’s Adzynma to fatality https://biobriefs.com/standards-and-automation-usp-bracco BioBriefs en 2025-11-26T09:32:47Z Standards and automation: USP, Bracco and Limula target cell and gene manufacturing bottlenecks https://biobriefs.com/gilead-scoops-sprints-trex1-program BioBriefs en 2025-11-26T09:32:47Z Gilead scoops Sprint’s TREX1 program: $14M now, $400M in milestones https://biobriefs.com/cms-finalizes-negotiated-prices-ozempic BioBriefs en 2025-11-26T09:32:47Z CMS finalizes negotiated prices: Ozempic, Wegovy among IRA second‑round cuts https://biobriefs.com/indian-crispr-startup-raises-3m BioBriefs en 2025-11-26T09:32:47Z Indian CRISPR startup raises $3M: CrisprBits to scale diagnostics and gene‑editing platforms https://biobriefs.com/otsukas-anti-april-win-fda BioBriefs en 2025-11-26T04:32:53Z Otsuka’s anti‑APRIL win: FDA clears first‑in‑class IgAN therapy https://biobriefs.com/itvisma-label-expanded-novartis-lands BioBriefs en 2025-11-26T04:32:53Z Itvisma label expanded: Novartis lands gene‑therapy approval for older SMA patients https://biobriefs.com/novos-alzheimer-gamble-fails-semaglutide BioBriefs en 2025-11-26T04:32:53Z Novo’s Alzheimer gamble fails: semaglutide misses two phase III trials https://biobriefs.com/bayer-revives-fxia-bets-asundexian BioBriefs en 2025-11-26T04:32:53Z Bayer revives FXIa bets: asundexian hits phase III stroke goal https://biobriefs.com/abbott-buys-exact-sciences-for BioBriefs en 2025-11-26T04:32:53Z Abbott buys Exact Sciences for $23B: diagnostics push reshapes Dx market https://biobriefs.com/gilead-snaps-up-trex1-program BioBriefs en 2025-11-26T04:32:53Z Gilead snaps up TREX1 program: $14M upfront, $400M in biobucks potential https://biobriefs.com/cdc-shake-up-controversial-hire BioBriefs en 2025-11-26T04:32:53Z CDC shake‑up: controversial hire and website edits raise scrutiny https://biobriefs.com/standards-and-automation-usp-and BioBriefs en 2025-11-26T04:32:53Z Standards and automation: USP and industry push to tame CGT manufacturing https://biobriefs.com/proteome-wide-ai-popeve-prioritizes BioBriefs en 2025-11-26T04:32:53Z Proteome‑wide AI: popEVE prioritizes rare‑disease variants for clinics https://biobriefs.com/nervgen-posts-durable-sci-gains BioBriefs en 2025-11-26T04:32:53Z NervGen posts durable SCI gains: NVG‑291 shows functional and neurophys signals https://biobriefs.com/novos-semaglutide-misses-endpoints-alzheimers BioBriefs en 2025-11-25T21:32:39Z Novo’s semaglutide misses endpoints — Alzheimer’s hopes dim https://biobriefs.com/bayers-oral-fxia-drug-cuts BioBriefs en 2025-11-25T21:32:39Z Bayer’s oral FXIa drug cuts stroke risk — market cheers https://biobriefs.com/fda-clears-novartis-intrathecal-gene BioBriefs en 2025-11-25T21:32:39Z FDA clears Novartis’ intrathecal gene therapy — Itvisma expands SMA reach https://biobriefs.com/fda-opens-probe-into-takedas BioBriefs en 2025-11-25T21:32:39Z FDA opens probe into Takeda’s Adzynma after neutralizing-antibody reports https://biobriefs.com/astrazeneca-to-invest-2-billion BioBriefs en 2025-11-25T21:32:39Z AstraZeneca to invest $2 billion in U.S. biologics capacity — jobs, onshoring push https://biobriefs.com/gilead-buys-trex1-oncology-program BioBriefs en 2025-11-25T21:32:39Z Gilead buys TREX1 oncology program — sprinting for preclinical advantage https://biobriefs.com/abbott-to-buy-exact-sciences BioBriefs en 2025-11-25T21:32:39Z Abbott to buy Exact Sciences for $23 billion — big med‑tech enters oncology testing https://biobriefs.com/cellaritys-ai-flags-drug-induced BioBriefs en 2025-11-25T21:32:39Z Cellarity’s AI flags drug‑induced liver injury — new toxicogenomics tool https://biobriefs.com/tempus-picks-up-oneome-pharmacogenetics BioBriefs en 2025-11-25T21:32:39Z Tempus picks up OneOme pharmacogenetics assets — PGx market consolidates https://biobriefs.com/lawmakers-press-fda-on-ultra BioBriefs en 2025-11-25T21:32:39Z Lawmakers press FDA on ultra‑fast review vouchers — transparency at issue https://biobriefs.com/semaglutide-fails-in-alzheimers-two BioBriefs en 2025-11-25T16:33:16Z Semaglutide fails in Alzheimer’s... Two Phase III trials show no benefit https://biobriefs.com/novo-accelerates-amycretin-pivots-pivotal BioBriefs en 2025-11-25T16:33:16Z Novo accelerates amycretin pivots – Pivotal diabetes trials launched after Phase 2 win https://biobriefs.com/bayers-asundexian-hits-phase-iii BioBriefs en 2025-11-25T16:33:16Z Bayer’s asundexian hits Phase III stroke goal – FXIa class revived https://biobriefs.com/abbott-to-buy-exact-sciences BioBriefs en 2025-11-25T16:33:16Z Abbott to buy Exact Sciences: $23 billion deal reshapes diagnostics https://biobriefs.com/astrazeneca-pledges-2-billion-to BioBriefs en 2025-11-25T16:33:16Z AstraZeneca pledges $2 billion to Maryland – Biomanufacturing onshored, jobs promised https://biobriefs.com/gilead-buys-trex1-cancer-program BioBriefs en 2025-11-25T16:33:16Z Gilead buys TREX1 cancer program – $14M up front, $400M in biobucks https://biobriefs.com/nervgen-posts-durable-gains-in BioBriefs en 2025-11-25T16:33:16Z NervGen posts durable gains in spinal cord injury – Expanded CONNECT data released https://biobriefs.com/lawmakers-press-fda-on-new BioBriefs en 2025-11-25T16:33:16Z Lawmakers press FDA on new priority voucher scheme – Transparency, corruption flagged https://biobriefs.com/fda-probes-takedas-adzynma-after BioBriefs en 2025-11-25T16:33:16Z FDA probes Takeda’s Adzynma after pediatric death – Neutralizing antibodies under review https://biobriefs.com/pharmacogenetics-consolidation-tempus-buys-oneome BioBriefs en 2025-11-25T16:33:16Z Pharmacogenetics consolidation: Tempus buys OneOme assets; Ovation and PrecisionLife to build GLP‑1 PGx test https://biobriefs.com/astrazeneca-doubles-us-biologics-footprint BioBriefs en 2025-11-25T14:32:38Z AstraZeneca doubles US biologics footprint: $2 billion Maryland build-out https://biobriefs.com/fda-clears-novartis-itvisma-gene BioBriefs en 2025-11-25T14:32:38Z FDA clears Novartis’ Itvisma: gene therapy widened to older SMA patients https://biobriefs.com/bayers-fxia-drug-snags-phase BioBriefs en 2025-11-25T14:32:38Z Bayer’s FXIa drug snags Phase 3 stroke win – class revived https://biobriefs.com/novos-glp-1-alzheimer-hope BioBriefs en 2025-11-25T14:32:38Z Novo’s GLP‑1 Alzheimer hope fails... major Phase 3 misses https://biobriefs.com/abbott-jumps-into-cancer-testing BioBriefs en 2025-11-25T14:32:38Z Abbott jumps into cancer testing: $23 billion Exact Sciences buy https://biobriefs.com/nervgen-posts-durable-gains-in BioBriefs en 2025-11-25T14:32:38Z NervGen posts durable gains in chronic spinal cord injury – expanded CONNECT data https://biobriefs.com/biogen-bets-on-oral-macrocycles BioBriefs en 2025-11-25T14:32:38Z Biogen bets on oral macrocycles: $50M deal with Versant spinout Dayra https://biobriefs.com/plasmidsaurus-undercuts-rna-seq-norms BioBriefs en 2025-11-25T14:32:38Z Plasmidsaurus undercuts RNA‑seq norms: fast, cheap transcriptomes https://biobriefs.com/tempus-scoops-up-oneome-pharmacogenetics BioBriefs en 2025-11-25T14:32:38Z Tempus scoops up OneOme pharmacogenetics assets: PGx consolidation continues https://biobriefs.com/africa-cdc-launches-agari-continent BioBriefs en 2025-11-25T14:32:38Z Africa CDC launches AGARI: continent‑wide pathogen genomics hub https://biobriefs.com/abbott-doubles-down-on-cancer BioBriefs en 2025-11-25T10:33:21Z Abbott doubles down on cancer testing: Exact Sciences buy for $23B https://biobriefs.com/bayers-fxia-inhibitor-cuts-stroke BioBriefs en 2025-11-25T10:33:21Z Bayer’s FXIa inhibitor cuts stroke risk: Phase 3 win revives drug class https://biobriefs.com/novos-glp-1-alzheimer-gamble BioBriefs en 2025-11-25T10:33:21Z Novo’s GLP‑1 Alzheimer gamble fails: two Phase 3 trials negative https://biobriefs.com/fda-oversight-frays-staffing-exodus BioBriefs en 2025-11-25T10:33:21Z FDA oversight frays: staffing exodus and leadership tensions surface https://biobriefs.com/crispr-pushes-beyond-therapeutics-glowing BioBriefs en 2025-11-25T10:33:21Z CRISPR pushes beyond therapeutics: glowing spider silk and nitrogen‑fixing wheat https://biobriefs.com/biogen-backs-versants-dayra-50m BioBriefs en 2025-11-25T10:33:21Z Biogen backs Versant’s Dayra: $50M deal launches oral macrocycle push https://biobriefs.com/nervgen-reports-durable-sci-gains BioBriefs en 2025-11-25T10:33:21Z NervGen reports durable SCI gains: NVG‑291 shows extended functional benefit https://biobriefs.com/ai-flags-liver-risk-cellaritys BioBriefs en 2025-11-25T10:33:21Z AI flags liver risk: Cellarity’s model predicts DILI with high accuracy https://biobriefs.com/tempus-buys-oneome-pharmacogenetics-assets BioBriefs en 2025-11-25T10:33:21Z Tempus buys OneOme pharmacogenetics assets after abrupt shutdown https://biobriefs.com/cheap-fast-rna-seq-shakes BioBriefs en 2025-11-25T10:33:21Z Cheap, fast RNA‑seq shakes up cores: Plasmidsaurus launches $50 assay https://biobriefs.com/abbott-doubles-down-on-oncology BioBriefs en 2025-11-25T09:32:44Z Abbott doubles down on oncology diagnostics: $23B Exact Sciences buy https://biobriefs.com/bayers-oral-fxia-drug-clears BioBriefs en 2025-11-25T09:32:44Z Bayer’s oral FXIa drug clears a late-stage hurdle – phase III stroke win https://biobriefs.com/novo-nordisks-semaglutide-fails-in BioBriefs en 2025-11-25T09:32:44Z Novo Nordisk’s semaglutide fails in Alzheimer’s: two phase III trials miss https://biobriefs.com/nervgens-nvg-291-shows-durable BioBriefs en 2025-11-25T09:32:44Z NervGen’s NVG‑291 shows durable gains in spinal cord injury — expanded CONNECT data https://biobriefs.com/biogen-inks-50m-pact-with BioBriefs en 2025-11-25T09:32:44Z Biogen inks $50M pact with Versant‑backed Dayra for oral macrocycles in immunology https://biobriefs.com/tempus-buys-oneome-pharmacogenetics-assets BioBriefs en 2025-11-25T09:32:44Z Tempus buys OneOme pharmacogenetics assets after lab shuts down https://biobriefs.com/fda-staffing-exodus-industry-warns BioBriefs en 2025-11-25T09:32:44Z FDA staffing exodus: industry warns oversight is weakening https://biobriefs.com/plasmidsaurus-launches-ultrafast-50-rna BioBriefs en 2025-11-25T09:32:44Z Plasmidsaurus launches ultrafast, $50 RNA‑seq service — cores on edge https://biobriefs.com/cellarity-debuts-toxpredictor-ai-flags BioBriefs en 2025-11-25T09:32:44Z Cellarity debuts ToxPredictor: AI flags drug‑induced liver injury with high accuracy https://biobriefs.com/fda-opens-probe-into-takedas BioBriefs en 2025-11-25T09:32:44Z FDA opens probe into Takeda’s Adzynma after pediatric death and neutralizing antibodies https://biobriefs.com/abbott-doubles-down-on-oncology BioBriefs en 2025-11-25T04:32:25Z Abbott doubles down on oncology diagnostics: Exact Sciences buyout https://biobriefs.com/bayers-oral-fxia-inhibitor-hits BioBriefs en 2025-11-25T04:32:25Z Bayer’s oral FXIa inhibitor hits phase III stroke endpoint https://biobriefs.com/novo-nordisks-semaglutide-fails-to BioBriefs en 2025-11-25T04:32:25Z Novo Nordisk’s semaglutide fails to slow Alzheimer’s in two large trials https://biobriefs.com/johnson-johnson-halts-anti-tau BioBriefs en 2025-11-25T04:32:25Z Johnson & Johnson halts anti‑tau program after negative mid‑stage readout https://biobriefs.com/nervgens-nvg-291-shows-durable BioBriefs en 2025-11-25T04:32:25Z NervGen’s NVG‑291 shows durable gains in chronic spinal cord injury https://biobriefs.com/tempus-picks-up-oneome-pharmacogenetics BioBriefs en 2025-11-25T04:32:25Z Tempus picks up OneOme pharmacogenetics assets after OneOme collapse https://biobriefs.com/plasmidsaurus-launches-ultra-fast-low BioBriefs en 2025-11-25T04:32:25Z Plasmidsaurus launches ultra‑fast, low‑cost RNA‑seq service – cores uneasy https://biobriefs.com/africa-cdc-launches-agari-continent BioBriefs en 2025-11-25T04:32:25Z Africa CDC launches AGARI: continent‑wide pathogen genomics hub https://biobriefs.com/cellarity-unveils-toxpredictor-ai-model BioBriefs en 2025-11-25T04:32:25Z Cellarity unveils ToxPredictor: AI model flags drug‑induced liver injury https://biobriefs.com/fda-probes-takedas-adzynma-after BioBriefs en 2025-11-25T04:32:25Z FDA probes Takeda’s Adzynma after pediatric death, neutralizing antibodies reported https://biobriefs.com/semaglutide-misses-in-pivotal-alzheimers BioBriefs en 2025-11-24T21:32:41Z Semaglutide misses in pivotal Alzheimer’s test — Novo setback https://biobriefs.com/bayers-asundexian-meets-stroke-endpoint BioBriefs en 2025-11-24T21:32:41Z Bayer’s asundexian meets stroke endpoint — FXIa hopes revive https://biobriefs.com/j-j-halts-anti-tau BioBriefs en 2025-11-24T21:32:41Z J&J halts anti‑tau study — posdinemab fails to slow decline https://biobriefs.com/fda-probes-takedas-adzynma-after BioBriefs en 2025-11-24T21:32:41Z FDA probes Takeda’s Adzynma after pediatric death; neutralizing antibodies flagged https://biobriefs.com/nervgen-reports-durable-functional-gains BioBriefs en 2025-11-24T21:32:41Z NervGen reports durable functional gains — CONNECT SCI data expand hope https://biobriefs.com/tempus-buys-oneomes-pgx-assets BioBriefs en 2025-11-24T21:32:41Z Tempus buys OneOme’s PGx assets — consolidation in pharmacogenetics https://biobriefs.com/cellaritys-ai-flags-dili-transcriptomics BioBriefs en 2025-11-24T21:32:41Z Cellarity’s AI flags DILI — transcriptomics model posts high performance https://biobriefs.com/biogen-pays-50m-for-dayras BioBriefs en 2025-11-24T21:32:41Z Biogen pays $50M for Dayra’s oral macrocycles — Versant-backed startup launches https://biobriefs.com/alphafold-at-five-jumper-outlines BioBriefs en 2025-11-24T21:32:41Z AlphaFold at five: Jumper outlines limits and next steps https://biobriefs.com/plasmidsaurus-50-rna-seq-service BioBriefs en 2025-11-24T21:32:41Z Plasmidsaurus’ $50 RNA‑seq service rattles cores — speed and price disrupt https://biobriefs.com/bayers-asundexian-cuts-stroke-risk BioBriefs en 2025-11-24T16:32:18Z Bayer’s asundexian cuts stroke risk – Phase 3 rebound for FXIa inhibitors https://biobriefs.com/j-j-halts-anti-tau BioBriefs en 2025-11-24T16:32:18Z J&J halts anti‑tau posdinemab – Phase 2 stops as efficacy misses https://biobriefs.com/novo-nordisks-semaglutide-misses-in BioBriefs en 2025-11-24T16:32:18Z Novo Nordisk’s semaglutide misses in Alzheimer’s trials – Two large studies negative https://biobriefs.com/nervgens-nvg-291-shows-durable BioBriefs en 2025-11-24T16:32:18Z NervGen’s NVG‑291 shows durable gains – Expanded CONNECT SCI data reported https://biobriefs.com/kelun-adc-plus-keytruda-wins BioBriefs en 2025-11-24T16:32:18Z Kelun ADC plus Keytruda wins Phase 3 – First‑line lung cancer data sent to China https://biobriefs.com/africa-cdc-launches-agari-continent BioBriefs en 2025-11-24T16:32:18Z Africa CDC launches AGARI... continent builds genomic backbone for outbreak response https://biobriefs.com/cellaritys-ai-predicts-dili-toxpredictor BioBriefs en 2025-11-24T16:32:18Z Cellarity’s AI predicts DILI – ToxPredictor validates large toxicogenomics set https://biobriefs.com/versants-dayra-boxes-50m-from BioBriefs en 2025-11-24T16:32:18Z Versant’s Dayra boxes $50M from Biogen – Oral macrocycles target immune and inflammatory disease https://biobriefs.com/lillys-asia-push-grabody-and BioBriefs en 2025-11-24T16:32:18Z Lilly’s Asia push: Grabody and LEAD pacts... $3.8B in platform bets https://biobriefs.com/crispr-wheat-triggers-nitrogen-fixation BioBriefs en 2025-11-24T16:32:18Z CRISPR wheat triggers nitrogen fixation – UC Davis engineers crops to recruit soil bacteria https://biobriefs.com/bayers-asundexian-cuts-stroke-risk BioBriefs en 2025-11-24T14:31:53Z Bayer’s asundexian cuts stroke risk – Phase 3 revives FXIa class https://biobriefs.com/novo-nordisks-semaglutide-misses-in BioBriefs en 2025-11-24T14:31:53Z Novo Nordisk’s semaglutide misses in Alzheimer’s – Two trials fail to slow progression https://biobriefs.com/eli-lilly-doubles-down-on BioBriefs en 2025-11-24T14:31:53Z Eli Lilly doubles down on bispecifics and RNAi: $3.8B in Asia deals https://biobriefs.com/biogen-pays-50m-upfront-to BioBriefs en 2025-11-24T14:31:53Z Biogen pays $50M upfront to Dayra – Oral macrocycles deal in I&I https://biobriefs.com/carolyn-bertozzi-returns-to-lilly BioBriefs en 2025-11-24T14:31:53Z Carolyn Bertozzi returns to Lilly board – Nobel laureate to rejoin Dec. 8 https://biobriefs.com/blood-four-gene-signature-rules BioBriefs en 2025-11-24T14:31:53Z Blood four‑gene signature rules out bacterial LRTI – Nature Communications validation https://biobriefs.com/blood-biomarkers-map-alzheimers-across BioBriefs en 2025-11-24T14:31:53Z Blood biomarkers map Alzheimer’s across cognitive stages – Accessible disease tracking https://biobriefs.com/giant-bacteriophage-targets-drug-resistant BioBriefs en 2025-11-24T14:31:53Z Giant bacteriophage targets drug‑resistant Pseudomonas – Phage therapy renewed https://biobriefs.com/automated-mri-flags-clinically-significant BioBriefs en 2025-11-24T14:31:53Z Automated MRI flags clinically significant prostate cancer – AI system validated https://biobriefs.com/craig-crews-and-mikael-dolsten BioBriefs en 2025-11-24T14:31:53Z Craig Crews and Mikael Dolsten raise $32M for Quarry Thera – New biotech funds launch https://biobriefs.com/avadel-takeover-duel-lundbeck-bids BioBriefs en 2025-11-24T10:32:04Z Avadel takeover duel: Lundbeck bids, Alkermes counters https://biobriefs.com/bertozzi-returns-to-lilly-board BioBriefs en 2025-11-24T10:32:04Z Bertozzi returns to Lilly board: Nobel laureate to rejoin Dec. 8 https://biobriefs.com/semaglutide-slows-ckd-progression-in BioBriefs en 2025-11-24T10:32:04Z Semaglutide slows CKD progression in diabetics — study https://biobriefs.com/asah1-linked-sphingolipid-pathway-fuels BioBriefs en 2025-11-24T10:32:04Z ASAH1-linked sphingolipid pathway fuels venetoclax resistance in AML https://biobriefs.com/immune-atlas-pins-cd4-memory BioBriefs en 2025-11-24T10:32:04Z Immune atlas pins CD4 memory program to type 1 diabetes https://biobriefs.com/apoe4-meets-crispr-gene-editing BioBriefs en 2025-11-24T10:32:04Z APOE4 meets CRISPR — gene editing and blood biomarkers reshape Alzheimer’s strategy https://biobriefs.com/multiple-myeloma-exosomes-and-complement BioBriefs en 2025-11-24T10:32:04Z Multiple myeloma: exosomes and complement signals reshape treatment response https://biobriefs.com/two-preclinical-tnbc-approaches-venom BioBriefs en 2025-11-24T10:32:04Z Two preclinical TNBC approaches: venom peptide targets PD‑L1 and gallium photosensitizers advance PDT https://biobriefs.com/automated-mri-flags-clinically-significant BioBriefs en 2025-11-24T10:32:04Z Automated MRI flags clinically significant prostate cancer: study in Nature Communications https://biobriefs.com/mrna-protects-muscle-from-snake BioBriefs en 2025-11-24T10:32:04Z mRNA protects muscle from snake venom: COVID platform repurposed https://biobriefs.com/carolyn-bertozzi-returns-to-eli BioBriefs en 2025-11-24T09:32:05Z Carolyn Bertozzi returns to Eli Lilly: Nobel chemist named to board Dec. 8 https://biobriefs.com/avadel-takeover-tussle-alkermes-and BioBriefs en 2025-11-24T09:32:05Z Avadel takeover tussle... Alkermes and Lundbeck spar in bidding duel https://biobriefs.com/blood-biomarkers-map-alzheimers-progression BioBriefs en 2025-11-24T09:32:05Z Blood biomarkers map Alzheimer’s progression: accessible tracking across cognitive stages https://biobriefs.com/automated-mri-for-prostate-cancer BioBriefs en 2025-11-24T09:32:05Z Automated MRI for prostate cancer: AI system flags clinically significant tumors https://biobriefs.com/asah1-drives-venetoclax-resistance-in BioBriefs en 2025-11-24T09:32:05Z ASAH1 drives venetoclax resistance in AML: sphingolipid metabolism implicated https://biobriefs.com/nsun7-m5c-axis-sustains-glioblastoma BioBriefs en 2025-11-24T09:32:05Z NSUN7–m5C axis sustains glioblastoma stemness: RNA modification as therapeutic target https://biobriefs.com/simple-outpatient-risk-score-predicts BioBriefs en 2025-11-24T09:32:05Z Simple outpatient risk score predicts gastric cancer: externally validated PRS https://biobriefs.com/tumor-exosomes-drive-brain-metastasis BioBriefs en 2025-11-24T09:32:05Z Tumor exosomes drive brain metastasis: miR‑221‑3p promotes breast cancer colonization of brain https://biobriefs.com/mef2c-reverses-cisplatin-resistance-in BioBriefs en 2025-11-24T09:32:05Z MEF2C reverses cisplatin resistance in ovarian cancer: apoptosis reactivated https://biobriefs.com/talazoparib-benefits-brca-mutant-metastatic BioBriefs en 2025-11-24T09:32:05Z Talazoparib benefits BRCA‑mutant metastatic disease: multicenter retrospective evidence https://biobriefs.com/eli-lilly-hits-1-trillion BioBriefs en 2025-11-24T04:32:13Z Eli Lilly hits $1 trillion — pharma milestone https://biobriefs.com/avadel-takeover-battle-alkermes-and BioBriefs en 2025-11-24T04:32:13Z Avadel takeover battle... Alkermes and Lundbeck duel https://biobriefs.com/medicaid-coverage-for-glp-1s BioBriefs en 2025-11-24T04:32:13Z Medicaid coverage for GLP‑1s varies widely — study https://biobriefs.com/semaglutide-slows-kidney-disease-progression BioBriefs en 2025-11-24T04:32:13Z Semaglutide slows kidney disease progression — trial data https://biobriefs.com/tirzepatide-maintains-weight-loss-and BioBriefs en 2025-11-24T04:32:13Z Tirzepatide maintains weight-loss and diabetes prevention at three years https://biobriefs.com/combicor-vax-trial-launches-immunotherapy BioBriefs en 2025-11-24T04:32:13Z CombiCoR‑Vax trial launches: immunotherapy plus chemo for refractory MSS mCRC https://biobriefs.com/prophylactic-third-party-nk-cells BioBriefs en 2025-11-24T04:32:13Z Prophylactic third‑party NK cells after HSCT: safety signals in AML https://biobriefs.com/distinct-cd4-memory-t-cell BioBriefs en 2025-11-24T04:32:13Z Distinct CD4 memory T‑cell program linked to type 1 diabetes — Science Immunology https://biobriefs.com/blood-biomarkers-track-alzheimers-across BioBriefs en 2025-11-24T04:32:13Z Blood biomarkers track Alzheimer’s across cognitive stages — Nature Communications https://biobriefs.com/automated-mri-system-flags-clinically BioBriefs en 2025-11-24T04:32:13Z Automated MRI system flags clinically significant prostate cancer https://biobriefs.com/thermal-one-pot-crispr-rapid BioBriefs en 2025-11-23T21:32:30Z Thermal one‑pot CRISPR: rapid on‑site viral surveillance https://biobriefs.com/iambic-ai-and-automation-shrink BioBriefs en 2025-11-23T21:32:30Z Iambic: AI and automation shrink chemistry‑to‑clinic to two years https://biobriefs.com/sydnexis-setback-highlights-fda-opacity BioBriefs en 2025-11-23T21:32:30Z Sydnexis setback highlights FDA opacity — CRL raises concerns https://biobriefs.com/biotech-follow-ons-raise-nearly BioBriefs en 2025-11-23T21:32:30Z Biotech follow‑ons raise nearly $950M — markets stay open https://biobriefs.com/plasma-ngs-reshapes-nsclc-care BioBriefs en 2025-11-23T21:32:30Z Plasma NGS reshapes NSCLC care in Asia — study shows https://biobriefs.com/cd4-memory-t-cell-subset BioBriefs en 2025-11-23T21:32:30Z CD4 memory T‑cell subset tied to type 1 diabetes — Science Immunology https://biobriefs.com/automated-mri-ai-system-spots BioBriefs en 2025-11-23T21:32:30Z Automated MRI: AI system spots clinically significant prostate cancer https://biobriefs.com/cfdna-fragment-chromatin-correlation-enables BioBriefs en 2025-11-23T21:32:30Z cfDNA fragment–chromatin correlation enables pan‑cancer detection https://biobriefs.com/asah1-axis-drives-venetoclax-resistance BioBriefs en 2025-11-23T21:32:30Z ASAH1 axis drives venetoclax resistance in AML https://biobriefs.com/combicor-vax-phase-ii-tests BioBriefs en 2025-11-23T21:32:30Z CombiCoR‑Vax phase II tests sequential immunotherapy and chemo in MSS mCRC https://biobriefs.com/eli-lilly-hits-1-trillion BioBriefs en 2025-11-23T16:32:30Z Eli Lilly hits $1 trillion – obesity drugs power rally https://biobriefs.com/resalis-aso-challenges-glp-1s BioBriefs en 2025-11-23T16:32:30Z Resalis ASO challenges GLP‑1s: precision obesity approach https://biobriefs.com/ginkgo-launches-virtual-cell-initiative BioBriefs en 2025-11-23T16:32:30Z Ginkgo launches Virtual Cell Initiative: builds 12 billion datapoint resource https://biobriefs.com/iambic-compresses-chemistry-to-clinic BioBriefs en 2025-11-23T16:32:30Z Iambic compresses chemistry‑to‑clinic to two years – AI and automation deliver https://biobriefs.com/novartis-to-build-u-s BioBriefs en 2025-11-23T16:32:30Z Novartis to build U.S. manufacturing hub in North Carolina: end‑to‑end capacity planned https://biobriefs.com/darpa-vet-fisher-tapped-to BioBriefs en 2025-11-23T16:32:30Z DARPA vet Fisher tapped to lead UK research agency ARIA https://biobriefs.com/ocean-diagnostics-pushes-rapid-sepsis BioBriefs en 2025-11-23T16:32:30Z Ocean Diagnostics pushes rapid sepsis ID toward 2028 launch after perfect pilot https://biobriefs.com/taiho-and-cullinan-file-rolling BioBriefs en 2025-11-23T16:32:30Z Taiho and Cullinan file rolling NDA for zipalertinib – EGFR exon‑20 program advances https://biobriefs.com/thermally-programmed-one-pot-crispr BioBriefs en 2025-11-23T16:32:30Z Thermally programmed one‑pot CRISPR assay enables on‑site viral surveillance https://biobriefs.com/sydnexis-fda-complete-response-spotlights BioBriefs en 2025-11-23T16:32:30Z Sydnexis FDA complete response spotlights transparency concerns https://biobriefs.com/ginkgo-launches-virtual-cell-initiative BioBriefs en 2025-11-23T14:32:32Z Ginkgo launches Virtual Cell Initiative: 12-billion-point pharmacology push https://biobriefs.com/ocean-dx-pilot-matches-culture BioBriefs en 2025-11-23T14:32:32Z Ocean Dx pilot matches culture — startup targets 3.5-hour sepsis ID https://biobriefs.com/eli-lilly-breaks-trillion-dollar BioBriefs en 2025-11-23T14:32:32Z Eli Lilly breaks trillion-dollar barrier — first drugmaker to reach $1T https://biobriefs.com/fda-transparency-under-fire-sydnexis BioBriefs en 2025-11-23T14:32:32Z FDA transparency under fire: Sydnexis CRL and industry letter press regulator https://biobriefs.com/big-pharma-onshores-novartis-and BioBriefs en 2025-11-23T14:32:32Z Big pharma onshores: Novartis and AstraZeneca pledge US manufacturing investment https://biobriefs.com/oligo-hits-obesity-at-its BioBriefs en 2025-11-23T14:32:32Z Oligo hits obesity at its source: Resalis presents miR-22 ASO data https://biobriefs.com/taiho-cullinan-file-rolling-nda BioBriefs en 2025-11-23T14:32:32Z Taiho, Cullinan file rolling NDA: zipalertinib seeks fast lane for exon‑20 NSCLC https://biobriefs.com/one-pot-thermally-programmed-crispr BioBriefs en 2025-11-23T14:32:32Z One‑pot thermally programmed CRISPR: a field-ready viral surveillance assay https://biobriefs.com/contineums-pipe-307-misses-endpoints BioBriefs en 2025-11-23T14:32:32Z Contineum’s PIPE‑307 misses endpoints — midstage MS study fails https://biobriefs.com/ge-healthcare-buys-intelerad-for BioBriefs en 2025-11-23T14:32:32Z GE Healthcare buys Intelerad for $2.3B — imaging push into outpatient cloud https://biobriefs.com/eli-lilly-hits-1-trillion BioBriefs en 2025-11-23T10:32:44Z Eli Lilly Hits $1 Trillion – Pharma First https://biobriefs.com/ginkgo-datapoints-launches-virtual-cell BioBriefs en 2025-11-23T10:32:44Z Ginkgo Datapoints Launches Virtual Cell Initiative: 12bn datapoints planned https://biobriefs.com/ocean-diagnostics-test-matched-cultures BioBriefs en 2025-11-23T10:32:44Z Ocean Diagnostics test matched cultures 100%: Rapid sepsis ID aims for 2028 launch https://biobriefs.com/resalis-unveils-mir-22-aso BioBriefs en 2025-11-23T10:32:44Z Resalis unveils miR‑22 ASO: preclinical data show durable weight loss https://biobriefs.com/fda-to-hire-1050-staffers BioBriefs en 2025-11-23T10:32:44Z FDA to hire 1,050 staffers — rolls out quick‑clarification pilot https://biobriefs.com/ge-to-buy-intelerad-for BioBriefs en 2025-11-23T10:32:44Z GE to buy Intelerad for $2.3B — imaging and cloud push https://biobriefs.com/taiho-cullinan-file-rolling-nda BioBriefs en 2025-11-23T10:32:44Z Taiho, Cullinan file rolling NDA for zipalertinib: exon‑20 priority path https://biobriefs.com/contineums-pipe-307-misses-midstage BioBriefs en 2025-11-23T10:32:44Z Contineum’s PIPE‑307 misses midstage endpoints — shares fall https://biobriefs.com/gsk-anaptysbio-sue-each-other BioBriefs en 2025-11-23T10:32:44Z GSK, AnaptysBio sue each other — Jemperli revenue dispute https://biobriefs.com/one-pot-thermally-programmed-crispr BioBriefs en 2025-11-23T10:32:44Z One‑pot thermally programmed CRISPR: on‑site viral surveillance assay https://biobriefs.com/eli-lilly-cracks-1-trillion BioBriefs en 2025-11-23T09:32:42Z Eli Lilly cracks $1 trillion — first pharma to hit milestone https://biobriefs.com/biotech-leaders-press-fda-for BioBriefs en 2025-11-23T09:32:42Z Biotech leaders press FDA for steadiness: letter to Makary https://biobriefs.com/fda-ramps-hires-to-1000 BioBriefs en 2025-11-23T09:32:42Z FDA ramps hires to 1,000: launches quick-clarification channel https://biobriefs.com/novartis-plans-north-carolina-flagship BioBriefs en 2025-11-23T09:32:42Z Novartis plans North Carolina flagship hub: $23B U.S. push https://biobriefs.com/astrazeneca-to-onshore-rare-disease BioBriefs en 2025-11-23T09:32:42Z AstraZeneca to onshore rare-disease manufacturing — Maryland expansion https://biobriefs.com/ginkgo-launches-virtual-cell-initiative BioBriefs en 2025-11-23T09:32:42Z Ginkgo launches Virtual Cell Initiative: open pharmacology standard https://biobriefs.com/one-pot-thermally-programmed-crispr BioBriefs en 2025-11-23T09:32:42Z One‑pot thermally programmed CRISPR: rapid on-site viral surveillance https://biobriefs.com/ocean-diagnostics-sepsis-test-matches BioBriefs en 2025-11-23T09:32:42Z Ocean Diagnostics’ sepsis test matches cultures — aims 3.5‑hour launch https://biobriefs.com/contineums-pipe-307-misses-midstage BioBriefs en 2025-11-23T09:32:42Z Contineum’s PIPE‑307 misses midstage MS endpoints — stock tumbles https://biobriefs.com/crispr-pro-livefish-live-cell BioBriefs en 2025-11-23T09:32:42Z CRISPR PRO‑liveFISH... live‑cell genome imaging for non‑repetitive loci https://biobriefs.com/iambic-compresses-chemistry-to-clinic BioBriefs en 2025-11-23T09:32:42Z Iambic compresses chemistry‑to‑clinic to two years — AI and automation https://biobriefs.com/gsk-and-anaptysbio-in-court BioBriefs en 2025-11-23T09:32:42Z GSK and AnaptysBiO in court: licensing dispute over Jemperli https://biobriefs.com/ginkgo-datapoints-virtual-cell-push BioBriefs en 2025-11-23T04:32:32Z Ginkgo Datapoints: Virtual cell push aims to standardize AI pharmacology https://biobriefs.com/ocean-diagnostics-rapid-sepsis-test BioBriefs en 2025-11-23T04:32:32Z Ocean Diagnostics: Rapid sepsis test posts perfect pilot concordance https://biobriefs.com/lilly-becomes-first-drugmaker-to BioBriefs en 2025-11-23T04:32:32Z Lilly becomes first drugmaker to hit $1 trillion — obesity portfolio drives surge https://biobriefs.com/fda-hiring-surge-1000-reviewers BioBriefs en 2025-11-23T04:32:32Z FDA hiring surge: 1,000 reviewers plus a fast‑reply email channel https://biobriefs.com/novartis-plans-north-carolina-flagship BioBriefs en 2025-11-23T04:32:32Z Novartis plans North Carolina flagship hub — U.S. manufacturing push https://biobriefs.com/gsk-vs-anaptysbio-lawsuits-flare BioBriefs en 2025-11-23T04:32:32Z GSK vs AnaptysBio — lawsuits flare over Jemperli licence and royalties https://biobriefs.com/iambic-ai-and-automation-compress BioBriefs en 2025-11-23T04:32:32Z Iambic: AI and automation compress chemistry‑to‑clinic to two years https://biobriefs.com/taiho-cullinan-file-rolling-nda BioBriefs en 2025-11-23T04:32:32Z Taiho, Cullinan file rolling NDA for zipalertinib — EGFR exon‑20 strategy https://biobriefs.com/resalis-aso-oligo-therapy-aims BioBriefs en 2025-11-23T04:32:32Z Resalis ASO: Oligo therapy aims beyond appetite — targets fat metabolism https://biobriefs.com/four-biotechs-raise-nearly-950m BioBriefs en 2025-11-23T04:32:32Z Four biotechs raise nearly $950M in follow‑on offerings — market liquidity persists https://biobriefs.com/eli-lilly-becomes-first-drugmaker BioBriefs en 2025-11-22T21:32:06Z Eli Lilly becomes first drugmaker to hit $1 trillion market value https://biobriefs.com/ginkgo-datapoints-launches-virtual-cell BioBriefs en 2025-11-22T21:32:06Z Ginkgo Datapoints launches Virtual Cell Initiative – open standard for pharmacology modeling https://biobriefs.com/novartis-to-build-flagship-manufacturing BioBriefs en 2025-11-22T21:32:06Z Novartis to build flagship manufacturing hub in North Carolina: U.S. onshoring push https://biobriefs.com/fda-hires-1000-staffers-pilots BioBriefs en 2025-11-22T21:32:06Z FDA hires 1,000 staffers; pilots rapid-sponsor email channel https://biobriefs.com/ocean-diagnostics-aims-2028-sepsis BioBriefs en 2025-11-22T21:32:06Z Ocean Diagnostics aims 2028 sepsis ID launch after pilot reports 100% concordance https://biobriefs.com/resalis-presents-antisense-oligonucleotide-targeting BioBriefs en 2025-11-22T21:32:06Z Resalis presents antisense oligonucleotide targeting miR‑22… obesity approach beyond GLP‑1 https://biobriefs.com/taiho-and-cullinan-file-rolling BioBriefs en 2025-11-22T21:32:06Z Taiho and Cullinan file rolling NDA for zipalertinib – EGFR exon‑20 insertion NSCLC https://biobriefs.com/gsk-and-anaptysbio-clash-over BioBriefs en 2025-11-22T21:32:06Z GSK and AnaptysBio clash over Jemperli licence; Anaptys launches $100M buyback https://biobriefs.com/contineums-pipe-307-misses-phase BioBriefs en 2025-11-22T21:32:06Z Contineum’s PIPE‑307 misses Phase 2 endpoints – shares plunge https://biobriefs.com/fda-opens-probe-into-pediatric BioBriefs en 2025-11-22T21:32:06Z FDA opens probe into pediatric death possibly linked to Takeda’s Adzynma https://biobriefs.com/abbott-to-buy-exact-sciences BioBriefs en 2025-11-22T16:33:46Z Abbott to buy Exact Sciences: $21 billion play for cancer diagnostics https://biobriefs.com/eli-lilly-reaches-1-trillion BioBriefs en 2025-11-22T16:33:46Z Eli Lilly reaches $1 trillion market value – obesity drugs drive surge https://biobriefs.com/biotech-chiefs-press-fda-for BioBriefs en 2025-11-22T16:33:46Z Biotech chiefs press FDA for stability as agency rolls out new review hires https://biobriefs.com/ms-setback-at-contineum-pipe BioBriefs en 2025-11-22T16:33:46Z MS setback at Contineum – PIPE‑307 misses primary endpoint https://biobriefs.com/new-obesity-axis-aso-targets BioBriefs en 2025-11-22T16:33:46Z New obesity axis: ASO targets miR‑22 while payers and employers probe access https://biobriefs.com/ginkgo-datapoints-launches-vcpi-open BioBriefs en 2025-11-22T16:33:46Z Ginkgo Datapoints launches VCPI: open‑source drive for virtual cell pharmacology https://biobriefs.com/quantum-si-targets-2026-for BioBriefs en 2025-11-22T16:33:46Z Quantum‑Si targets 2026 for Proteus protein sequencer launch https://biobriefs.com/rapid-infectious-diagnostics-race-ocean BioBriefs en 2025-11-22T16:33:46Z Rapid infectious diagnostics race: Ocean Dx sepsis test and a one‑pot CRISPR assay https://biobriefs.com/gsk-and-anaptysbio-legal-fight BioBriefs en 2025-11-22T16:33:46Z GSK and AnaptysBio legal fight escalates – disputes over Jemperli revenue https://biobriefs.com/mjff-backs-lrrk2-aso-scineuro BioBriefs en 2025-11-22T16:33:46Z MJFF backs LRRK2 ASO: Scineuro wins $5M to advance Parkinson’s antisense program https://biobriefs.com/abbott-to-buy-exact-sciences BioBriefs en 2025-11-22T14:32:41Z Abbott to buy Exact Sciences for $21 billion – Diagnostic play https://biobriefs.com/bayers-her2-drug-cleared-for BioBriefs en 2025-11-22T14:32:41Z Bayer’s HER2 drug cleared for lung cancer – Companion NGS test also approved https://biobriefs.com/contineums-ms-candidate-misses-endpoints BioBriefs en 2025-11-22T14:32:41Z Contineum’s MS candidate misses endpoints – Pipeline hit https://biobriefs.com/ocean-diagnostics-rapid-sepsis-test BioBriefs en 2025-11-22T14:32:41Z Ocean Diagnostics’ rapid sepsis test nails pilot results... Plans CE and FDA filings https://biobriefs.com/ginkgo-launches-virtual-cell-pharmacology BioBriefs en 2025-11-22T14:32:41Z Ginkgo launches Virtual Cell Pharmacology Initiative – 12 billion datapoints target https://biobriefs.com/iambic-claims-two-year-chemistry BioBriefs en 2025-11-22T14:32:41Z Iambic claims two‑year chemistry‑to‑clinic cycle – AI and automation in action https://biobriefs.com/aso-approach-targets-obesity-at BioBriefs en 2025-11-22T14:32:41Z ASO approach targets obesity at its source – Resalis reveals miR‑22 program https://biobriefs.com/nurix-trims-staff-as-pivotal BioBriefs en 2025-11-22T14:32:41Z Nurix trims staff as pivotal BTK degrader study launches https://biobriefs.com/gsk-and-anaptysbio-in-court BioBriefs en 2025-11-22T14:32:41Z GSK and AnaptysBio in court fight over Jemperli revenue and rights https://biobriefs.com/biotech-warns-of-fda-volatility BioBriefs en 2025-11-22T14:32:41Z Biotech warns of FDA volatility as agency hires staff and pilots new comms https://biobriefs.com/bayers-her2-lung-drug-cleared BioBriefs en 2025-11-22T10:32:52Z Bayer’s HER2 lung drug cleared: Thermo Fisher companion test OK https://biobriefs.com/abbott-snaps-up-exact-sciences BioBriefs en 2025-11-22T10:32:52Z Abbott snaps up Exact Sciences: $21B cancer‑diagnostics push https://biobriefs.com/fda-rolls-out-rapid-response BioBriefs en 2025-11-22T10:32:52Z FDA rolls out rapid‑response program — hiring surge meets review controversy https://biobriefs.com/lilly-becomes-first-1t-drugmaker BioBriefs en 2025-11-22T10:32:52Z Lilly becomes first $1T drugmaker — employers cut direct obesity‑drug deals https://biobriefs.com/ginkgo-datapoints-opens-virtual-cell BioBriefs en 2025-11-22T10:32:52Z Ginkgo Datapoints opens Virtual Cell: standard for AI‑driven pharmacology https://biobriefs.com/iambic-two-year-chemistry-to BioBriefs en 2025-11-22T10:32:52Z Iambic: two‑year chemistry‑to‑clinic — AI and automation deliver leads https://biobriefs.com/ocean-diagnostics-vows-3-5 BioBriefs en 2025-11-22T10:32:52Z Ocean Diagnostics vows 3.5‑hour sepsis ID — pilot matched culture at 100% https://biobriefs.com/heptas-cfdna-methylation-mirrors-liver BioBriefs en 2025-11-22T10:32:52Z Hepta’s cfDNA methylation mirrors liver biology — liquid biopsy for fibrosis https://biobriefs.com/contineums-j-j-partnered-ms BioBriefs en 2025-11-22T10:32:52Z Contineum’s J&J‑partnered MS drug misses key vision endpoint — shares fall https://biobriefs.com/taiho-and-cullinan-file-rolling BioBriefs en 2025-11-22T10:32:52Z Taiho and Cullinan file rolling NDA: zipalertinib targets EGFR exon‑20 NSCLC https://biobriefs.com/abbott-to-buy-exact-sciences BioBriefs en 2025-11-22T09:32:33Z Abbott to buy Exact Sciences: $23B play for cancer diagnostics https://biobriefs.com/lilly-crosses-1-trillion-mark BioBriefs en 2025-11-22T09:32:33Z Lilly crosses $1 trillion mark — obesity drugs drive value https://biobriefs.com/cdc-website-changes-language-suggests BioBriefs en 2025-11-22T09:32:33Z CDC website changes: language suggests vaccines-autism link https://biobriefs.com/ginkgo-launches-virtual-cell-open BioBriefs en 2025-11-22T09:32:33Z Ginkgo launches Virtual Cell: open pharmacology dataset for AI drug discovery https://biobriefs.com/ocean-dx-test-matches-cultures BioBriefs en 2025-11-22T09:32:33Z Ocean Dx test matches cultures 100% in pilot — sepsis ID in hours https://biobriefs.com/contineums-pipe-307-misses-phase BioBriefs en 2025-11-22T09:32:33Z Contineum’s PIPE‑307 misses phase 2 endpoints — shares tumble https://biobriefs.com/gsk-and-anaptys-in-court BioBriefs en 2025-11-22T09:32:33Z GSK and Anaptys in court — billion‑dollar royalties and rights at stake https://biobriefs.com/moderna-restructures-1-5b-lifeline BioBriefs en 2025-11-22T09:32:33Z Moderna restructures: $1.5B lifeline and pipeline pruning https://biobriefs.com/fda-ramps-hiring-and-starts BioBriefs en 2025-11-22T09:32:33Z FDA ramps hiring and starts email clarifications to speed reviews https://biobriefs.com/ai-accelerates-early-drug-discovery BioBriefs en 2025-11-22T09:32:33Z AI accelerates early drug discovery: Iambic and AI Proteins scale up https://biobriefs.com/abbott-to-buy-exact-sciences BioBriefs en 2025-11-22T04:32:18Z Abbott to buy Exact Sciences: $23 billion diagnostic push https://biobriefs.com/bayers-her2-drug-cleared-thermo BioBriefs en 2025-11-22T04:32:18Z Bayer’s HER2 drug cleared — Thermo Fisher test approved https://biobriefs.com/ginkgo-datapoints-launches-virtual-cell BioBriefs en 2025-11-22T04:32:18Z Ginkgo Datapoints launches Virtual Cell Initiative... 12 billion data-point goal https://biobriefs.com/ocean-diagnostics-rapid-sepsis-test BioBriefs en 2025-11-22T04:32:18Z Ocean Diagnostics’ rapid sepsis test matches culture results 100% https://biobriefs.com/novartis-to-build-flagship-us BioBriefs en 2025-11-22T04:32:18Z Novartis to build flagship US manufacturing hub — North Carolina expansion https://biobriefs.com/industry-pushes-for-fda-stability BioBriefs en 2025-11-22T04:32:18Z Industry pushes for FDA stability as Makary aide stays amid White House fracas https://biobriefs.com/contineums-pipe-307-misses-phase BioBriefs en 2025-11-22T04:32:18Z Contineum’s PIPE‑307 misses Phase II vision endpoints — shares tumble https://biobriefs.com/hepta-publishes-cfdna-methylation-proof BioBriefs en 2025-11-22T04:32:18Z Hepta publishes cfDNA methylation proof‑of‑concept for liver disease https://biobriefs.com/cassidy-bio-raises-8m-seed BioBriefs en 2025-11-22T04:32:18Z Cassidy Bio raises $8M seed to scale AI platform for gene‑editing design https://biobriefs.com/aspen-closes-115m-series-c BioBriefs en 2025-11-22T04:32:18Z Aspen closes $115M Series C to advance personalized Parkinson’s cell therapy https://biobriefs.com/abbott-to-buy-exact-sciences BioBriefs en 2025-11-21T21:32:07Z Abbott to buy Exact Sciences: $105-a-share deal reshapes cancer-diagnostics market https://biobriefs.com/fda-clears-bayers-hyrnuo-new BioBriefs en 2025-11-21T21:32:07Z FDA clears Bayer’s Hyrnuo: new HER2 therapy and companion test land https://biobriefs.com/pfizers-mrna-flu-shot-phase BioBriefs en 2025-11-21T21:32:07Z Pfizer’s mRNA flu shot... Phase 3 shows 34.5% efficacy advantage https://biobriefs.com/novartis-builds-flagship-us-hub BioBriefs en 2025-11-21T21:32:07Z Novartis builds flagship US hub: North Carolina chosen for end‑to‑end manufacturing https://biobriefs.com/fda-hires-1000-and-pilots BioBriefs en 2025-11-21T21:32:07Z FDA hires 1,000+ and pilots email clarifications to speed drug reviews https://biobriefs.com/lilly-hits-1-trillion-obesity BioBriefs en 2025-11-21T21:32:07Z Lilly hits $1 trillion: obesity drugs drive pharma’s first trillion‑dollar market cap https://biobriefs.com/big-pharma-shifts-novo-and BioBriefs en 2025-11-21T21:32:07Z Big pharma shifts: Novo and Lilly sell obesity drugs directly to employers — Waltz Health launches program https://biobriefs.com/cdc-vaccine-guidance-reversal-public BioBriefs en 2025-11-21T21:32:07Z CDC vaccine guidance reversal... public trust shaken as uptake falls https://biobriefs.com/ocean-diagnostics-rapid-sepsis-test BioBriefs en 2025-11-21T21:32:07Z Ocean Diagnostics’ rapid sepsis test... pilot matched cultures and eyes FDA path https://biobriefs.com/cassidy-bio-raises-8m-seed BioBriefs en 2025-11-21T21:32:07Z Cassidy Bio raises $8M seed... AI platform for designing gene‑editing therapies https://biobriefs.com/abbott-buys-exact-sciences-21 BioBriefs en 2025-11-21T16:32:06Z Abbott buys Exact Sciences: $21 billion leap into cancer diagnostics https://biobriefs.com/bayers-her2-drug-gets-fda BioBriefs en 2025-11-21T16:32:06Z Bayer’s HER2 drug gets FDA nod — Thermo Fisher supplies companion test https://biobriefs.com/function-health-hits-unicorn-valuation BioBriefs en 2025-11-21T16:32:06Z Function Health hits unicorn valuation: $298M Series B https://biobriefs.com/tessera-starts-first-in-human BioBriefs en 2025-11-21T16:32:06Z Tessera starts first-in-human gene-writing trial next month https://biobriefs.com/contineums-j-j-backed-ms BioBriefs en 2025-11-21T16:32:06Z Contineum’s J&J-backed MS candidate flops in Phase 2 https://biobriefs.com/anaptys-sues-gsk-unit-board BioBriefs en 2025-11-21T16:32:06Z Anaptys sues GSK unit — board greenlights $100M buyback https://biobriefs.com/uk-biobank-releases-500k-metabolomes BioBriefs en 2025-11-21T16:32:06Z UK Biobank releases 500K metabolomes: 249‑metabolite atlas https://biobriefs.com/hepta-shows-cfdna-methylation-mirrors BioBriefs en 2025-11-21T16:32:06Z Hepta shows cfDNA methylation mirrors liver biology: cfDNA assay proof https://biobriefs.com/cdc-updates-vaccine-guidance-agency BioBriefs en 2025-11-21T16:32:06Z CDC updates vaccine guidance: agency reopens autism link question https://biobriefs.com/moderna-secures-1-5b-financing BioBriefs en 2025-11-21T16:32:06Z Moderna secures $1.5B financing to pivot toward oncology https://biobriefs.com/abbott-to-acquire-exact-sciences BioBriefs en 2025-11-21T14:32:18Z Abbott to acquire Exact Sciences: $23B bet on cancer diagnostics https://biobriefs.com/gsk-picks-flagship-partners-profound BioBriefs en 2025-11-21T14:32:18Z GSK picks Flagship partners — Profound and Quotient to mine new targets https://biobriefs.com/contineums-j-j-partnered-ms BioBriefs en 2025-11-21T14:32:18Z Contineum’s J&J‑partnered MS drug misses vision endpoints — program under review https://biobriefs.com/prime-editing-breakthrough-single-agent BioBriefs en 2025-11-21T14:32:18Z Prime editing breakthrough: single‑agent strategies aim to treat many diseases https://biobriefs.com/tessera-launches-first-human-test BioBriefs en 2025-11-21T14:32:18Z Tessera launches first human test of in vivo gene‑writing platform https://biobriefs.com/profluent-nets-106m-bezos-backed BioBriefs en 2025-11-21T14:32:18Z Profluent nets $106M — Bezos‑backed bet to scale AI protein design https://biobriefs.com/function-health-hits-2-5b BioBriefs en 2025-11-21T14:32:18Z Function Health hits $2.5B valuation with $298M Series B https://biobriefs.com/bayers-her2-lung-drug-clears BioBriefs en 2025-11-21T14:32:18Z Bayer’s HER2 lung drug clears FDA — companion NGS test wins clearance https://biobriefs.com/nurix-trims-staff-as-pivotal BioBriefs en 2025-11-21T14:32:18Z Nurix trims staff as pivotal BTK degrader DAYBreak trial kicks off https://biobriefs.com/cdc-changes-vaccine-web-language BioBriefs en 2025-11-21T14:32:18Z CDC changes vaccine web language — experts and health groups push back https://biobriefs.com/abbott-to-buy-exact-sciences BioBriefs en 2025-11-21T10:32:25Z Abbott to buy Exact Sciences: $21B cash, enters cancer-diagnostics https://biobriefs.com/bayers-her2-lung-pill-clears BioBriefs en 2025-11-21T10:32:25Z Bayer’s HER2 lung pill clears FDA — companion CDx validated https://biobriefs.com/contineums-j-j-partnered-ms BioBriefs en 2025-11-21T10:32:25Z Contineum’s J&J‑partnered MS drug misses endpoints; company re‑examines data https://biobriefs.com/nurix-trims-staff-as-pivotal BioBriefs en 2025-11-21T10:32:25Z Nurix trims staff as pivotal BTK degrader DAYBreak trial kicks off https://biobriefs.com/ensoma-halves-workforce-after-shifting BioBriefs en 2025-11-21T10:32:25Z Ensoma halves workforce after shifting from platform to clinic https://biobriefs.com/cassidy-bio-raises-8m-to BioBriefs en 2025-11-21T10:32:25Z Cassidy Bio raises $8M to build AI platform for gene‑editing design https://biobriefs.com/profluent-closes-106m-to-scale BioBriefs en 2025-11-21T10:32:25Z Profluent closes $106M to scale AI protein design and commercialization https://biobriefs.com/broads-prime-editing-trick-one BioBriefs en 2025-11-21T10:32:25Z Broad’s prime‑editing trick: one agent to rescue many genetic disorders https://biobriefs.com/moderna-secures-1-5b-while BioBriefs en 2025-11-21T10:32:25Z Moderna secures $1.5B while pruning pipeline to sharpen focus https://biobriefs.com/function-healths-298m-series-b BioBriefs en 2025-11-21T10:32:25Z Function Health’s $298M Series B: lab testing startup hits unicorn mark https://biobriefs.com/abbott-to-buy-exact-sciences BioBriefs en 2025-11-21T09:32:22Z Abbott to buy Exact Sciences: $21B deal reshapes cancer diagnostics https://biobriefs.com/pfizers-mrna-flu-shot-shows BioBriefs en 2025-11-21T09:32:22Z Pfizer’s mRNA flu shot... shows 34.5% efficacy edge in phase 3 https://biobriefs.com/bayers-hyrnuo-wins-fda-nod BioBriefs en 2025-11-21T09:32:22Z Bayer’s Hyrnuo wins FDA nod — companion CDx cleared by Thermo Fisher https://biobriefs.com/contineums-j-j-partnered-ms BioBriefs en 2025-11-21T09:32:22Z Contineum’s J&J‑partnered MS drug flops in mid‑stage test — misses primary goals https://biobriefs.com/moderna-secures-1-5b-lifeline BioBriefs en 2025-11-21T09:32:22Z Moderna secures $1.5B lifeline — prunes pipeline to focus on seasonal vaccines and oncology https://biobriefs.com/function-health-raises-298m-lab BioBriefs en 2025-11-21T09:32:22Z Function Health raises $298M — lab‑testing startup hits $2.5B valuation https://biobriefs.com/profluent-nets-106m-to-scale BioBriefs en 2025-11-21T09:32:22Z Profluent nets $106M to scale AI protein design — Bezos, Altimeter join round https://biobriefs.com/cassidy-bio-raises-8m-seed BioBriefs en 2025-11-21T09:32:22Z Cassidy Bio raises $8M seed to AI‑drive gene‑editing design platform https://biobriefs.com/gsk-taps-flagship-platforms-profound BioBriefs en 2025-11-21T09:32:22Z GSK taps Flagship platforms: Profound and Quotient get first projects https://biobriefs.com/tessera-to-begin-first-human BioBriefs en 2025-11-21T09:32:22Z Tessera to begin first human gene‑writing trial — genomic AI designs follow https://biobriefs.com/abbott-buys-exact-sciences-23b BioBriefs en 2025-11-21T04:31:47Z Abbott buys Exact Sciences: $23B bet on cancer diagnostics https://biobriefs.com/bayers-her2-pill-cleared-fda BioBriefs en 2025-11-21T04:31:47Z Bayer’s HER2 pill cleared: FDA greenlights Hyrnuo for lung cancer https://biobriefs.com/contineum-trial-flop-j-j BioBriefs en 2025-11-21T04:31:47Z Contineum trial flop: J&J‑partnered MS asset misses Phase 2 goals https://biobriefs.com/cdc-website-revision-vaccine-autism BioBriefs en 2025-11-21T04:31:47Z CDC website revision... vaccine‑autism language sparks alarm https://biobriefs.com/function-health-hits-unicorn-mark BioBriefs en 2025-11-21T04:31:47Z Function Health hits unicorn mark: $298M Series B boosts valuation https://biobriefs.com/profluent-secures-106m-to-scale BioBriefs en 2025-11-21T04:31:47Z Profluent secures $106M to scale AI protein design https://biobriefs.com/aspen-raises-115m-to-advance BioBriefs en 2025-11-21T04:31:47Z Aspen raises $115M to advance Parkinson’s cell therapy https://biobriefs.com/gsk-taps-flagship-platforms-discovery BioBriefs en 2025-11-21T04:31:47Z GSK taps Flagship platforms: discovery pacts with Profound and Quotient https://biobriefs.com/broads-liu-lab-demos-pert BioBriefs en 2025-11-21T04:31:47Z Broad’s Liu lab demos PERT: one prime editor to treat many diseases https://biobriefs.com/tessera-to-begin-first-human BioBriefs en 2025-11-21T04:31:47Z Tessera to begin first human gene‑writing trial next month https://biobriefs.com/abbott-to-buy-exact-sciences BioBriefs en 2025-11-20T21:32:18Z Abbott to buy Exact Sciences: $21B push into cancer diagnostics https://biobriefs.com/fda-clears-bayers-hyrnuo-companion BioBriefs en 2025-11-20T21:32:18Z FDA clears Bayer’s Hyrnuo – companion test follows https://biobriefs.com/cdc-flips-vaccine-autism-language BioBriefs en 2025-11-20T21:32:18Z CDC flips vaccine-autism language: scientists alarmed https://biobriefs.com/function-health-raises-298m-lab BioBriefs en 2025-11-20T21:32:18Z Function Health raises $298M — lab testing boom intensifies https://biobriefs.com/moderna-nets-1-5b-lifeline BioBriefs en 2025-11-20T21:32:18Z Moderna nets $1.5B lifeline as it trims programs https://biobriefs.com/methylation-cfdna-test-for-liver BioBriefs en 2025-11-20T21:32:18Z Methylation cfDNA test for liver disease: Hepta posts proof-of-concept https://biobriefs.com/cassidy-bio-raises-8m-seed BioBriefs en 2025-11-20T21:32:18Z Cassidy Bio raises $8M seed to AI-design gene editors https://biobriefs.com/profluent-raises-106m-to-scale BioBriefs en 2025-11-20T21:32:18Z Profluent raises $106M to scale AI-driven protein design https://biobriefs.com/tessera-to-begin-first-human BioBriefs en 2025-11-20T21:32:18Z Tessera to begin first human trial with in vivo gene writing https://biobriefs.com/liu-labs-pert-prime-editing BioBriefs en 2025-11-20T21:32:18Z Liu lab’s PERT prime-editing advance: one agent for many nonsense mutations https://biobriefs.com/abbott-to-acquire-exact-sciences BioBriefs en 2025-11-20T16:32:27Z Abbott to acquire Exact Sciences: $23 billion bet on cancer diagnostics https://biobriefs.com/gsk-taps-flagship-platforms-proteomics BioBriefs en 2025-11-20T16:32:27Z GSK taps Flagship platforms: Proteomics and genomics pacts https://biobriefs.com/tessera-to-start-first-human BioBriefs en 2025-11-20T16:32:27Z Tessera to start first human gene-writing trial next month https://biobriefs.com/prime-editing-advances-single-agent BioBriefs en 2025-11-20T16:32:27Z Prime editing advances: single-agent and tRNA-enhanced approaches https://biobriefs.com/thermo-fisher-wins-fda-nod BioBriefs en 2025-11-20T16:32:27Z Thermo Fisher wins FDA nod for NGS companion test tied to Bayer lung drug https://biobriefs.com/arrowhead-wins-fda-approval-rnai BioBriefs en 2025-11-20T16:32:27Z Arrowhead wins FDA approval: RNAi reaches commercial stage https://biobriefs.com/j-j-buys-halda-for BioBriefs en 2025-11-20T16:32:27Z J&J buys Halda for $3.05B: precision oncology expansion https://biobriefs.com/ex-grail-founders-pitch-cfdna BioBriefs en 2025-11-20T16:32:27Z Ex-Grail founders pitch cfDNA methylation test for liver disease https://biobriefs.com/profluent-raises-106m-ai-protein BioBriefs en 2025-11-20T16:32:27Z Profluent raises $106M: AI protein design scales toward therapeutics https://biobriefs.com/fda-to-allow-one-post BioBriefs en 2025-11-20T16:32:27Z FDA to allow one post-meeting email clarification: small regulatory change, material impact https://biobriefs.com/abbott-to-buy-exact-sciences BioBriefs en 2025-11-20T14:33:14Z Abbott to buy Exact Sciences: $21B deal reshapes cancer‑testing market https://biobriefs.com/novartis-pays-up-for-avidity BioBriefs en 2025-11-20T14:33:14Z Novartis pays up for Avidity – doubles down on neuromuscular RNA bets https://biobriefs.com/bayers-her2-lung-pill-wins BioBriefs en 2025-11-20T14:33:14Z Bayer’s HER2 lung pill wins FDA: rapid approval to meet recent competitor https://biobriefs.com/arrowheads-rnai-drug-wins-fda BioBriefs en 2025-11-20T14:33:14Z Arrowhead’s RNAi drug wins FDA — price war looms with Ionis https://biobriefs.com/prime-editing-variant-one-agent BioBriefs en 2025-11-20T14:33:14Z Prime editing variant: one‑agent, many diseases – suppressor tRNAs advance https://biobriefs.com/profluent-raises-106m-ai-protein BioBriefs en 2025-11-20T14:33:14Z Profluent raises $106M: AI protein design hits commercial stride https://biobriefs.com/function-health-hits-2-5b BioBriefs en 2025-11-20T14:33:14Z Function Health hits $2.5B valuation after $298M Series B https://biobriefs.com/aspen-raises-115m-personalized-parkinsons BioBriefs en 2025-11-20T14:33:14Z Aspen raises $115M: personalized Parkinson’s cell therapy pushes toward Phase III https://biobriefs.com/tessera-to-start-first-human BioBriefs en 2025-11-20T14:33:14Z Tessera to start first human trial: gene‑writing moves into the clinic https://biobriefs.com/congress-moves-on-biomanufacturing-bill BioBriefs en 2025-11-20T14:33:14Z Congress moves on biomanufacturing: bill to create National Biopharma Manufacturing COE https://biobriefs.com/novartis-pays-12b-for-avidity BioBriefs en 2025-11-20T10:33:02Z Novartis pays $12B for Avidity – neuromuscular push https://biobriefs.com/j-j-pays-3-05b BioBriefs en 2025-11-20T10:33:02Z J&J pays $3.05B for Halda – adds precision oncology arm https://biobriefs.com/abbott-eyes-exact-sciences-diagnostics BioBriefs en 2025-11-20T10:33:02Z Abbott eyes Exact Sciences... diagnostics bet https://biobriefs.com/tessera-to-begin-first-human BioBriefs en 2025-11-20T10:33:02Z Tessera to begin first human gene‑writing trial – Flagship unit moves to clinic https://biobriefs.com/prime-editing-one-platform-for BioBriefs en 2025-11-20T10:33:02Z Prime editing: one platform for many diseases – suppressor tRNAs and PERT https://biobriefs.com/genomic-ai-scales-gene-design BioBriefs en 2025-11-20T10:33:02Z Genomic AI scales gene design and interpretation – semantic models and Genos https://biobriefs.com/ai-protein-design-draws-capital BioBriefs en 2025-11-20T10:33:02Z AI protein design draws capital—Profluent and Iambic scale platforms https://biobriefs.com/genetic-elements-stabilize-ecdna-tumor BioBriefs en 2025-11-20T10:33:02Z Genetic elements stabilize ecDNA; tumor‑reactive CD8 clusters mapped https://biobriefs.com/fda-clears-targeted-oncology-drugs BioBriefs en 2025-11-20T10:33:02Z FDA clears targeted oncology drugs – Komzifti and Bayer’s Hyrnuo https://biobriefs.com/u-s-biomanufacturing-push-gains BioBriefs en 2025-11-20T10:33:02Z U.S. biomanufacturing push gains momentum – COE bill and Thermo Fisher centers https://biobriefs.com/abbott-in-talks-exact-sciences BioBriefs en 2025-11-20T09:31:40Z Abbott in talks — Exact Sciences acquisition could reshape cancer testing https://biobriefs.com/prime-editing-one-platform-to BioBriefs en 2025-11-20T09:31:40Z Prime editing... one platform to treat many genetic diseases https://biobriefs.com/fda-clears-ziftomenib-first-menin BioBriefs en 2025-11-20T09:31:40Z FDA clears ziftomenib — first menin inhibitor for NPM1‑mutant AML https://biobriefs.com/tessera-to-test-gene-writing BioBriefs en 2025-11-20T09:31:40Z Tessera to test gene writing in humans — in vivo program enters clinic https://biobriefs.com/genomic-foundation-models-and-semantic BioBriefs en 2025-11-20T09:31:40Z Genomic foundation models and semantic design reshape synthetic biology https://biobriefs.com/merck-shells-out-for-cidara BioBriefs en 2025-11-20T09:31:40Z Merck shells out for Cidara — big bet on long‑acting influenza prevention https://biobriefs.com/roches-oral-serd-delays-recurrence BioBriefs en 2025-11-20T09:31:40Z Roche’s oral SERD delays recurrence — adjuvant win shakes breast‑cancer landscape https://biobriefs.com/first-in-class-fcgri-blockers BioBriefs en 2025-11-20T09:31:40Z First‑in‑class FcγRI blockers suppress autoimmune pathology in preclinical models https://biobriefs.com/ai-biotech-funding-surges-profluent BioBriefs en 2025-11-20T09:31:40Z AI biotech funding surges — Profluent and Iambic raise major rounds https://biobriefs.com/spatial-multi-omics-alliance-and BioBriefs en 2025-11-20T09:31:40Z Spatial multi‑omics alliance and tumor atlases boost translational cancer biology https://biobriefs.com/merck-snaps-up-cidara-for BioBriefs en 2025-11-20T04:31:46Z Merck snaps up Cidara for $9.2B — Influenza prevention bet https://biobriefs.com/j-j-shells-out-3 BioBriefs en 2025-11-20T04:31:46Z J&J shells out $3.05B for Halda — Precision oncology scale-up https://biobriefs.com/roches-oral-serd-wins-pivotal BioBriefs en 2025-11-20T04:31:46Z Roche’s oral SERD wins pivotal adjuvant readout — breast cancer landscape shifts https://biobriefs.com/broads-liu-unveils-pert-prime BioBriefs en 2025-11-20T04:31:46Z Broad’s Liu unveils PERT prime‑editing platform — one agent, many diseases https://biobriefs.com/tessera-to-enter-humans-flagships BioBriefs en 2025-11-20T04:31:46Z Tessera to enter humans: Flagship’s gene writing platform hits clinic https://biobriefs.com/arrowheads-rnai-drug-cleared-commercial BioBriefs en 2025-11-20T04:31:46Z Arrowhead’s RNAi drug cleared — commercial launch and pricing battle begins https://biobriefs.com/profluent-raises-106m-ai-protein BioBriefs en 2025-11-20T04:31:46Z Profluent raises $106M — AI protein design draws Bezos, Altimeter https://biobriefs.com/function-health-raises-298m-retail BioBriefs en 2025-11-20T04:31:46Z Function Health raises $298M — retail lab testing scales to $2.5B valuation https://biobriefs.com/congressional-push-for-a-biopharma BioBriefs en 2025-11-20T04:31:46Z Congressional push for a Biopharma Manufacturing Center of Excellence — bipartisan bill filed https://biobriefs.com/administration-unrest-clouds-vaccines-industry BioBriefs en 2025-11-20T04:31:46Z Administration unrest clouds vaccines: industry alarm over policy shifts https://biobriefs.com/j-j-spends-3-05b BioBriefs en 2025-11-19T21:31:52Z J&J spends $3.05B to buy Halda – expands precision oncology bets https://biobriefs.com/merck-buys-cidara-for-9 BioBriefs en 2025-11-19T21:31:52Z Merck buys Cidara for $9.2B – targets long-acting, strain-agnostic flu shot https://biobriefs.com/abbott-talks-to-buy-exact BioBriefs en 2025-11-19T21:31:52Z Abbott talks to buy Exact Sciences... takeover chatter lifts Exact stock https://biobriefs.com/roche-buys-global-rights-to BioBriefs en 2025-11-19T21:31:52Z Roche buys global rights to Freenome tests – $75M equity, $200M+ pact https://biobriefs.com/arrowheads-rnai-wins-fda-clearance BioBriefs en 2025-11-19T21:31:52Z Arrowhead’s RNAi wins FDA clearance – pricing pressures start https://biobriefs.com/tessera-to-start-first-human BioBriefs en 2025-11-19T21:31:52Z Tessera to start first human gene‑writing trial next month – rare disease target https://biobriefs.com/oncolytics-and-fda-align-on BioBriefs en 2025-11-19T21:31:52Z Oncolytics and FDA align on pivotal pelareorep study – mPDAC trial moves forward https://biobriefs.com/profluent-raises-106m-to-scale BioBriefs en 2025-11-19T21:31:52Z Profluent raises $106M to scale AI protein design – Bezos Expeditions joins https://biobriefs.com/function-health-bags-298m-series BioBriefs en 2025-11-19T21:31:52Z Function Health bags $298M Series B – $2.5B valuation for consumer labs https://biobriefs.com/gsk-pays-50m-upfront-to BioBriefs en 2025-11-19T21:31:52Z GSK pays $50M upfront to LTZ to develop myeloid cell engagers – oncology push https://biobriefs.com/arrowhead-rnai-approval-price-war BioBriefs en 2025-11-19T16:32:40Z Arrowhead RNAi approval: Price war with Ionis begins https://biobriefs.com/j-j-shells-out-3b BioBriefs en 2025-11-19T16:32:40Z J&J shells out $3B for Halda: Precision oncology bet deepens https://biobriefs.com/roches-oral-serd-clears-adjuvant BioBriefs en 2025-11-19T16:32:40Z Roche’s oral SERD clears adjuvant test: Giredestrant scores again https://biobriefs.com/merck-buys-cidara-for-9 BioBriefs en 2025-11-19T16:32:40Z Merck buys Cidara for $9.2B: Push into long-acting influenza prevention https://biobriefs.com/mercks-hiv-push-islatravir-two BioBriefs en 2025-11-19T16:32:40Z Merck’s HIV push: Islatravir two-drug combo meets Phase 3 goal https://biobriefs.com/profluent-raises-106m-ai-proteins BioBriefs en 2025-11-19T16:32:40Z Profluent raises $106M: AI proteins scale toward therapeutics https://biobriefs.com/iambic-raises-100m-ai-models BioBriefs en 2025-11-19T16:32:40Z Iambic raises $100M: AI models to drive cancer drug discovery https://biobriefs.com/nvidia-sheba-and-mount-sinai BioBriefs en 2025-11-19T16:32:40Z Nvidia, Sheba and Mount Sinai partner: Build genomic foundation model https://biobriefs.com/roche-expands-early-cancer-diagnostics BioBriefs en 2025-11-19T16:32:40Z Roche expands early-cancer diagnostics: Freenome licensing deal tops $200M https://biobriefs.com/kura-kyowa-menin-inhibitor-cleared BioBriefs en 2025-11-19T16:32:40Z Kura/Kyowa menin inhibitor cleared: Komzifti wins FDA approval ahead of PDUFA https://biobriefs.com/j-j-snaps-up-halda BioBriefs en 2025-11-19T14:32:32Z J&J snaps up Halda for $3.05B — gains 'hold-and-kill' oncology tech https://biobriefs.com/arrowhead-wins-fda-ok-rnai BioBriefs en 2025-11-19T14:32:32Z Arrowhead wins FDA OK: RNAi drug clears rare‑lipid hurdle — price duel looms https://biobriefs.com/roche-s-breast-cancer-pill BioBriefs en 2025-11-19T14:32:32Z Roche's breast‑cancer pill edges adjuvant trial — SERD field jolted https://biobriefs.com/zanidatamab-tops-phase-iii-in BioBriefs en 2025-11-19T14:32:32Z Zanidatamab tops phase III in gastric cancer: bispecific beats trastuzumab https://biobriefs.com/merck-pays-9-2b-for BioBriefs en 2025-11-19T14:32:32Z Merck pays $9.2B for Cidara to add long‑acting flu antiviral CD388 https://biobriefs.com/fda-clears-ziftomenib-komzifti-for BioBriefs en 2025-11-19T14:32:32Z FDA clears ziftomenib (Komzifti) for r/r NPM1‑mutant AML — menin inhibitor gets nod early https://biobriefs.com/gsk-joins-mce-race-50m BioBriefs en 2025-11-19T14:32:32Z GSK joins MCE race: $50M upfront for LTZ myeloid‑cell engager tech https://biobriefs.com/roche-inks-200m-plus-pact BioBriefs en 2025-11-19T14:32:32Z Roche inks $200M‑plus pact to commercialize Freenome’s cancer screens abroad https://biobriefs.com/administration-vaccine-proposals-roil-industry BioBriefs en 2025-11-19T14:32:32Z Administration vaccine proposals roil industry: makers warn of supply shock https://biobriefs.com/j-j-buys-halda-3 BioBriefs en 2025-11-19T10:32:15Z J&J buys Halda — $3.05B bet on RIPTAC oncology https://biobriefs.com/rnai-reaches-market-arrowhead-wins BioBriefs en 2025-11-19T10:32:15Z RNAi reaches market... Arrowhead wins FDA and ignites pricing fight https://biobriefs.com/roches-oral-serd-delays-recurrence BioBriefs en 2025-11-19T10:32:15Z Roche’s oral SERD delays recurrence — adjuvant Phase III win https://biobriefs.com/zanidatamab-shines-in-gea-phase BioBriefs en 2025-11-19T10:32:15Z Zanidatamab shines in GEA — Phase III PFS and OS signals https://biobriefs.com/merck-spends-9-2b-to BioBriefs en 2025-11-19T10:32:15Z Merck spends $9.2B to buy Cidara — lung, flu prevention play https://biobriefs.com/fda-clears-menin-inhibitor-komzifti BioBriefs en 2025-11-19T10:32:15Z FDA clears menin inhibitor Komzifti — early approval for NPM1 AML https://biobriefs.com/novo-nordisk-readies-alzheimer-verdict BioBriefs en 2025-11-19T10:32:15Z Novo Nordisk readies Alzheimer verdict — semaglutide results due https://biobriefs.com/white-house-vaccine-shakeup-manufacturers BioBriefs en 2025-11-19T10:32:15Z White House vaccine shakeup — manufacturers warn of supply and schedule risk https://biobriefs.com/nordic-capital-buys-evosep-proteomics BioBriefs en 2025-11-19T10:32:15Z Nordic Capital buys Evosep — proteomics scales toward clinical markets https://biobriefs.com/nvidia-sheba-mount-sinai-partner BioBriefs en 2025-11-19T10:32:15Z Nvidia, Sheba, Mount Sinai partner on genomic AI engine — gFM push https://biobriefs.com/j-j-buys-halda-for BioBriefs en 2025-11-19T09:32:20Z J&J buys Halda for $3.05B — gains RIPTAC prostate drug and platform https://biobriefs.com/arrowhead-wins-fda-ok-for BioBriefs en 2025-11-19T09:32:20Z Arrowhead wins FDA OK for RNAi drug — rivals brace for price fight https://biobriefs.com/roches-oral-serd-hits-primary BioBriefs en 2025-11-19T09:32:20Z Roche’s oral SERD hits primary goal — adjuvant breast‑cancer stakes rise https://biobriefs.com/zanidatamab-posts-phase-iii-win BioBriefs en 2025-11-19T09:32:20Z Zanidatamab posts Phase III win in gastroesophageal cancer — filing plans begin https://biobriefs.com/administration-mulls-sweeping-vaccine-changes BioBriefs en 2025-11-19T09:32:20Z Administration mulls sweeping vaccine changes — industry issues private warnings https://biobriefs.com/iambic-terray-land-ai-bets BioBriefs en 2025-11-19T09:32:20Z Iambic, Terray land AI bets — models fuel discovery and candidate selection https://biobriefs.com/fda-clears-ziftomenib-komzifti-menin BioBriefs en 2025-11-19T09:32:20Z FDA clears ziftomenib (Komzifti) — menin inhibitor approved for NPM1‑mutant AML https://biobriefs.com/dnae-and-ocean-dx-push BioBriefs en 2025-11-19T09:32:20Z DNAe and Ocean Dx push same‑day infectious diagnostics toward clinic use https://biobriefs.com/big-venture-vehicles-close-fresh BioBriefs en 2025-11-19T09:32:20Z Big venture vehicles close — fresh capital for early biotech in Europe and US https://biobriefs.com/thermo-fisher-purdue-and-partners BioBriefs en 2025-11-19T09:32:20Z Thermo Fisher, Purdue and partners expand hands‑on biomanufacturing capacity and training https://biobriefs.com/j-j-pays-3-05b BioBriefs en 2025-11-19T04:32:40Z J&J pays $3.05B for Halda — adds RIPTAC prostate asset https://biobriefs.com/arrowhead-wins-fda-approval-prices BioBriefs en 2025-11-19T04:32:40Z Arrowhead wins FDA approval — prices undercut Ionis https://biobriefs.com/roche-oral-serd-delays-recurrence BioBriefs en 2025-11-19T04:32:40Z Roche oral SERD delays recurrence — adjuvant phase III win https://biobriefs.com/xenotransplant-encyclopedia-61-day-pig BioBriefs en 2025-11-19T04:32:40Z Xenotransplant ‘encyclopedia’: 61-day pig kidney maps rejection https://biobriefs.com/trump-rfk-jr-mull-vaccine BioBriefs en 2025-11-19T04:32:40Z Trump, RFK Jr. mull vaccine rule changes — manufacturers warn https://biobriefs.com/roche-freenome-tie-up-and BioBriefs en 2025-11-19T04:32:40Z Roche, Freenome tie-up and new sequencer — diagnostics push abroad https://biobriefs.com/nvidia-sheba-mount-sinai-to BioBriefs en 2025-11-19T04:32:40Z Nvidia, Sheba, Mount Sinai to build genomic foundation model https://biobriefs.com/dnae-readies-rapid-sequencing-platform BioBriefs en 2025-11-19T04:32:40Z DNAe readies rapid sequencing platform — LiDia‑SEQ commercialization set for 2027 https://biobriefs.com/venture-capital-surge-iambic-100m BioBriefs en 2025-11-19T04:32:40Z Venture capital surge: Iambic $100M; Solve nets $120M for ADCs https://biobriefs.com/nih-cuts-halted-383-trials BioBriefs en 2025-11-19T04:32:40Z NIH cuts halted 383 trials — 74,000 participants affected https://biobriefs.com/administration-probes-vaccine-reform-makers BioBriefs en 2025-11-18T21:32:18Z Administration probes vaccine reform: makers warn of supply shock https://biobriefs.com/roches-serd-wins-in-early BioBriefs en 2025-11-18T21:32:18Z Roche’s SERD wins in early breast cancer – adjuvant data positive https://biobriefs.com/zanidatamab-cuts-progression-in-phase BioBriefs en 2025-11-18T21:32:18Z Zanidatamab cuts progression in Phase 3 — partners set regulatory push https://biobriefs.com/j-j-shells-out-3 BioBriefs en 2025-11-18T21:32:18Z J&J shells out $3.05B for Halda’s RIPTAC platform https://biobriefs.com/merck-buys-cidara-for-9 BioBriefs en 2025-11-18T21:32:18Z Merck buys Cidara for $9.2B — long-acting, strain-agnostic flu candidate in focus https://biobriefs.com/roche-invests-in-freenome-75m BioBriefs en 2025-11-18T21:32:18Z Roche invests in Freenome: $75M stake, ex-US commercialization deal https://biobriefs.com/iambic-raises-100m-to-scale BioBriefs en 2025-11-18T21:32:18Z Iambic raises $100M to scale AI drug discovery and bring candidates to clinic https://biobriefs.com/dnae-targets-2027-launch-for BioBriefs en 2025-11-18T21:32:18Z DNAe targets 2027 launch for LiDia-SEQ: same-day bloodstream infection sequencing https://biobriefs.com/nordic-capital-takes-majority-stake BioBriefs en 2025-11-18T21:32:18Z Nordic Capital takes majority stake in Evosep to push proteomics into clinic https://biobriefs.com/tcr-momentum-captain-t-cell BioBriefs en 2025-11-18T21:32:18Z TCR momentum: Captain T Cell funds pipeline and T-knife files CTA for solid tumors https://biobriefs.com/j-j-snaps-up-halda BioBriefs en 2025-11-18T16:32:07Z J&J snaps up Halda for $3.05B — acquires RIPTAC 'hold-and-kill' platform https://biobriefs.com/zanidatamab-clears-phase-3-barrier BioBriefs en 2025-11-18T16:32:07Z Zanidatamab clears phase 3 barrier — two positive reads reshape HER2 GEA market https://biobriefs.com/merck-buys-cidara-for-9 BioBriefs en 2025-11-18T16:32:07Z Merck buys Cidara for $9.2B — aims at long‑acting, strain‑agnostic influenza prevention https://biobriefs.com/roche-inks-licensing-pact-with BioBriefs en 2025-11-18T16:32:07Z Roche inks licensing pact with Freenome — $75M equity, ex‑US commercialization rights https://biobriefs.com/iambic-raises-100m-ai-platform BioBriefs en 2025-11-18T16:32:07Z Iambic raises $100M — AI platform funding to move oncology candidates into clinic https://biobriefs.com/hermes-biosciences-raises-6m-seed BioBriefs en 2025-11-18T16:32:07Z Hermes Biosciences raises $6M seed — automating extracellular vesicle isolation https://biobriefs.com/nvidia-sheba-mount-sinai-team BioBriefs en 2025-11-18T16:32:07Z Nvidia, Sheba, Mount Sinai team to build genomic LLM — noncoding DNA in focus https://biobriefs.com/fecal-exfoliome-foli-seq-validated BioBriefs en 2025-11-18T16:32:07Z Fecal exfoliome (Foli‑seq) validated — new noninvasive window into gut immune state https://biobriefs.com/solid-licenses-aav-slb101-to BioBriefs en 2025-11-18T16:32:07Z Solid licenses AAV‑SLB101 to Andelyn — next‑gen capsid expands CDMO offerings https://biobriefs.com/fda-tightens-elevidys-label-myocarditis BioBriefs en 2025-11-18T16:32:07Z FDA tightens Elevidys label: myocarditis warnings and use limits https://biobriefs.com/j-j-pays-3-05b BioBriefs en 2025-11-18T14:31:51Z J&J pays $3.05B for Halda: buys RIPTAC 'hold-and-kill' platform https://biobriefs.com/merck-snaps-up-cidara-for BioBriefs en 2025-11-18T14:31:51Z Merck snaps up Cidara for $9.2B: targets long‑acting influenza prevention https://biobriefs.com/zanidatamab-beats-trastuzumab-phase-iii BioBriefs en 2025-11-18T14:31:51Z Zanidatamab beats trastuzumab: Phase III HERIZON‑GEA‑01 posts positive topline data https://biobriefs.com/roche-s-oral-serd-clears BioBriefs en 2025-11-18T14:31:51Z Roche's oral SERD clears planned interim: adjuvant breast cancer hit https://biobriefs.com/nih-grant-cuts-halt-383 BioBriefs en 2025-11-18T14:31:51Z NIH grant cuts halt 383 trials — 74,311 participants left in limbo https://biobriefs.com/iambic-raises-100m-to-move BioBriefs en 2025-11-18T14:31:51Z Iambic raises $100M to move AI‑discovered oncology candidates toward clinic https://biobriefs.com/solve-therapeutics-pulls-in-120m BioBriefs en 2025-11-18T14:31:51Z Solve Therapeutics pulls in $120M: targets best‑in‑class ADCs https://biobriefs.com/rapid-sepsis-test-matches-blood BioBriefs en 2025-11-18T14:31:51Z Rapid sepsis test matches blood culture: Ocean Dx hits 100% sensitivity & specificity https://biobriefs.com/foli-seq-captures-the-exfoliome BioBriefs en 2025-11-18T14:31:51Z Foli‑seq captures the 'exfoliome': noninvasive fecal RNA tool maps gut immune states https://biobriefs.com/neural-stem-cell-transplant-restores BioBriefs en 2025-11-18T14:31:51Z Neural stem cell transplant restores primate forelimb function — major translational step https://biobriefs.com/j-j-buys-halda-for BioBriefs en 2025-11-18T10:31:38Z J&J buys Halda for $3.05B: acquires RIPTAC platform and lead prostate drug https://biobriefs.com/ziihera-phase-3-zanidatamab-shows BioBriefs en 2025-11-18T10:31:38Z Ziihera Phase 3: zanidatamab shows PFS and OS gains in first-line GEA https://biobriefs.com/stem-cell-transplant-restores-primate BioBriefs en 2025-11-18T10:31:38Z Stem cell transplant restores primate hand function: path to clinical translation https://biobriefs.com/foli-seq-fecal-exfoliome-sequencing BioBriefs en 2025-11-18T10:31:38Z Foli‑seq: fecal exfoliome sequencing maps gut immune and epithelial states https://biobriefs.com/roche-previews-axelios-1-fast BioBriefs en 2025-11-18T10:31:38Z Roche previews Axelios 1: fast SBX sequencing shows cancer‑genomics promise https://biobriefs.com/thermo-fisher-pushes-next-day BioBriefs en 2025-11-18T10:31:38Z Thermo Fisher pushes next‑day comprehensive genomic profiling on Genexus https://biobriefs.com/ocean-dx-sepsis-test-matches BioBriefs en 2025-11-18T10:31:38Z Ocean Dx sepsis test matches gold standard: 5‑hour, direct whole‑blood assay https://biobriefs.com/artios-raises-115m-dna-damage BioBriefs en 2025-11-18T10:31:38Z Artios raises $115M: DNA damage‑response specialist funds clinic expansion https://biobriefs.com/sofinnova-closes-eur650m-flagship-fund BioBriefs en 2025-11-18T10:31:38Z Sofinnova closes €650M flagship fund: more dry powder for early biotech https://biobriefs.com/nuvalents-alk-drug-posts-durable BioBriefs en 2025-11-18T10:31:38Z Nuvalent’s ALK drug posts durable responses: clinical rival to Pfizer’s Lorbrena https://biobriefs.com/j-j-snaps-up-halda BioBriefs en 2025-11-18T09:32:00Z J&J snaps up Halda for $3.05B — new anti-resistance approach added https://biobriefs.com/zanidatamab-wins-phase-3-potential BioBriefs en 2025-11-18T09:32:00Z Zanidatamab wins phase 3 — potential new HER2 standard in gastroesophageal cancer https://biobriefs.com/primates-regain-hand-function-neural BioBriefs en 2025-11-18T09:32:00Z Primates regain hand function — neural stem cell graft restores forelimb control https://biobriefs.com/fecal-exfoliome-sequencing-noninvasively-tracks BioBriefs en 2025-11-18T09:32:00Z Fecal 'exfoliome' sequencing noninvasively tracks gut inflammation — Foli‑seq unveiled https://biobriefs.com/new-sequencing-hardware-speeds-cancer BioBriefs en 2025-11-18T09:32:00Z New sequencing hardware speeds cancer genomics — Roche, Thermo present platform advances https://biobriefs.com/solid-licenses-aav-slb101-as BioBriefs en 2025-11-18T09:32:00Z Solid licenses AAV‑SLB101 as AAV field readies next‑gen vectors https://biobriefs.com/mirna-moves-from-wearables-to BioBriefs en 2025-11-18T09:32:00Z miRNA moves from wearables to exosomes: two new sensing and delivery advances https://biobriefs.com/ai-predicts-drug-mechanisms-and BioBriefs en 2025-11-18T09:32:00Z AI predicts drug mechanisms and prioritizes molecules — DeepTarget, Terray unveil tools https://biobriefs.com/rapid-diagnostics-advance-ocean-dx BioBriefs en 2025-11-18T09:32:00Z Rapid diagnostics advance: Ocean Dx sepsis test and WHO clearance for BD HPV assay https://biobriefs.com/big-biotech-and-vc-cash BioBriefs en 2025-11-18T09:32:00Z Big biotech and VC cash returns: Artios $115M and Sofinnova’s €650M close https://biobriefs.com/j-j-pays-3-05b BioBriefs en 2025-11-18T04:31:38Z J&J pays $3.05B for Halda... buys new anti‑resistance cancer platform https://biobriefs.com/ziihera-tops-trastuzumab-phase-3 BioBriefs en 2025-11-18T04:31:38Z Ziihera tops trastuzumab: Phase 3 HERIZON-GEA‑01 posts PFS, OS gains https://biobriefs.com/nuvalents-alk-inhibitor-posts-durable BioBriefs en 2025-11-18T04:31:38Z Nuvalent’s ALK inhibitor posts durable responses — FDA path opens https://biobriefs.com/solve-therapeutics-raises-120m-adc BioBriefs en 2025-11-18T04:31:38Z Solve Therapeutics raises $120M — ADC push lands Merck support https://biobriefs.com/artios-closes-115m-series-d BioBriefs en 2025-11-18T04:31:38Z Artios closes $115M Series D — DNA damage repair programs advance https://biobriefs.com/sofinnova-closes-eur650m-fund-extends BioBriefs en 2025-11-18T04:31:38Z Sofinnova closes €650M fund... extends early‑stage life‑science capital https://biobriefs.com/stem-cell-transplant-restores-hand BioBriefs en 2025-11-18T04:31:38Z Stem cell transplant restores hand function in monkeys... major translational step https://biobriefs.com/fecal-exfoliome-sequencing-foli-seq BioBriefs en 2025-11-18T04:31:38Z Fecal exfoliome sequencing (Foli‑seq) — noninvasive gut transcriptomics for IBD https://biobriefs.com/roches-axelios-1-previews-fast BioBriefs en 2025-11-18T04:31:38Z Roche’s Axelios 1 previews fast cancer genomics — early data promising https://biobriefs.com/thermo-fisher-touts-next-day BioBriefs en 2025-11-18T04:31:38Z Thermo Fisher touts next‑day CGP on Genexus — Oncomine assay trimmed to 24‑hour TAT https://biobriefs.com/j-j-buys-halda-for BioBriefs en 2025-11-17T21:32:22Z J&J buys Halda for $3.05B – adds anti‑resistance RIPTAC platform https://biobriefs.com/zanidatamab-phase-3-win-zymeworks BioBriefs en 2025-11-17T21:32:22Z Zanidatamab phase 3 win: Zymeworks and Jazz push HER2 standard https://biobriefs.com/merck-to-buy-cidara-for BioBriefs en 2025-11-17T21:32:22Z Merck to buy Cidara for $9.2B: bets on long‑acting influenza prevention https://biobriefs.com/sofinnova-closes-eur650m-fund-fresh BioBriefs en 2025-11-17T21:32:22Z Sofinnova closes €650M fund – fresh capital for early‑stage biotech https://biobriefs.com/artios-raises-115m-dna-damage BioBriefs en 2025-11-17T21:32:22Z Artios raises $115M – DNA damage repair programs get cash https://biobriefs.com/solve-nets-120m-to-refine BioBriefs en 2025-11-17T21:32:22Z Solve nets $120M to refine ADC linkers – Merck among backers https://biobriefs.com/stem-cells-restore-primate-forelimb BioBriefs en 2025-11-17T21:32:22Z Stem cells restore primate forelimb function: major step for spinal repair https://biobriefs.com/pig-kidney-survives-61-days BioBriefs en 2025-11-17T21:32:22Z Pig kidney survives 61 days — multi‑omics map immune rejection https://biobriefs.com/foli-seq-fecal-exfoliome-sequencing BioBriefs en 2025-11-17T21:32:22Z Foli‑seq: fecal exfoliome sequencing enables noninvasive IBD monitoring https://biobriefs.com/roches-axelios-1-shows-speed BioBriefs en 2025-11-17T21:32:22Z Roche’s Axelios 1 shows speed and concordance in cancer genomics trials https://biobriefs.com/merck-to-buy-cidara-for BioBriefs en 2025-11-17T16:32:16Z Merck to buy Cidara for $9.2B – adds Phase III long‑acting flu antiviral https://biobriefs.com/j-j-pays-3-05b BioBriefs en 2025-11-17T16:32:16Z J&J pays $3.05B for Halda... gains RIPTAC prostate program https://biobriefs.com/stem-cell-grafts-restore-monkey BioBriefs en 2025-11-17T16:32:16Z Stem cell grafts restore monkey hand function – milestone for spinal repair https://biobriefs.com/61-day-pig-kidney-study BioBriefs en 2025-11-17T16:32:16Z 61‑day pig kidney study maps immune rejection – a xenotransplantation 'encyclopedia' https://biobriefs.com/nuvalents-alk-drug-posts-responses BioBriefs en 2025-11-17T16:32:16Z Nuvalent’s ALK drug posts responses – FDA talks loom vs Pfizer’s Lorbrena https://biobriefs.com/solve-raises-120m-to-advance BioBriefs en 2025-11-17T16:32:16Z Solve raises $120M to advance ADCs – linkers aim to fix historical limits https://biobriefs.com/sofinnova-sews-up-eur650m-fund BioBriefs en 2025-11-17T16:32:16Z Sofinnova sews up €650M fund — more capital for early therapeutics https://biobriefs.com/foli-seq-captures-host-rna BioBriefs en 2025-11-17T16:32:16Z Foli‑seq captures host RNA in feces — a new noninvasive gut immune readout https://biobriefs.com/who-prequalifies-bd-onclarity-hpv BioBriefs en 2025-11-17T16:32:16Z WHO prequalifies BD Onclarity HPV test – expands screening in low‑resource settings https://biobriefs.com/korro-stock-collapses-after-rna BioBriefs en 2025-11-17T16:32:16Z Korro stock collapses after RNA‑editing miss — restructures to extend runway https://biobriefs.com/merck-to-buy-cidara-for BioBriefs en 2025-11-17T14:32:24Z Merck to buy Cidara for $9.2B — Adds long‑acting influenza antiviral https://biobriefs.com/nuvalent-posts-alk-response-rates BioBriefs en 2025-11-17T14:32:24Z Nuvalent posts ALK response rates — Eyes fast FDA filing https://biobriefs.com/stem-cell-transplant-restores-primate BioBriefs en 2025-11-17T14:32:24Z Stem cell transplant restores primate hand function — Major translational step https://biobriefs.com/crispr-edit-of-nrf2-reverses BioBriefs en 2025-11-17T14:32:24Z CRISPR edit of NRF2: reverses chemotherapy resistance in lung cancer https://biobriefs.com/solve-pulls-120m-moves-two BioBriefs en 2025-11-17T14:32:24Z Solve pulls $120M — Moves two ADCs toward clinic https://biobriefs.com/artios-pockets-115m-fuels-dna BioBriefs en 2025-11-17T14:32:24Z Artios pockets $115M — Fuels DNA‑damage repair oncology programs https://biobriefs.com/lilly-taps-abl-bio-40m BioBriefs en 2025-11-17T14:32:24Z Lilly taps ABL Bio: $40M upfront, $2.6B total https://biobriefs.com/lexicmap-searches-worlds-microbial-genomes BioBriefs en 2025-11-17T14:32:24Z LexicMap: Searches world’s microbial genomes in minutes https://biobriefs.com/foli-seq-captures-the-fecal BioBriefs en 2025-11-17T14:32:24Z Foli‑seq captures the fecal exfoliome — Noninvasive gut immune monitoring https://biobriefs.com/rapid-aav8-antibody-test-new BioBriefs en 2025-11-17T14:32:24Z Rapid AAV8 antibody test — New AAV variants expand vascular targeting https://biobriefs.com/merck-to-acquire-cidara-for BioBriefs en 2025-11-17T10:32:20Z Merck to acquire Cidara for $9.2B — Adds Phase III influenza candidate https://biobriefs.com/sofinnova-closes-eur650m-fund-pumps BioBriefs en 2025-11-17T10:32:20Z Sofinnova closes €650M fund — Pumps capital into clinic‑ready drugmakers https://biobriefs.com/korro-stock-craters-81-data BioBriefs en 2025-11-17T10:32:20Z Korro stock craters 81% — Data miss forces layoffs and R&D pivot https://biobriefs.com/iambic-secures-100m-funds-trials BioBriefs en 2025-11-17T10:32:20Z Iambic secures $100M — Funds trials for AI‑designed oncology drugs https://biobriefs.com/point-of-care-aav8-antibody BioBriefs en 2025-11-17T10:32:20Z Point‑of‑care AAV8 antibody test debuts — Speeds gene‑therapy screening https://biobriefs.com/aav-variants-unlock-vascular-delivery BioBriefs en 2025-11-17T10:32:20Z AAV variants unlock vascular delivery — Two teams report improved endothelial transduction https://biobriefs.com/spvn06-shows-promise-as-mutation BioBriefs en 2025-11-17T10:32:20Z SPVN06 shows promise as mutation‑independent retinal gene therapy https://biobriefs.com/til-therapy-advances-fda-nod BioBriefs en 2025-11-17T10:32:20Z TIL therapy advances — FDA nod meets manufacturing and access bottlenecks https://biobriefs.com/idr-mediated-condensation-boosts-car BioBriefs en 2025-11-17T10:32:20Z IDR‑mediated condensation boosts CAR‑T potency against low‑antigen tumors https://biobriefs.com/intranasal-nanogel-therapeutic-vaccine-prevents BioBriefs en 2025-11-17T10:32:20Z Intranasal nanogel therapeutic vaccine prevents HPV‑driven cervical tumors in preclinical models https://biobriefs.com/merck-buys-cidara-9-2b BioBriefs en 2025-11-17T09:31:38Z Merck buys Cidara: $9.2B deal adds long‑acting influenza antiviral https://biobriefs.com/korro-collapses-data-miss-triggers BioBriefs en 2025-11-17T09:31:38Z Korro collapses: Data miss triggers 81% slide, cuts and pivot https://biobriefs.com/sofinnova-raises-eur650m-new-flagship BioBriefs en 2025-11-17T09:31:38Z Sofinnova raises €650M: New flagship fund backs preclinical life sciences https://biobriefs.com/iambic-raises-100m-ai-discovered BioBriefs en 2025-11-17T09:31:38Z Iambic raises $100M: AI‑discovered oncology candidate moves toward trials https://biobriefs.com/point-of-care-aav8-antibody BioBriefs en 2025-11-17T09:31:38Z Point‑of‑care AAV8 antibody test: Tackles a key gene‑therapy bottleneck https://biobriefs.com/aav-variants-boost-vascular-delivery BioBriefs en 2025-11-17T09:31:38Z AAV variants boost vascular delivery: Two studies report improved transduction https://biobriefs.com/microglial-cars-enhance-amyloid-clearance BioBriefs en 2025-11-17T09:31:38Z Microglial CARs... Enhance amyloid clearance in preclinical models https://biobriefs.com/condensing-car-t-potency-idr BioBriefs en 2025-11-17T09:31:38Z Condensing CAR‑T potency: IDR strategy boosts activity against low‑antigen tumors https://biobriefs.com/aav-microdystrophin-therapy-update-elevidys BioBriefs en 2025-11-17T09:31:38Z AAV microdystrophin therapy update: Elevidys signals gene‑therapy momentum https://biobriefs.com/prime-editing-inversion-method-pie BioBriefs en 2025-11-17T09:31:38Z Prime‑editing inversion method: PIE enables chromosome‑scale DNA flips https://biobriefs.com/merck-to-acquire-cidara-for BioBriefs en 2025-11-17T04:31:55Z Merck to acquire Cidara for $9.2B — Adds long‑acting flu antiviral https://biobriefs.com/sofinnova-closes-eur650m-fund-capital BioBriefs en 2025-11-17T04:31:55Z Sofinnova closes €650M fund — Capital XI backs preclinical drugmakers and medtech https://biobriefs.com/korro-stock-collapses-81-after BioBriefs en 2025-11-17T04:31:55Z Korro stock collapses 81% after underwhelming RNA‑editing data https://biobriefs.com/iambic-raises-100m-to-move BioBriefs en 2025-11-17T04:31:55Z Iambic raises $100M to move AI‑designed oncology candidates into trials https://biobriefs.com/aav-vector-toolkit-expands-point BioBriefs en 2025-11-17T04:31:55Z AAV vector toolkit expands — Point‑of‑care antibody test and new capsids for vascular transduction https://biobriefs.com/gene-editing-toolkit-widens-collagen BioBriefs en 2025-11-17T04:31:55Z Gene‑editing toolkit widens — Collagen disorder therapies and chromosomal‑scale inversions https://biobriefs.com/car-platform-advances-intracellular-condensation BioBriefs en 2025-11-17T04:31:55Z CAR platform advances: intracellular condensation and microglial CARs https://biobriefs.com/decitabine-combination-improves-outcomes-for BioBriefs en 2025-11-17T04:31:55Z Decitabine combination improves outcomes for high‑risk AML https://biobriefs.com/cftr-triple-therapy-benefits-children BioBriefs en 2025-11-17T04:31:55Z CFTR triple therapy benefits children — ETI shows pediatric gains https://biobriefs.com/metabolic-therapies-advance-glutamine-driven BioBriefs en 2025-11-17T04:31:55Z Metabolic therapies advance — Glutamine‑driven bladder cancer and autophagy activator for NSCLC https://biobriefs.com/merck-to-buy-cidara-for BioBriefs en 2025-11-16T21:32:03Z Merck to buy Cidara for $9.2B: bolsters long‑acting influenza program https://biobriefs.com/iambic-raises-100m-advances-ai BioBriefs en 2025-11-16T21:32:03Z Iambic raises $100M: advances AI‑discovered cancer drug into trials https://biobriefs.com/point-of-care-aav8-antibody BioBriefs en 2025-11-16T21:32:03Z Point‑of‑care AAV8 antibody test... eases gene‑therapy screening bottleneck https://biobriefs.com/intranasal-nanogel-vaccine-slows-hpv BioBriefs en 2025-11-16T21:32:03Z Intranasal nanogel vaccine slows HPV‑driven cervical tumors – preclinical https://biobriefs.com/fda-restricts-elevidys-label-adds BioBriefs en 2025-11-16T21:32:03Z FDA restricts Elevidys label – adds boxed warning for DMD gene therapy https://biobriefs.com/biomimetic-mrna-delivery-restores-pten BioBriefs en 2025-11-16T21:32:03Z Biomimetic mRNA delivery restores PTEN in colorectal tumors – targeted immunotherapy advance https://biobriefs.com/engineered-cell-strategies-amplify-target BioBriefs en 2025-11-16T21:32:03Z Engineered cell strategies amplify target clearance: CAR‑T IDRs and microglial CARs https://biobriefs.com/targeted-genetic-assay-improves-diagnosis BioBriefs en 2025-11-16T21:32:03Z Targeted genetic assay improves diagnosis for X‑linked dystonia‑parkinsonism https://biobriefs.com/ctdna-ngs-shows-clinical-utility BioBriefs en 2025-11-16T21:32:03Z ctDNA‑NGS shows clinical utility in stage III/IV NSCLC – large Chinese cohort https://biobriefs.com/aav-gene-therapy-delivering-bdnf BioBriefs en 2025-11-16T21:32:03Z AAV gene therapy delivering BDNF/GAS6 delays ALS onset in mice https://biobriefs.com/merck-to-buy-cidara-for BioBriefs en 2025-11-16T16:32:15Z Merck to buy Cidara for $9.2B — secures late‑stage flu antiviral https://biobriefs.com/fda-narrows-elevidys-label-boxed BioBriefs en 2025-11-16T16:32:15Z FDA narrows Elevidys label: boxed warning, ambulatory‑only use https://biobriefs.com/aav-bottleneck-point-of-care BioBriefs en 2025-11-16T16:32:15Z AAV bottleneck: point‑of‑care antibody screening and high‑tropism capsids emerge https://biobriefs.com/nasal-nanogel-vaccine-slows-hpv BioBriefs en 2025-11-16T16:32:15Z Nasal nanogel vaccine slows HPV tumors: therapeutic approach advances https://biobriefs.com/gene-therapy-in-neurology-hearing BioBriefs en 2025-11-16T16:32:15Z Gene therapy in neurology: hearing restored and ALS onset delayed in mice https://biobriefs.com/md-anderson-launches-2-5b BioBriefs en 2025-11-16T16:32:15Z MD Anderson launches $2.5B campaign — 'Only Possible Here' aims to transform cancer research https://biobriefs.com/deeptarget-ai-maps-small-molecule BioBriefs en 2025-11-16T16:32:15Z DeepTarget: AI maps small‑molecule cancer mechanisms — computational discovery scales https://biobriefs.com/bovine-cell-immortalization-without-gm BioBriefs en 2025-11-16T16:32:15Z Bovine cell immortalization without GM: cultivated beef barrier falls https://biobriefs.com/third-arc-licenses-adagene-safebody BioBriefs en 2025-11-16T16:32:15Z Third Arc licenses Adagene Safebody — $840M deal to build masked CD3 engagers https://biobriefs.com/chmp-recommends-multiple-new-medicines BioBriefs en 2025-11-16T16:32:15Z CHMP recommends multiple new medicines — EMA advances gene therapy and oncology candidates https://biobriefs.com/merck-buys-cidara-for-9 BioBriefs en 2025-11-16T14:31:38Z Merck buys Cidara for $9.2B — bolsters influenza prevention push https://biobriefs.com/fda-tightens-elevidys-label-boxed BioBriefs en 2025-11-16T14:31:38Z FDA tightens Elevidys label: boxed warning added — use narrowed https://biobriefs.com/gene-therapy-toolkit-expands-new BioBriefs en 2025-11-16T14:31:38Z Gene therapy toolkit expands: new AAV capsids and bedside antibody test https://biobriefs.com/lundbeck-jumps-into-avadel-fight BioBriefs en 2025-11-16T14:31:38Z Lundbeck jumps into Avadel fight — Alkermes faces tougher bid https://biobriefs.com/triple-cftr-combination-benefits-children BioBriefs en 2025-11-16T14:31:38Z Triple CFTR combination benefits children with cystic fibrosis — pediatric data https://biobriefs.com/terasaki-institute-and-caltech-win BioBriefs en 2025-11-16T14:31:38Z Terasaki Institute and Caltech win $2.8M CIRM grant — embryo formation research https://biobriefs.com/intranasal-nanogel-therapeutic-vaccine-prevents BioBriefs en 2025-11-16T14:31:38Z Intranasal nanogel therapeutic vaccine prevents HPV-driven cervical tumors in animals https://biobriefs.com/non-gm-immortalization-of-bovine BioBriefs en 2025-11-16T14:31:38Z Non‑GM immortalization of bovine cells — scalable step for cultivated beef https://biobriefs.com/deeptarget-ai-uncovers-drug-mechanisms BioBriefs en 2025-11-16T14:31:38Z DeepTarget: AI uncovers drug mechanisms — computational route to new cancer targets https://biobriefs.com/targeted-genetic-test-improves-xdp BioBriefs en 2025-11-16T14:31:38Z Targeted genetic test improves XDP diagnosis — resolves hidden causes in Filipino patients https://biobriefs.com/merck-to-buy-cidara-for BioBriefs en 2025-11-16T10:32:10Z Merck to buy Cidara for $9.2B: bet on long‑acting flu prevention https://biobriefs.com/fda-clamps-down-on-elevidys BioBriefs en 2025-11-16T10:32:10Z FDA clamps down on Elevidys: boxed warning and ambulatory restriction https://biobriefs.com/lundbeck-ignites-avadel-bidding-war BioBriefs en 2025-11-16T10:32:10Z Lundbeck ignites Avadel bidding war — Alkermes under pressure https://biobriefs.com/chmp-recommends-five-products-telethon BioBriefs en 2025-11-16T10:32:10Z CHMP recommends five products — Telethon‑backed gene therapy surfaces https://biobriefs.com/tumor-infiltrating-lymphocytes-approval-momentum BioBriefs en 2025-11-16T10:32:10Z Tumor‑infiltrating lymphocytes: approval momentum and manufacturing gaps https://biobriefs.com/aav-toolbox-expands-point-of BioBriefs en 2025-11-16T10:32:10Z AAV toolbox expands: point‑of‑care antibody screen and vascular‑tropic variants https://biobriefs.com/ngs-automation-and-standards-accelerate BioBriefs en 2025-11-16T10:32:10Z NGS automation and standards accelerate clinical genomics workflows https://biobriefs.com/vglut3-gene-therapy-restores-hearing BioBriefs en 2025-11-16T10:32:10Z VGLUT3 gene therapy restores hearing in aged mice https://biobriefs.com/scientists-immortalize-bovine-cells-without BioBriefs en 2025-11-16T10:32:10Z Scientists immortalize bovine cells without genetic engineering — cultivated beef scale‑up https://biobriefs.com/machine-learning-predicts-dcd-donor BioBriefs en 2025-11-16T10:32:10Z Machine learning predicts DCD donor death — slashes futile liver procurements https://biobriefs.com/merck-stakes-9-2b-on BioBriefs en 2025-11-16T09:32:02Z Merck stakes $9.2B on long‑acting flu drug — Cidara takeover https://biobriefs.com/fda-tightens-elevidys-label-boxed BioBriefs en 2025-11-16T09:32:02Z FDA tightens Elevidys label: boxed warning, use narrowed https://biobriefs.com/aav-arms-race-point-of BioBriefs en 2025-11-16T09:32:02Z AAV arms race... point‑of‑care antibody test and new capsids emerge https://biobriefs.com/intranasal-nanogel-vaccine-slows-hpv BioBriefs en 2025-11-16T09:32:02Z Intranasal nanogel vaccine slows HPV‑driven cervical tumors — preclinical win https://biobriefs.com/prime-editing-inversion-method-scales BioBriefs en 2025-11-16T09:32:02Z Prime‑editing inversion method scales chromosomal rearrangements — PIE reported https://biobriefs.com/biomimetic-mrna-delivery-restores-pten BioBriefs en 2025-11-16T09:32:02Z Biomimetic mRNA delivery restores PTEN — targeted immunotherapy for colorectal cancer https://biobriefs.com/ai-flags-resistance-carbadetector-spots BioBriefs en 2025-11-16T09:32:02Z AI flags resistance — CarbaDetector spots carbapenemase from routine tests https://biobriefs.com/next-gen-blood-thinner-milvexian BioBriefs en 2025-11-16T09:32:02Z Next‑gen blood thinner milvexian fails key trial — anticoagulation program hit https://biobriefs.com/medicxi-raises-eur500m-fund-backers BioBriefs en 2025-11-16T09:32:02Z Medicxi raises €500M fund — backers target creation‑stage biotech https://biobriefs.com/amp-issues-draft-guidelines-on BioBriefs en 2025-11-16T09:32:02Z AMP issues draft guidelines on cancer sequencing variant interpretation https://biobriefs.com/merck-snaps-up-cidara-for BioBriefs en 2025-11-16T04:32:02Z Merck snaps up Cidara for $9.2B — late-stage flu antiviral in hand https://biobriefs.com/fda-narrows-elevidys-label-boxed BioBriefs en 2025-11-16T04:32:02Z FDA narrows Elevidys label — boxed warning, ambulatory restriction added https://biobriefs.com/factor-xia-program-stumbles-next BioBriefs en 2025-11-16T04:32:02Z Factor XIa program stumbles — next‑gen blood thinner fails Phase 3 readout https://biobriefs.com/new-aav-variants-boost-vascular BioBriefs en 2025-11-16T04:32:02Z New AAV variants boost vascular gene delivery — vascular transduction improved https://biobriefs.com/prime-editing-inversion-pie-enables BioBriefs en 2025-11-16T04:32:02Z Prime‑editing inversion (PIE) enables chromosome‑scale DNA rearrangements https://biobriefs.com/intranasal-nanogel-therapeutic-vaccine-slows BioBriefs en 2025-11-16T04:32:02Z Intranasal nanogel therapeutic vaccine slows HPV‑driven cervical cancer in animals https://biobriefs.com/terasaki-caltech-land-2-8m BioBriefs en 2025-11-16T04:32:02Z Terasaki, Caltech land $2.8M CIRM grant to model early human embryo formation https://biobriefs.com/volta-labs-neb-partner-to BioBriefs en 2025-11-16T04:32:02Z Volta Labs, NEB partner to automate NGS library prep on Callisto https://biobriefs.com/singleron-wins-china-medical-device BioBriefs en 2025-11-16T04:32:02Z Singleron wins China medical device registration for automated single‑cell platform https://biobriefs.com/non-gm-immortalization-opens-door BioBriefs en 2025-11-16T04:32:02Z Non‑GM immortalization opens door to scalable cultivated beef https://biobriefs.com/merck-stakes-9-2b-on BioBriefs en 2025-11-15T21:31:58Z Merck stakes $9.2B on Cidara’s long‑acting flu candidate https://biobriefs.com/lundbeck-jumps-into-avadel-bidding BioBriefs en 2025-11-15T21:31:58Z Lundbeck jumps into Avadel bidding war — Alkermes on edge https://biobriefs.com/fda-narrows-elevidys-label-boxed BioBriefs en 2025-11-15T21:31:58Z FDA narrows Elevidys label: boxed warning added https://biobriefs.com/chmp-backs-five-new-products BioBriefs en 2025-11-15T21:31:58Z CHMP backs five new products — EMA advances key filings https://biobriefs.com/charity-drives-eu-approval-push BioBriefs en 2025-11-15T21:31:58Z Charity drives EU approval push for Wiskott‑Aldrich gene therapy https://biobriefs.com/amp-drafts-cancer-sequencing-reporting BioBriefs en 2025-11-15T21:31:58Z AMP drafts cancer‑sequencing reporting rules; AI diagnostics featured https://biobriefs.com/engineered-aav-variants-and-assay BioBriefs en 2025-11-15T21:31:58Z Engineered AAV variants and assay fixes sharpen gene‑therapy toolbox https://biobriefs.com/mrna-delivery-system-restores-pten BioBriefs en 2025-11-15T21:31:58Z mRNA delivery system restores PTEN — sharpens colorectal immunotherapy https://biobriefs.com/intranasal-nanogel-vaccine-slows-hpv BioBriefs en 2025-11-15T21:31:58Z Intranasal nanogel vaccine slows HPV‑driven cervical tumors in models https://biobriefs.com/non-gm-bovine-cell-immortalization BioBriefs en 2025-11-15T21:31:58Z Non‑GM bovine cell immortalization clears a major cultivated‑meat hurdle https://biobriefs.com/merck-pays-9-2b-for BioBriefs en 2025-11-15T16:32:26Z Merck pays $9.2B for Cidara — bets on season‑long flu prevention https://biobriefs.com/pfizer-closes-up-to-10b BioBriefs en 2025-11-15T16:32:26Z Pfizer closes up to $10B Metsera deal — adds fast‑acting amylin, GLP assets https://biobriefs.com/fda-clears-komzifti-menin-inhibitor BioBriefs en 2025-11-15T16:32:26Z FDA clears Komzifti — menin inhibitor approved for NPM1‑mutant AML https://biobriefs.com/bms-j-j-next-gen BioBriefs en 2025-11-15T16:32:26Z BMS/J&J next‑gen blood thinner fails phase 3 — milvexian misses endpoint https://biobriefs.com/lundbeck-interrupts-alkermes-avadel-deal BioBriefs en 2025-11-15T16:32:26Z Lundbeck interrupts Alkermes‑Avadel deal — unsolicited higher bid tops earlier offer https://biobriefs.com/medicxi-closes-eur500m-fund-v BioBriefs en 2025-11-15T16:32:26Z Medicxi closes €500M Fund V — doubles down on asset‑centric biotech bets https://biobriefs.com/ema-panel-endorses-five-new BioBriefs en 2025-11-15T16:32:26Z EMA panel endorses five new medicines — gene therapy for Wiskott‑Aldrich included https://biobriefs.com/ai-pushes-into-discovery-and BioBriefs en 2025-11-15T16:32:26Z AI pushes into discovery and diagnostics — DeepTarget predicts drug mechanisms; CarbaDetector flags carbapenemase https://biobriefs.com/scientists-immortalize-bovine-cells-without BioBriefs en 2025-11-15T16:32:26Z Scientists immortalize bovine cells without genetic modification — cultivated beef milestone https://biobriefs.com/genetically-edited-pig-kidney-sustains BioBriefs en 2025-11-15T16:32:26Z Genetically edited pig kidney sustains function for 61 days in human recipient — xenotransplant advance https://biobriefs.com/merck-pays-9-2b-for BioBriefs en 2025-11-15T14:31:52Z Merck pays $9.2B for Cidara: buys late‑stage flu preventive https://biobriefs.com/pfizer-closes-up-to-10b BioBriefs en 2025-11-15T14:31:52Z Pfizer closes up to $10B Metsera deal: fast‑acting amylin added https://biobriefs.com/fda-clears-komzifti-kura-kyowas BioBriefs en 2025-11-15T14:31:52Z FDA clears Komzifti: Kura/Kyowa’s menin inhibitor wins in NPM1 AML https://biobriefs.com/milvexian-fails-key-trial-bms BioBriefs en 2025-11-15T14:31:52Z Milvexian fails key trial: BMS and J&J stop acute coronary study https://biobriefs.com/lundbeck-disrupts-alkermes-avadel-deal BioBriefs en 2025-11-15T14:31:52Z Lundbeck disrupts Alkermes’ Avadel deal: higher unsolicited offer arrives https://biobriefs.com/fda-restricts-elevidys-sarepta-gene BioBriefs en 2025-11-15T14:31:52Z FDA restricts Elevidys: Sarepta gene therapy label tightened https://biobriefs.com/medicxi-closes-eur500m-fund-v BioBriefs en 2025-11-15T14:31:52Z Medicxi closes €500M Fund V: renewed bet on asset‑centric startups https://biobriefs.com/md-anderson-unveils-2-5b BioBriefs en 2025-11-15T14:31:52Z MD Anderson unveils $2.5B campaign: fundraising to transform cancer care https://biobriefs.com/multi-omics-expose-pig-to BioBriefs en 2025-11-15T14:31:52Z Multi‑omics expose pig‑to‑human kidney immune barriers: rejection reversible https://biobriefs.com/ema-advisers-back-five-products BioBriefs en 2025-11-15T14:31:52Z EMA advisers back five products: Telethon gene therapy for Wiskott‑Aldrich among them https://biobriefs.com/merck-stakes-9-2b-on BioBriefs en 2025-11-15T10:32:20Z Merck stakes $9.2B on Cidara’s long-acting flu candidate https://biobriefs.com/fda-narrows-elevidys-label-boxed BioBriefs en 2025-11-15T10:32:20Z FDA narrows Elevidys label: boxed warning, ambulatory‑only restriction https://biobriefs.com/lundbecks-unsolicited-bid-ignites-avadel BioBriefs en 2025-11-15T10:32:20Z Lundbeck’s unsolicited bid ignites Avadel fight – Alkermes under pressure https://biobriefs.com/fda-clears-komzifti-new-menin BioBriefs en 2025-11-15T10:32:20Z FDA clears Komzifti – new menin inhibitor approved for NPM1‑mutant AML https://biobriefs.com/pfizer-closes-up-to-10b BioBriefs en 2025-11-15T10:32:20Z Pfizer closes up to $10B Metsera buy – fast‑acting obesity play locked in https://biobriefs.com/multi-omics-in-pig-to BioBriefs en 2025-11-15T10:32:20Z Multi‑omics in pig‑to‑human kidney grafts maps rejection — and reversal https://biobriefs.com/terasaki-caltech-win-cirm-grant BioBriefs en 2025-11-15T10:32:20Z Terasaki, Caltech win CIRM grant — Japan panel nudges embryo‑from‑stem‑cells path https://biobriefs.com/ai-tools-push-drug-target BioBriefs en 2025-11-15T10:32:20Z AI tools push drug‑target prediction and rapid resistance detection https://biobriefs.com/chmp-recommends-new-medicines-sanofi BioBriefs en 2025-11-15T10:32:20Z CHMP recommends new medicines: Sanofi diabetes, Lilly SERD and five more https://biobriefs.com/amp-issues-draft-guidelines-for BioBriefs en 2025-11-15T10:32:20Z AMP issues draft guidelines for reporting cancer sequencing variants https://biobriefs.com/merck-stakes-9-2b-on BioBriefs en 2025-11-15T09:32:47Z Merck stakes $9.2B on Cidara – buys late‑stage flu antiviral https://biobriefs.com/pfizer-seals-up-to-10b BioBriefs en 2025-11-15T09:32:47Z Pfizer seals up to $10B Metsera deal – picks up fast‑acting obesity asset https://biobriefs.com/lundbeck-jumps-into-avadel-fight BioBriefs en 2025-11-15T09:32:47Z Lundbeck jumps into Avadel fight – forces Alkermes into tougher spot https://biobriefs.com/fda-clears-kuras-menin-inhibitor BioBriefs en 2025-11-15T09:32:47Z FDA clears Kura’s menin inhibitor – new option for NPM1‑mutant AML https://biobriefs.com/pig-kidney-xenotransplant-mapped-multi BioBriefs en 2025-11-15T09:32:47Z Pig kidney xenotransplant mapped: multi‑omics traces rejection and rescue https://biobriefs.com/fda-tightens-sareptas-elevidys-label BioBriefs en 2025-11-15T09:32:47Z FDA tightens Sarepta’s Elevidys label – boxed warning and use limits https://biobriefs.com/ema-advisers-back-five-products BioBriefs en 2025-11-15T09:32:47Z EMA advisers back five products – charity‑led gene therapy clears EU hurdle https://biobriefs.com/day-one-acquires-mersana-backloaded BioBriefs en 2025-11-15T09:32:47Z Day One acquires Mersana – backloaded deal centers on B7‑H4 ADC https://biobriefs.com/deeptarget-and-ai-safety-models BioBriefs en 2025-11-15T09:32:47Z DeepTarget and AI safety models: computational tools reshape drug discovery https://biobriefs.com/cirm-funds-embryo-formation-work BioBriefs en 2025-11-15T09:32:47Z CIRM funds embryo‑formation work – ethics debate intensifies in Japan https://biobriefs.com/merck-stakes-9-2b-on BioBriefs en 2025-11-15T04:32:20Z Merck stakes $9.2B on Cidara: buys late‑stage flu asset https://biobriefs.com/pfizer-seals-metsera-deal-ends BioBriefs en 2025-11-15T04:32:20Z Pfizer seals Metsera deal: ends $10B bidding war https://biobriefs.com/lundbeck-interrupts-alkermes-avadel-deal BioBriefs en 2025-11-15T04:32:20Z Lundbeck interrupts Alkermes’ Avadel deal: offers higher bid https://biobriefs.com/fda-tightens-gene-therapy-safety BioBriefs en 2025-11-15T04:32:20Z FDA tightens gene therapy safety; AMP issues draft cancer‑NGS rules https://biobriefs.com/multi-omics-maps-immune-rejection BioBriefs en 2025-11-15T04:32:20Z Multi‑omics maps immune rejection in pig‑to‑human kidney graft https://biobriefs.com/fda-clears-komzifti-for-r BioBriefs en 2025-11-15T04:32:20Z FDA clears Komzifti for r/r NPM1‑mutant AML: ziftomenib approved https://biobriefs.com/ml-model-predicts-donor-death BioBriefs en 2025-11-15T04:32:20Z ML model predicts donor death timing – cuts futile liver procurements 60% https://biobriefs.com/non-gm-immortalization-of-bovine BioBriefs en 2025-11-15T04:32:20Z Non‑GM immortalization of bovine cells opens path for scalable cultivated beef https://biobriefs.com/deeptarget-ai-predicts-anti-cancer BioBriefs en 2025-11-15T04:32:20Z DeepTarget: AI predicts anti‑cancer drug mechanisms of action https://biobriefs.com/amp-2025-spotlights-next-gen BioBriefs en 2025-11-15T04:32:20Z AMP 2025 spotlights next‑gen blood cancer diagnostics; AI tools front and center https://biobriefs.com/merck-pays-9-2b-for BioBriefs en 2025-11-14T21:32:02Z Merck pays $9.2B for Cidara’s long‑acting flu biologic https://biobriefs.com/pfizer-closes-up-to-10b BioBriefs en 2025-11-14T21:32:02Z Pfizer closes up to $10B Metsera buy — fast‑acting obesity assets onboarded https://biobriefs.com/fda-adds-boxed-warning-to BioBriefs en 2025-11-14T21:32:02Z FDA adds boxed warning to Sarepta’s Elevidys: ambulatory use restricted https://biobriefs.com/fda-approves-kura-kyowas-komzifti BioBriefs en 2025-11-14T21:32:02Z FDA approves Kura/Kyowa’s Komzifti — first oral menin inhibitor for NPM1‑mutant AML https://biobriefs.com/novartis-ganlum-meets-phase-3 BioBriefs en 2025-11-14T21:32:02Z Novartis’ GanLum meets Phase‑3 goal: a candidate against drug‑resistant malaria https://biobriefs.com/multi-omics-maps-immune-drivers BioBriefs en 2025-11-14T21:32:02Z Multi‑omics maps immune drivers of pig‑to‑human kidney xenotransplant rejection https://biobriefs.com/bms-j-js-factor-xi BioBriefs en 2025-11-14T21:32:02Z BMS/J&J’s factor‑XI inhibitor fails key Phase‑3: milvexian trial stopped https://biobriefs.com/twist-reframes-reporting-as-ai BioBriefs en 2025-11-14T21:32:02Z Twist reframes reporting as AI‑driven drug discovery lifts revenues https://biobriefs.com/scientists-immortalize-bovine-cells-without BioBriefs en 2025-11-14T21:32:02Z Scientists immortalize bovine cells without genetic edits — cultivated beef barrier drops https://biobriefs.com/magnetic-microrobots-navigate-vasculature-to BioBriefs en 2025-11-14T21:32:02Z Magnetic microrobots navigate vasculature to release drugs with surgical precision https://biobriefs.com/merck-shells-out-9-2b BioBriefs en 2025-11-14T16:32:30Z Merck shells out $9.2B for Cidara — buys late‑stage flu prophylactic https://biobriefs.com/pfizer-closes-metsera-buyout-ends BioBriefs en 2025-11-14T16:32:30Z Pfizer closes Metsera buyout — ends Novo’s late bid https://biobriefs.com/fda-sketches-plausible-mechanism-path BioBriefs en 2025-11-14T16:32:30Z FDA sketches ‘plausible mechanism’ path: bespoke drugs get a roadmap https://biobriefs.com/fda-clears-kuras-ziftomenib-first BioBriefs en 2025-11-14T16:32:30Z FDA clears Kura’s ziftomenib — first menin inhibitor approved for NPM1‑mutant AML https://biobriefs.com/multi-omics-of-pig-to BioBriefs en 2025-11-14T16:32:30Z Multi‑omics of pig‑to‑human kidney transplant reveals immune drivers — rejection reversible https://biobriefs.com/medicxi-closes-eur500m-fund-v BioBriefs en 2025-11-14T16:32:30Z Medicxi closes €500M fund V to back asset‑centric biotech creation https://biobriefs.com/novartis-ganlum-meets-phase-iii BioBriefs en 2025-11-14T16:32:30Z Novartis’ GanLum meets Phase III goal — a new tool against resistant malaria https://biobriefs.com/magnetically-guided-microrobots-pass-large BioBriefs en 2025-11-14T16:32:30Z Magnetically guided microrobots pass large‑animal tests for targeted delivery https://biobriefs.com/ultra-mild-methylation-sequencing-overcomes BioBriefs en 2025-11-14T16:32:30Z Ultra‑mild methylation sequencing overcomes DNA damage limits in archival samples https://biobriefs.com/biotech-shakeups-layoffs-pivots-and BioBriefs en 2025-11-14T16:32:30Z Biotech shakeups: layoffs, pivots and cash‑preserving restructurings hit small firms https://biobriefs.com/merck-pays-9-2b-for BioBriefs en 2025-11-14T14:32:19Z Merck pays $9.2B for Cidara: bets on season-long flu biologic https://biobriefs.com/fda-clears-kura-kyowas-komzifti BioBriefs en 2025-11-14T14:32:19Z FDA clears Kura/Kyowa’s Komzifti — first menin inhibitor approved for NPM1 AML https://biobriefs.com/fda-unveils-plausible-mechanism-pathway BioBriefs en 2025-11-14T14:32:19Z FDA unveils plausible‑mechanism pathway: roadmap for bespoke rare‑disease therapies https://biobriefs.com/multi-omics-maps-rejection-in BioBriefs en 2025-11-14T14:32:19Z Multi‑omics maps rejection in pig‑to‑human kidney grafts — 61‑day physiology study https://biobriefs.com/pfizer-closes-up-to-10b BioBriefs en 2025-11-14T14:32:19Z Pfizer closes up to $10B Metsera deal — inside a high‑stakes bidding war https://biobriefs.com/novartis-ganlum-clears-phase-3 BioBriefs en 2025-11-14T14:32:19Z Novartis’ GanLum clears Phase 3: new antimalarial meets WHO efficacy bar https://biobriefs.com/medicxi-secures-eur500m-fund-pours BioBriefs en 2025-11-14T14:32:19Z Medicxi secures €500M fund — pours cash into asset‑centric biotech creation https://biobriefs.com/magnetic-microrobots-navigate-vasculature-in BioBriefs en 2025-11-14T14:32:19Z Magnetic microrobots navigate vasculature: in vivo delivery shown in large animals https://biobriefs.com/bms-j-js-next-gen BioBriefs en 2025-11-14T14:32:19Z BMS–J&J’s next‑gen blood thinner fails phase 3 — milvexian study stopped for futility https://biobriefs.com/lilly-bets-2-6b-on BioBriefs en 2025-11-14T14:32:19Z Lilly bets $2.6B on ABL Bio’s Grabody: brain‑shuttle licensing pact https://biobriefs.com/fda-clears-komzifti-kura-kyowa BioBriefs en 2025-11-14T10:32:37Z FDA clears Komzifti: Kura, Kyowa secure first menin inhibitor approval in NPM1 AML https://biobriefs.com/pfizer-closes-metsera-deal-obesity BioBriefs en 2025-11-14T10:32:37Z Pfizer closes Metsera deal: obesity biotech absorbed after heated bidding https://biobriefs.com/multi-omics-map-immune-triggers BioBriefs en 2025-11-14T10:32:37Z Multi-omics map immune triggers: pig‑to‑human kidney xenotransplant reveals rejection pathways https://biobriefs.com/novartis-ganlum-hits-phase-iii BioBriefs en 2025-11-14T10:32:37Z Novartis’ GanLum hits Phase III goal — a new weapon against resistant malaria https://biobriefs.com/medicxi-closes-eur500m-fund-european BioBriefs en 2025-11-14T10:32:37Z Medicxi closes €500m fund: European VC doubles down on asset‑centric biotech bets https://biobriefs.com/lilly-pays-2-6b-to BioBriefs en 2025-11-14T10:32:37Z Lilly pays $2.6B to access ABL’s Grabody‑B brain‑shuttle — CNS delivery deals accelerate https://biobriefs.com/nilo-launches-with-101m-neuro BioBriefs en 2025-11-14T10:32:37Z Nilo launches with $101M: neuro‑immune biotech backs neural circuit approach to inflammation https://biobriefs.com/fda-unveils-plausible-mechanism-pathway BioBriefs en 2025-11-14T10:32:37Z FDA unveils plausible‑mechanism pathway — a roadmap for bespoke gene‑editing therapies https://biobriefs.com/korro-pivots-after-rna-editing BioBriefs en 2025-11-14T10:32:37Z Korro pivots after RNA‑editing miss — layoffs, strategy rewrite follow disappointing data https://biobriefs.com/day-one-to-acquire-mersana BioBriefs en 2025-11-14T10:32:37Z Day One to acquire Mersana — buyer bets on B7‑H4 ADC with milestone‑heavy package https://biobriefs.com/pfizer-seals-metsera-buyout-obesity BioBriefs en 2025-11-14T09:32:00Z Pfizer seals Metsera buyout: obesity biotech goes to pharma https://biobriefs.com/multi-omics-maps-pig-to BioBriefs en 2025-11-14T09:32:00Z Multi-omics maps pig-to-human kidney rejection: drugs reverse immune attack https://biobriefs.com/novartis-ganlum-meets-phase-3 BioBriefs en 2025-11-14T09:32:00Z Novartis’ GanLum meets Phase 3 bar: new antimalarial advances https://biobriefs.com/fda-unveils-regulatory-path-for BioBriefs en 2025-11-14T09:32:00Z FDA unveils regulatory path for bespoke gene-editing therapies https://biobriefs.com/grabody-b-deal-with-lilly BioBriefs en 2025-11-14T09:32:00Z Grabody-B deal with Lilly: ABL Bio inks $2.6B platform pact https://biobriefs.com/kuras-ziftomenib-cleared-by-fda BioBriefs en 2025-11-14T09:32:00Z Kura’s ziftomenib cleared by FDA: new option for NPM1‑mutant AML https://biobriefs.com/vector-safety-spotlight-aav-assay BioBriefs en 2025-11-14T09:32:00Z Vector safety spotlight: AAV assay challenges and HSV‑1 vector mutations https://biobriefs.com/ultra-mild-methylation-sequencing-debuts BioBriefs en 2025-11-14T09:32:00Z Ultra‑mild methylation sequencing debuts: UMBS‑seq fixes bisulfite damage https://biobriefs.com/allen-institute-launches-brain-knowledge BioBriefs en 2025-11-14T09:32:00Z Allen Institute launches Brain Knowledge Platform: 34M cells, AI models https://biobriefs.com/medicxi-raises-eur500m-fund-to BioBriefs en 2025-11-14T09:32:00Z Medicxi raises €500M fund to back asset‑centric biotech startups https://biobriefs.com/fda-clears-komzifti-kuras-menin BioBriefs en 2025-11-14T04:32:13Z FDA clears Komzifti — Kura’s menin inhibitor approved for NPM1‑mutant AML https://biobriefs.com/pig-kidney-runs-61-days BioBriefs en 2025-11-14T04:32:13Z Pig kidney runs 61 days: Multi‑omics trace rejection and rescue https://biobriefs.com/novartis-ganlum-hits-phase-iii BioBriefs en 2025-11-14T04:32:13Z Novartis’ GanLum hits Phase III goal — potential new tool against resistance https://biobriefs.com/lilly-bets-on-brain-shuttle BioBriefs en 2025-11-14T04:32:13Z Lilly bets on brain shuttle: $2.6B ABL Bio pact advances CNS delivery https://biobriefs.com/pfizer-closes-metsera-buy-up BioBriefs en 2025-11-14T04:32:13Z Pfizer closes Metsera buy — up to $10B deal ends bidding war https://biobriefs.com/day-one-buys-mersana-emi BioBriefs en 2025-11-14T04:32:13Z Day One buys Mersana — Emi‑Le ADC central to the deal https://biobriefs.com/korro-pivots-after-failed-rna BioBriefs en 2025-11-14T04:32:13Z Korro pivots after failed RNA‑editing readout — mass layoffs follow https://biobriefs.com/fda-unveils-plausible-mechanism-pathway BioBriefs en 2025-11-14T04:32:13Z FDA unveils plausible‑mechanism pathway — roadmap for bespoke gene edits https://biobriefs.com/scientists-probe-neural-organoid-ethics BioBriefs en 2025-11-14T04:32:13Z Scientists probe neural‑organoid ethics — governance lags behind science https://biobriefs.com/neuro-immunology-and-degrader-startups BioBriefs en 2025-11-14T04:32:13Z Neuro‑immunology and degrader startups raise nine‑figure rounds — Nilo and Gate scale https://biobriefs.com/komzifti-cleared-kura-kyowa-win BioBriefs en 2025-11-13T21:33:03Z Komzifti cleared: Kura, Kyowa win FDA nod for NPM1‑mutant AML https://biobriefs.com/pfizer-seals-metsera-takeover-up BioBriefs en 2025-11-13T21:33:03Z Pfizer seals Metsera takeover: Up to $10B obesity deal completes https://biobriefs.com/pazdur-named-cder-head-fda BioBriefs en 2025-11-13T21:33:03Z Pazdur named CDER head — FDA lays out plausible‑mechanism path for bespoke edits https://biobriefs.com/multi-omics-map-xenograft-rejection BioBriefs en 2025-11-13T21:33:03Z Multi‑omics map xenograft rejection: Antibodies and T cells drive pig‑to‑human kidney response https://biobriefs.com/ganlum-meets-phase-3-goal BioBriefs en 2025-11-13T21:33:03Z GanLum meets Phase 3 goal: Novartis positions new malaria therapy against resistance https://biobriefs.com/day-one-buys-mersana-emi BioBriefs en 2025-11-13T21:33:03Z Day One buys Mersana: Emi‑Le ADC anchors back‑ended takeover https://biobriefs.com/allen-institute-launches-brain-knowledge BioBriefs en 2025-11-13T21:33:03Z Allen Institute launches Brain Knowledge Platform: 34M brain‑cell datasets, AI models https://biobriefs.com/nine-figure-rounds-back-neuro BioBriefs en 2025-11-13T21:33:03Z Nine‑figure rounds back neuro‑immune and degrader bets: Nilo $101M, Gate $65M https://biobriefs.com/clinical-lab-tools-roll-out BioBriefs en 2025-11-13T21:33:03Z Clinical lab tools roll out: OGT’s ultra‑sensitive MRD panel and automated single‑cell workflows https://biobriefs.com/amt-130-slows-huntington-s BioBriefs en 2025-11-13T21:33:03Z AMT‑130 slows Huntington's: Uniqure reports 75% disease‑slowing at three years https://biobriefs.com/novartis-ganlum-clears-phase-3 BioBriefs en 2025-11-13T16:32:22Z Novartis’ GanLum clears phase 3 — New tool vs resistant malaria https://biobriefs.com/fda-unveils-plausible-mechanism-route BioBriefs en 2025-11-13T16:32:22Z FDA unveils plausible‑mechanism route for bespoke gene edits https://biobriefs.com/pig-kidney-xenograft-rejection-reversed BioBriefs en 2025-11-13T16:32:22Z Pig kidney xenograft rejection reversed — Multi‑omics maps immune drivers https://biobriefs.com/allen-institute-launches-brain-knowledge BioBriefs en 2025-11-13T16:32:22Z Allen Institute launches Brain Knowledge Platform — 34M‑cell atlas with AI https://biobriefs.com/day-one-buys-mersana-emi BioBriefs en 2025-11-13T16:32:22Z Day One buys Mersana — Emi‑Le ADC moves to new home https://biobriefs.com/korro-cuts-staff-abandons-lead BioBriefs en 2025-11-13T16:32:22Z Korro cuts staff, abandons lead program — Stock tumbles https://biobriefs.com/cellarity-unveils-ai-multi-omics BioBriefs en 2025-11-13T16:32:22Z Cellarity unveils AI multi‑omics DILI predictor — New toxicology framework https://biobriefs.com/richard-pazdur-named-cder-director BioBriefs en 2025-11-13T16:32:22Z Richard Pazdur named CDER director — FDA taps veteran oncology regulator https://biobriefs.com/nilo-launches-with-101m-targets BioBriefs en 2025-11-13T16:32:22Z Nilo launches with $101M — Targets neural circuits to reset immunity https://biobriefs.com/ultra-mild-sequencing-fixes-methylation BioBriefs en 2025-11-13T16:32:22Z Ultra‑mild sequencing fixes methylation test damage — UMBS‑seq published https://biobriefs.com/fda-unveils-new-pathway-for BioBriefs en 2025-11-13T14:32:06Z FDA unveils new pathway for personalized rare‑disease therapies https://biobriefs.com/novartis-ganlum-passes-phase-3 BioBriefs en 2025-11-13T14:32:06Z Novartis’ GanLum passes phase 3 — targets artemisinin resistance https://biobriefs.com/uniqures-amt-130-shows-deep BioBriefs en 2025-11-13T14:32:06Z Uniqure’s AMT‑130 shows deep, durable slowing in Huntington’s https://biobriefs.com/abbvie-to-end-calico-collaboration BioBriefs en 2025-11-13T14:32:06Z AbbVie to end Calico collaboration — strategic pivot sends layoffs https://biobriefs.com/nilo-launches-with-101m-to BioBriefs en 2025-11-13T14:32:06Z Nilo launches with $101M to translate neuro‑immune circuits into drugs https://biobriefs.com/gate-bioscience-raises-65m-to BioBriefs en 2025-11-13T14:32:06Z Gate Bioscience raises $65M to advance novel small‑molecule degraders https://biobriefs.com/cellarity-publishes-ai-multi-omics BioBriefs en 2025-11-13T14:32:06Z Cellarity publishes AI multi‑omics test to predict drug‑induced liver injury https://biobriefs.com/beacon-biosignals-raises-86m-to BioBriefs en 2025-11-13T14:32:06Z Beacon Biosignals raises $86M to build global brain‑wave dataset https://biobriefs.com/evotec-earns-ind-milestone-from BioBriefs en 2025-11-13T14:32:06Z Evotec earns IND milestone from BMS protein‑degradation pact https://biobriefs.com/metagenomi-pivots-25-layoffs-while BioBriefs en 2025-11-13T14:32:06Z Metagenomi pivots — 25% layoffs while hemophilia program posts NHP success https://biobriefs.com/fda-unveils-plausible-mechanism-path BioBriefs en 2025-11-13T10:31:40Z FDA unveils plausible-mechanism path: roadmap for bespoke rare-disease therapies https://biobriefs.com/novartis-ganlum-meets-who-bar BioBriefs en 2025-11-13T10:31:40Z Novartis’ GanLum meets WHO bar: Phase 3 shows high cure rates https://biobriefs.com/pazdur-to-lead-cder-fda BioBriefs en 2025-11-13T10:31:40Z Pazdur to lead CDER — FDA picks cancer regulator to steady drug reviews https://biobriefs.com/metagenomi-sheds-staff-and-refocuses BioBriefs en 2025-11-13T10:31:40Z Metagenomi sheds staff and refocuses — CEO exits amid hemophilia pivot https://biobriefs.com/nilo-launches-with-101m-neuro BioBriefs en 2025-11-13T10:31:40Z Nilo launches with $101m: neuro-immunology startup targets brain–immune circuits https://biobriefs.com/beacon-biosignals-raises-86m-to BioBriefs en 2025-11-13T10:31:40Z Beacon Biosignals raises $86m to build brain dataset for neurology R&D https://biobriefs.com/trim25-and-vista-workpoints-suggest BioBriefs en 2025-11-13T10:31:40Z TRIM25 and VISTA workpoints suggest new immune-checkpoint strategies https://biobriefs.com/early-detection-tools-advance-mayo BioBriefs en 2025-11-13T10:31:40Z Early-detection tools advance: Mayo predictive model and gentler methylation sequencing https://biobriefs.com/gene-therapy-for-bladder-cancer BioBriefs en 2025-11-13T10:31:40Z Gene therapy for bladder cancer delivers: Engene posts pivotal data, eyes 2026 filing https://biobriefs.com/stanford-links-ebv-to-lupus BioBriefs en 2025-11-13T10:31:40Z Stanford links EBV to lupus: virus shown to reprogram immune B cells https://biobriefs.com/novartis-ganlum-passes-phase-3 BioBriefs en 2025-11-13T09:32:09Z Novartis’ GanLum passes Phase 3 — poised to tackle artemisinin resistance https://biobriefs.com/fda-taps-richard-pazdur-oncology BioBriefs en 2025-11-13T09:32:09Z FDA taps Richard Pazdur: Oncology veteran named CDER director https://biobriefs.com/fda-unveils-plausible-mechanism-path BioBriefs en 2025-11-13T09:32:09Z FDA unveils plausible‑mechanism path... bespoke gene edits could speed approvals https://biobriefs.com/glp-1s-go-mainstream-medicare BioBriefs en 2025-11-13T09:32:09Z GLP‑1s go mainstream: Medicare, sales reshape obesity market https://biobriefs.com/crisprs-split-week-clinical-death BioBriefs en 2025-11-13T09:32:09Z CRISPR’s split week — clinical death and technical wins roil field https://biobriefs.com/neuro-immunology-gets-a-101m BioBriefs en 2025-11-13T09:32:09Z Neuro‑immunology gets a $101M lift: startups build neural‑immune modality stacks https://biobriefs.com/vista-emerges-as-checkpoint-target BioBriefs en 2025-11-13T09:32:09Z VISTA emerges as checkpoint target: TRIM25 link boosts immunotherapy https://biobriefs.com/ultra-mild-methylation-sequencing-cancer BioBriefs en 2025-11-13T09:32:09Z Ultra‑mild methylation sequencing... cancer epigenetics gets gentler, deeper tools https://biobriefs.com/gene-therapy-for-bladder-cancer BioBriefs en 2025-11-13T09:32:09Z Gene therapy for bladder cancer surges — Engene posts pivotal Phase II https://biobriefs.com/ai-meets-tissue-biology-bostongene BioBriefs en 2025-11-13T09:32:09Z AI meets tissue biology: BostonGene‑Kyoto deal and Dyno’s AI capsids https://biobriefs.com/novartis-to-file-for-approval BioBriefs en 2025-11-13T04:32:47Z Novartis to file for approval after Phase 3 win – ganaplacide combo meets WHO cure target https://biobriefs.com/single-dose-malaria-cocktail-four BioBriefs en 2025-11-13T04:32:47Z Single-dose malaria cocktail: Four‑drug shot matches standard multi‑day regimen in Gabon https://biobriefs.com/fda-unveils-new-regulatory-pathway BioBriefs en 2025-11-13T04:32:47Z FDA unveils new regulatory pathway: faster routes for personalized rare‑disease therapies https://biobriefs.com/nilo-launches-with-101m-aims BioBriefs en 2025-11-13T04:32:47Z Nilo launches with $101M — aims to harness neural circuits to reset immunity https://biobriefs.com/crisprs-mixed-week-breakthrough-cholesterol BioBriefs en 2025-11-13T04:32:47Z CRISPR’s mixed week: breakthrough cholesterol data shadowed by trial death https://biobriefs.com/glp-1-drugs-linked-to BioBriefs en 2025-11-13T04:32:47Z GLP‑1 drugs linked to halved mortality in colon cancer cohort https://biobriefs.com/uniqure-gene-therapy-shows-large BioBriefs en 2025-11-13T04:32:47Z UniQure gene therapy shows large slowing of Huntington’s in early trial https://biobriefs.com/nucleai-and-bostongene-expand-ai BioBriefs en 2025-11-13T04:32:47Z Nucleai and BostonGene expand AI spatial‑biology efforts with academic partners https://biobriefs.com/lilly-doubles-down-on-genetic BioBriefs en 2025-11-13T04:32:47Z Lilly doubles down on genetic medicine: vision gene‑therapy deal and $1.2B RNAi pact https://biobriefs.com/beacon-raises-86m-building-a BioBriefs en 2025-11-13T04:32:47Z Beacon raises $86M — building a brain‑wave dataset to power neurology R&D https://biobriefs.com/fda-taps-pazdur-veteran-oncology BioBriefs en 2025-11-12T21:32:25Z FDA taps Pazdur: Veteran oncology chief named CDER director https://biobriefs.com/abbvie-exits-calico-11-year BioBriefs en 2025-11-12T21:32:25Z AbbVie exits Calico: 11-year aging partnership wound down, layoffs follow https://biobriefs.com/nilo-launches-with-101m-neuro BioBriefs en 2025-11-12T21:32:25Z Nilo launches with $101M: Neuro‑immunology startup aims to rewire inflammation https://biobriefs.com/lilly-licenses-meiragtx-gene-therapy BioBriefs en 2025-11-12T21:32:25Z Lilly licenses MeiraGTx gene therapy: $75M upfront for AAV‑AIPL1 in childhood blindness https://biobriefs.com/engene-engene-posts-pivotal-bladder BioBriefs en 2025-11-12T21:32:25Z EnGene/Engene posts pivotal bladder data — shares surge on Phase II results https://biobriefs.com/crisprs-mixed-week-therapy-win BioBriefs en 2025-11-12T21:32:25Z CRISPR’s mixed week: therapy win shadowed by fatal trial event https://biobriefs.com/beacon-biosignals-raises-86m-to BioBriefs en 2025-11-12T21:32:25Z Beacon Biosignals raises $86M to assemble brain‑wave dataset for neurology R&D https://biobriefs.com/mgi-south-africa-launch-110k BioBriefs en 2025-11-12T21:32:25Z MGI, South Africa launch 110K genome program: first national African reference https://biobriefs.com/lilly-doubles-down-on-rnai BioBriefs en 2025-11-12T21:32:25Z Lilly doubles down on RNAi: $1.2B deal for Sanegene’s tissue‑selective delivery tech https://biobriefs.com/glp-1-sales-top-20b BioBriefs en 2025-11-12T21:32:25Z GLP‑1 sales top $20B in 3Q25 — Mounjaro and Zepbound lead market surge https://biobriefs.com/fda-names-richard-pazdur-as BioBriefs en 2025-11-12T16:32:12Z FDA names Richard Pazdur as CDER director https://biobriefs.com/lilly-acquires-meiragtx-gene-therapy BioBriefs en 2025-11-12T16:32:12Z Lilly acquires MeiraGTx gene therapy rights and deepens AI drug discovery ties https://biobriefs.com/pfizer-closes-10-billion-metsera BioBriefs en 2025-11-12T16:32:12Z Pfizer closes $10 billion Metsera deal — Washington ties surfaced https://biobriefs.com/fda-moves-to-strip-boxed BioBriefs en 2025-11-12T16:32:12Z FDA moves to strip boxed warnings from menopause hormone therapies https://biobriefs.com/neurocrines-takeda-licensed-depression-candidate BioBriefs en 2025-11-12T16:32:12Z Neurocrine’s Takeda‑licensed depression candidate fails mid‑stage tests https://biobriefs.com/engene-posts-pivotal-phase-ii BioBriefs en 2025-11-12T16:32:12Z Engene posts pivotal Phase II detalimogene data — shares spike https://biobriefs.com/metagenomi-trims-workforce-while-hemophilia BioBriefs en 2025-11-12T16:32:12Z Metagenomi trims workforce while hemophilia program posts strong NHP data https://biobriefs.com/crispr-companies-face-a-mixed BioBriefs en 2025-11-12T16:32:12Z CRISPR companies face a mixed week: clinical victory and safety tragedy https://biobriefs.com/beacon-biosignals-raises-86-million BioBriefs en 2025-11-12T16:32:12Z Beacon Biosignals raises $86 million to build brain‑wave dataset https://biobriefs.com/nucleai-and-university-of-glasgow BioBriefs en 2025-11-12T16:32:12Z Nucleai and University of Glasgow launch colorectal spatial biomarker effort https://biobriefs.com/lilly-bets-on-sight-475m BioBriefs en 2025-11-12T14:32:05Z Lilly bets on sight: $475m buy for MeiraGTx’s LCA4 gene therapy https://biobriefs.com/pfizer-clinches-metsera-for-10 BioBriefs en 2025-11-12T14:32:05Z Pfizer clinches Metsera for $10 billion — Novo bows out https://biobriefs.com/fda-orders-removal-of-breast BioBriefs en 2025-11-12T14:32:05Z FDA orders removal of breast‑cancer box from menopause HRT labels https://biobriefs.com/crisprs-mixed-week-blockbuster-cholesterol BioBriefs en 2025-11-12T14:32:05Z CRISPR’s mixed week: blockbuster cholesterol data and a trial fatality https://biobriefs.com/glp-1-sales-surge-20 BioBriefs en 2025-11-12T14:32:05Z GLP‑1 sales surge: $20 billion in 3Q25 https://biobriefs.com/cogent-nails-second-pivotal-win BioBriefs en 2025-11-12T14:32:05Z Cogent nails second pivotal win — two NDAs on deck https://biobriefs.com/neurocrines-takeda-licensed-antidepressant-fails BioBriefs en 2025-11-12T14:32:05Z Neurocrine’s Takeda‑licensed antidepressant fails midstage https://biobriefs.com/richard-pazdur-named-cder-director BioBriefs en 2025-11-12T14:32:05Z Richard Pazdur named CDER director — veteran regulator returns https://biobriefs.com/cms-covers-personalis-mrd-assay BioBriefs en 2025-11-12T14:32:05Z CMS covers Personalis MRD assay for breast cancer surveillance https://biobriefs.com/lilly-bets-1-2b-on BioBriefs en 2025-11-12T14:32:05Z Lilly bets $1.2B on RNAi: Sanegene partnership targets obesity https://biobriefs.com/pfizer-clinches-metsera-for-10 BioBriefs en 2025-11-12T10:31:38Z Pfizer clinches Metsera for $10 billion – Novo bows out https://biobriefs.com/fda-moves-to-strip-hrt BioBriefs en 2025-11-12T10:31:38Z FDA moves to strip HRT black-box labels – access to menopause drugs widens https://biobriefs.com/crispr-field-endures-mixed-week BioBriefs en 2025-11-12T10:31:38Z CRISPR field endures mixed week – trial fatality and promising lipid data https://biobriefs.com/mercks-oral-pcsk9-pill-posts BioBriefs en 2025-11-12T10:31:38Z Merck’s oral PCSK9 pill posts near-injectable LDL cuts – data land at AHA https://biobriefs.com/cogents-bezuclastinib-clears-phase-3 BioBriefs en 2025-11-12T10:31:38Z Cogent’s bezuclastinib clears phase 3 hurdles – NDA planned for 2026 https://biobriefs.com/engene-posts-pivotal-bladder-gene BioBriefs en 2025-11-12T10:31:38Z Engene posts pivotal bladder gene-therapy data – stock surges https://biobriefs.com/lilly-inks-gene-therapy-rnai BioBriefs en 2025-11-12T10:31:38Z Lilly inks gene-therapy, RNAi pacts—expands genetic-medicine footprint https://biobriefs.com/mgi-to-sequence-110000-genomes BioBriefs en 2025-11-12T10:31:38Z MGI to sequence 110,000 genomes in South Africa – national reference aims launched https://biobriefs.com/iambic-raises-100m-plus-to BioBriefs en 2025-11-12T10:31:38Z Iambic raises $100M-plus to advance AI-discovered therapeutics https://biobriefs.com/fda-taps-richard-pazdur-to BioBriefs en 2025-11-12T10:31:38Z FDA taps Richard Pazdur to lead CDER – regulator returns to center stage https://biobriefs.com/fda-taps-veteran-richard-pazdur BioBriefs en 2025-11-12T09:31:38Z FDA taps veteran Richard Pazdur—names him CDER director https://biobriefs.com/pfizer-clinches-metsera-for-10 BioBriefs en 2025-11-12T09:31:38Z Pfizer clinches Metsera for $10 billion — bidding war ends https://biobriefs.com/crisprs-mixed-week-breakthrough-readouts BioBriefs en 2025-11-12T09:31:38Z CRISPR’s mixed week... breakthrough readouts and a trial fatality https://biobriefs.com/neurocrines-takeda-licensed-depression-drug BioBriefs en 2025-11-12T09:31:38Z Neurocrine’s Takeda‑licensed depression drug flunks mid‑stage tests https://biobriefs.com/mercks-oral-pcsk9-pill-posts BioBriefs en 2025-11-12T09:31:38Z Merck’s oral PCSK9 pill posts injectable‑like LDL cuts in phase studies https://biobriefs.com/engene-posts-more-pivotal-bladder BioBriefs en 2025-11-12T09:31:38Z Engene posts more pivotal bladder‑gene therapy data — stock jumps https://biobriefs.com/iambic-raises-100m-ai-discovered BioBriefs en 2025-11-12T09:31:38Z Iambic raises $100M+—AI‑discovered pipeline advances https://biobriefs.com/mgi-and-geneseeq-expand-national BioBriefs en 2025-11-12T09:31:38Z MGI and Geneseeq expand national genomics and CDx infrastructure https://biobriefs.com/ai-tools-for-single-cell BioBriefs en 2025-11-12T09:31:38Z AI tools for single‑cell work: parts lists and chat‑based analysis arrive https://biobriefs.com/fda-moves-to-strip-boxed BioBriefs en 2025-11-12T09:31:38Z FDA moves to strip boxed warnings from menopause HRTs https://biobriefs.com/pfizer-wins-metsera-bidding-war BioBriefs en 2025-11-12T04:32:13Z Pfizer wins Metsera bidding war: $10B deal sealed https://biobriefs.com/mercks-pcsk9-pill-mimics-injectables BioBriefs en 2025-11-12T04:32:13Z Merck’s PCSK9 pill mimics injectables: 59% LDL reduction https://biobriefs.com/crisprs-mixed-week-fatal-trial BioBriefs en 2025-11-12T04:32:13Z CRISPR’s mixed week: fatal trial event — gene edit halves lipids https://biobriefs.com/fda-taps-richard-pazdur-as BioBriefs en 2025-11-12T04:32:13Z FDA taps Richard Pazdur as CDER director — leadership pivot https://biobriefs.com/lilly-bulks-up-genetic-meds BioBriefs en 2025-11-12T04:32:13Z Lilly bulks up genetic meds: buys MeiraGTx eye therapy, inks $1.2B RNAi pact https://biobriefs.com/iambic-nets-100m-plus-ai BioBriefs en 2025-11-12T04:32:13Z Iambic nets $100M-plus — AI drug discovery attracts big backers https://biobriefs.com/scaling-genomics-mgi-launches-110k BioBriefs en 2025-11-12T04:32:13Z Scaling genomics: MGI launches 110K South Africa program — Geneseeq wins China CDx nod https://biobriefs.com/engene-posts-pivotal-bladder-gene BioBriefs en 2025-11-12T04:32:13Z Engene posts pivotal bladder gene‑therapy data — BLA plan intact https://biobriefs.com/cogents-bezuclastinib-halves-progression-risk BioBriefs en 2025-11-12T04:32:13Z Cogent’s bezuclastinib halves progression risk — two NDAs coming https://biobriefs.com/medicare-covers-personalis-mrd-assay BioBriefs en 2025-11-12T04:32:13Z Medicare covers Personalis MRD assay for breast‑cancer surveillance https://biobriefs.com/pfizer-wins-metsera-bidding-war BioBriefs en 2025-11-11T21:32:32Z Pfizer wins Metsera bidding war: $10 billion deal closes https://biobriefs.com/lilly-doubles-down-on-genetic BioBriefs en 2025-11-11T21:32:32Z Lilly doubles down on genetic and RNA bets — $1.2B Sanegene pact; retinal gene therapy buy https://biobriefs.com/mercks-oral-pcsk9-pill-posts BioBriefs en 2025-11-11T21:32:32Z Merck’s oral PCSK9 pill posts near-injectable LDL cuts — market race intensifies https://biobriefs.com/crispr-programs-face-a-split BioBriefs en 2025-11-11T21:32:32Z CRISPR programs face a split week: fatality at Intellia — cholesterol edits succeed https://biobriefs.com/neurocrines-takeda-licensed-depression-candidate BioBriefs en 2025-11-11T21:32:32Z Neurocrine’s Takeda‑licensed depression candidate fails Phase II — company issues update https://biobriefs.com/cogents-bezuclastinib-clears-pivotal-hurdle BioBriefs en 2025-11-11T21:32:32Z Cogent’s bezuclastinib clears pivotal hurdle — NDA timing accelerated https://biobriefs.com/fda-to-ease-hrt-boxed BioBriefs en 2025-11-11T21:32:32Z FDA to ease HRT boxed warnings — labeling shift announced https://biobriefs.com/ngs-and-cancer-diagnostics-sophia BioBriefs en 2025-11-11T21:32:32Z NGS and cancer diagnostics: Sophia Genetics partnerships and Medicare MRD coverage expand access https://biobriefs.com/ai-biotech-iambic-raises-100m BioBriefs en 2025-11-11T21:32:32Z AI biotech Iambic raises $100M+ — investors pile into AI‑discovered therapeutics https://biobriefs.com/roches-btk-inhibitor-posts-two BioBriefs en 2025-11-11T21:32:32Z Roche’s BTK inhibitor posts two Phase III wins — multiple sclerosis filings loom https://biobriefs.com/pfizer-wins-metsera-10-billion BioBriefs en 2025-11-11T16:32:26Z Pfizer Wins Metsera: $10 Billion Deal Closes the Bidding War https://biobriefs.com/fda-strips-hrt-black-box BioBriefs en 2025-11-11T16:32:26Z FDA Strips HRT Black Box: Warning Labels Narrowed https://biobriefs.com/mercks-oral-pcsk9-pill-posts BioBriefs en 2025-11-11T16:32:26Z Merck’s Oral PCSK9 Pill Posts Pivotal Wins — Oral Rival to Injectables https://biobriefs.com/crispr-week-breakthrough-cholesterol-data BioBriefs en 2025-11-11T16:32:26Z CRISPR Week: Breakthrough Cholesterol Data and a Trial Fatality https://biobriefs.com/lilly-expands-genetic-medicine-arsenal BioBriefs en 2025-11-11T16:32:26Z Lilly Expands Genetic Medicine Arsenal — Eye Gene Therapy and RNAi Pact https://biobriefs.com/roches-btk-wins-in-ms BioBriefs en 2025-11-11T16:32:26Z Roche’s BTK Wins in MS: Two Phase 3 Victories Reported https://biobriefs.com/aavantgarde-banks-141m-to-push BioBriefs en 2025-11-11T16:32:26Z AAVantgarde Banks $141M to Push Rare Eye Gene Therapies https://biobriefs.com/iambic-pads-war-chest-100m BioBriefs en 2025-11-11T16:32:26Z Iambic Pads War Chest: $100M Oversubscribed Round for AI‑Drug Engine https://biobriefs.com/cogents-double-win-phase-3 BioBriefs en 2025-11-11T16:32:26Z Cogent’s Double Win: Phase 3 Successes Propel NDA Timelines https://biobriefs.com/fda-puts-tenayas-heart-gene BioBriefs en 2025-11-11T16:32:26Z FDA Puts Tenaya’s Heart Gene Therapy on Hold — Immunosuppression Issues https://biobriefs.com/pfizer-seals-metsera-deal-10 BioBriefs en 2025-11-11T14:31:45Z Pfizer seals Metsera deal — $10 billion closing ends bidding war https://biobriefs.com/lilly-doubles-down-on-genetic BioBriefs en 2025-11-11T14:31:45Z Lilly doubles down on genetic medicines — RNAi and retinal gene therapy deals https://biobriefs.com/fda-to-lift-menopause-hrt BioBriefs en 2025-11-11T14:31:45Z FDA to lift menopause HRT boxed warnings — labeling reversal underway https://biobriefs.com/crispr-field-jolted-intellia-death BioBriefs en 2025-11-11T14:31:45Z CRISPR field jolted — Intellia death, CRISPR Therapeutics posts cholesterol wins https://biobriefs.com/mercks-oral-pcsk9-pill-posts BioBriefs en 2025-11-11T14:31:45Z Merck’s oral PCSK9 pill posts pivotal data — injectable‑level LDL cuts https://biobriefs.com/cogents-twin-wins-clear-nda BioBriefs en 2025-11-11T14:31:45Z Cogent’s twin wins clear NDA runway — oncology filings ahead https://biobriefs.com/celecors-phase-3-win-clears BioBriefs en 2025-11-11T14:31:45Z CeleCor’s phase 3 win clears path for rapid MI treatment filing https://biobriefs.com/roches-btk-wins-broaden-ms BioBriefs en 2025-11-11T14:31:45Z Roche’s BTK wins broaden MS portfolio — mixed questions on data depth https://biobriefs.com/gene-therapy-ecosystem-tests-capacity BioBriefs en 2025-11-11T14:31:45Z Gene‑therapy ecosystem tests capacity and oversight — Tenaya hold, Catalent cuts https://biobriefs.com/iambic-raises-100m-as-ai BioBriefs en 2025-11-11T14:31:45Z Iambic raises $100M as AI‑discovered drug firm scales programs and deals https://biobriefs.com/metsera-auction-ends-pfizer-lands BioBriefs en 2025-11-11T10:32:32Z Metsera auction ends: Pfizer lands obesity play at $10B https://biobriefs.com/lilly-bulks-up-genetic-medicines BioBriefs en 2025-11-11T10:32:32Z Lilly bulks up genetic medicines: eye gene therapy and RNAi pact https://biobriefs.com/fda-reverses-course-boxed-warnings BioBriefs en 2025-11-11T10:32:32Z FDA reverses course: boxed warnings to be removed from HRT labels https://biobriefs.com/mercks-oral-pcsk9-pill-posts BioBriefs en 2025-11-11T10:32:32Z Merck’s oral PCSK9 pill posts near-injectable LDL wins at AHA https://biobriefs.com/cogents-twin-wins-push-bezuclastinib BioBriefs en 2025-11-11T10:32:32Z Cogent’s twin wins push bezuclastinib toward NDA filings https://biobriefs.com/roches-btk-inhibitor-clears-two BioBriefs en 2025-11-11T10:32:32Z Roche’s BTK inhibitor clears two Phase 3 studies in multiple sclerosis https://biobriefs.com/iambic-raises-100m-to-scale BioBriefs en 2025-11-11T10:32:32Z Iambic raises $100M to scale AI-discovered drug pipeline https://biobriefs.com/fda-places-tenayas-heart-gene BioBriefs en 2025-11-11T10:32:32Z FDA places Tenaya’s heart-gene trial on hold over immunosuppression standardization https://biobriefs.com/ai-in-primary-care-zero BioBriefs en 2025-11-11T10:32:32Z AI in primary care: zero-cost tool raises dementia detection by a third https://biobriefs.com/crispr-edit-halves-cholesterol-early BioBriefs en 2025-11-11T10:32:32Z CRISPR edit halves cholesterol...early data hint at once‑and‑done therapy https://biobriefs.com/pfizer-wins-metsera-for-10 BioBriefs en 2025-11-11T09:32:55Z Pfizer wins Metsera for $10 billion – Novo bows out https://biobriefs.com/fda-moves-to-strip-boxed BioBriefs en 2025-11-11T09:32:55Z FDA moves to strip boxed warning from menopause HRT https://biobriefs.com/mercks-oral-pcsk9-draws-pivotal BioBriefs en 2025-11-11T09:32:55Z Merck’s oral PCSK9 draws pivotal data at AHA... https://biobriefs.com/lilly-scoops-retinal-gene-program BioBriefs en 2025-11-11T09:32:55Z Lilly scoops retinal gene program: another push into genetic medicines https://biobriefs.com/lilly-deepens-ai-drug-discovery BioBriefs en 2025-11-11T09:32:55Z Lilly deepens AI drug discovery tie with Insilico — $100M‑plus pact https://biobriefs.com/roches-btk-wins-two-phase BioBriefs en 2025-11-11T09:32:55Z Roche’s BTK wins two phase 3s – MS program clears key hurdles https://biobriefs.com/cogent-lines-up-ndas-after BioBriefs en 2025-11-11T09:32:55Z Cogent lines up NDAs after another Phase 3 win https://biobriefs.com/fda-places-hold-on-tenayas BioBriefs en 2025-11-11T09:32:55Z FDA places hold on Tenaya’s heart‑gene trial over immunosuppression standardization https://biobriefs.com/iambic-raises-100m-to-advance BioBriefs en 2025-11-11T09:32:55Z Iambic raises $100M to advance AI‑discovered therapeutics and platform https://biobriefs.com/ultrasound-clears-intracranial-debris-and BioBriefs en 2025-11-11T09:32:55Z Ultrasound clears intracranial debris and improves recovery in hemorrhagic stroke models https://biobriefs.com/pfizer-wins-metsera-10-billion BioBriefs en 2025-11-11T04:32:25Z Pfizer wins Metsera — $10 billion obesity deal sealed https://biobriefs.com/mercks-oral-pcsk9-pill-injectable BioBriefs en 2025-11-11T04:32:25Z Merck’s oral PCSK9 pill: injectable-like LDL cuts reported https://biobriefs.com/roches-btk-inhibitor-posts-phase BioBriefs en 2025-11-11T04:32:25Z Roche’s BTK inhibitor posts Phase 3 wins — multiple sclerosis filings ahead https://biobriefs.com/cogents-bezuclastinib-halves-progression-risk BioBriefs en 2025-11-11T04:32:25Z Cogent’s bezuclastinib halves progression risk — NDAs in view https://biobriefs.com/lilly-expands-insilico-pact-ai BioBriefs en 2025-11-11T04:32:25Z Lilly expands Insilico pact — AI moves from software to drug discovery https://biobriefs.com/lilly-signs-1-2b-rnai BioBriefs en 2025-11-11T04:32:25Z Lilly signs $1.2B RNAi pact with Sanegene — tissue-selective delivery in play https://biobriefs.com/lilly-buys-meiragtx-retinal-program BioBriefs en 2025-11-11T04:32:25Z Lilly buys MeiraGTx retinal program — $75 million upfront for LCA4 gene therapy https://biobriefs.com/fda-puts-tenaya-trial-on BioBriefs en 2025-11-11T04:32:25Z FDA puts Tenaya trial on hold — immunosuppression regimen under review https://biobriefs.com/researchers-build-phages-with-synthetic BioBriefs en 2025-11-11T04:32:25Z Researchers build phages with synthetic genomes — gene‑by‑gene editing unlocked https://biobriefs.com/two-mid-stage-misses-anaptys BioBriefs en 2025-11-11T04:32:25Z Two mid‑stage misses: Anaptys abandons UC; Neurocrine sees depression program fail https://biobriefs.com/pfizer-clinches-metsera-10-billion BioBriefs en 2025-11-10T21:32:39Z Pfizer clinches Metsera: $10 billion deal ends Novo challenge https://biobriefs.com/merck-pill-rivals-injectables-ldl BioBriefs en 2025-11-10T21:32:39Z Merck pill rivals injectables: LDL down nearly 60% https://biobriefs.com/cogent-soars-phase-3-shows BioBriefs en 2025-11-10T21:32:39Z Cogent soars: Phase 3 shows bezuclastinib halves progression risk https://biobriefs.com/lilly-nabs-meiragtx-retinal-program BioBriefs en 2025-11-10T21:32:39Z Lilly nabs MeiraGTx retinal program: $75M up front https://biobriefs.com/iambic-raises-100m-ai-drug BioBriefs en 2025-11-10T21:32:39Z Iambic raises $100M+ — AI drug discovery keeps attracting capital https://biobriefs.com/aavantgarde-banks-141m-pivots-to BioBriefs en 2025-11-10T21:32:39Z AAVantgarde banks $141M — pivots to Stargardt and Usher1B trials https://biobriefs.com/lilly-inks-1-2b-pact BioBriefs en 2025-11-10T21:32:39Z Lilly inks $1.2B pact with Sanegene — tissue‑targeted RNA push https://biobriefs.com/fda-puts-tenaya-trial-on BioBriefs en 2025-11-10T21:32:39Z FDA puts Tenaya trial on hold: standardize immunosuppression across sites https://biobriefs.com/medicare-covers-personalis-mrd-assay BioBriefs en 2025-11-10T21:32:39Z Medicare covers Personalis MRD assay — surveillance for stage II–III breast cancer https://biobriefs.com/ultrasound-clears-brain-debris-boosts BioBriefs en 2025-11-10T21:32:39Z Ultrasound clears brain debris... boosts recovery in hemorrhagic stroke models https://biobriefs.com/mercks-oral-pcsk9-pill-posts BioBriefs en 2025-11-10T16:32:00Z Merck’s oral PCSK9 pill posts near-injectable LDL cuts: pivotal readouts https://biobriefs.com/roches-btk-wins-clear-registrational BioBriefs en 2025-11-10T16:32:00Z Roche’s BTK wins clear registrational bar: two Phase 3 victories https://biobriefs.com/china-clears-sequencing-based-pan BioBriefs en 2025-11-10T16:32:00Z China clears sequencing‑based pan‑solid tumor CDx: Geneseeq gains NMPA nod https://biobriefs.com/medicare-covers-personalis-mrd-test BioBriefs en 2025-11-10T16:32:00Z Medicare covers Personalis MRD test for breast cancer surveillance https://biobriefs.com/crispr-editing-cuts-cholesterol-and BioBriefs en 2025-11-10T16:32:00Z CRISPR editing cuts cholesterol and triglycerides in early trial — AHA data https://biobriefs.com/aavantgarde-raises-141m-to-advance BioBriefs en 2025-11-10T16:32:00Z AAVantgarde raises $141M to advance retinal gene programs https://biobriefs.com/ai-drug-developer-iambic-scores BioBriefs en 2025-11-10T16:32:00Z AI‑drug developer Iambic scores $100M+ to advance platform and candidates https://biobriefs.com/fda-halts-tenaya-gene-therapy BioBriefs en 2025-11-10T16:32:00Z FDA halts Tenaya gene‑therapy trial over immunosuppression inconsistencies https://biobriefs.com/lilly-doubles-down-on-genetic BioBriefs en 2025-11-10T16:32:00Z Lilly doubles down on genetic and RNA strategies: deals with MeiraGTx and Sanegene https://biobriefs.com/anaptysbio-abandons-rosnilimab-for-ulcerative BioBriefs en 2025-11-10T16:32:00Z AnaptysBio abandons rosnilimab for ulcerative colitis after Phase 2 failure https://biobriefs.com/roches-btk-inhibitor-two-phase BioBriefs en 2025-11-10T14:31:42Z Roche’s BTK inhibitor: Two Phase 3 wins in multiple sclerosis https://biobriefs.com/mercks-pcsk9-pill-cuts-ldl BioBriefs en 2025-11-10T14:31:42Z Merck’s PCSK9 pill cuts LDL up to 60% — Phase 3 readout https://biobriefs.com/amgens-repatha-prevents-first-heart BioBriefs en 2025-11-10T14:31:42Z Amgen’s Repatha prevents first heart attacks — NEJM and AHA data https://biobriefs.com/crispr-gene-editing-trims-ldl BioBriefs en 2025-11-10T14:31:42Z CRISPR gene editing trims LDL and triglycerides in early human study https://biobriefs.com/fda-places-tenayas-heart-gene BioBriefs en 2025-11-10T14:31:42Z FDA places Tenaya’s heart gene therapy on clinical hold https://biobriefs.com/lilly-acquires-meiragtx-eye-program BioBriefs en 2025-11-10T14:31:42Z Lilly acquires MeiraGTx eye program – expands genetic‑medicine footprint https://biobriefs.com/iambic-raises-more-than-100m BioBriefs en 2025-11-10T14:31:42Z Iambic raises more than $100M from ARK and Regeneron to push AI‑bio pipeline https://biobriefs.com/lilly-bets-up-to-1 BioBriefs en 2025-11-10T14:31:42Z Lilly bets up to $1.2B on Sanegene’s LEAD platform for metabolic RNAi https://biobriefs.com/pfizer-clinches-metsera-for-10b BioBriefs en 2025-11-10T14:31:42Z Pfizer clinches Metsera for $10B after bidding war with Novo Nordisk https://biobriefs.com/pace-panel-presses-for-incentives BioBriefs en 2025-11-10T14:31:42Z PACE panel presses for incentives as Ionis touts Tryngolza’s potential https://biobriefs.com/pfizer-clinches-metsera-for-10 BioBriefs en 2025-11-10T10:31:57Z Pfizer clinches Metsera for $10 billion – Bidding war ends https://biobriefs.com/lilly-inks-1-2b-pact BioBriefs en 2025-11-10T10:31:57Z Lilly inks $1.2B pact with Sanegene – RNA delivery deal https://biobriefs.com/mercks-oral-pcsk9-pill-delivers BioBriefs en 2025-11-10T10:31:57Z Merck’s oral PCSK9 pill delivers up to 60% LDL cuts – Phase 3 wins https://biobriefs.com/amgens-repatha-prevents-first-heart BioBriefs en 2025-11-10T10:31:57Z Amgen’s Repatha prevents first heart attacks – VESALIUS‑CV confirms https://biobriefs.com/crispr-therapy-slashes-ldl-and BioBriefs en 2025-11-10T10:31:57Z CRISPR therapy slashes LDL and triglycerides in early human study https://biobriefs.com/fda-halts-tenayas-heart-gene BioBriefs en 2025-11-10T10:31:57Z FDA halts Tenaya’s heart gene‑therapy trial over immunosuppression standardization https://biobriefs.com/vir-posts-hepatitis-d-results BioBriefs en 2025-11-10T10:31:57Z Vir posts hepatitis D results, accelerates Phase 3 plans https://biobriefs.com/multi-cancer-liquid-biopsy-research BioBriefs en 2025-11-10T10:31:57Z Multi‑cancer liquid biopsy research suggests earlier detection potential https://biobriefs.com/prenatal-bifidobacterium-supplementation-alters-preterm BioBriefs en 2025-11-10T10:31:57Z Prenatal bifidobacterium supplementation alters preterm infant gut microbiome https://biobriefs.com/recursion-names-new-ceo-as BioBriefs en 2025-11-10T10:31:57Z Recursion names new CEO as losses widen — cash runway extended https://biobriefs.com/mercks-oral-pcsk9-up-to BioBriefs en 2025-11-10T09:31:35Z Merck’s oral PCSK9: up to 60% LDL drop in Phase 3 https://biobriefs.com/amgens-repatha-25-fewer-major BioBriefs en 2025-11-10T09:31:35Z Amgen’s Repatha: 25% fewer major CV events, 36% fewer first heart attacks https://biobriefs.com/crispr-in-humans-ldl-and BioBriefs en 2025-11-10T09:31:35Z CRISPR in humans... LDL and triglycerides plunge in early trial https://biobriefs.com/virs-hepatitis-d-combo-posts BioBriefs en 2025-11-10T09:31:35Z Vir’s hepatitis D combo posts strong suppression; Phase 3 plans accelerate https://biobriefs.com/pfizer-tops-novo-nordisk-with BioBriefs en 2025-11-10T09:31:35Z Pfizer tops Novo Nordisk with $10B Metsera bid – acquisition ends duel https://biobriefs.com/recursion-names-najat-khan-ceo BioBriefs en 2025-11-10T09:31:35Z Recursion names Najat Khan CEO as cash runway extends into 2027 https://biobriefs.com/amae-health-raises-25m-series BioBriefs en 2025-11-10T09:31:35Z Amae Health raises $25M Series B to expand severe mental‑illness care https://biobriefs.com/patient-advocates-urge-incentives-for BioBriefs en 2025-11-10T09:31:35Z Patient advocates urge incentives for genetically targeted technologies (GTTs) https://biobriefs.com/sequential-pd-1-inhibitors-improve BioBriefs en 2025-11-10T09:31:35Z Sequential PD‑1 inhibitors improve outcomes after CD19 CAR‑T consolidation https://biobriefs.com/toripalimab-plus-flot-shows-activity BioBriefs en 2025-11-10T09:31:35Z Toripalimab plus FLOT shows activity in peritoneal‑metastatic gastric cancer https://biobriefs.com/pfizer-seals-10-billion-takeover BioBriefs en 2025-11-10T04:31:18Z Pfizer seals $10 billion takeover: Metsera deal ends bidding war https://biobriefs.com/mercks-oral-pcsk9-pill-slashes BioBriefs en 2025-11-10T04:31:18Z Merck’s oral PCSK9 pill slashes LDL up to 60%: Phase 3 data https://biobriefs.com/early-crispr-gene-editing-lowers BioBriefs en 2025-11-10T04:31:18Z Early CRISPR gene-editing lowers lipids in humans... but safety questions remain https://biobriefs.com/amgens-repatha-prevents-first-heart BioBriefs en 2025-11-10T04:31:18Z Amgen’s Repatha prevents first heart attacks: detailed VESALIUS-CV results https://biobriefs.com/vir-presents-hepatitis-d-combo BioBriefs en 2025-11-10T04:31:18Z Vir presents hepatitis D combo data: Phase 3 program accelerated https://biobriefs.com/recursion-names-new-ceo-as BioBriefs en 2025-11-10T04:31:18Z Recursion names new CEO as losses widen — cash runway extended to 2027 https://biobriefs.com/amae-health-raises-25m-to BioBriefs en 2025-11-10T04:31:18Z Amae Health raises $25M to scale care for severe mental illness https://biobriefs.com/pd-1-inhibitors-as-consolidation BioBriefs en 2025-11-10T04:31:18Z PD‑1 inhibitors as consolidation after CD19 CAR‑T improve lymphoma outcomes https://biobriefs.com/targeted-vitamin-d3-halved-repeat BioBriefs en 2025-11-10T04:31:18Z Targeted vitamin D3 halved repeat heart attacks in post-MI patients: TARGET-D trial https://biobriefs.com/toripalimab-plus-flot-shows-promise BioBriefs en 2025-11-10T04:31:18Z Toripalimab plus FLOT shows promise in metastatic gastric cancer with peritoneal spread https://biobriefs.com/pfizer-ups-bid-and-clinches BioBriefs en 2025-11-09T21:31:27Z Pfizer ups bid and clinches Metsera: $10B takeover ends obesity duel https://biobriefs.com/mercks-oral-pcsk9-pill-slashes BioBriefs en 2025-11-09T21:31:27Z Merck’s oral PCSK9 pill slashes LDL by up to 60%: late‑stage win https://biobriefs.com/repatha-prevents-first-heart-attacks BioBriefs en 2025-11-09T21:31:27Z Repatha prevents first heart attacks – Amgen posts 25% event reduction https://biobriefs.com/crispr-therapy-trims-ldl-and BioBriefs en 2025-11-09T21:31:27Z CRISPR therapy trims LDL and triglycerides in early human test…safety questions linger https://biobriefs.com/fda-expands-fast-track-pilot BioBriefs en 2025-11-09T21:31:27Z FDA expands fast‑track pilot: six more drugs added to national‑interest review https://biobriefs.com/recursion-names-new-ceo-as BioBriefs en 2025-11-09T21:31:27Z Recursion names new CEO as cash runway extends; Q3 losses widen https://biobriefs.com/pd-1-inhibitors-after-cd19 BioBriefs en 2025-11-09T21:31:27Z PD‑1 inhibitors after CD19 CAR‑T improve consolidation outcomes in NHL https://biobriefs.com/stair18-therapy-boosts-survival-in BioBriefs en 2025-11-09T21:31:27Z STAiR18 therapy boosts survival in multiple myeloma – new clinical data https://biobriefs.com/sglt2-inhibitors-prove-beneficial-across BioBriefs en 2025-11-09T21:31:27Z SGLT2 inhibitors prove beneficial across GFR and albuminuria strata in kidney disease https://biobriefs.com/james-watson-co-discoverer-of BioBriefs en 2025-11-09T21:31:27Z James Watson, co‑discoverer of DNA’s double helix, dies at 97 https://biobriefs.com/pfizer-wins-metsera-10-billion BioBriefs en 2025-11-09T16:31:47Z Pfizer wins Metsera: $10 billion takeover ends Novo Nordisk fight https://biobriefs.com/intellia-pause-patient-death-prompts BioBriefs en 2025-11-09T16:31:47Z Intellia pause... patient death prompts FDA clinical hold https://biobriefs.com/mercks-oral-pcsk9-pill-rivals BioBriefs en 2025-11-09T16:31:47Z Merck’s oral PCSK9 pill rivals injectables: Phase 3 LDL drop to 60% https://biobriefs.com/crispr-gene-edits-cut-lipids BioBriefs en 2025-11-09T16:31:47Z CRISPR gene edits cut lipids... early trials show dramatic reductions https://biobriefs.com/pacbios-long-read-sequencer-cleared BioBriefs en 2025-11-09T16:31:47Z PacBio’s long‑read sequencer cleared in China: Sequel II gets NMPA nod https://biobriefs.com/qiagen-buys-parse-biosciences-single BioBriefs en 2025-11-09T16:31:47Z Qiagen buys Parse Biosciences – single‑cell consolidation continues https://biobriefs.com/swiss-rockets-licenses-coolmps-new BioBriefs en 2025-11-09T16:31:47Z Swiss Rockets licenses CoolMPS: new western challenger in NGS instruments https://biobriefs.com/mit-lnp-breakthrough-100-fold BioBriefs en 2025-11-09T16:31:47Z MIT LNP breakthrough: 100‑fold dose cut for influenza mRNA in mice https://biobriefs.com/fda-expands-fast-track-pilot BioBriefs en 2025-11-09T16:31:47Z FDA expands fast‑track pilot: six more drugs gain national‑interest vouchers https://biobriefs.com/thermo-fisher-board-oks-5b BioBriefs en 2025-11-09T16:31:47Z Thermo Fisher board OKs $5B buyback – capital returns after solid Q3 https://biobriefs.com/intellia-crispr-trial-death-dosing BioBriefs en 2025-11-09T14:31:41Z Intellia CRISPR trial death... dosing paused and FDA hits clinical hold https://biobriefs.com/pfizer-wins-metsera-10-billion BioBriefs en 2025-11-09T14:31:41Z Pfizer wins Metsera: $10 billion takeover ends bidding war https://biobriefs.com/mercks-oral-pcsk9-pill-delivers BioBriefs en 2025-11-09T14:31:41Z Merck’s oral PCSK9 pill delivers injectable‑level LDL cuts – Phase 3 readout https://biobriefs.com/early-crispr-editing-shows-deep BioBriefs en 2025-11-09T14:31:41Z Early CRISPR editing shows deep lipid drops... but safety questions linger https://biobriefs.com/sglt2s-broaden-kidney-care-benefits BioBriefs en 2025-11-09T14:31:41Z SGLT2s broaden kidney care: benefits hold across GFR and albuminuria https://biobriefs.com/china-clears-pacbio-long-read BioBriefs en 2025-11-09T14:31:41Z China clears PacBio long‑read sequencer for clinical use – first global regulatory win https://biobriefs.com/qiagen-buys-parse-biosciences-single BioBriefs en 2025-11-09T14:31:41Z Qiagen buys Parse Biosciences – single‑cell consolidation accelerates https://biobriefs.com/swiss-rockets-licenses-coolmps-aims BioBriefs en 2025-11-09T14:31:41Z Swiss Rockets licenses CoolMPS... aims to be western NGS instrument maker https://biobriefs.com/cms-launches-medicaid-drug-pricing BioBriefs en 2025-11-09T14:31:41Z CMS launches Medicaid drug pricing model – voluntary international‑reference approach https://biobriefs.com/hi-c-lymphoma-assay-shows BioBriefs en 2025-11-09T14:31:41Z Hi‑C lymphoma assay shows FISH‑replacement potential in clinical labs https://biobriefs.com/patient-dies-in-intellia-crispr BioBriefs en 2025-11-09T10:31:48Z Patient dies in Intellia CRISPR study — Phase III programs paused https://biobriefs.com/pfizer-outbids-novo-10-billion BioBriefs en 2025-11-09T10:31:48Z Pfizer outbids Novo — $10 billion Metsera takeover sealed https://biobriefs.com/mercks-oral-pcsk9-pill-matches BioBriefs en 2025-11-09T10:31:48Z Merck’s oral PCSK9 pill matches injectables: Phase 3 shows deep LDL cuts https://biobriefs.com/crispr-edit-cuts-ldl-and BioBriefs en 2025-11-09T10:31:48Z CRISPR edit cuts LDL and triglycerides in early human study — safety questions remain https://biobriefs.com/china-clears-pacbio-long-read BioBriefs en 2025-11-09T10:31:48Z China clears PacBio long‑read sequencer — clinical HiFi sequencing approved https://biobriefs.com/swiss-rockets-licenses-coolmps-western BioBriefs en 2025-11-09T10:31:48Z Swiss Rockets licenses CoolMPS — western push for MGI tech https://biobriefs.com/qiagen-to-buy-parse-biosciences BioBriefs en 2025-11-09T10:31:48Z Qiagen to buy Parse Biosciences — single‑cell consolidation deepens https://biobriefs.com/sglt2s-help-kidneys-broadly-benefit BioBriefs en 2025-11-09T10:31:48Z SGLT2s help kidneys broadly — benefit transcends diabetes and GFR bands https://biobriefs.com/u-s-drug-pricing-moves BioBriefs en 2025-11-09T10:31:48Z U.S. drug‑pricing moves: CMS launches Medicaid pricing model — FDA adds priority‑review meds https://biobriefs.com/new-lnp-cuts-influenza-mrna BioBriefs en 2025-11-09T10:31:48Z New LNP cuts influenza mRNA dose 100‑fold in mice — delivery advance https://biobriefs.com/patient-dies-in-intellia-crispr BioBriefs en 2025-11-09T09:31:54Z Patient dies in Intellia CRISPR trial — FDA puts MAGNITUDE studies on hold https://biobriefs.com/pfizer-clinches-metsera-for-10 BioBriefs en 2025-11-09T09:31:54Z Pfizer clinches Metsera for $10 billion — deal ends Novo fight https://biobriefs.com/cholesterol-drug-race-mercks-oral BioBriefs en 2025-11-09T09:31:54Z Cholesterol drug race... Merck’s oral PCSK9 and early CRISPR cuts shine https://biobriefs.com/china-clears-first-clinical-long BioBriefs en 2025-11-09T09:31:54Z China clears first clinical long‑read sequencer: PacBio/Berry get NMPA nod https://biobriefs.com/mit-particles-boost-mrna-potency BioBriefs en 2025-11-09T09:31:54Z MIT particles boost mRNA potency — same response at 1/100th dose https://biobriefs.com/qiagen-buys-parse-biosciences-single BioBriefs en 2025-11-09T09:31:54Z Qiagen buys Parse Biosciences — single‑cell consolidation accelerates https://biobriefs.com/swiss-rockets-to-commercialize-coolmps BioBriefs en 2025-11-09T09:31:54Z Swiss Rockets to commercialize CoolMPS—new Western NGS entrant readies platform https://biobriefs.com/chronic-kidney-disease-doubles-since BioBriefs en 2025-11-09T09:31:54Z Chronic kidney disease doubles since 1990 — nearly 800 million affected https://biobriefs.com/cms-launches-generous-drug-pricing BioBriefs en 2025-11-09T09:31:54Z CMS launches GENEROUS drug‑pricing model — states invited to opt in https://biobriefs.com/sana-suspends-allogeneic-car-t BioBriefs en 2025-11-09T09:31:54Z Sana suspends allogeneic CAR‑T programs — company trims cell therapy pipeline https://biobriefs.com/patient-dies-after-intellia-crispr BioBriefs en 2025-11-09T04:31:27Z Patient dies after Intellia CRISPR dose: Phase 3 trials halted https://biobriefs.com/pfizer-wins-metsera-10-billion BioBriefs en 2025-11-09T04:31:27Z Pfizer wins Metsera... $10 billion deal ends bidding war https://biobriefs.com/mit-lnp-breakthrough-same-immunity BioBriefs en 2025-11-09T04:31:27Z MIT LNP breakthrough: same immunity at 1/100th the dose https://biobriefs.com/sglt2-inhibitors-kidney-benefit-spans BioBriefs en 2025-11-09T04:31:27Z SGLT2 inhibitors: kidney benefit spans GFR and albuminuria levels https://biobriefs.com/amgens-repatha-reduces-first-time BioBriefs en 2025-11-09T04:31:27Z Amgen’s Repatha reduces first‑time events: 25% fewer deaths and MIs https://biobriefs.com/swiss-rockets-licenses-coolmps-enters BioBriefs en 2025-11-09T04:31:27Z Swiss Rockets licenses CoolMPS — enters NGS hardware race https://biobriefs.com/qiagen-buys-parse-biosciences-single BioBriefs en 2025-11-09T04:31:27Z Qiagen buys Parse Biosciences — single‑cell consolidation continues https://biobriefs.com/pacbio-berry-nmpa-nod-china BioBriefs en 2025-11-09T04:31:27Z PacBio‑Berry NMPA nod: China clears clinical long‑read sequencer https://biobriefs.com/fda-expands-national-priority-voucher BioBriefs en 2025-11-09T04:31:27Z FDA expands national‑priority voucher pilot: six more drugs added https://biobriefs.com/regulatory-u-turns-create-mixed BioBriefs en 2025-11-09T04:31:27Z Regulatory U‑turns create mixed messaging in rare‑disease approvals https://biobriefs.com/intellia-crispr-trial-death-phase BioBriefs en 2025-11-08T21:32:22Z Intellia CRISPR trial death — Phase 3 studies paused https://biobriefs.com/pfizer-tops-novo-nordisk-in BioBriefs en 2025-11-08T21:32:22Z Pfizer tops Novo Nordisk in Metsera bidding war — $10 billion deal https://biobriefs.com/cholesterol-care-pivots-mercks-oral BioBriefs en 2025-11-08T21:32:22Z Cholesterol care pivots: Merck’s oral PCSK9 matches injectables; Repatha prevents first events https://biobriefs.com/crispr-editing-shows-dramatic-lipid BioBriefs en 2025-11-08T21:32:22Z CRISPR editing shows dramatic lipid drops in small human study https://biobriefs.com/long-read-sequencing-cleared-in BioBriefs en 2025-11-08T21:32:22Z Long‑read sequencing cleared in China; CoolMPS license fuels global NGS push https://biobriefs.com/cms-launches-generous-medicaid-pricing BioBriefs en 2025-11-08T21:32:22Z CMS launches GENEROUS Medicaid pricing pilot — International benchmarks drive rebates https://biobriefs.com/fda-expands-national-priority-review BioBriefs en 2025-11-08T21:32:22Z FDA expands national priority review vouchers — Six more drugs added https://biobriefs.com/single-cell-market-consolidates-qiagen BioBriefs en 2025-11-08T21:32:22Z Single‑cell market consolidates: Qiagen buys Parse; 10x posts mixed quarter https://biobriefs.com/mrna-tech-leap-new-lnp BioBriefs en 2025-11-08T21:32:22Z mRNA tech leap: new LNP and RNA elements could slash doses and costs https://biobriefs.com/kidney-care-updates-sglt2s-show BioBriefs en 2025-11-08T21:32:22Z Kidney care updates: SGLT2s show benefits across subgroups; Takeda antibody sustains function https://biobriefs.com/intellia-patient-dies-phase-iii BioBriefs en 2025-11-08T16:32:19Z Intellia patient dies — Phase III CRISPR trials put on hold https://biobriefs.com/amgens-repatha-25-fewer-first BioBriefs en 2025-11-08T16:32:19Z Amgen’s Repatha: 25% fewer first‑time cardiovascular events https://biobriefs.com/pacbio-hifi-wins-clinical-clearance BioBriefs en 2025-11-08T16:32:19Z PacBio HiFi wins clinical clearance in China — first long‑read sequencer cleared https://biobriefs.com/pfizer-outbids-novo-10-billion BioBriefs en 2025-11-08T16:32:19Z Pfizer outbids Novo — $10 billion Metsera takeover complete https://biobriefs.com/fda-expands-commissioners-national-priority BioBriefs en 2025-11-08T16:32:19Z FDA expands Commissioner’s National Priority Vouchers — six more drugs added https://biobriefs.com/qiagen-buys-parse-biosciences-single BioBriefs en 2025-11-08T16:32:19Z Qiagen buys Parse Biosciences — single‑cell market consolidates https://biobriefs.com/swiss-rockets-licenses-coolmps-eyes BioBriefs en 2025-11-08T16:32:19Z Swiss Rockets licenses CoolMPS — eyes global NGS platform launch https://biobriefs.com/sana-and-peers-trim-pipelines BioBriefs en 2025-11-08T16:32:19Z Sana and peers trim pipelines — clinical‑stage programs deprioritized https://biobriefs.com/eledon-eyes-phase-iii-after BioBriefs en 2025-11-08T16:32:19Z Eledon eyes Phase III after mixed Phase II kidney transplant readout https://biobriefs.com/mit-lnp-cuts-effective-mrna BioBriefs en 2025-11-08T16:32:19Z MIT LNP cuts effective mRNA dose by 100x in mice — delivery breakthrough https://biobriefs.com/intellia-patient-dies-crispr-attr BioBriefs en 2025-11-08T14:31:55Z Intellia patient dies — CRISPR ATTR trials paused https://biobriefs.com/fda-expands-priority-review-vouchers BioBriefs en 2025-11-08T14:31:55Z FDA expands priority-review vouchers: six more drugs added https://biobriefs.com/pfizer-tops-novo-with-10b BioBriefs en 2025-11-08T14:31:55Z Pfizer tops Novo with $10B bid for Metsera https://biobriefs.com/mit-nanoparticle-cuts-influenza-mrna BioBriefs en 2025-11-08T14:31:55Z MIT nanoparticle cuts influenza mRNA dose 100‑fold — Potency up https://biobriefs.com/pacbios-sequel-ii-cndx-cleared BioBriefs en 2025-11-08T14:31:55Z PacBio’s Sequel II CNDx cleared in China — First clinical long‑read approval https://biobriefs.com/qiagen-to-acquire-parse-biosciences BioBriefs en 2025-11-08T14:31:55Z Qiagen to acquire Parse Biosciences for up to $280M — Single‑cell deal https://biobriefs.com/arimas-hi-c-lymphoma-assay BioBriefs en 2025-11-08T14:31:55Z Arima’s Hi‑C lymphoma assay aims to supplant FISH — FFPE‑compatible genomic mapping https://biobriefs.com/swiss-rockets-secures-coolmps-license BioBriefs en 2025-11-08T14:31:55Z Swiss Rockets secures CoolMPS license from MGI — Plans western NGS launch https://biobriefs.com/cms-unveils-generous-model-medicaid BioBriefs en 2025-11-08T14:31:55Z CMS unveils Generous model: Medicaid drug prices tied to international benchmarks https://biobriefs.com/sglt2-inhibitors-cut-kidney-risk BioBriefs en 2025-11-08T14:31:55Z SGLT2 inhibitors cut kidney risk across eGFR and albuminuria levels — JAMA analysis https://biobriefs.com/pfizer-wins-metsera-novo-ups BioBriefs en 2025-11-08T10:31:52Z Pfizer wins Metsera... Novo ups the ante https://biobriefs.com/intellia-crispr-trial-halted-after BioBriefs en 2025-11-08T10:31:52Z Intellia CRISPR trial halted after patient dies — liver signal under scrutiny https://biobriefs.com/fda-expands-national-priority-voucher BioBriefs en 2025-11-08T10:31:52Z FDA expands national‑priority voucher awards — more drugs fast‑tracked https://biobriefs.com/cms-launches-generous-medicaid-drug BioBriefs en 2025-11-08T10:31:52Z CMS launches 'GENERous' Medicaid drug model — prices tied to international benchmarks https://biobriefs.com/mit-lnp-cuts-mrna-dose BioBriefs en 2025-11-08T10:31:52Z MIT LNP cuts mRNA dose 100‑fold — Nature Nanotech data https://biobriefs.com/china-clears-clinical-long-read BioBriefs en 2025-11-08T10:31:52Z China clears clinical long‑read sequencer; Swiss Rockets licenses CoolMPS https://biobriefs.com/sglt2-class-shows-kidney-benefits BioBriefs en 2025-11-08T10:31:52Z SGLT2 class shows kidney benefits across populations — large analyses https://biobriefs.com/single-cell-consolidation-qiagen-buys BioBriefs en 2025-11-08T10:31:52Z Single‑cell consolidation — Qiagen buys Parse as 10x revenue softens https://biobriefs.com/braveheart-funding-surge-vcs-back BioBriefs en 2025-11-08T10:31:52Z Braveheart funding surge — VCs back new biotech trio https://biobriefs.com/onchilles-advances-elane-program-25m BioBriefs en 2025-11-08T10:31:52Z Onchilles advances ELANE program — $25M round to push N17350 https://biobriefs.com/intellia-crispr-patient-dies-phase BioBriefs en 2025-11-08T09:33:31Z Intellia CRISPR patient dies — Phase 3 ATTR studies halted https://biobriefs.com/fda-expands-national-priority-vouchers BioBriefs en 2025-11-08T09:33:31Z FDA expands National Priority Vouchers — six more drugs added https://biobriefs.com/pfizer-and-novo-nordisk-spar BioBriefs en 2025-11-08T09:33:31Z Pfizer and Novo Nordisk spar over Metsera — price approaches $10B https://biobriefs.com/china-clears-pacbio-long-read BioBriefs en 2025-11-08T09:33:31Z China clears PacBio long‑read sequencer — Illumina export ban lifted https://biobriefs.com/sglt2-inhibitors-show-kidney-benefit BioBriefs en 2025-11-08T09:33:31Z SGLT2 inhibitors show kidney benefit across GFR and albuminuria https://biobriefs.com/mit-lnp-cuts-mrna-vaccine BioBriefs en 2025-11-08T09:33:31Z MIT LNP cuts mRNA vaccine dose by 100x — new ionizable lipid https://biobriefs.com/qiagen-buys-parse-biosciences-single BioBriefs en 2025-11-08T09:33:31Z Qiagen buys Parse Biosciences — single‑cell tools consolidate https://biobriefs.com/lillys-amylin-eloralintide-posts-strong BioBriefs en 2025-11-08T09:33:31Z Lilly’s amylin eloralintide posts strong weight‑loss; Phase 3 planned https://biobriefs.com/fda-clears-darzalex-faspro-for BioBriefs en 2025-11-08T09:33:31Z FDA clears DARZALEX Faspro for high‑risk smoldering myeloma https://biobriefs.com/biohub-merges-ai-and-biology BioBriefs en 2025-11-08T09:33:31Z Biohub merges AI and biology — EvolutionaryScale team joins new initiative https://biobriefs.com/intellia-crispr-trial-patient-death BioBriefs en 2025-11-08T04:33:22Z Intellia CRISPR trial: patient death prompts FDA clinical hold https://biobriefs.com/fda-expands-priority-voucher-list BioBriefs en 2025-11-08T04:33:22Z FDA expands priority voucher list: six more therapies win fast-track https://biobriefs.com/metsera-takeover-fight-pfizer-tops BioBriefs en 2025-11-08T04:33:22Z Metsera takeover fight: Pfizer tops Novo with $10 billion offer https://biobriefs.com/mit-particles-slash-mrna-dose BioBriefs en 2025-11-08T04:33:22Z MIT particles slash mRNA dose: 100‑fold potency gain reported https://biobriefs.com/pacbio-sequel-ii-cndx-cleared BioBriefs en 2025-11-08T04:33:22Z PacBio Sequel II CNDx cleared: China approves first clinical long‑read sequencer https://biobriefs.com/swiss-rockets-scores-coolmps-license BioBriefs en 2025-11-08T04:33:22Z Swiss Rockets scores CoolMPS license — eyes NGS instrument market https://biobriefs.com/qiagen-buys-parse-biosciences-single BioBriefs en 2025-11-08T04:33:22Z Qiagen buys Parse Biosciences — single‑cell consolidation accelerates https://biobriefs.com/sglt2-benefit-broad-but-nuanced BioBriefs en 2025-11-08T04:33:22Z SGLT2 benefit broad but nuanced: kidney protection spans subgroups https://biobriefs.com/eledon-plots-phase-iii-despite BioBriefs en 2025-11-08T04:33:22Z Eledon plots phase III despite Bestow miss — transplant candidate under review https://biobriefs.com/biohub-snaps-up-evolutionaryscale-zuckerberg BioBriefs en 2025-11-08T04:33:22Z Biohub snaps up EvolutionaryScale: Zuckerberg backs frontier AI for biology https://biobriefs.com/patient-dies-after-intellia-crispr BioBriefs en 2025-11-07T21:33:27Z Patient dies after Intellia CRISPR dose — Phase 3 trials paused https://biobriefs.com/cms-launches-generous-medicaid-drug BioBriefs en 2025-11-07T21:33:27Z CMS launches ‘GENEROUS’ Medicaid drug-price pilot — manufacturers invited https://biobriefs.com/fda-awards-second-round-of BioBriefs en 2025-11-07T21:33:27Z FDA awards second round of priority vouchers — obesity drugs among winners https://biobriefs.com/trump-announces-novo-lilly-pricing BioBriefs en 2025-11-07T21:33:27Z Trump announces Novo‑Lilly pricing deals — White House event disrupted by medical emergency https://biobriefs.com/china-clears-pacbio-long-read BioBriefs en 2025-11-07T21:33:27Z China clears PacBio long‑read system — Illumina export ban lifted https://biobriefs.com/gileads-trodelvy-falls-short-in BioBriefs en 2025-11-07T21:33:27Z Gilead’s Trodelvy falls short in Phase 3 — breast cancer setback https://biobriefs.com/mit-lnp-breakthrough-mrna-vaccine BioBriefs en 2025-11-07T21:33:27Z MIT LNP breakthrough — mRNA vaccine potency up, dose down 100‑fold https://biobriefs.com/qiagen-to-buy-parse-biosciences BioBriefs en 2025-11-07T21:33:27Z Qiagen to buy Parse Biosciences — single‑cell consolidation deepens https://biobriefs.com/novo-ups-metsera-bid-ftc BioBriefs en 2025-11-07T21:33:27Z Novo ups Metsera bid — FTC flags deal structure for review https://biobriefs.com/evommune-prices-150m-ipo-inflammation BioBriefs en 2025-11-07T21:33:27Z Evommune prices $150M IPO — inflammation biotech lists amid shutdown https://biobriefs.com/crispr-trial-halted-after-patient BioBriefs en 2025-11-07T16:32:23Z CRISPR trial halted after patient death: Intellia updates https://biobriefs.com/white-house-cuts-obesity-drug BioBriefs en 2025-11-07T16:32:23Z White House cuts obesity drug prices; FDA grants priority vouchers https://biobriefs.com/novo-pfizer-metsera-fight-draws BioBriefs en 2025-11-07T16:32:23Z Novo-Pfizer Metsera fight draws antitrust scrutiny https://biobriefs.com/lillys-amylin-drug-drives-20 BioBriefs en 2025-11-07T16:32:23Z Lilly’s amylin drug drives 20% weight loss — amylin debate heats up https://biobriefs.com/arima-genomics-pushes-hi-c BioBriefs en 2025-11-07T16:32:23Z Arima Genomics pushes Hi‑C assay to challenge FISH in lymphoma https://biobriefs.com/hepta-emerges-with-cfdna-epigenetics BioBriefs en 2025-11-07T16:32:23Z Hepta emerges with cfDNA epigenetics to detect MASH — raises seed https://biobriefs.com/ginkgo-wins-barda-award-to BioBriefs en 2025-11-07T16:32:23Z Ginkgo wins BARDA award to scale monoclonal antibody manufacturing https://biobriefs.com/biovectra-and-revolution-link-mrna BioBriefs en 2025-11-07T16:32:23Z BIOVECTRA and Revolution link mRNA design to GMP manufacturing https://biobriefs.com/mit-lipid-nanoparticle-breakthrough-could BioBriefs en 2025-11-07T16:32:23Z MIT lipid nanoparticle breakthrough could slash mRNA dose 100x https://biobriefs.com/zuckerbergs-biohub-expands-with-evolutionaryscale BioBriefs en 2025-11-07T16:32:23Z Zuckerberg’s Biohub expands with EvolutionaryScale AI team https://biobriefs.com/intellia-crispr-trial-paused-patient BioBriefs en 2025-11-07T14:33:57Z Intellia CRISPR trial paused: patient dies after liver injury https://biobriefs.com/mit-lnps-promise-100x-potency BioBriefs en 2025-11-07T14:33:57Z MIT LNPs promise 100x potency — RNA elements extend mRNA durability https://biobriefs.com/lillys-amylin-delivers-up-to BioBriefs en 2025-11-07T14:33:57Z Lilly’s amylin delivers up to 20% weight loss — phase 3 imminent https://biobriefs.com/fda-grants-second-wave-of BioBriefs en 2025-11-07T14:33:57Z FDA grants second wave of 'national priority' vouchers — obesity drugs among winners https://biobriefs.com/metsera-bidding-war-escalates-novo BioBriefs en 2025-11-07T14:33:57Z Metsera bidding war escalates: Novo ups bid as court refuses Pfizer block https://biobriefs.com/site-specific-recombinases-debut-azalea BioBriefs en 2025-11-07T14:33:57Z Site‑specific recombinases debut — Azalea exits stealth to target in vivo gene engineering https://biobriefs.com/ai-designs-antibodies-with-atomic BioBriefs en 2025-11-07T14:33:57Z AI designs antibodies with atomic precision — Baker weighs in https://biobriefs.com/hepta-raises-6-7m-cfdna BioBriefs en 2025-11-07T14:33:57Z Hepta raises $6.7M — cfDNA AI targets liver disease https://biobriefs.com/biovectra-revolution-link-mrna-design BioBriefs en 2025-11-07T14:33:57Z BIOVECTRA, Revolution link mRNA design to GMP manufacturing https://biobriefs.com/onchilles-bags-25m-to-move BioBriefs en 2025-11-07T14:33:57Z Onchilles bags $25M to move cancer‑killing enzyme toward human trials https://biobriefs.com/intellia-crispr-patient-dies-magnitude BioBriefs en 2025-11-07T10:33:01Z Intellia CRISPR patient dies: MAGNITUDE investigations intensify https://biobriefs.com/eloralintide-rivals-glp-1s-lilly BioBriefs en 2025-11-07T10:33:01Z Eloralintide rivals GLP‑1s — Lilly pushes amylin into Phase 3 https://biobriefs.com/fda-expands-voucher-list-next BioBriefs en 2025-11-07T10:33:01Z FDA expands voucher list — next round includes obesity players https://biobriefs.com/ftc-flags-novos-metsera-bid BioBriefs en 2025-11-07T10:33:01Z FTC flags Novo’s Metsera bid — court denies Pfizer block https://biobriefs.com/ai-achieves-atomic-precision-antibody BioBriefs en 2025-11-07T10:33:01Z AI achieves atomic‑precision antibody design — structure confirms https://biobriefs.com/biohub-hires-evolutionaryscale-zuckerberg-backs BioBriefs en 2025-11-07T10:33:01Z Biohub hires EvolutionaryScale: Zuckerberg backs frontier AI for biology https://biobriefs.com/ginkgo-wins-barda-contract-to BioBriefs en 2025-11-07T10:33:01Z Ginkgo wins BARDA contract to tame mAb manufacturing costs https://biobriefs.com/mit-cell-electronic-hybrids-immune BioBriefs en 2025-11-07T10:33:01Z MIT cell‑electronic hybrids: immune cells ferry micrometer implants https://biobriefs.com/biovectra-pairs-with-revolution-to BioBriefs en 2025-11-07T10:33:01Z BIOVECTRA pairs with Revolution to offer end‑to‑end mRNA to GMP https://biobriefs.com/hepta-raises-6-7m-to BioBriefs en 2025-11-07T10:33:01Z Hepta raises $6.7M to read cfDNA methylomes for chronic liver disease https://biobriefs.com/intellia-trial-halted-patient-dies BioBriefs en 2025-11-07T09:32:52Z Intellia trial halted: patient dies after liver injury https://biobriefs.com/fda-unveils-second-round-of BioBriefs en 2025-11-07T09:32:52Z FDA unveils second round of national priority vouchers — obesity drugs among winners https://biobriefs.com/ftc-flags-novos-metsera-bid BioBriefs en 2025-11-07T09:32:52Z FTC flags Novo’s Metsera bid: pre‑merger concerns surface https://biobriefs.com/rfdiffusion-delivers-ai-designs-atomically BioBriefs en 2025-11-07T09:32:52Z RFdiffusion delivers: AI designs atomically precise antibodies https://biobriefs.com/hepta-emerges-with-6-7m BioBriefs en 2025-11-07T09:32:52Z Hepta emerges with $6.7M seed to read cfDNA epigenomes for liver disease https://biobriefs.com/human-stomach-organoids-reprogrammed-to BioBriefs en 2025-11-07T09:32:52Z Human stomach organoids reprogrammed to secrete insulin in vivo https://biobriefs.com/china-reopens-market-illumina-export BioBriefs en 2025-11-07T09:32:52Z China reopens market: Illumina export ban lifted, PacBio diagnostic cleared https://biobriefs.com/j-j-expands-caplyta-label BioBriefs en 2025-11-07T09:32:52Z J&J expands Caplyta label — broader depression use approved after big buyout https://biobriefs.com/lillys-amylin-drug-eloralintide-posts BioBriefs en 2025-11-07T09:32:52Z Lilly’s amylin drug eloralintide posts strong weight‑loss — heads to phase 3 https://biobriefs.com/biohub-bets-big-on-ai BioBriefs en 2025-11-07T09:32:52Z Biohub bets big on AI biology — acquires EvolutionaryScale team https://biobriefs.com/intellia-crispr-trial-death-regulators BioBriefs en 2025-11-07T04:33:19Z Intellia CRISPR trial death: regulators, partners increase scrutiny https://biobriefs.com/chan-zuckerberg-biohub-buys-ai BioBriefs en 2025-11-07T04:33:19Z Chan Zuckerberg Biohub buys AI lab: EvolutionaryScale team folds into Biohub https://biobriefs.com/ai-designs-atomically-precise-antibodies BioBriefs en 2025-11-07T04:33:19Z AI designs atomically precise antibodies: RFdiffusion validated by cryo-EM https://biobriefs.com/human-stomach-organoids-reprogrammed-to BioBriefs en 2025-11-07T04:33:19Z Human stomach organoids reprogrammed to make insulin: in vivo proof of concept https://biobriefs.com/evommune-prices-150m-ipo-amid BioBriefs en 2025-11-07T04:33:19Z Evommune prices $150M IPO amid market quirks https://biobriefs.com/hepta-emerges-with-6-7m BioBriefs en 2025-11-07T04:33:19Z Hepta emerges with $6.7M to apply cfDNA AI to liver disease diagnostics https://biobriefs.com/biovectra-ties-mrna-sequence-design BioBriefs en 2025-11-07T04:33:19Z BIOVECTRA ties mRNA sequence design to GMP manufacturing https://biobriefs.com/ginkgo-wins-barda-award-to BioBriefs en 2025-11-07T04:33:19Z Ginkgo wins BARDA award to speed monoclonal antibody manufacturing https://biobriefs.com/fda-expands-priority-review-vouchers BioBriefs en 2025-11-07T04:33:19Z FDA expands priority-review vouchers: Lilly, Novo among second-round winners https://biobriefs.com/abzena-and-mabqi-form-integrated BioBriefs en 2025-11-07T04:33:19Z Abzena and Mabqi form integrated antibody discovery-to-development alliance https://biobriefs.com/ftc-warns-novo-on-metsera BioBriefs en 2025-11-06T21:32:41Z FTC warns Novo on Metsera bid: HSR compliance questioned https://biobriefs.com/fda-awards-priority-vouchers-white BioBriefs en 2025-11-06T21:32:41Z FDA awards priority vouchers — White House seals GLP‑1 price deals https://biobriefs.com/fda-rejects-biohaven-filing-company BioBriefs en 2025-11-06T21:32:40Z FDA rejects Biohaven filing — company cuts R&D and reprioritizes https://biobriefs.com/braveheart-raises-185m-pushes-rival BioBriefs en 2025-11-06T21:32:40Z Braveheart raises $185M — pushes rival hypertrophic cardiomyopathy program https://biobriefs.com/ai-crafts-atom-level-antibodies BioBriefs en 2025-11-06T21:32:40Z AI crafts atom‑level antibodies: RFdiffusion delivers de‑novo binders https://biobriefs.com/china-lifts-illumina-ban-sequencer BioBriefs en 2025-11-06T21:32:40Z China lifts Illumina ban: sequencer imports to resume Nov. 10 https://biobriefs.com/fda-approves-ucbs-kygevvi-first BioBriefs en 2025-11-06T21:32:40Z FDA approves UCB’s Kygevvi — first therapy for TK2 deficiency https://biobriefs.com/ginkgo-wins-barda-mandate-22m BioBriefs en 2025-11-06T21:32:40Z Ginkgo wins BARDA mandate: $22M to scale domestic mAb production https://biobriefs.com/hepta-emerges-with-6-7m BioBriefs en 2025-11-06T21:32:40Z Hepta emerges with $6.7M seed to read cfDNA for chronic disease https://biobriefs.com/moderna-retreats-on-revenue-costs BioBriefs en 2025-11-06T21:32:40Z Moderna retreats on revenue: costs cut as vaccine uptake slows https://biobriefs.com/ftc-flags-metsera-deal-structure BioBriefs en 2025-11-06T16:33:48Z FTC flags Metsera deal structure: premerger review eyeing compliance https://biobriefs.com/fda-rebukes-biohavens-ataxia-filing BioBriefs en 2025-11-06T16:33:48Z FDA rebukes Biohaven’s ataxia filing — company to slash R&D https://biobriefs.com/lilly-advances-amylin-phase-3 BioBriefs en 2025-11-06T16:33:48Z Lilly advances amylin: phase 3 set after strong 48‑week results https://biobriefs.com/ai-designs-antibodies-with-atomic BioBriefs en 2025-11-06T16:33:48Z AI designs antibodies with atomic precision... cryo‑EM confirms binding https://biobriefs.com/hepta-raises-6-7m-to BioBriefs en 2025-11-06T16:33:48Z Hepta raises $6.7M to read cfDNA epigenome for chronic disease https://biobriefs.com/ginkgo-wins-barda-biomap-award BioBriefs en 2025-11-06T16:33:48Z Ginkgo wins BARDA BioMaP award to scale monoclonal‑antibody production https://biobriefs.com/caplyta-label-expansion-j-js BioBriefs en 2025-11-06T16:33:48Z Caplyta label expansion: J&J’s buyout validated with MDD clearance https://biobriefs.com/pim3-inhibition-restores-car-t BioBriefs en 2025-11-06T16:33:48Z PIM3 inhibition restores CAR‑T potency in hypoxic tumor niches https://biobriefs.com/amacathera-inks-230m-deal-with BioBriefs en 2025-11-06T16:33:48Z AmacaThera inks $230M deal with Pacira for long‑acting local anesthetic https://biobriefs.com/intranasal-h5-vaccine-primes-cross BioBriefs en 2025-11-06T16:33:48Z Intranasal H5 vaccine primes cross‑clade immunity in Phase I trial https://biobriefs.com/ai-designs-antibodies-at-atomic BioBriefs en 2025-11-06T14:33:40Z AI designs antibodies at atomic precision: RFdiffusion proves concept https://biobriefs.com/fda-rejects-biohaven-ataxia-bid BioBriefs en 2025-11-06T14:33:40Z FDA rejects Biohaven ataxia bid — company pivots to cuts https://biobriefs.com/ftc-flags-novos-metsera-move BioBriefs en 2025-11-06T14:33:40Z FTC flags Novo’s Metsera move — antitrust review warned https://biobriefs.com/lillys-amylin-jumps-to-phase BioBriefs en 2025-11-06T14:33:40Z Lilly’s amylin jumps to phase 3 — 20% weight‑loss signal https://biobriefs.com/hepta-raises-6-7m-ai BioBriefs en 2025-11-06T14:33:40Z Hepta raises $6.7M — AI liquid biopsy targets MASH https://biobriefs.com/crispr-live-imaging-captures-chromatin BioBriefs en 2025-11-06T14:33:40Z CRISPR live imaging... captures chromatin and enhancer dynamics https://biobriefs.com/china-reopens-to-illumina-sequencers BioBriefs en 2025-11-06T14:33:40Z China reopens to Illumina sequencers — export ban to lift Nov. 10 https://biobriefs.com/fda-approves-first-tk2-deficiency BioBriefs en 2025-11-06T14:33:40Z FDA approves first TK2 deficiency therapy — KYGEVVI clears https://biobriefs.com/ginkgo-wins-barda-contract-22 BioBriefs en 2025-11-06T14:33:40Z Ginkgo wins BARDA contract: $22.2M push to domestic mAb manufacturing https://biobriefs.com/automating-car-t-lonza-lays BioBriefs en 2025-11-06T14:33:40Z Automating CAR‑T: Lonza lays out scale and network strategy https://biobriefs.com/ftc-flags-novo-nordisk-deal BioBriefs en 2025-11-06T10:32:21Z FTC flags Novo Nordisk deal structure: premerger review risk https://biobriefs.com/metsera-board-backs-novos-topping BioBriefs en 2025-11-06T10:32:21Z Metsera board backs Novo’s topping bid — Pfizer fights on https://biobriefs.com/fda-rejects-biohaven-ataxia-filing BioBriefs en 2025-11-06T10:32:21Z FDA rejects Biohaven ataxia filing — company pivots to deep cuts https://biobriefs.com/fda-approves-first-therapy-for BioBriefs en 2025-11-06T10:32:21Z FDA approves first therapy for TK2 deficiency: Kygevvi clears the mark https://biobriefs.com/atomically-accurate-antibodies-rfdiffusion-delivers BioBriefs en 2025-11-06T10:32:21Z Atomically accurate antibodies: RFdiffusion delivers de novo binders https://biobriefs.com/ginkgo-lands-barda-pact-to BioBriefs en 2025-11-06T10:32:21Z Ginkgo lands BARDA pact to scale mAb manufacturing for filoviruses https://biobriefs.com/hepta-raises-6-7m-to BioBriefs en 2025-11-06T10:32:21Z Hepta raises $6.7M to commercialize cfDNA epigenetic liquid biopsy for MASH https://biobriefs.com/pim3-blockade-restores-car-t BioBriefs en 2025-11-06T10:32:21Z PIM3 blockade restores CAR‑T in hypoxia — manufacturing scale still a bottleneck https://biobriefs.com/ferroptosis-vulnerabilities-mapped-fsp1-and BioBriefs en 2025-11-06T10:32:21Z Ferroptosis vulnerabilities mapped: FSP1 and oxygen shape targets in lung and melanoma https://biobriefs.com/china-to-lift-illumina-sequencer BioBriefs en 2025-11-06T10:32:21Z China to lift Illumina sequencer import ban: market reopens Nov. 10 https://biobriefs.com/novo-ups-metsera-bid-to BioBriefs en 2025-11-06T09:33:01Z Novo ups Metsera bid to $10 billion — takeover fight intensifies https://biobriefs.com/fda-spurns-biohaven-ataxia-filing BioBriefs en 2025-11-06T09:33:01Z FDA spurns Biohaven ataxia filing — company readies deep cuts https://biobriefs.com/fda-approves-kygevvi-first-treatment BioBriefs en 2025-11-06T09:33:01Z FDA approves Kygevvi: first treatment for TK2 deficiency https://biobriefs.com/ai-designs-atom-precise-antibodies BioBriefs en 2025-11-06T09:33:01Z AI designs atom-precise antibodies — Nature validates RFdiffusion https://biobriefs.com/ginkgo-wins-barda-contract-to BioBriefs en 2025-11-06T09:33:01Z Ginkgo wins BARDA contract to scale monoclonal antibody manufacturing https://biobriefs.com/hepta-raises-6-7m-to BioBriefs en 2025-11-06T09:33:01Z Hepta raises $6.7M to commercialize cfDNA epigenetic liquid biopsy for MASH https://biobriefs.com/china-reopens-sequencing-market-illumina BioBriefs en 2025-11-06T09:33:01Z China reopens sequencing market — Illumina returns as PacBio gains Chinese approvals https://biobriefs.com/labs-go-autonomous-self-driving BioBriefs en 2025-11-06T09:33:01Z Labs go autonomous: self-driving materials lab and AI scientist debut https://biobriefs.com/fsp1-and-ferroptosis-vulnerabilities-new BioBriefs en 2025-11-06T09:33:01Z FSP1 and ferroptosis vulnerabilities: new targets in lung and melanoma https://biobriefs.com/scaling-cell-therapies-automation-cdmos BioBriefs en 2025-11-06T09:33:01Z Scaling cell therapies: automation, CDMOs and tissue-targeting delivery mapped https://biobriefs.com/ftc-flags-novos-metsera-offer BioBriefs en 2025-11-06T04:33:18Z FTC flags Novo’s Metsera offer — deal structure under scrutiny https://biobriefs.com/ai-designs-antibodies-rfdiffusion-achieves BioBriefs en 2025-11-06T04:33:18Z AI designs antibodies: RFdiffusion achieves atom-level binding https://biobriefs.com/fda-approves-first-treatment-for BioBriefs en 2025-11-06T04:33:18Z FDA approves first treatment for TK2 deficiency — UCB’s Kygevvi cleared https://biobriefs.com/ginkgo-wins-barda-award-22 BioBriefs en 2025-11-06T04:33:18Z Ginkgo wins BARDA award — $22.2M project to scale monoclonal antibody manufacturing https://biobriefs.com/sequencing-market-shakeup-pacbio-revenue BioBriefs en 2025-11-06T04:33:18Z Sequencing market shakeup: PacBio revenue slips as Berry wins China clearance https://biobriefs.com/fda-rejects-biohaven-filing-company BioBriefs en 2025-11-06T04:33:18Z FDA rejects Biohaven filing — company to cut R&D and reprioritize https://biobriefs.com/sareptas-confirmatory-miss-rattles-duchenne BioBriefs en 2025-11-06T04:33:18Z Sarepta’s confirmatory miss rattles Duchenne space — market reacts https://biobriefs.com/braveheart-raises-185m-backs-hcm BioBriefs en 2025-11-06T04:33:18Z Braveheart raises $185M — backs HCM challenger from Hengrui https://biobriefs.com/neok-bio-debuts-with-75m BioBriefs en 2025-11-06T04:33:18Z Neok Bio debuts with $75M — bispecific ADCs head to IND https://biobriefs.com/hepta-raises-6-7m-to BioBriefs en 2025-11-06T04:33:18Z Hepta raises $6.7M to push cfDNA epigenetic test for liver disease https://biobriefs.com/fda-rejects-biohavens-ataxia-bid BioBriefs en 2025-11-05T21:32:33Z FDA rejects Biohaven’s ataxia bid — company to cut R&D https://biobriefs.com/fda-approves-ucbs-kygevvi-first BioBriefs en 2025-11-05T21:32:33Z FDA approves UCB’s Kygevvi — first therapy for TK2 deficiency https://biobriefs.com/metsera-bidding-war-escalates-regulators BioBriefs en 2025-11-05T21:32:33Z Metsera bidding war escalates — regulators and rivals push back https://biobriefs.com/sareptas-duchenne-confirmatory-trial-misses BioBriefs en 2025-11-05T21:32:33Z Sarepta’s Duchenne confirmatory trial misses endpoint — debate erupts https://biobriefs.com/ai-designs-atom-accurate-antibodies BioBriefs en 2025-11-05T21:32:33Z AI designs atom‑accurate antibodies — Baker lab validates approach https://biobriefs.com/hepta-bio-raises-6-7m BioBriefs en 2025-11-05T21:32:33Z Hepta Bio raises $6.7M to apply cfDNA epigenetics to chronic disease https://biobriefs.com/ginkgo-wins-barda-award-to BioBriefs en 2025-11-05T21:32:33Z Ginkgo wins BARDA award to scale low‑cost mAb manufacturing https://biobriefs.com/qiagen-buys-parse-to-add BioBriefs en 2025-11-05T21:32:33Z Qiagen buys Parse to add scalable single‑cell capabilities https://biobriefs.com/non-surgical-cell-electronics-brain BioBriefs en 2025-11-05T21:32:33Z Non‑surgical cell‑electronics brain implants modulate targets in mice https://biobriefs.com/braveheart-nets-185m-to-advance BioBriefs en 2025-11-05T21:32:33Z Braveheart nets $185M to advance Hengrui‑licensed heart drug https://biobriefs.com/metsera-melee-novo-bids-10b BioBriefs en 2025-11-05T16:33:32Z Metsera melee: Novo bids $10B while Pfizer sues https://biobriefs.com/blackstone-banks-mercks-adc-push BioBriefs en 2025-11-05T16:33:32Z Blackstone banks Merck’s ADC push — $700M risk deal https://biobriefs.com/fda-clears-ucbs-kygevvi-first BioBriefs en 2025-11-05T16:33:32Z FDA clears UCB’s Kygevvi — first therapy for TK2 deficiency https://biobriefs.com/sarepta-setback-duchenne-confirmatory-trial BioBriefs en 2025-11-05T16:33:32Z Sarepta setback — Duchenne confirmatory trial fails; company to press FDA https://biobriefs.com/fda-rebuffs-biohavens-rwe-submission BioBriefs en 2025-11-05T16:33:32Z FDA rebuffs Biohaven’s RWE submission — troriluzole hit with CRL https://biobriefs.com/braveheart-raises-185m-to-challenge BioBriefs en 2025-11-05T16:33:32Z Braveheart raises $185M to challenge HCM market — Biogen chair on board https://biobriefs.com/azalea-raises-82m-doudna-spinoff BioBriefs en 2025-11-05T16:33:32Z Azalea raises $82M — Doudna spinoff targets single‑shot in vivo CAR‑T https://biobriefs.com/qiagen-buys-parse-biosciences-push BioBriefs en 2025-11-05T16:33:32Z Qiagen buys Parse Biosciences — push into single‑cell market https://biobriefs.com/tempus-ai-readies-for-mrd BioBriefs en 2025-11-05T16:33:32Z Tempus AI readies for MRD reimbursement — Q3 revenue jumps 85% https://biobriefs.com/fda-turmoil-cder-chief-resigns BioBriefs en 2025-11-05T16:33:32Z FDA turmoil: CDER chief resigns amid probe, critics warn credibility erodes https://biobriefs.com/metsera-m-a-melee-novo BioBriefs en 2025-11-05T14:32:35Z Metsera M&A melee: Novo raises bid to $10 billion https://biobriefs.com/fda-turmoil-cder-chief-exits BioBriefs en 2025-11-05T14:32:35Z FDA turmoil: CDER chief exits amid probe https://biobriefs.com/uniqure-stumble-fda-shifts-on BioBriefs en 2025-11-05T14:32:35Z UniQure stumble: FDA shifts on Huntington’s gene therapy https://biobriefs.com/sarepta-confirmatory-miss-duchenne-trial BioBriefs en 2025-11-05T14:32:35Z Sarepta confirmatory miss – Duchenne trial fails primary endpoint https://biobriefs.com/fda-rejects-biohavens-rwe-bid BioBriefs en 2025-11-05T14:32:35Z FDA rejects Biohaven’s RWE bid for troriluzole https://biobriefs.com/braveheart-raises-185m-to-advance BioBriefs en 2025-11-05T14:32:35Z Braveheart raises $185M to advance HCM candidate https://biobriefs.com/qiagen-to-buy-parse-biosciences BioBriefs en 2025-11-05T14:32:35Z Qiagen to buy Parse Biosciences for single‑cell push https://biobriefs.com/merck-sells-adc-risk-pays BioBriefs en 2025-11-05T14:32:35Z Merck sells ADC risk, pays to regain an asset – two‑check deal https://biobriefs.com/thermo-fisher-to-buy-clario BioBriefs en 2025-11-05T14:32:35Z Thermo Fisher to buy Clario for $8.8B to expand clinical‑trial tech https://biobriefs.com/azalea-therapeutics-launches-with-82m BioBriefs en 2025-11-05T14:32:35Z Azalea Therapeutics launches with $82M to pursue in‑vivo CAR‑T https://biobriefs.com/metsera-m-a-melee-novo BioBriefs en 2025-11-05T10:31:52Z Metsera M&A melee: Novo and Pfizer raise the ante https://biobriefs.com/cder-leadership-split-top-fda BioBriefs en 2025-11-05T10:31:52Z CDER leadership split: Top FDA drug regulator exits https://biobriefs.com/uniqure-data-reversal-huntingtons-gene BioBriefs en 2025-11-05T10:31:52Z UniQure data reversal: Huntington’s gene therapy timeline murky https://biobriefs.com/fda-rejects-biohavens-troriluzole-bid BioBriefs en 2025-11-05T10:31:52Z FDA rejects Biohaven’s troriluzole bid: RWE route blocked https://biobriefs.com/sareptas-confirmatory-miss-duchenne-approval BioBriefs en 2025-11-05T10:31:52Z Sarepta’s confirmatory miss: Duchenne approval path in flux https://biobriefs.com/arena-bioworks-shutters-billionaire-backed BioBriefs en 2025-11-05T10:31:52Z Arena BioWorks shutters: billionaire‑backed research hub folds https://biobriefs.com/qiagen-scoops-parse-biosciences-to BioBriefs en 2025-11-05T10:31:52Z Qiagen scoops Parse Biosciences to bulk up single‑cell toolkit https://biobriefs.com/colossal-buys-viagen-to-add BioBriefs en 2025-11-05T10:31:52Z Colossal buys Viagen to add cloning, biobank muscle https://biobriefs.com/nautilus-installs-single-molecule-proteomics BioBriefs en 2025-11-05T10:31:52Z Nautilus installs single‑molecule proteomics platform at Buck Institute https://biobriefs.com/exact-sciences-posts-strong-quarter BioBriefs en 2025-11-05T10:31:52Z Exact Sciences posts strong quarter as screening climbs https://biobriefs.com/uniqures-huntington-bid-stalls-fda BioBriefs en 2025-11-05T09:32:34Z UniQure’s Huntington bid stalls: FDA backs away from external‑control path https://biobriefs.com/fda-drug-leadership-in-turmoil BioBriefs en 2025-11-05T09:32:34Z FDA drug leadership in turmoil: CDER left helmless after Tidmarsh exit https://biobriefs.com/sareptas-duchenne-confirmatory-miss-company BioBriefs en 2025-11-05T09:32:34Z Sarepta’s Duchenne confirmatory miss: company vows to press FDA for full approvals https://biobriefs.com/metsera-takeover-melee-novo-ups BioBriefs en 2025-11-05T09:32:34Z Metsera takeover melee: Novo ups bid to $10B as Pfizer pushes back https://biobriefs.com/merck-taps-blackstone-for-700m BioBriefs en 2025-11-05T09:32:34Z Merck taps Blackstone for $700M ADC push; pays $150M to regain asset https://biobriefs.com/off-the-shelf-car-t BioBriefs en 2025-11-05T09:32:34Z Off‑the‑shelf CAR‑T shows promise: donor cells deliver deep lymphoma remissions https://biobriefs.com/qiagen-buys-parse-to-scale BioBriefs en 2025-11-05T09:32:34Z Qiagen buys Parse to scale single‑cell; PacBio partner wins China clearance https://biobriefs.com/new-lab-platforms-enter-early BioBriefs en 2025-11-05T09:32:34Z New lab platforms enter early access: single‑molecule proteomics and Tri‑Mod RNA assay https://biobriefs.com/doudna-spinoff-azalea-raises-82m BioBriefs en 2025-11-05T09:32:34Z Doudna spinoff Azalea raises $82M: single‑dose in vivo CAR‑T aims for clinic https://biobriefs.com/biotech-shake-ups-billionaire-backed BioBriefs en 2025-11-05T09:32:34Z Biotech shake‑ups: billionaire‑backed Arena shutters; Colossal buys Viagen cloning arm https://biobriefs.com/fda-leadership-shake-up-and BioBriefs en 2025-11-05T04:32:32Z FDA leadership shake-up and uniQure setback: regulator turmoil delays Huntington’s gene therapy https://biobriefs.com/sareptas-duchenne-confirmatory-failure-company BioBriefs en 2025-11-05T04:32:32Z Sarepta’s Duchenne confirmatory failure — company to press FDA despite negative readout https://biobriefs.com/metsera-takeover-battle-heats-up BioBriefs en 2025-11-05T04:32:32Z Metsera takeover battle heats up — Novo raises bid to $10B as Pfizer files lawsuits https://biobriefs.com/thermo-fisher-to-buy-clario BioBriefs en 2025-11-05T04:32:32Z Thermo Fisher to buy Clario for $8.8B: clinical trials data and digital push accelerates https://biobriefs.com/qiagen-buys-parse-biosciences-to BioBriefs en 2025-11-05T04:32:32Z Qiagen buys Parse Biosciences to jump into single‑cell genomics https://biobriefs.com/colossal-acquires-viagen-pets-equine BioBriefs en 2025-11-05T04:32:32Z Colossal acquires Viagen Pets & Equine — cloning and biobanks join de‑extinction push https://biobriefs.com/doudna-backed-azalea-launches-with BioBriefs en 2025-11-05T04:32:32Z Doudna‑backed Azalea launches with $82M to pursue single‑dose in‑vivo CAR‑T https://biobriefs.com/nautilus-places-single-molecule-protein BioBriefs en 2025-11-05T04:32:32Z Nautilus places single‑molecule protein platform at Buck — first external install lifts stock https://biobriefs.com/arena-bioworks-shutters-billionaire-backed BioBriefs en 2025-11-05T04:32:32Z Arena BioWorks shutters: billionaire‑backed research institute pulls plug amid funding squeeze https://biobriefs.com/roche-pays-55m-for-manifold BioBriefs en 2025-11-05T04:32:32Z Roche pays $55M for Manifold Bio brain‑shuttle pact — $2B program to cross blood‑brain barrier https://biobriefs.com/fda-leadership-crisis-cder-chief BioBriefs en 2025-11-04T21:32:55Z FDA leadership crisis: CDER chief exits after misconduct probe https://biobriefs.com/fda-reverses-course-on-uniqure BioBriefs en 2025-11-04T21:32:55Z FDA reverses course on uniQure Huntington's data — submission timeline in doubt https://biobriefs.com/metsera-m-a-melee-novos BioBriefs en 2025-11-04T21:32:55Z Metsera M&A melee: Novo’s $10B pitch meets Pfizer lawsuits https://biobriefs.com/sarepta-confirmatory-flop-duchenne-exon BioBriefs en 2025-11-04T21:32:55Z Sarepta confirmatory flop: Duchenne exon‑skipping trial fails primary endpoint https://biobriefs.com/off-the-shelf-car-t BioBriefs en 2025-11-04T21:32:55Z Off‑the‑shelf CAR‑T shows promise – Caribou posts encouraging lymphoma results https://biobriefs.com/nautilus-lands-at-buck-institute BioBriefs en 2025-11-04T21:32:55Z Nautilus lands at Buck Institute: single‑molecule proteomics reaches neurodegeneration labs https://biobriefs.com/pharmacogenomics-gap-widens-as-oneome BioBriefs en 2025-11-04T21:32:55Z Pharmacogenomics gap widens as OneOme shutters CLIA lab https://biobriefs.com/thermo-fisher-shells-out-8 BioBriefs en 2025-11-04T21:32:55Z Thermo Fisher shells out $8.8B for Clario to bolster clinical‑trial tech stack https://biobriefs.com/roche-bets-on-manifold-brain BioBriefs en 2025-11-04T21:32:55Z Roche bets on Manifold brain‑shuttle tech with multi‑hundred‑million pact https://biobriefs.com/private-capital-backs-merck-oncology BioBriefs en 2025-11-04T21:32:55Z Private capital backs Merck oncology push: Blackstone buys into ADC royalties https://biobriefs.com/metsera-m-a-melee-novo BioBriefs en 2025-11-04T16:32:18Z Metsera M&A melee: Novo pushes $10B bid, Pfizer strikes back https://biobriefs.com/fda-turbulence-cder-boss-resigns BioBriefs en 2025-11-04T16:32:18Z FDA turbulence: CDER boss resigns amid probe https://biobriefs.com/uniqure-setback-fda-questions-amt BioBriefs en 2025-11-04T16:32:18Z UniQure setback: FDA questions AMT‑130 data — filing timeline unclear https://biobriefs.com/thermo-fisher-expands-clinical-stack BioBriefs en 2025-11-04T16:32:18Z Thermo Fisher expands clinical stack: Clario deal to scale trials https://biobriefs.com/azalea-launches-82m-raise-to BioBriefs en 2025-11-04T16:32:18Z Azalea launches: $82M raise to enable single‑shot in vivo CAR‑T https://biobriefs.com/celltrion-gambit-744m-deal-for BioBriefs en 2025-11-04T16:32:18Z Celltrion gambit: $744M deal for Kaigene autoimmune antibodies https://biobriefs.com/sarepta-stumbles-duchenne-confirmatory-trial BioBriefs en 2025-11-04T16:32:18Z Sarepta stumbles: Duchenne confirmatory trial misses endpoint https://biobriefs.com/off-the-shelf-car-t BioBriefs en 2025-11-04T16:32:18Z Off‑the‑shelf CAR‑T shows promise — Caribou posts durable remissions https://biobriefs.com/astellas-unveils-kras-g12d-degrader BioBriefs en 2025-11-04T16:32:18Z Astellas unveils KRAS G12D degrader with tumor activity preclinically https://biobriefs.com/cas12l-nucleases-emerge-as-compact BioBriefs en 2025-11-04T16:32:18Z Cas12l nucleases emerge as compact CRISPR tools for therapeutics https://biobriefs.com/uniqures-huntingtons-therapy-hits-fda BioBriefs en 2025-11-04T14:31:43Z uniQure’s Huntington’s therapy hits FDA roadblock — shares tumble https://biobriefs.com/fda-leadership-crisis-deepens-after BioBriefs en 2025-11-04T14:31:43Z FDA leadership crisis deepens after CDER director resigns https://biobriefs.com/pfizer-sues-to-block-novo BioBriefs en 2025-11-04T14:31:43Z Pfizer sues to block Novo‑Metsera deal — legal battle escalates https://biobriefs.com/doudna-linked-azalea-raises-82m BioBriefs en 2025-11-04T14:31:43Z Doudna‑linked Azalea raises $82M to chase in vivo CAR‑T single‑dose therapy https://biobriefs.com/roche-pumps-billions-into-brain BioBriefs en 2025-11-04T14:31:43Z Roche pumps billions into brain‑shuttle technology with Manifold pact https://biobriefs.com/thermo-fisher-to-buy-clinical BioBriefs en 2025-11-04T14:31:43Z Thermo Fisher to buy clinical‑trial data firm Clario — $8.8B deal expands digital reach https://biobriefs.com/aavantgarde-raises-141m-series-b BioBriefs en 2025-11-04T14:31:43Z AAVantgarde raises $141M Series B to push retinal gene therapies forward https://biobriefs.com/caribous-allogeneic-car-t-shows BioBriefs en 2025-11-04T14:31:43Z Caribou’s allogeneic CAR‑T shows early promise — off‑the‑shelf story revives https://biobriefs.com/tscan-cuts-workforce-halts-solid BioBriefs en 2025-11-04T14:31:43Z TScan cuts workforce, halts solid‑tumor TCR program amid refocus https://biobriefs.com/cder-chief-resigns-fda-left BioBriefs en 2025-11-04T10:32:14Z CDER chief resigns: FDA left leaderless after conduct probe https://biobriefs.com/uniqure-stumbles-fda-signals-amt BioBriefs en 2025-11-04T10:32:14Z UniQure stumbles: FDA signals AMT‑130 data now inadequate https://biobriefs.com/pfizer-sues-to-block-novos BioBriefs en 2025-11-04T10:32:14Z Pfizer sues to block Novo’s Metsera counter‑offer — takeover fight turns legal https://biobriefs.com/thermo-fisher-shelled-out-for BioBriefs en 2025-11-04T10:32:14Z Thermo Fisher shelled out for Clario: $8.8B bet on digital trials https://biobriefs.com/amgen-ventures-backs-aavantgarde-141m BioBriefs en 2025-11-04T10:32:14Z Amgen Ventures backs AAVantgarde: $141M to push retinal gene programs https://biobriefs.com/caribous-off-the-shelf-car BioBriefs en 2025-11-04T10:32:14Z Caribou’s off‑the‑shelf CAR‑T shows promise — but cash question looms https://biobriefs.com/sareptas-duchenne-confirmatory-trial-fails BioBriefs en 2025-11-04T10:32:14Z Sarepta’s Duchenne confirmatory trial fails — company to press FDA anyway https://biobriefs.com/whole-genome-in-under-four BioBriefs en 2025-11-04T10:32:14Z Whole genome in under four hours: sequencing race accelerates newborn care https://biobriefs.com/weill-cornell-unveils-non-toxic BioBriefs en 2025-11-04T10:32:14Z Weill Cornell unveils non‑toxic gene‑switch — safer control for research and therapies https://biobriefs.com/lilly-to-build-3b-european BioBriefs en 2025-11-04T10:32:14Z Lilly to build $3B European plant for oral GLP‑1 pill https://biobriefs.com/fda-drug-regulator-tidmarsh-resigns BioBriefs en 2025-11-04T09:32:09Z FDA drug regulator Tidmarsh resigns: HHS probe leaves CDER leaderless https://biobriefs.com/fda-signals-no-approval-path BioBriefs en 2025-11-04T09:32:09Z FDA signals no approval path: uniQure’s Huntington filing timeline stalls https://biobriefs.com/pfizer-sues-to-halt-novos BioBriefs en 2025-11-04T09:32:09Z Pfizer sues to halt Novo’s Metsera bid — antitrust and breach claims filed https://biobriefs.com/thermo-fisher-to-buy-clario BioBriefs en 2025-11-04T09:32:09Z Thermo Fisher to buy Clario for $8.8B: expands trial data stack https://biobriefs.com/roche-bets-on-manifolds-brain BioBriefs en 2025-11-04T09:32:09Z Roche bets on Manifold’s brain shuttles — pact could top $2B https://biobriefs.com/lilly-to-build-3b-factory BioBriefs en 2025-11-04T09:32:09Z Lilly to build $3B factory in Netherlands for oral GLP‑1 drug https://biobriefs.com/myriad-posts-q3-revenue-dip BioBriefs en 2025-11-04T09:32:09Z Myriad posts Q3 revenue dip — bets on upcoming MyRisk and MRD launches https://biobriefs.com/california-medicaid-adds-mrd-and BioBriefs en 2025-11-04T09:32:09Z California Medicaid adds MRD and whole‑genome sequencing to benefits https://biobriefs.com/caribous-off-the-shelf-car BioBriefs en 2025-11-04T09:32:09Z Caribou’s off‑the‑shelf CAR‑T posts strong early responses — financing needed to scale https://biobriefs.com/sareptas-duchenne-confirmatory-trial-fails BioBriefs en 2025-11-04T09:32:09Z Sarepta’s Duchenne confirmatory trial fails — company to press FDA for approval anyway https://biobriefs.com/fda-drug-chief-resigns-cder BioBriefs en 2025-11-04T04:32:17Z FDA drug chief resigns — CDER left without a leader https://biobriefs.com/uniqures-huntingtons-gene-therapy-stalled BioBriefs en 2025-11-04T04:32:17Z UniQure’s Huntington’s gene therapy stalled — FDA questions sufficiency of Phase I/II data https://biobriefs.com/thermo-fisher-to-buy-clario BioBriefs en 2025-11-04T04:32:17Z Thermo Fisher to buy Clario — major push into clinical trial software and data https://biobriefs.com/california-medicaid-adds-mrd-and BioBriefs en 2025-11-04T04:32:17Z California Medicaid adds MRD and whole‑genome sequencing to covered benefits https://biobriefs.com/roche-bets-on-brain-shuttles BioBriefs en 2025-11-04T04:32:17Z Roche bets on brain shuttles — $55M upfront with Manifold; pact could top $2B https://biobriefs.com/caribous-off-the-shelf-car BioBriefs en 2025-11-04T04:32:17Z Caribou’s off‑the‑shelf CAR‑T shows promise — funding needed to proceed https://biobriefs.com/intellias-in-vivo-crispr-trial BioBriefs en 2025-11-04T04:32:17Z Intellia’s in vivo CRISPR trial faces clinical hold after liver safety signal https://biobriefs.com/aavantgarde-raises-141m-series-b BioBriefs en 2025-11-04T04:32:17Z AAVantgarde raises $141M Series B to advance retinal gene therapies https://biobriefs.com/mass-general-brigham-researchers-use BioBriefs en 2025-11-04T04:32:17Z Mass General Brigham researchers use tumor cells to kickstart antitumor immunity in models https://biobriefs.com/tscan-cuts-workforce-and-halts BioBriefs en 2025-11-04T04:32:17Z TScan cuts workforce and halts solid‑tumor TCR program to focus on blood cancers https://biobriefs.com/uniqures-huntington-hopes-hit-fda BioBriefs en 2025-11-03T21:31:54Z UniQure’s Huntington Hopes Hit: FDA Signals Data Shortfall https://biobriefs.com/fda-drug-office-in-turmoil BioBriefs en 2025-11-03T21:31:54Z FDA Drug Office in Turmoil: CDER Director Resigns After Leave https://biobriefs.com/pfizer-files-suit-to-block BioBriefs en 2025-11-03T21:31:54Z Pfizer Files Suit to Block Novo Nordisk–Metsera Deal — Antitrust Fight Starts https://biobriefs.com/thermo-fisher-expands-into-clinical BioBriefs en 2025-11-03T21:31:54Z Thermo Fisher Expands Into Clinical-Trial Tech: Clario Deal Agreed https://biobriefs.com/roche-taps-manifold-bios-platform BioBriefs en 2025-11-03T21:31:54Z Roche Taps Manifold Bio’s Platform: $55M Deal to Pilot Brain Shuttles https://biobriefs.com/off-the-shelf-car-t BioBriefs en 2025-11-03T21:31:54Z Off‑the‑Shelf CAR‑T Shows Promise: Caribou Posts Early Efficacy Signals https://biobriefs.com/intellia-halts-dosing-crispr-heart BioBriefs en 2025-11-03T21:31:54Z Intellia Halts Dosing: CRISPR Heart Program Faces FDA Clinical Hold https://biobriefs.com/clinical-program-cutbacks-tscan-lays BioBriefs en 2025-11-03T21:31:54Z Clinical Program Cutbacks: TScan Lays Off Staff, Stops Solid‑Tumor Trial https://biobriefs.com/cyclin-a2-reboots-human-heart BioBriefs en 2025-11-03T21:31:54Z Cyclin A2 Reboots Human Heart Cells: New Gene Therapy Drives Division https://biobriefs.com/non-toxic-gene-switch-cyclone BioBriefs en 2025-11-03T21:31:54Z Non‑toxic gene‑switch 'Cyclone' Debuts: Precise, Safer Control of Gene Activity https://biobriefs.com/uniqures-huntington-therapy-fda-flags BioBriefs en 2025-11-03T16:32:22Z uniQure’s Huntington therapy — FDA flags data shortfall https://biobriefs.com/roche-bets-on-brain-shuttles BioBriefs en 2025-11-03T16:32:22Z Roche bets on brain shuttles: $55M Manifold tie‑up to speed BBB delivery https://biobriefs.com/italian-gene-therapy-startup-raises BioBriefs en 2025-11-03T16:32:22Z Italian gene‑therapy startup raises $141M — Amgen joins Series B https://biobriefs.com/intellias-crispr-program-paused-fda BioBriefs en 2025-11-03T16:32:22Z Intellia’s CRISPR program paused — FDA places clinical hold after liver signal https://biobriefs.com/tscan-slashes-staff-abandons-solid BioBriefs en 2025-11-03T16:32:22Z TScan slashes staff, abandons solid‑tumor trial — refocus on blood cancers https://biobriefs.com/caribous-off-the-shelf-car BioBriefs en 2025-11-03T16:32:22Z Caribou’s off‑the‑shelf CAR‑T posts competitive lymphoma results — needs cash https://biobriefs.com/thermo-fisher-to-buy-clario BioBriefs en 2025-11-03T16:32:22Z Thermo Fisher to buy Clario for $9B — bet on clinical‑trial software https://biobriefs.com/biontech-lifts-guidance-after-bristol BioBriefs en 2025-11-03T16:32:22Z BioNTech lifts guidance after Bristol Myers bispecific payment https://biobriefs.com/cder-shakeup-george-tidmarsh-placed BioBriefs en 2025-11-03T16:32:22Z CDER shakeup: George Tidmarsh placed on leave — regulatory leadership in flux https://biobriefs.com/moderna-unravels-covid-windfall-fades BioBriefs en 2025-11-03T16:32:22Z Moderna unravels: Covid windfall fades, pipeline and contracts under strain https://biobriefs.com/uniqures-huntingtons-filing-timeline-clouds BioBriefs en 2025-11-03T14:31:55Z UniQure’s Huntington’s filing timeline clouds: FDA signals more data needed https://biobriefs.com/intellias-in-vivo-crispr-program BioBriefs en 2025-11-03T14:31:55Z Intellia’s in vivo CRISPR program halted: FDA clinical hold after liver safety event https://biobriefs.com/caribous-off-the-shelf-car BioBriefs en 2025-11-03T14:31:55Z Caribou’s off‑the‑shelf CAR‑T shows clinical promise — cash crunch looms https://biobriefs.com/aavantgarde-raises-141m-amgen-backs BioBriefs en 2025-11-03T14:31:55Z AAVantgarde raises $141M: Amgen backs retinal gene therapy push https://biobriefs.com/roche-buys-into-brain-shuttle BioBriefs en 2025-11-03T14:31:55Z Roche buys into brain‑shuttle tech: Manifold pact blends AI and BBB expertise https://biobriefs.com/thermo-fisher-to-buy-clario BioBriefs en 2025-11-03T14:31:55Z Thermo Fisher to buy Clario for $9B — software joins the lab stack https://biobriefs.com/pfizer-sues-to-block-metsera BioBriefs en 2025-11-03T14:31:55Z Pfizer sues to block Metsera‑Novo deal — obesity M&A turns litigious https://biobriefs.com/tscan-cuts-30-of-staff BioBriefs en 2025-11-03T14:31:55Z TScan cuts 30% of staff, halts solid‑tumor TCR program https://biobriefs.com/fda-leadership-in-flux-cder BioBriefs en 2025-11-03T14:31:55Z FDA leadership in flux: CDER director George Tidmarsh placed on leave https://biobriefs.com/intellia-clinical-hold-dosing-paused BioBriefs en 2025-11-03T10:31:38Z Intellia clinical hold–dosing paused after severe liver injury https://biobriefs.com/thermo-fisher-shells-out-9 BioBriefs en 2025-11-03T10:31:38Z Thermo Fisher shells out $9 billion: buys Clario to plug clinical‑data gap https://biobriefs.com/fda-turmoil-cder-director-placed BioBriefs en 2025-11-03T10:31:38Z FDA turmoil...CDER director placed on leave as agency faces leadership strain https://biobriefs.com/amgen-ventures-backs-aavantgarde-141 BioBriefs en 2025-11-03T10:31:38Z Amgen Ventures backs AAVantgarde: $141 million to accelerate retinal gene therapies https://biobriefs.com/moderna-unravels-vaccine-success-fails BioBriefs en 2025-11-03T10:31:38Z Moderna unravels: vaccine success fails to translate into broader pipeline wins https://biobriefs.com/optical-genome-mapping-augments-cll BioBriefs en 2025-11-03T10:31:38Z Optical genome mapping augments CLL workup: pilot shows broader structural variant capture https://biobriefs.com/plasma-ptau217-test-fujirebio-aims BioBriefs en 2025-11-03T10:31:38Z Plasma pTau217 test: Fujirebio aims to speed Alzheimer’s diagnosis with blood assay https://biobriefs.com/phage-tech-moves-from-farms BioBriefs en 2025-11-03T10:31:38Z Phage tech moves from farms to clinics: virus‑loaded patches and bird‑flu phage research advance https://biobriefs.com/ai-and-digital-twins-reshape BioBriefs en 2025-11-03T10:31:38Z AI and digital twins reshape R&D: binding‑affinity models and factory simulations scale discovery https://biobriefs.com/tumor-activated-therapy-and-cas9 BioBriefs en 2025-11-03T10:31:38Z Tumor‑activated therapy and Cas9 delivery advances push next‑gen oncology tools https://biobriefs.com/amgen-backs-milan-gene-therapy BioBriefs en 2025-11-03T09:33:16Z Amgen backs Milan gene-therapy play: AAVantgarde raises $141M https://biobriefs.com/intellia-paused-fda-places-clinical BioBriefs en 2025-11-03T09:33:16Z Intellia paused: FDA places clinical hold after serious liver event https://biobriefs.com/thermo-fisher-spends-9b-to BioBriefs en 2025-11-03T09:33:16Z Thermo Fisher spends $9B to add clinical-trial software: Clario deal https://biobriefs.com/fda-leadership-in-flux-cder BioBriefs en 2025-11-03T09:33:16Z FDA leadership in flux: CDER director George Tidmarsh placed on leave https://biobriefs.com/pfizer-drags-metsera-to-court BioBriefs en 2025-11-03T09:33:16Z Pfizer drags Metsera to court as Novo enters fray—obesity race intensifies https://biobriefs.com/modernas-post-pandemic-reset-contracts BioBriefs en 2025-11-03T09:33:16Z Moderna’s post‑pandemic reset: contracts cut, restructuring and pressure https://biobriefs.com/bird-flu-spillovers-push-phage BioBriefs en 2025-11-03T09:33:16Z Bird-flu spillovers push phage therapy and vaccine research forward https://biobriefs.com/orbitrap-astral-zoom-thermo-pushes BioBriefs en 2025-11-03T09:33:16Z Orbitrap Astral Zoom: Thermo pushes proteomics throughput and depth https://biobriefs.com/boltz-2-and-physics-based BioBriefs en 2025-11-03T09:33:16Z Boltz‑2 and physics‑based models: AI advances binding‑affinity prediction https://biobriefs.com/ultra-broad-hybrid-capture-ngs BioBriefs en 2025-11-03T09:33:16Z Ultra‑broad hybrid-capture NGS flags pathogens in plasma—new diagnostic tool https://biobriefs.com/cder-director-tidmarsh-placed-on BioBriefs en 2025-11-03T04:31:40Z CDER director Tidmarsh placed on leave — FDA leadership in flux https://biobriefs.com/intellia-trials-halted-fda-clinical BioBriefs en 2025-11-03T04:31:40Z Intellia trials halted: FDA clinical hold after serious liver event https://biobriefs.com/thermo-fisher-to-buy-clario BioBriefs en 2025-11-03T04:31:40Z Thermo Fisher to buy Clario for $9B — expands eClinical footprint https://biobriefs.com/pfizer-sues-to-block-metsera BioBriefs en 2025-11-03T04:31:40Z Pfizer sues to block Metsera-Novo approach — fight over obesity assets https://biobriefs.com/modernas-post-pandemic-pivot-falters BioBriefs en 2025-11-03T04:31:40Z Moderna’s post‑pandemic pivot falters: market value collapses https://biobriefs.com/thermos-orbitrap-astral-zoom-ms BioBriefs en 2025-11-03T04:31:40Z Thermo’s Orbitrap Astral Zoom MS accelerates proteomics throughput https://biobriefs.com/ai-models-move-toward-quantitative BioBriefs en 2025-11-03T04:31:40Z AI models move toward quantitative drug discovery: Boltz‑2 emerges https://biobriefs.com/adventhealth-ai-will-enable-segments BioBriefs en 2025-11-03T04:31:40Z AdventHealth: AI will enable ‘segments of one’ care personalization https://biobriefs.com/bird-flu-spillovers-spur-renewed BioBriefs en 2025-11-03T04:31:40Z Bird‑flu spillovers spur renewed phage‑therapy research https://biobriefs.com/230-billion-at-risk-top BioBriefs en 2025-11-03T04:31:40Z $230 billion at risk: Top blockbusters face 2026‑29 patent cliff https://biobriefs.com/thermo-fisher-buys-clario-9 BioBriefs en 2025-11-02T21:31:26Z Thermo Fisher buys Clario: $9 billion bet on trial data software https://biobriefs.com/pfizer-sues-metsera-and-novo BioBriefs en 2025-11-02T21:31:26Z Pfizer sues Metsera and Novo Nordisk... takeover fight turns legal https://biobriefs.com/modernas-retrenchment-covid-windfall-fails BioBriefs en 2025-11-02T21:31:26Z Moderna’s retrenchment... Covid windfall fails to translate to wider pipeline https://biobriefs.com/bird-flu-surge-spurs-phage BioBriefs en 2025-11-02T21:31:26Z Bird‑flu surge spurs phage therapy research: CDC and industry respond https://biobriefs.com/top-20-drugs-hit-patent BioBriefs en 2025-11-02T21:31:26Z Top 20 drugs hit patent cliff: $176.4 billion at risk through 2029 https://biobriefs.com/thermos-orbitrap-astral-zoom-ms BioBriefs en 2025-11-02T21:31:26Z Thermo’s Orbitrap Astral Zoom MS... mass spec scales multiomics https://biobriefs.com/ai-models-and-boltz-2 BioBriefs en 2025-11-02T21:31:26Z AI models and Boltz‑2 reshape binding‑affinity prediction for discovery https://biobriefs.com/health-canada-to-reclassify-cloned BioBriefs en 2025-11-02T21:31:26Z Health Canada to reclassify cloned‑animal products: silent policy shift https://biobriefs.com/human-kidney-organoids-scaled-for BioBriefs en 2025-11-02T21:31:26Z Human kidney organoids scaled for porcine transplant research https://biobriefs.com/turbocharged-cas9-nuclear-entry-internal BioBriefs en 2025-11-02T21:31:26Z Turbocharged Cas9 nuclear entry: internal NLS insertions boost editing https://biobriefs.com/pfizer-sues-to-block-novo BioBriefs en 2025-11-02T16:32:15Z Pfizer Sues to Block Novo Bid—Metsera Deal in Limbo https://biobriefs.com/fda-halts-intellia-s-crispr BioBriefs en 2025-11-02T16:32:15Z FDA Halts Intellia's CRISPR Trials After Liver Complications https://biobriefs.com/gene-therapy-cure-for-ada BioBriefs en 2025-11-02T16:32:15Z Gene Therapy 'Cure' for ADA‑SCID: 95% Success in Multi‑Year Follow‑Up https://biobriefs.com/human-kidney-organoids-scaled-porcine BioBriefs en 2025-11-02T16:32:15Z Human Kidney Organoids Scaled—Porcine Transplant Demonstrates Feasibility https://biobriefs.com/moderna-faces-downturn-restructuring-as BioBriefs en 2025-11-02T16:32:15Z Moderna Faces Downturn—Restructuring as Covid Windfall Erodes https://biobriefs.com/bird-flu-spillovers-revive-phage BioBriefs en 2025-11-02T16:32:15Z Bird flu spillovers revive phage therapy and vaccine research https://biobriefs.com/fda-commissioner-signals-new-deregulatory BioBriefs en 2025-11-02T16:32:15Z FDA Commissioner Signals New Deregulatory Moves—Industry Watches https://biobriefs.com/ai-models-close-in-on BioBriefs en 2025-11-02T16:32:15Z AI Models Close In on Binding Affinity—Boltz‑2 and Physics‑Grounded LQMs https://biobriefs.com/il-12-nanoparticles-eradicate-metastatic BioBriefs en 2025-11-02T16:32:15Z IL‑12 Nanoparticles Eradicate Metastatic Ovarian Tumors in Mice https://biobriefs.com/myeloid-ifng-signaling-identified-as BioBriefs en 2025-11-02T16:32:15Z Myeloid IFNγ Signaling Identified as Checkpoint Resistance Lever in Kidney Cancer https://biobriefs.com/pfizer-moves-to-enforce-metsera BioBriefs en 2025-11-02T14:31:50Z Pfizer moves to enforce Metsera deal – Delaware court fight begins https://biobriefs.com/fda-halts-intellia-crispr-trials BioBriefs en 2025-11-02T14:31:50Z FDA halts Intellia CRISPR trials – liver safety probe https://biobriefs.com/gene-therapy-achieves-95-success BioBriefs en 2025-11-02T14:31:50Z Gene therapy achieves 95% success in ADA‑SCID follow‑up – UCL and UCLA https://biobriefs.com/porcine-kidneys-infused-with-human BioBriefs en 2025-11-02T14:31:50Z Porcine kidneys infused with human organoids...first scalable transplant tests https://biobriefs.com/thermo-fisher-agrees-to-buy BioBriefs en 2025-11-02T14:31:50Z Thermo Fisher agrees to buy Clario for $8.88 billion – data and endpoints play https://biobriefs.com/modernas-post-vaccine-pivot-falters BioBriefs en 2025-11-02T14:31:50Z Moderna’s post‑vaccine pivot falters – restructuring and lost contracts https://biobriefs.com/ai-models-push-binding-affinity BioBriefs en 2025-11-02T14:31:50Z AI models push binding‑affinity prediction — Boltz‑2 and physics‑grounded LQMs https://biobriefs.com/il-12-releasing-nanoparticles-enable BioBriefs en 2025-11-02T14:31:50Z IL‑12‑releasing nanoparticles enable durable ovarian tumor clearance with checkpoint inhibitors https://biobriefs.com/ultra-broad-hybrid-capture-ngs BioBriefs en 2025-11-02T14:31:50Z Ultra‑broad hybrid capture NGS detects circulating pathogen DNA in plasma https://biobriefs.com/fda-signals-deregulation-push-agency BioBriefs en 2025-11-02T14:31:50Z FDA signals deregulation push — agency guidance and bespoke gene‑therapy pathway guidance emerge https://biobriefs.com/pfizer-sues-to-block-metsera BioBriefs en 2025-11-02T10:32:11Z Pfizer sues to block Metsera sale—Novo bid triggers courtroom fight https://biobriefs.com/fda-places-intellia-crispr-trials BioBriefs en 2025-11-02T10:32:11Z FDA places Intellia CRISPR trials on hold: liver safety probe https://biobriefs.com/moderna-retreats-cuts-canceled-contracts BioBriefs en 2025-11-02T10:32:11Z Moderna retreats: cuts, canceled contracts and a pivot after Covid boom https://biobriefs.com/gene-therapy-cure-for-ada BioBriefs en 2025-11-02T10:32:11Z Gene therapy ‘cure’ for ADA‑SCID posts 95% success—UCL, UCLA follow‑up https://biobriefs.com/scalable-human-kidney-organoids-integrated BioBriefs en 2025-11-02T10:32:11Z Scalable human kidney organoids integrated with porcine kidneys—transplant step https://biobriefs.com/il-12-nanoparticles-plus-checkpoint BioBriefs en 2025-11-02T10:32:11Z IL‑12 nanoparticles plus checkpoint inhibitors wipe out ovarian metastases in mice https://biobriefs.com/patent-cliff-looms-biopharma-m BioBriefs en 2025-11-02T10:32:11Z Patent cliff looms—Biopharma M&A surges as companies chase new revenues https://biobriefs.com/engineered-cas9-and-baby-kj BioBriefs en 2025-11-02T10:32:11Z Engineered Cas9 and Baby KJ pathway: lab fixes meet regulatory playbook https://biobriefs.com/myeloid-and-tumor-genomic-mechanisms BioBriefs en 2025-11-02T10:32:11Z Myeloid and tumor genomic mechanisms map immunotherapy resistance https://biobriefs.com/ai-sharpens-discovery-binding-affinity BioBriefs en 2025-11-02T10:32:11Z AI sharpens discovery—binding affinity models and scaled virtual cells https://biobriefs.com/pfizer-sues-to-enforce-metsera BioBriefs en 2025-11-02T09:32:10Z Pfizer sues to enforce Metsera buyout — court fight ignites https://biobriefs.com/modernas-post-covid-pivot-falters BioBriefs en 2025-11-02T09:32:10Z Moderna’s post‑Covid pivot falters — layoffs, contract losses and valuation collapse https://biobriefs.com/fda-halts-intellias-crispr-trials BioBriefs en 2025-11-02T09:32:10Z FDA halts Intellia’s CRISPR trials after liver safety signals https://biobriefs.com/gene-therapy-milestone-ada-scid BioBriefs en 2025-11-02T09:32:10Z Gene therapy milestone: ADA‑SCID ‘cure’ shows durable success https://biobriefs.com/human-kidney-organoids-scaled-and BioBriefs en 2025-11-02T09:32:10Z Human kidney organoids scaled and grafted into porcine kidneys https://biobriefs.com/thermo-fisher-moves-on-clario BioBriefs en 2025-11-02T09:32:10Z Thermo Fisher moves on Clario — $8.88B buy to tighten clinical data stack https://biobriefs.com/cas9-delivery-and-baby-kj BioBriefs en 2025-11-02T09:32:10Z Cas9 delivery and Baby KJ dossier reshape bespoke gene‑therapy pathway https://biobriefs.com/ai-and-compute-scale-speed BioBriefs en 2025-11-02T09:32:10Z AI and compute scale speed drug discovery and virtual cell modeling https://biobriefs.com/nanoparticles-reinvigorate-ovarian-cancer-immunotherapy BioBriefs en 2025-11-02T09:32:10Z Nanoparticles reinvigorate ovarian cancer immunotherapy https://biobriefs.com/bird-flu-spillovers-push-phage BioBriefs en 2025-11-02T09:32:10Z Bird‑flu spillovers push phage therapy and antiviral innovation https://biobriefs.com/pfizer-sues-to-block-novos BioBriefs en 2025-11-02T04:31:54Z Pfizer sues to block Novo’s Metsera bid—Delaware court showdown https://biobriefs.com/fda-halts-intellias-crispr-phase BioBriefs en 2025-11-02T04:31:54Z FDA halts Intellia’s CRISPR Phase 3 trials after liver safety signals https://biobriefs.com/ucl-ucla-gene-therapy-for BioBriefs en 2025-11-02T04:31:54Z UCL–UCLA gene therapy for ADA‑SCID hits curative milestone in long follow‑up https://biobriefs.com/baby-kj-model-fda-guidance BioBriefs en 2025-11-02T04:31:54Z Baby KJ model: FDA guidance and one‑off CRISPR therapies move toward scalability https://biobriefs.com/il-12-nanoparticles-reverse-ovarian BioBriefs en 2025-11-02T04:31:54Z IL‑12 nanoparticles reverse ovarian tumor immune suppression in mice https://biobriefs.com/scalable-human-kidney-organoids-integrated BioBriefs en 2025-11-02T04:31:54Z Scalable human kidney organoids integrated into porcine kidneys—first transplant success https://biobriefs.com/ai-models-accelerate-drug-discovery BioBriefs en 2025-11-02T04:31:54Z AI models accelerate drug discovery: Boltz‑2 and foundation models enter the lab https://biobriefs.com/boosting-cas9-nuclear-entry-internal BioBriefs en 2025-11-02T04:31:54Z Boosting Cas9 nuclear entry: internal NLS insertions raise editing efficiency https://biobriefs.com/4dmt-sells-apac-rights-to BioBriefs en 2025-11-02T04:31:54Z 4DMT sells APAC rights to fund phase 3—Otsuka deal backs retinal gene therapy https://biobriefs.com/patent-cliff-looms-230b-of BioBriefs en 2025-11-02T04:31:54Z Patent cliff looms: $230B of blockbusters face 2026–2029 expiries https://biobriefs.com/pfizer-sues-to-enforce-metsera BioBriefs en 2025-11-01T21:31:49Z Pfizer sues to enforce Metsera deal — Novo Nordisk counters with higher bid https://biobriefs.com/fda-places-intellias-crispr-candidate BioBriefs en 2025-11-01T21:31:49Z FDA places Intellia’s CRISPR candidate on hold after liver events https://biobriefs.com/ucl-ucla-gene-therapy-posts BioBriefs en 2025-11-01T21:31:49Z UCL–UCLA gene therapy posts near‑complete success in ADA‑SCID follow‑up https://biobriefs.com/baby-kj-case-spurs-pathway BioBriefs en 2025-11-01T21:31:49Z Baby KJ case spurs pathway playbook for bespoke CRISPR therapies https://biobriefs.com/scalable-human-kidney-organoids-integrated BioBriefs en 2025-11-01T21:31:49Z Scalable human kidney organoids integrated into porcine kidneys ex vivo https://biobriefs.com/cloud-connected-tubeless-pump-and BioBriefs en 2025-11-01T21:31:49Z Cloud‑connected tubeless pump and CGM turbulence reshape diabetes device landscape https://biobriefs.com/mrnas-promise-tested-modernas-struggles BioBriefs en 2025-11-01T21:31:49Z mRNA’s promise tested: Moderna’s struggles and a surprise oncology signal https://biobriefs.com/thermo-fisher-upgrades-mass-spec BioBriefs en 2025-11-01T21:31:49Z Thermo Fisher upgrades mass‑spec and acquires Clario in data‑driven push https://biobriefs.com/ai-accelerates-drug-discovery-open BioBriefs en 2025-11-01T21:31:49Z AI accelerates drug discovery — open models and big‑tech breakthroughs https://biobriefs.com/nanoparticle-il-12-strategies-revive BioBriefs en 2025-11-01T21:31:49Z Nanoparticle IL‑12 strategies revive ovarian cancer immunotherapy in preclinical models https://biobriefs.com/metsera-takeover-battle-pfizer-sues BioBriefs en 2025-11-01T16:32:12Z Metsera takeover battle: Pfizer sues, Novo counters with bigger bid https://biobriefs.com/fda-halts-intellias-crispr-trials BioBriefs en 2025-11-01T16:32:12Z FDA halts Intellia’s CRISPR trials after liver safety signals https://biobriefs.com/synthetic-biology-scales-industry-adopts BioBriefs en 2025-11-01T16:32:12Z Synthetic biology scales: industry adopts engineering and AI tools https://biobriefs.com/from-bench-to-one-off BioBriefs en 2025-11-01T16:32:12Z From bench to one‑off cures: Baby KJ pushes FDA pathway for bespoke gene therapy https://biobriefs.com/organoids-meet-xenotransplantation-scalable-human BioBriefs en 2025-11-01T16:32:12Z Organoids meet xenotransplantation: scalable human kidney organoids grafted in pigs https://biobriefs.com/ai-proposes-drugs-google-model BioBriefs en 2025-11-01T16:32:12Z AI proposes drugs: Google model and open tools speed discovery https://biobriefs.com/commercial-push-for-heritable-genome BioBriefs en 2025-11-01T16:32:12Z Commercial push for heritable genome editing draws scrutiny https://biobriefs.com/car-t-clinical-gains-clash BioBriefs en 2025-11-01T16:32:12Z CAR‑T: clinical gains clash with commercial headwinds https://biobriefs.com/mass-spec-scales-multiomics-instruments BioBriefs en 2025-11-01T16:32:12Z Mass‑spec scales multiomics: instruments boost throughput and depth https://biobriefs.com/regulatory-pivot-fda-signals-deregulatory BioBriefs en 2025-11-01T16:32:12Z Regulatory pivot: FDA signals deregulatory moves as key PDUFAs loom https://biobriefs.com/metsera-m-a-fight-erupts BioBriefs en 2025-11-01T14:31:52Z Metsera M&A fight erupts: Pfizer sues as Novo tops bid https://biobriefs.com/fda-halts-intellias-crispr-trials BioBriefs en 2025-11-01T14:31:52Z FDA halts Intellia’s CRISPR trials – liver safety alarm https://biobriefs.com/ucl-ucla-gene-therapy-posts BioBriefs en 2025-11-01T14:31:52Z UCL–UCLA gene therapy posts milestone: durable ADA‑SCID cures reported https://biobriefs.com/human-kidney-organoids-scaled-and BioBriefs en 2025-11-01T14:31:52Z Human kidney organoids scaled and grafted into porcine kidneys https://biobriefs.com/ai-accelerates-discovery-models-and BioBriefs en 2025-11-01T14:31:52Z AI accelerates discovery…models and infrastructure scale up https://biobriefs.com/car-t-market-jitters-sales BioBriefs en 2025-11-01T14:31:52Z CAR‑T market jitters: sales slip even as axi‑cel shows clinical promise https://biobriefs.com/thermo-fisher-to-buy-clario BioBriefs en 2025-11-01T14:31:52Z Thermo Fisher to buy Clario for $8.88B – clinical data play https://biobriefs.com/fda-signals-deregulatory-push-biomarkers BioBriefs en 2025-11-01T14:31:52Z FDA signals deregulatory push; biomarkers rise in agency agenda https://biobriefs.com/hhs-greenlights-340b-rebate-pilots BioBriefs en 2025-11-01T14:31:52Z HHS greenlights 340B rebate pilots — hospitals push back https://biobriefs.com/nanoparticles-deliver-il-12-to BioBriefs en 2025-11-01T14:31:52Z Nanoparticles deliver IL‑12 to tumors — MIT shows striking preclinical efficacy https://biobriefs.com/pfizer-sues-novo-nordisk-court BioBriefs en 2025-11-01T10:32:30Z Pfizer sues Novo Nordisk: Court fight erupts over Metsera takeover https://biobriefs.com/fda-halts-intellias-crispr-trials BioBriefs en 2025-11-01T10:32:30Z FDA halts Intellia’s CRISPR trials: Regulator opens formal review after liver toxicity https://biobriefs.com/scalable-kidney-organoids-porcine-platform BioBriefs en 2025-11-01T10:32:30Z Scalable kidney organoids...porcine platform bridges supply and transplantation testing https://biobriefs.com/nanoparticles-deliver-il-12-local BioBriefs en 2025-11-01T10:32:30Z Nanoparticles deliver IL‑12: Local cytokine therapy clears metastatic ovarian tumors in mice https://biobriefs.com/myeloid-ifng-signaling-tied-to BioBriefs en 2025-11-01T10:32:30Z Myeloid IFNγ signaling tied to ICI resistance in renal cancer https://biobriefs.com/gene-therapy-restores-immune-function BioBriefs en 2025-11-01T10:32:30Z Gene therapy restores immune function in ADA‑SCID: Multi‑year follow‑up shows high cure rate https://biobriefs.com/googles-ai-proposes-validated-cancer BioBriefs en 2025-11-01T10:32:30Z Google’s AI proposes validated cancer combo: Foundation model finds therapeutic leads https://biobriefs.com/from-one-off-to-pathway BioBriefs en 2025-11-01T10:32:30Z From one‑off to pathway: Baby KJ team publishes FDA interactions to scale bespoke gene editing https://biobriefs.com/multi-cancer-screening-gains-traction BioBriefs en 2025-11-01T10:32:30Z Multi‑cancer screening gains traction: Real‑world data and commercial launches collide https://biobriefs.com/covid-mrna-vaccines-tumor-response BioBriefs en 2025-11-01T10:32:30Z COVID mRNA vaccines...tumor response link: Retrospective data suggest improved immunotherapy outcomes https://biobriefs.com/bidding-war-erupts-for-metsera BioBriefs en 2025-11-01T09:32:06Z Bidding war erupts for Metsera: Pfizer sues as Novo tops offer https://biobriefs.com/fda-places-formal-hold-on BioBriefs en 2025-11-01T09:32:06Z FDA places formal hold on Intellia’s CRISPR trials: liver events prompt pause https://biobriefs.com/ai-accelerates-drug-discovery-google BioBriefs en 2025-11-01T09:32:06Z AI accelerates drug discovery... Google and Foundation roll out new tools https://biobriefs.com/4dmt-sells-retina-gene-therapy BioBriefs en 2025-11-01T09:32:06Z 4DMT sells retina gene therapy to Otsuka – upfront cash to fund phase 3 https://biobriefs.com/evommune-files-ipo-150m-target BioBriefs en 2025-11-01T09:32:06Z Evommune files IPO: $150M target to advance two mid‑stage programs https://biobriefs.com/nanobiotix-gets-royalty-loan-tubulis BioBriefs en 2025-11-01T09:32:06Z Nanobiotix gets royalty loan; Tubulis upsizes Series C to $401M https://biobriefs.com/lillys-tirzepatide-soars-novos-new BioBriefs en 2025-11-01T09:32:06Z Lilly’s tirzepatide soars — Novo’s new CEO doubles down on M&A https://biobriefs.com/human-kidney-organoids-integrated-with BioBriefs en 2025-11-01T09:32:06Z Human kidney organoids integrated with pig kidneys... scalable transplant step https://biobriefs.com/nanoparticle-il-12-therapy-revives BioBriefs en 2025-11-01T09:32:06Z Nanoparticle IL‑12 therapy revives ovarian immunotherapy responses https://biobriefs.com/gene-therapy-milestone-for-ada BioBriefs en 2025-11-01T09:32:06Z Gene therapy milestone for ADA‑SCID... Baby KJ roadmap published https://biobriefs.com/metsera-takeover-fight-novo-tops BioBriefs en 2025-11-01T04:32:33Z Metsera takeover fight: Novo tops Pfizer with higher bid, legal clash ensues https://biobriefs.com/intellia-crispr-trials-halted-fda BioBriefs en 2025-11-01T04:32:33Z Intellia CRISPR trials halted: FDA places formal hold after liver toxicity case https://biobriefs.com/human-kidney-organoids-scaled-and BioBriefs en 2025-11-01T04:32:33Z Human kidney organoids scaled and integrated into pig kidneys...first in‑vivo transplant milestone https://biobriefs.com/ai-accelerates-drug-discovery-and BioBriefs en 2025-11-01T04:32:33Z AI accelerates drug discovery and cell modeling: Google proposes a cancer drug; CZI and NVIDIA scale virtual cells https://biobriefs.com/heritable-genome-editing-and-bespoke BioBriefs en 2025-11-01T04:32:33Z Heritable genome editing and bespoke CRISPR: startups form and clinicians publish FDA playbook https://biobriefs.com/tumor-resistance-mechanisms-myeloid-ifng BioBriefs en 2025-11-01T04:32:33Z Tumor resistance mechanisms: Myeloid IFNγ signaling and copy-number changes undermine immunotherapy https://biobriefs.com/localized-cytokine-delivery-il-12 BioBriefs en 2025-11-01T04:32:33Z Localized cytokine delivery: IL‑12 nanoparticles revive ovarian tumor immunity in preclinical models https://biobriefs.com/lilly-commercial-moves-and-tirzepatide BioBriefs en 2025-11-01T04:32:33Z Lilly commercial moves and tirzepatide momentum: retail pickup and blockbuster sales https://biobriefs.com/diagnostics-market-expands-guardant-scales BioBriefs en 2025-11-01T04:32:33Z Diagnostics market expands: Guardant scales multi‑cancer blood screening as FDA clearances proliferate https://biobriefs.com/funding-and-pe-activity-tubulis BioBriefs en 2025-11-01T04:32:33Z Funding and PE activity: Tubulis upsizes Series C; GHO Capital closes largest European healthcare PE fund https://biobriefs.com/metsera-m-a-war-novo BioBriefs en 2025-10-31T21:32:11Z Metsera M&A War: Novo Nordisk Counters Pfizer With $9B Bid https://biobriefs.com/fda-halts-intellia-phase-3 BioBriefs en 2025-10-31T21:32:11Z FDA Halts Intellia Phase‑3 CRISPR Trials: Liver Safety Signal https://biobriefs.com/human-kidney-organoids-scaled-transplanted BioBriefs en 2025-10-31T21:32:11Z Human kidney organoids scaled: Transplanted into perfused pig kidneys https://biobriefs.com/targeted-immunotherapy-advances-il-12 BioBriefs en 2025-10-31T21:32:11Z Targeted immunotherapy advances: IL‑12 nanoparticles and myeloid resistance mechanisms https://biobriefs.com/ai-accelerates-discovery-google-finds BioBriefs en 2025-10-31T21:32:11Z AI accelerates discovery: Google finds drug lead; CZI and NVIDIA scale virtual cell models https://biobriefs.com/fda-deregulation-push-commissioner-signals BioBriefs en 2025-10-31T21:32:11Z FDA deregulation push: Commissioner signals loosening; biosimilar trial rule proposed https://biobriefs.com/illumina-navigates-china-headwinds-flat BioBriefs en 2025-10-31T21:32:11Z Illumina navigates China headwinds: flat Q3 but guidance nudged higher https://biobriefs.com/lillys-tirzepatide-era-10b-quarter BioBriefs en 2025-10-31T21:32:11Z Lilly’s tirzepatide era: $10B quarter powers upgraded outlook https://biobriefs.com/340b-rebate-pilot-approved-hrsa BioBriefs en 2025-10-31T21:32:11Z 340B rebate pilot approved: HRSA greenlights drugmaker models, hospitals push back https://biobriefs.com/bespoke-gene-editing-pathway-baby BioBriefs en 2025-10-31T21:32:11Z Bespoke gene‑editing pathway: Baby KJ team publishes FDA interactions https://biobriefs.com/novo-nordisks-9b-counteroffer-for BioBriefs en 2025-10-31T16:32:34Z Novo Nordisk’s $9B counteroffer for Metsera — Pfizer threatens legal action https://biobriefs.com/fda-proposes-slashing-biosimilar-trial BioBriefs en 2025-10-31T16:32:34Z FDA proposes slashing biosimilar trial burden — Phase 3 studies may be optional https://biobriefs.com/fda-halts-intellias-phase-3 BioBriefs en 2025-10-31T16:32:34Z FDA halts Intellia’s phase 3 CRISPR trials — liver safety signal stalls program https://biobriefs.com/illumina-posts-flat-q3-as BioBriefs en 2025-10-31T16:32:34Z Illumina posts flat Q3 as China export restrictions continue to bite https://biobriefs.com/4d-molecular-inks-apac-deal BioBriefs en 2025-10-31T16:32:34Z 4D Molecular inks APAC deal with Otsuka — $85M upfront to fuel retinal phase 3 https://biobriefs.com/thermo-fisher-to-buy-clario BioBriefs en 2025-10-31T16:32:34Z Thermo Fisher to buy Clario for roughly $8.9B — data consolidation for trials https://biobriefs.com/nanobiotix-secures-71m-royalty-backed BioBriefs en 2025-10-31T16:32:34Z Nanobiotix secures $71M royalty‑backed loan to fund late‑stage program https://biobriefs.com/tubulis-ups-series-c-to BioBriefs en 2025-10-31T16:32:34Z Tubulis ups Series C to $401M — doubling down on ADC platform https://biobriefs.com/evommune-prices-ipo-to-fund BioBriefs en 2025-10-31T16:32:34Z Evommune prices IPO to fund two phase‑2 inflammation programs https://biobriefs.com/google-ai-proposes-validated-cancer BioBriefs en 2025-10-31T16:32:34Z Google AI proposes validated cancer drug combo — AI reaches discovery milestone https://biobriefs.com/novo-nordisks-9b-bid-topples BioBriefs en 2025-10-31T14:32:34Z Novo Nordisk’s $9B bid topples Pfizer – Metsera board flags superior offer https://biobriefs.com/fda-puts-intellias-phase-3 BioBriefs en 2025-10-31T14:32:34Z FDA puts Intellia’s phase 3 CRISPR trials on hold – liver safety probe https://biobriefs.com/fda-plan-cut-efficacy-trials BioBriefs en 2025-10-31T14:32:34Z FDA plan: cut efficacy trials to speed biosimilars https://biobriefs.com/lillys-tirzepatide-drives-17-6b BioBriefs en 2025-10-31T14:32:34Z Lilly’s tirzepatide drives $17.6B quarter – sales surge 54% https://biobriefs.com/illumina-posts-flat-q3-nudges BioBriefs en 2025-10-31T14:32:34Z Illumina posts flat Q3: nudges up full‑year guidance https://biobriefs.com/4dmt-sells-apac-rights-to BioBriefs en 2025-10-31T14:32:34Z 4DMT sells APAC rights to Otsuka: $85M upfront, $420M upside https://biobriefs.com/nanobiotix-gets-71m-lifeline-royalty BioBriefs en 2025-10-31T14:32:34Z Nanobiotix gets $71M lifeline: royalty‑backed loan fuels phase 3 https://biobriefs.com/google-ai-proposes-new-cancer BioBriefs en 2025-10-31T14:32:34Z Google AI proposes new cancer drug combo: lab validation reported https://biobriefs.com/guardant-pushes-shield-mcd-into BioBriefs en 2025-10-31T14:32:34Z Guardant pushes Shield MCD into multi‑cancer market – stock jumps https://biobriefs.com/thermo-fisher-agrees-8-9b BioBriefs en 2025-10-31T14:32:34Z Thermo Fisher agrees $8.9B buyout of Clario – clinical data bet https://biobriefs.com/novo-nordisk-counters-9-billion BioBriefs en 2025-10-31T10:32:14Z Novo Nordisk counters: $9 billion bid for Metsera https://biobriefs.com/fda-eases-biosimilar-bar-draft BioBriefs en 2025-10-31T10:32:14Z FDA eases biosimilar bar: draft guidance to speed copycat biologics https://biobriefs.com/fda-halts-intellia-phase-3 BioBriefs en 2025-10-31T10:32:14Z FDA halts Intellia phase 3 CRISPR trials: liver safety under review https://biobriefs.com/4dmt-taps-otsuka-for-apac BioBriefs en 2025-10-31T10:32:14Z 4DMT taps Otsuka for APAC: $85M upfront to fast‑track retinal phase 3 https://biobriefs.com/nanobiotix-borrows-against-nbtxr3-royalties BioBriefs en 2025-10-31T10:32:14Z Nanobiotix borrows against NBTXR3 royalties to extend runway https://biobriefs.com/bridgebio-posts-back-to-back BioBriefs en 2025-10-31T10:32:14Z BridgeBio posts back‑to‑back rare‑disease hits: encaleret succeeds in Phase III https://biobriefs.com/illumina-posts-flat-q3-but BioBriefs en 2025-10-31T10:32:14Z Illumina posts flat Q3 but nudges up 2025 guidance https://biobriefs.com/lillys-tirzepatide-era-10-1b BioBriefs en 2025-10-31T10:32:14Z Lilly’s tirzepatide era: $10.1B quarter and a $1.2B plant bet https://biobriefs.com/10x-genomics-scales-single-cell BioBriefs en 2025-10-31T10:32:14Z 10x Genomics scales single‑cell: next‑gen Flex brings plate multiplexing https://biobriefs.com/thermo-fisher-moves-to-acquire BioBriefs en 2025-10-31T10:32:14Z Thermo Fisher moves to acquire Clario: $8.9B cash deal https://biobriefs.com/novos-9b-shock-metsera-deal BioBriefs en 2025-10-31T09:32:24Z Novo’s $9B Shock: Metsera Deal Sparks Antitrust Clash https://biobriefs.com/fda-signals-faster-biosimilar-path BioBriefs en 2025-10-31T09:32:24Z FDA Signals Faster Biosimilar Path: Trials Could Be Cut https://biobriefs.com/fda-halts-intellia-crispr-phase BioBriefs en 2025-10-31T09:32:24Z FDA Halts Intellia CRISPR Phase 3 Trials After Liver Signal https://biobriefs.com/lillys-glp-1-machine-revenue BioBriefs en 2025-10-31T09:32:24Z Lilly’s GLP-1 Machine: Revenue Surge and New Pill Factory https://biobriefs.com/thermo-fisher-to-buy-clario BioBriefs en 2025-10-31T09:32:24Z Thermo Fisher to Buy Clario: $8.9B Data Play https://biobriefs.com/10x-genomics-scales-single-cell BioBriefs en 2025-10-31T09:32:24Z 10x Genomics Scales Single‑Cell: Flex 384‑Plate Pushes Throughput https://biobriefs.com/bridgebios-late-stage-wins-encaleret BioBriefs en 2025-10-31T09:32:24Z BridgeBio’s Late‑Stage Wins: Encaleret Clears Phase III Threshold https://biobriefs.com/recursion-maps-microglia-roche-pays BioBriefs en 2025-10-31T09:32:24Z Recursion Maps Microglia — Roche Pays $30M Milestone https://biobriefs.com/gileads-cell-therapy-pullback-and BioBriefs en 2025-10-31T09:32:24Z Gilead’s Cell Therapy Pullback and Lenacapavir Partner Move https://biobriefs.com/price-versus-access-glp-1 BioBriefs en 2025-10-31T09:32:24Z Price Versus Access: GLP‑1 Economics and Retail Partnerships https://biobriefs.com/fda-places-formal-hold-on BioBriefs en 2025-10-31T04:32:24Z FDA places formal hold on Intellia’s Phase 3 CRISPR trials: liver‑safety signal https://biobriefs.com/novo-nordisk-ups-the-ante BioBriefs en 2025-10-31T04:32:24Z Novo Nordisk ups the ante: $9B bid challenges Pfizer for Metsera https://biobriefs.com/lilly-leans-in-tirzepatide-drives BioBriefs en 2025-10-31T04:32:24Z Lilly leans in: tirzepatide drives revenue and a $1.2B factory push https://biobriefs.com/fda-proposes-lighter-path-for BioBriefs en 2025-10-31T04:32:24Z FDA proposes lighter path for biosimilars: trials may no longer be required https://biobriefs.com/thermo-fisher-to-buy-clario BioBriefs en 2025-10-31T04:32:24Z Thermo Fisher to buy Clario for up to $9.4B: data play expands clinical services https://biobriefs.com/hhs-approves-340b-rebate-pilot BioBriefs en 2025-10-31T04:32:24Z HHS approves 340B rebate pilot participants: Merck, BMS and others join https://biobriefs.com/usda-clears-first-large-scale BioBriefs en 2025-10-31T04:32:24Z USDA clears first large‑scale cultivated meat facility: Believer Meats wins label and export access https://biobriefs.com/illumina-posts-flat-q3-revenue BioBriefs en 2025-10-31T04:32:24Z Illumina posts flat Q3 revenue, raises 2025 guidance: clinical segment supports recovery https://biobriefs.com/evommune-prices-ipo-as-inflammation BioBriefs en 2025-10-31T04:32:24Z Evommune prices IPO as inflammation biotech eyes Phase 2 progress https://biobriefs.com/bridgebio-scores-another-rare-disease BioBriefs en 2025-10-31T04:32:24Z BridgeBio scores another rare‑disease win: encaleret meets Phase 3 endpoints in ADH1 https://biobriefs.com/fda-halts-intellia-phase-3 BioBriefs en 2025-10-30T21:33:34Z FDA halts Intellia phase‑3 CRISPR trials — safety letters expected https://biobriefs.com/novo-bids-9b-for-metsera BioBriefs en 2025-10-30T21:33:34Z Novo bids $9B for Metsera — Pfizer cries foul https://biobriefs.com/illumina-posts-flat-q3-nudges BioBriefs en 2025-10-30T21:33:34Z Illumina posts flat Q3 — nudges 2025 guidance up https://biobriefs.com/lillys-tirzepatide-smashes-records-company BioBriefs en 2025-10-30T21:33:34Z Lilly’s tirzepatide smashes records — company doubles down on capacity https://biobriefs.com/fda-signals-easier-path-for BioBriefs en 2025-10-30T21:33:34Z FDA signals easier path for biosimilars — industry to get faster routes https://biobriefs.com/thermo-fisher-to-buy-clario BioBriefs en 2025-10-30T21:33:34Z Thermo Fisher to buy Clario for clinical‑trial data muscle — deal tops $9B https://biobriefs.com/bridgebios-encaleret-clears-phase-3 BioBriefs en 2025-10-30T21:33:34Z BridgeBio’s encaleret clears Phase 3 — rare disease readout succeeds https://biobriefs.com/tubulis-upsizes-series-c-to BioBriefs en 2025-10-30T21:33:34Z Tubulis upsizes Series C to $401M — ADC platform gets heavy backing https://biobriefs.com/10x-genomics-launches-next-gen BioBriefs en 2025-10-30T21:33:34Z 10x Genomics launches next‑gen Flex — single‑cycle, high‑throughput single‑cell push https://biobriefs.com/recursion-delivers-microglia-phenomap-roche BioBriefs en 2025-10-30T21:33:34Z Recursion delivers microglia phenomap — Roche pays $30M milestone https://biobriefs.com/fda-places-intellia-phase-3 BioBriefs en 2025-10-30T16:32:20Z FDA places Intellia phase‑3 CRISPR trials on hold: regulator steps in after liver injury https://biobriefs.com/novo-jumps-into-metsera-bidding BioBriefs en 2025-10-30T16:32:20Z Novo jumps into Metsera bidding war – Pfizer threatens legal fight https://biobriefs.com/lillys-tirzepatide-era-sales-surge BioBriefs en 2025-10-30T16:32:20Z Lilly’s tirzepatide era: sales surge and factory push to secure supply https://biobriefs.com/fda-moves-to-speed-biosimilars BioBriefs en 2025-10-30T16:32:20Z FDA moves to speed biosimilars: clinical trial bar lowered – policy shift ahead https://biobriefs.com/thermo-fisher-to-buy-clario BioBriefs en 2025-10-30T16:32:20Z Thermo Fisher to buy Clario in major market play: $8.9B cash deal https://biobriefs.com/lilly-buys-adverum-to-fast BioBriefs en 2025-10-30T16:32:20Z Lilly buys Adverum to fast‑track one‑time gene therapy for wet AMD https://biobriefs.com/bridgebio-racks-up-rare-disease BioBriefs en 2025-10-30T16:32:20Z BridgeBio racks up rare‑disease wins: encaleret Phase 3 success and FDA path eyed https://biobriefs.com/ai-drug-discovery-deals-accelerate BioBriefs en 2025-10-30T16:32:20Z AI drug discovery deals accelerate: phenomaps and multispecific antibody partnerships https://biobriefs.com/10x-genomics-launches-next-gen BioBriefs en 2025-10-30T16:32:20Z 10x Genomics launches next‑gen Flex: massive single‑cell scale meets cost cuts https://biobriefs.com/gsk-buys-adc-rights-adc BioBriefs en 2025-10-30T16:32:20Z GSK buys ADC rights, ADC developers present data: pharma doubles down on targeted payloads https://biobriefs.com/fda-halts-intellias-crispr-phase BioBriefs en 2025-10-30T14:33:30Z FDA halts Intellia’s CRISPR phase-3 trials — liver safety probe https://biobriefs.com/novo-storms-metsera-auction-pfizer BioBriefs en 2025-10-30T14:33:30Z Novo storms Metsera auction — Pfizer fights back https://biobriefs.com/gsk-takes-syndivia-adc-program BioBriefs en 2025-10-30T14:33:30Z GSK takes Syndivia ADC program — $357m upfront for prostate target https://biobriefs.com/bridgebio-posts-late-stage-wins BioBriefs en 2025-10-30T14:33:30Z BridgeBio posts late‑stage wins — rare disease filings next https://biobriefs.com/lilly-posts-blowout-quarter-builds BioBriefs en 2025-10-30T14:33:30Z Lilly posts blowout quarter — builds $1.2B plant for oral GLP‑1 https://biobriefs.com/thermo-fisher-to-buy-clario BioBriefs en 2025-10-30T14:33:30Z Thermo Fisher to buy Clario — $8.9B cash deal for trial data software https://biobriefs.com/fda-proposes-cutting-clinical-trial BioBriefs en 2025-10-30T14:33:30Z FDA proposes cutting clinical‑trial bar for biosimilars — faster copycats https://biobriefs.com/recursion-delivers-microglia-phenomap-to BioBriefs en 2025-10-30T14:33:30Z Recursion delivers microglia phenomap to Roche — $30m milestone hit https://biobriefs.com/sensei-winds-down-lead-program BioBriefs en 2025-10-30T14:33:30Z Sensei winds down lead program — halts trial, readies layoffs https://biobriefs.com/takeda-abandons-alpha-synuclein-program BioBriefs en 2025-10-30T14:33:30Z Takeda abandons alpha‑synuclein program after phase‑2 miss https://biobriefs.com/fda-halts-intellia-gene-editing BioBriefs en 2025-10-30T10:32:12Z FDA halts Intellia gene-editing trials: clinical hold after liver injury https://biobriefs.com/thermo-fisher-to-buy-clario BioBriefs en 2025-10-30T10:32:12Z Thermo Fisher to buy Clario — $8.9–$9.4B takeover targets trial data stack https://biobriefs.com/roche-pays-into-china-bispecific BioBriefs en 2025-10-30T10:32:12Z Roche pays into China bispecific — $1B+ pact for respiratory candidate https://biobriefs.com/fda-pivots-on-biosimilars-draft BioBriefs en 2025-10-30T10:32:12Z FDA pivots on biosimilars: draft guidance to cut clinical requirements https://biobriefs.com/bridgebio-posts-phase-iii-win BioBriefs en 2025-10-30T10:32:12Z BridgeBio posts Phase III win — encaleret meets endpoints in genetic hypoparathyroidism https://biobriefs.com/recursion-hands-roche-a-microglia BioBriefs en 2025-10-30T10:32:12Z Recursion hands Roche a microglia map — $30M milestone for AI phenomics https://biobriefs.com/tubulis-upsizes-series-c-to BioBriefs en 2025-10-30T10:32:12Z Tubulis upsizes Series C to $401M — doubling down on ADC platforms https://biobriefs.com/lilly-doubles-down-buys-adverum BioBriefs en 2025-10-30T10:32:12Z Lilly doubles down: buys Adverum for ocular gene therapy and builds AI supercomputer with Nvidia https://biobriefs.com/glp-1-commercialization-shift-lilly BioBriefs en 2025-10-30T10:32:12Z GLP‑1 commercialization shift: Lilly builds oral factory while DTC drives Zepbound scripts https://biobriefs.com/10x-genomics-launches-next-gen BioBriefs en 2025-10-30T10:32:12Z 10x Genomics launches next‑gen Chromium Flex — 384‑plex single‑cell at scale https://biobriefs.com/fda-moves-to-fast-track BioBriefs en 2025-10-30T09:32:40Z FDA moves to fast‑track biosimilars — clinical bar lowered https://biobriefs.com/fda-places-clinical-hold-on BioBriefs en 2025-10-30T09:32:40Z FDA places clinical hold on Intellia trials — gene‑editing safety alarms https://biobriefs.com/thermo-fisher-to-buy-clario BioBriefs en 2025-10-30T09:32:40Z Thermo Fisher to buy Clario — $8.9B cash for trial data muscle https://biobriefs.com/roche-licenses-qyuns-bispecific-1 BioBriefs en 2025-10-30T09:32:40Z Roche licenses Qyuns bispecific — $1.07B respiratory bet https://biobriefs.com/bridgebio-posts-phase-iii-wins BioBriefs en 2025-10-30T09:32:40Z BridgeBio posts Phase III wins — rare disease filings ahead https://biobriefs.com/lilly-doubles-down-on-scale BioBriefs en 2025-10-30T09:32:40Z Lilly doubles down on scale and AI — $1.2B plant and supercomputer https://biobriefs.com/lilly-buys-adverum-single-dose BioBriefs en 2025-10-30T09:32:40Z Lilly buys Adverum — single‑dose ocular gene therapy in hand https://biobriefs.com/kyverna-car-t-posts-robust BioBriefs en 2025-10-30T09:32:40Z Kyverna CAR‑T posts robust gMG signals — phase III next https://biobriefs.com/10x-genomics-launches-next-gen BioBriefs en 2025-10-30T09:32:40Z 10x Genomics launches next‑gen Flex — single‑cell at scale https://biobriefs.com/stat-profile-moderna-unravels-cash BioBriefs en 2025-10-30T09:32:40Z Stat profile: Moderna unravels — cash, contracts and strategy under pressure https://biobriefs.com/fda-moves-to-speed-biosimilars BioBriefs en 2025-10-30T04:31:42Z FDA moves to speed biosimilars: draft would drop clinical comparators https://biobriefs.com/thermo-fisher-to-buy-clario BioBriefs en 2025-10-30T04:31:42Z Thermo Fisher to buy Clario — up to $9.4 billion for trial data assets https://biobriefs.com/roche-inks-china-deal-for BioBriefs en 2025-10-30T04:31:42Z Roche inks China deal for bispecific respiratory antibody — $75M up front https://biobriefs.com/fda-halts-intellia-gene-editing BioBriefs en 2025-10-30T04:31:42Z FDA halts Intellia gene-editing trials after patient liver injury https://biobriefs.com/bridgebio-posts-two-phase-iii BioBriefs en 2025-10-30T04:31:42Z BridgeBio posts two Phase III wins — rare disease results move toward filings https://biobriefs.com/lilly-and-nvidia-to-build BioBriefs en 2025-10-30T04:31:42Z Lilly and Nvidia to build pharma supercomputer — AI drug discovery gets scale https://biobriefs.com/lilly-buys-adverum-to-advance BioBriefs en 2025-10-30T04:31:42Z Lilly buys Adverum to advance one‑time gene therapy for wet AMD https://biobriefs.com/gsk-licenses-empirico-sirna-for BioBriefs en 2025-10-30T04:31:42Z GSK licenses Empirico siRNA for COPD: $85M up front, multimillion milestones possible https://biobriefs.com/recursion-hands-roche-a-whole BioBriefs en 2025-10-30T04:31:42Z Recursion hands Roche a whole‑genome microglia map — $30M milestone triggered https://biobriefs.com/10x-genomics-launches-next-gen BioBriefs en 2025-10-30T04:31:42Z 10x Genomics launches next‑gen Flex: 384‑plex single‑cell at automation scale https://biobriefs.com/thermo-fisher-to-buy-clario BioBriefs en 2025-10-29T21:32:06Z Thermo Fisher to buy Clario – $9.4B bid for trial-data platform https://biobriefs.com/fda-moves-to-cut-red BioBriefs en 2025-10-29T21:32:06Z FDA moves to cut red tape for biosimilars: fewer comparative trials required https://biobriefs.com/novartis-buys-avidity-for-12b BioBriefs en 2025-10-29T21:32:06Z Novartis buys Avidity for $12B – bet on RNA delivery beyond the liver https://biobriefs.com/eli-lilly-nvidia-build-pharmas BioBriefs en 2025-10-29T21:32:06Z Eli Lilly, Nvidia build pharma’s most powerful AI supercomputer: drug discovery focus https://biobriefs.com/bridgebio-posts-phase-iii-win BioBriefs en 2025-10-29T21:32:06Z BridgeBio posts Phase III win – encaleret normalizes calcium in rare hypoparathyroidism https://biobriefs.com/recursion-delivers-microglia-phenomap-to BioBriefs en 2025-10-29T21:32:06Z Recursion delivers microglia phenomap to Roche – $30M milestone triggers https://biobriefs.com/10x-genomics-launches-next-gen BioBriefs en 2025-10-29T21:32:06Z 10x Genomics launches next‑gen Flex – scalable plate‑based single‑cell at 384‑plex https://biobriefs.com/iorganbio-launches-cellforge-with-2m BioBriefs en 2025-10-29T21:32:06Z iOrganBio launches CellForge with $2M seed – AI to scale cell manufacturing https://biobriefs.com/kyverna-car-t-shows-deep BioBriefs en 2025-10-29T21:32:06Z Kyverna CAR‑T shows deep, durable responses in small gMG cohort – moves toward phase III https://biobriefs.com/gsk-pays-85m-upfront-for BioBriefs en 2025-10-29T21:32:06Z GSK pays $85M upfront for Empirico siRNA – a new oligonucleotide play in COPD https://biobriefs.com/intellia-pauses-crispr-trials-on BioBriefs en 2025-10-29T16:32:40Z Intellia pauses CRISPR trials — on‑target liver toxicity flagged https://biobriefs.com/novartis-buys-avidity-for-12b BioBriefs en 2025-10-29T16:32:40Z Novartis buys Avidity for $12B — doubles down on RNA and neuroscience https://biobriefs.com/lilly-buys-adverum-one-and BioBriefs en 2025-10-29T16:32:40Z Lilly buys Adverum — one‑and‑done gene therapy enters big pharma orbit https://biobriefs.com/mercks-welireg-clears-two-big BioBriefs en 2025-10-29T16:32:40Z Merck’s Welireg clears two big trials — possible label expansion in kidney cancer https://biobriefs.com/bridgebio-scores-back-to-back BioBriefs en 2025-10-29T16:32:40Z BridgeBio scores back‑to‑back Phase 3 wins — rare disease pipeline heats up https://biobriefs.com/kyvernas-car-t-shows-promise BioBriefs en 2025-10-29T16:32:40Z Kyverna’s CAR‑T shows promise in myasthenia gravis — small cohort, deep responses https://biobriefs.com/recursion-delivers-microglia-phenomap-roche BioBriefs en 2025-10-29T16:32:40Z Recursion delivers microglia phenomap — Roche pays milestone and options programs https://biobriefs.com/regeneron-doubles-down-on-multispecifics BioBriefs en 2025-10-29T16:32:40Z Regeneron doubles down on multispecifics — ModeX partnership tops $1B potential https://biobriefs.com/gsk-pays-up-for-sirna BioBriefs en 2025-10-29T16:32:40Z GSK pays up for siRNA COPD candidate — Empirico deal underscores oligo push https://biobriefs.com/zag-bio-emerges-with-80m BioBriefs en 2025-10-29T16:32:40Z Zag Bio emerges with $80M to rewire thymus tolerance — big‑name backers onboard https://biobriefs.com/novartis-pays-12b-for-avidity BioBriefs en 2025-10-29T14:33:36Z Novartis pays $12B for Avidity — muscle-targeted RNA push https://biobriefs.com/intellia-pauses-crispr-phase-iii BioBriefs en 2025-10-29T14:33:36Z Intellia pauses CRISPR Phase III... liver toxicity forces safety review https://biobriefs.com/bridgebio-scores-back-to-back BioBriefs en 2025-10-29T14:33:36Z BridgeBio scores back‑to‑back Phase 3 wins — rare disease filings planned https://biobriefs.com/eli-lilly-nvidia-build-pharmas BioBriefs en 2025-10-29T14:33:36Z Eli Lilly, Nvidia... build pharma’s most powerful AI supercomputer https://biobriefs.com/lilly-acquires-adverum-bets-on BioBriefs en 2025-10-29T14:33:36Z Lilly acquires Adverum — bets on one‑time gene therapy for wAMD https://biobriefs.com/recursion-delivers-microglia-phenomap-to BioBriefs en 2025-10-29T14:33:36Z Recursion delivers microglia phenomap to Roche — $30M milestone paid https://biobriefs.com/10x-genomics-unveils-next-gen BioBriefs en 2025-10-29T14:33:36Z 10x Genomics unveils next‑gen Chromium Flex — 384‑plex, automation‑ready https://biobriefs.com/gsk-buys-empirico-sirna-for BioBriefs en 2025-10-29T14:33:36Z GSK buys Empirico siRNA for COPD — $85M upfront, broad rights https://biobriefs.com/zag-bio-launches-with-80m BioBriefs en 2025-10-29T14:33:36Z Zag Bio launches with $80M — thymus‑targeted tolerance platform https://biobriefs.com/electra-raises-183m-series-c BioBriefs en 2025-10-29T14:33:36Z Electra raises $183M Series C — pushes ELA026 pivotal sHLH trial https://biobriefs.com/novartis-to-buy-avidity-12b BioBriefs en 2025-10-29T10:31:53Z Novartis to buy Avidity: $12B bet on RNA neuromuscular drugs https://biobriefs.com/intellia-pauses-crispr-trials-liver BioBriefs en 2025-10-29T10:31:53Z Intellia pauses CRISPR trials: liver toxicity triggers safety review https://biobriefs.com/lilly-and-nvidia-partner-building BioBriefs en 2025-10-29T10:31:53Z Lilly and Nvidia partner: building pharma’s most powerful AI supercomputer https://biobriefs.com/lilly-buys-adverum-one-time BioBriefs en 2025-10-29T10:31:53Z Lilly buys Adverum – one-time gene therapy for wet AMD https://biobriefs.com/gsk-licenses-empirico-sirna-85m BioBriefs en 2025-10-29T10:31:53Z GSK licenses Empirico siRNA: $85M upfront for COPD candidate https://biobriefs.com/electra-raises-183m-funds-pivotal BioBriefs en 2025-10-29T10:31:53Z Electra raises $183M — funds pivotal sHLH trial and pipeline expansion https://biobriefs.com/fda-permits-at-home-dosing BioBriefs en 2025-10-29T10:31:53Z FDA permits at‑home dosing for Delix: trial tests non‑hallucinogenic neuroplastogen https://biobriefs.com/health-canada-clears-lecanemab-conditional BioBriefs en 2025-10-29T10:31:53Z Health Canada clears lecanemab: conditional approval for early Alzheimer’s https://biobriefs.com/guardant-inks-zephyr-ai-pact BioBriefs en 2025-10-29T10:31:53Z Guardant inks Zephyr AI pact: multimodal genomics meets machine learning https://biobriefs.com/zag-bio-emerges-with-80m BioBriefs en 2025-10-29T10:31:53Z Zag Bio emerges with $80M: thymus-targeted Treg approach for autoimmunity https://biobriefs.com/intellia-pauses-crispr-trials-liver BioBriefs en 2025-10-29T09:31:36Z Intellia pauses CRISPR trials—liver toxicity hospitalizes patient https://biobriefs.com/novartis-buys-avidity-12-billion BioBriefs en 2025-10-29T09:31:36Z Novartis buys Avidity: $12 billion deal expands RNA neuromuscular push https://biobriefs.com/lilly-nvidia-to-build-pharma BioBriefs en 2025-10-29T09:31:36Z Lilly, Nvidia to build pharma supercomputer—AI-driven drug design scale-up https://biobriefs.com/gsk-licenses-empirico-sirna-85m BioBriefs en 2025-10-29T09:31:36Z GSK licenses Empirico siRNA—$85M upfront to broaden COPD pipeline https://biobriefs.com/electra-raises-183m-pivotal-trial BioBriefs en 2025-10-29T09:31:36Z Electra raises $183M—pivotal trial starts for rare hyperinflammation drug https://biobriefs.com/zag-bio-launches-80m-to BioBriefs en 2025-10-29T09:31:36Z Zag Bio launches: $80M to develop thymus‑targeted tolerizing therapies https://biobriefs.com/fda-allows-at-home-dosing BioBriefs en 2025-10-29T09:31:36Z FDA allows at‑home dosing: Delix to test non‑hallucinogenic neuroplastogen https://biobriefs.com/haystack-mrd-debuts-ultrasensitive-ctdna BioBriefs en 2025-10-29T09:31:36Z Haystack MRD debuts: ultrasensitive ctDNA test for post‑surgical surveillance https://biobriefs.com/guardant-zephyr-ai-partner-multimodal BioBriefs en 2025-10-29T09:31:36Z Guardant, Zephyr AI partner—multimodal data to accelerate biomarker discovery https://biobriefs.com/hybrid-grnas-improve-adenine-base BioBriefs en 2025-10-29T09:31:36Z Hybrid gRNAs improve adenine base editing—better on‑target edits, lower off‑targets https://biobriefs.com/novartis-buys-avidity-for-12b BioBriefs en 2025-10-29T04:33:01Z Novartis buys Avidity for $12B – RNA delivery play expands neuroscience portfolio https://biobriefs.com/intellia-halts-two-crispr-trials BioBriefs en 2025-10-29T04:33:01Z Intellia halts two CRISPR trials after severe liver event: enrollment paused https://biobriefs.com/gsk-acquires-empirico-sirna-for BioBriefs en 2025-10-29T04:33:01Z GSK acquires Empirico siRNA for COPD – $85M upfront, broad respiratory ambitions https://biobriefs.com/lilly-and-nvidia-to-build BioBriefs en 2025-10-29T04:33:01Z Lilly and Nvidia to build pharma’s most powerful supercomputer – AI for drug discovery https://biobriefs.com/fda-allows-delix-at-home BioBriefs en 2025-10-29T04:33:01Z FDA allows Delix at‑home dosing in next study – non‑hallucinogenic neuroplastogen advances https://biobriefs.com/zag-bio-launches-with-80m BioBriefs en 2025-10-29T04:33:01Z Zag Bio launches with $80M to engineer thymus‑targeted tolerance medicines https://biobriefs.com/hemab-raises-157m-to-pursue BioBriefs en 2025-10-29T04:33:01Z Hemab raises $157M to pursue coagulation disorder pipeline – sutacimig pivotal next https://biobriefs.com/bridgebio-to-push-for-approval BioBriefs en 2025-10-29T04:33:01Z BridgeBio to push for approval after positive limb‑girdle Phase 3 readout https://biobriefs.com/zenas-obexelimab-drives-95-cut BioBriefs en 2025-10-29T04:33:01Z Zenas’ obexelimab drives 95% cut in new MS lesions in mid‑stage trial https://biobriefs.com/genedx-expands-into-general-pediatrics BioBriefs en 2025-10-29T04:33:01Z GeneDx expands into general pediatrics as exome/genome testing surges https://biobriefs.com/novartis-snaps-up-avidity-for BioBriefs en 2025-10-28T21:33:36Z Novartis snaps up Avidity for RNA push: $12B deal bolsters neuromuscular pipeline https://biobriefs.com/intellia-halts-crispr-trials-after BioBriefs en 2025-10-28T21:33:36Z Intellia halts CRISPR trials after liver toxicity — Phase III enrollment paused https://biobriefs.com/gsk-pays-up-for-empirico BioBriefs en 2025-10-28T21:33:36Z GSK pays up for Empirico siRNA: $85M upfront to target COPD inflammation https://biobriefs.com/lilly-and-nvidia-to-build BioBriefs en 2025-10-28T21:33:36Z Lilly and Nvidia to build pharma supercomputer — AI‑first drug discovery drive https://biobriefs.com/zenas-antibody-cuts-ms-lesions BioBriefs en 2025-10-28T21:33:36Z Zenas antibody cuts MS lesions by 95% in phase 2 MRI readout https://biobriefs.com/electra-closes-183m-to-fund BioBriefs en 2025-10-28T21:33:36Z Electra closes $183M to fund pivotal sHLH trial and expand I&I pipeline https://biobriefs.com/hemab-raises-157m-to-scale BioBriefs en 2025-10-28T21:33:36Z Hemab raises $157M to scale coagulation disorder pipeline https://biobriefs.com/genedx-doubles-down-on-pediatrics BioBriefs en 2025-10-28T21:33:36Z GeneDx doubles down on pediatrics: revenue surge and market expansion plan https://biobriefs.com/verily-embeds-nvidia-gpus-into BioBriefs en 2025-10-28T21:33:36Z Verily embeds Nvidia GPUs into Pre platform — omics and AI workflows accelerated https://biobriefs.com/co-diagnostics-sells-7m-offering BioBriefs en 2025-10-28T21:33:36Z Co‑Diagnostics sells $7M offering, forms MENA JV to commercialize diagnostics https://biobriefs.com/novartis-deal-12b-buy-of BioBriefs en 2025-10-28T16:33:08Z Novartis deal: $12B buy of Avidity expands RNA neuromuscular push https://biobriefs.com/intellia-halts-phase-3-crispr BioBriefs en 2025-10-28T16:33:08Z Intellia halts phase 3 CRISPR dosing — liver safety probe https://biobriefs.com/takeda-innovent-ink-11-4b BioBriefs en 2025-10-28T16:33:08Z Takeda, Innovent ink $11.4B I‑O/ADC pact — $1.2B up front https://biobriefs.com/bridgebio-posts-phase-3-win BioBriefs en 2025-10-28T16:33:08Z BridgeBio posts phase‑3 win — prepares FDA meeting on LGMD drug https://biobriefs.com/zenas-antibody-slashes-ms-lesions BioBriefs en 2025-10-28T16:33:08Z Zenas antibody slashes MS lesions — midstage readout impresses investors https://biobriefs.com/gsk-licenses-empirico-sirna-for BioBriefs en 2025-10-28T16:33:08Z GSK licenses Empirico siRNA for COPD — $85M upfront https://biobriefs.com/health-canada-clears-eisais-lecanemab BioBriefs en 2025-10-28T16:33:08Z Health Canada clears Eisai’s lecanemab for early Alzheimer’s https://biobriefs.com/guardant-and-zephyr-ai-partner BioBriefs en 2025-10-28T16:33:08Z Guardant and Zephyr AI partner to accelerate genomic biomarker discovery https://biobriefs.com/hemab-raises-157m-to-advance BioBriefs en 2025-10-28T16:33:08Z Hemab raises $157M to advance coagulation disorder pipeline https://biobriefs.com/ena-respiratory-nets-au-34m BioBriefs en 2025-10-28T16:33:08Z Ena Respiratory nets AU$34M to advance nasal antiviral INNA‑051 https://biobriefs.com/novartis-doubles-down-on-rna BioBriefs en 2025-10-28T14:33:59Z Novartis doubles down on RNA: $12B buyout brings late-stage muscle drugs https://biobriefs.com/intellia-halts-crispr-phase-3 BioBriefs en 2025-10-28T14:33:59Z Intellia halts CRISPR phase 3 dosing after severe liver event https://biobriefs.com/gsk-bets-on-inhaled-sirna BioBriefs en 2025-10-28T14:33:59Z GSK bets on inhaled siRNA: $85M upfront, broad COPD strategy https://biobriefs.com/zenas-posts-strong-ms-readout BioBriefs en 2025-10-28T14:33:58Z Zenas posts strong MS readout – near‑complete lesion suppression in midstage https://biobriefs.com/bridgebios-phase-3-surge-interim BioBriefs en 2025-10-28T14:33:58Z BridgeBio’s Phase 3 surge – interim data push FDA filing plans https://biobriefs.com/zag-bio-emerges-with-80m BioBriefs en 2025-10-28T14:33:58Z Zag Bio emerges with $80M: thymus‑targeted Treg engineering draws big pharma cash https://biobriefs.com/cepheid-tb-resistance-assay-wins BioBriefs en 2025-10-28T14:33:58Z Cepheid TB resistance assay wins WHO prequalification – enables global procurement https://biobriefs.com/revvitys-diagnostics-lift-newborn-screening BioBriefs en 2025-10-28T14:33:58Z Revvity’s diagnostics lift: newborn screening drives Q3 growth https://biobriefs.com/usp-issues-glp-1-quality BioBriefs en 2025-10-28T14:33:58Z USP issues GLP‑1 quality resources as counterfeit risk and demand surge https://biobriefs.com/hemab-raises-157m-to-tackle BioBriefs en 2025-10-28T14:33:58Z Hemab raises $157M to tackle underserved coagulation disorders https://biobriefs.com/novartis-doubles-down-on-rna BioBriefs en 2025-10-28T10:33:22Z Novartis doubles down on RNA: $12B Avidity buy https://biobriefs.com/intellia-halts-nex-z-trials BioBriefs en 2025-10-28T10:33:22Z Intellia halts nex‑z trials after liver toxicity https://biobriefs.com/bridgebios-phase-3-win-fda BioBriefs en 2025-10-28T10:33:22Z BridgeBio’s phase 3 win: FDA meeting looms https://biobriefs.com/zenas-posts-near-complete-lesion BioBriefs en 2025-10-28T10:33:22Z Zenas posts near‑complete lesion suppression in MS phase 2 https://biobriefs.com/hemab-secures-157m-to-target BioBriefs en 2025-10-28T10:33:22Z Hemab secures $157M to target underserved coagulation disorders https://biobriefs.com/marti-brings-real-time-metagenomics BioBriefs en 2025-10-28T10:33:22Z MARTi brings real‑time metagenomics to nanopore sequencing https://biobriefs.com/boltzgen-expands-ai-drug-design BioBriefs en 2025-10-28T10:33:22Z BoltzGen expands AI drug design: From structure to therapeutics https://biobriefs.com/guardant-and-zephyr-tie-up BioBriefs en 2025-10-28T10:33:22Z Guardant and Zephyr tie up: AI meets circulating tumor genomics https://biobriefs.com/usp-releases-glp-1-standards BioBriefs en 2025-10-28T10:33:22Z USP releases GLP‑1 standards: Quality push amid fraud and shortages https://biobriefs.com/nhs-vets-15-minute-blood BioBriefs en 2025-10-28T10:33:22Z NHS vets 15‑minute blood test for sepsis screening in children https://biobriefs.com/novartis-buys-avidity-for-12b BioBriefs en 2025-10-28T09:34:23Z Novartis buys Avidity for $12B — secures three late‑stage RNA neuromuscular drugs https://biobriefs.com/intellia-halts-phase-3-crispr BioBriefs en 2025-10-28T09:34:23Z Intellia halts Phase 3 CRISPR dosing — liver safety probe underway https://biobriefs.com/zenas-obexelimab-nearly-eradicates-new BioBriefs en 2025-10-28T09:34:23Z Zenas’ obexelimab nearly eradicates new MS lesions — mid‑stage readout https://biobriefs.com/bridgebio-posts-positive-phase-3 BioBriefs en 2025-10-28T09:34:23Z BridgeBio posts positive Phase 3—prepares FDA meeting for rare muscular dystrophy filing https://biobriefs.com/hemab-raises-157m-to-build BioBriefs en 2025-10-28T09:34:23Z Hemab raises $157M to build 'ultimate coagulation disorders' company https://biobriefs.com/real-time-nanopore-metagenomics-marti BioBriefs en 2025-10-28T09:34:23Z Real‑time nanopore metagenomics: MARTi enables in‑field pathogen surveillance https://biobriefs.com/usp-issues-glp-1-quality BioBriefs en 2025-10-28T09:34:23Z USP issues GLP‑1 quality standards as nonresponse and counterfeits spotlight market risks https://biobriefs.com/new-streptomyces-intermediate-yields-potent BioBriefs en 2025-10-28T09:34:23Z New Streptomyces intermediate yields potent antibiotic lead against MRSA and VRE https://biobriefs.com/proteomics-international-posts-sevenfold-q3 BioBriefs en 2025-10-28T09:34:23Z Proteomics International posts sevenfold Q3 revenue after UWA collaboration https://biobriefs.com/ai-meets-multimodal-biomolecules-and BioBriefs en 2025-10-28T09:34:23Z AI meets multimodal biomolecules and biomarkers — BoltzGen and Guardant‑Zephyr tie ups https://biobriefs.com/novartis-shells-out-12b-for BioBriefs en 2025-10-28T04:34:24Z Novartis shells out $12B for Avidity—gains three late‑stage RNA drugs https://biobriefs.com/intellia-halts-nex-z-phase BioBriefs en 2025-10-28T04:34:24Z Intellia halts nex‑z Phase III dosing after serious liver event https://biobriefs.com/bridgebio-posts-pivotal-win-pivots BioBriefs en 2025-10-28T04:34:24Z BridgeBio posts pivotal win — pivots filing plans for rare muscular dystrophy https://biobriefs.com/zenas-obexelimab-wipes-out-mri BioBriefs en 2025-10-28T04:34:24Z Zenas’ obexelimab wipes out MRI lesions — midstage multiple sclerosis win https://biobriefs.com/hemab-raises-157m-to-tackle BioBriefs en 2025-10-28T04:34:24Z Hemab raises $157M to tackle underserved coagulation disorders https://biobriefs.com/usp-issues-glp-1-standards BioBriefs en 2025-10-28T04:34:24Z USP issues GLP‑1 standards as patient response and counterfeit risks rise https://biobriefs.com/health-canada-clears-lecanemab-for BioBriefs en 2025-10-28T04:34:24Z Health Canada clears lecanemab for early Alzheimer’s — conditional authorization https://biobriefs.com/neumora-advances-nlrp3-obesity-program BioBriefs en 2025-10-28T04:34:24Z Neumora advances NLRP3 obesity program after competitor setbacks https://biobriefs.com/implantable-cmos-imager-records-single BioBriefs en 2025-10-28T04:34:24Z Implantable CMOS imager records single‑neuron activity deep in brain https://biobriefs.com/marti-brings-real-time-nanopore BioBriefs en 2025-10-28T04:34:24Z MARTi brings real‑time nanopore metagenomics to field surveillance https://biobriefs.com/novartis-bets-12b-on-rna BioBriefs en 2025-10-27T21:33:41Z Novartis bets $12B on RNA delivery: Avidity deal expands neuromuscular pipeline https://biobriefs.com/crispr-safety-alarm-intellia-halts BioBriefs en 2025-10-27T21:33:41Z CRISPR safety alarm: Intellia halts two late‑stage trials after liver toxicity https://biobriefs.com/zenas-posts-striking-mid-stage BioBriefs en 2025-10-27T21:33:41Z Zenas posts striking mid‑stage MS signal: Obexelimab slashes new lesions https://biobriefs.com/bridgebio-advances-toward-approval-after BioBriefs en 2025-10-27T21:33:41Z BridgeBio advances toward approval after Phase III win — FDA meeting planned https://biobriefs.com/leqembi-cleared-in-canada-eisai BioBriefs en 2025-10-27T21:33:41Z Leqembi cleared in Canada: Eisai and Biogen land conditional approval https://biobriefs.com/bayer-wins-fda-ok-for BioBriefs en 2025-10-27T21:33:41Z Bayer wins FDA OK for non‑hormonal menopause pill — Market competition heats up https://biobriefs.com/hemab-raises-157m-to-tackle BioBriefs en 2025-10-27T21:33:41Z Hemab raises $157M to tackle rare coagulation disorders — Late‑stage trials ahead https://biobriefs.com/guardant-joins-zephyr-ai-to BioBriefs en 2025-10-27T21:33:41Z Guardant joins Zephyr AI to speed genomic biomarker discovery https://biobriefs.com/glp-1-supply-and-science BioBriefs en 2025-10-27T21:33:41Z GLP‑1 supply and science: USP standards released as real‑world nonresponse questions rise https://biobriefs.com/revvity-leans-on-newborn-screening BioBriefs en 2025-10-27T21:33:41Z Revvity leans on newborn screening to drive diagnostics growth https://biobriefs.com/novartis-to-buy-avidity-for BioBriefs en 2025-10-27T16:33:47Z Novartis to buy Avidity for $12B — bet on RNA neuromuscular drugs https://biobriefs.com/intellia-pauses-crispr-trials-after BioBriefs en 2025-10-27T16:33:47Z Intellia pauses CRISPR trials after liver toxicity hospitalisation https://biobriefs.com/zenas-obexelimab-slashes-new-ms BioBriefs en 2025-10-27T16:33:47Z Zenas’ obexelimab slashes new MS lesions — a convincing mid‑stage readout https://biobriefs.com/health-canada-clears-lecanemab-for BioBriefs en 2025-10-27T16:33:47Z Health Canada clears lecanemab for early Alzheimer’s — conditional authorization https://biobriefs.com/fda-approves-bayers-non-hormonal BioBriefs en 2025-10-27T16:33:47Z FDA approves Bayer’s non‑hormonal menopause pill Lynkuet — new competition https://biobriefs.com/hemab-raises-157m-to-push BioBriefs en 2025-10-27T16:33:47Z Hemab raises $157M to push coagulation disorder pipeline forward https://biobriefs.com/bridgebio-pivots-filing-plans-after BioBriefs en 2025-10-27T16:33:47Z BridgeBio pivots filing plans after Phase 3 rare‑disease success https://biobriefs.com/guardant-health-and-zephyr-ai BioBriefs en 2025-10-27T16:33:47Z Guardant Health and Zephyr AI team up to accelerate genomic biomarker discovery https://biobriefs.com/mits-boltzgen-expands-ai-drug BioBriefs en 2025-10-27T16:33:47Z MIT’s BoltzGen expands AI drug design — open‑source model for therapeutic creation https://biobriefs.com/maplight-launches-with-250m-ipo BioBriefs en 2025-10-27T16:33:47Z MapLight launches with $250M IPO to bankroll schizophrenia drug challenger https://biobriefs.com/intellia-pauses-phase-3-trials BioBriefs en 2025-10-27T14:33:16Z Intellia pauses phase 3 trials: liver safety signal halts dosing https://biobriefs.com/novartis-buys-avidity-for-12b BioBriefs en 2025-10-27T14:33:16Z Novartis buys Avidity for $12B — three late‑stage RNA programs added https://biobriefs.com/bridgebio-eyes-fda-after-phase BioBriefs en 2025-10-27T14:33:16Z BridgeBio eyes FDA after Phase 3 win — filing plans shift https://biobriefs.com/zenas-antibody-slashes-ms-lesions BioBriefs en 2025-10-27T14:33:16Z Zenas antibody slashes MS lesions: 95% reduction reported https://biobriefs.com/hemab-pulls-in-157m-to BioBriefs en 2025-10-27T14:33:16Z Hemab pulls in $157M to target rare coagulation disorders https://biobriefs.com/guardant-health-zephyr-ai-partner BioBriefs en 2025-10-27T14:33:16Z Guardant Health, Zephyr AI partner: multimodal biomarkers in focus https://biobriefs.com/mits-boltzgen-opens-ai-drug BioBriefs en 2025-10-27T14:33:16Z MIT’s BoltzGen opens AI drug design: expands the druggable universe https://biobriefs.com/maplight-prices-250m-ipo-funding BioBriefs en 2025-10-27T14:33:16Z MapLight prices $250M IPO — funding Cobenfy challenger https://biobriefs.com/revvity-posts-modest-growth-as BioBriefs en 2025-10-27T14:33:16Z Revvity posts modest growth as newborn screening and immunodiagnostics lead https://biobriefs.com/expedition-medicines-launches-ai-startup BioBriefs en 2025-10-27T14:33:16Z Expedition Medicines launches: AI startup targets ‘undruggable’ proteins https://biobriefs.com/novartis-buys-avidity-for-12b BioBriefs en 2025-10-27T10:32:47Z Novartis buys Avidity for $12B — expands RNA neuromuscular push https://biobriefs.com/hemab-raises-157m-builds-ultimate BioBriefs en 2025-10-27T10:32:47Z Hemab raises $157M — builds 'ultimate' coagulation disorders company https://biobriefs.com/novo-re-engages-and-closes BioBriefs en 2025-10-27T10:32:47Z Novo re-engages and closes $4.7B MASH deal — deal talks resumed https://biobriefs.com/flagship-launches-expedition-medicines-ai BioBriefs en 2025-10-27T10:32:47Z Flagship launches Expedition Medicines — AI to target 'undruggable' proteins https://biobriefs.com/gsk-signs-357m-pact-with BioBriefs en 2025-10-27T10:32:47Z GSK signs $357M pact with French biotech — prostate ADC preclinical deal https://biobriefs.com/town-hall-raises-440m-vc BioBriefs en 2025-10-27T10:32:47Z Town Hall raises $440M — VC backs AI to improve healthcare access https://biobriefs.com/wastewater-and-metagenomics-sharpen-infectious BioBriefs en 2025-10-27T10:32:47Z Wastewater and metagenomics sharpen infectious-disease surveillance https://biobriefs.com/ai-and-single-cell-tools BioBriefs en 2025-10-27T10:32:47Z AI and single-cell tools refine molecular classification and discovery https://biobriefs.com/new-targets-revive-platinum-sensitivity BioBriefs en 2025-10-27T10:32:47Z New targets revive platinum sensitivity — paths to overcome resistance https://biobriefs.com/preclinical-platforms-reveal-therapy-leads BioBriefs en 2025-10-27T10:32:47Z Preclinical platforms reveal therapy leads in brain and breast cancer https://biobriefs.com/novartis-goes-big-for-neuromusculars BioBriefs en 2025-10-27T09:33:39Z Novartis goes big for neuromusculars: $12B Avidity buy https://biobriefs.com/gsk-bets-on-adcs-357m BioBriefs en 2025-10-27T09:33:39Z GSK bets on ADCs: $357M deal for prostate program https://biobriefs.com/novos-boardroom-drama-ends-with BioBriefs en 2025-10-27T09:33:39Z Novo’s boardroom drama ends with MASH buy: $4.7B Akero move https://biobriefs.com/flagship-launches-expedition-medicines-ai BioBriefs en 2025-10-27T09:33:39Z Flagship launches Expedition Medicines: AI for undruggable proteins https://biobriefs.com/town-hall-raises-440m-ai BioBriefs en 2025-10-27T09:33:39Z Town Hall raises $440M — AI startups targeted at care gaps https://biobriefs.com/biotech-etfs-rally-xbi-ibb BioBriefs en 2025-10-27T09:33:39Z Biotech ETFs rally: XBI, IBB, ARKG reassert momentum https://biobriefs.com/walgreens-frames-pharmacies-as-strategic BioBriefs en 2025-10-27T09:33:39Z Walgreens frames pharmacies as strategic partners for specialty care https://biobriefs.com/dnbseq-exome-showdown-four-capture BioBriefs en 2025-10-27T09:33:39Z DNBSEQ exome showdown: four capture platforms benchmarked https://biobriefs.com/agile-site-networks-sponsors-told BioBriefs en 2025-10-27T09:33:39Z Agile site networks: sponsors told to vet to speed oncology trials https://biobriefs.com/3d-printed-tumor-scaffolds-new BioBriefs en 2025-10-27T09:33:39Z 3D-printed tumor scaffolds: new platform for glioblastoma drug screens https://biobriefs.com/novartis-bets-12-billion-on BioBriefs en 2025-10-27T04:32:45Z Novartis bets $12 billion on RNA drugs — Avidity takeover https://biobriefs.com/flagship-launches-expedition-medicines-ai BioBriefs en 2025-10-27T04:32:45Z Flagship launches Expedition Medicines: AI hunts elusive targets https://biobriefs.com/town-hall-raises-440m-fund BioBriefs en 2025-10-27T04:32:45Z Town Hall raises $440M fund: AI for underserved healthcare https://biobriefs.com/long-acting-injectable-buprenorphine-lowers BioBriefs en 2025-10-27T04:32:45Z Long‑acting injectable buprenorphine... lowers inpatient burden https://biobriefs.com/wastewater-rotavirus-rna-mirrors-us BioBriefs en 2025-10-27T04:32:45Z Wastewater rotavirus RNA mirrors US infection and vaccine uptake https://biobriefs.com/metagenomics-reveals-strain-level-pneumonia BioBriefs en 2025-10-27T04:32:45Z Metagenomics reveals strain‑level pneumonia pathogens https://biobriefs.com/ai-algorithms-validated-for-urothelial BioBriefs en 2025-10-27T04:32:45Z AI algorithms validated for urothelial tumor classification https://biobriefs.com/car-t-and-car-nk BioBriefs en 2025-10-27T04:32:45Z CAR‑T and CAR‑NK therapies reshape AML research https://biobriefs.com/3d-printed-scaffolds-boost-glioblastoma BioBriefs en 2025-10-27T04:32:45Z 3D‑printed scaffolds boost glioblastoma drug screening https://biobriefs.com/targeting-fbxl5-reverses-oxaliplatin-resistance BioBriefs en 2025-10-27T04:32:45Z Targeting FBXL5 reverses oxaliplatin resistance in colorectal cancer https://biobriefs.com/novartis-to-buy-avidity-for BioBriefs en 2025-10-26T21:32:55Z Novartis to buy Avidity for $12B – Scores RNA neuromuscular pipeline https://biobriefs.com/nanopore-cfdna-test-spots-tissue BioBriefs en 2025-10-26T21:32:55Z Nanopore cfDNA test spots tissue origin and pathogens in ICU patients https://biobriefs.com/metagenomic-sequencing-unmasks-pneumonia-pathogens BioBriefs en 2025-10-26T21:32:55Z Metagenomic sequencing unmasks pneumonia pathogens at strain level https://biobriefs.com/car-based-cell-therapy-expands BioBriefs en 2025-10-26T21:32:55Z CAR‑based cell therapy expands into AML — CAR‑T and CAR‑NK advances https://biobriefs.com/nanotherapeutics-program-reprograms-macrophages-to BioBriefs en 2025-10-26T21:32:55Z Nanotherapeutics program reprograms macrophages to tackle atherosclerosis https://biobriefs.com/long-acting-injectable-buprenorphine-reduces BioBriefs en 2025-10-26T21:32:55Z Long‑acting injectable buprenorphine reduces inpatient service use https://biobriefs.com/3d-printed-glioblastoma-scaffolds-and BioBriefs en 2025-10-26T21:32:55Z 3D‑printed glioblastoma scaffolds and COX‑2 target reshape therapy testing https://biobriefs.com/mapping-metabolic-liver-disease-in BioBriefs en 2025-10-26T21:32:55Z Mapping metabolic liver disease in India — new population signals https://biobriefs.com/glycation-accelerates-alpha-synuclein-aggregation BioBriefs en 2025-10-26T21:32:55Z Glycation accelerates alpha‑synuclein aggregation and neuroinflammation in Parkinson’s https://biobriefs.com/wastewater-rotavirus-rna-reflects-us BioBriefs en 2025-10-26T21:32:55Z Wastewater rotavirus RNA reflects US infection and vaccination patterns https://biobriefs.com/biogen-buys-vanqua-c5ar1-program BioBriefs en 2025-10-26T16:32:34Z Biogen buys Vanqua C5aR1 program: $70M up front, $990M in milestones https://biobriefs.com/two-nonhormonal-menopause-drugs-win BioBriefs en 2025-10-26T16:32:34Z Two nonhormonal menopause drugs win FDA nod — Bayer’s Lynkuet, elinzanetant https://biobriefs.com/gepotidacin-approved-for-utis-gonorrhea BioBriefs en 2025-10-26T16:32:34Z Gepotidacin... approved for UTIs; gonorrhea filing remains active https://biobriefs.com/halda-posts-first-riptac-clinical BioBriefs en 2025-10-26T16:32:34Z Halda posts first RIPTAC clinical data: prostate responses emerge https://biobriefs.com/tetraneuron-advances-aav-gene-therapy BioBriefs en 2025-10-26T16:32:34Z Tetraneuron advances AAV gene therapy: targets E2F4 to restore memory https://biobriefs.com/nanopore-pinpoints-tissue-of-origin BioBriefs en 2025-10-26T16:32:34Z Nanopore pinpoints tissue‑of‑origin and pathogens in plasma cfDNA https://biobriefs.com/fda-flags-unauthorized-indian-api BioBriefs en 2025-10-26T16:32:34Z FDA flags unauthorized Indian API warehouse — lizards, cats found https://biobriefs.com/metagenomic-hunt-uncovers-retron-editors BioBriefs en 2025-10-26T16:32:34Z Metagenomic hunt uncovers retron editors — new gene‑editing candidates https://biobriefs.com/ucsd-engineers-yeast-cross-organelle BioBriefs en 2025-10-26T16:32:34Z UCSD engineers yeast: cross‑organelle tweaks boost plant‑compound yields https://biobriefs.com/vcs-spin-teijin-program-into BioBriefs en 2025-10-26T16:32:34Z VCs spin Teijin program into Elevara — finance report https://biobriefs.com/biogen-licenses-vanqua-c5ar1-program BioBriefs en 2025-10-26T14:33:13Z Biogen licenses Vanqua C5aR1 program: $70M upfront, nearly $1B in milestones https://biobriefs.com/lilly-to-acquire-adverum-upfront BioBriefs en 2025-10-26T14:33:13Z Lilly to acquire Adverum: upfront below last close, gene‑therapy assets included https://biobriefs.com/fda-greenlights-new-menopause-options BioBriefs en 2025-10-26T14:33:13Z FDA greenlights new menopause options: nonhormonal therapies expand clinical choices https://biobriefs.com/inhibrx-posts-registrational-win-ozekibart BioBriefs en 2025-10-26T14:33:13Z Inhibrx posts registrational win: ozekibart PFS gains spark BLA plans https://biobriefs.com/halda-unveils-first-riptac-clinical BioBriefs en 2025-10-26T14:33:13Z Halda unveils first RIPTAC clinical data: prostate study shows early activity https://biobriefs.com/gepotidacin-advances-as-oral-uti BioBriefs en 2025-10-26T14:33:13Z Gepotidacin advances as oral UTI drug; gonorrhea review ongoing https://biobriefs.com/nanopore-cfdna-pinpoints-tissue-origin BioBriefs en 2025-10-26T14:33:13Z Nanopore cfDNA pinpoints tissue origin and pathogens in critical‑care plasma https://biobriefs.com/c2s-scale-llm-repurposes-language BioBriefs en 2025-10-26T14:33:13Z C2S‑Scale LLM repurposes language models for single‑cell biology: pretrained on 50M profiles https://biobriefs.com/tetraneuron-advances-upstream-gene-therapy BioBriefs en 2025-10-26T14:33:13Z Tetraneuron advances upstream gene‑therapy approach for Alzheimer’s: E2F4 AAV program https://biobriefs.com/car-t-and-car-nk BioBriefs en 2025-10-26T14:33:13Z CAR‑T and CAR‑NK revive AML hopes: reviews highlight progress and challenges https://biobriefs.com/biogen-pays-70m-for-vanqua BioBriefs en 2025-10-26T10:33:28Z Biogen pays $70M for Vanqua drug – Secures C5aR1 rights https://biobriefs.com/lilly-widens-gene-therapy-bet BioBriefs en 2025-10-26T10:33:28Z Lilly widens gene-therapy bet – Acquires Adverum https://biobriefs.com/fda-clears-gsks-blenrep-third BioBriefs en 2025-10-26T10:33:28Z FDA clears GSK’s Blenrep: Third-line multiple myeloma use https://biobriefs.com/inhibrx-posts-phase-ii-win BioBriefs en 2025-10-26T10:33:28Z Inhibrx posts phase II win: Ozekibart extends PFS in chondrosarcoma https://biobriefs.com/nanopore-sequencing-detects-pathogens-and BioBriefs en 2025-10-26T10:33:28Z Nanopore sequencing detects pathogens and tissue signals in plasma cfDNA https://biobriefs.com/fda-greenlights-elinzanetant-nonhormonal-hot BioBriefs en 2025-10-26T10:33:28Z FDA greenlights elinzanetant: Nonhormonal hot‑flash therapy approved https://biobriefs.com/sting-il6-stat3-blockade-stops BioBriefs en 2025-10-26T10:33:28Z STING–IL6/STAT3 blockade stops breast cancer bone metastasis https://biobriefs.com/ucsd-tweaks-p450s-yeast-become BioBriefs en 2025-10-26T10:33:28Z UCSD tweaks P450s: Yeast become more efficient biofactories for plant compounds https://biobriefs.com/chugai-buys-kidney-biotech-icer BioBriefs en 2025-10-26T10:33:28Z Chugai buys kidney biotech – ICER flags rising launch prices https://biobriefs.com/fda-finds-unauthorized-api-warehouse BioBriefs en 2025-10-26T10:33:28Z FDA finds unauthorized API warehouse in India: Animal infestations cited https://biobriefs.com/biogen-bankrolls-vanqua-drug-70m BioBriefs en 2025-10-26T09:32:47Z Biogen bankrolls Vanqua drug: $70M upfront for C5aR1 program https://biobriefs.com/lilly-buys-adverum-gene-therapy BioBriefs en 2025-10-26T09:32:47Z Lilly buys Adverum gene‑therapy assets – strategic push into AAV space https://biobriefs.com/fda-greenlights-elinzanetant-nonhormonal-option BioBriefs en 2025-10-26T09:32:47Z FDA greenlights elinzanetant: nonhormonal option for menopausal hot flashes https://biobriefs.com/inhibrx-posts-win-in-rare BioBriefs en 2025-10-26T09:32:47Z Inhibrx posts win in rare bone cancer – phase II meets endpoint https://biobriefs.com/tango-prmt5-data-satisfy-paves BioBriefs en 2025-10-26T09:32:47Z Tango PRMT5 data satisfy — paves way to pivotal pancreatic trial https://biobriefs.com/regeneron-shelves-2seventy-acquired-car BioBriefs en 2025-10-26T09:32:47Z Regeneron shelves 2seventy‑acquired CAR‑T – strategic pipeline pruning https://biobriefs.com/lnp-shapes-mapped-structural-study BioBriefs en 2025-10-26T09:32:47Z LNP shapes mapped: structural study ties form to delivery efficiency https://biobriefs.com/teamwork-raced-to-make-baby BioBriefs en 2025-10-26T09:32:47Z Teamwork raced to make Baby KJ’s CRISPR therapy: months‑long feat https://biobriefs.com/nanopore-cfdna-assay-detects-tissue BioBriefs en 2025-10-26T09:32:47Z Nanopore cfDNA assay detects tissue‑of‑origin and pathogens in critical‑care plasma https://biobriefs.com/deep-learning-speeds-antibiotic-discovery BioBriefs en 2025-10-26T09:32:47Z Deep learning speeds antibiotic discovery — new computational scaffolds emerge https://biobriefs.com/biogen-bets-on-c5ar1-70m BioBriefs en 2025-10-26T04:32:56Z Biogen bets on C5aR1: $70M upfront for Vanqua’s preclinical immunology asset https://biobriefs.com/lilly-rescues-adverum-buys-cash BioBriefs en 2025-10-26T04:32:56Z Lilly rescues Adverum: buys cash‑strapped gene‑therapy developer for its phase‑3 asset https://biobriefs.com/inhibrx-posts-registrational-win-ozekibart BioBriefs en 2025-10-26T04:32:56Z Inhibrx posts registrational win: ozekibart hits primary endpoint in chondrosarcoma https://biobriefs.com/tangos-prmt5-data-clear-way BioBriefs en 2025-10-26T04:32:56Z Tango’s PRMT5 data clear way to pivotal pancreatic study — company to advance vopimetostat https://biobriefs.com/gepotidacins-approval-for-utis-fluoroquinolone BioBriefs en 2025-10-26T04:32:56Z Gepotidacin’s approval for UTIs: fluoroquinolone‑alternative gets greenlight, gonorrhea review continues https://biobriefs.com/lnp-structure-and-rapid-crispr BioBriefs en 2025-10-26T04:32:56Z LNP structure and rapid CRISPR manufacturing: delivery tech meets bespoke gene cures https://biobriefs.com/remix-shows-first-tumor-shrinkage BioBriefs en 2025-10-26T04:32:56Z Remix shows first tumor shrinkage with small‑molecule mRNA degrader in rare cancer https://biobriefs.com/merus-widens-oncology-reach-petosemtamab BioBriefs en 2025-10-26T04:32:56Z Merus widens oncology reach: petosemtamab shows activity in colorectal cancer https://biobriefs.com/tetraneuron-pursues-upstream-gene-therapy BioBriefs en 2025-10-26T04:32:56Z Tetraneuron pursues upstream gene‑therapy angle for Alzheimer’s: E2F4 AAV program advances https://biobriefs.com/deep-learning-accelerates-antibiotic-discovery BioBriefs en 2025-10-26T04:32:56Z Deep learning accelerates antibiotic discovery: models mine chemical space for new scaffolds https://biobriefs.com/biogen-bets-70m-on-vanquas BioBriefs en 2025-10-25T21:32:42Z Biogen bets $70M on Vanqua’s C5aR1 antagonist https://biobriefs.com/lilly-buys-adverum-snaps-up BioBriefs en 2025-10-25T21:32:42Z Lilly buys Adverum — snaps up phase‑3 eye gene therapy https://biobriefs.com/inhibrx-posts-phase-ii-win BioBriefs en 2025-10-25T21:32:42Z Inhibrx posts phase II win — eyes BLA for rare chondrosarcoma https://biobriefs.com/gepotidacin-wins-approval-for-utis BioBriefs en 2025-10-25T21:32:42Z Gepotidacin wins approval for UTIs; gonorrhea filing pending https://biobriefs.com/fda-finds-unauthorized-api-warehouse BioBriefs en 2025-10-25T21:32:42Z FDA finds unauthorized API warehouse — contamination and compliance flagged https://biobriefs.com/deep-learning-accelerates-antibiotic-discovery BioBriefs en 2025-10-25T21:32:42Z Deep learning accelerates antibiotic discovery: two Nature Biotech papers https://biobriefs.com/lnp-blueprints-and-a-bespoke BioBriefs en 2025-10-25T21:32:42Z LNP blueprints... and a bespoke CRISPR made in months https://biobriefs.com/tetraneuron-targets-e2f4-upstream-gene BioBriefs en 2025-10-25T21:32:42Z Tetraneuron targets E2F4 — upstream gene therapy strategy for Alzheimer’s https://biobriefs.com/takeda-pays-1-2bn-for BioBriefs en 2025-10-25T21:32:42Z Takeda pays $1.2bn for Innovent oncology duo — global rights outside China https://biobriefs.com/tangos-prmt5-data-satisfy-pivotal BioBriefs en 2025-10-25T21:32:42Z Tango’s PRMT5 data satisfy — pivotal pancreatic study planned https://biobriefs.com/biogen-licenses-vanqua-s-c5ar1 BioBriefs en 2025-10-25T16:33:47Z Biogen licenses Vanqua's C5aR1 antagonist: $70M now, $990M possible https://biobriefs.com/fda-returns-gsks-blenrep-to BioBriefs en 2025-10-25T16:33:47Z FDA returns GSK’s Blenrep to market – approval limited to specific combos https://biobriefs.com/lilly-buys-adverum-for-gene BioBriefs en 2025-10-25T16:33:47Z Lilly buys Adverum for gene therapy bet – cash rescue with CVR upside https://biobriefs.com/inhibrxs-rare-cancer-win-prompts BioBriefs en 2025-10-25T16:33:47Z Inhibrx’s rare cancer win prompts BLA talk – regulators in view https://biobriefs.com/tangos-prmt5-data-pivotal-path BioBriefs en 2025-10-25T16:33:47Z Tango’s PRMT5 data…pivotal path opens in pancreatic cancer https://biobriefs.com/takeda-inks-1-2b-oncology BioBriefs en 2025-10-25T16:33:47Z Takeda inks $1.2B oncology pact with Innovent — global rights outside China https://biobriefs.com/ai-accelerates-antibiotic-discovery-deep BioBriefs en 2025-10-25T16:33:47Z AI accelerates antibiotic discovery: deep‑learning screens reveal new scaffolds https://biobriefs.com/lnp-shapes-mapped-study-links BioBriefs en 2025-10-25T16:33:47Z LNP shapes mapped: study links particle architecture to delivery performance https://biobriefs.com/cellarity-publishes-cell-state-drug BioBriefs en 2025-10-25T16:33:47Z Cellarity publishes cell‑state drug framework in Science — AI meets transcriptomics https://biobriefs.com/10x-roche-and-prognosys-sue BioBriefs en 2025-10-25T16:33:47Z 10x, Roche and Prognosys sue Illumina — patent fights escalate in spatial and single‑cell https://biobriefs.com/biogen-bets-1b-on-vanquas BioBriefs en 2025-10-25T14:33:10Z Biogen bets $1B on Vanqua’s C5aR1 drug: upfront $70M, $990M in milestones https://biobriefs.com/lilly-rescues-adverum-gene-therapy BioBriefs en 2025-10-25T14:33:10Z Lilly rescues Adverum: gene-therapy buy priced below market with CVR upside https://biobriefs.com/fda-clears-new-nonhormonal-menopause BioBriefs en 2025-10-25T14:33:10Z FDA clears new nonhormonal menopause drugs: elinzanetant and Bayer’s Lynkuet win approval https://biobriefs.com/tangos-prmt5-data-clear-path BioBriefs en 2025-10-25T14:33:10Z Tango’s PRMT5 data clear path to pivotal study – $225M bridge financing follows https://biobriefs.com/inhibrx-posts-registrational-win-in BioBriefs en 2025-10-25T14:33:10Z Inhibrx posts registrational win in rare chondrosarcoma – BLA plans underway https://biobriefs.com/deep-learning-hunts-antibiotics-nature BioBriefs en 2025-10-25T14:33:10Z Deep learning hunts antibiotics: Nature Biotech papers deliver novel scaffolds https://biobriefs.com/retron-editors-resurface-metagenomic-search BioBriefs en 2025-10-25T14:33:10Z Retron editors resurface: metagenomic search yields new retron‑based gene editors https://biobriefs.com/personalized-crispr-in-months-baby BioBriefs en 2025-10-25T14:33:10Z Personalized CRISPR in months: Baby KJ’s bespoke gene‑editing program shows the model https://biobriefs.com/genomic-method-advances-ultra-mild BioBriefs en 2025-10-25T14:33:10Z Genomic‑method advances: ultra‑mild bisulfite sequencing and benchmarking toolkit EasyGeSe https://biobriefs.com/cellarity-publishes-ai-framework-for BioBriefs en 2025-10-25T14:33:10Z Cellarity publishes AI framework for cell‑state medicines in Science: transcriptomics meets models https://biobriefs.com/biogen-bets-on-innate-immunity BioBriefs en 2025-10-25T10:32:40Z Biogen bets on innate immunity: $70M deal for Vanqua's C5aR1 program https://biobriefs.com/fda-clears-nonhormonal-option-elinzanetant BioBriefs en 2025-10-25T10:32:40Z FDA clears nonhormonal option: elinzanetant approved for hot flashes https://biobriefs.com/gsks-blenrep-comeback-fda-clears BioBriefs en 2025-10-25T10:32:40Z GSK’s Blenrep comeback: FDA clears a narrower U.S. label https://biobriefs.com/lilly-buys-adverum-one-time BioBriefs en 2025-10-25T10:32:40Z Lilly buys Adverum... one‑time gene therapy prize for wet AMD https://biobriefs.com/inhibrx-posts-registrational-win-phase BioBriefs en 2025-10-25T10:32:40Z Inhibrx posts registrational win: phase II data push BLA talk https://biobriefs.com/deep-learning-revs-antibiotic-discovery BioBriefs en 2025-10-25T10:32:40Z Deep learning revs antibiotic discovery: two Nature Biotechnology reads https://biobriefs.com/lnp-anatomy-revealed-biophysics-links BioBriefs en 2025-10-25T10:32:40Z LNP anatomy revealed: biophysics links particle shape to delivery https://biobriefs.com/retrons-retooled-metagenomes-yield-new BioBriefs en 2025-10-25T10:32:40Z Retrons retooled: metagenomes yield new retron gene editors https://biobriefs.com/modernas-cmv-vaccine-misses-pivotal BioBriefs en 2025-10-25T10:32:40Z Moderna’s CMV vaccine misses: pivotal failure halts program https://biobriefs.com/tango-advances-prmt5-candidate-phase BioBriefs en 2025-10-25T10:32:40Z Tango advances PRMT5 candidate: Phase III and $225M to push pancreatic program https://biobriefs.com/biogen-stakes-70m-on-vanqua BioBriefs en 2025-10-25T09:34:06Z Biogen stakes $70M on Vanqua C5aR1 antagonist — immunology push https://biobriefs.com/lilly-scoops-adverum-buys-phase BioBriefs en 2025-10-25T09:34:06Z Lilly scoops Adverum — buys phase‑3 eye gene therapy at bargain price https://biobriefs.com/fda-clears-gsks-blenrep-u BioBriefs en 2025-10-25T09:34:06Z FDA clears GSK’s Blenrep — U.S. return comes with limits https://biobriefs.com/tango-pivots-prmt5-into-pivotal BioBriefs en 2025-10-25T09:34:06Z Tango pivots PRMT5 into pivotal PDAC study — raises $225M to fund push https://biobriefs.com/ai-accelerates-antibiotic-discovery-two BioBriefs en 2025-10-25T09:34:06Z AI accelerates antibiotic discovery — two Nature Biotechnology reports https://biobriefs.com/10x-roche-and-prognosys-sue BioBriefs en 2025-10-25T09:34:06Z 10x, Roche and Prognosys sue Illumina over spatial and single‑cell patents https://biobriefs.com/moderna-halts-cmv-vaccine-after BioBriefs en 2025-10-25T09:34:06Z Moderna halts CMV vaccine after Phase III miss https://biobriefs.com/ventyxs-oral-nlrp3-inhibitor-shows BioBriefs en 2025-10-25T09:34:06Z Ventyx’s oral NLRP3 inhibitor shows cardiovascular biomarker gains — partnership talks begin https://biobriefs.com/inhibrx-posts-phase-ii-win BioBriefs en 2025-10-25T09:34:06Z Inhibrx posts phase II win in rare chondrosarcoma — BLA filing eyed https://biobriefs.com/biophysics-maps-lnp-shapes-route BioBriefs en 2025-10-25T09:34:06Z Biophysics maps LNP shapes — route to tissue‑targeted RNA delivery https://biobriefs.com/biogen-pays-70m-upfront-for BioBriefs en 2025-10-25T04:32:44Z Biogen pays $70M upfront for Vanqua C5aR1 – up to $1B more https://biobriefs.com/lilly-buys-adverum-for-eye BioBriefs en 2025-10-25T04:32:44Z Lilly buys Adverum for eye-gene therapy assets – contingent-value rights included https://biobriefs.com/fda-clears-gsks-blenrep-in BioBriefs en 2025-10-25T04:32:44Z FDA clears GSK’s Blenrep in limited multiple myeloma use – mixed ruling https://biobriefs.com/ventyxs-nlrp3-inhibitor-slashes-inflammation BioBriefs en 2025-10-25T04:32:44Z Ventyx’s NLRP3 inhibitor slashes inflammation marker 78% in Phase 2 – shares surge https://biobriefs.com/tango-to-move-prmt5-inhibitor BioBriefs en 2025-10-25T04:32:44Z Tango to move PRMT5 inhibitor into Phase 3 for MTAP‑deleted pancreatic cancer – $225M raise https://biobriefs.com/inhibrx-posts-phase-2-win BioBriefs en 2025-10-25T04:32:44Z Inhibrx posts phase 2 win in rare bone cancer – FDA filing eyed for 2026 https://biobriefs.com/10x-roche-and-prognosys-sue BioBriefs en 2025-10-25T04:32:44Z 10x, Roche and Prognosys sue Illumina – nine spatial and single‑cell patents at issue https://biobriefs.com/deep-learning-accelerates-antibiotic-discovery BioBriefs en 2025-10-25T04:32:44Z Deep learning accelerates antibiotic discovery – Nature Biotechnology validates AI‑guided screens https://biobriefs.com/detailed-lnp-structures-revealed-path BioBriefs en 2025-10-25T04:32:44Z Detailed LNP structures revealed – path to tissue‑specific RNA delivery https://biobriefs.com/retrons-repurposed-as-a-new BioBriefs en 2025-10-25T04:32:44Z Retrons repurposed as a new class of genome editors – scalable, self‑priming DNA donors https://biobriefs.com/biogen-bets-on-c5ar1-70m BioBriefs en 2025-10-24T21:32:34Z Biogen bets on C5aR1: $70m upfront to Vanqua, $990m more possible https://biobriefs.com/lilly-swoops-on-adverum-gene BioBriefs en 2025-10-24T21:32:34Z Lilly swoops on Adverum: gene therapy buy as cash runs dry https://biobriefs.com/two-fda-moves-on-menopause BioBriefs en 2025-10-24T21:32:34Z Two FDA moves on menopause relief: nonhormonal and neurokinin options https://biobriefs.com/tangos-prmt5-readout-sparks-phase BioBriefs en 2025-10-24T21:32:34Z Tango’s PRMT5 readout sparks Phase‑3 plan and $225m haul https://biobriefs.com/ventyxs-nlrp3-program-swift-biomarker BioBriefs en 2025-10-24T21:32:34Z Ventyx’s NLRP3 program: swift biomarker cuts ignite buyout chatter https://biobriefs.com/modernas-cmv-setback-and-a BioBriefs en 2025-10-24T21:32:34Z Moderna’s CMV setback… and a quieter pivot to oncology https://biobriefs.com/deep-learning-accelerates-antibiotic-discovery BioBriefs en 2025-10-24T21:32:34Z Deep learning accelerates antibiotic discovery: two Nature Biotech papers https://biobriefs.com/biophysics-peels-back-lnp-structure BioBriefs en 2025-10-24T21:32:34Z Biophysics peels back LNP structure — design rules for delivery https://biobriefs.com/retrons-join-the-gene-editing BioBriefs en 2025-10-24T21:32:34Z Retrons join the gene‑editing toolkit: metagenomic discovery to engineering https://biobriefs.com/live-embryo-imaging-upends-assumptions BioBriefs en 2025-10-24T21:32:34Z Live embryo imaging upends assumptions about preimplantation aneuploidy https://biobriefs.com/lilly-buys-adverum-scoops-up BioBriefs en 2025-10-24T16:33:45Z Lilly buys Adverum — scoops up cash‑strapped gene therapy leader https://biobriefs.com/fda-returns-blenrep-limited-approval BioBriefs en 2025-10-24T16:33:45Z FDA returns Blenrep: limited approval with Velcade combo https://biobriefs.com/modernas-cmv-vaccine-fails-phase BioBriefs en 2025-10-24T16:33:45Z Moderna’s CMV vaccine fails Phase 3 — program largely halted https://biobriefs.com/ai-finds-antibiotics-deep-learning BioBriefs en 2025-10-24T16:33:45Z AI finds antibiotics: deep learning surfaces novel antibacterial scaffolds https://biobriefs.com/lnp-blueprints-emerge-biophysics-maps BioBriefs en 2025-10-24T16:33:45Z LNP blueprints emerge — biophysics maps nanoparticle diversity https://biobriefs.com/live-embryo-imaging-flags-mitotic BioBriefs en 2025-10-24T16:33:45Z Live embryo imaging flags mitotic errors — PGT‑A under scrutiny https://biobriefs.com/retrons-repurposed-new-retron-based BioBriefs en 2025-10-24T16:33:45Z Retrons repurposed — new retron‑based editors promise large DNA fixes https://biobriefs.com/biogen-bets-on-c5ar1-70m BioBriefs en 2025-10-24T16:33:45Z Biogen bets on C5aR1: $70M upfront for Vanqua’s preclinical asset https://biobriefs.com/ventyx-nlrp3-pill-slashes-inflammation BioBriefs en 2025-10-24T16:33:45Z Ventyx NLRP3 pill slashes inflammation markers — markets rally https://biobriefs.com/regeneron-shelves-2seventy-car-t BioBriefs en 2025-10-24T16:33:45Z Regeneron shelves 2seventy CAR‑T — early lymphoma candidate discontinued https://biobriefs.com/takeda-innovent-deal-11-4bn BioBriefs en 2025-10-24T14:33:26Z Takeda-Innovent deal: $11.4bn package, $1.2bn up front https://biobriefs.com/moderna-halts-cmv-shot-phase BioBriefs en 2025-10-24T14:33:26Z Moderna halts CMV shot: Phase III failure forces pullback https://biobriefs.com/regeneron-shelves-2seventy-car-t BioBriefs en 2025-10-24T14:33:26Z Regeneron shelves 2seventy CAR‑T bbT369: early program stopped https://biobriefs.com/ventyxs-nlrp3-inhibitor-single-arm BioBriefs en 2025-10-24T14:33:26Z Ventyx’s NLRP3 inhibitor: single‑arm signal shakes up cardio inflammation space https://biobriefs.com/inhibrx-posts-phase-ii-win BioBriefs en 2025-10-24T14:33:26Z Inhibrx posts phase II win in rare bone cancer — FDA path planned https://biobriefs.com/fda-clears-blenrep-comeback-approval BioBriefs en 2025-10-24T14:33:26Z FDA clears Blenrep comeback — approval split by regimen https://biobriefs.com/lnp-blueprints-biophysics-study-links BioBriefs en 2025-10-24T14:33:26Z LNP blueprints: biophysics study links shape to delivery https://biobriefs.com/retrons-retooled-new-genome-editing BioBriefs en 2025-10-24T14:33:26Z Retrons retooled: new genome‑editing tool boosts precise insertions https://biobriefs.com/10x-roche-prognosys-sue-illumina BioBriefs en 2025-10-24T14:33:26Z 10x, Roche, Prognosys sue Illumina — patents hit spatial, single‑cell tech https://biobriefs.com/alectors-dementia-drug-fails-phase BioBriefs en 2025-10-24T14:33:26Z Alector’s dementia drug fails Phase III: company halves staff and slumps https://biobriefs.com/takeda-innovent-ink-11-4bn BioBriefs en 2025-10-24T10:33:52Z Takeda, Innovent ink $11.4bn I‑O, ADC pact — $1.2bn up front https://biobriefs.com/moderna-cmv-miss-pivotal-phase BioBriefs en 2025-10-24T10:33:52Z Moderna CMV miss: pivotal Phase III fails — program largely halted https://biobriefs.com/fda-clears-blenrep-return-mixed BioBriefs en 2025-10-24T10:33:52Z FDA clears Blenrep return — mixed authorization for multiple myeloma https://biobriefs.com/deep-learning-accelerates-antibiotic-discovery BioBriefs en 2025-10-24T10:33:52Z Deep learning accelerates antibiotic discovery — two Nature Biotech reports https://biobriefs.com/live-embryo-imaging-finds-late BioBriefs en 2025-10-24T10:33:52Z Live embryo imaging finds late mitotic errors — PGT‑A accuracy questioned https://biobriefs.com/base-editors-hit-the-clinic BioBriefs en 2025-10-24T10:33:52Z Base editors hit the clinic: 23 programs now running — early activity seen https://biobriefs.com/ventyx-nlrp3-inhibitor-posts-striking BioBriefs en 2025-10-24T10:33:52Z Ventyx NLRP3 inhibitor posts striking Phase II biomarker drops — partner chatter https://biobriefs.com/10x-roche-and-prognosys-sue BioBriefs en 2025-10-24T10:33:52Z 10x, Roche and Prognosys sue Illumina — spatial and single‑cell patents at issue https://biobriefs.com/alectors-phase-iii-flop-triggers BioBriefs en 2025-10-24T10:33:52Z Alector’s Phase III flop triggers program halt and staff cuts https://biobriefs.com/fda-accepts-ind-supported-solely BioBriefs en 2025-10-24T10:33:52Z FDA accepts IND supported solely by organoid efficacy — regulators shift https://biobriefs.com/takeda-buys-global-rights-to BioBriefs en 2025-10-24T09:33:31Z Takeda buys global rights to Innovent’s oncology assets — $1.2bn upfront https://biobriefs.com/fda-grants-limited-return-for BioBriefs en 2025-10-24T09:33:31Z FDA grants limited return for GSK’s Blenrep — split approval narrows label https://biobriefs.com/moderna-halts-cmv-vaccine-program BioBriefs en 2025-10-24T09:33:31Z Moderna halts CMV vaccine program after Phase III failure — pivot to oncology https://biobriefs.com/base-editors-see-23-clinical BioBriefs en 2025-10-24T09:33:31Z Base editors see 23 clinical programs — early readouts point to activity https://biobriefs.com/ventyxs-oral-nlrp3-inhibitor-cuts BioBriefs en 2025-10-24T09:33:31Z Ventyx’s oral NLRP3 inhibitor cuts inflammation biomarkers — investors take notice https://biobriefs.com/10x-roche-and-prognosys-sue BioBriefs en 2025-10-24T09:33:31Z 10x, Roche and Prognosys sue Illumina over spatial and single‑cell patents https://biobriefs.com/cellarity-publishes-ai-driven-cell BioBriefs en 2025-10-24T09:33:31Z Cellarity publishes AI‑driven cell‑state discovery framework in Science https://biobriefs.com/retrons-repurposed-for-precise-genome BioBriefs en 2025-10-24T09:33:31Z Retrons repurposed for precise genome editing — new tools emerge https://biobriefs.com/fda-accepts-ind-based-solely BioBriefs en 2025-10-24T09:33:31Z FDA accepts IND based solely on human vascularized organoid efficacy data — first‑ever https://biobriefs.com/regeneron-halts-2seventy-acquired-car BioBriefs en 2025-10-24T09:33:31Z Regeneron halts 2seventy‑acquired CAR‑T bbT369 — program dropped https://biobriefs.com/fda-reinstates-gsks-blenrep-approval BioBriefs en 2025-10-24T04:33:46Z FDA reinstates GSK’s Blenrep — approval narrowed to Velcade combo https://biobriefs.com/modernas-cmv-vaccine-fails-phase BioBriefs en 2025-10-24T04:33:46Z Moderna’s CMV vaccine fails Phase 3 — company halts most development https://biobriefs.com/ventyxs-nlrp3-data-biomarker-collapse BioBriefs en 2025-10-24T04:33:46Z Ventyx’s NLRP3 data: biomarker collapse and a market fever https://biobriefs.com/10x-roche-and-prognosys-sue BioBriefs en 2025-10-24T04:33:46Z 10x, Roche and Prognosys sue Illumina: patent fight targets spatial and single‑cell tech https://biobriefs.com/cellarity-publishes-cell-state-drug BioBriefs en 2025-10-24T04:33:46Z Cellarity publishes cell‑state drug framework in Science — AI maps new discovery route https://biobriefs.com/retrons-repurposed-for-high-precision BioBriefs en 2025-10-24T04:33:46Z Retrons repurposed for high‑precision editing — new toolset for large DNA fixes https://biobriefs.com/live-embryo-imaging-raises-questions BioBriefs en 2025-10-24T04:33:46Z Live embryo imaging raises questions about PGT‑A accuracy — de novo mitotic errors found https://biobriefs.com/flagship-debuts-expedition-medicines-50m BioBriefs en 2025-10-24T04:33:46Z Flagship debuts Expedition Medicines — $50M bet on covalent, quantum‑informed discovery https://biobriefs.com/fda-accepts-ind-supported-by BioBriefs en 2025-10-24T04:33:46Z FDA accepts IND supported by organoid efficacy — first approval without animal POC https://biobriefs.com/takeda-wagers-on-innovents-oncology BioBriefs en 2025-10-24T04:33:46Z Takeda wagers on Innovent’s oncology lineup — $1.2B upfront in $11.4B deal https://biobriefs.com/ventyxs-oral-nlrp3-pill-slashes BioBriefs en 2025-10-23T21:32:54Z Ventyx’s oral NLRP3 pill slashes inflammation — partner talks ignite https://biobriefs.com/moderna-halts-cmv-program-after BioBriefs en 2025-10-23T21:32:54Z Moderna halts CMV program after pivotal miss https://biobriefs.com/alectors-gsk-backed-antibody-misses BioBriefs en 2025-10-23T21:32:54Z Alector’s GSK‑backed antibody misses Phase III — cuts follow https://biobriefs.com/takedas-major-oncology-blitz-11 BioBriefs en 2025-10-23T21:32:54Z Takeda’s major oncology blitz: $11.4B Innovent deal lands https://biobriefs.com/regeneron-halts-dual-target-car BioBriefs en 2025-10-23T21:32:54Z Regeneron halts dual‑target CAR‑T study — bbT369 program stopped https://biobriefs.com/10x-roche-and-prognosys-sue BioBriefs en 2025-10-23T21:32:54Z 10x, Roche and Prognosys sue Illumina over spatial and single‑cell patents https://biobriefs.com/flagship-debuts-expedition-50m-to BioBriefs en 2025-10-23T21:32:54Z Flagship debuts Expedition — $50M to chase covalent, AI‑driven drugs https://biobriefs.com/fda-accepts-ind-backed-only BioBriefs en 2025-10-23T21:32:54Z FDA accepts IND backed only by human organoid efficacy — a regulatory first https://biobriefs.com/roche-flags-china-pricing-pain BioBriefs en 2025-10-23T21:32:54Z Roche flags China pricing pain; diagnostics sales pressured this year https://biobriefs.com/electra-bags-183m-series-c BioBriefs en 2025-10-23T21:32:54Z Electra bags $183M Series C to advance rare‑disease and HLH programs https://biobriefs.com/merck-kgaa-to-exit-arklow BioBriefs en 2025-10-23T16:34:04Z Merck KGaA to exit Arklow API work — plant slated to close 2028 https://biobriefs.com/alector-slashes-workforce-gsk-linked BioBriefs en 2025-10-23T16:34:04Z Alector slashes workforce: GSK-linked antibody fails Phase III https://biobriefs.com/modernas-cmv-shot-phase-3 BioBriefs en 2025-10-23T16:34:04Z Moderna’s CMV shot... Phase 3 failure forces program halt https://biobriefs.com/ventyxs-nlrp3-inhibitor-cuts-inflammation BioBriefs en 2025-10-23T16:34:04Z Ventyx’s NLRP3 inhibitor cuts inflammation 78% — stock jumps https://biobriefs.com/flagship-launches-expedition-medicines-50m BioBriefs en 2025-10-23T16:34:04Z Flagship launches Expedition Medicines: $50M to back covalent drug discovery https://biobriefs.com/retrons-repurposed-bacterial-elements-enable BioBriefs en 2025-10-23T16:34:04Z Retrons repurposed: bacterial elements enable broad DNA editing https://biobriefs.com/engineered-casts-boost-precision-gene BioBriefs en 2025-10-23T16:34:04Z Engineered CASTs boost precision gene insertion — activity up to fourfold https://biobriefs.com/live-embryo-imaging-reveals-mitotic BioBriefs en 2025-10-23T16:34:04Z Live embryo imaging reveals mitotic errors in placenta-fated cells https://biobriefs.com/tango-moves-pancreatic-cancer-asset BioBriefs en 2025-10-23T16:34:04Z Tango moves pancreatic cancer asset into Phase 3 — raises $225M https://biobriefs.com/takeda-inks-11-4b-innovent BioBriefs en 2025-10-23T16:34:04Z Takeda inks $11.4B Innovent deal: $1.2B up front for oncology candidates https://biobriefs.com/moderna-cmv-flop-company-halts BioBriefs en 2025-10-23T14:32:58Z Moderna CMV flop: company halts most development after phase 3 miss https://biobriefs.com/arcturus-inhaled-mrna-disappoints-cystic BioBriefs en 2025-10-23T14:32:58Z Arcturus inhaled mRNA disappoints: cystic fibrosis interim data miss https://biobriefs.com/alector-hits-wall-phase-iii BioBriefs en 2025-10-23T14:32:58Z Alector hits wall: Phase III fail triggers layoffs and leadership exits https://biobriefs.com/takeda-innovent-pact-1-2b BioBriefs en 2025-10-23T14:32:58Z Takeda‑Innovent pact: $1.2B upfront, $11.4B deal reshapes oncology bets https://biobriefs.com/roche-trims-early-oncology-flags BioBriefs en 2025-10-23T14:32:58Z Roche trims early oncology, flags diagnostics headwinds in Q3 https://biobriefs.com/nlrp3-inhibitor-posts-rapid-biomarker BioBriefs en 2025-10-23T14:32:58Z NLRP3 inhibitor posts rapid biomarker wins — Ventyx stock soars https://biobriefs.com/long-read-metagenomics-tracks-donor BioBriefs en 2025-10-23T14:32:58Z Long‑read metagenomics tracks donor strains after FMT — new LongTrack pipeline https://biobriefs.com/retrons-for-precision-editing-metagenomic BioBriefs en 2025-10-23T14:32:58Z Retrons for precision editing: metagenomic screen yields therapeutic editors https://biobriefs.com/biophysics-of-lnps-mapping-structure BioBriefs en 2025-10-23T14:32:58Z Biophysics of LNPs: mapping structure to function to optimize RNA delivery https://biobriefs.com/live-embryo-imaging-mitotic-errors BioBriefs en 2025-10-23T14:32:58Z Live embryo imaging: mitotic errors seen in placenta‑fated cells https://biobriefs.com/takeda-bets-1-2b-upfront BioBriefs en 2025-10-23T10:33:51Z Takeda bets $1.2B upfront — China oncology pact with Innovent https://biobriefs.com/alectors-gsk-partnered-antibody-flops BioBriefs en 2025-10-23T10:33:51Z Alector’s GSK-partnered antibody flops: workforce halved https://biobriefs.com/modernas-cmv-shot-fails-phase BioBriefs en 2025-10-23T10:33:51Z Moderna’s CMV shot fails Phase 3 — company halts most development https://biobriefs.com/arcturus-interim-cf-readout-disappoints BioBriefs en 2025-10-23T10:33:51Z Arcturus interim CF readout disappoints — shares plunge https://biobriefs.com/electra-nets-183m-rare-disease BioBriefs en 2025-10-23T10:33:51Z Electra nets $183M — rare‑disease immunology play attracts big backers https://biobriefs.com/preclinical-car-t-advances-safer BioBriefs en 2025-10-23T10:33:51Z Preclinical CAR‑T advances: safer designs and targeted integration https://biobriefs.com/long-read-metagenomics-tracks-donor BioBriefs en 2025-10-23T10:33:51Z Long‑read metagenomics tracks donor strains — new FMT surveillance https://biobriefs.com/retrons-move-toward-precision-editing BioBriefs en 2025-10-23T10:33:51Z Retrons move toward precision editing — academic and metagenomic finds https://biobriefs.com/mrna-vaccines-spark-antitumor-immunity BioBriefs en 2025-10-23T10:33:51Z mRNA vaccines spark antitumor immunity — clinical and preclinical links https://biobriefs.com/alkermes-buys-avadel-for-2 BioBriefs en 2025-10-23T10:33:51Z Alkermes buys Avadel for $2.1B — instant entry to sleep market https://biobriefs.com/modernas-cmv-vaccine-fails-phase BioBriefs en 2025-10-23T09:33:14Z Moderna’s CMV vaccine fails Phase 3 — program largely halted https://biobriefs.com/arcturus-inhaled-mrna-for-cystic BioBriefs en 2025-10-23T09:33:14Z Arcturus inhaled mRNA for cystic fibrosis shows no FEV1 benefit — shares plunge https://biobriefs.com/alectors-dementia-antibody-fails-late BioBriefs en 2025-10-23T09:33:14Z Alector’s dementia antibody fails late‑stage test — company slashes workforce https://biobriefs.com/takeda-jets-11-4b-deal BioBriefs en 2025-10-23T09:33:14Z Takeda jets $11.4B deal for Innovent oncology assets — $1.2B up front https://biobriefs.com/alkermes-buys-avadel-for-2 BioBriefs en 2025-10-23T09:33:14Z Alkermes buys Avadel for $2.1B — instant commercial foothold in sleep medicine https://biobriefs.com/electra-raises-183m-series-c BioBriefs en 2025-10-23T09:33:14Z Electra raises $183M Series C to push rare‑disease immunotherapy into pivotal testing https://biobriefs.com/flagship-births-expedition-with-50m BioBriefs en 2025-10-23T09:33:14Z Flagship births Expedition with $50M to hunt covalent binders — AI and pharma tie‑ups https://biobriefs.com/esmo-shows-ctdna-can-guide BioBriefs en 2025-10-23T09:33:14Z ESMO shows ctDNA can guide treatment decisions — tumor microenvironment drives new first‑in‑human work https://biobriefs.com/new-genomic-assays-may-spare BioBriefs en 2025-10-23T09:33:14Z New genomic assays may spare melanoma patients sentinel‑node surgery https://biobriefs.com/engineered-casts-and-improved-editing BioBriefs en 2025-10-23T09:33:14Z Engineered CASTs and improved editing tools push precision gene insertion forward https://biobriefs.com/modernas-cmv-shot-fails-phase BioBriefs en 2025-10-23T04:34:45Z Moderna’s CMV shot fails Phase 3 — development halted https://biobriefs.com/arcturus-inhaled-mrna-shows-no BioBriefs en 2025-10-23T04:34:45Z Arcturus inhaled mRNA shows no lung improvement — stock tumbles https://biobriefs.com/alectors-gsk-antibody-flunks-phase BioBriefs en 2025-10-23T04:34:45Z Alector’s GSK antibody flunks Phase 3 — workforce halved https://biobriefs.com/takeda-inks-11-4b-pact BioBriefs en 2025-10-23T04:34:45Z Takeda inks $11.4B pact with Innovent — $1.2B upfront for oncology rights https://biobriefs.com/electra-closes-183m-series-c BioBriefs en 2025-10-23T04:34:45Z Electra closes $183M Series C — advances rare‑disease immunology programs https://biobriefs.com/10x-genomics-sues-illumina-over BioBriefs en 2025-10-23T04:34:45Z 10x Genomics sues Illumina over single‑cell and spatial patents https://biobriefs.com/long-read-pipeline-longtrack-follows BioBriefs en 2025-10-23T04:34:45Z Long‑read pipeline 'LongTrack' follows donor strains after FMT — high‑resolution engraftment https://biobriefs.com/engineered-casts-boost-precision-gene BioBriefs en 2025-10-23T04:34:45Z Engineered CASTs boost precision gene insertion — high‑throughput screen finds activity gains https://biobriefs.com/epigenetic-multi-gene-editing-and BioBriefs en 2025-10-23T04:34:45Z Epigenetic multi‑gene editing and in‑vivo CAR‑T moves — next wave in cell therapy https://biobriefs.com/genomic-tests-may-spare-melanoma BioBriefs en 2025-10-23T04:34:45Z Genomic tests may spare melanoma lymph‑node biopsies — multicenter validation https://biobriefs.com/modernas-cmv-vaccine-flops-company BioBriefs en 2025-10-22T21:33:04Z Moderna’s CMV vaccine flops: company halts broad development https://biobriefs.com/alector-phase-3-failure-workforce BioBriefs en 2025-10-22T21:33:04Z Alector Phase 3 failure... workforce slashed amid program pullback https://biobriefs.com/galapagos-abandons-cell-therapy-plan BioBriefs en 2025-10-22T21:33:04Z Galapagos abandons cell therapy plan: 365 jobs at risk https://biobriefs.com/takeda-bets-big-on-innovent BioBriefs en 2025-10-22T21:33:04Z Takeda bets big on Innovent: $1.2B up front in IO/ADC pact https://biobriefs.com/sanofis-buyout-drug-posts-phase BioBriefs en 2025-10-22T21:33:04Z Sanofi’s buyout drug posts Phase 2 win... rare disease opportunity https://biobriefs.com/alkermes-moves-into-sleep-market BioBriefs en 2025-10-22T21:33:04Z Alkermes moves into sleep market with Avadel takeover https://biobriefs.com/electra-closes-183m-series-c BioBriefs en 2025-10-22T21:33:04Z Electra closes $183M Series C to fund pivotal rare‑disease work https://biobriefs.com/arcturus-inhaled-mrna-shows-mixed BioBriefs en 2025-10-22T21:33:04Z Arcturus’ inhaled mRNA shows mixed Phase 2 data... efficacy shortfall https://biobriefs.com/sharper-gene-tools-cast-engineering BioBriefs en 2025-10-22T21:33:04Z Sharper gene tools: CAST engineering and new CRISPR advances https://biobriefs.com/new-genomic-tests-aim-to BioBriefs en 2025-10-22T21:33:04Z New genomic tests aim to spare melanoma patients lymph‑node surgery https://biobriefs.com/alector-halves-staff-gsk-partnered BioBriefs en 2025-10-22T16:33:36Z Alector halves staff – GSK‑partnered antibody fails late trial https://biobriefs.com/takeda-pays-1-2b-upfront BioBriefs en 2025-10-22T16:33:36Z Takeda pays $1.2B upfront – Buys China cancer candidates in multi‑billion pact https://biobriefs.com/electra-secures-183m-sanofi-and BioBriefs en 2025-10-22T16:33:36Z Electra secures $183M — Sanofi and life‑science investors back rare‑disease push https://biobriefs.com/flagship-launches-expedition-50m-bet BioBriefs en 2025-10-22T16:33:36Z Flagship launches Expedition: $50M bet on AI drug discovery with Pfizer tie https://biobriefs.com/biodesix-and-bio-rad-expand BioBriefs en 2025-10-22T16:33:36Z Biodesix and Bio‑Rad expand ddPCR pact to validate cancer liquid‑biopsy kits https://biobriefs.com/who-launches-global-forum-to BioBriefs en 2025-10-22T16:33:36Z WHO launches global forum to boost clinical‑trial transparency https://biobriefs.com/ctdna-proves-actionable-at-esmo BioBriefs en 2025-10-22T16:33:36Z ctDNA proves actionable at ESMO — blood tests guide post‑surgery therapy https://biobriefs.com/crispr-claims-a-leap-over BioBriefs en 2025-10-22T16:33:36Z CRISPR claims a leap over prime editing — rivals publicly dispute https://biobriefs.com/multiplex-epigenetic-editing-rewires-t BioBriefs en 2025-10-22T16:33:36Z Multiplex epigenetic editing rewires T cells — path to safer CAR‑T https://biobriefs.com/replimune-resubmits-rp1-fda-sets BioBriefs en 2025-10-22T16:33:36Z Replimune resubmits RP1 — FDA sets April review date, stock pops https://biobriefs.com/takeda-doubles-down-on-china BioBriefs en 2025-10-22T14:32:38Z Takeda doubles down on China oncology: $1.2B upfront, bigger strategic push https://biobriefs.com/electra-raises-183m-series-c BioBriefs en 2025-10-22T14:32:38Z Electra raises $183M: Series C funds pivotal rare-disease trial https://biobriefs.com/replimune-pushes-fda-resubmission-stock BioBriefs en 2025-10-22T14:32:38Z Replimune pushes FDA resubmission; stock surges on acceptance https://biobriefs.com/flagship-launches-expedition-50m-for BioBriefs en 2025-10-22T14:32:38Z Flagship launches Expedition: $50M for AI drug discovery partnership with Pfizer https://biobriefs.com/hologic-sale-confirmed-blackstone-and BioBriefs en 2025-10-22T14:32:38Z Hologic sale confirmed: Blackstone and TPG agree up to $18.3B take‑private https://biobriefs.com/grail-raises-325m-ahead-of BioBriefs en 2025-10-22T14:32:38Z Grail raises $325M ahead of FDA bid — Blood test data show big lift https://biobriefs.com/sanofi-inks-nanodisc-deal-with BioBriefs en 2025-10-22T14:32:38Z Sanofi inks NanoDisc deal with Evoq — $500M in milestones for autoimmune platform https://biobriefs.com/gsk-and-spero-send-oral BioBriefs en 2025-10-22T14:32:38Z GSK and Spero send oral tebipenem toward FDA after positive Phase 3 https://biobriefs.com/10x-genomics-sues-illumina-over BioBriefs en 2025-10-22T14:32:38Z 10x Genomics sues Illumina over single‑cell, spatial patents — Delaware filings follow https://biobriefs.com/galapagos-to-wind-down-cell BioBriefs en 2025-10-22T14:32:38Z Galapagos to wind down cell therapy business — Sites to close, major layoffs planned https://biobriefs.com/sanofi-bets-500m-on-evoqs BioBriefs en 2025-10-22T10:33:09Z Sanofi bets $500M on Evoq’s NanoDisc – Takeda inks $1.2B Innovent pact https://biobriefs.com/hologic-heads-for-buyout-18 BioBriefs en 2025-10-22T10:33:09Z Hologic heads for buyout: $18.3B take-private deal https://biobriefs.com/fda-to-re-review-replimunes BioBriefs en 2025-10-22T10:33:09Z FDA to re-review Replimune’s RP1 – Resubmission accepted https://biobriefs.com/two-oncology-filings-advance-exelixis BioBriefs en 2025-10-22T10:33:09Z Two oncology filings advance: Exelixis aims NDA after Stellar-303; Celcuity nears filing https://biobriefs.com/ctdna-guides-post-surgery-decisions BioBriefs en 2025-10-22T10:33:09Z ctDNA guides post‑surgery decisions: Trial shows personalized adjuvant care https://biobriefs.com/grail-raises-325m-to-push BioBriefs en 2025-10-22T10:33:09Z Grail raises $325M to push multi‑cancer early detection commercial effort https://biobriefs.com/10x-genomics-sues-illumina-ip BioBriefs en 2025-10-22T10:33:09Z 10x Genomics sues Illumina – IP fight over single‑cell and spatial patents https://biobriefs.com/ai-in-discovery-idt-partners BioBriefs en 2025-10-22T10:33:09Z AI in discovery: IDT partners Profluent – Genomics launches Mystra platform https://biobriefs.com/next-gen-cell-engineering-multiplex BioBriefs en 2025-10-22T10:33:09Z Next‑gen cell engineering: Multiplex epigenetic editing and novel CAR T candidates https://biobriefs.com/series-c-and-pre-seed BioBriefs en 2025-10-22T10:33:09Z Series C and pre‑seed rounds: Step and Cyclana fund next programs https://biobriefs.com/sanofi-bets-500m-on-evoqs BioBriefs en 2025-10-22T09:33:39Z Sanofi bets >$500M on Evoq’s NanoDisc: Autoimmunity pact sealed https://biobriefs.com/10x-genomics-sues-illumina-patent BioBriefs en 2025-10-22T09:33:39Z 10x Genomics sues Illumina: Patent fight escalates in sequencing wars https://biobriefs.com/grail-secures-325m-ahead-of BioBriefs en 2025-10-22T09:33:39Z Grail secures $325M ahead of FDA push — cash to fund commercial scale-up https://biobriefs.com/fda-accepts-replimune-resubmission-second BioBriefs en 2025-10-22T09:33:39Z FDA accepts Replimune resubmission — second review set, stock surges https://biobriefs.com/galapagos-to-exit-cell-therapy BioBriefs en 2025-10-22T09:33:39Z Galapagos to exit cell therapy — unit fails to find buyer, layoffs expected https://biobriefs.com/exelixis-readout-fuels-nda-plan BioBriefs en 2025-10-22T09:33:39Z Exelixis readout fuels NDA plan — zanzalintinib + atezolizumab heads to regulators https://biobriefs.com/ctdna-steers-adjuvant-care-at BioBriefs en 2025-10-22T09:33:39Z ctDNA steers adjuvant care at ESMO — Roche’s Tecentriq data and broader trials https://biobriefs.com/novo-board-overhaul-controlling-shareholder BioBriefs en 2025-10-22T09:33:39Z Novo board overhaul: Controlling shareholder reclaims operational focus https://biobriefs.com/pcsk9s-second-act-antibodies-editing BioBriefs en 2025-10-22T09:33:39Z PCSK9’s second act: Antibodies, editing and a Verve buy that rewrites playbook https://biobriefs.com/t-cell-expansion-signature-could BioBriefs en 2025-10-22T09:33:39Z T‑cell expansion signature could predict immunotherapy response — single‑cell TCR work https://biobriefs.com/novo-main-backer-forces-boardroom BioBriefs en 2025-10-22T04:33:08Z Novo main backer forces boardroom purge — chair to step down https://biobriefs.com/10x-sues-illumina-patent-fight BioBriefs en 2025-10-22T04:33:08Z 10x sues Illumina: patent fight targets single-cell expansion https://biobriefs.com/grail-pulls-325m-bankroll-to BioBriefs en 2025-10-22T04:33:08Z Grail pulls $325M — bankroll to support commercialization and FDA push https://biobriefs.com/fda-accepts-replimune-resubmission-review BioBriefs en 2025-10-22T04:33:08Z FDA accepts Replimune resubmission — review clock set for April https://biobriefs.com/exelixis-to-file-nda-after BioBriefs en 2025-10-22T04:33:08Z Exelixis to file NDA after Phase 3 OS win — colorectal combo trims mortality https://biobriefs.com/ai-arms-race-in-life BioBriefs en 2025-10-22T04:33:08Z AI arms race in life sciences... new models and lab partnerships accelerate discovery https://biobriefs.com/cdmos-take-center-stage-capacity BioBriefs en 2025-10-22T04:33:08Z CDMOs take center stage — capacity and capability strain in cell & gene era https://biobriefs.com/single-cell-signature-predicts-cd8 BioBriefs en 2025-10-22T04:33:08Z Single-cell signature predicts CD8+ T cell bursts — a potential biomarker for immunotherapy https://biobriefs.com/car-t-cells-target-hiv BioBriefs en 2025-10-22T04:33:08Z CAR T cells target HIV-linked B cell cancers — new antigen strategy https://biobriefs.com/hologic-to-be-taken-private BioBriefs en 2025-10-22T04:33:08Z Hologic to be taken private — Blackstone, TPG agree up to $18.3B deal https://biobriefs.com/multiplex-t-cell-programming-integrated BioBriefs en 2025-10-21T21:33:36Z Multiplex T‑cell programming: Integrated epigenetic–genetic platform reported https://biobriefs.com/grail-raises-325m-financing-extends BioBriefs en 2025-10-21T21:33:36Z Grail raises $325M: Financing extends commercial and reimbursement push https://biobriefs.com/replimune-resubmission-accepted-fda-sets BioBriefs en 2025-10-21T21:33:36Z Replimune resubmission accepted: FDA sets April 2026 review date https://biobriefs.com/exelixis-presses-nda-after-survival BioBriefs en 2025-10-21T21:33:36Z Exelixis presses NDA after survival win: zanzalintinib data detailed https://biobriefs.com/multiomics-push-illumina-ramps-roadmap BioBriefs en 2025-10-21T21:33:36Z Multiomics push... Illumina ramps roadmap as Element touts single‑run platform https://biobriefs.com/crispr-vs-prime-editing-company BioBriefs en 2025-10-21T21:33:36Z CRISPR vs prime editing: Company claims spark public dispute https://biobriefs.com/10x-sues-illumina-single-cell BioBriefs en 2025-10-21T21:33:36Z 10x sues Illumina: Single‑cell and spatial patents in the dock https://biobriefs.com/adcs-keep-deal-flow-hot BioBriefs en 2025-10-21T21:33:36Z ADCs keep deal flow hot — Aimedbio’s near‑$1B pact and ESMO buzz https://biobriefs.com/chugai-licenses-ranipill-oral-biologic BioBriefs en 2025-10-21T21:33:36Z Chugai licenses Ranipill: Oral biologic pact tops $1B https://biobriefs.com/galapagos-to-exit-cell-therapy BioBriefs en 2025-10-21T21:33:36Z Galapagos to exit cell therapy: buyer search fails, 365 roles on the line https://biobriefs.com/integrated-epigenetic-reprogramming-t-cells BioBriefs en 2025-10-21T16:32:31Z Integrated epigenetic reprogramming: T cells edited at scale in Nature Biotechnology https://biobriefs.com/replimune-wins-second-fda-review BioBriefs en 2025-10-21T16:32:31Z Replimune wins second FDA review – regulators set April decision https://biobriefs.com/grail-raises-325m-and-touts BioBriefs en 2025-10-21T16:32:31Z Grail raises $325M and touts Pathfinder 2 gains – cancer screening push https://biobriefs.com/aimedbio-licenses-adc-to-boehringer BioBriefs en 2025-10-21T16:32:31Z Aimedbio licenses ADC to Boehringer in near‑$1B pact https://biobriefs.com/chugai-licenses-ranis-ranipill-1b BioBriefs en 2025-10-21T16:32:31Z Chugai licenses Rani’s Ranipill—$1B deal to take oral biologics global https://biobriefs.com/exelixis-posts-survival-gain-eyes BioBriefs en 2025-10-21T16:32:31Z Exelixis posts survival gain, eyes NDA for zanzalintinib – investors mixed https://biobriefs.com/ctdna-guiding-adjuvant-decisions-bladder BioBriefs en 2025-10-21T16:32:31Z ctDNA guiding adjuvant decisions: bladder and colon trials show promise https://biobriefs.com/hologic-to-go-private-in BioBriefs en 2025-10-21T16:32:31Z Hologic to go private in $18.3B buy; Roche wins FDA nod for Gazyva in lupus nephritis https://biobriefs.com/big-ai-plays-for-life BioBriefs en 2025-10-21T16:32:31Z Big AI plays for life sciences: Anthropic and Genomics launch domain models https://biobriefs.com/adcs-and-regional-delivery-drive BioBriefs en 2025-10-21T16:32:31Z ADCs and regional delivery drive ESMO headlines – Delcath, combos in focus https://biobriefs.com/hologic-to-be-taken-private BioBriefs en 2025-10-21T14:33:03Z Hologic to be taken private in up-to-$18.3B buyout — Blackstone and TPG lead deal https://biobriefs.com/fda-accepts-replimunes-resubmission-for BioBriefs en 2025-10-21T14:33:03Z FDA accepts Replimune’s resubmission for RP1 — April 2026 decision set https://biobriefs.com/grail-lines-up-325m-financing BioBriefs en 2025-10-21T14:33:03Z Grail lines up $325M financing to extend Galleri commercialization https://biobriefs.com/ai-models-for-life-sciences BioBriefs en 2025-10-21T14:33:03Z AI models for life sciences: Anthropic and Genomics roll out specialist platforms https://biobriefs.com/safe-multiplexed-epigenetic-editing-enables BioBriefs en 2025-10-21T14:33:03Z Safe multiplexed epigenetic editing enables multi‑gene T cell programming — Nature Biotech https://biobriefs.com/boston-scientific-to-buy-nalu BioBriefs en 2025-10-21T14:33:03Z Boston Scientific to buy Nalu Medical for $533M — expands neuromodulation lineup https://biobriefs.com/bruker-wins-fda-510-k BioBriefs en 2025-10-21T14:33:03Z Bruker wins FDA 510(k) clearance for expanded MALDI Biotyper suite https://biobriefs.com/exelixis-plans-nda-for-zanzalintinib BioBriefs en 2025-10-21T14:33:03Z Exelixis plans NDA for zanzalintinib after Phase 3 OS benefit in colorectal cancer https://biobriefs.com/endometriosis-diagnostics-mature-new-tests BioBriefs en 2025-10-21T14:33:03Z Endometriosis diagnostics mature — new tests and UK tissue‑model startup raise funds https://biobriefs.com/ai-driven-3d-cell-analysis BioBriefs en 2025-10-21T14:33:03Z AI‑driven 3D cell analysis platforms take center stage — HCS‑3DX and capsule tech https://biobriefs.com/epigenetic-edits-in-t-cells BioBriefs en 2025-10-21T10:32:47Z Epigenetic edits in T cells: multiplex platform advances CAR‑T engineering https://biobriefs.com/grail-raises-cash-ctdna-test BioBriefs en 2025-10-21T10:32:47Z Grail raises cash — ctDNA test multiplies early cancer detection https://biobriefs.com/replimune-resubmission-accepted-fda-sets BioBriefs en 2025-10-21T10:32:47Z Replimune resubmission accepted — FDA sets new review clock https://biobriefs.com/exelixis-to-file-nda-after BioBriefs en 2025-10-21T10:32:47Z Exelixis to file NDA after STELLAR‑303 OS gain — regulators next https://biobriefs.com/adcs-at-esmo-combination-regimens BioBriefs en 2025-10-21T10:32:47Z ADCs at ESMO — combination regimens push into earlier settings https://biobriefs.com/mrna-vaccines-boost-checkpoint-efficacy BioBriefs en 2025-10-21T10:32:47Z mRNA vaccines boost checkpoint efficacy — clinical signals at ESMO https://biobriefs.com/ai-platforms-for-drug-discovery BioBriefs en 2025-10-21T10:32:47Z AI platforms for drug discovery: Anthropic and Genomics roll out life‑science tools https://biobriefs.com/roche-gains-fda-nod-for BioBriefs en 2025-10-21T10:32:47Z Roche gains FDA nod for Gazyva — new biologic enters lupus nephritis market https://biobriefs.com/jax-acquires-nyscf-scale-up BioBriefs en 2025-10-21T10:32:47Z JAX acquires NYSCF — scale-up bet on stem cells and precision therapies https://biobriefs.com/regulatory-strain-fda-staffing-losses BioBriefs en 2025-10-21T10:32:47Z Regulatory strain: FDA staffing losses and CBO flags orphan‑drug cost impact https://biobriefs.com/fda-accepts-replimune-resubmission-april BioBriefs en 2025-10-21T09:33:03Z FDA accepts Replimune resubmission — April action date set https://biobriefs.com/roches-gazyva-wins-fda-nod BioBriefs en 2025-10-21T09:33:03Z Roche’s Gazyva wins FDA nod for lupus nephritis https://biobriefs.com/exelixis-plans-nda-after-phase BioBriefs en 2025-10-21T09:33:03Z Exelixis plans NDA after Phase 3 survival gain — shares slip on mixed reaction https://biobriefs.com/adcs-take-center-stage-at BioBriefs en 2025-10-21T09:33:03Z ADCs take center stage at ESMO — combos and new generations advance https://biobriefs.com/grail-raises-325m-and-touts BioBriefs en 2025-10-21T09:33:03Z Grail raises $325M and touts ctDNA boost to screening yields https://biobriefs.com/anthropic-genomics-roll-out-life BioBriefs en 2025-10-21T09:33:03Z Anthropic, Genomics roll out life‑science LLMs and platforms https://biobriefs.com/ucsds-ai-driven-candit-and BioBriefs en 2025-10-21T09:33:03Z UCSD’s AI‑driven CANDiT and precision reprogramming target cancer stem cells https://biobriefs.com/summit-and-partners-press-ivonescimab BioBriefs en 2025-10-21T09:33:03Z Summit and partners press ivonescimab toward pivotal testing after China win https://biobriefs.com/jackson-laboratory-acquires-nyscf-to BioBriefs en 2025-10-21T09:33:03Z Jackson Laboratory acquires NYSCF to scale stem‑cell research and therapies https://biobriefs.com/cbo-revises-orphan-drug-cost BioBriefs en 2025-10-21T09:33:03Z CBO revises orphan‑drug cost estimates upward after new law; industry windfalls flagged https://biobriefs.com/fda-accepts-replimune-resubmission-april BioBriefs en 2025-10-21T04:34:08Z FDA Accepts Replimune Resubmission: April 10 Review Set https://biobriefs.com/grail-raises-325m-galleri-shows BioBriefs en 2025-10-21T04:34:08Z Grail Raises $325M; Galleri Shows Sevenfold Detection Gain https://biobriefs.com/exelixis-readies-nda-after-os BioBriefs en 2025-10-21T04:34:08Z Exelixis Readies NDA After OS Win: Zanzalintinib Data Revealed https://biobriefs.com/fda-expands-gazyva-label-new BioBriefs en 2025-10-21T04:34:08Z FDA Expands Gazyva Label: New Biologic Option for Lupus Nephritis https://biobriefs.com/anthropic-debuts-claude-for-life BioBriefs en 2025-10-21T04:34:08Z Anthropic Debuts Claude for Life Sciences: Industry Partnerships Signed https://biobriefs.com/ai-reprograms-cancer-stem-cells BioBriefs en 2025-10-21T04:34:08Z AI Reprograms Cancer Stem Cells: UCSD’s CANDiT Triggers Self‑Destruct https://biobriefs.com/jackson-laboratory-acquires-nyscf-scale BioBriefs en 2025-10-21T04:34:08Z Jackson Laboratory Acquires NYSCF: Scale for Precision Therapies https://biobriefs.com/chugai-licenses-ranis-ranipill-in BioBriefs en 2025-10-21T04:34:08Z Chugai Licenses Rani’s Ranipill in $1B Pact: Oral Biologics Advance https://biobriefs.com/fda-staffing-crunch-nearly-1000 BioBriefs en 2025-10-21T04:34:08Z FDA Staffing Crunch: Nearly 1,000 Net Departures in FY2025 Quarter https://biobriefs.com/ai-builds-the-brain-celltransformer BioBriefs en 2025-10-21T04:34:08Z AI Builds the Brain: CellTransformer Produces 1,300‑Region Mouse Atlas https://biobriefs.com/grail-secures-325m-financing-backs BioBriefs en 2025-10-20T21:33:05Z Grail secures $325M: Financing backs Galleri commercialization https://biobriefs.com/exelixis-to-file-nda-zanzalintinib BioBriefs en 2025-10-20T21:33:05Z Exelixis to file NDA: Zanzalintinib survival data spur regulatory push https://biobriefs.com/datroway-trodelvy-contest-esmo-elevates BioBriefs en 2025-10-20T21:33:05Z Datroway, Trodelvy contest: ESMO elevates ADCs in first‑line and hard cases https://biobriefs.com/replimune-resubmits-rp1-fda-sets BioBriefs en 2025-10-20T21:33:05Z Replimune resubmits RP1: FDA sets second review after resubmission https://biobriefs.com/anthropic-debuts-claude-for-life BioBriefs en 2025-10-20T21:33:05Z Anthropic debuts Claude for life sciences – partners with 10x, Benchling https://biobriefs.com/ctdna-guides-adjuvant-decisions-tecentriq BioBriefs en 2025-10-20T21:33:05Z ctDNA guides adjuvant decisions: Tecentriq, DYNAMIC‑III highlight precision uses https://biobriefs.com/mrna-vaccines-augment-immunotherapy-md BioBriefs en 2025-10-20T21:33:05Z mRNA vaccines augment immunotherapy: MD Anderson and UF findings converge https://biobriefs.com/chugai-licenses-rani-ranipill-1b BioBriefs en 2025-10-20T21:33:05Z Chugai licenses Rani Ranipill: $1B collaboration targets oral delivery of biologics https://biobriefs.com/new-immunotherapy-combo-drives-remissions BioBriefs en 2025-10-20T21:33:05Z New immunotherapy combo drives remissions in older ALL patients https://biobriefs.com/fda-staffing-slide-historic-departures BioBriefs en 2025-10-20T21:33:05Z FDA staffing slide: Historic departures hit drug and biologics centers https://biobriefs.com/datroway-edges-trodelvy-adcs-reshape BioBriefs en 2025-10-20T16:32:49Z Datroway edges Trodelvy – ADCs reshape frontline options for TNBC https://biobriefs.com/exelixis-tki-shows-survival-win BioBriefs en 2025-10-20T16:32:49Z Exelixis’ TKI shows survival win – Market reacts with a sell-off https://biobriefs.com/grail-locks-in-325m-private BioBriefs en 2025-10-20T16:32:49Z Grail locks in $325M: Private placement funds commercial push https://biobriefs.com/mystra-debuts-genomics-commercializes-human BioBriefs en 2025-10-20T16:32:49Z Mystra debuts: Genomics commercializes human‑genetics AI — Anthropic pushes into life sciences https://biobriefs.com/roche-posts-ctdna-benefit-and BioBriefs en 2025-10-20T16:32:49Z Roche posts ctDNA benefit and wins new indication for Gazyva https://biobriefs.com/prima-implant-restores-reading-vision BioBriefs en 2025-10-20T16:32:49Z PRIMA implant restores reading vision — Asset changes accelerate commercialization plans https://biobriefs.com/mrna-covid-shots-boost-checkpoint BioBriefs en 2025-10-20T16:32:49Z mRNA Covid shots boost checkpoint therapy — Retrospective analyses show survival signals https://biobriefs.com/ivonescimab-posts-strong-china-results BioBriefs en 2025-10-20T16:32:49Z Ivonescimab posts strong China results — Dual‑acting bispecific eyes global pivotal testing https://biobriefs.com/eli-lilly-backs-newlimit-with BioBriefs en 2025-10-20T16:32:49Z Eli Lilly backs NewLimit with $45M – Anti‑aging biotech scales up https://biobriefs.com/cyclana-closes-ps5m-pre-seed BioBriefs en 2025-10-20T16:32:49Z Cyclana closes £5M pre‑seed to model endometriosis — Tissue‑level discovery approach funded https://biobriefs.com/grail-raises-325m-private-placement BioBriefs en 2025-10-20T14:33:01Z Grail raises $325M — private placement fuels commercial push https://biobriefs.com/cyclana-bio-closes-ps5m-pre BioBriefs en 2025-10-20T14:33:01Z Cyclana Bio closes £5M pre-seed — tissue models target endometriosis https://biobriefs.com/bruker-wins-fda-clearance-for BioBriefs en 2025-10-20T14:33:01Z Bruker wins FDA clearance for MALDI Biotyper updates — lab workflow upgrade https://biobriefs.com/retinal-implant-restores-reading-vision BioBriefs en 2025-10-20T14:33:01Z Retinal implant restores reading vision… asset acquired at fire‑sale price https://biobriefs.com/mrna-covid-shots-boost-cancer BioBriefs en 2025-10-20T14:33:01Z mRNA Covid shots boost cancer immunotherapy — MD Anderson data https://biobriefs.com/fda-clears-roches-gazyva-for BioBriefs en 2025-10-20T14:33:01Z FDA clears Roche’s Gazyva for lupus nephritis — new CD20 indication https://biobriefs.com/sona-nanotech-posts-80-response BioBriefs en 2025-10-20T14:33:01Z Sona Nanotech posts 80% response in first‑in‑human THT melanoma study https://biobriefs.com/biocryst-buys-astria-for-700m BioBriefs en 2025-10-20T14:33:01Z BioCryst buys Astria for $700M — navenibart aims at HAE market https://biobriefs.com/zanzalintinib-plus-tecentriq-cuts-death BioBriefs en 2025-10-20T14:33:01Z Zanzalintinib plus Tecentriq cuts death risk 20% — Exelixis unveils Phase 3 data https://biobriefs.com/newlimit-raises-45m-with-lilly BioBriefs en 2025-10-20T14:33:01Z NewLimit raises $45M with Lilly Ventures backing — anti‑aging play https://biobriefs.com/fda-approves-roches-gazyva-for BioBriefs en 2025-10-20T10:32:51Z FDA approves Roche’s Gazyva for lupus nephritis https://biobriefs.com/indias-top-court-allows-natco BioBriefs en 2025-10-20T10:32:51Z India’s top court allows Natco to sell generic Evrysdi — Roche’s bid fails https://biobriefs.com/astrazeneca-and-gilead-square-off BioBriefs en 2025-10-20T10:32:51Z AstraZeneca and Gilead square off in triple‑negative breast cancer — ADCs vie for front line https://biobriefs.com/enhertu-shows-benefit-in-earlier BioBriefs en 2025-10-20T10:32:51Z Enhertu shows benefit in earlier breast cancer — Phase 3 data https://biobriefs.com/exelixis-zanzalintinib-plus-tecentriq-cuts BioBriefs en 2025-10-20T10:32:51Z Exelixis’ zanzalintinib plus Tecentriq cuts death risk 20% in colorectal cancer https://biobriefs.com/padcev-plus-keytruda-extends-survival BioBriefs en 2025-10-20T10:32:51Z Padcev plus Keytruda extends survival in Phase 3 bladder cancer https://biobriefs.com/biocryst-buys-astria-for-700m BioBriefs en 2025-10-20T10:32:51Z BioCryst buys Astria for $700M — gains Phase 3 HAE asset https://biobriefs.com/mrna-covid-shots-appear-to BioBriefs en 2025-10-20T10:32:51Z mRNA COVID shots appear to boost checkpoint immunotherapy outcomes https://biobriefs.com/eli-lillys-vc-arm-leads BioBriefs en 2025-10-20T10:32:51Z Eli Lilly’s VC arm leads $45M into anti‑aging biotech NewLimit https://biobriefs.com/anthropic-rolls-into-life-sciences BioBriefs en 2025-10-20T10:32:51Z Anthropic rolls into life sciences — GenAI adoption accelerates in pharma https://biobriefs.com/fda-approves-roches-gazyva-new BioBriefs en 2025-10-20T09:32:12Z FDA approves Roche’s Gazyva: new option for lupus nephritis https://biobriefs.com/exelixis-tki-trims-death-risk BioBriefs en 2025-10-20T09:32:12Z Exelixis TKI trims death risk 20% — Phase 3 readout https://biobriefs.com/adc-showdown-datroway-and-trodelvy BioBriefs en 2025-10-20T09:32:12Z ADC showdown: Datroway and Trodelvy produce competing Phase 3 results https://biobriefs.com/enhertu-moves-earlier-adcs-shifting BioBriefs en 2025-10-20T09:32:12Z Enhertu moves earlier — ADCs shifting into curative settings https://biobriefs.com/padcev-keytruda-combo-extends-survival BioBriefs en 2025-10-20T09:32:12Z Padcev–Keytruda combo extends survival in bladder cancer https://biobriefs.com/boehringer-bayer-neck-and-neck BioBriefs en 2025-10-20T09:32:12Z Boehringer, Bayer neck-and-neck in front-line HER2‑mutant lung https://biobriefs.com/first-in-class-yap-tead BioBriefs en 2025-10-20T09:32:12Z First‑in‑class YAP‑TEAD inhibitor shows early mesothelioma activity https://biobriefs.com/biocryst-shells-out-700m-for BioBriefs en 2025-10-20T09:32:12Z BioCryst shells out $700M for Astria to chase HAE market https://biobriefs.com/lilly-ventures-backs-newlimit-in BioBriefs en 2025-10-20T09:32:12Z Lilly Ventures backs NewLimit in $45M anti‑aging raise https://biobriefs.com/mrna-covid-shots-enhance-checkpoint BioBriefs en 2025-10-20T09:32:12Z mRNA COVID shots enhance checkpoint inhibitor outcomes — MD Anderson data https://biobriefs.com/biocryst-buys-astria-for-700m BioBriefs en 2025-10-20T04:33:10Z BioCryst buys Astria for $700M — HAE portfolio jumps https://biobriefs.com/gene-editing-stocks-brace-for BioBriefs en 2025-10-20T04:33:10Z Gene-editing stocks brace for Q3 — Intellia under the microscope https://biobriefs.com/adcs-climbing-the-ladder-enhertu BioBriefs en 2025-10-20T04:33:10Z ADCs climbing the ladder... Enhertu and next-gen agents push into earlier disease https://biobriefs.com/datroway-vs-trodelvy-tnbc-first BioBriefs en 2025-10-20T04:33:10Z Datroway vs Trodelvy — TNBC first‑line fight intensifies https://biobriefs.com/roches-serd-shows-benefit-in BioBriefs en 2025-10-20T04:33:10Z Roche’s SERD shows benefit in non‑mutant breast cancer — trial could redraw market https://biobriefs.com/tubulis-posts-59-response-tub BioBriefs en 2025-10-20T04:33:10Z Tubulis posts 59% response — TUB‑040 validates platform https://biobriefs.com/embl-unveils-sdr-seq-a BioBriefs en 2025-10-20T04:33:10Z EMBL unveils SDR‑seq: a tool to read hidden DNA regulatory code https://biobriefs.com/mrna-covid-shots-boost-immunotherapy BioBriefs en 2025-10-20T04:33:10Z mRNA Covid shots boost immunotherapy responses — ESMO and retrospective studies https://biobriefs.com/syngene-builds-peptide-lab-ramps BioBriefs en 2025-10-20T04:33:10Z Syngene builds peptide lab, ramps automation — CRDMO scale‑up https://biobriefs.com/india-court-allows-generic-evrysdi BioBriefs en 2025-10-20T04:33:10Z India court allows generic Evrysdi — Roche faces pricing blow https://biobriefs.com/enhertu-pushes-earlier-phase-3 BioBriefs en 2025-10-19T21:33:01Z Enhertu pushes earlier — Phase 3 signals curative potential https://biobriefs.com/datroway-vs-trodelvy-head-to BioBriefs en 2025-10-19T21:33:01Z Datroway vs Trodelvy: Head‑to‑head ESMO readouts sharpen choice https://biobriefs.com/padcev-keytruda-combo-extends-survival BioBriefs en 2025-10-19T21:33:01Z Padcev–Keytruda combo extends survival — Phase 3 bladder data https://biobriefs.com/grails-galleri-improves-accuracy-pathfinder BioBriefs en 2025-10-19T21:33:01Z Grail’s Galleri improves accuracy — PATHFINDER 2 readout alters filing narrative https://biobriefs.com/biontech-halts-late-stage-melanoma BioBriefs en 2025-10-19T21:33:01Z BioNTech halts late‑stage melanoma vaccine https://biobriefs.com/mrna-covid-shots-amplify-immunotherapy BioBriefs en 2025-10-19T21:33:01Z mRNA COVID shots amplify immunotherapy response — MD Anderson analysis https://biobriefs.com/tubulis-clinical-win-backs-hefty BioBriefs en 2025-10-19T21:33:01Z Tubulis clinical win backs hefty financing — investors take notice https://biobriefs.com/vt3989-demonstrates-early-activity-in BioBriefs en 2025-10-19T21:33:01Z VT3989 demonstrates early activity in refractory mesothelioma https://biobriefs.com/syngene-builds-automated-peptide-lab BioBriefs en 2025-10-19T21:33:01Z Syngene builds automated peptide lab to speed discovery https://biobriefs.com/fda-exodus-and-voucher-program BioBriefs en 2025-10-19T21:33:01Z FDA exodus and voucher program scrutiny reshape regulatory backdrop https://biobriefs.com/grails-galleri-improves-accuracy-fda BioBriefs en 2025-10-19T16:33:07Z Grail’s Galleri improves accuracy: FDA filing nears https://biobriefs.com/fda-unveils-nine-national-priority BioBriefs en 2025-10-19T16:33:07Z FDA unveils nine 'national priority' picks — review clock shortens https://biobriefs.com/sophia-genetics-launches-digital-twins BioBriefs en 2025-10-19T16:33:07Z Sophia Genetics launches Digital Twins: AI models simulate cancer patients https://biobriefs.com/new-mesothelioma-agents-show-activity BioBriefs en 2025-10-19T16:33:07Z New mesothelioma agents show activity: YAP‑TEAD inhibitor and Vivace readouts https://biobriefs.com/adcs-encroach-on-first-line BioBriefs en 2025-10-19T16:33:07Z ADCs encroach on first‑line TNBC: head‑to‑head presentations shift treatment choices https://biobriefs.com/tubulis-clinical-win-follows-big BioBriefs en 2025-10-19T16:33:07Z Tubulis clinical win follows big funding: investor thesis validated https://biobriefs.com/mrna-covid-shots-linked-to BioBriefs en 2025-10-19T16:33:07Z mRNA COVID shots linked to better checkpoint immunotherapy outcomes https://biobriefs.com/tumor-infiltrating-fusobacterium-induces-quiescence BioBriefs en 2025-10-19T16:33:07Z Tumor‑infiltrating Fusobacterium induces quiescence and blunts chemotherapy https://biobriefs.com/sdr-seq-decodes-noncoding-dna BioBriefs en 2025-10-19T16:33:07Z SDR‑seq decodes noncoding DNA and RNA from the same cell https://biobriefs.com/rutgers-maps-molecular-route-to BioBriefs en 2025-10-19T16:33:07Z Rutgers maps molecular route to AML therapy resistance https://biobriefs.com/astrazeneca-adc-push-enhertu-moves BioBriefs en 2025-10-19T14:32:37Z AstraZeneca ADC push: Enhertu moves earlier; AZD5335 posts activity https://biobriefs.com/tubulis-platform-vindicated-59-response BioBriefs en 2025-10-19T14:32:37Z Tubulis’ platform vindicated — 59% response riles investors https://biobriefs.com/tnbc-adc-showdown-datroway-versus BioBriefs en 2025-10-19T14:32:37Z TNBC ADC showdown: Datroway versus Trodelvy — clinicians to choose https://biobriefs.com/grails-galleri-improved-specificity-as BioBriefs en 2025-10-19T14:32:37Z Grail’s Galleri: improved specificity as FDA filing approaches https://biobriefs.com/fda-pilot-first-nine-cnpv BioBriefs en 2025-10-19T14:32:37Z FDA pilot: first nine CNPV picks aim to speed review — winners named